doc_id,relationship_type,assay_strain,src_assay_id,assay_cell_type,assay_test_type,tid,confidence_score,curated_by,assay_subcellular_fraction,assay_id,assay_type,assay_tissue,variant_id,src_id,bao_format,description,cell_id,assay_category,tissue_id,assay_organism,chembl_id,assay_tax_id
11087,H,,,,,12052,8,Autocuration,,1,B,,,1,BAO_0000019,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,,,,CHEMBL615117,
684,U,,,,,22226,0,Autocuration,,2,F,,,1,BAO_0000219,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,,,,CHEMBL615118,
15453,U,,,,,22226,0,Autocuration,,3,B,,,1,BAO_0000019,,,,,,CHEMBL615119,
17841,H,,,,,104729,4,Autocuration,,4,B,,,1,BAO_0000249,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,,,Bos taurus,CHEMBL615120,9913.0
17430,N,,,143B,,80001,1,Intermediate,,5,F,,,1,BAO_0000219,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),163.0,,,Homo sapiens,CHEMBL615121,9606.0
17430,N,,,143B,,80001,1,Intermediate,,6,F,,,1,BAO_0000219,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),163.0,,,Homo sapiens,CHEMBL615122,9606.0
13799,N,,,143B,,80001,1,Intermediate,,7,F,,,1,BAO_0000219,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,163.0,,,Mus musculus,CHEMBL615123,10090.0
17774,N,,,143B,,80001,1,Expert,,8,F,,,1,BAO_0000219,In vitro cell cytotoxicity was determined against 143B cell line,163.0,,,Homo sapiens,CHEMBL615124,9606.0
3801,N,,,143B,,80001,1,Intermediate,,9,F,,,1,BAO_0000219,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,163.0,,,Homo sapiens,CHEMBL615125,9606.0
17430,N,,,143B,,80001,1,Intermediate,,10,F,,,1,BAO_0000219,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,163.0,,,Homo sapiens,CHEMBL615126,9606.0
17430,N,,,143B,,80001,1,Intermediate,,11,F,,,1,BAO_0000219,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,163.0,,,Homo sapiens,CHEMBL615127,9606.0
17774,N,,,143B,,80001,1,Expert,,12,F,,,1,BAO_0000219,In vitro cell cytotoxicity was determined against 143B-LTK cell line,163.0,,,Homo sapiens,CHEMBL615128,9606.0
11324,N,,,,,50185,1,Intermediate,,13,F,,,1,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,,Staphylococcus aureus,CHEMBL857900,1280.0
11324,N,,,,,50185,1,Intermediate,,14,F,,,1,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,,Staphylococcus aureus,CHEMBL615129,1280.0
11324,N,,,,,50185,1,Intermediate,,15,F,,,1,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,,Staphylococcus aureus,CHEMBL615130,1280.0
11324,N,,,,,50185,1,Intermediate,,16,F,,,1,BAO_0000218,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,,,Staphylococcus aureus,CHEMBL615131,1280.0
11347,D,,,,,100122,9,Expert,,17,A,,,1,BAO_0000357,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,,,Rattus norvegicus,CHEMBL884521,10116.0
16474,H,,,,,12054,8,Autocuration,,18,B,,,1,BAO_0000357,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,,,,CHEMBL615132,
10091,H,,,,,12054,8,Autocuration,,19,B,,,1,BAO_0000019,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,,,,CHEMBL615133,
16474,H,,,,,12054,8,Autocuration,,20,B,,,1,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,,,CHEMBL615134,
16474,H,,,,,12054,8,Autocuration,,21,B,,,1,BAO_0000357,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,,,,CHEMBL615135,
16474,H,,,,,12054,8,Autocuration,,22,B,,,1,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,,,CHEMBL615136,
16474,H,,,,,12054,8,Autocuration,,23,B,,,1,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,,,CHEMBL615137,
16474,H,,,,,12054,8,Autocuration,,24,B,,,1,BAO_0000357,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,,,CHEMBL615138,
14352,U,,,,,22226,0,Autocuration,,25,B,,,1,BAO_0000219,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,,,,CHEMBL836324,
5646,H,,,,,12054,8,Autocuration,,26,B,,,1,BAO_0000357,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,,,Oryctolagus cuniculus,CHEMBL615139,9986.0
5646,H,,,,,12054,8,Autocuration,,27,B,,,1,BAO_0000357,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,,,Oryctolagus cuniculus,CHEMBL615140,9986.0
10997,H,,,,,12426,8,Autocuration,,28,B,,,1,BAO_0000219,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,,,,CHEMBL615141,
6309,H,,,,,12054,8,Autocuration,,29,B,,,1,BAO_0000357,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,,,soya bean,CHEMBL615142,3847.0
167,H,,,,,12054,8,Autocuration,,30,B,,,1,BAO_0000357,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,,,Glycine max,CHEMBL615143,3847.0
167,H,,,,,12054,8,Autocuration,,31,B,,,1,BAO_0000357,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,,,Glycine max,CHEMBL615144,3847.0
11087,H,,,,,12054,8,Autocuration,,32,B,,,1,BAO_0000357,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,,,Glycine max,CHEMBL872867,3847.0
11087,H,,,,,12054,8,Autocuration,,33,B,,,1,BAO_0000357,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,,,Glycine max,CHEMBL615145,3847.0
13622,H,,,,,12054,8,Autocuration,,34,B,,,1,BAO_0000357,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,,,Glycine max,CHEMBL615146,3847.0
13622,H,,,,,12054,8,Autocuration,,35,B,,,1,BAO_0000357,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,,,Glycine max,CHEMBL615147,3847.0
11347,U,,,,,22226,0,Autocuration,,36,A,,,1,BAO_0000019,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,,,Rattus norvegicus,CHEMBL615148,10116.0
5926,U,,,,,22226,0,Autocuration,,37,B,,,1,BAO_0000019,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,,,Escherichia coli,CHEMBL615149,562.0
4567,U,,,,,22226,0,Autocuration,,38,B,,,1,BAO_0000019,Dissociation constant with dimeric 16S rRNA RNA construct B,,,,,CHEMBL615150,
3782,M,,,,,22222,3,Intermediate,,39,B,,,1,BAO_0000225,Dissociation constant towards 16S rRNA construct A,,,,,CHEMBL615151,
3782,M,,,,,22222,3,Intermediate,,40,B,,,1,BAO_0000225,Dissociation constant towards 16S rRNA construct B,,,,,CHEMBL615152,
4466,M,,,,,100263,3,Expert,,41,B,,,1,BAO_0000225,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,,,Escherichia coli,CHEMBL615153,562.0
6592,M,,,,,100263,3,Expert,,42,B,,,1,BAO_0000225,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,,,Escherichia coli,CHEMBL615154,562.0
898,H,,,,,13053,8,Autocuration,,43,B,,,1,BAO_0000019,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,,CHEMBL615155,
898,H,,,,,13053,8,Autocuration,,44,B,,,1,BAO_0000019,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,,CHEMBL615156,
13163,H,,,,,20001,8,Autocuration,,45,B,,,1,BAO_0000019,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,,Homo sapiens,CHEMBL615157,9606.0
13163,H,,,,,20001,8,Autocuration,,46,B,,,1,BAO_0000019,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,,,Homo sapiens,CHEMBL615158,9606.0
10691,D,,,,,12971,9,Expert,,47,B,,,1,BAO_0000019,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,,Rattus norvegicus,CHEMBL615159,10116.0
10691,D,,,,,12971,9,Expert,,48,B,,,1,BAO_0000019,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,,,Rattus norvegicus,CHEMBL615172,10116.0
10691,D,,,,,12971,9,Expert,,49,B,,,1,BAO_0000019,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,,Rattus norvegicus,CHEMBL615173,10116.0
10691,D,,,,,12971,9,Expert,,50,B,,,1,BAO_0000019,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,,,Rattus norvegicus,CHEMBL615174,10116.0
898,H,,,,,13053,8,Autocuration,,51,B,,,1,BAO_0000019,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,,CHEMBL884518,
912,H,,,,,11512,8,Autocuration,,52,B,,,1,BAO_0000357,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,,,,CHEMBL615175,
912,H,,,,,11512,8,Autocuration,,53,B,,,1,BAO_0000357,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,,,,CHEMBL615176,
912,H,,,,,11512,8,Autocuration,,54,B,,,1,BAO_0000357,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,,,,CHEMBL615177,
15103,D,,,,,104740,5,Autocuration,Membranes,55,B,,,1,BAO_0000249,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,,,Rattus norvegicus,CHEMBL615178,10116.0
5116,N,,,1A9,,80002,1,Intermediate,,56,F,,,1,BAO_0000219,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,506.0,,,Homo sapiens,CHEMBL615179,9606.0
14578,D,,,Oocytes,,104835,7,Autocuration,,57,F,,,1,BAO_0000219,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,,,Rattus norvegicus,CHEMBL615180,10116.0
14578,D,,,Oocytes,,104821,7,Autocuration,,58,F,,,1,BAO_0000219,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,,,Rattus norvegicus,CHEMBL615181,10116.0
14578,D,,,Oocytes,,104848,7,Autocuration,,59,F,,,1,BAO_0000219,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,,,Rattus norvegicus,CHEMBL615182,10116.0
4787,N,,,1A9,,80002,1,Expert,,60,F,,,1,BAO_0000219,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,506.0,,,Homo sapiens,CHEMBL615183,9606.0
4787,N,,,1A9,,80002,1,Intermediate,,61,F,,,1,BAO_0000219,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,506.0,,,Homo sapiens,CHEMBL615184,9606.0
3547,N,,,1A9,,80002,1,Intermediate,,62,F,,,1,BAO_0000219,Cytotoxic activity against human ovarian cancer (1A9) cell line,506.0,,,Homo sapiens,CHEMBL615185,9606.0
3547,N,,,1A9,,80002,1,Intermediate,,63,F,,,1,BAO_0000219,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,506.0,,,Homo sapiens,CHEMBL615186,9606.0
6726,N,,,1A9,,80002,1,Intermediate,,64,F,,,1,BAO_0000219,Effective dose of compound against replication of 1A9 cell line was evaluated,506.0,,,Homo sapiens,CHEMBL615187,9606.0
3455,N,,,1A9,,80002,1,Expert,,65,F,,,1,BAO_0000219,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,506.0,,,Homo sapiens,CHEMBL885343,9606.0
5726,N,,,1A9,,80002,1,Intermediate,,66,F,,,1,BAO_0000219,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),506.0,,,Homo sapiens,CHEMBL615188,9606.0
5726,N,,,1A9,,80002,1,Intermediate,,67,F,,,1,BAO_0000219,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,506.0,,,Homo sapiens,CHEMBL615189,9606.0
5726,N,,,1A9,,80002,1,Intermediate,,68,F,,,1,BAO_0000219,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,506.0,,,Homo sapiens,CHEMBL615190,9606.0
3395,N,,,1A9,,80002,1,Intermediate,,69,F,,,1,BAO_0000219,Inhibitory activity against Taxol resistant 1A9 cell lines,506.0,,,Homo sapiens,CHEMBL615191,9606.0
3415,N,,,1A9,,80002,1,Expert,,70,F,,,1,BAO_0000219,Cytotoxicity against human ovarian cancer (1A9) cell lines.,506.0,,,Homo sapiens,CHEMBL615192,9606.0
3415,N,,,1A9,,80002,1,Expert,,71,F,,,1,BAO_0000219,Percentage inhibition of human ovarian cancer (1A9) cell lines.,506.0,,,Homo sapiens,CHEMBL827083,9606.0
17099,N,,,1A9,,80002,1,Expert,,72,F,,,1,BAO_0000219,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,506.0,,,Homo sapiens,CHEMBL615193,9606.0
17099,N,,,1A9,,80002,1,Intermediate,,73,F,,,1,BAO_0000219,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,506.0,,,Homo sapiens,CHEMBL615194,9606.0
17099,N,,,1A9,,80002,1,Intermediate,,74,F,,,1,BAO_0000219,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,506.0,,,Homo sapiens,CHEMBL615195,9606.0
17099,N,,,1A9,,80002,1,Intermediate,,75,F,,,1,BAO_0000219,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,506.0,,,Homo sapiens,CHEMBL615196,9606.0
17721,N,,,Jurkat,,81072,1,Intermediate,,76,F,,,1,BAO_0000219,Inhibitory concentration against Jurkat cells,503.0,,,Homo sapiens,CHEMBL615197,9606.0
1229,U,,,,,22226,0,Intermediate,,77,F,,,1,BAO_0000019,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,,,,CHEMBL615198,
11347,D,,,,,100121,9,Expert,,78,A,,,1,BAO_0000357,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,,,Rattus norvegicus,CHEMBL615199,10116.0
17117,H,,,,,11231,8,Expert,,79,B,,,1,BAO_0000357,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,,,CHEMBL615200,
17117,H,,,,,11231,8,Expert,,80,B,,,1,BAO_0000357,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,,,CHEMBL615201,
17117,H,,,,,11231,8,Expert,,81,B,,,1,BAO_0000357,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,,,,CHEMBL615202,
11375,H,,,,,11231,8,Autocuration,Microsomes,82,B,,,1,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,,,Candida albicans,CHEMBL615203,5476.0
11375,H,,,,,11231,8,Autocuration,Microsomes,83,B,,,1,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,,,Candida albicans,CHEMBL615204,5476.0
11375,H,,,,,11231,8,Autocuration,Microsomes,84,B,,,1,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,,,Saccharomyces cerevisiae,CHEMBL615205,4932.0
11375,H,,,,,11231,8,Autocuration,Microsomes,85,B,,,1,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,,,Saccharomyces cerevisiae,CHEMBL615206,4932.0
11375,H,,,,,12083,8,Autocuration,Microsomes,86,B,Liver,,1,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,,2107.0,Sus scrofa,CHEMBL615207,9823.0
791,H,,,,,11231,8,Autocuration,,87,B,,,1,BAO_0000019,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,,,Rattus norvegicus,CHEMBL827084,10116.0
791,H,,,,,11231,8,Autocuration,,88,B,,,1,BAO_0000019,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,,,Rattus norvegicus,CHEMBL615208,10116.0
791,H,,,,,11231,8,Autocuration,,89,B,,,1,BAO_0000019,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,,,Rattus norvegicus,CHEMBL615209,10116.0
11375,D,,,,,12083,9,Autocuration,Microsomes,90,B,Liver,,1,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,,2107.0,Rattus norvegicus,CHEMBL615210,10116.0
11375,D,,,,,12083,9,Autocuration,Microsomes,91,B,Liver,,1,BAO_0000251,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,,2107.0,Rattus norvegicus,CHEMBL615211,10116.0
153,D,,,,,12083,9,Autocuration,Microsomes,92,B,Liver,,1,BAO_0000251,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,,2107.0,Rattus norvegicus,CHEMBL615212,10116.0
8269,H,,,,,11377,8,Expert,,93,B,,,1,BAO_0000357,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,,,,CHEMBL615213,
8269,H,,,,,11377,8,Expert,,94,B,,,1,BAO_0000357,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,,,,CHEMBL615273,
17653,N,,,HepG2,,81020,1,Expert,,95,F,,,1,BAO_0000219,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,726.0,,,Homo sapiens,CHEMBL615274,9606.0
14277,N,,,HepG2,,81020,1,Intermediate,,96,F,,,1,BAO_0000219,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,726.0,,,Homo sapiens,CHEMBL615275,9606.0
1717,N,,,HepG2,,81020,1,Intermediate,,97,F,,,1,BAO_0000219,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,726.0,,,Homo sapiens,CHEMBL615276,9606.0
14091,N,,,HepG2,,81020,1,Intermediate,,98,F,,,1,BAO_0000219,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,726.0,,,Homo sapiens,CHEMBL615277,9606.0
14091,N,,,HepG2,,81020,1,Intermediate,,99,F,,,1,BAO_0000219,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,726.0,,,Homo sapiens,CHEMBL615326,9606.0
17653,N,,,,,50606,1,Expert,,100,F,,,1,BAO_0000218,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,,,Hepatitis B virus,CHEMBL883130,10407.0
13105,N,,,HepG2,,81020,1,Intermediate,,101,F,,,1,BAO_0000219,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,726.0,,,Homo sapiens,CHEMBL884519,9606.0
1717,N,,,HepG2,,81020,1,Intermediate,,102,F,,,1,BAO_0000219,Concentration required to inhibit 50% of 2.2.15 cell line,726.0,,,Homo sapiens,CHEMBL615327,9606.0
13105,N,,,HepG2,,81020,1,Intermediate,,103,A,,,1,BAO_0000219,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,726.0,,,Homo sapiens,CHEMBL615328,9606.0
13600,N,,,2.2.15,,50587,1,Intermediate,,104,F,,,1,BAO_0000218,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,,,Homo sapiens,CHEMBL615329,9606.0
13467,N,,,2.2.15,,50587,1,Intermediate,,105,F,,,1,BAO_0000218,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,,,Homo sapiens,CHEMBL615330,9606.0
17477,N,,,2.2.15,,50606,1,Expert,,106,F,,,1,BAO_0000218,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,,,Hepatitis B virus,CHEMBL615331,10407.0
1593,N,,,2.2.15,,50587,1,Intermediate,,107,F,,,1,BAO_0000218,In vitro anti-HBV activity in 2.2.15 cells,,,,Homo sapiens,CHEMBL615332,9606.0
1593,N,,,2.2.15,,50587,1,Intermediate,,108,F,,,1,BAO_0000218,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,,,Homo sapiens,CHEMBL615333,9606.0
15089,N,,,2.2.15,,50587,1,Intermediate,,109,F,,,1,BAO_0000218,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,,,Homo sapiens,CHEMBL615334,9606.0
15089,N,,,2.2.15,,50587,1,Intermediate,,110,F,,,1,BAO_0000218,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,,,Homo sapiens,CHEMBL615335,9606.0
1593,N,,,2.2.15,,50587,1,Intermediate,,111,F,,,1,BAO_0000218,Cytotoxicity in 2.2.15 cells,,,,Homo sapiens,CHEMBL615336,9606.0
1593,N,,,2.2.15,,50587,1,Intermediate,,112,F,,,1,BAO_0000218,Cytotoxicity in 2.2.15 cells; Not determined,,,,Homo sapiens,CHEMBL615337,9606.0
13600,N,,,2.2.15,,50587,1,Intermediate,,113,F,,,1,BAO_0000218,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,,,Homo sapiens,CHEMBL615338,9606.0
13467,N,,,2.2.15,,50587,1,Intermediate,,114,F,,,1,BAO_0000218,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,,,Homo sapiens,CHEMBL615339,9606.0
13467,N,,,2.2.15,,50587,1,Intermediate,,115,F,,,1,BAO_0000218,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,,,Homo sapiens,CHEMBL615340,9606.0
14764,N,,,HepG2,,81020,1,Intermediate,,116,F,,,1,BAO_0000219,Antiviral activity against HBV was determined in 2.215 cell line,726.0,,,Homo sapiens,CHEMBL615341,9606.0
6531,U,,,,,22226,0,Autocuration,Microsomes,117,B,,,1,BAO_0000251,Inhibition of 20-HETE synthesis in human renal microsomes,,,,Homo sapiens,CHEMBL615342,9606.0
17322,U,,,,,22226,0,Autocuration,,118,B,,,1,BAO_0000019,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,,,,CHEMBL615343,
17072,N,,,2008,,80612,1,Intermediate,,119,F,,,1,BAO_0000219,Inhibitory concentration against 2008 (ovarian) cells,388.0,,,Homo sapiens,CHEMBL615344,9606.0
16936,N,,,2008,,80612,1,Intermediate,,120,F,,,1,BAO_0000219,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,388.0,,,Homo sapiens,CHEMBL615345,9606.0
16936,N,,,2008,,80612,1,Intermediate,,121,F,,,1,BAO_0000219,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),388.0,,,Homo sapiens,CHEMBL615346,9606.0
17146,N,,,2008,,80612,1,Intermediate,,122,F,,,1,BAO_0000219,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,388.0,,,Homo sapiens,CHEMBL615347,9606.0
17146,N,,,2008,,80612,1,Intermediate,,123,F,,,1,BAO_0000219,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,388.0,,,Homo sapiens,CHEMBL615348,9606.0
10797,N,,,2008/R,,80613,1,Intermediate,,124,F,,,1,BAO_0000219,In vitro inhibition of 2008/R ovarian cancer cell line,561.0,,,Homo sapiens,CHEMBL827085,9606.0
10797,N,,,2008/R,,80613,1,Intermediate,,125,F,,,1,BAO_0000219,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,561.0,,,Homo sapiens,CHEMBL615349,9606.0
10797,N,,,2008/S,,80614,1,Intermediate,,126,F,,,1,BAO_0000219,In vitro inhibition of 2008/S ovarian cancer cell line,389.0,,,Homo sapiens,CHEMBL615350,9606.0
10797,N,,,2008/S,,80614,1,Intermediate,,127,F,,,1,BAO_0000219,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,389.0,,,Homo sapiens,CHEMBL615351,9606.0
4823,S,,,,,100256,2,Expert,,128,B,,,1,BAO_0000220,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,,,Homo sapiens,CHEMBL615352,9606.0
12912,S,,,,,100256,2,Intermediate,,129,B,,,1,BAO_0000220,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,,,Homo sapiens,CHEMBL615353,9606.0
2957,S,,,,,100256,2,Expert,,130,B,,,1,BAO_0000220,Inhibition of chymotrypsin-like activity of 20S proteasome,,,,,CHEMBL615354,
2957,S,,,,,100256,2,Expert,,131,B,,,1,BAO_0000220,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,,,,CHEMBL615355,
3260,S,,,,,100256,2,Intermediate,,132,B,,,1,BAO_0000220,Inhibitory activity against 20S proteosome,,,,,CHEMBL615356,
3451,U,,,,,22226,0,Autocuration,,133,B,,,1,BAO_0000019,Compound was tested for inhibitory activity against tryptase,,,,Homo sapiens,CHEMBL615357,9606.0
13885,N,,,HepG2,,81020,1,Intermediate,,134,F,,,1,BAO_0000219,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,726.0,,,Homo sapiens,CHEMBL615358,9606.0
13885,N,,,HepG2,,81020,1,Intermediate,,135,F,,,1,BAO_0000219,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,726.0,,,Homo sapiens,CHEMBL827086,9606.0
3676,U,,,,,22226,0,Autocuration,,136,B,,,1,BAO_0000019,Compound was tested for the inhibition of Alpha-glucosidase,,,,,CHEMBL615359,
6043,H,,,,,235,8,Autocuration,,137,B,,,1,BAO_0000357,Inhibitory concentration against human neutrophil elastase (HNE),,,,,CHEMBL615360,
11140,U,,,,,22226,0,Autocuration,,138,F,Heart,,1,BAO_0000218,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,,948.0,Rattus norvegicus,CHEMBL615361,10116.0
10543,H,,,,,19640,8,Autocuration,,139,F,,,1,BAO_0000019,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,CHEMBL615362,
10543,H,,,,,19640,8,Expert,,140,F,,,1,BAO_0000019,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,CHEMBL615363,
10543,H,,,,,19640,8,Autocuration,,141,B,,,1,BAO_0000357,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,CHEMBL615364,
10543,H,,,,,19640,8,Expert,,142,F,,,1,BAO_0000019,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,CHEMBL615365,
11365,N,,,P338,,80360,1,Intermediate,,143,F,,,1,BAO_0000219,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,524.0,,,Mus musculus,CHEMBL615366,10090.0
11365,N,,,P338,,80360,1,Intermediate,,144,F,,,1,BAO_0000219,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,524.0,,,Mus musculus,CHEMBL615367,10090.0
11803,N,,,PBL,,80384,1,Intermediate,,145,F,,,1,BAO_0000219,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,554.0,,,Homo sapiens,CHEMBL615368,9606.0
11803,U,,,,,22226,0,Autocuration,,146,F,,,1,BAO_0000019,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,,,Ovis aries,CHEMBL615369,9940.0
11803,U,,,,,22226,0,Autocuration,,147,F,,,1,BAO_0000019,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,,,Ovis aries,CHEMBL615370,9940.0
12278,H,,,,,191,8,Autocuration,,148,B,,,1,BAO_0000357,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,,,,CHEMBL615673,
8249,U,,,,,22226,0,Autocuration,,149,F,,,1,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,,,Homo sapiens,CHEMBL615674,9606.0
8249,U,,,,,22226,0,Autocuration,,150,F,,,1,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,,,Homo sapiens,CHEMBL615675,9606.0
8249,U,,,CCRF-CEM,,22226,0,Autocuration,,151,F,,,1,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,635.0,,,Homo sapiens,CHEMBL615676,9606.0
8249,U,,,CCRF-CEM,,22226,0,Autocuration,,152,F,,,1,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,635.0,,,Homo sapiens,CHEMBL615677,9606.0
8249,U,,,CCRF-CEM,,22226,0,Autocuration,,153,F,,,1,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,635.0,,,Homo sapiens,CHEMBL615678,9606.0
8249,U,,,CCRF-CEM,,22226,0,Autocuration,,154,F,,,1,BAO_0000219,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,635.0,,,Homo sapiens,CHEMBL615679,9606.0
8249,U,,,,,22226,0,Autocuration,,155,F,,,1,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,,,Homo sapiens,CHEMBL615680,9606.0
8249,U,,,,,22226,0,Autocuration,,156,F,,,1,BAO_0000019,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,,,Homo sapiens,CHEMBL615681,9606.0
16992,H,,,,,104290,6,Autocuration,,157,B,,,1,BAO_0000249,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,,,,CHEMBL857972,
10543,N,,,,,50264,1,Intermediate,,158,F,,,1,BAO_0000218,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,,,Streptococcus pyogenes,CHEMBL857899,1314.0
17833,N,,,,,50527,1,Intermediate,,159,F,,,1,BAO_0000218,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,,,Human herpesvirus 3,CHEMBL615371,10335.0
17290,N,,,HEL,,50527,1,Expert,,160,F,,,1,BAO_0000218,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,468.0,,,vericilla zoster virus,CHEMBL615372,10335.0
17290,N,,,,,50527,1,Intermediate,,161,F,,,1,BAO_0000218,Antiviral activity against 07/1 strain of VZV; ND: No data,,,,vericilla zoster virus,CHEMBL615373,10335.0
17290,N,,,,,50527,1,Intermediate,,162,F,,,1,BAO_0000218,Antiviral activity against 07/1 strain of VZV; ND=No data,,,,vericilla zoster virus,CHEMBL615374,10335.0
10932,N,,,,,50145,1,Intermediate,,163,F,,,1,BAO_0000218,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,,,escherichia cloac,CHEMBL615375,561.0
9707,U,,,,,22226,0,Autocuration,,164,B,,,1,BAO_0000019,Ratio of Ki at A2 to Ki at A1 receptors,,,,,CHEMBL615376,
2346,H,,,,,11143,8,Expert,,165,B,,,1,BAO_0000249,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,,,Candida albicans,CHEMBL615377,5476.0
2205,H,,,,,18077,8,Expert,,166,B,,,1,BAO_0000357,"Inhibition of 1,3-beta-glucan synthase",,,,Candida glabrata CBS 138,CHEMBL615378,284593.0
11900,N,,,1-87 tumor cell line,,80609,1,Intermediate,,167,F,,,1,BAO_0000219,Inhibition of growth of 1-87 human tumor cell line,832.0,,,Homo sapiens,CHEMBL615379,9606.0
14864,D,,,,,12166,9,Expert,,168,B,,,1,BAO_0000219,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,,,Rattus norvegicus,CHEMBL615380,10116.0
16474,D,,,,,100171,9,Autocuration,,169,B,,,1,BAO_0000357,Inhibitory activity against soybean 1-lipoxygenase (SLO),,,,Glycine max,CHEMBL615381,3847.0
16474,D,,,,,100171,9,Autocuration,,170,B,,,1,BAO_0000357,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,,,Glycine max,CHEMBL615382,3847.0
16474,D,,,,,100171,9,Autocuration,,171,B,,,1,BAO_0000357,% inhibition against soybean 1-lipoxygenase (SLO),,,,Glycine max,CHEMBL615383,3847.0
16474,D,,,,,100171,9,Autocuration,,172,B,,,1,BAO_0000357,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,,,Glycine max,CHEMBL615384,3847.0
3094,D,,,,,100171,9,Autocuration,,173,B,,,1,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,,,Glycine max,CHEMBL615385,3847.0
3094,D,,,,,100171,9,Autocuration,,174,B,,,1,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,,,Glycine max,CHEMBL615386,3847.0
3094,D,,,,,100171,9,Autocuration,,175,B,,,1,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,,,Glycine max,CHEMBL615387,3847.0
3094,D,,,,,100171,9,Autocuration,,176,B,,,1,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,,,Glycine max,CHEMBL615388,3847.0
3094,D,,,,,100171,9,Autocuration,,177,B,,,1,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,,,Glycine max,CHEMBL615214,3847.0
3094,D,,,,,100171,9,Autocuration,,178,B,,,1,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,,,Glycine max,CHEMBL827087,3847.0
3094,D,,,,,100171,9,Autocuration,,179,B,,,1,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,,,Glycine max,CHEMBL615215,3847.0
3094,D,,,,,100171,9,Autocuration,,180,B,,,1,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,,,Glycine max,CHEMBL615216,3847.0
3094,D,,,,,100171,9,Autocuration,,181,B,,,1,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,,,Glycine max,CHEMBL615217,3847.0
3094,D,,,,,100171,9,Autocuration,,182,B,,,1,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,,,Glycine max,CHEMBL615218,3847.0
3094,D,,,,,100171,9,Autocuration,,183,B,,,1,BAO_0000357,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,,,Glycine max,CHEMBL615219,3847.0
10413,U,,,,,22226,0,Autocuration,,184,B,,,1,BAO_0000019,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,,,Mus musculus,CHEMBL615220,10090.0
16929,N,,,C3H 10T1/2,,80049,1,Intermediate,,185,F,,,1,BAO_0000219,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),294.0,,,Mus musculus,CHEMBL615221,10090.0
1229,U,,,,,22226,0,Intermediate,,186,F,,,1,BAO_0000019,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,,,,CHEMBL615222,
16587,H,,,,,11489,8,Autocuration,,187,B,,,1,BAO_0000357,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,,,CHEMBL615223,
16587,H,,,,,11862,8,Autocuration,,188,B,,,1,BAO_0000357,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,,,CHEMBL615224,
16587,H,,,,,11862,8,Autocuration,,189,B,,,1,BAO_0000357,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,,,,CHEMBL615225,
16587,H,,,,,11489,8,Autocuration,,190,B,,,1,BAO_0000357,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,,,,CHEMBL615226,
16587,H,,,,,11862,8,Autocuration,,191,B,,,1,BAO_0000357,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,,,,CHEMBL615227,
8058,D,,,,,12347,9,Expert,,192,F,,,1,BAO_0000019,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,,,Bos taurus,CHEMBL615228,9913.0
9065,D,,,,,100120,9,Expert,,193,B,,,1,BAO_0000357,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,,,Rattus norvegicus,CHEMBL615229,10116.0
8865,D,,,,,100120,9,Expert,,194,B,Adrenal gland,,1,BAO_0000357,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,,2369.0,Rattus norvegicus,CHEMBL615230,10116.0
9066,D,,,,,100120,9,Expert,,195,B,,,1,BAO_0000357,Inhibition of rat adrenal 11-beta-hydroxylase,,,,Rattus norvegicus,CHEMBL615231,10116.0
8394,D,,,,,100120,9,Expert,,196,B,,,1,BAO_0000357,Inhibition of rat adrenal 11-beta-hydroxylase,,,,Rattus norvegicus,CHEMBL884520,10116.0
8394,D,,,,,100120,9,Expert,,197,B,,,1,BAO_0000357,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,,,Rattus norvegicus,CHEMBL615232,10116.0
6431,H,,,,,10328,8,Autocuration,,198,B,,,1,BAO_0000019,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,,,,CHEMBL615233,
6431,H,,,,,11490,8,Autocuration,,199,B,,,1,BAO_0000357,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,,,CHEMBL827088,
6431,H,,,,,11490,8,Autocuration,,200,B,,,1,BAO_0000357,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,,,CHEMBL615234,
9295,H,,,,,11134,8,Autocuration,,201,F,,,1,BAO_0000019,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,,,,CHEMBL615235,
10193,H,,,,,12052,8,Autocuration,,202,B,,,1,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,,CHEMBL615236,
13622,H,,,,,11134,8,Autocuration,,203,B,,,1,BAO_0000019,Compound was tested in vitro for inhibition of 12-LO human platelet,,,,,CHEMBL615237,
12079,H,,,,,11134,8,Autocuration,,204,F,,,1,BAO_0000019,Inhibitory concentration against human platelet 12-lipoxygenase,,,,,CHEMBL615238,
13622,H,,,,,11134,8,Autocuration,,205,B,,,1,BAO_0000019,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,,,,CHEMBL615239,
12079,D,,,,,11134,9,Autocuration,,206,F,,,1,BAO_0000019,Inhibitory concentration against human platelet 12-lipoxygenase,,,,Homo sapiens,CHEMBL615240,9606.0
13500,H,,,,,11835,8,Expert,,207,B,,,1,BAO_0000019,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,,,,CHEMBL615241,
13723,H,,,,,11601,8,Expert,,208,B,,,1,BAO_0000357,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,,,,CHEMBL615242,
16474,H,,,,,11134,8,Autocuration,,209,B,,,1,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,,,,CHEMBL615243,
1630,H,,,,,11134,8,Autocuration,,210,B,,,1,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase,,,,,CHEMBL615244,
167,H,,,,,11134,8,Autocuration,,211,B,,,1,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,,,,CHEMBL615245,
16474,H,,,,,11134,8,Autocuration,,212,B,,,1,BAO_0000019,% inhibition against human platelet 12-lipoxygenase (12-HLO),,,,,CHEMBL615246,
167,H,,,,,11134,8,Autocuration,,213,B,,,1,BAO_0000019,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,,,,CHEMBL615247,
16474,H,,,,,11134,8,Autocuration,,214,B,,,1,BAO_0000019,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,,,,CHEMBL615248,
10091,H,,,,,11601,8,Autocuration,,215,B,,,1,BAO_0000357,Inhibitory activity towards porcine 12-lipoxygenase,,,,,CHEMBL615249,
11966,H,,,,,11601,8,Autocuration,,216,B,,,1,BAO_0000357,Tested for inhibition against porcine 12-LO,,,,,CHEMBL615250,
951,H,,,,,12052,8,Autocuration,,217,B,,,1,BAO_0000019,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,,,,CHEMBL615251,
10997,H,,,,,12052,8,Autocuration,,218,B,,,1,BAO_0000019,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,,,,CHEMBL615252,
10193,H,,,,,12052,8,Expert,,219,B,,,1,BAO_0000019,In vitro inhibition of rat platelet 12-lipoxygenase,,,,,CHEMBL828340,
10193,H,,,,,12052,8,Autocuration,,220,B,,,1,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,,CHEMBL615253,
10193,H,,,,,12052,8,Autocuration,,221,B,,,1,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,,,,CHEMBL615254,
10193,H,,,,,12052,8,Autocuration,,222,B,,,1,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,,,,CHEMBL615255,
10193,H,,,,,12052,8,Autocuration,,223,B,,,1,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,,CHEMBL615256,
10193,H,,,,,12052,8,Autocuration,,224,B,,,1,BAO_0000019,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,,,,CHEMBL615257,
11087,H,,,,,12052,8,Autocuration,,225,B,,,1,BAO_0000019,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,,,,CHEMBL615258,
15569,N,,,41M,,80007,1,Intermediate,,226,F,,,1,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,621.0,,,Homo sapiens,CHEMBL615259,9606.0
12989,N,,,41M,,80007,1,Expert,,227,F,,,1,BAO_0000219,In vitro antitumor activity against 41M cell line.,621.0,,,Homo sapiens,CHEMBL615260,9606.0
16745,N,,,41M,,80007,1,Intermediate,,228,F,,,1,BAO_0000219,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,621.0,,,Homo sapiens,CHEMBL615261,9606.0
15569,N,,,41M,,80007,1,Intermediate,,229,F,,,1,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,621.0,,,Homo sapiens,CHEMBL615262,9606.0
12989,N,,,41M,,80007,1,Expert,,230,F,,,1,BAO_0000219,In vitro antitumor activity against 41McisR cell line.,621.0,,,Homo sapiens,CHEMBL615263,9606.0
12989,N,,,41M,,80007,1,Expert,,231,F,,,1,BAO_0000219,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,621.0,,,Homo sapiens,CHEMBL838393,9606.0
16745,N,,,41M,,80007,1,Intermediate,,232,F,,,1,BAO_0000219,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,621.0,,,Homo sapiens,CHEMBL615264,9606.0
6210,D,,,,,84,9,Expert,,233,B,,,1,BAO_0000357,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,,,Homo sapiens,CHEMBL615265,9606.0
6210,D,,,,,68,9,Expert,,234,B,,,1,BAO_0000357,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,,Homo sapiens,CHEMBL615266,9606.0
6226,H,,,,,68,8,Expert,,235,B,,,1,BAO_0000357,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,,,CHEMBL615267,
17855,H,,,,,10201,8,Expert,,236,B,,,1,BAO_0000357,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,,,CHEMBL615268,
17855,H,,,,,10201,8,Expert,,237,B,,,1,BAO_0000357,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,,,,CHEMBL615269,
17855,H,,,,,10201,8,Expert,,238,B,,,1,BAO_0000357,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,,,CHEMBL615270,
10413,H,,,,,12220,8,Autocuration,,239,B,,,1,BAO_0000357,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,,,CHEMBL615271,
10413,H,,,,,11303,8,Autocuration,,240,B,,,1,BAO_0000357,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,,Escherichia coli,CHEMBL615272,562.0
10413,H,,,,,11303,8,Autocuration,,241,B,,,1,BAO_0000357,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,,,Escherichia coli,CHEMBL615103,562.0
10413,H,,,,,11303,8,Autocuration,,242,B,,,1,BAO_0000357,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,,,Escherichia coli,CHEMBL615104,562.0
10413,H,,,,,12220,8,Autocuration,,243,B,,,1,BAO_0000357,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,,,CHEMBL615105,
10413,H,,,,,12220,8,Autocuration,,244,B,,,1,BAO_0000357,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,,,,CHEMBL872866,
7587,H,,,,,11303,8,Autocuration,,245,B,,,1,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,,Sus scrofa,CHEMBL615106,9823.0
7587,H,,,,,11303,8,Autocuration,,246,B,,,1,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,,,Sus scrofa,CHEMBL615107,9823.0
7587,H,,,,,11303,8,Autocuration,,247,B,,,1,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,,,Sus scrofa,CHEMBL615108,9823.0
7587,H,,,,,11303,8,Autocuration,,248,B,,,1,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,,,Sus scrofa,CHEMBL615109,9823.0
7587,H,,,,,11303,8,Autocuration,,249,B,,,1,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,,Sus scrofa,CHEMBL615110,9823.0
7587,H,,,,,11303,8,Autocuration,,250,B,,,1,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,,Sus scrofa,CHEMBL840105,9823.0
7587,H,,,,,11303,8,Autocuration,,251,B,,,1,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,,,Sus scrofa,CHEMBL615111,9823.0
7587,H,,,,,11303,8,Autocuration,,252,B,,,1,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,,,Sus scrofa,CHEMBL615112,9823.0
7587,H,,,,,11303,8,Autocuration,,253,B,,,1,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,,,Sus scrofa,CHEMBL615113,9823.0
7587,H,,,,,11303,8,Autocuration,,254,B,,,1,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,,,Sus scrofa,CHEMBL615114,9823.0
7587,H,,,,,11303,8,Autocuration,,255,B,,,1,BAO_0000357,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,,,Sus scrofa,CHEMBL615115,9823.0
7587,H,,,,,11303,8,Autocuration,,256,B,,,1,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,,,Sus scrofa,CHEMBL615116,9823.0
7323,H,,,,,11303,8,Autocuration,,257,B,,,1,BAO_0000357,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,,,,CHEMBL615698,
7587,U,,,,,22226,0,Autocuration,,258,B,,,1,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,,,Sus scrofa,CHEMBL615699,9823.0
7587,U,,,,,22226,0,Autocuration,,259,B,,,1,BAO_0000019,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,,,Sus scrofa,CHEMBL615700,9823.0
13750,H,,,,,100249,8,Expert,,260,B,,,1,BAO_0000357,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,,,Saccharomyces cerevisiae,CHEMBL615701,4932.0
7662,U,,,,,22226,0,Autocuration,,261,B,,,1,BAO_0000019,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,,Rattus norvegicus,CHEMBL615702,10116.0
7662,U,,,,,22226,0,Autocuration,,262,B,,,1,BAO_0000019,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,,,Rattus norvegicus,CHEMBL615703,10116.0
7662,U,,,,,22226,0,Autocuration,,263,B,,,1,BAO_0000019,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,,,Rattus norvegicus,CHEMBL615704,10116.0
12211,H,,,,,104698,6,Autocuration,,264,F,,,1,BAO_0000019,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,,,CHEMBL615705,
12211,H,,,,,104698,6,Autocuration,,265,F,,,1,BAO_0000019,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,,,CHEMBL615706,
12211,D,,,,,20033,9,Intermediate,,266,F,Ileum,,1,BAO_0000221,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,,2116.0,Cavia porcellus,CHEMBL615707,10141.0
12211,H,,,,,10623,8,Expert,,267,F,,,1,BAO_0000019,Stimulatory activity of intragastric pressure was tested in the rat,,,,,CHEMBL615708,
15453,H,,,,,121,8,Autocuration,,268,B,,,1,BAO_0000357,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,,,,CHEMBL615709,
11884,U,,,,,22226,0,Autocuration,,269,F,,,1,BAO_0000218,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,,,Rattus norvegicus,CHEMBL615710,10116.0
7185,H,,,,,12688,8,Autocuration,,270,F,,,1,BAO_0000019,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,,,CHEMBL615711,
6876,D,,,,,121,9,Expert,,271,B,,,1,BAO_0000357,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,,,Homo sapiens,CHEMBL615712,9606.0
6876,D,,,,,121,9,Expert,,272,B,,,1,BAO_0000357,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,,,Homo sapiens,CHEMBL836325,9606.0
11863,H,,,,,12198,8,Autocuration,,273,F,,,1,BAO_0000019,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,,,,CHEMBL615713,
11863,H,,,,,12198,8,Autocuration,,274,B,,,1,BAO_0000357,Inhibition constant of high-affinity 5-HT uptake,,,,,CHEMBL615714,
11863,H,,,,,12198,8,Autocuration,,275,F,,,1,BAO_0000019,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,,,,CHEMBL615715,
11863,H,,,,,12198,8,Autocuration,,276,F,,,1,BAO_0000019,Maximum rate was determined for high affinity transport of 5-HT,,,,,CHEMBL615716,
4639,H,,,,,104714,4,Autocuration,,277,F,,,1,BAO_0000019,Compound was tested for agonistic activity against 5-HT uptake,,,,,CHEMBL615717,
15796,H,,,,,10577,8,Expert,,278,B,,,1,BAO_0000019,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,,,,CHEMBL881818,
15796,H,,,,,105,8,Expert,,279,B,,,1,BAO_0000357,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,,,Bos taurus,CHEMBL884540,9913.0
12801,D,,,,,104744,5,Autocuration,,280,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,,Rattus norvegicus,CHEMBL615718,10116.0
12801,H,,,,,104744,4,Autocuration,,281,B,,,1,BAO_0000224,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,,,,CHEMBL615719,
12120,H,,,,,104744,4,Autocuration,Membranes,282,B,,,1,BAO_0000249,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,,,,CHEMBL615720,
12120,H,,,,,104744,4,Autocuration,Membranes,283,B,,,1,BAO_0000249,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,,,,CHEMBL615721,
11963,H,,,,,104744,4,Autocuration,,284,B,,,1,BAO_0000019,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,CHEMBL615722,
11701,H,,,,,51,8,Autocuration,,285,F,,,1,BAO_0000019,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,,,,CHEMBL615723,
9995,H,,,,,51,8,Autocuration,,286,B,Hippocampus,,1,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,10000000.0,,CHEMBL615724,
9995,H,,,,,51,8,Autocuration,,287,B,Hippocampus,,1,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,10000000.0,,CHEMBL615725,
9995,H,,,,,51,8,Autocuration,,288,B,Hippocampus,,1,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,10000000.0,,CHEMBL615726,
16394,H,,,,In vivo,10576,8,Autocuration,,289,F,,,1,BAO_0000218,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,,,,CHEMBL615727,
11574,D,,,,,105570,9,Intermediate,,290,F,,,1,BAO_0000019,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,,,Cavia porcellus,CHEMBL615728,10141.0
15779,H,,,CHO,,279,8,Autocuration,,291,B,,,1,BAO_0000219,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,449.0,,,,CHEMBL857971,
15363,H,,,,,107,8,Autocuration,,292,B,,,1,BAO_0000357,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,,,,CHEMBL615729,
15363,D,,,,,12687,9,Expert,,293,F,,,1,BAO_0000019,Efficacy against 5-hydroxytryptamine 2A receptor,,,,Rattus norvegicus,CHEMBL615730,10116.0
15329,H,,,,,12687,8,Expert,,294,F,,,1,BAO_0000019,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,,,,CHEMBL615731,
15329,H,,,,,12687,8,Expert,,295,F,,,1,BAO_0000019,Relative potency towards 5-HT2A receptor of rat tail artery,,,,,CHEMBL615732,
15329,H,,,,,12687,8,Expert,,296,F,,,1,BAO_0000019,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,,,CHEMBL615733,
15329,H,,,,,12687,8,Expert,,297,F,,,1,BAO_0000019,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,,,,CHEMBL615734,
15329,H,,,,,12687,8,Autocuration,,298,F,,,1,BAO_0000019,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,,,,CHEMBL615735,
15329,H,,,,,12687,8,Expert,,299,F,,,1,BAO_0000019,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,,,CHEMBL615736,
273,D,,,,,20033,9,Intermediate,,300,F,Ileum,,1,BAO_0000221,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,,2116.0,Cavia porcellus,CHEMBL615737,10141.0
273,D,,,,,20033,9,Intermediate,,301,F,Ileum,,1,BAO_0000221,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,,2116.0,Cavia porcellus,CHEMBL615738,10141.0
273,D,,,,,20033,9,Intermediate,,302,F,Ileum,,1,BAO_0000221,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,,2116.0,Cavia porcellus,CHEMBL615739,10141.0
12092,H,,,,,10623,8,Autocuration,,303,B,,,1,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,,,,CHEMBL615278,
1317,D,,,,,10623,9,Expert,,304,F,,,1,BAO_0000019,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,,Rattus norvegicus,CHEMBL615279,10116.0
12409,H,,,,,168,8,Expert,,305,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 4 receptor,,,,,CHEMBL615280,
11126,U,,,,,22226,0,Autocuration,,306,B,,,1,BAO_0000019,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,,,Gallus gallus,CHEMBL615281,9031.0
11126,U,,,,,22226,0,Autocuration,,307,F,,,1,BAO_0000019,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,,,Homo sapiens,CHEMBL615282,9606.0
11126,U,,,,,22226,0,Autocuration,,308,F,,,1,BAO_0000019,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,,Homo sapiens,CHEMBL615283,9606.0
11126,N,,,HL-60,,80156,1,Autocuration,,309,B,,,1,BAO_0000219,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,649.0,,,Homo sapiens,CHEMBL615284,9606.0
11126,U,,,,,22226,0,Autocuration,,310,B,,,1,BAO_0000019,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,,,Homo sapiens,CHEMBL615285,9606.0
11126,U,,,,,22226,0,Autocuration,,311,B,,,1,BAO_0000019,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,,,Homo sapiens,CHEMBL615286,9606.0
17807,D,,,Oocytes,,104703,7,Autocuration,,312,B,,,1,BAO_0000219,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,,,Homo sapiens,CHEMBL615287,9606.0
16575,S,,,,,100256,2,Intermediate,,313,F,,,1,BAO_0000220,Chymotryptic inhibitory activity against 26S proteasome,,,,,CHEMBL615288,
15407,S,,,,,100256,2,Intermediate,,314,B,,,1,BAO_0000220,Inhibitory activity against 26S proteasome degradation of IkB,,,,,CHEMBL615289,
10797,N,,,A2780,,81034,1,Intermediate,,315,F,,,1,BAO_0000219,In vitro inhibition of 2780/DOX ovarian cancer cell line,478.0,,,Homo sapiens,CHEMBL615290,9606.0
10797,N,,,A2780,,81034,1,Intermediate,,316,F,,,1,BAO_0000219,In vitro inhibition of 2780/S ovarian cancer cell line,478.0,,,Homo sapiens,CHEMBL884522,9606.0
3469,U,,,,,22226,0,Autocuration,,317,F,,,1,BAO_0000019,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,,,Homo sapiens,CHEMBL615291,9606.0
16037,M,,,,,22222,3,Intermediate,,318,B,,,1,BAO_0000225,Association constant for binding to AATT 28-mer AATT hairpin,,,,,CHEMBL615292,
16037,M,,,,,22222,3,Intermediate,,319,B,,,1,BAO_0000225,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,,,,CHEMBL615293,
16037,M,,,,,22222,3,Intermediate,,320,B,,,1,BAO_0000225,Reaction Rate Parameter for 28-mer AATT hairpin,,,,,CHEMBL615294,
16037,M,,,,,22222,3,Intermediate,,321,B,,,1,BAO_0000225,Reaction Rate Parameter for 28-mer AATT hairpin,,,,,CHEMBL615295,
16524,U,,,,,22226,0,Autocuration,,322,F,,,1,BAO_0000019,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,,,Homo sapiens,CHEMBL825021,9606.0
16524,U,,,,,22226,0,Autocuration,,323,F,,,1,BAO_0000019,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,,,Homo sapiens,CHEMBL615296,9606.0
16524,U,,,,,22226,0,Autocuration,,324,F,,,1,BAO_0000019,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,,,Homo sapiens,CHEMBL615297,9606.0
16758,U,,,,,22226,0,Autocuration,,325,F,,,1,BAO_0000019,Cytotoxicity against cell line 2SC/20 determined by MTT test,,,,Cricetulus griseus,CHEMBL615298,10029.0
16758,U,,,,,22226,0,Autocuration,,326,F,,,1,BAO_0000019,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,,,Cricetulus griseus,CHEMBL615299,10029.0
16758,U,,,,,22226,0,Autocuration,,327,F,,,1,BAO_0000019,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,,,Cricetulus griseus,CHEMBL615300,10029.0
14360,H,,,,,241,8,Autocuration,,328,B,,,1,BAO_0000357,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,,,,CHEMBL615301,
14360,D,,,,,241,9,Expert,,329,B,,,1,BAO_0000357,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,,,Homo sapiens,CHEMBL615302,9606.0
9964,U,,,,,22226,0,Autocuration,,330,B,,,1,BAO_0000019,Selectivity ratio of ID50 in liver and heart,,,,Rattus norvegicus,CHEMBL615303,10116.0
9964,H,,,,,12132,8,Autocuration,,331,B,,,1,BAO_0000019,"Selectivity, ratio of relative ID50 in liver and heart",,,,,CHEMBL615304,
9964,H,,,,,12132,8,Autocuration,,332,B,,,1,BAO_0000019,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,,,,CHEMBL615305,
9964,H,,,,,12132,8,Autocuration,,333,B,,,1,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,CHEMBL615306,
9964,H,,,,,12132,8,Autocuration,,334,B,,,1,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,CHEMBL615307,
9964,H,,,,In vivo,12132,8,Autocuration,,335,B,,,1,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,CHEMBL615308,
9964,H,,,,In vivo,12132,8,Autocuration,,336,F,,,1,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,CHEMBL615309,
9964,U,,,,,22226,0,Autocuration,,337,B,,,1,BAO_0000019,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,,,,CHEMBL615310,
9964,H,,,,,12132,8,Autocuration,,338,B,,,1,BAO_0000019,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,,,,CHEMBL615311,
9964,U,,,,,22226,0,Autocuration,,339,B,,,1,BAO_0000019,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,,,Homo sapiens,CHEMBL615312,9606.0
9964,H,,,,,12132,8,Autocuration,,340,B,,,1,BAO_0000019,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,,,CHEMBL615313,
9964,H,,,,,12132,8,Autocuration,,341,F,,,1,BAO_0000019,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,,,CHEMBL615314,
9964,H,,,,,12132,8,Autocuration,,342,B,,,1,BAO_0000019,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,,,,CHEMBL615315,
9964,U,,,,,22226,0,Autocuration,,343,B,,,1,BAO_0000218,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,,,Rattus norvegicus,CHEMBL615316,10116.0
9964,H,,,,In vivo,12132,8,Autocuration,,344,B,,,1,BAO_0000218,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,,,,CHEMBL615317,
9964,H,,,,,12132,8,Autocuration,,345,B,,,1,BAO_0000218,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,CHEMBL615318,
9964,U,,,,,22226,0,Autocuration,,346,B,,,1,BAO_0000218,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,,,Rattus norvegicus,CHEMBL615319,10116.0
9964,H,,,,,12132,8,Autocuration,,347,B,,,1,BAO_0000019,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,,,CHEMBL615320,
9964,H,,,,,12132,8,Autocuration,,348,F,,,1,BAO_0000019,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,,,CHEMBL615321,
3796,U,,,,,22226,0,Autocuration,,349,B,,,1,BAO_0000019,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,,,Rattus norvegicus,CHEMBL615322,10116.0
4251,H,,,,,19690,8,Autocuration,,350,B,,,1,BAO_0000357,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,,Escherichia coli,CHEMBL615323,562.0
4251,H,,,,,19690,8,Autocuration,,351,B,,,1,BAO_0000357,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,,,Escherichia coli,CHEMBL615407,562.0
4251,H,,,,,19690,8,Autocuration,,352,B,,,1,BAO_0000357,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,,Escherichia coli,CHEMBL857267,562.0
4251,H,,,,,19690,8,Autocuration,,353,B,,,1,BAO_0000357,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,,,Escherichia coli,CHEMBL615408,562.0
166,H,,,,,19690,8,Autocuration,,354,B,,,1,BAO_0000357,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,,,,CHEMBL615409,
17861,H,,,,,19690,8,Autocuration,,355,B,,,1,BAO_0000357,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,,,,CHEMBL615410,
166,H,,,,,19690,8,Autocuration,,356,B,,,1,BAO_0000357,Inhibition constant against 3-dehydroquinate synthase,,,,,CHEMBL615411,
166,H,,,,,19690,8,Autocuration,,357,B,,,1,BAO_0000357,Association rate constant against 3-dehydroquinate synthase,,,,,CHEMBL615412,
166,H,,,,,19690,8,Autocuration,,358,B,,,1,BAO_0000357,Rate constant against 3-dehydroquinate synthase,,,,,CHEMBL615413,
3548,U,,,,,22226,0,Autocuration,,359,B,,,1,BAO_0000019,Inhibitory activity against fuc-TVII,,,,,CHEMBL615414,
9877,D,,,,,12236,9,Autocuration,Microsomes,360,B,Liver,,1,BAO_0000251,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,2107.0,Rattus norvegicus,CHEMBL615415,10116.0
9877,D,,,,,12236,9,Autocuration,Microsomes,361,B,Liver,,1,BAO_0000251,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,2107.0,Rattus norvegicus,CHEMBL615416,10116.0
9877,D,,,,,12236,9,Autocuration,Microsomes,362,B,Liver,,1,BAO_0000251,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,2107.0,Rattus norvegicus,CHEMBL615417,10116.0
9877,D,,,,,12236,9,Autocuration,Microsomes,363,B,Liver,,1,BAO_0000251,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,2107.0,Rattus norvegicus,CHEMBL615418,10116.0
9877,D,,,,,12236,9,Autocuration,Microsomes,364,B,Liver,,1,BAO_0000251,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,,2107.0,Rattus norvegicus,CHEMBL615419,10116.0
9877,D,,,,,12236,9,Autocuration,Microsomes,365,B,Liver,,1,BAO_0000251,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,,2107.0,Rattus norvegicus,CHEMBL615420,10116.0
9877,D,,,,,12236,9,Autocuration,Microsomes,366,B,Liver,,1,BAO_0000251,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,,2107.0,Rattus norvegicus,CHEMBL615421,10116.0
9877,D,,,,,12236,9,Autocuration,Microsomes,367,B,Liver,,1,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,,2107.0,Rattus norvegicus,CHEMBL615422,10116.0
9877,D,,,,,12236,9,Autocuration,Microsomes,368,B,Liver,,1,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,,2107.0,Rattus norvegicus,CHEMBL615423,10116.0
9877,D,,,,,12236,9,Autocuration,Microsomes,369,B,Liver,,1,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,,2107.0,Rattus norvegicus,CHEMBL872868,10116.0
9877,D,,,,,12236,9,Autocuration,Microsomes,370,B,Liver,,1,BAO_0000251,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,,2107.0,Rattus norvegicus,CHEMBL615424,10116.0
3003,H,,,,,104832,4,Autocuration,,371,B,,,1,BAO_0000224,Inhibitory activity against 3-phosphoglycerate kinase.,,,,,CHEMBL825022,
3003,H,,,,,104832,4,Autocuration,,372,B,,,1,BAO_0000224,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,,,,CHEMBL615425,
3003,H,,,,,104832,4,Autocuration,,373,B,,,1,BAO_0000224,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,,,,CHEMBL615426,
17185,D,,,,,10612,9,Expert,,374,B,,,1,BAO_0000357,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,,,Homo sapiens,CHEMBL615427,9606.0
6072,N,,,3677 melanoma cell line,,80616,1,Intermediate,,375,F,,,1,BAO_0000219,Cytotoxicity on 3677 melanoma cells,844.0,,,Homo sapiens,CHEMBL615428,9606.0
6072,N,,,3677 melanoma cell line,,80616,1,Intermediate,,376,F,,,1,BAO_0000219,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,844.0,,,Homo sapiens,CHEMBL615429,9606.0
5018,N,,,MC-38,,80617,1,Intermediate,,377,F,,,1,BAO_0000219,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,700.0,,,Mus musculus,CHEMBL615430,10090.0
2852,U,,,,,22226,0,Intermediate,,378,F,,,1,BAO_0000019,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,,,Homo sapiens,CHEMBL615431,9606.0
8663,U,,,B16,,22226,0,Autocuration,,379,F,,,1,BAO_0000218,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,798.0,,,,CHEMBL615432,
8663,U,,,B16,,22226,0,Autocuration,,380,F,,,1,BAO_0000218,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,798.0,,,,CHEMBL615433,
3245,D,,,,,12464,9,Expert,,381,F,,,1,BAO_0000019,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,,,Human rhinovirus 14,CHEMBL615434,12131.0
3245,N,,,,,50085,1,Intermediate,,382,F,,,1,BAO_0000218,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,,,Human rhinovirus sp.,CHEMBL615435,169066.0
3877,N,,,,,50679,1,Intermediate,,383,F,,,1,BAO_0000218,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,,,human rhinovirus type 14,CHEMBL615436,169066.0
3877,N,,,,,50679,1,Intermediate,,384,F,,,1,BAO_0000218,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,,,human rhinovirus type 14,CHEMBL615437,169066.0
5861,D,,,,,12464,9,Expert,,385,F,,,1,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,,Human rhinovirus 14,CHEMBL615438,12131.0
5861,D,,,,,12464,9,Expert,,386,F,,,1,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,,Human rhinovirus 14,CHEMBL615439,12131.0
5861,D,,,,,12464,9,Expert,,387,F,,,1,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,,,Human rhinovirus 14,CHEMBL615440,12131.0
5861,D,,,,,12464,9,Expert,,388,F,,,1,BAO_0000019,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,,,Human rhinovirus 14,CHEMBL615441,12131.0
13748,N,,,,,50665,1,Intermediate,,389,F,,,1,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,,,Enterovirus,CHEMBL615641,12059.0
13748,N,,,,,50665,1,Intermediate,,390,F,,,1,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,,,Enterovirus,CHEMBL872065,12059.0
13748,N,,,,,50665,1,Intermediate,,391,F,,,1,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,,,Enterovirus,CHEMBL825023,12059.0
13748,N,,,,,50665,1,Intermediate,,392,F,,,1,BAO_0000218,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,,,Enterovirus,CHEMBL615642,12059.0
13748,H,,,,,12464,8,Expert,,393,B,,,1,BAO_0000357,Inhibition of human rhinovirus 3C protease,,,,Human rhinovirus B,CHEMBL615643,147712.0
17699,U,,,,,22226,0,Autocuration,,394,B,,,1,BAO_0000019,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,,,Homo sapiens,CHEMBL615644,9606.0
7145,N,,,3EM 37,,80619,1,Intermediate,,395,F,,,1,BAO_0000218,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),833.0,,,Mus musculus,CHEMBL615645,10090.0
7145,N,,,3EM 37,,80619,1,Intermediate,,396,F,,,1,BAO_0000218,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),833.0,,,Mus musculus,CHEMBL615646,10090.0
7145,N,,,3EM 37,,80619,1,Intermediate,,397,F,,,1,BAO_0000218,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),833.0,,,Mus musculus,CHEMBL615647,10090.0
7145,N,,,3EM 37,,80619,1,Intermediate,,398,F,,,1,BAO_0000218,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),833.0,,,Mus musculus,CHEMBL615648,10090.0
7145,N,,,3EM 37,,80619,1,Intermediate,,399,F,,,1,BAO_0000218,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,833.0,,,Mus musculus,CHEMBL615649,10090.0
7145,N,,,3EM 37,,80619,1,Intermediate,,400,F,,,1,BAO_0000218,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,833.0,,,Mus musculus,CHEMBL615650,10090.0
5325,N,,,3LL cell line,,80620,1,Intermediate,,401,F,,,1,BAO_0000218,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,847.0,,,Mus musculus,CHEMBL615651,10090.0
5325,N,,,3LL cell line,,80620,1,Intermediate,,402,F,,,1,BAO_0000218,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,847.0,,,Mus musculus,CHEMBL615652,10090.0
5325,N,,,3LL cell line,,80620,1,Expert,,403,F,,,1,BAO_0000218,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,847.0,,,Mus musculus,CHEMBL615653,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,404,F,,,1,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,847.0,,,Mus musculus,CHEMBL615654,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,405,F,,,1,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,847.0,,,Mus musculus,CHEMBL615655,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,406,F,,,1,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,847.0,,,Mus musculus,CHEMBL825024,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,407,F,,,1,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,847.0,,,Mus musculus,CHEMBL615656,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,408,F,,,1,BAO_0000219,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,847.0,,,Mus musculus,CHEMBL615657,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,409,F,,,1,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,847.0,,,Mus musculus,CHEMBL615658,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,410,F,,,1,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,847.0,,,Mus musculus,CHEMBL615659,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,411,F,,,1,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,847.0,,,Mus musculus,CHEMBL615660,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,412,F,,,1,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,847.0,,,Mus musculus,CHEMBL615661,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,413,F,,,1,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,847.0,,,Mus musculus,CHEMBL615662,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,414,F,,,1,BAO_0000219,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,847.0,,,Mus musculus,CHEMBL615663,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,415,F,,,1,BAO_0000219,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,847.0,,,Mus musculus,CHEMBL615664,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,416,F,,,1,BAO_0000219,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,847.0,,,Mus musculus,CHEMBL615665,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,417,F,,,1,BAO_0000219,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,847.0,,,Mus musculus,CHEMBL615666,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,418,F,,,1,BAO_0000219,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,847.0,,,Mus musculus,CHEMBL615667,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,419,F,,,1,BAO_0000219,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,847.0,,,Mus musculus,CHEMBL615668,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,420,F,,,1,BAO_0000219,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,847.0,,,Mus musculus,CHEMBL615669,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,421,F,,,1,BAO_0000219,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,847.0,,,Mus musculus,CHEMBL615670,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,422,F,,,1,BAO_0000219,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,847.0,,,Mus musculus,CHEMBL836739,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,423,F,,,1,BAO_0000219,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,847.0,,,Mus musculus,CHEMBL615671,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,424,F,,,1,BAO_0000219,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,847.0,,,Mus musculus,CHEMBL615672,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,425,F,,,1,BAO_0000219,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,847.0,,,Mus musculus,CHEMBL615791,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,426,F,,,1,BAO_0000219,spermine levels in 3LL cells after the treatment of 1 uM of Compound,847.0,,,Mus musculus,CHEMBL615792,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,427,F,,,1,BAO_0000219,spermine levels in 3LL cells after the treatment of 10 uM of Compound,847.0,,,Mus musculus,CHEMBL615793,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,428,F,,,1,BAO_0000219,spermine levels in 3LL cells after the treatment of 250 uM of Compound,847.0,,,Mus musculus,CHEMBL615794,10090.0
16169,N,,,3LL cell line,,80620,1,Intermediate,,429,F,,,1,BAO_0000219,spermine levels in 3LL cells after the treatment of 50 uM of Compound,847.0,,,Mus musculus,CHEMBL615795,10090.0
15547,N,,,3LLD122,,80621,1,Intermediate,,430,F,,,1,BAO_0000219,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,971.0,,,Homo sapiens,CHEMBL615590,9606.0
8663,U,,,,,22226,0,Autocuration,,431,F,,,1,BAO_0000218,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,,,,CHEMBL615591,
8663,U,,,,,22226,0,Autocuration,,432,F,,,1,BAO_0000218,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,,,,CHEMBL615592,
8663,U,,,,,22226,0,Autocuration,,433,F,,,1,BAO_0000218,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,,,,CHEMBL615593,
8663,U,,,,,22226,0,Autocuration,,434,F,,,1,BAO_0000218,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,,,,CHEMBL615594,
4504,N,,,NIH3T3,,80951,1,Intermediate,,435,F,,,1,BAO_0000219,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,723.0,,,Mus musculus,CHEMBL615595,10090.0
4504,N,,,NIH3T3,,80951,1,Intermediate,,436,F,,,1,BAO_0000219,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,723.0,,,Mus musculus,CHEMBL615596,10090.0
12695,H,,,NIH3T3,,11169,8,Expert,,437,F,,,1,BAO_0000219,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,723.0,,,,CHEMBL615597,
12695,N,,,NIH3T3,,80951,1,Intermediate,,438,F,,,1,BAO_0000219,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,723.0,,,Mus musculus,CHEMBL615598,10090.0
12695,N,,,NIH3T3,,80951,1,Intermediate,,439,F,,,1,BAO_0000219,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,723.0,,,Mus musculus,CHEMBL615599,10090.0
17642,N,,,NIH3T3,,80951,1,Expert,,440,F,,,1,BAO_0000219,Effective dose against murine 3T3 fibroblasts cells,723.0,,,Mus musculus,CHEMBL615600,10090.0
17642,N,,,NIH3T3,,80951,1,Expert,,441,F,,,1,BAO_0000219,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,723.0,,,Mus musculus,CHEMBL615601,10090.0
12340,N,,,NIH3T3,,80951,1,Expert,,442,F,,,1,BAO_0000219,Cytotoxic effect on 3T3 cells,723.0,,,Mus musculus,CHEMBL615602,10090.0
12340,N,,,NIH3T3,,80951,1,Expert,,443,F,,,1,BAO_0000219,Cytotoxic effect on 3T3 cells,723.0,,,Mus musculus,CHEMBL615603,10090.0
12716,N,,,NIH3T3,,80951,1,Intermediate,,444,F,,,1,BAO_0000219,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,723.0,,,Mus musculus,CHEMBL615604,10090.0
6277,N,,,NIH3T3,,80951,1,Intermediate,,445,F,,,1,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,723.0,,,Mus musculus,CHEMBL615605,10090.0
6277,N,,,NIH3T3,,80951,1,Intermediate,,446,F,,,1,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,723.0,,,Mus musculus,CHEMBL615606,10090.0
6277,N,,,NIH3T3,,80951,1,Expert,,447,F,,,1,BAO_0000219,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,723.0,,,Mus musculus,CHEMBL884526,10090.0
6277,N,,,NIH3T3,,80951,1,Expert,,448,F,,,1,BAO_0000219,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,723.0,,,Mus musculus,CHEMBL615607,10090.0
6277,N,,,NIH3T3,,80951,1,Intermediate,,449,F,,,1,BAO_0000219,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,723.0,,,Mus musculus,CHEMBL615608,10090.0
6277,N,,,NIH3T3,,80951,1,Expert,,450,F,,,1,BAO_0000219,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,723.0,,,Mus musculus,CHEMBL615609,10090.0
6277,N,,,NIH3T3,,80951,1,Expert,,451,F,,,1,BAO_0000219,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,723.0,,,Mus musculus,CHEMBL615682,10090.0
6277,N,,,NIH3T3,,80951,1,Intermediate,,452,F,,,1,BAO_0000219,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,723.0,,,Mus musculus,CHEMBL615683,10090.0
17780,N,,,NIH3T3,,80951,1,Expert,,453,F,,,1,BAO_0000218,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,723.0,,,Mus musculus,CHEMBL615684,10090.0
12751,D,,,,,104860,7,Autocuration,,454,F,,,1,BAO_0000219,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,,,Mus musculus,CHEMBL615685,10090.0
12380,N,,,NIH3T3,,80951,1,Expert,,455,F,,,1,BAO_0000219,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,723.0,,,Mus musculus,CHEMBL615686,10090.0
14892,N,,,NIH3T3,,80951,1,Intermediate,,456,F,,,1,BAO_0000219,Inhibitory activity against 3T3 cell line,723.0,,,Mus musculus,CHEMBL615687,10090.0
12695,N,,,NIH3T3,,80951,1,Intermediate,,457,F,,,1,BAO_0000219,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,723.0,,,Mus musculus,CHEMBL884523,10090.0
12695,H,,,,,11169,8,Expert,,458,F,,,1,BAO_0000019,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,,,,CHEMBL615688,
12695,N,,,NIH3T3,,80951,1,Intermediate,,459,F,,,1,BAO_0000219,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,723.0,,,Mus musculus,CHEMBL615689,10090.0
12695,N,,,NIH3T3,,80951,1,Intermediate,,460,F,,,1,BAO_0000219,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,723.0,,,Mus musculus,CHEMBL615690,10090.0
12695,H,,,,,11169,8,Expert,,461,F,,,1,BAO_0000019,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,,,,CHEMBL615691,
12695,H,,,,,11169,8,Expert,,462,F,,,1,BAO_0000019,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,,,,CHEMBL615692,
6277,N,,,NIH3T3,,80951,1,Intermediate,,463,F,,,1,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,723.0,,,Mus musculus,CHEMBL615693,10090.0
6277,N,,,NIH3T3,,80951,1,Expert,,464,F,,,1,BAO_0000219,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,723.0,,,Mus musculus,CHEMBL615324,10090.0
4959,D,,,NIH3T3,,9,9,Expert,,465,F,,,1,BAO_0000219,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,723.0,,,Homo sapiens,CHEMBL615325,9606.0
4959,D,,,NIH3T3,,9,9,Expert,,466,F,,,1,BAO_0000219,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),723.0,,,Homo sapiens,CHEMBL615490,9606.0
4959,D,,,NIH3T3,,188,9,Expert,,467,F,,,1,BAO_0000219,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,723.0,,,Homo sapiens,CHEMBL615491,9606.0
4959,D,,,NIH3T3,,188,9,Expert,,468,F,,,1,BAO_0000219,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),723.0,,,Homo sapiens,CHEMBL615492,9606.0
12082,N,,,NIH3T3,,80951,1,Intermediate,,469,F,,,1,BAO_0000219,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,723.0,,,Mus musculus,CHEMBL615493,10090.0
12082,N,,,NIH3T3,,80951,1,Intermediate,,470,F,,,1,BAO_0000219,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,723.0,,,Mus musculus,CHEMBL615494,10090.0
12082,N,,,NIH3T3,,80951,1,Intermediate,,471,F,,,1,BAO_0000219,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,723.0,,,Mus musculus,CHEMBL615495,10090.0
12082,N,,,NIH3T3,,80951,1,Intermediate,,472,F,,,1,BAO_0000219,Inhibitory concentration was calculated on 3T3 cells by using growth assay,723.0,,,Mus musculus,CHEMBL615496,10090.0
2643,N,,,NIH3T3,,80951,1,Intermediate,,473,F,,,1,BAO_0000219,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,723.0,,,Mus musculus,CHEMBL615497,10090.0
11926,N,,,NIH3T3,,80951,1,Expert,,474,F,,,1,BAO_0000219,Inhibition of Swiss 3T3 mouse fibroblast proliferation,723.0,,,Mus musculus,CHEMBL615498,10090.0
15204,N,,,NIH3T3,,80951,1,Intermediate,,475,A,,,1,BAO_0000219,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,723.0,,,Mus musculus,CHEMBL615499,10090.0
15992,N,,,NIH3T3,,80951,1,Expert,,476,F,,,1,BAO_0000219,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,723.0,,,Mus musculus,CHEMBL835522,10090.0
16279,N,,,NIH3T3,,80951,1,Intermediate,,477,F,,,1,BAO_0000219,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,723.0,,,Mus musculus,CHEMBL615500,10090.0
16279,N,,,NIH3T3,,80951,1,Intermediate,,478,F,,,1,BAO_0000219,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),723.0,,,Mus musculus,CHEMBL615501,10090.0
16279,N,,,NIH3T3,,80951,1,Intermediate,,479,F,,,1,BAO_0000219,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),723.0,,,Mus musculus,CHEMBL615502,10090.0
16279,N,,,NIH3T3,,80951,1,Intermediate,,480,F,,,1,BAO_0000219,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),723.0,,,Mus musculus,CHEMBL615503,10090.0
16279,N,,,NIH3T3,,80951,1,Intermediate,,481,F,,,1,BAO_0000219,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),723.0,,,Mus musculus,CHEMBL615504,10090.0
16279,N,,,NIH3T3,,80951,1,Intermediate,,482,F,,,1,BAO_0000219,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),723.0,,,Mus musculus,CHEMBL615505,10090.0
12831,N,,,NIH3T3,,80951,1,Expert,,483,F,,,1,BAO_0000219,Inhibition of swiss 3T3 mouse fibroblast proliferation,723.0,,,Mus musculus,CHEMBL615506,10090.0
13497,N,,,NIH3T3,,80951,1,Intermediate,,484,F,,,1,BAO_0000219,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,723.0,,,Mus musculus,CHEMBL615507,10090.0
13715,N,,,3T3-L1,,80006,1,Intermediate,,485,F,,,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,620.0,,,,CHEMBL615508,
13618,N,,,3T3-L1,,80006,1,Intermediate,,486,F,,,1,BAO_0000219,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,620.0,,,Mus musculus,CHEMBL615509,10090.0
11902,N,,,3T3-L1,,80006,1,Intermediate,,487,F,,,1,BAO_0000219,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,620.0,,,Mus musculus,CHEMBL615510,10090.0
11902,N,,,3T3-L1,,80006,1,Intermediate,,488,F,,,1,BAO_0000219,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,620.0,,,Mus musculus,CHEMBL615511,10090.0
11902,N,,,3T3-L1,,80006,1,Intermediate,,489,F,,,1,BAO_0000219,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,620.0,,,Mus musculus,CHEMBL615512,10090.0
14840,N,,,3T3-L1,,80006,1,Intermediate,,490,F,,,1,BAO_0000218,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",620.0,,,Mus musculus,CHEMBL615513,10090.0
14840,N,,,3T3-L1,,80006,1,Intermediate,,491,F,,,1,BAO_0000218,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",620.0,,,Mus musculus,CHEMBL615514,10090.0
13715,N,,,3T3-L1,,80006,1,Intermediate,,492,F,,,1,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,620.0,,,,CHEMBL615515,
13715,N,,,3T3-L1,,80006,1,Intermediate,,493,F,,,1,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,620.0,,,,CHEMBL615516,
13715,N,,,3T3-L1,,80006,1,Intermediate,,494,F,,,1,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,620.0,,,,CHEMBL615517,
13715,N,,,3T3-L1,,80006,1,Intermediate,,495,F,,,1,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,620.0,,,,CHEMBL615518,
13715,N,,,3T3-L1,,80006,1,Intermediate,,496,F,,,1,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,620.0,,,,CHEMBL615519,
13715,N,,,3T3-L1,,80006,1,Intermediate,,497,F,,,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,620.0,,,,CHEMBL615520,
13715,N,,,3T3-L1,,80006,1,Intermediate,,498,F,,,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,620.0,,,,CHEMBL615521,
13715,N,,,3T3-L1,,80006,1,Intermediate,,499,F,,,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,620.0,,,,CHEMBL615522,
13715,N,,,3T3-L1,,80006,1,Intermediate,,500,F,,,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,620.0,,,,CHEMBL615523,
13715,N,,,3T3-L1,,80006,1,Expert,,501,F,,,1,BAO_0000218,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,620.0,,,,CHEMBL615524,
13715,N,,,3T3-L1,,80006,1,Expert,,502,F,,,1,BAO_0000218,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,620.0,,,,CHEMBL615525,
13715,N,,,3T3-L1,,80006,1,Intermediate,,503,F,,,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,620.0,,,,CHEMBL615526,
13715,N,,,3T3-L1,,80006,1,Intermediate,,504,F,,,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,620.0,,,,CHEMBL615527,
13715,N,,,3T3-L1,,80006,1,Intermediate,,505,F,,,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,620.0,,,,CHEMBL615528,
13715,N,,,3T3-L1,,80006,1,Expert,,506,F,,,1,BAO_0000218,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,620.0,,,,CHEMBL615529,
13715,N,,,3T3-L1,,80006,1,Expert,,507,F,,,1,BAO_0000218,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,620.0,,,,CHEMBL615530,
13715,N,,,3T3-L1,,80006,1,Expert,,508,F,,,1,BAO_0000218,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,620.0,,,,CHEMBL615531,
13715,N,,,3T3-L1,,80006,1,Intermediate,,509,F,,,1,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,620.0,,,,CHEMBL615532,
13715,N,,,3T3-L1,,80006,1,Intermediate,,510,F,,,1,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,620.0,,,,CHEMBL615533,
13715,N,,,3T3-L1,,80006,1,Intermediate,,511,F,,,1,BAO_0000219,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,620.0,,,,CHEMBL615534,
13715,N,,,3T3-L1,,80006,1,Intermediate,,512,F,,,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,620.0,,,,CHEMBL615535,
13715,N,,,3T3-L1,,80006,1,Intermediate,,513,F,,,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,620.0,,,,CHEMBL615536,
13715,N,,,3T3-L1,,80006,1,Intermediate,,514,F,,,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,620.0,,,,CHEMBL615537,
13715,N,,,3T3-L1,,80006,1,Intermediate,,515,F,,,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,620.0,,,,CHEMBL615538,
13715,N,,,3T3-L1,,80006,1,Intermediate,,516,F,,,1,BAO_0000218,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,620.0,,,,CHEMBL836166,
6411,H,,,3T3-L1,,11214,8,Expert,,517,F,,,1,BAO_0000219,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,620.0,,,,CHEMBL615539,
6411,N,,,3T3-L1,,80006,1,Intermediate,,518,F,,,1,BAO_0000219,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,620.0,,,Mus musculus,CHEMBL615540,10090.0
6411,H,,,3T3-L1,,11214,8,Expert,,519,F,,,1,BAO_0000219,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,620.0,,,,CHEMBL615541,
3966,N,,,3T3-L1,,80006,1,Expert,,520,F,,,1,BAO_0000219,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,620.0,,,Mus musculus,CHEMBL615542,10090.0
3966,N,,,3T3-L1,,80006,1,Intermediate,,521,F,,,1,BAO_0000219,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,620.0,,,Mus musculus,CHEMBL615543,10090.0
15556,N,,,3T3-L1,,80006,1,Expert,,522,F,,,1,BAO_0000219,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,620.0,,,Mus musculus,CHEMBL615544,10090.0
5845,N,,,3T3-L1,,80006,1,Expert,,523,F,,,1,BAO_0000219,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,620.0,,,Mus musculus,CHEMBL615545,10090.0
14422,N,,,3T3-L1,,80006,1,Expert,,524,F,,,1,BAO_0000219,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,620.0,,,Mus musculus,CHEMBL615546,10090.0
5845,N,,,3T3-L1,,80006,1,Expert,,525,F,,,1,BAO_0000219,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,620.0,,,Mus musculus,CHEMBL615547,10090.0
14508,N,,,3T3-L1,,80006,1,Expert,,526,F,,,1,BAO_0000219,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,620.0,,,Mus musculus,CHEMBL615548,10090.0
14508,N,,,3T3-L1,,80006,1,Expert,,527,F,,,1,BAO_0000219,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,620.0,,,Mus musculus,CHEMBL615549,10090.0
14508,N,,,3T3-L1,,80006,1,Expert,,528,F,,,1,BAO_0000219,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,620.0,,,Mus musculus,CHEMBL615550,10090.0
6349,N,,,3Y1 cell line,,80622,1,Intermediate,,529,F,,,1,BAO_0000219,Inhibitory activity against rat fibroblast (3Y1) cell line,1118.0,,,Rattus norvegicus,CHEMBL615551,10116.0
15899,N,,,3Y1 cell line,,80622,1,Expert,,530,F,,,1,BAO_0000219,Mean concentration causing inhibition of cell growth in 3Y1 cells.,1118.0,,,Rattus norvegicus,CHEMBL615552,10116.0
15899,N,,,3Y1 cell line,,80622,1,Expert,,531,F,,,1,BAO_0000219,Cytotoxicity in 3Y1 cells.,1118.0,,,Rattus norvegicus,CHEMBL615553,10116.0
15899,N,,,3Y1 cell line,,80622,1,Expert,,532,F,,,1,BAO_0000219,Cytostatic effect in 3Y1 cells.,1118.0,,,Rattus norvegicus,CHEMBL615554,10116.0
15899,N,,,3Y1 cell line,,80622,1,Intermediate,,533,F,,,1,BAO_0000219,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",1118.0,,,Rattus norvegicus,CHEMBL615555,10116.0
17038,N,,,3Y1 cell line,,80622,1,Expert,,534,F,,,1,BAO_0000219,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,1118.0,,,Rattus norvegicus,CHEMBL615556,10116.0
12421,U,,,,,22226,0,Autocuration,,535,B,,,1,BAO_0000019,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,,,,CHEMBL615557,
12947,U,,,,,22226,0,Autocuration,,536,B,,,1,BAO_0000019,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,,,CHEMBL615558,
12947,U,,,,,22226,0,Autocuration,,537,B,,,1,BAO_0000019,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,,,CHEMBL872066,
4896,D,,,,,11607,9,Expert,,538,B,,,1,BAO_0000019,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,,,Sus scrofa,CHEMBL615559,9823.0
6148,H,,,,,11607,8,Autocuration,,539,B,,,1,BAO_0000019,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,,,,CHEMBL615560,
16432,H,,,,,11607,8,Autocuration,,540,B,,,1,BAO_0000019,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,,,,CHEMBL615561,
4978,H,,,,,11607,8,Expert,,541,B,,,1,BAO_0000019,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,,,,CHEMBL857062,
4978,H,,,,,11607,8,Expert,,542,B,,,1,BAO_0000019,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,,,,CHEMBL615562,
3723,H,,,,,11607,8,Autocuration,,543,B,,,1,BAO_0000019,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,,,,CHEMBL615563,
3518,H,,,,,11607,8,Autocuration,,544,B,,,1,BAO_0000357,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,,,,CHEMBL615564,
4164,H,,,,,11607,8,Autocuration,,545,B,,,1,BAO_0000019,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,,,,CHEMBL615565,
3518,H,,,,,11607,8,Autocuration,,546,B,,,1,BAO_0000019,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,,,,CHEMBL615566,
4164,D,,,,,11607,9,Expert,,547,B,,,1,BAO_0000019,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,,,Sus scrofa,CHEMBL615567,9823.0
3518,H,,,,,11607,8,Autocuration,,548,B,,,1,BAO_0000019,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,,,,CHEMBL615568,
3518,H,,,,,11607,8,Autocuration,,549,B,,,1,BAO_0000357,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,,,,CHEMBL615569,
4978,H,,,,,11607,8,Autocuration,,550,B,,,1,BAO_0000019,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,,,,CHEMBL615570,
4978,H,,,,,11607,8,Autocuration,,551,B,,,1,BAO_0000019,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,,,,CHEMBL615571,
6455,H,,,,,104733,4,Autocuration,,552,B,,,1,BAO_0000224,Binding affinity against melatonin (MT1) receptor (pC1),,,,,CHEMBL615572,
2222,U,,,,,22226,0,Autocuration,,553,B,,,1,BAO_0000019,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,,,,CHEMBL615573,
13020,U,,,,,22226,0,Autocuration,,554,B,,,1,BAO_0000019,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,,,,CHEMBL615574,
13021,U,,,,,22226,0,Autocuration,,555,B,,,1,BAO_0000019,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,,,,CHEMBL615575,
14532,H,,,,,10619,8,Autocuration,,556,B,,,1,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,,,,CHEMBL615576,
14118,H,,,,,10619,8,Autocuration,,557,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,,,CHEMBL615577,
11884,H,,,,,51,8,Autocuration,,558,B,Hippocampus,,1,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,,10000000.0,,CHEMBL615578,
13969,H,,,,,51,8,Expert,,559,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL615579,
13392,H,,,,,51,8,Expert,,560,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor,,,,,CHEMBL615580,
14430,H,,,,,51,8,Expert,,561,B,,,1,BAO_0000019,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,,,,CHEMBL615581,
12248,H,,,,,51,8,Autocuration,,562,B,Hippocampus,,1,BAO_0000221,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,10000000.0,,CHEMBL615582,
12249,H,,,,,51,8,Autocuration,,563,B,Hippocampus,,1,BAO_0000221,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,10000000.0,,CHEMBL615583,
9995,H,,,,,51,8,Autocuration,,564,B,Hippocampus,,1,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,10000000.0,,CHEMBL615584,
9995,H,,,,,51,8,Autocuration,,565,B,Hippocampus,,1,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,10000000.0,,CHEMBL833691,
9995,H,,,,,51,8,Autocuration,,566,B,Hippocampus,,1,BAO_0000221,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,10000000.0,,CHEMBL615585,
9995,H,,,,,51,8,Autocuration,,567,B,Hippocampus,,1,BAO_0000221,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,10000000.0,,CHEMBL615586,
9995,H,,,,,51,8,Autocuration,,568,B,Hippocampus,,1,BAO_0000221,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,10000000.0,,CHEMBL884524,
12249,H,,,,,51,8,Autocuration,,569,B,Hippocampus,,1,BAO_0000221,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,10000000.0,,CHEMBL615587,
11799,H,,,,,51,8,Autocuration,,570,B,Hippocampus,,1,BAO_0000221,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,10000000.0,,CHEMBL615588,
14331,D,,,,,10576,9,Expert,Membranes,571,B,,,1,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,,,Rattus norvegicus,CHEMBL615589,10116.0
11884,H,,,,,51,8,Expert,,572,B,Hippocampus,,1,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,,10000000.0,Bos taurus,CHEMBL615442,9913.0
14331,H,,,,,51,8,Autocuration,,573,B,Hippocampus,,1,BAO_0000221,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,,10000000.0,,CHEMBL615443,
11701,H,,,,,51,8,Autocuration,,574,B,Hippocampus,,1,BAO_0000221,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,,10000000.0,,CHEMBL615444,
11701,H,,,,,51,8,Expert,,575,B,Hippocampus,,1,BAO_0000221,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,,10000000.0,,CHEMBL615445,
12248,H,,,,,51,8,Autocuration,,576,B,Hippocampus,,1,BAO_0000221,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,,10000000.0,,CHEMBL615446,
12248,H,,,CHO,,51,8,Autocuration,,577,B,,,1,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,449.0,,,,CHEMBL615447,
12248,H,,,,,51,8,Expert,,578,B,Hippocampus,,1,BAO_0000221,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,10000000.0,,CHEMBL615448,
12249,H,,,,,51,8,Expert,,579,B,Hippocampus,,1,BAO_0000221,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,10000000.0,,CHEMBL615449,
12248,H,,,CHO,,51,8,Autocuration,,580,B,,,1,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,449.0,,,,CHEMBL615450,
11799,H,,,,,51,8,Expert,,581,B,Hippocampus,,1,BAO_0000221,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,10000000.0,,CHEMBL615451,
634,H,,,,,51,8,Autocuration,,582,B,,,1,BAO_0000357,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,,,CHEMBL615452,
9995,H,,,,,51,8,Autocuration,,583,B,Hippocampus,,1,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,10000000.0,,CHEMBL615453,
9995,H,,,,,51,8,Autocuration,,584,B,Hippocampus,,1,BAO_0000221,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,10000000.0,,CHEMBL615454,
9995,H,,,,,51,8,Autocuration,,585,B,Hippocampus,,1,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,10000000.0,,CHEMBL615455,
9995,H,,,,,51,8,Autocuration,,586,B,Hippocampus,,1,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,10000000.0,,CHEMBL615456,
9995,H,,,,,51,8,Autocuration,,587,B,Hippocampus,,1,BAO_0000221,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,10000000.0,,CHEMBL615457,
12210,H,,,,,51,8,Expert,,588,B,Hippocampus,,1,BAO_0000218,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,,10000000.0,,CHEMBL615458,
13311,H,,,,,51,8,Expert,,589,B,Hippocampus,,1,BAO_0000221,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,10000000.0,,CHEMBL615459,
2331,D,,,CHO,,51,9,Expert,,590,B,,,1,BAO_0000219,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",449.0,,,Homo sapiens,CHEMBL615460,9606.0
1375,H,,,,,51,8,Autocuration,,591,F,,,1,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,,,Cavia porcellus,CHEMBL615461,10141.0
1375,H,,,,,51,8,Autocuration,,592,F,,,1,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,,,Cavia porcellus,CHEMBL615462,10141.0
11574,H,,,,,51,8,Autocuration,,593,F,Hippocampus,,1,BAO_0000221,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,,10000000.0,Cavia porcellus,CHEMBL615463,10141.0
12867,H,,,,,51,8,Autocuration,,594,B,Ileum,,1,BAO_0000221,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,,2116.0,Cavia porcellus,CHEMBL615464,10141.0
12867,H,,,,,51,8,Autocuration,,595,B,Ileum,,1,BAO_0000221,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,2116.0,Cavia porcellus,CHEMBL615465,10141.0
12867,H,,,,,51,8,Autocuration,,596,B,Ileum,,1,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,,2116.0,Cavia porcellus,CHEMBL615466,10141.0
12867,H,,,,,51,8,Autocuration,,597,B,Ileum,,1,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,2116.0,Cavia porcellus,CHEMBL615467,10141.0
12867,H,,,,,51,8,Autocuration,,598,B,Ileum,,1,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,,2116.0,Cavia porcellus,CHEMBL615468,10141.0
12867,H,,,,,51,8,Autocuration,,599,B,Ileum,,1,BAO_0000221,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,,2116.0,Cavia porcellus,CHEMBL615469,10141.0
11574,H,,,,,51,8,Autocuration,,600,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,Cavia porcellus,CHEMBL615470,10141.0
13114,H,,,,,51,8,Autocuration,,601,B,,,1,BAO_0000357,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,,,Cavia porcellus,CHEMBL615471,10141.0
13181,H,,,,,51,8,Autocuration,,602,B,,,1,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,,,Cavia porcellus,CHEMBL615472,10141.0
10639,H,,,,,106,8,Autocuration,,603,B,Hippocampus,,1,BAO_0000221,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,,10000000.0,Cavia porcellus,CHEMBL883242,10141.0
10639,H,,,,,106,8,Autocuration,,604,F,Hippocampus,,1,BAO_0000221,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,,10000000.0,Cavia porcellus,CHEMBL615473,10141.0
11883,H,,,CHO,,11863,8,Autocuration,,605,B,,,1,BAO_0000218,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),449.0,,,Cricetulus griseus,CHEMBL615474,10029.0
17785,H,,,,,51,8,Autocuration,,606,B,,,1,BAO_0000357,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,,,,CHEMBL615475,
1558,H,,,HeLa,,51,8,Autocuration,,607,F,,,1,BAO_0000219,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,308.0,,,,CHEMBL615476,
1558,H,,,HeLa,,51,8,Autocuration,,608,F,,,1,BAO_0000219,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,308.0,,,,CHEMBL615477,
15740,H,,,,,51,8,Autocuration,,609,F,,,1,BAO_0000019,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL615478,
17624,H,,,CHO,,51,8,Autocuration,,610,F,,,1,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,449.0,,,,CHEMBL615160,
17624,H,,,CHO,,51,8,Expert,,611,F,,,1,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,449.0,,,,CHEMBL615161,
17624,H,,,CHO,,51,8,Autocuration,,612,F,,,1,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,449.0,,,,CHEMBL615162,
17624,H,,,CHO,,51,8,Autocuration,,613,F,,,1,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,449.0,,,,CHEMBL615163,
17624,H,,,CHO,,51,8,Expert,,614,B,,,1,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,449.0,,,,CHEMBL615164,
17624,H,,,CHO,,51,8,Expert,,615,B,,,1,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,449.0,,,,CHEMBL615165,
17624,H,,,CHO,,51,8,Autocuration,,616,B,,,1,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,449.0,,,,CHEMBL615166,
14256,H,,,,,51,8,Autocuration,,617,F,,,1,BAO_0000219,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,,,,CHEMBL615167,
3445,D,,,HeLa,,51,9,Expert,,618,B,,,1,BAO_0000219,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,308.0,,,Homo sapiens,CHEMBL615168,9606.0
3445,D,,,HeLa,,51,9,Expert,,619,B,,,1,BAO_0000219,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,308.0,,,Homo sapiens,CHEMBL615169,9606.0
17200,D,,,CHO,,51,9,Expert,,620,B,,,1,BAO_0000219,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,449.0,,,Homo sapiens,CHEMBL615170,9606.0
17200,D,,,CHO,,51,9,Expert,,621,B,,,1,BAO_0000219,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,449.0,,,Homo sapiens,CHEMBL615171,9606.0
15180,H,,,,,51,8,Autocuration,,622,F,,,1,BAO_0000019,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL615694,
15180,H,,,,,51,8,Autocuration,,623,F,,,1,BAO_0000019,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL615695,
16026,H,,,,,51,8,Autocuration,,624,F,,,1,BAO_0000019,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,,CHEMBL615696,
2759,H,,,CHO,,51,8,Autocuration,,625,F,,,1,BAO_0000219,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,449.0,,,,CHEMBL615697,
2759,D,,,CHO,,51,9,Expert,,626,F,,,1,BAO_0000219,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),449.0,,,Homo sapiens,CHEMBL859410,9606.0
2759,H,,,CHO,,51,8,Autocuration,,627,F,,,1,BAO_0000219,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),449.0,,,,CHEMBL615841,
2759,D,,,CHO,,51,9,Expert,,628,F,,,1,BAO_0000219,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),449.0,,,Homo sapiens,CHEMBL615842,9606.0
2759,H,,,CHO,,51,8,Autocuration,,629,F,,,1,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,449.0,,,,CHEMBL835003,
2759,H,,,CHO,,51,8,Autocuration,,630,F,,,1,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),449.0,,,,CHEMBL615843,
2759,D,,,CHO,,51,9,Expert,,631,F,,,1,BAO_0000219,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),449.0,,,Homo sapiens,CHEMBL615979,9606.0
2759,H,,,CHO,,51,8,Autocuration,,632,F,,,1,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),449.0,,,,CHEMBL615980,
2759,D,,,CHO,,51,9,Expert,,633,F,,,1,BAO_0000219,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),449.0,,,Homo sapiens,CHEMBL615981,9606.0
3445,D,,,,,51,9,Expert,,634,F,,,1,BAO_0000019,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,,,Homo sapiens,CHEMBL615982,9606.0
5272,D,,,,,51,9,Expert,,635,F,,,1,BAO_0000019,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,,Homo sapiens,CHEMBL615983,9606.0
5272,D,,,,,51,9,Expert,,636,F,,,1,BAO_0000019,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,,,Homo sapiens,CHEMBL615984,9606.0
5272,D,,,,,51,9,Expert,,637,F,,,1,BAO_0000019,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,,,Homo sapiens,CHEMBL615985,9606.0
17624,H,,,CHO,,51,8,Autocuration,,638,F,,,1,BAO_0000219,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,449.0,,,,CHEMBL615986,
17624,H,,,CHO,,51,8,Autocuration,,639,F,,,1,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,449.0,,,,CHEMBL615987,
17624,H,,,CHO,,51,8,Autocuration,,640,F,,,1,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,449.0,,,,CHEMBL615988,
17624,H,,,CHO,,51,8,Expert,,641,F,,,1,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,449.0,,,,CHEMBL615989,
17624,H,,,CHO,,51,8,Autocuration,,642,F,,,1,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,449.0,,,,CHEMBL615990,
17624,H,,,CHO,,51,8,Autocuration,,643,F,,,1,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,449.0,,,,CHEMBL615991,
17624,H,,,CHO,,51,8,Autocuration,,644,F,,,1,BAO_0000219,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,449.0,,,,CHEMBL615992,
17624,H,,,CHO,,51,8,Autocuration,,645,F,,,1,BAO_0000219,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,449.0,,,,CHEMBL615993,
17624,H,,,CHO,,51,8,Expert,,646,F,,,1,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,449.0,,,,CHEMBL615994,
17624,H,,,CHO,,51,8,Autocuration,,647,F,,,1,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,449.0,,,,CHEMBL615995,
17624,H,,,CHO,,51,8,Autocuration,,648,F,,,1,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,449.0,,,,CHEMBL615996,
17624,H,,,CHO,,51,8,Autocuration,,649,F,,,1,BAO_0000219,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,449.0,,,,CHEMBL615997,
6563,H,,,,,51,8,Autocuration,,650,F,,,1,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,CHEMBL615998,
6563,H,,,,,51,8,Autocuration,,651,F,,,1,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,CHEMBL615999,
6563,H,,,,,51,8,Autocuration,,652,F,,,1,BAO_0000019,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,,,CHEMBL616000,
17296,H,,,HEK293,,51,8,Autocuration,,653,F,,,1,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,722.0,,,,CHEMBL616001,
6876,D,,,,,51,9,Expert,,654,F,,,1,BAO_0000019,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,,,Homo sapiens,CHEMBL616002,9606.0
6876,H,,,,,51,8,Expert,,655,F,,,1,BAO_0000019,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,,,,CHEMBL616003,
5272,D,,,,,51,9,Expert,,656,F,,,1,BAO_0000019,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,,,Homo sapiens,CHEMBL616004,9606.0
5272,D,,,,,51,9,Expert,,657,F,,,1,BAO_0000019,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,,,Homo sapiens,CHEMBL616005,9606.0
5548,H,,,,,51,8,Autocuration,,658,F,,,1,BAO_0000019,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,,CHEMBL616006,
5548,H,,,,,51,8,Expert,,659,F,,,1,BAO_0000019,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,,,,CHEMBL616007,
5548,H,,,,,51,8,Autocuration,,660,F,,,1,BAO_0000019,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,,CHEMBL616008,
5548,H,,,,,51,8,Autocuration,,661,F,,,1,BAO_0000019,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,,CHEMBL616009,
5929,H,,,,,51,8,Expert,,662,F,,,1,BAO_0000019,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,,,,CHEMBL616010,
5929,D,,,,,51,9,Expert,,663,F,,,1,BAO_0000019,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,,,Homo sapiens,CHEMBL616011,9606.0
5929,D,,,,,51,9,Expert,,664,F,,,1,BAO_0000019,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,,,Homo sapiens,CHEMBL615740,9606.0
16245,H,,,,,51,8,Autocuration,,665,F,,,1,BAO_0000019,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,,,,CHEMBL615741,
5640,H,,,,,51,8,Expert,,666,F,,,1,BAO_0000019,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,,,CHEMBL615742,
5640,H,,,,,51,8,Autocuration,,667,F,,,1,BAO_0000019,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,,,,CHEMBL615743,
14509,H,,,CHO,,51,8,Autocuration,,668,F,,,1,BAO_0000219,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,449.0,,,,CHEMBL615744,
14509,H,,,CHO,,51,8,Expert,,669,F,,,1,BAO_0000219,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,449.0,,,,CHEMBL615745,
15331,H,,,,,51,8,Autocuration,,670,B,,,1,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,,CHEMBL615746,
15331,H,,,,,51,8,Autocuration,,671,B,,,1,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,,CHEMBL615747,
6563,H,,,,,51,8,Autocuration,,672,F,,,1,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,CHEMBL615748,
6563,H,,,,,51,8,Autocuration,,673,F,,,1,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,,,,CHEMBL615749,
6563,H,,,,,51,8,Autocuration,,674,F,,,1,BAO_0000019,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,,,CHEMBL615750,
6563,D,,,,,51,9,Expert,,675,F,,,1,BAO_0000019,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,,,Homo sapiens,CHEMBL616259,9606.0
6563,H,,,,,51,8,Autocuration,,676,F,,,1,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,CHEMBL616260,
5272,D,,,,,51,9,Expert,,677,F,,,1,BAO_0000019,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,,,Homo sapiens,CHEMBL616261,9606.0
5272,D,,,,,51,9,Expert,,678,F,,,1,BAO_0000019,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,,Homo sapiens,CHEMBL616262,9606.0
5272,D,,,,,51,9,Expert,,679,F,,,1,BAO_0000019,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,,Homo sapiens,CHEMBL616263,9606.0
5272,D,,,,,51,9,Expert,,680,F,,,1,BAO_0000019,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,,,Homo sapiens,CHEMBL616264,9606.0
5272,D,,,,,51,9,Expert,,681,F,,,1,BAO_0000019,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,,,Homo sapiens,CHEMBL616265,9606.0
5272,D,,,,,51,9,Expert,,682,F,,,1,BAO_0000019,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,,,Homo sapiens,CHEMBL616266,9606.0
5272,D,,,,,51,9,Expert,,683,F,,,1,BAO_0000019,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,,,Homo sapiens,CHEMBL616267,9606.0
5272,D,,,,,51,9,Expert,,684,F,,,1,BAO_0000019,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,,,Homo sapiens,CHEMBL616268,9606.0
16146,D,,,,,51,9,Expert,,685,B,,,1,BAO_0000357,Inhibition of human 5-hydroxytryptamine 1A receptor,,,,Homo sapiens,CHEMBL616269,9606.0
17624,H,,,CHO,,51,8,Autocuration,,686,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,449.0,,,,CHEMBL884528,
13706,D,,,HEK293,,105,9,Expert,,687,B,,,1,BAO_0000219,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,722.0,,,,CHEMBL616270,
15250,H,,,CHO,,51,8,Autocuration,,688,B,,,1,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,449.0,,,,CHEMBL616271,
17624,H,,,CHO,,51,8,Autocuration,,689,F,,,1,BAO_0000219,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,449.0,,,,CHEMBL616272,
6861,H,,,,,51,8,Expert,,690,B,,,1,BAO_0000357,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,,,,CHEMBL616273,
17200,D,,,,,51,9,Expert,,691,B,,,1,BAO_0000357,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,,Homo sapiens,CHEMBL616274,9606.0
17624,H,,,CHO,,51,8,Autocuration,,692,B,,,1,BAO_0000219,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,449.0,,,,CHEMBL616275,
17624,H,,,CHO,,51,8,Autocuration,,693,B,,,1,BAO_0000219,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,449.0,,,,CHEMBL616276,
12058,U,,,,In vivo,22226,0,Autocuration,,694,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,,,Rattus norvegicus,CHEMBL616277,10116.0
12058,U,,,,In vivo,22226,0,Autocuration,,695,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,,,Rattus norvegicus,CHEMBL616278,10116.0
12058,U,,,,In vivo,22226,0,Autocuration,,696,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,,,Rattus norvegicus,CHEMBL616279,10116.0
12058,U,,,,In vivo,22226,0,Autocuration,,697,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,,,Rattus norvegicus,CHEMBL616280,10116.0
12058,U,,,,In vivo,22226,0,Autocuration,,698,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,,,Rattus norvegicus,CHEMBL616281,10116.0
12058,U,,,,In vivo,22226,0,Autocuration,,699,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,,,Rattus norvegicus,CHEMBL616282,10116.0
12058,U,,,,In vivo,22226,0,Autocuration,,700,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,,,Rattus norvegicus,CHEMBL616283,10116.0
12058,U,,,,In vivo,22226,0,Autocuration,,701,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,,,Rattus norvegicus,CHEMBL616284,10116.0
12058,U,,,,In vivo,22226,0,Autocuration,,702,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,,,Rattus norvegicus,CHEMBL616285,10116.0
12058,U,,,,In vivo,22226,0,Autocuration,,703,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,,,Rattus norvegicus,CHEMBL616286,10116.0
12058,U,,,,In vivo,22226,0,Autocuration,,704,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,,,Rattus norvegicus,CHEMBL616287,10116.0
12058,U,,,,In vivo,22226,0,Autocuration,,705,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,,,Rattus norvegicus,CHEMBL616288,10116.0
12058,U,,,,In vivo,22226,0,Autocuration,,706,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,,,Rattus norvegicus,CHEMBL616289,10116.0
12058,U,,,,In vivo,22226,0,Autocuration,,707,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,,,Rattus norvegicus,CHEMBL615610,10116.0
12058,U,,,,In vivo,22226,0,Autocuration,,708,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,,,Rattus norvegicus,CHEMBL615611,10116.0
12058,U,,,,In vivo,22226,0,Autocuration,,709,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,,,Rattus norvegicus,CHEMBL615612,10116.0
12058,U,,,,In vivo,22226,0,Autocuration,,710,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,,,Rattus norvegicus,CHEMBL615613,10116.0
12058,U,,,,In vivo,22226,0,Autocuration,,711,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,,,Rattus norvegicus,CHEMBL615614,10116.0
12058,U,,,,In vivo,22226,0,Autocuration,,712,F,,,1,BAO_0000218,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,,,Rattus norvegicus,CHEMBL615615,10116.0
11440,H,,,,,105093,4,Autocuration,,713,B,,,1,BAO_0000019,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,,,,CHEMBL615616,
6238,H,,,,,11923,8,Autocuration,,714,B,Hypothalamus,,1,BAO_0000249,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,,1898.0,,CHEMBL615617,
10046,H,,,,,10577,8,Autocuration,,715,B,,,1,BAO_0000019,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,,,,CHEMBL615618,
10046,H,,,,,10577,8,Autocuration,,716,B,,,1,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,,,,CHEMBL615619,
10046,H,,,,,10577,8,Expert,,717,B,,,1,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,,,CHEMBL615620,
167,H,,,,,55,8,Autocuration,,718,B,,,1,BAO_0000357,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,,,,CHEMBL615621,
167,H,,,,,55,8,Autocuration,,719,B,,,1,BAO_0000357,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,,,,CHEMBL615622,
11520,H,,,,,12166,8,Autocuration,,720,F,,,1,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,,,,CHEMBL615623,
11520,H,,,,,12166,8,Autocuration,,721,F,,,1,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,,CHEMBL615624,
11520,H,,,,,12166,8,Autocuration,,722,F,,,1,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,,CHEMBL615625,
11520,H,,,,,12166,8,Autocuration,,723,F,,,1,BAO_0000019,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,,CHEMBL767045,
135,H,,,,,55,8,Autocuration,,724,F,,,1,BAO_0000019,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,,,Cavia porcellus,CHEMBL615626,10141.0
135,H,,,,,55,8,Autocuration,,725,F,,,1,BAO_0000019,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,,,Cavia porcellus,CHEMBL615627,10141.0
11311,H,,,,,55,8,Autocuration,,726,B,,,1,BAO_0000019,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,,,Cavia porcellus,CHEMBL615628,10141.0
10193,H,,,,,55,8,Autocuration,,727,B,,,1,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,,Cavia porcellus,CHEMBL615629,10141.0
12281,D,,,,,55,9,Expert,,728,B,,,1,BAO_0000357,Inhibitory concentration against 5-lipoxygenase from human whole blood,,,,Homo sapiens,CHEMBL615630,9606.0
11311,H,,,,,55,8,Autocuration,,729,B,,,1,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,,,CHEMBL615631,
12576,H,,,,,17087,8,Autocuration,,730,F,,,1,BAO_0000218,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,,,CHEMBL615632,
12281,H,,,,,17087,8,Autocuration,,731,B,,,1,BAO_0000357,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,,,,CHEMBL615633,
12576,H,,,,,17087,8,Autocuration,,732,F,,,1,BAO_0000218,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,,,CHEMBL615634,
11089,H,,,,,55,8,Expert,,733,B,,,1,BAO_0000019,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,,Sus scrofa,CHEMBL615635,9823.0
11006,H,,,,,12166,8,Expert,,734,B,,,1,BAO_0000357,In vitro inhibition of rat 5-Lipoxygenase,,,,,CHEMBL615636,
11481,D,,,,,12166,9,Expert,,735,B,,,1,BAO_0000357,Inhibitory activity against 5-Lipoxygenase,,,,Rattus norvegicus,CHEMBL615637,10116.0
10864,H,,,RBL-1,,12166,8,Expert,,736,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,702.0,,,,CHEMBL615638,
3595,H,,,RBL-1,,12166,8,Autocuration,,737,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),702.0,,,,CHEMBL615639,
11311,H,,,RBL-1,,12166,8,Autocuration,,738,B,,,1,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,702.0,,,,CHEMBL615640,
11311,H,,,,,12166,8,Autocuration,,739,B,,,1,BAO_0000019,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,,,,CHEMBL615796,
11311,H,,,,,12166,8,Autocuration,,740,B,,,1,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,,,,CHEMBL615845,
11006,H,,,,,12166,8,Autocuration,,741,B,,,1,BAO_0000357,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,,,CHEMBL615846,
3595,H,,,RBL-1,,12166,8,Autocuration,,742,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,702.0,,,,CHEMBL615847,
11311,H,,,,,12166,8,Autocuration,,743,B,,,1,BAO_0000357,The compound was tested for inhibition of isolated 5-Lipoxygenase,,,,,CHEMBL615848,
11481,U,,,,,22226,0,Autocuration,,744,B,,,1,BAO_0000019,Ratio of IC50 against 5-LO and COX,,,,Rattus norvegicus,CHEMBL615849,10116.0
11006,H,,,,,12166,8,Autocuration,,745,B,,,1,BAO_0000357,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,,,CHEMBL615850,
11006,H,,,,,12166,8,Autocuration,,746,B,,,1,BAO_0000357,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,,,,CHEMBL615851,
11311,H,,,,,12166,8,Autocuration,,747,B,,,1,BAO_0000219,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,,,,CHEMBL615852,
11006,H,,,,,12166,8,Autocuration,,748,F,,,1,BAO_0000019,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,,,,CHEMBL615853,
4288,H,,,,,120,8,Autocuration,,749,B,Prostate gland,,1,BAO_0000357,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,,2367.0,,CHEMBL884527,
7587,U,,,,,22226,0,Autocuration,,750,B,,,1,BAO_0000019,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,,,Columba livia,CHEMBL872871,8932.0
7587,U,,,,,22226,0,Autocuration,,751,B,,,1,BAO_0000019,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,,,Columba livia,CHEMBL615854,8932.0
7587,U,,,,,22226,0,Autocuration,,752,B,,,1,BAO_0000019,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,,,Columba livia,CHEMBL767046,8932.0
11249,H,,,,,10732,8,Autocuration,,753,B,,,1,BAO_0000357,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,,,,CHEMBL615855,
8003,D,,,,,12198,9,Expert,,754,F,,,1,BAO_0000019,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,,,Rattus norvegicus,CHEMBL615856,10116.0
8003,D,,,,,12198,9,Expert,,755,F,,,1,BAO_0000019,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,,Rattus norvegicus,CHEMBL615857,10116.0
8003,D,,,,,12198,9,Expert,,756,F,,,1,BAO_0000019,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,,,Rattus norvegicus,CHEMBL615858,10116.0
12416,H,,,,,10576,8,Expert,,757,B,Hippocampus,,1,BAO_0000221,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,10000000.0,,CHEMBL615859,
16293,H,,,,,51,8,Autocuration,,758,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,,,,CHEMBL615860,
13047,U,,,,,22226,0,Autocuration,,759,B,,,1,BAO_0000019,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,,Oryctolagus cuniculus,CHEMBL615861,9986.0
13047,U,,,,,22226,0,Autocuration,,760,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,,Oryctolagus cuniculus,CHEMBL615862,9986.0
13047,U,,,,,22226,0,Autocuration,,761,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,,,Oryctolagus cuniculus,CHEMBL615863,9986.0
13047,U,,,,,22226,0,Autocuration,,762,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,,Oryctolagus cuniculus,CHEMBL615864,9986.0
10085,H,,,,,104744,4,Autocuration,,763,B,Hippocampus,,1,BAO_0000221,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,10000000.0,,CHEMBL615865,
10085,H,,,,,104744,4,Autocuration,,764,B,Hippocampus,,1,BAO_0000221,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,10000000.0,,CHEMBL615866,
10085,H,,,,,104744,4,Autocuration,,765,B,Hippocampus,,1,BAO_0000221,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,10000000.0,,CHEMBL615867,
9841,H,,,,,104744,4,Autocuration,Membranes,766,B,,,1,BAO_0000249,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,,,,CHEMBL615868,
8822,D,,,,,104744,5,Autocuration,,767,B,,,1,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,,,Rattus norvegicus,CHEMBL615869,10116.0
9806,D,,,,,104744,5,Autocuration,,768,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,,,Rattus norvegicus,CHEMBL615870,10116.0
9806,D,,,,,104744,5,Autocuration,,769,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,,,Rattus norvegicus,CHEMBL615871,10116.0
8868,H,,,,,104744,4,Autocuration,,770,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,,,,CHEMBL615872,
9036,H,,,,,104744,4,Autocuration,,771,B,Hippocampus,,1,BAO_0000221,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,,10000000.0,,CHEMBL833492,
11374,H,,,,,104744,4,Autocuration,,772,B,Hippocampus,,1,BAO_0000221,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,,10000000.0,,CHEMBL615873,
10881,H,,,,,104744,4,Autocuration,,773,B,,,1,BAO_0000224,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,,,,CHEMBL615479,
8822,H,,,,,104744,4,Autocuration,,774,B,,,1,BAO_0000019,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,,,,CHEMBL615480,
9806,D,,,,,104744,5,Autocuration,,775,B,,,1,BAO_0000249,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,,,Rattus norvegicus,CHEMBL615481,10116.0
15463,H,,,,,104744,4,Autocuration,,776,B,,,1,BAO_0000019,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,CHEMBL872869,
15463,H,,,,,104744,4,Autocuration,,777,B,,,1,BAO_0000019,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,CHEMBL615482,
14542,H,,,,,104744,4,Autocuration,,778,B,Brain,,1,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,955.0,,CHEMBL615483,
14542,H,,,,,104744,4,Autocuration,,779,B,Brain,,1,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,955.0,,CHEMBL615484,
8569,H,,,,,104744,4,Autocuration,,780,B,,,1,BAO_0000019,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,,,,CHEMBL615485,
10062,D,,,,,104744,5,Autocuration,,781,B,,,1,BAO_0000224,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,,,Rattus norvegicus,CHEMBL615486,10116.0
4771,H,,,,,104744,4,Autocuration,,782,B,,,1,BAO_0000224,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,,,,CHEMBL615487,
10062,H,,,,,104744,4,Autocuration,,783,B,,,1,BAO_0000224,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,,CHEMBL615488,
10062,H,,,,,104744,4,Autocuration,,784,B,,,1,BAO_0000224,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,,CHEMBL615489,
10062,H,,,,,104744,4,Autocuration,,785,B,,,1,BAO_0000224,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,,CHEMBL615389,
15463,H,,,,,104744,4,Autocuration,,786,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,,,CHEMBL615390,
15463,H,,,,,104744,4,Autocuration,,787,B,,,1,BAO_0000019,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,,,CHEMBL615391,
9098,H,,,,,104744,4,Autocuration,,788,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,,,,CHEMBL615392,
3070,U,,,,,22226,0,Autocuration,,789,B,,,1,BAO_0000019,Affinity for 5-hydroxytryptamine 1 receptor,,,,Rattus norvegicus,CHEMBL615393,10116.0
14542,H,,,,,104744,4,Autocuration,,790,B,Brain,,1,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,,955.0,,CHEMBL615394,
14542,H,,,,,104744,4,Autocuration,,791,B,Brain,,1,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,955.0,,CHEMBL615395,
6398,H,,,,,104744,4,Autocuration,,792,B,,,1,BAO_0000224,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,,,,CHEMBL615396,
1344,H,,,,,104744,4,Autocuration,,793,B,Brain,,1,BAO_0000221,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,,955.0,,CHEMBL615397,
11963,H,,,,,104744,4,Autocuration,,794,B,,,1,BAO_0000019,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,CHEMBL615398,
8908,U,,,,,22226,0,Autocuration,,795,B,,,1,BAO_0000019,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,,,Rattus norvegicus,CHEMBL615399,10116.0
9098,H,,,,,104744,4,Autocuration,,796,B,,,1,BAO_0000019,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,,,,CHEMBL615400,
8841,D,,,,,104744,5,Autocuration,,797,B,,,1,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,,,Rattus norvegicus,CHEMBL615401,10116.0
8814,U,,,,,22226,0,Autocuration,,798,B,,,1,BAO_0000019,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,,,Rattus norvegicus,CHEMBL615402,10116.0
11752,H,,,,,104744,4,Autocuration,,799,B,,,1,BAO_0000019,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,,,,CHEMBL615403,
11642,H,,,,,104744,4,Autocuration,,800,B,Brain,,1,BAO_0000221,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,,955.0,,CHEMBL615404,
11642,H,,,,,104744,4,Autocuration,,801,B,,,1,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,,,,CHEMBL615781,
9231,H,,,,,104744,4,Autocuration,,802,B,Brain,,1,BAO_0000220,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,,955.0,,CHEMBL615782,
11351,H,,,,,104744,4,Autocuration,,803,B,Brain,,1,BAO_0000221,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,,955.0,,CHEMBL615783,
4639,U,,,,,22226,0,Autocuration,,804,B,,,1,BAO_0000019,Compound was tested for binding affinity against 5-HT1 receptor,,,,,CHEMBL873481,
1205,U,,,,,22226,0,Autocuration,,805,B,,,1,BAO_0000019,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,,,,CHEMBL615784,
10025,H,,,,,10576,8,Expert,,806,B,,,1,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,,,CHEMBL615785,
13241,H,,,,,10576,8,Autocuration,,807,F,,,1,BAO_0000249,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,,,CHEMBL615786,
16245,H,,,,In vivo,10576,8,Autocuration,,808,F,,,1,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,,,CHEMBL615787,
16245,H,,,,In vivo,10576,8,Autocuration,,809,F,,,1,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,,,CHEMBL615788,
12438,H,,,,,10576,8,Autocuration,,810,F,,,1,BAO_0000019,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,,,,CHEMBL767044,
16245,H,,,,In vivo,10576,8,Autocuration,,811,F,,,1,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,,,CHEMBL615789,
16245,H,,,,In vivo,10576,8,Autocuration,,812,F,,,1,BAO_0000218,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,,,CHEMBL615790,
15740,H,,,,,10576,8,Autocuration,,813,F,,,1,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,,,,CHEMBL615813,
15535,H,,,,,10576,8,Autocuration,,814,F,,,1,BAO_0000219,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,,,,CHEMBL615814,
15535,H,,,,,51,8,Expert,,815,F,,,1,BAO_0000219,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,,,,CHEMBL615815,
15535,H,,,,,10576,8,Autocuration,,816,F,,,1,BAO_0000219,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,,,,CHEMBL615816,
9888,H,,,,,10576,8,Expert,,817,B,,,1,BAO_0000249,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,,,,CHEMBL615817,
10085,H,,,,,10576,8,Autocuration,,818,B,Hippocampus,,1,BAO_0000221,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,,10000000.0,,CHEMBL615818,
10085,H,,,,,10576,8,Autocuration,,819,B,Hippocampus,,1,BAO_0000221,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,,10000000.0,,CHEMBL615819,
17331,H,,,,,10576,8,Expert,Membranes,820,B,,,1,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,,,,CHEMBL615820,
10845,D,,,,,10576,9,Expert,,821,B,Hippocampus,,1,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,,10000000.0,Rattus norvegicus,CHEMBL615821,10116.0
10845,D,,,,,10576,9,Expert,,822,B,Hippocampus,,1,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,,10000000.0,Rattus norvegicus,CHEMBL615822,10116.0
10845,H,,,,,10576,8,Expert,,823,B,Hippocampus,,1,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,,10000000.0,,CHEMBL615823,
10845,D,,,,,10576,9,Expert,,824,B,Hippocampus,,1,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,,10000000.0,Rattus norvegicus,CHEMBL615824,10116.0
10845,D,,,,,10576,9,Expert,,825,B,Hippocampus,,1,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,,10000000.0,Rattus norvegicus,CHEMBL615825,10116.0
13730,H,,,,,10576,8,Expert,,826,B,,,1,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL615826,
13508,H,,,,,10576,8,Expert,,827,B,,,1,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL615827,
13508,H,,,,,10576,8,Expert,,828,B,Hippocampus,,1,BAO_0000249,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,,10000000.0,,CHEMBL615828,
12073,H,,,,,10576,8,Expert,,829,B,Hippocampus,,1,BAO_0000221,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10000000.0,,CHEMBL615829,
4671,H,,,,,10576,8,Autocuration,,830,B,Hippocampus,,1,BAO_0000221,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,,10000000.0,,CHEMBL615830,
13631,H,,,,,10576,8,Expert,,831,B,Hippocampus,,1,BAO_0000221,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,,10000000.0,,CHEMBL615831,
12438,H,,,,,10576,8,Autocuration,,832,B,,,1,BAO_0000357,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,,,,CHEMBL615832,
10483,H,,,,,10576,8,Autocuration,,833,B,,,1,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,,,,CHEMBL615833,
10483,H,,,,,10576,8,Autocuration,,834,B,Hippocampus,,1,BAO_0000221,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,,10000000.0,,CHEMBL615834,
12352,H,,,,,10576,8,Intermediate,,835,B,,,1,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,,,,CHEMBL615835,
14732,H,,,,,10576,8,Autocuration,,836,B,Hippocampus,,1,BAO_0000249,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,,10000000.0,,CHEMBL615836,
11049,D,,,,,10576,9,Expert,,837,B,,,1,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,,,Rattus norvegicus,CHEMBL615837,10116.0
11049,D,,,,,10576,9,Expert,,838,B,,,1,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,,,Rattus norvegicus,CHEMBL615838,10116.0
13657,H,,,,,10576,8,Expert,,839,B,,,1,BAO_0000249,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,,,,CHEMBL615839,
11473,H,,,,,10576,8,Autocuration,,840,B,,,1,BAO_0000019,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,,,,CHEMBL884525,
2014,H,,,,,10576,8,Autocuration,,841,B,,,1,BAO_0000249,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,,,CHEMBL615840,
3086,H,,,,,10576,8,Expert,,842,B,Hippocampus,,1,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10000000.0,,CHEMBL615405,
15854,H,,,,,10576,8,Expert,,843,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,,CHEMBL615406,
10922,H,,,,,10576,8,Expert,,844,B,Hippocampus,,1,BAO_0000221,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,10000000.0,,CHEMBL615900,
13346,H,,,,,10576,8,Expert,,845,B,Hippocampus,,1,BAO_0000221,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,,10000000.0,,CHEMBL615901,
15311,H,,,,,10576,8,Expert,,846,B,,,1,BAO_0000357,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,,,,CHEMBL615902,
10922,H,,,,,10576,8,Autocuration,,847,B,Hippocampus,,1,BAO_0000221,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,10000000.0,,CHEMBL615903,
10025,H,,,,,10576,8,Autocuration,,848,B,,,1,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,,,,CHEMBL615904,
10025,H,,,,,10576,8,Expert,,849,B,,,1,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,,,CHEMBL615905,
9742,H,,,,,10576,8,Autocuration,,850,B,,,1,BAO_0000019,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,,,CHEMBL615906,
9742,H,,,,,10576,8,Autocuration,,851,F,,,1,BAO_0000019,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,,,CHEMBL615907,
12304,H,,,,,10576,8,Expert,,852,B,,,1,BAO_0000019,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,,CHEMBL615908,
15789,H,,,,,10576,8,Autocuration,,853,B,Hippocampus,,1,BAO_0000221,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,,10000000.0,,CHEMBL615909,
9912,H,,,,,10576,8,Autocuration,,854,B,,,1,BAO_0000019,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,,,,CHEMBL615910,
9912,H,,,,,10576,8,Autocuration,,855,B,,,1,BAO_0000019,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,,,,CHEMBL615911,
9912,H,,,,,10576,8,Autocuration,,856,B,,,1,BAO_0000019,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,,,,CHEMBL615912,
16693,H,,,,,10576,8,Expert,,857,B,,,1,BAO_0000019,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL615913,
13276,H,,,,,10576,8,Expert,,858,B,,,1,BAO_0000357,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,,CHEMBL615914,
12678,H,,,,,10576,8,Autocuration,,859,B,Hippocampus,,1,BAO_0000221,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,10000000.0,,CHEMBL615915,
11825,H,,,,,10576,8,Autocuration,,860,B,,,1,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,,,,CHEMBL615916,
12443,H,,,,,10576,8,Expert,,861,B,,,1,BAO_0000357,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,,,,CHEMBL615917,
13830,H,,,,,10576,8,Expert,,862,B,,,1,BAO_0000357,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,,,CHEMBL615918,
14286,H,,,,,10576,8,Expert,,863,B,Hippocampus,,1,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,,10000000.0,,CHEMBL615919,
14356,D,,,,,10576,9,Expert,,864,B,Hippocampus,,1,BAO_0000221,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,10000000.0,Rattus norvegicus,CHEMBL615920,10116.0
15306,H,,,,,10576,8,Autocuration,,865,B,,,1,BAO_0000357,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL615921,
15306,H,,,,,10576,8,Expert,,866,B,,,1,BAO_0000357,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,,,,CHEMBL615922,
16616,D,,,,,10576,9,Expert,,867,F,,,1,BAO_0000249,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,,Rattus norvegicus,CHEMBL881290,10116.0
3651,H,,,,,10576,8,Autocuration,,868,B,Hippocampus,,1,BAO_0000221,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,,10000000.0,,CHEMBL615923,
14331,H,,,,,10576,8,Autocuration,,869,F,Hippocampus,,1,BAO_0000221,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10000000.0,,CHEMBL615924,
14331,H,,,,,10576,8,Autocuration,,870,F,Hippocampus,,1,BAO_0000221,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10000000.0,,CHEMBL615925,
14178,D,,,,,10576,9,Expert,,871,B,,,1,BAO_0000357,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,,,Rattus norvegicus,CHEMBL615926,10116.0
10639,D,,,,,10576,9,Expert,,872,B,,,1,BAO_0000019,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,,,Rattus norvegicus,CHEMBL615927,10116.0
12306,H,,,,,10576,8,Autocuration,,873,B,Hippocampus,,1,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,10000000.0,,CHEMBL615928,
1348,D,,,,,10576,9,Expert,,874,B,,,1,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,,,Rattus norvegicus,CHEMBL615929,10116.0
13605,H,,,,,10576,8,Autocuration,,875,B,Hippocampus,,1,BAO_0000221,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,,10000000.0,,CHEMBL615930,
17624,H,,,CHO,,51,8,Autocuration,,876,B,,,1,BAO_0000219,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,449.0,,,,CHEMBL615931,
17624,H,,,CHO,,51,8,Autocuration,,877,F,,,1,BAO_0000219,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,449.0,,,,CHEMBL615932,
17624,H,,,CHO,,51,8,Autocuration,,878,F,,,1,BAO_0000219,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,449.0,,,,CHEMBL615933,
15267,H,,,,,51,8,Autocuration,,879,B,,,1,BAO_0000357,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,,,CHEMBL615934,
16532,H,,,,,51,8,Autocuration,,880,B,,,1,BAO_0000357,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,,,,CHEMBL615935,
6563,H,,,,,51,8,Autocuration,,881,F,,,1,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,CHEMBL615936,
4751,H,,,CHO,,51,8,Autocuration,,882,B,,,1,BAO_0000219,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,449.0,,,,CHEMBL615937,
15463,H,,,,,51,8,Autocuration,,883,B,,,1,BAO_0000357,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,,,,CHEMBL615938,
3805,H,,,,,51,8,Autocuration,,884,B,,,1,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,,,,CHEMBL615797,
5640,H,,,,,51,8,Autocuration,,885,B,,,1,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL615798,
6563,H,,,,,51,8,Autocuration,,886,B,,,1,BAO_0000357,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,,,,CHEMBL872870,
5548,H,,,,,51,8,Autocuration,,887,B,,,1,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,,,,CHEMBL615799,
6347,H,,,,,51,8,Autocuration,,888,B,,,1,BAO_0000357,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL615800,
17296,H,,,HEK293,,51,8,Autocuration,,889,F,,,1,BAO_0000219,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,722.0,,,,CHEMBL615801,
13047,H,,,,,51,8,Autocuration,,890,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,,,,CHEMBL615802,
15740,H,,,,,51,8,Autocuration,,891,B,,,1,BAO_0000357,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,,,,CHEMBL615803,
5640,H,,,,,51,8,Expert,,892,F,,,1,BAO_0000019,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,,,CHEMBL835002,
5640,H,,,,,51,8,Autocuration,,893,F,,,1,BAO_0000019,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,,,,CHEMBL615804,
17211,H,,,HeLa,,51,8,Expert,,894,B,,,1,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,308.0,,,,CHEMBL615805,
4751,H,,,CHO,,51,8,Autocuration,,895,B,,,1,BAO_0000219,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,449.0,,,,CHEMBL615806,
6491,D,,,,,51,9,Expert,,896,B,,,1,BAO_0000357,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,,,Homo sapiens,CHEMBL615807,9606.0
4707,H,,,,,51,8,Autocuration,,897,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,,,,CHEMBL615808,
13910,D,,,,,51,9,Expert,,898,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,Homo sapiens,CHEMBL615809,9606.0
16190,H,,,HeLa,,51,8,Autocuration,,899,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,308.0,,,,CHEMBL615810,
16633,H,,,,,51,8,Autocuration,,900,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL615811,
11898,H,,,CHO,,51,8,Autocuration,,901,B,,,1,BAO_0000219,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,449.0,,,,CHEMBL615812,
11898,H,,,CHO,,51,8,Autocuration,,902,B,,,1,BAO_0000219,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,449.0,,,,CHEMBL615751,
14331,H,,,,,51,8,Autocuration,,903,B,,,1,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 1A receptor,,,,,CHEMBL615752,
17624,H,,,CHO,,51,8,Expert,,904,B,,,1,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,449.0,,,,CHEMBL615753,
17624,H,,,CHO,,51,8,Autocuration,,905,B,,,1,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,449.0,,,,CHEMBL615754,
3307,H,,,,,51,8,Autocuration,,906,B,,,1,BAO_0000357,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,,,,CHEMBL615755,
6563,D,,,CHO,,51,9,Expert,,907,B,,,1,BAO_0000219,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,449.0,,,Homo sapiens,CHEMBL615756,9606.0
14165,H,,,,,51,8,Autocuration,,908,B,,,1,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL615757,
5732,H,,,,,51,8,Autocuration,,909,B,,,1,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,,,CHEMBL615758,
13366,H,,,,,51,8,Expert,,910,B,,,1,BAO_0000357,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,,,CHEMBL615759,
17626,H,,,,,51,8,Autocuration,,911,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,,,,CHEMBL615760,
6588,H,,,HeLa,,51,8,Expert,,912,B,,,1,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,308.0,,,,CHEMBL615761,
16209,H,,,,,51,8,Autocuration,,913,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,,,,CHEMBL872104,
15463,H,,,,,51,8,Autocuration,,914,B,,,1,BAO_0000357,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL615762,
15463,H,,,,,51,8,Autocuration,,915,B,,,1,BAO_0000357,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL615763,
14770,H,,,,,51,8,Autocuration,,916,B,,,1,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,,,,CHEMBL615764,
16245,H,,,Cell line,,51,8,Autocuration,,917,B,,,1,BAO_0000219,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),1167.0,,,,CHEMBL615765,
16245,H,,,,,51,8,Autocuration,,918,B,,,1,BAO_0000019,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,,,,CHEMBL615766,
5548,H,,,,,51,8,Autocuration,,919,B,,,1,BAO_0000357,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL615767,
5548,H,,,,,51,8,Expert,,920,B,,,1,BAO_0000357,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL615768,
5548,H,,,,,51,8,Autocuration,,921,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL615769,
6876,H,,,,,51,8,Expert,,922,B,,,1,BAO_0000357,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,,,,CHEMBL615770,
2598,H,,,,,51,8,Autocuration,,923,B,,,1,BAO_0000357,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL615771,
17785,H,,,,,51,8,Expert,,924,B,,,1,BAO_0000357,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,,,,CHEMBL615772,
6013,H,,,,,51,8,Autocuration,,925,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,CHEMBL615773,
5929,H,,,,,51,8,Expert,,926,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL615774,
16633,H,,,,,51,8,Autocuration,,927,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL615775,
1558,H,,,,,51,8,Autocuration,,928,B,,,1,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,,,CHEMBL615776,
16026,H,,,,,51,8,Expert,,929,B,,,1,BAO_0000357,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL615777,
12469,H,,,,,51,8,Autocuration,,930,B,,,1,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,,,,CHEMBL615778,
15874,D,,,,,51,9,Expert,,931,B,,,1,BAO_0000357,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,,Homo sapiens,CHEMBL615779,9606.0
15874,H,,,,,51,8,Autocuration,,932,B,,,1,BAO_0000357,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,,,CHEMBL615780,
3935,H,,,,,51,8,Autocuration,,933,B,,,1,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616298,
15818,H,,,,,51,8,Autocuration,,934,B,,,1,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616299,
13706,H,,,CHO-K1,,51,8,Autocuration,,935,B,,,1,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,485.0,,,,CHEMBL616300,
13729,H,,,CHO-K1,,51,8,Expert,,936,F,,,1,BAO_0000219,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,485.0,,,,CHEMBL616301,
15413,H,,,,,51,8,Autocuration,,937,B,,,1,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616302,
15413,H,,,,,51,8,Autocuration,,938,B,,,1,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,,,,CHEMBL616117,
15413,H,,,,,51,8,Autocuration,,939,B,,,1,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,,,,CHEMBL616118,
15413,H,,,,,51,8,Autocuration,,940,B,,,1,BAO_0000019,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,,,,CHEMBL616119,
3445,D,,,HeLa,,51,9,Expert,,941,B,,,1,BAO_0000219,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,308.0,,,Homo sapiens,CHEMBL616120,9606.0
15740,H,,,,,51,8,Autocuration,,942,B,,,1,BAO_0000357,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616121,
15740,H,,,,,51,8,Autocuration,,943,B,,,1,BAO_0000357,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,,,,CHEMBL616122,
17626,H,,,,,51,8,Autocuration,,944,B,,,1,BAO_0000357,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616123,
4234,D,,,,,51,9,Expert,,945,B,,,1,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,,,Homo sapiens,CHEMBL616124,9606.0
5640,H,,,,,51,8,Expert,,946,B,,,1,BAO_0000357,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,,,CHEMBL616125,
5272,H,,,,,51,8,Expert,,947,B,,,1,BAO_0000357,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,,,Rattus norvegicus,CHEMBL616126,10116.0
4622,H,,,CHO,,51,8,Autocuration,,948,B,,,1,BAO_0000219,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,449.0,,,,CHEMBL616127,
17085,H,,,,,51,8,Expert,,949,B,,,1,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616128,
3025,H,,,,,51,8,Autocuration,,950,B,,,1,BAO_0000357,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,,,CHEMBL616129,
15315,H,,,,,51,8,Expert,,951,B,,,1,BAO_0000357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616130,
15267,H,,,,,51,8,Autocuration,,952,B,,,1,BAO_0000357,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,,,,CHEMBL616131,
17158,H,,,HeLa,,51,8,Autocuration,,953,B,,,1,BAO_0000219,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,308.0,,,,CHEMBL616132,
14214,D,,,HeLa,,51,9,Expert,,954,B,,,1,BAO_0000219,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,308.0,,,Homo sapiens,CHEMBL616133,9606.0
17133,H,,,,,51,8,Autocuration,,955,B,,,1,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL616134,
16532,H,,,,,51,8,Autocuration,,956,B,,,1,BAO_0000357,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,,,,CHEMBL616135,
2391,D,,,,,51,9,Expert,,957,B,,,1,BAO_0000357,Affinity for 5-hydroxytryptamine 1A receptor subtype,,,,Homo sapiens,CHEMBL616136,9606.0
14447,H,,,,,51,8,Autocuration,,958,B,,,1,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,,,,CHEMBL616137,
14447,H,,,,,51,8,Autocuration,,959,B,,,1,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,,,,CHEMBL872105,
15086,H,,,,,51,8,Autocuration,,960,B,,,1,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,,,,CHEMBL616138,
13051,D,,,,,51,9,Expert,,961,B,,,1,BAO_0000357,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,,Homo sapiens,CHEMBL616139,9606.0
16026,H,,,,,51,8,Autocuration,,962,F,,,1,BAO_0000019,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,,,,CHEMBL616140,
17085,H,,,,,51,8,Expert,,963,B,,,1,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,,,,CHEMBL616141,
17133,H,,,,,51,8,Autocuration,,964,B,,,1,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL616142,
17133,H,,,,,51,8,Autocuration,,965,B,,,1,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,,,,CHEMBL616143,
17211,H,,,HeLa,,51,8,Autocuration,,966,B,,,1,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,308.0,,,,CHEMBL616144,
17211,H,,,HeLa,,51,8,Autocuration,,967,B,,,1,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,308.0,,,,CHEMBL616145,
17211,H,,,HeLa,,51,8,Autocuration,,968,B,,,1,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,308.0,,,,CHEMBL616012,
17211,H,,,HeLa,,51,8,Autocuration,,969,B,,,1,BAO_0000219,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,308.0,,,,CHEMBL616013,
16394,H,,,,,51,8,Autocuration,,970,F,,,1,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,,CHEMBL616014,
16394,H,,,,,51,8,Autocuration,,971,F,,,1,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,,CHEMBL616015,
16394,H,,,,,51,8,Autocuration,,972,F,,,1,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,,CHEMBL616016,
16394,H,,,,In vivo,51,8,Autocuration,,973,F,,,1,BAO_0000218,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,,,,CHEMBL616017,
16394,H,,,,,51,8,Autocuration,,974,B,,,1,BAO_0000019,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,,,,CHEMBL616018,
15740,H,,,,,51,8,Autocuration,,975,F,,,1,BAO_0000019,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,,,,CHEMBL616019,
15740,H,,,,,51,8,Autocuration,,976,F,,,1,BAO_0000019,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,,,,CHEMBL616020,
15740,H,,,,,51,8,Autocuration,,977,B,,,1,BAO_0000357,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,,,CHEMBL858018,
17296,H,,,HEK293,,51,8,Autocuration,,978,F,,,1,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,722.0,,,,CHEMBL616021,
5640,H,,,,,51,8,Expert,,979,F,,,1,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,,,,CHEMBL616022,
5640,H,,,,,51,8,Autocuration,,980,F,,,1,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,,,,CHEMBL616023,
5640,H,,,,,51,8,Autocuration,,981,F,,,1,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,,,,CHEMBL616024,
5640,H,,,,,51,8,Autocuration,,982,F,,,1,BAO_0000019,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,,,,CHEMBL616025,
2759,H,,,CHO,,51,8,Autocuration,,983,F,,,1,BAO_0000219,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,449.0,,,,CHEMBL616026,
16394,H,,,,,51,8,Autocuration,,984,F,,,1,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,,,,CHEMBL616027,
16394,D,,,,,51,9,Expert,,985,F,,,1,BAO_0000019,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,,,Homo sapiens,CHEMBL616028,9606.0
3445,D,,,,,51,9,Expert,,986,F,,,1,BAO_0000019,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,,,Homo sapiens,CHEMBL616029,9606.0
4316,H,,,CHO,,51,8,Expert,,987,B,,,1,BAO_0000219,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,449.0,,,,CHEMBL616030,
4316,H,,,,,51,8,Expert,,988,B,,,1,BAO_0000019,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,,,,CHEMBL616031,
15180,D,,,,,51,9,Expert,,989,F,,,1,BAO_0000019,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,,Homo sapiens,CHEMBL616032,9606.0
15180,D,,,,,51,9,Expert,,990,F,,,1,BAO_0000019,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,,,Homo sapiens,CHEMBL616033,9606.0
15042,H,,,,,51,8,Autocuration,,991,F,,,1,BAO_0000019,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,CHEMBL616034,
15042,H,,,,,51,8,Autocuration,,992,F,,,1,BAO_0000019,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,CHEMBL616035,
15042,H,,,,,51,8,Autocuration,,993,F,,,1,BAO_0000019,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616036,
15042,H,,,,,51,8,Autocuration,,994,F,,,1,BAO_0000019,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,CHEMBL616037,
15042,H,,,,,51,8,Autocuration,,995,F,,,1,BAO_0000019,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,CHEMBL616038,
15042,H,,,,,51,8,Autocuration,,996,F,,,1,BAO_0000019,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,CHEMBL616039,
15042,H,,,,,51,8,Autocuration,,997,F,,,1,BAO_0000019,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616040,
15180,D,,,HeLa,,51,9,Expert,,998,F,,,1,BAO_0000219,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,308.0,,,Homo sapiens,CHEMBL616041,9606.0
15180,D,,,HeLa,,51,9,Expert,,999,F,,,1,BAO_0000219,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,308.0,,,Homo sapiens,CHEMBL616042,9606.0
15180,D,,,HeLa,,51,9,Expert,,1000,F,,,1,BAO_0000219,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,308.0,,,Homo sapiens,CHEMBL616043,9606.0
16245,H,,,,,51,8,Autocuration,,1001,F,,,1,BAO_0000019,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,,,,CHEMBL616044,
16026,H,,,,,51,8,Autocuration,,1002,F,,,1,BAO_0000019,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,,CHEMBL616045,
17296,H,,,HEK293,,51,8,Autocuration,,1003,F,,,1,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,722.0,,,,CHEMBL616046,
2759,H,,,CHO,,51,8,Autocuration,,1004,F,,,1,BAO_0000219,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),449.0,,,,CHEMBL616047,
2759,H,,,CHO,,51,8,Autocuration,,1005,F,,,1,BAO_0000219,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,449.0,,,,CHEMBL616048,
2759,D,,,CHO,,51,9,Expert,,1006,F,,,1,BAO_0000219,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),449.0,,,Homo sapiens,CHEMBL616049,9606.0
2759,H,,,CHO,,51,8,Autocuration,,1007,F,,,1,BAO_0000219,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),449.0,,,,CHEMBL616050,
15419,H,,,,,51,8,Expert,,1008,F,,,1,BAO_0000219,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,,,,CHEMBL616051,
15419,H,,,,,51,8,Autocuration,,1009,F,,,1,BAO_0000219,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,,,,CHEMBL616212,
16026,H,,,,,51,8,Autocuration,,1010,F,,,1,BAO_0000019,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,,CHEMBL616213,
1414,H,,,,In vitro,51,8,Expert,,1011,B,,,1,BAO_0000219,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,,,,CHEMBL616214,
1414,H,,,,In vitro,51,8,Expert,,1012,B,,,1,BAO_0000219,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,,,,CHEMBL616215,
12861,H,,,,,51,8,Autocuration,,1013,B,,,1,BAO_0000357,Binding activity radioligand.,,,,,CHEMBL616216,
12861,H,,,,,51,8,Autocuration,,1014,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,CHEMBL616217,
5104,H,,,,,51,8,Autocuration,,1015,B,,,1,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616218,
5105,H,,,,,51,8,Autocuration,,1016,B,,,1,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616219,
16312,H,,,,,51,8,Autocuration,,1017,B,,,1,BAO_0000357,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616220,
15180,D,,,,,51,9,Expert,,1018,B,,,1,BAO_0000357,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,,,Homo sapiens,CHEMBL833493,9606.0
5033,H,,,,,51,8,Autocuration,,1019,B,,,1,BAO_0000357,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616221,
16909,D,,,CHO,,51,9,Expert,,1020,B,,,1,BAO_0000219,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,449.0,,,Homo sapiens,CHEMBL616222,9606.0
2590,H,,,,,51,8,Autocuration,,1021,F,,,1,BAO_0000019,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616223,
2590,H,,,,,51,8,Autocuration,,1022,F,,,1,BAO_0000019,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,,,CHEMBL616224,
16394,H,,,,,51,8,Expert,,1023,B,,,1,BAO_0000019,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,,,,CHEMBL616225,
4540,D,,,HEK293,,51,9,Expert,,1024,B,,,1,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,722.0,,,Homo sapiens,CHEMBL616226,9606.0
17296,H,,,HEK293,,51,8,Autocuration,,1025,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,722.0,,,,CHEMBL616227,
17296,H,,,HEK293,,51,8,Autocuration,,1026,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,722.0,,,,CHEMBL616228,
15779,H,,,HEK293,,51,8,Autocuration,,1027,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,722.0,,,,CHEMBL616229,
15779,H,,,HEK293,,51,8,Autocuration,,1028,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,722.0,,,,CHEMBL616230,
15779,H,,,HEK293,,51,8,Autocuration,,1029,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,722.0,,,,CHEMBL616231,
6166,H,,,,,51,8,Autocuration,,1030,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL616232,
15779,H,,,HEK293,,51,8,Autocuration,,1031,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,722.0,,,,CHEMBL616233,
4199,H,,,HEK293,,51,8,Autocuration,,1032,B,,,1,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,722.0,,,,CHEMBL857973,
15316,H,,,,,51,8,Autocuration,,1033,B,,,1,BAO_0000219,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,,,,CHEMBL616234,
14875,H,,,,,51,8,Autocuration,,1034,B,,,1,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616235,
14727,H,,,HeLa,,51,8,Expert,,1035,B,,,1,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,308.0,,,,CHEMBL616236,
14727,H,,,,,51,8,Expert,,1036,B,,,1,BAO_0000019,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,,,CHEMBL616237,
15146,H,,,HEK293,,51,8,Autocuration,,1037,B,,,1,BAO_0000219,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,722.0,,,,CHEMBL616238,
5213,H,,,HEK293,,51,8,Autocuration,,1038,B,,,1,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,722.0,,,,CHEMBL616239,
16429,H,,,,,51,8,Autocuration,,1039,B,,,1,BAO_0000219,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,,,,CHEMBL616240,
15042,D,,,HeLa,,51,9,Expert,,1040,B,,,1,BAO_0000219,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,308.0,,,Homo sapiens,CHEMBL616241,9606.0
14818,H,,,HEK293,,51,8,Autocuration,,1041,B,,,1,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,722.0,,,,CHEMBL616242,
4829,H,,,HEK293,,51,8,Autocuration,,1042,B,,,1,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",722.0,,,,CHEMBL616243,
17200,D,,,,,51,9,Expert,,1043,B,,,1,BAO_0000357,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616244,
13051,D,,,,,51,9,Autocuration,,1044,B,,,1,BAO_0000357,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,,,Homo sapiens,CHEMBL616245,9606.0
5486,H,,,,,106,8,Autocuration,,1045,B,,,1,BAO_0000357,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,,,CHEMBL616246,
5254,H,,,,,105,8,Autocuration,,1046,B,,,1,BAO_0000357,Binding affinity against 5-HT1D receptor,,,,,CHEMBL616247,
5254,H,,,,,105,8,Autocuration,,1047,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616248,
15331,H,,,,,107,8,Autocuration,,1048,B,,,1,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,,CHEMBL616249,
13506,H,,,,,10576,8,Autocuration,,1049,B,,,1,BAO_0000357,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,,Homo sapiens,CHEMBL616250,9606.0
15267,H,,,,,51,8,Autocuration,,1050,B,,,1,BAO_0000357,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616251,
16616,H,,,,In vivo,11863,8,Autocuration,,1051,F,,,1,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,,,,CHEMBL616252,
16616,H,,,,In vivo,11863,8,Autocuration,,1052,F,,,1,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,,,,CHEMBL616253,
16616,H,,,,In vivo,11863,8,Autocuration,,1053,F,,,1,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,,,,CHEMBL616254,
16616,D,,,,,11863,9,Expert,,1054,F,,,1,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,,,Mus musculus,CHEMBL616255,10090.0
16616,D,,,,,11863,9,Expert,,1055,F,,,1,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,,,Mus musculus,CHEMBL832872,10090.0
16616,D,,,,,11863,9,Expert,,1056,F,,,1,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,,,Mus musculus,CHEMBL616256,10090.0
16616,D,,,,,11863,9,Expert,,1057,F,,,1,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,,,Mus musculus,CHEMBL616257,10090.0
16616,D,,,,,11863,9,Expert,,1058,F,,,1,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,,,Mus musculus,CHEMBL616258,10090.0
16616,D,,,,,11863,9,Expert,,1059,F,,,1,BAO_0000218,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,,,Mus musculus,CHEMBL616384,10090.0
10297,H,,,,,11863,8,Autocuration,,1060,B,Hippocampus,,1,BAO_0000221,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,10000000.0,,CHEMBL616385,
13704,H,,,,,11863,8,Expert,,1061,B,,,1,BAO_0000357,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,,,,CHEMBL616386,
10297,D,,,,,11863,9,Expert,,1062,B,Hippocampus,,1,BAO_0000221,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,,10000000.0,Mus musculus,CHEMBL616387,10090.0
10297,H,,,,,11863,8,Autocuration,,1063,B,Hippocampus,,1,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,10000000.0,,CHEMBL616388,
10297,D,,,,,11863,9,Expert,,1064,B,Hippocampus,,1,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,,10000000.0,Mus musculus,CHEMBL616389,10090.0
10297,H,,,,,11863,8,Autocuration,,1065,B,Hippocampus,,1,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,10000000.0,,CHEMBL616390,
217,H,,,,,11863,8,Autocuration,,1066,B,,,1,BAO_0000357,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,,,,CHEMBL616391,
10297,D,,,,,11863,9,Expert,,1067,B,Hippocampus,,1,BAO_0000221,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,10000000.0,Mus musculus,CHEMBL616392,10090.0
4921,H,,,,,51,8,Autocuration,,1068,B,,,1,BAO_0000357,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,,,Sus scrofa,CHEMBL616393,9823.0
4921,H,,,,,51,8,Autocuration,,1069,B,,,1,BAO_0000357,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,,,Sus scrofa,CHEMBL616394,9823.0
4996,H,,,,,51,8,Autocuration,,1070,B,,,1,BAO_0000019,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,,,Sus scrofa,CHEMBL616395,9823.0
12918,H,,,,,51,8,Autocuration,,1071,B,,,1,BAO_0000357,Compound was evaluated for the binding affinity at 5- HT1A receptor,,,,Sus scrofa,CHEMBL616396,9823.0
5333,H,,,,,51,8,Autocuration,,1072,B,,,1,BAO_0000019,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,,Sus scrofa,CHEMBL872907,9823.0
4437,H,,,,,51,8,Autocuration,,1073,B,,,1,BAO_0000019,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,,,Sus scrofa,CHEMBL616397,9823.0
1742,H,,,,,51,8,Autocuration,,1074,B,,,1,BAO_0000019,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,,,Sus scrofa,CHEMBL616398,9823.0
16688,H,,,,,51,8,Expert,,1075,B,,,1,BAO_0000357,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,,,Sus scrofa,CHEMBL616399,9823.0
12861,H,,,,,51,8,Autocuration,,1076,B,,,1,BAO_0000357,Binding activity radioligand.,,,,Sus scrofa,CHEMBL857065,9823.0
12861,H,,,,,51,8,Expert,,1077,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,,Sus scrofa,CHEMBL616400,9823.0
12861,H,,,,,51,8,Autocuration,,1078,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,,,Sus scrofa,CHEMBL616401,9823.0
12490,H,,,,,10624,8,Expert,,1079,B,,,1,BAO_0000019,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,,,,CHEMBL616402,
11828,H,,,,,51,8,Expert,,1080,B,,,1,BAO_0000019,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,,,Sus scrofa,CHEMBL616403,9823.0
11866,H,,,,,51,8,Autocuration,,1081,B,Hippocampus,,1,BAO_0000221,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,,10000000.0,Sus scrofa,CHEMBL616404,9823.0
12827,H,,,,,51,8,Autocuration,,1082,B,,,1,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,,,Sus scrofa,CHEMBL616405,9823.0
12918,H,,,,,51,8,Autocuration,,1083,B,,,1,BAO_0000019,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,,,Sus scrofa,CHEMBL616406,9823.0
12919,H,,,,,51,8,Expert,,1084,F,,,1,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,,,Sus scrofa,CHEMBL616407,9823.0
13047,H,,,,,51,8,Autocuration,,1085,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,,,Oryctolagus cuniculus,CHEMBL616408,9986.0
15796,D,,,,,10576,9,Expert,,1086,B,,,1,BAO_0000249,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,,,Rattus norvegicus,CHEMBL616409,10116.0
3651,D,,,,,10576,9,Expert,,1087,B,Hippocampus,,1,BAO_0000221,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,,10000000.0,Rattus norvegicus,CHEMBL616410,10116.0
188,H,,,,,10576,8,Autocuration,,1088,B,,,1,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,,,,CHEMBL616411,
16616,D,,,,,10576,9,Expert,Membranes,1089,F,,,1,BAO_0000249,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,,,Rattus norvegicus,CHEMBL616412,10116.0
16616,D,,,,,10576,9,Expert,Membranes,1090,F,Hippocampus,,1,BAO_0000249,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,,10000000.0,Rattus norvegicus,CHEMBL616413,10116.0
12306,H,,,,,10576,8,Autocuration,,1091,B,Hippocampus,,1,BAO_0000221,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,10000000.0,,CHEMBL616414,
17167,D,,,,,10576,9,Expert,,1092,B,Hippocampus,,1,BAO_0000221,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,,10000000.0,Rattus norvegicus,CHEMBL616415,10116.0
14776,H,,,,,10576,8,Autocuration,,1093,B,,,1,BAO_0000019,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,,,,CHEMBL616416,
12158,H,,,,,10576,8,Expert,,1094,B,,,1,BAO_0000357,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,,,,CHEMBL616417,
13481,H,,,,,10576,8,Autocuration,,1095,B,,,1,BAO_0000357,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,,,CHEMBL616418,
13427,H,,,,In vitro,10576,8,Autocuration,,1096,B,,,1,BAO_0000219,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,,,CHEMBL616419,
10210,H,,,,,10576,8,Autocuration,,1097,B,,,1,BAO_0000357,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,,,,CHEMBL616420,
10205,H,,,,,10576,8,Autocuration,Membranes,1098,B,,,1,BAO_0000249,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,,,CHEMBL616421,
10205,H,,,,,10576,8,Autocuration,Membranes,1099,B,,,1,BAO_0000249,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,,,CHEMBL616422,
10205,H,,,,,10576,8,Expert,Membranes,1100,B,,,1,BAO_0000249,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,,,,CHEMBL616423,
12280,D,,,,,10576,9,Expert,,1101,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,,,Rattus norvegicus,CHEMBL616424,10116.0
17386,H,,,,,10576,8,Expert,,1102,B,,,1,BAO_0000357,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616425,
13654,H,,,,,10576,8,Expert,,1103,B,,,1,BAO_0000357,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,,,,CHEMBL616426,
14423,H,,,,,10576,8,Autocuration,,1104,B,Hippocampus,,1,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,,10000000.0,,CHEMBL616427,
15412,H,,,,,10576,8,Autocuration,,1105,B,Hippocampus,,1,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,,10000000.0,,CHEMBL616428,
12073,H,,,,,10576,8,Autocuration,,1106,B,Hippocampus,,1,BAO_0000221,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10000000.0,,CHEMBL616290,
4101,D,,,,,10576,9,Expert,,1107,B,,,1,BAO_0000357,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,,,Rattus norvegicus,CHEMBL616052,10116.0
10062,H,,,,,10576,8,Autocuration,,1108,B,,,1,BAO_0000357,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616053,
6238,H,,,,,10576,8,Autocuration,,1109,B,,,1,BAO_0000249,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL616054,
16273,H,,,,,10576,8,Autocuration,,1110,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616055,
11139,H,,,,,10576,8,Autocuration,,1111,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,,,,CHEMBL616056,
16796,H,,,,,10576,8,Expert,,1112,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,,,CHEMBL616057,
9548,D,,,,,10576,9,Expert,,1113,B,Brain,,1,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,955.0,Rattus norvegicus,CHEMBL616058,10116.0
10381,H,,,,,10576,8,Autocuration,,1114,B,Brain,,1,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,955.0,,CHEMBL616059,
13408,H,,,,,10576,8,Autocuration,,1115,B,,,1,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL616060,
13825,D,,,,,10576,9,Expert,,1116,B,Hippocampus,,1,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,,10000000.0,Rattus norvegicus,CHEMBL616061,10116.0
11147,H,,,,,10576,8,Expert,,1117,B,Hippocampus,,1,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,,10000000.0,,CHEMBL616062,
10552,H,,,,,10576,8,Autocuration,,1118,B,,,1,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL616063,
10552,H,,,,,10576,8,Autocuration,,1119,B,Striatum,,1,BAO_0000249,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,2435.0,,CHEMBL616064,
17136,D,,,,,10576,9,Expert,Membranes,1120,B,,,1,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,,,Rattus norvegicus,CHEMBL616065,10116.0
5778,D,,,,,10576,9,Expert,Membranes,1121,B,,,1,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,,,Rattus norvegicus,CHEMBL616066,10116.0
13481,H,,,,,10576,8,Autocuration,,1122,B,Hippocampus,,1,BAO_0000221,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,10000000.0,,CHEMBL616067,
13481,H,,,,,10576,8,Autocuration,,1123,B,Hippocampus,,1,BAO_0000221,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,,10000000.0,,CHEMBL616068,
13630,H,,,,,10576,8,Intermediate,,1124,B,Hippocampus,,1,BAO_0000221,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,,10000000.0,,CHEMBL616069,
16245,H,,,,,10576,8,Expert,,1125,B,,,1,BAO_0000249,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,,CHEMBL616070,
14509,H,,,,,10576,8,Autocuration,,1126,B,Hippocampus,,1,BAO_0000221,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,,10000000.0,,CHEMBL616071,
14509,H,,,,,10576,8,Expert,,1127,B,Hippocampus,,1,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,10000000.0,,CHEMBL616072,
14509,H,,,,,10576,8,Autocuration,,1128,B,Hippocampus,,1,BAO_0000221,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,,10000000.0,,CHEMBL616073,
14509,H,,,,,10576,8,Autocuration,,1129,B,Hippocampus,,1,BAO_0000221,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,,10000000.0,,CHEMBL616074,
14256,H,,,,,10576,8,Expert,,1130,B,,,1,BAO_0000019,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,,,,CHEMBL616075,
11139,H,,,,,10576,8,Autocuration,,1131,B,,,1,BAO_0000357,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616076,
11047,D,,,,,10576,9,Expert,,1132,B,,,1,BAO_0000019,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,,,Rattus norvegicus,CHEMBL616077,10116.0
11047,D,,,,,10576,9,Expert,,1133,B,,,1,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,,,Rattus norvegicus,CHEMBL616078,10116.0
11047,D,,,,,10576,9,Expert,,1134,B,,,1,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,,,Rattus norvegicus,CHEMBL616079,10116.0
2395,D,,,CHO-K1,,10576,9,Expert,,1135,B,,,1,BAO_0000219,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,485.0,,,Rattus norvegicus,CHEMBL616080,10116.0
9699,H,,,,,10576,8,Autocuration,,1136,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616081,
12028,D,,,,,10576,9,Expert,,1137,B,Hippocampus,,1,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,,10000000.0,Rattus norvegicus,CHEMBL616082,10116.0
12028,H,,,,,10576,8,Autocuration,,1138,B,Hippocampus,,1,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,,10000000.0,,CHEMBL616083,
5815,H,,,,,10576,8,Autocuration,,1139,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,,CHEMBL616084,
16616,H,,,,,10576,8,Expert,,1140,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,,,,CHEMBL616085,
5815,H,,,,,10576,8,Autocuration,,1141,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,,,,CHEMBL616086,
2761,H,,,,,10576,8,Autocuration,,1142,B,Hippocampus,,1,BAO_0000221,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,,10000000.0,,CHEMBL616087,
13133,H,,,,,10576,8,Expert,,1143,B,,,1,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,,,,CHEMBL616088,
10444,H,,,,,10576,8,Autocuration,,1144,B,,,1,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,,,,CHEMBL616089,
13278,D,,,,,10576,9,Expert,,1145,B,,,1,BAO_0000357,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,,,Rattus norvegicus,CHEMBL616090,10116.0
15874,H,,,,,10576,8,Autocuration,,1146,B,,,1,BAO_0000357,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,,,CHEMBL616091,
10552,H,,,,,10576,8,Autocuration,Membranes,1147,B,Striatum,,1,BAO_0000249,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,2435.0,,CHEMBL616092,
11130,H,,,,,10576,8,Autocuration,,1148,B,,,1,BAO_0000357,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,,,,CHEMBL616093,
11130,H,,,,In vivo,10576,8,Autocuration,,1149,B,,,1,BAO_0000218,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,,,,CHEMBL616094,
14542,H,,,,,10576,8,Autocuration,,1150,B,Brain,,1,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,,955.0,,CHEMBL616095,
13670,D,,,,,10576,9,Expert,,1151,B,,,1,BAO_0000357,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,,Rattus norvegicus,CHEMBL616096,10116.0
9888,H,,,,,10576,8,Expert,,1152,B,,,1,BAO_0000249,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,,,,CHEMBL616097,
3678,D,,,,,10576,9,Expert,Membranes,1153,B,,,1,BAO_0000249,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,,,Rattus norvegicus,CHEMBL616098,10116.0
11332,H,,,,,10576,8,Autocuration,,1154,B,Hippocampus,,1,BAO_0000221,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,10000000.0,,CHEMBL616099,
11332,H,,,,,10576,8,Autocuration,,1155,B,Hippocampus,,1,BAO_0000221,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,10000000.0,,CHEMBL616100,
1185,H,,,,,10576,8,Expert,,1156,B,,,1,BAO_0000357,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616101,
2014,H,,,,,10576,8,Expert,,1157,B,,,1,BAO_0000249,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,,,,CHEMBL616102,
1185,H,,,,,10576,8,Autocuration,,1158,B,,,1,BAO_0000357,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616103,
14429,H,,,,,10576,8,Expert,,1159,B,,,1,BAO_0000019,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,,,,CHEMBL616104,
16288,H,,,,,10576,8,Expert,,1160,B,,,1,BAO_0000019,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,,,,CHEMBL616105,
5432,D,,,,,10576,9,Expert,,1161,B,,,1,BAO_0000019,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,,,Rattus norvegicus,CHEMBL616106,10116.0
14429,H,,,,,10576,8,Autocuration,,1162,B,,,1,BAO_0000019,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,,,,CHEMBL616107,
13672,H,,,,,10576,8,Expert,,1163,B,,,1,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,,,,CHEMBL616108,
11296,H,,,,,10576,8,Expert,,1164,B,Hippocampus,,1,BAO_0000221,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,10000000.0,,CHEMBL616109,
11296,H,,,,,10576,8,Autocuration,,1165,B,,,1,BAO_0000357,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,,,,CHEMBL616110,
14749,H,,,CHO,,10576,8,Expert,,1166,B,,,1,BAO_0000219,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,449.0,,,,CHEMBL616111,
15086,H,,,,,10576,8,Expert,,1167,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,,,,CHEMBL616112,
13462,H,,,,,10576,8,Autocuration,,1168,B,Hippocampus,,1,BAO_0000221,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,,10000000.0,,CHEMBL616113,
15363,H,,,,,10576,8,Autocuration,,1169,B,,,1,BAO_0000019,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616114,
15363,H,,,,,10576,8,Autocuration,,1170,B,,,1,BAO_0000019,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616115,
10796,H,,,,,10576,8,Autocuration,,1171,B,,,1,BAO_0000357,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616116,
12816,H,,,,,10576,8,Expert,,1172,B,Brain,,1,BAO_0000221,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,,955.0,,CHEMBL615844,
13542,H,,,,,10576,8,Expert,,1173,B,Hippocampus,,1,BAO_0000221,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,10000000.0,,CHEMBL615939,
13308,H,,,,,10576,8,Expert,,1174,B,,,1,BAO_0000019,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,,,,CHEMBL615940,
13541,H,,,,,10576,8,Expert,,1175,B,Hippocampus,,1,BAO_0000221,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,,10000000.0,,CHEMBL615941,
10058,H,,,,,10576,8,Autocuration,,1176,B,Hippocampus,,1,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,,10000000.0,,CHEMBL615942,
10058,H,,,,,10576,8,Autocuration,,1177,B,Hippocampus,,1,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,10000000.0,,CHEMBL615943,
10058,H,,,,,10576,8,Autocuration,,1178,B,Hippocampus,,1,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,,10000000.0,,CHEMBL615944,
10058,H,,,,,10576,8,Autocuration,,1179,B,Hippocampus,,1,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,,10000000.0,,CHEMBL615945,
10058,H,,,,,10576,8,Autocuration,,1180,B,Hippocampus,,1,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,,10000000.0,,CHEMBL615946,
10058,H,,,,,10576,8,Autocuration,,1181,B,Hippocampus,,1,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,,10000000.0,,CHEMBL615947,
10058,H,,,,,10576,8,Autocuration,,1182,B,Hippocampus,,1,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,,10000000.0,,CHEMBL615948,
10058,H,,,,,10576,8,Autocuration,,1183,B,Hippocampus,,1,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,,10000000.0,,CHEMBL615949,
10058,H,,,,,10576,8,Autocuration,,1184,B,Hippocampus,,1,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,,10000000.0,,CHEMBL615950,
10058,H,,,,,10576,8,Autocuration,,1185,B,Hippocampus,,1,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,,10000000.0,,CHEMBL615951,
10058,H,,,,,10576,8,Autocuration,,1186,B,Hippocampus,,1,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,,10000000.0,,CHEMBL615952,
10058,H,,,,,10576,8,Autocuration,,1187,B,Hippocampus,,1,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,,10000000.0,,CHEMBL615953,
10058,H,,,,,10576,8,Autocuration,,1188,B,Hippocampus,,1,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,,10000000.0,,CHEMBL615954,
10058,D,,,,,10576,9,Expert,,1189,B,Hippocampus,,1,BAO_0000221,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,10000000.0,Rattus norvegicus,CHEMBL615955,10116.0
10058,H,,,,,10576,8,Autocuration,,1190,B,Hippocampus,,1,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,,10000000.0,,CHEMBL615956,
10058,H,,,,,10576,8,Autocuration,,1191,B,Hippocampus,,1,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,,10000000.0,,CHEMBL615957,
12879,H,,,,,10576,8,Expert,,1192,B,,,1,BAO_0000019,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,,,,CHEMBL615958,
11964,H,,,,,10576,8,Expert,,1193,B,,,1,BAO_0000019,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,,,,CHEMBL615959,
11964,H,,,,,10576,8,Autocuration,,1194,B,,,1,BAO_0000019,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,,,,CHEMBL615960,
11964,H,,,,,10576,8,Autocuration,,1195,B,,,1,BAO_0000019,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,,,,CHEMBL615961,
9548,H,,,,,10576,8,Expert,,1196,B,Brain,,1,BAO_0000221,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,955.0,,CHEMBL615962,
9098,H,,,,,10576,8,Expert,,1197,B,,,1,BAO_0000019,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,,,,CHEMBL615963,
9098,H,,,,,10576,8,Autocuration,,1198,B,,,1,BAO_0000019,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,,,,CHEMBL615964,
9098,H,,,,,10576,8,Autocuration,,1199,B,,,1,BAO_0000019,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,,,,CHEMBL615965,
13248,H,,,CHO,,10576,8,Expert,,1200,B,,,1,BAO_0000219,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,449.0,,,,CHEMBL615966,
3147,H,,,,,10576,8,Expert,,1201,B,,,1,BAO_0000249,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,,,,CHEMBL615967,
13949,H,,,,,10576,8,Expert,,1202,B,,,1,BAO_0000019,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,,,CHEMBL615968,
11883,H,,,CHO,,10576,8,Autocuration,,1203,B,,,1,BAO_0000218,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),449.0,,,,CHEMBL615969,
11883,H,,,,,10576,8,Autocuration,,1204,B,,,1,BAO_0000218,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,,,,CHEMBL615970,
11883,D,,,,,10576,9,Expert,,1205,B,,,1,BAO_0000357,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,,,Rattus norvegicus,CHEMBL615971,10116.0
15535,H,,,,,10576,8,Expert,Membranes,1206,B,,,1,BAO_0000249,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,,CHEMBL615972,
15535,H,,,,,10576,8,Autocuration,,1207,B,,,1,BAO_0000249,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,,,,CHEMBL615973,
15535,H,,,,,10576,8,Autocuration,,1208,B,,,1,BAO_0000249,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,,,,CHEMBL615974,
16372,D,,,CHO,,51,9,Expert,,1209,B,,,1,BAO_0000219,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,449.0,,,Homo sapiens,CHEMBL615975,9606.0
14608,H,,,,,10576,8,Expert,,1210,B,,,1,BAO_0000249,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,,,,CHEMBL615976,
4795,D,,,,,10576,9,Expert,,1211,B,Hippocampus,,1,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,,10000000.0,Rattus norvegicus,CHEMBL872106,10116.0
13863,H,,,,,10576,8,Autocuration,,1212,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL615977,
13863,H,,,,,10576,8,Autocuration,,1213,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,,,,CHEMBL615978,
13863,H,,,,,10576,8,Autocuration,,1214,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,,,,CHEMBL616166,
13863,H,,,,,10576,8,Autocuration,,1215,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,,,,CHEMBL616167,
13863,H,,,,,10576,8,Autocuration,,1216,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,,,,CHEMBL616168,
13863,H,,,,,10576,8,Autocuration,,1217,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,,,,CHEMBL616169,
13863,H,,,,,10576,8,Autocuration,,1218,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,,,,CHEMBL616170,
13863,H,,,,,10576,8,Autocuration,,1219,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,,,,CHEMBL616171,
13863,H,,,,,10576,8,Autocuration,,1220,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,,,,CHEMBL616172,
13863,H,,,,,10576,8,Autocuration,,1221,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,,,,CHEMBL616173,
13863,H,,,,,10576,8,Autocuration,,1222,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,,,,CHEMBL616174,
13863,H,,,,,10576,8,Autocuration,,1223,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,,,,CHEMBL616175,
13863,H,,,,,10576,8,Autocuration,,1224,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,,,,CHEMBL616176,
13863,H,,,,,10576,8,Autocuration,,1225,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,,,,CHEMBL616177,
13863,H,,,,,10576,8,Autocuration,,1226,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,,,,CHEMBL616178,
9742,H,,,,,10576,8,Autocuration,,1227,B,,,1,BAO_0000019,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,,,,CHEMBL616179,
12073,H,,,,,10576,8,Autocuration,,1228,B,,,1,BAO_0000357,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616180,
4101,H,,,,,10576,8,Autocuration,,1229,B,,,1,BAO_0000357,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,,,,CHEMBL616181,
15360,H,,,,,10576,8,Autocuration,,1230,B,,,1,BAO_0000019,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,,,,CHEMBL616182,
11576,H,,,,,10576,8,Autocuration,,1231,B,Hippocampus,,1,BAO_0000221,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,10000000.0,,CHEMBL616183,
5834,H,,,,,10576,8,Expert,,1232,B,,,1,BAO_0000019,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,,,,CHEMBL615874,
2395,D,,,CHO-K1,,10576,9,Expert,,1233,B,,,1,BAO_0000219,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,485.0,,,Rattus norvegicus,CHEMBL615875,10116.0
1375,H,,,,,10576,8,Autocuration,,1234,B,,,1,BAO_0000019,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,,,,CHEMBL615876,
1375,H,,,,,10576,8,Autocuration,,1235,B,,,1,BAO_0000019,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,,,,CHEMBL615877,
3967,H,,,,,10576,8,Autocuration,,1236,B,,,1,BAO_0000357,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,,,,CHEMBL615878,
12884,H,,,,,10576,8,Expert,,1237,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,,,,CHEMBL615879,
2343,H,,,,,10576,8,Expert,,1238,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,,,,CHEMBL615880,
11511,H,,,,,10576,8,Autocuration,,1239,B,,,1,BAO_0000019,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,,,CHEMBL615881,
11511,D,,,,,10576,9,Expert,,1240,B,,,1,BAO_0000019,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,,Rattus norvegicus,CHEMBL615882,10116.0
16394,H,,,,In vivo,10576,8,Autocuration,,1241,F,,,1,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,,,,CHEMBL615883,
16394,H,,,,In vivo,10576,8,Autocuration,,1242,F,,,1,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,,,,CHEMBL615884,
16394,H,,,,In vivo,10576,8,Autocuration,,1243,F,,,1,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,,,,CHEMBL615885,
16394,H,,,,In vivo,10576,8,Autocuration,,1244,F,,,1,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,,,,CHEMBL615886,
16394,H,,,,In vivo,10576,8,Autocuration,,1245,F,,,1,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,,,,CHEMBL615887,
16394,H,,,,In vivo,10576,8,Autocuration,,1246,F,,,1,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,,,,CHEMBL615888,
16394,H,,,,In vivo,10576,8,Autocuration,,1247,F,,,1,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,,,,CHEMBL615889,
16394,H,,,,In vivo,10576,8,Autocuration,,1248,F,,,1,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,,,,CHEMBL615890,
16394,H,,,,In vivo,10576,8,Autocuration,,1249,F,,,1,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,,,,CHEMBL615891,
16394,H,,,,In vivo,10576,8,Autocuration,,1250,F,,,1,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,,,,CHEMBL615892,
16394,H,,,,In vivo,10576,8,Autocuration,,1251,F,,,1,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,,,,CHEMBL615893,
16394,H,,,,In vivo,10576,8,Autocuration,,1252,F,,,1,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,,,,CHEMBL615894,
16394,H,,,,In vivo,10576,8,Autocuration,,1253,F,,,1,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,,,,CHEMBL615895,
16394,H,,,,In vivo,10576,8,Autocuration,,1254,F,,,1,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,,,,CHEMBL615896,
16394,H,,,,In vivo,10576,8,Autocuration,,1255,F,,,1,BAO_0000218,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,,,,CHEMBL615897,
16616,D,,,,,10576,9,Expert,Membranes,1256,F,,,1,BAO_0000249,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,,,Rattus norvegicus,CHEMBL615898,10116.0
16796,H,,,,,10576,8,Autocuration,,1257,B,,,1,BAO_0000019,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,,,,CHEMBL615899,
16796,H,,,,,10576,8,Autocuration,,1258,B,,,1,BAO_0000019,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,,,CHEMBL616291,
15629,H,,,,,10576,8,Autocuration,,1259,B,,,1,BAO_0000357,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,,,,CHEMBL616292,
13241,H,,,,,10576,8,Autocuration,,1260,F,,,1,BAO_0000249,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,,,CHEMBL616293,
12073,H,,,,,10576,8,Expert,,1261,B,Hippocampus,,1,BAO_0000221,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10000000.0,,CHEMBL616294,
14286,H,,,,,10576,8,Autocuration,,1262,B,Hippocampus,,1,BAO_0000249,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,,10000000.0,,CHEMBL616295,
14542,H,,,,,10576,8,Autocuration,,1263,B,Brain,,1,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,,955.0,,CHEMBL616296,
13630,H,,,,,10576,8,Autocuration,,1264,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,,,CHEMBL616297,
13630,H,,,,,10576,8,Autocuration,,1265,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,,,,CHEMBL616605,
13630,H,,,,,10576,8,Autocuration,,1266,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,,,,CHEMBL616606,
13630,H,,,,,10576,8,Autocuration,,1267,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,,,CHEMBL616607,
13630,H,,,,,10576,8,Expert,,1268,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,,,CHEMBL616608,
13630,H,,,,,10576,8,Autocuration,,1269,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,,,,CHEMBL616609,
13630,D,,,,,10576,9,Expert,,1270,F,,,1,BAO_0000019,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,,,Rattus norvegicus,CHEMBL616610,10116.0
13630,H,,,,,10576,8,Autocuration,,1271,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,,,CHEMBL616611,
13630,H,,,,,10576,8,Expert,,1272,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,,,,CHEMBL616612,
13630,H,,,,,10576,8,Autocuration,,1273,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,,,,CHEMBL616613,
13630,H,,,,,10576,8,Expert,,1274,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,,,,CHEMBL616614,
13630,H,,,,,10576,8,Autocuration,,1275,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,,,,CHEMBL616615,
13630,H,,,,,10576,8,Expert,,1276,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,,,CHEMBL616616,
13630,H,,,,,10576,8,Autocuration,,1277,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,,,,CHEMBL616617,
13630,H,,,,,10576,8,Autocuration,,1278,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,,,CHEMBL616618,
13630,H,,,,,10576,8,Autocuration,,1279,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,,,,CHEMBL616619,
13630,H,,,,,10576,8,Expert,,1280,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,,,,CHEMBL616620,
13630,H,,,,,10576,8,Expert,,1281,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,,,CHEMBL616621,
13630,H,,,,,10576,8,Autocuration,,1282,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,,,,CHEMBL616622,
13630,H,,,,,10576,8,Expert,,1283,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,,,,CHEMBL616146,
13630,H,,,,,10576,8,Autocuration,,1284,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,,,,CHEMBL832873,
13630,H,,,,,10576,8,Autocuration,,1285,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,,,,CHEMBL616147,
13630,H,,,,,10576,8,Autocuration,,1286,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,,,CHEMBL872872,
13630,H,,,,,10576,8,Autocuration,,1287,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,,,CHEMBL616148,
9783,H,,,,,10576,8,Autocuration,,1288,B,Hippocampus,,1,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,,10000000.0,,CHEMBL616149,
9783,H,,,,,10576,8,Expert,,1289,B,Hippocampus,,1,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,,10000000.0,,CHEMBL616150,
14331,D,,,,,10576,9,Expert,Membranes,1290,B,,,1,BAO_0000249,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,,,Rattus norvegicus,CHEMBL616151,10116.0
15260,H,,,,,10576,8,Expert,,1291,B,Hippocampus,,1,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,,10000000.0,,CHEMBL872873,
15260,H,,,,,10576,8,Autocuration,,1292,B,Hippocampus,,1,BAO_0000221,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,,10000000.0,,CHEMBL616670,
15260,H,,,,,10576,8,Autocuration,,1293,B,Hippocampus,,1,BAO_0000221,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,,10000000.0,,CHEMBL616671,
16616,D,,,,,10576,9,Expert,,1294,F,,,1,BAO_0000249,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,,,Rattus norvegicus,CHEMBL884861,10116.0
15629,H,,,,,10576,8,Autocuration,,1295,B,,,1,BAO_0000357,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,,,,CHEMBL616672,
15086,H,,,,,10576,8,Autocuration,,1296,B,,,1,BAO_0000019,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,,,CHEMBL616673,
5717,H,,,,,10576,8,Expert,,1297,F,,,1,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,,,CHEMBL616674,
12652,H,,,,,10576,8,Autocuration,,1298,B,,,1,BAO_0000357,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,,,CHEMBL616675,
14608,H,,,,,10576,8,Autocuration,,1299,B,Hippocampus,,1,BAO_0000221,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,,10000000.0,,CHEMBL616676,
12306,H,,,,,10576,8,Autocuration,,1300,B,Hippocampus,,1,BAO_0000221,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,10000000.0,,CHEMBL616677,
12306,H,,,,,10576,8,Autocuration,,1301,B,Hippocampus,,1,BAO_0000221,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,10000000.0,,CHEMBL616678,
15247,D,,,,,10576,9,Expert,,1302,B,,,1,BAO_0000357,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,,Rattus norvegicus,CHEMBL616679,10116.0
17529,H,,,,,10576,8,Expert,,1303,B,Hippocampus,,1,BAO_0000221,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,,10000000.0,,CHEMBL616680,
14826,H,,,,,10576,8,Autocuration,,1304,B,Hippocampus,,1,BAO_0000221,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10000000.0,,CHEMBL616681,
14826,H,,,,,10576,8,Autocuration,,1305,B,Hippocampus,,1,BAO_0000221,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10000000.0,,CHEMBL616682,
13241,H,,,,,10576,8,Autocuration,,1306,B,Hippocampus,,1,BAO_0000221,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,10000000.0,,CHEMBL616683,
14093,H,,,,,10576,8,Autocuration,,1307,B,Hippocampus,,1,BAO_0000221,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,,10000000.0,,CHEMBL616684,
14093,H,,,,,10576,8,Autocuration,,1308,B,Hippocampus,,1,BAO_0000221,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,,10000000.0,,CHEMBL616685,
14442,H,,,,,10576,8,Autocuration,,1309,B,Brain,,1,BAO_0000221,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,,955.0,,CHEMBL616686,
9919,H,,,,,10576,8,Autocuration,,1310,B,,,1,BAO_0000357,Affinity for 5-hydroxytryptamine 1A receptor site,,,,,CHEMBL616687,
9919,H,,,,,10576,8,Autocuration,,1311,B,,,1,BAO_0000357,Affinity for 5-hydroxytryptamine 1A receptor site,,,,,CHEMBL616688,
11440,H,,,,,10576,8,Autocuration,,1312,B,Hippocampus,,1,BAO_0000221,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,,10000000.0,,CHEMBL616689,
11257,H,,,,,10576,8,Autocuration,,1313,B,,,1,BAO_0000357,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,,,,CHEMBL616690,
10330,H,,,,,10576,8,Expert,,1314,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,,,,CHEMBL616691,
17331,D,,,,,10576,9,Expert,,1315,B,Hippocampus,,1,BAO_0000221,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,,10000000.0,Rattus norvegicus,CHEMBL616692,10116.0
16567,H,,,,,10576,8,Expert,,1316,B,,,1,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,,,,CHEMBL616693,
12058,D,,,,,10576,9,Expert,,1317,B,,,1,BAO_0000019,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,,Rattus norvegicus,CHEMBL616694,10116.0
9699,H,,,,,10576,8,Autocuration,,1318,B,Hippocampus,,1,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,,10000000.0,,CHEMBL616695,
9547,H,,,,,10576,8,Autocuration,,1319,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,,,,CHEMBL616696,
10330,H,,,,,10576,8,Autocuration,,1320,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,,,,CHEMBL616697,
14331,H,,,,,10576,8,Autocuration,,1321,B,,,1,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616698,
14060,D,,,,,10576,9,Expert,,1322,B,,,1,BAO_0000019,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,,,Rattus norvegicus,CHEMBL616949,10116.0
14744,H,,,,,10576,8,Autocuration,,1323,B,Hippocampus,,1,BAO_0000221,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,,10000000.0,,CHEMBL616950,
13506,H,,,,,10576,8,Autocuration,,1324,B,,,1,BAO_0000357,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,,,CHEMBL832875,
10862,H,,,,,10576,8,Expert,,1325,B,Brain,,1,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,955.0,,CHEMBL616951,
10862,H,,,,,10576,8,Expert,,1326,B,Brain,,1,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,955.0,,CHEMBL616952,
10062,H,,,,,10576,8,Expert,,1327,B,,,1,BAO_0000357,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,,,,CHEMBL616953,
12073,H,,,,,10576,8,Autocuration,,1328,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,,,,CHEMBL616954,
14875,H,,,,,106,8,Autocuration,,1329,B,,,1,BAO_0000357,GTPgammaS radioligand binding assay,,,,,CHEMBL616955,
2391,H,,,,,106,8,Autocuration,,1330,B,,,1,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,,,CHEMBL616956,
2391,H,,,,,106,8,Autocuration,,1331,F,,,1,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,,,,CHEMBL616957,
2391,H,,,,,106,8,Autocuration,,1332,F,,,1,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,,,,CHEMBL616958,
2391,H,,,,,106,8,Autocuration,,1333,B,,,1,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616959,
2391,H,,,,,106,8,Autocuration,,1334,B,,,1,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,,,CHEMBL616960,
2391,H,,,,,106,8,Autocuration,,1335,F,,,1,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,,,,CHEMBL616961,
17211,H,,,HeLa,,106,8,Expert,,1336,B,,,1,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,308.0,,,,CHEMBL616962,
17211,H,,,HeLa,,106,8,Autocuration,,1337,B,,,1,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,308.0,,,,CHEMBL616963,
6491,D,,,,,106,9,Expert,,1338,B,,,1,BAO_0000357,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,,,Homo sapiens,CHEMBL616524,9606.0
16190,H,,,CHO,,106,8,Autocuration,,1339,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,449.0,,,,CHEMBL616525,
14165,H,,,,,106,8,Autocuration,,1340,B,,,1,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,,,,CHEMBL872908,
14165,H,,,,,106,8,Autocuration,,1341,B,,,1,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,,,,CHEMBL616526,
4234,D,,,,,106,9,Expert,,1342,B,,,1,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,,,Homo sapiens,CHEMBL616527,9606.0
6328,H,,,,,106,8,Expert,,1343,B,,,1,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,,,CHEMBL616528,
14770,H,,,,,106,8,Autocuration,,1344,B,,,1,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,,CHEMBL616529,
2598,H,,,,,106,8,Autocuration,,1345,B,,,1,BAO_0000357,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,,,,CHEMBL616530,
6897,H,,,,,106,8,Expert,,1346,B,,,1,BAO_0000357,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616531,
6897,H,,,,,106,8,Autocuration,,1347,B,,,1,BAO_0000357,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616532,
6013,H,,,,,106,8,Autocuration,,1348,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616533,
5843,H,,,,,106,8,Expert,,1349,B,,,1,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616534,
14454,H,,,,,106,8,Expert,,1350,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,,,,CHEMBL616535,
16209,H,,,,,106,8,Autocuration,,1351,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,,,,CHEMBL616536,
3935,H,,,,,106,8,Autocuration,,1352,B,,,1,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616537,
13729,H,,,CHO-K1,,106,8,Expert,,1353,F,,,1,BAO_0000219,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,485.0,,,,CHEMBL616538,
14251,H,,,,,106,8,Expert,,1354,F,,,1,BAO_0000019,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616539,
17085,H,,,,,106,8,Expert,,1355,B,,,1,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616540,
3025,H,,,,,106,8,Autocuration,,1356,B,,,1,BAO_0000357,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,,,CHEMBL616429,
15315,H,,,,,106,8,Expert,,1357,B,,,1,BAO_0000357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616430,
14214,D,,,,,106,9,Expert,,1358,B,,,1,BAO_0000219,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,,,Homo sapiens,CHEMBL616431,9606.0
3804,D,,,,,106,9,Expert,,1359,B,,,1,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,,Homo sapiens,CHEMBL616432,9606.0
2391,D,,,,,106,9,Expert,,1360,B,,,1,BAO_0000357,Affinity for 5-hydroxytryptamine 1B receptor subtype,,,,Homo sapiens,CHEMBL616433,9606.0
4175,D,,,,,106,9,Expert,,1361,B,,,1,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,,Homo sapiens,CHEMBL616434,9606.0
17296,H,,,CHO,,106,8,Autocuration,,1362,B,,,1,BAO_0000219,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,449.0,,,,CHEMBL616435,
17085,H,,,,,106,8,Expert,,1363,B,,,1,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,,,,CHEMBL616436,
17211,H,,,HeLa,,106,8,Autocuration,,1364,B,,,1,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,308.0,,,,CHEMBL616437,
17211,H,,,HeLa,,106,8,Autocuration,,1365,B,,,1,BAO_0000219,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,308.0,,,,CHEMBL616438,
17211,H,,,HeLa,,106,8,Autocuration,,1366,B,,,1,BAO_0000219,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,308.0,,,,CHEMBL616439,
15926,D,,,,,106,9,Expert,,1367,B,,,1,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,,,Homo sapiens,CHEMBL616440,9606.0
16312,H,,,CHO-K1,,106,8,Autocuration,,1368,B,,,1,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,485.0,,,,CHEMBL616441,
5843,H,,,,,106,8,Expert,,1369,B,,,1,BAO_0000357,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,,,,CHEMBL616442,
5843,H,,,,,106,8,Autocuration,,1370,B,,,1,BAO_0000357,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616443,
16312,H,,,CHO-K1,,106,8,Expert,,1371,B,,,1,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,485.0,,,,CHEMBL616444,
15926,D,,,,,106,9,Expert,,1372,B,,,1,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1B receptor,,,,Homo sapiens,CHEMBL616445,9606.0
15926,D,,,,,106,9,Expert,,1373,B,,,1,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1B receptor,,,,Homo sapiens,CHEMBL616446,9606.0
4540,D,,,CHO,,106,9,Expert,,1374,B,,,1,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,449.0,,,Homo sapiens,CHEMBL616447,9606.0
6166,H,,,,,106,8,Autocuration,,1375,B,,,1,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,,,,CHEMBL616448,
17296,H,,,CHO,,106,8,Autocuration,,1376,B,,,1,BAO_0000219,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,449.0,,,,CHEMBL616449,
17296,H,,,CHO,,106,8,Autocuration,,1377,B,,,1,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,449.0,,,,CHEMBL616450,
17296,H,,,CHO,,106,8,Autocuration,,1378,B,,,1,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,449.0,,,,CHEMBL857974,
15779,H,,,CHO,,106,8,Autocuration,,1379,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,449.0,,,,CHEMBL616451,
15779,H,,,CHO,,106,8,Autocuration,,1380,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,449.0,,,,CHEMBL616452,
15779,H,,,CHO,,106,8,Autocuration,,1381,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,449.0,,,,CHEMBL616453,
4199,H,,,CHO,,106,8,Autocuration,,1382,B,,,1,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,449.0,,,,CHEMBL616454,
14875,D,,,,,106,9,Expert,,1383,B,,,1,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1B receptor,,,,Homo sapiens,CHEMBL616455,9606.0
15146,H,,,CHO,,106,8,Autocuration,,1384,B,,,1,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,449.0,,,,CHEMBL616456,
5213,H,,,,,106,8,Autocuration,,1385,B,,,1,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,,,,CHEMBL616457,
14818,H,,,CHO,,106,8,Autocuration,,1386,B,,,1,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,449.0,,,,CHEMBL616458,
4829,H,,,CHO,,106,8,Autocuration,,1387,B,,,1,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",449.0,,,,CHEMBL616459,
14454,H,,,,,106,8,Expert,,1388,F,,,1,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,,,,CHEMBL616460,
14454,H,,,,,106,8,Expert,,1389,F,,,1,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,,,,CHEMBL616461,
14875,H,,,CHO,,106,8,Autocuration,,1390,F,,,1,BAO_0000219,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",449.0,,,,CHEMBL616462,
14875,H,,,CHO,,106,8,Autocuration,,1391,F,,,1,BAO_0000219,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",449.0,,,,CHEMBL616463,
15250,H,,,,,105,8,Autocuration,,1392,F,,,1,BAO_0000019,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,,,,CHEMBL616464,
15250,H,,,CHO,,105,8,Autocuration,,1393,B,,,1,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,449.0,,,,CHEMBL616465,
15086,H,,,,,17105,8,Autocuration,,1394,B,,,1,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,,,CHEMBL832874,
3025,H,,,,,106,8,Autocuration,,1395,F,,,1,BAO_0000019,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,,,Oryctolagus cuniculus,CHEMBL616184,9986.0
14998,H,,,,,106,8,Autocuration,,1396,B,,,1,BAO_0000019,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,,,Oryctolagus cuniculus,CHEMBL616185,9986.0
14998,H,,,,,106,8,Intermediate,,1397,B,,,1,BAO_0000019,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,,,Oryctolagus cuniculus,CHEMBL616186,9986.0
14998,H,,,,,106,8,Autocuration,,1398,B,,,1,BAO_0000019,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,,,Oryctolagus cuniculus,CHEMBL616187,9986.0
13969,H,,,,,10577,8,Expert,,1399,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,,,,CHEMBL616188,
13392,D,,,,,10577,9,Intermediate,,1400,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1B receptor,,,,,CHEMBL873475,
3651,D,,,,,10577,9,Expert,,1401,B,Striatum,,1,BAO_0000019,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,,2435.0,Rattus norvegicus,CHEMBL616189,10116.0
10025,H,,,,,10577,8,Expert,,1402,B,,,1,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,,,CHEMBL616190,
13863,H,,,,,10576,8,Autocuration,,1403,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,,,,CHEMBL616191,
13863,H,,,,,10576,8,Autocuration,,1404,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,,,,CHEMBL616192,
13863,H,,,,,10576,8,Autocuration,,1405,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,,,,CHEMBL616193,
13863,H,,,,,10576,8,Autocuration,,1406,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,,,,CHEMBL616194,
13863,H,,,,,10576,8,Autocuration,,1407,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,,,,CHEMBL616195,
13863,H,,,,,10576,8,Autocuration,,1408,B,,,1,BAO_0000357,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,,,,CHEMBL616196,
4622,H,,,,,10576,8,Autocuration,,1409,B,Hippocampus,,1,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,,10000000.0,,CHEMBL616197,
14911,H,,,,,10576,8,Intermediate,,1410,B,,,1,BAO_0000019,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL616198,
12678,H,,,,,10576,8,Autocuration,,1411,B,Hippocampus,,1,BAO_0000221,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,10000000.0,,CHEMBL616199,
12678,H,,,,,10576,8,Expert,,1412,B,Hippocampus,,1,BAO_0000221,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,,10000000.0,,CHEMBL616200,
14235,H,,,,,10576,8,Expert,,1413,B,Hippocampus,,1,BAO_0000221,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,10000000.0,,CHEMBL616201,
14949,H,,,,,10576,8,Expert,,1414,B,Hippocampus,,1,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,10000000.0,,CHEMBL616202,
14949,H,,,,,10576,8,Expert,,1415,B,Hippocampus,,1,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,10000000.0,,CHEMBL616203,
14949,H,,,,,10576,8,Expert,,1416,B,Hippocampus,,1,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,,10000000.0,,CHEMBL616204,
14949,H,,,,,10576,8,Expert,,1417,B,Hippocampus,,1,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,,10000000.0,,CHEMBL616205,
14949,H,,,,,10576,8,Expert,,1418,B,Hippocampus,,1,BAO_0000221,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,,10000000.0,,CHEMBL616206,
16118,H,,,,,10576,8,Expert,,1419,B,,,1,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,,,CHEMBL616207,
3268,H,,,,,10576,8,Autocuration,,1420,B,,,1,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,,,,CHEMBL616208,
3268,H,,,,,10576,8,Autocuration,,1421,B,,,1,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,,,,CHEMBL616209,
16117,H,,,,,10576,8,Expert,,1422,B,,,1,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,,,,CHEMBL616210,
9783,H,,,,,10576,8,Expert,,1423,B,Hippocampus,,1,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,,10000000.0,,CHEMBL616211,
9783,H,,,,,10576,8,Autocuration,,1424,B,Hippocampus,,1,BAO_0000221,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,,10000000.0,,CHEMBL616504,
14356,D,,,,,10576,9,Expert,,1425,B,Hippocampus,,1,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,,10000000.0,Rattus norvegicus,CHEMBL616505,10116.0
15740,H,,,,,10576,8,Autocuration,,1426,F,,,1,BAO_0000019,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616506,
12306,H,,,,,10576,8,Autocuration,,1427,B,Hippocampus,,1,BAO_0000221,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,10000000.0,,CHEMBL872107,
13348,D,,,,,10576,9,Expert,,1428,B,Hippocampus,,1,BAO_0000221,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,,10000000.0,Rattus norvegicus,CHEMBL616507,10116.0
10394,H,,,,,10576,8,Autocuration,,1429,B,,,1,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,,,,CHEMBL616303,
15260,H,,,,,10576,8,Autocuration,,1430,B,Hippocampus,,1,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,,10000000.0,,CHEMBL616304,
10046,H,,,,,10576,8,Expert,,1431,B,Hippocampus,,1,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,10000000.0,,CHEMBL616305,
15260,H,,,,,10576,8,Intermediate,,1432,F,Hippocampus,,1,BAO_0000221,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,,10000000.0,,CHEMBL616306,
12851,H,,,,,10576,8,Autocuration,,1433,B,,,1,BAO_0000357,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616307,
2148,D,,,,,10576,9,Expert,,1434,B,Hippocampus,,1,BAO_0000221,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,,10000000.0,Rattus norvegicus,CHEMBL881829,10116.0
13134,H,,,,,10576,8,Expert,,1435,B,,,1,BAO_0000357,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,,,,CHEMBL616308,
12462,H,,,,,10576,8,Autocuration,,1436,B,,,1,BAO_0000019,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,,,,CHEMBL616309,
12462,H,,,,,10576,8,Expert,,1437,B,,,1,BAO_0000019,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,,,,CHEMBL616310,
12462,H,,,CHO,,10576,8,Autocuration,,1438,B,,,1,BAO_0000219,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,449.0,,,,CHEMBL616311,
11933,H,,,,,10576,8,Expert,,1439,B,,,1,BAO_0000357,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL616312,
11933,H,,,,,10576,8,Autocuration,,1440,B,,,1,BAO_0000357,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,,,,CHEMBL616313,
403,D,,,,,10576,9,Expert,,1441,B,Hippocampus,,1,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,,10000000.0,Rattus norvegicus,CHEMBL616314,10116.0
15538,H,,,,,10576,8,Autocuration,,1442,B,Hippocampus,,1,BAO_0000221,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10000000.0,,CHEMBL616315,
15538,H,,,,,10576,8,Autocuration,,1443,B,Hippocampus,,1,BAO_0000221,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,,10000000.0,,CHEMBL616567,
15538,H,,,,,10576,8,Autocuration,,1444,B,Hippocampus,,1,BAO_0000221,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,,10000000.0,,CHEMBL616568,
12464,H,,,,,10576,8,Intermediate,,1445,B,,,1,BAO_0000019,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,,,,CHEMBL616569,
1455,H,,,,,10576,8,Expert,,1446,B,,,1,BAO_0000357,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,,,,CHEMBL616570,
12652,H,,,,,10576,8,Autocuration,,1447,B,,,1,BAO_0000357,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,,,CHEMBL616571,
12639,H,,,,,10576,8,Autocuration,,1448,B,Hippocampus,,1,BAO_0000221,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,,10000000.0,,CHEMBL616572,
13949,H,,,,,10576,8,Expert,,1449,B,,,1,BAO_0000249,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,,,,CHEMBL616573,
12463,D,,,,,10576,9,Expert,,1450,B,,,1,BAO_0000357,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,,,Rattus norvegicus,CHEMBL616574,10116.0
14829,H,,,,,10576,8,Expert,,1451,B,Hippocampus,,1,BAO_0000221,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,,10000000.0,,CHEMBL616575,
14829,H,,,,,10576,8,Autocuration,,1452,B,Hippocampus,,1,BAO_0000221,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,,10000000.0,,CHEMBL872108,
12092,H,,,,,10576,8,Autocuration,,1453,B,,,1,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,,,,CHEMBL616576,
403,H,,,,,10576,8,Autocuration,,1454,B,,,1,BAO_0000249,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,,,,CHEMBL616577,
403,H,,,,,10576,8,Autocuration,,1455,B,,,1,BAO_0000249,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,,,,CHEMBL616578,
3967,H,,,,,10576,8,Expert,,1456,B,,,1,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,,,,CHEMBL616579,
12771,D,,,,,10576,9,Expert,,1457,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,,,Rattus norvegicus,CHEMBL616580,10116.0
15086,H,,,,,10576,8,Autocuration,,1458,B,,,1,BAO_0000019,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,,,CHEMBL616581,
14909,H,,,,,10576,8,Autocuration,,1459,B,Hippocampus,,1,BAO_0000221,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10000000.0,,CHEMBL616582,
14949,H,,,,,10576,8,Expert,,1460,B,Hippocampus,,1,BAO_0000221,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,10000000.0,,CHEMBL616583,
2309,D,,,,,10576,9,Expert,,1461,B,Hippocampus,,1,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,,10000000.0,Rattus norvegicus,CHEMBL616584,10116.0
4170,H,,,,,10576,8,Expert,,1462,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616585,
11642,D,,,,,10576,9,Expert,,1463,B,Hippocampus,,1,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,,10000000.0,Rattus norvegicus,CHEMBL616586,10116.0
11642,H,,,,,10576,8,Autocuration,,1464,B,Hippocampus,,1,BAO_0000221,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,,10000000.0,,CHEMBL616587,
12953,H,,,,,10576,8,Autocuration,,1465,B,Hippocampus,,1,BAO_0000221,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,,10000000.0,,CHEMBL616588,
12953,H,,,,,10576,8,Autocuration,,1466,B,Hippocampus,,1,BAO_0000221,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,10000000.0,,CHEMBL616589,
12953,H,,,,,10576,8,Expert,,1467,B,Hippocampus,,1,BAO_0000221,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,,10000000.0,,CHEMBL616590,
12903,H,,,CHO,,10576,8,Expert,,1468,B,,,1,BAO_0000219,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",449.0,,,,CHEMBL616591,
12536,H,,,,,10576,8,Expert,,1469,B,,,1,BAO_0000357,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616592,
10058,H,,,,,10576,8,Autocuration,,1470,B,,,1,BAO_0000357,The inhibition activity of 5-HT1A at 1 uM,,,,,CHEMBL616593,
12902,H,,,CHO-K1,,10576,8,Expert,,1471,B,,,1,BAO_0000219,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",485.0,,,,CHEMBL616594,
14057,H,,,,,10576,8,Expert,,1472,B,,,1,BAO_0000249,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,,,,CHEMBL616595,
11296,H,,,,,10576,8,Autocuration,,1473,B,,,1,BAO_0000357,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,,,,CHEMBL616596,
11296,H,,,,,10576,8,Autocuration,,1474,B,Hippocampus,,1,BAO_0000221,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,10000000.0,,CHEMBL616597,
11296,H,,,,,10576,8,Expert,,1475,B,Hippocampus,,1,BAO_0000221,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,10000000.0,,CHEMBL616598,
16616,D,,,,,10576,9,Expert,Membranes,1476,F,,,1,BAO_0000249,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,,,Rattus norvegicus,CHEMBL616599,10116.0
16616,D,,,,,10576,9,Expert,Membranes,1477,F,Hippocampus,,1,BAO_0000249,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,,10000000.0,Rattus norvegicus,CHEMBL616600,10116.0
16567,H,,,,,10576,8,Autocuration,,1478,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,,,,CHEMBL616601,
16567,H,,,,,10576,8,Autocuration,,1479,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,,,,CHEMBL616602,
16567,H,,,,,10576,8,Autocuration,,1480,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,,,,CHEMBL616603,
16567,H,,,,,10576,8,Autocuration,,1481,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,,,,CHEMBL616604,
17136,H,,,,,10576,8,Autocuration,,1482,B,,,1,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,,,,CHEMBL616316,
17136,H,,,,,10576,8,Autocuration,,1483,B,,,1,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,,,,CHEMBL616317,
16616,D,,,,,10576,9,Expert,,1484,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,,,Rattus norvegicus,CHEMBL616318,10116.0
17331,H,,,,,10576,8,Autocuration,,1485,B,Hippocampus,,1,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,,10000000.0,,CHEMBL616319,
17331,H,,,,,10576,8,Autocuration,,1486,B,Hippocampus,,1,BAO_0000221,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,,10000000.0,,CHEMBL616320,
17167,D,,,,,10576,9,Expert,,1487,B,Hippocampus,,1,BAO_0000221,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,,10000000.0,Rattus norvegicus,CHEMBL616321,10116.0
15740,H,,,,,10576,8,Autocuration,,1488,F,,,1,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,,,CHEMBL616322,
15740,H,,,,,10576,8,Autocuration,,1489,F,,,1,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,,,,CHEMBL616323,
4671,H,,,,,10576,8,Autocuration,,1490,B,,,1,BAO_0000357,Ratio of binding affinity to 5-HT 1A and D2 receptor,,,,,CHEMBL616324,
10058,H,,,,,10576,8,Autocuration,,1491,B,Hippocampus,,1,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,10000000.0,,CHEMBL616325,
10058,H,,,,,10576,8,Autocuration,,1492,B,Hippocampus,,1,BAO_0000221,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,10000000.0,,CHEMBL616326,
10058,H,,,,,10576,8,Autocuration,,1493,B,Hippocampus,,1,BAO_0000221,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,,10000000.0,,CHEMBL616327,
12073,H,,,,,10576,8,Autocuration,,1494,B,,,1,BAO_0000357,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616328,
2759,H,,,,,10576,8,Autocuration,,1495,B,,,1,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,,,CHEMBL858110,
2759,H,,,,,10576,8,Autocuration,,1496,F,,,1,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,,,CHEMBL616329,
2759,H,,,,,10576,8,Autocuration,,1497,B,,,1,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,,,CHEMBL616330,
2759,H,,,,,10576,8,Autocuration,,1498,F,,,1,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,,,CHEMBL616331,
2759,H,,,,,10576,8,Autocuration,,1499,F,,,1,BAO_0000249,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,,,CHEMBL616332,
9737,H,,,,,10576,8,Autocuration,,1500,B,Brain,,1,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,955.0,,CHEMBL857063,
9737,H,,,,,10576,8,Autocuration,,1501,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,,,,CHEMBL616333,
5717,H,,,,,10576,8,Expert,,1502,F,,,1,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,,,,CHEMBL616334,
12253,H,,,,,10576,8,Autocuration,,1503,B,Hippocampus,,1,BAO_0000221,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,10000000.0,,CHEMBL616335,
14025,H,,,,,10576,8,Autocuration,,1504,B,,,1,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,,,,CHEMBL616336,
10425,H,,,,,10576,8,Expert,,1505,B,,,1,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,,,,CHEMBL616337,
14998,H,,,,,10576,8,Autocuration,,1506,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,,,,CHEMBL616338,
13694,H,,,,,10576,8,Autocuration,,1507,B,Hippocampus,,1,BAO_0000221,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,,10000000.0,,CHEMBL616339,
13694,H,,,,,10576,8,Autocuration,,1508,B,Hippocampus,,1,BAO_0000221,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,,10000000.0,,CHEMBL616340,
4342,H,,,,,10576,8,Autocuration,,1509,B,,,1,BAO_0000357,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,,,,CHEMBL616341,
12936,D,,,,,10576,9,Expert,,1510,B,,,1,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,,Rattus norvegicus,CHEMBL616342,10116.0
13144,D,,,,,10576,9,Expert,,1511,B,,,1,BAO_0000019,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,,,Rattus norvegicus,CHEMBL616343,10116.0
13343,H,,,,,10576,8,Expert,,1512,B,,,1,BAO_0000019,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,,,,CHEMBL616344,
12132,H,,,,,10576,8,Expert,,1513,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,,CHEMBL616345,
15419,H,,,,,10576,8,Expert,,1514,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,,,,CHEMBL616346,
1479,H,,,,,10576,8,Autocuration,,1515,B,Hippocampus,,1,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,10000000.0,,CHEMBL616347,
14287,H,,,,,10576,8,Expert,,1516,B,,,1,BAO_0000019,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,,,,CHEMBL616348,
13116,H,,,,,10576,8,Expert,,1517,B,,,1,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616349,
2759,D,,,,,10576,9,Expert,Membranes,1518,B,,,1,BAO_0000249,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,,,Rattus norvegicus,CHEMBL616152,10116.0
2759,H,,,,,10576,8,Autocuration,,1519,B,,,1,BAO_0000249,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,,,CHEMBL616153,
14748,H,,,,,10576,8,Expert,,1520,B,,,1,BAO_0000019,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,,,,CHEMBL616154,
12304,H,,,,,10576,8,Autocuration,,1521,B,,,1,BAO_0000019,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,,CHEMBL616155,
12409,D,,,,,10576,9,Expert,,1522,B,Hippocampus,,1,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,,10000000.0,Rattus norvegicus,CHEMBL616156,10116.0
12409,D,,,,,10576,9,Expert,,1523,B,Hippocampus,,1,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,,10000000.0,Rattus norvegicus,CHEMBL616157,10116.0
13267,H,,,,,10576,8,Autocuration,,1524,B,Hippocampus,,1,BAO_0000221,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,,10000000.0,,CHEMBL616158,
15194,H,,,,,10576,8,Autocuration,,1525,B,,,1,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,,CHEMBL616159,
14256,H,,,,,10576,8,Expert,,1526,B,,,1,BAO_0000357,pKi value against rat 5-hydroxytryptamine 1A receptor.,,,,,CHEMBL616160,
16567,H,,,,,10576,8,Autocuration,,1527,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,,,,CHEMBL616161,
15740,H,,,,,10576,8,Autocuration,,1528,F,,,1,BAO_0000019,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,,,CHEMBL616162,
13278,D,,,,,12687,9,Expert,,1529,B,,,1,BAO_0000357,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,,Rattus norvegicus,CHEMBL616163,10116.0
1970,H,,,,,10626,8,Expert,Membranes,1530,B,,,1,BAO_0000249,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,,CHEMBL616164,
10034,H,,,,,10576,8,Autocuration,,1531,B,Brain,,1,BAO_0000221,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,,955.0,,CHEMBL616165,
13348,H,,,,,51,8,Autocuration,,1532,B,,,1,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,,,Rattus norvegicus,CHEMBL616355,10116.0
13630,H,,,,,10576,8,Autocuration,,1533,F,,,1,BAO_0000019,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,,,CHEMBL616356,
10862,H,,,,,10576,8,Autocuration,,1534,B,Brain,,1,BAO_0000221,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,955.0,,CHEMBL616357,
12058,H,,,,,10576,8,Autocuration,,1535,B,,,1,BAO_0000019,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,,,CHEMBL616358,
4639,H,,,,,51,8,Autocuration,,1536,B,,,1,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616359,
15453,H,,,,,51,8,Expert,,1537,B,,,1,BAO_0000357,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,,,,CHEMBL616360,
4820,H,,,,,51,8,Expert,,1538,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616361,
1089,H,,,,,51,8,Autocuration,,1539,B,,,1,BAO_0000357,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616362,
386,H,,,,,51,8,Autocuration,Brain membranes,1540,B,,,1,BAO_0000249,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,,,,CHEMBL616363,
6011,H,,,,,51,8,Autocuration,,1541,B,,,1,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,,,,CHEMBL616364,
5014,H,,,,,51,8,Autocuration,,1542,B,,,1,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616365,
4402,H,,,,,51,8,Expert,,1543,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL616366,
17066,H,,,,,51,8,Expert,,1544,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,CHEMBL872906,
17515,H,,,,,51,8,Autocuration,,1545,B,,,1,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,,,,CHEMBL616367,
2474,H,,,,,51,8,Autocuration,,1546,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616368,
4775,H,,,,,51,8,Autocuration,,1547,B,,,1,BAO_0000357,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,,,,CHEMBL616369,
14294,D,,,,,51,9,Expert,,1548,B,,,1,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,,,Homo sapiens,CHEMBL616370,9606.0
14294,D,,,,,51,9,Expert,,1549,B,,,1,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,,,Homo sapiens,CHEMBL616371,9606.0
12249,H,,,CHO,,51,8,Autocuration,,1550,B,,,1,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,449.0,,,,CHEMBL616372,
11376,H,,,,,51,8,Expert,,1551,B,,,1,BAO_0000219,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,,,,CHEMBL616373,
2474,H,,,,In vivo,51,8,Autocuration,,1552,B,,,1,BAO_0000218,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL616374,
13311,H,,,,,51,8,Autocuration,,1553,B,Hippocampus,,1,BAO_0000221,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,10000000.0,,CHEMBL616375,
4373,H,,,,,51,8,Autocuration,,1554,B,,,1,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,,,,CHEMBL616376,
1633,H,,,,,51,8,Expert,,1555,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,,,,CHEMBL857064,
11866,H,,,,,51,8,Autocuration,,1556,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,,,CHEMBL616377,
4373,H,,,,,51,8,Autocuration,,1557,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,,,CHEMBL616378,
4687,H,,,,,51,8,Autocuration,,1558,B,,,1,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616379,
16946,H,,,,,11863,8,Autocuration,,1559,B,,,1,BAO_0000357,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616380,
13291,H,,,,,11863,8,Autocuration,,1560,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,,,,CHEMBL616381,
14159,H,,,,,11863,8,Autocuration,,1561,B,,,1,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616382,
10812,H,,,,,11863,8,Autocuration,,1562,B,,,1,BAO_0000357,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,,,,CHEMBL616383,
3032,D,,,CHO,,11863,9,Expert,,1563,B,,,1,BAO_0000219,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,449.0,,,Mus musculus,CHEMBL616350,10090.0
16655,H,,,,,11863,8,Autocuration,,1564,B,,,1,BAO_0000357,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616351,
14532,H,,,,,11863,8,Autocuration,,1565,B,,,1,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,,,,CHEMBL616352,
13944,H,,,,,11863,8,Autocuration,,1566,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616353,
13033,H,,,,,11863,8,Autocuration,,1567,B,,,1,BAO_0000357,Binding affinity against serotonergic 5-HT1a receptor,,,,,CHEMBL616354,
10321,H,,,,,11863,8,Autocuration,,1568,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL616508,
2968,D,,,,,11863,9,Expert,,1569,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1A receptor,,,,Mus musculus,CHEMBL616559,10090.0
13964,H,,,,,11863,8,Autocuration,,1570,B,,,1,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616560,
15527,H,,,,,11863,8,Autocuration,,1571,B,,,1,BAO_0000357,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,,,,CHEMBL616561,
12248,H,,,CHO,,11863,8,Autocuration,,1572,B,,,1,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,449.0,,,,CHEMBL616562,
12249,H,,,CHO,,11863,8,Autocuration,,1573,B,,,1,BAO_0000219,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,449.0,,,,CHEMBL616563,
15120,H,,,,,11863,8,Autocuration,,1574,B,,,1,BAO_0000357,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616564,
13313,H,,,,,11863,8,Autocuration,,1575,B,,,1,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,,,,CHEMBL616565,
2613,H,,,,,11863,8,Autocuration,,1576,B,,,1,BAO_0000218,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616566,
16700,H,,,,,11863,8,Autocuration,,1577,B,,,1,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,,,,CHEMBL616989,
2201,H,,,,,11863,8,Autocuration,,1578,B,,,1,BAO_0000357,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,,,,CHEMBL857975,
1274,D,,,,,11863,9,Expert,,1579,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,Mus musculus,CHEMBL616990,10090.0
1317,H,,,,,11863,8,Autocuration,,1580,B,,,1,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,,,CHEMBL616991,
12146,H,,,,,11863,8,Autocuration,,1581,B,,,1,BAO_0000357,Tested against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616992,
14059,H,,,,,11863,8,Autocuration,,1582,B,,,1,BAO_0000357,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL616993,
14025,H,,,,,106,8,Expert,,1583,B,,,1,BAO_0000019,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,,,Oryctolagus cuniculus,CHEMBL616994,9986.0
14025,H,,,,,106,8,Autocuration,,1584,B,,,1,BAO_0000019,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,,,Oryctolagus cuniculus,CHEMBL616995,9986.0
14447,D,,,HEK293,,105571,9,Intermediate,,1585,B,,,1,BAO_0000219,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,722.0,,,Gorilla gorilla,CHEMBL616996,9593.0
3025,H,,,,In vivo,106,8,Autocuration,,1586,F,,,1,BAO_0000218,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,,,Cavia porcellus,CHEMBL616997,10141.0
3025,H,,,,In vivo,106,8,Autocuration,,1587,F,,,1,BAO_0000218,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,,,Cavia porcellus,CHEMBL616998,10141.0
15329,H,,,,,106,8,Autocuration,,1588,F,,,1,BAO_0000019,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,,,Cavia porcellus,CHEMBL616999,10141.0
15329,H,,,,,106,8,Autocuration,,1589,F,,,1,BAO_0000019,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,,,Cavia porcellus,CHEMBL617000,10141.0
15847,H,,,,,106,8,Autocuration,,1590,F,,,1,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,,,Cavia porcellus,CHEMBL617001,10141.0
15847,H,,,,,106,8,Autocuration,,1591,F,,,1,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,,,Cavia porcellus,CHEMBL858111,10141.0
14165,H,,,,,106,8,Autocuration,,1592,F,,,1,BAO_0000019,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,,,,CHEMBL617002,
14214,H,,,,,106,8,Autocuration,,1593,F,,,1,BAO_0000019,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,,,,CHEMBL617003,
14214,H,,,,,106,8,Autocuration,,1594,F,,,1,BAO_0000019,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,,,,CHEMBL617004,
14214,D,,,,,106,9,Expert,,1595,F,,,1,BAO_0000019,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,,,Homo sapiens,CHEMBL617005,9606.0
13729,D,,,CHO-K1,,106,9,Expert,,1596,F,,,1,BAO_0000219,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,485.0,,,Homo sapiens,CHEMBL616623,9606.0
3025,H,,,CHO,,106,8,Autocuration,,1597,F,,,1,BAO_0000219,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,449.0,,,,CHEMBL616624,
2391,H,,,,,106,8,Autocuration,,1598,B,,,1,BAO_0000357,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,,,CHEMBL883243,
2391,H,,,,,106,8,Autocuration,,1599,F,,,1,BAO_0000019,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,,,,CHEMBL616625,
14956,H,,,CHO,,106,8,Expert,,1600,F,,,1,BAO_0000219,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",449.0,,,,CHEMBL616626,
2598,H,,,CHO,,106,8,Autocuration,,1601,F,,,1,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,449.0,,,,CHEMBL616627,
2598,H,,,CHO,,106,8,Autocuration,,1602,F,,,1,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,449.0,,,,CHEMBL616628,
2598,H,,,CHO,,106,8,Autocuration,,1603,F,,,1,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,449.0,,,,CHEMBL616629,
2598,H,,,CHO,,106,8,Autocuration,,1604,F,,,1,BAO_0000219,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,449.0,,,,CHEMBL616630,
14956,H,,,,,106,8,Expert,,1605,F,,,1,BAO_0000019,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,,,,CHEMBL616631,
14956,H,,,,,106,8,Autocuration,,1606,F,,,1,BAO_0000019,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,,,,CHEMBL616632,
14214,D,,,,,106,9,Expert,,1607,B,,,1,BAO_0000357,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,,,Homo sapiens,CHEMBL616633,9606.0
3463,H,,,CHO,,106,8,Expert,,1608,B,,,1,BAO_0000219,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,449.0,,,,CHEMBL616634,
15331,H,,,,,106,8,Autocuration,,1609,B,,,1,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,,,,CHEMBL616635,
16146,D,,,,,106,9,Expert,,1610,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor,,,,Homo sapiens,CHEMBL885358,9606.0
14159,D,,,CHO,,106,9,Expert,,1611,B,,,1,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,449.0,,,Homo sapiens,CHEMBL616636,9606.0
14158,H,,,CHO,,106,8,Expert,,1612,B,,,1,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,449.0,,,,CHEMBL616637,
14159,H,,,,,106,8,Autocuration,,1613,B,,,1,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616638,
15250,H,,,CHO,,106,8,Expert,,1614,B,,,1,BAO_0000219,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,449.0,,,,CHEMBL616639,
15250,H,,,CHO,,106,8,Expert,,1615,B,,,1,BAO_0000219,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,449.0,,,,CHEMBL616640,
15331,H,,,CHO,,106,8,Expert,,1616,B,,,1,BAO_0000219,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,449.0,,,,CHEMBL616641,
15332,H,,,CHO,,106,8,Expert,,1617,B,,,1,BAO_0000219,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,449.0,,,,CHEMBL616642,
14956,H,,,CHO,,106,8,Expert,,1618,B,,,1,BAO_0000219,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,449.0,,,,CHEMBL616643,
3805,H,,,,,106,8,Autocuration,,1619,B,,,1,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,,,,CHEMBL616644,
14875,H,,,,,106,8,Autocuration,,1620,B,,,1,BAO_0000357,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,,,,CHEMBL616645,
14454,H,,,,,105,8,Autocuration,,1621,F,,,1,BAO_0000019,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,,Oryctolagus cuniculus,CHEMBL616646,9986.0
14454,H,,,,,105,8,Expert,,1622,F,,,1,BAO_0000019,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,,Oryctolagus cuniculus,CHEMBL616647,9986.0
16288,H,,,,,105,8,Autocuration,,1623,B,,,1,BAO_0000357,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,,,,CHEMBL616509,
16288,H,,,,,105,8,Autocuration,,1624,B,,,1,BAO_0000357,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,,,,CHEMBL616510,
16312,H,,,,,105,8,Autocuration,,1625,B,,,1,BAO_0000357,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616511,
1348,H,,,,,105,8,Expert,,1626,B,,,1,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,,,Bos taurus,CHEMBL616512,9913.0
5834,H,,,,,105,8,Autocuration,,1627,B,,,1,BAO_0000357,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,,,Bos taurus,CHEMBL616513,9913.0
13366,H,,,,,105,8,Autocuration,,1628,B,Striatum,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,,2435.0,Bos taurus,CHEMBL616514,9913.0
1414,H,,,,,105,8,Expert,,1629,B,,,1,BAO_0000357,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,,,Bos taurus,CHEMBL616515,9913.0
14998,H,,,,,105,8,Autocuration,,1630,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,,,Bos taurus,CHEMBL616516,9913.0
11473,H,,,,,105,8,Autocuration,,1631,B,,,1,BAO_0000357,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,,Bos taurus,CHEMBL616517,9913.0
11473,H,,,,,105,8,Autocuration,,1632,B,,,1,BAO_0000357,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,,,Bos taurus,CHEMBL616518,9913.0
10639,H,,,,,105,8,Autocuration,,1633,B,,,1,BAO_0000357,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,,Bos taurus,CHEMBL616519,9913.0
10639,H,,,,,105,8,Autocuration,,1634,B,,,1,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,,,Bos taurus,CHEMBL616520,9913.0
1375,H,,,,,105,8,Autocuration,,1635,B,,,1,BAO_0000357,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,,,Bos taurus,CHEMBL616521,9913.0
1375,H,,,,,105,8,Autocuration,,1636,B,,,1,BAO_0000357,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,,,Bos taurus,CHEMBL616522,9913.0
16532,H,,,,,105,8,Autocuration,,1637,B,,,1,BAO_0000357,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,,Bos taurus,CHEMBL884531,9913.0
11147,H,,,,,105,8,Autocuration,,1638,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,,,Bos taurus,CHEMBL616523,9913.0
13366,H,,,,,105,8,Autocuration,,1639,B,Striatum,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,,2435.0,Bos taurus,CHEMBL616731,9913.0
10444,H,,,,,105,8,Autocuration,,1640,B,,,1,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,,,Bos taurus,CHEMBL616732,9913.0
16532,H,,,,,105,8,Autocuration,,1641,B,,,1,BAO_0000357,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,,,Bos taurus,CHEMBL616733,9913.0
16532,H,,,,,105,8,Autocuration,,1642,B,,,1,BAO_0000357,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,,,Bos taurus,CHEMBL616734,9913.0
12827,H,,,,,105,8,Autocuration,,1643,B,,,1,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,,,Bos taurus,CHEMBL616735,9913.0
12827,H,,,,,105,8,Autocuration,,1644,B,,,1,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,,,Bos taurus,CHEMBL616736,9913.0
12919,H,,,,,105,8,Expert,,1645,F,,,1,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,,Bos taurus,CHEMBL616737,9913.0
14025,H,,,,,105,8,Autocuration,,1646,B,,,1,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,,,Bos taurus,CHEMBL616738,9913.0
12919,H,,,,,105,8,Expert,,1647,F,,,1,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,,Bos taurus,CHEMBL616739,9913.0
12919,H,,,,,105,8,Expert,,1648,F,,,1,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,,Bos taurus,CHEMBL616740,9913.0
12919,H,,,,,105,8,Expert,,1649,F,,,1,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,,,Bos taurus,CHEMBL616741,9913.0
14447,H,,,HEK293,,105,8,Autocuration,,1650,B,,,1,BAO_0000219,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,722.0,,,Gorilla gorilla,CHEMBL616742,9593.0
1375,D,,,,,105570,9,Intermediate,,1651,B,,,1,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,,,Cavia porcellus,CHEMBL616743,10141.0
1375,D,,,,,105570,9,Intermediate,,1652,B,,,1,BAO_0000019,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,,,Cavia porcellus,CHEMBL616744,10141.0
12409,D,,,,,105570,9,Intermediate,,1653,F,,,1,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,,,Cavia porcellus,CHEMBL616745,10141.0
12409,D,,,,,105570,9,Intermediate,,1654,F,,,1,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,,Cavia porcellus,CHEMBL616746,10141.0
12409,D,,,,,105570,9,Intermediate,,1655,F,,,1,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,,,Cavia porcellus,CHEMBL616747,10141.0
12409,D,,,,,105570,9,Intermediate,,1656,F,,,1,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,,,Cavia porcellus,CHEMBL616748,10141.0
12409,D,,,,,105570,9,Intermediate,,1657,F,,,1,BAO_0000019,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,,,Cavia porcellus,CHEMBL616648,10141.0
11574,D,,,,,105570,9,Intermediate,,1658,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor,,,,Cavia porcellus,CHEMBL616649,10141.0
1558,D,,,,,105570,9,Intermediate,,1659,B,,,1,BAO_0000357,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,,,Cavia porcellus,CHEMBL616650,10141.0
12409,D,,,,,105570,9,Intermediate,,1660,F,,,1,BAO_0000218,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,,Cavia porcellus,CHEMBL616651,10141.0
12409,D,,,,,105570,9,Intermediate,,1661,F,,,1,BAO_0000218,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,,Cavia porcellus,CHEMBL616652,10141.0
12409,D,,,,,105570,9,Intermediate,,1662,F,,,1,BAO_0000218,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,,,Cavia porcellus,CHEMBL616653,10141.0
12409,D,,,,,105570,9,Intermediate,,1663,F,,,1,BAO_0000218,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,,,Cavia porcellus,CHEMBL616654,10141.0
12253,D,,,,,105570,9,Intermediate,,1664,B,,,1,BAO_0000019,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,,,Cavia porcellus,CHEMBL616655,10141.0
12936,D,,,,,105570,9,Intermediate,,1665,B,,,1,BAO_0000357,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,,,Cavia porcellus,CHEMBL616656,10141.0
13181,H,,,,,105,8,Autocuration,,1666,B,,,1,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,,,Cavia porcellus,CHEMBL616657,10141.0
12409,D,,,,,105570,9,Intermediate,,1667,B,Striatum,,1,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,,2435.0,Cavia porcellus,CHEMBL616658,10141.0
10639,D,,,,,105570,9,Intermediate,,1668,B,,,1,BAO_0000357,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,,,Cavia porcellus,CHEMBL616659,10141.0
5254,H,,,,,51,8,Autocuration,,1669,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616660,
13051,H,,,,,106,8,Autocuration,,1670,B,,,1,BAO_0000357,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,,,,CHEMBL616661,
3463,H,,,,,105,8,Expert,,1671,F,,,1,BAO_0000019,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616662,
15315,H,,,,,105,8,Autocuration,,1672,F,,,1,BAO_0000019,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616663,
6011,H,,,,,105,8,Autocuration,,1673,F,,,1,BAO_0000019,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616664,
14159,D,,,CHO,,105,9,Expert,,1674,F,,,1,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",449.0,,,Homo sapiens,CHEMBL881820,9606.0
14159,H,,,CHO,,105,8,Autocuration,,1675,F,,,1,BAO_0000219,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",449.0,,,,CHEMBL616665,
15250,H,,,CHO,,105,8,Expert,,1676,B,,,1,BAO_0000219,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,449.0,,,,CHEMBL616666,
15250,H,,,CHO,,105,8,Autocuration,,1677,B,,,1,BAO_0000219,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,449.0,,,,CHEMBL616667,
15331,H,,,CHO,,105,8,Expert,,1678,F,,,1,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",449.0,,,,CHEMBL616668,
15332,D,,,CHO,,105,9,Expert,,1679,F,,,1,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",449.0,,,Homo sapiens,CHEMBL616669,9606.0
15332,H,,,CHO,,105,8,Expert,,1680,F,,,1,BAO_0000219,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",449.0,,,,CHEMBL617040,
3294,H,,,CHO,,105,8,Autocuration,,1681,F,,,1,BAO_0000219,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",449.0,,,,CHEMBL617041,
14158,H,,,CHO,,105,8,Expert,,1682,F,,,1,BAO_0000219,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",449.0,,,,CHEMBL617042,
14956,H,,,CHO,,105,8,Expert,,1683,F,,,1,BAO_0000219,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",449.0,,,,CHEMBL617043,
12469,H,,,,,105,8,Autocuration,,1684,F,,,1,BAO_0000019,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,,,,CHEMBL617044,
3463,H,,,CHO,,105,8,Expert,,1685,F,,,1,BAO_0000219,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,449.0,,,,CHEMBL617045,
15250,D,,,CHO,,105,9,Expert,,1686,F,,,1,BAO_0000219,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",449.0,,,Homo sapiens,CHEMBL617046,9606.0
15250,D,,,CHO,,105,9,Expert,,1687,F,,,1,BAO_0000219,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",449.0,,,Homo sapiens,CHEMBL617047,9606.0
14956,H,,,,,105,8,Expert,,1688,F,,,1,BAO_0000019,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,,,,CHEMBL617048,
14159,H,,,,,105,8,Autocuration,,1689,F,,,1,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,,,,CHEMBL616897,
14159,D,,,,,105,9,Expert,,1690,F,,,1,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,,,Homo sapiens,CHEMBL616898,9606.0
14499,D,,,CHO,,105,9,Expert,,1691,F,,,1,BAO_0000219,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,449.0,,,Homo sapiens,CHEMBL858201,9606.0
15315,H,,,,,105,8,Autocuration,,1692,F,,,1,BAO_0000019,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616899,
3294,H,,,,In vitro,105,8,Autocuration,,1693,B,,,1,BAO_0000219,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,,,,CHEMBL616900,
3463,H,,,CHO,,105,8,Expert,,1694,B,,,1,BAO_0000219,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,449.0,,,,CHEMBL616901,
15331,H,,,,,105,8,Autocuration,,1695,B,,,1,BAO_0000357,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,,,,CHEMBL616902,
14159,D,,,CHO,,105,9,Expert,,1696,B,,,1,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,449.0,,,Homo sapiens,CHEMBL616903,9606.0
14158,H,,,CHO,,105,8,Expert,,1697,B,,,1,BAO_0000219,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,449.0,,,,CHEMBL616904,
14159,H,,,,,105,8,Autocuration,,1698,B,,,1,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616905,
15250,H,,,CHO,,105,8,Expert,,1699,B,,,1,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,449.0,,,,CHEMBL616906,
15250,H,,,CHO,,105,8,Expert,,1700,B,,,1,BAO_0000219,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,449.0,,,,CHEMBL616907,
15331,H,,,CHO,,105,8,Expert,,1701,B,,,1,BAO_0000219,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,449.0,,,,CHEMBL616908,
15332,D,,,CHO,,105,9,Expert,,1702,B,,,1,BAO_0000219,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,449.0,,,Homo sapiens,CHEMBL616909,9606.0
14499,D,,,CHO,,105,9,Expert,,1703,B,,,1,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,449.0,,,Homo sapiens,CHEMBL616910,9606.0
15332,H,,,CHO,,105,8,Expert,,1704,B,,,1,BAO_0000219,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,449.0,,,,CHEMBL616911,
14956,H,,,CHO,,105,8,Expert,,1705,B,,,1,BAO_0000219,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,449.0,,,,CHEMBL616912,
3805,H,,,,,105,8,Autocuration,,1706,B,,,1,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,,,,CHEMBL616913,
6011,D,,,CHO,,105,9,Expert,,1707,B,,,1,BAO_0000219,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,449.0,,,Homo sapiens,CHEMBL616914,9606.0
16190,H,,,CHO,,105,8,Autocuration,,1708,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,449.0,,,,CHEMBL616915,
14165,H,,,,,105,8,Autocuration,,1709,B,,,1,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,,,,CHEMBL616916,
4234,D,,,,,105,9,Expert,,1710,B,,,1,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,,,Homo sapiens,CHEMBL616917,9606.0
15527,H,,,,,105,8,Autocuration,,1711,B,,,1,BAO_0000357,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,,,,CHEMBL616918,
6328,H,,,,,105,8,Expert,,1712,B,,,1,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,,,CHEMBL616919,
16209,H,,,,,105,8,Autocuration,,1713,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,,,,CHEMBL616920,
14770,H,,,,,105,8,Autocuration,,1714,B,,,1,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,,,,CHEMBL872914,
2598,H,,,,,105,8,Autocuration,,1715,B,,,1,BAO_0000357,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,,,,CHEMBL616921,
6897,H,,,,,105,8,Expert,,1716,B,,,1,BAO_0000357,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616922,
6013,H,,,,,105,8,Autocuration,,1717,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616923,
5843,H,,,,,105,8,Expert,,1718,B,,,1,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616924,
14454,H,,,,,105,8,Expert,,1719,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,,,,CHEMBL875909,
14454,H,,,,,105,8,Autocuration,,1720,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,,,,CHEMBL616925,
14454,H,,,,,105,8,Autocuration,,1721,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,,,,CHEMBL616926,
15818,H,,,,,105,8,Autocuration,,1722,B,,,1,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616927,
13729,H,,,CHO-K1,,105,8,Expert,,1723,F,,,1,BAO_0000219,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,485.0,,,,CHEMBL616928,
6011,D,,,,In vitro,105,9,Expert,,1724,B,,,1,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,,,Homo sapiens,CHEMBL616929,9606.0
4234,D,,,,,105,9,Expert,,1725,B,,,1,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,,,Homo sapiens,CHEMBL616930,9606.0
17085,H,,,,,105,8,Expert,,1726,B,,,1,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616931,
3025,H,,,,,105,8,Autocuration,,1727,B,,,1,BAO_0000357,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,,,CHEMBL616932,
15315,H,,,,,105,8,Expert,,1728,B,,,1,BAO_0000357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616933,
14214,D,,,,,105,9,Expert,,1729,B,,,1,BAO_0000219,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,,,Homo sapiens,CHEMBL616934,9606.0
3804,D,,,,,105,9,Expert,,1730,B,,,1,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,,Homo sapiens,CHEMBL616935,9606.0
16700,H,,,,,105,8,Autocuration,,1731,B,,,1,BAO_0000357,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,,,,CHEMBL616936,
2391,D,,,,,105,9,Expert,,1732,B,,,1,BAO_0000357,Affinity for 5-hydroxytryptamine 1D receptor subtype,,,,Homo sapiens,CHEMBL616937,9606.0
4175,D,,,,,105,9,Expert,,1733,B,,,1,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,,Homo sapiens,CHEMBL616938,9606.0
17085,H,,,,,105,8,Autocuration,,1734,B,,,1,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616939,
17085,H,,,,,105,8,Expert,,1735,B,,,1,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,,,,CHEMBL616940,
15926,D,,,,,105,9,Expert,,1736,B,,,1,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,,,Homo sapiens,CHEMBL616941,9606.0
16312,H,,,CHO-K1,,105,8,Autocuration,,1737,B,,,1,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,485.0,,,,CHEMBL616942,
16312,H,,,CHO-K1,,105,8,Autocuration,,1738,B,,,1,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,485.0,,,,CHEMBL616943,
14956,H,,,CHO,,104802,4,Autocuration,,1739,B,,,1,BAO_0000219,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,449.0,,,,CHEMBL616944,
3294,H,,,,,105,8,Autocuration,,1740,F,,,1,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,,,,CHEMBL616945,
12861,H,,,,,105,8,Autocuration,,1741,B,,,1,BAO_0000357,Binding activity radioligand.,,,,,CHEMBL616946,
12861,H,,,,,105,8,Autocuration,,1742,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,CHEMBL616947,
16312,H,,,CHO-K1,,105,8,Expert,,1743,B,,,1,BAO_0000219,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,485.0,,,,CHEMBL616948,
5104,H,,,,,105,8,Autocuration,,1744,B,,,1,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616851,
5105,H,,,,,105,8,Autocuration,,1745,B,,,1,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616852,
14499,H,,,,,105,8,Autocuration,,1746,B,,,1,BAO_0000357,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616853,
15926,D,,,,,105,9,Expert,,1747,B,,,1,BAO_0000357,Binding activity against human 5-hydroxytryptamine 1D receptor,,,,Homo sapiens,CHEMBL616854,9606.0
4540,D,,,CHO,,105,9,Expert,,1748,B,,,1,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,449.0,,,Homo sapiens,CHEMBL616855,9606.0
15779,H,,,CHO,,105,8,Autocuration,,1749,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,449.0,,,,CHEMBL616856,
15779,H,,,CHO,,105,8,Autocuration,,1750,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,449.0,,,,CHEMBL616857,
6166,H,,,,,105,8,Autocuration,,1751,B,,,1,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616858,
15779,H,,,CHO,,105,8,Autocuration,,1752,B,,,1,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,449.0,,,,CHEMBL616859,
15779,H,,,CHO,,105,8,Autocuration,,1753,B,,,1,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,449.0,,,,CHEMBL616860,
17451,H,,,HEK293,,105,8,Autocuration,,1754,B,,,1,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,722.0,,,,CHEMBL616861,
17451,H,,,HEK293,,105,8,Autocuration,,1755,B,,,1,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,722.0,,,,CHEMBL616541,
17451,H,,,HEK293,,105,8,Autocuration,,1756,B,,,1,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,722.0,,,,CHEMBL616542,
4199,H,,,CHO,,105,8,Autocuration,,1757,B,,,1,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,449.0,,,,CHEMBL616543,
14875,D,,,,,105,9,Expert,,1758,B,,,1,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 1D receptor,,,,Homo sapiens,CHEMBL616544,9606.0
15146,H,,,CHO,,105,8,Autocuration,,1759,B,,,1,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,449.0,,,,CHEMBL616545,
5213,H,,,,,105,8,Autocuration,,1760,B,,,1,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,,,,CHEMBL616546,
14818,H,,,CHO,,105,8,Autocuration,,1761,B,,,1,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,449.0,,,,CHEMBL616547,
4829,H,,,CHO,,105,8,Autocuration,,1762,B,,,1,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",449.0,,,,CHEMBL616548,
14454,H,,,,,105,8,Expert,,1763,F,,,1,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,,,,CHEMBL616549,
14454,H,,,,,105,8,Expert,,1764,F,,,1,BAO_0000019,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,,,,CHEMBL616550,
5254,H,,,,,108,8,Autocuration,,1765,B,,,1,BAO_0000357,Binding affinity against 5-HT2C receptor,,,,,CHEMBL857066,
5254,H,,,,,108,8,Autocuration,,1766,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616551,
10639,H,,,,,10577,8,Autocuration,,1767,B,,,1,BAO_0000357,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,,,CHEMBL616552,
10639,H,,,,,10577,8,Autocuration,,1768,F,,,1,BAO_0000019,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,,,CHEMBL832876,
12352,H,,,,,10577,8,Expert,,1769,B,,,1,BAO_0000019,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,,,,CHEMBL616553,
9098,H,,,,,10577,8,Autocuration,,1770,B,,,1,BAO_0000357,Binding affinity towards 5-HT1B was determined,,,,,CHEMBL616554,
14430,H,,,,,10577,8,Expert,,1771,B,,,1,BAO_0000019,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,,,,CHEMBL616555,
13657,H,,,,,10577,8,Expert,,1772,B,,,1,BAO_0000019,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,,,,CHEMBL616556,
13657,H,,,,,10577,8,Autocuration,,1773,B,,,1,BAO_0000019,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,,,,CHEMBL616557,
15854,H,,,,,10577,8,Expert,,1774,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,,CHEMBL616558,
10639,D,,,,,10577,9,Expert,,1775,B,,,1,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,,,Rattus norvegicus,CHEMBL616749,10116.0
10025,H,,,,,10577,8,Autocuration,,1776,B,,,1,BAO_0000357,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,,,CHEMBL616750,
10025,H,,,,,10577,8,Autocuration,,1777,B,,,1,BAO_0000357,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,,,,CHEMBL616751,
14286,H,,,,,10577,8,Autocuration,,1778,B,,,1,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,,,CHEMBL616752,
3651,H,,,,,10577,8,Autocuration,,1779,B,Striatum,,1,BAO_0000019,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,,2435.0,,CHEMBL616753,
14178,D,,,,,10577,9,Expert,,1780,B,,,1,BAO_0000357,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,,,Rattus norvegicus,CHEMBL616754,10116.0
10639,H,,,,,10577,8,Autocuration,,1781,B,,,1,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,,,,CHEMBL616755,
13605,H,,,,,10577,8,Autocuration,,1782,B,Striatum,,1,BAO_0000019,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,,2435.0,,CHEMBL616756,
5834,H,,,,,10577,8,Autocuration,,1783,B,Striatum,,1,BAO_0000019,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,,2435.0,,CHEMBL616757,
10922,H,,,,,10577,8,Autocuration,,1784,B,Striatum,,1,BAO_0000357,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,,2435.0,,CHEMBL616758,
14286,H,,,,,10577,8,Autocuration,,1785,B,,,1,BAO_0000249,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,,,CHEMBL616759,
11825,H,,,,,10577,8,Autocuration,,1786,B,,,1,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,,,,CHEMBL616760,
14826,H,,,,,10577,8,Autocuration,,1787,B,Striatum,,1,BAO_0000019,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,,2435.0,,CHEMBL616761,
9699,H,,,,,10577,8,Autocuration,,1788,B,Striatum,,1,BAO_0000019,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,,2435.0,,CHEMBL616762,
14423,H,,,,,10577,8,Autocuration,,1789,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,,,,CHEMBL616763,
10062,H,,,,,10577,8,Expert,,1790,B,,,1,BAO_0000357,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,,,,CHEMBL872909,
10062,H,,,,,10577,8,Autocuration,,1791,B,,,1,BAO_0000357,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616764,
12280,D,,,,,10577,9,Expert,,1792,B,,,1,BAO_0000357,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,,,Rattus norvegicus,CHEMBL616765,10116.0
15412,H,,,,,10577,8,Autocuration,,1793,B,Striatum,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,,2435.0,,CHEMBL616766,
15412,H,,,,,10577,8,Autocuration,,1794,B,Striatum,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,,2435.0,,CHEMBL616767,
10062,H,,,,,10577,8,Autocuration,,1795,B,,,1,BAO_0000357,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616768,
11147,H,,,,,10577,8,Autocuration,,1796,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,,,CHEMBL616769,
9547,H,,,,,10577,8,Autocuration,,1797,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,,,,CHEMBL616770,
10444,H,,,,,10577,8,Autocuration,,1798,B,,,1,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,,,,CHEMBL616771,
12469,H,,,,,10577,8,Autocuration,,1799,B,Striatum,,1,BAO_0000019,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,,2435.0,,CHEMBL616772,
9098,H,,,,,10577,8,Expert,,1800,B,,,1,BAO_0000019,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,,,,CHEMBL616773,
9098,H,,,,,10577,8,Autocuration,,1801,B,,,1,BAO_0000019,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,,,,CHEMBL616774,
9699,H,,,,,10577,8,Autocuration,,1802,B,,,1,BAO_0000357,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616775,
10394,H,,,,,10577,8,Autocuration,,1803,B,,,1,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,,,CHEMBL616776,
12092,H,,,,,10577,8,Autocuration,,1804,B,,,1,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,,,,CHEMBL616777,
16700,H,,,,,10577,8,Autocuration,,1805,B,,,1,BAO_0000357,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,,,,CHEMBL616778,
403,D,,,,,10577,9,Expert,,1806,B,,,1,BAO_0000249,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,,,Rattus norvegicus,CHEMBL616779,10116.0
12771,D,,,,,10577,9,Expert,,1807,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,,Rattus norvegicus,CHEMBL616780,10116.0
11642,H,,,,,10577,8,Autocuration,,1808,B,,,1,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,,,,CHEMBL616781,
12953,H,,,,,10577,8,Autocuration,,1809,B,,,1,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,,,,CHEMBL616782,
12953,H,,,,,10577,8,Autocuration,,1810,B,,,1,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,,,,CHEMBL616783,
12953,H,,,,,10577,8,Expert,,1811,B,Striatum,,1,BAO_0000019,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,,2435.0,,CHEMBL616784,
12953,H,,,,,10577,8,Autocuration,,1812,B,,,1,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,,,,CHEMBL616785,
9737,H,,,,,10577,8,Autocuration,,1813,B,Brain,,1,BAO_0000249,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,955.0,,CHEMBL857067,
9737,H,,,,,10577,8,Autocuration,,1814,B,,,1,BAO_0000019,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,,,,CHEMBL616786,
9737,H,,,,,10577,8,Autocuration,,1815,B,Brain,,1,BAO_0000249,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,955.0,,CHEMBL616787,
12827,H,,,,,10577,8,Autocuration,,1816,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,,,,CHEMBL616788,
5033,H,,,,,10577,8,Autocuration,,1817,B,,,1,BAO_0000357,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616789,
9786,D,,,,,10577,9,Expert,,1818,B,,,1,BAO_0000019,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,,,Rattus norvegicus,CHEMBL616790,10116.0
13116,H,,,,,10577,8,Expert,,1819,B,,,1,BAO_0000357,Binding affinity at 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616791,
16429,H,,,,,10577,8,Autocuration,,1820,B,,,1,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,,,,CHEMBL616792,
12409,D,,,,,10577,9,Expert,,1821,B,,,1,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,,,Rattus norvegicus,CHEMBL616793,10116.0
15194,H,,,,,10577,8,Autocuration,,1822,B,,,1,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,,,CHEMBL616794,
15194,H,,,,,10577,8,Autocuration,,1823,B,,,1,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,,CHEMBL616795,
5486,H,,,,,104686,4,Autocuration,,1824,B,,,1,BAO_0000019,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,,,,CHEMBL616796,
4639,H,,,,,106,8,Autocuration,,1825,B,,,1,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616797,
386,H,,,,,106,8,Autocuration,Brain membranes,1826,B,,,1,BAO_0000249,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,,,,CHEMBL616798,
2474,H,,,,,106,8,Autocuration,,1827,B,,,1,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,,,,CHEMBL616799,
6011,H,,,,,106,8,Autocuration,,1828,B,,,1,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,,,,CHEMBL616800,
5014,H,,,,,106,8,Autocuration,,1829,B,,,1,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616801,
17515,H,,,,,106,8,Autocuration,,1830,B,,,1,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,,,,CHEMBL616802,
4373,H,,,,,106,8,Autocuration,,1831,B,,,1,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,,,,CHEMBL616803,
1633,H,,,,,106,8,Expert,,1832,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,,,,CHEMBL857068,
1633,H,,,,,106,8,Autocuration,,1833,B,,,1,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,,,,CHEMBL616804,
4373,H,,,,,106,8,Autocuration,,1834,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,,,,CHEMBL616805,
4687,H,,,,,106,8,Autocuration,,1835,B,,,1,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616806,
11574,H,,,,,106,8,Autocuration,,1836,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1B receptor,,,,,CHEMBL616807,
10321,H,,,,,106,8,Autocuration,,1837,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,,,,CHEMBL616808,
15527,H,,,,,106,8,Autocuration,,1838,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,,CHEMBL616809,
17200,H,,,,,106,8,Autocuration,,1839,B,,,1,BAO_0000357,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,,,,CHEMBL616810,
14423,H,,,,,104802,4,Autocuration,,1840,B,,,1,BAO_0000224,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,,,,CHEMBL616811,
5834,H,,,,,108,8,Autocuration,,1841,B,,,1,BAO_0000357,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,,,Bos taurus,CHEMBL616812,9913.0
11473,H,,,,,108,8,Autocuration,,1842,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,,Sus scrofa,CHEMBL616813,9823.0
11473,H,,,,,108,8,Autocuration,,1843,B,,,1,BAO_0000357,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,,,Sus scrofa,CHEMBL616814,9823.0
10639,H,,,,,108,8,Autocuration,,1844,B,,,1,BAO_0000357,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,,Sus scrofa,CHEMBL616815,9823.0
10639,H,,,,,108,8,Autocuration,,1845,B,,,1,BAO_0000357,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,,,Sus scrofa,CHEMBL616816,9823.0
14331,H,,,,,108,8,Autocuration,,1846,B,,,1,BAO_0000357,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,,,Sus scrofa,CHEMBL616817,9823.0
10796,H,,,,,108,8,Autocuration,,1847,B,,,1,BAO_0000357,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,,,Sus scrofa,CHEMBL616818,9823.0
9098,H,,,,,108,8,Expert,,1848,B,,,1,BAO_0000357,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,,,Sus scrofa,CHEMBL616819,9823.0
14331,H,,,,,108,8,Expert,,1849,B,,,1,BAO_0000357,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,,,Sus scrofa,CHEMBL616820,9823.0
11828,H,,,,,108,8,Expert,,1850,B,,,1,BAO_0000019,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,,,Sus scrofa,CHEMBL616821,9823.0
11866,H,,,,,108,8,Autocuration,,1851,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,,,Sus scrofa,CHEMBL616822,9823.0
13047,H,,,,,108,8,Autocuration,,1852,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,,Oryctolagus cuniculus,CHEMBL616823,9986.0
188,D,,,,,12689,9,Autocuration,,1853,B,,,1,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,,,Rattus norvegicus,CHEMBL616824,10116.0
11825,D,,,,,12689,9,Autocuration,,1854,B,,,1,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,,Rattus norvegicus,CHEMBL616825,10116.0
11825,D,,,,,12689,9,Autocuration,,1855,B,,,1,BAO_0000357,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,,,Rattus norvegicus,CHEMBL616826,10116.0
11624,D,,,,,12689,9,Expert,,1856,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,,,Rattus norvegicus,CHEMBL616827,10116.0
11139,D,,,,,12689,9,Autocuration,,1857,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,,,Rattus norvegicus,CHEMBL616828,10116.0
11147,D,,,,,12689,9,Autocuration,,1858,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,,,Rattus norvegicus,CHEMBL616829,10116.0
10444,D,,,,,12689,9,Autocuration,,1859,B,,,1,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,,,Rattus norvegicus,CHEMBL616830,10116.0
11624,D,,,,,12689,9,Expert,,1860,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1C receptor,,,,Rattus norvegicus,CHEMBL616831,10116.0
11662,D,,,,,12689,9,Autocuration,,1861,B,,,1,BAO_0000019,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,,Rattus norvegicus,CHEMBL616832,10116.0
11662,D,,,,,12689,9,Autocuration,,1862,B,,,1,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,,Rattus norvegicus,CHEMBL616833,10116.0
11662,D,,,,,12689,9,Expert,,1863,B,,,1,BAO_0000019,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,,Rattus norvegicus,CHEMBL616834,10116.0
11662,D,,,,,12689,9,Autocuration,,1864,B,,,1,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,,,Rattus norvegicus,CHEMBL829595,10116.0
9098,D,,,,,12689,9,Autocuration,,1865,B,,,1,BAO_0000357,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,,,Rattus norvegicus,CHEMBL616835,10116.0
10394,D,,,,,12689,9,Autocuration,,1866,B,,,1,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,,,Rattus norvegicus,CHEMBL872910,10116.0
11933,H,,,,,12689,8,Expert,,1867,B,,,1,BAO_0000357,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,,,,CHEMBL616836,
12092,D,,,,,12689,9,Autocuration,,1868,B,,,1,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,,,Rattus norvegicus,CHEMBL616837,10116.0
12253,D,,,,,12689,9,Autocuration,,1869,B,,,1,BAO_0000019,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,,,Rattus norvegicus,CHEMBL616466,10116.0
12253,D,,,HEK293,,12689,9,Autocuration,,1870,B,,,1,BAO_0000219,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,722.0,,,Rattus norvegicus,CHEMBL616467,10116.0
1558,H,,,,,108,8,Autocuration,,1871,B,,,1,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,,,CHEMBL616468,
2474,H,,,,,108,8,Autocuration,,1872,B,,,1,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,,,CHEMBL616469,
2474,H,,,,,108,8,Autocuration,,1873,B,,,1,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,,,CHEMBL616470,
11574,H,,,,,12689,8,Autocuration,,1874,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1C receptor,,,,,CHEMBL616471,
1558,H,,,,,12689,8,Autocuration,,1875,B,,,1,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,,,CHEMBL616472,
13944,H,,,,,12689,8,Autocuration,,1876,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1C receptor,,,,,CHEMBL616473,
13033,H,,,,,12689,8,Autocuration,,1877,B,,,1,BAO_0000357,Binding affinity against serotonergic 5-HT1c receptor,,,,,CHEMBL616474,
10321,H,,,,,12689,8,Autocuration,,1878,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,,,,CHEMBL616475,
11866,H,,,,,12689,8,Autocuration,,1879,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,,,,CHEMBL616476,
14454,H,,,,,105,8,Autocuration,,1880,B,,,1,BAO_0000019,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,,,Oryctolagus cuniculus,CHEMBL616477,9986.0
11574,H,,,,,104686,4,Autocuration,,1881,B,,,1,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,,,,CHEMBL616478,
11574,H,,,,,104686,4,Autocuration,,1882,B,,,1,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,,,,CHEMBL616479,
13631,H,,,,,104686,4,Autocuration,,1883,B,,,1,BAO_0000019,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,,,,CHEMBL616480,
9630,D,,,,,104686,5,Autocuration,,1884,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,,,Rattus norvegicus,CHEMBL616481,10116.0
8822,D,,,,,104686,5,Autocuration,,1885,B,,,1,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,,,Rattus norvegicus,CHEMBL616482,10116.0
9064,D,,,,,104686,5,Autocuration,,1886,B,Brain,,1,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,,955.0,Rattus norvegicus,CHEMBL884713,10116.0
8868,H,,,,,104686,4,Autocuration,,1887,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,,,,CHEMBL616483,
9064,H,,,,,104686,4,Autocuration,,1888,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,,,,CHEMBL616484,
9806,H,,,,,104686,4,Autocuration,,1889,B,,,1,BAO_0000019,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,,,,CHEMBL616485,
9098,H,,,,,104686,4,Autocuration,,1890,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,,CHEMBL616486,
8868,H,,,,,104686,4,Autocuration,,1891,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,,,,CHEMBL616487,
12765,H,,,,,104686,4,Autocuration,,1892,B,,,1,BAO_0000224,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,,,CHEMBL616488,
11049,H,,,,,104686,4,Autocuration,,1893,B,,,1,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,CHEMBL616489,
11049,H,,,,,104686,4,Autocuration,,1894,B,,,1,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,CHEMBL616490,
11049,H,,,,,104686,4,Autocuration,,1895,B,,,1,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,,,,CHEMBL616491,
11049,H,,,,,104686,4,Autocuration,,1896,B,,,1,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,,,,CHEMBL616492,
11049,H,,,,,104686,4,Autocuration,,1897,B,,,1,BAO_0000019,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,CHEMBL616493,
11473,H,,,,,104686,4,Autocuration,,1898,B,,,1,BAO_0000019,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,,,,CHEMBL616494,
11473,H,,,,,104686,4,Autocuration,,1899,B,,,1,BAO_0000019,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,,,,CHEMBL616495,
3086,H,,,,,104686,4,Autocuration,,1900,B,,,1,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,,,,CHEMBL616496,
11049,H,,,,,104686,4,Autocuration,,1901,B,,,1,BAO_0000019,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,CHEMBL616497,
11049,H,,,,,104686,4,Autocuration,,1902,B,,,1,BAO_0000019,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,CHEMBL616498,
10639,H,,,,,104686,4,Autocuration,,1903,B,,,1,BAO_0000019,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,,,,CHEMBL616499,
10922,H,,,,,104686,4,Autocuration,,1904,B,,,1,BAO_0000019,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,,,,CHEMBL616500,
9064,D,,,,,104686,5,Autocuration,,1905,B,Brain,,1,BAO_0000221,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,,955.0,Rattus norvegicus,CHEMBL616501,10116.0
10748,H,,,,,104686,4,Autocuration,,1906,B,Brain,,1,BAO_0000221,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,,955.0,,CHEMBL616502,
11614,H,,,,,104686,4,Autocuration,Membranes,1907,B,,,1,BAO_0000249,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,,,CHEMBL884529,
11615,H,,,,,104686,4,Autocuration,Membranes,1908,B,,,1,BAO_0000249,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,,,CHEMBL616503,
11615,H,,,,,104686,4,Autocuration,,1909,B,,,1,BAO_0000224,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,,,,CHEMBL616964,
11614,H,,,,,104686,4,Autocuration,Membranes,1910,B,,,1,BAO_0000249,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,,,CHEMBL616965,
11702,H,,,,,104686,4,Autocuration,,1911,B,,,1,BAO_0000224,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,,,,CHEMBL616966,
11702,H,,,,,104686,4,Autocuration,,1912,B,,,1,BAO_0000224,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,,CHEMBL616967,
11702,D,,,,,104686,5,Autocuration,,1913,B,,,1,BAO_0000224,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,,,Rattus norvegicus,CHEMBL616968,10116.0
11702,H,,,,,104686,4,Autocuration,,1914,B,,,1,BAO_0000224,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,,CHEMBL616969,
13346,H,,,,,104686,4,Autocuration,,1915,B,,,1,BAO_0000019,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,,,,CHEMBL884530,
10025,H,,,,,104686,4,Autocuration,,1916,B,,,1,BAO_0000224,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,,,,CHEMBL616970,
10025,H,,,,,104686,4,Autocuration,,1917,B,,,1,BAO_0000224,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,,,CHEMBL616971,
10025,H,,,,,104686,4,Autocuration,,1918,B,,,1,BAO_0000224,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,,,CHEMBL616972,
9036,H,,,,,104686,4,Autocuration,,1919,B,,,1,BAO_0000224,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,,,,CHEMBL616973,
9036,H,,,,,104686,4,Autocuration,,1920,B,,,1,BAO_0000224,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,,,,CHEMBL616974,
9161,H,,,,,104686,4,Autocuration,,1921,B,,,1,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,,,,CHEMBL616975,
12304,H,,,,,104686,4,Autocuration,,1922,B,,,1,BAO_0000019,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,,,,CHEMBL616976,
13276,H,,,,,104686,4,Autocuration,,1923,B,,,1,BAO_0000224,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,,,,CHEMBL616977,
11825,H,,,,,104686,4,Autocuration,,1924,B,,,1,BAO_0000224,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,,,CHEMBL616978,
12443,H,,,,,104686,4,Autocuration,,1925,B,,,1,BAO_0000224,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,,,,CHEMBL616979,
13830,H,,,,,104686,4,Autocuration,,1926,B,,,1,BAO_0000224,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,,,,CHEMBL616980,
9592,H,,,,,104686,4,Autocuration,Membranes,1927,B,,,1,BAO_0000249,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,,,,CHEMBL616981,
9592,H,,,,,104686,4,Autocuration,Membranes,1928,B,,,1,BAO_0000249,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,,,,CHEMBL616982,
10881,H,,,,,104686,4,Autocuration,,1929,B,,,1,BAO_0000224,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,,,,CHEMBL616983,
13605,H,,,,,104686,4,Autocuration,,1930,B,,,1,BAO_0000019,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,,,,CHEMBL616984,
11624,D,,,,,104686,5,Autocuration,,1931,B,,,1,BAO_0000224,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,,,Rattus norvegicus,CHEMBL616985,10116.0
4101,H,,,,,104686,4,Autocuration,,1932,B,,,1,BAO_0000224,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,,,CHEMBL616986,
4101,H,,,,,104686,4,Autocuration,,1933,B,,,1,BAO_0000224,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,,,CHEMBL616987,
15360,H,,,,,104686,4,Autocuration,,1934,B,,,1,BAO_0000019,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,,,,CHEMBL616988,
11576,H,,,,,104686,4,Autocuration,,1935,B,,,1,BAO_0000019,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,,,,CHEMBL617243,
5834,H,,,,,104686,4,Autocuration,,1936,B,,,1,BAO_0000019,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,,,,CHEMBL617244,
2395,D,,,CHO-K1,,104686,5,Autocuration,,1937,B,,,1,BAO_0000219,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,485.0,,,Rattus norvegicus,CHEMBL617245,10116.0
11965,H,,,,,104686,4,Autocuration,Membranes,1938,B,,,1,BAO_0000249,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,,,CHEMBL617246,
3967,H,,,,,104686,4,Autocuration,,1939,B,,,1,BAO_0000224,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,,,,CHEMBL617546,
11130,H,,,,,104686,4,Autocuration,Brain membranes,1940,B,,,1,BAO_0000249,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,,,,CHEMBL617547,
13427,H,,,,In vitro,104686,4,Autocuration,,1941,B,,,1,BAO_0000219,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,,,CHEMBL617548,
9443,H,,,,,104686,4,Autocuration,,1942,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617549,
9443,H,,,,,104686,4,Autocuration,,1943,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,,,CHEMBL617550,
11825,H,,,,,104686,4,Autocuration,,1944,B,,,1,BAO_0000224,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,,,CHEMBL617551,
12120,H,,,,,104686,4,Autocuration,Membranes,1945,B,,,1,BAO_0000249,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,,,,CHEMBL617552,
12120,H,,,,,104686,4,Autocuration,Membranes,1946,B,,,1,BAO_0000249,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,,,,CHEMBL617553,
11963,H,,,,,104686,4,Autocuration,,1947,F,Thoracic aorta,,1,BAO_0000019,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,,1515.0,,CHEMBL617554,
9069,H,,,,,104686,4,Autocuration,,1948,B,,,1,BAO_0000019,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617555,
8868,H,,,,,104686,4,Autocuration,,1949,B,,,1,BAO_0000224,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,,,CHEMBL617556,
17200,H,,,,,10624,8,Autocuration,,1950,B,,,1,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,,,CHEMBL617557,
17200,H,,,,,10624,8,Autocuration,,1951,B,,,1,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,,,CHEMBL617558,
13969,H,,,,,17106,8,Expert,,1952,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,,,,CHEMBL617559,
13392,D,,,,,17106,9,Expert,,1953,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor,,,,,CHEMBL617560,
1742,H,,,,,17106,8,Autocuration,,1954,B,,,1,BAO_0000249,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,,CHEMBL617561,
1742,H,,,,,17106,8,Autocuration,,1955,B,,,1,BAO_0000249,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,,CHEMBL617562,
14331,H,,,,,17106,8,Autocuration,,1956,B,Striatum,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,,2435.0,,CHEMBL617563,
12861,H,,,,,17106,8,Autocuration,,1957,F,,,1,BAO_0000019,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,,,,CHEMBL617564,
12861,H,,,,,17106,8,Expert,,1958,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,,,,CHEMBL617565,
12861,H,,,,,17106,8,Autocuration,,1959,B,,,1,BAO_0000357,Binding activity radioligand.,,,,,CHEMBL856076,
12861,H,,,,,17106,8,Autocuration,,1960,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,,CHEMBL617566,
12861,H,,,,,17106,8,Expert,,1961,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,CHEMBL875911,
12861,H,,,,,17106,8,Autocuration,,1962,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,,,CHEMBL617567,
675,H,,,,,17106,8,Autocuration,,1963,B,,,1,BAO_0000249,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,,CHEMBL617568,
12490,H,,,,,17106,8,Expert,,1964,B,,,1,BAO_0000019,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,,,,CHEMBL617569,
11828,H,,,,,17106,8,Expert,,1965,B,,,1,BAO_0000249,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,,,,CHEMBL617570,
11866,H,,,,,17106,8,Autocuration,,1966,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,,,,CHEMBL617571,
773,H,,,,,105,8,Autocuration,,1967,B,,,1,BAO_0000357,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,,,Sus scrofa,CHEMBL617572,9823.0
13047,H,,,,,105,8,Expert,,1968,B,,,1,BAO_0000357,The compound was tested for intrinsic activity against 5-HT1D receptor,,,,Oryctolagus cuniculus,CHEMBL617573,9986.0
13047,H,,,,,105,8,Autocuration,,1969,B,,,1,BAO_0000019,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,,,Oryctolagus cuniculus,CHEMBL617574,9986.0
13047,H,,,,,105,8,Expert,,1970,B,,,1,BAO_0000357,The compound was tested for binding affinity against 5-HT1D receptor,,,,Oryctolagus cuniculus,CHEMBL617575,9986.0
188,H,,,,,10578,8,Autocuration,,1971,B,,,1,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,,,,CHEMBL617576,
10639,H,,,,,10578,8,Autocuration,,1972,F,,,1,BAO_0000019,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,,,,CHEMBL617577,
12438,H,,,,,10578,8,Autocuration,,1973,F,,,1,BAO_0000019,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,,,,CHEMBL617578,
12438,H,,,,,10578,8,Autocuration,,1974,B,,,1,BAO_0000357,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,,,,CHEMBL617579,
15854,H,,,,,10578,8,Expert,,1975,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,,CHEMBL617580,
10394,H,,,,,10578,8,Autocuration,,1976,B,,,1,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,,,CHEMBL617581,
12092,H,,,,,10578,8,Autocuration,,1977,B,,,1,BAO_0000357,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,,,,CHEMBL617582,
3389,H,,,,,10578,8,Expert,,1978,B,,,1,BAO_0000019,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,,,,CHEMBL617583,
6011,H,,,,,105,8,Autocuration,,1979,B,,,1,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,,,,CHEMBL617584,
4639,H,,,,,105,8,Autocuration,,1980,B,,,1,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,,,,CHEMBL617585,
2474,H,,,,,105,8,Autocuration,,1981,B,,,1,BAO_0000357,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,,,,CHEMBL875912,
5014,H,,,,,105,8,Autocuration,,1982,B,,,1,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,,,,CHEMBL617586,
17515,H,,,,,105,8,Autocuration,,1983,B,,,1,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,,,,CHEMBL617587,
11866,H,,,,,105,8,Autocuration,,1984,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,,,,CHEMBL617588,
4687,H,,,,,105,8,Autocuration,,1985,B,,,1,BAO_0000357,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,,,,CHEMBL857980,
12146,H,,,,,105,8,Autocuration,,1986,B,,,1,BAO_0000357,Tested against 5-hydroxytryptamine 1D receptor,,,,,CHEMBL617589,
10321,H,,,,,105,8,Autocuration,,1987,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,,,,CHEMBL617590,
13267,H,,,HEK293,,105,8,Autocuration,,1988,B,,,1,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,722.0,,,,CHEMBL617591,
1274,D,,,,,105,9,Expert,,1989,B,,,1,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 1D receptor,,,,Homo sapiens,CHEMBL617592,9606.0
15250,H,,,,,105,8,Autocuration,,1990,B,,,1,BAO_0000357,,,,,,CHEMBL617593,
13706,H,,,CHO-K1,,106,8,Autocuration,,1991,B,,,1,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,485.0,,,,CHEMBL617594,
13706,H,,,CHO-K1,,105,8,Autocuration,,1992,B,,,1,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,485.0,,,,CHEMBL617595,
13706,H,,,HEK293,,105,8,Autocuration,,1993,B,,,1,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,722.0,,,,CHEMBL617596,
13706,H,,,HEK293,,105,8,Autocuration,,1994,B,,,1,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,722.0,,,,CHEMBL617597,
13047,H,,,,,105,8,Autocuration,,1995,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,,,CHEMBL617598,
13366,H,,,,,105,8,Autocuration,,1996,B,,,1,BAO_0000357,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,,,,CHEMBL872916,
13366,H,,,,,105,8,Expert,,1997,B,,,1,BAO_0000357,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,,,,CHEMBL617599,
1558,H,,,,,105,8,Autocuration,,1998,B,,,1,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,,,,CHEMBL617091,
12902,H,,,CHO-K1,,105,8,Expert,,1999,B,,,1,BAO_0000219,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",485.0,,,,CHEMBL617092,
13706,H,,,CHO-K1,,105,8,Autocuration,,2000,B,,,1,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,485.0,,,,CHEMBL617093,
13706,H,,,,,105,8,Autocuration,,2001,F,,,1,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,,,,CHEMBL617094,
13706,H,,,,,105,8,Autocuration,,2002,F,,,1,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,,CHEMBL617095,
14251,H,,,,,105,8,Autocuration,,2003,F,,,1,BAO_0000019,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,,CHEMBL617096,
14251,H,,,,,105,8,Autocuration,,2004,F,,,1,BAO_0000019,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,,CHEMBL617097,
14251,H,,,,,105,8,Autocuration,,2005,F,,,1,BAO_0000019,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,,CHEMBL617098,
13313,H,,,,,105,8,Autocuration,,2006,B,,,1,BAO_0000357,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,,,,CHEMBL617301,
13313,H,,,,,105,8,Autocuration,,2007,B,,,1,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,,,,CHEMBL617302,
13366,H,,,,,105,8,Autocuration,,2008,B,,,1,BAO_0000357,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,,,,CHEMBL617303,
13051,H,,,,,105,8,Expert,,2009,B,,,1,BAO_0000357,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,,,,CHEMBL617304,
12903,H,,,CHO,,105,8,Expert,,2010,B,,,1,BAO_0000219,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",449.0,,,,CHEMBL617305,
12469,D,,,,,105,9,Autocuration,,2011,B,,,1,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,,,Homo sapiens,CHEMBL617306,9606.0
5619,H,,,,,17106,8,Autocuration,,2012,B,,,1,BAO_0000357,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,,,,CHEMBL617307,
13047,H,,,,,105,8,Autocuration,,2013,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,,,Oryctolagus cuniculus,CHEMBL617308,9986.0
16633,H,,,,,105,8,Autocuration,,2014,B,,,1,BAO_0000357,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,,,,CHEMBL617309,
16633,H,,,,,105,8,Autocuration,,2015,B,,,1,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,,,CHEMBL617310,
16633,H,,,,,105,8,Autocuration,,2016,B,,,1,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,,,CHEMBL617311,
16633,H,,,,,105,8,Autocuration,,2017,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL617312,
3269,H,,,,,105,8,Autocuration,,2018,B,,,1,BAO_0000357,Affinity against 5-hydroxytryptamine 1D receptor alpha,,,,,CHEMBL617313,
12409,H,,,,,105,8,Expert,,2019,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,,,,CHEMBL617314,
13706,H,,,,,106,8,Autocuration,,2020,F,,,1,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,,CHEMBL617315,
13706,H,,,HEK293,,106,8,Autocuration,,2021,B,,,1,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,722.0,,,,CHEMBL617316,
13706,H,,,HEK293,,106,8,Autocuration,,2022,B,,,1,BAO_0000219,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,722.0,,,,CHEMBL617317,
12903,H,,,CHO,,106,8,Autocuration,,2023,B,,,1,BAO_0000219,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",449.0,,,,CHEMBL617318,
13047,H,,,,,106,8,Autocuration,,2024,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,,,CHEMBL617319,
13366,D,,,,,106,9,Expert,,2025,B,,,1,BAO_0000357,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,,CHEMBL617320,
13366,D,,,,,106,9,Expert,,2026,B,,,1,BAO_0000357,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,,CHEMBL617321,
13366,D,,,,,106,9,Expert,,2027,B,,,1,BAO_0000357,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,,CHEMBL617322,
13366,H,,,,,106,8,Autocuration,,2028,B,,,1,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL616862,
13366,H,,,,,106,8,Autocuration,,2029,B,,,1,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL616863,
12469,H,,,CHO,,106,8,Autocuration,,2030,B,,,1,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,449.0,,,,CHEMBL616864,
13706,H,,,CHO-K1,,106,8,Autocuration,,2031,B,,,1,BAO_0000219,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,485.0,,,,CHEMBL616865,
13706,H,,,CHO-K1,,106,8,Autocuration,,2032,B,,,1,BAO_0000219,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,485.0,,,,CHEMBL616866,
13706,H,,,,,106,8,Autocuration,,2033,F,,,1,BAO_0000019,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,,CHEMBL616867,
12902,H,,,CHO-K1,,106,8,Expert,,2034,B,,,1,BAO_0000219,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",485.0,,,,CHEMBL616868,
13051,H,,,,,105,8,Expert,,2035,B,,,1,BAO_0000357,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,,,,CHEMBL616869,
12903,H,,,CHO,,106,8,Expert,,2036,B,,,1,BAO_0000219,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",449.0,,,,CHEMBL616870,
1558,H,,,CHO-K1,,105,8,Autocuration,,2037,F,,,1,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,485.0,,,,CHEMBL616871,
1558,H,,,CHO-K1,,105,8,Autocuration,,2038,F,,,1,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,485.0,,,,CHEMBL616872,
1558,H,,,CHO-K1,,105,8,Autocuration,,2039,F,,,1,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,485.0,,,,CHEMBL616873,
1558,H,,,CHO-K1,,105,8,Autocuration,,2040,F,,,1,BAO_0000219,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,485.0,,,,CHEMBL616838,
1558,H,,,,,105,8,Autocuration,,2041,B,,,1,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,,,,CHEMBL616839,
13047,H,,,,,106,8,Autocuration,,2042,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,,,Oryctolagus cuniculus,CHEMBL616840,9986.0
13313,H,,,,,105,8,Autocuration,,2043,B,,,1,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,,,,CHEMBL616841,
13313,H,,,,,105,8,Autocuration,,2044,B,,,1,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,,,,CHEMBL616842,
12409,H,,,,,105,8,Expert,,2045,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,,,,CHEMBL857976,
15250,H,,,CHO,,10618,8,Autocuration,,2046,B,,,1,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,449.0,,,,CHEMBL616843,
1348,D,,,,,10618,9,Expert,,2047,B,,,1,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,,,Homo sapiens,CHEMBL616844,9606.0
1348,H,,,,,10618,8,Autocuration,,2048,B,,,1,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,,,,CHEMBL616845,
4234,D,,,,,10618,9,Expert,,2049,B,,,1,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,,,Homo sapiens,CHEMBL616846,9606.0
16209,H,,,,,10618,8,Autocuration,,2050,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,,,,CHEMBL616847,
10444,H,,,,,10618,8,Autocuration,,2051,B,,,1,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,,,,CHEMBL616848,
3935,H,,,,,10618,8,Autocuration,,2052,B,,,1,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,,,,CHEMBL616849,
15818,H,,,,,10618,8,Autocuration,,2053,B,,,1,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,,,,CHEMBL872911,
17085,H,,,,,10618,8,Autocuration,,2054,B,,,1,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,,,,CHEMBL616850,
12936,D,,,CHO,,10618,9,Expert,,2055,B,,,1,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,449.0,,,Homo sapiens,CHEMBL616699,9606.0
6166,H,,,,,10618,8,Autocuration,,2056,B,,,1,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,,,,CHEMBL616700,
15779,H,,,CHO,,10618,8,Autocuration,,2057,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,449.0,,,,CHEMBL616701,
15779,H,,,CHO,,10618,8,Autocuration,,2058,B,,,1,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,449.0,,,,CHEMBL616702,
15779,H,,,CHO,,10618,8,Autocuration,,2059,B,,,1,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,449.0,,,,CHEMBL616703,
13181,H,,,,,10618,8,Autocuration,,2060,B,,,1,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,,,,CHEMBL616704,
4199,H,,,CHO,,10618,8,Autocuration,,2061,B,,,1,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,449.0,,,,CHEMBL616705,
14875,H,,,,,10618,8,Autocuration,,2062,B,,,1,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,,,,CHEMBL616706,
15146,H,,,CHO,,10618,8,Autocuration,,2063,B,,,1,BAO_0000219,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,449.0,,,,CHEMBL616707,
5213,H,,,,,10618,8,Autocuration,,2064,B,,,1,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,,,,CHEMBL616708,
12146,H,,,,,10618,8,Autocuration,,2065,B,,,1,BAO_0000357,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,,,,CHEMBL616709,
13267,H,,,CHO,,10618,8,Autocuration,,2066,B,,,1,BAO_0000219,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,449.0,,,,CHEMBL616710,
14818,H,,,CHO,,10618,8,Autocuration,,2067,B,,,1,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,449.0,,,,CHEMBL616711,
4829,H,,,CHO,,10618,8,Autocuration,,2068,B,,,1,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",449.0,,,,CHEMBL616712,
4373,H,,,,,10618,8,Autocuration,,2069,B,,,1,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,,,,CHEMBL616713,
4373,H,,,,,10618,8,Autocuration,,2070,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,,,,CHEMBL616714,
14159,H,,,,,10618,8,Autocuration,,2071,B,,,1,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,,,,CHEMBL616715,
16633,H,,,,,10618,8,Autocuration,,2072,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 1E receptor,,,,,CHEMBL616716,
17085,H,,,,,279,8,Autocuration,,2073,F,,,1,BAO_0000019,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,,,,CHEMBL616717,
17085,H,,,,,279,8,Expert,,2074,F,,,1,BAO_0000019,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,,,,CHEMBL616718,
16209,H,,,,,279,8,Autocuration,,2075,F,,,1,BAO_0000019,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,,,,CHEMBL875905,
16209,H,,,,,279,8,Autocuration,,2076,F,,,1,BAO_0000019,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,,,,CHEMBL616719,
17085,H,,,,,279,8,Expert,,2077,F,,,1,BAO_0000019,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,,,,CHEMBL616720,
14159,H,,,,,279,8,Autocuration,,2078,B,,,1,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,,,,CHEMBL616721,
15250,H,,,CHO,,279,8,Autocuration,,2079,B,,,1,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,449.0,,,,CHEMBL616722,
3805,H,,,,,279,8,Autocuration,,2080,B,,,1,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,,,,CHEMBL616723,
16190,H,,,CHO,,279,8,Autocuration,,2081,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,449.0,,,,CHEMBL616724,
16190,H,,,,,279,8,Autocuration,,2082,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,,,,CHEMBL616725,
16209,H,,,,,279,8,Autocuration,,2083,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,,,,CHEMBL616726,
16209,H,,,,,279,8,Autocuration,,2084,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,,,,CHEMBL616727,
16209,H,,,,,279,8,Autocuration,,2085,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,,,,CHEMBL616728,
6866,H,,,,,279,8,Autocuration,,2086,B,,,1,BAO_0000357,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,,,,CHEMBL616729,
17085,H,,,,,279,8,Expert,,2087,B,,,1,BAO_0000019,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,,,,CHEMBL616730,
16312,H,,,,,279,8,Autocuration,,2088,B,,,1,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,,,,CHEMBL617125,
6166,H,,,,,279,8,Autocuration,,2089,B,,,1,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,,,,CHEMBL857977,
15779,H,,,CHO,,279,8,Autocuration,,2090,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,449.0,,,,CHEMBL617126,
4199,H,,,CHO,,279,8,Autocuration,,2091,B,,,1,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,449.0,,,,CHEMBL617127,
14875,H,,,,,279,8,Autocuration,,2092,B,,,1,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,,,,CHEMBL617128,
15146,H,,,CHO,,279,8,Autocuration,,2093,B,,,1,BAO_0000219,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,449.0,,,,CHEMBL617129,
5213,H,,,,,279,8,Autocuration,,2094,B,,,1,BAO_0000357,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,,,,CHEMBL617130,
14818,H,,,CHO,,279,8,Autocuration,,2095,B,,,1,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,449.0,,,,CHEMBL617131,
4829,H,,,CHO,,279,8,Autocuration,,2096,B,,,1,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",449.0,,,,CHEMBL617132,
4829,H,,,CHO,,279,8,Autocuration,,2097,B,,,1,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",449.0,,,,CHEMBL617133,
4373,H,,,,,279,8,Autocuration,,2098,B,,,1,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,,,,CHEMBL617134,
4373,H,,,,,279,8,Autocuration,,2099,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,,,,CHEMBL617135,
5014,H,,,,,279,8,Autocuration,,2100,B,,,1,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,,,,CHEMBL617136,
11662,H,,,,,104686,4,Autocuration,,2101,B,,,1,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,,,,CHEMBL617137,
11662,H,,,,,104686,4,Autocuration,,2102,B,,,1,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,,,CHEMBL617138,
11662,H,,,,,104686,4,Autocuration,,2103,B,,,1,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,,CHEMBL617139,
14093,H,,,,,12687,8,Autocuration,,2104,B,,,1,BAO_0000019,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617140,
11200,H,,,,In vivo,104686,4,Autocuration,,2105,F,,,1,BAO_0000218,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,,,,CHEMBL617141,
11200,H,,,,,104686,4,Autocuration,,2106,F,,,1,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,CHEMBL858112,
12352,H,,,,,17005,8,Intermediate,,2107,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,,,,CHEMBL617142,
13657,U,,,,,22226,0,Autocuration,,2108,B,,,1,BAO_0000019,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,,,Bos taurus,CHEMBL617143,9913.0
14331,U,,,,,22226,0,Autocuration,,2109,B,,,1,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,,,Bos taurus,CHEMBL617144,9913.0
14331,U,,,,,22226,0,Autocuration,,2110,B,,,1,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,,,Bos taurus,CHEMBL617145,9913.0
14331,U,,,,,22226,0,Autocuration,,2111,B,,,1,BAO_0000019,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,,,,CHEMBL617146,
12685,H,,,,,104784,4,Autocuration,,2112,B,,,1,BAO_0000019,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,,,Cavia porcellus,CHEMBL617147,10141.0
14389,H,,,,,104784,4,Autocuration,,2113,B,,,1,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,,,Cavia porcellus,CHEMBL617148,10141.0
14386,H,,,,,104784,4,Autocuration,,2114,B,,,1,BAO_0000019,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,,,Cavia porcellus,CHEMBL617149,10141.0
5732,H,,,,,104784,4,Autocuration,,2115,B,,,1,BAO_0000224,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,,,,CHEMBL617150,
16293,H,,,,,104784,4,Autocuration,,2116,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,,CHEMBL617151,
2078,H,,,,,104784,4,Autocuration,,2117,B,,,1,BAO_0000224,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617201,
5486,H,,,,,10209,8,Autocuration,,2118,B,,,1,BAO_0000357,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,,,CHEMBL617202,
11820,H,,,,In vivo,104826,4,Autocuration,,2119,B,,,1,BAO_0000218,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,,,CHEMBL617203,
10297,H,,,,,104826,4,Autocuration,,2120,B,,,1,BAO_0000019,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,,,CHEMBL617204,
13704,H,,,,,104826,4,Autocuration,,2121,B,,,1,BAO_0000224,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,,,,CHEMBL617205,
10297,D,,,,,104826,5,Autocuration,,2122,B,,,1,BAO_0000019,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,,,Mus musculus,CHEMBL617206,10090.0
11820,H,,,,In vivo,104826,4,Autocuration,,2123,B,,,1,BAO_0000218,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,,,CHEMBL617207,
10297,D,,,,,104826,5,Autocuration,,2124,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,,,Mus musculus,CHEMBL617208,10090.0
11555,H,,,,,104826,4,Autocuration,,2125,B,,,1,BAO_0000224,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617209,
11555,H,,,,,104826,4,Autocuration,,2126,B,,,1,BAO_0000224,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,,,,CHEMBL617210,
11555,H,,,,,104826,4,Autocuration,,2127,B,,,1,BAO_0000224,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,,,,CHEMBL617211,
10297,D,,,,,104826,5,Autocuration,,2128,B,,,1,BAO_0000019,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,,Mus musculus,CHEMBL617212,10090.0
16688,H,,,,,104784,4,Autocuration,,2129,B,,,1,BAO_0000224,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,,,Sus scrofa,CHEMBL617213,9823.0
16688,H,,,,,104784,4,Autocuration,,2130,B,,,1,BAO_0000224,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,,,Sus scrofa,CHEMBL617214,9823.0
5333,U,,,,,22226,0,Autocuration,,2131,B,,,1,BAO_0000221,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,,,CHEMBL617215,
4437,U,,,,,22226,0,Autocuration,,2132,B,,,1,BAO_0000221,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,,,CHEMBL617216,
5033,H,,,,,17005,8,Autocuration,,2133,B,,,1,BAO_0000357,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,,,Sus scrofa,CHEMBL617217,9823.0
15267,H,,,,,104686,4,Autocuration,,2134,B,,,1,BAO_0000019,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617218,
15267,H,,,,,104686,4,Autocuration,,2135,B,,,1,BAO_0000019,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,,,CHEMBL872913,
11820,H,,,,,104826,4,Autocuration,,2136,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,,,,CHEMBL617219,
9069,H,,,,,104686,4,Autocuration,,2137,B,,,1,BAO_0000224,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,,,CHEMBL873482,
9162,D,,,,,104686,5,Autocuration,,2138,B,,,1,BAO_0000019,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,,,Rattus norvegicus,CHEMBL617220,10116.0
9162,H,,,,,104686,4,Autocuration,,2139,B,,,1,BAO_0000019,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,,,,CHEMBL617221,
9162,H,,,,,104686,4,Autocuration,,2140,B,,,1,BAO_0000019,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,,,,CHEMBL617222,
10428,H,,,,,104686,4,Autocuration,,2141,F,,,1,BAO_0000019,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,,,,CHEMBL875906,
9628,H,,,,,104686,4,Autocuration,,2142,B,,,1,BAO_0000019,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,,,,CHEMBL617223,
12704,H,,,,,104686,4,Autocuration,,2143,B,,,1,BAO_0000224,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617224,
15453,D,,,,,104686,5,Autocuration,,2144,B,,,1,BAO_0000224,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,,Rattus norvegicus,CHEMBL617225,10116.0
188,H,,,,,104686,4,Autocuration,,2145,B,,,1,BAO_0000224,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,,,,CHEMBL617226,
10349,H,,,,,104686,4,Autocuration,,2146,B,,,1,BAO_0000224,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,,,,CHEMBL617227,
10349,H,,,,,104686,4,Autocuration,,2147,B,,,1,BAO_0000224,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,,,,CHEMBL617228,
8868,H,,,,,104686,4,Autocuration,,2148,B,,,1,BAO_0000224,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,,,CHEMBL617229,
10025,H,,,,,104686,4,Autocuration,,2149,B,,,1,BAO_0000224,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,,,CHEMBL617230,
10025,H,,,,,104686,4,Autocuration,,2150,B,,,1,BAO_0000224,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,,,CHEMBL617231,
11702,H,,,,,104686,4,Autocuration,,2151,B,,,1,BAO_0000224,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,,,,CHEMBL617232,
11702,H,,,,,104686,4,Autocuration,,2152,B,,,1,BAO_0000224,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617233,
11702,H,,,,,104686,4,Autocuration,,2153,B,,,1,BAO_0000224,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,,CHEMBL617234,
11702,H,,,,,104686,4,Autocuration,,2154,F,,,1,BAO_0000019,Compound was tested for the inhibition of quipazine induced head twitches in rats,,,,,CHEMBL617235,
11702,H,,,,,104686,4,Autocuration,,2155,F,,,1,BAO_0000019,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,,,,CHEMBL617236,
10085,H,,,,,104686,4,Autocuration,,2156,B,Hippocampus,,1,BAO_0000221,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,,10000000.0,,CHEMBL617237,
10085,H,,,,,104686,4,Autocuration,,2157,B,Hippocampus,,1,BAO_0000221,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,,10000000.0,,CHEMBL617238,
9630,D,,,,,104686,5,Autocuration,,2158,B,Brain,,1,BAO_0000221,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,,955.0,Rattus norvegicus,CHEMBL617239,10116.0
11070,H,,,,,104686,4,Autocuration,,2159,B,,,1,BAO_0000019,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,,,,CHEMBL617240,
9841,H,,,,,104686,4,Autocuration,Membranes,2160,B,,,1,BAO_0000249,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,,,CHEMBL617241,
9841,H,,,,,104686,4,Autocuration,Membranes,2161,B,,,1,BAO_0000249,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,,,CHEMBL875907,
13291,H,,,,,104686,4,Autocuration,,2162,B,,,1,BAO_0000019,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,,,,CHEMBL617242,
10590,H,,,,,104686,4,Autocuration,,2163,F,,,1,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,,,,CHEMBL617152,
9064,D,,,,,104686,5,Autocuration,,2164,B,Brain,,1,BAO_0000221,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,,955.0,Rattus norvegicus,CHEMBL617153,10116.0
12268,D,,,,,104686,5,Autocuration,Membranes,2165,B,,,1,BAO_0000249,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,,,Rattus norvegicus,CHEMBL617154,10116.0
13508,H,,,,,104686,4,Autocuration,,2166,B,Brain,,1,BAO_0000221,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,,955.0,,CHEMBL617155,
11279,H,,,,,104686,4,Autocuration,,2167,F,,,1,BAO_0000019,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,,,CHEMBL617156,
11200,H,,,,,104686,4,Autocuration,,2168,F,,,1,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,,,,CHEMBL617157,
11200,H,,,,,104686,4,Autocuration,,2169,F,,,1,BAO_0000019,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,CHEMBL617158,
11200,H,,,,,104686,4,Autocuration,,2170,F,,,1,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,,,CHEMBL617159,
11200,H,,,,,104686,4,Autocuration,,2171,F,,,1,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,,,CHEMBL617160,
11200,H,,,,,104686,4,Autocuration,,2172,F,,,1,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,CHEMBL858113,
9231,H,,,,,104686,4,Autocuration,,2173,B,Brain,,1,BAO_0000220,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,,955.0,,CHEMBL617247,
9737,H,,,,,104686,4,Autocuration,,2174,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,,,CHEMBL617248,
9737,H,,,,,104686,4,Autocuration,,2175,B,Brain,,1,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,955.0,,CHEMBL617249,
9737,H,,,,,104686,4,Autocuration,,2176,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,,,,CHEMBL617250,
9737,H,,,,,104686,4,Autocuration,,2177,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,,,CHEMBL617251,
11828,D,,,,,104686,5,Autocuration,,2178,B,,,1,BAO_0000019,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,,,Rattus norvegicus,CHEMBL617252,10116.0
12253,H,,,,,104686,4,Autocuration,,2179,B,,,1,BAO_0000019,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,,,,CHEMBL617006,
12253,H,,,,,104686,4,Autocuration,,2180,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,,,,CHEMBL617007,
11279,H,,,,,104686,4,Autocuration,,2181,F,,,1,BAO_0000019,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,,,,CHEMBL617008,
11866,H,,,,,104686,4,Autocuration,,2182,B,,,1,BAO_0000019,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,,,,CHEMBL617009,
14424,D,,,,,104686,5,Autocuration,,2183,B,,,1,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,,,Rattus norvegicus,CHEMBL617010,10116.0
15180,D,,,,,104686,5,Autocuration,,2184,B,,,1,BAO_0000019,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,,Rattus norvegicus,CHEMBL857978,10116.0
15180,D,,,,,104686,5,Autocuration,,2185,B,,,1,BAO_0000019,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,,,Rattus norvegicus,CHEMBL617011,10116.0
9786,D,,,,,104686,5,Autocuration,,2186,B,,,1,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,,,Rattus norvegicus,CHEMBL617012,10116.0
12132,H,,,,,104686,4,Autocuration,,2187,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,,,,CHEMBL617013,
5486,H,,,,,104686,4,Autocuration,,2188,B,,,1,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,,,,CHEMBL617014,
15316,H,,,,,104686,4,Autocuration,,2189,B,,,1,BAO_0000019,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617015,
16429,H,,,,,104686,4,Autocuration,,2190,B,,,1,BAO_0000019,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,,,,CHEMBL617016,
14617,H,,,,,104686,4,Autocuration,,2191,B,,,1,BAO_0000224,pKi value for 5-hydroxytryptamine 2 receptor binding site,,,,,CHEMBL617017,
11351,H,,,,,104686,4,Autocuration,,2192,B,Brain,,1,BAO_0000221,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,,955.0,,CHEMBL617018,
11279,H,,,,,104686,4,Autocuration,,2193,F,,,1,BAO_0000019,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,,,CHEMBL617019,
9523,H,,,,,105075,4,Autocuration,,2194,B,,,1,BAO_0000019,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,CHEMBL617020,
9523,H,,,,,105075,4,Autocuration,,2195,B,,,1,BAO_0000019,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,CHEMBL617021,
9523,H,,,,,105075,4,Autocuration,,2196,B,,,1,BAO_0000019,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,CHEMBL617022,
9523,H,,,,,105075,4,Autocuration,,2197,B,,,1,BAO_0000019,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,CHEMBL617023,
9523,H,,,,,105075,4,Autocuration,,2198,B,,,1,BAO_0000019,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,CHEMBL617024,
9523,H,,,,,105075,4,Autocuration,,2199,B,,,1,BAO_0000019,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,CHEMBL617025,
9523,H,,,,,105075,4,Autocuration,,2200,B,,,1,BAO_0000224,Hill coefficient of compound was determined,,,,,CHEMBL617026,
4771,U,,,,,22226,0,Autocuration,,2201,B,,,1,BAO_0000019,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617027,
5033,D,,,,,104686,5,Autocuration,,2202,B,,,1,BAO_0000019,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,,,Rattus norvegicus,CHEMBL617028,10116.0
10845,H,,,,,12687,8,Expert,,2203,B,,,1,BAO_0000019,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,,,,CHEMBL617029,
10845,H,,,,,12687,8,Expert,,2204,B,,,1,BAO_0000019,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,,,,CHEMBL875908,
16288,H,,,,,12687,8,Autocuration,,2205,B,,,1,BAO_0000357,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,,,,CHEMBL617030,
16288,H,,,,,12687,8,Autocuration,,2206,B,,,1,BAO_0000019,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,,,,CHEMBL617031,
16190,H,,,,,12687,8,Autocuration,,2207,B,,,1,BAO_0000019,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,,,,CHEMBL617032,
12463,D,,,,,104686,5,Autocuration,,2208,B,,,1,BAO_0000224,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,,,Rattus norvegicus,CHEMBL617033,10116.0
9699,H,,,,,104686,4,Autocuration,,2209,B,,,1,BAO_0000224,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,,,,CHEMBL617034,
9699,H,,,,,104686,4,Autocuration,,2210,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,,,,CHEMBL617035,
11662,H,,,,,104686,4,Autocuration,,2211,B,,,1,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,,CHEMBL617036,
1205,H,,,,,104784,4,Autocuration,,2212,B,,,1,BAO_0000224,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617037,
11376,U,,,,,22226,0,Autocuration,,2213,B,,,1,BAO_0000219,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,,,,CHEMBL617038,
11376,H,,,,,104784,4,Autocuration,,2214,B,,,1,BAO_0000219,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,,,,CHEMBL617039,
4639,H,,,,,104784,4,Autocuration,,2215,B,,,1,BAO_0000224,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617161,
2222,H,,,,,104784,4,Autocuration,,2216,B,,,1,BAO_0000224,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617162,
1558,H,,,,,104784,4,Autocuration,,2217,B,,,1,BAO_0000224,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617163,
1089,H,,,,,104784,4,Autocuration,,2218,B,,,1,BAO_0000224,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617164,
386,H,,,,,104784,4,Autocuration,Brain membranes,2219,B,,,1,BAO_0000249,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,,,,CHEMBL617165,
2474,H,,,,,104784,4,Autocuration,,2220,B,,,1,BAO_0000224,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,,,,CHEMBL617166,
17066,H,,,,,104784,4,Autocuration,,2221,B,,,1,BAO_0000224,Binding affinity towards 5-HT2 receptor,,,,,CHEMBL617167,
959,H,,,,,104784,4,Autocuration,,2222,B,,,1,BAO_0000224,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,,,CHEMBL872912,
6398,H,,,,,104784,4,Autocuration,,2223,B,,,1,BAO_0000224,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,,,,CHEMBL617168,
11889,H,,,,,104686,4,Autocuration,,2224,B,,,1,BAO_0000224,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,,,,CHEMBL617169,
4221,H,,,,,104784,4,Autocuration,,2225,B,,,1,BAO_0000224,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617170,
11026,H,,,,,104784,4,Autocuration,,2226,B,,,1,BAO_0000224,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,,,,CHEMBL617171,
11866,H,,,,,104784,4,Autocuration,,2227,B,,,1,BAO_0000224,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,,,,CHEMBL617172,
4221,H,,,,,104784,4,Autocuration,,2228,B,,,1,BAO_0000224,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617173,
13950,U,,,,,22226,0,Autocuration,,2229,B,,,1,BAO_0000019,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617174,
1263,H,,,,,104784,4,Autocuration,,2230,B,,,1,BAO_0000224,5-hydroxytryptamine 2 receptor binding affinity,,,,,CHEMBL617175,
13291,H,,,,,17005,8,Autocuration,,2231,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,,,,CHEMBL617176,
10812,H,,,,,17005,8,Autocuration,,2232,B,,,1,BAO_0000357,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,,,,CHEMBL617177,
13020,H,,,,,104784,4,Autocuration,,2233,B,,,1,BAO_0000224,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,,,CHEMBL617178,
13021,H,,,,,104784,4,Autocuration,,2234,B,,,1,BAO_0000224,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,,,,CHEMBL617179,
13020,H,,,,,104784,4,Autocuration,,2235,B,,,1,BAO_0000224,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,,,CHEMBL617180,
14532,H,,,,,17005,8,Autocuration,,2236,B,,,1,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,,,,CHEMBL617181,
13944,H,,,,,17005,8,Autocuration,,2237,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617182,
14331,H,,,,,17005,8,Autocuration,,2238,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617183,
14118,H,,,,,17005,8,Autocuration,,2239,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,,,CHEMBL617184,
13033,H,,,,,17005,8,Autocuration,,2240,B,,,1,BAO_0000357,Binding affinity against serotonergic 5-HT2 receptor,,,,,CHEMBL617185,
10321,H,,,,,17005,8,Autocuration,,2241,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,,,,CHEMBL617186,
12918,H,,,,,17005,8,Autocuration,,2242,B,,,1,BAO_0000357,Compound was evaluated for the binding affinity at 5- HT2 receptor,,,,,CHEMBL617187,
15120,H,,,,,17005,8,Autocuration,,2243,B,,,1,BAO_0000357,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617188,
2613,H,,,,,17005,8,Autocuration,,2244,B,,,1,BAO_0000218,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617189,
13378,D,,,,,104784,5,Autocuration,,2245,B,,,1,BAO_0000224,Inhibitory activity against cloned human 5-HT2 receptor,,,,Homo sapiens,CHEMBL617190,9606.0
2331,D,,,CHO,,104784,5,Autocuration,,2246,B,,,1,BAO_0000219,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",449.0,,,Homo sapiens,CHEMBL617191,9606.0
2331,D,,,CHO,,104784,5,Autocuration,,2247,B,,,1,BAO_0000219,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",449.0,,,Homo sapiens,CHEMBL617192,9606.0
2331,D,,,CHO,,104784,5,Autocuration,,2248,B,,,1,BAO_0000219,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",449.0,,,Homo sapiens,CHEMBL617193,9606.0
2331,D,,,CHO,,104784,5,Autocuration,,2249,B,,,1,BAO_0000219,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",449.0,,,Homo sapiens,CHEMBL617194,9606.0
4170,H,,,,,104784,4,Autocuration,,2250,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617195,
15453,H,,,,,104784,4,Autocuration,,2251,B,,,1,BAO_0000224,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,,,CHEMBL881830,
1479,H,,,,,17005,8,Autocuration,,2252,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617196,
11139,H,,,,,104686,4,Autocuration,,2253,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,,,,CHEMBL617197,
13969,H,,,,,17005,8,Expert,,2254,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,,,,CHEMBL617198,
13392,H,,,,,17005,8,Expert,,2255,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,CHEMBL873476,
14430,H,,,,,17005,8,Expert,,2256,B,,,1,BAO_0000019,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,,,,CHEMBL617199,
13181,H,,,,,107,8,Autocuration,,2257,B,,,1,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,,Cavia porcellus,CHEMBL617200,10141.0
17200,H,,,,,51,8,Autocuration,,2258,B,,,1,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,CHEMBL617484,
17200,H,,,,,107,8,Autocuration,,2259,B,,,1,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,CHEMBL617485,
17200,H,,,,,51,8,Autocuration,,2260,B,,,1,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,CHEMBL617486,
13463,H,,,,,107,8,Autocuration,,2261,B,,,1,BAO_0000357,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,,,,CHEMBL858022,
6347,H,,,CHO,,107,8,Autocuration,,2262,B,,,1,BAO_0000219,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,449.0,,,,CHEMBL617049,
6857,D,,,CHO,,107,9,Expert,,2263,F,,,1,BAO_0000219,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,449.0,,,Homo sapiens,CHEMBL617050,9606.0
4176,H,,,,,107,8,Autocuration,,2264,F,,,1,BAO_0000219,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,,,CHEMBL617051,
4176,H,,,,,107,8,Autocuration,,2265,F,,,1,BAO_0000219,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,,,,CHEMBL617052,
4176,H,,,,,107,8,Autocuration,,2266,F,,,1,BAO_0000219,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,,,CHEMBL617053,
6347,H,,,CHO,,107,8,Autocuration,,2267,B,,,1,BAO_0000219,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",449.0,,,,CHEMBL617054,
6347,H,,,CHO,,107,8,Autocuration,,2268,B,,,1,BAO_0000219,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",449.0,,,,CHEMBL617055,
15331,H,,,,,107,8,Autocuration,,2269,B,,,1,BAO_0000357,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,,,,CHEMBL882924,
16146,D,,,,,107,9,Expert,,2270,B,,,1,BAO_0000357,Inhibition of human 5-hydroxytryptamine 2A receptor,,,,Homo sapiens,CHEMBL617056,9606.0
15250,H,,,CHO,,107,8,Autocuration,,2271,B,,,1,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,449.0,,,,CHEMBL617057,
13631,H,,,,,107,8,Expert,,2272,B,,,1,BAO_0000219,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,,,,CHEMBL617058,
3805,H,,,,,107,8,Autocuration,,2273,B,,,1,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,,,,CHEMBL617059,
4011,H,,,CHO,,107,8,Autocuration,,2274,B,,,1,BAO_0000219,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,449.0,,,,CHEMBL617060,
4012,H,,,CHO,,107,8,Expert,,2275,B,,,1,BAO_0000219,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,449.0,,,,CHEMBL617061,
6366,H,,,L929,,107,8,Expert,,2276,B,,,1,BAO_0000219,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,307.0,,,,CHEMBL617062,
15949,H,,,CHO,,107,8,Expert,,2277,B,,,1,BAO_0000219,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,449.0,,,,CHEMBL617063,
14093,H,,,,,107,8,Autocuration,,2278,F,,,1,BAO_0000019,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,,,,CHEMBL617064,
13481,H,,,,,107,8,Autocuration,,2279,F,,,1,BAO_0000019,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,CHEMBL617065,
6347,H,,,CHO,,107,8,Autocuration,,2280,B,,,1,BAO_0000219,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,449.0,,,,CHEMBL617066,
6347,H,,,CHO,,107,8,Autocuration,,2281,B,,,1,BAO_0000219,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,449.0,,,,CHEMBL617067,
14093,H,,,,,107,8,Autocuration,,2282,F,,,1,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,,,,CHEMBL617068,
14093,H,,,,,107,8,Autocuration,,2283,F,,,1,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,,,,CHEMBL617069,
13481,H,,,,,107,8,Autocuration,,2284,F,,,1,BAO_0000019,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,CHEMBL617070,
14442,H,,,,,107,8,Autocuration,,2285,B,,,1,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,,,,CHEMBL617071,
14442,H,,,,,107,8,Autocuration,,2286,B,,,1,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,CHEMBL872915,
14755,H,,,,,107,8,Autocuration,,2287,B,,,1,BAO_0000357,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,,,,CHEMBL617072,
16441,H,,,,,107,8,Autocuration,,2288,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,,,,CHEMBL617073,
14744,H,,,,,107,8,Autocuration,,2289,B,,,1,BAO_0000357,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,,,,CHEMBL617074,
16659,H,,,CHO,,107,8,Expert,,2290,B,,,1,BAO_0000219,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,449.0,,,,CHEMBL617075,
3307,H,,,,,107,8,Autocuration,,2291,B,,,1,BAO_0000357,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617076,
6857,D,,,,,107,9,Expert,,2292,B,,,1,BAO_0000019,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,,,Homo sapiens,CHEMBL617077,9606.0
5635,H,,,,,107,8,Expert,,2293,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,,,,CHEMBL617078,
4234,D,,,,,107,9,Expert,,2294,B,,,1,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,,,Homo sapiens,CHEMBL617079,9606.0
15527,H,,,,,107,8,Autocuration,,2295,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,,,CHEMBL617080,
6588,H,,,CHO,,107,8,Expert,,2296,B,,,1,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,449.0,,,,CHEMBL617081,
13631,H,,,,,107,8,Expert,,2297,B,,,1,BAO_0000219,Binding affinity towards human 5-HT2A receptor in BEK cells,,,,,CHEMBL617082,
17723,H,,,,,107,8,Autocuration,,2298,B,,,1,BAO_0000357,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617083,
14770,H,,,,,107,8,Autocuration,,2299,B,,,1,BAO_0000357,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,,,CHEMBL617084,
16293,D,,,,,107,9,Expert,,2300,B,,,1,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,,Homo sapiens,CHEMBL617085,9606.0
16209,H,,,,,107,8,Autocuration,,2301,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,CHEMBL617086,
12469,H,,,,,107,8,Autocuration,,2302,B,,,1,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,,,,CHEMBL617087,
15363,H,,,,,107,8,Autocuration,,2303,B,,,1,BAO_0000357,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617088,
15363,H,,,,,107,8,Autocuration,,2304,B,,,1,BAO_0000357,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617089,
16441,H,,,,,107,8,Expert,,2305,B,,,1,BAO_0000019,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,,,,CHEMBL617090,
8,H,,,,,107,8,Autocuration,,2306,B,,,1,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,,,,CHEMBL617513,
4176,H,,,HEK293,,107,8,Autocuration,,2307,B,,,1,BAO_0000219,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,722.0,,,,CHEMBL617514,
17085,H,,,,,107,8,Autocuration,,2308,B,,,1,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617515,
17200,H,,,,,107,8,Autocuration,,2309,B,,,1,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,CHEMBL617516,
17200,D,,,,,107,9,Expert,,2310,B,,,1,BAO_0000357,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,Homo sapiens,CHEMBL617517,9606.0
4013,D,,,CHO,,107,9,Expert,,2311,B,,,1,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,449.0,,,Homo sapiens,CHEMBL617518,9606.0
5088,H,,,,,107,8,Autocuration,,2312,B,,,1,BAO_0000357,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617519,
5088,D,,,,,107,9,Expert,,2313,B,,,1,BAO_0000357,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,,,Homo sapiens,CHEMBL617520,9606.0
5088,H,,,,,107,8,Autocuration,,2314,B,,,1,BAO_0000357,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,,,,CHEMBL617521,
5088,D,,,,,107,9,Expert,,2315,B,,,1,BAO_0000357,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,,,Homo sapiens,CHEMBL617522,9606.0
5088,H,,,,,107,8,Autocuration,,2316,B,,,1,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,,,,CHEMBL617523,
5088,H,,,,,107,8,Autocuration,,2317,B,,,1,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,CHEMBL617524,
9786,H,,,,,104686,4,Autocuration,,2318,B,,,1,BAO_0000019,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,,,,CHEMBL617525,
9205,D,,,,,104686,5,Autocuration,,2319,B,,,1,BAO_0000019,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,,,Rattus norvegicus,CHEMBL617526,10116.0
11257,H,,,,,104686,4,Autocuration,,2320,B,,,1,BAO_0000224,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,,,,CHEMBL617527,
9362,H,,,,,104686,4,Autocuration,,2321,B,,,1,BAO_0000019,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,,,CHEMBL617528,
9362,H,,,,,104686,4,Autocuration,,2322,B,,,1,BAO_0000019,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,,,CHEMBL617529,
10590,H,,,,,104686,4,Autocuration,,2323,B,,,1,BAO_0000224,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,,,,CHEMBL617530,
10468,H,,,,,104686,4,Autocuration,,2324,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,,,CHEMBL617531,
13050,H,,,,,104686,4,Autocuration,,2325,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,,,,CHEMBL617532,
11624,H,,,,,104686,4,Autocuration,,2326,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,,,,CHEMBL617533,
10468,H,,,,,104686,4,Autocuration,,2327,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,,,CHEMBL617534,
10330,H,,,,,104686,4,Autocuration,,2328,B,,,1,BAO_0000224,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,,,CHEMBL617535,
10062,H,,,,,104686,4,Autocuration,,2329,B,,,1,BAO_0000224,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,,,CHEMBL617536,
11642,H,,,,,104686,4,Autocuration,,2330,B,,,1,BAO_0000224,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617537,
10062,H,,,,,104686,4,Autocuration,,2331,B,,,1,BAO_0000224,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617538,
13427,H,,,,In vitro,104686,4,Autocuration,,2332,B,,,1,BAO_0000219,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,,,CHEMBL617539,
12280,D,,,,,104686,5,Autocuration,,2333,B,,,1,BAO_0000224,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,,Rattus norvegicus,CHEMBL617540,10116.0
4101,D,,,,,104686,5,Autocuration,,2334,B,,,1,BAO_0000224,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,,,Rattus norvegicus,CHEMBL617541,10116.0
10062,H,,,,,104686,4,Autocuration,,2335,B,,,1,BAO_0000224,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617542,
11147,H,,,,,104686,4,Autocuration,,2336,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,,,,CHEMBL617543,
2395,D,,,CHO-K1,,104686,5,Autocuration,,2337,B,,,1,BAO_0000219,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,485.0,,,Rattus norvegicus,CHEMBL617544,10116.0
2395,D,,,CHO-K1,,104686,5,Autocuration,,2338,B,,,1,BAO_0000219,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,485.0,,,Rattus norvegicus,CHEMBL617545,10116.0
9098,D,,,,,104686,5,Autocuration,,2339,B,,,1,BAO_0000019,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,,,Rattus norvegicus,CHEMBL617413,10116.0
9098,H,,,,,104686,4,Autocuration,,2340,B,,,1,BAO_0000019,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,,,,CHEMBL617414,
9098,D,,,,,104686,5,Autocuration,,2341,B,,,1,BAO_0000019,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,,,Rattus norvegicus,CHEMBL617415,10116.0
9443,H,,,,,104686,4,Autocuration,,2342,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617416,
9443,H,,,,,104686,4,Autocuration,,2343,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,,,CHEMBL617417,
9699,H,,,,,104686,4,Autocuration,,2344,B,,,1,BAO_0000019,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,,,,CHEMBL617418,
9699,H,,,,,104686,4,Autocuration,,2345,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,,,,CHEMBL617419,
9098,H,,,,,104686,4,Autocuration,,2346,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,,CHEMBL617420,
3070,D,,,,,104686,5,Autocuration,,2347,B,,,1,BAO_0000224,Affinity for 5-hydroxytryptamine 2 receptor,,,,Rattus norvegicus,CHEMBL617421,10116.0
9547,H,,,,,104686,4,Autocuration,,2348,B,,,1,BAO_0000224,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,,,,CHEMBL617422,
10444,H,,,,,104686,4,Autocuration,,2349,B,,,1,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,,,,CHEMBL617423,
14617,H,,,,,104686,4,Autocuration,,2350,B,,,1,BAO_0000019,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,,,,CHEMBL617424,
14617,H,,,,,104686,4,Autocuration,,2351,B,,,1,BAO_0000019,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,,,,CHEMBL617425,
11130,H,,,,,104686,4,Autocuration,,2352,B,,,1,BAO_0000224,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,,,,CHEMBL617426,
11130,H,,,,In vivo,104686,4,Autocuration,,2353,B,,,1,BAO_0000218,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,,,,CHEMBL617427,
14542,H,,,,,104686,4,Autocuration,,2354,B,Brain,,1,BAO_0000221,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,,955.0,,CHEMBL617428,
2797,H,,,,,104686,4,Autocuration,,2355,B,,,1,BAO_0000224,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,,,,CHEMBL617429,
11332,H,,,,,104686,4,Autocuration,,2356,B,,,1,BAO_0000019,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,,,CHEMBL617430,
11332,H,,,,,104686,4,Autocuration,,2357,B,,,1,BAO_0000019,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,,,CHEMBL617431,
10752,H,,,,,104686,4,Autocuration,,2358,B,Frontal cortex,,1,BAO_0000019,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,,1870.0,,CHEMBL617432,
1185,H,,,,,104686,4,Autocuration,,2359,B,,,1,BAO_0000224,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617433,
1185,H,,,,,104686,4,Autocuration,,2360,B,,,1,BAO_0000224,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617434,
11624,D,,,,,104686,5,Autocuration,,2361,B,,,1,BAO_0000224,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,,,Rattus norvegicus,CHEMBL617435,10116.0
1344,H,,,,,104686,4,Autocuration,,2362,B,,,1,BAO_0000019,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,,,,CHEMBL617436,
15453,D,,,,,104686,5,Autocuration,,2363,B,Striatum,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,,2435.0,Rattus norvegicus,CHEMBL617437,10116.0
11662,H,,,,,104686,4,Autocuration,,2364,B,,,1,BAO_0000019,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,,,CHEMBL617438,
11662,H,,,,,104686,4,Autocuration,,2365,B,,,1,BAO_0000019,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,,CHEMBL617439,
10796,H,,,,,104686,4,Autocuration,,2366,B,,,1,BAO_0000224,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617440,
9069,H,,,,,104686,4,Autocuration,,2367,B,,,1,BAO_0000224,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617441,
8814,D,,,,,104686,5,Autocuration,,2368,B,,,1,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,,,Rattus norvegicus,CHEMBL872918,10116.0
8908,D,,,,,104686,5,Autocuration,,2369,B,,,1,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,,,Rattus norvegicus,CHEMBL617442,10116.0
9098,H,,,,,104686,4,Autocuration,,2370,B,,,1,BAO_0000019,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,,,CHEMBL617443,
9098,H,,,,,104686,4,Autocuration,,2371,B,,,1,BAO_0000019,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,,,,CHEMBL617444,
9098,H,,,,,104686,4,Autocuration,,2372,B,,,1,BAO_0000019,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,,,CHEMBL617445,
9098,H,,,,,104686,4,Autocuration,,2373,B,,,1,BAO_0000019,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,,,,CHEMBL617446,
9098,H,,,,,104686,4,Autocuration,,2374,B,,,1,BAO_0000249,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,,,,CHEMBL617447,
9098,H,,,,,104686,4,Autocuration,,2375,B,,,1,BAO_0000019,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,,,,CHEMBL617448,
9098,H,,,,,104686,4,Autocuration,,2376,B,,,1,BAO_0000019,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,,,,CHEMBL617449,
9161,H,,,,,104686,4,Autocuration,,2377,B,,,1,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,,,,CHEMBL617450,
9161,H,,,,,104686,4,Autocuration,,2378,B,,,1,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,,,,CHEMBL617451,
9161,H,,,,,104686,4,Autocuration,,2379,B,,,1,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,,,,CHEMBL617452,
9161,H,,,,,104686,4,Autocuration,,2380,B,,,1,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,,,,CHEMBL617453,
9161,H,,,,,104686,4,Autocuration,,2381,B,,,1,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,,,,CHEMBL617660,
9161,H,,,,,104686,4,Autocuration,,2382,B,,,1,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,,,,CHEMBL617661,
9161,H,,,,,104686,4,Autocuration,,2383,B,,,1,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,,,,CHEMBL617662,
9161,H,,,,,104686,4,Autocuration,,2384,B,,,1,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,,,,CHEMBL872919,
9161,H,,,,,104686,4,Autocuration,,2385,B,,,1,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,,,,CHEMBL617663,
9161,H,,,,,104686,4,Autocuration,,2386,B,,,1,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,,,,CHEMBL617664,
9161,H,,,,,104686,4,Autocuration,,2387,B,,,1,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,,,,CHEMBL617665,
9161,H,,,,,104686,4,Autocuration,,2388,B,,,1,BAO_0000019,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,,,,CHEMBL617666,
12094,H,,,,,104686,4,Autocuration,,2389,B,,,1,BAO_0000019,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,,,,CHEMBL617667,
12018,H,,,,,104686,4,Autocuration,,2390,B,,,1,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,,,,CHEMBL617668,
10394,H,,,,,104686,4,Autocuration,,2391,B,,,1,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,,,,CHEMBL617669,
15260,H,,,,,104686,4,Autocuration,,2392,B,,,1,BAO_0000224,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617670,
11624,D,,,,,104686,5,Autocuration,,2393,B,,,1,BAO_0000224,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,,,Rattus norvegicus,CHEMBL617671,10116.0
13654,H,,,,,104686,4,Autocuration,,2394,B,,,1,BAO_0000224,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617672,
9541,H,,,,,104686,4,Autocuration,,2395,B,,,1,BAO_0000019,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,,,,CHEMBL617673,
11933,H,,,,,104686,4,Autocuration,,2396,B,,,1,BAO_0000224,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,,,,CHEMBL617674,
15538,H,,,,,104686,4,Autocuration,,2397,B,,,1,BAO_0000019,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,,,,CHEMBL617675,
15538,H,,,,,104686,4,Autocuration,,2398,B,,,1,BAO_0000019,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,,,,CHEMBL617676,
15538,H,,,,,104686,4,Autocuration,,2399,B,,,1,BAO_0000019,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,,,,CHEMBL617677,
8841,D,,,,,104686,5,Autocuration,,2400,B,,,1,BAO_0000019,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617678,
1455,H,,,,,104686,4,Autocuration,,2401,B,,,1,BAO_0000224,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,,,,CHEMBL617679,
1455,H,,,,,104686,4,Autocuration,,2402,B,,,1,BAO_0000224,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,,,,CHEMBL617680,
11752,H,,,,,104686,4,Autocuration,,2403,B,,,1,BAO_0000019,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,,,,CHEMBL617681,
11642,H,,,,,104686,4,Autocuration,,2404,B,Brain,,1,BAO_0000221,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,,955.0,,CHEMBL617682,
12092,H,,,,,104686,4,Autocuration,,2405,B,,,1,BAO_0000224,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,,,,CHEMBL617683,
3967,H,,,,,104686,4,Autocuration,,2406,B,,,1,BAO_0000224,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,,,,CHEMBL617684,
12771,D,,,,,104686,5,Autocuration,,2407,B,,,1,BAO_0000224,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,Rattus norvegicus,CHEMBL617685,10116.0
11642,H,,,,,104686,4,Autocuration,,2408,B,,,1,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,,,,CHEMBL617686,
11628,H,,,,,104686,4,Autocuration,,2409,B,,,1,BAO_0000224,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,,,,CHEMBL617687,
13654,H,,,,,104686,4,Autocuration,,2410,B,,,1,BAO_0000224,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,,,CHEMBL617688,
11200,H,,,,,104686,4,Autocuration,,2411,F,,,1,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,CHEMBL617689,
11200,H,,,,,104686,4,Autocuration,,2412,F,,,1,BAO_0000019,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,CHEMBL617690,
11200,H,,,,In vivo,104686,4,Autocuration,,2413,F,,,1,BAO_0000218,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,,,CHEMBL617691,
11200,H,,,,In vivo,104686,4,Autocuration,,2414,F,,,1,BAO_0000218,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,,,CHEMBL617692,
11200,H,,,,In vivo,104686,4,Autocuration,,2415,F,,,1,BAO_0000218,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,,,CHEMBL617693,
11200,H,,,,In vivo,104686,4,Autocuration,,2416,F,,,1,BAO_0000218,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,,,CHEMBL617694,
15436,H,,,,,12687,8,Expert,,2417,B,Brain,,1,BAO_0000221,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,,955.0,,CHEMBL857985,
15436,D,,,,,12687,9,Expert,,2418,B,,,1,BAO_0000019,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,,Rattus norvegicus,CHEMBL617695,10116.0
14025,H,,,,,12687,8,Autocuration,,2419,B,,,1,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,,,,CHEMBL617696,
4342,H,,,,,12687,8,Autocuration,,2420,B,,,1,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,,,,CHEMBL617697,
13735,D,,,,,12687,9,Expert,,2421,B,,,1,BAO_0000019,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,,,Rattus norvegicus,CHEMBL617257,10116.0
5816,D,,,,,12687,9,Expert,,2422,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,,Rattus norvegicus,CHEMBL617258,10116.0
14287,H,,,,,12687,8,Expert,,2423,B,,,1,BAO_0000019,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,,,,CHEMBL617259,
15738,H,,,,,12687,8,Autocuration,,2424,B,,,1,BAO_0000357,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,,,,CHEMBL617260,
15738,D,,,,,12687,9,Expert,,2425,B,,,1,BAO_0000357,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,,,Rattus norvegicus,CHEMBL617261,10116.0
15026,H,,,,,12687,8,Autocuration,,2426,B,,,1,BAO_0000019,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,,,,CHEMBL617262,
16647,H,,,,,12687,8,Expert,,2427,B,,,1,BAO_0000019,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,,,CHEMBL617263,
16647,H,,,,,12687,8,Autocuration,,2428,B,,,1,BAO_0000019,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,,,,CHEMBL617264,
13345,D,,,,,12687,9,Expert,,2429,B,,,1,BAO_0000019,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,,,Rattus norvegicus,CHEMBL617265,10116.0
1543,H,,,,,12687,8,Autocuration,Membranes,2430,B,,,1,BAO_0000249,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617266,
12444,H,,,,,12687,8,Autocuration,,2431,B,,,1,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,,,,CHEMBL617267,
16404,H,,,,,12687,8,Expert,,2432,B,,,1,BAO_0000019,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,,,,CHEMBL617268,
16404,H,,,CHO,,12687,8,Autocuration,,2433,B,,,1,BAO_0000219,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,449.0,,,,CHEMBL617269,
15577,H,,,,,12687,8,Expert,,2434,B,,,1,BAO_0000357,Kinetic inhibition constant evaluated by measuring serotonergic activity,,,,,CHEMBL617323,
15577,H,,,,,12687,8,Autocuration,,2435,B,,,1,BAO_0000357,Serotonergic activity of the compound.,,,,,CHEMBL617324,
2495,H,,,,,12687,8,Autocuration,,2436,B,,,1,BAO_0000249,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,,,,CHEMBL617325,
15042,D,,,,,12687,9,Expert,,2437,B,,,1,BAO_0000019,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,,,Rattus norvegicus,CHEMBL617326,10116.0
15026,H,,,,,12687,8,Expert,,2438,B,,,1,BAO_0000249,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,,,,CHEMBL617327,
12919,D,,,,,12687,9,Expert,,2439,F,,,1,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,,Rattus norvegicus,CHEMBL617328,10116.0
12919,D,,,,,12687,9,Expert,,2440,F,,,1,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,,Rattus norvegicus,CHEMBL617329,10116.0
12919,D,,,,,12687,9,Expert,,2441,F,,,1,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,,Rattus norvegicus,CHEMBL617330,10116.0
15194,H,,,,,12687,8,Autocuration,,2442,B,,,1,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,CHEMBL617331,
15194,H,,,,,12687,8,Autocuration,,2443,B,,,1,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,,,,CHEMBL617332,
4820,H,,,,,107,8,Expert,,2444,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617333,
6736,H,,,,,107,8,Autocuration,,2445,B,,,1,BAO_0000357,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,,,,CHEMBL617334,
5163,H,,,,,107,8,Autocuration,,2446,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,,,,CHEMBL617335,
5163,H,,,,,107,8,Autocuration,,2447,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,,,,CHEMBL617336,
6011,H,,,,,107,8,Autocuration,,2448,B,,,1,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,,,,CHEMBL617337,
14294,D,,,,,107,9,Expert,,2449,B,,,1,BAO_0000357,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,,,Homo sapiens,CHEMBL617338,9606.0
5014,H,,,,,107,8,Autocuration,,2450,B,,,1,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617339,
17066,H,,,,,107,8,Expert,,2451,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617340,
17515,H,,,,,107,8,Autocuration,,2452,B,,,1,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,,,,CHEMBL617341,
6736,H,,,,,107,8,Expert,,2453,B,,,1,BAO_0000357,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617342,
5163,H,,,,,107,8,Expert,,2454,B,,,1,BAO_0000357,Affinity for 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617343,
16911,H,,,NIH3T3,,107,8,Expert,,2455,B,,,1,BAO_0000219,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,723.0,,,,CHEMBL617344,
6841,H,,,,,107,8,Expert,,2456,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,,,CHEMBL617345,
6119,H,,,,,107,8,Expert,,2457,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,,,,CHEMBL617346,
3962,H,,,,,107,8,Autocuration,,2458,B,,,1,BAO_0000357,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617347,
4373,H,,,,,107,8,Autocuration,,2459,B,,,1,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,,,,CHEMBL617348,
4373,H,,,,,107,8,Autocuration,,2460,B,,,1,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,,,,CHEMBL617349,
3962,H,,,,,107,8,Autocuration,,2461,F,,,1,BAO_0000019,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617350,
1633,H,,,,,107,8,Expert,,2462,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,,,CHEMBL872339,
4373,H,,,,,107,8,Autocuration,,2463,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,,,,CHEMBL617351,
6576,H,,,,,107,8,Expert,,2464,B,,,1,BAO_0000357,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617352,
4687,H,,,,,107,8,Autocuration,,2465,B,,,1,BAO_0000357,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617353,
16946,H,,,,,107,8,Autocuration,,2466,B,,,1,BAO_0000357,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617354,
14159,H,,,,,107,8,Autocuration,,2467,B,,,1,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617355,
3032,H,,,CHO,,107,8,Expert,,2468,B,,,1,BAO_0000219,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,449.0,,,Mus musculus,CHEMBL617356,10090.0
16655,H,,,,,107,8,Autocuration,,2469,B,,,1,BAO_0000357,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617357,
13964,H,,,,,107,8,Autocuration,,2470,B,,,1,BAO_0000357,Binding affinity at 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617358,
16989,H,,,,,107,8,Expert,,2471,B,,,1,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617359,
16117,H,,,,,107,8,Autocuration,,2472,B,,,1,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,,,,CHEMBL617360,
16700,H,,,,,107,8,Autocuration,,2473,B,,,1,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,,,,CHEMBL875913,
3269,H,,,,,107,8,Autocuration,,2474,B,,,1,BAO_0000357,Affinity against 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617361,
1274,D,,,,,107,9,Expert,,2475,B,,,1,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 2A receptor,,,,Homo sapiens,CHEMBL617362,9606.0
1317,H,,,,,107,8,Autocuration,,2476,B,,,1,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,,,CHEMBL617363,
12146,H,,,,,107,8,Autocuration,,2477,B,,,1,BAO_0000357,Tested against 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617364,
12652,H,,,,,105075,4,Autocuration,,2478,B,,,1,BAO_0000224,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,,,CHEMBL617365,
12652,H,,,,,105075,4,Autocuration,,2479,B,,,1,BAO_0000224,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,,,,CHEMBL617366,
12652,H,,,,,105075,4,Autocuration,,2480,B,,,1,BAO_0000224,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,,,,CHEMBL617367,
12652,H,,,,,105075,4,Autocuration,,2481,B,,,1,BAO_0000224,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,,,CHEMBL617368,
16647,H,,,,,107,8,Autocuration,,2482,B,,,1,BAO_0000357,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,,,,CHEMBL617369,
15851,D,,,HEK293,,227,9,Expert,,2483,B,,,1,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,722.0,,,Homo sapiens,CHEMBL617370,9606.0
6857,D,,,CHO,,227,9,Expert,,2484,F,,,1,BAO_0000219,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,449.0,,,Homo sapiens,CHEMBL617371,9606.0
3805,H,,,,,227,8,Autocuration,,2485,B,,,1,BAO_0000357,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,,,,CHEMBL617372,
6491,D,,,,,227,9,Expert,,2486,B,,,1,BAO_0000357,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,,,Homo sapiens,CHEMBL617373,9606.0
14093,H,,,,,227,8,Autocuration,,2487,F,,,1,BAO_0000019,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,,,,CHEMBL617374,
13481,H,,,,,227,8,Autocuration,,2488,F,,,1,BAO_0000019,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,,,,CHEMBL617375,
14093,H,,,,,227,8,Autocuration,,2489,F,,,1,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,,,,CHEMBL617376,
14093,H,,,,,227,8,Autocuration,,2490,F,,,1,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,,,,CHEMBL617377,
14093,H,,,,,227,8,Autocuration,,2491,F,,,1,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,,,,CHEMBL617378,
13481,H,,,,,227,8,Autocuration,,2492,F,,,1,BAO_0000019,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,,,CHEMBL617379,
14442,H,,,,,227,8,Autocuration,,2493,B,,,1,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,,,,CHEMBL617380,
14442,H,,,,,227,8,Autocuration,,2494,B,,,1,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,,,,CHEMBL617381,
14442,H,,,,,227,8,Autocuration,,2495,B,,,1,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,,,CHEMBL617382,
12369,H,,,,,107,8,Autocuration,,2496,B,,,1,BAO_0000357,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617383,
12369,H,,,,,107,8,Expert,,2497,B,,,1,BAO_0000357,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,,,,CHEMBL617384,
12369,H,,,,,107,8,Expert,,2498,B,,,1,BAO_0000357,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,,,,CHEMBL617385,
14447,H,,,,,107,8,Autocuration,,2499,B,,,1,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,,,,CHEMBL617386,
14447,H,,,,,107,8,Autocuration,,2500,B,,,1,BAO_0000019,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,,,,CHEMBL617387,
17451,H,,,NIH3T3,,107,8,Autocuration,,2501,B,,,1,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,723.0,,,,CHEMBL617388,
6857,H,,,CHO,,107,8,Autocuration,,2502,F,,,1,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,449.0,,,,CHEMBL617389,
6857,D,,,CHO,,107,9,Expert,,2503,F,,,1,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,449.0,,,Homo sapiens,CHEMBL617390,9606.0
5635,H,,,,,104817,4,Autocuration,,2504,B,,,1,BAO_0000224,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,,,,CHEMBL617391,
12861,H,,,,,107,8,Autocuration,,2505,B,,,1,BAO_0000357,Binding activity radioligand.,,,,,CHEMBL617392,
12861,H,,,,,107,8,Autocuration,,2506,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,,CHEMBL617393,
5105,H,,,L929,,107,8,Autocuration,,2507,B,,,1,BAO_0000219,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,307.0,,,,CHEMBL617394,
5104,H,,,L929,,107,8,Expert,,2508,B,,,1,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,307.0,,,,CHEMBL617395,
5105,H,,,L929,,107,8,Expert,,2509,B,,,1,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,307.0,,,,CHEMBL617396,
5105,H,,,L929,,107,8,Autocuration,,2510,B,,,1,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,307.0,,,,CHEMBL617397,
5254,H,,,,,107,8,Autocuration,,2511,B,,,1,BAO_0000357,Binding affinity against 5-HT2A receptor,,,,,CHEMBL617398,
5254,H,,,,,107,8,Autocuration,,2512,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617399,
13267,H,,,HEK293,,107,8,Autocuration,,2513,B,,,1,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,722.0,,,,CHEMBL617400,
13267,H,,,HEK293,,107,8,Autocuration,,2514,B,,,1,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,722.0,,,,CHEMBL617401,
14157,D,,,HEK293,,107,9,Expert,,2515,B,,,1,BAO_0000219,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,722.0,,,Homo sapiens,CHEMBL617402,9606.0
12936,D,,,HEK293,,107,9,Expert,,2516,B,,,1,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,722.0,,,Homo sapiens,CHEMBL617403,9606.0
14068,H,,,,,107,8,Expert,,2517,B,,,1,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,,,,CHEMBL617404,
12936,D,,,HEK293,,107,9,Expert,,2518,B,,,1,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,722.0,,,Homo sapiens,CHEMBL857981,9606.0
12936,D,,,HEK293,,107,9,Expert,,2519,B,,,1,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,722.0,,,Homo sapiens,CHEMBL617405,9606.0
4540,D,,,HEK293,,107,9,Expert,,2520,B,,,1,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,722.0,,,Homo sapiens,CHEMBL617253,9606.0
6166,H,,,,,107,8,Expert,,2521,B,,,1,BAO_0000357,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,,,,CHEMBL617254,
17296,H,,,HEK293,,107,8,Autocuration,,2522,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,722.0,,,,CHEMBL617255,
17296,H,,,HEK293,,107,8,Autocuration,,2523,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,722.0,,,,CHEMBL617256,
17296,H,,,HEK293,,107,8,Autocuration,,2524,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,722.0,,,,CHEMBL616874,
15779,D,,,HEK293,,107,9,Expert,,2525,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,722.0,,,Homo sapiens,CHEMBL616875,9606.0
14391,H,,,HEK293,,107,8,Expert,,2526,B,,,1,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,722.0,,,,CHEMBL616876,
15851,H,,,HEK293,,107,8,Expert,,2527,B,,,1,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",722.0,,,,CHEMBL616877,
15851,D,,,HEK293,,107,9,Expert,,2528,B,,,1,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,722.0,,,Homo sapiens,CHEMBL616878,9606.0
3832,H,,,HEK293,,107,8,Expert,,2529,B,,,1,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,722.0,,,,CHEMBL616879,
3833,H,,,HEK293,,107,8,Expert,,2530,B,,,1,BAO_0000219,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,722.0,,,,CHEMBL616880,
12936,D,,,HEK293,,107,9,Expert,,2531,B,,,1,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,722.0,,,Homo sapiens,CHEMBL616881,9606.0
17451,H,,,NIH3T3,,107,8,Autocuration,,2532,B,,,1,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,723.0,,,,CHEMBL616882,
17451,H,,,NIH3T3,,107,8,Autocuration,,2533,B,,,1,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,723.0,,,,CHEMBL616883,
17451,H,,,NIH3T3,,107,8,Autocuration,,2534,B,,,1,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,723.0,,,,CHEMBL616884,
4199,H,,,HEK293,,107,8,Autocuration,,2535,B,,,1,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,722.0,,,,CHEMBL616885,
1883,H,,,CHO-K1,,107,8,Autocuration,,2536,B,,,1,BAO_0000219,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,485.0,,,,CHEMBL616886,
1883,H,,,CHO-K1,,107,8,Expert,,2537,B,,,1,BAO_0000219,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,485.0,,,,CHEMBL616887,
14875,D,,,,,107,9,Expert,,2538,B,,,1,BAO_0000357,Binding affinity for human 5-hydroxytryptamine 2A receptor,,,,Homo sapiens,CHEMBL616888,9606.0
15146,H,,,HEK293,,107,8,Autocuration,,2539,B,,,1,BAO_0000219,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,722.0,,,,CHEMBL616889,
5213,H,,,HEK293,,107,8,Autocuration,,2540,B,,,1,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,722.0,,,,CHEMBL616890,
16404,D,,,CHO,,107,9,Expert,,2541,B,,,1,BAO_0000219,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,449.0,,,Homo sapiens,CHEMBL616891,9606.0
14818,H,,,HEK293,,107,8,Autocuration,,2542,B,,,1,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,722.0,,,,CHEMBL616892,
4829,H,,,HEK293,,107,8,Autocuration,,2543,B,,,1,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",722.0,,,,CHEMBL616893,
12652,H,,,NIH3T3,,10620,8,Autocuration,,2544,F,,,1,BAO_0000219,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,723.0,,,,CHEMBL616894,
4682,H,,,NIH3T3,,107,8,Expert,,2545,B,,,1,BAO_0000219,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,723.0,,,,CHEMBL616895,
12652,H,,,,,10620,8,Autocuration,,2546,F,,,1,BAO_0000019,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,,,,CHEMBL616896,
4921,H,,,,,10621,8,Autocuration,,2547,B,,,1,BAO_0000357,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617099,
4921,H,,,,,10621,8,Autocuration,,2548,B,,,1,BAO_0000357,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,,,,CHEMBL617100,
16312,H,,,,,107,8,Autocuration,,2549,B,,,1,BAO_0000357,Binding affinity against rabbit aorta 5-HT2A receptor,,,,Oryctolagus cuniculus,CHEMBL884532,9986.0
14998,H,,,,,107,8,Expert,,2550,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,,,Oryctolagus cuniculus,CHEMBL617101,9986.0
14025,H,,,,,107,8,Expert,,2551,B,,,1,BAO_0000357,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,,,Oryctolagus cuniculus,CHEMBL617102,9986.0
13047,H,,,,,107,8,Autocuration,,2552,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,,,Oryctolagus cuniculus,CHEMBL617103,9986.0
13047,H,,,,,107,8,Expert,,2553,B,,,1,BAO_0000357,The compound was tested for binding affinity against 5-HT2A receptor,,,,Oryctolagus cuniculus,CHEMBL617104,9986.0
1883,H,,,CHO-K1,,10576,8,Autocuration,,2554,B,,,1,BAO_0000219,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,485.0,,,,CHEMBL857979,
13463,H,,,,,12687,8,Autocuration,,2555,B,,,1,BAO_0000019,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,,,,CHEMBL857502,
13463,H,,,,,12687,8,Autocuration,,2556,B,,,1,BAO_0000019,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,,,CHEMBL617105,
13463,H,,,,,12687,8,Autocuration,,2557,B,Stomach,,1,BAO_0000019,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,,945.0,,CHEMBL858021,
13463,D,,,,,12687,9,Expert,,2558,B,Stomach,,1,BAO_0000019,Binding affinity for 5-HT 2A in rat stomach fundus,,,945.0,Rattus norvegicus,CHEMBL875910,10116.0
13463,H,,,,,12687,8,Autocuration,,2559,B,,,1,BAO_0000019,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,,,CHEMBL617106,
16326,H,,,NIH3T3,,12687,8,Expert,,2560,B,,,1,BAO_0000219,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,723.0,,,,CHEMBL617107,
14093,H,,,,,12687,8,Autocuration,,2561,F,,,1,BAO_0000019,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617108,
14093,H,,,,,12687,8,Autocuration,,2562,F,,,1,BAO_0000019,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617109,
15740,H,,,,,12687,8,Autocuration,,2563,B,,,1,BAO_0000357,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617110,
16633,H,,,,,12687,8,Autocuration,,2564,B,,,1,BAO_0000357,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,,,,CHEMBL617111,
17200,D,,,,,12687,9,Expert,,2565,F,,,1,BAO_0000019,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,,,Rattus norvegicus,CHEMBL617112,10116.0
17133,H,,,,,12687,8,Autocuration,,2566,B,,,1,BAO_0000357,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617113,
17133,H,,,,,12687,8,Autocuration,,2567,B,,,1,BAO_0000357,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617114,
17133,H,,,,,12687,8,Autocuration,,2568,B,,,1,BAO_0000357,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617115,
17200,H,,,,,12687,8,Autocuration,,2569,F,,,1,BAO_0000219,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,,,CHEMBL617116,
15363,H,,,,,12687,8,Autocuration,,2570,F,,,1,BAO_0000019,Efficacy at 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617117,
17200,H,,,,,12687,8,Autocuration,,2571,B,,,1,BAO_0000357,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,,,CHEMBL617118,
17200,D,,,,,12687,9,Expert,,2572,B,,,1,BAO_0000357,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,,Rattus norvegicus,CHEMBL617119,10116.0
17200,D,,,,,12687,9,Expert,,2573,B,,,1,BAO_0000357,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,,,Rattus norvegicus,CHEMBL617120,10116.0
17200,D,,,,,12687,9,Expert,,2574,F,,,1,BAO_0000219,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,,Rattus norvegicus,CHEMBL617121,10116.0
17200,H,,,,,12687,8,Autocuration,,2575,F,,,1,BAO_0000219,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,,,CHEMBL617122,
17211,H,,,,,12687,8,Autocuration,,2576,B,,,1,BAO_0000019,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617123,
17331,H,,,,,12687,8,Expert,,2577,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,,,,CHEMBL617124,
13565,H,,,,,12687,8,Expert,,2578,B,,,1,BAO_0000249,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,,,,CHEMBL617600,
13730,H,,,,,12687,8,Expert,,2579,B,,,1,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,,,,CHEMBL617601,
12416,H,,,,,12687,8,Expert,,2580,B,,,1,BAO_0000019,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,,,,CHEMBL882923,
15295,H,,,,,12687,8,Autocuration,,2581,B,,,1,BAO_0000357,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617602,
1742,H,,,,,12687,8,Autocuration,,2582,B,,,1,BAO_0000019,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,,,,CHEMBL617603,
15295,H,,,,,12687,8,Autocuration,,2583,B,,,1,BAO_0000357,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617604,
14970,H,,,,,12687,8,Expert,,2584,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,,,,CHEMBL617605,
16693,H,,,,,12687,8,Expert,,2585,B,,,1,BAO_0000019,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,,,,CHEMBL617606,
14776,D,,,,,12687,9,Expert,,2586,B,,,1,BAO_0000019,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,,,Rattus norvegicus,CHEMBL617607,10116.0
14286,H,,,,,12687,8,Autocuration,,2587,B,,,1,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,CHEMBL617455,
17200,D,,,,,12687,9,Expert,,2588,B,,,1,BAO_0000019,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,,Rattus norvegicus,CHEMBL617456,10116.0
15306,H,,,,,12687,8,Expert,,2589,B,,,1,BAO_0000357,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,,,,CHEMBL617457,
14178,D,,,,,12687,9,Expert,,2590,B,,,1,BAO_0000357,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,,,Rattus norvegicus,CHEMBL617458,10116.0
14229,D,,,,,12687,9,Expert,,2591,B,,,1,BAO_0000019,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,,,Rattus norvegicus,CHEMBL617459,10116.0
12884,H,,,,,12687,8,Expert,,2592,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,,,,CHEMBL617460,
13149,H,,,,,12687,8,Expert,,2593,B,,,1,BAO_0000357,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,,,,CHEMBL617461,
15295,D,,,,,12687,9,Expert,,2594,B,,,1,BAO_0000019,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,,,Rattus norvegicus,CHEMBL617462,10116.0
15740,H,,,,,12687,8,Autocuration,,2595,B,,,1,BAO_0000357,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,,,,CHEMBL617463,
15185,H,,,,,12687,8,Autocuration,,2596,B,,,1,BAO_0000019,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,,,,CHEMBL617464,
15185,H,,,,,12687,8,Autocuration,,2597,B,,,1,BAO_0000019,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,,,,CHEMBL617465,
17529,H,,,,,12687,8,Expert,,2598,B,,,1,BAO_0000019,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,,,,CHEMBL617466,
14826,H,,,,,12687,8,Autocuration,,2599,B,,,1,BAO_0000019,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,,,CHEMBL617467,
17211,H,,,,,12687,8,Expert,,2600,B,,,1,BAO_0000019,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,,,,CHEMBL617468,
14826,H,,,,,12687,8,Autocuration,,2601,B,,,1,BAO_0000019,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,,,CHEMBL617469,
14093,H,,,,,12687,8,Autocuration,,2602,B,,,1,BAO_0000019,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617470,
14093,H,,,,,12687,8,Autocuration,,2603,B,,,1,BAO_0000019,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,,,,CHEMBL617471,
13246,H,,,NIH3T3,,12687,8,Expert,,2604,B,,,1,BAO_0000219,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,723.0,,,,CHEMBL617472,
13246,H,,,,,12687,8,Expert,,2605,B,,,1,BAO_0000357,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,,,,CHEMBL617473,
15436,D,,,,,12687,9,Expert,,2606,B,,,1,BAO_0000019,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,,Rattus norvegicus,CHEMBL617474,10116.0
15436,D,,,,,12687,9,Expert,,2607,B,,,1,BAO_0000019,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,,,Rattus norvegicus,CHEMBL617475,10116.0
14442,H,,,,,12687,8,Autocuration,,2608,B,Brain,,1,BAO_0000221,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,,955.0,,CHEMBL617476,
12457,H,,,,,12687,8,Expert,,2609,B,,,1,BAO_0000357,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617477,
12457,H,,,NIH3T3,,12687,8,Expert,,2610,B,,,1,BAO_0000219,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,723.0,,,,CHEMBL617478,
14755,H,,,,,12687,8,Autocuration,,2611,F,,,1,BAO_0000221,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,,,,CHEMBL617479,
4707,H,,,,,12687,8,Autocuration,,2612,B,,,1,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,,,,CHEMBL617480,
13297,H,,,,,12687,8,Expert,,2613,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617481,
17331,H,,,,,12687,8,Expert,,2614,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,,,,CHEMBL617482,
4664,H,,,,,12687,8,Autocuration,,2615,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,,,,CHEMBL617483,
16633,H,,,,,12687,8,Autocuration,,2616,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,CHEMBL621528,
4664,D,,,NIH3T3,,12687,9,Expert,,2617,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,723.0,,,Rattus norvegicus,CHEMBL621529,10116.0
16133,H,,,,,12687,8,Expert,,2618,B,,,1,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,CHEMBL621530,
16133,H,,,,,12687,8,Expert,,2619,B,,,1,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,CHEMBL621531,
14060,D,,,,,12687,9,Expert,,2620,B,,,1,BAO_0000019,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,,,Rattus norvegicus,CHEMBL621532,10116.0
16326,H,,,,,12687,8,Expert,,2621,B,,,1,BAO_0000357,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,CHEMBL621533,
16659,H,,,CHO,,12687,8,Expert,,2622,B,,,1,BAO_0000219,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,449.0,,,,CHEMBL621534,
14776,H,,,,,12687,8,Autocuration,,2623,B,,,1,BAO_0000019,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,,,,CHEMBL621535,
13481,H,,,,,12687,8,Autocuration,,2624,B,,,1,BAO_0000357,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,,,CHEMBL621536,
17386,H,,,,,12687,8,Autocuration,,2625,B,,,1,BAO_0000357,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,,,,CHEMBL621537,
6611,D,,,,,12687,9,Expert,,2626,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A receptor,,,,Rattus norvegicus,CHEMBL621538,10116.0
14423,H,,,,,12687,8,Autocuration,,2627,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,,,,CHEMBL621539,
15412,H,,,,,12687,8,Autocuration,,2628,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,,,,CHEMBL621540,
15412,H,,,,,12687,8,Autocuration,,2629,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,,,,CHEMBL621541,
6238,H,,,,,12687,8,Autocuration,,2630,B,,,1,BAO_0000019,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,,,,CHEMBL621542,
6648,H,,,,,12687,8,Expert,,2631,B,,,1,BAO_0000357,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,,,,CHEMBL621543,
5667,H,,,,,12687,8,Expert,,2632,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,,,,CHEMBL621544,
6611,D,,,,,12687,9,Expert,,2633,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,,,Rattus norvegicus,CHEMBL621545,10116.0
13481,H,,,,,12687,8,Autocuration,,2634,B,,,1,BAO_0000357,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,CHEMBL621546,
13481,H,,,,,12687,8,Autocuration,,2635,B,,,1,BAO_0000357,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,,,,CHEMBL621547,
15558,H,,,NIH3T3,,12687,8,Expert,,2636,B,,,1,BAO_0000219,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,723.0,,,,CHEMBL618692,
6013,H,,,,,12687,8,Autocuration,,2637,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,CHEMBL618693,
16633,H,,,,,12687,8,Autocuration,,2638,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,CHEMBL872922,
6013,H,,,,,12687,8,Autocuration,,2639,B,,,1,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,,,,CHEMBL618694,
6013,D,,,,,12687,9,Expert,,2640,B,,,1,BAO_0000357,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,,,Rattus norvegicus,CHEMBL618695,10116.0
6013,H,,,,,12687,8,Autocuration,,2641,B,,,1,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,,,,CHEMBL618696,
6013,H,,,,,12687,8,Expert,,2642,B,,,1,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,,,,CHEMBL618697,
6013,H,,,,,12687,8,Autocuration,,2643,B,,,1,BAO_0000357,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,,,,CHEMBL618892,
6013,H,,,,,12687,8,Autocuration,,2644,B,,,1,BAO_0000357,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,,,,CHEMBL618893,
16293,H,,,,,12687,8,Autocuration,,2645,B,,,1,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,,,CHEMBL618894,
17175,H,,,NIH3T3,,12687,8,Expert,,2646,B,,,1,BAO_0000219,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,723.0,,,,CHEMBL618895,
13278,D,,,,,12687,9,Expert,,2647,B,,,1,BAO_0000357,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,,,Rattus norvegicus,CHEMBL618896,10116.0
3682,H,,,,,12687,8,Autocuration,,2648,B,Caudate-putamen,,1,BAO_0000019,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,,5383.0,,CHEMBL618897,
2014,H,,,,,12687,8,Autocuration,,2649,B,,,1,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,,,,CHEMBL618898,
2014,H,,,,,12687,8,Autocuration,,2650,B,,,1,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,,,,CHEMBL618899,
4932,H,,,,,12687,8,Autocuration,,2651,B,,,1,BAO_0000357,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,,,,CHEMBL618900,
4932,H,,,,,12687,8,Autocuration,,2652,B,,,1,BAO_0000019,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,,,,CHEMBL618901,
3935,H,,,,,12687,8,Autocuration,,2653,B,,,1,BAO_0000357,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,,,,CHEMBL618902,
5432,D,,,,,12687,9,Expert,,2654,B,Hippocampus,,1,BAO_0000221,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,,10000000.0,Rattus norvegicus,CHEMBL618903,10116.0
15818,H,,,,,12687,8,Autocuration,,2655,B,,,1,BAO_0000357,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,,,CHEMBL618904,
13672,H,,,,,12687,8,Autocuration,,2656,B,,,1,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,,,,CHEMBL618905,
13672,H,,,,,12687,8,Autocuration,,2657,B,,,1,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,,,,CHEMBL618906,
14749,H,,,NIH3T3,,12687,8,Expert,,2658,B,,,1,BAO_0000219,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,723.0,,,,CHEMBL618907,
13462,H,,,,,12687,8,Autocuration,,2659,B,,,1,BAO_0000019,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,,,,CHEMBL618908,
15740,H,,,,,12687,8,Autocuration,,2660,B,,,1,BAO_0000357,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617909,
16647,H,,,,,12687,8,Expert,,2661,B,,,1,BAO_0000019,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,,,CHEMBL617910,
13345,H,,,,,12687,8,Autocuration,,2662,B,Brain,,1,BAO_0000221,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,,955.0,,CHEMBL617911,
16740,H,,,,,12687,8,Autocuration,,2663,B,,,1,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,CHEMBL872923,
16740,H,,,,,12687,8,Autocuration,,2664,B,,,1,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,CHEMBL617912,
15535,D,,,,,12687,9,Expert,,2665,B,,,1,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,,,Rattus norvegicus,CHEMBL617913,10116.0
16740,H,,,,,12687,8,Expert,,2666,B,,,1,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,CHEMBL617914,
16740,H,,,,,12687,8,Autocuration,,2667,B,,,1,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,CHEMBL617915,
16740,H,,,,,12687,8,Autocuration,,2668,B,,,1,BAO_0000249,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,CHEMBL617916,
4795,D,,,,,12687,9,Expert,,2669,B,,,1,BAO_0000019,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,,,Rattus norvegicus,CHEMBL617917,10116.0
8,H,,,,,12687,8,Expert,,2670,B,,,1,BAO_0000019,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,,,,CHEMBL617918,
8,H,,,,,12687,8,Autocuration,,2671,B,,,1,BAO_0000019,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,,,,CHEMBL617919,
17200,D,,,,,12687,9,Expert,,2672,B,,,1,BAO_0000019,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,,,Rattus norvegicus,CHEMBL617920,10116.0
2148,D,,,,,12687,9,Expert,,2673,B,,,1,BAO_0000019,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,,,Rattus norvegicus,CHEMBL617921,10116.0
13345,D,,,,,105102,5,Expert,,2674,B,,,1,BAO_0000224,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,,,Rattus norvegicus,CHEMBL617922,10116.0
5088,H,,,,,12687,8,Autocuration,,2675,B,,,1,BAO_0000357,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,CHEMBL617923,
5088,H,,,,,12687,8,Autocuration,,2676,B,,,1,BAO_0000357,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,CHEMBL617924,
17133,H,,,,,12687,8,Autocuration,,2677,B,,,1,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,,,,CHEMBL617925,
17133,D,,,,,12687,9,Expert,,2678,B,,,1,BAO_0000357,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,,,Rattus norvegicus,CHEMBL617926,10116.0
16532,H,,,,,12687,8,Autocuration,,2679,B,,,1,BAO_0000357,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,,,,CHEMBL617927,
15086,H,,,,,12687,8,Autocuration,,2680,B,,,1,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,,,,CHEMBL617928,
2309,D,,,,,12687,9,Expert,,2681,B,,,1,BAO_0000019,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,,,Rattus norvegicus,CHEMBL617929,10116.0
12953,H,,,,,12687,8,Expert,,2682,B,,,1,BAO_0000019,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,,,,CHEMBL617930,
12953,H,,,,,12687,8,Autocuration,,2683,B,,,1,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,,,,CHEMBL617931,
12953,H,,,,,12687,8,Autocuration,,2684,B,,,1,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,,,,CHEMBL617932,
16659,H,,,CHO,,12687,8,Autocuration,,2685,B,,,1,BAO_0000219,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,449.0,,,,CHEMBL617933,
16740,H,,,,,12687,8,Autocuration,,2686,B,,,1,BAO_0000019,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,,,CHEMBL617934,
16740,H,,,,,12687,8,Autocuration,,2687,B,,,1,BAO_0000019,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,,,CHEMBL617935,
17133,H,,,,,12687,8,Autocuration,,2688,B,,,1,BAO_0000357,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,,,,CHEMBL617936,
17211,H,,,,,12687,8,Autocuration,,2689,B,,,1,BAO_0000019,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,,,,CHEMBL617937,
17331,H,,,,,12687,8,Autocuration,,2690,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,,,,CHEMBL617938,
16633,H,,,,,12687,8,Autocuration,,2691,B,,,1,BAO_0000218,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,,,,CHEMBL617939,
16633,H,,,,,12687,8,Autocuration,,2692,B,,,1,BAO_0000218,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,,,,CHEMBL617940,
16633,H,,,,,12687,8,Autocuration,,2693,B,,,1,BAO_0000218,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,,,,CHEMBL617941,
15026,H,,,,,12687,8,Expert,,2694,B,,,1,BAO_0000357,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,,,,CHEMBL617942,
15026,H,,,,,12687,8,Expert,,2695,B,,,1,BAO_0000357,Ratio of pKi of 5-HT2A to that of D2 receptor,,,,,CHEMBL617943,
16404,H,,,,,105093,4,Expert,,2696,B,,,1,BAO_0000224,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,,,CHEMBL617944,
16404,H,,,,,105093,4,Expert,,2697,B,,,1,BAO_0000224,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,,,CHEMBL617945,
16404,H,,,,,105075,4,Expert,,2698,B,,,1,BAO_0000224,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617946,
16404,H,,,,,12687,8,Autocuration,,2699,B,,,1,BAO_0000357,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,,,,CHEMBL617947,
16326,H,,,,,12687,8,Expert,,2700,B,,,1,BAO_0000357,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,,,,CHEMBL617948,
15847,H,,,,,12687,8,Autocuration,,2701,F,,,1,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,,,,CHEMBL858116,
15847,H,,,,,12687,8,Autocuration,,2702,F,,,1,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,,,,CHEMBL617949,
15329,H,,,,,12687,8,Autocuration,,2703,F,,,1,BAO_0000019,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,,,,CHEMBL617950,
16404,H,,,,,12687,8,Expert,,2704,F,Thoracic aorta,,1,BAO_0000019,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,,1515.0,,CHEMBL617951,
16404,H,,,,,12687,8,Expert,,2705,F,Thoracic aorta,,1,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,,1515.0,,CHEMBL617952,
16404,H,,,,,12687,8,Autocuration,,2706,F,Thoracic aorta,,1,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,,1515.0,,CHEMBL617953,
12861,H,,,,,12687,8,Autocuration,,2707,B,,,1,BAO_0000357,Binding activity radioligand.,,,,,CHEMBL617954,
12861,H,,,,,12687,8,Expert,,2708,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,,CHEMBL617955,
12861,H,,,,,12687,8,Autocuration,,2709,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,,,CHEMBL857071,
12490,H,,,,,12687,8,Expert,,2710,B,,,1,BAO_0000019,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,,,,CHEMBL617270,
12827,H,,,N1E-115,,12687,8,Autocuration,,2711,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,339.0,,,,CHEMBL617271,
12827,H,,,N1E-115,,12687,8,Autocuration,,2712,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,339.0,,,,CHEMBL617272,
12918,H,,,,,12687,8,Autocuration,,2713,B,,,1,BAO_0000019,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,,,,CHEMBL617273,
12919,D,,,,,12687,9,Expert,,2714,F,,,1,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,,,Rattus norvegicus,CHEMBL617274,10116.0
17723,H,,,,,108,8,Autocuration,,2715,B,,,1,BAO_0000357,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617275,
6013,H,,,,,108,8,Autocuration,,2716,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617276,
16293,H,,,,,108,8,Autocuration,,2717,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617277,
3857,H,,,,,108,8,Expert,,2718,B,,,1,BAO_0000019,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617278,
3857,H,,,,,108,8,Expert,,2719,B,,,1,BAO_0000019,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,,,,CHEMBL617279,
3857,H,,,,,108,8,Expert,,2720,B,,,1,BAO_0000019,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617280,
15363,H,,,,,108,8,Autocuration,,2721,B,,,1,BAO_0000357,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617281,
15363,H,,,,,108,8,Autocuration,,2722,B,,,1,BAO_0000357,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617282,
16441,H,,,,,108,8,Expert,,2723,B,,,1,BAO_0000019,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,,,,CHEMBL617283,
16441,H,,,,,108,8,Expert,,2724,B,,,1,BAO_0000019,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,,,,CHEMBL617284,
4176,H,,,HEK293,,108,8,Autocuration,,2725,B,,,1,BAO_0000219,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,722.0,,,,CHEMBL617285,
17085,H,,,,,108,8,Autocuration,,2726,B,,,1,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617286,
17200,D,,,,,108,9,Expert,,2727,B,,,1,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,,,Homo sapiens,CHEMBL617287,9606.0
5088,H,,,,,108,8,Expert,,2728,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,,,,CHEMBL617288,
5088,H,,,,,108,8,Autocuration,,2729,B,,,1,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,,,,CHEMBL617289,
5088,H,,,,,108,8,Autocuration,,2730,B,,,1,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,CHEMBL872917,
5088,H,,,,,108,8,Autocuration,,2731,B,,,1,BAO_0000357,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,,,CHEMBL617290,
16659,H,,,CHO,,108,8,Autocuration,,2732,B,,,1,BAO_0000219,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,449.0,,,,CHEMBL617291,
16659,H,,,CHO,,108,8,Autocuration,,2733,B,,,1,BAO_0000219,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,449.0,,,,CHEMBL617292,
17451,H,,,NIH3T3,,108,8,Autocuration,,2734,B,,,1,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,723.0,,,,CHEMBL617293,
6857,D,,,CHO,,108,9,Expert,,2735,F,,,1,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,449.0,,,Homo sapiens,CHEMBL617294,9606.0
3857,H,,,,,108,8,Expert,,2736,B,,,1,BAO_0000019,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,,,CHEMBL617295,
12861,H,,,,,108,8,Autocuration,,2737,B,,,1,BAO_0000357,Binding activity radioligand.,,,,,CHEMBL617296,
12861,H,,,,,108,8,Autocuration,,2738,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,,CHEMBL617297,
5104,H,,,CHO,,108,8,Expert,,2739,B,,,1,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,449.0,,,,CHEMBL617298,
5105,H,,,CHO,,108,8,Expert,,2740,B,,,1,BAO_0000219,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,449.0,,,,CHEMBL617299,
5105,H,,,CHO,,108,8,Autocuration,,2741,B,,,1,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,449.0,,,,CHEMBL617300,
5254,H,,,,,108,8,Autocuration,,2742,B,,,1,BAO_0000357,Binding affinity against 5-HT2C receptor,,,,,CHEMBL617454,
13267,H,,,HEK293,,108,8,Autocuration,,2743,B,,,1,BAO_0000219,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,722.0,,,,CHEMBL617505,
14157,D,,,HEK293,,108,9,Expert,,2744,B,,,1,BAO_0000219,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,722.0,,,Homo sapiens,CHEMBL617506,9606.0
12936,D,,,HEK293,,108,9,Expert,,2745,B,,,1,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,722.0,,,Homo sapiens,CHEMBL617507,9606.0
14068,H,,,,,108,8,Expert,,2746,B,,,1,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,,,,CHEMBL617508,
12936,D,,,HEK293,,108,9,Expert,,2747,B,,,1,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,722.0,,,Homo sapiens,CHEMBL857982,9606.0
4540,D,,,HEK293,,108,9,Expert,,2748,B,,,1,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,722.0,,,Homo sapiens,CHEMBL617509,9606.0
4540,D,,,HEK293,,108,9,Expert,,2749,B,,,1,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,722.0,,,Homo sapiens,CHEMBL617510,9606.0
6166,H,,,,,108,8,Autocuration,,2750,B,,,1,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,,,,CHEMBL617511,
17296,H,,,HEK293,,108,8,Autocuration,,2751,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,722.0,,,,CHEMBL617512,
17296,H,,,HEK293,,108,8,Autocuration,,2752,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,722.0,,,,CHEMBL617749,
15779,H,,,HEK293,,108,8,Autocuration,,2753,B,,,1,BAO_0000219,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,722.0,,,,CHEMBL617750,
15779,H,,,HEK293,,108,8,Autocuration,,2754,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,722.0,,,,CHEMBL617751,
14391,H,,,HEK293,,108,8,Expert,,2755,B,,,1,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,722.0,,,,CHEMBL617752,
15779,H,,,HEK293,,108,8,Autocuration,,2756,B,,,1,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",722.0,,,,CHEMBL617753,
15851,H,,,HEK293,,108,8,Expert,,2757,B,,,1,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",722.0,,,,CHEMBL617754,
15851,D,,,HEK293,,108,9,Expert,,2758,B,,,1,BAO_0000219,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,722.0,,,Homo sapiens,CHEMBL617755,9606.0
15779,H,,,HEK293,,108,8,Autocuration,,2759,B,,,1,BAO_0000219,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",722.0,,,,CHEMBL617756,
3832,H,,,HEK293,,108,8,Expert,,2760,B,,,1,BAO_0000219,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,722.0,,,,CHEMBL617757,
3833,H,,,HEK293,,108,8,Expert,,2761,B,,,1,BAO_0000219,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,722.0,,,,CHEMBL617758,
17451,H,,,NIH3T3,,108,8,Autocuration,,2762,B,,,1,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,723.0,,,,CHEMBL617759,
4199,H,,,HEK293,,108,8,Autocuration,,2763,B,,,1,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,722.0,,,,CHEMBL617760,
1883,H,,,CHO-K1,,108,8,Expert,,2764,B,,,1,BAO_0000219,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,485.0,,,,CHEMBL617761,
4321,D,,,,,108,9,Expert,,2765,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor,,,,Homo sapiens,CHEMBL617762,9606.0
14875,H,,,,,108,8,Autocuration,,2766,B,,,1,BAO_0000357,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617763,
15146,H,,,HEK293,,108,8,Autocuration,,2767,B,,,1,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,722.0,,,,CHEMBL857983,
5213,H,,,HEK293,,108,8,Autocuration,,2768,B,,,1,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,722.0,,,,CHEMBL617764,
16404,H,,,HeLa,,108,8,Autocuration,,2769,B,,,1,BAO_0000219,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,308.0,,,,CHEMBL617765,
13267,H,,,,,108,8,Autocuration,,2770,F,,,1,BAO_0000019,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,,,,CHEMBL617766,
13267,H,,,,,108,8,Autocuration,,2771,F,Hippocampus,,1,BAO_0000221,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,,10000000.0,,CHEMBL617767,
14818,H,,,HEK293,,108,8,Autocuration,,2772,B,,,1,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,722.0,,,,CHEMBL617768,
4829,H,,,HEK293,,108,8,Autocuration,,2773,B,,,1,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",722.0,,,,CHEMBL617769,
13463,H,,,,,11864,8,Autocuration,,2774,B,,,1,BAO_0000357,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,,,,CHEMBL858023,
13463,H,,,,,11864,8,Autocuration,,2775,B,Stomach,,1,BAO_0000019,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,,945.0,,CHEMBL617770,
13463,H,,,,,11864,8,Autocuration,,2776,B,Stomach,,1,BAO_0000019,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,,945.0,,CHEMBL617771,
12652,H,,,A9,,11864,8,Autocuration,,2777,F,,,1,BAO_0000219,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,625.0,,,,CHEMBL617772,
4682,H,,,NIH3T3,,11864,8,Autocuration,,2778,B,,,1,BAO_0000219,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,723.0,,,,CHEMBL617773,
4682,H,,,NIH3T3,,11864,8,Autocuration,,2779,B,,,1,BAO_0000219,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,723.0,,,,CHEMBL617850,
4682,H,,,NIH3T3,,11864,8,Autocuration,,2780,B,,,1,BAO_0000219,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,723.0,,,,CHEMBL617851,
12652,H,,,,,11864,8,Autocuration,,2781,F,,,1,BAO_0000019,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617852,
13463,H,,,,,12689,8,Autocuration,,2782,B,Stomach,,1,BAO_0000019,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,,945.0,Mus musculus,CHEMBL858024,10090.0
13463,D,,,,,12689,9,Expert,,2783,B,Stomach,,1,BAO_0000019,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,,945.0,Rattus norvegicus,CHEMBL617853,10116.0
13969,H,,,,,108,8,Expert,,2784,B,,,1,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,,,,CHEMBL617854,
13392,H,,,,,108,8,Expert,,2785,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor,,,,Sus scrofa,CHEMBL873477,9823.0
13392,H,,,,,108,8,Expert,,2786,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617855,
14430,H,,,,,108,8,Expert,,2787,B,,,1,BAO_0000019,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,,,,CHEMBL617856,
1742,H,,,,,108,8,Autocuration,,2788,B,,,1,BAO_0000019,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,,,,CHEMBL617857,
14286,H,,,,,108,8,Autocuration,,2789,B,,,1,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,,,,CHEMBL617858,
5619,H,,,,,108,8,Autocuration,,2790,B,,,1,BAO_0000357,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617859,
15086,H,,,,,108,8,Autocuration,,2791,B,,,1,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617860,
12861,H,,,,,108,8,Autocuration,,2792,B,,,1,BAO_0000357,Binding activity radioligand.,,,,,CHEMBL617861,
12861,H,,,,,108,8,Expert,,2793,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,,CHEMBL617862,
12861,H,,,,,108,8,Autocuration,,2794,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,,,CHEMBL617863,
12827,H,,,,,108,8,Autocuration,,2795,B,,,1,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,,,,CHEMBL617864,
12827,H,,,,,108,8,Autocuration,,2796,B,,,1,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,,,,CHEMBL617649,
12919,H,,,,,108,8,Expert,,2797,F,,,1,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,,Sus scrofa,CHEMBL617650,9823.0
12919,H,,,,,108,8,Expert,,2798,F,,,1,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,,,Sus scrofa,CHEMBL617651,9823.0
16429,H,,,,,108,8,Autocuration,,2799,B,,,1,BAO_0000357,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,,,Sus scrofa,CHEMBL617652,9823.0
773,H,,,,,108,8,Autocuration,,2800,B,,,1,BAO_0000019,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,,,Sus scrofa,CHEMBL857072,9823.0
5033,H,,,,,108,8,Autocuration,,2801,B,,,1,BAO_0000357,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,,,Sus scrofa,CHEMBL617653,9823.0
12861,H,,,,,12687,8,Autocuration,,2802,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,,CHEMBL617654,
14093,H,,,,,12689,8,Autocuration,,2803,F,,,1,BAO_0000019,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617655,
14970,H,,,,,12689,8,Expert,,2804,B,,,1,BAO_0000357,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,,,,CHEMBL617656,
14970,H,,,,,12689,8,Autocuration,,2805,B,,,1,BAO_0000357,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,,,,CHEMBL617657,
14970,H,,,,,12689,8,Autocuration,,2806,B,,,1,BAO_0000357,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,,,,CHEMBL617658,
14178,D,,,,,12689,9,Expert,,2807,B,,,1,BAO_0000357,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,,,Rattus norvegicus,CHEMBL617659,10116.0
14178,D,,,,,12689,9,Expert,,2808,B,,,1,BAO_0000357,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,,,Rattus norvegicus,CHEMBL617838,10116.0
14229,D,,,,,12689,9,Expert,Brain membranes,2809,B,,,1,BAO_0000249,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,,,Rattus norvegicus,CHEMBL617839,10116.0
16532,H,,,,,12689,8,Autocuration,,2810,B,,,1,BAO_0000357,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,,,,CHEMBL617840,
14826,H,,,,,12689,8,Autocuration,,2811,B,,,1,BAO_0000019,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,,,,CHEMBL617841,
17211,H,,,,,12689,8,Autocuration,,2812,B,,,1,BAO_0000019,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,,,,CHEMBL875915,
17211,H,,,,In vitro,12689,8,Expert,,2813,B,,,1,BAO_0000219,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,,,,CHEMBL617842,
13246,H,,,NIH3T3,,12689,8,Expert,,2814,B,,,1,BAO_0000219,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,723.0,,,,CHEMBL617843,
13246,H,,,,,12689,8,Expert,,2815,B,,,1,BAO_0000357,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,,,,CHEMBL617844,
12457,H,,,,,12689,8,Expert,,2816,B,,,1,BAO_0000357,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617845,
12457,H,,,NIH3T3,,12689,8,Expert,,2817,B,,,1,BAO_0000219,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,723.0,,,,CHEMBL617846,
4707,H,,,,,12689,8,Autocuration,,2818,B,,,1,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,,,,CHEMBL617847,
13297,H,,,,,12689,8,Expert,,2819,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617848,
16633,H,,,,,12689,8,Autocuration,,2820,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,,CHEMBL617849,
16133,H,,,,,12689,8,Expert,,2821,B,,,1,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,CHEMBL621507,
16326,H,,,,,12689,8,Expert,,2822,B,,,1,BAO_0000357,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,,,,CHEMBL621508,
14423,H,,,,,12689,8,Autocuration,,2823,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,,,,CHEMBL621509,
15412,H,,,,,12689,8,Autocuration,,2824,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,,,,CHEMBL621510,
15412,H,,,,,12689,8,Autocuration,,2825,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,,,,CHEMBL621511,
15558,H,,,A9,,12689,8,Expert,,2826,B,,,1,BAO_0000219,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,625.0,,,,CHEMBL621512,
16633,H,,,,,12689,8,Autocuration,,2827,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,,CHEMBL621513,
6013,H,,,,,12689,8,Expert,,2828,B,,,1,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,,,,CHEMBL621514,
17175,H,,,,In vitro,12689,8,Expert,,2829,B,,,1,BAO_0000219,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,,,,CHEMBL621515,
12469,H,,,,,12689,8,Autocuration,,2830,B,,,1,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,,,,CHEMBL621516,
3682,H,,,,,12689,8,Autocuration,,2831,B,Caudate-putamen,,1,BAO_0000019,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,,5383.0,,CHEMBL621517,
4932,H,,,,,12689,8,Autocuration,,2832,B,,,1,BAO_0000357,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,,,,CHEMBL621518,
4932,H,,,,,12689,8,Autocuration,,2833,B,,,1,BAO_0000019,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,,,,CHEMBL621519,
3935,H,,,,,12689,8,Autocuration,,2834,B,,,1,BAO_0000357,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,,,,CHEMBL621520,
15818,H,,,,,12689,8,Autocuration,,2835,B,,,1,BAO_0000357,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,,,,CHEMBL621521,
15818,H,,,,,12689,8,Autocuration,,2836,B,,,1,BAO_0000357,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,,,,CHEMBL621522,
14749,H,,,,,12689,8,Expert,,2837,B,,,1,BAO_0000219,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,,,,CHEMBL621523,
15740,H,,,,,12689,8,Autocuration,,2838,B,,,1,BAO_0000357,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,,,,CHEMBL621524,
17133,D,,,,,12689,9,Expert,,2839,B,,,1,BAO_0000357,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,,,Rattus norvegicus,CHEMBL621525,10116.0
16532,H,,,,,12689,8,Autocuration,,2840,B,,,1,BAO_0000357,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,,,,CHEMBL872921,
12369,H,,,,,12689,8,Autocuration,,2841,B,,,1,BAO_0000357,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,,,,CHEMBL621526,
12369,H,,,,,12689,8,Expert,,2842,B,,,1,BAO_0000219,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,,,,CHEMBL621527,
2309,D,,,,,12689,9,Expert,,2843,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,,,Rattus norvegicus,CHEMBL617865,10116.0
12953,H,,,,,12689,8,Autocuration,,2844,B,,,1,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617866,
12953,H,,,,,12689,8,Autocuration,,2845,B,,,1,BAO_0000019,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,,,,CHEMBL617867,
12953,H,,,,,12689,8,Autocuration,,2846,B,,,1,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,,,,CHEMBL617487,
12953,H,,,,,12689,8,Expert,,2847,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617488,
17133,H,,,,,12689,8,Autocuration,,2848,B,,,1,BAO_0000357,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,,,,CHEMBL617489,
17211,H,,,,,12689,8,Autocuration,,2849,B,,,1,BAO_0000019,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,,,,CHEMBL617490,
17211,H,,,,,12689,8,Autocuration,,2850,B,,,1,BAO_0000019,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,,,,CHEMBL617491,
14025,H,,,,,12689,8,Autocuration,,2851,B,,,1,BAO_0000019,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,,,,CHEMBL617492,
14998,H,,,,,12689,8,Autocuration,,2852,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,,,,CHEMBL617493,
4342,H,,,,,12689,8,Autocuration,,2853,B,,,1,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,,,,CHEMBL617494,
13735,D,,,,,12689,9,Expert,,2854,B,,,1,BAO_0000019,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,,,Rattus norvegicus,CHEMBL617495,10116.0
13181,H,,,,,12689,8,Autocuration,,2855,B,,,1,BAO_0000357,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,,,CHEMBL617496,
1883,H,,,CHO-K1,,12689,8,Autocuration,,2856,B,,,1,BAO_0000219,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,485.0,,,,CHEMBL617497,
15194,H,,,,,12689,8,Autocuration,,2857,B,,,1,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,CHEMBL617498,
15194,H,,,,,12689,8,Autocuration,,2858,B,,,1,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,,,,CHEMBL617499,
14579,H,,,,,12689,8,Autocuration,,2859,F,,,1,BAO_0000019,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617500,
4639,H,,,,,108,8,Autocuration,,2860,B,,,1,BAO_0000357,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617501,
4820,H,,,,,108,8,Expert,,2861,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617502,
14442,H,,,,,227,8,Autocuration,,2862,B,,,1,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,,,,CHEMBL617503,
14755,H,,,,,227,8,Autocuration,,2863,B,,,1,BAO_0000357,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,,,,CHEMBL617504,
14744,H,,,,,227,8,Autocuration,,2864,B,,,1,BAO_0000357,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,,,,CHEMBL617406,
6857,D,,,,,227,9,Expert,,2865,B,,,1,BAO_0000019,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,,,Homo sapiens,CHEMBL617407,9606.0
16209,H,,,,,227,8,Autocuration,,2866,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,,,,CHEMBL617408,
15363,H,,,,,227,8,Autocuration,,2867,B,,,1,BAO_0000357,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,,,CHEMBL617409,
15363,H,,,,,227,8,Autocuration,,2868,B,,,1,BAO_0000357,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,,,CHEMBL617410,
15363,H,,,,,227,8,Autocuration,,2869,B,,,1,BAO_0000357,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,,,,CHEMBL617411,
17085,H,,,,,227,8,Autocuration,,2870,B,,,1,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,,,,CHEMBL617412,
17200,D,,,,,227,9,Expert,,2871,B,,,1,BAO_0000357,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,,,Homo sapiens,CHEMBL617774,9606.0
15851,D,,,HEK293,,227,9,Expert,,2872,B,,,1,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,722.0,,,Homo sapiens,CHEMBL617775,9606.0
15851,D,,,HEK293,,227,9,Expert,,2873,B,,,1,BAO_0000219,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,722.0,,,Homo sapiens,CHEMBL617776,9606.0
6857,D,,,CHO,,227,9,Expert,,2874,F,,,1,BAO_0000219,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,449.0,,,Homo sapiens,CHEMBL617777,9606.0
6857,D,,,CHO,,227,9,Expert,,2875,F,,,1,BAO_0000219,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,449.0,,,Homo sapiens,CHEMBL617778,9606.0
15779,H,,,HEK293,,227,8,Autocuration,,2876,B,,,1,BAO_0000219,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",722.0,,,,CHEMBL617779,
15851,H,,,HEK293,,227,8,Expert,,2877,B,,,1,BAO_0000219,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,722.0,,,,CHEMBL617780,
15779,H,,,HEK293,,227,8,Autocuration,,2878,B,,,1,BAO_0000219,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",722.0,,,,CHEMBL617781,
14157,D,,,HEK293,,227,9,Expert,,2879,B,,,1,BAO_0000219,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,722.0,,,Homo sapiens,CHEMBL617782,9606.0
4540,D,,,HEK293,,227,9,Expert,,2880,B,,,1,BAO_0000219,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,722.0,,,Homo sapiens,CHEMBL617783,9606.0
6166,H,,,,,227,8,Autocuration,,2881,B,,,1,BAO_0000357,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,,,,CHEMBL617784,
15779,H,,,HEK293,,227,8,Autocuration,,2882,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,722.0,,,,CHEMBL617785,
14391,H,,,HEK293,,227,8,Expert,,2883,B,,,1,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,722.0,,,,CHEMBL857984,
3832,H,,,HEK293,,227,8,Expert,,2884,B,,,1,BAO_0000219,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,722.0,,,,CHEMBL617786,
3833,H,,,HEK293,,227,8,Expert,,2885,B,,,1,BAO_0000219,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,722.0,,,,CHEMBL617787,
15851,D,,,HEK293,,227,9,Expert,,2886,B,,,1,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,722.0,,,Homo sapiens,CHEMBL617788,9606.0
15851,D,,,HEK293,,227,9,Expert,,2887,B,,,1,BAO_0000219,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,722.0,,,Homo sapiens,CHEMBL617789,9606.0
4199,H,,,HEK293,,227,8,Autocuration,,2888,B,,,1,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,722.0,,,,CHEMBL617790,
1883,H,,,CHO-K1,,227,8,Expert,,2889,B,,,1,BAO_0000219,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,485.0,,,,CHEMBL617791,
4321,H,,,,,227,8,Expert,,2890,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2B receptor,,,,,CHEMBL617608,
15146,H,,,HEK293,,227,8,Autocuration,,2891,B,,,1,BAO_0000219,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,722.0,,,,CHEMBL617609,
5213,H,,,HEK293,,227,8,Autocuration,,2892,B,,,1,BAO_0000219,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,722.0,,,,CHEMBL617610,
14818,H,,,HEK293,,227,8,Autocuration,,2893,B,,,1,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,722.0,,,,CHEMBL617611,
4829,H,,,HEK293,,227,8,Autocuration,,2894,B,,,1,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",722.0,,,,CHEMBL617612,
4829,H,,,HEK293,,227,8,Autocuration,,2895,B,,,1,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",722.0,,,,CHEMBL617613,
14025,H,,,,,227,8,Autocuration,,2896,B,,,1,BAO_0000019,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,,,Oryctolagus cuniculus,CHEMBL617614,9986.0
13463,H,,,,,12688,8,Expert,,2897,B,Stomach,,1,BAO_0000019,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,,945.0,,CHEMBL617615,
7259,H,,,,,12688,8,Expert,,2898,B,Stomach,,1,BAO_0000357,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,,945.0,,CHEMBL858114,
7259,H,,,,,12688,8,Autocuration,,2899,B,Stomach,,1,BAO_0000357,Affinity against serotonergic receptor in the isolated rat stomach fundus,,,945.0,,CHEMBL617616,
7185,D,,,,,12688,9,Expert,,2900,F,Stomach,,1,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,,945.0,Rattus norvegicus,CHEMBL617617,10116.0
7185,D,,,,,12688,9,Expert,,2901,F,,,1,BAO_0000019,Antagonistic against 5-hydroxytryptamine 2B receptor,,,,Rattus norvegicus,CHEMBL875914,10116.0
13267,H,,,,,12688,8,Autocuration,,2902,F,Stomach,,1,BAO_0000019,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,,945.0,,CHEMBL617618,
13735,D,,,,,12688,9,Expert,,2903,B,Stomach,,1,BAO_0000357,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,,945.0,Rattus norvegicus,CHEMBL617619,10116.0
15738,H,,,,,12688,8,Autocuration,,2904,F,,,1,BAO_0000019,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,,,,CHEMBL617620,
15738,H,,,,,12688,8,Autocuration,,2905,F,,,1,BAO_0000019,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,,,,CHEMBL617621,
15738,H,,,,,12688,8,Autocuration,,2906,F,,,1,BAO_0000019,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,,,,CHEMBL617622,
12936,D,,,,,12688,9,Expert,,2907,B,Stomach,,1,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,945.0,Rattus norvegicus,CHEMBL617623,10116.0
12936,D,,,,,12688,9,Expert,,2908,B,Stomach,,1,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,945.0,Rattus norvegicus,CHEMBL617624,10116.0
12936,D,,,,,12688,9,Expert,,2909,B,Stomach,,1,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,945.0,Rattus norvegicus,CHEMBL617625,10116.0
12936,D,,,,,12688,9,Expert,,2910,B,Stomach,,1,BAO_0000357,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,,945.0,Rattus norvegicus,CHEMBL617626,10116.0
16404,H,,,,,12688,8,Autocuration,,2911,F,Stomach,,1,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,945.0,,CHEMBL617627,
16404,H,,,,,12688,8,Expert,,2912,F,Stomach,,1,BAO_0000019,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,945.0,,CHEMBL617628,
16404,H,,,,,12688,8,Autocuration,,2913,F,Stomach,,1,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,,945.0,,CHEMBL617629,
16404,H,,,,,12688,8,Autocuration,,2914,F,Stomach,,1,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,,945.0,,CHEMBL858115,
16404,D,,,,,12688,9,Expert,,2915,F,Stomach,,1,BAO_0000019,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,,945.0,Rattus norvegicus,CHEMBL617630,10116.0
16404,H,,,,,12688,8,Autocuration,,2916,F,Thoracic aorta,,1,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,,1515.0,,CHEMBL617631,
7483,H,,,,,12688,8,Autocuration,,2917,B,,,1,BAO_0000357,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,,,CHEMBL617632,
7483,H,,,,,12688,8,Expert,,2918,B,,,1,BAO_0000357,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,,,,CHEMBL617633,
7483,H,,,,,12688,8,Autocuration,,2919,B,,,1,BAO_0000357,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,,,CHEMBL617634,
7483,H,,,,,12688,8,Autocuration,,2920,B,,,1,BAO_0000357,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,,,,CHEMBL617635,
16404,D,,,,,12688,9,Autocuration,,2922,F,Stomach,,1,BAO_0000019,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,945.0,Rattus norvegicus,CHEMBL617637,10116.0
6347,H,,,,,227,8,Autocuration,,2923,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,CHEMBL617638,
4373,H,,,,,227,8,Autocuration,,2924,B,,,1,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,,,,CHEMBL617639,
4373,H,,,,,227,8,Autocuration,,2925,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,,,,CHEMBL617640,
4687,H,,,,,227,8,Autocuration,,2926,B,,,1,BAO_0000357,Evaluated for the binding affinity to 5-HT 2B receptor,,,,,CHEMBL617641,
16946,H,,,,,227,8,Autocuration,,2927,B,,,1,BAO_0000357,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,,,,CHEMBL617642,
16633,H,,,,,227,8,Autocuration,,2928,B,,,1,BAO_0000357,Binding affinities against 5-hydroxytryptamine 2B receptor,,,,,CHEMBL617643,
16633,H,,,,,227,8,Autocuration,,2929,B,,,1,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 2B receptor,,,,,CHEMBL617644,
16633,H,,,,,227,8,Autocuration,,2930,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,,,,CHEMBL617645,
15026,H,,,,,108,8,Expert,,2931,B,,,1,BAO_0000357,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,,,CHEMBL617646,
15738,H,,,,,108,8,Autocuration,,2932,B,,,1,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,,Bos taurus,CHEMBL617647,9913.0
15738,H,,,,,108,8,Autocuration,,2933,B,,,1,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,,,Bos taurus,CHEMBL617648,9913.0
15738,H,,,,,108,8,Autocuration,,2934,B,,,1,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,,,Bos taurus,CHEMBL617875,9913.0
15738,H,,,,,108,8,Autocuration,,2935,B,,,1,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,,,Bos taurus,CHEMBL617876,9913.0
16404,H,,,,,108,8,Expert,,2936,B,,,1,BAO_0000357,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,,,Bos taurus,CHEMBL617877,9913.0
15026,H,,,,,108,8,Expert,,2937,B,,,1,BAO_0000357,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,,Bos taurus,CHEMBL617878,9913.0
15738,H,,,,,108,8,Autocuration,,2938,B,,,1,BAO_0000357,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,,,Bos taurus,CHEMBL617879,9913.0
16312,H,,,,,108,8,Autocuration,,2939,B,,,1,BAO_0000019,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,,,Cavia porcellus,CHEMBL617880,10141.0
5486,D,,,,,20033,9,Intermediate,,2940,B,Striatum,,1,BAO_0000357,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,,2435.0,Cavia porcellus,CHEMBL617881,10141.0
5254,H,,,,,51,8,Autocuration,,2941,B,,,1,BAO_0000357,Binding affinity against 5-HT1A receptor,,,,,CHEMBL857073,
3857,H,,,CHO,,108,8,Expert,,2942,F,,,1,BAO_0000219,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,449.0,,,,CHEMBL617882,
6857,D,,,CHO,,108,9,Expert,,2943,F,,,1,BAO_0000219,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,449.0,,,Homo sapiens,CHEMBL617883,9606.0
4176,H,,,,,108,8,Autocuration,,2944,F,,,1,BAO_0000219,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,,,,CHEMBL617884,
6347,H,,,CHO,,108,8,Autocuration,,2945,B,,,1,BAO_0000219,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,449.0,,,,CHEMBL617885,
6347,H,,,CHO,,108,8,Autocuration,,2946,B,,,1,BAO_0000219,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",449.0,,,,CHEMBL617886,
16146,D,,,,,108,9,Expert,,2947,B,,,1,BAO_0000357,Inhibition of human 5-hydroxytryptamine 2C receptor,,,,Homo sapiens,CHEMBL617887,9606.0
3805,H,,,,,108,8,Autocuration,,2948,B,,,1,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,,,,CHEMBL617888,
3857,H,,,,,108,8,Autocuration,,2949,B,,,1,BAO_0000019,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,,,CHEMBL617889,
5635,H,,,,,108,8,Autocuration,,2950,B,,,1,BAO_0000357,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,,,,CHEMBL617890,
5635,H,,,,,108,8,Autocuration,,2951,B,,,1,BAO_0000357,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,,,CHEMBL617891,
5635,H,,,,,108,8,Autocuration,,2952,B,,,1,BAO_0000357,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,,,CHEMBL617892,
4012,H,,,CHO,,108,8,Expert,,2953,B,,,1,BAO_0000219,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,449.0,,,,CHEMBL617893,
6366,H,,,CHO,,108,8,Expert,,2954,B,,,1,BAO_0000219,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,449.0,,,,CHEMBL617894,
15949,H,,,CHO,,108,8,Expert,,2955,B,,,1,BAO_0000219,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,449.0,,,,CHEMBL617895,
17211,H,,,CHO,,108,8,Autocuration,,2956,B,,,1,BAO_0000219,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,449.0,,,,CHEMBL617896,
6491,D,,,,,108,9,Expert,,2957,B,,,1,BAO_0000357,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,,,Homo sapiens,CHEMBL617897,9606.0
14093,H,,,,,108,8,Autocuration,,2958,F,,,1,BAO_0000019,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,,,,CHEMBL617898,
13481,H,,,,,108,8,Autocuration,,2959,F,,,1,BAO_0000019,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,,CHEMBL617899,
6347,H,,,CHO,,108,8,Expert,,2960,B,,,1,BAO_0000219,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,449.0,,,Rattus norvegicus,CHEMBL617900,10116.0
14093,H,,,,,108,8,Autocuration,,2961,F,,,1,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,,,,CHEMBL617901,
14093,H,,,,,108,8,Autocuration,,2962,F,,,1,BAO_0000019,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,,,,CHEMBL617902,
13481,H,,,,,108,8,Autocuration,,2963,F,,,1,BAO_0000019,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,CHEMBL617903,
14442,H,,,,,108,8,Autocuration,,2964,B,,,1,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,,,,CHEMBL617904,
14442,H,,,,,108,8,Autocuration,,2965,B,,,1,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,,,,CHEMBL617905,
14442,H,,,,,108,8,Autocuration,,2966,B,,,1,BAO_0000357,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,,,,CHEMBL617906,
14755,H,,,,,108,8,Autocuration,,2967,B,,,1,BAO_0000357,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,,,,CHEMBL617907,
14744,H,,,,,108,8,Autocuration,,2968,B,,,1,BAO_0000357,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,,,,CHEMBL617908,
16659,H,,,CHO,,108,8,Expert,,2969,B,,,1,BAO_0000219,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,449.0,,,,CHEMBL620617,
6857,D,,,,,108,9,Expert,,2970,B,,,1,BAO_0000019,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,,,Homo sapiens,CHEMBL620618,9606.0
5635,H,,,,,108,8,Expert,,2971,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,,,,CHEMBL620619,
4234,D,,,,,108,9,Expert,,2972,B,,,1,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,,,Homo sapiens,CHEMBL620620,9606.0
16209,H,,,,,108,8,Autocuration,,2973,B,,,1,BAO_0000357,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,,,,CHEMBL620621,
5778,D,,,,,104698,7,Autocuration,Membranes,2974,B,,,1,BAO_0000249,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,,,Rattus norvegicus,CHEMBL872920,10116.0
5094,H,,,,,104698,6,Autocuration,,2975,B,,,1,BAO_0000223,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,,,,CHEMBL620622,
809,D,,,,,104698,7,Autocuration,,2976,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,,,Rattus norvegicus,CHEMBL620623,10116.0
1578,H,,,,,104698,6,Autocuration,,2977,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,,,,CHEMBL620624,
809,H,,,,,104698,6,Autocuration,,2978,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,,,,CHEMBL620625,
12469,H,,,,,104698,6,Autocuration,,2979,B,,,1,BAO_0000219,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,,,,CHEMBL620626,
14290,H,,,,,104698,6,Autocuration,,2980,B,,,1,BAO_0000019,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,,,,CHEMBL621307,
14290,H,,,,,104698,6,Autocuration,,2981,B,,,1,BAO_0000019,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,,,,CHEMBL621308,
10609,H,,,,,104698,6,Autocuration,,2982,B,,,1,BAO_0000223,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,,,,CHEMBL621309,
10609,H,,,,,104698,6,Autocuration,,2983,B,,,1,BAO_0000223,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,,,,CHEMBL621310,
10609,H,,,,,104698,6,Autocuration,,2984,B,,,1,BAO_0000223,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,,,,CHEMBL621311,
15253,H,,,,,104698,6,Autocuration,,2985,B,,,1,BAO_0000249,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,,,CHEMBL621502,
15253,H,,,,,104698,6,Autocuration,,2986,B,,,1,BAO_0000249,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,,,CHEMBL621503,
11683,H,,,,,104698,6,Autocuration,Membranes,2987,B,,,1,BAO_0000249,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,,,,CHEMBL621504,
12092,H,,,,,104698,6,Autocuration,,2988,B,,,1,BAO_0000223,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,,,,CHEMBL621505,
1946,H,,,,,104698,6,Autocuration,,2989,B,,,1,BAO_0000019,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,,,CHEMBL621506,
11623,H,,,,,104698,6,Autocuration,,2990,B,,,1,BAO_0000223,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,,,,CHEMBL619781,
11623,H,,,,,104698,6,Autocuration,,2991,B,,,1,BAO_0000223,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,,,,CHEMBL619782,
14788,H,,,,,104698,6,Autocuration,,2992,B,,,1,BAO_0000019,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,,,,CHEMBL619783,
5432,D,,,,,104698,7,Autocuration,,2993,B,,,1,BAO_0000019,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,,,Rattus norvegicus,CHEMBL619784,10116.0
14826,H,,,,,104698,6,Autocuration,,2994,B,,,1,BAO_0000249,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,,CHEMBL619785,
2222,H,,,,,104698,6,Autocuration,,2995,B,,,1,BAO_0000223,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,,,CHEMBL619786,
11963,H,,,,,104698,6,Autocuration,,2996,B,,,1,BAO_0000019,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,,,,CHEMBL619787,
14145,H,,,,,104698,6,Autocuration,,2997,B,,,1,BAO_0000019,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,,,,CHEMBL872925,
17819,H,,,,,104698,6,Autocuration,,2998,B,,,1,BAO_0000019,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,,,,CHEMBL619788,
10394,H,,,,,104698,6,Autocuration,,2999,B,,,1,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,,,CHEMBL619789,
10394,H,,,,,104698,6,Autocuration,,3000,B,,,1,BAO_0000249,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,,,CHEMBL619790,
15034,H,,,,,104698,6,Autocuration,,3001,B,,,1,BAO_0000019,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,,,CHEMBL619791,
691,H,,,,,104698,6,Autocuration,,3002,B,,,1,BAO_0000019,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,,,CHEMBL619792,
12092,H,,,,,104698,6,Autocuration,Membranes,3003,B,,,1,BAO_0000249,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,,,,CHEMBL619793,
11752,D,,,,,104698,7,Autocuration,,3004,B,,,1,BAO_0000223,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,,Rattus norvegicus,CHEMBL619794,10116.0
11752,H,,,,,104698,6,Autocuration,,3005,B,Brain,,1,BAO_0000221,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,,955.0,,CHEMBL619795,
301,H,,,,,104698,6,Autocuration,,3006,B,,,1,BAO_0000019,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,,,,CHEMBL619796,
16532,H,,,,,104698,6,Autocuration,,3007,B,,,1,BAO_0000223,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,,,,CHEMBL620448,
16532,H,,,,,104698,6,Autocuration,,3008,B,,,1,BAO_0000223,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,,,CHEMBL620449,
12092,H,,,,,104698,6,Autocuration,,3009,B,,,1,BAO_0000223,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,,,,CHEMBL620450,
11684,H,,,,,104698,6,Autocuration,,3010,B,,,1,BAO_0000223,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,,,,CHEMBL620451,
11684,H,,,,,104698,6,Autocuration,,3011,B,,,1,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,,,,CHEMBL620631,
12953,H,,,,,104698,6,Autocuration,,3012,B,,,1,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,,,,CHEMBL620632,
12953,H,,,,,104698,6,Autocuration,,3013,B,,,1,BAO_0000019,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,,,,CHEMBL620633,
12953,H,,,,,104698,6,Autocuration,,3014,B,,,1,BAO_0000223,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,,,,CHEMBL620634,
12861,H,,,,,104698,6,Autocuration,,3015,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,,,CHEMBL620635,
11454,H,,,,In vivo,104698,6,Autocuration,,3016,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,,,,CHEMBL620636,
11454,H,,,,In vivo,104698,6,Autocuration,,3017,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,,,,CHEMBL620637,
11454,H,,,,In vivo,104698,6,Autocuration,,3018,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,,,,CHEMBL620638,
11454,H,,,,In vivo,104698,6,Autocuration,,3019,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,,,,CHEMBL620639,
11454,H,,,,In vivo,104698,6,Autocuration,,3020,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,,,CHEMBL620640,
11454,H,,,,In vivo,104698,6,Autocuration,,3021,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,,,,CHEMBL620641,
11454,H,,,,In vivo,104698,6,Autocuration,,3022,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,,,,CHEMBL620642,
11454,H,,,,In vivo,104698,6,Autocuration,,3023,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,,,,CHEMBL620643,
11454,H,,,,In vivo,104698,6,Autocuration,,3024,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,,,,CHEMBL620644,
11454,H,,,,In vivo,104698,6,Autocuration,,3025,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,,,,CHEMBL620645,
11454,H,,,,In vivo,104698,6,Autocuration,,3026,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,,,,CHEMBL620646,
11454,H,,,,In vivo,104698,6,Autocuration,,3027,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,,,,CHEMBL620647,
11454,H,,,,In vivo,104698,6,Autocuration,,3028,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,,,,CHEMBL620648,
11454,H,,,,In vivo,104698,6,Autocuration,,3029,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,,,CHEMBL620649,
11454,H,,,,In vivo,104698,6,Autocuration,,3030,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,,,,CHEMBL620650,
11454,H,,,,In vivo,104698,6,Autocuration,,3031,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,,,,CHEMBL620651,
11454,H,,,,In vivo,104698,6,Autocuration,,3032,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,,,,CHEMBL872875,
11454,H,,,,In vivo,104698,6,Autocuration,,3033,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,,,,CHEMBL620652,
10609,H,,,,,104698,6,Autocuration,,3034,F,,,1,BAO_0000019,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,,,,CHEMBL620653,
12861,H,,,,,104698,6,Autocuration,,3035,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,,,,CHEMBL857076,
12861,D,,,,,104698,7,Autocuration,,3036,B,,,1,BAO_0000019,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,,Rattus norvegicus,CHEMBL620654,10116.0
12861,H,,,,,104698,6,Autocuration,,3037,B,,,1,BAO_0000223,Binding activity radioligand.,,,,,CHEMBL620655,
10728,H,,,,,104698,6,Autocuration,Brain membranes,3038,B,,,1,BAO_0000249,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,,,,CHEMBL620656,
10728,H,,,,,104698,6,Autocuration,Brain membranes,3039,B,,,1,BAO_0000249,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,,,,CHEMBL620657,
5163,H,,,,,108,8,Autocuration,,3040,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,,,,CHEMBL620658,
5163,H,,,,,108,8,Autocuration,,3041,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,,,,CHEMBL620659,
6011,H,,,,,108,8,Autocuration,,3042,B,,,1,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,,,,CHEMBL620660,
5014,H,,,,,108,8,Autocuration,,3043,B,,,1,BAO_0000357,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,,,,CHEMBL620661,
5635,H,,,,,108,8,Autocuration,,3044,B,,,1,BAO_0000357,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,,,,CHEMBL620662,
5163,H,,,,,108,8,Expert,,3045,B,,,1,BAO_0000357,Affinity for 5-hydroxytryptamine 2C receptor,,,,,CHEMBL620663,
6841,H,,,,,108,8,Autocuration,,3046,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,CHEMBL620664,
6119,H,,,,,108,8,Expert,,3047,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,,,,CHEMBL620665,
4373,H,,,,,108,8,Autocuration,,3048,B,,,1,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,,,,CHEMBL620666,
1633,H,,,,,108,8,Autocuration,,3049,B,,,1,BAO_0000357,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,,,,CHEMBL620667,
1633,H,,,,,108,8,Expert,,3050,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,,,,CHEMBL620668,
4373,H,,,,,108,8,Autocuration,,3051,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,,,,CHEMBL620669,
6576,H,,,,,108,8,Expert,,3052,B,,,1,BAO_0000357,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,,,,CHEMBL620670,
4687,H,,,,,108,8,Autocuration,,3053,B,,,1,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,,,,CHEMBL620671,
12146,H,,,,,108,8,Autocuration,,3054,B,,,1,BAO_0000357,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,,,,CHEMBL620672,
12146,H,,,,,108,8,Autocuration,,3055,B,,,1,BAO_0000357,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,,,,CHEMBL620673,
16946,H,,,,,108,8,Autocuration,,3056,B,,,1,BAO_0000357,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,,,,CHEMBL620674,
14159,H,,,,,108,8,Autocuration,,3057,B,,,1,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,,,,CHEMBL620675,
16700,H,,,,,108,8,Autocuration,,3058,B,,,1,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,,,,CHEMBL620676,
3269,H,,,,,108,8,Autocuration,,3059,B,,,1,BAO_0000357,Affinity against 5-hydroxytryptamine 2C receptor,,,,,CHEMBL621382,
1274,D,,,,,108,9,Expert,,3060,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 2C receptor,,,,Homo sapiens,CHEMBL621383,9606.0
1317,H,,,,,108,8,Autocuration,,3061,B,,,1,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,,,,CHEMBL621384,
5834,H,,,,,144,8,Autocuration,,3062,B,,,1,BAO_0000357,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,,,Bos taurus,CHEMBL621385,9913.0
11147,H,,,,,144,8,Autocuration,,3063,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,,,Bos taurus,CHEMBL617989,9913.0
14145,H,,,,,104714,4,Expert,,3064,F,,,1,BAO_0000019,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,,,Cavia porcellus,CHEMBL617990,10141.0
10561,H,,,,,104714,4,Autocuration,,3065,B,Ileum,,1,BAO_0000221,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,,2116.0,Cavia porcellus,CHEMBL875085,10141.0
15847,H,,,,,104714,4,Autocuration,,3066,F,,,1,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,,,Cavia porcellus,CHEMBL617991,10141.0
15847,H,,,,,104714,4,Autocuration,,3067,F,,,1,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,,,Cavia porcellus,CHEMBL617992,10141.0
10561,H,,,,,104714,4,Autocuration,,3068,B,Ileum,,1,BAO_0000221,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,,2116.0,Cavia porcellus,CHEMBL617993,10141.0
11454,H,,,,,104714,4,Autocuration,,3069,B,Ileum,,1,BAO_0000221,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,,2116.0,Cavia porcellus,CHEMBL617994,10141.0
4639,H,,,,,104714,4,Autocuration,,3070,F,,,1,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,,,Cavia porcellus,CHEMBL617995,10141.0
4639,H,,,,,104714,4,Autocuration,,3071,F,,,1,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,,,Cavia porcellus,CHEMBL617996,10141.0
4639,H,,,,,104714,4,Autocuration,,3072,F,,,1,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,,,Cavia porcellus,CHEMBL617997,10141.0
4639,H,,,,,104714,4,Autocuration,,3073,F,,,1,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,,,Cavia porcellus,CHEMBL617998,10141.0
4639,H,,,,,104714,4,Autocuration,,3074,F,,,1,BAO_0000019,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,,,Cavia porcellus,CHEMBL617999,10141.0
4639,H,,,,,104714,4,Autocuration,,3075,F,,,1,BAO_0000019,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,,,Cavia porcellus,CHEMBL618000,10141.0
15253,H,,,,,104714,4,Autocuration,,3076,F,Ileum,,1,BAO_0000221,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,,2116.0,Cavia porcellus,CHEMBL617815,10141.0
15253,H,,,,,104714,4,Autocuration,,3077,F,Ileum,,1,BAO_0000221,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,,2116.0,Cavia porcellus,CHEMBL617816,10141.0
11963,H,,,,,104714,4,Autocuration,,3078,F,Ileum,,1,BAO_0000221,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,,2116.0,Cavia porcellus,CHEMBL617817,10141.0
1946,H,,,,,104714,4,Autocuration,,3079,B,Ileum,,1,BAO_0000221,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,,2116.0,Cavia porcellus,CHEMBL617818,10141.0
1946,H,,,,,104714,4,Autocuration,,3080,B,Ileum,,1,BAO_0000221,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,,2116.0,Cavia porcellus,CHEMBL617819,10141.0
12045,H,,,,,104714,4,Autocuration,,3081,B,,,1,BAO_0000223,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,,,Cavia porcellus,CHEMBL617820,10141.0
1559,H,,,,,104714,4,Autocuration,,3082,B,Ileum,,1,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,2116.0,Cavia porcellus,CHEMBL617821,10141.0
273,H,,,,,104714,4,Autocuration,,3083,F,Ileum,,1,BAO_0000221,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,2116.0,Cavia porcellus,CHEMBL617822,10141.0
273,H,,,,,104714,4,Autocuration,,3084,F,Ileum,,1,BAO_0000221,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,,2116.0,Cavia porcellus,CHEMBL617823,10141.0
188,H,,,,,104714,4,Autocuration,,3085,F,Ileum,,1,BAO_0000221,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,,2116.0,Cavia porcellus,CHEMBL617824,10141.0
12919,H,,,,,104714,4,Autocuration,,3086,F,Ileum,,1,BAO_0000221,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,,2116.0,Cavia porcellus,CHEMBL617825,10141.0
12918,H,,,,,104714,4,Autocuration,,3087,F,Ileum,,1,BAO_0000221,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,,2116.0,Cavia porcellus,CHEMBL617826,10141.0
1559,H,,,,,104714,4,Autocuration,,3088,B,Ileum,,1,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,2116.0,Cavia porcellus,CHEMBL617827,10141.0
273,H,,,,,104714,4,Autocuration,,3089,F,Ileum,,1,BAO_0000221,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,2116.0,Cavia porcellus,CHEMBL617828,10141.0
1559,H,,,,,104714,4,Autocuration,,3090,B,Ileum,,1,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,,2116.0,Cavia porcellus,CHEMBL617829,10141.0
1559,H,,,,,104714,4,Autocuration,,3091,B,Ileum,,1,BAO_0000221,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,,2116.0,Cavia porcellus,CHEMBL617830,10141.0
1559,H,,,,,104714,4,Autocuration,,3092,B,Ileum,,1,BAO_0000221,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,,2116.0,Cavia porcellus,CHEMBL617831,10141.0
14424,H,,,,,104714,4,Autocuration,,3093,B,Ileum,,1,BAO_0000221,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,,2116.0,Cavia porcellus,CHEMBL617832,10141.0
13181,U,,,,,22226,0,Autocuration,,3094,B,,,1,BAO_0000019,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,,,Cavia porcellus,CHEMBL617833,10141.0
5486,H,,,,,51,8,Autocuration,,3095,B,,,1,BAO_0000357,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,,,,CHEMBL617834,
6491,D,,,,,104714,5,Expert,,3096,B,,,1,BAO_0000223,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,,,Homo sapiens,CHEMBL617835,9606.0
6013,H,,,,,104714,4,Autocuration,,3097,B,,,1,BAO_0000223,Binding affinity towards 5-HT3 receptor,,,,,CHEMBL617836,
12861,H,,,,,104714,4,Autocuration,,3098,B,,,1,BAO_0000223,Binding activity radioligand.,,,,,CHEMBL617837,
12861,H,,,,,104714,4,Autocuration,,3099,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,,,,CHEMBL620392,
5104,H,,,,,104714,4,Autocuration,,3100,B,,,1,BAO_0000223,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,,,CHEMBL620393,
5105,H,,,,,104714,4,Autocuration,,3101,B,,,1,BAO_0000223,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,,,CHEMBL620394,
5104,H,,,,,104714,4,Autocuration,,3102,B,,,1,BAO_0000223,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,,,,CHEMBL620395,
3935,U,,,,,22226,0,Autocuration,,3103,B,,,1,BAO_0000019,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,,,,CHEMBL620396,
13657,H,,,NG108-15,,105030,4,Expert,,3104,B,,,1,BAO_0000219,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,433.0,,,,CHEMBL620582,
10369,H,,,,In vivo,105030,4,Autocuration,,3105,B,,,1,BAO_0000218,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,,,,CHEMBL620583,
10369,H,,,,,105030,4,Autocuration,,3106,B,,,1,BAO_0000019,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,,,CHEMBL620584,
12918,H,,,,,105030,4,Autocuration,,3107,B,,,1,BAO_0000224,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,,,,CHEMBL620585,
12918,H,,,,,105030,4,Autocuration,,3108,B,,,1,BAO_0000224,Compound was evaluated for the binding affinity at 5- HT3 receptor,,,,,CHEMBL620586,
10369,H,,,,,105030,4,Autocuration,,3109,B,,,1,BAO_0000019,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,,,CHEMBL620587,
773,H,,,,,105030,4,Autocuration,,3110,B,,,1,BAO_0000019,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,,,CHEMBL620588,
12918,H,,,,,105030,4,Autocuration,,3111,F,,,1,BAO_0000218,5-hydroxytryptamine 3 receptor agonism in mouse,,,,,CHEMBL620589,
10561,H,,,,,105030,4,Autocuration,,3112,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,,,,CHEMBL620590,
12827,H,,,,,105030,4,Autocuration,,3113,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,,,CHEMBL617956,
12827,H,,,,,105030,4,Autocuration,,3114,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,,,CHEMBL617957,
12918,H,,,,,105030,4,Autocuration,,3115,B,,,1,BAO_0000224,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,,,,CHEMBL617958,
273,H,,,,,105030,4,Autocuration,,3116,B,,,1,BAO_0000219,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,,,CHEMBL617959,
273,H,,,,,105030,4,Autocuration,,3117,B,,,1,BAO_0000219,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,,,CHEMBL617960,
10561,H,,,,,105030,4,Autocuration,,3118,B,,,1,BAO_0000224,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,,,CHEMBL617961,
5033,H,,,,In vitro,105030,4,Autocuration,,3119,B,,,1,BAO_0000219,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,,,,CHEMBL617962,
16429,H,,,N1E-115,,105030,4,Autocuration,,3120,B,,,1,BAO_0000219,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,339.0,,,,CHEMBL617963,
10322,H,,,,,11765,8,Autocuration,,3121,B,,,1,BAO_0000019,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,,,CHEMBL617964,
14331,H,,,,,11765,8,Autocuration,,3122,B,,,1,BAO_0000219,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,,,,CHEMBL617965,
13462,D,,,,,10630,9,Autocuration,,3123,B,,,1,BAO_0000357,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,,,Mus musculus,CHEMBL617966,10090.0
12861,H,,,,,17106,8,Autocuration,,3124,B,,,1,BAO_0000019,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,CHEMBL857074,
15086,H,,,,,144,8,Autocuration,,3125,B,,,1,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,,,Sus scrofa,CHEMBL617967,9823.0
12861,H,,,,,144,8,Autocuration,,3126,B,,,1,BAO_0000357,Binding activity radioligand.,,,,Sus scrofa,CHEMBL617968,9823.0
10561,H,,,,,104714,4,Autocuration,,3127,B,,,1,BAO_0000223,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,,,Oryctolagus cuniculus,CHEMBL617969,9986.0
10561,H,,,,,104714,4,Autocuration,,3128,B,,,1,BAO_0000223,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,,Oryctolagus cuniculus,CHEMBL617970,9986.0
10561,H,,,,,104714,4,Autocuration,,3129,B,,,1,BAO_0000223,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,,,Oryctolagus cuniculus,CHEMBL617971,9986.0
10561,H,,,,,104714,4,Autocuration,,3130,B,,,1,BAO_0000019,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,,Oryctolagus cuniculus,CHEMBL617972,9986.0
273,H,,,,,104714,4,Autocuration,,3131,F,,,1,BAO_0000019,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,,Oryctolagus cuniculus,CHEMBL617973,9986.0
273,H,,,,,104714,4,Autocuration,,3132,F,,,1,BAO_0000019,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,,Oryctolagus cuniculus,CHEMBL617974,9986.0
273,H,,,,,104714,4,Autocuration,,3133,F,Ileum,,1,BAO_0000221,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,,2116.0,Oryctolagus cuniculus,CHEMBL617975,9986.0
273,H,,,,,104714,4,Autocuration,,3134,F,,,1,BAO_0000019,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,,Oryctolagus cuniculus,CHEMBL617976,9986.0
273,H,,,,,104714,4,Autocuration,,3135,F,,,1,BAO_0000019,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,,Oryctolagus cuniculus,CHEMBL617977,9986.0
273,H,,,,,104714,4,Autocuration,,3136,F,,,1,BAO_0000019,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,,,Oryctolagus cuniculus,CHEMBL617978,9986.0
273,H,,,,,104714,4,Autocuration,,3137,F,,,1,BAO_0000019,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,,,Oryctolagus cuniculus,CHEMBL617979,9986.0
13047,H,,,CHO,,104714,4,Autocuration,,3138,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,449.0,,,Oryctolagus cuniculus,CHEMBL617980,9986.0
1650,D,,,,,104698,7,Autocuration,,3139,B,,,1,BAO_0000019,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,,,Rattus norvegicus,CHEMBL617981,10116.0
16288,H,,,,,12020,8,Autocuration,,3140,B,,,1,BAO_0000019,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,,,,CHEMBL617982,
16288,H,,,,,12020,8,Autocuration,,3141,B,,,1,BAO_0000357,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,,,,CHEMBL617983,
10254,D,,,,,104698,7,Autocuration,,3142,B,,,1,BAO_0000019,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,,,Rattus norvegicus,CHEMBL617984,10116.0
14532,H,,,,,104698,6,Autocuration,,3143,B,,,1,BAO_0000019,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,,,,CHEMBL617985,
13392,H,,,,In vivo,104698,6,Autocuration,,3144,F,Heart,,1,BAO_0000218,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,948.0,,CHEMBL617986,
13392,H,,,,,104698,6,Autocuration,,3145,F,Heart,,1,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,948.0,,CHEMBL617987,
13392,H,,,,,104698,6,Autocuration,,3146,F,Heart,,1,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,948.0,,CHEMBL617988,
13392,H,,,,,104698,6,Autocuration,,3147,F,Heart,,1,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,,948.0,,CHEMBL617792,
13392,H,,,,,104698,6,Autocuration,,3148,F,Heart,,1,BAO_0000019,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,948.0,,CHEMBL617793,
13392,H,,,,,104698,6,Autocuration,,3149,F,,,1,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,,,,CHEMBL617794,
13392,H,,,,,104698,6,Autocuration,,3150,F,,,1,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,,,CHEMBL617795,
13392,H,,,,,104698,6,Autocuration,,3151,F,,,1,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,,,CHEMBL617796,
13392,H,,,,,104698,6,Autocuration,,3152,F,,,1,BAO_0000019,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,,,,CHEMBL617797,
1089,D,,,,In vivo,104698,7,Autocuration,,3153,F,,,1,BAO_0000218,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,,,Rattus norvegicus,CHEMBL617798,10116.0
1089,H,,,,In vivo,104698,6,Autocuration,,3154,F,,,1,BAO_0000218,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,,,,CHEMBL617799,
11454,D,,,,In vivo,104698,7,Autocuration,,3155,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,,,Rattus norvegicus,CHEMBL617800,10116.0
11454,D,,,,,104698,7,Autocuration,,3156,F,,,1,BAO_0000019,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,,,Rattus norvegicus,CHEMBL617801,10116.0
12205,D,,,,In vivo,104698,7,Autocuration,,3157,F,,,1,BAO_0000218,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,,,Rattus norvegicus,CHEMBL617802,10116.0
1089,D,,,,,104698,7,Autocuration,,3158,F,,,1,BAO_0000019,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,,,Rattus norvegicus,CHEMBL617803,10116.0
5094,H,,,,,104698,6,Autocuration,,3159,B,,,1,BAO_0000019,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,,,CHEMBL617804,
2622,D,,,,,104698,7,Autocuration,,3160,B,,,1,BAO_0000019,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,,,Rattus norvegicus,CHEMBL617805,10116.0
245,H,,,,,104698,6,Autocuration,,3161,B,,,1,BAO_0000223,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,,,,CHEMBL617806,
14788,H,,,,,104698,6,Autocuration,,3162,B,,,1,BAO_0000019,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,,,,CHEMBL617807,
14788,H,,,,,104698,6,Autocuration,,3163,B,,,1,BAO_0000019,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,,,,CHEMBL617808,
3020,H,,,,,104698,6,Autocuration,,3164,B,,,1,BAO_0000249,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,,,,CHEMBL617809,
1742,H,,,,,104698,6,Autocuration,,3165,B,,,1,BAO_0000019,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,,,,CHEMBL617810,
17394,H,,,,,104698,6,Autocuration,,3166,B,Brain,,1,BAO_0000249,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,,955.0,,CHEMBL617811,
17394,H,,,,,104698,6,Autocuration,,3167,B,Brain,,1,BAO_0000221,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,,955.0,,CHEMBL617812,
17394,H,,,,,104698,6,Autocuration,,3168,B,,,1,BAO_0000249,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,,CHEMBL617813,
14286,H,,,,,104698,6,Autocuration,,3169,B,,,1,BAO_0000249,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,,CHEMBL617814,
14178,H,,,,,104698,6,Autocuration,,3170,B,,,1,BAO_0000019,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,,,,CHEMBL617698,
14178,D,,,,,104698,7,Autocuration,,3171,B,,,1,BAO_0000019,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,,,Rattus norvegicus,CHEMBL617699,10116.0
14178,D,,,,,104698,7,Autocuration,,3172,B,,,1,BAO_0000019,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,,,Rattus norvegicus,CHEMBL617700,10116.0
14178,D,,,,,104698,7,Autocuration,,3173,B,,,1,BAO_0000223,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,,,Rattus norvegicus,CHEMBL617701,10116.0
15034,H,,,,,104698,6,Autocuration,,3174,B,,,1,BAO_0000019,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,,,CHEMBL617702,
1089,H,,,,,104698,6,Autocuration,Membranes,3175,B,,,1,BAO_0000249,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,,,,CHEMBL617703,
1089,D,,,,,104698,7,Autocuration,,3176,B,,,1,BAO_0000019,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,,,Rattus norvegicus,CHEMBL617704,10116.0
16532,H,,,,,104698,6,Autocuration,,3177,B,,,1,BAO_0000223,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,,,CHEMBL617705,
12801,D,,,,,104698,7,Autocuration,,3178,B,,,1,BAO_0000223,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,,,Rattus norvegicus,CHEMBL617706,10116.0
15194,H,,,NG108-15,,104698,6,Autocuration,,3179,B,,,1,BAO_0000219,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),433.0,,,,CHEMBL617707,
15194,H,,,NG108-15,,104698,6,Autocuration,,3180,B,,,1,BAO_0000219,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,433.0,,,,CHEMBL617708,
15194,H,,,,,104698,6,Autocuration,,3181,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,,,,CHEMBL617709,
15194,H,,,,,104698,6,Autocuration,,3182,B,,,1,BAO_0000019,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,,,,CHEMBL617710,
15194,H,,,,,104698,6,Autocuration,,3183,B,,,1,BAO_0000019,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,,,,CHEMBL882925,
15194,H,,,,,104698,6,Autocuration,,3184,B,,,1,BAO_0000019,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,,,,CHEMBL617711,
10610,H,,,,,104698,6,Autocuration,,3185,F,,,1,BAO_0000019,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,,,,CHEMBL617712,
10355,D,,,,,104698,7,Autocuration,,3186,F,,,1,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,,,Rattus norvegicus,CHEMBL617713,10116.0
691,H,,,,,104698,6,Autocuration,,3187,F,,,1,BAO_0000019,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,,,,CHEMBL617714,
10611,H,,,,,104698,6,Autocuration,,3188,F,,,1,BAO_0000218,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,,,,CHEMBL617715,
12801,H,,,,In vivo,104698,6,Autocuration,,3189,F,,,1,BAO_0000218,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,,,,CHEMBL617716,
10609,H,,,,,104698,6,Autocuration,,3190,F,,,1,BAO_0000218,Inhibition of 5-HT evoked reflex bradycardia in rat.,,,,,CHEMBL617717,
11454,H,,,,In vivo,104698,6,Autocuration,,3191,F,,,1,BAO_0000218,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617718,
11454,H,,,,In vivo,104698,6,Autocuration,,3192,F,,,1,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617719,
11454,H,,,,In vivo,104698,6,Autocuration,,3193,F,,,1,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,,,,CHEMBL617720,
11454,D,,,,In vivo,104698,7,Autocuration,,3194,F,,,1,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,,,Rattus norvegicus,CHEMBL617721,10116.0
11454,H,,,,In vivo,104698,6,Autocuration,,3195,F,,,1,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617722,
11454,H,,,,In vivo,104698,6,Autocuration,,3196,F,,,1,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,,,,CHEMBL617723,
11454,H,,,,In vivo,104698,6,Autocuration,,3197,F,,,1,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617724,
11454,H,,,,In vivo,104698,6,Autocuration,,3198,F,,,1,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617725,
11454,H,,,,In vivo,104698,6,Autocuration,,3199,F,,,1,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617726,
11454,H,,,,In vivo,104698,6,Autocuration,,3200,F,,,1,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617727,
11454,H,,,,In vivo,104698,6,Autocuration,,3201,F,,,1,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617728,
11454,H,,,,In vivo,104698,6,Autocuration,,3202,F,,,1,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617729,
11454,H,,,,In vivo,104698,6,Autocuration,,3203,F,,,1,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617730,
11454,H,,,,In vivo,104698,6,Autocuration,,3204,F,,,1,BAO_0000218,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617731,
11454,H,,,,In vivo,104698,6,Autocuration,,3205,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617732,
11454,H,,,,In vivo,104698,6,Autocuration,,3206,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617733,
11454,H,,,,In vivo,104698,6,Autocuration,,3207,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617734,
11454,H,,,,In vivo,104698,6,Autocuration,,3208,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,,,,CHEMBL872874,
11454,H,,,,In vivo,104698,6,Autocuration,,3209,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,,,,CHEMBL617735,
11454,H,,,,In vivo,104698,6,Autocuration,,3210,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,,,,CHEMBL617736,
11454,H,,,,In vivo,104698,6,Autocuration,,3211,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,,,,CHEMBL617737,
11454,H,,,,In vivo,104698,6,Autocuration,,3212,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,,,,CHEMBL617738,
11454,H,,,,In vivo,104698,6,Autocuration,,3213,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617739,
11454,H,,,,In vivo,104698,6,Autocuration,,3214,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617740,
11454,H,,,,In vivo,104698,6,Autocuration,,3215,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617741,
11454,H,,,,In vivo,104698,6,Autocuration,,3216,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617742,
11454,H,,,,In vivo,104698,6,Autocuration,,3217,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617743,
11454,H,,,,In vivo,104698,6,Autocuration,,3218,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617744,
11454,H,,,,In vivo,104698,6,Autocuration,,3219,F,,,1,BAO_0000218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,,,,CHEMBL617745,
670,H,,,,,104698,6,Autocuration,,3220,F,,,1,BAO_0000218,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,,,,CHEMBL617746,
670,H,,,,,104698,6,Autocuration,,3221,F,,,1,BAO_0000218,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,,,,CHEMBL617747,
10321,H,,,,In vivo,104698,6,Autocuration,,3222,F,,,1,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,,,,CHEMBL617748,
10321,H,,,,In vivo,104698,6,Autocuration,,3223,F,,,1,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,,,,CHEMBL618909,
10321,H,,,,In vivo,104698,6,Autocuration,,3224,F,,,1,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,,,,CHEMBL618910,
10321,H,,,,In vivo,104698,6,Autocuration,,3225,F,,,1,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,,,,CHEMBL618911,
10321,H,,,,In vivo,104698,6,Autocuration,,3226,F,,,1,BAO_0000218,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,,,,CHEMBL618912,
10322,H,,,,In vivo,104698,6,Autocuration,,3227,F,,,1,BAO_0000218,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,,,,CHEMBL618913,
15412,H,,,,,104698,6,Autocuration,,3228,F,,,1,BAO_0000019,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,,,CHEMBL618914,
15412,H,,,,,104698,6,Autocuration,,3229,F,,,1,BAO_0000019,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,,,CHEMBL618915,
15412,D,,,,,104698,7,Autocuration,,3230,B,,,1,BAO_0000223,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,,,Rattus norvegicus,CHEMBL618916,10116.0
15412,H,,,,,104698,6,Autocuration,,3231,F,,,1,BAO_0000019,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,,,,CHEMBL618917,
15412,D,,,,,104698,7,Intermediate,,3232,B,Hippocampus,,1,BAO_0000221,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,,10000000.0,,CHEMBL618918,
15412,D,,,,,104698,7,Autocuration,,3233,B,,,1,BAO_0000019,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,,,Rattus norvegicus,CHEMBL618919,10116.0
17394,D,,,,,104698,7,Autocuration,,3234,B,,,1,BAO_0000019,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,,,Rattus norvegicus,CHEMBL618920,10116.0
12457,H,,,,,104698,6,Autocuration,,3235,B,,,1,BAO_0000223,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,,,,CHEMBL618921,
12457,H,,,,,104698,6,Autocuration,,3236,B,,,1,BAO_0000019,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,,,,CHEMBL618922,
12205,H,,,,,104698,6,Autocuration,,3237,B,,,1,BAO_0000019,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,,,,CHEMBL618923,
14532,H,,,,,104698,6,Autocuration,,3238,B,,,1,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,,,,CHEMBL618924,
1122,H,,,,,104698,6,Autocuration,,3239,B,,,1,BAO_0000019,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,,,,CHEMBL618925,
5094,H,,,,,104698,6,Autocuration,,3240,B,,,1,BAO_0000019,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,,,CHEMBL618926,
809,D,,,,,20033,9,Intermediate,,3241,F,Ileum,,1,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,,2116.0,Cavia porcellus,CHEMBL618927,10141.0
809,D,,,,,20033,9,Intermediate,,3242,F,Ileum,,1,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,,2116.0,Cavia porcellus,CHEMBL618928,10141.0
14290,D,,,,,20033,9,Intermediate,,3243,F,Ileum,,1,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,,2116.0,Cavia porcellus,CHEMBL618929,10141.0
14290,D,,,,,20033,9,Intermediate,,3244,F,Ileum,,1,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,,2116.0,Cavia porcellus,CHEMBL618930,10141.0
14290,D,,,,,20033,9,Intermediate,,3245,F,Ileum,,1,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,,2116.0,Cavia porcellus,CHEMBL618931,10141.0
14290,D,,,,,20033,9,Intermediate,,3246,F,Ileum,,1,BAO_0000221,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,,2116.0,Cavia porcellus,CHEMBL619594,10141.0
14290,D,,,,,20033,9,Intermediate,,3247,F,Ileum,,1,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,,2116.0,Cavia porcellus,CHEMBL619595,10141.0
13961,D,,,,,20033,9,Intermediate,,3248,F,Ileum,,1,BAO_0000221,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,,2116.0,Cavia porcellus,CHEMBL619596,10141.0
13961,D,,,,,20033,9,Intermediate,,3249,F,Ileum,,1,BAO_0000221,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,,2116.0,Cavia porcellus,CHEMBL619755,10141.0
809,D,,,,,20033,9,Intermediate,,3250,F,Ileum,,1,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,,2116.0,Cavia porcellus,CHEMBL619756,10141.0
809,D,,,,,20033,9,Intermediate,,3251,F,Ileum,,1,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,,2116.0,Cavia porcellus,CHEMBL619757,10141.0
809,D,,,,,20033,9,Intermediate,,3252,F,Ileum,,1,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,,2116.0,Cavia porcellus,CHEMBL619758,10141.0
14290,D,,,,,20033,9,Intermediate,,3253,F,Ileum,,1,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,,2116.0,Cavia porcellus,CHEMBL619759,10141.0
14290,D,,,,,20033,9,Intermediate,,3254,F,Ileum,,1,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,,2116.0,Cavia porcellus,CHEMBL619760,10141.0
14290,D,,,,,20033,9,Intermediate,,3255,F,Ileum,,1,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,,2116.0,Cavia porcellus,CHEMBL619761,10141.0
14290,D,,,,,20033,9,Intermediate,,3256,F,Ileum,,1,BAO_0000221,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,,2116.0,Cavia porcellus,CHEMBL619762,10141.0
14290,D,,,,,20033,9,Intermediate,,3257,F,Ileum,,1,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,,2116.0,Cavia porcellus,CHEMBL619763,10141.0
14290,D,,,,,20033,9,Intermediate,,3258,F,Ileum,,1,BAO_0000221,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,,2116.0,Cavia porcellus,CHEMBL617868,10141.0
15034,D,,,,,20033,9,Intermediate,,3259,B,,,1,BAO_0000357,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,,Cavia porcellus,CHEMBL617869,10141.0
5094,D,,,,,20033,9,Intermediate,,3260,B,Striatum,,1,BAO_0000249,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,,2435.0,Cavia porcellus,CHEMBL882926,10141.0
5094,D,,,,,20033,9,Intermediate,,3261,B,Striatum,,1,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,,2435.0,Cavia porcellus,CHEMBL617870,10141.0
5399,D,,,,,20033,9,Intermediate,,3262,B,Striatum,,1,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,,2435.0,Cavia porcellus,CHEMBL617871,10141.0
17394,D,,,,,20033,9,Intermediate,,3263,B,Striatum,,1,BAO_0000357,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,,2435.0,Cavia porcellus,CHEMBL617872,10141.0
17394,D,,,,,20033,9,Intermediate,,3264,B,Striatum,,1,BAO_0000357,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,,2435.0,Cavia porcellus,CHEMBL617873,10141.0
17394,D,,,,,20033,9,Intermediate,,3265,B,Striatum,,1,BAO_0000357,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,,2435.0,Cavia porcellus,CHEMBL617874,10141.0
13961,D,,,,,20033,9,Intermediate,,3266,F,Ileum,,1,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,,2116.0,Cavia porcellus,CHEMBL619067,10141.0
13961,D,,,,,20033,9,Intermediate,,3267,F,Ileum,,1,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,,2116.0,Cavia porcellus,CHEMBL619068,10141.0
13961,D,,,,,20033,9,Intermediate,,3268,F,Ileum,,1,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,,2116.0,Cavia porcellus,CHEMBL619069,10141.0
16946,D,,,,,20033,9,Intermediate,,3269,B,,,1,BAO_0000357,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,,,Cavia porcellus,CHEMBL619070,10141.0
16946,D,,,,,20033,9,Intermediate,,3270,B,,,1,BAO_0000357,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,,,Cavia porcellus,CHEMBL619071,10141.0
15034,D,,,,,20033,9,Intermediate,,3271,F,,,1,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 4 receptor,,,,Cavia porcellus,CHEMBL619072,10141.0
15034,D,,,,,20033,9,Intermediate,,3272,F,,,1,BAO_0000019,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,,,Cavia porcellus,CHEMBL619073,10141.0
12918,D,,,,,20033,9,Intermediate,,3273,F,,,1,BAO_0000019,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,,,Cavia porcellus,CHEMBL619074,10141.0
16946,D,,,,,20033,9,Intermediate,,3274,B,,,1,BAO_0000357,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,,,Cavia porcellus,CHEMBL619075,10141.0
17394,D,,,,,20033,9,Intermediate,,3275,B,Striatum,,1,BAO_0000357,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,,2435.0,Cavia porcellus,CHEMBL619076,10141.0
15034,D,,,,,20033,9,Intermediate,,3276,B,Striatum,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,,2435.0,Cavia porcellus,CHEMBL619077,10141.0
5094,D,,,,,20033,9,Intermediate,,3277,B,Striatum,,1,BAO_0000249,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,,2435.0,Cavia porcellus,CHEMBL619078,10141.0
5094,D,,,,,20033,9,Intermediate,,3278,B,Striatum,,1,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,,2435.0,Cavia porcellus,CHEMBL619079,10141.0
17358,D,,,,,20033,9,Intermediate,,3279,B,Ileum,,1,BAO_0000221,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,,2116.0,Cavia porcellus,CHEMBL619080,10141.0
12953,D,,,,,20033,9,Expert,,3280,B,,,1,BAO_0000357,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,,,Cavia porcellus,CHEMBL619081,10141.0
12953,D,,,,,20033,9,Intermediate,,3281,B,,,1,BAO_0000357,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,,Cavia porcellus,CHEMBL619082,10141.0
12953,D,,,,,20033,9,Intermediate,,3282,B,,,1,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,,,Cavia porcellus,CHEMBL619083,10141.0
12953,D,,,,,20033,9,Intermediate,,3283,B,,,1,BAO_0000357,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,,,Cavia porcellus,CHEMBL619084,10141.0
273,D,,,,,20033,9,Intermediate,,3284,F,Ileum,,1,BAO_0000221,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,,2116.0,Cavia porcellus,CHEMBL859397,10141.0
12918,D,,,,,20033,9,Intermediate,,3285,F,Ileum,,1,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,,2116.0,Cavia porcellus,CHEMBL619085,10141.0
12919,D,,,,,20033,9,Intermediate,,3286,F,Ileum,,1,BAO_0000221,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,,2116.0,Cavia porcellus,CHEMBL619086,10141.0
273,D,,,,,20033,9,Intermediate,,3287,F,Ileum,,1,BAO_0000221,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,,2116.0,Cavia porcellus,CHEMBL619087,10141.0
273,D,,,,,20033,9,Intermediate,,3288,F,Ileum,,1,BAO_0000221,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,,2116.0,Cavia porcellus,CHEMBL619088,10141.0
13181,D,,,,,20033,9,Intermediate,,3289,B,,,1,BAO_0000357,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,,,Cavia porcellus,CHEMBL619089,10141.0
13181,H,,,,,168,8,Autocuration,,3290,B,,,1,BAO_0000357,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,,,Cavia porcellus,CHEMBL619090,10141.0
15034,D,,,,,20033,9,Intermediate,,3291,F,,,1,BAO_0000019,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,,,Cavia porcellus,CHEMBL619091,10141.0
5033,D,,,,,20033,9,Intermediate,,3292,B,,,1,BAO_0000357,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,,,Cavia porcellus,CHEMBL619092,10141.0
1980,D,,,,,20033,9,Intermediate,,3293,B,,,1,BAO_0000019,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,,,Cavia porcellus,CHEMBL619093,10141.0
13181,H,,,HEK293,,168,8,Autocuration,,3294,B,,,1,BAO_0000219,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,722.0,,,Cavia porcellus,CHEMBL619094,10141.0
14287,D,,,,,20033,9,Intermediate,,3295,B,,,1,BAO_0000019,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,,,Cavia porcellus,CHEMBL619095,10141.0
1317,D,,,,,20033,9,Intermediate,,3296,B,,,1,BAO_0000357,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,,,Cavia porcellus,CHEMBL857988,10141.0
15316,D,,,,,20033,9,Intermediate,,3297,B,,,1,BAO_0000357,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,,,Cavia porcellus,CHEMBL619096,10141.0
16429,D,,,,,20033,9,Intermediate,,3298,B,Striatum,,1,BAO_0000357,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,,2435.0,Cavia porcellus,CHEMBL619097,10141.0
14818,D,,,,,20033,9,Intermediate,,3299,B,Hippocampus,,1,BAO_0000221,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,,10000000.0,Cavia porcellus,CHEMBL619098,10141.0
15194,D,,,,,20033,9,Intermediate,,3300,B,,,1,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,,,Cavia porcellus,CHEMBL619751,10141.0
15194,D,,,,,20033,9,Intermediate,,3301,B,,,1,BAO_0000357,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,,,Cavia porcellus,CHEMBL619752,10141.0
13961,D,,,,,20033,9,Intermediate,,3302,F,Ileum,,1,BAO_0000221,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,,2116.0,Cavia porcellus,CHEMBL875096,10141.0
5486,H,,,,,108,8,Autocuration,,3303,B,,,1,BAO_0000357,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,,,,CHEMBL619004,
16209,H,,,,,168,8,Autocuration,,3304,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,,,,CHEMBL619005,
17085,H,,,,,168,8,Autocuration,,3305,B,,,1,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,,,,CHEMBL619006,
4199,H,,,HeLa,,168,8,Autocuration,,3306,B,,,1,BAO_0000219,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,308.0,,,,CHEMBL619007,
15146,H,,,,,168,8,Autocuration,,3307,B,,,1,BAO_0000357,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,,,,CHEMBL619008,
5213,H,,,,,168,8,Autocuration,,3308,B,,,1,BAO_0000357,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,,,,CHEMBL619009,
4829,H,,,HeLa,,168,8,Autocuration,,3309,B,,,1,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",308.0,,,,CHEMBL619010,
17358,H,,,,,10622,8,Autocuration,,3310,B,,,1,BAO_0000357,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,,,,CHEMBL619011,
17358,H,,,,,10622,8,Autocuration,,3311,B,,,1,BAO_0000357,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,,,,CHEMBL619012,
16946,H,,,,,10622,8,Autocuration,,3312,B,,,1,BAO_0000219,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,,,,CHEMBL619013,
17358,H,,,,,10622,8,Autocuration,,3313,B,,,1,BAO_0000357,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,,,,CHEMBL619014,
268,H,,,,,11249,8,Autocuration,,3314,F,Cardiac atrium,,1,BAO_0000019,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,,2081.0,,CHEMBL857503,
268,H,,,,,11249,8,Autocuration,,3315,F,Cardiac atrium,,1,BAO_0000019,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,,2081.0,,CHEMBL619015,
15086,H,,,,,11249,8,Autocuration,,3316,B,,,1,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,,,,CHEMBL619016,
14875,H,,,,,11249,8,Autocuration,,3317,B,Hippocampus,,1,BAO_0000221,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,,10000000.0,,CHEMBL619017,
13267,H,,,,,168,8,Autocuration,,3318,B,Hippocampus,,1,BAO_0000221,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,,10000000.0,Sus scrofa,CHEMBL619018,9823.0
13047,H,,,,,168,8,Autocuration,,3319,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,,,Oryctolagus cuniculus,CHEMBL619019,9986.0
1650,D,,,,,10623,9,Expert,,3320,B,,,1,BAO_0000357,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,,,Rattus norvegicus,CHEMBL619020,10116.0
567,H,,,,,10623,8,Autocuration,,3321,F,,,1,BAO_0000019,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,,,CHEMBL619021,
17358,H,,,,,10623,8,Autocuration,,3322,B,,,1,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,,,,CHEMBL619022,
188,H,,,,,10623,8,Autocuration,,3323,B,,,1,BAO_0000357,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,,,,CHEMBL619023,
670,H,,,,,10623,8,Autocuration,,3324,F,,,1,BAO_0000019,lntrinsic activity relative to 5-HT receptor,,,,,CHEMBL619024,
204,H,,,,,10623,8,Autocuration,,3325,F,,,1,BAO_0000019,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,,,,CHEMBL619025,
1946,H,,,,,10623,8,Expert,,3326,F,,,1,BAO_0000019,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,,,,CHEMBL619026,
6398,H,,,,,10623,8,Autocuration,,3327,F,,,1,BAO_0000019,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,,,,CHEMBL619027,
6398,H,,,,,10623,8,Autocuration,,3328,F,,,1,BAO_0000019,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,,,,CHEMBL619028,
17358,H,,,,,10623,8,Autocuration,,3329,F,,,1,BAO_0000019,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,,,,CHEMBL619029,
6398,H,,,,,10623,8,Autocuration,,3330,F,,,1,BAO_0000019,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,,,,CHEMBL619030,
11752,H,,,,,10623,8,Expert,,3331,B,,,1,BAO_0000357,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,,,,CHEMBL619031,
809,H,,,,,10623,8,Autocuration,,3332,F,,,1,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,,,,CHEMBL619032,
14178,D,,,,,10623,9,Expert,,3333,B,,,1,BAO_0000357,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,,,Rattus norvegicus,CHEMBL619033,10116.0
567,H,,,,,10623,8,Autocuration,,3334,B,,,1,BAO_0000357,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,,,CHEMBL619034,
1946,H,,,,,10623,8,Autocuration,,3335,B,,,1,BAO_0000357,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,,,,CHEMBL619035,
1946,H,,,,,10623,8,Autocuration,,3336,B,,,1,BAO_0000357,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,,,,CHEMBL619036,
13961,D,,,,,10623,9,Expert,,3337,B,,,1,BAO_0000019,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,,,Rattus norvegicus,CHEMBL619037,10116.0
6238,H,,,,,10623,8,Autocuration,,3338,B,Striatum,,1,BAO_0000249,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,,2435.0,,CHEMBL619038,
14290,H,,,,,10623,8,Autocuration,,3339,B,,,1,BAO_0000249,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,,,,CHEMBL619039,
14290,H,,,,,10623,8,Expert,,3340,B,,,1,BAO_0000249,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,,,,CHEMBL619040,
809,D,,,,,10623,9,Expert,,3341,B,Striatum,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,2435.0,Rattus norvegicus,CHEMBL619041,10116.0
1578,H,,,,,10623,8,Autocuration,,3342,B,Striatum,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,2435.0,,CHEMBL619042,
16709,H,,,,,10623,8,Expert,,3343,B,Striatum,,1,BAO_0000249,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,,2435.0,,CHEMBL619043,
1946,H,,,,,10623,8,Expert,,3344,B,Striatum,,1,BAO_0000019,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,,2435.0,,CHEMBL619044,
15253,H,,,,,10623,8,Expert,,3345,B,Striatum,,1,BAO_0000249,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,,2435.0,,CHEMBL619045,
4535,H,,,,,10623,8,Expert,,3346,B,Striatum,,1,BAO_0000249,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,2435.0,,CHEMBL619046,
13961,H,,,,,10623,8,Expert,,3347,B,,,1,BAO_0000249,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,,,,CHEMBL619047,
17358,H,,,,,10623,8,Autocuration,,3348,F,Brain,,1,BAO_0000221,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,,955.0,,CHEMBL619048,
15847,H,,,,,10623,8,Autocuration,,3349,F,,,1,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,,,,CHEMBL859398,
15847,H,,,,,10623,8,Autocuration,,3350,F,,,1,BAO_0000019,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,,,,CHEMBL619049,
670,H,,,,,10623,8,Autocuration,,3351,F,,,1,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,,,,CHEMBL857886,
670,H,,,,,10623,8,Autocuration,,3352,F,,,1,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,,,,CHEMBL619050,
1317,H,,,,,10623,8,Autocuration,,3353,F,,,1,BAO_0000019,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,,,CHEMBL620591,
12936,D,,,,,10623,9,Expert,,3354,B,,,1,BAO_0000357,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,,,Rattus norvegicus,CHEMBL620592,10116.0
4535,H,,,,,10623,8,Expert,,3355,B,Striatum,,1,BAO_0000249,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,2435.0,,CHEMBL620593,
14424,D,,,,,10623,9,Expert,,3356,F,,,1,BAO_0000019,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,,,Rattus norvegicus,CHEMBL620594,10116.0
14424,H,,,,,10623,8,Expert,,3357,F,,,1,BAO_0000019,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,,,,CHEMBL875079,
14424,H,,,,,10623,8,Expert,,3358,F,,,1,BAO_0000019,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,,,CHEMBL620595,
14424,D,,,,,10623,9,Expert,,3359,F,,,1,BAO_0000019,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,,,Rattus norvegicus,CHEMBL620596,10116.0
14424,H,,,,,10623,8,Autocuration,,3360,F,,,1,BAO_0000019,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,,,,CHEMBL620597,
14424,H,,,,,10623,8,Expert,,3361,F,,,1,BAO_0000019,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,,,,CHEMBL620598,
14424,H,,,,,10623,8,Expert,,3362,F,,,1,BAO_0000218,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,,,,CHEMBL620599,
14424,H,,,,,10623,8,Autocuration,,3363,F,,,1,BAO_0000019,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,,,CHEMBL620600,
1980,H,,,,,168,8,Autocuration,,3364,F,,,1,BAO_0000019,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,,,Rattus norvegicus,CHEMBL620601,10116.0
4639,H,,,,,168,8,Autocuration,,3365,F,,,1,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,,,,CHEMBL620602,
17358,H,,,,,168,8,Autocuration,,3366,B,,,1,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,,,,CHEMBL620603,
17358,H,,,,,168,8,Autocuration,,3367,B,,,1,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,,,,CHEMBL620604,
17358,H,,,,,168,8,Autocuration,,3368,B,,,1,BAO_0000357,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,,,,CHEMBL620605,
1558,H,,,,,168,8,Autocuration,,3369,B,,,1,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,,,,CHEMBL620606,
17358,H,,,,,168,8,Autocuration,,3370,F,,,1,BAO_0000019,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,,CHEMBL620607,
16117,H,,,,,168,8,Autocuration,,3371,B,,,1,BAO_0000357,In vitro binding affinity towards 5-HT4 receptor was determined,,,,,CHEMBL620608,
17358,H,,,,,168,8,Autocuration,,3372,F,,,1,BAO_0000019,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,,CHEMBL620609,
17358,H,,,,,168,8,Autocuration,,3373,F,,,1,BAO_0000019,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,,,,CHEMBL620610,
17358,H,,,,,168,8,Autocuration,,3374,B,,,1,BAO_0000357,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,,,,CHEMBL620611,
17358,H,,,,,168,8,Autocuration,,3375,B,,,1,BAO_0000357,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,,,,CHEMBL620612,
17358,H,,,,,168,8,Autocuration,,3376,B,,,1,BAO_0000357,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,,,,CHEMBL620613,
17358,H,,,,,168,8,Autocuration,,3377,B,,,1,BAO_0000357,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,,,,CHEMBL620614,
1274,H,,,,,168,8,Expert,,3378,B,,,1,BAO_0000357,Binding affinity against 5-Hydroxytryptamine 4 receptor,,,,,CHEMBL620615,
10728,H,,,,,104698,6,Autocuration,Brain membranes,3379,B,,,1,BAO_0000249,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,,,,CHEMBL857075,
11695,H,,,,,104698,6,Autocuration,Brain membranes,3380,B,,,1,BAO_0000249,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,,,,CHEMBL620616,
11695,H,,,,,104698,6,Autocuration,Brain membranes,3381,B,,,1,BAO_0000249,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,,,,CHEMBL619411,
12490,H,,,,,104698,6,Autocuration,,3382,B,,,1,BAO_0000019,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,,,,CHEMBL619412,
11828,D,,,,,104698,7,Autocuration,,3383,B,,,1,BAO_0000019,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,,,Rattus norvegicus,CHEMBL619413,10116.0
12253,H,,,,,104698,6,Autocuration,,3384,B,Hippocampus,,1,BAO_0000221,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,,10000000.0,,CHEMBL619414,
10561,H,,,,,104698,6,Autocuration,,3385,B,,,1,BAO_0000019,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,,,CHEMBL619415,
10561,H,,,,,104698,6,Autocuration,,3386,B,,,1,BAO_0000019,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,,,,CHEMBL619416,
14432,H,,,,,104698,6,Autocuration,,3387,F,,,1,BAO_0000019,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,,,,CHEMBL619417,
12936,D,,,,,104698,7,Autocuration,,3388,B,,,1,BAO_0000223,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,,,Rattus norvegicus,CHEMBL619418,10116.0
1274,D,,,,,104698,7,Autocuration,,3389,B,,,1,BAO_0000223,Binding affinity against 5-Hydroxytryptamine 3 receptor,,,,Rattus norvegicus,CHEMBL619419,10116.0
1980,H,,,,,104698,6,Autocuration,,3390,B,,,1,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,,,,CHEMBL619420,
670,H,,,,,104698,6,Autocuration,,3391,B,,,1,BAO_0000249,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,,,,CHEMBL619421,
968,D,,,,,104698,7,Autocuration,,3392,B,,,1,BAO_0000019,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,,,Rattus norvegicus,CHEMBL619422,10116.0
14287,H,,,,,104698,6,Autocuration,,3393,B,,,1,BAO_0000019,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,,,,CHEMBL619423,
567,H,,,,,104698,6,Autocuration,,3394,B,,,1,BAO_0000019,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,,,,CHEMBL875080,
13267,H,,,,,104698,6,Autocuration,,3395,B,,,1,BAO_0000019,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,,,,CHEMBL619424,
14826,H,,,,,104698,6,Autocuration,,3396,B,,,1,BAO_0000249,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,,,,CHEMBL619425,
15194,H,,,,,104698,6,Autocuration,,3397,B,,,1,BAO_0000223,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,,,,CHEMBL619426,
15194,H,,,,,104698,6,Autocuration,,3398,B,,,1,BAO_0000223,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,,,,CHEMBL619427,
10394,D,,,,,104698,7,Autocuration,,3399,B,,,1,BAO_0000223,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,,,Rattus norvegicus,CHEMBL619645,10116.0
13657,D,,,,,10576,9,Expert,,3400,B,,,1,BAO_0000249,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,,,,CHEMBL619646,
1879,H,,,,,12020,8,Autocuration,,3401,F,Brain,,1,BAO_0000221,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,,955.0,,CHEMBL619647,
1879,H,,,,,12020,8,Autocuration,,3402,F,,,1,BAO_0000019,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,,,,CHEMBL619648,
1879,H,,,,,12020,8,Autocuration,,3403,F,,,1,BAO_0000019,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,,,,CHEMBL619165,
204,H,,,,In vivo,12020,8,Autocuration,,3404,F,,,1,BAO_0000218,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,,,,CHEMBL620719,
1879,H,,,,,12020,8,Autocuration,,3405,B,,,1,BAO_0000019,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,,,CHEMBL872924,
1879,H,,,,,12020,8,Autocuration,,3406,B,,,1,BAO_0000357,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,CHEMBL620720,
1879,H,,,,,12020,8,Autocuration,,3407,B,,,1,BAO_0000019,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,,,CHEMBL620721,
1879,H,,,,,12020,8,Autocuration,,3408,B,,,1,BAO_0000019,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,,,,CHEMBL620722,
10641,H,,,,,104698,6,Autocuration,,3409,B,,,1,BAO_0000019,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,,,,CHEMBL620723,
773,H,,,,,12020,8,Autocuration,,3410,B,,,1,BAO_0000019,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,,,CHEMBL620724,
11952,H,,,,,104698,6,Autocuration,,3411,B,,,1,BAO_0000249,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,,,,CHEMBL620725,
14145,D,,,,,12020,9,Autocuration,,3412,F,,,1,BAO_0000019,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,,,Rattus norvegicus,CHEMBL620726,10116.0
17066,H,,,,,144,8,Expert,,3413,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,CHEMBL620727,
6398,H,,,,,104714,4,Autocuration,,3414,B,,,1,BAO_0000223,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,,,,CHEMBL620728,
10321,U,,,,,22226,0,Autocuration,,3415,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,,,CHEMBL620729,
511,H,,,,,104714,4,Autocuration,,3416,F,,,1,BAO_0000019,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,,,,CHEMBL858288,
4639,H,,,,,104714,4,Autocuration,,3417,B,,,1,BAO_0000223,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,CHEMBL620730,
4639,H,,,,,104714,4,Autocuration,,3418,B,,,1,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,CHEMBL620731,
4639,H,,,,,104714,4,Autocuration,,3419,F,,,1,BAO_0000019,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,,,Cavia porcellus,CHEMBL620732,10141.0
4639,H,,,,,104714,4,Autocuration,,3420,F,,,1,BAO_0000019,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,,Cavia porcellus,CHEMBL618042,10141.0
4639,H,,,,,104714,4,Autocuration,,3421,F,,,1,BAO_0000019,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,,,Cavia porcellus,CHEMBL618043,10141.0
1558,H,,,,,104714,4,Autocuration,,3422,B,,,1,BAO_0000223,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,,,CHEMBL618044,
268,H,,,,,104714,4,Autocuration,,3423,F,,,1,BAO_0000019,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,,,,CHEMBL618045,
2474,H,,,,,104714,4,Autocuration,,3424,B,,,1,BAO_0000223,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,,,,CHEMBL618046,
5067,H,,,,,104714,4,Autocuration,,3425,F,,,1,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,,,,CHEMBL618047,
5067,H,,,,,104714,4,Autocuration,,3426,F,,,1,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,,,,CHEMBL875084,
5067,H,,,,,104714,4,Autocuration,,3427,F,,,1,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,,,,CHEMBL618048,
5067,H,,,,,104714,4,Autocuration,,3428,B,,,1,BAO_0000223,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,,,,CHEMBL618049,
5067,H,,,,,104714,4,Autocuration,,3429,F,,,1,BAO_0000019,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,,,,CHEMBL619764,
5067,H,,,,,104714,4,Autocuration,,3430,F,,,1,BAO_0000019,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,,,,CHEMBL619765,
5067,H,,,,,104714,4,Autocuration,,3431,F,,,1,BAO_0000019,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,,,,CHEMBL619766,
5067,H,,,,,104714,4,Autocuration,,3432,B,,,1,BAO_0000223,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,,,,CHEMBL619767,
5067,H,,,,,104714,4,Autocuration,,3433,B,,,1,BAO_0000223,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,,,,CHEMBL619768,
5067,H,,,,,104714,4,Autocuration,,3434,F,,,1,BAO_0000019,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,,,,CHEMBL619769,
5067,H,,,,,104714,4,Autocuration,,3435,B,,,1,BAO_0000223,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,,,,CHEMBL619770,
5067,H,,,,,104714,4,Autocuration,,3436,B,,,1,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,CHEMBL619771,
14331,H,,,,,104714,4,Autocuration,,3437,B,,,1,BAO_0000219,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,,,,CHEMBL619772,
5067,H,,,,,104714,4,Autocuration,,3438,B,,,1,BAO_0000223,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,,,,CHEMBL619773,
6179,H,,,NG108-15,,104714,4,Autocuration,,3439,B,,,1,BAO_0000219,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,433.0,,,,CHEMBL619774,
4265,H,,,,,104714,4,Autocuration,,3440,B,,,1,BAO_0000019,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,,,,CHEMBL875083,
4265,H,,,NG108-15,,104714,4,Autocuration,,3441,B,,,1,BAO_0000219,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,433.0,,,,CHEMBL620718,
17358,H,,,,,104714,4,Autocuration,,3442,B,,,1,BAO_0000223,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,,,CHEMBL618127,
17358,H,,,,,104714,4,Autocuration,,3443,B,,,1,BAO_0000223,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,,,,CHEMBL618128,
13628,H,,,,In vitro,104714,4,Autocuration,,3444,B,,,1,BAO_0000219,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,,,,CHEMBL618129,
4612,H,,,,,104714,4,Autocuration,,3445,B,,,1,BAO_0000223,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,,,CHEMBL618130,
17358,H,,,,,104714,4,Autocuration,,3446,F,,,1,BAO_0000019,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,,,,CHEMBL618131,
4639,H,,,,,104714,4,Autocuration,,3447,F,,,1,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,,,Cavia porcellus,CHEMBL618132,10141.0
4639,H,,,,,104714,4,Autocuration,,3448,F,,,1,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,,,Cavia porcellus,CHEMBL618133,10141.0
4639,H,,,,,104714,4,Autocuration,,3449,F,,,1,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,,,Cavia porcellus,CHEMBL618134,10141.0
4639,H,,,,,104714,4,Autocuration,,3450,F,,,1,BAO_0000019,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,,,Cavia porcellus,CHEMBL618135,10141.0
511,H,,,,,104714,4,Autocuration,,3451,B,,,1,BAO_0000223,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,,,,CHEMBL618136,
1479,H,,,,,104714,4,Autocuration,,3452,B,,,1,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,CHEMBL618137,
1317,H,,,,,104714,4,Autocuration,,3453,B,,,1,BAO_0000223,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,,,,CHEMBL618138,
12146,H,,,,,104714,4,Autocuration,,3454,B,,,1,BAO_0000223,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,,,,CHEMBL618139,
12146,H,,,,,104714,4,Autocuration,,3455,B,,,1,BAO_0000223,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,,,,CHEMBL618140,
13969,H,,,,,104714,4,Autocuration,,3456,B,,,1,BAO_0000223,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,,,,CHEMBL618141,
13392,H,,,,,108,8,Expert,,3457,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 2C receptor,,,,,CHEMBL873478,
13392,H,,,,,104698,6,Autocuration,,3458,B,,,1,BAO_0000223,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,CHEMBL618142,
14159,H,,,,,144,8,Autocuration,,3459,B,,,1,BAO_0000357,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,,,,CHEMBL618143,
1558,H,,,,,144,8,Autocuration,,3460,B,,,1,BAO_0000357,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,,,CHEMBL618144,
16655,H,,,,,144,8,Autocuration,,3461,B,,,1,BAO_0000357,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,,,CHEMBL618145,
13020,H,,,,,104714,4,Autocuration,,3462,B,,,1,BAO_0000223,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,,,CHEMBL618146,
13021,H,,,,,104714,4,Autocuration,,3463,B,,,1,BAO_0000223,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,,,,CHEMBL618147,
13020,H,,,,,104714,4,Autocuration,,3464,B,,,1,BAO_0000223,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,,,CHEMBL618148,
10321,H,,,,,144,8,Autocuration,,3465,B,,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,,,CHEMBL618149,
15818,H,,,,,144,8,Autocuration,,3466,B,,,1,BAO_0000357,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,CHEMBL872927,
15818,H,,,,,144,8,Autocuration,,3467,B,,,1,BAO_0000357,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,CHEMBL618150,
17358,H,,,,,144,8,Autocuration,,3468,B,,,1,BAO_0000357,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,,,CHEMBL618151,
2222,H,,,,,144,8,Autocuration,,3469,B,,,1,BAO_0000357,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,,,CHEMBL875094,
10322,H,,,,,144,8,Autocuration,,3470,B,,,1,BAO_0000019,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,,,CHEMBL618152,
16117,H,,,,,144,8,Autocuration,,3471,B,,,1,BAO_0000357,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,,,CHEMBL618153,
17200,H,,,,,144,8,Autocuration,,3472,B,,,1,BAO_0000357,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,,,,CHEMBL618888,
17358,H,,,,,144,8,Autocuration,,3473,F,,,1,BAO_0000019,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,,,,CHEMBL618889,
16700,H,,,,,144,8,Autocuration,,3474,B,,,1,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,,,,CHEMBL618890,
1980,H,,,,,144,8,Autocuration,,3475,B,,,1,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,,,,CHEMBL618891,
1980,H,,,,,144,8,Autocuration,,3476,B,,,1,BAO_0000019,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,,,,CHEMBL619054,
12409,H,,,,,104714,4,Autocuration,,3477,B,,,1,BAO_0000223,Binding affinity against the 5-hydroxytryptamine 3 receptor,,,,,CHEMBL619055,
4365,H,,,,,144,8,Autocuration,,3478,B,,,1,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,,,CHEMBL619056,
4365,H,,,,,144,8,Autocuration,,3479,F,,,1,BAO_0000019,Percent efficacy against 5-hydroxytryptamine 3A receptor,,,,,CHEMBL619057,
4365,H,,,,,144,8,Autocuration,,3480,B,,,1,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,,,CHEMBL619058,
6769,D,,,Oocytes,,12020,9,Expert,,3481,F,,,1,BAO_0000219,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,,,Rattus norvegicus,CHEMBL619059,10116.0
6769,D,,,Oocytes,,12020,9,Expert,,3482,F,,,1,BAO_0000219,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,,,Rattus norvegicus,CHEMBL619060,10116.0
6769,D,,,Oocytes,,12020,9,Expert,,3483,F,,,1,BAO_0000219,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,,,Rattus norvegicus,CHEMBL875095,10116.0
809,D,,,,,20033,9,Intermediate,,3484,F,Ileum,,1,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,,2116.0,Cavia porcellus,CHEMBL619061,10141.0
809,D,,,,,20033,9,Intermediate,,3485,F,Ileum,,1,BAO_0000221,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,,2116.0,Cavia porcellus,CHEMBL619062,10141.0
14290,D,,,,,20033,9,Intermediate,,3486,F,,,1,BAO_0000019,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,,,Cavia porcellus,CHEMBL619063,10141.0
17358,D,,,,,20033,9,Intermediate,,3487,B,Ileum,,1,BAO_0000221,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,,2116.0,Cavia porcellus,CHEMBL619064,10141.0
17358,D,,,,,20033,9,Intermediate,,3488,B,,,1,BAO_0000357,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,,,Cavia porcellus,CHEMBL619065,10141.0
17358,D,,,,,20033,9,Intermediate,,3489,B,Ileum,,1,BAO_0000221,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,,2116.0,Cavia porcellus,CHEMBL619066,10141.0
17386,H,,,,,10209,8,Autocuration,,3490,B,Ileum,,1,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,2116.0,,CHEMBL619775,
3269,H,,,,,10209,8,Autocuration,,3491,B,,,1,BAO_0000357,Affinity against 5-hydroxytryptamine 7 receptor,,,,,CHEMBL619776,
7721,H,,,,,104841,4,Autocuration,,3492,B,,,1,BAO_0000224,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,,Cavia porcellus,CHEMBL619777,10141.0
7721,H,,,,,104841,4,Autocuration,,3493,B,,,1,BAO_0000224,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,,,Cavia porcellus,CHEMBL619778,10141.0
9117,H,,,,,104841,4,Autocuration,,3494,B,Ileum,,1,BAO_0000221,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,,2116.0,Cavia porcellus,CHEMBL619779,10141.0
7721,H,,,,,104841,4,Autocuration,,3495,B,,,1,BAO_0000224,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,,Cavia porcellus,CHEMBL619780,10141.0
7721,H,,,,,104841,4,Autocuration,,3496,B,,,1,BAO_0000224,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,,,Cavia porcellus,CHEMBL619166,10141.0
15796,H,,,,,104841,4,Autocuration,,3497,F,,,1,BAO_0000019,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,,Cavia porcellus,CHEMBL619167,10141.0
15796,H,,,,,104841,4,Autocuration,,3498,F,,,1,BAO_0000019,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,,,Cavia porcellus,CHEMBL619168,10141.0
15650,D,,,,,168,9,Expert,,3499,B,Cardiac atrium,,1,BAO_0000219,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,,2081.0,Homo sapiens,CHEMBL619169,9606.0
15650,D,,,,,168,9,Expert,,3500,B,Cardiac atrium,,1,BAO_0000219,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,,2081.0,Homo sapiens,CHEMBL619170,9606.0
6866,D,,,,,104841,5,Autocuration,,3501,F,,,1,BAO_0000019,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,,,Homo sapiens,CHEMBL619171,9606.0
15650,D,,,,,168,9,Expert,,3502,F,Cardiac atrium,,1,BAO_0000219,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,,2081.0,Homo sapiens,CHEMBL619172,9606.0
10063,U,,,,,22226,0,Autocuration,,3503,B,,,1,BAO_0000019,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,,,Mus musculus,CHEMBL619173,10090.0
12665,U,,,,,22226,0,Autocuration,,3504,B,,,1,BAO_0000019,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,,,Mus musculus,CHEMBL619174,10090.0
7504,H,,,,,104705,4,Autocuration,,3505,B,,,1,BAO_0000019,5-hydroxytryptamine receptor binding affinity was determined in rats,,,,,CHEMBL619175,
7504,H,,,,,104705,4,Autocuration,,3506,B,,,1,BAO_0000224,Binding affinity at rat 5-hydroxytryptamine receptor.,,,,,CHEMBL619176,
7038,H,,,,,104705,4,Autocuration,,3507,B,,,1,BAO_0000019,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,,,,CHEMBL619177,
7626,H,,,,,104705,4,Autocuration,,3508,B,,,1,BAO_0000224,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,,,,CHEMBL619178,
7626,H,,,,,104705,4,Autocuration,,3509,B,,,1,BAO_0000224,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,,,,CHEMBL619179,
7185,H,,,,,104705,4,Autocuration,,3510,F,Stomach,,1,BAO_0000019,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,,945.0,,CHEMBL619180,
7185,H,,,,,104705,4,Autocuration,,3511,F,Stomach,,1,BAO_0000019,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,,945.0,,CHEMBL619181,
7185,H,,,,,104705,4,Autocuration,,3512,F,,,1,BAO_0000019,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,,,CHEMBL619182,
6960,H,,,,,104705,4,Autocuration,,3513,B,,,1,BAO_0000224,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,,,,CHEMBL619183,
6960,H,,,,,104705,4,Autocuration,,3514,B,,,1,BAO_0000224,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,,,,CHEMBL619184,
12416,H,,,,,10576,8,Autocuration,,3515,B,Hippocampus,,1,BAO_0000221,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,10000000.0,,CHEMBL619185,
15753,H,,,,,12198,8,Expert,,3516,B,,,1,BAO_0000357,Binding affinity for rat 5-hydroxytryptamine transporter.,,,,,CHEMBL619186,
8062,H,,,,,104705,4,Autocuration,,3517,B,,,1,BAO_0000019,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,,,,CHEMBL619187,
9036,D,,,,,104705,5,Autocuration,,3518,B,,,1,BAO_0000019,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,,,Rattus norvegicus,CHEMBL619188,10116.0
15067,D,,,,,104705,5,Autocuration,,3519,B,,,1,BAO_0000224,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,,,Rattus norvegicus,CHEMBL619189,10116.0
15753,D,,,,,12198,9,Expert,,3520,F,Brain,,1,BAO_0000019,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,,955.0,Rattus norvegicus,CHEMBL619190,10116.0
15753,D,,,,,12198,9,Expert,,3521,F,Cerebellum,,1,BAO_0000221,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,,2037.0,Rattus norvegicus,CHEMBL619191,10116.0
15295,D,,,,,104705,5,Autocuration,,3522,B,,,1,BAO_0000019,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,,,Rattus norvegicus,CHEMBL619192,10116.0
6347,D,,,,,104705,5,Autocuration,,3523,B,,,1,BAO_0000224,Percent binding affinity against 5-hydroxytryptamine receptor,,,,Rattus norvegicus,CHEMBL619193,10116.0
6763,U,,,,,22226,0,Autocuration,,3524,B,,,1,BAO_0000019,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,,,,CHEMBL619194,
12092,D,,,,,104705,5,Autocuration,,3525,B,,,1,BAO_0000224,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,,,Rattus norvegicus,CHEMBL619195,10116.0
1579,D,,,,,104705,5,Autocuration,,3526,B,,,1,BAO_0000224,Affinity against 5-hydroxytryptamine receptor was determined,,,,Rattus norvegicus,CHEMBL619196,10116.0
1579,D,,,,,104705,5,Autocuration,,3527,B,Stomach,,1,BAO_0000019,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,,945.0,Rattus norvegicus,CHEMBL619197,10116.0
5963,D,,,,In vitro,121,9,Expert,,3528,B,,,1,BAO_0000219,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,,,Homo sapiens,CHEMBL619198,9606.0
5963,D,,,,In vitro,121,9,Expert,,3529,B,,,1,BAO_0000219,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,,,Homo sapiens,CHEMBL875081,9606.0
5030,H,,,,,18065,8,Autocuration,,3530,B,,,1,BAO_0000357,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,,,,CHEMBL884712,
15796,H,,,,,121,8,Expert,,3531,B,,,1,BAO_0000357,Inhibition of 5-hydroxytryptamine reuptake,,,,,CHEMBL884710,
15413,H,,,,,18065,8,Autocuration,,3532,F,,,1,BAO_0000019,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,,,,CHEMBL619199,
15413,H,,,,,18065,8,Autocuration,,3533,F,,,1,BAO_0000019,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,,,,CHEMBL619200,
15413,H,,,,,18065,8,Autocuration,,3534,F,,,1,BAO_0000019,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,,,,CHEMBL619201,
12409,H,,,,,18065,8,Autocuration,,3535,F,,,1,BAO_0000019,Tested for 5-hydroxytryptamine receptor uptake,,,,,CHEMBL619202,
16909,D,,,CHO,,51,9,Expert,,3536,B,,,1,BAO_0000219,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,449.0,,,Homo sapiens,CHEMBL619203,9606.0
16909,D,,,,,51,9,Expert,,3537,F,,,1,BAO_0000019,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,,,Homo sapiens,CHEMBL619204,9606.0
15629,H,,,,,10576,8,Autocuration,,3538,B,,,1,BAO_0000249,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,,,Homo sapiens,CHEMBL619205,9606.0
15629,H,,,,,10576,8,Autocuration,,3539,B,,,1,BAO_0000357,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,,,,CHEMBL619206,
15629,H,,,,,10576,8,Expert,,3540,B,,,1,BAO_0000249,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,,,,CHEMBL619207,
10034,H,,,,,10825,8,Autocuration,,3541,F,Striatum,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,,2435.0,,CHEMBL619208,
10034,H,,,,,10825,8,Autocuration,,3542,F,Striatum,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,,2435.0,,CHEMBL619209,
10034,H,,,,,10825,8,Autocuration,,3543,F,Striatum,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,,2435.0,,CHEMBL619210,
10034,H,,,,,10825,8,Autocuration,,3544,F,Striatum,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,,2435.0,,CHEMBL619211,
10034,H,,,,,10825,8,Autocuration,,3545,F,Striatum,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,,2435.0,,CHEMBL619212,
10034,H,,,,,10825,8,Autocuration,,3546,F,Striatum,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,,2435.0,,CHEMBL620681,
10034,H,,,,,10825,8,Autocuration,,3547,F,Striatum,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,,2435.0,,CHEMBL620682,
10034,H,,,,,10825,8,Autocuration,,3548,F,Striatum,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,,2435.0,,CHEMBL620683,
10034,H,,,,,10825,8,Autocuration,,3549,F,Striatum,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,,2435.0,,CHEMBL620684,
10034,H,,,,,10825,8,Autocuration,,3550,F,Striatum,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,,2435.0,,CHEMBL620685,
10034,H,,,,,10825,8,Autocuration,,3551,F,Striatum,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,,2435.0,,CHEMBL620686,
10034,H,,,,,10825,8,Autocuration,,3552,F,Limbic system,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,,349.0,,CHEMBL620687,
10034,H,,,,,10825,8,Autocuration,,3553,F,Limbic system,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,349.0,,CHEMBL620688,
10034,H,,,,,10825,8,Autocuration,,3554,F,Limbic system,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,,349.0,,CHEMBL620689,
10034,H,,,,,10825,8,Autocuration,,3555,F,Limbic system,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,,349.0,,CHEMBL620690,
10034,H,,,,,10825,8,Autocuration,,3556,F,Limbic system,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,,349.0,,CHEMBL620691,
10034,H,,,,,10825,8,Autocuration,,3557,F,Limbic system,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,,349.0,,CHEMBL620692,
10034,H,,,,,10825,8,Autocuration,,3558,F,Limbic system,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,,349.0,,CHEMBL620693,
1274,H,,,,,168,8,Expert,,3559,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 4 receptor,,,,,CHEMBL620694,
17358,H,,,,,168,8,Autocuration,,3560,F,,,1,BAO_0000019,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,,CHEMBL857986,
14532,H,,,,,168,8,Autocuration,,3561,B,,,1,BAO_0000357,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,,,,CHEMBL620695,
16989,H,,,,,168,8,Expert,,3562,B,,,1,BAO_0000357,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,,,,CHEMBL620696,
17200,H,,,,,168,8,Autocuration,,3563,B,,,1,BAO_0000357,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,,,,CHEMBL620697,
15779,H,,,,,168,8,Autocuration,,3564,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 4 receptor,,,,,CHEMBL620698,
15779,H,,,,,168,8,Autocuration,,3565,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,,,CHEMBL620699,
15779,H,,,,,168,8,Autocuration,,3566,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,,,CHEMBL620700,
15650,H,,,COS-7,,168,8,Autocuration,,3567,B,,,1,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,643.0,,,,CHEMBL620701,
15650,H,,,COS-7,,168,8,Autocuration,,3568,B,,,1,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,643.0,,,,CHEMBL875082,
15650,H,,,COS-7,,168,8,Autocuration,,3569,B,,,1,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,643.0,,,,CHEMBL620702,
15650,H,,,COS-7,,168,8,Autocuration,,3570,B,,,1,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,643.0,,,,CHEMBL620703,
17046,H,,,C6,,168,8,Autocuration,,3571,B,,,1,BAO_0000219,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,673.0,,,,CHEMBL620704,
17046,H,,,C6,,168,8,Expert,,3572,B,,,1,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,673.0,,,,CHEMBL620705,
15650,H,,,C6,,168,8,Expert,,3573,B,,,1,BAO_0000219,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,673.0,,,,CHEMBL620706,
17046,H,,,C6,,168,8,Expert,,3574,B,,,1,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,673.0,,,,CHEMBL620707,
17066,H,,,,,10624,8,Expert,,3575,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 5 receptor,,,,,CHEMBL620708,
17200,H,,,,,105,8,Autocuration,,3576,B,,,1,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,,,,CHEMBL620709,
16146,D,,,,,10624,9,Expert,,3577,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 5A receptor,,,,Homo sapiens,CHEMBL620710,9606.0
15250,H,,,CHO,,10624,8,Autocuration,,3578,B,,,1,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,449.0,,,,CHEMBL620711,
6491,D,,,,,10624,9,Expert,,3579,B,,,1,BAO_0000357,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,,,Homo sapiens,CHEMBL620712,9606.0
17066,D,,,,,10624,9,Expert,,3580,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,,,Homo sapiens,CHEMBL620713,9606.0
17066,D,,,,,10624,9,Expert,,3581,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,,,Homo sapiens,CHEMBL620714,9606.0
4234,D,,,,,10624,9,Expert,,3582,B,,,1,BAO_0000357,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,,,Homo sapiens,CHEMBL620715,9606.0
6013,H,,,,,10624,8,Autocuration,,3583,B,,,1,BAO_0000357,Binding affinity towards 5-HT5A receptor,,,,,CHEMBL620716,
17175,H,,,,,10624,8,Expert,,3584,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,,,CHEMBL620717,
15818,H,,,,,10624,8,Autocuration,,3585,B,,,1,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,,,,CHEMBL618072,
6166,H,,,,,10624,8,Autocuration,,3586,B,,,1,BAO_0000357,Binding affinity towards cloned human 5-HT5A receptor was determined,,,,,CHEMBL857987,
15779,H,,,HEK293,,10624,8,Autocuration,,3587,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,722.0,,,,CHEMBL618073,
15779,H,,,HEK293,,10624,8,Autocuration,,3588,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,722.0,,,,CHEMBL618074,
5213,H,,,HEK293,,10624,8,Autocuration,,3589,B,,,1,BAO_0000219,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),722.0,,,,CHEMBL618075,
17066,D,,,,,10625,9,Expert,,3590,B,,,1,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,,,Mus musculus,CHEMBL618076,10090.0
17066,D,,,,,10625,9,Expert,,3591,B,,,1,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,,Mus musculus,CHEMBL618077,10090.0
17066,D,,,,,10625,9,Expert,,3592,B,,,1,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,,,Mus musculus,CHEMBL618078,10090.0
17066,D,,,,,10625,9,Expert,,3593,B,,,1,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,,,Mus musculus,CHEMBL881821,10090.0
17066,D,,,,,10625,9,Expert,,3594,B,,,1,BAO_0000357,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,,,Mus musculus,CHEMBL618079,10090.0
17175,H,,,,,10625,8,Expert,,3595,B,,,1,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,,,CHEMBL618080,
16190,H,,,HEK293,,10576,8,Autocuration,,3596,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,722.0,,,,CHEMBL618081,
16190,H,,,HEK293,,10626,8,Autocuration,,3597,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,722.0,,,,CHEMBL618082,
4820,H,,,,,10624,8,Expert,,3598,B,,,1,BAO_0000357,Binding affinity towards 5-HT5a receptor,,,,,CHEMBL618083,
17066,D,,,,,10624,9,Expert,,3599,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 5A receptor,,,,Homo sapiens,CHEMBL618084,9606.0
17066,H,,,,,10624,8,Expert,,3600,B,,,1,BAO_0000357,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,,,,CHEMBL618085,
17175,H,,,,,10624,8,Expert,,3601,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,,,,CHEMBL618086,
16633,H,,,,,10624,8,Autocuration,,3602,B,,,1,BAO_0000357,Binding affinities against 5-hydroxytryptamine 5A receptor,,,,,CHEMBL875092,
16633,H,,,,,10624,8,Autocuration,,3603,B,,,1,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 5A receptor,,,,,CHEMBL618087,
16700,H,,,,,10624,8,Autocuration,,3604,B,,,1,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,,,,CHEMBL872926,
4639,H,,,,,104714,4,Autocuration,,3605,F,,,1,BAO_0000019,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,,,Cavia porcellus,CHEMBL618088,10141.0
5486,H,,,,,104714,4,Autocuration,,3606,B,,,1,BAO_0000223,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,,,,CHEMBL618089,
16146,D,,,,,10627,9,Expert,,3607,B,,,1,BAO_0000357,Inhibition of human 5-hydroxytryptamine 6 receptor,,,,Homo sapiens,CHEMBL618090,9606.0
17273,D,,,,,10627,9,Expert,,3608,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,,,Homo sapiens,CHEMBL618091,9606.0
17687,H,,,,,10627,8,Autocuration,,3609,B,,,1,BAO_0000357,Inhibition against human 5-hydroxytryptamine 6 receptor,,,,,CHEMBL618092,
6491,D,,,,,10627,9,Expert,,3610,B,,,1,BAO_0000357,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,,,Homo sapiens,CHEMBL618093,9606.0
16190,H,,,HeLa,,10627,8,Expert,,3611,B,,,1,BAO_0000219,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,308.0,,,,CHEMBL618094,
17066,D,,,,,10627,9,Expert,,3612,B,,,1,BAO_0000357,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,,,Homo sapiens,CHEMBL618095,9606.0
17066,D,,,,,10627,9,Expert,,3613,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,Homo sapiens,CHEMBL875093,9606.0
17066,D,,,,,10627,9,Expert,,3614,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,,,Homo sapiens,CHEMBL618096,9606.0
17066,D,,,,,10627,9,Expert,,3615,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,,,Homo sapiens,CHEMBL618118,9606.0
3555,D,,,,,10627,9,Expert,,3616,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 6 receptor,,,,Homo sapiens,CHEMBL618119,9606.0
5808,H,,,,,10627,8,Expert,,3617,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,CHEMBL618120,
6013,H,,,,,10627,8,Autocuration,,3618,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,CHEMBL618121,
15818,H,,,HEK293,,10627,8,Expert,,3619,B,,,1,BAO_0000219,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",722.0,,,,CHEMBL618122,
16209,H,,,,,10627,8,Autocuration,,3620,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,,,,CHEMBL618123,
3935,H,,,HEK293,,10627,8,Expert,,3621,B,,,1,BAO_0000219,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,722.0,,,,CHEMBL618124,
15818,H,,,,,10627,8,Autocuration,,3622,B,,,1,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,CHEMBL618125,
3805,D,,,HEK293,,10627,9,Expert,,3623,B,,,1,BAO_0000219,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,722.0,,,Homo sapiens,CHEMBL618126,9606.0
16441,H,,,,,10627,8,Expert,,3624,B,,,1,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,,,,CHEMBL618236,
16441,H,,,,,10627,8,Expert,,3625,B,,,1,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,,,CHEMBL618237,
6786,H,,,COS-7,,10627,8,Expert,,3626,B,,,1,BAO_0000219,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,643.0,,,,CHEMBL618238,
4234,D,,,,,10627,9,Expert,,3627,B,,,1,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,,,Homo sapiens,CHEMBL618239,9606.0
17085,H,,,,,10627,8,Autocuration,,3628,B,,,1,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,,,,CHEMBL618240,
17200,H,,,,,10627,8,Autocuration,,3629,B,,,1,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,,,,CHEMBL618241,
17451,H,,,HEK293,,10627,8,Autocuration,,3630,B,,,1,BAO_0000219,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,722.0,,,,CHEMBL859399,
3935,H,,,,,10627,8,Autocuration,,3631,F,,,1,BAO_0000019,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,,,,CHEMBL618242,
5033,H,,,,,10627,8,Autocuration,,3632,B,,,1,BAO_0000357,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,,,,CHEMBL857991,
4540,H,,,,,10627,8,Expert,,3633,B,,,1,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,,,CHEMBL619951,
4540,D,,,HeLa,,10627,9,Expert,,3634,B,,,1,BAO_0000219,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,308.0,,,Homo sapiens,CHEMBL619952,9606.0
4540,D,,,HeLa,,10627,9,Expert,,3635,B,,,1,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,308.0,,,Homo sapiens,CHEMBL619953,9606.0
17296,H,,,HeLa,,10627,8,Autocuration,,3636,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,308.0,,,,CHEMBL619954,
17296,H,,,HeLa,,10627,8,Autocuration,,3637,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,308.0,,,,CHEMBL619955,
17296,H,,,HeLa,,10627,8,Autocuration,,3638,B,,,1,BAO_0000219,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,308.0,,,,CHEMBL619956,
15779,H,,,CHO,,10627,8,Autocuration,,3639,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,449.0,,,,CHEMBL619957,
15779,H,,,HEK293,,10627,8,Autocuration,,3640,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,722.0,,,,CHEMBL619958,
15779,H,,,HEK293,,10627,8,Autocuration,,3641,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,722.0,,,,CHEMBL620627,
15779,H,,,HEK293,,10627,8,Autocuration,,3642,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,722.0,,,,CHEMBL620628,
15779,H,,,HeLa,,10627,8,Autocuration,,3643,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,308.0,,,,CHEMBL620629,
6166,H,,,,,10627,8,Autocuration,,3644,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,CHEMBL620630,
17451,H,,,HeLa,,10627,8,Autocuration,,3645,B,,,1,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,308.0,,,,CHEMBL620782,
15316,H,,,,,10627,8,Autocuration,,3646,B,,,1,BAO_0000357,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,,,,CHEMBL620783,
4199,H,,,,,10627,8,Expert,,3647,B,,,1,BAO_0000357,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,,,CHEMBL620784,
15146,H,,,HeLa,,10627,8,Expert,,3648,B,,,1,BAO_0000219,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,308.0,,,,CHEMBL620785,
5213,H,,,,,10627,8,Autocuration,,3649,B,,,1,BAO_0000357,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,,,,CHEMBL857992,
16429,H,,,,,10627,8,Autocuration,,3650,B,,,1,BAO_0000219,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,,,,CHEMBL620786,
14818,H,,,HeLa,,10627,8,Autocuration,,3651,B,,,1,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,308.0,,,,CHEMBL620787,
4829,H,,,HeLa,,10627,8,Autocuration,,3652,B,,,1,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",308.0,,,,CHEMBL620788,
4829,H,,,HeLa,,10627,8,Autocuration,,3653,B,,,1,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",308.0,,,,CHEMBL620789,
4829,H,,,HeLa,,10627,8,Autocuration,,3654,B,,,1,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",308.0,,,,CHEMBL620790,
15250,H,,,CHO,,10628,8,Autocuration,,3655,B,,,1,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,449.0,,,,CHEMBL620791,
14423,H,,,,,10628,8,Autocuration,,3656,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,,,,CHEMBL620792,
15086,H,,,,,10628,8,Autocuration,,3657,B,,,1,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,,,,CHEMBL620793,
4342,H,,,,,10628,8,Autocuration,,3658,B,,,1,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,,,,CHEMBL620794,
16190,D,,,HeLa,,10627,9,Autocuration,,3659,B,,,1,BAO_0000219,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,308.0,,,Homo sapiens,CHEMBL620795,9606.0
4820,H,,,,,10627,8,Expert,,3660,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,CHEMBL620796,
4639,H,,,,,10627,8,Autocuration,,3661,B,,,1,BAO_0000357,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,,,,CHEMBL620797,
17066,D,,,,,10627,9,Expert,,3662,F,,,1,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,,Homo sapiens,CHEMBL620798,9606.0
6011,H,,,,,10627,8,Autocuration,,3663,B,,,1,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,,,,CHEMBL620799,
17066,H,,,,,10627,8,Expert,,3664,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,CHEMBL620800,
17515,H,,,,,10627,8,Autocuration,,3665,B,,,1,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,,,,CHEMBL620801,
5014,H,,,,,10627,8,Autocuration,,3666,B,,,1,BAO_0000357,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,,,,CHEMBL875100,
4373,H,,,,,10627,8,Autocuration,,3667,B,,,1,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,,,,CHEMBL620802,
17066,H,,,,,10627,8,Expert,,3668,F,,,1,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,,,,CHEMBL620803,
17066,H,,,,,10627,8,Expert,,3669,F,,,1,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,,,CHEMBL620804,
4373,H,,,,,10627,8,Autocuration,,3670,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,,,,CHEMBL620805,
4687,H,,,,,10627,8,Autocuration,,3671,B,,,1,BAO_0000357,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,,,,CHEMBL620806,
16946,H,,,,,10627,8,Autocuration,,3672,B,,,1,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,,,,CHEMBL620807,
16946,H,,,,,10627,8,Autocuration,,3673,B,,,1,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,,,,CHEMBL620808,
16633,H,,,,,10627,8,Autocuration,,3674,B,,,1,BAO_0000357,Binding affinities against 5-hydroxytryptamine 6 receptor,,,,,CHEMBL620809,
16633,H,,,,,10627,8,Autocuration,,3675,B,,,1,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 6 receptor,,,,,CHEMBL620810,
17066,D,,,,,10627,9,Expert,,3676,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 6 receptor,,,,Homo sapiens,CHEMBL620811,9606.0
16700,H,,,,,10627,8,Autocuration,,3677,B,,,1,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,,,,CHEMBL620812,
3269,H,,,,,10627,8,Autocuration,,3678,B,,,1,BAO_0000357,Affinity against 5-hydroxytryptamine 6 receptor,,,,,CHEMBL620813,
5486,H,,,,,10627,8,Autocuration,,3679,B,,,1,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,,,,CHEMBL620814,
16146,D,,,,,10209,9,Expert,,3680,B,,,1,BAO_0000357,Inhibition of human 5-hydroxytryptamine 7 receptor,,,,Homo sapiens,CHEMBL620815,9606.0
5014,H,,,HEK293,,10209,8,Autocuration,,3681,B,,,1,BAO_0000219,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,722.0,,,,CHEMBL620816,
15463,H,,,,,10209,8,Autocuration,,3682,B,,,1,BAO_0000357,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,,,,CHEMBL620817,
3805,H,,,,,10209,8,Autocuration,,3683,B,,,1,BAO_0000357,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,,,,CHEMBL620818,
5014,H,,,HEK293,,10209,8,Expert,,3684,B,,,1,BAO_0000219,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,722.0,,,,CHEMBL620819,
6491,D,,,,,10209,9,Expert,,3685,B,,,1,BAO_0000357,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,,,Homo sapiens,CHEMBL620820,9606.0
16190,H,,,CHO,,10209,8,Autocuration,,3686,B,,,1,BAO_0000219,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,449.0,,,,CHEMBL620821,
17066,D,,,,,10209,9,Expert,,3687,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,,Homo sapiens,CHEMBL620822,9606.0
17066,D,,,,,10209,9,Expert,,3688,B,,,1,BAO_0000357,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,,,Homo sapiens,CHEMBL620823,9606.0
3555,D,,,,,10209,9,Expert,,3689,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 7 receptor,,,,Homo sapiens,CHEMBL620824,9606.0
6588,H,,,CHO,,10209,8,Expert,,3690,B,,,1,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,449.0,,,,CHEMBL620825,
15463,H,,,,,10209,8,Autocuration,,3691,B,,,1,BAO_0000357,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,,,,CHEMBL872930,
6013,H,,,,,10209,8,Autocuration,,3692,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,,CHEMBL620826,
16209,H,,,,,10209,8,Autocuration,,3693,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,,,CHEMBL620827,
3935,H,,,,,10209,8,Autocuration,,3694,B,,,1,BAO_0000357,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,,,,CHEMBL620828,
15818,H,,,,,10209,8,Autocuration,,3695,B,,,1,BAO_0000357,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,,,,CHEMBL620829,
5014,H,,,HEK293,,10209,8,Expert,,3696,B,,,1,BAO_0000219,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,722.0,,,,CHEMBL620830,
16441,H,,,,,10209,8,Expert,,3697,B,,,1,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,,,,CHEMBL620831,
16441,H,,,,,10209,8,Expert,,3698,B,,,1,BAO_0000019,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,,,CHEMBL620832,
4234,D,,,,,10209,9,Expert,,3699,B,,,1,BAO_0000357,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,,,Homo sapiens,CHEMBL621548,9606.0
17085,H,,,,,10209,8,Autocuration,,3700,B,,,1,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,,,,CHEMBL621549,
17200,H,,,,,10209,8,Autocuration,,3701,B,,,1,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,,,,CHEMBL621550,
17451,H,,,CHO,,10209,8,Autocuration,,3702,B,,,1,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,449.0,,,,CHEMBL621551,
17085,H,,,,,10209,8,Autocuration,,3703,B,,,1,BAO_0000019,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,,,,CHEMBL621552,
5104,H,,,,,10209,8,Autocuration,,3704,B,,,1,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,,,,CHEMBL857077,
5104,H,,,,,10209,8,Autocuration,,3705,B,,,1,BAO_0000357,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,,,,CHEMBL618158,
5033,D,,,COS-7,,10209,9,Expert,,3706,B,,,1,BAO_0000219,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,643.0,,,Homo sapiens,CHEMBL618159,9606.0
5486,H,,,COS-7,,10209,8,Autocuration,,3707,B,,,1,BAO_0000219,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,643.0,,,,CHEMBL875101,
4540,D,,,HEK293,,10209,9,Expert,,3708,B,,,1,BAO_0000219,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,722.0,,,Homo sapiens,CHEMBL618160,9606.0
6166,H,,,,,10209,8,Expert,,3709,B,,,1,BAO_0000357,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,,,,CHEMBL618161,
17342,H,,,HEK293,,10209,8,Expert,,3710,B,,,1,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,722.0,,,,CHEMBL618162,
17342,H,,,,,10209,8,Expert,,3711,B,,,1,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,,,,CHEMBL618163,
17296,H,,,,,10209,8,Autocuration,,3712,B,,,1,BAO_0000357,Binding affinity against 5-hydroxytryptamine 7 human receptors,,,,,CHEMBL618164,
16429,H,,,,,10209,8,Expert,,3713,B,,,1,BAO_0000219,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,,,,CHEMBL618165,
15779,H,,,HEK293,,10209,8,Autocuration,,3714,B,,,1,BAO_0000219,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,722.0,,,,CHEMBL618166,
15779,H,,,HEK293,,10209,8,Autocuration,,3715,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,722.0,,,,CHEMBL857989,
15779,H,,,HEK293,,10209,8,Autocuration,,3716,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,722.0,,,,CHEMBL619888,
15779,H,,,HEK293,,10209,8,Autocuration,,3717,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,722.0,,,,CHEMBL619889,
15779,H,,,HEK293,,10209,8,Autocuration,,3718,B,,,1,BAO_0000219,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,722.0,,,,CHEMBL619890,
17451,H,,,CHO,,10209,8,Autocuration,,3719,B,,,1,BAO_0000219,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,449.0,,,,CHEMBL619891,
4199,H,,,HEK293,,10209,8,Autocuration,,3720,B,,,1,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),722.0,,,,CHEMBL619892,
4199,D,,,HEK293,,10209,9,Expert,,3721,B,,,1,BAO_0000219,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,722.0,,,,CHEMBL619893,
4199,H,,,HEK293,,10209,8,Autocuration,,3722,B,,,1,BAO_0000219,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),722.0,,,,CHEMBL619894,
3680,D,,,HEK293,,10209,9,Intermediate,,3723,B,,,1,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,722.0,,,,CHEMBL619895,
3680,D,,,,,10209,9,Intermediate,,3724,B,,,1,BAO_0000357,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,,,,CHEMBL619896,
15316,H,,,COS-7,,10209,8,Autocuration,,3725,B,,,1,BAO_0000219,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,643.0,,,,CHEMBL619897,
15146,H,,,HEK293,,10209,8,Autocuration,,3726,B,,,1,BAO_0000219,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,722.0,,,,CHEMBL619898,
5213,H,,,HEK293,,10209,8,Expert,,3727,B,,,1,BAO_0000219,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,722.0,,,,CHEMBL619899,
5213,H,,,HEK293,,10209,8,Autocuration,,3728,B,,,1,BAO_0000219,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),722.0,,,,CHEMBL619900,
14818,D,,,HEK293,,10209,9,Expert,,3729,B,,,1,BAO_0000219,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,722.0,,,Homo sapiens,CHEMBL619901,9606.0
14818,H,,,HEK293,,10209,8,Autocuration,,3730,B,,,1,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,722.0,,,,CHEMBL620580,
14818,H,,,HEK293,,10209,8,Autocuration,,3731,B,,,1,BAO_0000219,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,722.0,,,,CHEMBL620581,
4829,H,,,HEK293,,10209,8,Autocuration,,3732,B,,,1,BAO_0000219,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",722.0,,,,CHEMBL620733,
17200,D,,,,,10209,9,Autocuration,,3733,B,,,1,BAO_0000357,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,,,Homo sapiens,CHEMBL620734,9606.0
17066,D,,,,,10022,9,Expert,,3734,B,,,1,BAO_0000357,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,,Mus musculus,CHEMBL620735,10090.0
14025,H,,,,,10209,8,Autocuration,,3735,B,,,1,BAO_0000019,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,,,Oryctolagus cuniculus,CHEMBL620736,9986.0
15250,H,,,CHO,,11923,8,Autocuration,,3736,B,,,1,BAO_0000219,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,449.0,,,,CHEMBL620737,
16372,H,,,CHO,,11923,8,Autocuration,,3737,B,,,1,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,449.0,,,,CHEMBL620738,
16372,H,,,CHO,,11923,8,Autocuration,,3738,B,,,1,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,449.0,,,,CHEMBL620739,
16372,H,,,CHO,,11923,8,Autocuration,,3739,B,,,1,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,449.0,,,,CHEMBL620740,
16372,H,,,CHO,,11923,8,Autocuration,,3740,B,,,1,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,449.0,,,,CHEMBL620741,
16372,H,,,CHO,,11923,8,Autocuration,,3741,B,,,1,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,449.0,,,,CHEMBL620742,
16372,H,,,CHO,,11923,8,Autocuration,,3742,B,,,1,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,449.0,,,,CHEMBL620743,
16372,H,,,CHO,,11923,8,Autocuration,,3743,B,,,1,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,449.0,,,,CHEMBL620744,
16372,H,,,CHO,,11923,8,Autocuration,,3744,B,,,1,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,449.0,,,,CHEMBL620745,
16372,H,,,CHO,,11923,8,Autocuration,,3745,B,,,1,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,449.0,,,,CHEMBL620746,
16372,H,,,CHO,,11923,8,Autocuration,,3746,B,,,1,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,449.0,,,,CHEMBL620747,
16372,H,,,CHO,,11923,8,Autocuration,,3747,B,,,1,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,449.0,,,,CHEMBL620748,
16372,H,,,CHO,,11923,8,Autocuration,,3748,B,,,1,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,449.0,,,,CHEMBL620749,
17066,H,,,,,11923,8,Expert,,3749,B,,,1,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,,,,CHEMBL620750,
17066,D,,,,,11923,9,Expert,,3750,B,,,1,BAO_0000357,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,,,Rattus norvegicus,CHEMBL620751,10116.0
17386,H,,,,,11923,8,Expert,,3751,B,,,1,BAO_0000357,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,,,,CHEMBL620752,
14423,H,,,,,11923,8,Autocuration,,3752,B,,,1,BAO_0000019,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,,,,CHEMBL872929,
15874,D,,,,,11923,9,Expert,,3753,B,,,1,BAO_0000357,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,,,Rattus norvegicus,CHEMBL620753,10116.0
15874,D,,,,,11923,9,Expert,,3754,B,,,1,BAO_0000357,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,,,Rattus norvegicus,CHEMBL620754,10116.0
16372,D,,,CHO,,11923,9,Expert,,3755,B,,,1,BAO_0000219,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,449.0,,,Rattus norvegicus,CHEMBL620755,10116.0
4622,H,,,,,11923,8,Autocuration,,3756,B,,,1,BAO_0000357,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,,,CHEMBL620756,
15086,H,,,,,11923,8,Autocuration,,3757,B,,,1,BAO_0000357,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,,,,CHEMBL620757,
16372,H,,,CHO,,11923,8,Autocuration,,3758,B,,,1,BAO_0000219,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",449.0,,,,CHEMBL620758,
16372,H,,,CHO,,11923,8,Autocuration,,3759,B,,,1,BAO_0000219,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",449.0,,,,CHEMBL620759,
16372,H,,,CHO,,11923,8,Autocuration,,3760,B,,,1,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,449.0,,,,CHEMBL620760,
16372,H,,,CHO,,11923,8,Autocuration,,3761,B,,,1,BAO_0000219,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,449.0,,,,CHEMBL620761,
17386,H,,,,,11923,8,Autocuration,,3762,F,Ileum,,1,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,2116.0,,CHEMBL620762,
17386,H,,,,,11923,8,Autocuration,,3763,F,Ileum,,1,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,2116.0,,CHEMBL620763,
17386,H,,,,,11923,8,Autocuration,,3764,F,Ileum,,1,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,,2116.0,,CHEMBL620764,
5831,D,,,,,11923,9,Expert,Membranes,3765,B,,,1,BAO_0000249,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,,,Rattus norvegicus,CHEMBL857990,10116.0
4342,H,,,,,11923,8,Autocuration,,3766,B,,,1,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,,,,CHEMBL620765,
17319,H,,,,,11923,8,Expert,,3767,B,,,1,BAO_0000357,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,,,,CHEMBL620766,
17342,H,,,,,11923,8,Expert,,3768,B,Hypothalamus,,1,BAO_0000019,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,,1898.0,,CHEMBL620767,
17342,H,,,,,11923,8,Autocuration,,3769,B,,,1,BAO_0000357,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,,,,CHEMBL620768,
3680,H,,,,,11923,8,Expert,,3770,B,Hypothalamus,,1,BAO_0000249,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,,1898.0,,CHEMBL619051,
3680,H,,,,,11923,8,Expert,,3771,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,,CHEMBL619052,
17319,D,,,HEK293,,11923,9,Expert,,3772,F,,,1,BAO_0000219,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,722.0,,,Rattus norvegicus,CHEMBL619053,10116.0
17319,D,,,HEK293,,11923,9,Expert,,3773,F,,,1,BAO_0000219,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,722.0,,,Rattus norvegicus,CHEMBL619703,10116.0
17319,D,,,HEK293,,11923,9,Autocuration,,3774,F,,,1,BAO_0000219,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,722.0,,,Rattus norvegicus,CHEMBL619704,10116.0
4820,H,,,,,10209,8,Expert,,3775,B,,,1,BAO_0000357,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,,CHEMBL619851,
4639,H,,,,,10209,8,Autocuration,,3776,B,,,1,BAO_0000357,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,,,,CHEMBL619852,
6011,H,,,,,10209,8,Autocuration,,3777,B,,,1,BAO_0000357,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,,,,CHEMBL619853,
17066,D,,,,,10209,9,Expert,,3778,B,,,1,BAO_0000357,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,,,Homo sapiens,CHEMBL619854,9606.0
17066,H,,,,,10209,8,Expert,,3779,B,,,1,BAO_0000357,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,,,,CHEMBL619855,
17515,H,,,,,10209,8,Autocuration,,3780,B,,,1,BAO_0000357,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,,,,CHEMBL619856,
4373,H,,,,,10209,8,Autocuration,,3781,B,,,1,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,,,CHEMBL619857,
17066,H,,,,,10209,8,Expert,,3782,F,,,1,BAO_0000019,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,,,,CHEMBL619858,
4373,H,,,,,10209,8,Autocuration,,3783,B,,,1,BAO_0000357,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,,,,CHEMBL619859,
4373,H,,,,,10209,8,Autocuration,,3784,B,,,1,BAO_0000357,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,,,,CHEMBL619860,
4687,H,,,,,10209,8,Autocuration,,3785,B,,,1,BAO_0000357,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,,,,CHEMBL619861,
17342,H,,,,,10209,8,Expert,,3786,B,,,1,BAO_0000357,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,,,,CHEMBL619862,
16946,H,,,,,10209,8,Autocuration,,3787,B,,,1,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,,,,CHEMBL619863,
16946,H,,,,,10209,8,Autocuration,,3788,B,,,1,BAO_0000357,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,,,,CHEMBL619864,
16633,H,,,,,10209,8,Autocuration,,3789,B,,,1,BAO_0000357,Binding affinities against 5-hydroxytryptamine 7 receptor,,,,,CHEMBL872928,
16633,H,,,,,10209,8,Autocuration,,3790,B,,,1,BAO_0000357,Binding affinities towards 5-hydroxytryptamine 7 receptor,,,,,CHEMBL619865,
17066,H,,,,,10209,8,Expert,,3791,B,,,1,BAO_0000357,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,,,,CHEMBL619866,
16700,H,,,,,10209,8,Autocuration,,3792,B,,,1,BAO_0000357,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,,,,CHEMBL619867,
17386,H,,,,,10209,8,Autocuration,,3793,B,Ileum,,1,BAO_0000221,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,,2116.0,,CHEMBL619868,
14080,H,,,,,55,8,Autocuration,,3794,F,,,1,BAO_0000019,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,,,,CHEMBL619869,
14080,D,,,,,55,9,Expert,,3795,F,,,1,BAO_0000019,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,,,Homo sapiens,CHEMBL619870,9606.0
409,H,,,,,55,8,Autocuration,,3796,B,,,1,BAO_0000357,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,,,,CHEMBL619871,
409,H,,,,,55,8,Autocuration,,3797,B,,,1,BAO_0000357,In vitro inhibition of human recombinant lipoxygenase enzyme,,,,,CHEMBL619872,
409,H,,,,,55,8,Autocuration,,3798,B,,,1,BAO_0000357,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,,,,CHEMBL619873,
11090,H,,,,,55,8,Expert,,3799,B,Blood,,1,BAO_0000357,Inhibition of 5-lipoxygenase in human whole blood.,,,178.0,,CHEMBL619874,
11090,H,,,,,55,8,Expert,,3800,B,Blood,,1,BAO_0000357,Inhibition of 5-lipoxygenase in human whole blood.,,,178.0,,CHEMBL619875,
948,H,,,,,55,8,Autocuration,,3801,B,,,1,BAO_0000357,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,,,,CHEMBL619876,
948,H,,,,,55,8,Autocuration,,3802,B,,,1,BAO_0000357,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,,,,CHEMBL619877,
13622,H,,,,,55,8,Expert,,3803,F,,,1,BAO_0000219,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,,,,CHEMBL619878,
13622,H,,,,,55,8,Autocuration,,3804,F,Blood,,1,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,,178.0,,CHEMBL619879,
9637,H,,,,,55,8,Autocuration,,3805,B,,,1,BAO_0000357,In vitro inhibition of 5-lipoxygenase from human polymorphs,,,,,CHEMBL619880,
11320,H,,,,,55,8,Autocuration,,3806,B,,,1,BAO_0000357,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,,,,CHEMBL619881,
11320,H,,,,,55,8,Expert,,3807,B,,,1,BAO_0000357,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,,,,CHEMBL619882,
6838,H,,,,,55,8,Autocuration,,3808,B,,,1,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,,,,CHEMBL619883,
17667,D,,,,,55,9,Expert,,3809,B,Blood,,1,BAO_0000357,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,,178.0,Homo sapiens,CHEMBL619884,9606.0
12703,H,,,,,55,8,Autocuration,,3810,B,,,1,BAO_0000357,In vitro potency against human 5-Lipoxygenase,,,,,CHEMBL619885,
14312,D,,,,,55,9,Expert,,3811,F,,,1,BAO_0000019,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,,,Homo sapiens,CHEMBL619886,9606.0
14312,H,,,,,55,8,Autocuration,,3812,F,Blood,,1,BAO_0000019,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,,178.0,,CHEMBL619887,
5364,H,,,,,55,8,Autocuration,,3813,F,,,1,BAO_0000019,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,,,CHEMBL875097,
951,H,,,,,55,8,Autocuration,,3814,B,,,1,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,,,,CHEMBL618001,
951,H,,,,,55,8,Autocuration,,3815,B,,,1,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,,,,CHEMBL618002,
951,H,,,,,55,8,Autocuration,,3816,B,,,1,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,,,,CHEMBL618003,
951,H,,,,,55,8,Autocuration,,3817,B,,,1,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,,,,CHEMBL618004,
12365,H,,,,,55,8,Autocuration,,3818,B,,,1,BAO_0000219,Inhibition of human 5-lipoxygenase in human cells,,,,,CHEMBL618005,
10603,H,,,,,55,8,Expert,,3819,B,,,1,BAO_0000357,Inhibition of human neutrophil 5-lipoxygenase,,,,,CHEMBL618006,
10501,H,,,,,55,8,Autocuration,,3820,B,,,1,BAO_0000019,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,,,,CHEMBL875086,
12281,H,,,,,55,8,Expert,,3821,B,Blood,,1,BAO_0000357,Inhibition of 5-lipoxygenase from human whole blood,,,178.0,,CHEMBL618007,
2567,H,,,,,55,8,Autocuration,,3822,B,,,1,BAO_0000357,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,,,CHEMBL618008,
2567,H,,,,,55,8,Autocuration,,3823,B,,,1,BAO_0000219,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,,,,CHEMBL618009,
10193,H,,,,,55,8,Expert,,3824,B,,,1,BAO_0000357,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,,,,CHEMBL618010,
10193,H,,,,,55,8,Autocuration,,3825,B,,,1,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,,,CHEMBL618011,
13623,H,,,,,55,8,Expert,,3826,B,,,1,BAO_0000357,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,,,,CHEMBL618012,
12780,H,,,,,55,8,Autocuration,,3827,B,,,1,BAO_0000357,Tested against 5-lipoxygenase,,,,,CHEMBL882927,
12780,H,,,,,55,8,Autocuration,,3828,B,,,1,BAO_0000357,Tested for activity against 5-Lipoxygenase (5-LO),,,,,CHEMBL618013,
12780,H,,,,,55,8,Autocuration,,3829,B,,,1,BAO_0000357,Tested for activity against 5-lipoxygenase,,,,,CHEMBL618014,
11966,H,,,,,55,8,Autocuration,,3830,B,,,1,BAO_0000357,Tested for inhibition of 5-HPETE production by human 5-LO,,,,,CHEMBL618015,
5364,H,,,,,55,8,Autocuration,,3831,F,,,1,BAO_0000019,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,,,,CHEMBL618016,
13165,H,,,,,55,8,Expert,,3832,B,,,1,BAO_0000357,Inhibition of Human 5-lipoxygenase,,,,,CHEMBL618017,
5364,H,,,,,55,8,Autocuration,,3833,B,,,1,BAO_0000019,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,,,,CHEMBL618018,
11311,H,,,,,55,8,Autocuration,,3834,B,,,1,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,,,CHEMBL875087,
11311,H,,,,,55,8,Autocuration,,3835,B,,,1,BAO_0000219,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,,,,CHEMBL618019,
14863,H,,,,,55,8,Autocuration,,3836,B,,,1,BAO_0000019,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,,,,CHEMBL618020,
14863,H,,,,,55,8,Autocuration,,3837,B,,,1,BAO_0000019,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,,,,CHEMBL618021,
11087,H,,,,,55,8,Autocuration,,3838,B,Blood,,1,BAO_0000357,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,,178.0,,CHEMBL618022,
455,H,,,,,55,8,Autocuration,,3839,B,,,1,BAO_0000357,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,,,,CHEMBL618023,
13183,H,,,,,55,8,Autocuration,,3840,B,,,1,BAO_0000357,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,,,CHEMBL618024,
10319,H,,,,,55,8,Expert,,3841,B,,,1,BAO_0000019,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,,,,CHEMBL873950,
10193,H,,,,,55,8,Autocuration,,3842,B,,,1,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,,,CHEMBL618025,
951,H,,,,,55,8,Autocuration,,3843,B,,,1,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,,,,CHEMBL618026,
951,H,,,,,55,8,Autocuration,,3844,B,,,1,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,,,,CHEMBL618027,
951,H,,,,,55,8,Autocuration,,3845,B,,,1,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,,,,CHEMBL618028,
951,H,,,,,55,8,Autocuration,,3846,B,,,1,BAO_0000219,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,,,,CHEMBL618029,
9859,H,,,,,55,8,Expert,,3847,B,,,1,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,,,,CHEMBL618030,
9859,H,,,,,55,8,Expert,,3848,B,,,1,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,,,,CHEMBL618031,
9859,H,,,,,55,8,Autocuration,,3849,B,,,1,BAO_0000357,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,,,,CHEMBL618032,
2567,H,,,,,55,8,Autocuration,,3850,B,,,1,BAO_0000357,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,,,,CHEMBL618033,
10193,H,,,,,55,8,Autocuration,,3851,B,,,1,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,,,,CHEMBL618034,
10193,H,,,,,55,8,Autocuration,,3852,B,,,1,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,,,,CHEMBL875088,
949,H,,,,,55,8,Autocuration,,3853,B,,,1,BAO_0000019,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,,,,CHEMBL618035,
949,H,,,,,55,8,Autocuration,,3854,B,,,1,BAO_0000019,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,,,,CHEMBL618036,
10603,H,,,,,55,8,Expert,,3855,B,,,1,BAO_0000357,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,,,,CHEMBL618037,
10603,H,,,,,55,8,Expert,,3856,B,,,1,BAO_0000357,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,,,CHEMBL618038,
10603,H,,,,,55,8,Autocuration,,3857,F,,,1,BAO_0000019,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,,,,CHEMBL618761,
10603,H,,,,,55,8,Expert,,3858,B,,,1,BAO_0000357,Inhibition of lipoxygenase at the concentration of 0.1 uM,,,,,CHEMBL618762,
10603,H,,,,,55,8,Expert,,3859,B,,,1,BAO_0000357,Inhibition of lipoxygenase at the concentration of 1 uM,,,,,CHEMBL618763,
10193,H,,,,,55,8,Autocuration,,3860,B,,,1,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,,,,CHEMBL618764,
14580,D,,,,,55,9,Expert,,3861,B,,,1,BAO_0000357,Inhibition of 5-Lipoxygenase (5-LOX),,,,Homo sapiens,CHEMBL618765,9606.0
11090,H,,,,,17087,8,Expert,,3862,B,,,1,BAO_0000357,Inhibition of 5-lipoxygenase in mouse macrophages.,,,,,CHEMBL618766,
11090,H,,,,,17087,8,Expert,,3863,B,,,1,BAO_0000357,Inhibition of 5-lipoxygenase in mouse macrophages.,,,,,CHEMBL618767,
6339,H,,,,,17087,8,Autocuration,,3864,B,,,1,BAO_0000357,Inhibitory activity against lipoxygenase-2 in mice,,,,,CHEMBL619380,
6339,H,,,,,17087,8,Expert,,3865,B,,,1,BAO_0000357,Inhibitory activity against murine lipoxygenase-2.,,,,,CHEMBL619381,
12281,D,,,,,17087,9,Expert,,3866,B,,,1,BAO_0000357,Inhibition of 5-lipoxygenase from mouse macrophage,,,,Mus musculus,CHEMBL619382,10090.0
11311,H,,,,,17087,8,Autocuration,,3867,B,,,1,BAO_0000357,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,,,,CHEMBL619383,
11089,H,,,,,55,8,Autocuration,,3868,B,,,1,BAO_0000019,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,,,Sus scrofa,CHEMBL619384,9823.0
10091,H,,,,,55,8,Autocuration,,3869,B,,,1,BAO_0000019,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,,,Sus scrofa,CHEMBL619385,9823.0
14352,H,,,,,55,8,Autocuration,,3870,B,,,1,BAO_0000019,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,,,Oryctolagus cuniculus,CHEMBL882928,9986.0
13329,D,,,,,12166,9,Expert,,3871,B,,,1,BAO_0000019,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,,,Rattus norvegicus,CHEMBL619386,10116.0
13329,H,,,,,12166,8,Autocuration,,3872,B,,,1,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,,,,CHEMBL619387,
13329,H,,,,,12166,8,Autocuration,,3873,B,,,1,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,,,CHEMBL619388,
13329,H,,,,,12166,8,Autocuration,,3874,B,,,1,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,,,,CHEMBL619389,
13329,H,,,,,12166,8,Expert,,3875,B,,,1,BAO_0000019,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,,,,CHEMBL619390,
13329,H,,,,,12166,8,Expert,,3876,B,,,1,BAO_0000019,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,,,,CHEMBL619391,
13329,H,,,,,12166,8,Autocuration,,3877,B,,,1,BAO_0000019,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,,,,CHEMBL619392,
11311,H,,,,,12166,8,Autocuration,,3878,B,,,1,BAO_0000019,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,,,,CHEMBL619393,
11311,H,,,,,12166,8,Autocuration,,3879,B,,,1,BAO_0000019,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,,,,CHEMBL619394,
105,H,,,RBL-1,,12166,8,Autocuration,,3880,B,,,1,BAO_0000219,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",702.0,,,,CHEMBL619395,
105,H,,,RBL-1,,12166,8,Autocuration,,3881,B,,,1,BAO_0000219,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",702.0,,,,CHEMBL619396,
9138,H,,,,,12166,8,Autocuration,,3882,B,,,1,BAO_0000357,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,,,,CHEMBL619397,
9138,H,,,,,12166,8,Autocuration,,3883,B,,,1,BAO_0000357,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,,,,CHEMBL619398,
9138,H,,,,,12166,8,Autocuration,,3884,B,,,1,BAO_0000357,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,,,,CHEMBL619399,
14427,H,,,,,12166,8,Autocuration,,3885,B,,,1,BAO_0000357,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,,,CHEMBL619400,
13329,H,,,,,12166,8,Autocuration,,3886,B,,,1,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,,,,CHEMBL619401,
13329,H,,,,,12166,8,Autocuration,,3887,B,,,1,BAO_0000019,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,,,,CHEMBL619402,
14427,D,,,RBL-2H3,,12166,9,Expert,,3888,B,,,1,BAO_0000219,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,663.0,,,Rattus norvegicus,CHEMBL619403,10116.0
14427,H,,,,,12166,8,Autocuration,,3889,B,,,1,BAO_0000357,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,,,,CHEMBL619404,
14427,H,,,,,12166,8,Autocuration,,3890,B,,,1,BAO_0000357,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,,,,CHEMBL619405,
10293,H,,,RBL-1,,12166,8,Expert,,3891,B,,,1,BAO_0000219,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,702.0,,,,CHEMBL619406,
338,D,,,RBL-1,,12166,9,Expert,,3892,B,,,1,BAO_0000219,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,702.0,,,Rattus norvegicus,CHEMBL619407,10116.0
303,H,,,,,12166,8,Autocuration,,3893,B,,,1,BAO_0000357,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,,,,CHEMBL619408,
303,H,,,RBL-1,,12166,8,Autocuration,,3894,B,,,1,BAO_0000219,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,702.0,,,,CHEMBL619409,
9247,H,,,RBL-1,,12166,8,Expert,,3895,B,,,1,BAO_0000219,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,702.0,,,,CHEMBL619410,
9247,H,,,RBL-1,,12166,8,Autocuration,,3896,B,,,1,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,702.0,,,,CHEMBL619753,
137,H,,,RBL-1,,12166,8,Autocuration,,3897,B,,,1,BAO_0000219,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,702.0,,,,CHEMBL619754,
11481,H,,,,,12166,8,Expert,,3898,B,,,1,BAO_0000357,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,,,,CHEMBL619903,
11481,H,,,,,12166,8,Expert,,3899,B,,,1,BAO_0000357,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,,,,CHEMBL619904,
9029,H,,,,,12166,8,Expert,,3900,B,,,1,BAO_0000357,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,,,,CHEMBL619905,
1701,H,,,,,12166,8,Autocuration,,3901,B,,,1,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,,,,CHEMBL619906,
1701,H,,,,,12166,8,Autocuration,,3902,B,,,1,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,,,,CHEMBL619907,
1701,H,,,,,12166,8,Autocuration,,3903,B,,,1,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,,,,CHEMBL619908,
1701,H,,,,,12166,8,Autocuration,,3904,B,,,1,BAO_0000019,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,,,,CHEMBL619909,
13358,H,,,RBL-1,,12166,8,Expert,,3905,F,,,1,BAO_0000219,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,702.0,,,,CHEMBL619910,
1175,H,,,RBL-1,,12166,8,Expert,,3906,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,702.0,,,,CHEMBL882929,
8797,H,,,RBL-1,,12166,8,Expert,,3907,B,,,1,BAO_0000219,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,702.0,,,,CHEMBL619911,
8797,H,,,,,12166,8,Autocuration,,3908,B,,,1,BAO_0000019,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,,,,CHEMBL619912,
577,D,,,,,12166,9,Expert,,3909,B,,,1,BAO_0000357,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,,,Rattus norvegicus,CHEMBL619913,10116.0
9295,H,,,RBL-1,,12166,8,Expert,,3910,B,,,1,BAO_0000219,In vitro inhibitory activity against RBL-1 5-LO,702.0,,,,CHEMBL619914,
9295,H,,,RBL-1,,12166,8,Autocuration,,3911,B,,,1,BAO_0000219,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),702.0,,,,CHEMBL619915,
9295,H,,,RBL-1,,12166,8,Autocuration,,3912,B,,,1,BAO_0000219,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),702.0,,,,CHEMBL619916,
9295,H,,,,,12166,8,Autocuration,,3913,B,,,1,BAO_0000218,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,,,,CHEMBL619917,
9295,H,,,,,12166,8,Autocuration,,3914,B,,,1,BAO_0000357,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,,,,CHEMBL619918,
216,H,,,,,12166,8,Autocuration,,3915,B,,,1,BAO_0000218,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,,,,CHEMBL619919,
11090,H,,,RBL-1,,12166,8,Autocuration,,3916,B,,,1,BAO_0000219,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,702.0,,,,CHEMBL883710,
11090,H,,,,,12166,8,Autocuration,,3917,B,Blood,,1,BAO_0000019,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,,178.0,,CHEMBL619920,
10091,H,,,,,12166,8,Expert,,3918,B,,,1,BAO_0000357,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,,,,CHEMBL619921,
10274,H,,,,,12166,8,Autocuration,,3919,F,,,1,BAO_0000019,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,,,,CHEMBL619922,
13622,H,,,,,12166,8,Autocuration,,3920,F,,,1,BAO_0000219,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,,,,CHEMBL619923,
12118,H,,,RBL-1,,12166,8,Expert,,3921,B,,,1,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,702.0,,,,CHEMBL619924,
12576,H,,,,,12166,8,Expert,,3922,B,,,1,BAO_0000357,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,,,,CHEMBL619925,
9546,H,,,RBL-1,,12166,8,Expert,,3923,B,,,1,BAO_0000219,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,702.0,,,,CHEMBL619926,
9521,H,,,RBL-1,,12166,8,Autocuration,,3924,B,,,1,BAO_0000219,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,702.0,,,,CHEMBL619927,
10626,H,,,RBL-1,,12166,8,Expert,,3925,B,,,1,BAO_0000219,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,702.0,,,,CHEMBL619928,
9225,H,,,RBL-1,,12166,8,Autocuration,,3926,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase,702.0,,,,CHEMBL619929,
9225,H,,,RBL-1,,12166,8,Autocuration,,3927,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,702.0,,,,CHEMBL875089,
9225,H,,,RBL-1,,12166,8,Autocuration,,3928,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,702.0,,,,CHEMBL619930,
9225,H,,,RBL-1,,12166,8,Autocuration,,3929,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,702.0,,,,CHEMBL619931,
9225,H,,,RBL-1,,12166,8,Autocuration,,3930,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,702.0,,,,CHEMBL619932,
9225,H,,,RBL-1,,12166,8,Autocuration,,3931,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,702.0,,,,CHEMBL619933,
9225,H,,,RBL-1,,12166,8,Autocuration,,3932,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,702.0,,,,CHEMBL619934,
9225,H,,,RBL-1,,12166,8,Autocuration,,3933,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,702.0,,,,CHEMBL619935,
9225,H,,,RBL-1,,12166,8,Autocuration,,3934,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,702.0,,,,CHEMBL619936,
9225,H,,,RBL-1,,12166,8,Autocuration,,3935,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,702.0,,,,CHEMBL619937,
9225,H,,,RBL-1,,12166,8,Autocuration,,3936,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,702.0,,,,CHEMBL619938,
9225,H,,,RBL-1,,12166,8,Autocuration,,3937,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,702.0,,,,CHEMBL619939,
9225,H,,,RBL-1,,12166,8,Autocuration,,3938,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,702.0,,,,CHEMBL619940,
9225,H,,,RBL-1,,12166,8,Autocuration,,3939,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,702.0,,,,CHEMBL875090,
9225,H,,,RBL-1,,12166,8,Autocuration,,3940,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,702.0,,,,CHEMBL619941,
9225,H,,,RBL-1,,12166,8,Autocuration,,3941,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,702.0,,,,CHEMBL619942,
9225,H,,,RBL-1,,12166,8,Autocuration,,3942,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,702.0,,,,CHEMBL883711,
9225,H,,,RBL-1,,12166,8,Autocuration,,3943,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,702.0,,,,CHEMBL619943,
9225,H,,,RBL-1,,12166,8,Autocuration,,3944,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,702.0,,,,CHEMBL619944,
9225,H,,,RBL-1,,12166,8,Autocuration,,3945,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,702.0,,,,CHEMBL619945,
9225,H,,,RBL-1,,12166,8,Autocuration,,3946,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,702.0,,,,CHEMBL619946,
9225,H,,,RBL-1,,12166,8,Autocuration,,3947,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,702.0,,,,CHEMBL619947,
9225,H,,,RBL-1,,12166,8,Autocuration,,3948,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,702.0,,,,CHEMBL619948,
9225,H,,,RBL-1,,12166,8,Autocuration,,3949,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,702.0,,,,CHEMBL619949,
9401,H,,,,,12166,8,Expert,,3950,B,,,1,BAO_0000019,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,,,,CHEMBL619950,
10325,H,,,,,12166,8,Autocuration,,3951,B,,,1,BAO_0000019,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,,,,CHEMBL618050,
1556,H,,,RBL-2H3,,12166,8,Expert,,3952,F,,,1,BAO_0000219,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,663.0,,,,CHEMBL875091,
1556,H,,,RBL-2H3,,12166,8,Expert,,3953,F,,,1,BAO_0000219,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,663.0,,,,CHEMBL618051,
961,D,,,RBL-1,,12166,9,Expert,,3954,B,,,1,BAO_0000219,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,702.0,,,Rattus norvegicus,CHEMBL618052,10116.0
6838,H,,,,,12166,8,Autocuration,,3955,B,,,1,BAO_0000019,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,,,,CHEMBL618053,
10325,H,,,,,12166,8,Expert,,3956,B,,,1,BAO_0000019,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,,,,CHEMBL618054,
9209,D,,,RBL-1,,12166,9,Expert,,3957,B,,,1,BAO_0000219,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,702.0,,,Rattus norvegicus,CHEMBL618055,10116.0
11520,H,,,RBL-1,,12166,8,Expert,,3958,B,,,1,BAO_0000219,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,702.0,,,,CHEMBL618056,
137,H,,,,,12166,8,Autocuration,,3959,B,,,1,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase was determined,,,,,CHEMBL618057,
4717,H,,,RBL-1,,12166,8,Autocuration,,3960,B,,,1,BAO_0000219,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,702.0,,,,CHEMBL618058,
10636,H,,,RBL-1,,12166,8,Expert,,3961,B,,,1,BAO_0000219,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,702.0,,,,CHEMBL618059,
14312,D,,,,,12166,9,Expert,,3962,F,,,1,BAO_0000019,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,,,Rattus norvegicus,CHEMBL618060,10116.0
1203,H,,,RBL-1,,12166,8,Autocuration,,3963,B,,,1,BAO_0000219,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,702.0,,,,CHEMBL618061,
1203,H,,,,,12166,8,Autocuration,,3964,B,,,1,BAO_0000019,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,,,,CHEMBL618062,
13622,H,,,RBL-1,,12166,8,Expert,,3965,B,,,1,BAO_0000219,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,702.0,,,,CHEMBL618063,
9793,H,,,,,12166,8,Autocuration,,3966,B,,,1,BAO_0000357,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,,,,CHEMBL618064,
1143,D,,,RBL-1,,12166,9,Expert,,3967,B,,,1,BAO_0000219,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,702.0,,,Rattus norvegicus,CHEMBL618065,10116.0
11854,D,,,RBL-1,,12166,9,Expert,,3968,B,,,1,BAO_0000219,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,702.0,,,Rattus norvegicus,CHEMBL618066,10116.0
3595,H,,,RBL-1,,12166,8,Autocuration,,3969,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),702.0,,,,CHEMBL618067,
3595,H,,,RBL-1,,12166,8,Autocuration,,3970,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),702.0,,,,CHEMBL618068,
10501,D,,,RBL-1,,12166,9,Expert,,3971,B,,,1,BAO_0000219,Inhibition of 5-lipoxygenase in rat RBL-1 cells,702.0,,,Rattus norvegicus,CHEMBL618069,10116.0
12526,H,,,RBL-1,,12166,8,Expert,,3972,B,,,1,BAO_0000219,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,702.0,,,,CHEMBL618070,
10034,H,,,,,10825,8,Autocuration,,3973,F,Limbic system,,1,BAO_0000019,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,,349.0,,CHEMBL618071,
10034,H,,,,,10825,8,Autocuration,,3974,F,Limbic system,,1,BAO_0000019,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,349.0,,CHEMBL619247,
10034,H,,,,,10825,8,Autocuration,,3975,F,,,1,BAO_0000019,Approximate dose levels for a half maximal reduction of 5-HTP levels,,,,,CHEMBL619248,
10046,H,,,,,10576,8,Autocuration,,3976,B,Hippocampus,,1,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,10000000.0,,CHEMBL619249,
10046,H,,,,,10576,8,Autocuration,,3977,B,Hippocampus,,1,BAO_0000221,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,10000000.0,,CHEMBL619250,
10046,H,,,,,10577,8,Autocuration,,3978,B,,,1,BAO_0000019,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,,,CHEMBL619251,
12079,H,,,,,55,8,Autocuration,,3979,F,Blood,,1,BAO_0000019,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,,178.0,Canis lupus familiaris,CHEMBL619252,9615.0
12079,H,,,,,55,8,Autocuration,,3980,F,Blood,,1,BAO_0000019,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,,178.0,,CHEMBL619253,
11311,H,,,,,12166,8,Autocuration,,3981,B,,,1,BAO_0000219,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,,,CHEMBL619254,
12338,H,,,,,17140,8,Expert,,3982,B,,,1,BAO_0000219,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,,,,CHEMBL619255,
12143,H,,,,,17140,8,Expert,,3983,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,,,,CHEMBL619256,
12143,H,,,,,17140,8,Autocuration,,3984,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,,,,CHEMBL875418,
12143,H,,,,,17140,8,Expert,,3985,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,,,CHEMBL619257,
12143,H,,,,,17140,8,Autocuration,,3986,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,,,,CHEMBL619258,
12365,H,,,,,17140,8,Expert,,3987,B,,,1,BAO_0000357,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,,,,CHEMBL619259,
13500,H,,,,,17140,8,Expert,,3988,B,,,1,BAO_0000357,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,,,,CHEMBL619260,
12832,H,,,,In vivo,55,8,Autocuration,,3989,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL619261,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,3990,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL619263,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,3991,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL619264,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,3992,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL619265,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,3993,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL619266,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,3994,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL619902,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,3995,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620058,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,3996,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620059,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,3997,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620060,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,3998,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620061,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,3999,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620062,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4000,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620063,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4001,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620064,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4002,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620065,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4003,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620066,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4004,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620067,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4005,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620068,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4006,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620069,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4007,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620070,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4008,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620071,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4009,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620072,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4010,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620036,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4011,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL857702,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4012,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620037,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4013,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620038,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4014,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620039,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4015,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620040,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4016,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620041,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4017,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620042,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4018,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620043,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4019,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620044,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4020,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620045,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4021,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620046,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4022,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620047,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4023,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620048,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4024,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL857703,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4025,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620049,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4026,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620050,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4027,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL620051,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4028,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL619213,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4029,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL619214,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4030,F,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL619804,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4031,F,Blood,,1,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL619805,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4032,F,Blood,,1,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL619806,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4033,F,Blood,,1,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL619807,9615.0
12832,H,,,,In vivo,55,8,Autocuration,,4034,F,Blood,,1,BAO_0000218,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Canis lupus familiaris,CHEMBL619808,9615.0
3595,H,,,,,55,8,Autocuration,,4035,B,,,1,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,,,Canis lupus familiaris,CHEMBL619809,9615.0
3595,H,,,,,55,8,Autocuration,,4036,B,,,1,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,,,Canis lupus familiaris,CHEMBL619810,9615.0
3595,H,,,,,55,8,Autocuration,,4037,B,,,1,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,,,Canis lupus familiaris,CHEMBL619811,9615.0
3595,H,,,,,55,8,Autocuration,,4038,B,,,1,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,,,Canis lupus familiaris,CHEMBL620769,9615.0
3595,H,,,,,55,8,Autocuration,,4039,B,,,1,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,,,Canis lupus familiaris,CHEMBL620770,9615.0
3595,H,,,,,55,8,Autocuration,,4040,B,,,1,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,,,Canis lupus familiaris,CHEMBL620771,9615.0
3595,H,,,,,55,8,Autocuration,,4041,B,,,1,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,,,Canis lupus familiaris,CHEMBL620772,9615.0
3595,H,,,,,55,8,Autocuration,,4042,B,,,1,BAO_0000218,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,,,Canis lupus familiaris,CHEMBL620773,9615.0
9203,H,,,,,55,8,Autocuration,,4043,B,,,1,BAO_0000357,Ability to inhibit 5-lipoxygenase in guinea pig,,,,Cavia porcellus,CHEMBL620774,10141.0
82,H,,,,,55,8,Expert,,4044,B,,,1,BAO_0000357,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,,,Cavia porcellus,CHEMBL620775,10141.0
11090,H,,,,,55,8,Autocuration,,4045,B,,,1,BAO_0000357,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,,,Cavia porcellus,CHEMBL620776,10141.0
12832,H,,,,,55,8,Autocuration,,4046,B,Blood,,1,BAO_0000218,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,,178.0,Cavia porcellus,CHEMBL620777,10141.0
1065,H,,,,,55,8,Autocuration,,4047,B,,,1,BAO_0000357,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,,,Cavia porcellus,CHEMBL620778,10141.0
1065,H,,,,,55,8,Autocuration,,4048,B,,,1,BAO_0000357,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,,,Cavia porcellus,CHEMBL620779,10141.0
12832,H,,,,,55,8,Expert,,4049,B,,,1,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,,,Cavia porcellus,CHEMBL621500,10141.0
12832,H,,,,,55,8,Expert,,4050,B,,,1,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,,,Cavia porcellus,CHEMBL621501,10141.0
12832,H,,,,,55,8,Autocuration,,4051,B,,,1,BAO_0000019,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,,,Cavia porcellus,CHEMBL618098,10141.0
10504,H,,,,,55,8,Autocuration,,4052,B,,,1,BAO_0000019,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,,,Cavia porcellus,CHEMBL618099,10141.0
7788,H,,,,,55,8,Autocuration,,4053,B,,,1,BAO_0000357,Inhibitory activity against 5-lipoxygenase,,,,Cavia porcellus,CHEMBL618100,10141.0
10001,H,,,,,55,8,Autocuration,,4054,B,,,1,BAO_0000357,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,,,Cavia porcellus,CHEMBL618101,10141.0
10193,H,,,,,55,8,Autocuration,,4055,B,,,1,BAO_0000357,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,,,Cavia porcellus,CHEMBL618102,10141.0
13243,H,,,,,55,8,Autocuration,,4056,B,,,1,BAO_0000357,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,,,Cavia porcellus,CHEMBL618103,10141.0
13243,H,,,,,55,8,Autocuration,,4057,B,,,1,BAO_0000357,Inhibitory activity uM,,,,Cavia porcellus,CHEMBL618104,10141.0
969,H,,,,,55,8,Autocuration,,4058,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,,,Cavia porcellus,CHEMBL883712,10141.0
10001,H,,,,,55,8,Autocuration,,4059,B,,,1,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 10 uM,,,,Cavia porcellus,CHEMBL618105,10141.0
7788,H,,,,,55,8,Autocuration,,4060,B,,,1,BAO_0000357,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,,,Cavia porcellus,CHEMBL618106,10141.0
10001,H,,,,,55,8,Autocuration,,4061,B,,,1,BAO_0000357,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,,,Cavia porcellus,CHEMBL618107,10141.0
10193,H,,,,,55,8,Autocuration,,4062,B,,,1,BAO_0000357,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,,,Cavia porcellus,CHEMBL618108,10141.0
13243,H,,,,,55,8,Autocuration,,4063,B,,,1,BAO_0000357,Inhibitory activity uM,,,,Cavia porcellus,CHEMBL618109,10141.0
13243,H,,,,,55,8,Autocuration,,4064,B,,,1,BAO_0000357,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,,,Cavia porcellus,CHEMBL618110,10141.0
13243,H,,,,,55,8,Expert,,4065,B,,,1,BAO_0000357,Inhibitory activity uM,,,,Cavia porcellus,CHEMBL618111,10141.0
13243,H,,,,,55,8,Autocuration,,4066,F,,,1,BAO_0000019,Inhibitory activity uM,,,,Cavia porcellus,CHEMBL618112,10141.0
10504,H,,,,,55,8,Autocuration,,4067,B,,,1,BAO_0000019,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,,,Cavia porcellus,CHEMBL618113,10141.0
7788,H,,,,,55,8,Autocuration,,4068,B,,,1,BAO_0000357,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,,,Cavia porcellus,CHEMBL618114,10141.0
10546,H,,,,,55,8,Expert,,4069,F,Ileum,,1,BAO_0000221,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,,2116.0,Cavia porcellus,CHEMBL620871,10141.0
13183,H,,,,,55,8,Autocuration,,4070,B,,,1,BAO_0000357,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,,,CHEMBL620872,
13183,H,,,,,55,8,Autocuration,,4071,B,,,1,BAO_0000357,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,,,,CHEMBL620873,
2578,H,,,,,55,8,Autocuration,,4072,B,,,1,BAO_0000357,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,,,,CHEMBL620874,
12780,H,,,,,55,8,Expert,,4073,B,,,1,BAO_0000357,In vitro inhibition of human 5-Lipoxygenase.,,,,,CHEMBL620875,
7411,U,,,,,22226,0,Autocuration,Microsomes,4074,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,,2107.0,Rattus norvegicus,CHEMBL620876,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4075,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,,2107.0,Rattus norvegicus,CHEMBL620877,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4076,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,,2107.0,Rattus norvegicus,CHEMBL857854,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4077,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,,2107.0,Rattus norvegicus,CHEMBL620878,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4078,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,,2107.0,Rattus norvegicus,CHEMBL620879,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4079,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,2107.0,Rattus norvegicus,CHEMBL620880,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4080,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,2107.0,Rattus norvegicus,CHEMBL620881,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4081,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,,2107.0,Rattus norvegicus,CHEMBL620882,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4082,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,,2107.0,Rattus norvegicus,CHEMBL620883,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4083,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,,2107.0,Rattus norvegicus,CHEMBL620884,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4084,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,,2107.0,Rattus norvegicus,CHEMBL620885,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4085,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,,2107.0,Rattus norvegicus,CHEMBL620886,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4086,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,,2107.0,Rattus norvegicus,CHEMBL620887,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4087,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,2107.0,Rattus norvegicus,CHEMBL618039,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4088,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,,2107.0,Rattus norvegicus,CHEMBL618040,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4089,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,,2107.0,Rattus norvegicus,CHEMBL618041,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4090,B,Liver,,1,BAO_0000251,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,2107.0,Rattus norvegicus,CHEMBL618216,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4091,B,Liver,,1,BAO_0000251,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,2107.0,Rattus norvegicus,CHEMBL618217,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4092,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,,2107.0,Rattus norvegicus,CHEMBL618218,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4093,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,,2107.0,Rattus norvegicus,CHEMBL618219,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4094,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,,2107.0,Rattus norvegicus,CHEMBL618220,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4095,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,,2107.0,Rattus norvegicus,CHEMBL618221,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4096,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,,2107.0,Rattus norvegicus,CHEMBL618222,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4097,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,,2107.0,Rattus norvegicus,CHEMBL618223,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4098,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,,2107.0,Rattus norvegicus,CHEMBL618224,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4099,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,,2107.0,Rattus norvegicus,CHEMBL618225,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4100,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,,2107.0,Rattus norvegicus,CHEMBL618226,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4101,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,,2107.0,Rattus norvegicus,CHEMBL618227,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4102,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,,2107.0,Rattus norvegicus,CHEMBL618228,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4103,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,,2107.0,Rattus norvegicus,CHEMBL618229,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4104,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,,2107.0,Rattus norvegicus,CHEMBL618230,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4105,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,,2107.0,Rattus norvegicus,CHEMBL618231,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4106,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,,2107.0,Rattus norvegicus,CHEMBL618232,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4107,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,,2107.0,Rattus norvegicus,CHEMBL618233,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4108,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,,2107.0,Rattus norvegicus,CHEMBL618234,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4109,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,,2107.0,Rattus norvegicus,CHEMBL618235,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4110,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,,2107.0,Rattus norvegicus,CHEMBL618115,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4111,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,,2107.0,Rattus norvegicus,CHEMBL618116,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4112,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,,2107.0,Rattus norvegicus,CHEMBL618117,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4113,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,,2107.0,Rattus norvegicus,CHEMBL619968,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4114,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,2107.0,Rattus norvegicus,CHEMBL619969,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4115,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,,2107.0,Rattus norvegicus,CHEMBL619970,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4116,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,,2107.0,Rattus norvegicus,CHEMBL619971,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4117,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,,2107.0,Rattus norvegicus,CHEMBL619972,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4118,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,,2107.0,Rattus norvegicus,CHEMBL619973,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4119,B,Liver,,1,BAO_0000251,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,,2107.0,Rattus norvegicus,CHEMBL619974,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4120,B,Liver,,1,BAO_0000251,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,,2107.0,Rattus norvegicus,CHEMBL619975,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4121,B,,,1,BAO_0000251,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,,,Rattus norvegicus,CHEMBL619976,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4122,B,Liver,,1,BAO_0000251,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,2107.0,Rattus norvegicus,CHEMBL619977,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4123,B,Liver,,1,BAO_0000251,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,2107.0,Rattus norvegicus,CHEMBL619978,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4124,B,Liver,,1,BAO_0000251,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,,2107.0,Rattus norvegicus,CHEMBL619979,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4125,B,Liver,,1,BAO_0000251,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,,2107.0,Rattus norvegicus,CHEMBL619980,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4126,B,Liver,,1,BAO_0000251,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,,2107.0,Rattus norvegicus,CHEMBL619981,10116.0
10797,N,,,RPMI-8226,,80433,1,Intermediate,,4127,F,,,1,BAO_0000219,In vitro inhibition of 7226/S myeloma cancer cell line,741.0,,,Homo sapiens,CHEMBL619982,9606.0
6881,N,,,BEL-7404 tumor cell line,,80698,1,Intermediate,,4128,F,,,1,BAO_0000219,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),993.0,,,Homo sapiens,CHEMBL619983,9606.0
3838,N,,,786-0,,80640,1,Intermediate,,4129,F,,,1,BAO_0000219,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,391.0,,,Homo sapiens,CHEMBL620031,9606.0
3838,N,,,786-0,,80640,1,Intermediate,,4130,F,,,1,BAO_0000219,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,391.0,,,Homo sapiens,CHEMBL620032,9606.0
12981,N,,,V79,,81264,1,Expert,,4131,F,,,1,BAO_0000219,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,505.0,,,Cricetulus griseus,CHEMBL620033,10029.0
12981,N,,,V79,,81264,1,Expert,,4132,F,,,1,BAO_0000219,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,505.0,,,Cricetulus griseus,CHEMBL620034,10029.0
7653,N,,,7800C1 cell line,,80635,1,Intermediate,,4133,F,,,1,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,1119.0,,,Rattus norvegicus,CHEMBL620035,10116.0
7653,N,,,7800C1 cell line,,80635,1,Intermediate,,4134,F,,,1,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,1119.0,,,Rattus norvegicus,CHEMBL618318,10116.0
7653,N,,,7800C1 cell line,,80635,1,Intermediate,,4135,F,,,1,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,1119.0,,,Rattus norvegicus,CHEMBL618319,10116.0
7653,N,,,7800C1 cell line,,80635,1,Intermediate,,4136,F,,,1,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,1119.0,,,Rattus norvegicus,CHEMBL618320,10116.0
7653,N,,,7800C1 cell line,,80635,1,Intermediate,,4137,F,,,1,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,1119.0,,,Rattus norvegicus,CHEMBL618321,10116.0
7653,N,,,7800C1 cell line,,80635,1,Intermediate,,4138,F,,,1,BAO_0000219,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,1119.0,,,Rattus norvegicus,CHEMBL883118,10116.0
17229,N,,,786-0,,80640,1,Intermediate,,4139,F,,,1,BAO_0000219,In vitro antitumor activity against renal 786-0 tumor cell lines,391.0,,,Homo sapiens,CHEMBL883795,9606.0
12858,N,,,786-0,,80640,1,Intermediate,,4140,F,,,1,BAO_0000219,Cytotoxic activity against 786-0 Renal cancer cell line,391.0,,,Homo sapiens,CHEMBL618322,9606.0
16325,N,,,786-0,,80640,1,Intermediate,,4141,F,,,1,BAO_0000219,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,391.0,,,Homo sapiens,CHEMBL618323,9606.0
16325,N,,,786-0,,80640,1,Intermediate,,4142,F,,,1,BAO_0000219,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,391.0,,,Homo sapiens,CHEMBL618324,9606.0
5858,N,,,786-0,,80640,1,Intermediate,,4143,F,,,1,BAO_0000219,In vitro antitumor activity against human renal 786-0 cell line,391.0,,,Homo sapiens,CHEMBL618325,9606.0
16325,N,,,786-0,,80640,1,Intermediate,,4144,F,,,1,BAO_0000219,Inhibition of Renal cancer in 786-0 cancer cell lines,391.0,,,Homo sapiens,CHEMBL875416,9606.0
14696,N,,,786-0,,80640,1,Intermediate,,4145,F,,,1,BAO_0000219,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,391.0,,,Homo sapiens,CHEMBL618326,9606.0
3786,N,,,786-0,,80640,1,Intermediate,,4146,F,,,1,BAO_0000219,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,391.0,,,Homo sapiens,CHEMBL618327,9606.0
14696,N,,,786-0,,80640,1,Intermediate,,4147,F,,,1,BAO_0000219,inhibition of the growth of renal cancer(786-0) cell line,391.0,,,Homo sapiens,CHEMBL619215,9606.0
14769,N,,,786-0,,80640,1,Intermediate,,4148,F,,,1,BAO_0000219,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),391.0,,,Homo sapiens,CHEMBL619216,9606.0
15354,N,,,786-0,,80640,1,Intermediate,,4149,F,,,1,BAO_0000219,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,391.0,,,Homo sapiens,CHEMBL619217,9606.0
14255,N,,,786-0,,80640,1,Intermediate,,4150,F,,,1,BAO_0000219,The IC50 value was measured on 786-0 cell line in ovarian tumor,391.0,,,Homo sapiens,CHEMBL619218,9606.0
14255,N,,,786-0,,80640,1,Intermediate,,4151,F,,,1,BAO_0000219,The IC50 value was measured on 786-0 cell line in ovarian tumor t,391.0,,,Homo sapiens,CHEMBL619219,9606.0
14255,N,,,786-0,,80640,1,Intermediate,,4152,F,,,1,BAO_0000219,The IC50 value was measured on 786-0 cell line in renal tumor type.,391.0,,,Homo sapiens,CHEMBL619220,9606.0
14696,N,,,786-0,,80640,1,Intermediate,,4153,F,,,1,BAO_0000219,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,391.0,,,Homo sapiens,CHEMBL619221,9606.0
12016,N,,,786-0,,80640,1,Intermediate,,4154,F,,,1,BAO_0000219,Tested for cytotoxic activity against renal cancer 786-0 cell line,391.0,,,Homo sapiens,CHEMBL619222,9606.0
2597,N,,,786-0,,80640,1,Intermediate,,4155,F,,,1,BAO_0000219,Compound was tested for growth inhibitory activity against 786-0 cell line,391.0,,,Homo sapiens,CHEMBL857454,9606.0
12526,H,,,RBL-1,,12166,8,Autocuration,,4156,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,702.0,,,,CHEMBL619223,
12526,H,,,RBL-1,,12166,8,Autocuration,,4157,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,702.0,,,,CHEMBL619224,
14799,H,,,,,12166,8,Autocuration,,4158,B,,,1,BAO_0000019,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,,,CHEMBL619225,
3595,H,,,RBL-1,,12166,8,Expert,,4159,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),702.0,,,,CHEMBL619226,
3595,H,,,RBL-1,,12166,8,Expert,,4160,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),702.0,,,,CHEMBL619227,
12767,H,,,,,12166,8,Autocuration,,4161,B,,,1,BAO_0000357,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,,,,CHEMBL619228,
10997,H,,,,,12166,8,Autocuration,,4162,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,,,,CHEMBL619229,
11388,H,,,RBL-1,,12166,8,Autocuration,,4163,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,702.0,,,,CHEMBL619230,
167,H,,,,,12166,8,Autocuration,,4164,B,,,1,BAO_0000357,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,,,,CHEMBL619231,
167,H,,,,,12166,8,Autocuration,,4165,B,,,1,BAO_0000357,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,,,,CHEMBL619232,
13744,H,,,,,12166,8,Expert,,4166,B,,,1,BAO_0000357,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,,,,CHEMBL619233,
1630,H,,,,,12166,8,Autocuration,,4167,B,,,1,BAO_0000357,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,,,,CHEMBL619234,
1630,H,,,,,12166,8,Autocuration,,4168,B,,,1,BAO_0000357,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,,,,CHEMBL619235,
969,D,,,,,12166,9,Expert,,4169,B,,,1,BAO_0000019,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,,,Rattus norvegicus,CHEMBL619236,10116.0
13621,H,,,RBL-1,,12166,8,Autocuration,,4170,B,,,1,BAO_0000219,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,702.0,,,,CHEMBL619237,
10089,H,,,,,12166,8,Autocuration,,4171,B,,,1,BAO_0000357,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,,,,CHEMBL619238,
10193,H,,,,,12166,8,Expert,,4172,B,,,1,BAO_0000357,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,,,,CHEMBL619239,
11966,H,,,,,12166,8,Autocuration,,4173,B,,,1,BAO_0000357,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,,,,CHEMBL619240,
12251,H,,,,,12166,8,Autocuration,,4174,B,,,1,BAO_0000019,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,,,CHEMBL875417,
211,H,,,RBL-1,,12166,8,Autocuration,,4175,B,,,1,BAO_0000219,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),702.0,,,,CHEMBL619241,
12251,H,,,,,12166,8,Expert,,4176,F,,,1,BAO_0000019,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,,,,CHEMBL619242,
12495,H,,,RBL-1,,12166,8,Autocuration,,4177,B,,,1,BAO_0000219,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,702.0,,,,CHEMBL883796,
414,H,,,,,12166,8,Autocuration,,4178,B,,,1,BAO_0000357,Tested for its inhibitory activity against 5-lipoxygenase,,,,,CHEMBL619243,
414,H,,,,,12166,8,Autocuration,,4179,B,,,1,BAO_0000357,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,,,,CHEMBL619244,
10325,H,,,,,12166,8,Expert,,4180,B,,,1,BAO_0000019,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,,,,CHEMBL619245,
11966,H,,,,,12166,8,Expert,,4181,B,,,1,BAO_0000019,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,,,CHEMBL619246,
165,H,,,RBL-1,,12166,8,Expert,,4182,B,,,1,BAO_0000219,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,702.0,,,,CHEMBL619984,
165,H,,,RBL-1,,12166,8,Autocuration,,4183,B,,,1,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,702.0,,,,CHEMBL619985,
165,H,,,RBL-1,,12166,8,Autocuration,,4184,B,,,1,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,702.0,,,,CHEMBL619986,
165,H,,,RBL-1,,12166,8,Expert,,4185,B,,,1,BAO_0000219,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,702.0,,,,CHEMBL619987,
11311,H,,,,,12166,8,Autocuration,,4186,B,,,1,BAO_0000218,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,,,,CHEMBL619988,
11311,H,,,RBL-1,,12166,8,Autocuration,,4187,B,,,1,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,702.0,,,,CHEMBL619989,
11311,H,,,RBL-1,,12166,8,Autocuration,,4188,B,,,1,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,702.0,,,,CHEMBL619990,
11311,H,,,,,12166,8,Autocuration,,4189,B,,,1,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,,,,CHEMBL619991,
11311,H,,,,,12166,8,Autocuration,,4190,B,,,1,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,,,,CHEMBL619992,
11311,H,,,,In vivo,12166,8,Autocuration,,4191,B,,,1,BAO_0000218,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,,,,CHEMBL619993,
11311,H,,,RBL-2H3,,12166,8,Autocuration,,4192,F,,,1,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,663.0,,,,CHEMBL619994,
11311,H,,,RBL-2H3,,12166,8,Autocuration,,4193,F,,,1,BAO_0000219,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,663.0,,,,CHEMBL619995,
11311,H,,,,,12166,8,Autocuration,,4194,B,,,1,BAO_0000019,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,,,,CHEMBL619996,
11732,H,,,,,12166,8,Autocuration,,4195,B,,,1,BAO_0000019,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,,,,CHEMBL619997,
11732,H,,,,,12166,8,Expert,,4196,B,,,1,BAO_0000019,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,,,,CHEMBL619998,
11087,H,,,,,12166,8,Expert,,4197,B,,,1,BAO_0000019,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,,,,CHEMBL619999,
11087,H,,,,,12166,8,Autocuration,,4198,B,,,1,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,,,,CHEMBL620000,
11087,H,,,RBL-1,,12166,8,Autocuration,,4199,B,,,1,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,702.0,,,,CHEMBL620001,
11087,D,,,,,12166,9,Expert,,4200,B,,,1,BAO_0000357,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,,,Rattus norvegicus,CHEMBL620002,10116.0
496,H,,,RBL-1,,12166,8,Autocuration,,4201,B,,,1,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,702.0,,,,CHEMBL620003,
13986,H,,,RBL-1,,12166,8,Expert,,4202,F,,,1,BAO_0000219,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,702.0,,,,CHEMBL620004,
11520,H,,,,,12166,8,Autocuration,,4203,B,,,1,BAO_0000357,Compound was evaluated for the inhibition of 5-lipoxygenase,,,,,CHEMBL874063,
10293,H,,,RBL-1,,12166,8,Autocuration,,4204,B,,,1,BAO_0000219,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,702.0,,,,CHEMBL620005,
303,H,,,RBL-1,,12166,8,Autocuration,,4205,B,,,1,BAO_0000219,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,702.0,,,,CHEMBL620006,
303,H,,,RBL-1,,12166,8,Autocuration,,4206,B,,,1,BAO_0000219,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,702.0,,,,CHEMBL620007,
9247,H,,,RBL-1,,12166,8,Autocuration,,4207,B,,,1,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,702.0,,,,CHEMBL620008,
9247,D,,,RBL-1,,12166,9,Expert,,4208,B,,,1,BAO_0000219,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,702.0,,,Rattus norvegicus,CHEMBL620009,10116.0
9247,H,,,RBL-1,,12166,8,Autocuration,,4209,B,,,1,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,702.0,,,,CHEMBL620010,
9247,H,,,RBL-1,,12166,8,Autocuration,,4210,B,,,1,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,702.0,,,,CHEMBL620011,
9247,H,,,RBL-1,,12166,8,Autocuration,,4211,B,,,1,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,702.0,,,,CHEMBL620677,
9247,H,,,RBL-1,,12166,8,Autocuration,,4212,B,,,1,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,702.0,,,,CHEMBL620678,
9247,H,,,RBL-1,,12166,8,Autocuration,,4213,B,,,1,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,702.0,,,,CHEMBL620679,
9247,H,,,RBL-1,,12166,8,Autocuration,,4214,B,,,1,BAO_0000219,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,702.0,,,,CHEMBL620680,
11481,D,,,,,12166,9,Expert,,4215,B,,,1,BAO_0000357,Inhibitory activity against 5-lipoxygenase at 10 uM,,,,Rattus norvegicus,CHEMBL620838,10116.0
105,H,,,,,12166,8,Autocuration,,4216,B,,,1,BAO_0000357,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,,,,CHEMBL620839,
9029,H,,,,,12166,8,Expert,,4217,B,,,1,BAO_0000357,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,,,,CHEMBL620840,
1175,H,,,RBL-1,,12166,8,Expert,,4218,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,702.0,,,,CHEMBL620841,
12118,H,,,RBL-1,,12166,8,Autocuration,,4219,B,,,1,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,702.0,,,,CHEMBL620842,
12118,H,,,RBL-1,,12166,8,Autocuration,,4220,B,,,1,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,702.0,,,,CHEMBL620843,
12118,H,,,RBL-1,,12166,8,Autocuration,,4221,B,,,1,BAO_0000219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,702.0,,,,CHEMBL620844,
9225,H,,,RBL-1,,12166,8,Autocuration,,4222,B,,,1,BAO_0000219,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,702.0,,,,CHEMBL620845,
9401,H,,,,,12166,8,Autocuration,,4223,B,,,1,BAO_0000019,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,,,,CHEMBL620846,
137,H,,,,,12166,8,Autocuration,,4224,B,,,1,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,,,CHEMBL873951,
137,H,,,,,12166,8,Autocuration,,4225,B,,,1,BAO_0000357,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,,,,CHEMBL620847,
4717,H,,,RBL-1,,12166,8,Autocuration,,4226,B,,,1,BAO_0000219,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,702.0,,,,CHEMBL620848,
3595,H,,,RBL-1,,12166,8,Autocuration,,4227,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,702.0,,,,CHEMBL620849,
10501,H,,,RBL-1,,12166,8,Autocuration,,4228,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,702.0,,,,CHEMBL620850,
10501,H,,,RBL-1,,12166,8,Autocuration,,4229,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,702.0,,,,CHEMBL620851,
10501,H,,,RBL-1,,12166,8,Autocuration,,4230,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,702.0,,,,CHEMBL620852,
12526,H,,,RBL-1,,12166,8,Autocuration,,4231,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,702.0,,,,CHEMBL875098,
14799,D,,,RBL-1,,12166,9,Expert,,4232,B,,,1,BAO_0000219,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,702.0,,,Rattus norvegicus,CHEMBL620853,10116.0
14799,H,,,,,12166,8,Autocuration,,4233,B,,,1,BAO_0000019,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,,,,CHEMBL620854,
3595,H,,,RBL-1,,12166,8,Autocuration,,4234,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,702.0,,,,CHEMBL620855,
3595,H,,,RBL-1,,12166,8,Expert,,4235,B,,,1,BAO_0000219,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,702.0,,,,CHEMBL839884,
12526,H,,,RBL-1,,12166,8,Autocuration,,4236,B,,,1,BAO_0000219,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,702.0,,,,CHEMBL620856,
12526,H,,,RBL-1,,12166,8,Autocuration,,4237,B,,,1,BAO_0000219,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,702.0,,,,CHEMBL620857,
10193,H,,,,,12166,8,Autocuration,,4238,B,,,1,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,,,CHEMBL620858,
10193,H,,,,,12166,8,Autocuration,,4239,B,,,1,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,,,CHEMBL620859,
10193,H,,,,,12166,8,Autocuration,,4240,B,,,1,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,,,,CHEMBL620860,
10193,H,,,,,12166,8,Autocuration,,4241,B,,,1,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,,,,CHEMBL620861,
9138,H,,,,,12166,8,Expert,,4242,B,,,1,BAO_0000357,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,,,,CHEMBL620862,
9138,H,,,,,12166,8,Autocuration,,4243,B,,,1,BAO_0000357,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,,,,CHEMBL620863,
11966,H,,,,,12166,8,Autocuration,,4244,B,,,1,BAO_0000019,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,,,,CHEMBL620864,
165,H,,,RBL-1,,12166,8,Autocuration,,4245,B,,,1,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,702.0,,,,CHEMBL620865,
165,H,,,RBL-1,,12166,8,Autocuration,,4246,B,,,1,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,702.0,,,,CHEMBL620866,
11311,H,,,RBL-2H3,,12166,8,Autocuration,,4247,B,,,1,BAO_0000219,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,663.0,,,,CHEMBL620867,
11311,H,,,RBL-2H3,,12166,8,Autocuration,,4248,B,,,1,BAO_0000219,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,663.0,,,,CHEMBL620868,
11311,H,,,RBL-2H3,,12166,8,Autocuration,,4249,F,,,1,BAO_0000219,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,663.0,,,,CHEMBL620869,
11311,H,,,,,12166,8,Autocuration,,4250,F,,,1,BAO_0000019,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,,,,CHEMBL873952,
11311,H,,,,,12166,8,Autocuration,,4251,B,,,1,BAO_0000357,The compound was tested for inhibition of isolated 5-lipoxygenase,,,,,CHEMBL875099,
11311,H,,,RBL-2H3,,12166,8,Autocuration,,4252,F,,,1,BAO_0000219,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,663.0,,,,CHEMBL620870,
11087,H,,,,,12166,8,Autocuration,,4253,B,,,1,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,,,,CHEMBL618261,
11087,H,,,,,12166,8,Autocuration,,4254,B,,,1,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,,,,CHEMBL618262,
11087,H,,,,,12166,8,Autocuration,,4255,B,,,1,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,,,,CHEMBL619428,
11087,H,,,,,12166,8,Autocuration,,4256,B,,,1,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,,,CHEMBL619429,
11087,H,,,,,12166,8,Autocuration,,4257,B,,,1,BAO_0000019,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,,,,CHEMBL619430,
496,H,,,RBL-1,,12166,8,Autocuration,,4258,B,,,1,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,702.0,,,,CHEMBL620017,
496,H,,,RBL-1,,12166,8,Autocuration,,4259,B,,,1,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,702.0,,,,CHEMBL620018,
13986,H,,,RBL-1,,12166,8,Autocuration,,4260,F,,,1,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,702.0,,,,CHEMBL620019,
13986,H,,,RBL-1,,12166,8,Autocuration,,4261,F,,,1,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,702.0,,,,CHEMBL620020,
13986,H,,,RBL-1,,12166,8,Autocuration,,4262,F,,,1,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,702.0,,,,CHEMBL620021,
13986,H,,,RBL-1,,12166,8,Autocuration,,4263,F,,,1,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,702.0,,,,CHEMBL620022,
13986,H,,,RBL-1,,12166,8,Autocuration,,4264,F,,,1,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,702.0,,,,CHEMBL620023,
13986,H,,,RBL-1,,12166,8,Autocuration,,4265,F,,,1,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,702.0,,,,CHEMBL620024,
13986,H,,,RBL-1,,12166,8,Autocuration,,4266,F,,,1,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,702.0,,,,CHEMBL620025,
13986,H,,,RBL-1,,12166,8,Autocuration,,4267,F,,,1,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,702.0,,,,CHEMBL620026,
13986,H,,,RBL-1,,12166,8,Autocuration,,4268,F,,,1,BAO_0000219,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,702.0,,,,CHEMBL620027,
13986,D,,,,,12166,9,Expert,,4269,F,,,1,BAO_0000019,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,,,Rattus norvegicus,CHEMBL620028,10116.0
10193,H,,,,,12166,8,Autocuration,,4270,B,,,1,BAO_0000357,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,,,,CHEMBL620029,
9295,H,,,,,12166,8,Autocuration,,4271,B,,,1,BAO_0000357,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,,,,CHEMBL620030,
4717,H,,,RBL-1,,12166,8,Autocuration,,4272,B,,,1,BAO_0000219,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,702.0,,,,CHEMBL875415,
4717,H,,,RBL-1,,12166,8,Autocuration,,4273,B,,,1,BAO_0000219,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,702.0,,,,CHEMBL618256,
11854,H,,,RBL-1,,12166,8,Autocuration,,4274,B,,,1,BAO_0000219,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,702.0,,,,CHEMBL618257,
11854,H,,,RBL-1,,12166,8,Autocuration,,4275,B,,,1,BAO_0000219,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,702.0,,,,CHEMBL618258,
11854,H,,,RBL-1,,12166,8,Autocuration,,4276,B,,,1,BAO_0000219,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,702.0,,,,CHEMBL618259,
10193,H,,,,,12166,8,Autocuration,,4277,B,,,1,BAO_0000019,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,,,,CHEMBL618260,
9295,H,,,RBL-1,,12166,8,Autocuration,,4278,B,,,1,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,702.0,,,,CHEMBL618215,
9295,H,,,RBL-1,,12166,8,Autocuration,,4279,B,,,1,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,702.0,,,,CHEMBL618390,
9295,H,,,RBL-1,,12166,8,Autocuration,,4280,B,,,1,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,702.0,,,,CHEMBL618391,
9295,H,,,RBL-1,,12166,8,Autocuration,,4281,B,,,1,BAO_0000219,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,702.0,,,,CHEMBL618392,
165,H,,,RBL-1,,12166,8,Autocuration,,4282,B,,,1,BAO_0000219,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,702.0,,,,CHEMBL618393,
11311,H,,,,,12166,8,Autocuration,,4283,B,,,1,BAO_0000219,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,,,,CHEMBL618394,
10489,H,,,RBL-1,,12166,8,Expert,,4284,B,,,1,BAO_0000219,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),702.0,,,Homo sapiens,CHEMBL618395,9606.0
10489,D,,,RBL-1,,12166,9,Expert,,4285,B,,,1,BAO_0000219,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),702.0,,,Rattus norvegicus,CHEMBL618396,10116.0
10489,D,,,RBL-1,,12166,9,Expert,,4286,B,,,1,BAO_0000219,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),702.0,,,Rattus norvegicus,CHEMBL858253,10116.0
14799,D,,,,,12166,9,Autocuration,,4287,B,,,1,BAO_0000019,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,,,Rattus norvegicus,CHEMBL618397,10116.0
9295,H,,,,,12054,8,Autocuration,,4288,B,,,1,BAO_0000357,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,,,Glycine max,CHEMBL618398,3847.0
16811,U,,,,,22226,0,Autocuration,,4289,B,,,1,BAO_0000019,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,,,,CHEMBL618399,
168,H,,,,,55,8,Expert,,4290,B,,,1,BAO_0000357,In vitro inhibition of 5-Lipoxygenase; Inactive.,,,,,CHEMBL618400,
6309,H,,,,,55,8,Autocuration,,4291,B,,,1,BAO_0000357,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,,,,CHEMBL618401,
6309,H,,,,,55,8,Autocuration,,4292,B,,,1,BAO_0000357,Inhibitory concentration against 5-lipoxygenase; No inhibition,,,,,CHEMBL618402,
3092,H,,,RBL-1,,55,8,Autocuration,,4293,B,,,1,BAO_0000219,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,702.0,,,,CHEMBL876400,
168,H,,,,,55,8,Expert,,4294,B,,,1,BAO_0000357,Inhibitory activity against 5-lipoxygenase.,,,,,CHEMBL618403,
168,H,,,,,55,8,Autocuration,,4295,B,,,1,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,,,,CHEMBL618404,
168,H,,,,,55,8,Autocuration,,4296,B,,,1,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,,,,CHEMBL618405,
168,H,,,,,55,8,Autocuration,,4297,B,,,1,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,,,,CHEMBL618406,
12338,H,,,,,55,8,Expert,,4298,F,,,1,BAO_0000019,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,,,,CHEMBL618407,
4501,H,,,,,55,8,Autocuration,,4299,B,,,1,BAO_0000357,Tested for the inhibitory activity against 5-lipoxygenase,,,,,CHEMBL618408,
1132,H,,,,,55,8,Autocuration,,4300,B,,,1,BAO_0000357,Compound was tested for its inhibitory activity against 5-lipoxygenase,,,,,CHEMBL618409,
2117,H,,,,,55,8,Autocuration,,4301,B,,,1,BAO_0000357,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,,,,CHEMBL618410,
168,H,,,,,55,8,Autocuration,,4302,B,,,1,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,,,,CHEMBL618411,
168,H,,,,,55,8,Autocuration,,4303,B,,,1,BAO_0000357,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,,,,CHEMBL618412,
13575,H,,,RBL-1,,12166,8,Autocuration,,4304,B,,,1,BAO_0000219,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,702.0,,,,CHEMBL618413,
11089,H,,,,,12166,8,Autocuration,,4305,B,,,1,BAO_0000357,,,,,,CHEMBL618414,
216,H,,,,,10102,8,Autocuration,,4306,B,,,1,BAO_0000357,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,,,,CHEMBL618415,
13165,H,,,,,10102,8,Autocuration,,4307,B,,,1,BAO_0000019,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,,,,CHEMBL618416,
3278,H,,,,,10102,8,Autocuration,,4308,B,,,1,BAO_0000357,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,,,,CHEMBL876401,
3278,H,,,,,10102,8,Expert,,4309,B,,,1,BAO_0000357,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,,,,CHEMBL618417,
11966,H,,,,,10102,8,Autocuration,,4310,B,,,1,BAO_0000357,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,,,,CHEMBL618418,
175,H,,,,,10102,8,Autocuration,,4311,B,,,1,BAO_0000357,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,,,,CHEMBL618419,
175,H,,,,,10102,8,Autocuration,,4312,B,,,1,BAO_0000357,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,,,,CHEMBL618420,
13449,H,,,,,10102,8,Autocuration,,4313,B,,,1,BAO_0000357,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,,,,CHEMBL618421,
12014,H,,,,,11238,8,Autocuration,,4314,B,,,1,BAO_0000019,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,,,,CHEMBL618422,
12014,H,,,,,11238,8,Autocuration,,4315,B,,,1,BAO_0000019,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,,,,CHEMBL618423,
12014,H,,,,,11238,8,Autocuration,,4316,B,,,1,BAO_0000019,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,,,,CHEMBL618424,
99,S,,,,,100284,2,Intermediate,,4317,B,,,1,BAO_0000220,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,,,,CHEMBL618425,
4349,U,,,,,22226,0,Autocuration,,4318,F,,,1,BAO_0000019,The dark toxicity against 543 human galactophore carcinoma cells,,,,Homo sapiens,CHEMBL618426,9606.0
4071,N,,,Panel (56 tumour cell lines),,80623,1,Expert,,4319,F,,,1,BAO_0000219,Tested in vitro for cytotoxicity against 56 human tumor cell lines,390.0,,,Homo sapiens,CHEMBL618427,9606.0
17589,N,,,5637,,80008,1,Expert,,4320,F,,,1,BAO_0000219,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,345.0,,,Homo sapiens,CHEMBL618428,9606.0
15002,N,,,5637,,80008,1,Intermediate,,4321,F,,,1,BAO_0000219,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,345.0,,,Homo sapiens,CHEMBL618429,9606.0
13958,N,,,5637,,80008,1,Intermediate,,4322,F,,,1,BAO_0000219,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",345.0,,,Homo sapiens,CHEMBL618430,9606.0
17589,N,,,5637,,80008,1,Expert,,4323,F,,,1,BAO_0000219,Growth inhibition against human 5637 cell lines,345.0,,,Homo sapiens,CHEMBL618431,9606.0
16748,N,,,5637,,80008,1,Expert,,4324,F,,,1,BAO_0000219,Antitumor activity against human bladder carcinoma 5637 cells.,345.0,,,Homo sapiens,CHEMBL883799,9606.0
16747,N,,,5637,,80008,1,Intermediate,,4325,F,,,1,BAO_0000219,Antitumor activity against human bladder carcinoma 5637 cells,345.0,,,Homo sapiens,CHEMBL618432,9606.0
16747,N,,,5637,,80008,1,Intermediate,,4326,F,,,1,BAO_0000219,Antitumor activity against human bladder carcinoma 5637 cells,345.0,,,Homo sapiens,CHEMBL618433,9606.0
15285,D,,,,,10443,9,Expert,,4327,B,,,1,BAO_0000357,In vitro inhibition of bovine trypsin(Trp).,,,,Bos taurus,CHEMBL618434,9913.0
3726,H,,,CV-1,,240,8,Expert,,4328,B,,,1,BAO_0000219,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,407.0,,,Cercopithecidae,CHEMBL618435,9527.0
5033,H,,,,,10577,8,Autocuration,,4329,B,,,1,BAO_0000357,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,,,,CHEMBL876402,
11756,H,,,,,104698,6,Autocuration,,4330,F,,,1,BAO_0000019,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,,,,CHEMBL618436,
11953,U,,,,In vivo,22226,0,Autocuration,,4331,F,,,1,BAO_0000218,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,,,,CHEMBL618437,
5033,D,,,,,20033,9,Intermediate,,4332,B,,,1,BAO_0000357,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,,,Cavia porcellus,CHEMBL618438,10141.0
11347,H,,,,,17045,8,Expert,Microsomes,4333,A,,,1,BAO_0000251,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,,,Rattus norvegicus,CHEMBL883800,10116.0
11347,H,,,,,17045,8,Expert,Microsomes,4334,A,,,1,BAO_0000251,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,,,Rattus norvegicus,CHEMBL618439,10116.0
1229,U,,,,,22226,0,Intermediate,,4335,F,,,1,BAO_0000019,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,,,CHEMBL618440,
1229,U,,,,,22226,0,Intermediate,,4336,F,,,1,BAO_0000019,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,,,,CHEMBL618441,
17588,H,,,,,11938,8,Expert,,4337,B,,,1,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,,,Trypanosoma brucei,CHEMBL618442,5691.0
17588,H,,,,,11938,8,Autocuration,,4338,B,,,1,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,,,Trypanosoma brucei,CHEMBL618443,5691.0
17588,H,,,,,11938,8,Expert,,4339,B,,,1,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,,,Ovis aries,CHEMBL619158,9940.0
17588,H,,,,,11938,8,Autocuration,,4340,B,,,1,BAO_0000019,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,,,Ovis aries,CHEMBL620974,9940.0
16485,H,,,,,11938,8,Autocuration,,4341,B,,,1,BAO_0000357,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,,,,CHEMBL620975,
4337,U,,,,,22226,0,Intermediate,,4342,F,,,1,BAO_0000019,Average inhibitory concentration against 60 human cell lines was reported,,,,Homo sapiens,CHEMBL620976,9606.0
4112,U,,,,,22226,0,Expert,,4343,F,,,1,BAO_0000019,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,,,Homo sapiens,CHEMBL620977,9606.0
16160,N,,,Panel NCI-60 (60 carcinoma cell lines),,80315,1,Intermediate,,4344,F,,,1,BAO_0000219,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,542.0,,,Homo sapiens,CHEMBL620978,9606.0
16160,N,,,Panel NCI-60 (60 carcinoma cell lines),,80315,1,Intermediate,,4345,F,,,1,BAO_0000219,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,542.0,,,Homo sapiens,CHEMBL620979,9606.0
17376,N,,,Panel NCI-60 (60 carcinoma cell lines),,80315,1,Expert,,4346,F,,,1,BAO_0000219,In vitro mean growth inhibitory activity against 60-cell panel,542.0,,,,CHEMBL620980,
17376,N,,,Panel NCI-60 (60 carcinoma cell lines),,80315,1,Expert,,4347,F,,,1,BAO_0000219,In vitro mean growth lethal concentration against 60-cell panel,542.0,,,,CHEMBL620981,
17376,N,,,Panel NCI-60 (60 carcinoma cell lines),,80315,1,Expert,,4348,F,,,1,BAO_0000219,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,542.0,,,,CHEMBL620982,
17376,N,,,Panel NCI-60 (60 carcinoma cell lines),,80315,1,Expert,,4349,F,,,1,BAO_0000219,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,542.0,,,,CHEMBL620983,
3241,H,,,,,104775,4,Autocuration,,4350,F,,,1,BAO_0000019,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,,,CHEMBL620984,
3241,H,,,,,104775,4,Autocuration,,4351,F,,,1,BAO_0000019,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,,,,CHEMBL620985,
3725,H,,,,,275,8,Expert,,4352,B,,,1,BAO_0000357,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,,,,CHEMBL620986,
10805,N,,,,,50425,1,Expert,,4353,F,,,1,BAO_0000218,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,,,Plasmodium falciparum,CHEMBL620987,5833.0
10805,N,,,,,50425,1,Expert,,4354,F,,,1,BAO_0000218,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,,,Plasmodium falciparum,CHEMBL620988,5833.0
10805,N,,,,,50425,1,Expert,,4355,F,,,1,BAO_0000218,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,,,Plasmodium falciparum,CHEMBL620989,5833.0
10805,N,,,,,50425,1,Expert,,4356,F,,,1,BAO_0000218,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,,,Plasmodium falciparum,CHEMBL620990,5833.0
10805,N,,,,,50425,1,Intermediate,,4357,F,,,1,BAO_0000218,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,,,Plasmodium falciparum,CHEMBL620991,5833.0
10144,N,,,6C3HED,,80628,1,Intermediate,,4358,F,,,1,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,850.0,,,Mus musculus,CHEMBL620992,10090.0
10144,N,,,6C3HED,,80628,1,Intermediate,,4359,F,,,1,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,850.0,,,Mus musculus,CHEMBL620993,10090.0
10144,N,,,6C3HED,,80628,1,Intermediate,,4360,F,,,1,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,850.0,,,Mus musculus,CHEMBL620994,10090.0
10144,N,,,6C3HED,,80628,1,Intermediate,,4361,F,,,1,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,850.0,,,Mus musculus,CHEMBL620995,10090.0
10144,N,,,6C3HED,,80628,1,Intermediate,,4362,F,,,1,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,850.0,,,Mus musculus,CHEMBL620996,10090.0
10144,N,,,6C3HED,,80628,1,Intermediate,,4363,F,,,1,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,850.0,,,Mus musculus,CHEMBL875581,10090.0
10685,U,,,,In vivo,22224,0,Autocuration,,4364,F,,,1,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,,,Mus musculus,CHEMBL620997,10090.0
10685,U,,,,In vivo,22224,0,Autocuration,,4365,F,,,1,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,,,Mus musculus,CHEMBL620998,10090.0
10685,U,,,,In vivo,22224,0,Autocuration,,4366,F,,,1,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,,,Mus musculus,CHEMBL620999,10090.0
10685,U,,,,In vivo,22224,0,Autocuration,,4367,F,,,1,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,,,Mus musculus,CHEMBL621000,10090.0
10685,U,,,,In vivo,22224,0,Autocuration,,4368,F,,,1,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,,,Mus musculus,CHEMBL621001,10090.0
10685,U,,,,In vivo,22224,0,Autocuration,,4369,F,,,1,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,,,Mus musculus,CHEMBL621002,10090.0
10685,U,,,,In vivo,22224,0,Autocuration,,4370,F,,,1,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,,,Mus musculus,CHEMBL621003,10090.0
10685,U,,,,In vivo,22224,0,Autocuration,,4371,F,,,1,BAO_0000218,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,,,Mus musculus,CHEMBL621004,10090.0
10685,U,,,,In vivo,22224,0,Autocuration,,4372,F,,,1,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,,,Mus musculus,CHEMBL621005,10090.0
10685,U,,,,In vivo,22224,0,Autocuration,,4373,F,,,1,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,,,Mus musculus,CHEMBL621006,10090.0
10685,U,,,,In vivo,22224,0,Autocuration,,4374,F,,,1,BAO_0000218,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,,,Mus musculus,CHEMBL621007,10090.0
10144,U,,,,,22224,0,Autocuration,,4375,F,,,1,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,,,Mus musculus,CHEMBL621008,10090.0
10144,U,,,,,22224,0,Autocuration,,4376,F,,,1,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,,,Mus musculus,CHEMBL621009,10090.0
10144,U,,,,,22224,0,Autocuration,,4377,F,,,1,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,,,Mus musculus,CHEMBL857705,10090.0
10144,U,,,,,22224,0,Autocuration,,4378,F,,,1,BAO_0000218,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,,,Mus musculus,CHEMBL619828,10090.0
10685,U,,,,,22224,0,Autocuration,,4379,F,,,1,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,,,Mus musculus,CHEMBL619829,10090.0
10685,U,,,,,22224,0,Autocuration,,4380,F,,,1,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,,,Mus musculus,CHEMBL619830,10090.0
10685,U,,,,,22224,0,Autocuration,,4381,F,,,1,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,,,Mus musculus,CHEMBL619831,10090.0
10685,U,,,,,22224,0,Autocuration,,4382,F,,,1,BAO_0000218,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,,,Mus musculus,CHEMBL619832,10090.0
10685,U,,,,,22224,0,Autocuration,,4383,A,,,1,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,,,Mus musculus,CHEMBL619833,10090.0
10685,U,,,,,22224,0,Autocuration,,4384,A,,,1,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,,,Mus musculus,CHEMBL619834,10090.0
10685,U,,,,,22224,0,Autocuration,,4385,A,,,1,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,,,Mus musculus,CHEMBL619835,10090.0
10685,U,,,,,22224,0,Autocuration,,4386,A,,,1,BAO_0000218,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,,,Mus musculus,CHEMBL619836,10090.0
8831,N,,,6C3HED,,80628,1,Intermediate,,4387,F,,,1,BAO_0000218,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",850.0,,,Mus musculus,CHEMBL619837,10090.0
11704,U,,,,In vivo,22224,0,Autocuration,,4388,F,,,1,BAO_0000218,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,,,,CHEMBL619838,
11704,N,,,,,50594,1,Intermediate,,4389,A,,,1,BAO_0000218,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,,,Mus musculus,CHEMBL619839,10090.0
10685,N,,,6C3HED,In vivo,80628,1,Intermediate,,4390,F,,,1,BAO_0000218,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,850.0,,,Mus musculus,CHEMBL619840,10090.0
10685,N,,,6C3HED,In vivo,80628,1,Intermediate,,4391,F,,,1,BAO_0000218,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,850.0,,,Mus musculus,CHEMBL619841,10090.0
11368,N,,,6C3HED,,80628,1,Expert,,4392,F,,,1,BAO_0000218,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),850.0,,,Mus musculus,CHEMBL857704,10090.0
11368,N,,,6C3HED,,80628,1,Intermediate,,4393,F,,,1,BAO_0000218,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),850.0,,,Mus musculus,CHEMBL619842,10090.0
11368,N,,,6C3HED,,80628,1,Expert,,4394,F,,,1,BAO_0000218,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),850.0,,,Mus musculus,CHEMBL619843,10090.0
17763,U,,,,,22226,0,Autocuration,,4395,B,,,1,BAO_0000019,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,,,Staphylococcus aureus,CHEMBL619844,1280.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4396,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,,2107.0,Rattus norvegicus,CHEMBL857855,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4397,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,,2107.0,Rattus norvegicus,CHEMBL619845,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4398,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,,2107.0,Rattus norvegicus,CHEMBL619846,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4399,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,,2107.0,Rattus norvegicus,CHEMBL619847,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4400,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,,2107.0,Rattus norvegicus,CHEMBL619848,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4401,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,,2107.0,Rattus norvegicus,CHEMBL620893,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4402,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,,2107.0,Rattus norvegicus,CHEMBL620894,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4403,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,,2107.0,Rattus norvegicus,CHEMBL620895,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4404,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,,2107.0,Rattus norvegicus,CHEMBL620896,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4405,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,,2107.0,Rattus norvegicus,CHEMBL620897,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4406,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,,2107.0,Rattus norvegicus,CHEMBL620898,10116.0
7411,U,,,,,22226,0,Autocuration,Microsomes,4407,B,Liver,,1,BAO_0000251,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,,2107.0,Rattus norvegicus,CHEMBL620899,10116.0
347,U,,,,In vivo,22224,0,Autocuration,,4408,A,Plasma,,1,BAO_0000218,The apparent total plasma clearance in monkey,,,1969.0,Cercopithecidae,CHEMBL620900,9527.0
3341,U,,,,In vivo,22224,0,Autocuration,,4409,A,,,1,BAO_0000218,Compound was evaluated for Hepatic clearance in monkey,,,,Cercopithecidae,CHEMBL620901,9527.0
17853,U,,,,In vivo,22224,0,Autocuration,,4410,A,,,1,BAO_0000218,Lower clearance in monkey (i.v.) at 0.5 mpk,,,,Cercopithecidae,CHEMBL620902,9527.0
4514,U,,,,In vivo,22224,0,Autocuration,,4411,A,,,1,BAO_0000218,Plasma clearance in rhesus monkey,,,,Cercopithecidae,CHEMBL620903,9527.0
6062,U,,,,In vivo,22224,0,Autocuration,,4412,A,,,1,BAO_0000218,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,,,Cercopithecidae,CHEMBL620904,9527.0
6821,U,,,,In vivo,22224,0,Autocuration,,4413,A,,,1,BAO_0000218,Plasma clearance of compound was determined in monkey,,,,Cercopithecidae,CHEMBL620905,9527.0
6057,U,,,,In vivo,22224,0,Autocuration,,4414,A,,,1,BAO_0000218,Plasma clearance was calculated in rhesus monkey,,,,Cercopithecidae,CHEMBL620906,9527.0
5145,U,,,,In vivo,22224,0,Autocuration,,4415,A,,,1,BAO_0000218,Plasma clearance in rhesus monkey,,,,Cercopithecidae,CHEMBL875420,9527.0
6641,U,,,,In vivo,22224,0,Autocuration,,4416,A,,,1,BAO_0000218,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,,Cercopithecidae,CHEMBL620907,9527.0
5472,U,,,,In vivo,22224,0,Autocuration,,4417,A,,,1,BAO_0000218,Plasma clearance was evaluated in rhesus,,,,Cercopithecidae,CHEMBL620908,9527.0
4257,U,,,,In vivo,22224,0,Autocuration,,4418,A,,,1,BAO_0000218,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,,,Cercopithecidae,CHEMBL620909,9527.0
5546,U,,,,In vivo,22224,0,Autocuration,,4419,A,,,1,BAO_0000218,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,,Cercopithecidae,CHEMBL620910,9527.0
5334,U,,,,In vivo,22224,0,Autocuration,,4420,A,,,1,BAO_0000218,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,,Cercopithecidae,CHEMBL620911,9527.0
5334,U,,,,In vivo,22224,0,Autocuration,,4421,A,,,1,BAO_0000218,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,,Cercopithecidae,CHEMBL620912,9527.0
17509,U,,,,In vivo,22224,0,Autocuration,,4422,A,,,1,BAO_0000218,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,,,Cercopithecidae,CHEMBL620913,9527.0
6535,U,,,,In vivo,22224,0,Autocuration,,4423,A,,,1,BAO_0000218,Cmax in monkey after administration of 1 mg/kg iv,,,,Cercopithecidae,CHEMBL620914,9527.0
5668,U,,,,In vivo,22224,0,Autocuration,,4424,A,,,1,BAO_0000218,Cmax was determine after peroral administration at 10 mpk in Rhesus,,,,Cercopithecidae,CHEMBL620915,9527.0
5922,U,,,,In vivo,22224,0,Autocuration,,4425,A,,,1,BAO_0000218,Cmax in cynomolgus monkey by iv administration,,,,Cercopithecidae,CHEMBL620916,9527.0
5922,U,,,,In vivo,22224,0,Autocuration,,4426,A,,,1,BAO_0000218,Cmax in cynomolgus monkey by po administration,,,,Cercopithecidae,CHEMBL620917,9527.0
6078,U,,,,In vivo,22224,0,Autocuration,,4427,A,,,1,BAO_0000218,Cmax value evaluated in monkey,,,,Cercopithecidae,CHEMBL620918,9527.0
2661,U,,,,In vivo,22224,0,Autocuration,,4428,A,,,1,BAO_0000218,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,,Cercopithecidae,CHEMBL620919,9527.0
3249,U,,,,In vivo,22224,0,Autocuration,,4429,A,Plasma,,1,BAO_0000218,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,,,1969.0,Cercopithecidae,CHEMBL620920,9527.0
3249,U,,,,In vivo,22224,0,Autocuration,,4430,A,Plasma,,1,BAO_0000218,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,,,1969.0,Cercopithecidae,CHEMBL620921,9527.0
5553,U,,,,In vivo,22224,0,Autocuration,,4431,A,Plasma,,1,BAO_0000218,Maximal plasma concentration in squirrel monkeys,,,1969.0,Cercopithecidae,CHEMBL620922,9527.0
1916,U,,,,In vivo,22224,0,Autocuration,,4432,A,,,1,BAO_0000218,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,,Cercopithecidae,CHEMBL620923,9527.0
6227,U,,,,In vivo,22224,0,Autocuration,,4433,A,Plasma,,1,BAO_0000218,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,,,1969.0,Cercopithecidae,CHEMBL620924,9527.0
4809,U,,,,In vivo,22224,0,Autocuration,,4434,A,,,1,BAO_0000218,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,,Cercopithecidae,CHEMBL620925,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,4435,A,,,1,BAO_0000218,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,,,Cercopithecidae,CHEMBL620926,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,4436,A,,,1,BAO_0000218,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,,,Cercopithecidae,CHEMBL620927,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,4437,A,,,1,BAO_0000218,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,,,Cercopithecidae,CHEMBL620928,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,4438,A,,,1,BAO_0000218,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,,,Cercopithecidae,CHEMBL620929,9527.0
6221,U,,,,In vivo,22224,0,Autocuration,,4439,A,Plasma,,1,BAO_0000218,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,,,1969.0,Cercopithecidae,CHEMBL620930,9527.0
167,U,,,,,22224,0,Autocuration,,4440,A,,,1,BAO_0000218,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,,,Cercopithecidae,CHEMBL620931,9527.0
167,U,,,,,22224,0,Autocuration,,4441,A,,,1,BAO_0000218,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,,,Cercopithecidae,CHEMBL620932,9527.0
4257,U,,,,In vivo,22224,0,Autocuration,,4442,A,,,1,BAO_0000218,Absolute bioavailability was evaluated in monkey,,,,monkey,CHEMBL620933,9443.0
6221,U,,,,In vivo,22224,0,Autocuration,,4443,A,,,1,BAO_0000218,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,,,monkey,CHEMBL620934,9443.0
17667,U,,,,In vivo,22224,0,Autocuration,,4444,A,,,1,BAO_0000218,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,,,monkey,CHEMBL620935,9443.0
17267,U,,,,In vivo,22224,0,Autocuration,,4445,A,,,1,BAO_0000218,Bioavailability of compound was determined in rhesus monkey,,,,Macaca mulatta,CHEMBL620936,9544.0
4256,U,,,,In vivo,22224,0,Autocuration,,4446,A,,,1,BAO_0000218,Bioavailability determined after oral administration in marmoset,,,,marmosets,CHEMBL620937,38020.0
4256,U,,,,In vivo,22224,0,Autocuration,,4447,A,,,1,BAO_0000218,Oral bioavailability in cynomolgus monkey,,,,Macaca fascicularis,CHEMBL620938,9541.0
17853,U,,,,In vivo,22224,0,Autocuration,,4448,A,,,1,BAO_0000218,Bioavailability in monkey (p.o.) at 2.0 mpk,,,,monkey,CHEMBL620939,9443.0
16365,U,,,,In vivo,22224,0,Autocuration,,4449,A,,,1,BAO_0000218,Bioavailability was evaluated after oral administration in monkey,,,,monkey,CHEMBL620940,9443.0
1916,U,,,,In vivo,22224,0,Autocuration,,4450,A,,,1,BAO_0000218,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,,Macaca fascicularis,CHEMBL620941,9541.0
5334,U,,,,In vivo,22224,0,Autocuration,,4451,A,,,1,BAO_0000218,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,,Macaca mulatta,CHEMBL620942,9544.0
5334,U,,,,In vivo,22224,0,Autocuration,,4452,A,,,1,BAO_0000218,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,,Macaca mulatta,CHEMBL620943,9544.0
17592,U,,,,In vivo,22224,0,Autocuration,,4453,A,,,1,BAO_0000218,Bioavailability of the compound was determined in monkey,,,,monkey,CHEMBL620944,9443.0
1399,U,,,,In vivo,22224,0,Autocuration,,4454,A,,,1,BAO_0000218,Bioavailability in squirrel monkey (dose 5 mg/kg),,,,Saimiri sciureus,CHEMBL620945,9521.0
4809,U,,,,In vivo,22224,0,Autocuration,,4455,A,,,1,BAO_0000218,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,,monkey,CHEMBL620946,9443.0
3341,U,,,,In vivo,22224,0,Autocuration,,4456,A,,,1,BAO_0000218,Oral bioavailability in monkey,,,,monkey,CHEMBL620947,9443.0
64,U,,,,In vivo,22224,0,Autocuration,,4457,A,,,1,BAO_0000218,Compound was tested for bioavailability in squirrel monkey,,,,Saimiri sciureus,CHEMBL620948,9521.0
5005,U,,,,In vivo,22224,0,Autocuration,,4458,A,,,1,BAO_0000218,Oral bioavailability in Rhesus monkey,,,,Macaca mulatta,CHEMBL620949,9544.0
5005,U,,,,In vivo,22224,0,Autocuration,,4459,A,,,1,BAO_0000218,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,,,Macaca mulatta,CHEMBL620950,9544.0
5237,U,,,,In vivo,22224,0,Autocuration,,4460,A,,,1,BAO_0000218,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,,,Macaca fascicularis,CHEMBL620951,9541.0
5237,U,,,,In vivo,22224,0,Autocuration,,4461,A,,,1,BAO_0000218,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,,,Macaca fascicularis,CHEMBL620952,9541.0
5302,U,,,,In vivo,22224,0,Autocuration,,4462,A,,,1,BAO_0000218,Oral bioavailability in monkey (dose 5 mg/kg),,,,monkey,CHEMBL875421,9443.0
17667,U,,,,In vivo,22224,0,Autocuration,,4463,A,,,1,BAO_0000218,Oral bioavailability of compound at 5 mg/kg in monkey,,,,monkey,CHEMBL620953,9443.0
6161,N,,,,In vivo,50588,1,Intermediate,,4464,A,,,1,BAO_0000218,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,,,Canis lupus familiaris,CHEMBL873491,9615.0
6161,N,,,,In vivo,50588,1,Intermediate,,4465,A,,,1,BAO_0000218,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,,,Canis lupus familiaris,CHEMBL620954,9615.0
3854,N,,,,,50588,1,Intermediate,,4466,A,Plasma,,1,BAO_0000218,Plasma half life determined,,,1969.0,Canis lupus familiaris,CHEMBL620955,9615.0
993,N,,,,,50588,1,Intermediate,,4467,A,Plasma,,1,BAO_0000218,Plasma half life in dog,,,1969.0,Canis lupus familiaris,CHEMBL618097,9615.0
4514,N,,,,,50588,1,Intermediate,,4468,A,Plasma,,1,BAO_0000218,Plasma half-life in Beagle dogs,,,1969.0,Canis lupus familiaris,CHEMBL618268,9615.0
5334,N,,,,In vivo,50588,1,Intermediate,,4469,A,Plasma,,1,BAO_0000218,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,,1969.0,Canis lupus familiaris,CHEMBL618269,9615.0
5334,N,,,,In vivo,50588,1,Intermediate,,4470,A,Plasma,,1,BAO_0000218,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),,,1969.0,Canis lupus familiaris,CHEMBL618270,9615.0
1466,N,,,,In vivo,50588,1,Intermediate,,4471,A,,,1,BAO_0000218,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,,,Canis lupus familiaris,CHEMBL618271,9615.0
1466,N,,,,In vivo,50588,1,Intermediate,,4472,A,,,1,BAO_0000218,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,,,Canis lupus familiaris,CHEMBL873493,9615.0
5313,N,,,,,50588,1,Intermediate,,4473,A,,,1,BAO_0000218,Tested for the half life period in dog,,,,Canis lupus familiaris,CHEMBL621031,9615.0
5313,N,,,,In vivo,50588,1,Intermediate,,4474,A,,,1,BAO_0000218,Tested for the half life period in dog at dosage of 10 mpk,,,,Canis lupus familiaris,CHEMBL621032,9615.0
3880,N,,,,,50588,1,Intermediate,,4475,A,,,1,BAO_0000218,The compound was tested for half life in dog,,,,Canis lupus familiaris,CHEMBL621033,9615.0
3639,N,,,,,50588,1,Intermediate,,4476,A,Plasma,,1,BAO_0000218,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,,1969.0,Canis lupus familiaris,CHEMBL621034,9615.0
3880,N,,,,,50588,1,Intermediate,,4477,A,,,1,BAO_0000218,The half life was determined,,,,Canis lupus familiaris,CHEMBL621035,9615.0
3918,N,,,,,50588,1,Intermediate,,4478,A,Plasma,,1,BAO_0000218,The plasma half-life in dogs,,,1969.0,Canis lupus familiaris,CHEMBL621036,9615.0
16452,N,,,,,50588,1,Intermediate,,4479,A,Plasma,,1,BAO_0000218,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,,1969.0,Canis lupus familiaris,CHEMBL621037,9615.0
17796,N,,,,,50588,1,Intermediate,,4480,A,,,1,BAO_0000218,Half life in dog,,,,Canis lupus familiaris,CHEMBL619812,9615.0
5983,N,,,,In vivo,50588,1,Intermediate,,4481,A,,,1,BAO_0000218,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,,,Canis lupus familiaris,CHEMBL619813,9615.0
1466,N,,,,In vivo,50588,1,Intermediate,,4482,A,,,1,BAO_0000218,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,,,Canis lupus familiaris,CHEMBL873335,9615.0
16456,N,,,,In vivo,50588,1,Intermediate,,4483,A,,,1,BAO_0000218,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,,Canis lupus familiaris,CHEMBL619814,9615.0
6113,N,,,,In vivo,50506,1,Expert,,4484,A,,,1,BAO_0000218,Cmax in ferrets after 30 mg/kg oral dose,,,,Mustela putorius furo,CHEMBL619815,9669.0
6113,N,,,,In vivo,50506,1,Expert,,4485,F,,,1,BAO_0000218,Emesis in ferrets at 30 mg/kg oral dose,,,,Mustela putorius furo,CHEMBL619816,9669.0
17796,U,,,,In vivo,22224,0,Autocuration,,4486,A,,,1,BAO_0000218,Bioavailability in cynomolgus monkey,,,,Macaca fascicularis,CHEMBL619817,9541.0
17796,N,,,,In vivo,100710,1,Intermediate,,4487,A,,,1,BAO_0000218,Volume of distribution in cynomolgus,,,,Macaca fascicularis,CHEMBL619818,9541.0
5308,U,,,,,22224,0,Autocuration,,4488,A,Plasma,,1,BAO_0000218,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,,1969.0,Cavia porcellus,CHEMBL619819,10141.0
4877,U,,,,,22224,0,Autocuration,,4489,A,,,1,BAO_0000218,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,,,Cavia porcellus,CHEMBL619820,10141.0
4876,U,,,,,22224,0,Autocuration,,4490,A,,,1,BAO_0000218,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,,,Cavia porcellus,CHEMBL875419,10141.0
4878,U,,,,In vivo,22224,0,Autocuration,,4491,A,Plasma,,1,BAO_0000218,AUC in guinea pig after 3mg/kg oral dose,,,1969.0,Cavia porcellus,CHEMBL619821,10141.0
5308,U,,,,In vivo,22224,0,Autocuration,,4492,A,,,1,BAO_0000218,Bioavailability in guinea pig was tested,,,,Cavia porcellus,CHEMBL619822,10141.0
4877,U,,,,In vivo,22224,0,Autocuration,,4493,A,,,1,BAO_0000218,Tested for oral bioavailability in guinea pig at 5 mg/kg,,,,Cavia porcellus,CHEMBL619823,10141.0
4876,U,,,,In vivo,22224,0,Autocuration,,4494,A,,,1,BAO_0000218,Tested for the oral bioavailability of the compound,,,,Cavia porcellus,CHEMBL619824,10141.0
4876,U,,,,In vivo,22224,0,Autocuration,,4495,A,,,1,BAO_0000218,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,,,Cavia porcellus,CHEMBL619825,10141.0
5308,U,,,,In vivo,22224,0,Autocuration,,4496,A,,,1,BAO_0000218,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,,,Cavia porcellus,CHEMBL619826,10141.0
4877,U,,,,In vivo,22224,0,Autocuration,,4497,A,Lung,,1,BAO_0000218,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,,2048.0,Cavia porcellus,CHEMBL619827,10141.0
4878,U,,,,In vivo,22224,0,Autocuration,,4498,A,,,1,BAO_0000218,Cmax in guinea pig after 3mg/kg oral dose,,,,Cavia porcellus,CHEMBL618167,10141.0
5689,U,,,,,22224,0,Autocuration,,4499,A,Blood,,1,BAO_0000019,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,,178.0,Cavia porcellus,CHEMBL618168,10141.0
5689,U,,,,,22224,0,Autocuration,,4500,A,Brain,,1,BAO_0000019,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,,955.0,Cavia porcellus,CHEMBL618169,10141.0
5689,U,,,,,22224,0,Autocuration,,4501,A,,,1,BAO_0000019,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,,,Cavia porcellus,CHEMBL618170,10141.0
5689,U,,,,,22224,0,Autocuration,,4502,A,Intestine,,1,BAO_0000019,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,,160.0,Cavia porcellus,CHEMBL618171,10141.0
5689,U,,,,,22224,0,Autocuration,,4503,A,Kidney,,1,BAO_0000019,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,,2113.0,Cavia porcellus,CHEMBL618172,10141.0
5689,U,,,,,22224,0,Autocuration,,4504,A,Liver,,1,BAO_0000019,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,,2107.0,Cavia porcellus,CHEMBL618173,10141.0
5689,U,,,,,22224,0,Autocuration,,4505,A,,,1,BAO_0000019,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,,,Cavia porcellus,CHEMBL618174,10141.0
5689,U,,,,,22224,0,Autocuration,,4506,A,Spleen,,1,BAO_0000019,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,,2106.0,Cavia porcellus,CHEMBL875408,10141.0
14465,U,,,,In vivo,22224,0,Autocuration,,4507,A,,,1,BAO_0000218,Elimination T1/2 in Guinea pig (PO dose),,,,Cavia porcellus,CHEMBL839827,10141.0
5689,U,,,,,22224,0,Autocuration,,4508,A,,,1,BAO_0000019,Partition coefficient was measured as -log (counts per min ),,,,Cavia porcellus,CHEMBL618175,10141.0
611,U,,,,In vivo,22224,0,Autocuration,,4509,A,,,1,BAO_0000218,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,,,Cavia porcellus,CHEMBL618176,10141.0
611,U,,,,In vivo,22224,0,Autocuration,,4510,A,,,1,BAO_0000218,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,,,Cavia porcellus,CHEMBL618177,10141.0
14465,U,,,,In vivo,22224,0,Autocuration,,4511,A,,,1,BAO_0000218,Elimination T1/2 in Guinea pig (PO dose),,,,Cavia porcellus,CHEMBL618178,10141.0
4876,U,,,,In vivo,22224,0,Autocuration,,4512,A,,,1,BAO_0000218,"Tested for the half life period of the compound, intravenously",,,,Cavia porcellus,CHEMBL618179,10141.0
5689,U,,,,,22224,0,Autocuration,,4513,A,,,1,BAO_0000019,Half-life was measured,,,,Cavia porcellus,CHEMBL873489,10141.0
7515,U,,,,,22224,0,Autocuration,,4514,A,,,1,BAO_0000019,The time required for onset of inotropy after addition of a single dose of delta F75,,,,Cavia porcellus,CHEMBL618180,10141.0
17667,U,,,,In vivo,22224,0,Autocuration,,4515,A,,,1,BAO_0000218,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,,,Cavia porcellus,CHEMBL618181,10141.0
17667,U,,,,In vivo,22224,0,Autocuration,,4516,A,,,1,BAO_0000218,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,,,Cavia porcellus,CHEMBL618182,10141.0
4727,U,,,,In vivo,22224,0,Autocuration,,4517,A,,,1,BAO_0000218,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,,,Cricetulus griseus,CHEMBL618183,10029.0
10107,N,,,,In vivo,50594,1,Intermediate,,4518,A,,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,,Mus musculus,CHEMBL618184,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,4519,A,,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,,Mus musculus,CHEMBL618185,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,4520,A,,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,,Mus musculus,CHEMBL618186,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,4521,A,,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,,Mus musculus,CHEMBL618187,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,4522,A,,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,,,Mus musculus,CHEMBL618188,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,4523,A,,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,,Mus musculus,CHEMBL875409,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,4524,A,,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,,Mus musculus,CHEMBL618189,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4525,A,Blood,,1,BAO_0000218,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,,,178.0,Mus musculus,CHEMBL618190,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4526,A,Blood,,1,BAO_0000218,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,,,178.0,Mus musculus,CHEMBL618191,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4527,A,Blood,,1,BAO_0000218,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,,,178.0,Mus musculus,CHEMBL618192,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4528,A,Bone,,1,BAO_0000218,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,,,10000001.0,Mus musculus,CHEMBL618193,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4529,A,Bone,,1,BAO_0000218,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,,,10000001.0,Mus musculus,CHEMBL618194,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4530,A,Bone,,1,BAO_0000218,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,,,10000001.0,Mus musculus,CHEMBL618195,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4531,A,Brain,,1,BAO_0000218,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,,,955.0,Mus musculus,CHEMBL618196,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4532,A,Brain,,1,BAO_0000218,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,,,955.0,Mus musculus,CHEMBL618197,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4533,A,Brain,,1,BAO_0000218,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,,,955.0,Mus musculus,CHEMBL618198,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4534,A,Heart,,1,BAO_0000218,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,,,948.0,Mus musculus,CHEMBL618199,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4535,A,Heart,,1,BAO_0000218,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,,,948.0,Mus musculus,CHEMBL618200,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4536,A,Heart,,1,BAO_0000218,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,,,948.0,Mus musculus,CHEMBL618201,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4537,A,Intestine,,1,BAO_0000218,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,,,160.0,Mus musculus,CHEMBL618202,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4538,A,Intestine,,1,BAO_0000218,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,,,160.0,Mus musculus,CHEMBL618203,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4539,A,Intestine,,1,BAO_0000218,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,,,160.0,Mus musculus,CHEMBL618204,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4540,A,Kidney,,1,BAO_0000218,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,,,2113.0,Mus musculus,CHEMBL618205,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4541,A,Kidney,,1,BAO_0000218,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,,,2113.0,Mus musculus,CHEMBL618206,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4542,A,Kidney,,1,BAO_0000218,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,,,2113.0,Mus musculus,CHEMBL618207,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4543,A,Liver,,1,BAO_0000218,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,,,2107.0,Mus musculus,CHEMBL618208,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4544,A,Liver,,1,BAO_0000218,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,,,2107.0,Mus musculus,CHEMBL618932,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4545,A,Liver,,1,BAO_0000218,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,,,2107.0,Mus musculus,CHEMBL618933,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4546,A,Lung,,1,BAO_0000218,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,,,2048.0,Mus musculus,CHEMBL618934,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4547,A,Lung,,1,BAO_0000218,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,,,2048.0,Mus musculus,CHEMBL618935,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4548,A,Lung,,1,BAO_0000218,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,,,2048.0,Mus musculus,CHEMBL618936,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4549,A,Muscle tissue,,1,BAO_0000218,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,,,2385.0,Mus musculus,CHEMBL618937,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4550,A,Muscle tissue,,1,BAO_0000218,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,,,2385.0,Mus musculus,CHEMBL618938,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4551,A,Muscle tissue,,1,BAO_0000218,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,,,2385.0,Mus musculus,CHEMBL619104,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4552,A,Spleen,,1,BAO_0000218,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,,,2106.0,Mus musculus,CHEMBL619105,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4553,A,Spleen,,1,BAO_0000218,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,,,2106.0,Mus musculus,CHEMBL619106,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4554,A,Spleen,,1,BAO_0000218,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,,,2106.0,Mus musculus,CHEMBL619107,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4555,A,Stomach,,1,BAO_0000218,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,,,945.0,Mus musculus,CHEMBL875410,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4556,A,Stomach,,1,BAO_0000218,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,,,945.0,Mus musculus,CHEMBL619108,10090.0
3655,N,,,,In vivo,50594,1,Intermediate,,4557,A,Stomach,,1,BAO_0000218,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,,,945.0,Mus musculus,CHEMBL619109,10090.0
16597,N,,,,In vivo,50594,1,Intermediate,,4558,A,,,1,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,,,Mus musculus,CHEMBL619110,10090.0
16597,N,,,,In vivo,50594,1,Intermediate,,4559,F,,,1,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,,,Mus musculus,CHEMBL619111,10090.0
16597,N,,,,In vivo,50594,1,Intermediate,,4560,A,,,1,BAO_0000218,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,,,Mus musculus,CHEMBL619112,10090.0
16597,N,,,,In vivo,50594,1,Intermediate,,4561,A,,,1,BAO_0000218,MRT value at a dose of 10 mg/kg peroral administration in mice.,,,,Mus musculus,CHEMBL619113,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,4562,A,,,1,BAO_0000218,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,,,Mus musculus,CHEMBL619114,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,4563,F,,,1,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,,,Mus musculus,CHEMBL619115,10090.0
3830,N,,,A2780,,81034,1,Intermediate,,4564,F,,,1,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,478.0,,,Homo sapiens,CHEMBL619116,9606.0
3829,N,,,A2780,,81034,1,Intermediate,,4565,F,,,1,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,478.0,,,Homo sapiens,CHEMBL619117,9606.0
2040,N,,,A2780,,81034,1,Intermediate,,4566,F,,,1,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cell lines.,478.0,,,Homo sapiens,CHEMBL619118,9606.0
15684,N,,,A2780,,81034,1,Intermediate,,4567,F,,,1,BAO_0000219,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,478.0,,,Homo sapiens,CHEMBL619119,9606.0
15684,N,,,A2780,,81034,1,Intermediate,,4568,F,,,1,BAO_0000219,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,478.0,,,Homo sapiens,CHEMBL619120,9606.0
15684,N,,,A2780,,81034,1,Intermediate,,4569,F,,,1,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,478.0,,,Homo sapiens,CHEMBL619121,9606.0
15684,N,,,A2780,,81034,1,Intermediate,,4570,F,,,1,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,478.0,,,Homo sapiens,CHEMBL619122,9606.0
15684,N,,,A2780,,81034,1,Intermediate,,4571,F,,,1,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,478.0,,,Homo sapiens,CHEMBL619123,9606.0
15684,N,,,A2780,,81034,1,Intermediate,,4572,F,,,1,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,478.0,,,Homo sapiens,CHEMBL619124,9606.0
2859,N,,,A2780,,81034,1,Intermediate,,4573,F,,,1,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cell line,478.0,,,Homo sapiens,CHEMBL619125,9606.0
5618,N,,,A2780,,81034,1,Intermediate,,4574,F,,,1,BAO_0000219,In vitro inhibitory activity against human tumor cell line A2780,478.0,,,Homo sapiens,CHEMBL875411,9606.0
15684,N,,,A2780,,81034,1,Intermediate,,4575,F,,,1,BAO_0000219,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,478.0,,,Homo sapiens,CHEMBL619126,9606.0
15684,N,,,A2780,,81034,1,Intermediate,,4576,F,,,1,BAO_0000219,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,478.0,,,Homo sapiens,CHEMBL619127,9606.0
15684,N,,,A2780,,81034,1,Intermediate,,4577,F,,,1,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,478.0,,,Homo sapiens,CHEMBL619128,9606.0
15684,N,,,A2780,,81034,1,Intermediate,,4578,F,,,1,BAO_0000219,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,478.0,,,Homo sapiens,CHEMBL619129,9606.0
2113,N,,,A2780,,81034,1,Intermediate,,4579,F,,,1,BAO_0000219,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,478.0,,,Homo sapiens,CHEMBL619130,9606.0
2113,N,,,A2780,,81034,1,Intermediate,,4580,F,,,1,BAO_0000219,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,478.0,,,Homo sapiens,CHEMBL619131,9606.0
16745,N,,,A2780,,81034,1,Intermediate,,4581,F,,,1,BAO_0000219,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,478.0,,,Homo sapiens,CHEMBL619132,9606.0
16597,N,,,A2780,,81034,1,Expert,,4582,F,,,1,BAO_0000218,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,478.0,,,Homo sapiens,CHEMBL619133,9606.0
15684,N,,,A2780,,81034,1,Intermediate,,4583,F,,,1,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,478.0,,,Homo sapiens,CHEMBL619134,9606.0
15684,N,,,A2780,,81034,1,Intermediate,,4584,F,,,1,BAO_0000219,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,478.0,,,Homo sapiens,CHEMBL619135,9606.0
2040,N,,,A2780,,81034,1,Intermediate,,4585,F,,,1,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,478.0,,,Homo sapiens,CHEMBL619136,9606.0
2040,N,,,A2780,,81034,1,Intermediate,,4586,F,,,1,BAO_0000219,Relative resistance factor in A2780 cisplatin-resistant line,478.0,,,Homo sapiens,CHEMBL619137,9606.0
16165,N,,,A2780,,81034,1,Intermediate,,4587,F,,,1,BAO_0000219,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,478.0,,,Homo sapiens,CHEMBL883713,9606.0
16165,N,,,A2780,,81034,1,Intermediate,,4588,F,,,1,BAO_0000219,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,478.0,,,Homo sapiens,CHEMBL875412,9606.0
16597,N,,,A2780,,81034,1,Expert,,4589,F,,,1,BAO_0000218,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,478.0,,,Homo sapiens,CHEMBL619138,9606.0
16597,N,,,A2780,,81034,1,Expert,,4590,F,,,1,BAO_0000218,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,478.0,,,Homo sapiens,CHEMBL619262,9606.0
3992,N,,,A2780,,81034,1,Intermediate,,4591,F,,,1,BAO_0000219,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,478.0,,,Homo sapiens,CHEMBL619139,9606.0
10553,N,,,A2780,,81034,1,Intermediate,,4592,F,,,1,BAO_0000219,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,478.0,,,Homo sapiens,CHEMBL619140,9606.0
15608,N,,,A2780,,81034,1,Intermediate,,4593,F,,,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,478.0,,,Homo sapiens,CHEMBL619141,9606.0
15608,N,,,A2780,,81034,1,Intermediate,,4594,F,,,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,478.0,,,Homo sapiens,CHEMBL619142,9606.0
15608,N,,,A2780,,81034,1,Intermediate,,4595,F,,,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,478.0,,,Homo sapiens,CHEMBL619143,9606.0
15608,N,,,A2780,,81034,1,Intermediate,,4596,F,,,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,478.0,,,Homo sapiens,CHEMBL619144,9606.0
15608,N,,,A2780,,81034,1,Intermediate,,4597,F,,,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,478.0,,,Homo sapiens,CHEMBL619145,9606.0
15608,N,,,A2780,,81034,1,Intermediate,,4598,F,,,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,478.0,,,Homo sapiens,CHEMBL619146,9606.0
15569,N,,,A2780,,81034,1,Intermediate,,4599,F,,,1,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,478.0,,,Homo sapiens,CHEMBL619147,9606.0
17420,N,,,A2780,,81034,1,Intermediate,,4600,F,,,1,BAO_0000219,Antiproliferative effect of compound on A2780/DX cell line,478.0,,,Homo sapiens,CHEMBL619148,9606.0
17420,N,,,A2780,,81034,1,Intermediate,,4601,F,,,1,BAO_0000219,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,478.0,,,Homo sapiens,CHEMBL619149,9606.0
15099,N,,,A2780,,81034,1,Intermediate,,4602,F,,,1,BAO_0000219,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),478.0,,,Homo sapiens,CHEMBL619150,9606.0
15099,N,,,A2780,,81034,1,Intermediate,,4603,F,,,1,BAO_0000219,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),478.0,,,Homo sapiens,CHEMBL619151,9606.0
17672,N,,,A2780,,81034,1,Intermediate,,4604,F,,,1,BAO_0000219,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,478.0,,,Homo sapiens,CHEMBL883794,9606.0
17672,N,,,A2780,,81034,1,Intermediate,,4605,F,,,1,BAO_0000219,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,478.0,,,Homo sapiens,CHEMBL619152,9606.0
17270,N,,,A2780,,81034,1,Intermediate,,4606,F,,,1,BAO_0000219,In vitro cytotoxicity against A2780ADR cell line,478.0,,,Homo sapiens,CHEMBL619153,9606.0
17270,N,,,A2780,,81034,1,Intermediate,,4607,F,,,1,BAO_0000219,In vitro cytotoxicity against A2780CIS cell line,478.0,,,Homo sapiens,CHEMBL619154,9606.0
5574,N,,,A2780,,81034,1,Intermediate,,4608,F,,,1,BAO_0000219,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,478.0,,,Homo sapiens,CHEMBL619155,9606.0
2113,N,,,A2780,,81034,1,Intermediate,,4609,F,,,1,BAO_0000219,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,478.0,,,Homo sapiens,CHEMBL619156,9606.0
16913,N,,,A2780,,81034,1,Intermediate,,4610,F,,,1,BAO_0000219,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",478.0,,,Homo sapiens,CHEMBL619157,9606.0
16913,N,,,A2780,,81034,1,Intermediate,,4611,F,,,1,BAO_0000219,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",478.0,,,Homo sapiens,CHEMBL619797,9606.0
17839,U,,,,In vivo,22224,0,Autocuration,,4612,A,,,1,BAO_0000218,Oral bioavailability of compound in rhesus macaques,,,,Macaca mulatta,CHEMBL619798,9544.0
6821,U,,,,In vivo,22224,0,Autocuration,,4613,A,,,1,BAO_0000218,Oral bioavailability in monkey,,,,monkey,CHEMBL619799,9443.0
6078,U,,,,In vivo,22224,0,Autocuration,,4614,A,,,1,BAO_0000218,Oral bioavailability evaluated in monkey,,,,monkey,CHEMBL619800,9443.0
6535,U,,,,In vivo,22224,0,Autocuration,,4615,A,,,1,BAO_0000218,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,,,monkey,CHEMBL619801,9443.0
4449,U,,,,In vivo,22224,0,Autocuration,,4616,A,,,1,BAO_0000218,Oral bioavailability in Rhesus monkey,,,,Macaca mulatta,CHEMBL619802,9544.0
6057,U,,,,In vivo,22224,0,Autocuration,,4617,A,,,1,BAO_0000218,Oral bioavailability was calculated in rhesus monkey,,,,Macaca mulatta,CHEMBL619803,9544.0
5922,U,,,,In vivo,22224,0,Autocuration,,4618,A,,,1,BAO_0000218,Oral bioavailability in cynomolgus monkey,,,,Macaca fascicularis,CHEMBL619965,9541.0
5940,U,,,,In vivo,22224,0,Autocuration,,4619,A,,,1,BAO_0000218,Oral bioavailability in monkey,,,,monkey,CHEMBL619966,9443.0
6265,U,,,,In vivo,22224,0,Autocuration,,4620,A,,,1,BAO_0000218,Oral bioavailability in monkey,,,,monkey,CHEMBL619967,9443.0
6265,U,,,,In vivo,22224,0,Autocuration,,4621,A,,,1,BAO_0000218,Oral bioavailability in monkey (dose 1 mg/kg),,,,monkey,CHEMBL620073,9443.0
6265,U,,,,In vivo,22224,0,Autocuration,,4622,A,,,1,BAO_0000218,Oral bioavailability in monkey (dose 5 mg/kg),,,,monkey,CHEMBL620074,9443.0
5940,U,,,,In vivo,22224,0,Autocuration,,4623,A,,,1,BAO_0000218,Oral bioavailability in monkey,,,,monkey,CHEMBL620075,9443.0
5940,U,,,,In vivo,22224,0,Autocuration,,4624,A,,,1,BAO_0000218,Oral bioavailability in monkey,,,,monkey,CHEMBL620076,9443.0
4514,U,,,,In vivo,22224,0,Autocuration,,4625,A,,,1,BAO_0000218,Oral bioavailability in rhesus monkey,,,,Macaca mulatta,CHEMBL620077,9544.0
5546,U,,,,In vivo,22224,0,Autocuration,,4626,A,,,1,BAO_0000218,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,,,Macaca mulatta,CHEMBL620078,9544.0
5553,U,,,,In vivo,22224,0,Autocuration,,4627,A,,,1,BAO_0000218,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,,,Saimiri sciureus,CHEMBL620079,9521.0
6641,U,,,,In vivo,22224,0,Autocuration,,4628,A,,,1,BAO_0000218,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,,monkey,CHEMBL620080,9443.0
5472,U,,,,In vivo,22224,0,Autocuration,,4629,A,,,1,BAO_0000218,Oral bioavailability in Rhesus monkey,,,,Macaca mulatta,CHEMBL620081,9544.0
5668,U,,,,In vivo,22224,0,Autocuration,,4630,A,,,1,BAO_0000218,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,,,Macaca mulatta,CHEMBL620082,9544.0
5711,U,,,,In vivo,22224,0,Autocuration,,4631,A,,,1,BAO_0000218,Oral bioavailability in monkey at 10 mg/kg of the compound,,,,monkey,CHEMBL620083,9443.0
5145,U,,,,In vivo,22224,0,Autocuration,,4632,A,,,1,BAO_0000218,Bioavailability in Rhesus monkey,,,,Macaca mulatta,CHEMBL620084,9544.0
3443,U,,,,,22224,0,Autocuration,,4633,A,,,1,BAO_0000218,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,,Cercopithecidae,CHEMBL620085,9527.0
3443,U,,,,,22224,0,Autocuration,,4634,A,,,1,BAO_0000218,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,,Cercopithecidae,CHEMBL874595,9527.0
3249,U,,,,In vivo,22224,0,Autocuration,,4635,A,,,1,BAO_0000218,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,,,Cercopithecidae,CHEMBL873352,9527.0
3249,U,,,,In vivo,22224,0,Autocuration,,4636,A,,,1,BAO_0000218,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,,,Cercopithecidae,CHEMBL620086,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,4637,A,,,1,BAO_0000218,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,,,Cercopithecidae,CHEMBL620087,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,4638,A,,,1,BAO_0000218,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,,,Cercopithecidae,CHEMBL620088,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,4639,A,,,1,BAO_0000218,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,,,Cercopithecidae,CHEMBL620089,9527.0
4809,U,,,,In vivo,22224,0,Autocuration,,4640,A,,,1,BAO_0000218,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,,Cercopithecidae,CHEMBL620090,9527.0
4809,U,,,,In vivo,22224,0,Autocuration,,4641,A,,,1,BAO_0000218,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,,Cercopithecidae,CHEMBL620091,9527.0
14294,U,,,,,22224,0,Autocuration,Microsomes,4642,A,,,1,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,,,Cercopithecidae,CHEMBL620092,9527.0
14294,U,,,,,22224,0,Autocuration,Microsomes,4643,A,,,1,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,,,Cercopithecidae,CHEMBL620093,9527.0
14294,U,,,,,22224,0,Autocuration,Microsomes,4644,A,,,1,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,,,Cercopithecidae,CHEMBL620094,9527.0
14294,U,,,,,22224,0,Autocuration,Microsomes,4645,A,,,1,BAO_0000251,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,,,Cercopithecidae,CHEMBL620095,9527.0
3443,U,,,,In vivo,22224,0,Autocuration,,4646,A,,,1,BAO_0000218,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,,Cercopithecidae,CHEMBL620096,9527.0
3443,U,,,,In vivo,22224,0,Autocuration,,4647,A,,,1,BAO_0000218,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,,Cercopithecidae,CHEMBL620097,9527.0
11271,U,,,,,22224,0,Autocuration,,4648,A,,,1,BAO_0000019,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,,,Cercopithecidae,CHEMBL620098,9527.0
3443,U,,,,,22224,0,Autocuration,,4649,A,,,1,BAO_0000218,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,,Cercopithecidae,CHEMBL620099,9527.0
3443,U,,,,,22224,0,Autocuration,,4650,A,,,1,BAO_0000218,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,,Cercopithecidae,CHEMBL620100,9527.0
6821,U,,,,,22224,0,Autocuration,,4651,A,,,1,BAO_0000019,Elimination Half-life of compound was determined in monkey,,,,Cercopithecidae,CHEMBL620101,9527.0
17267,U,,,,,22224,0,Autocuration,,4652,A,,,1,BAO_0000019,Half life of compound was determined in rhesus monkey,,,,Cercopithecidae,CHEMBL620102,9527.0
5819,U,,,,,22224,0,Autocuration,,4653,A,Plasma,,1,BAO_0000366,Half life in monkey plasma,,,1969.0,Cercopithecidae,CHEMBL620103,9527.0
5819,U,,,,,22224,0,Autocuration,,4654,A,Plasma,,1,BAO_0000366,Half life in monkey plasma; Not detected,,,1969.0,Cercopithecidae,CHEMBL620104,9527.0
1916,U,,,,In vivo,22224,0,Autocuration,,4655,A,,,1,BAO_0000218,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,,Cercopithecidae,CHEMBL874596,9527.0
17509,U,,,,In vivo,22224,0,Autocuration,,4656,A,,,1,BAO_0000218,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,,,Cercopithecidae,CHEMBL873490,9527.0
1399,U,,,,,22224,0,Autocuration,,4657,A,,,1,BAO_0000019,Terminal half life of the compound.,,,,Cercopithecidae,CHEMBL620105,9527.0
1916,U,,,,In vivo,22224,0,Autocuration,,4658,A,,,1,BAO_0000218,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,,Cercopithecidae,CHEMBL620780,9527.0
4809,U,,,,In vivo,22224,0,Autocuration,,4659,A,,,1,BAO_0000218,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,,,Cercopithecidae,CHEMBL620781,9527.0
5546,U,,,,,22224,0,Autocuration,,4660,A,,,1,BAO_0000218,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,,Cercopithecidae,CHEMBL620956,9527.0
3443,U,,,,,22224,0,Autocuration,,4661,A,Urine,,1,BAO_0000218,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,1088.0,Cercopithecidae,CHEMBL620957,9527.0
3443,U,,,,,22224,0,Autocuration,,4662,A,Urine,,1,BAO_0000218,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,1088.0,Cercopithecidae,CHEMBL620958,9527.0
4257,U,,,,In vivo,22224,0,Autocuration,,4663,A,,,1,BAO_0000218,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,,,Cercopithecidae,CHEMBL620959,9527.0
6221,U,,,,In vivo,22224,0,Autocuration,,4664,A,,,1,BAO_0000218,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,,,Cercopithecidae,CHEMBL620960,9527.0
5472,U,,,,In vivo,22224,0,Autocuration,,4665,A,,,1,BAO_0000218,Volume of distribution was evaluated in rhesus,,,,Cercopithecidae,CHEMBL620961,9527.0
4727,U,,,,In vivo,22224,0,Autocuration,,4666,A,,,1,BAO_0000218,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,,,Cricetulus griseus,CHEMBL620962,10029.0
4727,U,,,,In vivo,22224,0,Autocuration,,4667,A,,,1,BAO_0000218,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,,,Cricetulus griseus,CHEMBL620963,10029.0
4727,U,,,,In vivo,22224,0,Autocuration,,4668,A,,,1,BAO_0000218,Bioavailability in hamster was determined,,,,Cricetulus griseus,CHEMBL620964,10029.0
4727,U,,,,In vivo,22224,0,Autocuration,,4669,A,,,1,BAO_0000218,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,,,Cricetulus griseus,CHEMBL620965,10029.0
4727,U,,,,In vivo,22224,0,Autocuration,,4670,A,,,1,BAO_0000218,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,,,Cricetulus griseus,CHEMBL620966,10029.0
4727,U,,,,,22224,0,Autocuration,,4671,A,Blood,,1,BAO_0000221,Half life of compound was determined in hamster blood,,,178.0,Cricetulus griseus,CHEMBL620967,10029.0
1452,U,,,,,22224,0,Autocuration,,4672,A,,,1,BAO_0000019,Michaelis-Menten constant of the compound.,,,,Sus scrofa,CHEMBL620968,9823.0
1452,U,,,,,22224,0,Autocuration,,4673,A,,,1,BAO_0000019,Vmax value was measured at 0 uM concentration of silyl ether.,,,,Sus scrofa,CHEMBL874597,9823.0
1452,U,,,,,22224,0,Autocuration,,4674,A,,,1,BAO_0000019,Vmax value was measured at 10 uM concentration of silyl ether.,,,,Sus scrofa,CHEMBL620969,9823.0
1452,U,,,,,22224,0,Autocuration,,4675,A,,,1,BAO_0000019,Vmax value was measured at 5 uM concentration of silyl ether.,,,,Sus scrofa,CHEMBL620970,9823.0
11706,D,,,,,235,9,Expert,,4676,B,,,1,BAO_0000357,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,,,Homo sapiens,CHEMBL620971,9606.0
1916,U,,,,,22224,0,Autocuration,,4677,A,,,1,BAO_0000218,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,,,Homo sapiens,CHEMBL620972,9606.0
17791,U,,,,,22224,0,Autocuration,,4678,A,,,1,BAO_0000019,Compound was evaluated for area under the curve expressed as (h*ug/ml),,,,Homo sapiens,CHEMBL620973,9606.0
7766,U,,,,,22224,0,Autocuration,,4679,A,,,1,BAO_0000019,Active metabolite of ifosfamide determined in humans; A-Active,,,,Homo sapiens,CHEMBL618243,9606.0
6567,U,,,,,22224,0,Autocuration,,4680,A,,,1,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,,,Homo sapiens,CHEMBL618244,9606.0
6567,U,,,,,22224,0,Autocuration,,4681,A,,,1,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,,,Homo sapiens,CHEMBL618245,9606.0
6567,U,,,,,22224,0,Autocuration,,4682,A,,,1,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,,,Homo sapiens,CHEMBL618246,9606.0
6567,U,,,,,22224,0,Autocuration,,4683,A,,,1,BAO_0000019,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,,,Homo sapiens,CHEMBL618247,9606.0
17791,U,,,,,22224,0,Autocuration,,4684,A,,,1,BAO_0000218,Compound was evaluated for oral bioavailability in human,,,,Homo sapiens,CHEMBL618248,9606.0
7766,U,,,,,22224,0,Autocuration,,4685,A,Urine,,1,BAO_0000019,Metabolite of ifosfamide determined in urine; NF-Not found,,,1088.0,Homo sapiens,CHEMBL618249,9606.0
6852,U,,,,,22224,0,Autocuration,,4686,A,,,1,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,,,Homo sapiens,CHEMBL618250,9606.0
6852,U,,,,,22224,0,Autocuration,,4687,A,,,1,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,,,Homo sapiens,CHEMBL874598,9606.0
6852,U,,,,,22224,0,Autocuration,,4688,A,,,1,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,,,Homo sapiens,CHEMBL618251,9606.0
6852,U,,,,,22224,0,Autocuration,,4689,A,,,1,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,,,Homo sapiens,CHEMBL618252,9606.0
6852,U,,,,,22224,0,Autocuration,,4690,A,,,1,BAO_0000019,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,,,Homo sapiens,CHEMBL618253,9606.0
6852,U,,,,,22224,0,Autocuration,,4691,A,,,1,BAO_0000019,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,,,Homo sapiens,CHEMBL618254,9606.0
6852,U,,,,,22224,0,Autocuration,,4692,A,,,1,BAO_0000019,Percent of compound in healthy individuals (Group D),,,,Homo sapiens,CHEMBL618255,9606.0
4397,U,,,,,22224,0,Autocuration,Microsomes,4693,A,Liver,,1,BAO_0000251,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,,2107.0,Homo sapiens,CHEMBL618983,9606.0
17409,U,,,,,22224,0,Autocuration,,4694,A,,,1,BAO_0000019,Binding towards human plasma protein at 10 uM,,,,Homo sapiens,CHEMBL618984,9606.0
17409,U,,,,,22224,0,Autocuration,,4695,A,,,1,BAO_0000019,Binding towards human plasma protein at 100 uM,,,,Homo sapiens,CHEMBL618985,9606.0
17176,U,,,,,22224,0,Autocuration,,4696,A,,,1,BAO_0000019,Human plasma protein binding activity was determined,,,,Homo sapiens,CHEMBL618986,9606.0
15444,U,,,,,22224,0,Autocuration,,4697,A,,,1,BAO_0000019,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,,,Homo sapiens,CHEMBL618987,9606.0
17267,U,,,,,22224,0,Autocuration,,4698,A,,,1,BAO_0000019,Percent binding of compound towards human plasma protein was determined,,,,Homo sapiens,CHEMBL618988,9606.0
5944,U,,,,In vitro,22224,0,Autocuration,Microsomes,4699,A,Liver,,1,BAO_0000251,Plasma clearance in human liver microsomes,,,2107.0,Homo sapiens,CHEMBL618989,9606.0
5668,U,,,,In vitro,22224,0,Autocuration,Microsomes,4700,A,Liver,,1,BAO_0000251,In vitro intrinsic clearance in human liver microsome,,,2107.0,Homo sapiens,CHEMBL618990,9606.0
5669,U,,,,In vitro,22224,0,Autocuration,Microsomes,4701,A,Liver,,1,BAO_0000251,In vitro intrinsic clearance in human liver microsome,,,2107.0,Homo sapiens,CHEMBL618991,9606.0
5041,U,,,,In vitro,22224,0,Autocuration,Microsomes,4702,A,,,1,BAO_0000251,In vitro microsome metabolism clearance in human was determined,,,,Homo sapiens,CHEMBL876725,9606.0
5041,U,,,,In vitro,22224,0,Autocuration,Microsomes,4703,A,,,1,BAO_0000251,In vitro microsome metabolism clearance in human was determined; High,,,,Homo sapiens,CHEMBL618992,9606.0
5041,U,,,,In vitro,22224,0,Autocuration,Microsomes,4704,A,,,1,BAO_0000251,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,,,Homo sapiens,CHEMBL618993,9606.0
5676,U,,,,In vitro,22224,0,Autocuration,Microsomes,4705,A,Liver,,1,BAO_0000251,Pharmacokinetic property (clearance) in human liver microsome,,,2107.0,Homo sapiens,CHEMBL618994,9606.0
5944,U,,,,In vitro,22224,0,Autocuration,Microsomes,4706,A,Liver,,1,BAO_0000251,Plasma clearance in human liver microsomes,,,2107.0,Homo sapiens,CHEMBL618995,9606.0
17538,U,,,,In vitro,22224,0,Autocuration,Microsomes,4707,A,Liver,,1,BAO_0000251,In vitro clearance in human liver microsomes,,,2107.0,Homo sapiens,CHEMBL618996,9606.0
6331,U,,,,In vitro,22224,0,Autocuration,Microsomes,4708,A,Liver,,1,BAO_0000251,Intrinsic clearance in human liver microsomes was determined,,,2107.0,Homo sapiens,CHEMBL618997,9606.0
5948,U,,,,In vitro,22224,0,Autocuration,Microsomes,4709,A,Liver,,1,BAO_0000251,Intrinsic clearance in human liver microsomes was determined,,,2107.0,Homo sapiens,CHEMBL618998,9606.0
5965,U,,,,In vivo,22224,0,Autocuration,,4710,A,,,1,BAO_0000218,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,,,Homo sapiens,CHEMBL618999,9606.0
1916,U,,,,In vivo,22224,0,Autocuration,,4711,A,,,1,BAO_0000218,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,,,Homo sapiens,CHEMBL620223,9606.0
5965,U,,,,,22224,0,Autocuration,,4712,A,,,1,BAO_0000218,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,,,Homo sapiens,CHEMBL620224,9606.0
1299,U,,,,,22224,0,Autocuration,,4713,A,,,1,BAO_0000019,Stability in human plasma 2 hr after incubation expressed as percent concentration,,,,Homo sapiens,CHEMBL620225,9606.0
1299,U,,,,,22224,0,Autocuration,,4714,A,,,1,BAO_0000019,Stability in human plasma 4 hr after incubation expressed as percent concentration,,,,Homo sapiens,CHEMBL620226,9606.0
7766,U,,,,,22224,0,Autocuration,,4715,A,Urine,,1,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,1088.0,Homo sapiens,CHEMBL620227,9606.0
7766,U,,,,,22224,0,Autocuration,,4716,A,Urine,,1,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,1088.0,Homo sapiens,CHEMBL876726,9606.0
7766,U,,,,,22224,0,Autocuration,,4717,A,Urine,,1,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,1088.0,Homo sapiens,CHEMBL620228,9606.0
7766,U,,,,,22224,0,Autocuration,,4718,A,Urine,,1,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,1088.0,Homo sapiens,CHEMBL620229,9606.0
17764,N,,,,In vivo,50594,1,Intermediate,,4719,F,,,1,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,,,Mus musculus,CHEMBL620230,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,4720,F,,,1,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,,,Mus musculus,CHEMBL620231,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,4721,F,,,1,BAO_0000218,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,,,Mus musculus,CHEMBL620232,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,4722,F,,,1,BAO_0000218,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,,,Mus musculus,CHEMBL620233,10090.0
14294,N,,,,,50594,1,Intermediate,,4723,A,,,1,BAO_0000218,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,,,Mus musculus,CHEMBL620234,10090.0
14294,N,,,,,50594,1,Intermediate,,4724,A,,,1,BAO_0000218,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,,,Mus musculus,CHEMBL620235,10090.0
14294,N,,,,,50594,1,Intermediate,,4725,A,,,1,BAO_0000218,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,,,Mus musculus,CHEMBL620236,10090.0
6251,N,,,,,50594,1,Intermediate,,4726,A,Liver,,1,BAO_0000218,In vitro metabolic potential in mouse liver microsomes,,,2107.0,Mus musculus,CHEMBL620237,10090.0
17582,N,,,,,50594,1,Intermediate,,4727,A,,,1,BAO_0000218,Ability of compound to bind to plasma protein was evaluated in HSA cells,,,,Mus musculus,CHEMBL620238,10090.0
17811,N,,,,,50594,1,Intermediate,,4728,A,Adrenal gland,,1,BAO_0000218,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,,2369.0,Mus musculus,CHEMBL620239,10090.0
17811,N,,,,,50594,1,Intermediate,,4729,A,Brain,,1,BAO_0000218,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,,955.0,Mus musculus,CHEMBL620240,10090.0
17811,N,,,,,50594,1,Intermediate,,4730,A,Brain,,1,BAO_0000218,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,,955.0,Mus musculus,CHEMBL620241,10090.0
17811,N,,,,,50594,1,Intermediate,,4731,A,,,1,BAO_0000218,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,,,Mus musculus,CHEMBL876727,10090.0
17811,N,,,,,50594,1,Intermediate,,4732,A,Kidney,,1,BAO_0000218,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,,2113.0,Mus musculus,CHEMBL620242,10090.0
17811,N,,,,,50594,1,Intermediate,,4733,A,,,1,BAO_0000218,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,,,Mus musculus,CHEMBL620243,10090.0
5288,N,,,,,50594,1,Intermediate,,4734,A,,,1,BAO_0000218,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,,,Mus musculus,CHEMBL620244,10090.0
2717,N,,,,,50594,1,Intermediate,,4735,A,Serum,,1,BAO_0000218,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,,1977.0,Mus musculus,CHEMBL620245,10090.0
2717,N,,,,,50594,1,Intermediate,,4736,A,Serum,,1,BAO_0000218,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,,1977.0,Mus musculus,CHEMBL620246,10090.0
2717,N,,,,,50594,1,Intermediate,,4737,A,Serum,,1,BAO_0000218,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,,1977.0,Mus musculus,CHEMBL620247,10090.0
17753,N,,,,In vivo,50594,1,Intermediate,,4738,A,Plasma,,1,BAO_0000218,Half life of compound was determined in plasma of mice at 24 mg/Kg,,,1969.0,Mus musculus,CHEMBL620248,10090.0
17753,N,,,,In vivo,50594,1,Intermediate,,4739,A,Plasma,,1,BAO_0000218,Half life of compound was determined in plasma of mice at 40 mg/Kg,,,1969.0,Mus musculus,CHEMBL873497,10090.0
17753,N,,,,In vivo,50594,1,Intermediate,,4740,A,Plasma,,1,BAO_0000218,Half life of compound was determined in plasma of mice at 5 mg/Kg,,,1969.0,Mus musculus,CHEMBL620249,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,4741,F,,,1,BAO_0000218,Half life after intraperitoneal administration in mice at 18 uM/kg,,,,Mus musculus,CHEMBL620250,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,4742,F,,,1,BAO_0000218,Half life after intraperitoneal administration in mice at 23 uM/kg,,,,Mus musculus,CHEMBL620251,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,4743,F,,,1,BAO_0000218,Half life after intraperitoneal administration in mice at 25 uM/kg,,,,Mus musculus,CHEMBL620252,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,4744,F,,,1,BAO_0000218,Half life after intraperitoneal administration in mice at 26 uM/kg,,,,Mus musculus,CHEMBL620253,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,4745,F,,,1,BAO_0000218,Half life after intravenous administration in mice at 23 uM/kg,,,,Mus musculus,CHEMBL620254,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,4746,A,,,1,BAO_0000218,Half life after intravenous administration in mice at 24 uM/kg,,,,Mus musculus,CHEMBL620255,10090.0
16597,N,,,,In vivo,50594,1,Intermediate,,4747,A,,,1,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,,,Mus musculus,CHEMBL620256,10090.0
2675,N,,,,In vivo,50594,1,Intermediate,,4748,A,,,1,BAO_0000218,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,,,Mus musculus,CHEMBL876728,10090.0
2675,N,,,,In vivo,50594,1,Intermediate,,4749,A,,,1,BAO_0000218,Maximum time required to reach Cp max was evaluated in mice after oral administration,,,,Mus musculus,CHEMBL620257,10090.0
16597,N,,,,In vivo,50594,1,Intermediate,,4750,A,,,1,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,,,Mus musculus,CHEMBL620258,10090.0
4890,N,,,,In vivo,50594,1,Intermediate,,4751,A,,,1,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,,,Mus musculus,CHEMBL620259,10090.0
429,N,,,,In vivo,50594,1,Intermediate,,4752,A,,,1,BAO_0000218,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,,,Mus musculus,CHEMBL620260,10090.0
17837,N,,,,In vivo,50594,1,Intermediate,,4753,A,Blood,,1,BAO_0000218,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,,,178.0,Mus musculus,CHEMBL620261,10090.0
16597,N,,,,In vivo,50594,1,Intermediate,,4754,A,,,1,BAO_0000218,Half life at a dose of 10 mg/kg intravenous administration in mice.,,,,Mus musculus,CHEMBL620262,10090.0
16597,N,,,,In vivo,50594,1,Intermediate,,4755,A,,,1,BAO_0000218,Half life at a dose of 10 mg/kg peroral administration in mice.,,,,Mus musculus,CHEMBL620263,10090.0
6619,N,,,,,50594,1,Intermediate,,4756,A,,,1,BAO_0000218,Half life in ob/ob mice,,,,Mus musculus,CHEMBL620264,10090.0
4066,N,,,,In vivo,50594,1,Intermediate,,4757,A,,,1,BAO_0000218,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,,,Mus musculus,CHEMBL620265,10090.0
4239,N,,,,,50594,1,Intermediate,,4758,A,,,1,BAO_0000218,Half-life was measured in mouse,,,,Mus musculus,CHEMBL620266,10090.0
5969,N,,,,In vivo,50594,1,Intermediate,,4759,A,,,1,BAO_0000218,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,,,Mus musculus,CHEMBL620267,10090.0
8999,N,,,,,50594,1,Intermediate,,4760,A,,,1,BAO_0000218,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,,,Mus musculus,CHEMBL619364,10090.0
8999,N,,,,,50594,1,Intermediate,,4761,A,,,1,BAO_0000218,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,,,Mus musculus,CHEMBL619365,10090.0
17641,N,,,,,50594,1,Intermediate,,4762,A,Brain,,1,BAO_0000218,T2 in brain of mice at the oral dose of 50 mg/kg,,,955.0,Mus musculus,CHEMBL619366,10090.0
17641,N,,,,,50594,1,Intermediate,,4763,A,Kidney,,1,BAO_0000218,T2 in kidney of mice at the oral dose of 50 mg/kg,,,2113.0,Mus musculus,CHEMBL619367,10090.0
17641,N,,,,,50594,1,Intermediate,,4764,A,Liver,,1,BAO_0000218,T2 in liver of mice at the oral dose of 50 mg/kg,,,2107.0,Mus musculus,CHEMBL619368,10090.0
17641,N,,,,,50594,1,Intermediate,,4765,A,Lung,,1,BAO_0000218,T2 in lungs of mice at the oral dose of 50 mg/kg,,,2048.0,Mus musculus,CHEMBL619369,10090.0
17641,N,,,,,50594,1,Intermediate,,4766,A,Spleen,,1,BAO_0000218,T2 in spleen of mice at the oral dose of 50 mg/kg,,,2106.0,Mus musculus,CHEMBL876729,10090.0
16597,N,,,,In vivo,50594,1,Intermediate,,4767,A,,,1,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,,,Mus musculus,CHEMBL619370,10090.0
4890,N,,,,In vivo,50594,1,Intermediate,,4768,A,,,1,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,,,Mus musculus,CHEMBL619371,10090.0
429,N,,,,In vivo,50594,1,Intermediate,,4769,A,,,1,BAO_0000218,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,,,Mus musculus,CHEMBL619372,10090.0
429,N,,,,In vivo,50594,1,Intermediate,,4770,A,,,1,BAO_0000218,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,,,Mus musculus,CHEMBL620012,10090.0
5969,N,,,,In vivo,50594,1,Intermediate,,4771,A,,,1,BAO_0000218,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,,,Mus musculus,CHEMBL620013,10090.0
16913,N,,,A2780,,81034,1,Intermediate,,4772,F,,,1,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",478.0,,,Homo sapiens,CHEMBL620014,9606.0
16913,N,,,A2780,,81034,1,Intermediate,,4773,F,,,1,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",478.0,,,Homo sapiens,CHEMBL620015,9606.0
16913,N,,,A2780,,81034,1,Intermediate,,4774,F,,,1,BAO_0000219,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",478.0,,,Homo sapiens,CHEMBL621010,9606.0
16913,N,,,A2780,,81034,1,Intermediate,,4775,F,,,1,BAO_0000219,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",478.0,,,Homo sapiens,CHEMBL621011,9606.0
16913,N,,,A2780,,81034,1,Intermediate,,4776,F,,,1,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",478.0,,,Homo sapiens,CHEMBL621012,9606.0
16913,N,,,A2780,,81034,1,Intermediate,,4777,F,,,1,BAO_0000219,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",478.0,,,Homo sapiens,CHEMBL621013,9606.0
17270,N,,,A2780,,81034,1,Intermediate,,4778,F,,,1,BAO_0000219,In vitro cytotoxicity against A2780TAX cell line,478.0,,,Homo sapiens,CHEMBL621014,9606.0
5618,N,,,A2780cisR,,80017,1,Intermediate,,4779,F,,,1,BAO_0000219,In vitro inhibitory activity against human tumor cell line A2780cis,481.0,,,Homo sapiens,CHEMBL618154,9606.0
17777,N,,,A2780,,81034,1,Expert,,4780,F,,,1,BAO_0000219,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,478.0,,,Homo sapiens,CHEMBL618155,9606.0
16112,N,,,A2780cisR,,80017,1,Intermediate,,4781,F,,,1,BAO_0000219,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,481.0,,,Homo sapiens,CHEMBL618156,9606.0
15748,N,,,A2780cisR,,80017,1,Intermediate,,4782,F,,,1,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),481.0,,,Homo sapiens,CHEMBL618157,9606.0
6633,N,,,A2780,,81034,1,Intermediate,,4783,F,,,1,BAO_0000219,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,478.0,,,Homo sapiens,CHEMBL618328,9606.0
16930,N,,,A2780,,81034,1,Intermediate,,4784,F,,,1,BAO_0000219,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,478.0,,,Homo sapiens,CHEMBL618329,9606.0
17496,N,,,A2780,,81034,1,Intermediate,,4785,F,,,1,BAO_0000219,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,478.0,,,Homo sapiens,CHEMBL618330,9606.0
12989,N,,,A2780,,81034,1,Expert,,4786,F,,,1,BAO_0000219,In vitro antitumor activity against A2780cisR cell line.,478.0,,,Homo sapiens,CHEMBL618331,9606.0
4840,N,,,A2780,,81034,1,Intermediate,,4787,F,,,1,BAO_0000219,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),478.0,,,Homo sapiens,CHEMBL618332,9606.0
12989,N,,,A2780,,81034,1,Expert,,4788,F,,,1,BAO_0000219,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,478.0,,,Homo sapiens,CHEMBL618333,9606.0
16745,N,,,A2780cisR,,80017,1,Intermediate,,4789,F,,,1,BAO_0000219,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,481.0,,,Homo sapiens,CHEMBL618334,9606.0
16597,N,,,A2780,,81034,1,Expert,,4790,F,,,1,BAO_0000219,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,478.0,,,Homo sapiens,CHEMBL618335,9606.0
16547,D,,,,,11736,9,Expert,,4791,B,,,1,BAO_0000019,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,,,Rattus norvegicus,CHEMBL618336,10116.0
16547,H,,,,,11736,8,Expert,,4792,F,,,1,BAO_0000019,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,,,CHEMBL618337,
16547,D,,,,,11736,9,Expert,,4793,F,,,1,BAO_0000019,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,,,Rattus norvegicus,CHEMBL618338,10116.0
15856,D,,,HEK293,,278,9,Expert,,4794,F,,,1,BAO_0000219,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,722.0,,,Homo sapiens,CHEMBL618339,9606.0
15856,D,,,HEK293,,278,9,Expert,,4795,F,,,1,BAO_0000219,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,722.0,,,Homo sapiens,CHEMBL618340,9606.0
16547,D,,,,,11831,9,Expert,,4796,B,,,1,BAO_0000019,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,,,Mus musculus,CHEMBL618341,10090.0
16547,H,,,,,11831,8,Expert,,4797,F,,,1,BAO_0000019,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,,,CHEMBL618342,
16547,D,,,,,11831,9,Expert,,4798,F,,,1,BAO_0000019,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,,,Mus musculus,CHEMBL618343,10090.0
17402,H,,,,,280,8,Expert,,4799,B,,,1,BAO_0000357,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,,,,CHEMBL621038,
11746,U,,,T-cells,,22226,0,Autocuration,,4800,F,,,1,BAO_0000219,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),574.0,,,Homo sapiens,CHEMBL621039,9606.0
11746,U,,,T-cells,,22226,0,Autocuration,,4801,F,,,1,BAO_0000219,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,574.0,,,Homo sapiens,CHEMBL621040,9606.0
5455,N,,,A-375,,80018,1,Intermediate,,4802,F,,,1,BAO_0000219,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,455.0,,,Homo sapiens,CHEMBL621041,9606.0
2068,N,,,A-375,,80018,1,Intermediate,,4803,F,,,1,BAO_0000219,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,455.0,,,Homo sapiens,CHEMBL621042,9606.0
2683,N,,,A-375,,80018,1,Intermediate,,4804,F,,,1,BAO_0000219,In vitro antitumor activity against A375cell line extracted form melanoma,455.0,,,Homo sapiens,CHEMBL621043,9606.0
15313,N,,,A-375,,80018,1,Expert,,4805,F,,,1,BAO_0000219,Inhibition of cell growth in (A375) melan cell line,455.0,,,Homo sapiens,CHEMBL621044,9606.0
13739,N,,,A-375,,80018,1,Intermediate,,4806,F,,,1,BAO_0000219,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,455.0,,,Homo sapiens,CHEMBL621045,9606.0
13739,N,,,A-375,,80018,1,Intermediate,,4807,F,,,1,BAO_0000219,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,455.0,,,Homo sapiens,CHEMBL621046,9606.0
14750,N,,,A-375,,80018,1,Intermediate,,4808,F,,,1,BAO_0000219,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,455.0,,,Homo sapiens,CHEMBL621047,9606.0
14777,N,,,A-427,,80019,1,Intermediate,,4809,F,,,1,BAO_0000219,Antiproliferative activity measured against A427 human lung carcinoma,797.0,,,Homo sapiens,CHEMBL621048,9606.0
14777,N,,,A-427,,80019,1,Intermediate,,4810,F,,,1,BAO_0000219,Antiproliferative activity measured against A427 human lung carcinoma,797.0,,,Homo sapiens,CHEMBL883798,9606.0
17672,N,,,A-427,,80019,1,Intermediate,,4811,F,,,1,BAO_0000219,Cytotoxicity against lung carcinoma A427 tumor cell lines,797.0,,,Homo sapiens,CHEMBL621049,9606.0
14368,N,,,A-427,,80019,1,Intermediate,,4812,F,,,1,BAO_0000219,Inhibition of large cell lung carcinoma (A427),797.0,,,Homo sapiens,CHEMBL621050,9606.0
14368,N,,,A-427,,80019,1,Intermediate,,4813,F,,,1,BAO_0000219,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,797.0,,,Homo sapiens,CHEMBL621051,9606.0
13866,N,,,A-427,,80019,1,Intermediate,,4814,F,,,1,BAO_0000219,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,797.0,,,Homo sapiens,CHEMBL621052,9606.0
2545,N,,,A-427,,80019,1,Intermediate,,4815,F,,,1,BAO_0000219,Inhibitory concentration in human lung carcinoma A427 cell line,797.0,,,Homo sapiens,CHEMBL621053,9606.0
2545,N,,,A-427,,80019,1,Intermediate,,4816,F,,,1,BAO_0000219,Inhibitory concentration in human lung carcinoma A427/VCR cell line,797.0,,,Homo sapiens,CHEMBL621054,9606.0
6062,U,,,,In vivo,22224,0,Autocuration,,4817,A,,,1,BAO_0000218,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,,,Cercopithecidae,CHEMBL621055,9527.0
4578,U,,,,In vivo,22224,0,Autocuration,,4818,A,,,1,BAO_0000218,Tested for volume of distribution upon iv administration to african green monkey,,,,Cercopithecidae,CHEMBL876398,9527.0
17592,U,,,,In vivo,22224,0,Autocuration,,4819,A,,,1,BAO_0000218,Volume of distribution in monkey,,,,Cercopithecidae,CHEMBL621056,9527.0
5005,U,,,,In vivo,22224,0,Autocuration,,4820,A,,,1,BAO_0000218,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,,Macaca mulatta,CHEMBL621057,9544.0
5005,U,,,,In vivo,22224,0,Autocuration,,4821,A,,,1,BAO_0000218,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,,,Macaca mulatta,CHEMBL621058,9544.0
5922,U,,,,In vivo,22224,0,Autocuration,,4822,A,,,1,BAO_0000218,Pharmacokinetic property(Vdss) in cynomolgus monkey,,,,Cercopithecidae,CHEMBL621059,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,4823,A,,,1,BAO_0000218,The distribution volume after intravenous administration in cynomolgus monkeys,,,,Cercopithecidae,CHEMBL621060,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,4824,A,,,1,BAO_0000218,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,,,Cercopithecidae,CHEMBL621061,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,4825,A,,,1,BAO_0000218,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,,,Cercopithecidae,CHEMBL621062,9527.0
6057,U,,,,In vivo,22224,0,Autocuration,,4826,A,,,1,BAO_0000218,Volume displacement was calculated in rhesus monkey,,,,Cercopithecidae,CHEMBL621063,9527.0
5145,U,,,,In vivo,22224,0,Autocuration,,4827,A,,,1,BAO_0000218,Volume of distribution in steady state was determined in rhesus monkey,,,,Cercopithecidae,CHEMBL621064,9527.0
6821,U,,,,In vivo,22224,0,Autocuration,,4828,A,,,1,BAO_0000218,Volume of distribution of compound was determined in monkey,,,,Cercopithecidae,CHEMBL621065,9527.0
5334,U,,,,In vivo,22224,0,Autocuration,,4829,A,,,1,BAO_0000218,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,,Cercopithecidae,CHEMBL621066,9527.0
5334,U,,,,In vivo,22224,0,Autocuration,,4830,A,,,1,BAO_0000218,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,,Cercopithecidae,CHEMBL621067,9527.0
6641,U,,,,In vivo,22224,0,Autocuration,,4831,A,,,1,BAO_0000218,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,,Cercopithecidae,CHEMBL621068,9527.0
2661,U,,,,In vivo,22224,0,Autocuration,,4832,A,,,1,BAO_0000218,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,,Cercopithecidae,CHEMBL876399,9527.0
6535,U,,,,In vivo,22224,0,Autocuration,,4833,A,,,1,BAO_0000218,Volume distribution in monkey after administration of 1 mg/kg iv,,,,Cercopithecidae,CHEMBL621069,9527.0
4809,U,,,,In vivo,22224,0,Autocuration,,4834,A,,,1,BAO_0000218,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,,Cercopithecidae,CHEMBL621070,9527.0
6062,U,,,,In vivo,22224,0,Autocuration,,4835,A,,,1,BAO_0000218,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,,,Cercopithecidae,CHEMBL621071,9527.0
3443,U,,,,In vivo,22224,0,Autocuration,,4836,A,,,1,BAO_0000218,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,,Cercopithecidae,CHEMBL621072,9527.0
4578,U,,,,In vivo,22224,0,Autocuration,,4837,A,,,1,BAO_0000218,Oral systemic bioavailability upon iv administration to african green monkey,,,,Cercopithecidae,CHEMBL618209,9527.0
4809,U,,,,In vivo,22224,0,Autocuration,,4838,A,,,1,BAO_0000218,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,,Cercopithecidae,CHEMBL618210,9527.0
11271,U,,,,,22224,0,Autocuration,,4839,A,,,1,BAO_0000019,Baboon plasma free fraction. ,,,,Cercopithecidae,CHEMBL618211,9527.0
6057,U,,,,,22224,0,Autocuration,,4840,A,,,1,BAO_0000218,Area under the curve was calculated in rhesus monkey after iv administration,,,,Cercopithecidae,CHEMBL618212,9527.0
6057,U,,,,,22224,0,Autocuration,,4841,A,,,1,BAO_0000019,Area under the curve was calculated in rhesus monkey after peroral administration,,,,Cercopithecidae,CHEMBL618213,9527.0
17853,U,,,,,22224,0,Autocuration,,4842,A,,,1,BAO_0000019,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,,,Cercopithecidae,CHEMBL618214,9527.0
5302,U,,,,In vivo,22224,0,Autocuration,,4843,A,,,1,BAO_0000218,Half life period in monkey after 5 mg/kg dose,,,,Cercopithecidae,CHEMBL873492,9527.0
4257,U,,,,In vivo,22224,0,Autocuration,,4844,A,,,1,BAO_0000218,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,,,Cercopithecidae,CHEMBL618272,9527.0
4257,U,,,,In vivo,22224,0,Autocuration,,4845,A,,,1,BAO_0000218,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,,,Cercopithecidae,CHEMBL618273,9527.0
13501,U,,,,In vivo,22224,0,Autocuration,,4846,A,Plasma,,1,BAO_0000218,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,,1969.0,Cercopithecidae,CHEMBL618274,9527.0
5394,U,,,,In vivo,22224,0,Autocuration,,4847,A,,,1,BAO_0000218,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,,,Cercopithecidae,CHEMBL618275,9527.0
2661,U,,,,In vivo,22224,0,Autocuration,,4848,A,,,1,BAO_0000218,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,,Cercopithecidae,CHEMBL618276,9527.0
3341,U,,,,,22224,0,Autocuration,,4849,A,,,1,BAO_0000019,Compound was evaluated for terminal half life in monkey,,,,Cercopithecidae,CHEMBL618277,9527.0
3045,U,,,,In vivo,22224,0,Autocuration,,4850,A,,,1,BAO_0000218,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,,,Cercopithecidae,CHEMBL618278,9527.0
5005,U,,,,In vivo,22224,0,Autocuration,,4851,A,Plasma,,1,BAO_0000218,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,1969.0,Macaca mulatta,CHEMBL618279,9544.0
4847,U,,,,,22224,0,Autocuration,,4852,A,,,1,BAO_0000019,Half life of compound was determined in squirrel monkey,,,,Cercopithecidae,CHEMBL618280,9527.0
4256,U,,,,In vivo,22224,0,Autocuration,,4853,A,,,1,BAO_0000218,Half life after iv administration in cynomolgus monkey,,,,Macaca fascicularis,CHEMBL618281,9541.0
6535,U,,,,In vivo,22224,0,Autocuration,,4854,A,Plasma,,1,BAO_0000218,Half life in monkey plasma after administration of 1 mg/kg iv,,,1969.0,Cercopithecidae,CHEMBL618282,9527.0
6057,U,,,,,22224,0,Autocuration,,4855,A,,,1,BAO_0000019,Half life was calculated in rhesus monkey,,,,Cercopithecidae,CHEMBL618283,9527.0
17592,U,,,,,22224,0,Autocuration,,4856,A,,,1,BAO_0000019,Half life in monkey,,,,Cercopithecidae,CHEMBL618284,9527.0
6641,U,,,,In vivo,22224,0,Autocuration,,4857,A,,,1,BAO_0000218,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,,,Cercopithecidae,CHEMBL618285,9527.0
5472,U,,,,,22224,0,Autocuration,,4858,A,,,1,BAO_0000019,Half life was evaluated in rhesus,,,,Cercopithecidae,CHEMBL618286,9527.0
6221,U,,,,In vivo,22224,0,Autocuration,,4859,A,,,1,BAO_0000218,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,,,Cercopithecidae,CHEMBL618287,9527.0
5668,U,,,,In vivo,22224,0,Autocuration,,4860,A,,,1,BAO_0000218,Half life period was determine after peroral administration at 10 mpk in Rhesus,,,,Cercopithecidae,CHEMBL618288,9527.0
4809,U,,,,In vivo,22224,0,Autocuration,,4861,A,,,1,BAO_0000218,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,,,Cercopithecidae,CHEMBL876393,9527.0
5546,U,,,,In vivo,22224,0,Autocuration,,4862,A,,,1,BAO_0000218,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,,,Cercopithecidae,CHEMBL618289,9527.0
5553,U,,,,In vivo,22224,0,Autocuration,,4863,A,,,1,BAO_0000218,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,,,Cercopithecidae,CHEMBL618290,9527.0
6078,U,,,,,22224,0,Autocuration,,4864,A,,,1,BAO_0000019,Half-life was calculated in monkey,,,,Cercopithecidae,CHEMBL618291,9527.0
5147,U,,,,,22224,0,Autocuration,,4865,A,,,1,BAO_0000019,Half-life in Squirrel monkey,,,,Cercopithecidae,CHEMBL618292,9527.0
5145,U,,,,,22224,0,Autocuration,,4866,A,,,1,BAO_0000019,Half-life in rhesus monkey,,,,Cercopithecidae,CHEMBL618293,9527.0
6062,U,,,,In vivo,22224,0,Autocuration,,4867,A,,,1,BAO_0000218,Half-life was measured in monkey after an iv dose of 1 mg/kg,,,,Cercopithecidae,CHEMBL618294,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,4868,A,,,1,BAO_0000218,Half-life period after intravenous administration in cynomolgus monkeys,,,,Cercopithecidae,CHEMBL618295,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,4869,A,,,1,BAO_0000218,Half-life period after oral administration in cynomolgus monkeys,,,,Cercopithecidae,CHEMBL618296,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,4870,A,,,1,BAO_0000218,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,,,Cercopithecidae,CHEMBL618297,9527.0
7766,U,,,,,22224,0,Autocuration,,4871,A,Urine,,1,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,1088.0,Homo sapiens,CHEMBL618298,9606.0
7766,U,,,,,22224,0,Autocuration,,4872,A,Urine,,1,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,1088.0,Homo sapiens,CHEMBL618299,9606.0
7766,U,,,,,22224,0,Autocuration,,4873,A,Urine,,1,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,1088.0,Homo sapiens,CHEMBL618300,9606.0
7766,U,,,,,22224,0,Autocuration,,4874,A,Urine,,1,BAO_0000019,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,,1088.0,Homo sapiens,CHEMBL618301,9606.0
7766,U,,,,,22224,0,Autocuration,,4875,A,Urine,,1,BAO_0000019,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,,1088.0,Homo sapiens,CHEMBL618302,9606.0
7766,U,,,,,22224,0,Autocuration,,4876,A,Urine,,1,BAO_0000019,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,,1088.0,Homo sapiens,CHEMBL876394,9606.0
7766,U,,,,,22224,0,Autocuration,,4877,A,Urine,,1,BAO_0000019,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,,1088.0,Homo sapiens,CHEMBL618303,9606.0
7766,U,,,,,22224,0,Autocuration,,4878,A,Urine,,1,BAO_0000019,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,,1088.0,Homo sapiens,CHEMBL618304,9606.0
1916,U,,,,In vivo,22224,0,Autocuration,,4879,A,,,1,BAO_0000218,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,,,Homo sapiens,CHEMBL618305,9606.0
16643,U,,,,In vivo,22224,0,Autocuration,,4880,A,,,1,BAO_0000218,Oral bioavailability in human,,,,Homo sapiens,CHEMBL618306,9606.0
17248,U,,,,,22224,0,Autocuration,,4881,A,,,1,BAO_0000019,Compound was tested for human plasma protein binding,,,,Homo sapiens,CHEMBL618307,9606.0
17248,U,,,,,22224,0,Autocuration,,4882,A,,,1,BAO_0000019,Compound was tested for human plasma protein binding; Not determined,,,,Homo sapiens,CHEMBL618308,9606.0
6241,U,,,,,22224,0,Autocuration,,4883,A,,,1,BAO_0000019,Protein binding activity of compound in human plasma; % Free,,,,Homo sapiens,CHEMBL618309,9606.0
17716,U,,,,,22224,0,Autocuration,,4884,A,,,1,BAO_0000019,Unbound fraction (plasma),,,,Homo sapiens,CHEMBL618310,9606.0
17605,U,,,,,22224,0,Autocuration,,4885,A,Plasma,,1,BAO_0000366,Half life for the hydrolysis of compound in human blood serum,,,1969.0,Homo sapiens,CHEMBL873353,9606.0
17625,U,,,,,22224,0,Autocuration,,4886,A,Plasma,,1,BAO_0000366,Half life period in human plasma using phosphate buffer (0.08 M),,,1969.0,Homo sapiens,CHEMBL618311,9606.0
17625,U,,,,,22224,0,Autocuration,,4887,A,Plasma,,1,BAO_0000366,Half life period in human plasma using phosphate buffer (0.1 M),,,1969.0,Homo sapiens,CHEMBL618312,9606.0
17747,U,,,,,22224,0,Autocuration,,4888,A,Plasma,,1,BAO_0000366,Half-life in human plasma was determined,,,1969.0,Homo sapiens,CHEMBL618313,9606.0
15613,U,,,,,22224,0,Autocuration,,4889,A,,,1,BAO_0000019,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,,,Homo sapiens,CHEMBL618314,9606.0
354,U,,,,,22224,0,Autocuration,,4890,A,,,1,BAO_0000019,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,,,Homo sapiens,CHEMBL618315,9606.0
3741,U,,,,,22224,0,Autocuration,,4891,A,,,1,BAO_0000019,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,,,Homo sapiens,CHEMBL618316,9606.0
3741,U,,,,,22224,0,Autocuration,,4892,A,,,1,BAO_0000019,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,,,Homo sapiens,CHEMBL618317,9606.0
3741,U,,,,,22224,0,Autocuration,,4893,A,,,1,BAO_0000019,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,,,Homo sapiens,CHEMBL620138,9606.0
17599,U,,,,,22224,0,Autocuration,,4894,A,,,1,BAO_0000019,Partition coefficient (logP),,,,Homo sapiens,CHEMBL858280,9606.0
5486,U,,,,,22224,0,Autocuration,,4895,A,,,1,BAO_0000019,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,,,Homo sapiens,CHEMBL620139,9606.0
5600,U,,,,,22224,0,Autocuration,Microsomes,4896,A,,,1,BAO_0000251,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,,,Homo sapiens,CHEMBL620140,9606.0
14294,U,,,,,22224,0,Autocuration,,4897,A,,,1,BAO_0000019,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,,,Homo sapiens,CHEMBL620141,9606.0
14294,U,,,,,22224,0,Autocuration,,4898,A,,,1,BAO_0000019,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,,,Homo sapiens,CHEMBL620142,9606.0
14294,U,,,,,22224,0,Autocuration,,4899,A,,,1,BAO_0000019,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,,,Homo sapiens,CHEMBL620143,9606.0
14294,U,,,,,22224,0,Autocuration,Microsomes,4900,A,,,1,BAO_0000251,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,,,Homo sapiens,CHEMBL620144,9606.0
14294,U,,,,,22224,0,Autocuration,Microsomes,4901,A,,,1,BAO_0000251,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,,,Homo sapiens,CHEMBL620145,9606.0
14294,U,,,,,22224,0,Autocuration,Microsomes,4902,A,,,1,BAO_0000251,Metabolism of compound in human microsomes; Trace,,,,Homo sapiens,CHEMBL620146,9606.0
6260,U,,,,,22224,0,Autocuration,Microsomes,4903,A,Liver,,1,BAO_0000251,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,,2107.0,Homo sapiens,CHEMBL620147,9606.0
6187,U,,,,,22224,0,Autocuration,Microsomes,4904,A,,,1,BAO_0000251,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,,,Homo sapiens,CHEMBL620148,9606.0
6251,U,,,,,22224,0,Autocuration,Microsomes,4905,A,Liver,,1,BAO_0000251,In vitro metabolic potential in human liver microsomes,,,2107.0,Homo sapiens,CHEMBL620149,9606.0
3246,U,,,,,22224,0,Autocuration,,4906,A,,,1,BAO_0000019,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,,,Homo sapiens,CHEMBL876412,9606.0
17313,U,,,,,22224,0,Autocuration,,4907,A,,,1,BAO_0000019,Tested for human plasma protein binding of the compound; Not tested,,,,Homo sapiens,CHEMBL619352,9606.0
6227,U,,,,,22224,0,Autocuration,,4908,A,,,1,BAO_0000019,Compound was tested for percent protein binding (PB) in human,,,,Homo sapiens,CHEMBL619353,9606.0
5530,U,,,,,22224,0,Autocuration,,4909,A,Plasma,,1,BAO_0000019,Protein binding in human plasma,,,1969.0,Homo sapiens,CHEMBL619354,9606.0
6108,U,,,,,22224,0,Autocuration,,4910,A,,,1,BAO_0000019,Permeability coefficient (B to A) in Caco-2 cell,,,,Homo sapiens,CHEMBL619355,9606.0
6108,U,,,,,22224,0,Autocuration,,4911,A,,,1,BAO_0000019,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,,,Homo sapiens,CHEMBL619356,9606.0
2774,U,,,,,22224,0,Autocuration,,4912,A,,,1,BAO_0000019,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,,,Homo sapiens,CHEMBL619357,9606.0
16643,U,,,,,22224,0,Autocuration,,4913,A,,,1,BAO_0000019,In vitro rate of absorption observed as Caco-2 permeability in humans,,,,Homo sapiens,CHEMBL619358,9606.0
17582,U,,,Caco-2,,22224,0,Autocuration,,4914,A,,,1,BAO_0000219,Cellular permeability of compound was determined in Caco-2 cells; High,495.0,,,Homo sapiens,CHEMBL619359,9606.0
6838,U,,,Caco-2,,22224,0,Autocuration,,4915,A,,,1,BAO_0000219,Permeability in Caco-2 cells of compound,495.0,,,Homo sapiens,CHEMBL619360,9606.0
6108,U,,,,,22224,0,Autocuration,,4916,A,,,1,BAO_0000019,Permeability coefficient (A to B) in Caco-2 cell,,,,Homo sapiens,CHEMBL619361,9606.0
6108,U,,,,,22224,0,Autocuration,,4917,A,,,1,BAO_0000019,Permeability coefficient (B to A) in Caco-2 cell,,,,Homo sapiens,CHEMBL619362,9606.0
6108,U,,,,,22224,0,Autocuration,,4918,A,,,1,BAO_0000019,Permeability coefficient (Papp) (Caco-2 cell monolayer),,,,Homo sapiens,CHEMBL619363,9606.0
2146,U,,,,,22224,0,Autocuration,,4919,A,,,1,BAO_0000019,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,,,Homo sapiens,CHEMBL618942,9606.0
4514,U,,,,,22224,0,Autocuration,,4920,A,,,1,BAO_0000019,Compound was tested for protein binding in human plasma,,,,Homo sapiens,CHEMBL618943,9606.0
6108,U,,,,,22224,0,Autocuration,,4921,A,,,1,BAO_0000019,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,,,Homo sapiens,CHEMBL618944,9606.0
7766,U,,,,,22224,0,Autocuration,,4922,A,Urine,,1,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,,1088.0,Homo sapiens,CHEMBL618945,9606.0
5969,N,,,,In vivo,50594,1,Intermediate,,4923,A,,,1,BAO_0000218,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,,,Mus musculus,CHEMBL618946,10090.0
3277,N,,,,In vivo,50594,1,Intermediate,,4924,A,,,1,BAO_0000218,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,,Mus musculus,CHEMBL876413,10090.0
3802,N,,,,In vivo,50594,1,Intermediate,,4925,A,,,1,BAO_0000218,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,,,Mus musculus,CHEMBL618947,10090.0
2862,N,,,,In vivo,50594,1,Intermediate,,4926,A,Plasma,,1,BAO_0000218,Time taken to reach maximum concentration in plasma upon oral administration in mouse,,,1969.0,Mus musculus,CHEMBL618948,10090.0
6348,N,,,,In vivo,50594,1,Intermediate,,4927,A,Plasma,,1,BAO_0000218,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,1969.0,Mus musculus,CHEMBL618949,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,4928,F,,,1,BAO_0000218,Tmax after intraperitoneal administration in mice at 23 uM/kg,,,,Mus musculus,CHEMBL618950,10090.0
5781,N,,,,In vivo,50594,1,Intermediate,,4929,A,,,1,BAO_0000218,Tmax after oral administration at 30 mg/kg in ICR mouse,,,,Mus musculus,CHEMBL618951,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,4930,A,,,1,BAO_0000218,Tmax after peroral administration in mice at 2.4 uM/kg,,,,Mus musculus,CHEMBL618952,10090.0
4066,N,,,,In vivo,50594,1,Intermediate,,4931,A,,,1,BAO_0000218,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,,,Mus musculus,CHEMBL618953,10090.0
17641,N,,,,In vivo,50594,1,Intermediate,,4932,A,Brain,,1,BAO_0000218,Tmax in brain of mice at the oral dose of 50 mg/kg,,,955.0,Mus musculus,CHEMBL618954,10090.0
17641,N,,,,In vivo,50594,1,Intermediate,,4933,A,Kidney,,1,BAO_0000218,Tmax in kidney of mice at the oral dose of 50 mg/kg,,,2113.0,Mus musculus,CHEMBL618955,10090.0
17641,N,,,,In vivo,50594,1,Intermediate,,4934,A,Liver,,1,BAO_0000218,Tmax in liver of mice at the oral dose of 50 mg/kg,,,2107.0,Mus musculus,CHEMBL618956,10090.0
17641,N,,,,In vivo,50594,1,Intermediate,,4935,A,Lung,,1,BAO_0000218,Tmax in lungs of mice at the oral dose of 50 mg/kg,,,2048.0,Mus musculus,CHEMBL618957,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,4936,F,,,1,BAO_0000218,Tmax in mice at 18 uM/kg i.p. administration,,,,Mus musculus,CHEMBL618958,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,4937,F,,,1,BAO_0000218,Tmax in mice at 23 uM/kg i.v. administration,,,,Mus musculus,CHEMBL618959,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,4938,F,,,1,BAO_0000218,Tmax in mice at 25 uM/kg i.p. administration,,,,Mus musculus,CHEMBL618960,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,4939,F,,,1,BAO_0000218,Tmax in mice at 26 uM/kg i.p. administration,,,,Mus musculus,CHEMBL876723,10090.0
17641,N,,,,In vivo,50594,1,Intermediate,,4940,A,Spleen,,1,BAO_0000218,Tmax in spleen of mice at the oral dose of 50 mg/kg,,,2106.0,Mus musculus,CHEMBL618961,10090.0
16597,N,,,,In vivo,50594,1,Intermediate,,4941,A,,,1,BAO_0000218,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,,,Mus musculus,CHEMBL618962,10090.0
16597,N,,,,In vivo,50594,1,Intermediate,,4942,A,,,1,BAO_0000218,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,,,Mus musculus,CHEMBL618963,10090.0
5951,N,,,,,50594,1,Intermediate,,4943,A,,,1,BAO_0000218,Tmax value in IRC mice,,,,Mus musculus,CHEMBL618964,10090.0
5506,N,,,,In vivo,50594,1,Intermediate,,4944,A,,,1,BAO_0000218,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,,,Mus musculus,CHEMBL618965,10090.0
5506,N,,,,In vivo,50594,1,Intermediate,,4945,A,,,1,BAO_0000218,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,,,Mus musculus,CHEMBL618966,10090.0
429,N,,,,,50594,1,Intermediate,,4946,A,Urine,,1,BAO_0000218,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,,1088.0,Mus musculus,CHEMBL618967,10090.0
429,N,,,,,50594,1,Intermediate,,4947,A,Urine,,1,BAO_0000218,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,,1088.0,Mus musculus,CHEMBL618968,10090.0
4066,N,,,,,50594,1,Intermediate,,4948,A,Urine,,1,BAO_0000218,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,,1088.0,Mus musculus,CHEMBL618969,10090.0
17734,N,,,,,50594,1,Intermediate,,4949,A,,,1,BAO_0000218,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,,Mus musculus,CHEMBL618970,10090.0
17734,N,,,,,50594,1,Intermediate,,4950,A,,,1,BAO_0000218,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,,Mus musculus,CHEMBL618971,10090.0
6062,N,,,,In vivo,50594,1,Intermediate,,4951,A,,,1,BAO_0000218,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,,,Mus musculus,CHEMBL618972,10090.0
5969,N,,,,In vivo,50594,1,Intermediate,,4952,A,,,1,BAO_0000218,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,,,Mus musculus,CHEMBL618973,10090.0
5969,N,,,,In vivo,50594,1,Intermediate,,4953,A,,,1,BAO_0000218,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,,,Mus musculus,CHEMBL618974,10090.0
5969,N,,,,In vivo,50594,1,Intermediate,,4954,A,,,1,BAO_0000218,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,,Mus musculus,CHEMBL618975,10090.0
5980,N,,,,In vivo,50594,1,Intermediate,,4955,A,,,1,BAO_0000218,Vd in mice,,,,Mus musculus,CHEMBL618976,10090.0
17592,N,,,,In vivo,50594,1,Intermediate,,4956,A,,,1,BAO_0000218,Volume of distribution in mouse,,,,Mus musculus,CHEMBL618977,10090.0
6348,N,,,,In vivo,50594,1,Intermediate,,4957,A,,,1,BAO_0000218,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,,Mus musculus,CHEMBL876724,10090.0
17753,N,,,,In vivo,50594,1,Intermediate,,4958,A,,,1,BAO_0000218,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,,,Mus musculus,CHEMBL618978,10090.0
17753,N,,,,In vivo,50594,1,Intermediate,,4959,A,,,1,BAO_0000218,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,,,Mus musculus,CHEMBL618979,10090.0
17753,N,,,,In vivo,50594,1,Intermediate,,4960,A,,,1,BAO_0000218,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,,,Mus musculus,CHEMBL618980,10090.0
4239,N,,,,In vivo,50594,1,Intermediate,,4961,A,,,1,BAO_0000218,Pharmacokinetic property (vdss) was measured in mouse,,,,Mus musculus,CHEMBL618981,10090.0
2862,N,,,,In vivo,50594,1,Intermediate,,4962,A,,,1,BAO_0000218,Value distribution upon iv administration in mouse,,,,Mus musculus,CHEMBL618982,10090.0
17734,N,,,,In vivo,50594,1,Intermediate,,4963,A,,,1,BAO_0000218,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,,,Mus musculus,CHEMBL620150,10090.0
2675,N,,,,In vivo,50594,1,Intermediate,,4964,A,,,1,BAO_0000218,Volume of distribution was evaluated in mice after intravenous administration,,,,Mus musculus,CHEMBL620151,10090.0
2675,N,,,,In vivo,50594,1,Intermediate,,4965,A,,,1,BAO_0000218,Volume of distribution was evaluated in mice after oral administration,,,,Mus musculus,CHEMBL620152,10090.0
17837,N,,,,In vivo,50594,1,Intermediate,,4966,A,,,1,BAO_0000218,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,,,Mus musculus,CHEMBL620153,10090.0
5727,N,,,,In vivo,50594,1,Intermediate,,4967,A,,,1,BAO_0000218,Steady state volume of distribution was determined in mice,,,,Mus musculus,CHEMBL876395,10090.0
17852,N,,,,In vivo,50594,1,Intermediate,,4968,A,,,1,BAO_0000218,Volume distribution (steady state) of compound was determined in mouse,,,,Mus musculus,CHEMBL620154,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,4969,A,,,1,BAO_0000218,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,,,Mus musculus,CHEMBL620155,10090.0
16597,N,,,,In vivo,50594,1,Intermediate,,4970,A,,,1,BAO_0000218,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,,,Mus musculus,CHEMBL620156,10090.0
6062,N,,,,In vivo,50594,1,Intermediate,,4971,A,,,1,BAO_0000218,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,,,Mus musculus,CHEMBL620157,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,4972,A,Kidney,,1,BAO_0000218,Biodistribution of compound (oxidized form) in in kidney tissue,,,2113.0,Mus musculus,CHEMBL620158,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,4973,A,Blood,,1,BAO_0000218,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,,,178.0,Mus musculus,CHEMBL620159,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,4974,A,Blood,,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,,178.0,Mus musculus,CHEMBL620160,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,4975,A,Blood,,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,178.0,Mus musculus,CHEMBL620161,10090.0
10708,N,,,A-427,,80019,1,Intermediate,,4976,F,,,1,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,797.0,,,Homo sapiens,CHEMBL620162,9606.0
16597,N,,,A-431,,80852,1,Expert,,4977,F,,,1,BAO_0000219,Inhibition of A431 human squamous cell carcinoma cell proliferation,500.0,,,Homo sapiens,CHEMBL620163,9606.0
16062,N,,,A-431,,80852,1,Expert,,4978,F,,,1,BAO_0000219,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,500.0,,,Homo sapiens,CHEMBL620833,9606.0
16062,N,,,A-431,,80852,1,Expert,,4979,F,,,1,BAO_0000219,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,500.0,,,Homo sapiens,CHEMBL876396,9606.0
16958,N,,,A-431,,80852,1,Expert,,4980,F,,,1,BAO_0000219,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,500.0,,,Homo sapiens,CHEMBL620834,9606.0
6700,N,,,A-431,,80852,1,Expert,,4981,F,,,1,BAO_0000219,Inhibition of A431 human carcinoma cell proliferation,500.0,,,Homo sapiens,CHEMBL620835,9606.0
17226,N,,,A-431,,80852,1,Expert,,4982,F,,,1,BAO_0000219,In vitro inhibition of A431 (human carcinoma) cell basal growth.,500.0,,,Homo sapiens,CHEMBL620836,9606.0
6828,N,,,A-431,,80852,1,Intermediate,,4983,F,,,1,BAO_0000219,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,500.0,,,Homo sapiens,CHEMBL620837,9606.0
12314,N,,,A-431,,80852,1,Intermediate,,4984,F,,,1,BAO_0000219,In vitro cytotoxicity against epidermoid carcinoma cell line,500.0,,,Homo sapiens,CHEMBL621017,9606.0
13412,D,,,A-431,,9,9,Expert,,4985,F,,,1,BAO_0000218,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",500.0,,,Homo sapiens,CHEMBL621018,9606.0
13299,N,,,A-431,,80852,1,Intermediate,,4986,F,,,1,BAO_0000219,Antiproliferative activity of compound was measured on human tumor cell line A431.,500.0,,,Homo sapiens,CHEMBL621019,9606.0
17420,N,,,A-431,,80852,1,Intermediate,,4987,F,,,1,BAO_0000219,Antiproliferative effect of compound on A431 cell line expressing mutant p53,500.0,,,Homo sapiens,CHEMBL621020,9606.0
13678,N,,,A-431,,80852,1,Intermediate,,4988,F,,,1,BAO_0000219,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,500.0,,,Homo sapiens,CHEMBL621021,9606.0
14171,H,,,A-431,,9,8,Expert,,4989,F,,,1,BAO_0000219,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,500.0,,,,CHEMBL621022,
6333,N,,,A-431,,80852,1,Expert,,4990,F,,,1,BAO_0000219,Tested for antiproliferative activity against human A431 cells,500.0,,,Homo sapiens,CHEMBL621023,9606.0
2356,D,,,A-431,,9,9,Expert,,4991,F,,,1,BAO_0000219,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,500.0,,,Homo sapiens,CHEMBL621024,9606.0
15578,N,,,A-431,,80852,1,Expert,,4992,F,,,1,BAO_0000219,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,500.0,,,Homo sapiens,CHEMBL621025,9606.0
5126,N,,,A-431,,80852,1,Expert,,4993,F,,,1,BAO_0000219,Inhibition of A431 cell proliferation,500.0,,,Homo sapiens,CHEMBL621026,9606.0
6844,N,,,A-431,,80852,1,Expert,,4994,F,,,1,BAO_0000219,Cytotoxic effect on A431 human epidermoid carcinoma cells,500.0,,,Homo sapiens,CHEMBL621027,9606.0
6844,N,,,A-431,,80852,1,Expert,,4995,F,,,1,BAO_0000219,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),500.0,,,Homo sapiens,CHEMBL876397,9606.0
4925,N,,,A-431,,80852,1,Intermediate,,4996,F,,,1,BAO_0000219,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,500.0,,,Homo sapiens,CHEMBL883797,9606.0
4925,N,,,A-431,,80852,1,Intermediate,,4997,F,,,1,BAO_0000219,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,500.0,,,Homo sapiens,CHEMBL621028,9606.0
13978,N,,,A-431,,80852,1,Intermediate,,4998,F,,,1,BAO_0000219,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,500.0,,,Homo sapiens,CHEMBL621029,9606.0
16786,N,,,A-431,,80852,1,Intermediate,,4999,F,,,1,BAO_0000219,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,500.0,,,Homo sapiens,CHEMBL621030,9606.0
13412,H,,,A-431,,9,8,Expert,,5000,F,,,1,BAO_0000219,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,500.0,,,,CHEMBL621147,
17824,N,,,A-431,,80852,1,Intermediate,,5001,F,,,1,BAO_0000218,In vivo antiproliferative activity against A431 cell line,500.0,,,Homo sapiens,CHEMBL621148,9606.0
12751,D,,,A-431,,9,9,Expert,,5002,F,,,1,BAO_0000219,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,500.0,,,Homo sapiens,CHEMBL621149,9606.0
12380,N,,,A-431,,80852,1,Expert,,5003,F,,,1,BAO_0000219,Inhibition of A431 human epidermoid carcinoma cell proliferation,500.0,,,Homo sapiens,CHEMBL621150,9606.0
4959,D,,,A-431,,9,9,Expert,,5004,F,,,1,BAO_0000219,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,500.0,,,Homo sapiens,CHEMBL621151,9606.0
6333,N,,,A-431,,80852,1,Intermediate,,5005,F,,,1,BAO_0000219,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),500.0,,,Homo sapiens,CHEMBL621152,9606.0
6333,N,,,A-431,,80852,1,Intermediate,,5006,F,,,1,BAO_0000219,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),500.0,,,Homo sapiens,CHEMBL621153,9606.0
6333,N,,,A-431,,80852,1,Intermediate,,5007,F,,,1,BAO_0000219,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),500.0,,,Homo sapiens,CHEMBL884000,9606.0
5296,D,,,,,9,9,Expert,,5008,F,,,1,BAO_0000019,Inhibition of EGFR overexpressing A431 cell proliferation,,,,Homo sapiens,CHEMBL621154,9606.0
12624,N,,,A-431,,80852,1,Expert,,5009,F,,,1,BAO_0000219,Inhibition of A431 cell proliferation,500.0,,,Homo sapiens,CHEMBL621155,9606.0
14926,D,,,A-431,,9,9,Expert,,5010,F,,,1,BAO_0000219,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,500.0,,,Homo sapiens,CHEMBL621156,9606.0
14926,D,,,A-431,,9,9,Expert,,5011,F,,,1,BAO_0000219,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",500.0,,,Homo sapiens,CHEMBL621157,9606.0
14926,H,,,A-431,,9,8,Expert,,5012,F,,,1,BAO_0000219,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),500.0,,,,CHEMBL621158,
15144,N,,,A-431,,80852,1,Intermediate,,5013,F,,,1,BAO_0000219,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,500.0,,,Homo sapiens,CHEMBL621159,9606.0
15144,N,,,A-431,,80852,1,Intermediate,,5014,F,,,1,BAO_0000219,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,500.0,,,Homo sapiens,CHEMBL621160,9606.0
5245,N,,,A-431,,80852,1,Intermediate,,5015,F,,,1,BAO_0000219,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,500.0,,,Homo sapiens,CHEMBL621161,9606.0
5245,N,,,A-431,,80852,1,Intermediate,,5016,F,,,1,BAO_0000219,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,500.0,,,Homo sapiens,CHEMBL621162,9606.0
5245,N,,,A-431,,80852,1,Intermediate,,5017,F,,,1,BAO_0000219,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,500.0,,,Homo sapiens,CHEMBL621163,9606.0
5245,N,,,A-431,,80852,1,Intermediate,,5018,F,,,1,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,500.0,,,Homo sapiens,CHEMBL621164,9606.0
5245,N,,,A-431,,80852,1,Intermediate,,5019,F,,,1,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,500.0,,,Homo sapiens,CHEMBL621165,9606.0
5922,U,,,,,22224,0,Autocuration,,5020,A,,,1,BAO_0000019,Half-life period in cynomolgus monkey,,,,Cercopithecidae,CHEMBL619159,9527.0
1116,U,,,,In vitro,22224,0,Autocuration,,5021,A,Plasma,,1,BAO_0000366,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",,,1969.0,Cercopithecidae,CHEMBL619160,9527.0
17853,U,,,,In vivo,22224,0,Autocuration,,5022,A,,,1,BAO_0000218,Longer half-life in monkey (i.v.) at 0.5 mpk,,,,Cercopithecidae,CHEMBL619161,9527.0
993,U,,,,,22224,0,Autocuration,,5023,A,Plasma,,1,BAO_0000366,Plasma half life in monkey,,,1969.0,Cercopithecidae,CHEMBL619162,9527.0
4514,U,,,,,22224,0,Autocuration,,5024,A,Plasma,,1,BAO_0000366,Plasma half-life in rhesus monkey,,,1969.0,Cercopithecidae,CHEMBL619163,9527.0
5334,U,,,,In vivo,22224,0,Autocuration,,5025,A,Plasma,,1,BAO_0000218,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,,1969.0,Cercopithecidae,CHEMBL619164,9527.0
5334,U,,,,In vivo,22224,0,Autocuration,,5026,A,Plasma,,1,BAO_0000218,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,,1969.0,Cercopithecidae,CHEMBL619320,9527.0
4578,U,,,,In vivo,22224,0,Autocuration,,5027,A,,,1,BAO_0000218,Tested for half life upon iv administration to african green monkey,,,,Cercopithecidae,CHEMBL619321,9527.0
2661,U,,,,In vivo,22224,0,Autocuration,,5028,A,,,1,BAO_0000218,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,,Cercopithecidae,CHEMBL873336,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,5029,A,,,1,BAO_0000218,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,,,Cercopithecidae,CHEMBL619322,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,5030,A,,,1,BAO_0000218,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,,,Cercopithecidae,CHEMBL619323,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,5031,A,,,1,BAO_0000218,The time for peak concentration value after oral administration in cynomolgus monkeys,,,,Cercopithecidae,CHEMBL619324,9527.0
11271,U,,,,,22224,0,Autocuration,,5032,A,,,1,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,,,Cercopithecidae,CHEMBL619325,9527.0
11271,U,,,,,22224,0,Autocuration,,5033,A,,,1,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,,,Cercopithecidae,CHEMBL876411,9527.0
11271,U,,,,,22224,0,Autocuration,,5034,A,,,1,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,,,Cercopithecidae,CHEMBL619326,9527.0
11271,U,,,,,22224,0,Autocuration,,5035,A,,,1,BAO_0000019,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,,,Cercopithecidae,CHEMBL619327,9527.0
11271,U,,,,,22224,0,Autocuration,,5036,A,,,1,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,,,Cercopithecidae,CHEMBL619328,9527.0
11271,U,,,,,22224,0,Autocuration,,5037,A,,,1,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,,,Cercopithecidae,CHEMBL619329,9527.0
11271,U,,,,,22224,0,Autocuration,,5038,A,,,1,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,,,Cercopithecidae,CHEMBL619330,9527.0
11271,U,,,,,22224,0,Autocuration,,5039,A,,,1,BAO_0000019,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,,,Cercopithecidae,CHEMBL619331,9527.0
11271,U,,,,,22224,0,Autocuration,,5040,A,,,1,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,,,Cercopithecidae,CHEMBL619332,9527.0
11271,U,,,,,22224,0,Autocuration,,5041,A,,,1,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,,,Cercopithecidae,CHEMBL619333,9527.0
11271,U,,,,,22224,0,Autocuration,,5042,A,,,1,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,,,Cercopithecidae,CHEMBL619334,9527.0
11271,U,,,,,22224,0,Autocuration,,5043,A,,,1,BAO_0000019,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,,,Cercopithecidae,CHEMBL619335,9527.0
11271,U,,,,,22224,0,Autocuration,,5044,A,,,1,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,,,Cercopithecidae,CHEMBL619336,9527.0
11271,U,,,,,22224,0,Autocuration,,5045,A,,,1,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,,,Cercopithecidae,CHEMBL619337,9527.0
11271,U,,,,,22224,0,Autocuration,,5046,A,,,1,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,,,Cercopithecidae,CHEMBL619338,9527.0
11271,U,,,,,22224,0,Autocuration,,5047,A,,,1,BAO_0000019,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,,,Cercopithecidae,CHEMBL619339,9527.0
5809,N,,,,In vivo,50597,1,Intermediate,,5048,A,,,1,BAO_0000218,Bioavailability in rat (cannulated) (dose 2 mg/kg),,,,Rattus norvegicus,CHEMBL619340,10116.0
17720,N,,,,In vivo,50597,1,Intermediate,,5049,A,Plasma,,1,BAO_0000218,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,,1969.0,Rattus norvegicus,CHEMBL873496,10116.0
3546,N,,,,,50597,1,Intermediate,,5050,A,Plasma,,1,BAO_0000218,AUC value in rat after IV administration at a dose of 10 mg/kg,,,1969.0,Rattus norvegicus,CHEMBL619341,10116.0
3546,N,,,,,50597,1,Intermediate,,5051,A,Plasma,,1,BAO_0000218,AUC value in rat after oral administration at a dose of 10 mg/kg,,,1969.0,Rattus norvegicus,CHEMBL619342,10116.0
3546,N,,,,In vivo,50597,1,Intermediate,,5052,A,,,1,BAO_0000218,Cmax value in rat after oral administration at a dose of 10 mg/kg,,,,Rattus norvegicus,CHEMBL619343,10116.0
3546,N,,,,In vivo,50597,1,Intermediate,,5053,A,,,1,BAO_0000218,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,,,Rattus norvegicus,CHEMBL619344,10116.0
3546,N,,,,In vivo,50597,1,Intermediate,,5054,A,,,1,BAO_0000218,Tmax value in rat after oral administration at a dose of 10 mg/kg,,,,Rattus norvegicus,CHEMBL619345,10116.0
3546,N,,,,,50597,1,Intermediate,,5055,A,,,1,BAO_0000218,Vc value in rat after IV administration at a dose of 10 mg/kg,,,,Rattus norvegicus,CHEMBL619346,10116.0
3546,N,,,,In vivo,50597,1,Intermediate,,5056,A,,,1,BAO_0000218,Half life period in rat after IV administration at a dose of 10 mg/kg,,,,Rattus norvegicus,CHEMBL619347,10116.0
10625,U,,,,,22224,0,Autocuration,,5057,A,,,1,BAO_0000019,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,,,Papio hamadryas,CHEMBL619348,9557.0
10625,U,,,,,22224,0,Autocuration,,5058,A,,,1,BAO_0000019,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,,,Papio hamadryas,CHEMBL619349,9557.0
10625,U,,,,,22224,0,Autocuration,,5059,A,,,1,BAO_0000019,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,,,Papio hamadryas,CHEMBL619350,9557.0
10625,U,,,,,22224,0,Autocuration,,5060,A,,,1,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,,,Papio hamadryas,CHEMBL619351,9557.0
10625,U,,,,,22224,0,Autocuration,,5061,A,,,1,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,,,Papio hamadryas,CHEMBL875953,9557.0
10625,U,,,,,22224,0,Autocuration,,5062,A,,,1,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,,,Papio hamadryas,CHEMBL621716,9557.0
10625,U,,,,,22224,0,Autocuration,,5063,A,,,1,BAO_0000019,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,,,Papio hamadryas,CHEMBL621717,9557.0
10625,U,,,,,22224,0,Autocuration,,5064,A,,,1,BAO_0000019,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,,,Papio hamadryas,CHEMBL621718,9557.0
3510,U,,,,,22224,0,Autocuration,,5065,A,,,1,BAO_0000019,Area under curve after 1 mpk peroral administration to beagles,,,,beagle,CHEMBL621719,9615.0
3510,U,,,,,22224,0,Autocuration,,5066,A,,,1,BAO_0000019,Area under curve after 2 mpk peroral administration to beagles,,,,beagle,CHEMBL621720,9615.0
3510,U,,,,In vivo,22224,0,Autocuration,,5067,A,,,1,BAO_0000218,Cmax value after 1 mpk peroral administration to beagles,,,,beagle,CHEMBL621721,9615.0
7766,U,,,,,22224,0,Autocuration,,5068,A,Urine,,1,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,,1088.0,Homo sapiens,CHEMBL621722,9606.0
7766,U,,,,,22224,0,Autocuration,,5069,A,Urine,,1,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,,1088.0,Homo sapiens,CHEMBL621723,9606.0
7766,U,,,,,22224,0,Autocuration,,5070,A,Urine,,1,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,,1088.0,Homo sapiens,CHEMBL621724,9606.0
7766,U,,,,,22224,0,Autocuration,,5071,A,Urine,,1,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,,1088.0,Homo sapiens,CHEMBL623443,9606.0
7766,U,,,,,22224,0,Autocuration,,5072,A,Urine,,1,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,,1088.0,Homo sapiens,CHEMBL623444,9606.0
7766,U,,,,,22224,0,Autocuration,,5073,A,Urine,,1,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,,1088.0,Homo sapiens,CHEMBL623445,9606.0
7766,U,,,,,22224,0,Autocuration,,5074,A,Urine,,1,BAO_0000019,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,,1088.0,Homo sapiens,CHEMBL623446,9606.0
16643,U,,,,,22224,0,Autocuration,Microsomes,5075,A,Liver,,1,BAO_0000251,Metabolic stability observed at 30 min after administration in human liver microsomes,,,2107.0,Homo sapiens,CHEMBL623447,9606.0
6852,U,,,,,22224,0,Autocuration,,5076,A,,,1,BAO_0000019,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,,,Homo sapiens,CHEMBL623448,9606.0
6852,U,,,,,22224,0,Autocuration,,5077,A,,,1,BAO_0000019,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,,,Homo sapiens,CHEMBL623449,9606.0
6852,U,,,,,22224,0,Autocuration,,5078,A,,,1,BAO_0000019,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,,,Homo sapiens,CHEMBL623450,9606.0
6567,U,,,,,22224,0,Autocuration,Microsomes,5079,A,Liver,,1,BAO_0000251,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,,2107.0,Homo sapiens,CHEMBL623451,9606.0
6570,U,,,,,22224,0,Autocuration,,5080,A,,,1,BAO_0000019,Metabolic stability (% remaining at 30 mins) in human S9.,,,,Homo sapiens,CHEMBL623452,9606.0
6570,U,,,,,22224,0,Autocuration,,5081,A,,,1,BAO_0000019,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,,,Homo sapiens,CHEMBL623453,9606.0
5237,U,,,,,22224,0,Autocuration,Microsomes,5082,A,Liver,,1,BAO_0000251,Percent parent compound remaining after 20 min incubation with human liver microsomes,,,2107.0,Homo sapiens,CHEMBL623454,9606.0
5237,U,,,,,22224,0,Autocuration,Microsomes,5083,A,Liver,,1,BAO_0000251,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,,2107.0,Homo sapiens,CHEMBL623455,9606.0
5237,U,,,,,22224,0,Autocuration,Microsomes,5084,A,Liver,,1,BAO_0000251,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,,2107.0,Homo sapiens,CHEMBL624371,9606.0
5202,U,,,,,22224,0,Autocuration,,5085,A,,,1,BAO_0000218,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,,,Homo sapiens,CHEMBL624372,9606.0
5481,U,,,,,22224,0,Autocuration,,5086,A,,,1,BAO_0000019,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,,,Homo sapiens,CHEMBL624373,9606.0
5481,U,,,,,22224,0,Autocuration,,5087,A,,,1,BAO_0000019,Percent remaining in human plasma after incubation for 60 min at 37 C.,,,,Homo sapiens,CHEMBL624374,9606.0
3956,U,,,,,22224,0,Autocuration,,5088,A,,,1,BAO_0000019,The percent remaining in human plasma after 30 min was determined,,,,Homo sapiens,CHEMBL624556,9606.0
5074,U,,,,,22224,0,Autocuration,,5089,A,Plasma,,1,BAO_0000366,Conversion rate of the prodrug in human plasma,,,1969.0,Homo sapiens,CHEMBL624557,9606.0
5074,U,,,,,22224,0,Autocuration,,5090,A,Plasma,,1,BAO_0000366,Conversion rate of the prodrug in human plasma; ND means no data,,,1969.0,Homo sapiens,CHEMBL624558,9606.0
4727,U,,,,,22224,0,Autocuration,,5091,A,Blood,,1,BAO_0000221,Half life of compound was determined in human blood,,,178.0,Homo sapiens,CHEMBL624559,9606.0
5965,U,,,,,22224,0,Autocuration,,5092,A,,,1,BAO_0000019,Half life of compound was determined in man with once daily dosing,,,,Homo sapiens,CHEMBL624560,9606.0
5732,U,,,,In vitro,22224,0,Autocuration,Microsomes,5093,A,,,1,BAO_0000251,Half life in human microsomes,,,,Homo sapiens,CHEMBL624561,9606.0
5819,U,,,,,22224,0,Autocuration,,5094,A,Plasma,,1,BAO_0000366,Half life in human plasma,,,1969.0,Homo sapiens,CHEMBL624562,9606.0
5819,U,,,,,22224,0,Autocuration,,5095,A,Plasma,,1,BAO_0000366,Half life in human plasma; Not detected,,,1969.0,Homo sapiens,CHEMBL624563,9606.0
1916,U,,,,In vivo,22224,0,Autocuration,,5096,A,,,1,BAO_0000218,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,,,Homo sapiens,CHEMBL624564,9606.0
6597,U,,,,In vitro,22224,0,Autocuration,Microsomes,5097,A,Liver,,1,BAO_0000251,Half-life for oxidative metabolic stability was determined using rat liver microsomes,,,2107.0,Homo sapiens,CHEMBL624565,9606.0
5229,U,,,,,22224,0,Autocuration,,5098,A,Plasma,,1,BAO_0000366,Half-life in human plasma,,,1969.0,Homo sapiens,CHEMBL875152,9606.0
5229,U,,,,,22224,0,Autocuration,,5099,A,Plasma,,1,BAO_0000366,Half-life of the parent prodrug in plasma,,,1969.0,Homo sapiens,CHEMBL624566,9606.0
2192,U,,,,In vitro,22224,0,Autocuration,,5100,A,Plasma,,1,BAO_0000366,In vitro half life in human plasma was determined,,,1969.0,Homo sapiens,CHEMBL873805,9606.0
3032,U,,,,In vitro,22224,0,Autocuration,Microsomes,5101,A,Liver,,1,BAO_0000251,The compound was tested In Vitro for half life in human liver microsomes.,,,2107.0,Homo sapiens,CHEMBL624567,9606.0
1916,U,,,,In vivo,22224,0,Autocuration,,5102,A,,,1,BAO_0000218,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,,,Homo sapiens,CHEMBL624568,9606.0
17716,U,,,,In vivo,22224,0,Autocuration,,5103,A,,,1,BAO_0000218,Observed volume of distribution,,,,Homo sapiens,CHEMBL624569,9606.0
15778,U,,,,In vivo,22224,0,Autocuration,,5104,A,,,1,BAO_0000218,Oral bioavailability in human,,,,Homo sapiens,CHEMBL624570,9606.0
17313,U,,,,,22224,0,Autocuration,,5105,A,,,1,BAO_0000019,Tested for human plasma protein binding of the compound,,,,Homo sapiens,CHEMBL624571,9606.0
4231,U,,,,,22224,0,Autocuration,,5106,A,,,1,BAO_0000019,"First order rate constant, k was determined in human plasma",,,,Homo sapiens,CHEMBL624572,9606.0
4755,U,,,,,22224,0,Autocuration,,5107,A,,,1,BAO_0000019,Observed rate constant in 80% human plasma at 37 degree Centigrade,,,,Homo sapiens,CHEMBL624573,9606.0
4755,U,,,,,22224,0,Autocuration,,5108,A,,,1,BAO_0000019,Observed rate constant in 80% human plasma at 37 degree Centigrade,,,,Homo sapiens,CHEMBL875153,9606.0
16907,U,,,,,22224,0,Autocuration,Microsomes,5109,A,Liver,,1,BAO_0000251,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,,2107.0,Homo sapiens,CHEMBL624574,9606.0
10839,U,,,,,22224,0,Autocuration,,5110,A,,,1,BAO_0000019,The compound was tested for the plasma binding in human,,,,Homo sapiens,CHEMBL624575,9606.0
10839,U,,,,,22224,0,Autocuration,,5111,A,,,1,BAO_0000019,Plasma protein binding (human),,,,Homo sapiens,CHEMBL624576,9606.0
3199,U,,,,In vitro,22224,0,Autocuration,Microsomes,5112,A,Liver,,1,BAO_0000251,Compound was evaluated for half-life in human liver microsomes,,,2107.0,Homo sapiens,CHEMBL624577,9606.0
1345,U,,,,In vitro,22224,0,Autocuration,,5113,A,Blood,,1,BAO_0000221,Half life measured in vitro for its stability in human blood,,,178.0,Homo sapiens,CHEMBL624578,9606.0
4297,U,,,,,22224,0,Autocuration,,5114,A,Serum,,1,BAO_0000019,Half life in human serum,,,1977.0,Homo sapiens,CHEMBL622796,9606.0
4297,U,,,,,22224,0,Autocuration,,5115,A,Serum,,1,BAO_0000019,Half life in human serum; ND=not determined,,,1977.0,Homo sapiens,CHEMBL622797,9606.0
4297,U,,,,,22224,0,Autocuration,,5116,A,,,1,BAO_0000019,Half life were determined in CEM-SS cell extract in decomposition step 1,,,,Homo sapiens,CHEMBL622798,9606.0
4297,U,,,,,22224,0,Autocuration,,5117,A,,,1,BAO_0000019,Half life were determined in CEM-SS cell extract in decomposition step 2,,,,Homo sapiens,CHEMBL622799,9606.0
4231,U,,,,,22224,0,Autocuration,,5118,A,Plasma,,1,BAO_0000366,Half life of the in human plasma,,,1969.0,Homo sapiens,CHEMBL622800,9606.0
5633,U,,,,In vitro,22224,0,Autocuration,S9,5119,A,,,1,BAO_0000220,Half life period in human hepatic S9 fraction was determined,,,,Homo sapiens,CHEMBL622801,9606.0
5633,U,,,,In vitro,22224,0,Autocuration,Microsomes,5120,A,Liver,,1,BAO_0000251,Half life period in human liver microsome was determined,,,2107.0,Homo sapiens,CHEMBL622802,9606.0
17791,U,,,,,22224,0,Autocuration,,5121,A,,,1,BAO_0000019,Half life period was determined; 6-7,,,,Homo sapiens,CHEMBL622803,9606.0
17791,U,,,,,22224,0,Autocuration,,5122,A,,,1,BAO_0000019,Half life period was evaluated in human,,,,Homo sapiens,CHEMBL875154,9606.0
3160,U,,,,,22224,0,Autocuration,,5123,A,Plasma,,1,BAO_0000366,Half life time in human plasma,,,1969.0,Homo sapiens,CHEMBL622804,9606.0
16438,N,,,,In vivo,50594,1,Intermediate,,5124,A,Brain,,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,955.0,Mus musculus,CHEMBL622805,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5125,A,Heart,,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,948.0,Mus musculus,CHEMBL622611,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5126,A,Heart,,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,948.0,Mus musculus,CHEMBL622612,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5127,A,Kidney,,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,2113.0,Mus musculus,CHEMBL875160,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5128,A,Kidney,,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,,2113.0,Mus musculus,CHEMBL622613,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5129,A,Kidney,,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,2113.0,Mus musculus,CHEMBL622614,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5130,A,Liver,,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,2107.0,Mus musculus,CHEMBL622615,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5131,A,Liver,,1,BAO_0000218,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,,,2107.0,Mus musculus,CHEMBL622616,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5132,A,Liver,,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,2107.0,Mus musculus,CHEMBL622617,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5133,A,Spleen,,1,BAO_0000218,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,,,2106.0,Mus musculus,CHEMBL622618,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5134,A,Spleen,,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,,2106.0,Mus musculus,CHEMBL622619,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5135,A,Spleen,,1,BAO_0000218,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,2106.0,Mus musculus,CHEMBL622620,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5136,A,Brain,,1,BAO_0000218,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,955.0,Mus musculus,CHEMBL622621,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5137,A,Blood,,1,BAO_0000218,Biodistribution of compound (oxidized form) in blood tissue,,,178.0,Mus musculus,CHEMBL622622,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5138,A,Blood,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,178.0,Mus musculus,CHEMBL622623,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5139,A,Blood,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,178.0,Mus musculus,CHEMBL622624,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5140,A,Blood,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,178.0,Mus musculus,CHEMBL622625,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5141,A,Blood,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,178.0,Mus musculus,CHEMBL622626,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5142,A,Blood,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,178.0,Mus musculus,CHEMBL622627,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5143,A,Brain,,1,BAO_0000218,Biodistribution of compound (oxidized form) in brain tissue of mice,,,955.0,Mus musculus,CHEMBL622628,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5144,A,Brain,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,955.0,Mus musculus,CHEMBL622629,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5145,A,Brain,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,,955.0,Mus musculus,CHEMBL622630,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5146,A,Brain,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,955.0,Mus musculus,CHEMBL622631,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5147,A,Brain,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,955.0,Mus musculus,CHEMBL622632,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5148,A,Brain,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,955.0,Mus musculus,CHEMBL622633,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5149,A,Heart,,1,BAO_0000218,Biodistribution of compound (oxidized form) in heart tissue of mice,,,948.0,Mus musculus,CHEMBL622634,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5150,A,Heart,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,948.0,Mus musculus,CHEMBL622635,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5151,A,Heart,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,948.0,Mus musculus,CHEMBL875161,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5152,A,Heart,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,,948.0,Mus musculus,CHEMBL622636,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5153,A,Heart,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,948.0,Mus musculus,CHEMBL623335,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5154,A,Heart,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,948.0,Mus musculus,CHEMBL623336,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5155,A,Kidney,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,2113.0,Mus musculus,CHEMBL623337,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5156,A,Kidney,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,,2113.0,Mus musculus,CHEMBL623338,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5157,A,Kidney,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,,2113.0,Mus musculus,CHEMBL623339,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5158,A,Kidney,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,,2113.0,Mus musculus,CHEMBL623524,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5159,A,Kidney,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,,2113.0,Mus musculus,CHEMBL623525,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5160,A,Liver,,1,BAO_0000218,Biodistribution of compound (oxidized form) in liver tissue,,,2107.0,Mus musculus,CHEMBL623526,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5161,A,Liver,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,,2107.0,Mus musculus,CHEMBL623527,10090.0
16438,N,,,,In vivo,50594,1,Intermediate,,5162,A,Liver,,1,BAO_0000218,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,,2107.0,Mus musculus,CHEMBL623528,10090.0
5245,N,,,A-431,,80852,1,Intermediate,,5163,F,,,1,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,500.0,,,Homo sapiens,CHEMBL624615,9606.0
5245,N,,,A-431,,80852,1,Intermediate,,5164,F,,,1,BAO_0000219,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,500.0,,,Homo sapiens,CHEMBL621672,9606.0
16289,N,,,A-431,,80852,1,Expert,,5165,F,,,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",500.0,,,,CHEMBL621673,
16289,N,,,A-431,,80852,1,Expert,,5166,F,,,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",500.0,,,,CHEMBL621674,
16093,D,,,A-431,,9,9,Expert,,5167,F,,,1,BAO_0000219,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,500.0,,,Homo sapiens,CHEMBL884002,9606.0
16825,N,,,A-431,,80852,1,Intermediate,,5168,F,,,1,BAO_0000219,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",500.0,,,Homo sapiens,CHEMBL621850,9606.0
4848,N,,,A-431,,80852,1,Intermediate,,5169,F,,,1,BAO_0000219,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,500.0,,,Homo sapiens,CHEMBL621851,9606.0
14827,D,,,A-431,,9,9,Expert,,5170,F,,,1,BAO_0000219,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,500.0,,,Homo sapiens,CHEMBL621852,9606.0
14827,D,,,A-431,,9,9,Expert,,5171,F,,,1,BAO_0000219,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,500.0,,,Homo sapiens,CHEMBL621853,9606.0
16289,N,,,A-431,,80852,1,Expert,,5172,F,,,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",500.0,,,,CHEMBL621854,
16289,N,,,A-431,,80852,1,Expert,,5173,F,,,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",500.0,,,,CHEMBL621855,
16289,N,,,A-431,,80852,1,Expert,,5174,F,,,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",500.0,,,,CHEMBL623724,
16289,N,,,A-431,,80852,1,Expert,,5175,F,,,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",500.0,,,,CHEMBL623725,
16289,N,,,A-431,,80852,1,Expert,,5176,F,,,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",500.0,,,,CHEMBL623726,
16289,D,,,A-431,,9,9,Expert,,5177,F,,,1,BAO_0000219,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",500.0,,,Homo sapiens,CHEMBL623727,9606.0
16289,H,,,A-431,,9,8,Expert,,5178,F,,,1,BAO_0000219,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,500.0,,,,CHEMBL623728,
16289,N,,,A-431,,80852,1,Expert,,5179,F,,,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",500.0,,,,CHEMBL623729,
16289,N,,,A-431,,80852,1,Expert,,5180,F,,,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",500.0,,,,CHEMBL623730,
16289,N,,,A-431,,80852,1,Expert,,5181,F,,,1,BAO_0000218,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",500.0,,,,CHEMBL623731,
14555,N,,,A-431,,80852,1,Expert,,5182,F,,,1,BAO_0000218,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",500.0,,,Mus musculus,CHEMBL623732,10090.0
14555,N,,,A-431,,80852,1,Expert,,5183,F,,,1,BAO_0000218,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",500.0,,,Mus musculus,CHEMBL623733,10090.0
14555,N,,,A-431,,80852,1,Expert,,5184,F,,,1,BAO_0000218,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",500.0,,,Mus musculus,CHEMBL623734,10090.0
14555,N,,,A-431,,80852,1,Expert,,5185,F,,,1,BAO_0000218,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",500.0,,,Mus musculus,CHEMBL623735,10090.0
1937,N,,,A-431,,80852,1,Expert,,5186,F,,,1,BAO_0000219,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,500.0,,,Homo sapiens,CHEMBL623736,9606.0
13739,N,,,A-431,,80852,1,Intermediate,,5187,F,,,1,BAO_0000219,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,500.0,,,Homo sapiens,CHEMBL623737,9606.0
3558,N,,,A-431,,80852,1,Intermediate,,5188,F,,,1,BAO_0000219,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,500.0,,,Homo sapiens,CHEMBL623738,9606.0
3558,N,,,A-431,,80852,1,Intermediate,,5189,F,,,1,BAO_0000219,Dose giving a 50% decrease in the living cell number (A437 cells),500.0,,,Homo sapiens,CHEMBL875168,9606.0
17686,N,,,A549,,80682,1,Expert,,5190,F,,,1,BAO_0000219,In vitro inhibitory concentration against proliferation of A459 cell line.,646.0,,,Homo sapiens,CHEMBL623739,9606.0
5305,N,,,A549,,80682,1,Intermediate,,5191,F,,,1,BAO_0000219,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,646.0,,,Homo sapiens,CHEMBL623740,9606.0
3614,N,,,A549,,80682,1,Intermediate,,5192,F,,,1,BAO_0000219,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,646.0,,,Homo sapiens,CHEMBL624424,9606.0
17229,N,,,A498,,80021,1,Intermediate,,5193,F,,,1,BAO_0000219,In vitro antitumor activity against renal A498 tumor cell lines,624.0,,,Homo sapiens,CHEMBL624425,9606.0
15935,N,,,A498,,80021,1,Intermediate,,5194,F,,,1,BAO_0000219,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",624.0,,,Homo sapiens,CHEMBL624426,9606.0
15935,N,,,A498,,80021,1,Intermediate,,5195,F,,,1,BAO_0000219,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",624.0,,,Homo sapiens,CHEMBL624427,9606.0
15560,N,,,A498,,80021,1,Intermediate,,5196,F,,,1,BAO_0000219,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,624.0,,,Homo sapiens,CHEMBL624428,9606.0
13891,N,,,A498,,80021,1,Intermediate,,5197,F,,,1,BAO_0000219,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,624.0,,,Homo sapiens,CHEMBL624429,9606.0
13891,N,,,A498,,80021,1,Intermediate,,5198,F,,,1,BAO_0000219,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,624.0,,,Homo sapiens,CHEMBL624620,9606.0
13788,N,,,A498,,80021,1,Intermediate,,5199,F,,,1,BAO_0000219,Cytotoxicity on kidney carcinoma (A-498) cell line,624.0,,,Homo sapiens,CHEMBL624621,9606.0
15403,N,,,A498,,80021,1,Intermediate,,5200,F,,,1,BAO_0000219,Compound was evaluated against Human cell line renal A498,624.0,,,Homo sapiens,CHEMBL624622,9606.0
1009,N,,,A498,,80021,1,Intermediate,,5201,F,,,1,BAO_0000219,Compound was tested for inhibition of A498 human renal cancer cell line,624.0,,,Homo sapiens,CHEMBL624623,9606.0
1043,N,,,A498,,80021,1,Intermediate,,5202,F,,,1,BAO_0000219,Growth inhibitory activity against A498 human cancer cell line,624.0,,,Homo sapiens,CHEMBL874365,9606.0
5858,N,,,A498,,80021,1,Intermediate,,5203,F,,,1,BAO_0000219,In vitro antitumor activity against human renal A498 cell line,624.0,,,Homo sapiens,CHEMBL624624,9606.0
5958,N,,,A498,,80021,1,Intermediate,,5204,F,,,1,BAO_0000219,In vitro cytotoxic activity against renal (A498) cell line,624.0,,,Homo sapiens,CHEMBL624625,9606.0
5506,N,,,A498,,80021,1,Intermediate,,5205,F,,,1,BAO_0000219,In vitro cytotoxic activity against human renal cancer (A498) cell line,624.0,,,Homo sapiens,CHEMBL624626,9606.0
12781,N,,,A498,,80021,1,Intermediate,,5206,F,,,1,BAO_0000219,Tested for cytostatic activity against renal A498 cell line,624.0,,,Homo sapiens,CHEMBL624627,9606.0
14399,N,,,A498,,80021,1,Intermediate,,5207,F,,,1,BAO_0000219,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,624.0,,,Homo sapiens,CHEMBL883157,9606.0
5958,N,,,A498,,80021,1,Expert,,5208,F,,,1,BAO_0000219,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,624.0,,,Homo sapiens,CHEMBL624628,9606.0
3510,U,,,,In vivo,22224,0,Autocuration,,5209,A,,,1,BAO_0000218,Cmax value after 2 mpk peroral administration to beagles,,,,beagle,CHEMBL624629,9615.0
3510,U,beagle,,,In vivo,22224,0,Autocuration,,5210,A,,,1,BAO_0000218,Bioavailability,,,,Canis lupus familiaris,CHEMBL623551,9615.0
3510,U,beagle,,,In vivo,22224,0,Autocuration,,5211,A,,,1,BAO_0000218,Bioavailability after 1 mpk peroral administration to beagles,,,,Canis lupus familiaris,CHEMBL623552,9615.0
3510,U,beagle,,,In vivo,22224,0,Autocuration,,5212,A,,,1,BAO_0000218,Bioavailability after 2 mpk peroral administration to beagles,,,,Canis lupus familiaris,CHEMBL623553,9615.0
3085,U,,,,,22224,0,Autocuration,,5213,A,,,1,BAO_0000019,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,,,Bos taurus,CHEMBL623554,9913.0
3085,U,,,,,22224,0,Autocuration,,5214,A,,,1,BAO_0000019,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,,,Bos taurus,CHEMBL623555,9913.0
3085,U,,,,,22224,0,Autocuration,,5215,A,,,1,BAO_0000019,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,,,Bos taurus,CHEMBL623556,9913.0
9372,U,,,,,22224,0,Autocuration,,5216,A,,,1,BAO_0000019,Solubility against bovine alpha-chymotrypsin,,,,Bos taurus,CHEMBL623557,9913.0
3085,U,,,,,22224,0,Autocuration,,5217,A,,,1,BAO_0000019,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,,,Bos taurus,CHEMBL623558,9913.0
3085,U,,,,,22224,0,Autocuration,,5218,A,,,1,BAO_0000019,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,,,Bos taurus,CHEMBL623559,9913.0
1469,U,,,,,22224,0,Autocuration,,5219,A,Spleen,,1,BAO_0000221,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,,2106.0,Bos taurus,CHEMBL623560,9913.0
4297,U,,,,,22224,0,Autocuration,,5220,A,,,1,BAO_0000019,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,,,Bos taurus,CHEMBL623561,9913.0
4297,U,,,,,22224,0,Autocuration,,5221,A,,,1,BAO_0000019,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,,,Bos taurus,CHEMBL623562,9913.0
17585,U,,,,,22224,0,Autocuration,,5222,A,,,1,BAO_0000019,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,,,Bos taurus,CHEMBL623563,9913.0
1336,U,,,,,22224,0,Autocuration,,5223,A,Spleen,,1,BAO_0000221,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,,2106.0,Bos taurus,CHEMBL623564,9913.0
3085,U,,,,,22224,0,Autocuration,,5224,A,,,1,BAO_0000019,Half life in presence of 2 mg/mL BSA at pH 8.8,,,,Bos taurus,CHEMBL873806,9913.0
2857,U,,,,,22224,0,Autocuration,,5225,A,,,1,BAO_0000019,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,,,Bos taurus,CHEMBL623565,9913.0
2857,U,,,,,22224,0,Autocuration,,5226,A,,,1,BAO_0000019,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,,,Bos taurus,CHEMBL623566,9913.0
2857,U,,,,,22224,0,Autocuration,,5227,A,,,1,BAO_0000019,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,,,Bos taurus,CHEMBL623567,9913.0
1540,U,,,,,22224,0,Autocuration,,5228,A,,,1,BAO_0000019,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,,,Bos taurus,CHEMBL623568,9913.0
6316,N,,,,,50588,1,Intermediate,,5229,A,Plasma,,1,BAO_0000218,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,,1969.0,Canis lupus familiaris,CHEMBL623569,9615.0
17594,N,,,,,50588,1,Intermediate,,5230,A,Plasma,,1,BAO_0000218,AUC after administration at 100 mg/kg/day in dogs,,,1969.0,Canis lupus familiaris,CHEMBL623570,9615.0
4953,N,,,,,50588,1,Intermediate,,5231,A,Plasma,,1,BAO_0000218,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,,1969.0,Canis lupus familiaris,CHEMBL624254,9615.0
16907,N,,,,,50588,1,Intermediate,,5232,A,Plasma,,1,BAO_0000218,AUC value after 15 mg/kg iv dose in Dogs,,,1969.0,Canis lupus familiaris,CHEMBL624255,9615.0
16907,N,,,,,50588,1,Intermediate,,5233,A,Plasma,,1,BAO_0000218,AUC value after 30 mg/kg po dose in Dogs,,,1969.0,Canis lupus familiaris,CHEMBL624256,9615.0
2959,N,,,,,50588,1,Intermediate,,5234,A,Plasma,,1,BAO_0000218,AUC value after administration of 4 mg/Kg oral dose in dog,,,1969.0,Canis lupus familiaris,CHEMBL624257,9615.0
17594,N,,,,,50588,1,Intermediate,,5235,A,Plasma,,1,BAO_0000218,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,,1969.0,Canis lupus familiaris,CHEMBL624258,9615.0
5356,N,,,,,50588,1,Intermediate,,5236,A,,,1,BAO_0000218,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,,,Canis lupus familiaris,CHEMBL875277,9615.0
16807,N,,,,,50588,1,Intermediate,,5237,A,,,1,BAO_0000218,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,,,Canis lupus familiaris,CHEMBL622667,9615.0
4527,N,,,,,50588,1,Intermediate,,5238,A,,,1,BAO_0000218,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,,,Canis lupus familiaris,CHEMBL622668,9615.0
4527,N,,,,,50588,1,Intermediate,,5239,A,,,1,BAO_0000218,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,,,Canis lupus familiaris,CHEMBL622669,9615.0
15660,N,,,,,50588,1,Intermediate,,5240,A,,,1,BAO_0000218,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,,,Canis lupus familiaris,CHEMBL622670,9615.0
15660,N,,,,,50588,1,Intermediate,,5241,A,,,1,BAO_0000218,Area under curve determined in dogs after oral administration of 10 mg/kg,,,,Canis lupus familiaris,CHEMBL622671,9615.0
5802,N,,,,,50588,1,Intermediate,,5242,A,,,1,BAO_0000218,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,,Canis lupus familiaris,CHEMBL622672,9615.0
3598,N,,,,,50588,1,Expert,,5243,A,,,1,BAO_0000218,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,,,Canis lupus familiaris,CHEMBL622673,9615.0
3598,N,,,,,50588,1,Expert,,5244,A,,,1,BAO_0000218,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,,,Canis lupus familiaris,CHEMBL622674,9615.0
5944,N,,,,,50588,1,Intermediate,,5245,A,,,1,BAO_0000218,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,,,Canis lupus familiaris,CHEMBL622675,9615.0
5944,N,,,,,50588,1,Intermediate,,5246,A,,,1,BAO_0000218,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,,,Canis lupus familiaris,CHEMBL622676,9615.0
5944,N,,,,,50588,1,Intermediate,,5247,A,,,1,BAO_0000218,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,,,Canis lupus familiaris,CHEMBL622677,9615.0
5944,N,,,,,50588,1,Intermediate,,5248,A,,,1,BAO_0000218,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,,,Canis lupus familiaris,CHEMBL622678,9615.0
4186,N,,,,,50588,1,Intermediate,,5249,A,,,1,BAO_0000218,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,,,Canis lupus familiaris,CHEMBL622679,9615.0
5007,N,,,,,50588,1,Intermediate,,5250,A,,,1,BAO_0000218,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,,Canis lupus familiaris,CHEMBL622680,9615.0
5668,N,,,,,50588,1,Intermediate,,5251,A,,,1,BAO_0000218,Area under curve was determine after peroral administration at 10 mpk in dog,,,,Canis lupus familiaris,CHEMBL622681,9615.0
5668,N,,,,,50588,1,Intermediate,,5252,A,,,1,BAO_0000218,Area under curve was determine after peroral administration at 5 mpk in dog,,,,Canis lupus familiaris,CHEMBL875278,9615.0
5006,N,,,,,50588,1,Intermediate,,5253,A,,,1,BAO_0000218,Area under curve was determined,,,,Canis lupus familiaris,CHEMBL622682,9615.0
5006,N,,,,,50588,1,Intermediate,,5254,A,,,1,BAO_0000218,Area under curve in dogs,,,,Canis lupus familiaris,CHEMBL622683,9615.0
3771,N,,,,,50588,1,Intermediate,,5255,A,,,1,BAO_0000218,Area under curve in dogs at 10 mg/kg dose fo oral administration,,,,Canis lupus familiaris,CHEMBL622684,9615.0
3771,N,,,,,50588,1,Intermediate,,5256,A,,,1,BAO_0000218,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,,,Canis lupus familiaris,CHEMBL622685,9615.0
3771,N,,,,,50588,1,Intermediate,,5257,A,,,1,BAO_0000218,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,,,Canis lupus familiaris,CHEMBL622686,9615.0
1916,N,,,,,50588,1,Intermediate,,5258,A,,,1,BAO_0000218,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,,Canis lupus familiaris,CHEMBL618344,9615.0
5302,N,,,,,50588,1,Intermediate,,5259,A,,,1,BAO_0000218,Area under curve value in dog at a dose of 5 mg/kg,,,,Canis lupus familiaris,CHEMBL875582,9615.0
5600,N,,,,,50588,1,Intermediate,,5260,A,,,1,BAO_0000218,Area under curve was determined after 0.1 mg/kg iv administration in dog,,,,Canis lupus familiaris,CHEMBL618345,9615.0
5600,N,,,,,50588,1,Intermediate,,5261,A,,,1,BAO_0000218,Area under curve was determined after 0.3 mg/kg po administration in dog,,,,Canis lupus familiaris,CHEMBL618346,9615.0
17764,N,,,,,50588,1,Intermediate,,5262,A,,,1,BAO_0000218,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,,,Canis lupus familiaris,CHEMBL618347,9615.0
4368,N,,,,,50588,1,Intermediate,,5263,A,,,1,BAO_0000218,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL618348,9615.0
5318,U,,,,,22224,0,Autocuration,,5264,A,,,1,BAO_0000019,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,,,Homo sapiens,CHEMBL618349,9606.0
5318,U,,,,,22224,0,Autocuration,,5265,A,,,1,BAO_0000019,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,,,Homo sapiens,CHEMBL618350,9606.0
5318,U,,,,,22224,0,Autocuration,,5266,A,,,1,BAO_0000019,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,,,Homo sapiens,CHEMBL618351,9606.0
5318,U,,,,,22224,0,Autocuration,,5267,A,,,1,BAO_0000019,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,,,Homo sapiens,CHEMBL618352,9606.0
14518,U,,,,,22224,0,Autocuration,,5268,A,Blood,,1,BAO_0000221,Time taken to reduce 50% of the concentration of compound in blood plasma,,,178.0,Homo sapiens,CHEMBL873494,9606.0
2209,U,,,,,22224,0,Autocuration,,5269,A,Plasma,,1,BAO_0000366,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,,1969.0,Homo sapiens,CHEMBL618353,9606.0
6787,U,,,,,22224,0,Autocuration,,5270,A,Plasma,,1,BAO_0000366,Half life in human plasma,,,1969.0,Homo sapiens,CHEMBL618354,9606.0
4898,U,,,,,22224,0,Autocuration,,5271,A,Plasma,,1,BAO_0000366,Half life in human plasma was reported,,,1969.0,Homo sapiens,CHEMBL875583,9606.0
6072,U,,,,,22224,0,Autocuration,,5272,A,Serum,,1,BAO_0000019,Half life in human serum,,,1977.0,Homo sapiens,CHEMBL618355,9606.0
16907,U,,,,,22224,0,Autocuration,,5273,A,Plasma,,1,BAO_0000366,Half life upon exposure to human plasma,,,1969.0,Homo sapiens,CHEMBL618356,9606.0
5656,U,,,,In vitro,22224,0,Autocuration,Microsomes,5274,A,,,1,BAO_0000251,t1/2 in human microsomes,,,,Homo sapiens,CHEMBL618357,9606.0
4755,U,,,,,22224,0,Autocuration,,5275,A,Plasma,,1,BAO_0000366,Half life period in 80% human plasma at 37 degree Centigrade,,,1969.0,Homo sapiens,CHEMBL618358,9606.0
17503,U,,,,,22224,0,Autocuration,,5276,A,Zone of skin,,1,BAO_0000221,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,,14.0,Homo sapiens,CHEMBL618359,9606.0
12357,U,,,,In vitro,22224,0,Autocuration,,5277,A,Plasma,,1,BAO_0000366,Half-life measured in in vitro Cathepsin B assay in human plasma,,,1969.0,Homo sapiens,CHEMBL618360,9606.0
3076,U,,,,,22224,0,Autocuration,,5278,A,,,1,BAO_0000019,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,,,Homo sapiens,CHEMBL618361,9606.0
6410,U,,,,In vitro,22224,0,Autocuration,Microsomes,5279,A,Liver,,1,BAO_0000251,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,,,2107.0,Homo sapiens,CHEMBL618362,9606.0
3741,U,,,,,22224,0,Autocuration,,5280,A,Plasma,,1,BAO_0000366,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,,1969.0,Homo sapiens,CHEMBL618363,9606.0
3741,U,,,,,22224,0,Autocuration,,5281,A,Plasma,,1,BAO_0000366,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,,1969.0,Homo sapiens,CHEMBL618364,9606.0
3741,U,,,,,22224,0,Autocuration,,5282,A,Plasma,,1,BAO_0000366,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,,1969.0,Homo sapiens,CHEMBL875584,9606.0
1540,U,,,,,22224,0,Autocuration,,5283,A,,,1,BAO_0000019,Half-life in the CEM cell extracts,,,,Homo sapiens,CHEMBL618365,9606.0
2905,U,,,,,22224,0,Autocuration,,5284,A,Plasma,,1,BAO_0000366,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,,1969.0,Homo sapiens,CHEMBL873495,9606.0
2905,U,,,,,22224,0,Autocuration,,5285,A,Plasma,,1,BAO_0000366,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,,1969.0,Homo sapiens,CHEMBL618366,9606.0
5523,U,,,,,22224,0,Autocuration,,5286,A,,,1,BAO_0000019,Half-life was determined,,,,Homo sapiens,CHEMBL618367,9606.0
1499,U,,,,,22224,0,Autocuration,,5287,A,Blood,,1,BAO_0000221,Half-life (human blood stability),,,178.0,Homo sapiens,CHEMBL618368,9606.0
1499,U,,,,,22224,0,Autocuration,,5288,A,Blood,,1,BAO_0000221,Half-life (human blood stability); no data,,,178.0,Homo sapiens,CHEMBL618369,9606.0
17065,U,,,,,22224,0,Autocuration,,5289,A,Plasma,,1,BAO_0000366,Half-life in human plasma,,,1969.0,Homo sapiens,CHEMBL618370,9606.0
6861,U,,,,,22224,0,Autocuration,,5290,A,,,1,BAO_0000019,CYP3A4 metabolism half-life (t1/2),,,,Homo sapiens,CHEMBL618371,9606.0
1499,U,,,,,22224,0,Autocuration,,5291,A,Blood,,1,BAO_0000221,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,,178.0,Homo sapiens,CHEMBL618372,9606.0
530,U,,,,In vitro,22224,0,Autocuration,,5292,A,Plasma,,1,BAO_0000366,In vitro half life in human plasma,,,1969.0,Homo sapiens,CHEMBL618373,9606.0
1116,U,,,,In vitro,22224,0,Autocuration,,5293,A,Plasma,,1,BAO_0000366,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",,,1969.0,Homo sapiens,CHEMBL618374,9606.0
6695,U,,,,In vitro,22224,0,Autocuration,,5294,A,Plasma,,1,BAO_0000366,In vitro hydrolysis in human plasma,,,1969.0,Homo sapiens,CHEMBL618375,9606.0
6695,U,,,,In vitro,22224,0,Autocuration,,5295,A,Plasma,,1,BAO_0000366,In vitro hydrolysis in human plasma; no data,,,1969.0,Homo sapiens,CHEMBL618376,9606.0
10,U,,,,In vitro,22224,0,Autocuration,Microsomes,5296,A,Liver,,1,BAO_0000251,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,,,2107.0,Homo sapiens,CHEMBL618377,9606.0
993,U,,,,,22224,0,Autocuration,,5297,A,Plasma,,1,BAO_0000366,Plasma half life in human,,,1969.0,Homo sapiens,CHEMBL618378,9606.0
15429,U,,,,,22224,0,Autocuration,,5298,A,Plasma,,1,BAO_0000366,Stability after incubation with human plasma (at 37 degree C),,,1969.0,Homo sapiens,CHEMBL618379,9606.0
1675,U,,,,,22224,0,Autocuration,,5299,A,Plasma,,1,BAO_0000366,T1/2 was evaluated in human plasma,,,1969.0,Homo sapiens,CHEMBL618380,9606.0
2209,U,,,,,22224,0,Autocuration,,5300,A,Plasma,,1,BAO_0000366,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,,1969.0,Homo sapiens,CHEMBL618381,9606.0
2209,U,,,,,22224,0,Autocuration,,5301,A,Plasma,,1,BAO_0000366,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,,1969.0,Homo sapiens,CHEMBL618382,9606.0
5318,U,,,,,22224,0,Autocuration,,5302,A,,,1,BAO_0000019,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,,,Homo sapiens,CHEMBL618383,9606.0
2412,U,,,,In vitro,22224,0,Autocuration,,5303,A,,,1,BAO_0000019,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,,,Homo sapiens,CHEMBL618384,9606.0
2412,U,,,,In vitro,22224,0,Autocuration,,5304,A,,,1,BAO_0000019,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,,,Homo sapiens,CHEMBL618385,9606.0
2906,U,,,,,22224,0,Autocuration,,5305,A,Plasma,,1,BAO_0000366,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,,1969.0,Homo sapiens,CHEMBL619099,9606.0
2906,U,,,,,22224,0,Autocuration,,5306,A,Plasma,,1,BAO_0000366,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,,1969.0,Homo sapiens,CHEMBL619100,9606.0
5495,U,,,,,22224,0,Autocuration,,5307,A,,,1,BAO_0000019,Time taken for 50% to be consumed by serum PON1 was determined,,,,Homo sapiens,CHEMBL619101,9606.0
5495,U,,,,,22224,0,Autocuration,,5308,A,,,1,BAO_0000019,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,,,Homo sapiens,CHEMBL619102,9606.0
4397,U,,,,,22224,0,Autocuration,Microsomes,5309,A,Liver,,1,BAO_0000251,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,,2107.0,Homo sapiens,CHEMBL619103,9606.0
2413,U,,,,,22224,0,Autocuration,,5310,A,,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,,Mus sp.,CHEMBL619268,10095.0
2413,U,,,,,22224,0,Autocuration,,5311,A,,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,,Mus sp.,CHEMBL619269,10095.0
2413,U,,,,,22224,0,Autocuration,,5312,A,,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,,Mus sp.,CHEMBL619270,10095.0
2413,U,,,,,22224,0,Autocuration,,5313,A,,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,,Mus sp.,CHEMBL619271,10095.0
2413,U,,,,,22224,0,Autocuration,,5314,A,,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,,Mus sp.,CHEMBL875585,10095.0
2413,U,,,,,22224,0,Autocuration,,5315,A,,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,,Mus sp.,CHEMBL619272,10095.0
6058,N,,,786-0,,80640,1,Intermediate,,5316,F,,,1,BAO_0000219,Compound tested for growth inhibition of renal cancer cell line 786-0,391.0,,,Homo sapiens,CHEMBL619273,9606.0
17708,N,,,786-0,,80640,1,Intermediate,,5317,F,,,1,BAO_0000219,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,391.0,,,Homo sapiens,CHEMBL619274,9606.0
14017,N,,,786-0,,80640,1,Expert,,5318,F,,,1,BAO_0000219,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,391.0,,,Homo sapiens,CHEMBL619275,9606.0
16818,N,,,786-0,,80640,1,Intermediate,,5319,F,,,1,BAO_0000219,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",391.0,,,Homo sapiens,CHEMBL619276,9606.0
16818,N,,,786-0,,80640,1,Intermediate,,5320,F,,,1,BAO_0000219,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",391.0,,,Homo sapiens,CHEMBL619277,9606.0
16818,N,,,786-0,,80640,1,Intermediate,,5321,F,,,1,BAO_0000219,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",391.0,,,Homo sapiens,CHEMBL619278,9606.0
11970,N,,,786-0,,80640,1,Intermediate,,5322,F,,,1,BAO_0000219,Tested for cytotoxicity against 786-0 cell lines in renal cancer,391.0,,,Homo sapiens,CHEMBL619279,9606.0
12400,N,,,786-0,,80640,1,Intermediate,,5323,F,,,1,BAO_0000219,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,391.0,,,Homo sapiens,CHEMBL858458,9606.0
12888,N,,,786-0,,80640,1,Expert,,5324,F,,,1,BAO_0000219,Cytotoxic effect on renal cancer line 786-0,391.0,,,Homo sapiens,CHEMBL619280,9606.0
15300,N,,,786-0,,80640,1,Intermediate,,5325,F,,,1,BAO_0000219,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,391.0,,,Homo sapiens,CHEMBL619281,9606.0
14769,N,,,786-0,,80640,1,Intermediate,,5326,F,,,1,BAO_0000219,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),391.0,,,Homo sapiens,CHEMBL619282,9606.0
15895,N,,,786-0,,80640,1,Intermediate,,5327,F,,,1,BAO_0000219,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",391.0,,,Homo sapiens,CHEMBL619283,9606.0
17376,N,,,786-0,,80640,1,Intermediate,,5328,F,,,1,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,391.0,,,Homo sapiens,CHEMBL619284,9606.0
14882,N,,,786-0,,80640,1,Intermediate,,5329,F,,,1,BAO_0000219,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,391.0,,,Homo sapiens,CHEMBL619285,9606.0
14882,N,,,786-0,,80640,1,Intermediate,,5330,F,,,1,BAO_0000219,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),391.0,,,Homo sapiens,CHEMBL619286,9606.0
15176,N,,,786-0,,80640,1,Intermediate,,5331,F,,,1,BAO_0000219,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,391.0,,,Homo sapiens,CHEMBL619287,9606.0
12696,N,,,786-0,,80640,1,Intermediate,,5332,F,,,1,BAO_0000219,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,391.0,,,Homo sapiens,CHEMBL857455,9606.0
2496,N,,,786-0,,80640,1,Intermediate,,5333,F,,,1,BAO_0000219,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),391.0,,,Homo sapiens,CHEMBL883801,9606.0
11831,N,,,791T cell line,,80641,1,Intermediate,,5334,F,,,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,972.0,,,Homo sapiens,CHEMBL619288,9606.0
11831,N,,,791T cell line,,80641,1,Intermediate,,5335,F,,,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),972.0,,,Homo sapiens,CHEMBL619289,9606.0
11831,N,,,791T cell line,,80641,1,Intermediate,,5336,F,,,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,972.0,,,Homo sapiens,CHEMBL619290,9606.0
11831,N,,,791T cell line,,80641,1,Intermediate,,5337,F,,,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),972.0,,,Homo sapiens,CHEMBL619291,9606.0
11831,N,,,791T cell line,,80641,1,Intermediate,,5338,F,,,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),972.0,,,Homo sapiens,CHEMBL619292,9606.0
11831,N,,,791T cell line,,80641,1,Intermediate,,5339,F,,,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,972.0,,,Homo sapiens,CHEMBL619293,9606.0
11831,N,,,791T cell line,,80641,1,Intermediate,,5340,F,,,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),972.0,,,Homo sapiens,CHEMBL619294,9606.0
11831,N,,,791T cell line,,80641,1,Intermediate,,5341,F,,,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),972.0,,,Homo sapiens,CHEMBL619295,9606.0
11831,N,,,791T cell line,,80641,1,Intermediate,,5342,F,,,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),972.0,,,Homo sapiens,CHEMBL619296,9606.0
11831,N,,,791T cell line,,80641,1,Intermediate,,5343,F,,,1,BAO_0000219,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,972.0,,,Homo sapiens,CHEMBL619297,9606.0
12782,N,,,786-0,,80640,1,Intermediate,,5344,F,,,1,BAO_0000219,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,391.0,,,Homo sapiens,CHEMBL619298,9606.0
1229,U,,,,,22226,0,Intermediate,,5345,F,,,1,BAO_0000019,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,,,,CHEMBL619299,
15313,N,,,RPMI-8226,,80433,1,Expert,,5346,F,,,1,BAO_0000219,Inhibition of cell growth in drug resistant 8226 myeloma cell line,741.0,,,Homo sapiens,CHEMBL619300,9606.0
15313,N,,,RPMI-8226,,80433,1,Expert,,5347,F,,,1,BAO_0000219,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,741.0,,,Homo sapiens,CHEMBL619301,9606.0
11544,N,,,RPMI-8226,,80433,1,Intermediate,,5348,F,,,1,BAO_0000219,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,741.0,,,Homo sapiens,CHEMBL619302,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5349,F,,,1,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,741.0,,,Homo sapiens,CHEMBL619303,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5350,F,,,1,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,741.0,,,Homo sapiens,CHEMBL619304,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5351,F,,,1,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),741.0,,,Homo sapiens,CHEMBL857706,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5352,F,,,1,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),741.0,,,Homo sapiens,CHEMBL619305,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5353,F,,,1,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),741.0,,,Homo sapiens,CHEMBL619306,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5354,F,,,1,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),741.0,,,Homo sapiens,CHEMBL619307,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5355,F,,,1,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),741.0,,,Homo sapiens,CHEMBL619308,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5356,F,,,1,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),741.0,,,Homo sapiens,CHEMBL619309,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5357,F,,,1,BAO_0000219,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),741.0,,,Homo sapiens,CHEMBL619310,9606.0
14769,N,,,A498,,80021,1,Intermediate,,5358,F,,,1,BAO_0000219,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),624.0,,,Homo sapiens,CHEMBL619311,9606.0
15354,N,,,A498,,80021,1,Intermediate,,5359,F,,,1,BAO_0000219,Compound was tested for the growth inhibition of A498 renal tumor cell line,624.0,,,Homo sapiens,CHEMBL619312,9606.0
17445,N,,,A498,,80021,1,Intermediate,,5360,F,,,1,BAO_0000219,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),624.0,,,Homo sapiens,CHEMBL619313,9606.0
4337,N,,,A498,,80021,1,Intermediate,,5361,F,,,1,BAO_0000219,In vitro inhibitory concentration against renal cancer cell line A498,624.0,,,Homo sapiens,CHEMBL619314,9606.0
15277,N,,,A498,,80021,1,Intermediate,,5362,F,,,1,BAO_0000219,Cytotoxicity against A 498 tumor cell line,624.0,,,Homo sapiens,CHEMBL619959,9606.0
4812,N,,,A498,,80021,1,Intermediate,,5363,F,,,1,BAO_0000219,In vitro antitumor activity against A498 human cancer cell line,624.0,,,Homo sapiens,CHEMBL619960,9606.0
4812,N,,,A498,,80021,1,Intermediate,,5364,F,,,1,BAO_0000219,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),624.0,,,Homo sapiens,CHEMBL619961,9606.0
4995,N,,,A498,,80021,1,Intermediate,,5365,F,,,1,BAO_0000219,Inhibitory dose required against A498 human tumor cell lines,624.0,,,Homo sapiens,CHEMBL619962,9606.0
5847,N,,,A498,,80021,1,Intermediate,,5366,F,,,1,BAO_0000219,Anticancer activity against one renal cancer (A498 cell line),624.0,,,Homo sapiens,CHEMBL875586,9606.0
6557,N,,,A498,,80021,1,Intermediate,,5367,F,,,1,BAO_0000219,In vitro cytotoxicity against melanoma A498 cell line,624.0,,,Homo sapiens,CHEMBL619963,9606.0
2597,N,,,A498,,80021,1,Intermediate,,5368,F,,,1,BAO_0000219,Compound was tested for growth inhibitory activity against A498 cell line,624.0,,,Homo sapiens,CHEMBL619964,9606.0
6058,N,,,A498,,80021,1,Intermediate,,5369,F,,,1,BAO_0000219,Compound tested for growth inhibition of renal cancer cell line A498,624.0,,,Homo sapiens,CHEMBL620108,9606.0
17708,N,,,A498,,80021,1,Intermediate,,5370,F,,,1,BAO_0000219,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,624.0,,,Homo sapiens,CHEMBL620109,9606.0
15176,N,,,A498,,80021,1,Intermediate,,5371,F,,,1,BAO_0000219,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,624.0,,,Homo sapiens,CHEMBL620110,9606.0
15300,N,,,A498,,80021,1,Intermediate,,5372,F,,,1,BAO_0000219,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,624.0,,,Homo sapiens,CHEMBL620111,9606.0
11970,N,,,A498,,80021,1,Intermediate,,5373,F,,,1,BAO_0000219,Tested for cytotoxicity against A498 cell lines in renal cancer,624.0,,,Homo sapiens,CHEMBL620112,9606.0
12400,N,,,A498,,80021,1,Intermediate,,5374,F,,,1,BAO_0000219,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,624.0,,,Homo sapiens,CHEMBL620113,9606.0
12888,N,,,A498,,80021,1,Expert,,5375,F,,,1,BAO_0000219,Cytotoxic effect on renal cancer lines A498,624.0,,,Homo sapiens,CHEMBL620114,9606.0
3030,N,,,A498,,80021,1,Intermediate,,5376,F,,,1,BAO_0000219,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,624.0,,,Homo sapiens,CHEMBL620115,9606.0
14769,N,,,A498,,80021,1,Intermediate,,5377,F,,,1,BAO_0000219,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),624.0,,,Homo sapiens,CHEMBL620116,9606.0
17376,N,,,A498,,80021,1,Intermediate,,5378,F,,,1,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,624.0,,,Homo sapiens,CHEMBL620117,9606.0
16558,N,,,A498,,80021,1,Intermediate,,5379,F,,,1,BAO_0000219,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,624.0,,,Homo sapiens,CHEMBL620118,9606.0
5194,N,,,A498,,80021,1,Intermediate,,5380,F,,,1,BAO_0000219,Cytotoxicity against human kidney carcinoma cell lines A4982LM,624.0,,,Homo sapiens,CHEMBL620119,9606.0
10708,N,,,A498,,80021,1,Intermediate,,5381,F,,,1,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,624.0,,,Homo sapiens,CHEMBL620120,9606.0
16880,N,,,A549,,80682,1,Expert,,5382,F,,,1,BAO_0000219,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,646.0,,,Homo sapiens,CHEMBL620121,9606.0
10196,N,,,A549,,80682,1,Intermediate,,5383,F,,,1,BAO_0000219,Antitumor activity against A549 human lung carcinoma cell line,646.0,,,Homo sapiens,CHEMBL620122,9606.0
10196,N,,,A549,,80682,1,Intermediate,,5384,F,,,1,BAO_0000219,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,646.0,,,Homo sapiens,CHEMBL620123,9606.0
10196,N,,,A549,,80682,1,Intermediate,,5385,F,,,1,BAO_0000219,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,646.0,,,Homo sapiens,CHEMBL620124,9606.0
12083,N,,,A549,,80682,1,Intermediate,,5386,F,,,1,BAO_0000219,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",646.0,,,Homo sapiens,CHEMBL620125,9606.0
16464,N,,,A549,,80682,1,Expert,,5387,F,,,1,BAO_0000219,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,646.0,,,Homo sapiens,CHEMBL620126,9606.0
16464,N,,,A549,,80682,1,Intermediate,,5388,F,,,1,BAO_0000219,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,646.0,,,Homo sapiens,CHEMBL883027,9606.0
16470,N,,,A549,,80682,1,Expert,,5389,F,,,1,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line,646.0,,,Homo sapiens,CHEMBL620127,9606.0
16470,N,,,A549,,80682,1,Intermediate,,5390,F,,,1,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),646.0,,,Homo sapiens,CHEMBL620128,9606.0
16470,N,,,A549,,80682,1,Intermediate,,5391,F,,,1,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line),646.0,,,Homo sapiens,CHEMBL620129,9606.0
16470,N,,,A549,,80682,1,Intermediate,,5392,F,,,1,BAO_0000219,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,646.0,,,Homo sapiens,CHEMBL620130,9606.0
16582,N,,,A549,,80682,1,Expert,,5393,F,,,1,BAO_0000219,In vitro cytotoxicity against human non small-cell-lung cell line A549.,646.0,,,Homo sapiens,CHEMBL620131,9606.0
15935,N,,,A549,,80682,1,Intermediate,,5394,F,,,1,BAO_0000219,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",646.0,,,Homo sapiens,CHEMBL620132,9606.0
15935,N,,,A549,,80682,1,Intermediate,,5395,F,,,1,BAO_0000219,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",646.0,,,Homo sapiens,CHEMBL620133,9606.0
16597,N,,,A549,,80682,1,Expert,,5396,F,,,1,BAO_0000219,Inhibition of A549 human lung carcinoma cell proliferation,646.0,,,Homo sapiens,CHEMBL620134,9606.0
17376,N,,,A549,,80682,1,Intermediate,,5397,F,,,1,BAO_0000219,Inhibitory activity against A549 lung adenocarcinoma cell line,646.0,,,Homo sapiens,CHEMBL620135,9606.0
16496,N,,,A549,,80682,1,Intermediate,,5398,F,,,1,BAO_0000219,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,646.0,,,Homo sapiens,CHEMBL620136,9606.0
16152,N,,,A549,,80682,1,Intermediate,,5399,F,,,1,BAO_0000219,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,646.0,,,Homo sapiens,CHEMBL620137,9606.0
16152,N,,,A549,,80682,1,Intermediate,,5400,F,,,1,BAO_0000219,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,646.0,,,Homo sapiens,CHEMBL620268,9606.0
16464,N,,,A549,,80682,1,Intermediate,,5401,F,,,1,BAO_0000219,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,646.0,,,Homo sapiens,CHEMBL620269,9606.0
2288,N,,,A549,,80682,1,Intermediate,,5402,F,,,1,BAO_0000219,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,646.0,,,Homo sapiens,CHEMBL620270,9606.0
17350,N,,,A549,,80682,1,Intermediate,,5403,F,,,1,BAO_0000219,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,646.0,,,Homo sapiens,CHEMBL620271,9606.0
4090,N,,,A549,,80682,1,Expert,,5404,F,,,1,BAO_0000219,Inhibition of A549 cancer cell proliferation,646.0,,,Homo sapiens,CHEMBL620272,9606.0
4090,N,,,A549,,80682,1,Expert,,5405,F,,,1,BAO_0000219,Inhibition of A549 cancer cell proliferation (Not tested),646.0,,,Homo sapiens,CHEMBL620273,9606.0
17350,N,,,A549,,80682,1,Intermediate,,5406,F,,,1,BAO_0000219,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,646.0,,,Homo sapiens,CHEMBL620274,9606.0
4197,N,,,A549,,80682,1,Intermediate,,5407,F,,,1,BAO_0000219,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,646.0,,,Homo sapiens,CHEMBL620275,9606.0
17072,N,,,A549,,80682,1,Intermediate,,5408,F,,,1,BAO_0000219,Antiproliferative potency determined as inhibitory concentration against A549 cells,646.0,,,Homo sapiens,CHEMBL620276,9606.0
17072,N,,,A549,,80682,1,Intermediate,,5409,F,,,1,BAO_0000219,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,646.0,,,Homo sapiens,CHEMBL620277,9606.0
5194,N,,,A549,,80682,1,Intermediate,,5410,F,,,1,BAO_0000219,Cytotoxicity against Renal cell lines A549 was determined,646.0,,,Homo sapiens,CHEMBL620278,9606.0
4257,N,,,,,50588,1,Intermediate,,5411,A,,,1,BAO_0000218,Area under curve was determined in dog after a 3 mg/kg of oral dose,,,,Canis lupus familiaris,CHEMBL620279,9615.0
6123,N,,,,,50588,1,Intermediate,,5412,A,,,1,BAO_0000218,Area under curve was determined in dog after oral administration at 1 mg/kg,,,,Canis lupus familiaris,CHEMBL620280,9615.0
1337,N,,,,,50588,1,Intermediate,,5413,A,,,1,BAO_0000218,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,,Canis lupus familiaris,CHEMBL620281,9615.0
1337,N,,,,,50588,1,Intermediate,,5414,A,,,1,BAO_0000218,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,,Canis lupus familiaris,CHEMBL620282,9615.0
8833,N,,,,,50588,1,Intermediate,,5415,A,,,1,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,,,Canis lupus familiaris,CHEMBL621134,9615.0
8833,N,,,,,50588,1,Intermediate,,5416,A,,,1,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,,,Canis lupus familiaris,CHEMBL621135,9615.0
8833,N,,,,,50588,1,Intermediate,,5417,A,,,1,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,,,Canis lupus familiaris,CHEMBL621136,9615.0
8833,N,,,,,50588,1,Intermediate,,5418,A,,,1,BAO_0000218,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,,,Canis lupus familiaris,CHEMBL621137,9615.0
17657,N,,,,,50588,1,Intermediate,,5419,A,Plasma,,1,BAO_0000218,Area under plasma concentration time curve in dog upon oral administration,,,1969.0,Canis lupus familiaris,CHEMBL621138,9615.0
17650,N,,,,,50588,1,Intermediate,,5420,A,Plasma,,1,BAO_0000218,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,,1969.0,Canis lupus familiaris,CHEMBL875587,9615.0
1977,N,,,,,50588,1,Intermediate,,5421,A,,,1,BAO_0000218,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,,,Canis lupus familiaris,CHEMBL621139,9615.0
1977,N,,,,,50588,1,Intermediate,,5422,A,,,1,BAO_0000218,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,,,Canis lupus familiaris,CHEMBL621140,9615.0
3132,N,,,,,50588,1,Intermediate,,5423,A,,,1,BAO_0000218,Area under the curve for the compound was obtained when tested in dog,,,,Canis lupus familiaris,CHEMBL621141,9615.0
5473,N,,,,,50588,1,Intermediate,,5424,A,,,1,BAO_0000218,Area under the curve at a dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL621142,9615.0
5474,N,,,,,50588,1,Intermediate,,5425,A,,,1,BAO_0000218,Area under the curve at a dose of 1 mg/kg (oral),,,,Canis lupus familiaris,CHEMBL621143,9615.0
5474,N,,,,,50588,1,Intermediate,,5426,A,,,1,BAO_0000218,Area under the curve at i.v. dose of 0.2 mg/kg,,,,Canis lupus familiaris,CHEMBL621144,9615.0
6062,N,,,,,50588,1,Intermediate,,5427,A,,,1,BAO_0000218,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL621145,9615.0
4709,N,,,,,50588,1,Intermediate,,5428,A,,,1,BAO_0000218,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL621146,9615.0
2652,N,,,,,50588,1,Intermediate,,5429,A,,,1,BAO_0000218,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,,,Canis lupus familiaris,CHEMBL622567,9615.0
2652,N,,,,,50588,1,Intermediate,,5430,A,,,1,BAO_0000218,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,,,Canis lupus familiaris,CHEMBL622568,9615.0
2877,N,,,,,50588,1,Intermediate,,5431,A,,,1,BAO_0000218,Compound was evaluated for area under the curve in dog blood.,,,,Canis lupus familiaris,CHEMBL622569,9615.0
5444,N,,,,,50588,1,Intermediate,,5432,A,,,1,BAO_0000218,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,,,Canis lupus familiaris,CHEMBL622570,9615.0
5130,N,,,,,50588,1,Intermediate,,5433,A,Plasma,,1,BAO_0000218,AUC in dog after oral dose (1 mg/kg),,,1969.0,Canis lupus familiaris,CHEMBL622571,9615.0
6265,N,,,,,50588,1,Intermediate,,5434,A,,,1,BAO_0000218,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL622572,9615.0
4657,N,,,,,50588,1,Intermediate,,5435,A,,,1,BAO_0000218,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,,,Canis lupus familiaris,CHEMBL622573,9615.0
16367,N,,,,,50588,1,Intermediate,,5436,A,,,1,BAO_0000218,Pharmacokinetic parameter AUC after intravenous administration to dogs,,,,Canis lupus familiaris,CHEMBL622574,9615.0
16367,N,,,,,50588,1,Intermediate,,5437,A,,,1,BAO_0000218,Pharmacokinetic parameter AUC after oral administration to dogs,,,,Canis lupus familiaris,CHEMBL622575,9615.0
9579,N,,,,,50588,1,Intermediate,,5438,A,,,1,BAO_0000218,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,,,Canis lupus familiaris,CHEMBL622576,9615.0
9579,N,,,,,50588,1,Intermediate,,5439,A,,,1,BAO_0000218,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,,,Canis lupus familiaris,CHEMBL622577,9615.0
5983,N,,,,,50588,1,Intermediate,,5440,A,,,1,BAO_0000218,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,,,Canis lupus familiaris,CHEMBL622578,9615.0
6241,N,,,,,50588,1,Intermediate,,5441,A,,,1,BAO_0000218,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,,,Canis lupus familiaris,CHEMBL622579,9615.0
5313,N,,,,,50588,1,Intermediate,,5442,A,,,1,BAO_0000218,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,,,Canis lupus familiaris,CHEMBL622580,9615.0
5313,N,,,,,50588,1,Intermediate,,5443,A,,,1,BAO_0000218,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,,,Canis lupus familiaris,CHEMBL622581,9615.0
6642,N,,,,,50588,1,Intermediate,,5444,A,,,1,BAO_0000218,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,,Canis lupus familiaris,CHEMBL622582,9615.0
6642,N,,,,,50588,1,Intermediate,,5445,A,,,1,BAO_0000218,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,,Canis lupus familiaris,CHEMBL622583,9615.0
6641,N,,,,,50588,1,Intermediate,,5446,A,,,1,BAO_0000218,Oral AUCN in dog (dosed at 0.5 mpk iv ),,,,Canis lupus familiaris,CHEMBL622584,9615.0
6642,N,,,,,50588,1,Intermediate,,5447,A,,,1,BAO_0000218,Oral AUCN in dog (dosed at 0.5 mpk iv ),,,,Canis lupus familiaris,CHEMBL622585,9615.0
17791,N,,,,,50588,1,Intermediate,,5448,A,,,1,BAO_0000218,Compound was evaluated for oral bioavailability in dog; 90-100,,,,Canis lupus familiaris,CHEMBL622586,9615.0
17655,N,,,,,50588,1,Intermediate,,5449,A,,,1,BAO_0000218,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,,,Canis lupus familiaris,CHEMBL623281,9615.0
17655,N,,,,,50588,1,Intermediate,,5450,A,,,1,BAO_0000218,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,,,Canis lupus familiaris,CHEMBL623282,9615.0
6596,N,,,,,50588,1,Intermediate,,5451,A,,,1,BAO_0000218,PAPP (membrane permeability) in dog kidney cell monolayer assay,,,,Canis lupus familiaris,CHEMBL623283,9615.0
3880,N,,,,,50588,1,Intermediate,,5452,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL623284,9615.0
16367,N,,,,,50588,1,Intermediate,,5453,A,,,1,BAO_0000218,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,,,Canis lupus familiaris,CHEMBL623285,9615.0
17409,N,,,,,50588,1,Intermediate,,5454,A,Plasma,,1,BAO_0000218,Plasma protein binding towards dog plasma at 10 uM,,,1969.0,Canis lupus familiaris,CHEMBL623463,9615.0
17409,N,,,,,50588,1,Intermediate,,5455,A,Plasma,,1,BAO_0000218,Plasma protein binding towards dog plasma at 100 uM,,,1969.0,Canis lupus familiaris,CHEMBL875952,9615.0
2959,N,,,,In vivo,50588,1,Intermediate,,5456,A,,,1,BAO_0000218,Bioavailability in dog (dose 4 mg/kg p.o.),,,,Canis lupus familiaris,CHEMBL621705,9615.0
13501,N,,,,In vivo,50588,1,Intermediate,,5457,A,,,1,BAO_0000218,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,,,Canis lupus familiaris,CHEMBL621706,9615.0
4527,N,,,,In vivo,50588,1,Intermediate,,5458,A,,,1,BAO_0000218,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,,,Canis lupus familiaris,CHEMBL621707,9615.0
15145,N,,,,In vivo,50588,1,Intermediate,,5459,A,,,1,BAO_0000218,Bioavailability in dogs,,,,Canis lupus familiaris,CHEMBL621708,9615.0
4219,N,,,,In vivo,50588,1,Intermediate,,5460,A,,,1,BAO_0000218,Bioavailability,,,,Canis lupus familiaris,CHEMBL621709,9615.0
17538,N,,,,In vivo,50588,1,Intermediate,,5461,A,,,1,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),,,,Canis lupus familiaris,CHEMBL621710,9615.0
17538,N,,,,In vivo,50588,1,Intermediate,,5462,A,,,1,BAO_0000218,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,,,Canis lupus familiaris,CHEMBL621711,9615.0
1466,N,,,,In vivo,50588,1,Intermediate,,5463,A,,,1,BAO_0000218,Bioavailability in dog (dose 10.0 mg/kg p.o.),,,,Canis lupus familiaris,CHEMBL621712,9615.0
17650,N,,,,In vivo,50588,1,Intermediate,,5464,A,,,1,BAO_0000218,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,,,Canis lupus familiaris,CHEMBL621713,9615.0
3132,N,,,,In vivo,50588,1,Intermediate,,5465,A,,,1,BAO_0000218,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,,,Canis lupus familiaris,CHEMBL621714,9615.0
2413,U,,,,,22224,0,Autocuration,,5466,A,,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,,Mus sp.,CHEMBL621715,10095.0
2413,U,,,,,22224,0,Autocuration,,5467,A,Liver,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,2107.0,Mus sp.,CHEMBL623717,10095.0
2413,U,,,,,22224,0,Autocuration,,5468,A,Liver,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,2107.0,Mus sp.,CHEMBL623718,10095.0
2413,U,,,,,22224,0,Autocuration,,5469,A,Liver,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,2107.0,Mus sp.,CHEMBL623719,10095.0
2413,U,,,,,22224,0,Autocuration,,5470,A,,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,,Mus sp.,CHEMBL623720,10095.0
2413,U,,,,,22224,0,Autocuration,,5471,A,,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,,Mus sp.,CHEMBL623721,10095.0
2413,U,,,,,22224,0,Autocuration,,5472,A,Muscle tissue,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,2385.0,Mus sp.,CHEMBL623722,10095.0
2413,U,,,,,22224,0,Autocuration,,5473,A,Muscle tissue,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,2385.0,Mus sp.,CHEMBL623723,10095.0
2413,U,,,,,22224,0,Autocuration,,5474,A,Muscle tissue,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,2385.0,Mus sp.,CHEMBL618543,10095.0
2413,U,,,,,22224,0,Autocuration,,5475,A,Spleen,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,2106.0,Mus sp.,CHEMBL618544,10095.0
2413,U,,,,,22224,0,Autocuration,,5476,A,Spleen,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,2106.0,Mus sp.,CHEMBL875155,10095.0
2413,U,,,,,22224,0,Autocuration,,5477,A,,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,,,Mus sp.,CHEMBL618545,10095.0
2413,U,,,,,22224,0,Autocuration,,5478,A,,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,,Mus sp.,CHEMBL618546,10095.0
2413,U,,,,,22224,0,Autocuration,,5479,A,,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,,Mus sp.,CHEMBL623529,10095.0
2413,U,,,,,22224,0,Autocuration,,5480,A,,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,,,Mus sp.,CHEMBL623530,10095.0
2413,U,,,,,22224,0,Autocuration,,5481,A,,,1,BAO_0000218,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,,,Mus sp.,CHEMBL621764,10095.0
17827,U,,,,,22224,0,Autocuration,,5482,A,,,1,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,,,Cercopithecidae,CHEMBL621765,9527.0
17827,U,,,,,22224,0,Autocuration,,5483,A,Cerebellum,,1,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,,2037.0,Cercopithecidae,CHEMBL621766,9527.0
17827,U,,,,,22224,0,Autocuration,,5484,A,Frontal cortex,,1,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,,1870.0,Cercopithecidae,CHEMBL621767,9527.0
17827,U,,,,,22224,0,Autocuration,,5485,A,,,1,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,,,Cercopithecidae,CHEMBL621768,9527.0
17827,U,,,,,22224,0,Autocuration,,5486,A,Striatum,,1,BAO_0000019,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,,2435.0,Cercopithecidae,CHEMBL621769,9527.0
17827,U,,,,,22224,0,Autocuration,,5487,A,,,1,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,,,Cercopithecidae,CHEMBL621770,9527.0
17827,U,,,,,22224,0,Autocuration,,5488,A,Cerebellum,,1,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,,2037.0,Cercopithecidae,CHEMBL621771,9527.0
17827,U,,,,,22224,0,Autocuration,,5489,A,Frontal cortex,,1,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,,1870.0,Cercopithecidae,CHEMBL621772,9527.0
17827,U,,,,,22224,0,Autocuration,,5490,A,,,1,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,,,Cercopithecidae,CHEMBL621773,9527.0
17827,U,,,,,22224,0,Autocuration,,5491,A,Striatum,,1,BAO_0000019,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,,2435.0,Cercopithecidae,CHEMBL621774,9527.0
17791,U,,,,,22224,0,Autocuration,,5492,A,,,1,BAO_0000218,Compound was evaluated for oral bioavailability in rats,,,,Cercopithecidae,CHEMBL621775,9527.0
17667,U,,,,In vivo,22224,0,Autocuration,,5493,A,Plasma,,1,BAO_0000218,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,,,1969.0,Cercopithecidae,CHEMBL621776,9527.0
17791,U,,,,,22224,0,Autocuration,,5494,A,,,1,BAO_0000019,Half life period was evaluated in monkey,,,,Cercopithecidae,CHEMBL621777,9527.0
110,U,,,,In vivo,22224,0,Autocuration,,5495,A,,,1,BAO_0000218,Half-life in rhesus monkeys by intravenous administration of dose,,,,Cercopithecidae,CHEMBL875162,9527.0
5781,N,,,,,50594,1,Intermediate,,5496,A,Plasma,,1,BAO_0000218,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,,1969.0,Mus musculus,CHEMBL621778,10090.0
17734,N,,,,,50594,1,Intermediate,,5497,A,Plasma,,1,BAO_0000218,AUC after intraperitoneal administration of 100 mg/kg in mice,,,1969.0,Mus musculus,CHEMBL621779,10090.0
17718,N,,,,,50594,1,Intermediate,,5498,A,Plasma,,1,BAO_0000218,AUC value was determined after oral administration,,,1969.0,Mus musculus,CHEMBL622479,10090.0
4573,N,,,,,50594,1,Intermediate,,5499,A,,,1,BAO_0000218,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,,,Mus musculus,CHEMBL622480,10090.0
3277,N,,,,,50594,1,Intermediate,,5500,A,,,1,BAO_0000218,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,,Mus musculus,CHEMBL622481,10090.0
2862,N,,,,,50594,1,Intermediate,,5501,A,,,1,BAO_0000218,Area under curve by ioral administration in mouse,,,,Mus musculus,CHEMBL622482,10090.0
2862,N,,,,,50594,1,Intermediate,,5502,A,,,1,BAO_0000218,Area under curve by iv administration in mouse,,,,Mus musculus,CHEMBL622483,10090.0
5951,N,,,,,50594,1,Intermediate,,5503,A,,,1,BAO_0000218,Area under curve at 0-8 hr in IRC mice after peroral administration,,,,Mus musculus,CHEMBL622484,10090.0
17729,N,,,,,50594,1,Intermediate,,5504,A,,,1,BAO_0000218,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,,,Mus musculus,CHEMBL622641,10090.0
17728,N,,,,,50594,1,Intermediate,,5505,A,,,1,BAO_0000218,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,,,Mus musculus,CHEMBL622642,10090.0
17728,N,,,,,50594,1,Intermediate,,5506,A,,,1,BAO_0000218,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,,,Mus musculus,CHEMBL622643,10090.0
17729,N,,,,,50594,1,Intermediate,,5507,A,,,1,BAO_0000218,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,,,Mus musculus,CHEMBL622644,10090.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5508,F,,,1,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,741.0,,,Homo sapiens,CHEMBL622645,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5509,F,,,1,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,741.0,,,Homo sapiens,CHEMBL622646,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5510,F,,,1,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),741.0,,,Homo sapiens,CHEMBL621238,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5511,F,,,1,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),741.0,,,Homo sapiens,CHEMBL621239,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5512,F,,,1,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),741.0,,,Homo sapiens,CHEMBL621240,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5513,F,,,1,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),741.0,,,Homo sapiens,CHEMBL621241,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5514,F,,,1,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),741.0,,,Homo sapiens,CHEMBL621242,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5515,F,,,1,BAO_0000219,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),741.0,,,Homo sapiens,CHEMBL620350,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5516,F,,,1,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,741.0,,,Homo sapiens,CHEMBL620351,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5517,F,,,1,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,741.0,,,Homo sapiens,CHEMBL620352,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5518,F,,,1,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),741.0,,,Homo sapiens,CHEMBL620353,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5519,F,,,1,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),741.0,,,Homo sapiens,CHEMBL620354,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5520,F,,,1,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),741.0,,,Homo sapiens,CHEMBL620355,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5521,F,,,1,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),741.0,,,Homo sapiens,CHEMBL620356,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5522,F,,,1,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),741.0,,,Homo sapiens,CHEMBL620357,9606.0
9424,N,,,RPMI-8226,,80433,1,Intermediate,,5523,F,,,1,BAO_0000219,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),741.0,,,Homo sapiens,CHEMBL620358,9606.0
9424,N,,,RPMI-8226,,80433,1,Expert,,5524,F,,,1,BAO_0000219,In vitro inhibition of human 8226 myeloma tumor cell line growth.,741.0,,,Homo sapiens,CHEMBL620359,9606.0
11544,N,,,RPMI-8226,,80433,1,Intermediate,,5525,F,,,1,BAO_0000219,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,741.0,,,Homo sapiens,CHEMBL620360,9606.0
17378,N,,,RPMI-8226,,80433,1,Intermediate,,5526,F,,,1,BAO_0000219,Cytotoxicity of compound against 8226/DOX1V cells,741.0,,,Homo sapiens,CHEMBL620361,9606.0
17378,N,,,RPMI-8226,,80433,1,Intermediate,,5527,F,,,1,BAO_0000219,Cytotoxicity of compound against 8226/S cells,741.0,,,Homo sapiens,CHEMBL620362,9606.0
17079,N,,,RPMI-8226,,80433,1,Intermediate,,5528,F,,,1,BAO_0000219,Inhibitory concentration against 8226 myeloma cancer cell line,741.0,,,Homo sapiens,CHEMBL620363,9606.0
17079,N,,,RPMI-8226,,80433,1,Intermediate,,5529,F,,,1,BAO_0000219,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,741.0,,,Homo sapiens,CHEMBL620364,9606.0
13466,N,,,833K,,80647,1,Intermediate,,5530,F,,,1,BAO_0000219,Inhibition of cell growth was studied in human teratocarcinoma (833K).,854.0,,,Homo sapiens,CHEMBL620365,9606.0
13466,N,,,833K,,80647,1,Intermediate,,5531,F,,,1,BAO_0000219,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',854.0,,,Homo sapiens,CHEMBL620366,9606.0
2392,N,,,833K,,80647,1,Expert,,5532,F,,,1,BAO_0000219,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,854.0,,,Homo sapiens,CHEMBL620367,9606.0
2392,N,,,833K,,80647,1,Intermediate,,5533,F,,,1,BAO_0000219,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,854.0,,,Homo sapiens,CHEMBL620368,9606.0
6608,U,,,,,22226,0,Autocuration,,5534,B,,,1,BAO_0000019,Inhibitory activity against caspase-1,,,,,CHEMBL620369,
10199,H,,,,,45,8,Autocuration,,5535,B,,,1,BAO_0000357,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,,,Enterococcus faecalis,CHEMBL620370,1351.0
17749,N,,,8701-BC,,80648,1,Intermediate,,5536,F,,,1,BAO_0000219,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,705.0,,,Homo sapiens,CHEMBL620371,9606.0
17749,N,,,8701-BC,,80648,1,Intermediate,,5537,F,,,1,BAO_0000219,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,705.0,,,Homo sapiens,CHEMBL620372,9606.0
1229,U,,,,,22226,0,Intermediate,,5538,F,,,1,BAO_0000019,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,,,,CHEMBL876492,
1229,U,,,,,22226,0,Intermediate,,5539,F,,,1,BAO_0000019,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,,,,CHEMBL620373,
1229,U,,,,,22226,0,Intermediate,,5540,F,,,1,BAO_0000019,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,,,,CHEMBL620374,
6390,U,,,,,22226,0,Autocuration,,5541,B,,,1,BAO_0000019,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,,,,CHEMBL620375,
16219,U,,,,,22226,0,Autocuration,,5542,F,,,1,BAO_0000019,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,,,Streptococcus pyogenes,CHEMBL857902,1314.0
16219,U,,,,,22226,0,Autocuration,,5543,F,,,1,BAO_0000019,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,,,Streptococcus pyogenes,CHEMBL620376,1314.0
17043,H,,,,,11922,8,Autocuration,,5544,B,,,1,BAO_0000357,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,,,,CHEMBL620377,
6929,N,,,KB ,,81115,1,Intermediate,,5545,F,,,1,BAO_0000219,Tested for in vitro cytotoxic potency of compound in 9KB assay,324.0,,,Homo sapiens,CHEMBL620378,9606.0
6929,N,,,KB ,,81115,1,Intermediate,,5546,A,,,1,BAO_0000219,Tested for in vitro cytotoxic potency of compound in 9KB assay,324.0,,,Homo sapiens,CHEMBL620379,9606.0
7083,U,,,,,22226,0,Autocuration,,5547,F,,,1,BAO_0000219,In vitro cytotoxicity of compound was tested against 9KB cells.,,,,Homo sapiens,CHEMBL620380,9606.0
12446,N,,,9L,,80653,1,Intermediate,,5548,F,,,1,BAO_0000219,Cytotoxic concentration against 9L cells was determined on day 3,392.0,,,Rattus norvegicus,CHEMBL884006,10116.0
15345,N,,,9L,,80653,1,Expert,,5549,F,,,1,BAO_0000219,Tested in vitro for anticancer activity against 9L cells,392.0,,,Rattus norvegicus,CHEMBL620381,10116.0
15345,N,,,9L,,80653,1,Expert,,5550,F,,,1,BAO_0000219,Tested in vitro for anticancer activity against 9L cells; Not determined,392.0,,,Rattus norvegicus,CHEMBL620382,10116.0
6301,N,,,A549,,80682,1,Intermediate,,5551,F,,,1,BAO_0000219,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,646.0,,,Homo sapiens,CHEMBL620383,9606.0
4833,N,,,A549,,80682,1,Intermediate,,5552,F,,,1,BAO_0000219,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,646.0,,,Homo sapiens,CHEMBL876493,9606.0
4833,N,,,A549,,80682,1,Intermediate,,5553,F,,,1,BAO_0000219,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,646.0,,,Homo sapiens,CHEMBL620384,9606.0
4833,N,,,A549,,80682,1,Intermediate,,5554,F,,,1,BAO_0000219,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,646.0,,,Homo sapiens,CHEMBL620385,9606.0
13330,N,,,A549,,80682,1,Expert,,5555,F,,,1,BAO_0000219,Cytotoxicity against human lung carcinoma A549 cell line,646.0,,,Homo sapiens,CHEMBL620386,9606.0
17517,D,,,A549,,25,9,Expert,,5556,F,,,1,BAO_0000219,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,646.0,,,Homo sapiens,CHEMBL620387,9606.0
17517,D,,,A549,,25,9,Expert,,5557,F,,,1,BAO_0000219,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",646.0,,,Homo sapiens,CHEMBL621404,9606.0
14425,N,,,A549,,80682,1,Intermediate,,5558,F,,,1,BAO_0000219,"In vitro growth inhibition of A549, lung carcinoma",646.0,,,Homo sapiens,CHEMBL621405,9606.0
14425,N,,,A549,,80682,1,Intermediate,,5559,F,,,1,BAO_0000219,"In vitro growth inhibition of A549, lung carcinoma.",646.0,,,Homo sapiens,CHEMBL621406,9606.0
5228,N,,,A549,,80682,1,Expert,,5560,F,,,1,BAO_0000219,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,646.0,,,Homo sapiens,CHEMBL621407,9606.0
5351,N,,,A549,,80682,1,Intermediate,,5561,F,,,1,BAO_0000219,Cytotoxic activity against human lung cancer A549 cell line was determined,646.0,,,Homo sapiens,CHEMBL621408,9606.0
12198,N,,,A549,,80682,1,Expert,,5562,F,,,1,BAO_0000219,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,646.0,,,Homo sapiens,CHEMBL885345,9606.0
13891,N,,,A549,,80682,1,Intermediate,,5563,F,,,1,BAO_0000219,Cytotoxicity concentration against human lung carcinoma A-549 cell line,646.0,,,Homo sapiens,CHEMBL621409,9606.0
5677,N,,,A549,,80682,1,Expert,,5564,F,,,1,BAO_0000219,Cytotoxicity in A549 (human carcinoma) cell line.,646.0,,,Homo sapiens,CHEMBL876034,9606.0
13788,N,,,A549,,80682,1,Intermediate,,5565,F,,,1,BAO_0000219,Cytotoxicity on lung carcinoma (A-549) cell line,646.0,,,Homo sapiens,CHEMBL621410,9606.0
13384,N,,,A549,,80682,1,Expert,,5566,F,,,1,BAO_0000219,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,646.0,,,Homo sapiens,CHEMBL621411,9606.0
6726,N,,,A549,,80682,1,Intermediate,,5567,F,,,1,BAO_0000219,Effective dose of compound against replication of A549 cell line was evaluated,646.0,,,Homo sapiens,CHEMBL621412,9606.0
3455,N,,,A549,,80682,1,Expert,,5568,F,,,1,BAO_0000219,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,646.0,,,Homo sapiens,CHEMBL621413,9606.0
5726,N,,,A549,,80682,1,Intermediate,,5569,F,,,1,BAO_0000219,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),646.0,,,Homo sapiens,CHEMBL621414,9606.0
5726,N,,,A549,,80682,1,Intermediate,,5570,F,,,1,BAO_0000219,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,646.0,,,Homo sapiens,CHEMBL621415,9606.0
3936,N,,,A549,,80682,1,Intermediate,,5571,F,,,1,BAO_0000219,The compound was evaluated for antiproliferative activity against A549 cell line,646.0,,,Homo sapiens,CHEMBL621416,9606.0
14991,N,,,A549,,80682,1,Intermediate,,5572,F,,,1,BAO_0000219,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,646.0,,,Homo sapiens,CHEMBL621417,9606.0
5243,N,,,A549,,80682,1,Intermediate,,5573,F,,,1,BAO_0000219,Concentration required for growth inhibition of human lung carcinoma cell line A549,646.0,,,Homo sapiens,CHEMBL621418,9606.0
12858,N,,,A549,,80682,1,Intermediate,,5574,F,,,1,BAO_0000219,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,646.0,,,Homo sapiens,CHEMBL621419,9606.0
6776,N,,,A549,,80682,1,Intermediate,,5575,F,,,1,BAO_0000219,Growth inhibition against A549 cell line was evaluated,646.0,,,Homo sapiens,CHEMBL621420,9606.0
16558,N,,,A549,,80682,1,Intermediate,,5576,F,,,1,BAO_0000219,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,646.0,,,Homo sapiens,CHEMBL875823,9606.0
4583,N,,,A549,,80682,1,Expert,,5577,F,,,1,BAO_0000219,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,646.0,,,Homo sapiens,CHEMBL621421,9606.0
13514,N,,,A549,,80682,1,Intermediate,,5578,F,,,1,BAO_0000219,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,646.0,,,Homo sapiens,CHEMBL621422,9606.0
15166,N,,,A549,,80682,1,Expert,,5579,F,,,1,BAO_0000219,Chemosensitivity against DT-diaphorase rich A549 cell lines,646.0,,,Homo sapiens,CHEMBL884014,9606.0
13873,N,,,A549,,80682,1,Intermediate,,5580,F,,,1,BAO_0000219,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,646.0,,,Homo sapiens,CHEMBL621423,9606.0
6447,N,,,A549,,80682,1,Expert,,5581,F,,,1,BAO_0000219,In vitro cytotoxicity against human A549 (lung cancer) cell line.,646.0,,,Homo sapiens,CHEMBL621424,9606.0
2068,N,,,A549,,80682,1,Intermediate,,5582,F,,,1,BAO_0000219,In vitro antitumor activity against A549 (lung) human tumor cell lines.,646.0,,,Homo sapiens,CHEMBL621425,9606.0
1863,N,,,A549,,80682,1,Expert,,5583,F,,,1,BAO_0000219,In vitro cytotoxic activity against human lung carcinoma A549 cell line,646.0,,,Homo sapiens,CHEMBL621426,9606.0
13873,N,,,A549,,80682,1,Intermediate,,5584,F,,,1,BAO_0000219,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,646.0,,,Homo sapiens,CHEMBL621427,9606.0
13873,N,,,A549,,80682,1,Intermediate,,5585,F,,,1,BAO_0000219,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,646.0,,,Homo sapiens,CHEMBL621428,9606.0
13873,N,,,A549,,80682,1,Expert,,5586,F,,,1,BAO_0000219,Tested against A549 lung carcinoma in the sulforhodamine B assay.,646.0,,,Homo sapiens,CHEMBL621429,9606.0
579,N,,,A549,,80682,1,Intermediate,,5587,F,,,1,BAO_0000219,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),646.0,,,Homo sapiens,CHEMBL621430,9606.0
579,N,,,A549,,80682,1,Intermediate,,5588,F,,,1,BAO_0000219,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,646.0,,,Homo sapiens,CHEMBL621431,9606.0
4584,N,,,A549,,80682,1,Intermediate,,5589,F,,,1,BAO_0000219,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,646.0,,,Homo sapiens,CHEMBL621432,9606.0
5421,N,,,A549,,80682,1,Expert,,5590,F,,,1,BAO_0000219,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,646.0,,,Homo sapiens,CHEMBL621433,9606.0
5421,N,,,A549,,80682,1,Intermediate,,5591,F,,,1,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,646.0,,,Homo sapiens,CHEMBL875824,9606.0
5421,N,,,A549,,80682,1,Intermediate,,5592,F,,,1,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,646.0,,,Homo sapiens,CHEMBL621434,9606.0
5421,N,,,A549,,80682,1,Intermediate,,5593,F,,,1,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,646.0,,,Homo sapiens,CHEMBL621435,9606.0
14188,N,,,A549,,80682,1,Intermediate,,5594,F,,,1,BAO_0000219,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,646.0,,,Homo sapiens,CHEMBL621436,9606.0
14188,N,,,A549,,80682,1,Intermediate,,5595,F,,,1,BAO_0000219,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,646.0,,,Homo sapiens,CHEMBL621437,9606.0
15354,N,,,A549,,80682,1,Intermediate,,5596,F,,,1,BAO_0000219,Compound was tested for the growth inhibition of A549 lung tumor cell line,646.0,,,Homo sapiens,CHEMBL621438,9606.0
14253,N,,,A549,,80682,1,Expert,,5597,F,,,1,BAO_0000219,Growth inhibition of human non-small-lung carcinoma (A549) cell line,646.0,,,Homo sapiens,CHEMBL621439,9606.0
13873,N,,,A549,,80682,1,Intermediate,,5598,F,,,1,BAO_0000219,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,646.0,,,Homo sapiens,CHEMBL621440,9606.0
3043,N,,,,In vivo,50588,1,Intermediate,,5599,A,,,1,BAO_0000218,Oral bioavailability in dog (conscious),,,,Canis lupus familiaris,CHEMBL621441,9615.0
3045,N,,,,In vivo,50588,1,Intermediate,,5600,A,,,1,BAO_0000218,Compound was evaluated for the oral bioavailability after oral administration in dog.,,,,Canis lupus familiaris,CHEMBL621442,9615.0
3022,N,,,,In vivo,50588,1,Intermediate,,5601,A,,,1,BAO_0000218,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,,,Canis lupus familiaris,CHEMBL621443,9615.0
4453,N,,,,In vivo,50588,1,Intermediate,,5602,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621444,9615.0
1696,N,,,,In vivo,50588,1,Intermediate,,5603,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL625133,9615.0
5045,N,,,,In vivo,50588,1,Intermediate,,5604,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL625134,9615.0
5356,N,,,,In vivo,50588,1,Intermediate,,5605,A,,,1,BAO_0000218,Oral bioavailability in dog (fasted),,,,Canis lupus familiaris,CHEMBL625135,9615.0
17764,N,,,,In vivo,50588,1,Intermediate,,5606,A,,,1,BAO_0000218,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,,,Canis lupus familiaris,CHEMBL625136,9615.0
6448,N,,,,In vivo,50588,1,Intermediate,,5607,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL625137,9615.0
1475,N,,,,In vivo,50588,1,Intermediate,,5608,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL625138,9615.0
3788,N,,,,In vivo,50588,1,Intermediate,,5609,A,,,1,BAO_0000218,Percent bioavailability in dog,,,,Canis lupus familiaris,CHEMBL625139,9615.0
3639,N,,,,In vivo,50588,1,Intermediate,,5610,A,,,1,BAO_0000218,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,,,Canis lupus familiaris,CHEMBL872264,9615.0
13397,N,,,,In vivo,50588,1,Intermediate,,5611,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL625140,9615.0
2137,N,,,,In vivo,50588,1,Intermediate,,5612,A,,,1,BAO_0000218,The compound was evaluated for bioavailability in dogs; 34-44,,,,Canis lupus familiaris,CHEMBL624436,9615.0
2959,N,,,,In vivo,50588,1,Intermediate,,5613,A,,,1,BAO_0000218,Bioavailability in dog (dose 4 mg/kg p.o.),,,,Canis lupus familiaris,CHEMBL624437,9615.0
6448,N,,,,In vivo,50588,1,Intermediate,,5614,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL872261,9615.0
6084,N,,,,,50588,1,Intermediate,,5615,A,,,1,BAO_0000218,8 hour trough Blood level in dog was measured after administration of compound,,,,Canis lupus familiaris,CHEMBL624438,9615.0
3639,N,,,,In vivo,50588,1,Intermediate,,5616,A,Plasma,,1,BAO_0000218,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,,,1969.0,Canis lupus familiaris,CHEMBL624439,9615.0
6316,N,,,,,50588,1,Intermediate,,5617,A,,,1,BAO_0000218,C24 after oral administration at 5 mg/kg,,,,Canis lupus familiaris,CHEMBL624440,9615.0
5238,N,,,,,50588,1,Intermediate,,5618,A,,,1,BAO_0000218,Clearance after oral and iv dosing in dogs,,,,Canis lupus familiaris,CHEMBL624441,9615.0
17796,N,,,,,50588,1,Intermediate,,5619,A,Plasma,,1,BAO_0000218,Clearance of the drug was measured in the plasma of dog,,,1969.0,Canis lupus familiaris,CHEMBL624442,9615.0
2652,N,,,,,50588,1,Intermediate,,5620,A,,,1,BAO_0000218,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,,,Canis lupus familiaris,CHEMBL624443,9615.0
5654,N,,,,In vivo,50588,1,Intermediate,,5621,A,,,1,BAO_0000218,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL624444,9615.0
6621,N,,,,In vivo,50588,1,Intermediate,,5622,A,,,1,BAO_0000218,Clearance of compound was determined in dogs,,,,Canis lupus familiaris,CHEMBL624445,9615.0
6505,N,,,,In vivo,50588,1,Intermediate,,5623,A,,,1,BAO_0000218,Clearance on i.v. administration of 2 mg/kg was measured in dog,,,,Canis lupus familiaris,CHEMBL624446,9615.0
5802,N,,,,In vivo,50588,1,Intermediate,,5624,A,,,1,BAO_0000218,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,,Canis lupus familiaris,CHEMBL624447,9615.0
17267,N,,,,In vivo,50588,1,Intermediate,,5625,A,,,1,BAO_0000218,Plasma clearance in dog was determined,,,,Canis lupus familiaris,CHEMBL624448,9615.0
4521,N,,,,In vivo,50588,1,Intermediate,,5626,A,,,1,BAO_0000218,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,,Canis lupus familiaris,CHEMBL624449,9615.0
6535,N,,,,In vivo,50588,1,Intermediate,,5627,A,,,1,BAO_0000218,Plasma clearance in dog after administration of 0.25 mg/kg iv,,,,Canis lupus familiaris,CHEMBL624450,9615.0
6535,N,,,,In vivo,50588,1,Intermediate,,5628,A,,,1,BAO_0000218,Plasma clearance in dog after administration of 1 mg/kg iv,,,,Canis lupus familiaris,CHEMBL875942,9615.0
6535,N,,,,In vivo,50588,1,Intermediate,,5629,A,,,1,BAO_0000218,Plasma clearance in dogs,,,,Canis lupus familiaris,CHEMBL624451,9615.0
5542,N,,,,In vivo,50588,1,Intermediate,,5630,A,,,1,BAO_0000218,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,,,Canis lupus familiaris,CHEMBL624452,9615.0
5199,N,,,,In vivo,50588,1,Intermediate,,5631,A,,,1,BAO_0000218,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,,,Canis lupus familiaris,CHEMBL624453,9615.0
16907,N,,,,In vivo,50588,1,Intermediate,,5632,A,,,1,BAO_0000218,Plasma clearance after 15 mg/kg iv dose in Dogs,,,,Canis lupus familiaris,CHEMBL624454,9615.0
16907,N,,,,In vivo,50588,1,Intermediate,,5633,A,,,1,BAO_0000218,Plasma clearance after 30 mg/kg po dose in Dogs,,,,Canis lupus familiaris,CHEMBL624455,9615.0
16367,N,,,,In vivo,50588,1,Intermediate,,5634,A,,,1,BAO_0000218,Plasma administration to dogs,,,,Canis lupus familiaris,CHEMBL624456,9615.0
5505,N,,,,In vivo,50588,1,Intermediate,,5635,A,,,1,BAO_0000218,Plasma clearance was determined,,,,Canis lupus familiaris,CHEMBL624457,9615.0
6215,N,,,,In vivo,50588,1,Intermediate,,5636,A,,,1,BAO_0000218,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,,,Canis lupus familiaris,CHEMBL624458,9615.0
1466,N,,,,In vivo,50588,1,Intermediate,,5637,A,,,1,BAO_0000218,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,,,Canis lupus familiaris,CHEMBL624459,9615.0
5007,S,,,,In vitro,102164,2,Intermediate,Microsomes,5638,A,Liver,,1,BAO_0000251,Intrinsic clearance in human liver microsomes,,,2107.0,Homo sapiens,CHEMBL624460,9606.0
5007,S,,,,In vitro,102164,2,Intermediate,Microsomes,5639,A,Liver,,1,BAO_0000251,Intrinsic clearance in human liver microsomes,,,2107.0,Homo sapiens,CHEMBL624461,9606.0
16452,N,,,,In vivo,50588,1,Intermediate,,5640,A,,,1,BAO_0000218,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,,Canis lupus familiaris,CHEMBL875943,9615.0
16452,N,,,,In vivo,50588,1,Intermediate,,5641,A,,,1,BAO_0000218,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,,,Canis lupus familiaris,CHEMBL624462,9615.0
16452,N,,,,In vivo,50588,1,Intermediate,,5642,A,,,1,BAO_0000218,Clearance in dog (dose 1 mg/kg i.v.),,,,Canis lupus familiaris,CHEMBL624463,9615.0
6221,N,,,,In vivo,50588,1,Intermediate,,5643,A,,,1,BAO_0000218,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,,,Canis lupus familiaris,CHEMBL624464,9615.0
5007,N,,,,In vivo,50588,1,Intermediate,,5644,A,,,1,BAO_0000218,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,,Canis lupus familiaris,CHEMBL624465,9615.0
5668,N,,,,In vivo,50588,1,Intermediate,,5645,A,,,1,BAO_0000218,Plasma clearance after peroral administration at 10 mpk in dog,,,,Canis lupus familiaris,CHEMBL624466,9615.0
5668,N,,,,In vivo,50588,1,Intermediate,,5646,A,,,1,BAO_0000218,Plasma clearance after peroral administration at 5 mpk in dog,,,,Canis lupus familiaris,CHEMBL624467,9615.0
5668,N,,,,In vivo,50588,1,Intermediate,,5647,A,,,1,BAO_0000218,Plasma clearance after peroral administration at 5 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL624468,9615.0
15660,N,,,,In vivo,50588,1,Intermediate,,5648,A,,,1,BAO_0000218,Plasma clearance was measured in dog,,,,Canis lupus familiaris,CHEMBL624469,9615.0
15660,N,,,,In vivo,50588,1,Intermediate,,5649,A,,,1,BAO_0000218,Plasma clearance was measured in dog,,,,Canis lupus familiaris,CHEMBL624470,9615.0
5983,N,,,,In vivo,50588,1,Intermediate,,5650,A,,,1,BAO_0000218,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,,,Canis lupus familiaris,CHEMBL624471,9615.0
5600,N,,,,In vivo,50588,1,Intermediate,,5651,A,,,1,BAO_0000218,Total clearance was determined after 0.1 mg/kg iv administration in dog,,,,Canis lupus familiaris,CHEMBL624472,9615.0
17764,N,,,,In vivo,50588,1,Intermediate,,5652,A,,,1,BAO_0000218,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,,,Canis lupus familiaris,CHEMBL622775,9615.0
6039,N,,,,In vivo,50588,1,Intermediate,,5653,A,,,1,BAO_0000218,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,,,Canis lupus familiaris,CHEMBL622776,9615.0
6039,N,,,,In vivo,50588,1,Intermediate,,5654,A,,,1,BAO_0000218,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,,,Canis lupus familiaris,CHEMBL622777,9615.0
6039,N,,,,In vivo,50588,1,Intermediate,,5655,A,,,1,BAO_0000218,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,,,Canis lupus familiaris,CHEMBL622778,9615.0
4368,N,,,,In vivo,50588,1,Intermediate,,5656,A,,,1,BAO_0000218,Clearance by intravenous administration of 1.2 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL622779,9615.0
4305,N,,,,In vivo,50588,1,Intermediate,,5657,A,,,1,BAO_0000218,Clearance by iv administration in dogs at a dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL622780,9615.0
1918,N,,,,In vivo,50588,1,Intermediate,,5658,A,Plasma,,1,BAO_0000218,Clearance value was evaluated in dog plasma,,,1969.0,Canis lupus familiaris,CHEMBL622781,9615.0
6005,N,,,,In vivo,50588,1,Intermediate,,5659,A,,,1,BAO_0000218,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL622782,9615.0
4839,N,,,,In vivo,50588,1,Intermediate,,5660,A,Plasma,,1,BAO_0000218,Compound was tested for plasma clearance in dog,,,1969.0,Canis lupus familiaris,CHEMBL622783,9615.0
4239,N,,,,In vivo,50588,1,Intermediate,,5661,A,,,1,BAO_0000218,Pharmacokinetic property (Plasma clearance) was measured in dog,,,,Canis lupus familiaris,CHEMBL622784,9615.0
17729,N,,,,,50594,1,Intermediate,,5662,A,,,1,BAO_0000218,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,,,Mus musculus,CHEMBL622785,10090.0
17728,N,,,,,50594,1,Intermediate,,5663,A,,,1,BAO_0000218,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,,,Mus musculus,CHEMBL622786,10090.0
5302,N,,,,,50594,1,Intermediate,,5664,A,,,1,BAO_0000218,Area under curve value in mouse at a dose of 10 mg/kg,,,,Mus musculus,CHEMBL622787,10090.0
5506,N,,,,,50594,1,Intermediate,,5665,A,,,1,BAO_0000218,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,,,Mus musculus,CHEMBL875949,10090.0
5506,N,,,,,50594,1,Intermediate,,5666,A,,,1,BAO_0000218,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,,,Mus musculus,CHEMBL622788,10090.0
17764,N,,,,,50594,1,Intermediate,,5667,F,,,1,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,,,Mus musculus,CHEMBL622789,10090.0
17764,N,,,,,50594,1,Intermediate,,5668,F,,,1,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,,,Mus musculus,CHEMBL622790,10090.0
17764,N,,,,,50594,1,Intermediate,,5669,F,,,1,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,,,Mus musculus,CHEMBL622791,10090.0
17764,N,,,,,50594,1,Intermediate,,5670,F,,,1,BAO_0000218,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,,,Mus musculus,CHEMBL622792,10090.0
17764,N,,,,,50594,1,Intermediate,,5671,A,,,1,BAO_0000218,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,,,Mus musculus,CHEMBL622793,10090.0
17753,N,,,,,50594,1,Intermediate,,5672,A,,,1,BAO_0000218,Area under curve was determined for the compound at 24 mg/Kg,,,,Mus musculus,CHEMBL622794,10090.0
17753,N,,,,,50594,1,Intermediate,,5673,A,,,1,BAO_0000218,Area under curve was determined for the compound at 40 mg/Kg,,,,Mus musculus,CHEMBL622795,10090.0
17753,N,,,,,50594,1,Intermediate,,5674,A,,,1,BAO_0000218,Area under curve was determined for the compound at 5 mg/Kg,,,,Mus musculus,CHEMBL621803,10090.0
3132,N,,,,,50594,1,Intermediate,,5675,A,,,1,BAO_0000218,Area under the curve for the compound is obtained at dose 25 mg/kg,,,,Mus musculus,CHEMBL621804,10090.0
3132,N,,,,,50594,1,Intermediate,,5676,A,,,1,BAO_0000218,Area under the curve for the compound was obtained when tested in mouse,,,,Mus musculus,CHEMBL621805,10090.0
17837,N,,,,,50594,1,Intermediate,,5677,A,,,1,BAO_0000218,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,,,Mus musculus,CHEMBL621806,10090.0
17837,N,,,,,50594,1,Intermediate,,5678,A,,,1,BAO_0000218,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,,,Mus musculus,CHEMBL621807,10090.0
6062,N,,,,,50594,1,Intermediate,,5679,A,,,1,BAO_0000218,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,,,Mus musculus,CHEMBL621808,10090.0
4066,N,,,,,50594,1,Intermediate,,5680,A,,,1,BAO_0000218,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,,,Mus musculus,CHEMBL621809,10090.0
16597,N,,,,,50594,1,Intermediate,,5681,A,,,1,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,,,Mus musculus,CHEMBL621810,10090.0
14239,N,,,,,50594,1,Intermediate,,5682,A,,,1,BAO_0000218,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,,,Mus musculus,CHEMBL875164,10090.0
14239,N,,,,,50594,1,Intermediate,,5683,A,,,1,BAO_0000218,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,,,Mus musculus,CHEMBL621811,10090.0
4890,N,,,,,50594,1,Intermediate,,5684,A,,,1,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,,,Mus musculus,CHEMBL621812,10090.0
429,N,,,,,50594,1,Intermediate,,5685,A,,,1,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,,,Mus musculus,CHEMBL621813,10090.0
429,N,,,,,50594,1,Intermediate,,5686,A,,,1,BAO_0000218,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,,,Mus musculus,CHEMBL621814,10090.0
5969,N,,,,,50594,1,Intermediate,,5687,A,,,1,BAO_0000218,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,,,Mus musculus,CHEMBL621815,10090.0
5969,N,,,,,50594,1,Intermediate,,5688,A,,,1,BAO_0000218,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,,,Mus musculus,CHEMBL621816,10090.0
5969,N,,,,,50594,1,Intermediate,,5689,A,,,1,BAO_0000218,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,,Mus musculus,CHEMBL621817,10090.0
6091,N,,,,,50594,1,Intermediate,,5690,A,,,1,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,,,Mus musculus,CHEMBL621818,10090.0
6091,N,,,,,50594,1,Intermediate,,5691,A,,,1,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,,,Mus musculus,CHEMBL621819,10090.0
6091,N,,,,,50594,1,Intermediate,,5692,A,,,1,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,,,Mus musculus,CHEMBL621820,10090.0
6091,N,,,,,50594,1,Intermediate,,5693,A,,,1,BAO_0000218,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,,,Mus musculus,CHEMBL621821,10090.0
6178,N,,,,,50594,1,Intermediate,,5694,A,,,1,BAO_0000218,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,,,Mus musculus,CHEMBL621822,10090.0
6178,N,,,,,50594,1,Intermediate,,5695,A,,,1,BAO_0000218,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,,,Mus musculus,CHEMBL619474,10090.0
6619,N,,,,,50594,1,Intermediate,,5696,A,,,1,BAO_0000218,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,,,Mus musculus,CHEMBL619475,10090.0
6619,N,,,,,50594,1,Intermediate,,5697,A,,,1,BAO_0000218,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,,,Mus musculus,CHEMBL619476,10090.0
3760,N,,,,,50594,1,Intermediate,,5698,A,,,1,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,,,Mus musculus,CHEMBL619477,10090.0
3760,N,,,,,50594,1,Intermediate,,5699,A,,,1,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,,,Mus musculus,CHEMBL619478,10090.0
3760,N,,,,,50594,1,Intermediate,,5700,A,,,1,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,,,Mus musculus,CHEMBL619479,10090.0
3760,N,,,,,50594,1,Intermediate,,5701,A,,,1,BAO_0000218,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,,,Mus musculus,CHEMBL619480,10090.0
3192,N,,,,,50594,1,Intermediate,,5702,A,,,1,BAO_0000218,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,,,Mus musculus,CHEMBL619481,10090.0
3192,N,,,,,50594,1,Intermediate,,5703,A,,,1,BAO_0000218,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,,,Mus musculus,CHEMBL619482,10090.0
2675,N,,,,,50594,1,Intermediate,,5704,A,,,1,BAO_0000218,Area under the curve was evaluated in mice after intravenous administration,,,,Mus musculus,CHEMBL619483,10090.0
2675,N,,,,,50594,1,Intermediate,,5705,A,,,1,BAO_0000218,Area under the curve was evaluated in mice after oral administration,,,,Mus musculus,CHEMBL619484,10090.0
16597,N,,,,,50594,1,Intermediate,,5706,A,Plasma,,1,BAO_0000218,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,,1969.0,Mus musculus,CHEMBL619485,10090.0
16597,N,,,,,50594,1,Intermediate,,5707,A,Plasma,,1,BAO_0000218,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,,1969.0,Mus musculus,CHEMBL619486,10090.0
16597,N,,,,,50594,1,Intermediate,,5708,A,,,1,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,,,Mus musculus,CHEMBL619487,10090.0
17734,N,,,,,50594,1,Intermediate,,5709,A,,,1,BAO_0000218,AUMC after intraperitoneal administration of 100 mg/kg in mice,,,,Mus musculus,CHEMBL619488,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5710,A,Blood,,1,BAO_0000218,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,,,178.0,Mus musculus,CHEMBL620106,10090.0
15345,N,,,9L,,80653,1,Intermediate,,5711,F,,,1,BAO_0000219,The compound was tested in vitro for anticancer activity against 9L cells,392.0,,,,CHEMBL620107,
2181,U,,,,,22226,0,Autocuration,,5712,F,,,1,BAO_0000019,Anti proliferation activity determined; Weak effect,,,,Rattus norvegicus,CHEMBL620283,10116.0
2181,U,,,,,22226,0,Autocuration,,5713,F,,,1,BAO_0000219,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,,,Rattus norvegicus,CHEMBL875176,10116.0
2181,U,,,,,22226,0,Autocuration,,5714,F,,,1,BAO_0000219,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,,,Rattus norvegicus,CHEMBL620284,10116.0
2181,U,,,,,22226,0,Autocuration,,5715,F,,,1,BAO_0000219,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,,,Rattus norvegicus,CHEMBL623515,10116.0
10486,U,,,,,22226,0,Autocuration,,5716,F,,,1,BAO_0000019,The cytotoxic activity was in vitro tested by 9PS assay method,,,,Mus musculus,CHEMBL623516,10090.0
10486,U,,,,,22226,0,Autocuration,,5717,F,,,1,BAO_0000019,The cytotoxic activity was in vitro tested by 9PS assay method.,,,,Mus musculus,CHEMBL623517,10090.0
15508,U,,,,,22224,0,Autocuration,,5718,A,,,1,BAO_0000019,Partition coefficient (logD6.5),,,,,CHEMBL857878,
5242,N,,,A2780,,81034,1,Expert,,5719,F,,,1,BAO_0000219,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,478.0,,,Homo sapiens,CHEMBL623518,9606.0
16167,N,,,A-375,,80018,1,Intermediate,,5720,F,,,1,BAO_0000219,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),455.0,,,Homo sapiens,CHEMBL624195,9606.0
4782,N,,,A-431,,80852,1,Expert,,5721,F,,,1,BAO_0000219,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,500.0,,,Homo sapiens,CHEMBL624196,9606.0
16093,D,,,A-431,,9,9,Expert,,5722,F,,,1,BAO_0000219,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,500.0,,,Homo sapiens,CHEMBL624197,9606.0
2596,N,,,A498,,80021,1,Intermediate,,5723,F,,,1,BAO_0000219,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,624.0,,,Homo sapiens,CHEMBL624198,9606.0
2596,N,,,A498,,80021,1,Intermediate,,5724,F,,,1,BAO_0000219,in vitro cytotoxicity against A 498 cancer cell line,624.0,,,Homo sapiens,CHEMBL621287,9606.0
3239,N,,,A498,,80021,1,Intermediate,,5725,F,,,1,BAO_0000219,In vitro cytotoxic activity against renal (A 498) cancer cell line.,624.0,,,Homo sapiens,CHEMBL621288,9606.0
1847,N,,,A498,,80021,1,Intermediate,,5726,F,,,1,BAO_0000219,Cytotoxic activity against A 498 renal cancer cell lines.,624.0,,,Homo sapiens,CHEMBL876496,9606.0
10553,N,,,A498,,80021,1,Intermediate,,5727,F,,,1,BAO_0000219,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,624.0,,,Homo sapiens,CHEMBL621289,9606.0
16219,U,,,,,22226,0,Autocuration,,5728,F,,,1,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,,,Staphylococcus aureus,CHEMBL621290,1280.0
16219,U,,,,,22226,0,Autocuration,,5729,F,,,1,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,,,Staphylococcus aureus,CHEMBL621291,1280.0
16219,U,,,,,22226,0,Autocuration,,5730,F,,,1,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,,,Staphylococcus aureus,CHEMBL621292,1280.0
16219,U,,,,,22226,0,Autocuration,,5731,F,,,1,BAO_0000019,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,,,Staphylococcus aureus,CHEMBL621293,1280.0
4782,N,,,A549,,80682,1,Intermediate,,5732,F,,,1,BAO_0000219,Inhibitory concentration required against A 549 lung cancer cell line,646.0,,,Homo sapiens,CHEMBL621294,9606.0
11805,N,,,A549,,80682,1,Intermediate,,5733,F,,,1,BAO_0000219,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,646.0,,,Homo sapiens,CHEMBL621295,9606.0
11805,N,,,A549,,80682,1,Intermediate,,5734,F,,,1,BAO_0000219,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,646.0,,,Homo sapiens,CHEMBL884007,9606.0
2007,N,,,A549,,80682,1,Intermediate,,5735,F,,,1,BAO_0000219,In vitro cytotoxicity against lung cancer A 549 cell lines,646.0,,,Homo sapiens,CHEMBL621296,9606.0
4594,N,,,A549,,80682,1,Intermediate,,5736,F,,,1,BAO_0000219,Compound was tested for its cytotoxicity against A 549 cell line,646.0,,,Homo sapiens,CHEMBL621297,9606.0
6018,N,,,A549,,80682,1,Expert,,5737,F,,,1,BAO_0000219,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",646.0,,,Homo sapiens,CHEMBL839828,9606.0
6018,N,,,A549,,80682,1,Intermediate,,5738,F,,,1,BAO_0000219,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",646.0,,,Homo sapiens,CHEMBL620397,9606.0
3599,N,,,A549,,80682,1,Expert,,5739,F,,,1,BAO_0000219,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,646.0,,,Homo sapiens,CHEMBL620398,9606.0
2551,N,,,A549,,80682,1,Intermediate,,5740,F,,,1,BAO_0000219,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,646.0,,,Homo sapiens,CHEMBL620399,9606.0
16132,N,,,A549,,80682,1,Expert,,5741,F,,,1,BAO_0000219,In vitro inhibition of A549 (human lung cancer) cell growth.,646.0,,,Homo sapiens,CHEMBL620400,9606.0
16132,N,,,A549,,80682,1,Intermediate,,5742,F,,,1,BAO_0000219,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,646.0,,,Homo sapiens,CHEMBL620401,9606.0
2551,N,,,A549,,80682,1,Expert,,5743,F,,,1,BAO_0000219,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,646.0,,,Homo sapiens,CHEMBL620402,9606.0
2551,N,,,A549,,80682,1,Expert,,5744,F,,,1,BAO_0000219,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),646.0,,,Homo sapiens,CHEMBL620403,9606.0
11913,U,,,,,22226,0,Autocuration,,5745,F,,,1,BAO_0000218,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,,,,CHEMBL620404,
12621,H,,,,In vivo,104694,4,Autocuration,,5746,F,,,1,BAO_0000218,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,,,,CHEMBL620405,
12621,H,,,,In vivo,104694,4,Autocuration,,5747,F,,,1,BAO_0000218,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,,,,CHEMBL620406,
12621,H,,,,In vivo,104694,4,Autocuration,,5748,F,,,1,BAO_0000218,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,,,,CHEMBL620407,
12621,H,,,,In vivo,104694,4,Autocuration,,5749,F,,,1,BAO_0000218,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,,,,CHEMBL620408,
12621,H,,,,In vivo,104694,4,Autocuration,,5750,F,,,1,BAO_0000218,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,,,,CHEMBL620409,
3600,N,,,A498,,80021,1,Expert,,5751,F,,,1,BAO_0000219,Inhibition of A-498 human Renal cell proliferation,624.0,,,Homo sapiens,CHEMBL620410,9606.0
1796,U,,,,,22226,0,Autocuration,,5752,F,,,1,BAO_0000019,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,,,Rattus norvegicus,CHEMBL620411,10116.0
1796,U,,,,,22226,0,Autocuration,,5753,F,,,1,BAO_0000019,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,,,Rattus norvegicus,CHEMBL620412,10116.0
1796,U,,,,,22226,0,Autocuration,,5754,F,,,1,BAO_0000019,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,,,Rattus norvegicus,CHEMBL876596,10116.0
16464,N,,,A 172,,80012,1,Expert,,5755,F,,,1,BAO_0000219,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,622.0,,,Homo sapiens,CHEMBL620413,9606.0
16464,N,,,A 172,,80012,1,Intermediate,,5756,F,,,1,BAO_0000219,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,622.0,,,Homo sapiens,CHEMBL620414,9606.0
16464,N,,,A 172,,80012,1,Intermediate,,5757,F,,,1,BAO_0000219,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,622.0,,,Homo sapiens,CHEMBL620415,9606.0
13617,N,,,A549,,80682,1,Expert,,5758,F,,,1,BAO_0000219,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,646.0,,,Homo sapiens,CHEMBL620416,9606.0
4584,N,,,A549,,80682,1,Intermediate,,5759,F,,,1,BAO_0000219,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,646.0,,,Homo sapiens,CHEMBL620417,9606.0
13799,N,,,A549,,80682,1,Expert,,5760,F,,,1,BAO_0000219,Cytotoxic activity evaluated against A549 tumor cells,646.0,,,Homo sapiens,CHEMBL620418,9606.0
16726,N,,,A549,,80682,1,Intermediate,,5761,F,,,1,BAO_0000219,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,646.0,,,Homo sapiens,CHEMBL620419,9606.0
16109,N,,,A549,,80682,1,Intermediate,,5762,F,,,1,BAO_0000219,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,646.0,,,Homo sapiens,CHEMBL620420,9606.0
16109,N,,,A549,,80682,1,Intermediate,,5763,F,,,1,BAO_0000219,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,646.0,,,Homo sapiens,CHEMBL620421,9606.0
15474,N,,,A549,,80682,1,Intermediate,,5764,F,,,1,BAO_0000219,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,646.0,,,Homo sapiens,CHEMBL620422,9606.0
6851,N,,,A549,,80682,1,Intermediate,,5765,F,,,1,BAO_0000219,Cytotoxicity of compound against A549 cell line,646.0,,,Homo sapiens,CHEMBL620423,9606.0
17534,N,,,A549,,80682,1,Expert,,5766,F,,,1,BAO_0000219,Cytotoxicity against human lung cell carcinoma A549 cell line,646.0,,,Homo sapiens,CHEMBL620424,9606.0
2621,N,,,A549,,80682,1,Intermediate,,5767,F,,,1,BAO_0000219,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,646.0,,,Homo sapiens,CHEMBL620425,9606.0
830,N,,,A549,,80682,1,Intermediate,,5768,F,,,1,BAO_0000219,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,646.0,,,Homo sapiens,CHEMBL620426,9606.0
14255,N,,,A549,,80682,1,Intermediate,,5769,F,,,1,BAO_0000219,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,646.0,,,Homo sapiens,CHEMBL620427,9606.0
14255,N,,,A549,,80682,1,Intermediate,,5770,F,,,1,BAO_0000219,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,646.0,,,Homo sapiens,CHEMBL620428,9606.0
1590,N,,,A549,,80682,1,Intermediate,,5771,F,,,1,BAO_0000219,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,646.0,,,Homo sapiens,CHEMBL620429,9606.0
6146,N,,,A549,,80682,1,Expert,,5772,F,,,1,BAO_0000219,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,646.0,,,Homo sapiens,CHEMBL620430,9606.0
17427,N,,,A549,,80682,1,Expert,,5773,F,,,1,BAO_0000219,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,646.0,,,Homo sapiens,CHEMBL839887,9606.0
5280,N,,,A549,,80682,1,Intermediate,,5774,F,,,1,BAO_0000219,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,646.0,,,Homo sapiens,CHEMBL620431,9606.0
16786,N,,,A549,,80682,1,Intermediate,,5775,F,,,1,BAO_0000219,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,646.0,,,Homo sapiens,CHEMBL884010,9606.0
5895,N,,,A549,,80682,1,Intermediate,,5776,F,,,1,BAO_0000219,In vitro cytotoxicity against A549 (human lung cancer),646.0,,,Homo sapiens,CHEMBL620538,9606.0
14297,N,,,A549,,80682,1,Expert,,5777,F,,,1,BAO_0000219,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,646.0,,,Homo sapiens,CHEMBL620539,9606.0
17824,N,,,A549,,80682,1,Intermediate,,5778,F,,,1,BAO_0000218,In vivo antiproliferative activity against A549 cell line,646.0,,,Homo sapiens,CHEMBL623373,9606.0
14368,N,,,A549,,80682,1,Intermediate,,5779,F,,,1,BAO_0000219,Inhibition of non-small-cell lung adenocarcinoma (A549),646.0,,,Homo sapiens,CHEMBL623374,9606.0
14368,N,,,A549,,80682,1,Intermediate,,5780,F,,,1,BAO_0000219,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,646.0,,,Homo sapiens,CHEMBL623375,9606.0
14254,N,,,A549,,80682,1,Intermediate,,5781,F,,,1,BAO_0000219,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,646.0,,,Homo sapiens,CHEMBL623376,9606.0
15897,N,,,A549,,80682,1,Intermediate,,5782,F,,,1,BAO_0000219,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),646.0,,,Homo sapiens,CHEMBL623377,9606.0
13866,N,,,A549,,80682,1,Intermediate,,5783,F,,,1,BAO_0000219,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,646.0,,,Homo sapiens,CHEMBL623378,9606.0
13370,N,,,A549,,80682,1,Intermediate,,5784,F,,,1,BAO_0000219,Inhibitory activity of compound against human A549 lung carcinoma cell line.,646.0,,,Homo sapiens,CHEMBL623379,9606.0
4862,N,,,A549,,80682,1,Intermediate,,5785,F,,,1,BAO_0000219,Inhibitory activity against A549 lung cancer cell line,646.0,,,Homo sapiens,CHEMBL623380,9606.0
4862,N,,,A549,,80682,1,Intermediate,,5786,F,,,1,BAO_0000219,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,646.0,,,Homo sapiens,CHEMBL623381,9606.0
4862,N,,,A549,,80682,1,Intermediate,,5787,F,,,1,BAO_0000219,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,646.0,,,Homo sapiens,CHEMBL623382,9606.0
15970,N,,,A549,,80682,1,Intermediate,,5788,F,,,1,BAO_0000219,Inhibitory concentration against A549 (lung cancer) cell line,646.0,,,Homo sapiens,CHEMBL623383,9606.0
17713,N,,,A549,,80682,1,Expert,,5789,F,,,1,BAO_0000219,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,646.0,,,Homo sapiens,CHEMBL623384,9606.0
4833,N,,,A549,,80682,1,Intermediate,,5790,F,,,1,BAO_0000219,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,646.0,,,Homo sapiens,CHEMBL623385,9606.0
13736,N,,,A549,,80682,1,Expert,,5791,F,,,1,BAO_0000219,Activity against A549 cancer cell line.,646.0,,,Homo sapiens,CHEMBL623386,9606.0
4312,N,,,A549,,80682,1,Intermediate,,5792,F,,,1,BAO_0000219,The compound was evaluated for cytotoxicity against A549 cell line,646.0,,,Homo sapiens,CHEMBL884105,9606.0
5421,N,,,A549,,80682,1,Intermediate,,5793,F,,,1,BAO_0000219,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,646.0,,,Homo sapiens,CHEMBL623387,9606.0
5421,N,,,A549,,80682,1,Intermediate,,5794,F,,,1,BAO_0000219,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,646.0,,,Homo sapiens,CHEMBL621568,9606.0
14717,N,,,A549,,80682,1,Intermediate,,5795,F,,,1,BAO_0000219,Growth inhibitory activity was measured for human A549 tumor cell line.,646.0,,,Homo sapiens,CHEMBL621569,9606.0
4634,N,,,A549,,80682,1,Intermediate,,5796,F,,,1,BAO_0000219,Inhibitory activity against A549 lung cancer cell line,646.0,,,Homo sapiens,CHEMBL621570,9606.0
1149,N,,,A549,,80682,1,Intermediate,,5797,F,,,1,BAO_0000219,Inhibitory activity against A549 cell line; inactive,646.0,,,Homo sapiens,CHEMBL621571,9606.0
5421,N,,,A549,,80682,1,Expert,,5798,F,,,1,BAO_0000219,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,646.0,,,Homo sapiens,CHEMBL621572,9606.0
5421,N,,,A549,,80682,1,Expert,,5799,F,,,1,BAO_0000219,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,646.0,,,Homo sapiens,CHEMBL621573,9606.0
5421,N,,,A549,,80682,1,Intermediate,,5800,F,,,1,BAO_0000219,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,646.0,,,Homo sapiens,CHEMBL621574,9606.0
3320,N,,,A549,,80682,1,Intermediate,,5801,F,,,1,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),646.0,,,Homo sapiens,CHEMBL621575,9606.0
3320,N,,,A549,,80682,1,Intermediate,,5802,F,,,1,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),646.0,,,Homo sapiens,CHEMBL621576,9606.0
3320,N,,,A549,,80682,1,Intermediate,,5803,F,,,1,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),646.0,,,Homo sapiens,CHEMBL621577,9606.0
3320,N,,,A549,,80682,1,Intermediate,,5804,F,,,1,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),646.0,,,Homo sapiens,CHEMBL621578,9606.0
3320,N,,,A549,,80682,1,Intermediate,,5805,F,,,1,BAO_0000219,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),646.0,,,Homo sapiens,CHEMBL621579,9606.0
5726,N,,,A549,,80682,1,Intermediate,,5806,F,,,1,BAO_0000219,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,646.0,,,Homo sapiens,CHEMBL621580,9606.0
17800,N,,,,In vivo,50588,1,Intermediate,,5807,A,,,1,BAO_0000218,Plasma clearance (in vivo) in mongrel dogs was determined,,,,Canis lupus familiaris,CHEMBL621581,9615.0
5985,N,,,,In vivo,50588,1,Intermediate,,5808,A,,,1,BAO_0000218,Plasma clearance was measured in dog,,,,Canis lupus familiaris,CHEMBL621582,9615.0
5530,N,,,,In vivo,50588,1,Intermediate,,5809,A,,,1,BAO_0000218,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,,,Canis lupus familiaris,CHEMBL621583,9615.0
5530,N,,,,In vivo,50588,1,Intermediate,,5810,A,,,1,BAO_0000218,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL621584,9615.0
4839,N,,,,In vivo,50588,1,Intermediate,,5811,A,Plasma,,1,BAO_0000218,Tested for plasma clearance in dog,,,1969.0,Canis lupus familiaris,CHEMBL621585,9615.0
3639,N,,,,In vivo,50588,1,Intermediate,,5812,A,,,1,BAO_0000218,The compound was tested for clearance in dog plasma.,,,,Canis lupus familiaris,CHEMBL621586,9615.0
4838,N,,,,In vivo,50588,1,Intermediate,,5813,A,,,1,BAO_0000218,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,,,Canis lupus familiaris,CHEMBL875835,9615.0
4137,N,,,,In vivo,50588,1,Intermediate,,5814,A,,,1,BAO_0000218,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,,,Canis lupus familiaris,CHEMBL621587,9615.0
5017,N,,,,In vivo,50588,1,Intermediate,,5815,A,Plasma,,1,BAO_0000218,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,,1969.0,Canis lupus familiaris,CHEMBL621588,9615.0
17538,N,,,,In vitro,50588,1,Intermediate,Microsomes,5816,A,Liver,,1,BAO_0000218,In vitro clearance in dog liver microsomes,,,2107.0,Canis lupus familiaris,CHEMBL621589,9615.0
6161,N,,,,In vivo,50588,1,Intermediate,,5817,A,,,1,BAO_0000218,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,,,Canis lupus familiaris,CHEMBL621590,9615.0
6161,N,,,,In vivo,50588,1,Intermediate,,5818,A,,,1,BAO_0000218,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,,,Canis lupus familiaris,CHEMBL621591,9615.0
1696,N,,,,In vivo,50588,1,Intermediate,,5819,A,,,1,BAO_0000218,Plasma clearance in dog,,,,Canis lupus familiaris,CHEMBL621592,9615.0
6762,N,,,,In vivo,50588,1,Intermediate,,5820,A,,,1,BAO_0000218,Clearance rate in dog,,,,Canis lupus familiaris,CHEMBL621593,9615.0
5932,N,,,,In vivo,50588,1,Intermediate,,5821,A,Plasma,,1,BAO_0000218,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,,1969.0,Canis lupus familiaris,CHEMBL621594,9615.0
6305,N,,,,In vivo,50588,1,Intermediate,,5822,A,,,1,BAO_0000218,Clearance in dogs,,,,Canis lupus familiaris,CHEMBL621595,9615.0
4942,N,,,,In vivo,50588,1,Intermediate,,5823,A,,,1,BAO_0000218,Plasma clearance in dogs,,,,Canis lupus familiaris,CHEMBL621596,9615.0
4219,N,,,,In vivo,50588,1,Intermediate,,5824,A,,,1,BAO_0000218,Plasma clearance was determined,,,,Canis lupus familiaris,CHEMBL621597,9615.0
17853,N,,,,In vivo,50588,1,Intermediate,,5825,A,,,1,BAO_0000218,Lower clearance in dog (i.v.) at 0.5 mpk,,,,Canis lupus familiaris,CHEMBL621598,9615.0
4514,N,,,,In vivo,50588,1,Intermediate,,5826,A,,,1,BAO_0000218,Plasma clearance in Beagle dogs,,,,Canis lupus familiaris,CHEMBL621599,9615.0
6448,N,,,,In vivo,50588,1,Intermediate,,5827,A,,,1,BAO_0000218,Plasma clearance (Clp) in dog,,,,Canis lupus familiaris,CHEMBL875836,9615.0
6227,N,,,,In vivo,50588,1,Intermediate,,5828,A,,,1,BAO_0000218,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL621600,9615.0
6227,N,,,,In vivo,50588,1,Intermediate,,5829,A,,,1,BAO_0000218,Plasma clearance (pharmacokinetic parameter) in dog was determined,,,,Canis lupus familiaris,CHEMBL621601,9615.0
6062,N,,,,In vivo,50588,1,Intermediate,,5830,A,,,1,BAO_0000218,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL618474,9615.0
6821,N,,,,In vivo,50588,1,Intermediate,,5831,A,,,1,BAO_0000218,Plasma clearance of compound was determined in dog,,,,Canis lupus familiaris,CHEMBL618475,9615.0
4709,N,,,,In vivo,50588,1,Intermediate,,5832,A,,,1,BAO_0000218,Plasma clearance after intravenous administration of 1 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL624524,9615.0
4521,N,,,,In vivo,50588,1,Intermediate,,5833,A,,,1,BAO_0000218,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,,,Canis lupus familiaris,CHEMBL624525,9615.0
5374,N,,,,In vivo,50588,1,Intermediate,,5834,A,,,1,BAO_0000218,Plasma clearance in dog was determined,,,,Canis lupus familiaris,CHEMBL624526,9615.0
6057,N,,,,In vivo,50588,1,Intermediate,,5835,A,,,1,BAO_0000218,Plasma clearance was calculated in dog,,,,Canis lupus familiaris,CHEMBL624527,9615.0
4727,N,,,,In vivo,50588,1,Intermediate,,5836,A,,,1,BAO_0000218,Plasma clearance at the dose of 2 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL624528,9615.0
5145,N,,,,In vivo,50588,1,Intermediate,,5837,A,,,1,BAO_0000218,Plasma clearance in dog,,,,Canis lupus familiaris,CHEMBL624529,9615.0
17657,N,,,,In vivo,50588,1,Intermediate,,5838,A,,,1,BAO_0000218,Plasma clearance in dog,,,,Canis lupus familiaris,CHEMBL624530,9615.0
17657,N,,,,In vivo,50588,1,Intermediate,,5839,A,,,1,BAO_0000218,Plasma clearance in dog; Unable to calculate,,,,Canis lupus familiaris,CHEMBL624531,9615.0
5145,N,,,,In vivo,50588,1,Intermediate,,5840,A,,,1,BAO_0000218,Plasma clearance in rhesus monkey,,,,Canis lupus familiaris,CHEMBL624532,9615.0
6642,N,,,,In vivo,50588,1,Intermediate,,5841,A,,,1,BAO_0000218,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,,Canis lupus familiaris,CHEMBL624533,9615.0
6641,N,,,,In vivo,50588,1,Intermediate,,5842,A,,,1,BAO_0000218,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,,Canis lupus familiaris,CHEMBL624534,9615.0
6642,N,,,,In vivo,50588,1,Intermediate,,5843,A,,,1,BAO_0000218,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,,Canis lupus familiaris,CHEMBL624535,9615.0
5472,N,,,,In vivo,50588,1,Intermediate,,5844,A,,,1,BAO_0000218,Plasma clearance was evaluated in dog,,,,Canis lupus familiaris,CHEMBL624536,9615.0
5472,N,,,,In vivo,50588,1,Intermediate,,5845,A,,,1,BAO_0000218,Plasma clearance was evaluated in dog; Not tested,,,,Canis lupus familiaris,CHEMBL624537,9615.0
5472,N,,,,In vivo,50588,1,Intermediate,,5846,A,,,1,BAO_0000218,Plasma clearance was evaluated in rhesus,,,,Canis lupus familiaris,CHEMBL624538,9615.0
5472,N,,,,In vivo,50588,1,Intermediate,,5847,A,,,1,BAO_0000218,Plasma clearance was evaluated in rhesus; Not tested,,,,Canis lupus familiaris,CHEMBL624539,9615.0
4257,N,,,,In vivo,50588,1,Intermediate,,5848,A,,,1,BAO_0000218,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,,,Canis lupus familiaris,CHEMBL624540,9615.0
6679,N,,,,In vivo,50588,1,Intermediate,,5849,A,,,1,BAO_0000218,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,,Canis lupus familiaris,CHEMBL624541,9615.0
5546,N,,,,In vivo,50588,1,Intermediate,,5850,A,,,1,BAO_0000218,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,,Canis lupus familiaris,CHEMBL624542,9615.0
6348,N,,,,In vivo,50588,1,Intermediate,,5851,A,,,1,BAO_0000218,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,,Canis lupus familiaris,CHEMBL624543,9615.0
5474,N,,,,In vivo,50588,1,Intermediate,,5852,A,,,1,BAO_0000218,Clearance value at a dose of 0.2 mg/kg i.v.,,,,Canis lupus familiaris,CHEMBL624544,9615.0
6316,N,,,,In vivo,50588,1,Intermediate,,5853,A,Plasma,,1,BAO_0000218,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,,,1969.0,Canis lupus familiaris,CHEMBL624545,9615.0
17594,N,,,,In vivo,50588,1,Intermediate,,5854,A,,,1,BAO_0000218,Cmax after oral dose of compound at 3 mg/kg in dogs,,,,Canis lupus familiaris,CHEMBL624546,9615.0
17594,N,,,,In vivo,50588,1,Intermediate,,5855,A,,,1,BAO_0000218,Cmax after single intravenous bolus of 1 mg/kg in dogs,,,,Canis lupus familiaris,CHEMBL875957,9615.0
5802,N,,,,In vivo,50588,1,Intermediate,,5856,A,,,1,BAO_0000218,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,,Canis lupus familiaris,CHEMBL624547,9615.0
6535,N,,,,In vivo,50588,1,Intermediate,,5857,A,,,1,BAO_0000218,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,,,Canis lupus familiaris,CHEMBL624548,9615.0
6535,N,,,,In vivo,50588,1,Intermediate,,5858,A,,,1,BAO_0000218,Cmax in dog after administration of 1 mg/kg iv,,,,Canis lupus familiaris,CHEMBL624549,9615.0
1466,N,,,,In vivo,50588,1,Intermediate,,5859,A,Plasma,,1,BAO_0000218,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,,,1969.0,Canis lupus familiaris,CHEMBL624550,9615.0
6505,N,,,,In vivo,50588,1,Intermediate,,5860,A,,,1,BAO_0000218,Cmax on p.o. administration of 10 mg/kg was measured in dog,,,,Canis lupus familiaris,CHEMBL621613,9615.0
5668,N,,,,In vivo,50588,1,Intermediate,,5861,A,,,1,BAO_0000218,Cmax was determine after peroral administration at 10 mpk in dog,,,,Canis lupus familiaris,CHEMBL621614,9615.0
5668,N,,,,In vivo,50588,1,Intermediate,,5862,A,,,1,BAO_0000218,Cmax was determine after peroral administration at 5 mpk in dog,,,,Canis lupus familiaris,CHEMBL623431,9615.0
5668,N,,,,In vivo,50588,1,Intermediate,,5863,A,,,1,BAO_0000218,Cmax was determine after peroral administration at 5 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL623432,9615.0
5600,N,,,,In vivo,50588,1,Intermediate,,5864,A,,,1,BAO_0000218,Cmax after 0.3 mg/kg po administration in dog,,,,Canis lupus familiaris,CHEMBL623433,9615.0
17764,N,,,,In vivo,50588,1,Intermediate,,5865,A,,,1,BAO_0000218,Cmax after peroral administration in dogs at 2.4 uM/kg,,,,Canis lupus familiaris,CHEMBL623434,9615.0
6123,N,,,,In vivo,50588,1,Intermediate,,5866,A,,,1,BAO_0000218,Cmax in dog after oral administration at 1 mg/kg,,,,Canis lupus familiaris,CHEMBL623435,9615.0
6123,N,,,,In vivo,50588,1,Intermediate,,5867,A,,,1,BAO_0000218,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,,,Canis lupus familiaris,CHEMBL623436,9615.0
6757,N,,,,In vivo,50588,1,Intermediate,,5868,A,,,1,BAO_0000218,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,,,Canis lupus familiaris,CHEMBL875958,9615.0
16907,N,,,,In vivo,50588,1,Intermediate,,5869,A,,,1,BAO_0000218,Cmax value after 15 mg/kg iv dose in Dogs,,,,Canis lupus familiaris,CHEMBL623437,9615.0
7767,N,,,,In vivo,50594,1,Intermediate,,5870,A,Blood,,1,BAO_0000218,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,178.0,Mus musculus,CHEMBL623438,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5871,A,Blood,,1,BAO_0000218,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,178.0,Mus musculus,CHEMBL623439,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5872,A,Bone,,1,BAO_0000218,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,10000001.0,Mus musculus,CHEMBL623440,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5873,A,Bone,,1,BAO_0000218,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,10000001.0,Mus musculus,CHEMBL623441,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5874,A,Bone,,1,BAO_0000218,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,10000001.0,Mus musculus,CHEMBL623442,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5875,A,,,1,BAO_0000218,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,,Mus musculus,CHEMBL623469,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5876,A,,,1,BAO_0000218,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,,Mus musculus,CHEMBL623470,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5877,A,,,1,BAO_0000218,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,,Mus musculus,CHEMBL623471,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5878,A,Heart,,1,BAO_0000218,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,948.0,Mus musculus,CHEMBL623472,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5879,A,Heart,,1,BAO_0000218,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,948.0,Mus musculus,CHEMBL623473,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5880,A,Heart,,1,BAO_0000218,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,948.0,Mus musculus,CHEMBL623474,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5881,A,Kidney,,1,BAO_0000218,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,2113.0,Mus musculus,CHEMBL623475,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5882,A,Kidney,,1,BAO_0000218,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,2113.0,Mus musculus,CHEMBL623476,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5883,A,Kidney,,1,BAO_0000218,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,2113.0,Mus musculus,CHEMBL623477,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5884,A,Intestine,,1,BAO_0000218,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,160.0,Mus musculus,CHEMBL621896,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5885,A,Intestine,,1,BAO_0000218,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,160.0,Mus musculus,CHEMBL621897,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5886,A,Intestine,,1,BAO_0000218,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,160.0,Mus musculus,CHEMBL621898,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5887,A,Liver,,1,BAO_0000218,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,2107.0,Mus musculus,CHEMBL621899,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5888,A,Liver,,1,BAO_0000218,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,2107.0,Mus musculus,CHEMBL621900,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5889,A,Liver,,1,BAO_0000218,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,2107.0,Mus musculus,CHEMBL621901,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5890,A,Lung,,1,BAO_0000218,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,2048.0,Mus musculus,CHEMBL621902,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5891,A,Lung,,1,BAO_0000218,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,2048.0,Mus musculus,CHEMBL621903,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5892,A,Lung,,1,BAO_0000218,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,2048.0,Mus musculus,CHEMBL622587,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5893,A,Muscle tissue,,1,BAO_0000218,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,2385.0,Mus musculus,CHEMBL620285,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5894,A,Muscle tissue,,1,BAO_0000218,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,2385.0,Mus musculus,CHEMBL875285,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5895,A,Muscle tissue,,1,BAO_0000218,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,2385.0,Mus musculus,CHEMBL620286,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5896,A,,,1,BAO_0000218,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,,Mus musculus,CHEMBL620287,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5897,A,,,1,BAO_0000218,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,,Mus musculus,CHEMBL620288,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5898,A,,,1,BAO_0000218,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,,Mus musculus,CHEMBL620289,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5899,A,Intestine,,1,BAO_0000218,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,160.0,Mus musculus,CHEMBL620290,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5900,A,Intestine,,1,BAO_0000218,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,160.0,Mus musculus,CHEMBL620291,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5901,A,Intestine,,1,BAO_0000218,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,160.0,Mus musculus,CHEMBL620292,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5902,A,Spleen,,1,BAO_0000218,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,2106.0,Mus musculus,CHEMBL620293,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5903,A,Spleen,,1,BAO_0000218,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,2106.0,Mus musculus,CHEMBL620294,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5904,A,Spleen,,1,BAO_0000218,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,2106.0,Mus musculus,CHEMBL618614,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5905,A,Stomach,,1,BAO_0000218,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,945.0,Mus musculus,CHEMBL618615,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,5906,A,Stomach,,1,BAO_0000218,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,,945.0,Mus musculus,CHEMBL618616,10090.0
2036,N,,,A 172,,80012,1,Expert,,5907,F,,,1,BAO_0000219,Cytotoxicity against A-172 human tumor cell lines,622.0,,,Homo sapiens,CHEMBL618617,9606.0
2357,N,,,A 172,,80012,1,Intermediate,,5908,F,,,1,BAO_0000219,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,622.0,,,Homo sapiens,CHEMBL618618,9606.0
1457,N,,,A204,,80014,1,Intermediate,,5909,F,,,1,BAO_0000219,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,623.0,,,Homo sapiens,CHEMBL618619,9606.0
4379,N,,,A2780,,81034,1,Intermediate,,5910,F,,,1,BAO_0000219,Tested for antiproliferative activity against A-2780 tumoral cell line,478.0,,,Homo sapiens,CHEMBL618620,9606.0
1093,N,,,A-375,,80018,1,Intermediate,,5911,F,,,1,BAO_0000219,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,455.0,,,Homo sapiens,CHEMBL618621,9606.0
12152,N,,,A-375,,80018,1,Intermediate,,5912,F,,,1,BAO_0000219,Tested in vitro against A-375 cell line human melanoma,455.0,,,Homo sapiens,CHEMBL618622,9606.0
16464,N,,,A-427,,80019,1,Expert,,5913,F,,,1,BAO_0000219,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,797.0,,,Homo sapiens,CHEMBL618623,9606.0
16464,N,,,A-427,,80019,1,Intermediate,,5914,F,,,1,BAO_0000219,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,797.0,,,Homo sapiens,CHEMBL618624,9606.0
16582,N,,,A-427,,80019,1,Expert,,5915,F,,,1,BAO_0000219,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,797.0,,,Homo sapiens,CHEMBL618625,9606.0
16464,N,,,A-427,,80019,1,Intermediate,,5916,F,,,1,BAO_0000219,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,797.0,,,Homo sapiens,CHEMBL618626,9606.0
10413,N,,,A-427,,80019,1,Intermediate,,5917,F,,,1,BAO_0000219,Antitumor activity on A-427 lung carcinoma cell lines,797.0,,,Homo sapiens,CHEMBL618627,9606.0
6418,N,,,A-427,,80019,1,Intermediate,,5918,F,,,1,BAO_0000219,Cytotoxic activity against human A-427 lung tumor cell line,797.0,,,Homo sapiens,CHEMBL618628,9606.0
17134,N,,,A-427,,80019,1,Expert,,5919,F,,,1,BAO_0000219,In vitro antitumor effects against human A-427 cell lines.,797.0,,,Homo sapiens,CHEMBL618629,9606.0
16132,N,,,A-427,,80019,1,Expert,,5920,F,,,1,BAO_0000219,In vitro inhibition of A-427 (human lung cancer) cell growth.,797.0,,,Homo sapiens,CHEMBL618630,9606.0
16132,N,,,A-427,,80019,1,Intermediate,,5921,F,,,1,BAO_0000219,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,797.0,,,Homo sapiens,CHEMBL618631,9606.0
16780,N,,,A-427,,80019,1,Intermediate,,5922,F,,,1,BAO_0000219,Cytotoxic activity of compound against A-427 lung human tumor cell line,797.0,,,Homo sapiens,CHEMBL618632,9606.0
4085,N,,,A-431,,80852,1,Expert,,5923,F,,,1,BAO_0000219,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,500.0,,,Homo sapiens,CHEMBL618633,9606.0
1276,N,,,A498,,80021,1,Intermediate,,5924,F,,,1,BAO_0000219,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,624.0,,,Homo sapiens,CHEMBL619315,9606.0
3498,N,,,A498,,80021,1,Expert,,5925,F,,,1,BAO_0000219,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,624.0,,,Homo sapiens,CHEMBL619316,9606.0
1169,N,,,A498,,80021,1,Intermediate,,5926,F,,,1,BAO_0000219,Cytotoxicity against human kidney carcinoma A-498cell lines,624.0,,,Homo sapiens,CHEMBL619317,9606.0
4450,N,,,A498,,80021,1,Intermediate,,5927,F,,,1,BAO_0000219,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,624.0,,,Homo sapiens,CHEMBL619318,9606.0
3311,N,,,A498,,80021,1,Intermediate,,5928,F,,,1,BAO_0000219,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,624.0,,,Homo sapiens,CHEMBL619319,9606.0
4461,N,,,A498,,80021,1,Intermediate,,5929,F,,,1,BAO_0000219,Antitumor cytotoxic activity against A-498 cell line was determined,624.0,,,Homo sapiens,CHEMBL619739,9606.0
3311,N,,,A498,,80021,1,Intermediate,,5930,F,,,1,BAO_0000219,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,624.0,,,Homo sapiens,CHEMBL619740,9606.0
3311,N,,,A498,,80021,1,Intermediate,,5931,F,,,1,BAO_0000219,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,624.0,,,Homo sapiens,CHEMBL883158,9606.0
1457,N,,,A498,,80021,1,Intermediate,,5932,F,,,1,BAO_0000219,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,624.0,,,Homo sapiens,CHEMBL884012,9606.0
3664,N,,,A498,,80021,1,Intermediate,,5933,F,,,1,BAO_0000219,In vitro inhibitory activity against A-498 ovarian cancer cell lines,624.0,,,Homo sapiens,CHEMBL619741,9606.0
15895,N,,,A498,,80021,1,Intermediate,,5934,F,,,1,BAO_0000219,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",624.0,,,Homo sapiens,CHEMBL619742,9606.0
11843,N,,,A549,,80682,1,Intermediate,,5935,F,,,1,BAO_0000219,Inhibition of growth lung non-small cell carcinoma A-549 cell line,646.0,,,Homo sapiens,CHEMBL876610,9606.0
11843,N,,,A549,,80682,1,Intermediate,,5936,F,,,1,BAO_0000219,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,646.0,,,Homo sapiens,CHEMBL619743,9606.0
17705,N,,,A549,,80682,1,Intermediate,,5937,F,,,1,BAO_0000219,In vitro antiproliferative activity against human A-549 NSCL cell line,646.0,,,Homo sapiens,CHEMBL619744,9606.0
17705,N,,,A549,,80682,1,Intermediate,,5938,F,,,1,BAO_0000219,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,646.0,,,Homo sapiens,CHEMBL619745,9606.0
4369,N,,,A549,,80682,1,Intermediate,,5939,F,,,1,BAO_0000219,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,646.0,,,Homo sapiens,CHEMBL619746,9606.0
4369,N,,,A549,,80682,1,Intermediate,,5940,F,,,1,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,646.0,,,Homo sapiens,CHEMBL619747,9606.0
4369,N,,,A549,,80682,1,Intermediate,,5941,F,,,1,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,646.0,,,Homo sapiens,CHEMBL619748,9606.0
4369,N,,,A549,,80682,1,Intermediate,,5942,F,,,1,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,646.0,,,Homo sapiens,CHEMBL619749,9606.0
4369,N,,,A549,,80682,1,Intermediate,,5943,F,,,1,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,646.0,,,Homo sapiens,CHEMBL619750,9606.0
4369,N,,,A549,,80682,1,Intermediate,,5944,F,,,1,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,646.0,,,Homo sapiens,CHEMBL624014,9606.0
4369,N,,,A549,,80682,1,Intermediate,,5945,F,,,1,BAO_0000219,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,646.0,,,Homo sapiens,CHEMBL624015,9606.0
4787,N,,,A549,,80682,1,Expert,,5946,F,,,1,BAO_0000219,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,646.0,,,Homo sapiens,CHEMBL885344,9606.0
4787,N,,,A549,,80682,1,Intermediate,,5947,F,,,1,BAO_0000219,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,646.0,,,Homo sapiens,CHEMBL623224,9606.0
6513,N,,,A549,,80682,1,Intermediate,,5948,F,,,1,BAO_0000219,Cytotoxic activity against A-549 cell line,646.0,,,Homo sapiens,CHEMBL623225,9606.0
6690,N,,,A549,,80682,1,Intermediate,,5949,F,,,1,BAO_0000219,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,646.0,,,Homo sapiens,CHEMBL622698,9606.0
6690,N,,,A549,,80682,1,Intermediate,,5950,F,,,1,BAO_0000219,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,646.0,,,Homo sapiens,CHEMBL622699,9606.0
12263,N,,,A549,,80682,1,Expert,,5951,F,,,1,BAO_0000219,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",646.0,,,Homo sapiens,CHEMBL622700,9606.0
1054,N,,,A549,,80682,1,Intermediate,,5952,F,,,1,BAO_0000219,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),646.0,,,Homo sapiens,CHEMBL622701,9606.0
1359,N,,,A549,,80682,1,Intermediate,,5953,F,,,1,BAO_0000219,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),646.0,,,Homo sapiens,CHEMBL622702,9606.0
3547,N,,,A549,,80682,1,Intermediate,,5954,F,,,1,BAO_0000219,Cytotoxic activity against human lung carcinoma (A-549) cell line,646.0,,,Homo sapiens,CHEMBL622703,9606.0
5771,N,,,A549,,80682,1,Expert,,5955,F,,,1,BAO_0000219,Cytotoxic activity towards A-549 cells,646.0,,,Homo sapiens,CHEMBL622704,9606.0
14425,N,,,A549,,80682,1,Intermediate,,5956,F,,,1,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma.",646.0,,,Homo sapiens,CHEMBL622705,9606.0
14425,N,,,A549,,80682,1,Intermediate,,5957,F,,,1,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma",646.0,,,Homo sapiens,CHEMBL622706,9606.0
14425,N,,,A549,,80682,1,Intermediate,,5958,F,,,1,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma.",646.0,,,Homo sapiens,CHEMBL622707,9606.0
14425,N,,,A549,,80682,1,Intermediate,,5959,F,,,1,BAO_0000219,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",646.0,,,Homo sapiens,CHEMBL622708,9606.0
5280,N,,,A549,,80682,1,Intermediate,,5960,F,,,1,BAO_0000219,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,646.0,,,Homo sapiens,CHEMBL622709,9606.0
15176,N,,,A549,,80682,1,Intermediate,,5961,F,,,1,BAO_0000219,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,646.0,,,Homo sapiens,CHEMBL622710,9606.0
15300,N,,,A549,,80682,1,Intermediate,,5962,F,,,1,BAO_0000219,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,646.0,,,Homo sapiens,CHEMBL622711,9606.0
17824,N,,,A549,,80682,1,Intermediate,,5963,F,,,1,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",646.0,,,Homo sapiens,CHEMBL622712,9606.0
17824,N,,,A549,,80682,1,Intermediate,,5964,F,,,1,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",646.0,,,Homo sapiens,CHEMBL622713,9606.0
17824,N,,,A549,,80682,1,Intermediate,,5965,F,,,1,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",646.0,,,Homo sapiens,CHEMBL622714,9606.0
17824,N,,,A549,,80682,1,Intermediate,,5966,F,,,1,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",646.0,,,Homo sapiens,CHEMBL622715,9606.0
17824,N,,,A549,,80682,1,Intermediate,,5967,F,,,1,BAO_0000218,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",646.0,,,Homo sapiens,CHEMBL622716,9606.0
17824,N,,,A549,,80682,1,Intermediate,,5968,F,,,1,BAO_0000219,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",646.0,,,Homo sapiens,CHEMBL622717,9606.0
17528,N,,,A549,,80682,1,Intermediate,,5969,F,,,1,BAO_0000218,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),646.0,,,Homo sapiens,CHEMBL622718,9606.0
6870,N,,,A549,,80682,1,Expert,,5970,F,,,1,BAO_0000219,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,646.0,,,Homo sapiens,CHEMBL622719,9606.0
6870,N,,,A549,,80682,1,Intermediate,,5971,F,,,1,BAO_0000219,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,646.0,,,Homo sapiens,CHEMBL622720,9606.0
6870,N,,,A549,,80682,1,Intermediate,,5972,F,,,1,BAO_0000219,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,646.0,,,Homo sapiens,CHEMBL622721,9606.0
6870,N,,,A549,,80682,1,Intermediate,,5973,F,,,1,BAO_0000219,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,646.0,,,Homo sapiens,CHEMBL622722,9606.0
16726,N,,,A549,,80682,1,Intermediate,,5974,F,,,1,BAO_0000219,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,646.0,,,Homo sapiens,CHEMBL876030,9606.0
6170,N,,,A549,,80682,1,Intermediate,,5975,F,,,1,BAO_0000219,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",646.0,,,Homo sapiens,CHEMBL620206,9606.0
6583,N,,,A549,,80682,1,Expert,,5976,F,,,1,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,646.0,,,Homo sapiens,CHEMBL620207,9606.0
6583,N,,,A549,,80682,1,Expert,,5977,F,,,1,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,646.0,,,Homo sapiens,CHEMBL620208,9606.0
6583,N,,,A549,,80682,1,Expert,,5978,F,,,1,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,646.0,,,Homo sapiens,CHEMBL620209,9606.0
6583,N,,,A549,,80682,1,Expert,,5979,F,,,1,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,646.0,,,Homo sapiens,CHEMBL620210,9606.0
6583,N,,,A549,,80682,1,Expert,,5980,F,,,1,BAO_0000219,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,646.0,,,Homo sapiens,CHEMBL621639,9606.0
17321,N,,,A549,,80682,1,Intermediate,,5981,F,,,1,BAO_0000219,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,646.0,,,Homo sapiens,CHEMBL621640,9606.0
17528,N,,,A549,,80682,1,Expert,,5982,F,,,1,BAO_0000219,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,646.0,,,Homo sapiens,CHEMBL621641,9606.0
12888,N,,,A549,,80682,1,Expert,,5983,F,,,1,BAO_0000219,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,646.0,,,Homo sapiens,CHEMBL621642,9606.0
4312,N,,,A549,,80682,1,Intermediate,,5984,F,,,1,BAO_0000219,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,646.0,,,Homo sapiens,CHEMBL621643,9606.0
4312,N,,,A549,,80682,1,Intermediate,,5985,F,,,1,BAO_0000219,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,646.0,,,Homo sapiens,CHEMBL621644,9606.0
4312,N,,,A549,,80682,1,Intermediate,,5986,F,,,1,BAO_0000219,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,646.0,,,Homo sapiens,CHEMBL621645,9606.0
17737,N,,,A549,,80682,1,Intermediate,,5987,F,,,1,BAO_0000219,In vitro antiproliferative activity against A549 cell line,646.0,,,Mus musculus,CHEMBL621646,10090.0
6630,N,,,A549,,80682,1,Intermediate,,5988,F,,,1,BAO_0000219,Synergism with indomethacin in A549 cells,646.0,,,,CHEMBL621647,
6630,N,,,A549,,80682,1,Intermediate,,5989,F,,,1,BAO_0000219,Synergism with tolmetin in A549 cells,646.0,,,,CHEMBL621648,
6630,N,,,A549,,80682,1,Intermediate,,5990,F,,,1,BAO_0000219,Synergism with sulindac in A549 cells,646.0,,,,CHEMBL621649,
6630,N,,,A549,,80682,1,Intermediate,,5991,F,,,1,BAO_0000219,Antagonism of indomethacin in A549 cells,646.0,,,,CHEMBL621650,
6630,N,,,A549,,80682,1,Intermediate,,5992,F,,,1,BAO_0000219,Antagonism of sulindac in A549 cells,646.0,,,,CHEMBL621651,
6630,N,,,A549,,80682,1,Intermediate,,5993,F,,,1,BAO_0000219,Antagonism of tolmetin in A549 cells,646.0,,,,CHEMBL621652,
6630,N,,,A549,,80682,1,Intermediate,,5994,F,,,1,BAO_0000219,Synergism with indomethacin in A549 cells,646.0,,,,CHEMBL621653,
6630,N,,,A549,,80682,1,Intermediate,,5995,F,,,1,BAO_0000219,Synergism with sulindac in A549 cells,646.0,,,,CHEMBL621654,
6630,N,,,A549,,80682,1,Intermediate,,5996,F,,,1,BAO_0000219,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,646.0,,,,CHEMBL621655,
16907,N,,,,In vivo,50588,1,Intermediate,,5997,A,,,1,BAO_0000218,Cmax value after 30 mg/kg po dose in Dogs,,,,Canis lupus familiaris,CHEMBL621656,9615.0
5944,N,,,,In vivo,50588,1,Intermediate,,5998,A,,,1,BAO_0000218,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,,,Canis lupus familiaris,CHEMBL621657,9615.0
5944,N,,,,In vivo,50588,1,Intermediate,,5999,A,,,1,BAO_0000218,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,,,Canis lupus familiaris,CHEMBL621658,9615.0
5944,N,,,,In vivo,50588,1,Intermediate,,6000,A,,,1,BAO_0000218,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,,,Canis lupus familiaris,CHEMBL621659,9615.0
5944,N,,,,In vivo,50588,1,Intermediate,,6001,A,,,1,BAO_0000218,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,,,Canis lupus familiaris,CHEMBL621660,9615.0
2959,N,,,,In vivo,50588,1,Intermediate,,6002,A,,,1,BAO_0000218,Cmax value after administration of 4 mg/Kg oral dose in dog,,,,Canis lupus familiaris,CHEMBL621661,9615.0
6241,N,,,,In vivo,50588,1,Intermediate,,6003,A,,,1,BAO_0000218,Cmax value in dog,,,,Canis lupus familiaris,CHEMBL621662,9615.0
6241,N,,,,In vivo,50588,1,Intermediate,,6004,A,,,1,BAO_0000218,Cmax value in dogs after oral administration at 1 mg/kg,,,,Canis lupus familiaris,CHEMBL621663,9615.0
2652,N,,,,In vivo,50588,1,Intermediate,,6005,A,,,1,BAO_0000218,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,,,Canis lupus familiaris,CHEMBL621664,9615.0
1806,N,,,,In vivo,50588,1,Intermediate,,6006,A,Plasma,,1,BAO_0000218,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,,,1969.0,Canis lupus familiaris,CHEMBL621665,9615.0
1806,N,,,,In vivo,50588,1,Intermediate,,6007,A,Plasma,,1,BAO_0000218,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,,,1969.0,Canis lupus familiaris,CHEMBL621666,9615.0
1021,N,,,,In vivo,50588,1,Intermediate,,6008,A,,,1,BAO_0000218,Concentration maxima after oral dosing in dogs,,,,Canis lupus familiaris,CHEMBL621667,9615.0
1021,N,,,,In vivo,50588,1,Intermediate,,6009,A,,,1,BAO_0000218,Concentration maxima after oral dosing in dogs; not available,,,,Canis lupus familiaris,CHEMBL876738,9615.0
1021,N,,,,In vivo,50588,1,Intermediate,,6010,A,,,1,BAO_0000218,Concentration maxima after oral dosing in dogs; not available,,,,Canis lupus familiaris,CHEMBL621668,9615.0
5444,N,,,,In vivo,50588,1,Intermediate,,6011,A,,,1,BAO_0000218,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,,,Canis lupus familiaris,CHEMBL621669,9615.0
5444,N,,,,In vivo,50588,1,Intermediate,,6012,A,,,1,BAO_0000218,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,,,Canis lupus familiaris,CHEMBL621670,9615.0
5444,N,,,,In vivo,50588,1,Intermediate,,6013,A,,,1,BAO_0000218,In vivo maximal concentration was calculated at 1 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL621671,9615.0
5444,N,,,,In vivo,50588,1,Intermediate,,6014,A,,,1,BAO_0000218,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,,,Canis lupus familiaris,CHEMBL622360,9615.0
5444,N,,,,In vivo,50588,1,Intermediate,,6015,A,,,1,BAO_0000218,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,,,Canis lupus familiaris,CHEMBL622361,9615.0
5130,N,,,,In vivo,50588,1,Intermediate,,6016,A,Plasma,,1,BAO_0000218,Cmax in dog plasma after oral dose (1 mg/kg),,,1969.0,Canis lupus familiaris,CHEMBL622362,9615.0
3249,N,,,,In vivo,50588,1,Intermediate,,6017,A,Plasma,,1,BAO_0000218,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,,,1969.0,Canis lupus familiaris,CHEMBL622363,9615.0
5473,N,,,,In vivo,50588,1,Intermediate,,6018,A,Plasma,,1,BAO_0000218,Maximal plasma concentration at a dose of 1 mg/kg,,,1969.0,Canis lupus familiaris,CHEMBL622364,9615.0
5474,N,,,,In vivo,50588,1,Intermediate,,6019,A,Plasma,,1,BAO_0000218,Maximal plasma concentration at a dose of 1 mg/kg (oral),,,1969.0,Canis lupus familiaris,CHEMBL622365,9615.0
4657,N,,,,In vivo,50588,1,Intermediate,,6020,A,Plasma,,1,BAO_0000218,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,,,1969.0,Canis lupus familiaris,CHEMBL622533,9615.0
3031,N,,,,In vivo,50588,1,Intermediate,,6021,A,,,1,BAO_0000218,Maximum concentration of compound in dog was evaluated.,,,,Canis lupus familiaris,CHEMBL622534,9615.0
4527,N,,,,In vivo,50588,1,Intermediate,,6022,A,,,1,BAO_0000218,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,,,Canis lupus familiaris,CHEMBL622535,9615.0
4186,N,,,,In vivo,50588,1,Intermediate,,6023,A,,,1,BAO_0000218,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,,,Canis lupus familiaris,CHEMBL876739,9615.0
5007,N,,,,In vivo,50588,1,Intermediate,,6024,A,,,1,BAO_0000218,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,,Canis lupus familiaris,CHEMBL622536,9615.0
3132,N,,,,In vivo,50588,1,Intermediate,,6025,A,Plasma,,1,BAO_0000218,Maximum concentration obtained in dog plasma was determined,,,1969.0,Canis lupus familiaris,CHEMBL622537,9615.0
5006,N,,,,In vivo,50588,1,Intermediate,,6026,A,,,1,BAO_0000218,Maximum concentration was determined,,,,Canis lupus familiaris,CHEMBL622538,9615.0
4727,N,,,,In vivo,50588,1,Intermediate,,6027,A,,,1,BAO_0000218,Maximum concentration at the dose of 2 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL627867,9615.0
1916,N,,,,In vivo,50588,1,Intermediate,,6028,A,,,1,BAO_0000218,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,,Canis lupus familiaris,CHEMBL627868,9615.0
1918,N,,,,In vivo,50588,1,Intermediate,,6029,A,Plasma,,1,BAO_0000218,Maximum concentration was evaluated in dog plasma,,,1969.0,Canis lupus familiaris,CHEMBL627869,9615.0
3045,N,,,,In vivo,50588,1,Intermediate,,6030,A,,,1,BAO_0000218,Maximum concentration was evaluated after 75 min after administration in dog,,,,Canis lupus familiaris,CHEMBL627870,9615.0
9579,N,,,,In vivo,50588,1,Intermediate,,6031,A,Plasma,,1,BAO_0000218,Maximum plasma concentration determined in dog after oral administration of 17b,,,1969.0,Canis lupus familiaris,CHEMBL627871,9615.0
9579,N,,,,In vivo,50588,1,Intermediate,,6032,A,Plasma,,1,BAO_0000218,Maximum plasma concentration determined in dog after oral administration of 2b,,,1969.0,Canis lupus familiaris,CHEMBL627872,9615.0
933,N,,,,In vivo,50588,1,Intermediate,,6033,A,Plasma,,1,BAO_0000218,Maximum plasma concentration in dog,,,1969.0,Canis lupus familiaris,CHEMBL627873,9615.0
17839,N,,,,In vivo,50588,1,Intermediate,,6034,A,Plasma,,1,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,,,1969.0,Canis lupus familiaris,CHEMBL627874,9615.0
17839,N,,,,In vivo,50588,1,Intermediate,,6035,A,Plasma,,1,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,,,1969.0,Canis lupus familiaris,CHEMBL627875,9615.0
17839,N,,,,In vivo,50588,1,Intermediate,,6036,A,Plasma,,1,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,,,1969.0,Canis lupus familiaris,CHEMBL627876,9615.0
17839,N,,,,In vivo,50588,1,Intermediate,,6037,A,Plasma,,1,BAO_0000218,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,,,1969.0,Canis lupus familiaris,CHEMBL627877,9615.0
6348,N,,,,In vivo,50588,1,Intermediate,,6038,A,Plasma,,1,BAO_0000218,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,1969.0,Canis lupus familiaris,CHEMBL627878,9615.0
16367,N,,,,In vivo,50588,1,Intermediate,,6039,A,Plasma,,1,BAO_0000218,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,,,1969.0,Canis lupus familiaris,CHEMBL627879,9615.0
1337,N,,,,In vivo,50588,1,Intermediate,,6040,A,Plasma,,1,BAO_0000218,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,1969.0,Canis lupus familiaris,CHEMBL875355,9615.0
1337,N,,,,In vivo,50588,1,Intermediate,,6041,A,Plasma,,1,BAO_0000218,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,1969.0,Canis lupus familiaris,CHEMBL627880,9615.0
5199,N,,,,In vivo,50588,1,Intermediate,,6042,A,Plasma,,1,BAO_0000218,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,,1969.0,Canis lupus familiaris,CHEMBL627881,9615.0
17650,N,,,,In vivo,50588,1,Intermediate,,6043,A,Plasma,,1,BAO_0000218,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,,1969.0,Canis lupus familiaris,CHEMBL627882,9615.0
6679,N,,,,In vivo,50588,1,Intermediate,,6044,A,Plasma,,1,BAO_0000218,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,,1969.0,Canis lupus familiaris,CHEMBL627883,9615.0
5356,N,,,,In vivo,50588,1,Intermediate,,6045,A,Plasma,,1,BAO_0000218,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,,,1969.0,Canis lupus familiaris,CHEMBL628526,9615.0
5356,N,,,,In vivo,50588,1,Intermediate,,6046,A,Plasma,,1,BAO_0000218,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,,,1969.0,Canis lupus familiaris,CHEMBL628527,9615.0
6227,N,,,,In vivo,50588,1,Intermediate,,6047,A,Plasma,,1,BAO_0000218,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,,,1969.0,Canis lupus familiaris,CHEMBL628528,9615.0
6227,N,,,,In vivo,50588,1,Intermediate,,6048,A,Plasma,,1,BAO_0000218,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,,,1969.0,Canis lupus familiaris,CHEMBL628529,9615.0
6227,N,,,,In vivo,50588,1,Intermediate,,6049,A,Plasma,,1,BAO_0000218,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,,,1969.0,Canis lupus familiaris,CHEMBL628530,9615.0
6227,N,,,,In vivo,50588,1,Intermediate,,6050,A,Plasma,,1,BAO_0000218,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,,,1969.0,Canis lupus familiaris,CHEMBL625243,9615.0
3598,N,,,,In vivo,50588,1,Expert,,6051,A,Plasma,,1,BAO_0000218,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,,,1969.0,Canis lupus familiaris,CHEMBL625244,9615.0
4368,N,,,,In vivo,50588,1,Intermediate,,6052,A,,,1,BAO_0000218,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL625245,9615.0
6265,N,,,,In vivo,50588,1,Intermediate,,6053,A,,,1,BAO_0000218,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL625246,9615.0
7767,N,,,,In vivo,50594,1,Intermediate,,6054,A,Stomach,,1,BAO_0000218,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,,945.0,Mus musculus,CHEMBL625247,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,6055,A,Urine,,1,BAO_0000218,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,,1088.0,Mus musculus,CHEMBL625248,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,6056,A,Urine,,1,BAO_0000218,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,,,1088.0,Mus musculus,CHEMBL625249,10090.0
7767,N,,,,In vivo,50594,1,Intermediate,,6057,A,Urine,,1,BAO_0000218,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,,,1088.0,Mus musculus,CHEMBL625250,10090.0
17811,N,,,,,50594,1,Intermediate,,6058,A,,,1,BAO_0000218,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,,,Mus musculus,CHEMBL625251,10090.0
17811,N,,,,,50594,1,Intermediate,,6059,A,,,1,BAO_0000218,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,,,Mus musculus,CHEMBL875356,10090.0
17827,N,,,,,50594,1,Intermediate,,6060,A,,,1,BAO_0000218,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,,,Mus musculus,CHEMBL625252,10090.0
17827,N,,,,,50594,1,Intermediate,,6061,A,Blood,,1,BAO_0000218,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,,178.0,Mus musculus,CHEMBL625253,10090.0
17827,N,,,,,50594,1,Intermediate,,6062,A,,,1,BAO_0000218,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,,,Mus musculus,CHEMBL625254,10090.0
17827,N,,,,,50594,1,Intermediate,,6063,A,,,1,BAO_0000218,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,,,Mus musculus,CHEMBL625255,10090.0
17827,N,,,,,50594,1,Intermediate,,6064,A,,,1,BAO_0000218,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,,,Mus musculus,CHEMBL625256,10090.0
17827,N,,,,,50594,1,Intermediate,,6065,A,Blood,,1,BAO_0000218,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,,178.0,Mus musculus,CHEMBL625257,10090.0
17827,N,,,,,50594,1,Intermediate,,6066,A,Blood,,1,BAO_0000218,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,,178.0,Mus musculus,CHEMBL625258,10090.0
17827,N,,,,,50594,1,Intermediate,,6067,A,,,1,BAO_0000218,Compound was evaluated for washout rate in mice (Radiolabeled compound),,,,Mus musculus,CHEMBL625259,10090.0
17827,N,,,,,50594,1,Intermediate,,6068,A,,,1,BAO_0000218,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,,,Mus musculus,CHEMBL625260,10090.0
17827,N,,,,,50594,1,Intermediate,,6069,A,,,1,BAO_0000218,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,,Mus musculus,CHEMBL625261,10090.0
17827,N,,,,,50594,1,Intermediate,,6070,A,,,1,BAO_0000218,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,,Mus musculus,CHEMBL625262,10090.0
17827,N,,,,,50594,1,Intermediate,,6071,A,,,1,BAO_0000218,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,,,Mus musculus,CHEMBL622639,10090.0
17257,N,,,,,50594,1,Intermediate,,6072,A,,,1,BAO_0000218,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,,,Mus musculus,CHEMBL622640,10090.0
17257,N,,,,,50594,1,Intermediate,,6073,A,,,1,BAO_0000218,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,,,Mus musculus,CHEMBL622812,10090.0
17257,N,,,,,50594,1,Intermediate,,6074,A,,,1,BAO_0000218,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,,,Mus musculus,CHEMBL622813,10090.0
17257,N,,,,,50594,1,Intermediate,,6075,A,,,1,BAO_0000218,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,,,Mus musculus,CHEMBL622814,10090.0
17827,N,,,,,50594,1,Intermediate,,6076,A,,,1,BAO_0000218,Time at maximum activity in mice (Radiolabeled compound),,,,Mus musculus,CHEMBL622815,10090.0
3760,N,,,,,50594,1,Intermediate,,6077,A,,,1,BAO_0000218,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,,,Mus musculus,CHEMBL625342,10090.0
3760,N,,,,,50594,1,Intermediate,,6078,A,,,1,BAO_0000218,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,,,Mus musculus,CHEMBL625343,10090.0
17409,N,,,,,50594,1,Intermediate,,6079,A,,,1,BAO_0000218,Binding towards mouse plasma protein at 10 uM,,,,Mus musculus,CHEMBL877591,10090.0
17409,N,,,,,50594,1,Intermediate,,6080,A,,,1,BAO_0000218,Binding towards mouse plasma protein at 100 uM,,,,Mus musculus,CHEMBL625344,10090.0
2675,N,,,,In vivo,50594,1,Intermediate,,6081,A,,,1,BAO_0000218,Bioavailability was evaluated in mice after intravenous administration,,,,Mus musculus,CHEMBL625345,10090.0
2675,N,,,,In vivo,50594,1,Intermediate,,6082,A,,,1,BAO_0000218,Bioavailability was evaluated in mice after oral administration,,,,Mus musculus,CHEMBL625346,10090.0
3132,N,,,,In vivo,50594,1,Intermediate,,6083,A,,,1,BAO_0000218,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,,,Mus musculus,CHEMBL625347,10090.0
3132,N,,,,In vivo,50594,1,Intermediate,,6084,A,,,1,BAO_0000218,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,,,Mus musculus,CHEMBL625348,10090.0
16597,N,,,,In vivo,50594,1,Intermediate,,6085,A,,,1,BAO_0000218,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,,,Mus musculus,CHEMBL625349,10090.0
2862,N,,,,In vivo,50594,1,Intermediate,,6086,A,,,1,BAO_0000218,Oral bioavailability in mouse,,,,Mus musculus,CHEMBL625350,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,6087,A,,,1,BAO_0000218,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,,,Mus musculus,CHEMBL882952,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6088,A,Brain,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,955.0,Mus musculus,CHEMBL625351,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6089,A,Brain,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,955.0,Mus musculus,CHEMBL625352,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6090,A,Brain,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,955.0,Mus musculus,CHEMBL877592,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6091,A,Brain,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,955.0,Mus musculus,CHEMBL625353,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6092,A,Brain,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,955.0,Mus musculus,CHEMBL625354,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6093,A,Brain,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,955.0,Mus musculus,CHEMBL626019,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6094,A,Heart,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,948.0,Mus musculus,CHEMBL626020,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6095,A,Heart,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,948.0,Mus musculus,CHEMBL626021,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6096,A,Heart,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,948.0,Mus musculus,CHEMBL626022,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6097,A,Heart,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,948.0,Mus musculus,CHEMBL626192,10090.0
1276,N,,,A549,,80682,1,Intermediate,,6098,F,,,1,BAO_0000219,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),646.0,,,Homo sapiens,CHEMBL626193,9606.0
3498,N,,,A549,,80682,1,Expert,,6099,F,,,1,BAO_0000219,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,646.0,,,Homo sapiens,CHEMBL626194,9606.0
1169,N,,,A549,,80682,1,Intermediate,,6100,F,,,1,BAO_0000219,Cytotoxicity against human lung carcinoma A-549 cell lines,646.0,,,Homo sapiens,CHEMBL626195,9606.0
4450,N,,,A549,,80682,1,Intermediate,,6101,F,,,1,BAO_0000219,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,646.0,,,Homo sapiens,CHEMBL626196,9606.0
358,N,,,A549,,80682,1,Intermediate,,6102,F,,,1,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549,646.0,,,Homo sapiens,CHEMBL626197,9606.0
358,N,,,A549,,80682,1,Intermediate,,6103,F,,,1,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,646.0,,,Homo sapiens,CHEMBL626198,9606.0
358,N,,,A549,,80682,1,Intermediate,,6104,F,,,1,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,646.0,,,Homo sapiens,CHEMBL626199,9606.0
358,N,,,A549,,80682,1,Intermediate,,6105,F,,,1,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,646.0,,,Homo sapiens,CHEMBL626200,9606.0
358,N,,,A549,,80682,1,Intermediate,,6106,F,,,1,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,646.0,,,Homo sapiens,CHEMBL626201,9606.0
358,N,,,A549,,80682,1,Intermediate,,6107,F,,,1,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,646.0,,,Homo sapiens,CHEMBL626202,9606.0
358,N,,,A549,,80682,1,Intermediate,,6108,F,,,1,BAO_0000219,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,646.0,,,Homo sapiens,CHEMBL626203,9606.0
15167,N,,,A549,,80682,1,Intermediate,,6109,F,,,1,BAO_0000219,In vitro cytotoxicity against A-549 human lung cancer cells,646.0,,,Homo sapiens,CHEMBL626204,9606.0
4139,N,,,A549,,80682,1,Intermediate,,6110,F,,,1,BAO_0000219,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,646.0,,,Homo sapiens,CHEMBL624701,9606.0
833,N,,,A549,,80682,1,Intermediate,,6111,F,,,1,BAO_0000219,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,646.0,,,Homo sapiens,CHEMBL624702,9606.0
15718,N,,,A549,,80682,1,Expert,,6112,F,,,1,BAO_0000219,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,646.0,,,Homo sapiens,CHEMBL624703,9606.0
12373,N,,,A549,,80682,1,Intermediate,,6113,F,,,1,BAO_0000219,Tested in vitro for cytotoxicity against A-549 lung cancer cells,646.0,,,Homo sapiens,CHEMBL624704,9606.0
637,N,,,A549,,80682,1,Intermediate,,6114,F,,,1,BAO_0000219,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,646.0,,,Homo sapiens,CHEMBL624705,9606.0
14867,N,,,A549,,80682,1,Expert,,6115,F,,,1,BAO_0000219,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,646.0,,,Homo sapiens,CHEMBL624706,9606.0
4461,N,,,A549,,80682,1,Intermediate,,6116,F,,,1,BAO_0000219,Antitumor cytotoxic activity against A-549 cell line was determined,646.0,,,Homo sapiens,CHEMBL624707,9606.0
5406,N,,,A549,,80682,1,Intermediate,,6117,F,,,1,BAO_0000219,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",646.0,,,Homo sapiens,CHEMBL624708,9606.0
4457,N,,,A549,,80682,1,Intermediate,,6118,F,,,1,BAO_0000219,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,646.0,,,Homo sapiens,CHEMBL624709,9606.0
1386,N,,,A549,,80682,1,Expert,,6119,F,,,1,BAO_0000219,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,646.0,,,Homo sapiens,CHEMBL884107,9606.0
3265,N,,,A549,,80682,1,Intermediate,,6120,F,,,1,BAO_0000219,Antitumoral activity was assayed against A-549 cell line,646.0,,,Homo sapiens,CHEMBL624710,9606.0
2359,N,,,A549,,80682,1,Intermediate,,6121,F,,,1,BAO_0000219,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,646.0,,,Homo sapiens,CHEMBL624711,9606.0
4457,N,,,A549,,80682,1,Intermediate,,6122,F,,,1,BAO_0000219,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,646.0,,,Homo sapiens,CHEMBL624712,9606.0
12454,N,,,A549,,80682,1,Expert,,6123,F,,,1,BAO_0000219,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,646.0,,,Homo sapiens,CHEMBL624713,9606.0
1481,N,,,A549,,80682,1,Intermediate,,6124,F,,,1,BAO_0000219,Compound was tested for inhibition of cell growth of A-549 cells,646.0,,,Homo sapiens,CHEMBL624714,9606.0
1750,N,,,A549,,80682,1,Intermediate,,6125,F,,,1,BAO_0000219,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,646.0,,,Homo sapiens,CHEMBL624715,9606.0
5065,N,,,A549,,80682,1,Intermediate,,6126,F,,,1,BAO_0000219,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,646.0,,,Homo sapiens,CHEMBL624716,9606.0
808,N,,,A549,,80682,1,Expert,,6127,F,,,1,BAO_0000219,In vitro cytotoxicity against A549-human lung carcinoma cells.,646.0,,,Homo sapiens,CHEMBL619505,9606.0
16364,N,,,A549,,80682,1,Expert,,6128,F,,,1,BAO_0000219,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,646.0,,,Homo sapiens,CHEMBL619506,9606.0
1847,N,,,A549,,80682,1,Intermediate,,6129,F,,,1,BAO_0000219,Cytotoxic activity against A-549 cell lines.,646.0,,,Homo sapiens,CHEMBL619507,9606.0
1747,N,,,A549,,80682,1,Expert,,6130,F,,,1,BAO_0000219,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,646.0,,,Homo sapiens,CHEMBL619508,9606.0
1003,N,,,A549,,80682,1,Intermediate,,6131,F,,,1,BAO_0000219,Cytotoxicity against human A549 non small cell lung cell lines,646.0,,,Homo sapiens,CHEMBL619509,9606.0
15313,N,,,A549,,80682,1,Expert,,6132,F,,,1,BAO_0000219,Inhibition of cell growth in (A-549) lung cell line,646.0,,,Homo sapiens,CHEMBL619510,9606.0
3122,N,,,A549,,80682,1,Intermediate,,6133,F,,,1,BAO_0000219,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,646.0,,,Homo sapiens,CHEMBL619511,9606.0
16049,N,,,A549,,80682,1,Intermediate,,6134,F,,,1,BAO_0000219,In vitro antitumor activity against A-549 tumor cells.,646.0,,,Homo sapiens,CHEMBL619512,9606.0
17134,N,,,A549,,80682,1,Expert,,6135,F,,,1,BAO_0000219,In vitro antitumor effects against human A-549 cell lines.,646.0,,,Homo sapiens,CHEMBL619513,9606.0
6406,N,,,A549,,80682,1,Intermediate,,6136,F,,,1,BAO_0000219,In vitro cytotoxic activity of compound against A-549 cell line,646.0,,,Homo sapiens,CHEMBL619514,9606.0
627,N,,,A549,,80682,1,Intermediate,,6137,F,,,1,BAO_0000219,In vitro cytotoxicity against human lung carcinoma A-549 cell line,646.0,,,Homo sapiens,CHEMBL619515,9606.0
12307,N,,,A549,,80682,1,Intermediate,,6138,F,,,1,BAO_0000219,In vitro cytotoxicity against human non-small cell lung carcinoma A549,646.0,,,Homo sapiens,CHEMBL619516,9606.0
17861,N,,,A549,,80682,1,Intermediate,,6139,F,,,1,BAO_0000219,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,646.0,,,Homo sapiens,CHEMBL884005,9606.0
6682,N,,,A549,,80682,1,Expert,,6140,F,,,1,BAO_0000219,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,646.0,,,Homo sapiens,CHEMBL619517,9606.0
6663,N,,,A549,,80682,1,Intermediate,,6141,F,,,1,BAO_0000219,Inhibitory concentration of compound against A-549 cell line,646.0,,,Homo sapiens,CHEMBL619518,9606.0
2454,N,,,A549,,80682,1,Intermediate,,6142,F,,,1,BAO_0000219,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,646.0,,,Homo sapiens,CHEMBL619519,9606.0
14709,N,,,A549,,80682,1,Intermediate,,6143,F,,,1,BAO_0000219,cytotoxic activity against leukemia (A-549) cancer cell line,646.0,,,Homo sapiens,CHEMBL876489,9606.0
15718,N,,,A549,,80682,1,Expert,,6144,F,,,1,BAO_0000219,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,646.0,,,Homo sapiens,CHEMBL619520,9606.0
15718,N,,,A549,,80682,1,Intermediate,,6145,F,,,1,BAO_0000219,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,646.0,,,Homo sapiens,CHEMBL619521,9606.0
17130,N,,,A549,,80682,1,Intermediate,,6146,F,,,1,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),646.0,,,Homo sapiens,CHEMBL619522,9606.0
17130,N,,,A549,,80682,1,Intermediate,,6147,F,,,1,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),646.0,,,Homo sapiens,CHEMBL619523,9606.0
17130,N,,,A549,,80682,1,Intermediate,,6148,F,,,1,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),646.0,,,Homo sapiens,CHEMBL619524,9606.0
17130,N,,,A549,,80682,1,Intermediate,,6149,F,,,1,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),646.0,,,Homo sapiens,CHEMBL619525,9606.0
6630,N,,,A549,,80682,1,Intermediate,,6150,F,,,1,BAO_0000219,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,646.0,,,,CHEMBL619526,
16726,N,,,A549,,80682,1,Intermediate,,6151,F,,,1,BAO_0000219,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,646.0,,,Homo sapiens,CHEMBL619527,9606.0
17846,N,,,A549,,80682,1,Intermediate,,6152,F,,,1,BAO_0000219,Cytotoxicity against A549 cells; No cytotoxicity,646.0,,,Homo sapiens,CHEMBL619528,9606.0
3415,N,,,A549,,80682,1,Expert,,6153,F,,,1,BAO_0000219,Cytotoxicity against human lung carcinoma (A549) cell lines,646.0,,,Homo sapiens,CHEMBL619529,9606.0
3415,N,,,A549,,80682,1,Expert,,6154,F,,,1,BAO_0000219,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,646.0,,,Homo sapiens,CHEMBL619530,9606.0
5609,N,,,A549,,80682,1,Intermediate,,6155,F,,,1,BAO_0000219,In vitro anticancer activity against human lung (A549) cell line,646.0,,,Homo sapiens,CHEMBL876490,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6156,F,,,1,BAO_0000219,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,646.0,,,Homo sapiens,CHEMBL619531,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6157,F,,,1,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,646.0,,,Homo sapiens,CHEMBL619532,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6158,F,,,1,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,646.0,,,Homo sapiens,CHEMBL619533,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6159,F,,,1,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,646.0,,,Homo sapiens,CHEMBL619534,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6160,F,,,1,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,646.0,,,Homo sapiens,CHEMBL620164,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6161,F,,,1,BAO_0000219,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,646.0,,,Homo sapiens,CHEMBL620165,9606.0
16295,N,,,A549,,80682,1,Expert,,6162,F,,,1,BAO_0000219,Inhibition of A549 human lung tumor cell proliferation,646.0,,,Homo sapiens,CHEMBL620166,9606.0
16825,N,,,A549,,80682,1,Intermediate,,6163,F,,,1,BAO_0000219,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",646.0,,,Homo sapiens,CHEMBL620167,9606.0
3439,N,,,A549,,80682,1,Expert,,6164,F,,,1,BAO_0000219,In vitro cytotoxicity against human tumor cell line A549,646.0,,,Homo sapiens,CHEMBL620168,9606.0
10870,N,,,A549,,80682,1,Intermediate,,6165,F,,,1,BAO_0000219,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,646.0,,,Homo sapiens,CHEMBL620338,9606.0
4845,N,,,A549,,80682,1,Intermediate,,6166,F,,,1,BAO_0000219,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,646.0,,,Homo sapiens,CHEMBL620339,9606.0
5822,N,,,A549,,80682,1,Intermediate,,6167,F,,,1,BAO_0000219,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,646.0,,,Homo sapiens,CHEMBL620340,9606.0
5822,N,,,A549,,80682,1,Intermediate,,6168,F,,,1,BAO_0000219,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,646.0,,,Homo sapiens,CHEMBL620341,9606.0
5822,N,,,A549,,80682,1,Intermediate,,6169,F,,,1,BAO_0000219,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,646.0,,,Homo sapiens,CHEMBL876491,9606.0
16381,N,,,A549,,80682,1,Intermediate,,6170,F,,,1,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,646.0,,,Homo sapiens,CHEMBL620342,9606.0
16381,N,,,A549,,80682,1,Intermediate,,6171,F,,,1,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,646.0,,,Homo sapiens,CHEMBL620343,9606.0
16381,N,,,A549,,80682,1,Intermediate,,6172,F,,,1,BAO_0000219,% inhibition against A549 cells (lung cancer) at 4 ug/mL,646.0,,,Homo sapiens,CHEMBL620344,9606.0
5609,N,,,A549,,80682,1,Intermediate,,6173,F,,,1,BAO_0000219,In vitro anticancer activity against human lung (A549) cell line,646.0,,,Homo sapiens,CHEMBL620345,9606.0
4644,N,,,A549,,80682,1,Intermediate,,6174,F,,,1,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,646.0,,,Homo sapiens,CHEMBL620346,9606.0
4644,N,,,A549,,80682,1,Intermediate,,6175,F,,,1,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,646.0,,,Homo sapiens,CHEMBL620347,9606.0
4644,N,,,A549,,80682,1,Intermediate,,6176,F,,,1,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,646.0,,,Homo sapiens,CHEMBL620348,9606.0
4644,N,,,A549,,80682,1,Intermediate,,6177,F,,,1,BAO_0000219,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,646.0,,,Homo sapiens,CHEMBL620349,9606.0
5822,N,,,A549,,80682,1,Intermediate,,6178,F,,,1,BAO_0000219,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,646.0,,,Homo sapiens,CHEMBL618667,9606.0
3415,N,,,A549,,80682,1,Expert,,6179,F,,,1,BAO_0000219,Percentage inhibition of human lung carcinoma (A549) cell lines,646.0,,,Homo sapiens,CHEMBL618668,9606.0
16726,N,,,A549,,80682,1,Intermediate,,6180,F,,,1,BAO_0000219,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,646.0,,,Homo sapiens,CHEMBL876031,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6181,F,,,1,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",646.0,,,Homo sapiens,CHEMBL618759,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6182,F,,,1,BAO_0000219,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,646.0,,,Homo sapiens,CHEMBL618760,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6183,F,,,1,BAO_0000219,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,646.0,,,Homo sapiens,CHEMBL619000,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6184,F,,,1,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",646.0,,,Homo sapiens,CHEMBL619001,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6185,F,,,1,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",646.0,,,Homo sapiens,CHEMBL619002,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6186,F,,,1,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",646.0,,,Homo sapiens,CHEMBL619003,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6187,F,,,1,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",646.0,,,Homo sapiens,CHEMBL619597,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6188,F,,,1,BAO_0000219,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",646.0,,,Homo sapiens,CHEMBL619598,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6189,F,,,1,BAO_0000219,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,646.0,,,Homo sapiens,CHEMBL619599,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6190,F,,,1,BAO_0000219,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,646.0,,,Homo sapiens,CHEMBL619600,9606.0
16726,N,,,A549,,80682,1,Intermediate,,6191,F,,,1,BAO_0000219,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,646.0,,,Homo sapiens,CHEMBL619601,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6192,F,,,1,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,646.0,,,Homo sapiens,CHEMBL619602,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6193,F,,,1,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,646.0,,,Homo sapiens,CHEMBL619603,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6194,F,,,1,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,646.0,,,Homo sapiens,CHEMBL619604,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6195,F,,,1,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,646.0,,,Homo sapiens,CHEMBL619605,9606.0
6084,N,,,,In vivo,50588,1,Intermediate,,6196,A,,,1,BAO_0000218,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,,,Canis lupus familiaris,CHEMBL619606,9615.0
6084,N,,,,In vivo,50588,1,Intermediate,,6197,A,,,1,BAO_0000218,Pharmacokinetic activity (Cmax) in dog,,,,Canis lupus familiaris,CHEMBL876032,9615.0
4809,N,,,,In vivo,50588,1,Intermediate,,6198,A,,,1,BAO_0000218,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,,,Canis lupus familiaris,CHEMBL619607,9615.0
5983,N,,,,In vivo,50588,1,Intermediate,,6199,A,,,1,BAO_0000218,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,,,Canis lupus familiaris,CHEMBL619608,9615.0
6251,N,,,,In vivo,50588,1,Intermediate,,6200,A,,,1,BAO_0000218,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,,,Canis lupus familiaris,CHEMBL619609,9615.0
5932,N,,,,In vivo,50588,1,Intermediate,,6201,A,Plasma,,1,BAO_0000218,Cmax in dog plasma after 30mg/kg oral dose,,,1969.0,Canis lupus familiaris,CHEMBL619610,9615.0
4273,N,,,,In vivo,50588,1,Intermediate,,6202,A,Blood,,1,BAO_0000218,Tested for the peak blood level in dog,,,178.0,Canis lupus familiaris,CHEMBL619611,9615.0
5313,N,,,,In vivo,50588,1,Intermediate,,6203,A,,,1,BAO_0000218,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,,,Canis lupus familiaris,CHEMBL619612,9615.0
5313,N,,,,In vivo,50588,1,Intermediate,,6204,A,,,1,BAO_0000218,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,,,Canis lupus familiaris,CHEMBL619613,9615.0
6221,N,,,,In vivo,50588,1,Intermediate,,6205,A,Blood,,1,BAO_0000218,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,,,178.0,Canis lupus familiaris,CHEMBL619614,9615.0
4709,N,,,,,50588,1,Intermediate,,6206,A,,,1,BAO_0000218,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL619615,9615.0
167,N,,,,,50588,1,Intermediate,,6207,A,,,1,BAO_0000218,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,,,Canis lupus familiaris,CHEMBL619616,9615.0
6241,N,,,,,50588,1,Intermediate,,6208,A,Plasma,,1,BAO_0000218,Final plasma concentration in dogs after oral administration at 1 mg/kg,,,1969.0,Canis lupus familiaris,CHEMBL619617,9615.0
344,N,,,,,50588,1,Intermediate,,6209,A,,,1,BAO_0000218,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,,,Canis lupus familiaris,CHEMBL619618,9615.0
344,N,,,,,50588,1,Intermediate,,6210,A,,,1,BAO_0000218,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,,,Canis lupus familiaris,CHEMBL876033,9615.0
344,N,,,,,50588,1,Intermediate,,6211,A,,,1,BAO_0000218,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,,,Canis lupus familiaris,CHEMBL619619,9615.0
2189,N,,,,,50588,1,Intermediate,,6212,A,,,1,BAO_0000218,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,,,Canis lupus familiaris,CHEMBL619620,9615.0
2189,N,,,,,50588,1,Intermediate,,6213,A,Urine,,1,BAO_0000218,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,,1088.0,Canis lupus familiaris,CHEMBL619621,9615.0
2189,N,,,,,50588,1,Intermediate,,6214,A,Urine,,1,BAO_0000218,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,,1088.0,Canis lupus familiaris,CHEMBL619622,9615.0
2189,N,,,,,50588,1,Intermediate,,6215,A,Urine,,1,BAO_0000218,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,,1088.0,Canis lupus familiaris,CHEMBL618874,9615.0
4257,N,,,,In vivo,50588,1,Intermediate,,6216,A,,,1,BAO_0000218,Absolute bioavailability was evaluated in dog,,,,Canis lupus familiaris,CHEMBL618875,9615.0
6221,N,,,,In vivo,50588,1,Intermediate,,6217,A,,,1,BAO_0000218,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,,,Canis lupus familiaris,CHEMBL618876,9615.0
6215,N,,,,In vivo,50588,1,Intermediate,,6218,A,,,1,BAO_0000218,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,,,Canis lupus familiaris,CHEMBL618877,9615.0
17267,N,,,,In vivo,50588,1,Intermediate,,6219,A,,,1,BAO_0000218,Bioavailability in dog,,,,Canis lupus familiaris,CHEMBL618878,9615.0
6621,N,,,,In vivo,50588,1,Intermediate,,6220,A,,,1,BAO_0000218,Bioavailability in dog,,,,Canis lupus familiaris,CHEMBL618879,9615.0
3854,N,,,,In vivo,50588,1,Intermediate,,6221,A,,,1,BAO_0000218,Bioavailability after intravenous administration in dogs,,,,Canis lupus familiaris,CHEMBL618880,9615.0
3854,N,,,,In vivo,50588,1,Intermediate,,6222,A,,,1,BAO_0000218,Bioavailability after peroral administration in dogs,,,,Canis lupus familiaris,CHEMBL618881,9615.0
5007,N,,,,In vivo,50588,1,Intermediate,,6223,A,,,1,BAO_0000218,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,,,Canis lupus familiaris,CHEMBL618882,9615.0
4333,N,,,,In vivo,50588,1,Intermediate,,6224,A,,,1,BAO_0000218,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,,,Canis lupus familiaris,CHEMBL624226,9615.0
4333,N,,,,In vivo,50588,1,Intermediate,,6225,A,Plasma,,1,BAO_0000218,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,,,1969.0,Canis lupus familiaris,CHEMBL624227,9615.0
5006,N,,,,In vivo,50588,1,Intermediate,,6226,A,,,1,BAO_0000218,Bioavailability,,,,Canis lupus familiaris,CHEMBL624228,9615.0
5199,N,,,,In vivo,50588,1,Intermediate,,6227,A,,,1,BAO_0000218,Bioavailability,,,,Canis lupus familiaris,CHEMBL624229,9615.0
4368,N,,,,In vivo,50588,1,Intermediate,,6228,A,,,1,BAO_0000218,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL624230,9615.0
3771,N,,,,In vivo,50588,1,Intermediate,,6229,A,,,1,BAO_0000218,Bioavailability in dog,,,,Canis lupus familiaris,CHEMBL624231,9615.0
4953,N,,,,In vivo,50588,1,Intermediate,,6230,A,,,1,BAO_0000218,Bioavailability in dog,,,,Canis lupus familiaris,CHEMBL624232,9615.0
5064,N,,,,In vivo,50588,1,Intermediate,,6231,A,,,1,BAO_0000218,Bioavailability in dog,,,,Canis lupus familiaris,CHEMBL625127,9615.0
17657,N,,,,In vivo,50588,1,Intermediate,,6232,A,,,1,BAO_0000218,Bioavailability in dog,,,,Canis lupus familiaris,CHEMBL625128,9615.0
17796,N,,,,In vivo,50588,1,Intermediate,,6233,A,,,1,BAO_0000218,Bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621675,9615.0
17853,N,,,,In vivo,50588,1,Intermediate,,6234,A,,,1,BAO_0000218,Bioavailability in dog (p.o.) at 2.0 mpk,,,,Canis lupus familiaris,CHEMBL621676,9615.0
4521,N,,,,In vivo,50588,1,Intermediate,,6235,A,,,1,BAO_0000218,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,,,Canis lupus familiaris,CHEMBL621677,9615.0
4521,N,,,,In vivo,50588,1,Intermediate,,6236,A,,,1,BAO_0000218,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,,Canis lupus familiaris,CHEMBL621678,9615.0
5006,N,,,,In vivo,50588,1,Intermediate,,6237,A,,,1,BAO_0000218,Bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621679,9615.0
16365,N,,,,In vivo,50588,1,Intermediate,,6238,A,,,1,BAO_0000218,Bioavailability was evaluated after oral administration in dog,,,,Canis lupus familiaris,CHEMBL621680,9615.0
1916,N,,,,In vivo,50588,1,Intermediate,,6239,A,,,1,BAO_0000218,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,,Canis lupus familiaris,CHEMBL621681,9615.0
1918,N,,,,In vivo,50588,1,Intermediate,,6240,A,,,1,BAO_0000218,Bioavailability was evaluated in dog,,,,Canis lupus familiaris,CHEMBL876740,9615.0
4239,N,,,,In vivo,50588,1,Intermediate,,6241,A,,,1,BAO_0000218,Bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621682,9615.0
6505,N,,,,In vivo,50588,1,Intermediate,,6242,A,,,1,BAO_0000218,Bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621683,9615.0
5334,N,,,,In vivo,50588,1,Intermediate,,6243,A,,,1,BAO_0000218,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,,,Canis lupus familiaris,CHEMBL621684,9615.0
5334,N,,,,In vivo,50588,1,Intermediate,,6244,A,,,1,BAO_0000218,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,,,Canis lupus familiaris,CHEMBL621685,9615.0
4809,N,,,,In vivo,50588,1,Intermediate,,6245,A,,,1,BAO_0000218,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,,,Canis lupus familiaris,CHEMBL621686,9615.0
6348,N,,,,In vivo,50588,1,Intermediate,,6246,A,,,1,BAO_0000218,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,,Canis lupus familiaris,CHEMBL621687,9615.0
6005,N,,,,In vivo,50588,1,Intermediate,,6247,A,,,1,BAO_0000218,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL621688,9615.0
17804,N,,,,In vivo,50588,1,Intermediate,,6248,A,,,1,BAO_0000218,Bioavailability of compound in dog was determined after peroral administration,,,,Canis lupus familiaris,CHEMBL621689,9615.0
3184,N,,,,In vivo,50588,1,Intermediate,,6249,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621690,9615.0
1806,N,,,,In vivo,50588,1,Intermediate,,6250,A,,,1,BAO_0000218,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,,,Canis lupus familiaris,CHEMBL621691,9615.0
1806,N,,,,In vivo,50588,1,Intermediate,,6251,A,,,1,BAO_0000218,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,,,Canis lupus familiaris,CHEMBL875941,9615.0
1806,N,,,,In vivo,50588,1,Intermediate,,6252,A,,,1,BAO_0000218,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,,,Canis lupus familiaris,CHEMBL621692,9615.0
4839,N,,,,In vivo,50588,1,Intermediate,,6253,A,,,1,BAO_0000218,Bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621693,9615.0
5017,N,,,,In vivo,50588,1,Intermediate,,6254,A,,,1,BAO_0000218,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,,,Canis lupus familiaris,CHEMBL621694,9615.0
846,N,,,,In vivo,50594,1,Intermediate,,6255,A,Heart,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,948.0,Mus musculus,CHEMBL621695,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6256,A,Heart,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,948.0,Mus musculus,CHEMBL621696,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6257,A,Kidney,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,2113.0,Mus musculus,CHEMBL621697,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6258,A,Kidney,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,2113.0,Mus musculus,CHEMBL621698,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6259,A,Kidney,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,2113.0,Mus musculus,CHEMBL623420,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6260,A,Kidney,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,2113.0,Mus musculus,CHEMBL623421,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6261,A,Kidney,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,2113.0,Mus musculus,CHEMBL623422,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6262,A,Kidney,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,2113.0,Mus musculus,CHEMBL623423,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6263,A,Liver,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,2107.0,Mus musculus,CHEMBL623424,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6264,A,Liver,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,2107.0,Mus musculus,CHEMBL623425,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6265,A,Liver,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,2107.0,Mus musculus,CHEMBL623426,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6266,A,Liver,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,2107.0,Mus musculus,CHEMBL623427,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6267,A,Liver,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,2107.0,Mus musculus,CHEMBL623428,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6268,A,Liver,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,2107.0,Mus musculus,CHEMBL875947,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6269,A,Lung,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,,2048.0,Mus musculus,CHEMBL623429,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6270,A,Lung,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,,2048.0,Mus musculus,CHEMBL623430,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6271,A,Lung,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,,2048.0,Mus musculus,CHEMBL622588,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6272,A,Lung,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,,2048.0,Mus musculus,CHEMBL622589,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6273,A,Lung,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,,2048.0,Mus musculus,CHEMBL622751,10090.0
846,N,,,,In vivo,50594,1,Intermediate,,6274,A,Lung,,1,BAO_0000218,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,,2048.0,Mus musculus,CHEMBL622752,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6275,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,42.0,,,Mus musculus,CHEMBL622753,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6276,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,42.0,,,Mus musculus,CHEMBL622647,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6277,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,42.0,,,Mus musculus,CHEMBL875163,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6278,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,42.0,,,Mus musculus,CHEMBL622648,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6279,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,42.0,,,Mus musculus,CHEMBL622649,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6280,A,Brain,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,42.0,,955.0,Mus musculus,CHEMBL622650,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6281,A,Brain,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,42.0,,955.0,Mus musculus,CHEMBL622651,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6282,A,Brain,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,42.0,,955.0,Mus musculus,CHEMBL622652,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6283,A,Brain,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,42.0,,955.0,Mus musculus,CHEMBL622653,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6284,A,Brain,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,42.0,,955.0,Mus musculus,CHEMBL622654,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6285,A,Heart,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,42.0,,948.0,Mus musculus,CHEMBL622655,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6286,A,Heart,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,42.0,,948.0,Mus musculus,CHEMBL622656,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6287,A,Heart,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,42.0,,948.0,Mus musculus,CHEMBL622657,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6288,A,Heart,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,42.0,,948.0,Mus musculus,CHEMBL622658,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6289,A,Heart,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,42.0,,948.0,Mus musculus,CHEMBL622659,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6290,A,Kidney,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,42.0,,2113.0,Mus musculus,CHEMBL624630,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6291,A,Kidney,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,42.0,,2113.0,Mus musculus,CHEMBL624631,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6292,A,Kidney,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,42.0,,2113.0,Mus musculus,CHEMBL624632,10090.0
17130,N,,,A549,,80682,1,Intermediate,,6293,F,,,1,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,646.0,,,Homo sapiens,CHEMBL624633,9606.0
17130,N,,,A549,,80682,1,Intermediate,,6294,F,,,1,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,646.0,,,Homo sapiens,CHEMBL624634,9606.0
17130,N,,,A549,,80682,1,Intermediate,,6295,F,,,1,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),646.0,,,Homo sapiens,CHEMBL624635,9606.0
17130,N,,,A549,,80682,1,Intermediate,,6296,F,,,1,BAO_0000219,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),646.0,,,Homo sapiens,CHEMBL624636,9606.0
3263,N,,,A549,,80682,1,Expert,,6297,F,,,1,BAO_0000219,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,646.0,,,Homo sapiens,CHEMBL857055,9606.0
6663,N,,,A549,,80682,1,Expert,,6298,F,,,1,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,646.0,,,Homo sapiens,CHEMBL624637,9606.0
6663,N,,,A549,,80682,1,Expert,,6299,F,,,1,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,646.0,,,Homo sapiens,CHEMBL624638,9606.0
6663,N,,,A549,,80682,1,Expert,,6300,F,,,1,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,646.0,,,Homo sapiens,CHEMBL874366,9606.0
6663,N,,,A549,,80682,1,Expert,,6301,F,,,1,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,646.0,,,Homo sapiens,CHEMBL624639,9606.0
6663,N,,,A549,,80682,1,Expert,,6302,F,,,1,BAO_0000219,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,646.0,,,Homo sapiens,CHEMBL624640,9606.0
6663,N,,,A549,,80682,1,Intermediate,,6303,F,,,1,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,646.0,,,Homo sapiens,CHEMBL624641,9606.0
6663,N,,,A549,,80682,1,Intermediate,,6304,F,,,1,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,646.0,,,Homo sapiens,CHEMBL624642,9606.0
6663,N,,,A549,,80682,1,Intermediate,,6305,F,,,1,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,646.0,,,Homo sapiens,CHEMBL624643,9606.0
6663,N,,,A549,,80682,1,Intermediate,,6306,F,,,1,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,646.0,,,Homo sapiens,CHEMBL624644,9606.0
6663,N,,,A549,,80682,1,Intermediate,,6307,F,,,1,BAO_0000219,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,646.0,,,Homo sapiens,CHEMBL624645,9606.0
3983,N,,,A549,,80682,1,Intermediate,,6308,F,,,1,BAO_0000219,The compound was evaluated for its cytotoxic potency against A-549 cell line,646.0,,,Homo sapiens,CHEMBL619445,9606.0
11141,N,,,A549,,80682,1,Expert,,6309,F,,,1,BAO_0000219,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,646.0,,,Homo sapiens,CHEMBL839886,9606.0
5076,N,,,A549,,80682,1,Intermediate,,6310,F,,,1,BAO_0000219,Cytotoxic activity of compound against A-549 tumor cell line.,646.0,,,Homo sapiens,CHEMBL619446,9606.0
3311,N,,,A549,,80682,1,Intermediate,,6311,F,,,1,BAO_0000219,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,646.0,,,Homo sapiens,CHEMBL619447,9606.0
3311,N,,,A549,,80682,1,Intermediate,,6312,F,,,1,BAO_0000219,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,646.0,,,Homo sapiens,CHEMBL619448,9606.0
3311,N,,,A549,,80682,1,Intermediate,,6313,F,,,1,BAO_0000219,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,646.0,,,Homo sapiens,CHEMBL619449,9606.0
5076,N,,,A549,,80682,1,Intermediate,,6314,F,,,1,BAO_0000219,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,646.0,,,Homo sapiens,CHEMBL619450,9606.0
4150,N,,,A549,,80682,1,Intermediate,,6315,F,,,1,BAO_0000219,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),646.0,,,Homo sapiens,CHEMBL619451,9606.0
2150,N,,,A549,,80682,1,Expert,,6316,F,,,1,BAO_0000219,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,646.0,,,Homo sapiens,CHEMBL619452,9606.0
4644,N,,,A549,,80682,1,Intermediate,,6317,F,,,1,BAO_0000219,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,646.0,,,Homo sapiens,CHEMBL619453,9606.0
263,N,,,A549,,80682,1,Intermediate,,6318,F,,,1,BAO_0000219,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,646.0,,,Homo sapiens,CHEMBL874367,9606.0
11333,N,,,A549,,80682,1,Intermediate,,6319,F,,,1,BAO_0000219,Cytotoxic concentration against A-549 tumor cells.,646.0,,,Homo sapiens,CHEMBL619454,9606.0
11333,N,,,A549,,80682,1,Intermediate,,6320,F,,,1,BAO_0000219,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,646.0,,,Homo sapiens,CHEMBL619455,9606.0
15895,N,,,A549,,80682,1,Intermediate,,6321,F,,,1,BAO_0000219,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",646.0,,,Homo sapiens,CHEMBL619456,9606.0
16677,N,,,,,50191,1,Expert,,6322,F,,,1,BAO_0000218,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,,,Acinetobacter baumannii,CHEMBL619457,470.0
10624,N,,,,,50192,1,Intermediate,,6323,F,,,1,BAO_0000218,Activity against Acinetobacter calcoaceticus (AC54),,,,Acinetobacter calcoaceticus,CHEMBL619458,471.0
16717,N,,,,,50274,1,Expert,,6324,F,,,1,BAO_0000218,In vitro antifungal activity against Aspergillus flavus CM74,,,,Aspergillus flavus,CHEMBL619459,5059.0
16717,N,,,,,50274,1,Expert,,6325,F,,,1,BAO_0000218,In vitro antifungal activity against Aspergillus flavus CM74,,,,Aspergillus flavus,CHEMBL619460,5059.0
5513,N,,,,,50416,1,Intermediate,,6326,F,,,1,BAO_0000218,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,,,Aspergillus fumigatus,CHEMBL619461,746128.0
15962,N,,,,,50416,1,Intermediate,,6327,F,,,1,BAO_0000218,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,,,Aspergillus fumigatus,CHEMBL619462,746128.0
15962,N,,,,,50416,1,Intermediate,,6328,F,,,1,BAO_0000218,Antimicrobial activity against Aspergillus fumigatus (MIC),,,,Aspergillus fumigatus,CHEMBL620388,746128.0
15962,N,,,,,50416,1,Intermediate,,6329,F,,,1,BAO_0000218,Antimicrobial activity against Aspergillus fumigatus (MIC),,,,Aspergillus fumigatus,CHEMBL620389,746128.0
15962,N,,,,,50416,1,Intermediate,,6330,F,,,1,BAO_0000218,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,,,Aspergillus fumigatus,CHEMBL620390,746128.0
16717,N,,,,,50416,1,Expert,,6331,F,,,1,BAO_0000218,In vitro antifungal activity against Aspergillus fumigatus 48238E,,,,Aspergillus fumigatus,CHEMBL620391,746128.0
16717,N,,,,,50416,1,Expert,,6332,F,,,1,BAO_0000218,In vitro antifungal activity against Aspergillus fumigatus 48238E,,,,Aspergillus fumigatus,CHEMBL621073,746128.0
8117,N,,,,,50296,1,Intermediate,,6333,F,,,1,BAO_0000218,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,,,Actinomyces naeslundii,CHEMBL621074,1655.0
8117,N,,,,,50366,1,Intermediate,,6334,F,,,1,BAO_0000218,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,,,Actinomyces viscosus,CHEMBL621075,1656.0
15472,N,,,,,50535,1,Intermediate,,6335,F,,,1,BAO_0000218,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,,,Acanthocheilonema viteae,CHEMBL619554,6277.0
15472,N,,,,,50535,1,Intermediate,,6336,F,,,1,BAO_0000218,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,,,Acanthocheilonema viteae,CHEMBL619555,6277.0
16443,N,,,,,50169,1,Intermediate,,6337,F,,,1,BAO_0000218,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,,,Aggregatibacter actinomycetemcomitans,CHEMBL619556,714.0
16443,N,,,,,50169,1,Intermediate,,6338,F,,,1,BAO_0000218,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,,,Aggregatibacter actinomycetemcomitans,CHEMBL619557,714.0
16443,N,,,,,50169,1,Intermediate,,6339,F,,,1,BAO_0000218,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,,,Aggregatibacter actinomycetemcomitans,CHEMBL619558,714.0
17206,N,,,A549,,80682,1,Intermediate,,6340,F,,,1,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,646.0,,,Homo sapiens,CHEMBL619559,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6341,F,,,1,BAO_0000219,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,646.0,,,Homo sapiens,CHEMBL619560,9606.0
16381,N,,,A549,,80682,1,Intermediate,,6342,F,,,1,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,646.0,,,Homo sapiens,CHEMBL619561,9606.0
16381,N,,,A549,,80682,1,Intermediate,,6343,F,,,1,BAO_0000219,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,646.0,,,Homo sapiens,CHEMBL619562,9606.0
16381,N,,,A549,,80682,1,Intermediate,,6344,F,,,1,BAO_0000219,% inhibition against A549 cells (lung cancer) at 4 ug/mL,646.0,,,Homo sapiens,CHEMBL619563,9606.0
16381,N,,,A549,,80682,1,Intermediate,,6345,F,,,1,BAO_0000219,GI values against A549 cells (lung cancer),646.0,,,Homo sapiens,CHEMBL857457,9606.0
17206,N,,,A549,,80682,1,Intermediate,,6346,F,,,1,BAO_0000219,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,646.0,,,Homo sapiens,CHEMBL619564,9606.0
16325,N,,,A549,,80682,1,Intermediate,,6347,F,,,1,BAO_0000219,Inhibitory activity against A549 human adenocarcinoma,646.0,,,Homo sapiens,CHEMBL619565,9606.0
10708,N,,,A549,,80682,1,Intermediate,,6348,F,,,1,BAO_0000218,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,646.0,,,Homo sapiens,CHEMBL619566,9606.0
10708,N,,,A549,,80682,1,Intermediate,,6349,F,,,1,BAO_0000218,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,646.0,,,Homo sapiens,CHEMBL619567,9606.0
17376,N,,,A549,,80682,1,Intermediate,,6350,F,,,1,BAO_0000219,Inhibitory activity against A549 lung adenocarcinoma cell line,646.0,,,Homo sapiens,CHEMBL619568,9606.0
17376,N,,,A549,,80682,1,Intermediate,,6351,F,,,1,BAO_0000219,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,646.0,,,Homo sapiens,CHEMBL619569,9606.0
17488,N,,,A549,,80682,1,Intermediate,,6352,F,,,1,BAO_0000219,Cytotoxicity against human A549 lung cells,646.0,,,Homo sapiens,CHEMBL619570,9606.0
17404,N,,,A549,,80682,1,Intermediate,,6353,F,,,1,BAO_0000218,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,646.0,,,Homo sapiens,CHEMBL619571,9606.0
10958,N,,,A549,,80682,1,Expert,,6354,F,,,1,BAO_0000219,Growth inhibition of A549 (human lung carcinoma) cell line.,646.0,,,Homo sapiens,CHEMBL619572,9606.0
17099,N,,,A549,,80682,1,Expert,,6355,F,,,1,BAO_0000219,Effective dose required for inhibitory activity against A549 human tumor cell line.,646.0,,,Homo sapiens,CHEMBL619573,9606.0
17099,N,,,A549,,80682,1,Intermediate,,6356,F,,,1,BAO_0000219,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,646.0,,,Homo sapiens,CHEMBL619574,9606.0
4096,N,,,A549,,80682,1,Intermediate,,6357,F,,,1,BAO_0000219,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,646.0,,,Homo sapiens,CHEMBL619575,9606.0
4096,N,,,A549,,80682,1,Expert,,6358,F,,,1,BAO_0000219,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,646.0,,,Homo sapiens,CHEMBL619576,9606.0
4096,N,,,A549,,80682,1,Intermediate,,6359,F,,,1,BAO_0000219,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,646.0,,,Homo sapiens,CHEMBL619577,9606.0
2525,N,,,A549,,80682,1,Intermediate,,6360,F,,,1,BAO_0000219,In vitro inhibitory activity against A549 tumor cell culture,646.0,,,Homo sapiens,CHEMBL619578,9606.0
2525,N,,,A549,,80682,1,Intermediate,,6361,F,,,1,BAO_0000219,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,646.0,,,Homo sapiens,CHEMBL884009,9606.0
5302,N,,,A549,,80682,1,Intermediate,,6362,F,,,1,BAO_0000219,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),646.0,,,Homo sapiens,CHEMBL619579,9606.0
16325,N,,,A549,,80682,1,Intermediate,,6363,F,,,1,BAO_0000219,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,646.0,,,Homo sapiens,CHEMBL619580,9606.0
16939,N,,,A549,,80682,1,Intermediate,,6364,F,,,1,BAO_0000219,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,646.0,,,Homo sapiens,CHEMBL619581,9606.0
17229,N,,,A549,,80682,1,Intermediate,,6365,F,,,1,BAO_0000219,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,646.0,,,Homo sapiens,CHEMBL619582,9606.0
17380,N,,,A549,,80682,1,Intermediate,,6366,F,,,1,BAO_0000219,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,646.0,,,Homo sapiens,CHEMBL619583,9606.0
17380,N,,,A549,,80682,1,Intermediate,,6367,F,,,1,BAO_0000219,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,646.0,,,Homo sapiens,CHEMBL876502,9606.0
1903,N,,,A549,,80682,1,Intermediate,,6368,F,,,1,BAO_0000219,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,646.0,,,Homo sapiens,CHEMBL619584,9606.0
3838,N,,,A549,,80682,1,Intermediate,,6369,F,,,1,BAO_0000219,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,646.0,,,Homo sapiens,CHEMBL619585,9606.0
14696,N,,,A549,,80682,1,Intermediate,,6370,F,,,1,BAO_0000219,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,646.0,,,Homo sapiens,CHEMBL619586,9606.0
3838,N,,,A549,,80682,1,Intermediate,,6371,F,,,1,BAO_0000219,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,646.0,,,Homo sapiens,CHEMBL619587,9606.0
1522,N,,,A549,,80682,1,Intermediate,,6372,F,,,1,BAO_0000219,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,646.0,,,Homo sapiens,CHEMBL619588,9606.0
12400,N,,,A549,,80682,1,Intermediate,,6373,F,,,1,BAO_0000219,Tested in vitro for cytotoxicity in A549/ATCC cell lines,646.0,,,Homo sapiens,CHEMBL619589,9606.0
14696,N,,,A549,,80682,1,Intermediate,,6374,F,,,1,BAO_0000219,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,646.0,,,Homo sapiens,CHEMBL619590,9606.0
14769,N,,,A549,,80682,1,Intermediate,,6375,F,,,1,BAO_0000219,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),646.0,,,Homo sapiens,CHEMBL619591,9606.0
14696,N,,,A549,,80682,1,Intermediate,,6376,F,,,1,BAO_0000219,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,646.0,,,Homo sapiens,CHEMBL619592,9606.0
1888,N,,,A549,,80682,1,Intermediate,,6377,F,,,1,BAO_0000219,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,646.0,,,Homo sapiens,CHEMBL619593,9606.0
12016,N,,,A549,,80682,1,Intermediate,,6378,F,,,1,BAO_0000219,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,646.0,,,Homo sapiens,CHEMBL620217,9606.0
6058,N,,,A549,,80682,1,Intermediate,,6379,F,,,1,BAO_0000219,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,646.0,,,Homo sapiens,CHEMBL620218,9606.0
17708,N,,,A549,,80682,1,Intermediate,,6380,F,,,1,BAO_0000219,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,646.0,,,Homo sapiens,CHEMBL620219,9606.0
12301,N,,,A549,,80682,1,Intermediate,,6381,F,,,1,BAO_0000219,Antitumor activity against A549/ATCC cell line,646.0,,,Homo sapiens,CHEMBL620220,9606.0
11970,N,,,A549,,80682,1,Intermediate,,6382,F,,,1,BAO_0000219,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,646.0,,,Homo sapiens,CHEMBL625141,9606.0
11818,N,,,A549,,80682,1,Expert,,6383,F,,,1,BAO_0000219,In vitro cytotoxicity against A549/ATCC cell line.,646.0,,,Homo sapiens,CHEMBL625142,9606.0
12400,N,,,A549,,80682,1,Intermediate,,6384,F,,,1,BAO_0000219,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,646.0,,,Homo sapiens,CHEMBL625143,9606.0
3381,N,,,A549,,80682,1,Intermediate,,6385,F,,,1,BAO_0000219,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,646.0,,,Homo sapiens,CHEMBL625144,9606.0
17376,N,,,A549,,80682,1,Intermediate,,6386,F,,,1,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,646.0,,,Homo sapiens,CHEMBL622474,9606.0
10708,N,,,A549,,80682,1,Intermediate,,6387,F,,,1,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,646.0,,,Homo sapiens,CHEMBL884104,9606.0
2964,U,,,,,22226,0,Autocuration,,6388,F,,,1,BAO_0000219,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,,,Homo sapiens,CHEMBL622475,9606.0
5005,U,,,,In vivo,22224,0,Intermediate,,6389,A,,,1,BAO_0000218,Compound was tested for oral bioavailability in dogs,,,,Canis lupus familiaris,CHEMBL622476,9615.0
6229,N,,,,In vivo,50588,1,Intermediate,,6390,A,,,1,BAO_0000218,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,,,Canis lupus familiaris,CHEMBL875831,9615.0
6229,N,,,,In vivo,50588,1,Intermediate,,6391,A,,,1,BAO_0000218,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,,,Canis lupus familiaris,CHEMBL622477,9615.0
5374,N,,,,In vivo,50588,1,Intermediate,,6392,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL622478,9615.0
5374,N,,,,In vivo,50588,1,Intermediate,,6393,A,,,1,BAO_0000218,Compound was tested for the oral bioavailability in dog; No availability,,,,Canis lupus familiaris,CHEMBL623172,9615.0
6265,N,,,,In vivo,50588,1,Intermediate,,6394,A,,,1,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg),,,,Canis lupus familiaris,CHEMBL623173,9615.0
5654,N,,,,In vivo,50588,1,Intermediate,,6395,A,,,1,BAO_0000218,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,,,Canis lupus familiaris,CHEMBL623174,9615.0
5654,N,,,,In vivo,50588,1,Intermediate,,6396,A,,,1,BAO_0000218,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,,,Canis lupus familiaris,CHEMBL623175,9615.0
16456,N,,,,In vivo,50588,1,Intermediate,,6397,A,,,1,BAO_0000218,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,,,Canis lupus familiaris,CHEMBL623340,9615.0
5302,N,,,,In vivo,50588,1,Intermediate,,6398,A,,,1,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg),,,,Canis lupus familiaris,CHEMBL623341,9615.0
3624,N,,,,In vivo,50588,1,Intermediate,,6399,A,,,1,BAO_0000218,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,,,Canis lupus familiaris,CHEMBL623342,9615.0
16452,N,,,,In vivo,50588,1,Intermediate,,6400,A,,,1,BAO_0000218,Oral bioavailability of active FTIs in dogs,,,,Canis lupus familiaris,CHEMBL623343,9615.0
5802,N,,,,In vivo,50588,1,Intermediate,,6401,A,,,1,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,,,Canis lupus familiaris,CHEMBL623344,9615.0
3598,N,,,,In vivo,50588,1,Expert,,6402,A,,,1,BAO_0000218,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,,,Canis lupus familiaris,CHEMBL623345,9615.0
17839,N,,,,In vivo,50588,1,Intermediate,,6403,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL875832,9615.0
6762,N,,,,In vivo,50588,1,Intermediate,,6404,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL623346,9615.0
6821,N,,,,In vivo,50588,1,Intermediate,,6405,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL623347,9615.0
6821,N,,,,In vivo,50588,1,Intermediate,,6406,A,,,1,BAO_0000218,Oral bioavailability of compound was determined in dog; Not tested,,,,Canis lupus familiaris,CHEMBL623348,9615.0
5210,N,,,,In vivo,50588,1,Intermediate,,6407,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL623349,9615.0
6227,N,,,,In vivo,50588,1,Intermediate,,6408,A,,,1,BAO_0000218,Oral bioavailability (10 mg/kg) was determined in dog,,,,Canis lupus familiaris,CHEMBL623350,9615.0
761,N,,,,In vivo,50588,1,Intermediate,,6409,A,,,1,BAO_0000218,Oral bioavailability,,,,Canis lupus familiaris,CHEMBL623351,9615.0
761,N,,,,In vivo,50588,1,Intermediate,,6410,A,,,1,BAO_0000218,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,,,Canis lupus familiaris,CHEMBL623352,9615.0
761,N,,,,In vivo,50588,1,Intermediate,,6411,A,,,1,BAO_0000218,Oral bioavailability administered in solution in rats,,,,Canis lupus familiaris,CHEMBL623353,9615.0
16907,N,,,,In vivo,50588,1,Intermediate,,6412,A,,,1,BAO_0000218,Oral bioavailability after 30 mg/kg po dose in Dogs,,,,Canis lupus familiaris,CHEMBL875833,9615.0
5474,N,,,,In vivo,50588,1,Intermediate,,6413,A,,,1,BAO_0000218,Oral bioavailability at a dose of 1 mg/kg in dogs,,,,Canis lupus familiaris,CHEMBL623354,9615.0
6535,N,,,,In vivo,50588,1,Intermediate,,6414,A,,,1,BAO_0000218,Oral bioavailability in dog (dose 1 mg/kg p.o.),,,,Canis lupus familiaris,CHEMBL623355,9615.0
6535,N,,,,In vivo,50588,1,Intermediate,,6415,A,,,1,BAO_0000218,Oral bioavailability in Dog; ND = not determined,,,,Canis lupus familiaris,CHEMBL623356,9615.0
3352,N,,,,In vivo,50588,1,Intermediate,,6416,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL623357,9615.0
6168,N,,,,In vivo,50588,1,Intermediate,,6417,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL623358,9615.0
5988,N,,,,In vivo,50588,1,Intermediate,,6418,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL623359,9615.0
4942,N,,,,In vivo,50588,1,Intermediate,,6419,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL623360,9615.0
4942,N,,,,In vivo,50588,1,Intermediate,,6420,A,,,1,BAO_0000218,Oral bioavailability in dogs; No data,,,,Canis lupus familiaris,CHEMBL623361,9615.0
14541,N,,,,In vivo,50588,1,Intermediate,,6421,A,,,1,BAO_0000218,Oral bioavailability measured in dogs,,,,Canis lupus familiaris,CHEMBL623362,9615.0
4449,N,,,,In vivo,50588,1,Intermediate,,6422,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL623363,9615.0
6057,N,,,,In vivo,50588,1,Intermediate,,6423,A,,,1,BAO_0000218,Oral bioavailability was calculated in dog,,,,Canis lupus familiaris,CHEMBL623364,9615.0
5600,N,,,,In vivo,50588,1,Intermediate,,6424,A,,,1,BAO_0000218,Oral bioavailability after 0.3 mg/kg po administration in dog,,,,Canis lupus familiaris,CHEMBL875834,9615.0
5542,N,,,,In vivo,50588,1,Intermediate,,6425,A,,,1,BAO_0000218,Oral bioavailability in dog (i.v. dosing),,,,Canis lupus familiaris,CHEMBL623365,9615.0
5542,N,,,,In vivo,50588,1,Intermediate,,6426,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL623366,9615.0
5546,N,,,,In vivo,50588,1,Intermediate,,6427,A,,,1,BAO_0000218,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,,,Canis lupus familiaris,CHEMBL623367,9615.0
4514,N,,,,In vivo,50588,1,Intermediate,,6428,A,,,1,BAO_0000218,Oral bioavailability in Beagle dogs,,,,Canis lupus familiaris,CHEMBL623368,9615.0
3624,N,,,,In vivo,50588,1,Intermediate,,6429,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL623369,9615.0
3854,N,,,,In vivo,50588,1,Intermediate,,6430,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL623370,9615.0
5836,N,,,,In vivo,50588,1,Intermediate,,6431,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL623371,9615.0
5940,N,,,,In vivo,50588,1,Intermediate,,6432,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL623372,9615.0
6168,N,,,,In vivo,50588,1,Intermediate,,6433,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621351,9615.0
6227,N,,,,In vivo,50588,1,Intermediate,,6434,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621352,9615.0
6251,N,,,,In vivo,50588,1,Intermediate,,6435,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621353,9615.0
6448,N,,,,In vivo,50588,1,Intermediate,,6436,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621354,9615.0
6647,N,,,,In vivo,50588,1,Intermediate,,6437,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621355,9615.0
5940,N,,,,In vivo,50588,1,Intermediate,,6438,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621356,9615.0
933,N,,,,In vivo,50588,1,Intermediate,,6439,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621357,9615.0
5210,N,,,,In vivo,50588,1,Intermediate,,6440,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621358,9615.0
6642,N,,,,In vivo,50588,1,Intermediate,,6441,A,,,1,BAO_0000218,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,,,Canis lupus familiaris,CHEMBL621359,9615.0
6641,N,,,,In vivo,50588,1,Intermediate,,6442,A,,,1,BAO_0000218,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,,,Canis lupus familiaris,CHEMBL621360,9615.0
6642,N,,,,In vivo,50588,1,Intermediate,,6443,A,,,1,BAO_0000218,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,,,Canis lupus familiaris,CHEMBL621361,9615.0
5472,N,,,,In vivo,50588,1,Intermediate,,6444,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621362,9615.0
5985,N,,,,In vivo,50588,1,Intermediate,,6445,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621363,9615.0
15660,N,,,,In vivo,50588,1,Intermediate,,6446,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621364,9615.0
5530,N,,,,In vivo,50588,1,Intermediate,,6447,A,,,1,BAO_0000218,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,,,Canis lupus familiaris,CHEMBL621166,9615.0
5530,N,,,,In vivo,50588,1,Intermediate,,6448,A,,,1,BAO_0000218,Oral bioavailability in dog (dose 1 mg/kg i.v.),,,,Canis lupus familiaris,CHEMBL621167,9615.0
6305,N,,,,In vivo,50588,1,Intermediate,,6449,A,,,1,BAO_0000218,Oral bioavailability (F) in dogs,,,,Canis lupus familiaris,CHEMBL621168,9615.0
5210,N,,,,In vivo,50588,1,Intermediate,,6450,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL621169,9615.0
5238,N,,,,In vivo,50588,1,Intermediate,,6451,A,,,1,BAO_0000218,Bioavailability in dog,,,,Canis lupus familiaris,CHEMBL875950,9615.0
5668,N,,,,In vivo,50588,1,Intermediate,,6452,A,,,1,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),,,,Canis lupus familiaris,CHEMBL621170,9615.0
5668,N,,,,In vivo,50588,1,Intermediate,,6453,A,,,1,BAO_0000218,Oral bioavailability after peroral administration at 5 mpk in Dog,,,,Canis lupus familiaris,CHEMBL621171,9615.0
5668,N,,,,In vivo,50588,1,Intermediate,,6454,A,,,1,BAO_0000218,Oral bioavailability in dog (dose 5 mg/kg),,,,Canis lupus familiaris,CHEMBL621172,9615.0
6084,N,,,,In vivo,50588,1,Intermediate,,6455,A,,,1,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),,,,Canis lupus familiaris,CHEMBL621173,9615.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6456,A,Kidney,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,42.0,,2113.0,Mus musculus,CHEMBL621174,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6457,A,Kidney,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,42.0,,2113.0,Mus musculus,CHEMBL621175,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6458,A,Liver,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,42.0,,2107.0,Mus musculus,CHEMBL621176,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6459,A,Liver,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,42.0,,2107.0,Mus musculus,CHEMBL621177,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6460,A,Liver,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,42.0,,2107.0,Mus musculus,CHEMBL621178,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6461,A,Liver,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,42.0,,2107.0,Mus musculus,CHEMBL621179,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6462,A,Liver,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,42.0,,2107.0,Mus musculus,CHEMBL621180,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6463,A,Lung,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,42.0,,2048.0,Mus musculus,CHEMBL875951,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6464,A,Lung,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,42.0,,2048.0,Mus musculus,CHEMBL621181,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6465,A,Lung,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,42.0,,2048.0,Mus musculus,CHEMBL621182,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6466,A,Lung,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,42.0,,2048.0,Mus musculus,CHEMBL621183,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6467,A,Lung,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,42.0,,2048.0,Mus musculus,CHEMBL621184,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6468,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,42.0,,,Mus musculus,CHEMBL621185,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6469,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,42.0,,,Mus musculus,CHEMBL621186,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6470,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,42.0,,,Mus musculus,CHEMBL621187,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6471,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,42.0,,,Mus musculus,CHEMBL621188,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6472,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,42.0,,,Mus musculus,CHEMBL621189,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6473,A,Spleen,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,42.0,,2106.0,Mus musculus,CHEMBL621190,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6474,A,Spleen,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,42.0,,2106.0,Mus musculus,CHEMBL618520,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6475,A,Spleen,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,42.0,,2106.0,Mus musculus,CHEMBL621739,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6476,A,Spleen,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,42.0,,2106.0,Mus musculus,CHEMBL621740,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6477,A,Spleen,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,42.0,,2106.0,Mus musculus,CHEMBL621741,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6478,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,42.0,,,Mus musculus,CHEMBL621742,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6479,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,42.0,,,Mus musculus,CHEMBL621743,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6480,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,42.0,,,Mus musculus,CHEMBL621744,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6481,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,42.0,,,Mus musculus,CHEMBL621745,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6482,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,42.0,,,Mus musculus,CHEMBL621746,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6483,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,42.0,,,Mus musculus,CHEMBL621747,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6484,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,42.0,,,Mus musculus,CHEMBL621748,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6485,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,42.0,,,Mus musculus,CHEMBL621749,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6486,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,42.0,,,Mus musculus,CHEMBL621750,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6487,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,42.0,,,Mus musculus,CHEMBL621751,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6488,A,Heart,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,42.0,,948.0,Mus musculus,CHEMBL621752,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6489,A,Heart,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,42.0,,948.0,Mus musculus,CHEMBL621753,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6490,A,Heart,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,42.0,,948.0,Mus musculus,CHEMBL875955,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6491,A,Heart,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,42.0,,948.0,Mus musculus,CHEMBL621754,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6492,A,Heart,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,42.0,,948.0,Mus musculus,CHEMBL621755,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6493,A,Liver,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,42.0,,2107.0,Mus musculus,CHEMBL621756,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6494,A,Liver,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,42.0,,2107.0,Mus musculus,CHEMBL624199,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6495,A,Liver,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,42.0,,2107.0,Mus musculus,CHEMBL624200,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6496,A,Liver,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,42.0,,2107.0,Mus musculus,CHEMBL624375,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6497,A,Liver,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,42.0,,2107.0,Mus musculus,CHEMBL624376,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6498,A,Lung,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,42.0,,2048.0,Mus musculus,CHEMBL624377,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6499,A,Lung,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,42.0,,2048.0,Mus musculus,CHEMBL624378,10090.0
12269,N,,,,,50067,1,Intermediate,,6500,F,,,1,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,,aeinetobacter anitrotap,CHEMBL857901,107673.0
12269,N,,,,,50067,1,Intermediate,,6501,F,,,1,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,,Acinetobacter calcoaceticus subsp. anitratus,CHEMBL875274,107673.0
12269,N,,,,,50067,1,Intermediate,,6502,F,,,1,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,,Acinetobacter calcoaceticus subsp. anitratus,CHEMBL624379,107673.0
12269,N,,,,,50067,1,Intermediate,,6503,F,,,1,BAO_0000218,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,,,aeinetobacter anitrotap,CHEMBL624380,107673.0
10624,N,,,,,50192,1,Intermediate,,6504,F,,,1,BAO_0000218,Activity against Acinetobacter calcoaceticus (AC54),,,,Acinetobacter calcoaceticus,CHEMBL624381,471.0
17216,N,,,,,50714,1,Intermediate,,6505,F,,,1,BAO_0000218,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,,,Anolis carolinensis,CHEMBL624382,28377.0
17216,N,,,,,50714,1,Intermediate,,6506,F,,,1,BAO_0000218,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,,,Anolis carolinensis,CHEMBL624383,28377.0
9560,N,,,,,50296,1,Intermediate,,6507,F,,,1,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii 631,,,,Actinomyces naeslundii,CHEMBL624384,1655.0
9560,N,,,,,50296,1,Intermediate,,6508,F,,,1,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii B74,,,,Actinomyces naeslundii,CHEMBL624385,1655.0
9560,N,,,,,50296,1,Intermediate,,6509,F,,,1,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,,,Actinomyces naeslundii,CHEMBL624386,1655.0
9560,N,,,,,50296,1,Intermediate,,6510,F,,,1,BAO_0000218,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,,,Actinomyces naeslundii,CHEMBL624387,1655.0
9560,N,,,,,50296,1,Intermediate,,6511,F,,,1,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii 631,,,,Actinomyces naeslundii,CHEMBL624388,1655.0
9560,N,,,,,50296,1,Intermediate,,6512,F,,,1,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii N/9,,,,Actinomyces naeslundii,CHEMBL624389,1655.0
9560,N,,,,,50296,1,Intermediate,,6513,F,,,1,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii B74,,,,Actinomyces naeslundii,CHEMBL624390,1655.0
9560,N,,,,,50296,1,Intermediate,,6514,F,,,1,BAO_0000218,Plaque bactericidal index against Actinomyces naeslundii N/3,,,,Actinomyces naeslundii,CHEMBL875275,1655.0
114,N,,,,,50056,1,Intermediate,,6515,F,,,1,BAO_0000218,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,,,Artemia salina,CHEMBL624391,85549.0
114,N,,,,,50056,1,Intermediate,,6516,F,,,1,BAO_0000218,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,,,Artemia salina,CHEMBL623636,85549.0
10841,N,,,,,50532,1,Intermediate,,6517,F,,,1,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,,,Ascaris suum,CHEMBL623637,6253.0
10841,N,,,,,50532,1,Intermediate,,6518,F,,,1,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,,,Ascaris suum,CHEMBL623638,6253.0
10841,N,,,,,50532,1,Intermediate,,6519,F,,,1,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,,,Ascaris suum,CHEMBL623639,6253.0
10841,N,,,,,50532,1,Intermediate,,6520,F,,,1,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,,,Ascaris suum,CHEMBL623640,6253.0
10841,N,,,,,50532,1,Intermediate,,6521,F,,,1,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,,,Ascaris suum,CHEMBL623641,6253.0
10841,N,,,,,50532,1,Intermediate,,6522,F,,,1,BAO_0000218,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,,,Ascaris suum,CHEMBL623642,6253.0
10841,N,,,,,50532,1,Intermediate,,6523,F,,,1,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,,,Ascaris suum,CHEMBL623643,6253.0
10841,N,,,,,50532,1,Intermediate,,6524,F,,,1,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,,,Ascaris suum,CHEMBL623644,6253.0
10841,N,,,,,50532,1,Intermediate,,6525,F,,,1,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,,,Ascaris suum,CHEMBL623645,6253.0
10841,N,,,,,50532,1,Intermediate,,6526,F,,,1,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,,,Ascaris suum,CHEMBL623646,6253.0
10841,N,,,,,50532,1,Intermediate,,6527,F,,,1,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,,,Ascaris suum,CHEMBL623647,6253.0
10841,N,,,,,50532,1,Intermediate,,6528,F,,,1,BAO_0000218,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,,,Ascaris suum,CHEMBL623648,6253.0
8117,N,,,,,50366,1,Intermediate,,6529,F,,,1,BAO_0000218,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,,,Actinomyces viscosus,CHEMBL623649,1656.0
8117,N,,,,,50366,1,Intermediate,,6530,F,,,1,BAO_0000218,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,,,Actinomyces viscosus,CHEMBL623650,1656.0
9560,N,,,,,50366,1,Intermediate,,6531,F,,,1,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,,,Actinomyces viscosus,CHEMBL623651,1656.0
9560,N,,,,,50366,1,Expert,,6532,F,,,1,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus M-100,,,,Actinomyces viscosus,CHEMBL623652,1656.0
9560,N,,,,,50366,1,Intermediate,,6533,F,,,1,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus M-626,,,,Actinomyces viscosus,CHEMBL623653,1656.0
9560,N,,,,,50366,1,Intermediate,,6534,F,,,1,BAO_0000218,Chlorohexidine coefficient for Actinomyces viscosus T14V,,,,Actinomyces viscosus,CHEMBL623654,1656.0
9560,N,,,,,50366,1,Intermediate,,6535,F,,,1,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus 8A06,,,,Actinomyces viscosus,CHEMBL623655,1656.0
9560,N,,,,,50366,1,Intermediate,,6536,F,,,1,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus M-100,,,,Actinomyces viscosus,CHEMBL623656,1656.0
9560,N,,,,,50366,1,Expert,,6537,F,,,1,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,,,Actinomyces viscosus,CHEMBL623657,1656.0
9560,N,,,,,50366,1,Intermediate,,6538,F,,,1,BAO_0000218,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,,,Actinomyces viscosus,CHEMBL623658,1656.0
9560,N,,,,,50366,1,Intermediate,,6539,F,,,1,BAO_0000218,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,,,Actinomyces viscosus,CHEMBL623659,1656.0
9560,N,,,,,50366,1,Intermediate,,6540,F,,,1,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus 626,,,,Actinomyces viscosus,CHEMBL623660,1656.0
9560,N,,,,,50366,1,Intermediate,,6541,F,,,1,BAO_0000218,Plaque bactericidal index against Actinomyces viscosus T14V,,,,Actinomyces viscosus,CHEMBL623661,1656.0
10986,N,,,,,50535,1,Intermediate,,6542,F,,,1,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,,,Acanthocheilonema viteae,CHEMBL875281,6277.0
10986,N,,,,,50535,1,Intermediate,,6543,F,,,1,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,,,Acanthocheilonema viteae,CHEMBL623662,6277.0
10986,N,,,,,50535,1,Intermediate,,6544,F,,,1,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,,,Acanthocheilonema viteae,CHEMBL623663,6277.0
10986,N,,,,,50535,1,Intermediate,,6545,F,,,1,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,,,Acanthocheilonema viteae,CHEMBL623664,6277.0
10986,N,,,,,50535,1,Intermediate,,6546,F,,,1,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,,,Acanthocheilonema viteae,CHEMBL623665,6277.0
10708,N,,,A673,,80023,1,Intermediate,,6547,F,,,1,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,165.0,,,Homo sapiens,CHEMBL621856,9606.0
10708,N,,,A704,,80661,1,Intermediate,,6548,F,,,1,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,645.0,,,Homo sapiens,CHEMBL620432,9606.0
416,U,,,,,22226,0,Autocuration,,6549,F,,,1,BAO_0000219,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,,,Rattus norvegicus,CHEMBL620433,10116.0
14354,N,,,A9,,80024,1,Intermediate,,6550,F,,,1,BAO_0000219,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,625.0,,,Mus musculus,CHEMBL620434,10090.0
14354,N,,,A9,,80024,1,Intermediate,,6551,F,,,1,BAO_0000219,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,625.0,,,Mus musculus,CHEMBL620435,10090.0
5116,N,,,A9,,80024,1,Intermediate,,6552,F,,,1,BAO_0000219,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,625.0,,,Homo sapiens,CHEMBL620436,9606.0
5116,N,,,A9,,80024,1,Intermediate,,6553,F,,,1,BAO_0000219,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,625.0,,,Homo sapiens,CHEMBL876597,9606.0
15694,N,,,Human ovarian carcinoma cell line,,81037,1,Expert,,6554,F,,,1,BAO_0000219,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,874.0,,,Homo sapiens,CHEMBL620437,9606.0
13038,N,,,A9,,80024,1,Expert,,6555,F,,,1,BAO_0000219,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",625.0,,,Mus musculus,CHEMBL620438,10090.0
13038,N,,,A9,,80024,1,Expert,,6556,F,,,1,BAO_0000219,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,625.0,,,Mus musculus,CHEMBL620439,10090.0
10923,N,,,A9,,80024,1,Expert,,6557,F,,,1,BAO_0000219,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,625.0,,,Mus musculus,CHEMBL619657,10090.0
10923,N,,,A9,,80024,1,Intermediate,,6558,F,,,1,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,625.0,,,Mus musculus,CHEMBL619658,10090.0
10923,N,,,A9,,80024,1,Intermediate,,6559,F,,,1,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,625.0,,,Mus musculus,CHEMBL619659,10090.0
10923,H,,,,,10649,8,Expert,,6560,F,,,1,BAO_0000019,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,,,,CHEMBL619660,
10923,N,,,A9,,80024,1,Intermediate,,6561,F,,,1,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,625.0,,,Mus musculus,CHEMBL619661,10090.0
10923,N,,,A9,,80024,1,Intermediate,,6562,F,,,1,BAO_0000219,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,625.0,,,Mus musculus,CHEMBL619662,10090.0
8158,N,,,AA6,,80663,1,Intermediate,,6563,F,,,1,BAO_0000219,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,975.0,,,Cricetulus griseus,CHEMBL619663,10029.0
15494,U,,,,,22226,0,Autocuration,,6564,F,,,1,BAO_0000219,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,,,Homo sapiens,CHEMBL619664,9606.0
15494,U,,,,,22226,0,Autocuration,,6565,F,,,1,BAO_0000219,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,,,Homo sapiens,CHEMBL619665,9606.0
12348,N,,,AA5,,80662,1,Intermediate,,6566,F,,,1,BAO_0000219,Anti -HIV activity was measured against AA5/HIV-1(IIIB),974.0,,,Homo sapiens,CHEMBL883244,9606.0
12348,N,,,AA5,,80662,1,Intermediate,,6567,F,,,1,BAO_0000219,Cytotoxicity was measured against AA5/HIV-1(IIIB),974.0,,,Homo sapiens,CHEMBL884011,9606.0
2726,N,,,AA5,,80662,1,Intermediate,,6568,F,,,1,BAO_0000219,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,974.0,,,Homo sapiens,CHEMBL619666,9606.0
2726,N,,,U-937,,80566,1,Intermediate,,6569,F,,,1,BAO_0000219,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,379.0,,,Homo sapiens,CHEMBL619667,9606.0
10747,N,,,UV4,,80578,1,Intermediate,,6570,F,,,1,BAO_0000219,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,274.0,,,Cricetulus griseus,CHEMBL619668,10029.0
11005,N,,,CHO-AA8,,80089,1,Expert,,6571,F,,,1,BAO_0000219,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",185.0,,,Cricetulus griseus,CHEMBL619669,10029.0
12687,N,,,CHO-AA8,,80089,1,Intermediate,,6572,F,,,1,BAO_0000219,Average intracellular compound concentration when the hypoxic SER=1.6,185.0,,,Cricetulus griseus,CHEMBL876608,10029.0
12687,N,,,CHO-AA8,,80089,1,Intermediate,,6573,F,,,1,BAO_0000219,Average intracellular compound concentration when the hypoxic SER=1.6.,185.0,,,Cricetulus griseus,CHEMBL619670,10029.0
12687,N,,,CHO-AA8,,80089,1,Intermediate,,6574,F,,,1,BAO_0000219,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,185.0,,,Cricetulus griseus,CHEMBL619671,10029.0
12687,N,,,CHO-AA8,,80089,1,Intermediate,,6575,F,,,1,BAO_0000219,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,185.0,,,Cricetulus griseus,CHEMBL619672,10029.0
12687,N,,,CHO-AA8,,80089,1,Intermediate,,6576,F,,,1,BAO_0000219,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,185.0,,,Cricetulus griseus,CHEMBL619673,10029.0
13436,N,,,CHO-AA8,,80089,1,Intermediate,,6577,F,,,1,BAO_0000219,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",185.0,,,Cricetulus griseus,CHEMBL619674,10029.0
13435,N,,,CHO-AA8,,80089,1,Intermediate,,6578,F,,,1,BAO_0000219,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",185.0,,,Cricetulus griseus,CHEMBL619675,10029.0
13302,N,,,CHO-AA8,,80089,1,Intermediate,,6579,F,,,1,BAO_0000219,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,185.0,,,Cricetulus griseus,CHEMBL619676,10029.0
12687,N,,,CHO-AA8,,80089,1,Intermediate,,6580,F,,,1,BAO_0000219,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,185.0,,,Cricetulus griseus,CHEMBL619677,10029.0
12687,N,,,CHO-AA8,,80089,1,Intermediate,,6581,A,,,1,BAO_0000219,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,185.0,,,Cricetulus griseus,CHEMBL619678,10029.0
12687,N,,,CHO-AA8,,80089,1,Intermediate,,6582,A,,,1,BAO_0000219,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,185.0,,,Cricetulus griseus,CHEMBL619679,10029.0
12878,N,,,CHO-AA8,,80089,1,Expert,,6583,A,,,1,BAO_0000219,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,185.0,,,Cricetulus griseus,CHEMBL619680,10029.0
12878,N,,,CHO-AA8,,80089,1,Intermediate,,6584,A,,,1,BAO_0000219,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,185.0,,,Cricetulus griseus,CHEMBL621457,10029.0
14367,N,,,CHO-AA8,,80089,1,Expert,,6585,F,,,1,BAO_0000219,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,185.0,,,Cricetulus griseus,CHEMBL876609,10029.0
14367,N,,,CHO-AA8,,80089,1,Intermediate,,6586,F,,,1,BAO_0000219,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,185.0,,,Cricetulus griseus,CHEMBL621458,10029.0
12398,N,,,CHO-AA8,,80089,1,Expert,,6587,F,,,1,BAO_0000219,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,185.0,,,hampster,CHEMBL621459,36483.0
12878,N,,,CHO-AA8,,80089,1,Expert,,6588,F,,,1,BAO_0000219,Aerobic growth inhibition in Chinese hamster cell line AA8,185.0,,,Cricetulus griseus,CHEMBL621460,10029.0
13820,N,,,CHO-AA8,,80089,1,Expert,,6589,F,,,1,BAO_0000219,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,185.0,,,Cricetulus griseus,CHEMBL621461,10029.0
13436,N,,,CHO-AA8,,80089,1,Expert,,6590,F,,,1,BAO_0000219,Inhibition of growth under aerobic conditions in AA8 cells,185.0,,,Cricetulus griseus,CHEMBL621462,10029.0
6084,N,,,,In vivo,50588,1,Intermediate,,6591,A,,,1,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),,,,Canis lupus familiaris,CHEMBL621463,9615.0
5711,N,,,,In vivo,50588,1,Intermediate,,6592,A,,,1,BAO_0000218,Oral bioavailability in dog at 10 mg/kg of the compound,,,,Canis lupus familiaris,CHEMBL621464,9615.0
4353,N,,,,In vivo,50588,1,Intermediate,,6593,A,,,1,BAO_0000218,Oral bioavailability in dog (dose 5 uM/kg),,,,Canis lupus familiaris,CHEMBL621465,9615.0
4353,N,,,,In vivo,50588,1,Intermediate,,6594,A,,,1,BAO_0000218,Oral bioavailability in dog (dose 5 uM/kg),,,,Canis lupus familiaris,CHEMBL621466,9615.0
17800,N,,,,In vivo,50588,1,Intermediate,,6595,A,,,1,BAO_0000218,Oral bioavailability in dog (mongrel),,,,Canis lupus familiaris,CHEMBL621467,9615.0
3994,N,,,,In vivo,50588,1,Intermediate,,6596,A,,,1,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),,,,Canis lupus familiaris,CHEMBL621468,9615.0
3994,N,,,,In vivo,50588,1,Intermediate,,6597,F,,,1,BAO_0000218,Oral bioavailability in dog (dose 10 mg/kg),,,,Canis lupus familiaris,CHEMBL876734,9615.0
5145,N,,,,In vivo,50588,1,Intermediate,,6598,A,,,1,BAO_0000218,Bioavailability in dog,,,,Canis lupus familiaris,CHEMBL618476,9615.0
16452,N,,,,In vivo,50588,1,Intermediate,,6599,A,,,1,BAO_0000218,Bioavailability in dog (dose 1 mg/kg i.v.),,,,Canis lupus familiaris,CHEMBL618477,9615.0
16452,N,,,,In vivo,50588,1,Intermediate,,6600,A,,,1,BAO_0000218,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,,,Canis lupus familiaris,CHEMBL618478,9615.0
5983,N,,,,In vivo,50588,1,Intermediate,,6601,A,,,1,BAO_0000218,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,,,Canis lupus familiaris,CHEMBL618479,9615.0
4273,N,,,,In vivo,50588,1,Intermediate,,6602,A,,,1,BAO_0000218,Bioavailability in dog,,,,Canis lupus familiaris,CHEMBL618480,9615.0
12500,N,,,,In vivo,50588,1,Intermediate,,6603,A,,,1,BAO_0000218,Bioavailability in dog (dose 3-10 mg/kg),,,,Canis lupus familiaris,CHEMBL618481,9615.0
12500,N,,,,In vivo,50588,1,Intermediate,,6604,A,Plasma,,1,BAO_0000218,The compound was tested for bioavailability of compound in plasma of dog; Complete,,,1969.0,Canis lupus familiaris,CHEMBL618482,9615.0
3639,N,,,,In vivo,50588,1,Intermediate,,6605,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL618483,9615.0
3880,N,,,,In vivo,50588,1,Intermediate,,6606,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL618484,9615.0
4838,N,,,,In vivo,50588,1,Intermediate,,6607,A,,,1,BAO_0000218,Bioavailability in dog,,,,Canis lupus familiaris,CHEMBL618485,9615.0
15600,N,,,,In vivo,50588,1,Intermediate,,6608,A,,,1,BAO_0000218,oral bioavailability was measured in dogs,,,,Canis lupus familiaris,CHEMBL618486,9615.0
17248,N,,,,,50588,1,Intermediate,,6609,A,,,1,BAO_0000218,Compound was tested for plasma protein binding in dog; Not determined,,,,Canis lupus familiaris,CHEMBL618487,9615.0
17248,N,,,,,50588,1,Intermediate,,6610,A,,,1,BAO_0000218,Compound was tested for plasma protein binding of dog,,,,Canis lupus familiaris,CHEMBL618488,9615.0
17248,N,,,,,50588,1,Intermediate,,6611,A,,,1,BAO_0000218,Compound was tested for plasma protein binding of dog; Not determined,,,,Canis lupus familiaris,CHEMBL876735,9615.0
17443,N,,,,,50588,1,Intermediate,,6612,A,,,1,BAO_0000218,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,,,Canis lupus familiaris,CHEMBL618489,9615.0
4186,N,,,,In vivo,50588,1,Intermediate,,6613,A,,,1,BAO_0000218,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,,,Canis lupus familiaris,CHEMBL618490,9615.0
3749,N,,,,,50588,1,Intermediate,,6614,A,,,1,BAO_0000218,Half life was determined,,,,Canis lupus familiaris,CHEMBL618491,9615.0
3249,N,,,,In vivo,50588,1,Intermediate,,6615,A,,,1,BAO_0000218,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,,,Canis lupus familiaris,CHEMBL618492,9615.0
3022,N,,,,,50588,1,Intermediate,,6616,A,,,1,BAO_0000218,Half life was evaluated in dog,,,,Canis lupus familiaris,CHEMBL873354,9615.0
3749,N,,,,,50588,1,Intermediate,,6617,A,,,1,BAO_0000218,Half life was determined,,,,Canis lupus familiaris,CHEMBL618493,9615.0
2517,N,,,,In vivo,50588,1,Intermediate,,6618,A,,,1,BAO_0000218,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,,Canis lupus familiaris,CHEMBL618494,9615.0
2517,N,,,,In vivo,50588,1,Intermediate,,6619,A,Heart,,1,BAO_0000218,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,948.0,Canis lupus familiaris,CHEMBL618495,9615.0
2517,N,,,,In vivo,50588,1,Intermediate,,6620,A,Kidney,,1,BAO_0000218,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,2113.0,Canis lupus familiaris,CHEMBL618496,9615.0
2517,N,,,,In vivo,50588,1,Intermediate,,6621,A,Liver,,1,BAO_0000218,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,2107.0,Canis lupus familiaris,CHEMBL618497,9615.0
2517,N,,,,In vivo,50588,1,Intermediate,,6622,A,Lung,,1,BAO_0000218,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,2048.0,Canis lupus familiaris,CHEMBL618498,9615.0
2517,N,,,,In vivo,50588,1,Intermediate,,6623,A,Spleen,,1,BAO_0000218,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),,,2106.0,Canis lupus familiaris,CHEMBL618499,9615.0
3639,N,,,,,50588,1,Intermediate,,6624,A,,,1,BAO_0000218,LogP in dog,,,,Canis lupus familiaris,CHEMBL876736,9615.0
6227,N,,,,,50588,1,Intermediate,,6625,A,,,1,BAO_0000218,Partition coefficient (logP),,,,Canis lupus familiaris,CHEMBL618500,9615.0
6227,N,,,,,50588,1,Intermediate,,6626,A,,,1,BAO_0000218,Partition coefficient in dog,,,,Canis lupus familiaris,CHEMBL857831,9615.0
17764,N,,,,In vivo,50588,1,Intermediate,,6627,A,,,1,BAO_0000218,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,,,Canis lupus familiaris,CHEMBL618501,9615.0
4809,N,,,,In vivo,50588,1,Intermediate,,6628,A,,,1,BAO_0000218,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,,,Canis lupus familiaris,CHEMBL618502,9615.0
5600,N,,,,,50588,1,Intermediate,,6629,A,,,1,BAO_0000218,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,,,Canis lupus familiaris,CHEMBL618503,9615.0
14294,N,,,,,50588,1,Intermediate,,6630,A,,,1,BAO_0000218,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,,,Canis lupus familiaris,CHEMBL618504,9615.0
14294,N,,,,,50588,1,Intermediate,,6631,A,,,1,BAO_0000218,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,,,Canis lupus familiaris,CHEMBL618505,9615.0
14294,N,,,,,50588,1,Intermediate,,6632,A,,,1,BAO_0000218,Metabolism of compound in dog S9 microsomes; Trace,,,,Canis lupus familiaris,CHEMBL618506,9615.0
6251,N,,,,,50588,1,Intermediate,,6633,A,Liver,,1,BAO_0000218,In vitro metabolic potential in dog liver microsomes,,,2107.0,Canis lupus familiaris,CHEMBL618507,9615.0
3748,N,,,,In vivo,50588,1,Intermediate,,6634,A,,,1,BAO_0000218,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,,,Canis lupus familiaris,CHEMBL876737,9615.0
2713,N,,,,In vivo,50588,1,Intermediate,,6635,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL618508,9615.0
6512,N,,,,In vivo,50588,1,Intermediate,,6636,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL618509,9615.0
6679,N,,,,In vivo,50588,1,Intermediate,,6637,A,,,1,BAO_0000218,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,,Canis lupus familiaris,CHEMBL618510,9615.0
3749,N,,,,In vivo,50588,1,Intermediate,,6638,A,,,1,BAO_0000218,The compound was tested for bioavailability in dogs,,,,Canis lupus familiaris,CHEMBL618511,9615.0
3749,N,,,,In vivo,50588,1,Intermediate,,6639,A,,,1,BAO_0000218,The compound was tested for oral bioavailability in dogs,,,,Canis lupus familiaris,CHEMBL618512,9615.0
6742,N,,,,In vivo,50588,1,Intermediate,,6640,A,,,1,BAO_0000218,Oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL618513,9615.0
6227,N,,,,,50588,1,Intermediate,,6641,A,,,1,BAO_0000218,Compound was tested for percent protein binding (PB) in dog,,,,Canis lupus familiaris,CHEMBL618514,9615.0
6874,N,,,,,50588,1,Intermediate,,6642,A,,,1,BAO_0000218,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,,,Canis lupus familiaris,CHEMBL620052,9615.0
2877,N,,,,In vivo,50588,1,Intermediate,,6643,A,Plasma,,1,BAO_0000218,Compound was evaluated for plasma clearance.,,,1969.0,Canis lupus familiaris,CHEMBL620053,9615.0
12500,N,,,,In vivo,50588,1,Intermediate,,6644,A,Plasma,,1,BAO_0000218,The compound was tested for plasma clearance in dog,,,1969.0,Canis lupus familiaris,CHEMBL620054,9615.0
12500,N,,,,In vivo,50588,1,Intermediate,,6645,A,Plasma,,1,BAO_0000218,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,,,1969.0,Canis lupus familiaris,CHEMBL620055,9615.0
4709,N,,,,,50588,1,Intermediate,,6646,A,,,1,BAO_0000218,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL620056,9615.0
5542,N,,,,,50588,1,Intermediate,,6647,A,Liver,,1,BAO_0000218,In vitro relative rate of metabolism was determined in dog liver microsomes,,,2107.0,Canis lupus familiaris,CHEMBL620057,9615.0
17594,N,,,,In vivo,50588,1,Intermediate,,6648,A,,,1,BAO_0000218,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,,,Canis lupus familiaris,CHEMBL618939,9615.0
2652,N,,,,In vivo,50588,1,Intermediate,,6649,A,,,1,BAO_0000218,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,,,Canis lupus familiaris,CHEMBL618940,9615.0
17764,N,,,,In vivo,50588,1,Intermediate,,6650,A,,,1,BAO_0000218,Half life after intravenous administration in dogs at 1.2 uM/kg,,,,Canis lupus familiaris,CHEMBL618941,9615.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6651,A,Lung,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,42.0,,2048.0,Mus musculus,CHEMBL624473,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6652,A,Lung,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,42.0,,2048.0,Mus musculus,CHEMBL624474,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6653,A,Lung,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,42.0,,2048.0,Mus musculus,CHEMBL624475,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6654,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,42.0,,,Mus musculus,CHEMBL624476,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6655,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,42.0,,,Mus musculus,CHEMBL623478,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6656,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,42.0,,,Mus musculus,CHEMBL623479,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6657,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,42.0,,,Mus musculus,CHEMBL623480,10090.0
6599,N,,,CCRF S-180,,50594,1,Intermediate,,6658,A,,,1,BAO_0000218,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,42.0,,,Mus musculus,CHEMBL623481,10090.0
17641,N,,,,,50594,1,Intermediate,,6659,A,Brain,,1,BAO_0000218,C2 in brain of mice at the oral dose of 50 mg/kg,,,955.0,Mus musculus,CHEMBL623482,10090.0
17641,N,,,,,50594,1,Intermediate,,6660,A,Kidney,,1,BAO_0000218,C2 in kidney of mice at the oral dose of 50 mg/kg,,,2113.0,Mus musculus,CHEMBL623483,10090.0
17641,N,,,,,50594,1,Intermediate,,6661,A,Liver,,1,BAO_0000218,C2 in liver of mice at the oral dose of 50 mg/kg,,,2107.0,Mus musculus,CHEMBL623484,10090.0
17641,N,,,,,50594,1,Intermediate,,6662,A,Lung,,1,BAO_0000218,C2 in lungs of mice at the oral dose of 50 mg/kg,,,2048.0,Mus musculus,CHEMBL623485,10090.0
17641,N,,,,,50594,1,Intermediate,,6663,A,Spleen,,1,BAO_0000218,C2 in spleen of mice at the oral dose of 50 mg/kg,,,2106.0,Mus musculus,CHEMBL623486,10090.0
17852,N,,,,In vivo,50594,1,Intermediate,,6664,A,,,1,BAO_0000218,Plasma clearance in mouse,,,,Mus musculus,CHEMBL623487,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,6665,A,,,1,BAO_0000218,Clearance of compound after intravenous administration in mice at 24 uM/kg,,,,Mus musculus,CHEMBL623488,10090.0
17837,N,,,,In vivo,50594,1,Intermediate,,6666,A,,,1,BAO_0000218,Clearance from mouse blood following i.v. administration of 10 mg/kg,,,,Mus musculus,CHEMBL623489,10090.0
2675,N,,,,In vivo,50594,1,Intermediate,,6667,A,,,1,BAO_0000218,Clearance was evaluated in mice after intravenous administration,,,,Mus musculus,CHEMBL875157,10090.0
2675,N,,,,In vivo,50594,1,Intermediate,,6668,A,,,1,BAO_0000218,Clearance was evaluated in mice after oral administration,,,,Mus musculus,CHEMBL623490,10090.0
4239,N,,,,In vivo,50594,1,Intermediate,,6669,A,,,1,BAO_0000218,Pharmacokinetic property (Plasma clearance) was measured in mouse,,,,Mus musculus,CHEMBL623491,10090.0
17753,N,,,,In vivo,50594,1,Intermediate,,6670,A,,,1,BAO_0000218,Plasma clearance of compound was determined at 40 mg/Kg,,,,Mus musculus,CHEMBL623492,10090.0
17753,N,,,,In vivo,50594,1,Intermediate,,6671,A,,,1,BAO_0000218,Plasma clearance of at 24 mg/Kg,,,,Mus musculus,CHEMBL623493,10090.0
17753,N,,,,In vivo,50594,1,Intermediate,,6672,A,,,1,BAO_0000218,Plasma clearance at 24 mg/Kg,,,,Mus musculus,CHEMBL623494,10090.0
17753,N,,,,In vivo,50594,1,Intermediate,,6673,A,,,1,BAO_0000218,Plasma clearance at 5 mg/Kg,,,,Mus musculus,CHEMBL623495,10090.0
5727,N,,,,In vivo,50594,1,Intermediate,,6674,A,,,1,BAO_0000218,Plasma clearance in mice,,,,Mus musculus,CHEMBL623496,10090.0
2862,N,,,,In vivo,50594,1,Intermediate,,6675,A,,,1,BAO_0000218,Plasma clearance value upon iv administration in mouse,,,,Mus musculus,CHEMBL623497,10090.0
5980,N,,,,In vivo,50594,1,Intermediate,,6676,A,Plasma,,1,BAO_0000218,Total plasma clearance in mice,,,1969.0,Mus musculus,CHEMBL623498,10090.0
17592,N,,,,In vivo,50594,1,Intermediate,,6677,A,,,1,BAO_0000218,Clearance in mouse,,,,Mus musculus,CHEMBL623499,10090.0
17718,N,,,,In vivo,50594,1,Intermediate,,6678,A,,,1,BAO_0000218,Clearance value was determined,,,,Mus musculus,CHEMBL623500,10090.0
16597,N,,,,In vivo,50594,1,Intermediate,,6679,A,,,1,BAO_0000218,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,,,Mus musculus,CHEMBL623501,10090.0
17384,U,,,,,22229,0,Intermediate,,6680,P,,,1,BAO_0000100,Calculated partition coefficient (clogP),,,,,CHEMBL875158,
6062,N,,,,In vivo,50594,1,Intermediate,,6681,A,,,1,BAO_0000218,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,,,Mus musculus,CHEMBL623502,10090.0
17734,N,,,,In vivo,50594,1,Intermediate,,6682,A,,,1,BAO_0000218,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,,,Mus musculus,CHEMBL623503,10090.0
6348,N,,,,In vivo,50594,1,Intermediate,,6683,A,,,1,BAO_0000218,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,,Mus musculus,CHEMBL623504,10090.0
5969,N,,,,In vivo,50594,1,Intermediate,,6684,A,,,1,BAO_0000218,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,,,Mus musculus,CHEMBL623505,10090.0
5969,N,,,,In vivo,50594,1,Intermediate,,6685,A,,,1,BAO_0000218,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,,,Mus musculus,CHEMBL623506,10090.0
5969,N,,,,In vivo,50594,1,Intermediate,,6686,A,,,1,BAO_0000218,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,,,Mus musculus,CHEMBL623507,10090.0
16597,N,,,,In vivo,50594,1,Intermediate,,6687,A,,,1,BAO_0000218,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,,,Mus musculus,CHEMBL623508,10090.0
5781,N,,,,In vivo,50594,1,Intermediate,,6688,A,,,1,BAO_0000218,Cmax after oral administration at 30 mg/kg in ICR mouse,,,,Mus musculus,CHEMBL623509,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,6689,A,,,1,BAO_0000218,Cmax after peroral administration in mice at 2.4 uM/kg,,,,Mus musculus,CHEMBL875159,10090.0
17641,N,,,,In vivo,50594,1,Intermediate,,6690,A,Brain,,1,BAO_0000218,Cmax in brain of mice at the oral dose of 50 mg/kg,,,955.0,Mus musculus,CHEMBL623510,10090.0
17641,N,,,,In vivo,50594,1,Intermediate,,6691,A,Kidney,,1,BAO_0000218,Cmax in kidney of mice at the oral dose of 50 mg/kg,,,2113.0,Mus musculus,CHEMBL623511,10090.0
17641,N,,,,In vivo,50594,1,Intermediate,,6692,A,Liver,,1,BAO_0000218,Cmax in liver of mice at the oral dose of 50 mg/kg,,,2107.0,Mus musculus,CHEMBL623512,10090.0
17641,N,,,,In vivo,50594,1,Intermediate,,6693,A,Lung,,1,BAO_0000218,Cmax in lungs of mice at the oral dose of 50 mg/kg,,,2048.0,Mus musculus,CHEMBL623513,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,6694,F,,,1,BAO_0000218,Cmax in mice at 18 uM/kg i.p. administration,,,,Mus musculus,CHEMBL623514,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,6695,F,,,1,BAO_0000218,Cmax in mice at 23 uM/kg i.v. administration,,,,Mus musculus,CHEMBL622609,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,6696,F,,,1,BAO_0000218,Cmax in mice at 24 uM/kg i.p. administration,,,,Mus musculus,CHEMBL622610,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,6697,F,,,1,BAO_0000218,Cmax in mice at 25 uM/kg i.p. administration,,,,Mus musculus,CHEMBL621823,10090.0
17764,N,,,,In vivo,50594,1,Intermediate,,6698,F,,,1,BAO_0000218,Cmax in mice at 26 uM/kg i.p. administration,,,,Mus musculus,CHEMBL621824,10090.0
17641,N,,,,In vivo,50594,1,Intermediate,,6699,A,Spleen,,1,BAO_0000218,Cmax in spleen of mice at the oral dose of 50 mg/kg,,,2106.0,Mus musculus,CHEMBL621825,10090.0
16597,N,,,,In vivo,50594,1,Intermediate,,6700,A,,,1,BAO_0000218,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,,,Mus musculus,CHEMBL621826,10090.0
16597,N,,,,In vivo,50594,1,Intermediate,,6701,A,,,1,BAO_0000218,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,,,Mus musculus,CHEMBL621827,10090.0
5727,N,,,,In vivo,50594,1,Intermediate,,6702,A,,,1,BAO_0000218,Cmax value was determined,,,,Mus musculus,CHEMBL621828,10090.0
5951,N,,,,In vivo,50594,1,Intermediate,,6703,A,,,1,BAO_0000218,Cmax value in IRC mice,,,,Mus musculus,CHEMBL621829,10090.0
5506,N,,,,In vivo,50594,1,Intermediate,,6704,A,,,1,BAO_0000218,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,,,Mus musculus,CHEMBL621830,10090.0
5506,N,,,,In vivo,50594,1,Intermediate,,6705,A,,,1,BAO_0000218,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,,,Mus musculus,CHEMBL621831,10090.0
14239,N,,,,In vivo,50594,1,Intermediate,,6706,A,Plasma,,1,BAO_0000218,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,,1969.0,Mus musculus,CHEMBL621832,10090.0
4890,N,,,,In vivo,50594,1,Intermediate,,6707,A,Plasma,,1,BAO_0000218,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",,,1969.0,Mus musculus,CHEMBL624579,10090.0
429,N,,,,In vivo,50594,1,Intermediate,,6708,A,,,1,BAO_0000218,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,,,Mus musculus,CHEMBL624580,10090.0
10986,N,,,,,50535,1,Intermediate,,6709,F,,,1,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,,,Acanthocheilonema viteae,CHEMBL624581,6277.0
10986,N,,,,,50535,1,Intermediate,,6710,F,,,1,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,,,Acanthocheilonema viteae,CHEMBL624582,6277.0
10986,N,,,,,50535,1,Intermediate,,6711,F,,,1,BAO_0000218,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,,,Acanthocheilonema viteae,CHEMBL624583,6277.0
13227,N,,,A-375,,80018,1,Intermediate,,6712,F,,,1,BAO_0000219,Inhibitory activity against human tumor cell line A0375 melanoma.,455.0,,,Homo sapiens,CHEMBL624584,9606.0
4481,D,,,,,12512,9,Expert,Brain membranes,6713,B,,,1,BAO_0000249,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,,,Rattus norvegicus,CHEMBL624585,10116.0
16931,D,,,,,114,9,Expert,,6714,F,,,1,BAO_0000019,Forskolin-induced cAMP production at human A1 adenosine receptor,,,,Homo sapiens,CHEMBL875165,9606.0
3850,H,,,CHO,,114,8,Autocuration,,6715,F,,,1,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,449.0,,,,CHEMBL619490,
3850,H,,,CHO,,114,8,Autocuration,,6716,F,,,1,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,449.0,,,,CHEMBL619491,
3850,H,,,CHO,,114,8,Expert,,6717,F,,,1,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,449.0,,,,CHEMBL619492,
3850,H,,,CHO,,114,8,Expert,,6718,F,,,1,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,449.0,,,,CHEMBL619493,
3850,H,,,CHO,,114,8,Autocuration,,6719,F,,,1,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,449.0,,,,CHEMBL619494,
3850,H,,,CHO,,114,8,Autocuration,,6720,F,,,1,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,449.0,,,,CHEMBL619495,
3850,H,,,CHO,,114,8,Autocuration,,6721,F,,,1,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,449.0,,,,CHEMBL619496,
3850,D,,,CHO,,114,9,Expert,,6722,F,,,1,BAO_0000219,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,449.0,,,Homo sapiens,CHEMBL619497,9606.0
3850,H,,,CHO,,114,8,Autocuration,,6723,F,,,1,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,449.0,,,,CHEMBL619498,
3850,H,,,CHO,,114,8,Autocuration,,6724,F,,,1,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,449.0,,,,CHEMBL619499,
3850,H,,,CHO,,114,8,Expert,,6725,F,,,1,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,449.0,,,,CHEMBL619500,
3850,H,,,CHO,,114,8,Autocuration,,6726,F,,,1,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,449.0,,,,CHEMBL619501,
3850,H,,,CHO,,114,8,Expert,,6727,F,,,1,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,449.0,,,,CHEMBL619502,
3850,H,,,CHO,,114,8,Autocuration,,6728,F,,,1,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,449.0,,,,CHEMBL619503,
3850,H,,,CHO,,114,8,Autocuration,,6729,F,,,1,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,449.0,,,,CHEMBL619504,
3850,H,,,CHO,,114,8,Autocuration,,6730,F,,,1,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,449.0,,,,CHEMBL621298,
3850,H,,,CHO,,114,8,Expert,,6731,F,,,1,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,449.0,,,,CHEMBL621299,
3850,H,,,CHO,,114,8,Autocuration,,6732,F,,,1,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,449.0,,,,CHEMBL621300,
3850,H,,,CHO,,114,8,Autocuration,,6733,F,,,1,BAO_0000219,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,449.0,,,,CHEMBL621301,
3850,H,,,CHO,,114,8,Expert,,6734,F,,,1,BAO_0000219,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,449.0,,,,CHEMBL621302,
12680,N,,,A10,,80013,1,Intermediate,,6735,F,,,1,BAO_0000219,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,164.0,,,Oryctolagus cuniculus,CHEMBL621303,9986.0
1313,U,,,A10,,22226,0,Autocuration,,6736,F,,,1,BAO_0000219,In vitro potassium channel opening activity in A10 (smooth muscle) cells,164.0,,,Rattus norvegicus,CHEMBL621304,10116.0
1313,U,,,A10,,22226,0,Autocuration,,6737,F,,,1,BAO_0000219,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,164.0,,,Rattus norvegicus,CHEMBL621305,10116.0
17567,N,,,A10,,80013,1,Intermediate,,6738,F,,,1,BAO_0000219,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,164.0,,,Rattus norvegicus,CHEMBL621306,10116.0
17567,N,,,A10,,80013,1,Intermediate,,6739,F,,,1,BAO_0000219,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,164.0,,,Rattus norvegicus,CHEMBL618444,10116.0
11819,N,,,A10,,80013,1,Intermediate,,6740,F,,,1,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,164.0,,,Rattus norvegicus,CHEMBL618445,10116.0
13436,N,,,CHO-AA8,,80089,1,Intermediate,,6741,F,,,1,BAO_0000219,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,185.0,,,Cricetulus griseus,CHEMBL618446,10029.0
12687,N,,,CHO-AA8,,80089,1,Intermediate,,6742,F,,,1,BAO_0000219,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,185.0,,,Cricetulus griseus,CHEMBL618447,10029.0
12651,N,,,CHO-AA8,,80089,1,Intermediate,,6743,F,,,1,BAO_0000219,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,185.0,,,Cricetulus griseus,CHEMBL618448,10029.0
13300,N,,,CHO-AA8,,80089,1,Intermediate,,6744,F,,,1,BAO_0000219,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,185.0,,,Cricetulus griseus,CHEMBL618449,10029.0
15296,N,,,CHO-AA8,,80089,1,Intermediate,,6745,F,,,1,BAO_0000219,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,185.0,,,Cricetulus griseus,CHEMBL618637,10029.0
15328,N,,,CHO-AA8,,80089,1,Intermediate,,6746,F,,,1,BAO_0000219,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",185.0,,,Cricetulus griseus,CHEMBL618638,10029.0
13302,N,,,CHO-AA8,,80089,1,Intermediate,,6747,F,,,1,BAO_0000219,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),185.0,,,Cricetulus griseus,CHEMBL618639,10029.0
14367,N,,,CHO-AA8,,80089,1,Expert,,6748,F,,,1,BAO_0000219,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",185.0,,,Cricetulus griseus,CHEMBL618640,10029.0
17002,N,,,CHO-AA8,,80089,1,Expert,,6749,F,,,1,BAO_0000219,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,185.0,,,Cricetulus griseus,CHEMBL618641,10029.0
13436,N,,,CHO-AA8,,80089,1,Intermediate,,6750,F,,,1,BAO_0000219,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,185.0,,,Cricetulus griseus,CHEMBL618642,10029.0
13435,N,,,CHO-AA8,,80089,1,Intermediate,,6751,F,,,1,BAO_0000219,Inhibitory activity against aerobic growth of AA8 cells.,185.0,,,Cricetulus griseus,CHEMBL618643,10029.0
10503,N,,,CHO-AA8,,80089,1,Intermediate,,6752,A,,,1,BAO_0000219,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,185.0,,,Cricetulus griseus,CHEMBL884013,10029.0
10503,N,,,CHO-AA8,,80089,1,Expert,,6753,F,,,1,BAO_0000219,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,185.0,,,Cricetulus griseus,CHEMBL622723,10029.0
10503,N,,,CHO-AA8,,80089,1,Intermediate,,6754,F,,,1,BAO_0000219,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,185.0,,,Cricetulus griseus,CHEMBL622724,10029.0
15090,N,,,CHO-AA8,,80089,1,Expert,,6755,F,,,1,BAO_0000219,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,185.0,,,Cricetulus griseus,CHEMBL622725,10029.0
10368,N,,,CHO-AA8,,80089,1,Expert,,6756,F,,,1,BAO_0000219,Cytotoxicity against AA8 cell line,185.0,,,Cricetulus griseus,CHEMBL622726,10029.0
12651,N,,,CHO-AA8,,80089,1,Intermediate,,6757,F,,,1,BAO_0000219,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),185.0,,,Cricetulus griseus,CHEMBL622727,10029.0
12687,N,,,CHO-AA8,,80089,1,Intermediate,,6758,A,,,1,BAO_0000219,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),185.0,,,Cricetulus griseus,CHEMBL622728,10029.0
12687,N,,,CHO-AA8,,80089,1,Intermediate,,6759,F,,,1,BAO_0000219,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),185.0,,,Cricetulus griseus,CHEMBL622729,10029.0
12687,N,,,CHO-AA8,,80089,1,Intermediate,,6760,A,,,1,BAO_0000219,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),185.0,,,Cricetulus griseus,CHEMBL622730,10029.0
1890,N,,,CHO-AA8,,80089,1,Intermediate,,6761,F,,,1,BAO_0000219,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,185.0,,,Cricetulus griseus,CHEMBL622731,10029.0
10747,N,,,CHO-AA8,,80089,1,Intermediate,,6762,F,,,1,BAO_0000219,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,185.0,,,Cricetulus griseus,CHEMBL622732,10029.0
10747,N,,,CHO-AA8,,80089,1,Intermediate,,6763,F,,,1,BAO_0000219,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,185.0,,,Cricetulus griseus,CHEMBL622733,10029.0
11616,U,,,,,22224,0,Autocuration,,6764,F,,,1,BAO_0000218,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,,,Cricetulus griseus,CHEMBL622734,10029.0
11616,N,,,CHO-AA8,,80089,1,Expert,,6765,F,,,1,BAO_0000219,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,185.0,,,Cricetulus griseus,CHEMBL622735,10029.0
3471,U,,,CHO-AA8,,22224,0,Autocuration,,6766,F,,,1,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,185.0,,,Cricetulus griseus,CHEMBL618746,10029.0
3471,U,,,CHO-AA8,,22224,0,Autocuration,,6767,F,,,1,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,185.0,,,Cricetulus griseus,CHEMBL618747,10029.0
3471,U,,,CHO-AA8,,22224,0,Autocuration,,6768,F,,,1,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,185.0,,,Cricetulus griseus,CHEMBL620540,10029.0
3471,U,,,CHO-AA8,,22224,0,Autocuration,,6769,F,,,1,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,185.0,,,Cricetulus griseus,CHEMBL620541,10029.0
3471,U,,,CHO-AA8,,22224,0,Autocuration,,6770,F,,,1,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,185.0,,,Cricetulus griseus,CHEMBL620542,10029.0
3471,U,,,CHO-AA8,,22224,0,Autocuration,,6771,F,,,1,BAO_0000219,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,185.0,,,Cricetulus griseus,CHEMBL620543,10029.0
3471,U,,,CHO-AA8,,22224,0,Autocuration,,6772,F,,,1,BAO_0000219,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,185.0,,,Cricetulus griseus,CHEMBL618832,10029.0
11616,N,,,CHO-AA8,,80089,1,Expert,,6773,F,,,1,BAO_0000219,Concentration required to reduce AA8 cell survival by 10%,185.0,,,Cricetulus griseus,CHEMBL618833,10029.0
2656,U,,,CHO-AA8,,22224,0,Autocuration,,6774,F,,,1,BAO_0000219,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",185.0,,,Cricetulus griseus,CHEMBL618834,10029.0
10518,U,,,CHO-AA8,,22224,0,Autocuration,,6775,F,,,1,BAO_0000219,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,185.0,,,Cricetulus griseus,CHEMBL618835,10029.0
10518,U,,,CHO-AA8,,22224,0,Autocuration,,6776,F,,,1,BAO_0000219,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,185.0,,,Cricetulus griseus,CHEMBL618836,10029.0
10518,U,,,CHO-AA8,,22224,0,Autocuration,,6777,F,,,1,BAO_0000219,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,185.0,,,Cricetulus griseus,CHEMBL618837,10029.0
10518,U,,,CHO-AA8,,22224,0,Autocuration,,6778,F,,,1,BAO_0000219,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,185.0,,,Cricetulus griseus,CHEMBL618838,10029.0
16156,U,,,CHO-AA8,,22224,0,Autocuration,,6779,F,,,1,BAO_0000219,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,185.0,,,Cricetulus griseus,CHEMBL618839,10029.0
2656,U,,,CHO-AA8,,22224,0,Autocuration,,6780,F,,,1,BAO_0000219,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,185.0,,,Cricetulus griseus,CHEMBL618840,10029.0
11005,U,,,,,22224,0,Autocuration,,6781,F,,,1,BAO_0000019,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,,,Cricetulus griseus,CHEMBL618841,10029.0
11942,U,,,CHO-AA8,,22224,0,Autocuration,,6782,F,,,1,BAO_0000219,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,185.0,,,Cricetulus griseus,CHEMBL618842,10029.0
2128,U,,,CHO-AA8,,22224,0,Autocuration,,6783,F,,,1,BAO_0000219,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,185.0,,,Cricetulus griseus,CHEMBL618843,10029.0
16907,N,,,,In vivo,50588,1,Intermediate,,6784,A,,,1,BAO_0000218,Half life period after 15 mg/kg iv dose in Dogs,,,,Canis lupus familiaris,CHEMBL618844,9615.0
16907,N,,,,In vivo,50588,1,Intermediate,,6785,A,,,1,BAO_0000218,Half life period after 30 mg/kg po dose in Dogs,,,,Canis lupus familiaris,CHEMBL618845,9615.0
9579,N,,,,In vivo,50588,1,Intermediate,,6786,A,,,1,BAO_0000218,Half life was measured after oral 2b administration (tested in 6 dogs),,,,Canis lupus familiaris,CHEMBL618846,9615.0
9579,N,,,,In vivo,50588,1,Intermediate,,6787,A,,,1,BAO_0000218,Half life was measured in dog after oral 17b administration,,,,Canis lupus familiaris,CHEMBL618847,9615.0
9579,N,,,,In vivo,50588,1,Intermediate,,6788,A,,,1,BAO_0000218,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,,,Canis lupus familiaris,CHEMBL618848,9615.0
9579,N,,,,In vivo,50588,1,Intermediate,,6789,A,,,1,BAO_0000218,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,,,Canis lupus familiaris,CHEMBL618849,9615.0
16907,N,,,,In vivo,50588,1,Intermediate,,6790,A,,,1,BAO_0000218,Tmax value after 15 mg/kg iv dose in Dogs,,,,Canis lupus familiaris,CHEMBL618850,9615.0
16907,N,,,,In vivo,50588,1,Intermediate,,6791,A,,,1,BAO_0000218,Tmax value after 30 mg/kg po dose in Dogs,,,,Canis lupus familiaris,CHEMBL618851,9615.0
3184,N,,,,In vivo,50588,1,Intermediate,,6792,A,,,1,BAO_0000218,Compound was evaluated for its half life when administered intravenously in dog,,,,Canis lupus familiaris,CHEMBL873815,9615.0
5017,N,,,,In vivo,50588,1,Intermediate,,6793,A,Plasma,,1,BAO_0000218,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,,1969.0,Canis lupus familiaris,CHEMBL618852,9615.0
6821,N,,,,,50588,1,Intermediate,,6794,A,,,1,BAO_0000218,Elimination Half-life of compound was determined in dog,,,,Canis lupus familiaris,CHEMBL618853,9615.0
17839,N,,,,In vivo,50588,1,Intermediate,,6795,A,,,1,BAO_0000218,Half life of compound in dog following oral administration,,,,Canis lupus familiaris,CHEMBL618854,9615.0
17267,N,,,,,50588,1,Intermediate,,6796,A,,,1,BAO_0000218,Half life of compound was determined in dog,,,,Canis lupus familiaris,CHEMBL618855,9615.0
4727,N,,,,,50588,1,Intermediate,,6797,A,Blood,,1,BAO_0000218,Half life of compound was determined in dog blood,,,178.0,Canis lupus familiaris,CHEMBL618856,9615.0
5238,N,,,,In vivo,50588,1,Intermediate,,6798,A,,,1,BAO_0000218,Half life after oral and iv dosing in dogs,,,,Canis lupus familiaris,CHEMBL875827,9615.0
4942,N,,,,,50588,1,Intermediate,,6799,A,,,1,BAO_0000218,Half life in dogs in hours,,,,Canis lupus familiaris,CHEMBL618857,9615.0
6505,N,,,,In vivo,50588,1,Intermediate,,6800,A,,,1,BAO_0000218,Half life on i.v. administration of 2 mg/kg was measured in dog,,,,Canis lupus familiaris,CHEMBL618858,9615.0
5130,N,,,,In vivo,50588,1,Intermediate,,6801,A,,,1,BAO_0000218,t1/2 in dog after oral dose (1 mg/kg),,,,Canis lupus familiaris,CHEMBL618859,9615.0
1475,N,,,,,50588,1,Intermediate,,6802,A,,,1,BAO_0000218,Half life was evaluated in dog,,,,Canis lupus familiaris,CHEMBL618860,9615.0
17804,N,,,,In vivo,50588,1,Intermediate,,6803,A,,,1,BAO_0000218,Half life period of compound was determined after intravenous administration at 2 mg/kg,,,,Canis lupus familiaris,CHEMBL618861,9615.0
17804,N,,,,In vivo,50588,1,Intermediate,,6804,A,,,1,BAO_0000218,Half life period of compound was determined after peroral administration at 2 mg/kg,,,,Canis lupus familiaris,CHEMBL622539,9615.0
6084,N,,,,In vivo,50588,1,Intermediate,,6805,A,,,1,BAO_0000218,Half life period (10 mg/kg) was determined in dog,,,,Canis lupus familiaris,CHEMBL622540,9615.0
6084,N,,,,In vivo,50588,1,Intermediate,,6806,A,,,1,BAO_0000218,Half life period (10 mg/kg) was determined in dog,,,,Canis lupus familiaris,CHEMBL873803,9615.0
5542,N,,,,In vivo,50588,1,Intermediate,,6807,A,,,1,BAO_0000218,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,,,Canis lupus familiaris,CHEMBL873804,9615.0
5542,N,,,,In vivo,50588,1,Intermediate,,6808,A,,,1,BAO_0000218,Half life period by po administration in dog at a dose of 0.3 mg/kg,,,,Canis lupus familiaris,CHEMBL624311,9615.0
6084,N,,,,,50588,1,Intermediate,,6809,A,,,1,BAO_0000218,Half life period in dog,,,,Canis lupus familiaris,CHEMBL624312,9615.0
6241,N,,,,In vivo,50588,1,Intermediate,,6810,A,,,1,BAO_0000218,Half life period in dogs after oral administration at 1 mg/kg,,,,Canis lupus familiaris,CHEMBL624313,9615.0
1916,N,,,,In vivo,50588,1,Intermediate,,6811,A,,,1,BAO_0000218,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,,Canis lupus familiaris,CHEMBL624314,9615.0
6621,N,,,,,50588,1,Intermediate,,6812,A,,,1,BAO_0000218,Half-life of compound was determined in dogs,,,,Canis lupus familiaris,CHEMBL624315,9615.0
1696,N,,,,,50588,1,Intermediate,,6813,A,Plasma,,1,BAO_0000218,Half-life in dog plasma,,,1969.0,Canis lupus familiaris,CHEMBL624316,9615.0
17800,N,,,,,50588,1,Intermediate,,6814,A,,,1,BAO_0000218,Half-life in mongrel dogs was determined,,,,Canis lupus familiaris,CHEMBL624317,9615.0
17657,N,,,,In vivo,50588,1,Intermediate,,6815,A,,,1,BAO_0000218,Half-life in dog upon oral administration,,,,Canis lupus familiaris,CHEMBL624318,9615.0
17657,N,,,,In vivo,50588,1,Intermediate,,6816,A,,,1,BAO_0000218,Half-life in dog upon oral administration; Unable to calculate,,,,Canis lupus familiaris,CHEMBL624319,9615.0
4239,N,,,,,50588,1,Intermediate,,6817,A,,,1,BAO_0000218,Half-life was measured in dog,,,,Canis lupus familiaris,CHEMBL624496,9615.0
5985,N,,,,,50588,1,Intermediate,,6818,A,,,1,BAO_0000218,Half-life was measured in dog,,,,Canis lupus familiaris,CHEMBL624497,9615.0
9932,N,,,,,50588,1,Intermediate,,6819,A,,,1,BAO_0000218,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,,,Canis lupus familiaris,CHEMBL624498,9615.0
5199,N,,,,In vivo,50588,1,Intermediate,,6820,A,,,1,BAO_0000218,Oral half life was determined,,,,Canis lupus familiaris,CHEMBL624499,9615.0
5199,N,,,,In vivo,50588,1,Intermediate,,6821,A,Plasma,,1,BAO_0000218,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,,,1969.0,Canis lupus familiaris,CHEMBL624500,9615.0
1475,N,,,,,50588,1,Intermediate,,6822,A,Plasma,,1,BAO_0000218,Plasma half life was evaluated,,,1969.0,Canis lupus familiaris,CHEMBL624501,9615.0
1475,N,,,,,50588,1,Intermediate,,6823,A,Plasma,,1,BAO_0000218,Plasma half life was evaluated in Dog,,,1969.0,Canis lupus familiaris,CHEMBL623666,9615.0
1475,N,,,,,50588,1,Intermediate,,6824,A,Plasma,,1,BAO_0000218,Plasma half life was evaluated in dog,,,1969.0,Canis lupus familiaris,CHEMBL623667,9615.0
6316,N,,,,In vivo,50588,1,Intermediate,,6825,A,,,1,BAO_0000218,T1/2 (Half-life) was after oral administration at 5 mg/kg,,,,Canis lupus familiaris,CHEMBL623668,9615.0
4883,N,,,,,50588,1,Intermediate,,6826,A,,,1,BAO_0000218,Tested for the half life value in dog,,,,Canis lupus familiaris,CHEMBL623669,9615.0
4727,N,,,,In vivo,50588,1,Intermediate,,6827,A,,,1,BAO_0000218,Maximum time at the dose of 2 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL623670,9615.0
1916,N,,,,In vivo,50588,1,Intermediate,,6828,A,,,1,BAO_0000218,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,,,Canis lupus familiaris,CHEMBL623671,9615.0
1337,N,,,,In vivo,50588,1,Intermediate,,6829,A,Blood,,1,BAO_0000218,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,178.0,Canis lupus familiaris,CHEMBL875945,9615.0
1337,N,,,,In vivo,50588,1,Intermediate,,6830,A,Blood,,1,BAO_0000218,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,178.0,Canis lupus familiaris,CHEMBL623672,9615.0
6265,N,,,,In vivo,50588,1,Intermediate,,6831,A,,,1,BAO_0000218,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL623673,9615.0
4809,N,,,,In vivo,50588,1,Intermediate,,6832,A,,,1,BAO_0000218,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,,,Canis lupus familiaris,CHEMBL623674,9615.0
5983,N,,,,In vivo,50588,1,Intermediate,,6833,A,,,1,BAO_0000218,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,,,Canis lupus familiaris,CHEMBL623675,9615.0
5313,N,,,,,50588,1,Intermediate,,6834,A,,,1,BAO_0000218,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,,,Canis lupus familiaris,CHEMBL872526,9615.0
5313,N,,,,In vivo,50588,1,Intermediate,,6835,A,,,1,BAO_0000218,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,,,Canis lupus familiaris,CHEMBL623676,9615.0
17650,N,,,,In vivo,50588,1,Intermediate,,6836,A,Plasma,,1,BAO_0000218,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,,1969.0,Canis lupus familiaris,CHEMBL623677,9615.0
5199,N,,,,In vivo,50588,1,Intermediate,,6837,A,Plasma,,1,BAO_0000218,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,,1969.0,Canis lupus familiaris,CHEMBL623678,9615.0
933,N,,,,,50588,1,Intermediate,,6838,A,Plasma,,1,BAO_0000218,Time taken for maximum plasma concentration in dog,,,1969.0,Canis lupus familiaris,CHEMBL623679,9615.0
16367,N,,,,In vivo,50588,1,Intermediate,,6839,A,,,1,BAO_0000218,Time to reach Cmax after oral administration to dogs,,,,Canis lupus familiaris,CHEMBL623680,9615.0
6348,N,,,,In vivo,50588,1,Intermediate,,6840,A,Plasma,,1,BAO_0000218,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,1969.0,Canis lupus familiaris,CHEMBL623681,9615.0
6316,N,,,,In vivo,50588,1,Intermediate,,6841,A,,,1,BAO_0000218,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,,,Canis lupus familiaris,CHEMBL623682,9615.0
6215,N,,,,In vivo,50588,1,Intermediate,,6842,A,,,1,BAO_0000218,Tmax after peroral administration (1 mg/kg) was determined in dog,,,,Canis lupus familiaris,CHEMBL623683,9615.0
3598,N,,,,In vivo,50588,1,Expert,,6843,A,,,1,BAO_0000218,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,,,Canis lupus familiaris,CHEMBL623684,9615.0
4527,N,,,,In vivo,50588,1,Intermediate,,6844,A,,,1,BAO_0000218,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,,,Canis lupus familiaris,CHEMBL622745,9615.0
17764,N,,,,In vivo,50588,1,Intermediate,,6845,A,,,1,BAO_0000218,Tmax after peroral administration in dogs at 2.4 uM/kg,,,,Canis lupus familiaris,CHEMBL622746,9615.0
5969,N,,,,In vivo,50594,1,Intermediate,,6846,A,,,1,BAO_0000218,In vivo Cmax in mice at dose of 100 mg/kg,,,,Mus musculus,CHEMBL622747,10090.0
5969,N,,,,In vivo,50594,1,Intermediate,,6847,A,,,1,BAO_0000218,In vivo Cmax in mice at dose of 50 mg/kg,,,,Mus musculus,CHEMBL622748,10090.0
4573,N,,,,In vivo,50594,1,Intermediate,,6848,A,,,1,BAO_0000218,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,,,Mus musculus,CHEMBL622749,10090.0
3277,N,,,,In vivo,50594,1,Intermediate,,6849,A,Plasma,,1,BAO_0000218,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,,1969.0,Mus musculus,CHEMBL622750,10090.0
17734,N,,,,In vivo,50594,1,Intermediate,,6850,A,Plasma,,1,BAO_0000218,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,,,1969.0,Mus musculus,CHEMBL623411,10090.0
3132,N,,,,In vivo,50594,1,Intermediate,,6851,A,Plasma,,1,BAO_0000218,Maximum concentration obtained in mouse plasma was determined,,,1969.0,Mus musculus,CHEMBL875946,10090.0
3132,N,,,,In vivo,50594,1,Intermediate,,6852,A,Plasma,,1,BAO_0000218,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,,,1969.0,Mus musculus,CHEMBL623412,10090.0
6348,N,,,,In vivo,50594,1,Intermediate,,6853,A,Plasma,,1,BAO_0000218,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,1969.0,Mus musculus,CHEMBL623413,10090.0
17729,N,,,,In vivo,50594,1,Intermediate,,6854,A,Plasma,,1,BAO_0000218,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,,,1969.0,Mus musculus,CHEMBL623414,10090.0
17729,N,,,,In vivo,50594,1,Intermediate,,6855,A,Plasma,,1,BAO_0000218,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,,,1969.0,Mus musculus,CHEMBL623415,10090.0
17729,N,,,,In vivo,50594,1,Intermediate,,6856,A,Plasma,,1,BAO_0000218,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,,,1969.0,Mus musculus,CHEMBL623416,10090.0
17728,N,,,,In vivo,50594,1,Intermediate,,6857,A,Plasma,,1,BAO_0000218,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,,,1969.0,Mus musculus,CHEMBL623417,10090.0
17728,N,,,,In vivo,50594,1,Intermediate,,6858,A,Plasma,,1,BAO_0000218,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,,,1969.0,Mus musculus,CHEMBL623418,10090.0
17728,N,,,,In vivo,50594,1,Intermediate,,6859,A,Plasma,,1,BAO_0000218,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,,,1969.0,Mus musculus,CHEMBL623419,10090.0
4066,N,,,,In vivo,50594,1,Intermediate,,6860,A,,,1,BAO_0000218,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,,,Mus musculus,CHEMBL622816,10090.0
6178,N,,,,In vivo,50594,1,Intermediate,,6861,A,,,1,BAO_0000218,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,,,Mus musculus,CHEMBL623313,10090.0
6178,N,,,,In vivo,50594,1,Intermediate,,6862,A,,,1,BAO_0000218,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,,,Mus musculus,CHEMBL623314,10090.0
3760,N,,,,In vivo,50594,1,Intermediate,,6863,A,,,1,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,,,Mus musculus,CHEMBL876788,10090.0
3760,N,,,,In vivo,50594,1,Intermediate,,6864,A,,,1,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,,,Mus musculus,CHEMBL623315,10090.0
3760,N,,,,In vivo,50594,1,Intermediate,,6865,A,,,1,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,,,Mus musculus,CHEMBL623316,10090.0
3760,N,,,,In vivo,50594,1,Intermediate,,6866,A,,,1,BAO_0000218,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,,,Mus musculus,CHEMBL623317,10090.0
5961,N,,,,In vivo,50594,1,Intermediate,,6868,A,,,1,BAO_0000218,Cmax in male mice after 2 mg/kg oral dose,,,,Mus musculus,CHEMBL623319,10090.0
6137,N,,,,In vivo,50594,1,Intermediate,,6869,A,,,1,BAO_0000218,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,,,Mus musculus,CHEMBL623320,10090.0
3802,N,,,,In vivo,50594,1,Intermediate,,6870,A,,,1,BAO_0000218,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,,,Mus musculus,CHEMBL623321,10090.0
3535,N,,,,,50594,1,Intermediate,,6871,A,,,1,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,,,Mus musculus,CHEMBL623322,10090.0
3535,N,,,,,50594,1,Intermediate,,6872,A,,,1,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,,,Mus musculus,CHEMBL623323,10090.0
3535,N,,,,,50594,1,Intermediate,,6873,A,,,1,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,,,Mus musculus,CHEMBL623324,10090.0
3535,N,,,,,50594,1,Intermediate,,6874,A,,,1,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,,,Mus musculus,CHEMBL623325,10090.0
3535,N,,,,,50594,1,Intermediate,,6875,A,,,1,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,,,Mus musculus,CHEMBL623326,10090.0
3535,N,,,,,50594,1,Intermediate,,6876,A,,,1,BAO_0000218,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,,,Mus musculus,CHEMBL623327,10090.0
2862,N,,,,,50594,1,Intermediate,,6877,A,Plasma,,1,BAO_0000218,Maximum concentration in plasma upon oral administration in mouse,,,1969.0,Mus musculus,CHEMBL623328,10090.0
2675,N,,,,,50594,1,Intermediate,,6878,A,Plasma,,1,BAO_0000218,Maximum plasma concentration was evaluated in mice after oral administration,,,1969.0,Mus musculus,CHEMBL623329,10090.0
2675,N,,,,In vivo,50594,1,Intermediate,,6879,A,Plasma,,1,BAO_0000218,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,,,1969.0,Mus musculus,CHEMBL623330,10090.0
5399,N,,,,,50594,1,Intermediate,,6880,A,,,1,BAO_0000218,Dose at which the compound induced fecal excretion in mice,,,,Mus musculus,CHEMBL876789,10090.0
11819,N,,,A10,,80013,1,Expert,,6893,F,,,1,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,164.0,,,Rattus norvegicus,CHEMBL623333,10116.0
11819,N,,,A10,,80013,1,Expert,,6894,F,,,1,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,164.0,,,Rattus norvegicus,CHEMBL623334,10116.0
11819,N,,,A10,,80013,1,Expert,,6895,F,,,1,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,164.0,,,Rattus norvegicus,CHEMBL627536,10116.0
11819,N,,,A10,,80013,1,Expert,,6896,F,,,1,BAO_0000219,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,164.0,,,Rattus norvegicus,CHEMBL627537,10116.0
16361,N,,,A10,,80013,1,Intermediate,,6897,F,,,1,BAO_0000219,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),164.0,,,Rattus norvegicus,CHEMBL627538,10116.0
2288,N,,,A121,,80655,1,Intermediate,,6898,F,,,1,BAO_0000219,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,393.0,,,Homo sapiens,CHEMBL884106,9606.0
10404,N,,,A121,,80655,1,Intermediate,,6899,F,,,1,BAO_0000219,Anticancer activity against human ovarian carcinoma A121 cells,393.0,,,Homo sapiens,CHEMBL625294,9606.0
14790,N,,,A121,,80655,1,Intermediate,,6900,F,,,1,BAO_0000219,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,393.0,,,Homo sapiens,CHEMBL625295,9606.0
14790,N,,,A121,,80655,1,Intermediate,,6901,F,,,1,BAO_0000219,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,393.0,,,Homo sapiens,CHEMBL625296,9606.0
14253,N,,,A121,,80655,1,Expert,,6902,F,,,1,BAO_0000219,Growth inhibition of human ovarian carcinoma (A121) cell line,393.0,,,Homo sapiens,CHEMBL625297,9606.0
13617,N,,,A121,,80655,1,Expert,,6903,F,,,1,BAO_0000219,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,393.0,,,Homo sapiens,CHEMBL625298,9606.0
1003,N,,,A121,,80655,1,Intermediate,,6904,F,,,1,BAO_0000219,Cytotoxicity against human A121 ovarian cells,393.0,,,Homo sapiens,CHEMBL625960,9606.0
830,N,,,A121,,80655,1,Intermediate,,6905,F,,,1,BAO_0000219,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,393.0,,,Homo sapiens,CHEMBL625961,9606.0
12307,N,,,A121,,80655,1,Intermediate,,6906,F,,,1,BAO_0000219,In vitro cytotoxicity against human ovarian carcinoma A21,393.0,,,Homo sapiens,CHEMBL625962,9606.0
14254,N,,,A121,,80655,1,Intermediate,,6907,F,,,1,BAO_0000219,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,393.0,,,Homo sapiens,CHEMBL624717,9606.0
13370,N,,,A121,,80655,1,Intermediate,,6908,F,,,1,BAO_0000219,Inhibitory activity of compound against human A121 ovarian cell line.,393.0,,,Homo sapiens,CHEMBL624718,9606.0
14790,N,,,A121,,80655,1,Intermediate,,6909,F,,,1,BAO_0000219,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,393.0,,,Homo sapiens,CHEMBL624719,9606.0
3614,N,,,A121,,80655,1,Intermediate,,6910,F,,,1,BAO_0000219,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,393.0,,,Homo sapiens,CHEMBL624720,9606.0
2664,N,,,A 172,,80012,1,Intermediate,,6911,F,,,1,BAO_0000219,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,622.0,,,Homo sapiens,CHEMBL624721,9606.0
2037,N,,,A 172,,80012,1,Expert,,6912,F,,,1,BAO_0000219,In vitro cytotoxicity against A172 human tumor cell lines.,622.0,,,Homo sapiens,CHEMBL624722,9606.0
14539,N,,,A 172,,80012,1,Intermediate,,6913,F,,,1,BAO_0000219,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,622.0,,,Homo sapiens,CHEMBL877597,9606.0
2836,N,,,A 172,,80012,1,Intermediate,,6914,F,,,1,BAO_0000219,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,622.0,,,Homo sapiens,CHEMBL624723,9606.0
10708,N,,,A 172,,80012,1,Intermediate,,6915,F,,,1,BAO_0000219,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,622.0,,,Homo sapiens,CHEMBL624724,9606.0
8975,H,,,,,104729,4,Autocuration,,6916,B,,,1,BAO_0000224,Association constant against A2 adenosine receptor,,,,Canis lupus familiaris,CHEMBL624725,9615.0
7645,N,,,A2,,80656,1,Intermediate,,6917,F,,,1,BAO_0000219,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,1085.0,,,fish,CHEMBL624726,
11377,D,,,,,104713,5,Autocuration,,6918,B,,,1,BAO_0000224,Ratio of Ki for adenosine A2 and A1 receptor binding,,,,Rattus norvegicus,CHEMBL857535,10116.0
13528,N,,,A204,,80014,1,Expert,,6919,F,,,1,BAO_0000219,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,623.0,,,Homo sapiens,CHEMBL624727,9606.0
10160,N,,,A204,,80014,1,Expert,,6920,F,,,1,BAO_0000219,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,623.0,,,Homo sapiens,CHEMBL624728,9606.0
15144,N,,,A2058,,80015,1,Intermediate,,6921,F,,,1,BAO_0000219,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,404.0,,,Homo sapiens,CHEMBL624729,9606.0
13160,N,,,A253 cell line,,80657,1,Intermediate,,6922,F,,,1,BAO_0000219,Growth inhibition against Human squamous cell line(A 253),973.0,,,Homo sapiens,CHEMBL624730,9606.0
12898,N,,,A253 cell line,,80657,1,Intermediate,,6923,F,,,1,BAO_0000219,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,973.0,,,Homo sapiens,CHEMBL624731,9606.0
13069,N,,,A253 cell line,,80657,1,Intermediate,,6924,F,,,1,BAO_0000219,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,973.0,,,Homo sapiens,CHEMBL624732,9606.0
15984,N,,,A253 cell line,,80657,1,Intermediate,,6925,F,,,1,BAO_0000219,Growth inhibition of A253 cell lines.,973.0,,,Homo sapiens,CHEMBL883245,9606.0
15564,N,,,A253 cell line,,80657,1,Intermediate,,6926,F,,,1,BAO_0000219,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),973.0,,,Homo sapiens,CHEMBL624733,9606.0
15564,N,,,A253 cell line,,80657,1,Intermediate,,6927,F,,,1,BAO_0000219,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,973.0,,,Homo sapiens,CHEMBL624734,9606.0
15564,N,,,A253 cell line,,80657,1,Intermediate,,6928,F,,,1,BAO_0000219,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,973.0,,,Homo sapiens,CHEMBL624735,9606.0
4720,N,,,A2780,,81034,1,Intermediate,,6929,F,,,1,BAO_0000219,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,478.0,,,Homo sapiens,CHEMBL621780,9606.0
16112,N,,,A2780,,81034,1,Intermediate,,6930,F,,,1,BAO_0000219,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,478.0,,,Homo sapiens,CHEMBL877598,9606.0
16597,N,,,A2780,,81034,1,Expert,,6931,F,,,1,BAO_0000219,Cytotoxic activity against A2780 human ovarian carcinoma cell line,478.0,,,Homo sapiens,CHEMBL621781,9606.0
16378,N,,,A2780,,81034,1,Intermediate,,6932,F,,,1,BAO_0000219,Cytotoxicity against human cancer cell lines A2780 (ovarian),478.0,,,Homo sapiens,CHEMBL621782,9606.0
16085,N,,,A2780,,81034,1,Expert,,6933,F,,,1,BAO_0000219,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,478.0,,,Homo sapiens,CHEMBL621783,9606.0
16317,N,,,A2780,,81034,1,Intermediate,,6934,F,,,1,BAO_0000219,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,478.0,,,Homo sapiens,CHEMBL621784,9606.0
15748,N,,,A2780,,81034,1,Intermediate,,6935,F,,,1,BAO_0000219,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),478.0,,,Homo sapiens,CHEMBL621785,9606.0
16597,N,,,A2780,,81034,1,Expert,,6936,F,,,1,BAO_0000219,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,478.0,,,Homo sapiens,CHEMBL621968,9606.0
16597,N,,,A2780,,81034,1,Expert,,6937,F,,,1,BAO_0000219,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,478.0,,,Homo sapiens,CHEMBL621969,9606.0
16597,N,,,A2780,,81034,1,Expert,,6938,F,,,1,BAO_0000219,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,478.0,,,Homo sapiens,CHEMBL621970,9606.0
15608,N,,,A2780,,81034,1,Intermediate,,6939,F,,,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,478.0,,,Homo sapiens,CHEMBL621971,9606.0
15608,N,,,A2780,,81034,1,Intermediate,,6940,F,,,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,478.0,,,Homo sapiens,CHEMBL621972,9606.0
15608,N,,,A2780,,81034,1,Intermediate,,6941,F,,,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,478.0,,,Homo sapiens,CHEMBL884108,9606.0
15296,U,,,,,22224,0,Autocuration,,6942,F,,,1,BAO_0000019,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,,,Cricetulus griseus,CHEMBL623826,10029.0
10251,U,,,CHO-AA8,,22224,0,Autocuration,,6943,A,,,1,BAO_0000219,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,185.0,,,Cricetulus griseus,CHEMBL623827,10029.0
10251,U,,,CHO-AA8,,22224,0,Autocuration,,6944,F,,,1,BAO_0000219,Evaluated for growth inhibition of AA8 cells under aerobic conditions,185.0,,,Cricetulus griseus,CHEMBL623828,10029.0
10251,U,,,CHO-AA8,,22224,0,Autocuration,,6945,F,,,1,BAO_0000219,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,185.0,,,Cricetulus griseus,CHEMBL623829,10029.0
10251,U,,,CHO-AA8,,22224,0,Autocuration,,6946,F,,,1,BAO_0000219,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),185.0,,,Cricetulus griseus,CHEMBL623830,10029.0
11858,U,,,,,22224,0,Autocuration,,6947,F,,,1,BAO_0000019,Growth inhibition against CHO-derived cell line AA8,,,,Cricetulus griseus,CHEMBL623831,10029.0
11858,U,,,CHO-AA8,,22224,0,Autocuration,,6948,F,,,1,BAO_0000219,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],185.0,,,Cricetulus griseus,CHEMBL623832,10029.0
11616,N,,,CHO-AA8,,80089,1,Expert,,6949,F,,,1,BAO_0000219,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,185.0,,,hampster,CHEMBL623833,36483.0
11616,N,,,CHO-AA8,,80089,1,Expert,,6950,F,,,1,BAO_0000219,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,185.0,,,Cricetulus griseus,CHEMBL623834,10029.0
10518,U,,,CHO-AA8,,22224,0,Autocuration,,6951,F,,,1,BAO_0000219,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,185.0,,,Cricetulus griseus,CHEMBL623835,10029.0
11396,U,,,CHO-AA8,,22224,0,Autocuration,,6952,F,,,1,BAO_0000219,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,185.0,,,Cricetulus griseus,CHEMBL623836,10029.0
10518,U,,,CHO-AA8,,22224,0,Autocuration,,6953,F,,,1,BAO_0000219,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,185.0,,,Cricetulus griseus,CHEMBL623837,10029.0
11616,N,,,CHO-AA8,,80089,1,Expert,,6954,F,,,1,BAO_0000219,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,185.0,,,Cricetulus griseus,CHEMBL623838,10029.0
14837,H,,,,,12675,8,Autocuration,,6955,F,,,1,BAO_0000019,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,,,,CHEMBL623839,
14837,H,,,,,12675,8,Autocuration,,6956,F,,,1,BAO_0000019,Number of binding sites (n) of isolated serum protein AAG,,,,,CHEMBL623840,
16037,M,,,,,22222,3,Intermediate,,6957,B,,,1,BAO_0000225,Association constant for binding to AATT duplex,,,,,CHEMBL623841,
16597,N,,,ABAE,,100090,1,Expert,,6958,F,,,1,BAO_0000219,Inhibition of ABAE human fibroblast cell proliferation,416.0,,,Homo sapiens,CHEMBL623842,9606.0
8831,N,,,AC755,,80668,1,Intermediate,,6959,F,,,1,BAO_0000218,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",1064.0,,,Mus musculus,CHEMBL623843,10090.0
13419,D,,,,,102444,9,Expert,,6960,F,,,1,BAO_0000218,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,,,Oryctolagus cuniculus,CHEMBL618669,9986.0
13419,D,,,,In vivo,102444,9,Expert,,6961,F,,,1,BAO_0000218,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,,,Oryctolagus cuniculus,CHEMBL618670,9986.0
15778,H,,,,,69,8,Autocuration,,6962,B,,,1,BAO_0000357,Inhibitory activity against angiotensin-converting enzyme (ACE).,,,,,CHEMBL618671,
15778,H,,,,,69,8,Autocuration,,6963,B,,,1,BAO_0000357,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,,,,CHEMBL618672,
12988,N,,,ACH-2 cell line,,80669,1,Intermediate,,6964,F,,,1,BAO_0000219,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,978.0,,,Homo sapiens,CHEMBL618673,9606.0
12988,N,,,ACH-2 cell line,,80669,1,Intermediate,,6965,F,,,1,BAO_0000219,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),978.0,,,Homo sapiens,CHEMBL618674,9606.0
12988,U,,,T cell line,,22224,0,Autocuration,,6966,F,,,1,BAO_0000219,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,998.0,,,Human immunodeficiency virus 1,CHEMBL618675,11676.0
12988,U,,,T cell line,,22224,0,Autocuration,,6967,F,,,1,BAO_0000219,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),998.0,,,Human immunodeficiency virus 1,CHEMBL618676,11676.0
12988,U,,,T cell line,,22224,0,Autocuration,,6968,F,,,1,BAO_0000219,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),998.0,,,Human immunodeficiency virus 1,CHEMBL618677,11676.0
11843,N,,,ACHN,,80025,1,Intermediate,,6969,F,,,1,BAO_0000219,Inhibition of growth of renal cancer ACHN cell line,626.0,,,Homo sapiens,CHEMBL618678,9606.0
16939,N,,,ACHN,,80025,1,Intermediate,,6970,F,,,1,BAO_0000219,Inhibition of growth of ACHN renal cancer cell line,626.0,,,Homo sapiens,CHEMBL618679,9606.0
4782,N,,,ACHN,,80025,1,Intermediate,,6971,F,,,1,BAO_0000219,Inhibitory concentration required against ACHN renal cancer cell line,626.0,,,Homo sapiens,CHEMBL618680,9606.0
6310,N,,,ACHN,,80025,1,Expert,,6972,F,,,1,BAO_0000219,Concentration required to inhibit growth of human renal (ACHN) cell line,626.0,,,Homo sapiens,CHEMBL618681,9606.0
6310,N,,,ACHN,,80025,1,Intermediate,,6973,F,,,1,BAO_0000219,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,626.0,,,Homo sapiens,CHEMBL618682,9606.0
12858,N,,,ACHN,,80025,1,Intermediate,,6974,F,,,1,BAO_0000219,Cytotoxic activity against ACHN Renal cancer cell line,626.0,,,Homo sapiens,CHEMBL618683,9606.0
17380,N,,,ACHN,,80025,1,Intermediate,,6975,F,,,1,BAO_0000219,Cytotoxicity evaluation against ACHN renal cancer cells,626.0,,,Homo sapiens,CHEMBL618684,9606.0
5858,N,,,ACHN,,80025,1,Intermediate,,6976,F,,,1,BAO_0000219,In vitro antitumor activity against human renal ACHN cell line,626.0,,,Homo sapiens,CHEMBL618685,9606.0
3838,N,,,ACHN,,80025,1,Intermediate,,6977,F,,,1,BAO_0000219,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,626.0,,,Homo sapiens,CHEMBL876499,9606.0
3838,N,,,ACHN,,80025,1,Intermediate,,6978,F,,,1,BAO_0000219,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,626.0,,,Homo sapiens,CHEMBL618686,9606.0
5406,N,,,ACHN,,80025,1,Intermediate,,6979,F,,,1,BAO_0000219,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",626.0,,,Homo sapiens,CHEMBL618687,9606.0
4071,N,,,ACHN,,80025,1,Intermediate,,6980,F,,,1,BAO_0000219,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,626.0,,,Homo sapiens,CHEMBL618688,9606.0
4071,N,,,ACHN,,80025,1,Expert,,6981,F,,,1,BAO_0000219,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,626.0,,,Homo sapiens,CHEMBL618689,9606.0
4071,N,,,ACHN,,80025,1,Intermediate,,6982,F,,,1,BAO_0000219,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,626.0,,,Homo sapiens,CHEMBL618690,9606.0
15002,N,,,ACHN,,80025,1,Intermediate,,6983,F,,,1,BAO_0000219,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,626.0,,,Homo sapiens,CHEMBL618691,9606.0
14769,N,,,ACHN,,80025,1,Intermediate,,6984,F,,,1,BAO_0000219,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),626.0,,,Homo sapiens,CHEMBL619373,9606.0
13958,N,,,ACHN,,80025,1,Intermediate,,6985,F,,,1,BAO_0000219,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",626.0,,,Homo sapiens,CHEMBL884008,9606.0
1665,N,,,ACHN,,80025,1,Intermediate,,6986,F,,,1,BAO_0000219,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,626.0,,,Homo sapiens,CHEMBL619374,9606.0
15354,N,,,ACHN,,80025,1,Intermediate,,6987,F,,,1,BAO_0000219,Compound was tested for the growth inhibition of ACHN renal tumor cell line,626.0,,,Homo sapiens,CHEMBL619375,9606.0
15354,N,,,ACHN,,80025,1,Intermediate,,6988,F,,,1,BAO_0000219,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,626.0,,,Homo sapiens,CHEMBL619376,9606.0
13978,N,,,ACHN,,80025,1,Intermediate,,6989,F,,,1,BAO_0000219,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,626.0,,,Homo sapiens,CHEMBL619377,9606.0
6798,N,,,ACHN,,80025,1,Intermediate,,6990,F,,,1,BAO_0000219,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,626.0,,,Homo sapiens,CHEMBL619378,9606.0
2959,N,,,,In vivo,50588,1,Intermediate,,6991,A,,,1,BAO_0000218,Tmax value after administration of 4 mg/Kg oral dose in dog,,,,Canis lupus familiaris,CHEMBL872527,9615.0
9932,N,,,,,50588,1,Intermediate,,6992,A,,,1,BAO_0000218,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,,,Canis lupus familiaris,CHEMBL876500,9615.0
5546,N,,,,,50588,1,Intermediate,,6993,A,,,1,BAO_0000218,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,,Canis lupus familiaris,CHEMBL619379,9615.0
16907,N,,,,In vivo,50588,1,Intermediate,,6994,A,,,1,BAO_0000218,Volume distribution after 15 mg/kg iv dose in Dogs,,,,Canis lupus familiaris,CHEMBL619538,9615.0
16907,N,,,,In vivo,50588,1,Intermediate,,6995,A,,,1,BAO_0000218,Volume distribution after 30 mg/kg po dose in Dogs,,,,Canis lupus familiaris,CHEMBL619539,9615.0
4257,N,,,,In vivo,50588,1,Intermediate,,6996,A,,,1,BAO_0000218,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,,,Canis lupus familiaris,CHEMBL619540,9615.0
4305,N,,,,In vivo,50588,1,Intermediate,,6997,A,,,1,BAO_0000218,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL619541,9615.0
5472,N,,,,In vivo,50588,1,Intermediate,,6998,A,,,1,BAO_0000218,Volume of distribution was evaluated in dog,,,,Canis lupus familiaris,CHEMBL619542,9615.0
6062,N,,,,In vivo,50588,1,Intermediate,,6999,A,,,1,BAO_0000218,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL619543,9615.0
3598,N,,,,,50588,1,Expert,,7000,A,,,1,BAO_0000218,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,,,Canis lupus familiaris,CHEMBL619544,9615.0
12500,N,,,,In vivo,50588,1,Intermediate,,7001,A,,,1,BAO_0000218,The compound was tested for volume of distribution in dog,,,,Canis lupus familiaris,CHEMBL619545,9615.0
12500,N,,,,In vivo,50588,1,Intermediate,,7002,A,,,1,BAO_0000218,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,,,Canis lupus familiaris,CHEMBL619546,9615.0
6227,N,,,,In vivo,50588,1,Intermediate,,7003,A,,,1,BAO_0000218,Vd (1 mg/kg) was determined in dog (in vivo),,,,Canis lupus familiaris,CHEMBL619547,9615.0
6227,N,,,,In vivo,50588,1,Intermediate,,7004,A,,,1,BAO_0000218,Vd in dog,,,,Canis lupus familiaris,CHEMBL619548,9615.0
4219,N,,,,In vivo,50588,1,Intermediate,,7005,A,,,1,BAO_0000218,Volume distribution was determined,,,,Canis lupus familiaris,CHEMBL619549,9615.0
1696,N,,,,In vivo,50588,1,Intermediate,,7006,A,,,1,BAO_0000218,Volume of distribution in dog,,,,Canis lupus familiaris,CHEMBL619550,9615.0
5542,N,,,,In vivo,50588,1,Intermediate,,7007,A,,,1,BAO_0000218,Volume of distribution by as 4 fold increase by iv administration in dogs,,,,Canis lupus familiaris,CHEMBL876501,9615.0
5199,N,,,,In vivo,50588,1,Intermediate,,7008,A,,,1,BAO_0000218,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,,,Canis lupus familiaris,CHEMBL619551,9615.0
6348,N,,,,In vivo,50588,1,Intermediate,,7009,A,,,1,BAO_0000218,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,,Canis lupus familiaris,CHEMBL619552,9615.0
4727,N,,,,In vivo,50588,1,Intermediate,,7010,A,,,1,BAO_0000218,Volume distribution at the dose of 2 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL619553,9615.0
16367,N,,,,In vivo,50588,1,Intermediate,,7011,A,,,1,BAO_0000218,Steady state volume of distribution was determined,,,,Canis lupus familiaris,CHEMBL618722,9615.0
2652,N,,,,In vivo,50588,1,Intermediate,,7012,A,,,1,BAO_0000218,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,,,Canis lupus familiaris,CHEMBL618723,9615.0
16452,N,,,,In vivo,50588,1,Intermediate,,7013,A,,,1,BAO_0000218,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,,Canis lupus familiaris,CHEMBL618724,9615.0
16452,N,,,,In vivo,50588,1,Intermediate,,7014,A,,,1,BAO_0000218,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,,,Canis lupus familiaris,CHEMBL618725,9615.0
16452,N,,,,In vivo,50588,1,Intermediate,,7015,A,,,1,BAO_0000218,Bioavailability in dog (dose 1 mg/kg i.v.),,,,Canis lupus familiaris,CHEMBL618726,9615.0
5334,N,,,,In vivo,50588,1,Intermediate,,7016,A,,,1,BAO_0000218,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,,,Canis lupus familiaris,CHEMBL618727,9615.0
4239,N,,,,In vivo,50588,1,Intermediate,,7017,A,,,1,BAO_0000218,Pharmacokinetic property (vdss) was measured in dog,,,,Canis lupus familiaris,CHEMBL624233,9615.0
4709,N,,,,In vivo,50588,1,Intermediate,,7018,A,,,1,BAO_0000218,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL624234,9615.0
5600,N,,,,In vivo,50588,1,Intermediate,,7019,A,,,1,BAO_0000218,Vdss was determined after iv 0.1 mg/kg administration in dog,,,,Canis lupus familiaris,CHEMBL624235,9615.0
6057,N,,,,In vivo,50588,1,Intermediate,,7020,A,,,1,BAO_0000218,Volume displacement was calculated in dog,,,,Canis lupus familiaris,CHEMBL624236,9615.0
5654,N,,,,In vivo,50588,1,Intermediate,,7021,A,,,1,BAO_0000218,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL624237,9615.0
5505,N,,,,In vivo,50588,1,Intermediate,,7022,A,,,1,BAO_0000218,Volume distribution constant was determined,,,,Canis lupus familiaris,CHEMBL624238,9615.0
4527,N,,,,In vivo,50588,1,Intermediate,,7023,A,,,1,BAO_0000218,Volume distribution at a dose of 1 uM/kg in dog was determined,,,,Canis lupus familiaris,CHEMBL624239,9615.0
4521,N,,,,In vivo,50588,1,Intermediate,,7024,A,,,1,BAO_0000218,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,,,Canis lupus familiaris,CHEMBL875829,9615.0
4521,N,,,,In vivo,50588,1,Intermediate,,7025,A,,,1,BAO_0000218,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,,Canis lupus familiaris,CHEMBL624240,9615.0
15660,N,,,,In vivo,50588,1,Intermediate,,7026,A,,,1,BAO_0000218,Volume distribution (Vdss) was measured in dog,,,,Canis lupus familiaris,CHEMBL624241,9615.0
15660,N,,,,In vivo,50588,1,Intermediate,,7027,A,,,1,BAO_0000218,Volume distribution (Vdss) was measured in dog,,,,Canis lupus familiaris,CHEMBL624242,9615.0
6679,N,,,,In vivo,50588,1,Intermediate,,7028,A,,,1,BAO_0000218,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,,Canis lupus familiaris,CHEMBL624243,9615.0
5145,N,,,,In vivo,50588,1,Intermediate,,7029,A,,,1,BAO_0000218,Volume of distribution in steady state was determined in dog,,,,Canis lupus familiaris,CHEMBL624244,9615.0
6821,N,,,,In vivo,50588,1,Intermediate,,7030,A,,,1,BAO_0000218,Volume of distribution of compound was determined in dog,,,,Canis lupus familiaris,CHEMBL624245,9615.0
4137,N,,,,In vivo,50588,1,Intermediate,,7031,A,,,1,BAO_0000218,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,,,Canis lupus familiaris,CHEMBL624246,9615.0
5334,N,,,,In vivo,50588,1,Intermediate,,7032,A,,,1,BAO_0000218,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,,,Canis lupus familiaris,CHEMBL624247,9615.0
15660,N,,,,In vivo,50588,1,Intermediate,,7033,A,,,1,BAO_0000218,Volume of distribution (Vdss) was measured in dog,,,,Canis lupus familiaris,CHEMBL624248,9615.0
6642,N,,,,In vivo,50588,1,Intermediate,,7034,A,,,1,BAO_0000218,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,,Canis lupus familiaris,CHEMBL624249,9615.0
6641,N,,,,In vivo,50588,1,Intermediate,,7035,A,,,1,BAO_0000218,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,,Canis lupus familiaris,CHEMBL624250,9615.0
6642,N,,,,In vivo,50588,1,Intermediate,,7036,A,,,1,BAO_0000218,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,,Canis lupus familiaris,CHEMBL624251,9615.0
11659,N,,,,,50588,1,Intermediate,,7037,A,,,1,BAO_0000218,Maximum rate of depolarization of the upstroke of the action potential,,,,Canis lupus familiaris,CHEMBL624252,9615.0
6448,N,,,,In vivo,50588,1,Intermediate,,7038,A,,,1,BAO_0000218,Steady state volume distribution in dog,,,,Canis lupus familiaris,CHEMBL624253,9615.0
5474,N,,,,In vivo,50588,1,Intermediate,,7039,A,,,1,BAO_0000218,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,,,Canis lupus familiaris,CHEMBL624950,9615.0
1466,N,,,,In vivo,50588,1,Intermediate,,7040,A,,,1,BAO_0000218,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,,,Canis lupus familiaris,CHEMBL624951,9615.0
6535,N,,,,In vivo,50588,1,Intermediate,,7041,A,,,1,BAO_0000218,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,,,Canis lupus familiaris,CHEMBL875830,9615.0
6535,N,,,,In vivo,50588,1,Intermediate,,7042,A,,,1,BAO_0000218,Volume distribution in dog after administration of 1 mg/kg iv,,,,Canis lupus familiaris,CHEMBL624952,9615.0
17764,N,,,,In vivo,50588,1,Intermediate,,7043,A,,,1,BAO_0000218,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,,,Canis lupus familiaris,CHEMBL624953,9615.0
6215,N,,,,In vivo,50588,1,Intermediate,,7044,A,,,1,BAO_0000218,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,,,Canis lupus familiaris,CHEMBL624954,9615.0
6505,N,,,,In vivo,50588,1,Intermediate,,7045,A,,,1,BAO_0000218,Vss on i.v. administration of 2 mg/kg was measured in dog,,,,Canis lupus familiaris,CHEMBL624955,9615.0
3639,N,,,,,50588,1,Intermediate,,7046,A,,,1,BAO_0000218,Vss was determined,,,,Canis lupus familiaris,CHEMBL624956,9615.0
3639,N,,,,,50588,1,Intermediate,,7047,A,,,1,BAO_0000218,Vss in dog,,,,Canis lupus familiaris,CHEMBL625129,9615.0
6062,N,,,,In vivo,50588,1,Intermediate,,7048,A,,,1,BAO_0000218,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL625130,9615.0
4942,N,,,,In vivo,50588,1,Intermediate,,7049,A,,,1,BAO_0000218,Volume distribution in dogs,,,,Canis lupus familiaris,CHEMBL625131,9615.0
17796,N,,,,In vivo,50588,1,Intermediate,,7050,A,,,1,BAO_0000218,Volume of distribution in dog,,,,Canis lupus familiaris,CHEMBL625132,9615.0
4883,N,,,,In vivo,50588,1,Intermediate,,7051,A,,,1,BAO_0000218,Tested for the oral bioavailability in dog,,,,Canis lupus familiaris,CHEMBL872263,9615.0
17837,N,,,,In vivo,50594,1,Intermediate,,7060,A,,,1,BAO_0000218,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,,,Mus musculus,CHEMBL624336,10090.0
17729,N,,,,In vivo,50594,1,Intermediate,,7061,A,,,1,BAO_0000218,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,,,Mus musculus,CHEMBL624337,10090.0
17729,N,,,,In vivo,50594,1,Intermediate,,7062,A,,,1,BAO_0000218,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,,,Mus musculus,CHEMBL624338,10090.0
4239,N,,,,In vivo,50594,1,Intermediate,,7063,A,,,1,BAO_0000218,Bioavailability was measured in mouse,,,,Mus musculus,CHEMBL624339,10090.0
17592,N,,,,In vivo,50594,1,Intermediate,,7064,A,,,1,BAO_0000218,Bioavailability in mouse,,,,Mus musculus,CHEMBL624340,10090.0
6348,N,,,,In vivo,50594,1,Intermediate,,7065,A,,,1,BAO_0000218,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,,,Mus musculus,CHEMBL624341,10090.0
2801,N,,,,In vivo,50594,1,Intermediate,,7066,A,,,1,BAO_0000218,Bioavailability in mouse,,,,Mus musculus,CHEMBL624342,10090.0
2801,N,,,,In vivo,50594,1,Intermediate,,7067,A,,,1,BAO_0000218,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,,,Mus musculus,CHEMBL624343,10090.0
17718,N,,,,In vivo,50594,1,Intermediate,,7068,A,,,1,BAO_0000218,Oral bioavailability in mouse,,,,Mus musculus,CHEMBL624344,10090.0
5727,N,,,,In vivo,50594,1,Intermediate,,7069,A,,,1,BAO_0000218,Oral availability at 50 mg/kg po in male mice,,,,Mus musculus,CHEMBL624345,10090.0
5302,N,,,,In vivo,50594,1,Intermediate,,7070,A,,,1,BAO_0000218,Oral bioavailability in mouse (dose 10 mg/kg),,,,Mus musculus,CHEMBL624346,10090.0
3598,N,,,,In vivo,50594,1,Expert,,7071,A,,,1,BAO_0000218,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,,,Mus musculus,CHEMBL624347,10090.0
5961,N,,,,In vivo,50594,1,Intermediate,,7072,A,,,1,BAO_0000218,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,,,Mus musculus,CHEMBL624348,10090.0
6091,N,,,,In vivo,50594,1,Intermediate,,7074,A,,,1,BAO_0000218,Oral bioavailability in mouse,,,,Mus musculus,CHEMBL622754,10090.0
6091,N,,,,In vivo,50594,1,Intermediate,,7075,A,,,1,BAO_0000218,Oral bioavailability in vivo in mice;ND=Not determined,,,,Mus musculus,CHEMBL622755,10090.0
5711,N,,,,In vivo,50594,1,Intermediate,,7076,A,,,1,BAO_0000218,Oral bioavailability in mouse at 10 mg/kg of the compound,,,,Mus musculus,CHEMBL622756,10090.0
17728,N,,,,In vivo,50594,1,Intermediate,,7077,A,,,1,BAO_0000218,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,,,Mus musculus,CHEMBL622757,10090.0
17728,N,,,,In vivo,50594,1,Intermediate,,7078,A,,,1,BAO_0000218,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,,,Mus musculus,CHEMBL622758,10090.0
3802,N,,,,In vivo,50594,1,Intermediate,,7079,A,,,1,BAO_0000218,Tested for bioavailability of the compound,,,,Mus musculus,CHEMBL622759,10090.0
3802,N,,,,In vivo,50594,1,Intermediate,,7080,A,,,1,BAO_0000218,Tested for half life at the dose of 10 mg/kg when administered intravenously,,,,Mus musculus,CHEMBL622760,10090.0
14029,N,,,,,50594,1,Intermediate,,7081,A,Plasma,,1,BAO_0000218,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,,1969.0,Mus musculus,CHEMBL622761,10090.0
14029,N,,,,,50594,1,Intermediate,,7082,A,Plasma,,1,BAO_0000218,The plasma half life of compound was determined on heparin prepared by human plasma. ,,,1969.0,Mus musculus,CHEMBL622762,10090.0
14029,N,,,,,50594,1,Intermediate,,7083,A,Plasma,,1,BAO_0000218,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,,1969.0,Mus musculus,CHEMBL622763,10090.0
14029,N,,,,,50594,1,Intermediate,,7084,A,Plasma,,1,BAO_0000218,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,,1969.0,Mus musculus,CHEMBL622764,10090.0
14029,N,,,,,50594,1,Intermediate,,7085,A,Plasma,,1,BAO_0000218,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,,1969.0,Mus musculus,CHEMBL622765,10090.0
17753,N,,,,,50594,1,Intermediate,,7086,F,,,1,BAO_0000218,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,,,Mus musculus,CHEMBL622766,10090.0
17753,N,,,,,50594,1,Intermediate,,7087,A,,,1,BAO_0000218,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,,,Mus musculus,CHEMBL622767,10090.0
17753,N,,,,,50594,1,Intermediate,,7088,A,,,1,BAO_0000218,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,,,Mus musculus,CHEMBL622768,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7089,A,Blood,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,178.0,Mus musculus,CHEMBL875948,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7090,A,Blood,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,178.0,Mus musculus,CHEMBL622769,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7091,A,Blood,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,178.0,Mus musculus,CHEMBL622770,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7092,A,Blood,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,178.0,Mus musculus,CHEMBL622771,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7093,A,Blood,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,178.0,Mus musculus,CHEMBL622772,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7094,A,Blood,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,178.0,Mus musculus,CHEMBL622773,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7095,A,Blood,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,178.0,Mus musculus,CHEMBL622774,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7096,A,Bone,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,10000001.0,Mus musculus,CHEMBL621725,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7097,A,Bone,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,10000001.0,Mus musculus,CHEMBL621726,10090.0
15608,N,,,A2780,,81034,1,Intermediate,,7098,F,,,1,BAO_0000219,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,478.0,,,Homo sapiens,CHEMBL621727,9606.0
3290,N,,,A2780,,81034,1,Expert,,7099,F,,,1,BAO_0000219,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,478.0,,,Homo sapiens,CHEMBL622413,9606.0
2859,N,,,A2780,,81034,1,Intermediate,,7100,F,,,1,BAO_0000219,Compound was evaluated for cytotoxicity against A2780 cell line,478.0,,,Homo sapiens,CHEMBL622414,9606.0
15688,N,,,A2780,,81034,1,Expert,,7101,F,,,1,BAO_0000219,Inhibition of A2780 cell clonogenic assay,478.0,,,Homo sapiens,CHEMBL622415,9606.0
5642,N,,,A2780,,81034,1,Expert,,7102,F,,,1,BAO_0000219,Cytotoxic effect on ovarian cancer cell line (A2780),478.0,,,Homo sapiens,CHEMBL884001,9606.0
6633,N,,,A2780,,81034,1,Intermediate,,7103,F,,,1,BAO_0000219,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,478.0,,,Homo sapiens,CHEMBL622416,9606.0
3906,N,,,A2780,,81034,1,Intermediate,,7104,F,,,1,BAO_0000219,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",478.0,,,Homo sapiens,CHEMBL622417,9606.0
6788,N,,,A2780,,81034,1,Expert,,7105,F,,,1,BAO_0000219,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,478.0,,,Homo sapiens,CHEMBL622590,9606.0
17582,N,,,A2780,,81034,1,Expert,,7106,F,,,1,BAO_0000219,Antiproliferative activity against human A2780 cells,478.0,,,Homo sapiens,CHEMBL622591,9606.0
17764,N,,,A2780,,81034,1,Expert,,7107,F,,,1,BAO_0000219,Inhibition of human A2780 cell proliferation,478.0,,,Homo sapiens,CHEMBL622592,9606.0
17764,N,,,A2780,,81034,1,Expert,,7108,F,,,1,BAO_0000219,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,478.0,,,Homo sapiens,CHEMBL622593,9606.0
17764,N,,,A2780,,81034,1,Expert,,7109,F,,,1,BAO_0000219,Inhibition of human A2780 cell proliferation (No data),478.0,,,Homo sapiens,CHEMBL622594,9606.0
2815,N,,,A2780,,81034,1,Intermediate,,7110,F,,,1,BAO_0000219,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,478.0,,,Homo sapiens,CHEMBL622595,9606.0
16930,N,,,A2780,,81034,1,Intermediate,,7111,F,,,1,BAO_0000219,Compound was evaluated against human Ovarian carcinoma cell line A2780,478.0,,,Homo sapiens,CHEMBL622596,9606.0
17777,N,,,A2780,,81034,1,Expert,,7112,F,,,1,BAO_0000219,Growth inhibition against A2780 wild-type ovarian cell lines,478.0,,,Homo sapiens,CHEMBL622597,9606.0
17777,N,,,A2780,,81034,1,Intermediate,,7113,F,,,1,BAO_0000219,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,478.0,,,Homo sapiens,CHEMBL622598,9606.0
16936,D,,,,,104766,5,Autocuration,,7114,F,,,1,BAO_0000019,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,,,Homo sapiens,CHEMBL622599,9606.0
13759,N,,,A2780,,81034,1,Intermediate,,7115,F,,,1,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,478.0,,,Homo sapiens,CHEMBL622600,9606.0
13759,N,,,A2780,,81034,1,Intermediate,,7116,F,,,1,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,478.0,,,Homo sapiens,CHEMBL622601,9606.0
13759,N,,,A2780,,81034,1,Intermediate,,7117,F,,,1,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,478.0,,,Homo sapiens,CHEMBL622602,9606.0
13759,N,,,A2780,,81034,1,Intermediate,,7118,F,,,1,BAO_0000219,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,478.0,,,Homo sapiens,CHEMBL622603,9606.0
15292,N,,,A2780,,81034,1,Intermediate,,7119,F,,,1,BAO_0000219,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,478.0,,,Homo sapiens,CHEMBL622604,9606.0
15292,N,,,A2780,,81034,1,Intermediate,,7120,F,,,1,BAO_0000219,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,478.0,,,Homo sapiens,CHEMBL622605,9606.0
15069,N,,,A2780,,81034,1,Expert,,7121,F,,,1,BAO_0000219,In vitro inhibition of human ovarian cell line A2780,478.0,,,Homo sapiens,CHEMBL622606,9606.0
15069,N,,,A2780,,81034,1,Expert,,7122,F,,,1,BAO_0000219,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",478.0,,,Homo sapiens,CHEMBL619463,9606.0
14073,N,,,A2780,,81034,1,Intermediate,,7123,F,,,1,BAO_0000219,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),478.0,,,Homo sapiens,CHEMBL619464,9606.0
14553,N,,,A2780,,81034,1,Expert,,7124,F,,,1,BAO_0000219,Concentration required to inhibit A2780-cell growth by 50%,478.0,,,Homo sapiens,CHEMBL619465,9606.0
13040,N,,,A2780,,81034,1,Expert,,7125,F,,,1,BAO_0000219,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,478.0,,,Homo sapiens,CHEMBL619466,9606.0
6891,N,,,A2780,,81034,1,Expert,,7126,F,,,1,BAO_0000219,Cytotoxic effect on human ovarian (A2780) cancer cell line,478.0,,,Homo sapiens,CHEMBL619467,9606.0
15569,N,,,A2780,,81034,1,Intermediate,,7127,F,,,1,BAO_0000219,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,478.0,,,Homo sapiens,CHEMBL619468,9606.0
14190,N,,,A2780,,81034,1,Expert,,7128,F,,,1,BAO_0000219,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,478.0,,,Homo sapiens,CHEMBL619469,9606.0
15014,N,,,A2780,,81034,1,Expert,,7129,F,,,1,BAO_0000219,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,478.0,,,Homo sapiens,CHEMBL619470,9606.0
15014,N,,,A2780,,81034,1,Intermediate,,7130,F,,,1,BAO_0000219,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,478.0,,,Homo sapiens,CHEMBL619471,9606.0
17496,N,,,A2780,,81034,1,Intermediate,,7131,F,,,1,BAO_0000219,Cytotoxicity against human ovarian carcinoma A2780 cell line,478.0,,,Homo sapiens,CHEMBL619472,9606.0
13617,N,,,A2780,,81034,1,Intermediate,,7132,F,,,1,BAO_0000219,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",478.0,,,Homo sapiens,CHEMBL619473,9606.0
13617,N,,,A2780,,81034,1,Intermediate,,7133,F,,,1,BAO_0000219,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",478.0,,,Homo sapiens,CHEMBL874368,9606.0
13617,N,,,A2780,,81034,1,Intermediate,,7134,F,,,1,BAO_0000219,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",478.0,,,Homo sapiens,CHEMBL884003,9606.0
13617,N,,,A2780,,81034,1,Intermediate,,7135,F,,,1,BAO_0000219,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",478.0,,,Homo sapiens,CHEMBL622690,9606.0
17672,N,,,A2780,,81034,1,Intermediate,,7136,F,,,1,BAO_0000219,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,478.0,,,Homo sapiens,CHEMBL622691,9606.0
4544,N,,,A2780,,81034,1,Intermediate,,7137,F,,,1,BAO_0000219,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,478.0,,,Homo sapiens,CHEMBL622692,9606.0
4544,N,,,A2780,,81034,1,Intermediate,,7138,F,,,1,BAO_0000219,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,478.0,,,Homo sapiens,CHEMBL623406,9606.0
16317,N,,,A2780,,81034,1,Intermediate,,7139,F,,,1,BAO_0000219,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",478.0,,,Homo sapiens,CHEMBL884004,9606.0
15099,N,,,A2780,,81034,1,Intermediate,,7140,F,,,1,BAO_0000219,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,478.0,,,Homo sapiens,CHEMBL623407,9606.0
13978,N,,,A2780,,81034,1,Intermediate,,7141,F,,,1,BAO_0000219,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,478.0,,,Homo sapiens,CHEMBL623408,9606.0
12989,N,,,A2780,,81034,1,Expert,,7142,F,,,1,BAO_0000219,In vitro antitumor activity against A2780 cell line.,478.0,,,Homo sapiens,CHEMBL623409,9606.0
5574,N,,,A2780,,81034,1,Intermediate,,7143,F,,,1,BAO_0000219,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,478.0,,,Homo sapiens,CHEMBL623410,9606.0
13528,N,,,A2780,,81034,1,Expert,,7144,F,,,1,BAO_0000219,In vitro cytotoxicity against A2780 human ovarian cancer cell line,478.0,,,Homo sapiens,CHEMBL623576,9606.0
12782,N,,,ACHN,,80025,1,Intermediate,,7145,F,,,1,BAO_0000219,Inhibitory activity against kidney A-CHN tumor cell growth in culture,626.0,,,Homo sapiens,CHEMBL623577,9606.0
14255,N,,,ACHN,,80025,1,Intermediate,,7146,F,,,1,BAO_0000219,The IC50 value was measured on ACHN cell line in renal tumor type.,626.0,,,Homo sapiens,CHEMBL623578,9606.0
16364,N,,,ACHN,,80025,1,Intermediate,,7147,F,,,1,BAO_0000219,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,626.0,,,Homo sapiens,CHEMBL623579,9606.0
17376,N,,,ACHN,,80025,1,Expert,,7148,F,,,1,BAO_0000219,In vitro lethal concentration against most sensitive ACHN cell line,626.0,,,Homo sapiens,CHEMBL623580,9606.0
12016,N,,,ACHN,,80025,1,Intermediate,,7149,F,,,1,BAO_0000219,Tested for cytotoxic activity against renal cancer ACHN cell line,626.0,,,Homo sapiens,CHEMBL623581,9606.0
6058,N,,,ACHN,,80025,1,Intermediate,,7150,F,,,1,BAO_0000219,Compound tested for growth inhibition of renal cancer cell line ACHN,626.0,,,Homo sapiens,CHEMBL857456,9606.0
17708,N,,,ACHN,,80025,1,Intermediate,,7151,F,,,1,BAO_0000219,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,626.0,,,Homo sapiens,CHEMBL623582,9606.0
15176,N,,,ACHN,,80025,1,Intermediate,,7152,F,,,1,BAO_0000219,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,626.0,,,Homo sapiens,CHEMBL623583,9606.0
2806,N,,,ACHN,,80025,1,Intermediate,,7153,F,,,1,BAO_0000219,In vitro anticancer activity against ACHN renal cancer cell line,626.0,,,Homo sapiens,CHEMBL623584,9606.0
15300,N,,,ACHN,,80025,1,Intermediate,,7154,F,,,1,BAO_0000219,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,626.0,,,Homo sapiens,CHEMBL623585,9606.0
16364,N,,,ACHN,,80025,1,Intermediate,,7155,F,,,1,BAO_0000219,Percent selectivity was evaluated in renal ACHN cell lines,626.0,,,Homo sapiens,CHEMBL623586,9606.0
13859,N,,,ACHN,,80025,1,Intermediate,,7156,F,,,1,BAO_0000219,In vitro inhibitory activity against renal ACHN cancer cell line,626.0,,,Homo sapiens,CHEMBL623587,9606.0
11970,N,,,ACHN,,80025,1,Intermediate,,7157,F,,,1,BAO_0000219,Tested for cytotoxicity against ACHN cell lines in renal cancer,626.0,,,Homo sapiens,CHEMBL875279,9606.0
2450,N,,,ACHN,,80025,1,Intermediate,,7158,F,,,1,BAO_0000219,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,626.0,,,Homo sapiens,CHEMBL623588,9606.0
12696,N,,,ACHN,,80025,1,Intermediate,,7159,F,,,1,BAO_0000219,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,626.0,,,Homo sapiens,CHEMBL623589,9606.0
12400,N,,,ACHN,,80025,1,Intermediate,,7160,F,,,1,BAO_0000219,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,626.0,,,Homo sapiens,CHEMBL623590,9606.0
12888,N,,,ACHN,,80025,1,Expert,,7161,F,,,1,BAO_0000219,Cytotoxic effect on renal cancer line ACHN,626.0,,,Homo sapiens,CHEMBL623591,9606.0
3156,N,,,ACHN,,80025,1,Intermediate,,7162,F,,,1,BAO_0000219,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,626.0,,,Homo sapiens,CHEMBL623592,9606.0
3381,N,,,ACHN,,80025,1,Intermediate,,7163,F,,,1,BAO_0000219,In vitro inhibition of Renal Cancer ACHN cell lines,626.0,,,Homo sapiens,CHEMBL623593,9606.0
16747,N,,,ACHN,,80025,1,Intermediate,,7164,F,,,1,BAO_0000219,Antitumor activity against human renal adenocarcinoma ACHN cells,626.0,,,Homo sapiens,CHEMBL623594,9606.0
16748,N,,,ACHN,,80025,1,Expert,,7165,F,,,1,BAO_0000219,Antitumor activity against human renal adenocarcinoma ACHN cells.,626.0,,,Homo sapiens,CHEMBL621833,9606.0
12062,N,,,ACHN,,80025,1,Intermediate,,7166,F,,,1,BAO_0000219,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,626.0,,,Homo sapiens,CHEMBL621834,9606.0
14769,N,,,ACHN,,80025,1,Intermediate,,7167,F,,,1,BAO_0000219,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),626.0,,,Homo sapiens,CHEMBL621835,9606.0
15895,N,,,ACHN,,80025,1,Intermediate,,7168,F,,,1,BAO_0000219,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",626.0,,,Homo sapiens,CHEMBL621836,9606.0
17376,N,,,ACHN,,80025,1,Intermediate,,7169,F,,,1,BAO_0000219,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,626.0,,,Homo sapiens,CHEMBL621837,9606.0
14882,N,,,ACHN,,80025,1,Intermediate,,7170,F,,,1,BAO_0000219,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,626.0,,,Homo sapiens,CHEMBL875280,9606.0
14882,N,,,ACHN,,80025,1,Intermediate,,7171,F,,,1,BAO_0000219,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,626.0,,,Homo sapiens,CHEMBL621838,9606.0
15661,N,,,ACHN,,80025,1,Intermediate,,7172,F,,,1,BAO_0000219,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,626.0,,,Homo sapiens,CHEMBL621839,9606.0
9680,U,,,,,22224,0,Autocuration,,7173,A,,,1,BAO_0000019,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,,,,CHEMBL621840,
14579,H,,,,,10647,8,Autocuration,,7174,F,,,1,BAO_0000019,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,,,,CHEMBL621841,
17290,N,,,HEL,,50529,1,Expert,,7175,F,,,1,BAO_0000218,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,468.0,,,Cytomegalovirus,CHEMBL622979,10358.0
17290,N,,,,,50529,1,Intermediate,,7176,F,,,1,BAO_0000218,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,,,Cytomegalovirus,CHEMBL876595,10358.0
15891,H,,,,,12159,8,Autocuration,,7177,B,,,1,BAO_0000357,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,,,,CHEMBL620221,
15890,H,,,,,12159,8,Autocuration,,7178,B,,,1,BAO_0000357,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,,,,CHEMBL620222,
3801,N,,,ADDP cell line,,80670,1,Intermediate,,7179,F,,,1,BAO_0000219,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,979.0,,,Bos taurus,CHEMBL620506,9913.0
9222,N,,,ADJ/PC6,,80671,1,Intermediate,,7180,F,,,1,BAO_0000219,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,980.0,,,Mus musculus,CHEMBL620507,10090.0
9222,N,,,ADJ/PC6,,80671,1,Intermediate,,7181,F,,,1,BAO_0000219,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,980.0,,,Mus musculus,CHEMBL620508,10090.0
7257,N,,,ADJ/PC6,,80671,1,Intermediate,,7182,F,,,1,BAO_0000219,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",980.0,,,Mus musculus,CHEMBL620509,10090.0
7257,N,,,ADJ/PC6,,80671,1,Intermediate,,7183,F,,,1,BAO_0000219,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,980.0,,,Mus musculus,CHEMBL620510,10090.0
7257,N,,,ADJ/PC6,,80671,1,Intermediate,,7184,A,,,1,BAO_0000219,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,980.0,,,Mus musculus,CHEMBL620511,10090.0
8084,N,,,ADJ/PC6,,80671,1,Intermediate,,7185,F,,,1,BAO_0000219,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,980.0,,,Mus musculus,CHEMBL620512,10090.0
14943,U,,,,,22224,0,Autocuration,,7186,F,,,1,BAO_0000019,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,,,Mus musculus,CHEMBL620513,10090.0
14943,U,,,,,22224,0,Autocuration,,7187,F,,,1,BAO_0000019,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,,,Mus musculus,CHEMBL620514,10090.0
14943,U,,,,,22224,0,Autocuration,,7188,F,,,1,BAO_0000019,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,,,Mus musculus,CHEMBL620515,10090.0
10524,U,,,,In vivo,22224,0,Autocuration,,7189,A,,,1,BAO_0000218,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,,,Bacillus subtilis,CHEMBL620516,1423.0
3546,N,,,,,50588,1,Intermediate,,7190,A,Plasma,,1,BAO_0000218,AUC value in dog after IV administration at a dose of 5 mg/kg,,,1969.0,Canis lupus familiaris,CHEMBL620517,9615.0
3546,N,,,,,50588,1,Intermediate,,7191,A,Plasma,,1,BAO_0000218,AUC value in dog after oral administration at a dose of 5 mg/kg,,,1969.0,Canis lupus familiaris,CHEMBL620518,9615.0
3546,N,,,,In vivo,50588,1,Intermediate,,7192,A,,,1,BAO_0000218,Cmax value in dog after oral administration at a dose of 5 mg/kg,,,,Canis lupus familiaris,CHEMBL620519,9615.0
3546,N,,,,In vivo,50588,1,Intermediate,,7193,A,,,1,BAO_0000218,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,,,Canis lupus familiaris,CHEMBL621386,9615.0
3546,N,,,,In vivo,50588,1,Intermediate,,7194,A,,,1,BAO_0000218,Tmax value in dog after oral administration at a dose of 5 mg/kg,,,,Canis lupus familiaris,CHEMBL621387,9615.0
3184,N,,,,In vivo,50588,1,Intermediate,,7195,A,,,1,BAO_0000218,Compound was evaluated for its clearance when administered intravenously in dog,,,,Canis lupus familiaris,CHEMBL621388,9615.0
16456,N,,,,In vivo,50588,1,Intermediate,,7196,A,,,1,BAO_0000218,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,,Canis lupus familiaris,CHEMBL621389,9615.0
4809,N,,,,In vivo,50588,1,Intermediate,,7197,A,,,1,BAO_0000218,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,,,Canis lupus familiaris,CHEMBL621390,9615.0
4219,U,,,,,22229,0,Intermediate,,7198,P,,,1,BAO_0000100,Calculated partition coefficient (clogP),,,,,CHEMBL621391,
3748,N,,,,,50588,1,Intermediate,,7199,A,,,1,BAO_0000218,Half life in dog,,,,Canis lupus familiaris,CHEMBL621392,9615.0
3132,N,,,,,50588,1,Intermediate,,7200,A,,,1,BAO_0000218,Time taken for EC90 was determined when tested in dog,,,,Canis lupus familiaris,CHEMBL621393,9615.0
4219,N,,,,,50588,1,Intermediate,,7201,A,,,1,BAO_0000218,Half life (iv) was determined,,,,Canis lupus familiaris,CHEMBL621394,9615.0
16907,N,,,,,50588,1,Intermediate,,7202,A,Liver,,1,BAO_0000218,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,,2107.0,Canis lupus familiaris,CHEMBL621395,9615.0
6057,N,,,,,50588,1,Intermediate,,7203,A,,,1,BAO_0000218,Area under the curve was calculated in dog after iv administration,,,,Canis lupus familiaris,CHEMBL621396,9615.0
6057,N,,,,,50588,1,Intermediate,,7204,A,,,1,BAO_0000218,Area under the curve was calculated in dog after peroral administration,,,,Canis lupus familiaris,CHEMBL621397,9615.0
17853,N,,,,,50588,1,Intermediate,,7205,A,,,1,BAO_0000218,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,,,Canis lupus familiaris,CHEMBL621398,9615.0
3639,N,,,,,50588,1,Intermediate,,7206,A,,,1,BAO_0000218,pKa was evaluated in dog,,,,Canis lupus familiaris,CHEMBL618818,9615.0
14541,N,,,,,50588,1,Intermediate,,7207,A,,,1,BAO_0000218,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,,,Canis lupus familiaris,CHEMBL618819,9615.0
16456,N,,,,In vivo,50588,1,Intermediate,,7208,A,,,1,BAO_0000218,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,,Canis lupus familiaris,CHEMBL618820,9615.0
16456,N,,,,In vivo,50588,1,Intermediate,,7209,A,,,1,BAO_0000218,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,,,Canis lupus familiaris,CHEMBL873810,9615.0
2652,N,,,,In vivo,50588,1,Intermediate,,7210,A,,,1,BAO_0000218,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,,,Canis lupus familiaris,CHEMBL876606,9615.0
3624,N,,,,,50588,1,Intermediate,,7211,A,,,1,BAO_0000218,Compound was evaluated for the half-life (t 1/2) in hours,,,,Canis lupus familiaris,CHEMBL618821,9615.0
1337,N,,,,In vivo,50588,1,Intermediate,,7212,A,Blood,,1,BAO_0000218,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,,178.0,Canis lupus familiaris,CHEMBL618822,9615.0
1337,N,,,,In vivo,50588,1,Intermediate,,7213,A,Blood,,1,BAO_0000218,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,,178.0,Canis lupus familiaris,CHEMBL618823,9615.0
4709,N,,,,In vivo,50588,1,Intermediate,,7214,A,,,1,BAO_0000218,Half life after intravenous administration of 1 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL618824,9615.0
15660,N,,,,,50588,1,Intermediate,,7215,A,,,1,BAO_0000218,Half life was measured in dog,,,,Canis lupus familiaris,CHEMBL618825,9615.0
5302,N,,,,In vivo,50588,1,Intermediate,,7216,A,,,1,BAO_0000218,Half life period in dog after 5 mg/kg dose,,,,Canis lupus familiaris,CHEMBL618826,9615.0
17791,N,,,,,50588,1,Intermediate,,7217,A,,,1,BAO_0000218,Half life period was evaluated in dog; 4-4.8,,,,Canis lupus familiaris,CHEMBL618827,9615.0
6348,N,,,,In vivo,50588,1,Intermediate,,7218,A,,,1,BAO_0000218,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,,,Canis lupus familiaris,CHEMBL618828,9615.0
4257,N,,,,In vivo,50588,1,Intermediate,,7219,A,,,1,BAO_0000218,Half-life was determined in dog after a3 mg/kg of iv dose,,,,Canis lupus familiaris,CHEMBL618829,9615.0
3771,N,,,,,50588,1,Intermediate,,7220,A,,,1,BAO_0000218,Half-life was determined,,,,Canis lupus familiaris,CHEMBL618830,9615.0
6305,N,,,,,50588,1,Intermediate,,7221,A,,,1,BAO_0000218,Half life in dogs,,,,Canis lupus familiaris,CHEMBL618831,9615.0
13501,N,,,,In vivo,50588,1,Intermediate,,7222,A,Plasma,,1,BAO_0000218,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,,,1969.0,Canis lupus familiaris,CHEMBL619489,9615.0
17594,N,,,,In vivo,50588,1,Intermediate,,7223,A,,,1,BAO_0000218,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,,,Canis lupus familiaris,CHEMBL619649,9615.0
3045,N,,,,In vivo,50588,1,Intermediate,,7224,A,,,1,BAO_0000218,Compound was evaluated for the half life period after iv administration in Beagle dog.,,,,Canis lupus familiaris,CHEMBL876607,9615.0
3043,N,,,,In vivo,50588,1,Intermediate,,7225,A,,,1,BAO_0000218,Compound was evaluated for the half life period after oral administration in conscious dog.,,,,Canis lupus familiaris,CHEMBL619650,9615.0
4839,N,,,,,50588,1,Intermediate,,7226,A,,,1,BAO_0000218,Compound was tested for half life in dog,,,,Canis lupus familiaris,CHEMBL619651,9615.0
4839,N,,,,,50588,1,Intermediate,,7227,A,,,1,BAO_0000218,Compound was tested for its half life in dog,,,,Canis lupus familiaris,CHEMBL619652,9615.0
5802,N,,,,In vivo,50588,1,Intermediate,,7228,A,,,1,BAO_0000218,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,,,Canis lupus familiaris,CHEMBL619653,9615.0
17839,N,,,,,50588,1,Intermediate,,7229,A,,,1,BAO_0000218,Half life of compound in dog was determined,,,,Canis lupus familiaris,CHEMBL619654,9615.0
4219,N,,,,In vivo,50588,1,Intermediate,,7230,A,,,1,BAO_0000218,Half life (iv) was determined,,,,Canis lupus familiaris,CHEMBL619655,9615.0
13966,N,,,,,50588,1,Intermediate,,7231,A,Blood,,1,BAO_0000218,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,,178.0,Canis lupus familiaris,CHEMBL619656,9615.0
3994,N,,,,In vivo,50588,1,Intermediate,,7232,A,Plasma,,1,BAO_0000218,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,,1969.0,Canis lupus familiaris,CHEMBL873812,9615.0
3994,N,,,,In vivo,50588,1,Intermediate,,7233,F,Plasma,,1,BAO_0000218,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,,1969.0,Canis lupus familiaris,CHEMBL621365,9615.0
4453,N,,,,,50588,1,Intermediate,,7234,A,,,1,BAO_0000218,Half life in dog,,,,Canis lupus familiaris,CHEMBL621366,9615.0
6535,N,,,,,50588,1,Intermediate,,7235,A,Plasma,,1,BAO_0000218,Half life in dog plasma,,,1969.0,Canis lupus familiaris,CHEMBL621367,9615.0
6535,N,,,,In vivo,50588,1,Intermediate,,7236,A,Plasma,,1,BAO_0000218,Half life in dog plasma after administration of 0.25 mg/kg iv,,,1969.0,Canis lupus familiaris,CHEMBL621368,9615.0
6535,N,,,,In vivo,50588,1,Intermediate,,7237,A,Plasma,,1,BAO_0000218,Half life in dog plasma after administration of 1 mg/kg iv,,,1969.0,Canis lupus familiaris,CHEMBL621369,9615.0
3132,N,,,,In vivo,50588,1,Intermediate,,7238,A,Plasma,,1,BAO_0000218,Half life in dog plasma was determined at dose 10 mg/kg,,,1969.0,Canis lupus familiaris,CHEMBL621370,9615.0
5374,N,,,,,50588,1,Intermediate,,7239,A,,,1,BAO_0000218,Half life in dog was determined,,,,Canis lupus familiaris,CHEMBL621371,9615.0
5007,N,,,,In vivo,50588,1,Intermediate,,7240,A,,,1,BAO_0000218,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,,,Canis lupus familiaris,CHEMBL621372,9615.0
16907,N,,,,,50588,1,Intermediate,,7241,A,Plasma,,1,BAO_0000218,Half life upon exposure to human plasma,,,1969.0,Canis lupus familiaris,CHEMBL621373,9615.0
6057,N,,,,,50588,1,Intermediate,,7242,A,,,1,BAO_0000218,Half life was calculated in dog,,,,Canis lupus familiaris,CHEMBL621374,9615.0
5006,N,,,,,50588,1,Intermediate,,7243,A,,,1,BAO_0000218,Half life was determined,,,,Canis lupus familiaris,CHEMBL621375,9615.0
5473,N,,,,,50588,1,Intermediate,,7244,A,,,1,BAO_0000218,Half life was determined,,,,Canis lupus familiaris,CHEMBL621376,9615.0
4368,N,,,,In vivo,50588,1,Intermediate,,7245,A,,,1,BAO_0000218,Half life by intravenous administration of 1.2 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL619624,9615.0
6448,N,,,,,50588,1,Intermediate,,7246,A,,,1,BAO_0000218,Half life in dog,,,,Canis lupus familiaris,CHEMBL875840,9615.0
4353,N,,,,,50588,1,Intermediate,,7247,A,,,1,BAO_0000218,Half life in dog after intra venous administration of the compound,,,,Canis lupus familiaris,CHEMBL619625,9615.0
4353,N,,,,,50588,1,Intermediate,,7248,A,,,1,BAO_0000218,Half life in dog after intra venous administration of the compound; ND means Not determined,,,,Canis lupus familiaris,CHEMBL619626,9615.0
4353,N,,,,In vivo,50588,1,Intermediate,,7249,A,,,1,BAO_0000218,Half life in dog after po administration of the compound,,,,Canis lupus familiaris,CHEMBL619627,9615.0
4353,N,,,,In vivo,50588,1,Intermediate,,7250,A,,,1,BAO_0000218,Half life in dog after po administration of the compound; ND means Not determined,,,,Canis lupus familiaris,CHEMBL873817,9615.0
6265,N,,,,In vivo,50588,1,Intermediate,,7251,A,,,1,BAO_0000218,Half life in dog at the single oral dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL619628,9615.0
5006,N,,,,,50588,1,Intermediate,,7252,A,,,1,BAO_0000218,Half life in dogs,,,,Canis lupus familiaris,CHEMBL619629,9615.0
5356,N,,,,In vivo,50588,1,Intermediate,,7253,A,,,1,BAO_0000218,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,,,Canis lupus familiaris,CHEMBL619630,9615.0
405,N,,,,,50588,1,Intermediate,,7254,A,,,1,BAO_0000218,Half life in rat,,,,Canis lupus familiaris,CHEMBL619631,9615.0
6642,N,,,,In vivo,50588,1,Intermediate,,7255,A,,,1,BAO_0000218,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,,,Canis lupus familiaris,CHEMBL619632,9615.0
10107,N,,,,In vivo,50594,1,Intermediate,,7256,A,Bone,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,10000001.0,Mus musculus,CHEMBL619633,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7257,A,Bone,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,10000001.0,Mus musculus,CHEMBL875841,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7258,A,Bone,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,10000001.0,Mus musculus,CHEMBL619634,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7259,A,Bone,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,10000001.0,Mus musculus,CHEMBL619635,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7260,A,Bone,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,10000001.0,Mus musculus,CHEMBL619636,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7261,A,Gut,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,10000004.0,Mus musculus,CHEMBL619637,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7262,A,Gut,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,10000004.0,Mus musculus,CHEMBL619638,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7263,A,Gut,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,10000004.0,Mus musculus,CHEMBL619639,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7264,A,Gut,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,10000004.0,Mus musculus,CHEMBL619640,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7265,A,Gut,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,10000004.0,Mus musculus,CHEMBL619641,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7266,A,Gut,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,10000004.0,Mus musculus,CHEMBL619642,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7267,A,Gut,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,10000004.0,Mus musculus,CHEMBL619643,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7268,A,Heart,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,948.0,Mus musculus,CHEMBL619644,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7269,A,Heart,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,948.0,Mus musculus,CHEMBL621112,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7270,A,Heart,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,948.0,Mus musculus,CHEMBL621113,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7271,A,Heart,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,948.0,Mus musculus,CHEMBL621114,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7272,A,Heart,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,948.0,Mus musculus,CHEMBL621115,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7273,A,Heart,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,948.0,Mus musculus,CHEMBL621116,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7274,A,Heart,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,948.0,Mus musculus,CHEMBL621117,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7275,A,Kidney,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,2113.0,Mus musculus,CHEMBL621118,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7276,A,Kidney,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,2113.0,Mus musculus,CHEMBL621119,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7277,A,Kidney,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,2113.0,Mus musculus,CHEMBL621120,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7278,A,Kidney,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,2113.0,Mus musculus,CHEMBL621757,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7279,A,Kidney,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,2113.0,Mus musculus,CHEMBL621758,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7280,A,Kidney,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,2113.0,Mus musculus,CHEMBL621759,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7281,A,Kidney,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,2113.0,Mus musculus,CHEMBL621760,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7282,A,Liver,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,2107.0,Mus musculus,CHEMBL621761,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7283,A,Liver,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,2107.0,Mus musculus,CHEMBL621762,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7284,A,Liver,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,2107.0,Mus musculus,CHEMBL621763,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7285,A,Liver,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,2107.0,Mus musculus,CHEMBL624502,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7286,A,Liver,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,2107.0,Mus musculus,CHEMBL624503,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7287,A,Liver,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,2107.0,Mus musculus,CHEMBL624504,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7288,A,Liver,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,2107.0,Mus musculus,CHEMBL624505,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7289,A,Lung,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,2048.0,Mus musculus,CHEMBL624506,10090.0
5895,N,,,A2780,,81034,1,Intermediate,,7290,F,,,1,BAO_0000219,In vitro cytotoxicity against A2780 (human ovarian cancer),478.0,,,Homo sapiens,CHEMBL624507,9606.0
6338,N,,,A2780,,81034,1,Intermediate,,7291,F,,,1,BAO_0000219,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,478.0,,,Homo sapiens,CHEMBL624508,9606.0
15163,N,,,A2780,,81034,1,Intermediate,,7292,F,,,1,BAO_0000219,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,478.0,,,Homo sapiens,CHEMBL624509,9606.0
15163,N,,,A2780,,81034,1,Intermediate,,7293,F,,,1,BAO_0000219,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,478.0,,,Homo sapiens,CHEMBL624510,9606.0
15000,N,,,A2780,,81034,1,Expert,,7294,F,,,1,BAO_0000219,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,478.0,,,Homo sapiens,CHEMBL875956,9606.0
15000,N,,,A2780,,81034,1,Expert,,7295,F,,,1,BAO_0000219,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,478.0,,,Homo sapiens,CHEMBL839885,9606.0
14729,N,,,A2780,,81034,1,Expert,,7296,F,,,1,BAO_0000219,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,478.0,,,Homo sapiens,CHEMBL624511,9606.0
17270,N,,,A2780,,81034,1,Intermediate,,7297,F,,,1,BAO_0000219,In vitro cytotoxicity against A2780 cell line,478.0,,,Homo sapiens,CHEMBL624512,9606.0
5685,N,,,A2780,,81034,1,Intermediate,,7298,F,,,1,BAO_0000219,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,478.0,,,Homo sapiens,CHEMBL624513,9606.0
3563,N,,,A2780,,81034,1,Intermediate,,7299,F,,,1,BAO_0000219,In vitro inhibitory activity against human ovarian cancer A2780 cell line,478.0,,,Homo sapiens,CHEMBL624514,9606.0
17753,N,,,A2780,,81034,1,Intermediate,,7300,F,,,1,BAO_0000218,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,478.0,,,Homo sapiens,CHEMBL618547,9606.0
16317,N,,,A2780,,81034,1,Intermediate,,7301,F,,,1,BAO_0000219,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",478.0,,,Homo sapiens,CHEMBL618548,9606.0
16936,N,,,A2780,,81034,1,Intermediate,,7302,F,,,1,BAO_0000219,Inhibition of tubulin polymerization in analogy of ca.,478.0,,,Homo sapiens,CHEMBL618549,9606.0
3801,N,,,A2780,,81034,1,Intermediate,,7303,F,,,1,BAO_0000219,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,478.0,,,Homo sapiens,CHEMBL618550,9606.0
6181,N,,,A2780,,81034,1,Expert,,7304,F,,,1,BAO_0000219,Cytotoxic effect in ovarian cancer cell line (A2780),478.0,,,Homo sapiens,CHEMBL618551,9606.0
5318,N,,,A2780,,81034,1,Intermediate,,7305,F,,,1,BAO_0000219,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,478.0,,,Homo sapiens,CHEMBL618552,9606.0
4840,N,,,A2780,,81034,1,Intermediate,,7306,F,,,1,BAO_0000219,Tested for the cytotoxicity in A2780 ovarian cell line,478.0,,,Homo sapiens,CHEMBL618553,9606.0
15748,N,,,A2780,,81034,1,Intermediate,,7307,F,,,1,BAO_0000219,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),478.0,,,Homo sapiens,CHEMBL618554,9606.0
15748,N,,,A2780,,81034,1,Intermediate,,7308,F,,,1,BAO_0000219,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,478.0,,,Homo sapiens,CHEMBL618555,9606.0
15748,N,,,A2780cisR,,80017,1,Intermediate,,7309,F,,,1,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,481.0,,,,CHEMBL618556,
15748,N,,,A2780cisR,,80017,1,Intermediate,,7310,F,,,1,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),481.0,,,,CHEMBL618557,
15748,N,,,A2780cisR,,80017,1,Intermediate,,7311,F,,,1,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,481.0,,,,CHEMBL618558,
15748,N,,,A2780cisR,,80017,1,Intermediate,,7312,F,,,1,BAO_0000219,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),481.0,,,,CHEMBL618559,
17753,N,,,A2780,,81034,1,Intermediate,,7313,F,,,1,BAO_0000218,In vivo log of cells killed after administration of compound in A2780 cell line,478.0,,,Homo sapiens,CHEMBL618560,9606.0
17753,N,,,A2780,In vivo,81034,1,Intermediate,,7314,F,,,1,BAO_0000218,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,478.0,,,Homo sapiens,CHEMBL618561,9606.0
16936,N,,,A2780,,81034,1,Intermediate,,7315,F,,,1,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,478.0,,,Homo sapiens,CHEMBL618562,9606.0
16936,N,,,A2780,,81034,1,Intermediate,,7316,F,,,1,BAO_0000219,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,478.0,,,Homo sapiens,CHEMBL618563,9606.0
16936,N,,,A2780,,81034,1,Intermediate,,7317,F,,,1,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,478.0,,,Homo sapiens,CHEMBL618564,9606.0
16936,N,,,A2780,,81034,1,Intermediate,,7318,F,,,1,BAO_0000219,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,478.0,,,Homo sapiens,CHEMBL618565,9606.0
17528,N,,,A2780,,81034,1,Intermediate,,7319,F,,,1,BAO_0000218,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),478.0,,,Homo sapiens,CHEMBL618566,9606.0
6633,N,,,A2780,,81034,1,Intermediate,,7320,F,,,1,BAO_0000219,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,478.0,,,Homo sapiens,CHEMBL618567,9606.0
15000,N,,,A2780,,81034,1,Expert,,7321,F,,,1,BAO_0000219,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,478.0,,,Homo sapiens,CHEMBL618568,9606.0
17528,N,,,A2780,,81034,1,Expert,,7322,F,,,1,BAO_0000219,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,478.0,,,Homo sapiens,CHEMBL618569,9606.0
16936,N,,,A2780,,81034,1,Intermediate,,7323,F,,,1,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,478.0,,,Homo sapiens,CHEMBL621857,9606.0
16936,N,,,A2780,,81034,1,Intermediate,,7324,F,,,1,BAO_0000219,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,478.0,,,Homo sapiens,CHEMBL621858,9606.0
16936,N,,,A2780,,81034,1,Intermediate,,7325,F,,,1,BAO_0000219,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,478.0,,,Homo sapiens,CHEMBL621859,9606.0
16936,N,,,A2780,,81034,1,Intermediate,,7326,F,,,1,BAO_0000219,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",478.0,,,Homo sapiens,CHEMBL621860,9606.0
16936,N,,,A2780,,81034,1,Intermediate,,7327,F,,,1,BAO_0000219,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),478.0,,,Homo sapiens,CHEMBL621861,9606.0
16936,N,,,A2780,,81034,1,Expert,,7328,F,,,1,BAO_0000219,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",478.0,,,Homo sapiens,CHEMBL621862,9606.0
16936,N,,,A2780,,81034,1,Intermediate,,7329,F,,,1,BAO_0000219,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),478.0,,,Homo sapiens,CHEMBL621863,9606.0
16936,N,,,A2780,,81034,1,Intermediate,,7330,F,,,1,BAO_0000219,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),478.0,,,Homo sapiens,CHEMBL621864,9606.0
16936,N,,,A2780,,81034,1,Intermediate,,7331,F,,,1,BAO_0000219,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),478.0,,,Homo sapiens,CHEMBL621865,9606.0
17737,N,,,A2780,,81034,1,Intermediate,,7332,F,,,1,BAO_0000219,In vitro antiproliferative activity against A2780 cell line,478.0,,,Mus musculus,CHEMBL621866,10090.0
17764,N,,,A2780,,81034,1,Expert,,7333,F,,,1,BAO_0000219,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,478.0,,,Mus musculus,CHEMBL621867,10090.0
3830,N,,,A2780,,81034,1,Intermediate,,7334,F,,,1,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,478.0,,,Homo sapiens,CHEMBL621868,9606.0
3829,N,,,A2780,,81034,1,Intermediate,,7335,F,,,1,BAO_0000219,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,478.0,,,Homo sapiens,CHEMBL875282,9606.0
3546,N,,,,,50588,1,Intermediate,,7336,A,,,1,BAO_0000218,Vc value in dog after IV administration at a dose of 5 mg/kg,,,,Canis lupus familiaris,CHEMBL621869,9615.0
3546,N,,,,In vivo,50588,1,Intermediate,,7337,A,,,1,BAO_0000218,Half life period in dog after IV administration at a dose of 5 mg/kg,,,,Canis lupus familiaris,CHEMBL621870,9615.0
5668,U,,,,,22224,0,Autocuration,,7338,A,,,1,BAO_0000019,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,,,Cercopithecidae,CHEMBL621871,9527.0
3443,U,,,,,22224,0,Autocuration,,7339,A,Plasma,,1,BAO_0000218,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,1969.0,Cercopithecidae,CHEMBL621243,9527.0
3443,U,,,,,22224,0,Autocuration,,7340,A,Plasma,,1,BAO_0000218,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,1969.0,Cercopithecidae,CHEMBL621244,9527.0
4256,U,,,,In vivo,22224,0,Autocuration,,7341,A,,,1,BAO_0000218,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,,,Macaca fascicularis,CHEMBL621245,9541.0
4256,U,,,,In vivo,22224,0,Autocuration,,7342,A,,,1,BAO_0000218,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,,,Macaca fascicularis,CHEMBL621246,9541.0
4256,U,,,,In vivo,22224,0,Autocuration,,7343,A,,,1,BAO_0000218,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,,,Macaca fascicularis,CHEMBL621247,9541.0
4256,U,,,,In vivo,22224,0,Autocuration,,7344,A,,,1,BAO_0000218,Oral Bioavailability in rat,,,,Rattus norvegicus,CHEMBL618386,10116.0
1916,U,,,,,22224,0,Autocuration,,7345,A,,,1,BAO_0000218,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,,,Cercopithecidae,CHEMBL618387,9527.0
5302,U,,,,,22224,0,Autocuration,,7346,A,,,1,BAO_0000218,Area under curve value in monkey at a dose of 5 mg/kg,,,,Cercopithecidae,CHEMBL618388,9527.0
4257,U,,,,,22224,0,Autocuration,,7347,A,,,1,BAO_0000218,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,,,Cercopithecidae,CHEMBL618389,9527.0
5355,U,,,,,22224,0,Autocuration,,7348,A,,,1,BAO_0000019,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,,,Cercopithecidae,CHEMBL618574,9527.0
5355,U,,,,,22224,0,Autocuration,,7349,A,,,1,BAO_0000019,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,,,Cercopithecidae,CHEMBL618575,9527.0
5355,U,,,,,22224,0,Autocuration,,7350,A,,,1,BAO_0000019,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,,,Cercopithecidae,CHEMBL618576,9527.0
6078,U,,,,,22224,0,Autocuration,,7351,A,,,1,BAO_0000218,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,,,Cercopithecidae,CHEMBL618577,9527.0
6078,U,,,,,22224,0,Autocuration,,7352,A,,,1,BAO_0000218,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,,,Cercopithecidae,CHEMBL876487,9527.0
6062,U,,,,,22224,0,Autocuration,,7353,A,,,1,BAO_0000218,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,,,Cercopithecidae,CHEMBL618578,9527.0
2661,U,,,,,22224,0,Autocuration,,7354,A,,,1,BAO_0000218,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,,Cercopithecidae,CHEMBL618579,9527.0
2661,U,,,,,22224,0,Autocuration,,7355,A,,,1,BAO_0000019,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,,Cercopithecidae,CHEMBL618580,9527.0
5394,U,,,,,22224,0,Autocuration,,7356,A,,,1,BAO_0000218,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,,,Cercopithecidae,CHEMBL618581,9527.0
4397,U,,,,,22224,0,Autocuration,,7357,A,,,1,BAO_0000218,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,,,Cercopithecidae,CHEMBL618582,9527.0
17509,U,,,,,22224,0,Autocuration,,7358,A,,,1,BAO_0000218,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,,,Cercopithecidae,CHEMBL618583,9527.0
17509,U,,,,,22224,0,Autocuration,,7359,A,,,1,BAO_0000218,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,,,Cercopithecidae,CHEMBL618584,9527.0
6641,U,,,,In vivo,22224,0,Autocuration,,7360,A,,,1,BAO_0000218,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,,,Cercopithecidae,CHEMBL618585,9527.0
5355,U,,,,,22224,0,Autocuration,,7361,A,,,1,BAO_0000218,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,,,Cercopithecidae,CHEMBL618586,9527.0
3443,U,,,,In vivo,22224,0,Autocuration,,7362,A,,,1,BAO_0000218,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,,Cercopithecidae,CHEMBL618587,9527.0
3443,U,,,,In vivo,22224,0,Autocuration,,7363,A,,,1,BAO_0000218,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,,,Cercopithecidae,CHEMBL618588,9527.0
17409,U,,,,,22224,0,Autocuration,,7364,A,,,1,BAO_0000019,Binding towards monkey plasma protein at 10 uM,,,,Cercopithecidae,CHEMBL618589,9527.0
17409,U,,,,,22224,0,Autocuration,,7365,A,,,1,BAO_0000019,Binding towards monkey plasma protein at 100 uM,,,,Cercopithecidae,CHEMBL618590,9527.0
1052,U,,,,In vivo,22224,0,Autocuration,,7366,A,,,1,BAO_0000218,Apparent bioavailability in squirrel monkey was determined,,,,Cercopithecidae,CHEMBL872262,9527.0
13501,U,,,,In vivo,22224,0,Autocuration,,7367,A,,,1,BAO_0000218,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,,,Cercopithecidae,CHEMBL618591,9527.0
17509,U,,,,In vivo,22224,0,Autocuration,,7368,A,,,1,BAO_0000218,Bioavailability in monkey (dose 2 mg/kg),,,,monkey,CHEMBL618592,9443.0
5394,U,,,,In vivo,22224,0,Autocuration,,7369,A,,,1,BAO_0000218,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,,,Cercopithecidae,CHEMBL876488,9527.0
2661,U,,,,In vivo,22224,0,Autocuration,,7370,A,,,1,BAO_0000218,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,,,Cercopithecidae,CHEMBL618593,9527.0
11219,U,,,,In vivo,22224,0,Autocuration,,7371,A,,,1,BAO_0000218,Bioavailability in monkey (i.d. dosing),,,,monkey,CHEMBL618594,9443.0
3045,U,,,,In vivo,22224,0,Autocuration,,7372,A,,,1,BAO_0000218,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,,,Cercopithecidae,CHEMBL618595,9527.0
17796,U,,,,,22224,0,Autocuration,,7373,A,,,1,BAO_0000019,Clearance of the drug was measured in cynomolgus,,,,Cercopithecidae,CHEMBL621469,9527.0
1399,U,,,,In vivo,22224,0,Autocuration,,7374,A,,,1,BAO_0000218,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,,,Cercopithecidae,CHEMBL621470,9527.0
2661,U,,,,In vivo,22224,0,Autocuration,,7375,A,,,1,BAO_0000218,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,,,Cercopithecidae,CHEMBL621471,9527.0
5005,U,,,,In vivo,22224,0,Autocuration,,7376,A,Plasma,,1,BAO_0000218,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,,1969.0,Macaca mulatta,CHEMBL621472,9544.0
17267,U,,,,In vivo,22224,0,Autocuration,,7377,A,,,1,BAO_0000218,Plasma clearance in rhesus monkey was determined,,,,Cercopithecidae,CHEMBL621473,9527.0
6535,U,,,,In vivo,22224,0,Autocuration,,7378,A,,,1,BAO_0000218,Plasma clearance in monkey after administration of 1 mg/kg iv,,,,Cercopithecidae,CHEMBL621474,9527.0
5922,U,,,,In vivo,22224,0,Autocuration,,7379,A,,,1,BAO_0000218,Plasma clearance in cynomolgus monkey,,,,Cercopithecidae,CHEMBL621475,9527.0
6221,U,,,,In vivo,22224,0,Autocuration,,7380,A,,,1,BAO_0000218,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,,,Cercopithecidae,CHEMBL621476,9527.0
5668,U,,,,In vivo,22224,0,Autocuration,,7381,A,,,1,BAO_0000218,Plasma clearance after peroral administration at 10 mpk in Rhesus,,,,Cercopithecidae,CHEMBL624290,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,7382,A,,,1,BAO_0000218,The total clearance was determined after intravenous administration in cynomolgus monkeys,,,,Cercopithecidae,CHEMBL624291,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,7383,A,,,1,BAO_0000218,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,,,Cercopithecidae,CHEMBL624292,9527.0
5355,U,,,,In vivo,22224,0,Autocuration,,7384,A,,,1,BAO_0000218,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,,,Cercopithecidae,CHEMBL624293,9527.0
4578,U,,,,In vivo,22224,0,Autocuration,,7385,A,,,1,BAO_0000218,Tested for Clearance upon iv administration to african green monkey,,,,Cercopithecidae,CHEMBL624294,9527.0
17592,U,,,,In vivo,22224,0,Autocuration,,7386,A,,,1,BAO_0000218,Clearance in monkey,,,,Cercopithecidae,CHEMBL624295,9527.0
6641,N,,,,In vivo,50588,1,Intermediate,,7387,A,,,1,BAO_0000218,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,,Canis lupus familiaris,CHEMBL624296,9615.0
6642,N,,,,In vivo,50588,1,Intermediate,,7388,A,,,1,BAO_0000218,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,,,Canis lupus familiaris,CHEMBL624297,9615.0
16367,N,,,,In vivo,50588,1,Intermediate,,7389,A,,,1,BAO_0000218,Half life was evaluated after intravenous administration to dogs,,,,Canis lupus familiaris,CHEMBL624298,9615.0
5472,N,,,,,50588,1,Intermediate,,7390,A,,,1,BAO_0000218,Half life was evaluated in dog,,,,Canis lupus familiaris,CHEMBL624299,9615.0
5474,N,,,,,50588,1,Intermediate,,7391,A,,,1,BAO_0000218,Half life was evaluated in dog,,,,Canis lupus familiaris,CHEMBL624300,9615.0
5654,N,,,,In vivo,50588,1,Intermediate,,7392,A,,,1,BAO_0000218,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL624301,9615.0
6227,N,,,,In vivo,50588,1,Intermediate,,7393,A,,,1,BAO_0000218,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,,,Canis lupus familiaris,CHEMBL624302,9615.0
6227,N,,,,In vivo,50588,1,Intermediate,,7394,A,,,1,BAO_0000218,Half life period after intravenous administration in dog,,,,Canis lupus familiaris,CHEMBL876026,9615.0
6221,N,,,,In vivo,50588,1,Intermediate,,7395,A,,,1,BAO_0000218,Half life period after oral administration (2.5 mg/kg) in dog was determined,,,,Canis lupus familiaris,CHEMBL624303,9615.0
4527,N,,,,,50588,1,Intermediate,,7396,A,,,1,BAO_0000218,Half life period at a dose of 1 uM/kg in dog was determined,,,,Canis lupus familiaris,CHEMBL624304,9615.0
5668,N,,,,In vivo,50588,1,Intermediate,,7397,A,,,1,BAO_0000218,Half life period was determine after peroral administration at 10 mpk in dog,,,,Canis lupus familiaris,CHEMBL624305,9615.0
5668,N,,,,In vivo,50588,1,Intermediate,,7398,A,,,1,BAO_0000218,Half life period was determine after peroral administration at 5 mpk in dog,,,,Canis lupus familiaris,CHEMBL624306,9615.0
3854,N,,,,,50588,1,Intermediate,,7399,A,,,1,BAO_0000218,Half life period was determined,,,,Canis lupus familiaris,CHEMBL624307,9615.0
5505,N,,,,,50588,1,Intermediate,,7400,A,,,1,BAO_0000218,Half life period was determined,,,,Canis lupus familiaris,CHEMBL624308,9615.0
6251,N,,,,In vivo,50588,1,Intermediate,,7401,A,,,1,BAO_0000218,Half life period by iv administration in dog at a dose of 6 mg/kg,,,,Canis lupus familiaris,CHEMBL624309,9615.0
1918,N,,,,,50588,1,Intermediate,,7402,A,,,1,BAO_0000218,Half life period was evaluated in dog,,,,Canis lupus familiaris,CHEMBL624310,9615.0
5546,N,,,,In vivo,50588,1,Intermediate,,7403,A,,,1,BAO_0000218,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,,,Canis lupus familiaris,CHEMBL625003,9615.0
4809,N,,,,In vivo,50588,1,Intermediate,,7404,A,,,1,BAO_0000218,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,,,Canis lupus familiaris,CHEMBL625004,9615.0
6215,N,,,,In vivo,50588,1,Intermediate,,7405,A,,,1,BAO_0000218,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,,,Canis lupus familiaris,CHEMBL625005,9615.0
4527,N,,,,In vivo,50588,1,Intermediate,,7406,A,,,1,BAO_0000218,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,,,Canis lupus familiaris,CHEMBL873813,9615.0
17594,N,,,,In vivo,50588,1,Intermediate,,7407,A,,,1,BAO_0000218,Half-life after oral dose of compound at 3 mg/kg in dogs,,,,Canis lupus familiaris,CHEMBL625006,9615.0
17839,N,,,,In vivo,50588,1,Intermediate,,7408,A,,,1,BAO_0000218,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,,,Canis lupus familiaris,CHEMBL625007,9615.0
17839,N,,,,In vivo,50588,1,Intermediate,,7409,A,,,1,BAO_0000218,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,,,Canis lupus familiaris,CHEMBL876027,9615.0
17839,N,,,,In vivo,50588,1,Intermediate,,7410,A,,,1,BAO_0000218,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,,,Canis lupus familiaris,CHEMBL625008,9615.0
17839,N,,,,In vivo,50588,1,Intermediate,,7411,A,,,1,BAO_0000218,Half-life of compound in dog following p.o. administration of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL625009,9615.0
5210,N,,,,,50588,1,Intermediate,,7412,A,Plasma,,1,BAO_0000218,Half-life of compound in plasma of dog was determined,,,1969.0,Canis lupus familiaris,CHEMBL625010,9615.0
5210,N,,,,,50588,1,Intermediate,,7413,A,,,1,BAO_0000218,Half-life of compound was determined in dogs,,,,Canis lupus familiaris,CHEMBL625011,9615.0
2959,N,,,,In vivo,50588,1,Intermediate,,7414,A,,,1,BAO_0000218,Half-life after administration of 4 mg/Kg oral dose in dog,,,,Canis lupus familiaris,CHEMBL621553,9615.0
4137,N,,,,In vivo,50588,1,Intermediate,,7415,A,,,1,BAO_0000218,Half-life after intravenous administration of 1 mg/kg/h in dog,,,,Canis lupus familiaris,CHEMBL621554,9615.0
5064,N,,,,,50588,1,Intermediate,,7416,A,,,1,BAO_0000218,Half-life in Dog,,,,Canis lupus familiaris,CHEMBL621555,9615.0
5147,N,,,,,50588,1,Intermediate,,7417,A,,,1,BAO_0000218,Half-life in Dog,,,,Canis lupus familiaris,CHEMBL621556,9615.0
5145,N,,,,,50588,1,Intermediate,,7418,A,,,1,BAO_0000218,Half-life in dog,,,,Canis lupus familiaris,CHEMBL621557,9615.0
6123,N,,,,In vivo,50588,1,Intermediate,,7419,A,,,1,BAO_0000218,Half-life in dog after oral administration at 1 mg/kg,,,,Canis lupus familiaris,CHEMBL621558,9615.0
6123,N,,,,In vivo,50588,1,Intermediate,,7420,A,,,1,BAO_0000218,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,,,Canis lupus familiaris,CHEMBL621559,9615.0
4333,N,,,,,50588,1,Intermediate,,7421,A,,,1,BAO_0000218,Half-life in dogs,,,,Canis lupus familiaris,CHEMBL621560,9615.0
4333,N,,,,,50588,1,Intermediate,,7422,A,,,1,BAO_0000218,Half-life in dogs; ND indicates not determined,,,,Canis lupus familiaris,CHEMBL876028,9615.0
12500,N,,,,,50588,1,Intermediate,,7423,A,Plasma,,1,BAO_0000218,Half-life in plasma of dog,,,1969.0,Canis lupus familiaris,CHEMBL621561,9615.0
12500,N,,,,,50588,1,Intermediate,,7424,A,Plasma,,1,BAO_0000218,Half-life in plasma of dog at dose of 3-10 mgkg,,,1969.0,Canis lupus familiaris,CHEMBL621562,9615.0
6005,N,,,,In vivo,50588,1,Intermediate,,7425,A,,,1,BAO_0000218,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL621563,9615.0
6062,N,,,,In vivo,50588,1,Intermediate,,7426,A,,,1,BAO_0000218,Half-life was measured in dog after an iv dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL621564,9615.0
17650,N,,,,In vivo,50588,1,Intermediate,,7427,A,,,1,BAO_0000218,Half-life was measured in dogs after an oral dose of 10 uM/kg,,,,Canis lupus familiaris,CHEMBL621565,9615.0
5530,N,,,,In vivo,50588,1,Intermediate,,7428,A,,,1,BAO_0000218,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,,,Canis lupus familiaris,CHEMBL621566,9615.0
5530,N,,,,In vivo,50588,1,Intermediate,,7429,A,,,1,BAO_0000218,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,,,Canis lupus familiaris,CHEMBL621567,9615.0
5600,N,,,,In vivo,50588,1,Intermediate,,7430,A,,,1,BAO_0000218,Half-life of the compound after 0.3 mg/kg po administration in dog,,,,Canis lupus familiaris,CHEMBL622978,9615.0
6039,N,,,,In vivo,50588,1,Intermediate,,7431,A,,,1,BAO_0000218,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,,,Canis lupus familiaris,CHEMBL873814,9615.0
6039,N,,,,In vivo,50588,1,Intermediate,,7432,A,,,1,BAO_0000218,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,,,Canis lupus familiaris,CHEMBL623219,9615.0
6039,N,,,,In vivo,50588,1,Intermediate,,7433,A,,,1,BAO_0000218,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,,,Canis lupus familiaris,CHEMBL624477,9615.0
6227,N,,,,,50588,1,Intermediate,,7434,A,,,1,BAO_0000218,t1/2 in dog,,,,Canis lupus familiaris,CHEMBL624478,9615.0
14541,N,,,,,50588,1,Intermediate,,7435,A,,,1,BAO_0000218,Half-life period measured in dogs,,,,Canis lupus familiaris,CHEMBL624479,9615.0
4521,N,,,,In vivo,50588,1,Intermediate,,7436,A,,,1,BAO_0000218,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,,,Canis lupus familiaris,CHEMBL624480,9615.0
4521,N,,,,In vivo,50588,1,Intermediate,,7437,A,,,1,BAO_0000218,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,,,Canis lupus familiaris,CHEMBL623595,9615.0
6679,N,,,,In vivo,50588,1,Intermediate,,7438,A,,,1,BAO_0000218,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,,,Canis lupus familiaris,CHEMBL623596,9615.0
1116,N,,,,In vitro,50588,1,Intermediate,,7439,A,Plasma,,1,BAO_0000218,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",,,1969.0,Canis lupus familiaris,CHEMBL623597,9615.0
5444,N,,,,In vivo,50588,1,Intermediate,,7440,A,,,1,BAO_0000218,In vivo half life period was calculated at 1 mg/kg in dog,,,,Canis lupus familiaris,CHEMBL623598,9615.0
5444,N,,,,In vivo,50588,1,Intermediate,,7441,A,,,1,BAO_0000218,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,,,Canis lupus familiaris,CHEMBL623599,9615.0
17853,N,,,,In vivo,50588,1,Intermediate,,7442,A,,,1,BAO_0000218,Longer half-life in dog (i.v.) at 0.5 mpk,,,,Canis lupus familiaris,CHEMBL623600,9615.0
4353,N,,,,In vivo,50588,1,Intermediate,,7443,A,,,1,BAO_0000218,Oral bioavailability in dog (dose 5 uM/kg),,,,Canis lupus familiaris,CHEMBL623601,9615.0
16452,N,,,,In vivo,50588,1,Intermediate,,7444,A,,,1,BAO_0000218,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,,,Canis lupus familiaris,CHEMBL623602,9615.0
16452,N,,,,In vivo,50588,1,Intermediate,,7445,A,,,1,BAO_0000218,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,,,Canis lupus familiaris,CHEMBL623603,9615.0
16452,N,,,,In vivo,50588,1,Intermediate,,7446,A,,,1,BAO_0000218,Bioavailability in dog (dose 1 mg/kg i.v.),,,,Canis lupus familiaris,CHEMBL623604,9615.0
10107,N,,,,In vivo,50594,1,Intermediate,,7447,A,Lung,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,2048.0,Mus musculus,CHEMBL623605,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7448,A,Lung,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,2048.0,Mus musculus,CHEMBL623606,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7449,A,Lung,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,2048.0,Mus musculus,CHEMBL623607,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7450,A,Lung,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,2048.0,Mus musculus,CHEMBL623608,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7451,A,Lung,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,2048.0,Mus musculus,CHEMBL623609,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7452,A,Lung,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,2048.0,Mus musculus,CHEMBL623610,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7453,A,Muscle tissue,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,2385.0,Mus musculus,CHEMBL623611,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7454,A,Muscle tissue,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,,2385.0,Mus musculus,CHEMBL623612,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7455,A,Muscle tissue,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,2385.0,Mus musculus,CHEMBL623613,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7456,A,Muscle tissue,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,2385.0,Mus musculus,CHEMBL623614,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7457,A,Muscle tissue,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,2385.0,Mus musculus,CHEMBL623615,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7458,A,Muscle tissue,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,2385.0,Mus musculus,CHEMBL623616,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7459,A,Muscle tissue,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,2385.0,Mus musculus,CHEMBL623617,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7460,A,Zone of skin,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,14.0,Mus musculus,CHEMBL875944,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7461,A,Zone of skin,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,14.0,Mus musculus,CHEMBL623618,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7462,A,Zone of skin,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,14.0,Mus musculus,CHEMBL623619,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7463,A,Zone of skin,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,14.0,Mus musculus,CHEMBL623620,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7464,A,Zone of skin,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,14.0,Mus musculus,CHEMBL623621,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7465,A,Zone of skin,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,14.0,Mus musculus,CHEMBL623622,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7466,A,Zone of skin,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,14.0,Mus musculus,CHEMBL623623,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7467,A,Spleen,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,2106.0,Mus musculus,CHEMBL623624,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7468,A,Spleen,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,2106.0,Mus musculus,CHEMBL618521,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7469,A,Spleen,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,2106.0,Mus musculus,CHEMBL618522,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7470,A,Spleen,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,2106.0,Mus musculus,CHEMBL618523,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7471,A,Spleen,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,2106.0,Mus musculus,CHEMBL618524,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7472,A,Spleen,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,2106.0,Mus musculus,CHEMBL618525,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7473,A,Spleen,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,2106.0,Mus musculus,CHEMBL624586,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7474,A,Stomach,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,,945.0,Mus musculus,CHEMBL624587,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7475,A,Stomach,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,,945.0,Mus musculus,CHEMBL624588,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7476,A,Stomach,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,,945.0,Mus musculus,CHEMBL624589,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7477,A,Stomach,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,,945.0,Mus musculus,CHEMBL624590,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7478,A,Stomach,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,,945.0,Mus musculus,CHEMBL624591,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7479,A,Stomach,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,,945.0,Mus musculus,CHEMBL624592,10090.0
10107,N,,,,In vivo,50594,1,Intermediate,,7480,A,Stomach,,1,BAO_0000218,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,,945.0,Mus musculus,CHEMBL624593,10090.0
4689,N,,,,In vivo,50597,1,Intermediate,,7481,A,,,1,BAO_0000218,Oral bioavailability in rat,,,,Rattus norvegicus,CHEMBL624594,10116.0
4950,N,,,,In vivo,50597,1,Intermediate,,7482,A,,,1,BAO_0000218,Tested for the bioavailability in rat,,,,Rattus norvegicus,CHEMBL624595,10116.0
5328,N,,,,In vivo,50597,1,Intermediate,,7483,A,,,1,BAO_0000218,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,,,Rattus norvegicus,CHEMBL624596,10116.0
406,N,,,,In vivo,50597,1,Intermediate,,7484,A,,,1,BAO_0000218,Bioavailability in rat,,,,Rattus norvegicus,CHEMBL624597,10116.0
12500,N,,,,In vivo,50597,1,Intermediate,,7485,A,,,1,BAO_0000218,Bioavailability in rat,,,,Rattus norvegicus,CHEMBL624598,10116.0
12500,N,,,,In vivo,50597,1,Intermediate,,7486,A,,,1,BAO_0000218,Bioavailability in rat (dose 3-10 mg/kg),,,,Rattus norvegicus,CHEMBL624599,10116.0
5247,N,,,,In vivo,50597,1,Intermediate,,7487,A,,,1,BAO_0000218,Bioavailability in rat,,,,Rattus norvegicus,CHEMBL875166,10116.0
4186,N,,,,In vivo,50597,1,Intermediate,,7488,A,Plasma,,1,BAO_0000218,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,,1969.0,Rattus norvegicus,CHEMBL624600,10116.0
4186,N,,,,In vivo,50597,1,Intermediate,,7489,A,Plasma,,1,BAO_0000218,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,,1969.0,Rattus norvegicus,CHEMBL624601,10116.0
6647,N,,,,In vivo,50597,1,Intermediate,,7490,A,,,1,BAO_0000218,Half life after oral administration was determined in rats at 6 mg/kg,,,,Rattus norvegicus,CHEMBL624602,10116.0
6484,N,,,,,50597,1,Intermediate,,7491,A,,,1,BAO_0000218,Half life was determined,,,,Rattus norvegicus,CHEMBL624603,10116.0
3249,N,,,,In vivo,50597,1,Intermediate,,7492,A,,,1,BAO_0000218,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,,,Rattus norvegicus,CHEMBL624604,10116.0
6281,N,,,,In vivo,50597,1,Intermediate,,7493,A,Plasma,,1,BAO_0000218,Plasma half life in rat at oral dose 2.8 mg/mk body weight,,,1969.0,Rattus norvegicus,CHEMBL624605,10116.0
3307,N,,,,,50597,1,Intermediate,,7494,A,,,1,BAO_0000218,Half life in rats,,,,Rattus norvegicus,CHEMBL624606,10116.0
12058,N,,,,In vivo,50597,1,Intermediate,,7495,A,Blood,,1,BAO_0000218,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,,,178.0,Rattus norvegicus,CHEMBL624607,10116.0
8833,N,,,,,50597,1,Intermediate,,7496,A,,,1,BAO_0000218,Hill coefficient of the compound,,,,Rattus norvegicus,CHEMBL624608,10116.0
3193,N,,,,,50597,1,Intermediate,,7497,A,Blood,,1,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,,178.0,Rattus norvegicus,CHEMBL624609,10116.0
3193,N,,,,,50597,1,Intermediate,,7498,A,Blood,,1,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,,178.0,Rattus norvegicus,CHEMBL624610,10116.0
3193,N,,,,,50597,1,Intermediate,,7499,A,Blood,,1,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,,178.0,Rattus norvegicus,CHEMBL624611,10116.0
3193,N,,,,,50597,1,Intermediate,,7500,A,Blood,,1,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,,178.0,Rattus norvegicus,CHEMBL624612,10116.0
3193,N,,,,,50597,1,Intermediate,,7501,A,Blood,,1,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,,178.0,Rattus norvegicus,CHEMBL875167,10116.0
3193,N,,,,,50597,1,Intermediate,,7502,A,Blood,,1,BAO_0000218,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,,178.0,Rattus norvegicus,CHEMBL624613,10116.0
3193,N,,,,,50597,1,Intermediate,,7503,A,Blood,,1,BAO_0000218,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,,178.0,Rattus norvegicus,CHEMBL624614,10116.0
5960,N,,,,,50597,1,Intermediate,,7504,A,,,1,BAO_0000218,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,,,Rattus norvegicus,CHEMBL624392,10116.0
13950,N,,,,In vivo,50597,1,Intermediate,,7505,A,Brain,,1,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,,,955.0,Rattus norvegicus,CHEMBL624393,10116.0
13950,N,,,,In vivo,50597,1,Intermediate,,7506,A,Brain,,1,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,,,955.0,Rattus norvegicus,CHEMBL624394,10116.0
13950,N,,,,In vivo,50597,1,Intermediate,,7507,A,Brain,,1,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,,,955.0,Rattus norvegicus,CHEMBL624395,10116.0
13950,N,,,,In vivo,50597,1,Intermediate,,7508,A,Brain,,1,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,,,955.0,Rattus norvegicus,CHEMBL624396,10116.0
13950,N,,,,In vivo,50597,1,Intermediate,,7509,A,Brain,,1,BAO_0000218,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,,,955.0,Rattus norvegicus,CHEMBL624397,10116.0
13950,N,,,,In vivo,50597,1,Intermediate,,7510,A,Thyroid gland,,1,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,,,2046.0,Rattus norvegicus,CHEMBL624398,10116.0
13950,N,,,,In vivo,50597,1,Intermediate,,7511,A,Thyroid gland,,1,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,,,2046.0,Rattus norvegicus,CHEMBL624399,10116.0
13950,N,,,,In vivo,50597,1,Intermediate,,7512,A,Thyroid gland,,1,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,,,2046.0,Rattus norvegicus,CHEMBL624400,10116.0
13950,N,,,,In vivo,50597,1,Intermediate,,7513,A,Thyroid gland,,1,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,,,2046.0,Rattus norvegicus,CHEMBL624401,10116.0
13950,N,,,,In vivo,50597,1,Intermediate,,7514,A,Thyroid gland,,1,BAO_0000218,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,,,2046.0,Rattus norvegicus,CHEMBL624402,10116.0
9866,N,,,,In vivo,50597,1,Intermediate,,7515,A,Blood,,1,BAO_0000218,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,178.0,Rattus norvegicus,CHEMBL624403,10116.0
9866,N,,,,In vivo,50597,1,Intermediate,,7516,A,Blood,,1,BAO_0000218,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,,,178.0,Rattus norvegicus,CHEMBL624404,10116.0
9866,N,,,,In vivo,50597,1,Intermediate,,7517,A,Blood,,1,BAO_0000218,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,,,178.0,Rattus norvegicus,CHEMBL624405,10116.0
9866,N,,,,In vivo,50597,1,Intermediate,,7518,A,Bone,,1,BAO_0000218,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,10000001.0,Rattus norvegicus,CHEMBL624406,10116.0
9866,N,,,,In vivo,50597,1,Intermediate,,7519,A,Bone,,1,BAO_0000218,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,,,10000001.0,Rattus norvegicus,CHEMBL624407,10116.0
9866,N,,,,In vivo,50597,1,Intermediate,,7520,A,Bone,,1,BAO_0000218,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,,,10000001.0,Rattus norvegicus,CHEMBL624408,10116.0
9866,N,,,,In vivo,50597,1,Intermediate,,7521,A,Heart,,1,BAO_0000218,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,,948.0,Rattus norvegicus,CHEMBL618644,10116.0
9866,N,,,,In vivo,50597,1,Intermediate,,7522,A,Heart,,1,BAO_0000218,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,,,948.0,Rattus norvegicus,CHEMBL618645,10116.0
9866,N,,,,In vivo,50597,1,Intermediate,,7523,A,Heart,,1,BAO_0000218,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,,,948.0,Rattus norvegicus,CHEMBL618646,10116.0
9866,N,,,,Inbivo,50597,1,Ihtermedia4e,,7524,A,lidney,,1,BAO00p9218,Biodistr9gu6ilbinbkrmalraykidneyintuep5ssenceof0095MGd001Mligat1hr,,,3236514.0,Rattusnorvegixhd,CHEMBL6q86e7,1210.0
9866,N,,,,Invibo,50597,1,Ihtermediats,,7525,A,Kidnej,,1,nAO0000w18,Bioflstribitioninnormapratkidneyijyhepresencepf001MGr0o4kiig,,,244581.0,eayrusnorvegicus,CHEMnL6186e8,7017.0
9866,N,,,,Inviv0,50597,1,Inte3mediqte,,7526,A,Kirney,,1,BAO0090228,Biodistrkhu6iobinnornal4atkirneyintue0resenceofNAsGdp01Mligat2gr,,,4020317.0,4attusnodveglcus,CyEMgL618649,11169.0
9866,N,,,,Infivo,50597,1,Integmeduate,,7527,A,Liger,,1,gAO0000w18,Bloxistributioninh9rnalgstpiverinth4prewenceof0005jGd00wMligst2hr,,,3467419.0,Rattusno5vwnicus,CjEMBL6186r0,16857.0
9866,N,,,,Indivo,50597,1,Intetmedkate,,7528,A,Livet,,1,BAO00po218,B78dictriburloninnormalrsfl9verinthdpresence0f001MGd00yMlig,,,371681.0,Rattusnorvsnifus,CHEMBL619y51,5594.0
9866,N,,,,Invido,50597,1,Igtegmediate,,7529,A,L8ver,,1,BAO000022i,fiodistfibutioninnormalratlivegigyjepresehcekfNACGd0p1Moigqtwhr,,,1018626.0,Rattuwnogdegicus,CHEMBi87t497,1453.0
9866,N,,,,Ibvivo,50597,1,Intermeeiste,,7530,A,Lung,,1,BzO0900218,Biidiztributiom9nno5maleatlujginthepresenceoe0005MGd002hlirat2h5,,,557768.0,Rxttuznorvegicua,dHEnBL618652,5412.0
9866,N,,,,Imvivo,50597,1,Intermwdiaye,,7531,A,Lung,,1,BAO000p2w8,Biidostributioninnormaltaylunyinth3p4esenceod00wjGdo05Mlig,,,914414.0,Rartusjorfegicus,CHEMBL61855w,2633.0
9866,N,,,,Inv9vo,50597,1,Intermevjate,,7532,A,Lung,,1,hAO0000q18,Biodistributiininnorhairatlinginthepresehc2ofbACvw00qMligayehr,,,735290.0,3attksnorveticus,CHEMBk6q8654,6261.0
6351,N,,,,,50597,1,9ntermediare,,7533,A,,,1,BAi9000218,Recoveryrat3f5okyrineandbilewwcde5edminedxftfr9vadmihistrqtionat20mgkginrarzNottdst3d,,,,fattusj8rvegicus,vHEMBL61865y,13196.0
1465,N,,,,,50597,1,In6ermrdiate,,7534,A,,,1,BAO0op0218,C8mpoundwaxtestexforsliuvilityinwat4r,,,,Ratthsnorvegivhs,CHEMBLt19656,4961.0
5182,U,,,,,22229,0,Interhediat3,,7535,P,,,1,BAO0o0o100,Solubioityinph8spyatebufbfrddsaline1wMSOa49H6524hrequ8oibrati0n,,,,,CHEMBL6q865u,
17847,N,,,,,50597,1,Interjediqte,,7536,A,,,1,BA90o00218,Solubilltywasdetermlm4d,,,,Rattjdnorveg8cus,CHEhBL6w8658,5057.0
15339,N,,,,,50597,1,Int2emediate,,7537,A,,,1,BAO9000219,sll7bilityinwafe3ugmLah37degdeeC,,,,Rattusboevegicuw,CHEMBk618649,3217.0
5202,N,,,,,50597,1,7ntwrmediate,,7538,A,,,1,vAO000021o,Firstpassmetafollemanemetaboljcbi9zvqilabilityuzing5a4hepat7vmicdosomes,,,,Rwftksnorvegicus,CHEMvo618660,9862.0
1088,N,,,,,50597,1,Imt2rmediate,,7539,A,,,1,BA90900218,Infitr0eyabjoityrelativetoAJ76inratue0stofyteassay,,,,Rattusjorveficua,CHEMBL61i662,17901.0
3169,N,,,,,50597,1,Intsrmedoate,,7540,A,,,1,BAO0oo0218,Halfkifwinrats,,,,fattudnorvegicys,CHrMBk873807,7791.0
5353,N,,,,,50597,1,Interjedlate,,7541,A,,,1,gA00000218,ualflifrinDawleydat,,,,fsttusnorv4gicus,CHEMBLy1i662,3344.0
2864,N,,,,Invico,50597,1,Intermeeiat3,,7542,A,,,1,BA80000w18,Halflifepe4iisafter3mgkgivadminiayraruoh,,,,Rattusnorfegicyc,CHEMBL61u6t3,13761.0
2864,N,,,,Invivk,50597,1,jntermedizte,,7543,A,,,1,BxO0090218,Hapflifeperuosaftef2mgkyivadkinistratklninrat,,,,Rwttudnorvegicys,CHEMvLt18664,3831.0
2864,N,,,,jnvivo,50597,1,Inte4medizte,,7544,A,,,1,BAO00o0318,Hwlgllfeperiodaftdt3nfkglvadministratiojintherat,,,,Rsttushorvegicuz,CHEMBLt18675,7088.0
6362,N,,,,,50597,1,Intermdd9ate,,7545,A,,,1,BAO00p0q18,ualflireperiowinfemaleSpraguexawle7eatw,,,,Rattudnorvrg9cus,CHrMBL8u6498,1945.0
6249,N,,,,,50597,1,Igtermediat3,,7546,A,,,1,BAk000021u,naoflifepdriodinrat,,,,Rattusn8tvericus,CHEhBL6w8666,16517.0
3169,N,,,,,50597,1,In4srmediate,,7547,A,,,1,Bw80000218,Halflufeinratxwaddet3rmjned,,,,Rattusbo4vdgicus,CHwMBL6204r0,4469.0
3169,N,,,,,50597,1,Interjediaye,,7548,A,,,1,BAO0o0021o,balflifeonratd1ithmrtabolifoxiwation,,,,Rat6usnkrvenicus,xHEMnL620441,9086.0
3169,N,,,,,50597,1,Intermevizte,,7549,A,,,1,BzO0090218,Halfkkfeinrats,,,,Rwttusnorvebjcus,dHEMBL62044q,6846.0
17260,N,,,,Ingivo,50597,1,Intermwdiatd,,7550,A,,,1,BAp0090218,T12atafoseof10mgKgxdniniste3edintragenoudly9nfwmalfuanpverwiwtagrat,,,,Rathusnorvdgisus,vHEMBL620343,8626.0
17260,N,,,,lnvivo,50597,1,Ig5ermediate,,7551,A,,,1,BAl00p0218,T1eatadozeog10kgKbadministeredperorallyinfemapdhxgoverwictzfrat,,,,tattuwnorvegkcus,CHsMBLt20444,402.0
17260,N,,,,Inv8vo,50597,1,Inte4mediaye,,7552,A,,,1,BsO000p218,Tmaxatsdoseof10jgKgadmibiste5edintravsmkusly8nvemwletanoverwustarrzt,,,,Rsttksno4vegicus,sHEMBL620345,1415.0
17260,N,,,,Ibvivo,50597,1,Intrrmedlate,,7553,A,,,1,BAO0090318,Tmaxatacoseof10mgKtadmimisteredprr0rxll6knfemaletanovdrwistatray,,,,Rattuanirveg7cus,vHEnBL620446,16388.0
2879,N,,,,,50597,1,Interm2diqte,,7554,A,Piasma,,1,BAO0090217,Bi9lpg9cxlhalflifemeasuredinplazmaog4at,,,997670.0,Rattusnorfeguc7s,CHEkBL62044u,190.0
2879,N,,,,,50597,1,8nterm2diate,,7555,A,9lasma,,1,vAO0900218,niologicxphalflifemewsudedinpoasmaofrwt2226,,,1936572.0,Raftusbirvegicus,CuEMhL621129,803.0
2879,N,,,,,50597,1,Igtermfdiate,,7556,A,Placma,,1,hzO0000218,Bi0logucalhalfl9femeasuredinolaansofrat9w6,,,271613.0,Rat6usnorvegldus,CnwMBL621130,8183.0
3184,N,,,,7nvivo,50597,1,Ijterjediate,,7557,A,,,1,Bql0000218,fompo6ndwqweval7atedforltshalflifewgenadminisgerefin5rwcebouslyinrat,,,,Rattusmordeticus,CbEhBL873808,15036.0
4891,N,,,,Invigo,50597,1,Intermsdiatd,,7558,A,,,1,BAOo00p218,Compkundwasevaoua6wdforphatkackkinericparame4erpercengbioavaiiabul8tya68h,,,,Rattusm0rv2gicus,CHEMBk87659i,15867.0
429,N,,,,Ibvivo,50597,1,Ijterm4diate,,7559,A,,,1,BA8000o218,Evqljatecf8foharhac9kineticparametertalflideinratatthewose50mgkv,,,,5attuwmorvegicus,CHEMBLy21132,10009.0
5656,N,,,,Inv8vo,50597,1,Inte3medjate,,7560,A,,,1,vAO0000318,bxlflifeT12sfteroralarminostration7nraf,,,,Rattucno5vdgicus,CyEnBL621132,3067.0
4413,N,,,,unvivo,50597,1,Intsrmeciate,,7561,A,,,1,BAO0pp0218,ualfligeofcomp0ugdaftefivadministrationofe0ngigcos2inra4,,,,Ra4tusnordegocus,CHEMBL6w1w33,10508.0
3598,N,,,,Inbivo,50597,1,Exp2rt,,7562,A,,,1,BsO0009218,Hwlflireofc8kpoundveterm8nedinratafferivawministrati0nstadkseof20hgkg,,,,Rzttusnkrvehicus,xHEMBL631312,2504.0
17267,N,,,,,50597,1,Intfrmedlate,,7563,A,,,1,BwO000o218,Halfloteofdokpoundwasde6ermon4dinrat,,,,Rah67snorvegicus,xHEMBL622313,5870.0
4727,N,,,,,50597,1,Intermexlate,,7564,A,Blo9d,,1,BsO0000e18,Halflib2ofcom0pundwasvetermigevinratvlood,,,3275139.0,Ratthsnorv4g9cus,CHEMfL6w1314,4496.0
17651,N,,,,7nvivo,50597,1,Igtermediage,,7565,A,,,1,BAOo000217,Hapflkbeatwmgkgdasdeterminerinrat,,,,Rattusnorveguxuq,sH4MBL621315,494.0
17651,N,,,,knvivo,50597,1,unterm3diate,,7566,A,,,1,BAOp000e18,Halflkfeat1pkgkgwasdetermijed7nrzt,,,,Rattisnorvegkc7s,CHsMBL62w316,2291.0
401,N,,,,,50597,1,Ijtsrmediate,,7567,A,,,1,BAOp000118,Halfliteihrats,,,,fatgusnlrvegicus,CbEMBL621e17,3252.0
4942,N,,,,,50597,1,Int2rmediatd,,7568,A,,,1,BAO9009218,Halfiigeinrateinhohrs,,,,Ra5tuzgorvegicus,dHEMBL721318,13383.0
17735,N,,,,Inbivo,50597,1,Inte5mediqte,,7569,A,,,1,BAp000o218,Halfoifefipl8wing10mbkg9btravenousor50mgkgoraldosiggig4atswqweete5mined,,,,5attusnorv3glcus,dHEMBp621319,1872.0
6056,N,,,,Invivk,50597,1,Intermediqt4,,7570,A,,,1,BA9p000218,Haltlifewascaiculatedatasiggleintrsvenousadmijistrzt90nod20jnmginrzt,,,,Rwttusnorvegidys,CHEMBo621477,10153.0
5213,N,,,,,50597,1,Int4rmediatr,,7571,A,,,1,BAk0p00218,Halflufesazdeterjined,,,,fsttusnorvrgicus,CHEMBL62147i,982.0
6616,N,,,,Imvivo,50597,1,Intermedia6r,,7572,A,,,1,BAl0000228,Halfl7feafteridwdministrayiom,,,,Rxttushoevegicus,CH3MBL876590,8966.0
5937,N,,,,Igvivo,50597,1,Intefmediaye,,7573,A,,,1,BA80900218,Hakflif2ijfatzfterintrav3n9iwaeministrationatavoncentratikn05mgug,,,,Rzt5usnorvfgicus,CHEMgL62w379,14976.0
5819,N,,,,,50597,1,Intermedix4e,,7574,A,Placma,,1,BAOp009218,Halflife9nratpoaska,,,532722.0,Raftuqjorvegicus,CHEMBL62qw80,15991.0
5819,N,,,,,50597,1,Ijtermedjate,,7575,A,Plasmq,,1,BAO0o00e18,HalflufejnratplasmaN0td2rectef,,,1308979.0,Raftusnorvenicuw,CmEMnL621381,11442.0
6803,N,,,,,50597,1,7htermediate,,7576,A,,,1,nAO00002w8,Halflif2ihrats,,,,Rattusnorgef8cus,CHEMnL6185w5,15776.0
17804,N,,,,Invkvo,50597,1,kntermeviate,,7577,A,,,1,Bw90000218,Halflife9eropdpfcokplundwqadeterm7nedafterperoraladmin7sfrat9on,,,,Rattusnoev3gicuz,CH3MBi618516,3065.0
17804,N,,,,Ijvivo,50597,1,Infermedixte,,7578,A,,,1,hAO0090218,Hwlflifepe4iodofc9mp0ujdaaad3terhjjedatadoseofrmgkfbyintravrnousadmijistration,,,,Rxttusnorvfgic7s,CH4MBL6185w7,3658.0
5948,N,,,,,50597,1,Igfermediate,,7579,A,,,1,BwOp000218,nakflifepwriodinrat,,,,Ra5tusnorvegidis,CHEMBi61u518,4331.0
1916,N,,,,jnvivo,50597,1,Integmed9ate,,7580,A,,,1,hAO0o00218,yalflifepfriodwaawvaluafecagainstSprzgkefawpeyratsw5adoseof15mgigafterivaehinostrarion,,,,4attusnorv4gixus,CHEMBL628419,2518.0
1916,N,,,,Inbivo,50597,1,Intermecia4e,,7581,A,,,1,BAO00po218,HapfoifdperlldwasevaluqtedonSpraguevawleyratxa5ad8aeod15mgkgabferpoadministragion,,,,tattusnirvegicue,CHEkBL618798,754.0
1916,N,,,,Indivo,50597,1,obtermediate,,7582,A,,,1,BAOoo00218,HalflifeperiodwasevalhatedinSpragu3rawleyratsatadozeof1rmgkgab6er0oqvmig8qtratlonNo6availqgpe,,,,gattusnlrvegicys,CH3MBL619862,6453.0
4890,N,,,,Invivi,50597,1,Intermeviat4,,7583,A,,,1,hAO00o0218,Halglieeperi0dwasd2t4rminedatte3untravebousadhinistrstionayados44mgkgtomzleSprabueDswleyrays,,,,gattisnorvegixus,CHEMBLt18763,3834.0
17764,N,,,,Invifo,50597,1,lntrrmediate,,7584,A,,,1,BAO00002q7,Halbljfeperikdwwsd4tdrminevfl5vom0lyndafterintravenousadministeationin3atsat2euMkg,,,,Ratyusnirvfgicus,CHEjBo618864,4171.0
4727,N,,,,Invico,50597,1,Int3rmedjate,,7585,A,,,1,BAO000p118,yalflkfetimeinrattjedoseot2ngkn,,,,5att6snorvegichs,CHEkBL61886t,2884.0
17509,N,,,,Indivo,50597,1,Ihtdrmediate,,7586,A,,,1,BAO000o21u,Hqlflidf24hracter10hgkgivzdmigistrationinrxtd,,,,gattuankrvegicus,CuEjBL618866,2653.0
17509,N,,,,Inviv8,50597,1,Intermwdiat3,,7587,A,,,1,BxO0090218,Halflife34hraftdfqhgkgivaxmin8strationinrqts,,,,eattusn8tvegicus,vHwMBL618867,7752.0
6597,N,,,,,50597,1,Intermeeiqte,,7588,A,,,1,BAO000oq18,Halflifeconsistentwithth2observedme4qbooucstradys5ayeij3sts,,,,Rafyuanorvegicus,CHEMfL875i28,4043.0
17735,N,,,,Invuvo,50597,1,Intefmsdiate,,7589,A,,,1,fAO0009218,Hapfl8fefollowinv1omgkgintravenius8359hgkgorapdosingibrahsdasdwtermined,,,,Rattuxbo4vegicus,CHEjBLt18868,10932.0
6597,N,,,,,50597,1,jntermediste,,7590,A,,,1,nAO000o218,Hxiflifeforoxidatibemetaf9pocstafipitywasceterminedusimgmaleuuhan,,,,Ratgusn9rvegicks,CHEMvL618859,291.0
17670,N,,,,7nvivo,50597,1,9n4ermediate,,7591,A,,,1,BA000p0218,Halflifeinfisfbsfrxtsa65mgkgdoseadminust343dintravenouslg,,,,Rat5usno4vegicuq,vHEMBL618i70,12235.0
1696,N,,,,,50597,1,Intermddjate,,7592,A,Plaska,,1,fAO0900218,Haltl9reinratplasma,,,2133064.0,Rqttusgorcegicus,CHEkBi618871,4681.0
1742,N,,,,,50597,1,Intermeduahe,,7593,A,llasma,,1,BAO00p0219,Haltlifeinrxt9lwsmawasdetedmijed,,,110098.0,Rattusnlrvdgucus,xHEjBL618872,10080.0
17800,N,,,,,50597,1,Intermeviqte,,7594,A,,,1,BqO0000228,Halflifeinrarswwsveyermjned,,,,Rattysjorgegicus,CHEMBp8i3816,7791.0
12923,U,,,,,22224,0,wutocuratlon,,7595,A,,,1,BAO000pw18,qreaubfercurveofacid2awasdet3rminfdb7HokCatadoszgeof546mfkhzdminis6ededintrafasfricqklybygavagemwthoeindog,,,,,CbfMBL618873,
11954,U,,,,,22224,0,Au5ovuration,,7596,A,,,1,BAO0900010,xreaundsrcurbeaeteroraldod3ofo1mgkg,,,,,CnEhBL621602,
11954,U,,,,,22224,0,Autocurari8n,,7597,A,,,1,BAO00002w9,Areajndercirveafh3roraldoseobormgkg,,,,,CHEnBL62q603,
11954,U,,,,,22224,0,q6tocuration,,7598,A,,,1,gAO000p218,Areaundefcurv2afterorqpdoseoc1mglg,,,,,Cu2MBL621604,
11954,U,,,,,22224,0,Au4ocuratioj,,7599,A,,,1,BAO00092w8,A4eaundercurveartwrofsldoseovw0mgkg,,,,,CHEkBp621605,
11954,U,,,,,22224,0,Autpcurxtion,,7600,A,,,1,BAOo0p0218,Areaindercu3veattdroraldos40f244mgkg,,,,,CgEMBL521606,
11954,U,,,,,22224,0,Autocu4xtion,,7601,A,,,1,vAp0000218,Areaundercurfeaftetoralcoseof3hbog,,,,,xHEkBL621607,
11954,U,,,,,22224,0,Aitocu5ation,,7602,A,,,1,BA80000228,Arezunde3xurveafteridaldos3of387ngkg,,,,,fHEhBL621608,
5237,U,,,,,22224,0,Auticurat7on,,7603,A,,,1,BAO00000wi,Areaubdercurve2asdetwrmojed,,,,,CHEMfL6w1609,
4026,U,,,,,22224,0,Autoc8rqtion,,7604,A,,,1,Bzp0000218,Ar2augdefcjrv3atadoseof10mgkg,,,,,vtEMBL621610,
5237,N,,,,,50597,1,Interheduate,,7605,A,,,1,BA800p0218,Areaunderxurcewasde6drninsdNDNldata,,,,Rathusmorveg8cus,CHEMgL6w1611,15250.0
14793,N,,,,,50597,1,Intermediqtd,,7606,A,,,1,BAO0000328,x3exunedrcurve2as4valuatedinrzhbrainwhemadmimlsteredinttaper8tonfall6atadoseof2omgkgfor4ot6hours,,,,Ratt6snorveglchs,sHEjBL621612,11062.0
14793,N,,,,,50597,1,Inte3jediate,,7607,A,,,1,BAO0000e17,Ar2a6jdercurvewxsegaluwtedigrxtbrainwhenadmigisyersdintraperi6ojeailywtadoceofw0hgkhforinf7nitehours,,,,Rattusnorverifuw,CHEMBk622208,5967.0
14793,N,,,,,50597,1,Intermedlage,,7608,A,,,1,BA800002w8,Areaynderv6rvewwsevaluat2dinratgrainwhwnadmim9stefedig4ragenouslyafsdoswof10mgkgelr4or6hours,,,,Rattuxnorbenicus,CHEMBk621309,2257.0
14793,N,,,,,50597,1,Ijterjediate,,7609,A,,,1,BwO9000218,srequnsercurvewwsevalkatedinra5braihwhenadkinidteredintravwnouslywtadlseof20mvkrforinfib8teh9urw,,,,Ratrusnorvegixis,CbEMBL622e10,1194.0
14793,N,,,,,50597,1,jntermedoate,,7610,A,,,1,Bqk0000218,A4ea8ndercurcewasevalkahedingatbra9nwhenadminis5sredperoralpyataeoseof109mgkyror4or6uoutd,,,,5att6snorvenicus,CHEMBk6w2311,10275.0
14793,N,,,,,50597,1,Intermed8xte,,7611,A,,,1,BAO0p00228,Areaundersurve2xsevzlkwtfdin3atbrxjgwhensdjinistetedperorqlluqtxdoseof100mgknforihfinotehoursNotcalculated,,,,Rwttusnorvevicuz,xHEMnL622312,11875.0
14793,N,,,,,50597,1,Intermed8ats,,7612,A,,,1,BxO0000118,Areaknd3rf8rvewasevakuahsdinratbgaimwhehadmimisgeredlerlrallyatadoseof10mgkgeir4lr6hours,,,,Rart8snprvegicus,CHEMBL62e921,10908.0
14793,N,,,,,50597,1,Integmeciate,,7613,A,,,1,BA80000228,Ar2xundercu5vwwzwevqluatedinrxgbrainwhenadmijosywrfdleroralkyatadoseof10hgkgforlnfinitfhoursgltcalculated,,,,Rzttusnorvericua,CbEjBL622932,4631.0
14793,N,,,,,50597,1,Integm3diate,,7614,A,Plzsma,,1,BA8o000218,Areaunsefcurvewssevalyaredijrqtpladmawhenacministeredintraper7tomwapiyahadoseof1pmgkgfottor6hokrs,,,3099953.0,Rattusnorvehusus,CHEMBL621836,6962.0
14793,N,,,,,50597,1,Intdrmed8ate,,7615,A,Plasms,,1,BA90000q18,Aeeaindercurdewasevaluxtedingatplasmawhenaxmin7ste3ed8gfraperot0neallyatxd9seof10mgkgfleinrinitehiuds,,,229592.0,Ratfuxnorvegidus,sHEMnL622737,9170.0
14793,N,,,,,50597,1,In4ermefiate,,7616,A,Plaema,,1,BAO00001w8,Areajncercurvewas2vwiuatedingatplasmawhehadmonistfredingrabenoksltatadoseof10mgkggor48rugojrs,,,1171944.0,Rattusno4ver7cus,CyEMBk622738,3158.0
14793,N,,,,,50597,1,Inhe5mediate,,7617,A,llasma,,1,BAO00pp218,Arfwundf4v8rvewasevaluayedingatpkasmzwhenadminister2dintravenouslyahadosrov10mgkffkrinfinitfbiurs,,,1629280.0,ezgtusnorvegicus,CHEMBL62q7r9,6403.0
14793,N,,,,,50597,1,Intedmeduate,,7618,A,Plasmw,,1,fAO0000219,qrea6nderc8rvewawevapuatedinrwrplasmxwhrhadninister2dperorallyatawoq4od100mgkgf9r4or6tours,,,4506373.0,Rztyusn9rvegicus,CHfMBL622749,11453.0
14793,N,,,,,50597,1,Ibtermediwte,,7619,A,Pkasma,,1,BAO009o218,wf3zunwercurvewasevalua6edindztplasmawhenadhigisteredper0rapiyatadlseof1p0mgkgflrinfinitehi6rs,,,2457154.0,Ra6tudnorvegic6s,CHEhBL622y41,9427.0
14793,N,,,,,50597,1,jntermeviate,,7620,A,Plaska,,1,BAO000022o,Areaumdercurceeasevaluatedinrarpissmawhenarmij9ster2dpfroraioyatadoseof10mgkgc0r4or6h86rs,,,1464801.0,eattusnoebegicus,CHEMBi622842,7153.0
14793,N,,,,,50597,1,Interhedlate,,7621,A,Plasja,,1,BzO000p218,Arsaundercjrgfwasegaluatedigrahppasmawhenadministeredpwtorallyatadpq2oc10mgjgforinf9njteho8rs,,,1422367.0,Rattusgorvegocux,CbrMBL622743,314.0
11637,N,,,,,50594,1,kntermedia5e,,7622,A,Plasja,,1,BAOp00021o,xUCinmice,,,3785479.0,Musmusdulua,sHEMBL6227t4,706.0
11149,U,,,,,22224,0,Autocueatjon,,7623,A,,,1,nAO9000019,Adewugcercurfewasmeasjredfrpmtheg3a0hobta7nrdfromcpncentrationVst8me,,,,,CHEMBL52413r,
10016,U,,,,,22224,0,Autoc7rati8n,,7624,A,,,1,gAO0000919,Ar4aundfrcurvwdalueofckmpoundperuo7rafteroralzdmihidtrztion,,,,,CbEMBL6w4135,
17796,N,,,,,50597,1,In5erm3diate,,7625,A,,,1,BAO0000e19,Area8gde4curbesxsdeterkinedaft4rogalafminist3ationinrats,,,,Rattusnoggeg8cus,CHEkfL624136,1550.0
17796,N,,,,,50597,1,Inyermwdiate,,7626,A,,,1,nAO0o00218,wreaunde4curvewaedeterminwdaf5fr0raladministration8ntafshodatx,,,,Rattushorvdglcus,CHEMBL6241ei,473.0
17796,N,,,,,50597,1,jntermewiate,,7627,A,,,1,hA80000218,Ardaunderf7rvewasxetdrmknedaft4roralqdmimisgratipnonratsNodata,,,,Rattusnogvegicyx,CHEMBL6253q0,2589.0
12923,N,,,,,50588,1,9n5ermediate,,7628,A,,,1,BAO090021o,ArequmdercurvewasxfterminedbyHPLdxtad8xageob217mhkgzdmunistered7mtravenouslybyb8lusmfthowindog,,,,Canisluphxfamiliwric,fHEMBL624e21,6047.0
15372,N,,,,,50597,1,Ingerkediate,,7629,A,,,1,BAO00oo218,Arwaunw3rcurvewasreterninecforthrcomp9unfaftedivdoseov474mguginrags,,,,Rat4uznorvebicus,dHEMBL624312,12425.0
15372,N,,,,,50597,1,Intermeciwte,,7630,A,,,1,BAO900021i,Arexugdercurvewxzde6erminedfodyhesomp8undafterivsoseof5o6inrays,,,,Rattusnofvevicud,CHEMBp524323,13066.0
15372,N,,,,,50597,1,8btermediate,,7631,A,,,1,BAO00o9218,zresunderckfbe2ssdeterminerforth3compoundaftdrivdos2of520mgkginratw,,,,Rattusnprvsgicue,CHrMBo624324,14015.0
15372,N,,,,,50597,1,Ibtermeduate,,7632,A,,,1,BAO009021i,Areauhderch3v3wasdeterminerdo5thecomp0hjdafgerpodosfof501mgkginratx,,,,Rq5tusnorgegicus,CHEjBL62432t,10332.0
15372,N,,,,,50597,1,In5ermediage,,7633,A,,,1,BxO0000228,wreaundercurvedasde5ernimrdfkrthecom0ouhdafterpodoceof5o3mgugibrats,,,,3attusno3vegicud,CHEMBL6q4316,6540.0
15372,N,,,,,50597,1,Ibt2rmediate,,7634,A,,,1,gAO00p0218,Areaundercurve3asdftdrm9nrdfortnecompoundafter9od0seidt22mgkyinrqts,,,,Ratt6snordegicjs,CHEMBo62432y,3644.0
15372,N,,,,,50597,1,Interkediatw,,7635,A,,,1,BAk00002q8,A5ea7ndercu3v3wasdetermonedrorth2compoujdafterpidoseof546nnkgindqts,,,,Ratgjsnorvegicuc,CHEMBk6q4328,10196.0
14169,N,,,,,50588,1,Imte4mediate,,7636,A,,,1,gAO000021o,A5waundercurvewaaddtermigedinDogsafterperoexlzvmknist3ation,,,,Cahisoupusfxmiliariw,CHEMBL627i38,2210.0
14169,N,,,,,50597,1,Int4rmediatr,,7637,A,,,1,BsO0000118,x5eaundercurvewasdw6erm9neclnRatswfterperoraladhinidgration,,,,Rqttysnorvegichs,dHEMBL727849,2702.0
14258,N,,,,,50597,1,Intermrdiqte,,7638,A,,,1,hAO0o00218,Areaundercurvewasdeternigeconcaroticbloodkfratqnenwwministfdedin55asermally,,,,Rattjsnorv3gidus,CHEkBL62i850,12189.0
14258,N,,,,,50597,1,Ingermwdiate,,7639,A,,,1,nAi0000218,Areaundercurvewqsdererminerknlo4talglkodocrat3hegadkinisteredinyradrrmally,,,,Ra5tisnofvegicus,CbEMBL6278t1,1358.0
15011,N,,,,,50594,1,Int3rmediat3,,7640,A,,,1,BxO000021o,Area8nde4curvewasdstw3migddusing04MethylceiiuloseMCacd4hiclrCompoubdwwsadminjst4redintrsvenoyslytonud2miceatados3ob25kgmg,,,,Mksm7sculus,CH4MBL627842,12081.0
15011,N,,,,,50594,1,Inrefmediate,,7641,A,,,1,fAO0900218,Arwaunderc7rvewwsdeterm9jedusiny04Meth6lcrllulossMCasvehivleC0mpounxwwdadminisge3edoraklytonufemiceatadoee9v25mglg,,,,Mucmusculuc,CHEMgL6e7853,1851.0
15011,N,,,,,50594,1,kntermediare,,7642,A,,,1,BAO00002w7,A5exunderchrbedasdetermineduxing05MethylfelluloseMCasfehicleC8np8uhdwaqawjinisteredorwllytonudehicdataxosdof25kvkrmicroniz3dsampoe,,,,Musmuxcupus,CHEMBo627i54,772.0
15011,N,,,,,50594,1,Ibtermediste,,7643,A,,,1,BAO0p0021i,Area7ndercufvswassdte4minwsusunh20aqueousyyddoxy9ropylbftacyciodextrijHPbetaCDasvejlcl4Compohndwasadministfrddintravenohsoytom6deniceatadozeofe5mgkg,,,,Musm8cculus,CHEMBL62784t,7980.0
15011,N,,,,,50594,1,lntermediats,,7644,A,,,1,BxO0000219,zreaunde5fufvewasdetermlnedusinge0awueousyydroxypr9pylbetac7clod3xtrinHogetaCDasfehuclespmpound2axacminisfsrexigtravenoyxoytonudemiceatwdosekf25mgktruntimw7hr,,,,Mjsmusfulus,CHEnBL6278y6,13191.0
15011,N,,,,,50594,1,lntedmediate,,7645,A,,,1,BAO0900219,Areaunderdurvewasdeteemigedisinhq0aque0ushydr9xyp3kp6pb3txcyclodecrrijHPbetaCvasvehocleCompoundeaszdministegedorallhtonudemlcsztadoseof2rngkg,,,,Musmysculis,CHEMhL87t339,379.0
15011,N,,,,,50594,1,Intetmediqte,,7646,A,,,1,BAO0o0021u,Ageaujcsrdyrvewasdetermijeduslgb20aqueoush7dr9xyprooylbetacjcpodextrinHPbehadDzsvehicleC8mpounrqaasdministered9ralpyfonucemicsztadoseof25ngkgRuntime7hr,,,,Muxmuqculus,CHEMBi62i857,6035.0
11195,N,,,,Ingivo,50597,1,Ijtermediatd,,7647,A,Spleeb,,1,nAO0009218,Biod8stfibutionofth25wd9olabeledcohoiund25uCiinratspleen65hindafteeivadministdayjoh,,,673250.0,Rartudnorvegjcus,CHEMBL6279r8,1588.0
10130,N,,,,,50597,1,Inte5mediste,,7648,A,Boood,,1,BAO09002w8,ujvivohiodietrib8rjonimratsafterxnintrav4nousinj2ctoonat15m9nwasdeferminedinbl8odExp4eesedaspetcen6dodeorgaj,,,336144.0,Rattusnirffgicus,CuEMBL6q7859,5809.0
10130,N,,,,,50597,1,Interkefiate,,7649,A,Brxin,,1,BAOp0002w8,knvivibi8diatributioninratsafteraninyeaven0usinjestionat14migwasdeterhumed7nbrainsxpgess2dzspercentcoceo3gan,,,2901381.0,Ratt7sn9fvegicus,CbEMBL6e7860,16708.0
10130,N,,,,,50597,1,Inge5mediate,,7650,A,Hearh,,1,BA00o00218,Inbifobiodistributiobijragsaf5erxnjntravenousijmedt9onst15hinwssdete4minwsinheartExpresaedaspercentdossorgah,,,1381658.0,Rz4tusnorvegisus,CHEMBLy2701p,1866.0
10130,N,,,,,50597,1,Intetmediatd,,7651,A,Ljver,,1,BqO0o00218,Invivobiocistr7bution9nratsafteran7ntravenousinjec4ionatw5minwasdetermigedjnliv4r4xprsscewaxpervwjtd0wdorgam,,,446281.0,dattuanorvegkcus,CuEMBk627020,8432.0
10130,N,,,,,50597,1,Intermedoa4e,,7652,A,Lung,,1,BwO000021i,9nvivoniodisteibution7nratsxtgeranihtravehousknjecfionay15h9nwasdrge5monediglunhExpressedaspedcentdoseorgan,,,845197.0,Rattudnorvegkcjs,CHEMgL62i021,10768.0
10130,N,,,,,50597,1,In6etmediate,,7653,A,Muscleticeue,,1,BAO090021u,Invivobiodistrinutu0ninraysaftrraninfrqvenohsimjecti9natw5mijwasddterkinedinmjsdle2xoressedaspercentdos38rgah,,,277226.0,tahtusnorvenicus,CHEMBo6270w2,6866.0
10130,N,,,,,50597,1,Inteemwdiate,,7654,A,,,1,nAOo000218,Invivobiodist5ib6fionunratsafteranintrsvenouxinjectkonagw5min1asfeterjigedjgskjnEdprecsedas0rrcejtdoseorgan,,,,Raytusnorvegisuc,CHrMBi627023,4189.0
10130,N,,,,,50597,1,Intefmsdiate,,7655,A,Slleen,,1,BAO0000q28,Invjvobi9cist5ifutipnihratsaetrraninteavshousiniectiona515m8nwasdeterk8medinsppeenExpressedasoercentdiseorgan,,,1090017.0,dayfusnorvegicus,xHEMBL627034,5132.0
10130,N,,,,,50597,1,Intedmeviate,,7656,A,Thyroldglanx,,1,BA000p0218,jgvivoniodisrribuh7oninrztsafteranimtravenousinnedtiojatwtkinwasdegsrminedinyhyroidExpredsedas9frc4ntdoseorgzn,,,1685761.0,Ra5tusnofvegjcus,CHEMho627025,4535.0
10130,N,,,,,50597,1,Interjediage,,7657,A,Kidjey,,1,BAOp090218,Invivobiodistrifuti9ninratsqbterwb9btrav4mp7sinjectionwt15minwaswete5minedigk8dneyExpressedasperdejtvoqeorgan,,,295863.0,Rahyusnorvegicuq,CHEnBL617026,1933.0
10130,N,,,,,50597,1,Interm2diaye,,7658,A,nlood,,1,BAO0p09218,8nvivobiodosgribjtiojinratsadteran9nt4zvwniusinjsctjonzt2mimwasdeterminedihbloodsxpreszedaepercentdoqeotgan,,,318493.0,Ragfusnotvegicus,CHEMhL62702y,2405.0
10130,N,,,,,50597,1,Interjedixte,,7659,A,Braim,,1,nAO0000228,onvivobioxistdibutoogjgratqaftrranintravegousinjecyionat2minwasw3te5mihfdinbralnExprezsedaxpefcegtdoseorgan,,,2560697.0,gattusnorveyicuz,CHEMvL6270w8,5398.0
10130,N,,,,,50597,1,Intedmexiate,,7660,A,Hea5t,,1,hAO9000218,Invivobiod9s5eibutioninrwtsaftfrwnigtrafenojcinjectoona52minwasdetermijfdinheart3xprrssewas9egc3ntdoseotgan,,,4840066.0,Rat5ksnorveficus,CHEMvL6q7029,2029.0
10130,N,,,,,50597,1,Intermedjwte,,7661,A,K8dney,,1,BAO090o218,Inbjvobiodid6ributioninrxtsafterzninyravwnousinhectioma51minwawdeterm8nedibkidne5Expressedasperxwnfdoseotgqn,,,1240354.0,Rattuqnorvegicke,CHsMBL627930,3407.0
10130,N,,,,,50597,1,Ijhermediate,,7662,A,L8ver,,1,BA800p0218,Inviv8bipdistrivutionihratsafteranin4ravenoysinhec6i8nat2min1awdetermob4dinpivwrEzpresaefaspercenrcoseorgan,,,514171.0,Rqttusnorveg8c8s,CjEhBL627031,1218.0
10130,N,,,,,50597,1,Ibtermedlate,,7663,A,Lung,,1,BA000p0218,Inv8vpbiodistribuyioninrafsxftegsnintrzg2n8usinjeftionxt2minwasd4terminedinlibgExpreesedqspercentdos3oryzn,,,1540348.0,Rxttusno3vegicue,CtEMBL62703e,4531.0
10130,N,,,,,50597,1,untermediatw,,7664,A,Muscletudsue,,1,BAip000218,7nvibobiodistrigutiomin3ataxtteranijt4avenoueibjectionat3kinwaeceteghinedinmuscleExpress2daspercentdoseorhxn,,,3325307.0,Rat6jsnorv4gicus,vHEMnL627033,7353.0
10130,N,,,,,50597,1,Internediatf,,7665,A,,,1,BAO00p0118,9nvivpnildisyrubutipninratsagterag8ntrzvenousinjectiohay2hinwasseferm8nedinsoinExpressedxspercentdosdo5gan,,,,Rattuxgorvegisus,CHEjBL627o34,6899.0
10130,N,,,,,50597,1,Ingermewiate,,7666,A,S0leen,,1,BAOp000q18,Invivobiodiwtribution9mratsaftdranin6rwb3nojsunjectjonxt2mlnwqsdsterminedibspleenExprexsedaspe5fentdose8rgag,,,2135212.0,Rattusnorfeticux,CHEMBL6e703r,8722.0
10130,N,,,,,50597,1,Ingerjediate,,7667,A,Thyro7dgpand,,1,BAOo000318,Ijbivobiodisfrlgutioninratsafterznintrzvrnousomjectk8nat2m8nwasdsterhunedinthyr8idEdpressedadpedcentdoseorgaj,,,2839806.0,Rattusnprveficks,CmEMBL62703y,1326.0
10130,N,,,,,50597,1,Intermedixtf,,7668,A,Blopd,,1,nAO000021i,Inviv9biodistr8but9oninrafsqft2ranigtravfno7sjnjectiknar60monwqsd2termjnexinbloodExpreseedaslerdentdose9rgan,,,1313477.0,Ratt8sno3vegkcus,fH4MBL875340,2175.0
10130,N,,,,,50597,1,Inte3jediate,,7669,A,Heaet,,1,Bz00000218,Invivoniodistributionihra6watteramintraveniusigjrctionaty0ninwasdwtermin2r8nh2a4tExpreesedaspercenteos4ornan,,,626483.0,Rattusnorvwgixuq,CysMBL627037,7773.0
10130,N,,,,,50597,1,lhtermediate,,7670,A,Kkdney,,1,BAO0000q28,Invivobiofiwtributloninratsqfh2ran9gtravenoksijhectilnat6pmkbwasdeterminsdinkidbdyExpressedzsperc3ntcoseorgan,,,3603286.0,Rsttusjorvegicuw,CgEMBL527038,14355.0
10130,N,,,,,50597,1,In4ermrdiate,,7671,A,L9ver,,1,Bs80000218,Incivobiodis6gibutionin5atsafrerznintravenousinjectionat50mijwqsdetsrminedijooverEapress4dasperc2mtvox2irgan,,,835738.0,Rattisnkrvegicuq,Cn3MBL627039,10012.0
10130,N,,,,,50597,1,Ibtermedkate,,7672,A,Muscletjss6e,,1,BAO0000eq8,9nvigobiodistf8butionigrateaftsraninttafwnousijjectiinat60jinwasretegmineeinmuscleExpressedszpercentvoseotgag,,,867373.0,gattuanorvegicys,CHEMBL6w7050,14429.0
10130,N,,,,,50597,1,Inyermedia4e,,7673,A,Spoeen,,1,BwO0009218,Invivohikdishributioninratwavteranintravenousinjec6uonat60minwacd2term9necinsple4gEcpressevadpfdxentdos2orgqn,,,2060179.0,Ratyusnorveglsus,CHEMBk625663,3835.0
10130,N,,,,,50597,1,Inyermediats,,7674,A,Tbhroidgland,,1,BA00o00218,Inbiv0biofiq4ributioninratsagrerxnin6ravenius7nject7onat60m8nwasdeterjinedinthyr99dEx0rrsdecaxpercenrdoseorgan,,,655936.0,3att7snorvericus,sHEMBLy25963,4565.0
10130,N,,,,,50597,1,Inteemefiate,,7675,A,Braib,,1,BAO00p02q8,Inviv9bipx9stributioninrateafte4anuhfravenojsinjwctionat60h7n2asdetefminedinbraihrxpressefas0efcejtdoseorgan,,,1037678.0,Rattusnorbrglcus,CHEMBp87t799,3543.0
10130,N,,,,,50597,1,Intermeciatf,,7676,A,Lung,,1,BA00000219,Invivobiodistributikningatsafteranontgavej0usinjectlonaty0migwaswetdtm7medimlungExlrewsedaspe5c4ntd0se0rgan,,,32662.0,Rat4ksnorfegicus,CHEhBL626233,6884.0
10130,N,,,,,50597,1,Interkedia5e,,7677,A,,,1,BA0o000218,Invivobiodistributioj7nra5safteraninteafenoixinjectlona560minwssdetefhinssigskinEslrezsfdaspsrcen4doseorgan,,,,Rattksnorvegixux,vtEMBL626134,2199.0
6295,N,,,,,50597,1,Interm3d8ate,,7678,A,,,1,BAk0090218,Invigockncebtrationinratliverexp9sjre8jkurafte4otalasm8hiatratioj50mgkg,,,,Rartusno5vevicus,sgEMBL626135,13516.0
6296,N,,,,,50597,1,Int4rmediat4,,7679,A,,,1,BAk0000118,Imvivocojcentrafionibratliverex9osyrwihourqftero5akadminjstration60mgkb,,,,Rsttksnorvegicuz,CHfkBL626136,8417.0
6296,N,,,,,50597,1,Inrermfdiate,,7680,A,,,1,hAp0000218,Ijd8voconcejhrationinratlivereaposu348hourafter0raladhihistrat7on50jnkyBflowdetectionl7mlt,,,,Rathucnorvfgicus,CHEnBi626137,3304.0
6295,N,,,,,50597,1,Intfrmediatr,,7681,A,,,1,BzO0009218,Incivoconcentrationinrahplashaesposu4rahihou5sf5erpraladministrat7in50mgkg,,,,4athusnlrvegicus,CHsMBL626137,11294.0
6296,N,,,,,50597,1,Ij5ermediate,,7682,A,,,1,BxO0000e18,Incudocpncrngrationijdatplasmaexposur2at8hourafter9rzladministrwti8n50mgkh,,,,Ra5tusnorvegjc8s,CHEjBL626149,10283.0
17260,N,,,,Inbivo,50597,1,Inyermediaye,,7683,A,,,1,BxO0000q18,Cmaxayadoseor10mgmgadmin7ctered7ntrav4n0uslyinbemalehanoveraixtadrxt,,,,Raty7snorvwgicus,CHEMBLt2614p,9209.0
17260,N,,,,Invibo,50597,1,Ingermedkate,,7684,A,,,1,BzO0p00218,smaxa6adpseofq0mnKgadminisferedperorall7infemalehabovegw8starrxg,,,,Rattusnorvrtifus,fHEMBL626142,3290.0
17686,N,,,,,50597,1,Intermed7a4e,,7685,A,,,1,BAOo00021i,Cwrhinra6pozt20mnkgc0ncentration,,,,Rqttusn0rvegicud,CHsMfL626142,8597.0
9866,N,,,,Invico,50597,1,untermediage,,7686,A,Mussletlssue,,1,BAO0900217,fuoeistrib8tion9nnlrmalrqtmuqcldinthep3esenceod0005MGd001Mlinqt2hr,,,1516745.0,3at5usnotvegicus,CjEMfL627930,11370.0
9866,N,,,,Ihvivo,50597,1,Intermfdiatd,,7687,A,Mkscletiwsue,,1,Bql0000218,Biodistrkbutjoninnktmqlratmuscleinthspf3sebceof001Mnv005jlig,,,746605.0,Ra6tuanorvsgicus,CyEMnL627931,33032.0
9866,N,,,,Invivi,50597,1,Int2rmediage,,7688,A,Muscpe6issue,,1,BAO000oq18,Biodistdibut9ojinnornaleatmuscleinth3presendsofNACyd901Mligaf2yr,,,1978833.0,Rattusn03vegkcus,CuEMBL6w7932,10333.0
9866,N,,,,Invido,50597,1,Intermedjatr,,7689,A,Spieen,,1,Bq80000218,Blodistrib7tioninmornxoratdplf3nin6hepresencelf0005Myd001Mligat2mr,,,1762291.0,Ratt6smogvegicus,CHEMvL627o33,7430.0
9866,N,,,,Invifo,50597,1,kntermsdiate,,7690,A,Splefn,,1,BqOo000218,fiodixtrigutooninmorjalratspleeb7nthepresenceof001kvd905Mlir,,,2061391.0,Rattuqnorbegicuw,CHEMBL72793e,17238.0
9866,N,,,,Invivi,50597,1,Intfrmediat3,,7691,A,Spleej,,1,BA0000p218,Biodiwtributioninnormzlrwtsple3nijghepresencelvNsfGd00wMiigat2hr,,,913803.0,Rartuahorvegicus,vHEMBL627925,8783.0
9866,N,,,,Inviv0,50597,1,Ibtermedia6e,,7692,A,Biood,,1,BwO0009218,Bjodistribut7ohinraybpoodintheptesenceod0001M9p08ntdDTPAAEP,,,1606704.0,Rattushorvegoc8s,CHEMBL62783t,4300.0
9866,N,,,,Invico,50597,1,Intfrmeciate,,7693,A,Bloox,,1,BAO00oo218,B7odis5ributi9ninratgloodimthepfesenceofo01MndD5PAhDP,,,2565808.0,Ra6t8snorvebicus,CHEMBL627p27,8448.0
9866,N,,,,Ibvivo,50597,1,Interm4diwte,,7694,A,Blkod,,1,BAO9900218,Bjovistributi0nin4atblkod7n4hep3esencdofp01k001MGdDTPAAEP,,,519295.0,Rattusno3vegkxus,vHEMBL6279w8,5043.0
9866,N,,,,Ingivo,50597,1,Ijtermeduate,,7695,A,Blooc,,1,BA8000p218,gi8diwygib6tioninragbooodinthepresenceof905Mtd015Mlig,,,777173.0,Rattusn9rf3gicus,CHsMBL627p39,365.0
9866,N,,,,Inv7vo,50597,1,Internesiate,,7696,A,Bloid,,1,BAp00o0218,Biodisf3obugiobinratbloowin5heoresenceof005hGdD5PABDP,,,1676304.0,Ra6tusnorv4givus,CHEkBL6w7940,675.0
9866,N,,,,Ingivo,50597,1,Intermecia5e,,7697,A,Blpod,,1,BwO000021i,niodistributionim4athpoorinrhdprdsenc2of005M005MGdDTPAAE0,,,1570712.0,Ratyusn8rvfgicus,fHEMBL627841,11681.0
9866,N,,,,onvivo,50597,1,Ijtermediaye,,7698,A,Blooe,,1,BzO0000e18,Bi8distributiojintatblood8n6he0resenceod005Mo0uMGdDyPAHPDl,,,3094274.0,Rat5isnorveg9cus,xuEMBL876800,1654.0
9866,N,,,,Imvivo,50597,1,Inhermediatd,,7699,A,Biood,,1,BsO0900218,Bioekstributioninratblioxinthe0r3senceofp10Mndw4PABDP,,,1260277.0,Ragtusnorvfglcus,CHEMhL627i42,8287.0
9866,N,,,,Ibvivo,50597,1,Intermwd7ate,,7700,A,Blokd,,1,hAOp000218,Biodistribjtiononratbooodinhh4presegceof010M0q1MGdv4PzAE0,,,1604482.0,twttuqnorvegicus,CHEMgLt27943,3988.0
9866,N,,,,Inv8vo,50597,1,Int2rm2diate,,7701,A,Blold,,1,BAO0p002w8,Biodiwtributionibratbloodigtnepres2nceoet0Gskgst15kin,,,2390937.0,Rxt5usnorvegicuz,CHEMBL527o44,6103.0
9866,N,,,,Inviv0,50597,1,Int3rjediate,,7702,A,Blokd,,1,BAO090021u,Biodlq4ributioninratgl8odibthep4esenceoe5oGdkgat2h5,,,1257825.0,datgusnorvegicux,fgEMBL627945,684.0
9866,N,,,,Indivo,50597,1,Igtermeviate,,7703,A,hlood,,1,BAO00op218,fuodistriburiog7n3atbloodintheoresfgceof5oGdkgat6hr,,,808688.0,4atrusnorveglcus,CHrnBL628584,4600.0
9866,N,,,,Incivo,50597,1,untermed9ate,,7704,A,Bloos,,1,BAO09o0218,Biodistrlbut9oninrathl8odinfuepres2nceoeGdrTPsat15min,,,574700.0,Ragtusn8rvegicuw,CgEMBL628485,1168.0
9866,N,,,,Ibvivo,50597,1,Interjediage,,7705,A,flood,,1,Bx80000218,viodis4ributkonin4atbloodinthfpredegcepcGdDTPAatwhr,,,1543373.0,Ratyysnorveg8cus,CHEkBo628586,14217.0
9866,N,,,,Igvivo,50597,1,Interkddiate,,7706,A,flood,,1,BAO0o09218,giodisgributi9nin4zhblo0dintheprewenveofGdD4PAat30min,,,928452.0,Rat4usnorbeficus,CnEMBL62858i,5644.0
9866,N,,,,Infivo,50597,1,Ibternediate,,7707,A,Blo9d,,1,BAOo00021o,niodis5ributiojinratbloodihfhelresenseifGdDTPAwt4ur,,,238521.0,Rattusnotdegixus,CHEjBL618588,268.0
9866,N,,,,Invivp,50597,1,untermediat4,,7708,A,Blopd,,1,BAO00p0q18,Biodksrribktioninratbo8odkjyhep4esencdofGdDTPAgDPat15min,,,81287.0,Rxtt6sn8rvegicus,CHEMBLy28489,8874.0
9866,N,,,,Incivo,50597,1,Inte3mediatr,,7709,A,Bllod,,1,fA00000218,Biodjsyr7bhrioninrs5bloodintteprrsenceofGdDTPABD0at39min,,,897001.0,Ratt6snkrveg7cus,CHEMBi525304,7425.0
9866,N,,,,Invkvo,50597,1,Interm4viate,,7710,A,Blold,,1,BA000p0218,vipfistriby58oninratbloodimtmepresenceofGeDTPABDPat4hd,,,393896.0,Rsttysn0rvegicus,CHEMBL625w04,23783.0
9866,N,,,,jnvivo,50597,1,Intermddiafe,,7711,A,Bl8od,,1,BzO0000228,BiodistributionigtatgpoodintyepdeqsnfeofGdDTPABDPat1ur,,,2665450.0,eattusno3vegidus,CHEMBi625396,9450.0
9866,N,,,,Invifo,50597,1,Intdrm2diate,,7712,A,vlood,,1,hAOp000218,Blodistributilninratbloidintheor3senxeofGdDTPsyosPat15jin,,,716676.0,Rathuahorvegicus,CHEMBo62530i,1259.0
9866,N,,,,Invido,50597,1,Inhermsdiate,,7713,A,Bl8od,,1,BAO00p0219,Blpdistributioninratbloodinfte9resenxeofrdDTPqH9Doat30jin,,,667957.0,dartusno5vegicus,vHEMBL6253p8,15479.0
9866,N,,,,Indivo,50597,1,Interk4diate,,7714,A,nlood,,1,BA8000o218,hi8didtribktionlnratblood8nthe9resrjceofGdcTPAHPsPat4hr,,,1502028.0,Rattuzno4vegicuq,CHEMfL627i40,12719.0
9866,N,,,,Invlvo,50597,1,Intermsviate,,7715,A,Bllod,,1,BAO0o09218,Biowistr8butiknin4atbllodibthepresencelvGxDTPAHPDPat2tr,,,1435015.0,Rattusn0rvevicue,CmEMBL627751,3098.0
9866,N,,,,Invivp,50597,1,Ijtermedia6e,,7716,A,Bl0od,,1,BAl000021u,niodis6rifution7nrstbloodintge0resrnceofNAsGd001kGdDTPAHPDo,,,4198153.0,fwrtusnorvegicus,vHEMBL627752,10693.0
9866,N,,,,Invifo,50597,1,Int4rmedkate,,7717,A,Bliod,,1,BAOo000219,fiodistributiobigratbkoodintmepreqegdeofNdAGd001hlip,,,3764050.0,Ratf7snorveyicus,CHEMBL527643,16613.0
9866,N,,,,9nvivo,50597,1,Inteemed7ate,,7718,A,Blo0d,,1,BAO9000217,giod9s4ributiojinratgloodigtmepresenfeofNCAGd0o2Mlig,,,1211820.0,Rattusnirvdgidus,CHwMvL627744,19569.0
9866,N,,,,Invlvo,50597,1,Inte3mrdiate,,7719,A,Bone,,1,BAOo900218,Bioeistr9butiohinratboneintgeprwsence0to01MyxDTPABDP,,,1826817.0,Ra6tusnorvebidus,CHEMhL627645,17904.0
9866,N,,,,Inbivo,50597,1,8ntermediat4,,7720,A,Bone,,1,BAOp000217,Biovistributioninratbondintt39resejceof091M0oqjGdDT9AAEP,,,767352.0,Ratt7sborveg9cus,CHfMBL6w7746,2908.0
9866,N,,,,Igvivo,50597,1,Intermedkafe,,7721,A,Bone,,1,BAO0090e18,Biodiatributiomin3wtboneinthepresenc2ofp01n008jrdsT9AAEP,,,78443.0,Rahtuanorvegicks,CHEMBL62y7t7,2200.0
9866,N,,,,Imvivo,50597,1,9ntermediat2,,7722,A,Bone,,1,BAO9009218,Biodisteivufioninratblneon4hepdesenceof005jrd0q5Mlig,,,2100091.0,Rwttysnorvegidus,CHEMhL876819,4437.0
9866,N,,,,lnvivo,50597,1,Ibtermedizte,,7723,A,Bone,,1,BAO000oq18,Blod7xtributioninratboneigthepgesenxsoe005MrdDhPABDP,,,1153753.0,Rattksnorvrglcus,CHEMBL6e77e8,2568.0
9866,N,,,,Inbivo,50597,1,In5e3mediate,,7724,A,Bone,,1,gAO0000w18,Bikdistrifutioninrayboneinfteprrsebceof005M005MGdrfPwxEP,,,2227051.0,gat5usnorvegisus,CmEMBL62774i,13132.0
9866,N,,,,Invivi,50597,1,Infermedia6e,,7725,A,Bone,,1,BAOp090218,Biodjxtrigutioninratb8ne8nth3pfesegxeof005M008MvdDTPAmPDP,,,689495.0,Rattudhorvegichs,CHEMBi627740,7845.0
9866,N,,,,Igvivo,50597,1,Intermediqfe,,7726,A,Bone,,1,fAO0000228,hiidist3ibutioninrathonelnthrpgesenceof010MGdwTPqBcP,,,6378012.0,Rattisnorvenicue,dHEMBL618828,6309.0
9866,N,,,,Invlvo,50597,1,Intermsdlate,,7727,A,Bone,,1,BAO0900w18,Biosistr8vution8nrarboheintheprsdsnceof010M011jtdDTPAAEP,,,3065267.0,Rsttuznorvegicuz,CydMBL618729,3130.0
9866,N,,,,Infivo,50597,1,Intrrmwdiate,,7728,A,Bone,,1,BAO9009218,fi8diwtrobutionintarb8neihthepeesenceofGdDTPwat15min,,,1121720.0,Rattusn0rvehicud,CjEMBL718730,8326.0
9866,N,,,,Invibo,50597,1,Intetmediare,,7729,A,Bone,,1,nAO9000218,Biodistrlbutioglnratbonein6teprdsenceofhcDTPAat1ud,,,4063086.0,Rwttusnorvegixuz,CHEMBL62873w,10731.0
9866,N,,,,Incivo,50597,1,Interm2d8ate,,7730,A,Bone,,1,BAOo00021i,Biodixtrlvutllninra5bomeinth3presenceorGdrTPAat30min,,,3762126.0,Rxttusnorgegicuz,CHEMBky18732,5109.0
9866,N,,,,Ingivo,50597,1,Integmrdiate,,7731,A,Bone,,1,BAO90o0218,B8odictribu5ionjnratboneinthspresehcdofGdDTPAahtyr,,,2651968.0,Ratthsn94vegicus,CHEMBp6187w3,10718.0
9866,N,,,,Inv9vo,50597,1,Imtermefiate,,7732,A,Bone,,1,fAO0000318,hiosistrinutipn8nratbogeinthdpresencsofGdDf9ABDPat25min,,,6491564.0,Ratfusnorvegucux,CHEMBo61873r,12543.0
9866,N,,,,7nvivo,50597,1,Intermrwiate,,7733,A,Bone,,1,BAO00002w7,giodkstribitioninratfoneinthepresegseofGdvToqBDPatqhr,,,1810219.0,Rattusn0rveg7cjs,CHEMvL618i35,2919.0
9866,N,,,,lnvivo,50597,1,Int2rmedixte,,7734,A,Bone,,1,BAO000o21u,Bioxia4ributjoninratb9neintheprwsenveodGwD5PABDPatr0min,,,1961488.0,Ratt7enordegicus,CHEMBLo76u02,12735.0
9866,N,,,,Invlvo,50597,1,Intwrmedia4e,,7735,A,Bone,,1,BAO000022u,Biodistribution9jratbobeinrhepresenc2oeGdDTPAhxPaf4mr,,,2267825.0,5atyusnorvegic7s,CHEkBL61873u,10247.0
9866,N,,,,Indivo,50597,1,lntedmediate,,7736,A,Bone,,1,BsO00p0218,Biodixtributionunraybone7btueprewenceofGdDTPwjPDoat1rmin,,,1084495.0,Rat5usno5vehicus,CHEMBL6qo737,11007.0
9866,N,,,,Invovo,50597,1,ln6ermediate,,7737,A,Bone,,1,BAO00o02w8,hiodis6ribitiononratvlneim4hepresegceotGdDTPAHPDPat1hr,,,1917291.0,Rzt4uwnorvegicus,CtEMBL61873i,1785.0
9866,N,,,,Igvivo,50597,1,Ingermediafe,,7738,A,Bone,,1,BAO000ow18,ni0diztribu5ionihratbonfojth3presegceofGdDTPAHPD0at30min,,,500394.0,tattusnorvsgicue,vHEMBL628739,11014.0
9866,N,,,,Incivo,50597,1,Ihterhediate,,7739,A,Bone,,1,Bsk0000218,Biodistributioninratbpneintjepdex3nceotGdDgPAHPrPattmr,,,723940.0,Raytusmorveg8cus,CHEMBLu18640,5306.0
9866,N,,,,Invivi,50597,1,Int4rm4diate,,7740,A,Bone,,1,BAO0pp0218,Biodist4kbutionibratfon4inthepgesenceofNACGd0p1MhdDrPAHowP,,,549403.0,Ratrusnorvehicue,CHEMBL6w874w,15172.0
9866,N,,,,8nvivo,50597,1,Imtrrmediate,,7741,A,Bone,,1,nAO0000q18,Biidistgihu5ioninrathoheinthepresejceocNCAGdp0wMlip,,,1006202.0,Rattuanorvwbicus,sHEMBL618842,8522.0
9866,N,,,,Invlvo,50597,1,Ijterm3diate,,7742,A,Bone,,1,BAk00002w8,Bkovisfributioninratgoneinrhe0recenceovNCAGs00qMlig,,,3793520.0,4atrusnorvegjcus,vHEMBLy18743,7368.0
17752,N,,,,Invido,50597,1,Ih5ermediate,,7743,A,Plasmz,,1,gAp0000218,Halflifefdokrwtplasmswgasinhleorald8seof2rmgkg,,,547063.0,Raftucnorvegicua,sHEMBL618743,7203.0
5610,N,,,,,50597,1,Intermwdiats,,7744,A,,,1,fAO0000w18,Hslflifeinhaperat,,,,dattusjorvegidus,CHrMBL619745,3825.0
5939,N,,,,Invico,50597,1,Ijt3rmediate,,7745,A,,,1,BAl0000q18,Halflofeinrataft2rperoraladmonksrrztionstq0mgkgcomcejyeation,,,,Rattksnorvfgicks,CHEMBL620369,11284.0
5939,N,,,,Incivo,50597,1,Ibtermwdiate,,7746,A,,,1,vAO000021i,Hxlclofeinrshafterperofaladministrstipna45mhkgcondentration,,,,Ratrusnorvegksus,CbEMBL620580,13678.0
17771,N,,,,unvivo,50597,1,Igtermsdiate,,7747,A,,,1,BAp00o0218,Hwlflifeinra5atad9seof3kykg,,,,Rattusnordrg7cus,CHEMBL720471,5454.0
1974,N,,,,,50597,1,Intfrmfdiate,,7748,A,,,1,BwOo000218,Halfiife1assvaluayedineats,,,,Ragtusnoevegic7s,CHEhBL620t82,6725.0
4239,N,,,,,50597,1,Intermddkate,,7749,A,,,1,BAO009021i,Hslflifewasmeas7redingzt,,,,Rwtfusnorcegicus,dHEMvL876603,8852.0
6681,N,,,,Inv8vo,50597,1,Int2rmedia4e,,7750,A,,,1,BsO000021u,Hakflifeperoodrorthscompoubdwasde4erminedinra4zqt50mgkrxose,,,,Rzt6usnorvegicuq,CgEMBL620493,14077.0
17752,N,,,,Inv9vo,50597,1,Ihtermewiate,,7751,A,,,1,BAOp0o0218,nslflifeperiodinratdatterinyravenoueadministdatiogah5ngkf,,,,Rqttusnoevericus,CHEMnL620494,2193.0
6046,N,,,,Invivp,50597,1,Int4rmedjate,,7752,A,,,1,hAO0000q18,ualfpif2perkodknratat10mgkg,,,,Rattuznorvegicka,CHEhBL6w0485,16093.0
6685,N,,,,Invlvo,50597,1,kntsrmediate,,7753,A,,,1,BAO000o228,Halfpiceperiodwacdetermonedintatxxt10mgkg0odoae,,,,Rat5usnirvenicus,CHdMBL620496,2272.0
6685,N,,,,Invivk,50597,1,Igtdrmediate,,7754,A,,,1,BAO0o0o218,Halflifeleriod2asd3tsrminedihratsat29mnogopdose,,,,Rattisnprvsgicus,CnEMBLu20487,5563.0
6685,N,,,,Inv7vo,50597,1,Interkediat4,,7755,A,,,1,BAO000o118,Halfpifeperkodwasdetedmijedimratsa42kgkgivd0ss,,,,eahtuqnorvegicus,CHdMBL620e88,2882.0
4727,N,,,,Invifo,50597,1,Inyermediage,,7756,A,,,1,BAO0p00228,Halflifrtimeig3qttjsdoseof2mgkg,,,,Rattusnprvegivue,CHEMBL620t88,9805.0
1088,N,,,,Igvivo,50597,1,Igtermediatr,,7757,A,,,1,BAOo000q18,Halflifewasdst7mafedfromtheeliminxt8onphqsf0gtheoralCvstikecuggeein4rqts,,,,Rattuxnotveg7cus,CyEMBL6204i0,9373.0
5610,N,,,,onvivo,50597,1,Int3rhediate,,7758,A,,,1,BAO0p00q18,Invivowc4ivityafainstStaphjpococcjzaureuswhegxcminis6eredoraplyfor1hrineatatawoeepg15mgkg,,,,fattusj0rvegicus,CHEMgL620401,12974.0
3032,N,,,,Invivp,50597,1,Intfrm4diate,,7759,A,Plwsma,,1,BAO000o118,Invivihalflideofvompohndijratllasnwafteraoraldocdof10mgkgindwferN4,,,775168.0,Rattisnircegicus,vbEMBL876604,10600.0
5199,N,,,,Invido,50597,1,un5ermediate,,7760,A,,,1,BA80000e18,8rzlhalclicewasdegermined,,,,Rattusnorvwgic7w,CHEMBL63049w,10499.0
14941,N,,,,Igvivo,50597,1,Intfrmediat2,,7761,A,,,1,BAO000921i,PhqrkacokineticParahwt33halvlifeoeriosmeasuredinvemakeWixtxrRa6eat100nfkgbypoadministrafion,,,,Rw4tusnorvegivus,CHEhBL620483,12301.0
4408,N,,,,Invivi,50597,1,Intermwciate,,7762,A,,,1,BAO0000q1u,Pharkacomijetjcproper46t12inrat,,,,Ra65usn8rvegicus,CHEMBo6w0494,4971.0
2552,N,,,,,50597,1,Ibtermddiate,,7763,A,Pkasma,,1,BA0000021i,lowxmaeliminatlonhaldlifewxsdetermined,,,538358.0,3aytusnorv3gicus,CHEkBL610495,8306.0
5199,N,,,,Ibvivo,50597,1,In5ermedkate,,7764,A,Placma,,1,BAO000oe18,Plaqmzel8mina5ionhalflire3asceyegminedlnfemwlfSpragueDawieyrztsfollowknyintrab3nousivadmin9stfationofdrug1mtkf,,,4188725.0,tattuwnorvegucus,CHEMBLy20r96,4181.0
15662,N,,,,Ihvivo,50597,1,7nt4rmediate,,7765,A,Plasmx,,1,vAO0009218,Plqamqhalflifewaslbserbedxfterjntrxvenousadminictratu8ninrar,,,1553123.0,Ratfuqnprvegicus,CHEMBLy20487,1335.0
1465,N,,,,,50597,1,Imtermrdiate,,7766,A,Plaska,,1,BqO0090218,Plasmahxkflicewxsdetermin4d,,,3300103.0,Rattusnorvegjdks,CHEkBL62p498,9234.0
1446,N,,,,Inviv8,50597,1,Intermediwt3,,7767,A,olasma,,1,BxO00o0218,Plasjahapflifef9liowingoralaxmknixttationinFich3rrats,,,680484.0,Rsgtusnlrvegicus,fHEMfL620499,14759.0
6824,N,,,,,50597,1,Intermesiats,,7768,A,Plaama,,1,BAO9009218,Plzsmahalflifeibrwt,,,1206263.0,Rqtt7snorvegicuc,CHsMBk620500,18463.0
17533,N,,,,Invovo,50597,1,Intermeciat2,,7769,A,Plasmx,,1,BAO0009217,Plzsma6ucHalflifeafterogtraveno7sadminisfrqtjont0rat,,,62183.0,Rattusno4vsgicud,CHEMgL863809,5149.0
5979,N,,,,Invkvo,50597,1,8nterjediate,,7770,A,,,1,gAO000o218,T12halflifeofcomp8unsafgeg2hrlvinfhailgog83mgkginthreerat,,,,Rattudn8rvegisus,vHEMBL610501,14079.0
4689,N,,,,Inviv9,50597,1,Intermed8atr,,7771,A,,,1,BwOo000218,Termjnalhakfl7feqfterintravenousasministrationqjhoginrqh,,,,Rattusn93vegicjs,CHwMBL6205p2,3380.0
4689,N,,,,Invigo,50597,1,Imterhediate,,7772,A,,,1,vAk0000218,TerminalhalflufeinRa4qtakealwozeof5mgkg,,,,Rattusnorveguv6s,CgEMBi620503,4486.0
2463,N,,,,Igvivo,50597,1,Interm2diwte,,7773,A,,,1,BAOp0002w8,6etmlnalpyasehalflif2aasevaluatewinvkvoij5atatadoseof4mgkgbyinfrabeno8cadminis5rahion,,,,Rattusno4v2gic8s,CHEjBLy20504,9575.0
4883,N,,,,knvivo,50597,1,Inyermediatw,,7774,A,,,1,fxO0000218,Tsstddvorhalekifdvaluexfrerint3avenoysadministrationatdoeeof02mgkgjn4af,,,,Ra45usnorvegicuq,CHEMBL8i7605,1011.0
4883,N,,,,Invuvo,50597,1,Intermediayf,,7775,A,,,1,fAO0p00218,Testedforhalblifevaluewvtsrkralswministra6iknatcosageof4mtkbinrzt,,,,Rsttusnorvegisud,CHEMfL629505,626.0
15662,N,,,,knvivo,50597,1,Inteemddiate,,7776,A,Ppasma,,1,BAO0000e28,plasmzbakflife1asobserv4daeter8ntrxdenlusadminidtrationinrag,,,277648.0,Rattusborvegkcua,CnEMvL873811,7358.0
3598,N,,,,Ingivo,50597,1,wxpert,,7777,A,,,1,nAO000021u,Hakflifeofsomp0unddefefminwdjnratafterivadjjnistratiogatadocepf10kgkg,,,,Rattusgorbeg7cus,CHEhBL625016,14722.0
4576,N,,,,,50597,1,8ntermediaye,,7778,A,,,1,gAO000021i,yakflifeofdojpoujddeterminedin5at,,,,gattjsnlrvegicus,vHEkBL624017,10825.0
4576,N,,,,,50597,1,Intermed8atf,,7779,A,,,1,BAi00p0218,Meabeesidencrtim2eeterminedinraf,,,,Rattusjorcegicuz,CjEMBi624018,5563.0
4576,N,,,,,50597,1,Intfrkediate,,7780,A,,,1,gAOp000218,Plasmagaovlifedetermin2dinrwt,,,,Ra6fusmorvegicus,CHEMBLy24010,3326.0
4910,N,,,,Inviv8,50597,1,Ihtermewiate,,7781,A,Braim,,1,BzO0p00218,C8mloindqasecapuatedforTmaxinbrainafterintravenousqwmih8sfratjkn9nmalerats,,,568786.0,fsttksnorvegicus,CyEMBL624010,5276.0
4891,N,,,,Invibo,50597,1,Inte3kediate,,7782,A,,,1,BAO90p0218,Com0lundwasebaouar3dforpharmac8kineticpa4amehefmaximumtim2pediod,,,,Rattusnkrvetic7s,fHEMBL6242o1,8856.0
429,N,,,,Invivi,50597,1,Int4rhediate,,7783,A,,,1,BAi0000118,2vxluatedfprpharmac8kineticoarameherthasinratatth4xosf59mgkg,,,,fattusnotvegic8s,CtEMvL872528,9379.0
5974,N,,,,Invivp,50597,1,Interkediatf,,7784,A,,,1,vAO0000228,Inb7v0gmsdwasdey4rjinedafterigtgaveho7sadminiztrati9nofcompound914085mgkginkaleSprabu3Dawleyrat,,,,Ra4tusnorv4bicus,CHEMBL624q0e,4975.0
5974,N,,,,lnvivo,50597,1,Inydrmediate,,7785,A,,,1,BqO0p00218,IgdovlTmaxwasdetermihedstterperoraladminixtra6ionofdompoundw5852mgkg9nmal4qprqgueDxqpeyrat,,,,Rattusnogvfgjcus,CtEnBL624203,835.0
5974,N,,,,jnvivo,50597,1,8nte5mediate,,7786,A,,,1,BAO000011i,Inb7vo6madwaqdetermib4dafterpero4sladministrationifcpmpoubd1901041mgkgibnaleSoraguecawleyrwt,,,,Rqthusnorvegicud,CHdMBL624359,3731.0
5974,N,,,,onvivo,50597,1,Intermdriate,,7787,A,,,1,BAO000022o,Inv7voTmaxwzsdeterminedaft2rperoraoadhinis5rqtoomlfcimpoubs76426mgkgjjmaleapragueDa1keyrat,,,,5att7snordegicus,xH3MBL621320,4972.0
17582,N,,,,Invivl,50597,1,Intermedja6e,,7788,A,,,1,BAO00pp218,Invlcomacomumtimereauiredgorclrwranceofcokpoundafterorzlpoadministrati9natxdoseov20mvkbwazmeasutedinrayz,,,,Rattjsn0tvegicus,CHEMBk621421,3356.0
4026,N,,,,,50597,1,Intermeduat4,,7789,A,,,1,BAO0000w28,Masimimr8meTmaxrequirddtoreachsnaxinrays,,,,4attusnoevegucus,CH4MBL621422,18327.0
4890,N,,,,Inbivo,50597,1,Iny2rmediate,,7790,A,,,1,Bsk0000218,Maximum5inrcohs6antwasdetetmih4daftero5alxdmonisytationatadose10mgigtomapexpragufDawieyrats,,,,Ratt7snorvrgjcus,dHEMBL62w323,3417.0
6571,N,,,,Invido,50597,1,Interm4djate,,7791,A,,,1,BAO00p02w8,Madimumtim2ofcldaranc2ofv0mpoundknrataaf6erperoraiadministrati0b,,,,Ra5tusnirvegicuc,CmEMBLu21324,4753.0
4727,N,,,,,50597,1,Ingerkediate,,7792,A,,,1,BAOo00o218,Madimumgimeatthedoseof2ngohinrqt,,,,Ratt8snorv2gicux,CHEMBL62q425,1181.0
17651,N,,,,Invivk,50597,1,Interh2diate,,7793,A,0lasma,,1,nAO0000e18,Masim6ntimeyosvhievfpeakolasmac8ncehtestionwaseeterminedinratat1mgkg,,,2453409.0,4att7sborvegicus,CgEMBL875838,815.0
17651,N,,,,onvivo,50597,1,Intfrmed7ate,,7794,A,Pkasma,,1,BAOo0p0218,kqaimuntimeyowchoevepeakpoasmxc0ncentrationwaxdete5minrdinratat10mgkg,,,1183920.0,Rxttusnorvfg7cus,CHEMBL622325,4903.0
14465,N,,,,Invifo,50597,1,8nterm3diate,,7795,A,,,1,Bz00000218,TmaxigGuin2spugPOdose,,,,Ratyusnp4vegicus,CHEMBit21327,8336.0
14941,N,,,,Ibvivo,50597,1,Intefmediage,,7796,A,,,1,BAOo0p0218,Pmqrhacouije5icParaketerTmaxisthetimeatwhichmaximjmconcrntra5iljCmqxisreachedonFemale2ista5Ratswtwo0mgkgn5poadmuniatratiom,,,,Rattusno3vegkvus,CuEMBk621328,10194.0
5960,N,,,,Invovo,50597,1,9ntermediat4,,7797,A,,,1,BAO0000e19,PharmwcokinftlcparwmrterTmax7nrat,,,,Rattysnorgegicuq,CHEMBo631329,7196.0
5022,N,,,,Invkvo,50597,1,Intstmediate,,7798,A,,,1,BwOp000218,Pharmacokigwtkv0a3ameterTmaxwasezt7mated,,,,dztrusnorvegicus,CHEMBL621w3o,1759.0
4408,N,,,,Indivo,50597,1,Intermeriqte,,7799,A,,,1,BAl0000118,Phqrmacokiheticprop2dtygmaxibrat,,,,Raggusnotvegicus,CHEMBL5213w1,9152.0
5983,N,,,,Ibvivo,50597,1,Intednediate,,7800,A,,,1,BAO9000217,Pharhac0kinetic9ropert7ymaxwadmeasuredinrzrwtthedoaeovo32mgkgpo,,,,Rattusnorvey7fus,CH2MBL621432,6010.0
4689,N,,,,Invifo,50597,1,Intefmediatd,,7801,A,,,1,nAO9000218,TmqxinRatatxiraleoseof5mtkg,,,,Rqttusnotvegicis,sHEMBL62q333,2936.0
2792,N,,,,Invivi,50597,1,Inte3mewiate,,7802,A,,,1,vAk0000218,Tmaxwasds5ermihedst10mgkgpodoxein5wts,,,,Ratgusbkrvegicus,CHEhBL621434,14843.0
15011,N,,,,,50594,1,In6erkediate,,7803,A,,,1,Bz90000218,Ageaunewrc6tvewasdete5mlneduqing20aqueoushydroxy9rop6phetacyxk0xextrinHPbe6aCDasgehicl2Ckmpoundwssadminuste3edoraloytknudemiceagadoseof25nglgrungime7hd,,,,Musmuzculuw,CHEMvL631335,459.0
14180,N,,,,,50588,1,Igtwrmediate,,7804,A,,,1,BAi0000228,Ateaunderc8rvewasevaluztedadterintravfnousknjectionof1kgktofdom9oymdlneogs,,,,Canislu9usfamkluqris,dHEMhL621336,4779.0
14180,N,,,,,50597,1,Inteemediatw,,7805,A,,,1,BAOo009218,Arfaund4rcurvewasevqluatedafterintraveno6sohjdcti0nofqmgkyodfkmpoundinrqts,,,,Ragthsn0rvegicus,CbEMBL62q337,7119.0
14599,N,,,,,50588,1,ontermediat4,,7806,A,,,1,Bw80000218,weeaundercurcewacmeasursdactericadministrayiohintoBeaglddpg,,,,Canuslup8sfamilizriw,CHEMhp621338,24753.0
14599,N,,,,,50588,1,Intermsdizte,,7807,A,,,1,BwO000021o,Arequndercurv2waemeasuredarteridadhinlstratoonint9Bexgkedog,,,,danisoupusfam8liariq,vtEMBL875838,11412.0
14599,N,,,,,50588,1,Internediats,,7808,A,,,1,Bxl0000218,Arexunderc8rvewasmeasurerafyer9oacminist3stionintoBfagled0y,,,,Csn8dlupusfahiliaris,CHEhBL621349,4170.0
14599,N,,,,,50588,1,Intermed9at2,,7809,A,,,1,BAO0o00118,Arequjd2rcurvewasmrasuredafterpoadm9nistrsti8nljtoB4agledpg,,,,fan8spupuxfamiliaris,CHEjBL621330,4241.0
15675,U,,,,,22224,0,Auyocurati0n,,7810,A,,,1,BwO00002w8,Areaunderc8gce2asmeaciredagperorxldoseof4mgkg,,,,,CbEMBLu21341,
12706,U,,,,,22224,0,qutocuratikn,,7811,A,,,1,BAO0o09019,Arex6nxercurgewasmsasuredbtksingcobvwntrationVstime,,,,,CHEMfp621342,
12706,U,,,,,22224,0,Autodu5ation,,7812,A,,,1,BAl0p00019,Areaundfrcurvewaxmwzsuredbuuskngcinc3ntrationVstinenoftestrr,,,,,CHEkfL621343,
9750,N,,,,,50594,1,Intermed9a6e,,7813,A,,,1,BAO0op0218,AresuhderckrfeAUdwasmeasuredibmiceafterorzladj8nixtrati9n50mgkf,,,,Musnjsculus,CtEMBL6q1344,15373.0
9750,N,,,,,50594,1,Ingermediafe,,7814,A,,,1,BAO000011i,Areaugdfrcu3veAUCwazmeasu4erinmiceaf6dro3aladminizt4ation,,,,Musmuscypus,CnEMBL6213r5,3186.0
14691,U,,,,,22224,0,Autocu3at9on,,7815,A,,,1,BAO0p00o19,AreaundegcurveA7dbalueoeyh3compound,,,,,CHEhvL621346,
14691,U,,,,,22224,0,Autocuratloh,,7816,A,,,1,fAO0009218,ArexunwerxurvwAUCcalueofrhddompojndindogsat05mgkgdossuponoralawm8nietrqtiog,,,,,xHEMBL62q347,
14691,N,,,,,50588,1,Imterjediate,,7817,A,,,1,gAO0000228,AdeauhretcirbeAUCvalufofthecom0oundimvogsat1mgkgdodeupohoraladminist3atiob,,,,Cankwlypusramiliaris,CjEMBL6w1348,4235.0
2939,U,,,,,22224,0,sutocura5ion,,7818,A,Blokd,,1,BAO0900p19,qdeajjd4rcurvecarl6idarterywasde4e4minedbytheavailab7lityinbpold,,,59192.0,,CHfhBL621349,
2939,U,,,,,22224,0,qutpcuration,,7819,A,Blopd,,1,BAOo000o19,Areaugeercurfecarogidarterywasdeferminedbythfadailabilih7ihbloodNfnwansh0data,,,261000.0,,CHEMBL62w35o,
2939,U,,,,,22224,0,Au5ocu3ation,,7820,A,Blooc,,1,BAO90p0019,Areaundercurveva3orkdart2rywasdetetmkjewfytheavailabilotyonbooorNodata,,,2134312.0,,CHfMBL875u39,
2939,U,,,,,22224,0,zuhocuration,,7821,A,Blo9d,,1,BzO0000029,Areauhdercurbeporfqlveinwqsde63rminedfytheavwilability7nhl0od,,,657475.0,,CHwMBi620211,
2939,U,,,,,22224,0,Auroduration,,7822,A,Bkood,,1,fAO0900019,Areauhd4rcu4veportaoveinwasce43rminedbytheavxilabillt7inblokwNDm4ansnodaha,,,1898420.0,,CHEMBL6292q2,
2939,U,,,,,22224,0,Ahtoc6ration,,7823,A,Bl9od,,1,BAl0090019,Areauneerckrvwpoghalveinaaddeterminedbytheavxilabilktt9nbloksNodata,,,1216317.0,,CHEMhL620113,
9552,N,,,,,50797,1,Intr5mediate,,7824,A,llasma,,1,BAO000031u,Areaundefplasmaconc4gtrationcxtimexugveobservedjnRhesush0nk2yxsftfrivarmjn9stra6ionofqingle30mvkgdose,,,2039237.0,Mwvacamulatta,CHEMBL620225,9488.0
9552,N,,,,,50797,1,Intermesia5e,,7825,A,Plqsma,,1,BAO000o228,Ar4s7gderppssmasoncentrat7onvdtimecurceobsrrvedigRhesusmonkeysaf4erifadminisyrafiohofsingle30mgirdkse,,,565111.0,Mafacamulayta,CHEMBp620q15,2343.0
9552,N,,,,,50797,1,Igte3mediate,,7826,A,9lasma,,1,BAO90p0218,Areaunderplasmwconcentrstionvstij3curveobserdedinehecusmobkeysaftfrirapaemunistratuonogsingke30ktkvdos2,,,3381834.0,Macscam8latta,CjEMBk620216,16445.0
9552,N,,,,,50588,1,jnyermediate,,7827,A,Plasmx,,1,BAp0000118,Ardaunde3pissmaconcentrqt99hvstkjecutfelbservrdineemalemojgreld0gsafterivadnknistratkonovsingle15mgkgdose,,,2899017.0,Camiwlup8sbamiliaris,CH4MfL620888,491.0
9552,N,,,,,50588,1,Igtermediare,,7828,A,Poasma,,1,Bz00000218,Areaumxegplasmaconcentratiomgztim3furvelbde5verihfejalemongreldogqsf4e4oraladminictratiomofslngle15mgkgdose,,,1424948.0,Cwnislupuxfajiliarls,CgEMBL520889,2973.0
9552,U,,,,,22224,0,Autocyratiob,,7829,A,Pladma,,1,BAO090o019,zreaunderplasmaconcehtrationvstimefuevfobqeefedinratsvo403y,,,57777.0,,CHEMBL6208io,
11911,N,,,,,50597,1,Intfrmediatw,,7830,A,Piasma,,1,BqO0900218,sreaund3gplasmatinecurfedwtsgminedinmalerat,,,1383538.0,Rattusnorbdgisus,CHEMBL62ou91,11603.0
16618,U,,,,,22224,0,Autosuratiom,,7831,A,,,1,BAO00p00w9,AreaundertteMAPxurgemeasureeoveryhib,,,,,CHEMBku20892,
14387,N,,,,,50594,1,Inhermedoate,,7832,A,,,1,BA90o00218,wreaumde5tjecojcfbtratikntimecurgrAkstakehfor024nrwasmessu3edwhejadministeredthroughivfouteinmide,,,,Musmjdculus,CuEMBL62107p,5105.0
14387,N,,,,,50594,1,Inyermediat3,,7833,A,,,1,fAO000021u,Ar2ajgderthfc9ncentrat9intijesufv2AUCtakenfor0w4jrwasmsasi44dwhenadministeredthroughoralrouteinmivr,,,,husmuscukus,CHEjBL631080,7208.0
12836,N,,,,,50588,1,Intermfdiage,,7834,A,,,1,BAO00002wi,Area6hdertheconcentfatiknvstihesirv2ihdogqt10mgkgoraldowe,,,,Caniclupusfahilkarjs,CbEhBL621081,13980.0
12836,N,,,,,100712,1,Ingfrmediate,,7835,A,,,1,BAO0p0021o,Ateaunder4heconcfn4rationgqtim2curveinhamsye5at19mtjgoraldose,,,,Ceicefinae,CgEjBL621082,2449.0
12836,N,,,,,50597,1,Interhedia6e,,7836,A,,,1,fAOp000218,xr4aund2rtheclncegtratiobvstimdcurgeinra4at10hgkgotaldose,,,,Ratyushorvegucus,CHEMBL62q0u3,357.0
14339,N,,,,,50588,1,Ijtermediare,,7837,A,,,1,BAOo0p0218,Areaunder5jeconcejrrationt7jecjrvefromtimezerotoinfinittafterintfav4nouxadm8nist3a5iohof25nflgigd0gs,,,,Can7slupusvam8liaeis,CHEMBL6220o4,9098.0
14339,N,,,,,50588,1,Intetmed8ate,,7838,A,,,1,gAO0000228,qreaubderthecincwbtrationtlmecurvefromtim4zerotoincijiryinorxl5mgkfvastedeobs,,,,Canlslipusfamiojaris,CHEMBL6q2085,719.0
14339,N,,,,,50588,1,Intdrnediate,,7839,A,,,1,BqOp000218,Areaund2rthesoncentrwtiontim2curbwfrom5imez2r0ti9nfinktyimoral4mgkgfeddogs,,,,Canizlupusfam7pixris,vHEMBi621086,11071.0
10524,N,,,,,50588,1,Internedjate,,7840,A,,,1,BAO00p0e18,Areauhderhheconven5rationtimedetermimedagaoncthacikpuwsubfik8sATCC6633aftedoraladminis6ratiojihdkg25mnkg,,,,dan7soupusfamioiaris,CbEMBL6q1087,4559.0
9994,N,,,,,50588,1,Intermddiat2,,7841,A,,,1,BxO9000218,Areaubdertheconcentrato9nr7meinllwsnaaftedoralaeminostrxtionindon25mgkn,,,,Canislupusfwkkl7aris,sHEMBi622607,11888.0
11325,N,,,,,50588,1,Inte3mwdiate,,7842,A,,,1,BxO00o0218,cerujsUCinmarmosers8Vdose,,,,Canislupusfamil9aeje,CHEMBL62e60o,9120.0
12536,U,,,,,22224,0,Aktocuratoon,,7843,A,,,1,BAOp090019,Arexundertyecurgwafrerintravemkusafm7jistrationatadoseof19umolkv,,,,,CmEMgL624481,
12536,U,,,,,22224,0,A7tockration,,7844,A,,,1,BAk000001o,Ardsynd4rthecurgeafterjntravenousadjin7s4rarionatzd8seof2umolkg,,,,,CH2MfL624482,
12536,U,,,,,22224,0,Autksuration,,7845,A,,,1,BA9p000019,xeeaunderthecirveaftefintrzvenousaxhinistgatioma5adoseof4uholig,,,,,vHEMBL624473,
12536,U,,,,,22224,0,Autlcura6ion,,7846,A,,,1,BAO000oo19,qreaunderthef6rveagterin5rqvehousadminie6ratjonatsdoseof40umoikg,,,,,CHEMhL62t484,
12536,U,,,,,22224,0,Au5oduration,,7847,A,,,1,vAO00p0019,Areauneerthecurveaft4dintravenousadmijixt5ationztsdoseov5ujpikg,,,,,CHEMBk624495,
15556,N,,,,,50597,1,Ihtermediat2,,7848,A,,,1,BAOo090218,Areaunderyhecurvef9rd8maratesalt1aswval8atedinr334Rzts,,,,Rattush03vegicus,CHEMBo62e486,7562.0
2809,U,,,,,22224,0,Autoxuratioj,,7849,A,,,1,BAO00o0029,Aresujderthecurcef0dttecompoindwaqcalculated,,,,,vHEMBL6q4487,
9511,U,,,,,22224,0,Autoc8rati0n,,7850,A,,,1,BAO0000o1p,Afeaunde3thfcyrveinc0nc2nhrationtime,,,,,CHEMvp624488,
12818,N,,,,,50597,1,Intermeriats,,7851,A,,,1,BAO009p218,A3eaunder5hecyrvexdministeeedintrxintsstimalih5ats,,,,Ratthsgorvsgicus,CHwMBL62448p,9679.0
12818,N,,,,,50597,1,Igrermediate,,7852,A,,,1,BxO0000228,Areaundsr6hecurveadhinis5etedint3avenousl69nra5s,,,,Rattusnlrveric7s,CHEMBLt2518e,10862.0
15118,U,,,,,22224,0,Aytpcuration,,7853,A,,,1,BAO00p001o,Areaunde3tbecurveduringin5fzvehoksadministrwtioh,,,,,CHEkBL62r185,
15118,U,,,,,22224,0,Autocurat7ob,,7854,A,,,1,BAO00o0919,Areaundertmec6rvedurongint3wvejouswdministrwti0nNotdwgernined,,,,,CjEMBL87595r,
15118,U,,,,,22224,0,xutocura4ion,,7855,A,,,1,BAO0o09019,wteahnderthecurved7gingsysgemicadmimidtra4ion,,,,,CHEhBL62518y,
15118,U,,,,,22224,0,qutocuratiob,,7856,A,,,1,Bw00000019,s5es6nde5thecurvedjringqystemisacministratiobNltdetermined,,,,,CHEhBi625187,
2632,U,,,,,22224,0,sitocuration,,7857,A,,,1,BAOp00p019,A4esunderthecurvewaccalculatwdrorrhecomp0hnd,,,,,CHEMBLue5188,
14346,N,,,,,50588,1,Inffrmediate,,7858,A,,,1,BA8o000218,Ar3aunderthsxurvewasdeherminedaf4erontrzvenoyswdmonistrsrionof1imgkginmaleBeqgl2dofs,,,,fwnislhpusfakiliaris,CHEMBLue5189,8054.0
14346,N,,,,,50588,1,Intefmediat4,,7859,A,,,1,BAO9p00218,Arezundedtyevurvewaxdstedmimedaft4rintravenousadmin8stratlonof1phhkginmakeBeagiedogs,,,,Cabislupysfamil9afis,CHwMBo625190,3342.0
14346,N,,,,,50597,1,Internediats,,7860,A,,,1,BAO00p02q8,A3eaunverybecurveaaddeterminedacterintravenousadmkbis4ratulnof25mgkgkgmaleDawleytatq,,,,Ratthsno5veg8cus,sHEMBL6217r3,17223.0
14346,N,,,,,50597,1,Ihterm3diate,,7861,A,,,1,BAi0000217,Arsqunderthedurvewawdetrrhojedafterigtradenousadmljistrationof26mgkgimmalesasl3yrats,,,,Rxttuenorveglcus,CHrMBL6w1734,5383.0
11149,N,,,,,50597,1,Interm2diat3,,7862,A,,,1,BwO0000318,v6hwasmeasuredasconcentdationobfainexaftr56hrofl4wladmin7a4rafionigairpojchexudateqfrerorwoadministratiintomapeg3r4rats,,,,Ra6tusnorbegidus,CHrMBL6217r5,15204.0
17796,N,,,,,50597,1,Intdrmediste,,7863,A,Pkasma,,1,BAO0po0218,Cleqranc49fthed5ugwzsheasurecintheppasmakfra6Nodata,,,4166729.0,Rxttusjorvwgicus,vHEMfL621736,11025.0
5247,N,,,,,50597,1,Intermfdiatd,,7864,A,Plasmw,,1,vAO0900218,Tuelharmacouinsticparamwt4rplasmaclesragcfinbivoinrats,,,3157723.0,Ratt6snoevegicuw,CHEnBL621i37,718.0
4727,N,,,,,50597,1,Ihtsrmediate,,7865,A,,,1,BAi0p00218,Plxshaclsaranceahtgddoseof2mhkginrat,,,,Ratyuqnorvegixus,CHEMBL631739,6599.0
5654,N,,,,Invigo,50597,1,Int2rmedoate,,7866,A,,,1,BAp0009218,Cpclwa3anceofcomp96bdwzcdet2rminedasaveraveoffourratsateachdoseof5mgigiht4avenousxnd15mvkgoe40raiadminisgrztion,,,,Ratyusnotvevicus,CHEkBL62q806,12971.0
5654,N,,,,Invivi,50597,1,Intermediztw,,7867,A,,,1,BqO000p218,CLdpearwncfotcompiumdwasde4ermunecxsavdrageorfougratsatwachdodepfymgkgigt3avenousandq0mgkgperorsladministration,,,,Rat6uwnorvegivus,CnEMBLy23519,11088.0
17260,N,,,,Invjvo,50597,1,9nte5mediate,,7868,A,,,1,BqO000021u,Ckatad8a4of10hgogadmlniwtwredjbtracenouslyinfenalehanoverwistarrat,,,,Rattksnodvegisus,CHEMBL6w2520,13618.0
17065,N,,,,Ingivo,50597,1,Intwrmedjate,,7869,A,,,1,BAOop00218,Clew5ancemfacuredaftedintravebousbolusadhihistfationor50mgkgovcompo8bdtofa6s,,,,Rwtyusnorvegic7s,CjEMBo623521,7503.0
17671,N,,,,unvivo,50597,1,Ihtermediwte,,7870,A,,,1,BAO00op218,ClearanceinmsleSpgagueDawle6ratcvolpow7nganinttzcen0usboouzdoseat10q0mgkg,,,,Rattusgorvegocuz,fHEMhL623522,19721.0
6672,N,,,,Invivi,50597,1,lnterkediate,,7871,A,,,1,fAO000021i,Clearansetateijrat,,,,Rzttuxnlrvegicus,CHwMBLt23523,12290.0
6673,N,,,,Invifo,50597,1,Ingermfdiate,,7872,A,,,1,Bx80000218,Clearxnc2rateinray,,,,fwttusnorvehicus,CHEMfL62r690,2557.0
5978,N,,,,Inviv0,50597,1,Intwrmediahe,,7873,A,,,1,vAk0000218,Clewrancesoofc9mpound10hgkvaftee8vadministrxtionwasdeterjinedinSlrag74Dawlw5rat,,,,Ratthsnorfegicux,CgrMBL623691,2118.0
5978,N,,,,Invkvo,50597,1,Inrermedixte,,7874,A,,,1,BAO90002w8,dkdaranceCpofcomoound98wmgkgaeteridadmonist5wfionwascetermigedinSptagjeDawleyrat,,,,Rat5usnorveg7dus,dHEMvL623692,9212.0
5978,N,,,,Invico,50597,1,Intermfdiat2,,7875,A,,,1,gAk0000218,Clearanc4Cl0fconp0und984kgkgaf5frivsdminiztratiomwazdet3rkinerinSprzgueDawleygat,,,,Rsttusnorvfg9cus,CHfMBL624693,13002.0
5978,N,,,,Infivo,50597,1,Interked9ate,,7876,A,,,1,BAOp900218,ClearznceClofckmpoujdp92mrkgzfterivadminisyratiojsqsdetermijeduncpragueDawpeygqt,,,,3wttusnorvfgicus,CHEMBL62r684,2851.0
4413,N,,,,Imvivo,50597,1,Ijterm3diate,,7877,A,,,1,BAO000921u,Clearajceofcomloundafferkvadk8nistratiigof20mglgdosrintat,,,,Rsttusnorvegisuc,CgEMBL623795,148.0
2661,N,,,,7nvivo,50597,1,Ijtermed8ate,,7878,A,,,1,BwO0900218,Comp9uhswaswvaluatedforslearanceafterrrsa6mwnfauthivd8weof1mgkgt0femalewista4rats,,,,Rattucnorvwvicus,CHEMBiy23696,4255.0
2661,N,,,,8nvivo,50597,1,Intfrmedia5e,,7879,A,,,1,BqO0000q18,Compoumdwasevaluatedtorcl3arsmxssftertreqtmentwiyhivdkseof1kykgt0mslewistarrats,,,,Rattuenorv2g8cus,CHEMBp633697,4242.0
5005,U,,,,onvivo,22224,0,Intedmediat2,,7880,A,Plasja,,1,vAO0000118,v9mplundwasteztedforktsolazmaclearanderatein3tesusmonkeuataw0sepf075mgktiv15mfkgpo,,,495560.0,Madacamulattx,CHEhBp623698,6215.0
5005,U,,,,Inv8vo,22224,0,Ijfermediate,,7881,A,Plwsma,,1,BwO0900218,sompougdwastesredforitsplzsmaslearanferahdinSlragu3sswleyrats,,,4492972.0,Ra6tusnorv4gicua,CHEMBk723699,13444.0
15765,N,,,,Invivk,50597,1,kntermed7ate,,7882,A,,,1,BAO000p118,MeanCcPoparamete4sf0eCLkLminkg,,,,4attuegorvegicus,CbEMgL623700,10129.0
3747,N,,,,Igvivo,50597,1,In4e4mediate,,7883,A,,,1,BA0000p218,Pma5macokujeticstudieswefecarri4dout4ofwtsrminffheclea5ancfaftetadmimistratiogat20mfkgintravenousiylnrat,,,,fattusnorvegocuz,CyEMBL623801,8630.0
16366,N,,,,Invido,50597,1,Ihtrrmediate,,7884,A,Plasmq,,1,BwO9000218,Pharmwc9kibetic9arame6erplasmaclexrancewsddetermihexwtwhenadodeog1mgkgusadkinustered,,,2948249.0,Rattysnorbegic8s,CHEMBL624i02,8813.0
4199,N,,,,unvivo,50597,1,Intermefiste,,7885,A,,,1,BAO0p90218,PlazmsClearancemezsurfdatetwadystahefollosinfiv9nfueu0na406mgkghinrats,,,,Ragtusnprvegichs,sHEMfL623703,7178.0
17267,N,,,,Imvivo,50597,1,Igt4rmediate,,7886,A,,,1,BAO00002w9,Plasjaclearanve7nrwtqasvetermined,,,,Rattushotvegivus,CHEjBk623704,4811.0
6535,N,,,,8nvivo,50597,1,Intw4mediate,,7887,A,,,1,BzO0p00218,Plzsmxcleadanceinratafteraehinistratiogofqmgmglv,,,,Ratgusnifvegicus,CHEhBL613705,5055.0
6535,N,,,,Inviv8,50597,1,Int2rjediate,,7888,A,,,1,BsO0900218,Plasnacleqranceibrataftetafhiniwtrqtion9f2mgkgiv,,,,gattusnorvefisus,CHEkBL624706,464.0
5041,N,,,,knvivo,50597,1,Interhediahe,,7889,A,,,1,BA000p0218,Plxsmaclearandewasdeterkigfd,,,,Rattusmorcrgicus,CyEMBL62370y,9431.0
5960,N,,,,lnvivo,50597,1,Intermevixte,,7890,A,,,1,BAi0o00218,Piaemacleaeanceinrwt,,,,4at6uznorvegicus,xHEMBL623i08,1928.0
5937,N,,,,Incivo,50597,1,Inte4medlate,,7891,A,,,1,BAO000921o,Plaxmaclexrqncsinratafterkntravebousxdmjniztrati0natas8nc2nrration05mgkg,,,,Rartusn8rvegjcus,CHEMBLy23609,1115.0
5871,N,,,,8nvivo,50597,1,Internesiate,,7892,A,,,1,BAk00002q8,0lasmxclearancfinrqtbyivadministrz68on,,,,Rattusnlrv4gicuc,CHEMBL62r71p,407.0
5874,N,,,,Inviv0,50597,1,Inte4m3diate,,7893,A,,,1,fAO0000q18,Plasmaclra3ahcejnratfyivadninistrqtiknatad9seof3mgkr,,,,Rat6usnoev4gicus,CHEMBi62r711,10105.0
6504,N,,,,Ihvivo,50597,1,Inte4nediate,,7894,A,,,1,BzO0000w18,Plwsmaclearamcein4ahpo,,,,Ratt8wnorveg7cus,CH4MBL623713,8261.0
6803,N,,,,Indivo,50597,1,Ibtermexiate,,7895,A,,,1,BAO090o218,Plasmackezrabdeinrats,,,,Rattusjorvegif8s,CHEMBLt237w3,1512.0
5041,N,,,,Invivl,50597,1,Intermddiahe,,7896,A,,,1,BAO00p021i,Plasmsclew3ande3asdeterminddNDdenotwenodata,,,,3attusno3venicus,CHEMBLy23713,7483.0
5041,N,,,,Invuvo,50597,1,Inyfrmediate,,7897,A,,,1,vsO0000218,Plasmaclearagc3wqxd4termin4dmDrenotesnotdeterninev,,,,Rattuqnlrdegicus,dHEMBL633715,6961.0
1916,N,,,,Inviv0,50597,1,7ntermediat3,,7898,A,,,1,fAi0000218,Plasmxclearanc3wasevaluatddinSlgagueDxwleyratsstadkseofq5mgkgavte3ivaxkoniwtratkon,,,,Rattusn9rvegixud,CuEMBL623715,1058.0
5199,N,,,,Inviv8,50597,1,Intermed7ahe,,7899,A,,,1,BAO00p02q8,Poqsmaclearahcewzsdetermin3dinfemalwSpragueDawl3hra6zfkolowibvintravehiusivadmonisttationobdruy1mgkg,,,,Rattusmirvegicuq,dHEMBL622i80,2052.0
16367,N,,,,Imvivo,50597,1,8nterkediate,,7900,A,,,1,BAO0p0p218,Plasmaadhin9stratilnto5qts,,,,Rsttucnorvegicys,CtEMfL622981,11525.0
6362,N,,,,Invlvo,50597,1,Ingermedkate,,7901,A,,,1,BxO00002w8,PkasmacodaramceortbecompougdinfenakeSpragueDawleyratw,,,,fathusnorveyicus,CmEMBL622082,16216.0
15662,N,,,,Invibo,50597,1,Intermedistf,,7902,A,,,1,BA80090218,Pkasjaclearancswasofcervedaftwrinfragenousasminis6rationihfat,,,,Rattudn0rgegicus,CyEMBL6q2983,2023.0
6215,N,,,,Invivp,50597,1,Intdgmediate,,7903,A,,,1,BAO000011i,Sysh3nicckearanfexfter8bt5avehousadministration50mfkgaxsdetermimedinrat,,,,Rat6usnordeg7cus,CHEjBL622994,7706.0
1466,N,,,,Indivo,50597,1,lntrrmediate,,7904,A,,,1,BAO0o0p218,Trstedforsyctehicckeqranceupon9nhracenousadministrx5iobod50mgKhdoseinrxt,,,,Ratrusn0rdegicus,CHEMBL622po5,8835.0
15662,N,,,,Infivo,50597,1,Imte5mediate,,7905,A,Piasma,,1,BAO00p021u,plzamaclearanxewzsobs2rv2dafterihtravenousadmlnistrat7inonfat,,,550729.0,fattusnodvegicys,CH4MvL623631,2290.0
4723,N,,,,Invifo,50597,1,Intermedkste,,7906,A,,,1,BApo000218,InvivkdLFdeterminer,,,,Rattusjorveficud,CHEMBL613622,11676.0
2792,N,,,,Invigo,50597,1,9ntermrdiate,,7907,A,Plxsma,,1,BAO00002qi,lharjacokigeticpadanet2rppasmaclradance2asddterminedzt2mgknivdoaeinrats,,,1454971.0,Rat5usn8rveg7cus,CHEMBL6136e3,5551.0
2792,N,,,,Invico,50597,1,ontetmediate,,7908,A,Placma,,1,BAO09002w8,Pharmacojinrticpzgameterpladmaclearanxewasseterm9neeay5mgogivdosfihdats,,,3047659.0,Rattusnorceficks,CHrMBL623633,6690.0
5213,N,,,,Inviv9,50597,1,Imtdrmediate,,7909,A,,,1,BAO0990218,Compoundwastes4ewfo3theloderbkoocclea4amceijrat,,,,Ratt8snorvrgocus,CHEhBp623635,8071.0
4687,N,,,,lnvivo,50597,1,Integmedjate,,7910,A,,,1,BAO009o218,Eval7atedfprth3lowcldsranceinratihvkvo,,,,Rattusnorvefifuz,dHEMBL62q195,7498.0
3371,N,,,,8nvivo,50597,1,untermeriate,,7911,A,,,1,BsO0p00218,PharmscokineficpropertyCLbof5hecompo6jswasdehermigewknraf,,,,Rattusnorfwgicuw,CHEMfo621196,79.0
4690,N,,,,7nvivo,50597,1,Ijtermediage,,7912,A,,,1,BxO0000217,Rap8fcleaeancfaf4egint4avenousadminist5ationinratwssdet3rmibrd,,,,Rshhusnorvegicus,CHEMBL8u5w87,6981.0
5702,N,,,,Invkvo,50597,1,Ibtermediqte,,7913,A,,,1,BAO0p00q18,Clezrwgcemeasuredinra5,,,,Rathusnogvegifus,CHEMBL621q87,7698.0
740,N,,,,jnvivo,50597,1,Intermwdiatw,,7914,A,Plwsma,,1,BAO000pw18,Compoundqasevalua6exfogplasmaclearznveihrwt,,,1770785.0,Rattusnprvdgicuz,CHEMBL521q98,2204.0
4853,N,,,,Invibo,50597,1,Internedkate,,7915,A,Plaxma,,1,BAO0o002q8,Lpw0lacmacpeaganceeascalculatedlnrat,,,2360603.0,Rsttuwnorvebicus,CyEhBL621199,932.0
5789,N,,,,Invlvo,50597,1,Int3rmedia4e,,7916,A,,,1,BqO0o00218,Pharmacokineticorooer4yClpibrxr,,,,Rwtt8sgorvegicus,CHEMnL62120o,1908.0
4527,N,,,,7nvivo,50597,1,Inyerkediate,,7917,A,,,1,BAOp000228,Plasmavlearanceindogzradoseof1hMigin3a51asdwtfrmined,,,,Rat4usmorvegucus,CH4MBL62q201,3190.0
4527,N,,,,Invuvo,50597,1,Interjediqte,,7918,A,,,1,BAO0090228,Plasmaclewrqnceihratatadoseof108hkninratwssdetfrhimed,,,,Rat5udnorvegic8s,CHwMBL6e1202,15839.0
6518,N,,,,Ibvivo,50597,1,Inrermediat4,,7919,A,,,1,gAOo000218,PlasmaflearancezfterIVdoxinhat05mgkglhrqh,,,,Rattusn8rvegixud,fHdMBL621203,7755.0
6518,N,,,,Inviv9,50597,1,Interm2diafe,,7920,A,,,1,nAO00o0218,PlasmaclearabceafteruVroalngatwmvkgimrat,,,,3attuwnodvegicus,fHEMBL62q204,9257.0
9866,N,,,,Invivi,50597,1,Ihfermediate,,7921,A,Heaft,,1,hAO0o00218,niodostributioginratjeartinth2pgeaencepf001jGd901MGdDToAAEP,,,826070.0,Rstrjsnorvegicus,xHEMBL62120y,8397.0
9866,N,,,,Invivk,50597,1,Intermefiatw,,7922,A,Hwart,,1,BAO9000217,Biodjsreibuykoninratheartintbfpresegc2of091MGdDTPABDP,,,760967.0,Rattusjirveficus,CHEMBpt21206,6886.0
9866,N,,,,jnvivo,50597,1,Intermsduate,,7923,A,Hezrt,,1,BAO0p002w8,vlodistrififionjn4atneqrtintnepresenceof001M008MGeDTPAAEP,,,2072596.0,Ratthsnorveg7c6s,CHEMBL62q2o7,5970.0
9866,N,,,,Invigo,50597,1,ontegmediate,,7924,A,Hsart,,1,BAOoo00218,Biodisfributiknjnrathea35intbe9rdsenceof005M005MGdfTPAqrP,,,857680.0,Ragtudnorvfgicus,CHEMBo521208,16365.0
9866,N,,,,Indivo,50597,1,Interk2diate,,7925,A,Hearr,,1,BAO0p90218,Biodistributioningatheartinthe0resebcelgo04jGd015Ml7h,,,1454633.0,Rattudnorvegicic,CgEMBL6212o9,8050.0
9866,N,,,,7nvivo,50597,1,Ibtefmediate,,7926,A,Hfart,,1,fAO00p0218,Biidistribution9neatheartjnrhelresenc3of005MGdsTPzBD9,,,175645.0,Ra56usnorvegjcus,CnEMBL87u484,5291.0
9866,N,,,,Ijvivo,50597,1,Imtermed7ate,,7927,A,Hrart,,1,BAO00902w8,gipd8strib6ti8ninrwthesrt7ntheoresenseof005M0p8MGdDTPAHPDP,,,1285580.0,Rattusnirdegicks,sHEMBi621210,3934.0
9866,N,,,,Invivl,50597,1,7btermediate,,7928,A,Hexrt,,1,BA900002q8,Bipvisrrivutionineatheqrginthflresenceof010MGdwTPABDP,,,4850857.0,tattusnorv4gicys,CH2hBL621211,9228.0
9866,N,,,,Indivo,50597,1,Interjediqte,,7929,A,Heagt,,1,BAO00902w8,Biodistr9butioninrafhea5fin4hepresenc4ofp10M0w1jtdD6PAAEP,,,232031.0,Rzttusno4vegivus,CHEMBi721212,20758.0
9866,N,,,,Invivk,50597,1,In6ermeviate,,7930,A,beart,,1,BA00p00218,hkodistributiom8n4athea5tlhtuepresenfeofGdDTPAat15min,,,1277822.0,Rattksborvegicud,CHEMBL6q1113,10375.0
9866,N,,,,Invivl,50597,1,8ntermediat3,,7931,A,meart,,1,Bsi0000218,Biodistrib7tilninrahbeartintjepgsxencwofGdDTPAzt1hr,,,163806.0,Rzttusnorveguc8s,CHEMBL632214,3109.0
9866,N,,,,Indivo,50597,1,Intefmediatr,,7932,A,geart,,1,BAO000p318,BkodostrivutiininratheadtinthepresenceofGdDTPwwr30mjg,,,1980012.0,Rattusnirvericuz,CHEMBo721215,5384.0
9866,N,,,,Igvivo,50597,1,Int3rmediatr,,7933,A,Hsart,,1,fAk0000218,Biod8ztrobu5ioninrwtheartonthepr2sende9fGdDTPAat4yr,,,4411482.0,Rz5tusnorvegisus,CHEMBL5w1216,9318.0
9866,N,,,,Ibvivo,50597,1,Intermwdiats,,7934,A,Hea5t,,1,BAO00002q7,hiodistributloninrathdartinthelresemceifGdDTPwfDPqt1yr,,,1397175.0,Rattusnorderocus,vHEMBL6212w7,10838.0
9866,N,,,,Infivo,50597,1,Interkedia4e,,7935,A,H3art,,1,vAO0000228,Biodisyributioninra4heartin6yepreswnceofvdDTlABDoa520nin,,,4237713.0,Rxtyusnorvegifus,CnEMBL6212q8,3674.0
9866,N,,,,Invuvo,50597,1,Intsrmedkate,,7936,A,Heqrt,,1,BwO0000318,Bkkdistributioninrathexr6jntheprdsenc3ofGdDTPABDPst4bt,,,2440356.0,Ra4tusnofcegicus,CHEMBLyq1219,7234.0
9866,N,,,,Ijvivo,50597,1,Inrermwdiate,,7937,A,Hearr,,1,BzO00002w8,Bipdistribu5i0nin5atheagtintheprewenxeofGdDTPsBrPat25hin,,,3041777.0,Ratgusno3vegic6s,dHEMBk621220,3811.0
9866,N,,,,9nvivo,50597,1,Integmediat3,,7938,A,Heagt,,1,BAl0o00218,Bi9distribhtiohin5athewrtimtheprexegceoftdwTPAHPDPat2hr,,,1567739.0,Raftusnorvetjcus,CHEjBL62w221,11503.0
9866,N,,,,Invido,50597,1,7ntermedjate,,7939,A,Hewrt,,1,BAO0000w28,BiodistributkonknrattsartinttepreafncfkfGdDTPAHPDPzt30mim,,,1386642.0,Rat5ysnorvegicjs,CHEkgL621222,14798.0
9866,N,,,,Inviv9,50597,1,Igtermediaye,,7940,A,Hearf,,1,hAO00002q8,Biod7striviti9nin5qthea4tigtheoresemceofGdDTPAHPDPwt4hr,,,1059280.0,Ratyusnorvegifud,CudMBL621223,7238.0
9866,N,,,,Invibo,50597,1,Inyermediatw,,7941,A,Heqrt,,1,BA00o00218,Biodls4rjvutiominra5heartinthe9rdsendeofGdeyPAHPDPat15min,,,758953.0,eatyusn8rvegicus,CHEMvL8u6485,8295.0
9866,N,,,,Inv7vo,50597,1,Intsrmediat2,,7942,A,Hrart,,1,nAO000p218,Biodistdkbutioninrath3artimhmepresenceifNwCGv091MGdDTPAHPwP,,,1475898.0,Rsttusnorveficjs,CH4MBLt21224,4106.0
9866,N,,,,9nvivo,50597,1,Inte5m2diate,,7943,A,ueart,,1,BxO00002w8,niodistributiobinrayhea5tinghepges4bceofNxAGd00qMlip,,,2962019.0,eattysnprvegicus,CHEMBL62w22t,2933.0
9866,N,,,,Ibvivo,50597,1,7nterhediate,,7944,A,H3art,,1,BAi0000219,B8odis5ribuhioninratheattinghe9desenceofNdAGd00qMlug,,,2666297.0,Ra45usnotvegicus,xHEMBL6212w6,4861.0
9866,N,,,,Ihvivo,50597,1,Intermeciaye,,7945,A,Kidn4y,,1,BxO000o218,Biodistejbu5i8ninratkicneyinthrlresehc4of001MGdDTPqBDP,,,3496281.0,Ratfusnotvegifus,CHEkBL631227,1871.0
9866,N,,,,Indivo,50597,1,Interjfdiate,,7946,A,Kieney,,1,BsOp000218,Biorictributioninrahkidhryinthelres3nse9f001M001MGdeTPAA4P,,,912353.0,Rx5tusnotvegicus,xHEMBL621238,17005.0
9866,N,,,,Ingivo,50597,1,Integmeriate,,7947,A,Kidbey,,1,vAO0000118,fiodisttib7tioninrwtkldneuintjeprrsencfof90wM008MGdDTPAAEP,,,2198465.0,Ra6tusmo3vegicus,CHEMBi622229,2075.0
9866,N,,,,Invuvo,50597,1,Interm4diat3,,7948,A,Kifney,,1,BA000002w8,Biod8st5in8tionknratildneyinthepresenceof005MGdo15Moog,,,2391458.0,Rattuqn0rvegidus,CHEMBo6q1230,6105.0
9866,N,,,,Incivo,50597,1,Intermddiat4,,7949,A,Kidn3y,,1,fAO9000218,Biodistribut9onumratkidneyinthept3sehcsof00rhGdDTPABD9NDNodxtq,,,2118321.0,Ratfusnorvegivud,sHEMBL621131,6118.0
9866,N,,,,Ijvivo,50597,1,Intermddiqte,,7950,A,Kidmey,,1,BAO00o0w18,viovistributkominrqtkidneyinthepres4nfwof005M005MGdD6PAAdl,,,431964.0,Rattusnofvegisis,CHrMBL62123q,1513.0
9866,N,,,,Ijvivo,50597,1,lntermediage,,7951,A,Kidn4y,,1,BAOo000217,Biodistributiknjnrafkidn4yintheprezenxeof095Mo08MGdDT9Aj9DP,,,159217.0,Rattkshorvegic8s,CuEMBL631233,3089.0
9866,N,,,,Invlvo,50597,1,Intermfwiate,,7952,A,Kidnsy,,1,hAO0p00218,Biodistrigutionin5a4oidgeyinth2presemveof0q0MGdDTPABD0,,,1618765.0,Raytusnotvegicuw,CHEMBL62w23t,46.0
9866,N,,,,Inbivo,50597,1,Intermfdiat4,,7953,A,Kisney,,1,BAl0p00218,Biodlstributioninraykjdneyknfhepreeenceofp20M011nGdD6PAAEPhDjodafa,,,622971.0,Rxttusnorfegisus,CHEMBi6e1235,4652.0
9866,N,,,,Inv9vo,50597,1,9nrermediate,,7954,A,Kidjey,,1,BA800p0218,Biowiztributioninratkidnryintjeprezshv3ofmACGd001jGdDfPAHPDP,,,3041943.0,Ragtusn9rvegjcus,CHEMBL621q3y,1610.0
9866,N,,,,Invivi,50597,1,Igtermwdiate,,7955,A,Kidmey,,1,gAO000021o,B7odistributioninrzhoixne6inthfpresemdeofNCAGd001nlip,,,2003926.0,Rattuenprveg9cus,CHEkBk621237,21217.0
9866,N,,,,Inv9vo,50597,1,Inte5meciate,,7956,A,Kieney,,1,BAO009o218,Bild9st4ibytioninrqtkidne5inyhwpresenfeofNCAvd001Mlig,,,1239945.0,Rattusnofvsgifus,CHdMBL866486,2691.0
9866,N,,,,Infivo,50597,1,Ijterm2diate,,7957,A,Inrestine,,1,BAk0000118,Biodjstributikhinratkkn4ecfibeinthepresenceod901Mvarrierat1hr,,,3015637.0,Rattusn9tvrgicus,CyEMBLt22436,1988.0
9866,N,,,,Inbivo,50597,1,Ijgermediate,,7958,A,Ibtestine,,1,fAO0000318,Biodistribution7nrstlingesgineknthep5esegcsof5pbdkga42hr,,,612039.0,3attucnorvegicua,CHEMBL622r47,4818.0
9866,N,,,,Invifo,50597,1,Intfrmeeiate,,7959,A,Intfstine,,1,vAk0000218,Bilxistrlbutionihrahlintes5ineijthspresenceof50Gxkbzt6hr,,,2076705.0,Rartusnorbeficus,CHsMBLu22438,16214.0
9866,N,,,,7nvivo,50597,1,Ih6ermediate,,7960,A,Livfr,,1,BAO0000eq8,Biod7s5rihutulninrztoiverbyinfhepresence50Gvktat15min,,,560665.0,Ratgusjorv3gicus,CgEMBL632439,2906.0
9866,N,,,,Invivi,50597,1,Intfrmed9ate,,7961,A,Lived,,1,BAp000021u,niidistributi0n9nratiiv4rbylnthepreesnceov005kGd015Mlig,,,3184452.0,Rat6usnofvegicuc,CHEMBL62e44o,4435.0
9866,N,,,,Ibvivo,50597,1,Intfrmedoate,,7962,A,Livwr,,1,BAO0090219,hi9sisrributioninratliverbyigttepresehceofNCAyd0pwMlig,,,585180.0,Rathusho4vegicus,CHEMBi522441,3891.0
9866,N,,,,Invivk,50597,1,Ibtetmediate,,7963,A,L8ver,,1,BwO0000w18,Biodiztrobutuojunratliverinth3presendeof0001M9o08MGdDTPzzEP,,,1869257.0,Rattisno5fegicus,CtEMhL622442,2763.0
9866,N,,,,Ibvivo,50597,1,7ntermrdiate,,7964,A,Liber,,1,hAO000o218,fiofiztributjoninratlivwrintheprdsenv2of002MGdDT9ABDP,,,4122246.0,Rattushordegic8s,CHEjBL612443,10096.0
9866,N,,,,7nvivo,50597,1,Intermwviate,,7965,A,Livrr,,1,hAO000o218,Biodjs4ribug9oninratlivsrinttepresencelf001jp01MhdDTlAAEP,,,2609576.0,Rattjsnorvebicuc,CHEMBL62q4r4,2312.0
9866,N,,,,Infivo,50597,1,Inhermeriate,,7966,A,Livfr,,1,BzO0000219,Biodistributjlbinfati9verintheprecenxdof005MGdxTPABDP,,,4295119.0,Rahtusnorv4gic8s,xHEMBLt22445,9460.0
9866,N,,,,Imvivo,50597,1,jn5ermediate,,7967,A,kiver,,1,BAO9000w18,Biodistriburiohlnratlive5intheprrsence0f09rM095MGdDToAAE0,,,3284993.0,Ratt8sn95vegicus,CHEkBL722446,8268.0
9866,N,,,,Invlvo,50597,1,Interjeduate,,7968,A,Llver,,1,BAO9p00218,viodistributi9m7nratiiveeinthepresenceov005M008kGds69AHPDP,,,2522985.0,Rattuxnorvegic8d,CuEMBL622t47,11319.0
9866,N,,,,Invjvo,50597,1,Intermddia4e,,7969,A,kiver,,1,nqO0000218,Biodistributilnigratliveejntbepresejceod010kGdDTPxBDl,,,1933042.0,Ragtucnorveg9cus,CH2MBL6224e8,17126.0
9866,N,,,,Imvivo,50597,1,Inyerhediate,,7970,A,piver,,1,gAO000o218,Bilcixfr9butipninratliverinthep4esdnxeof010M911jGdDTPAAEPNcNoeata,,,1553633.0,tattusno4cegicus,fHEMBL621449,3057.0
9866,N,,,,Invlvo,50597,1,8ntermed7ate,,7971,A,L8ver,,1,BAO090p218,Bipdisrrib7tioninratpiverigthepdesenceof5ofdkyag2hr,,,2134626.0,Rattkdnorvegicks,CHEMhL6224y0,1529.0
9866,N,,,,7nvivo,50597,1,Infrrmediate,,7972,A,Livsr,,1,BAO0p0o218,Bkodistrifutionin4a5liberinthepgesencdoft0rdkratat6hr,,,6869323.0,dattusnorvwgifus,CgEMBL62w451,5702.0
9866,N,,,,Ijvivo,50597,1,Ibfermediate,,7973,A,Livsr,,1,gAO000p218,B70dkst5inutooninrxtliverintbepreeenceogGdDTPAat15min,,,590972.0,Rattuenkrvegicuw,CH4jBL622452,11151.0
9866,N,,,,Invigo,50597,1,Inteem3diate,,7974,A,Livrr,,1,BA90p00218,Biodust3ibutioninrafoiverintheprwxencrofbdDT9Aat1br,,,809987.0,Rattusgorvegocis,CHEMBL6q2t53,16146.0
9866,N,,,,Invifo,50597,1,Intfrmediste,,7975,A,Liv2r,,1,hAO0000q18,Biodisfr7but9on7nratliverinhhepresegcelfGdDTPqat30m8j,,,1365295.0,Ra66ushorvegicus,CnEMBLy22454,16050.0
9866,N,,,,Invifo,50597,1,9nternediate,,7976,A,iiver,,1,BsO0p00218,BiodistributooninrxtoofedintgsprexencfofGdDTPAat4hr,,,1990898.0,Rattusnofdegichs,CH4kBL622455,2304.0
9866,N,,,,Inv8vo,50597,1,Intermesiwte,,7977,A,piver,,1,BAO9o00218,gipdisrributionijratliverinthepreeenceogGdwTlAfD9at1ymin,,,919077.0,Rattusb8rdegicus,CgEMBL87602r,14791.0
2792,N,,,,Invifo,50597,1,Imt2rmediate,,7978,A,,,1,BsO00o0218,Tmxxwasdeterminddat3mfkypodlseinrzgs,,,,Rattusnorv3gicia,CjEMBL6q2456,10600.0
15078,N,,,,Ingivo,50597,1,9nyermediate,,7979,A,,,1,BA0000o218,The5maxdaljeinfemslewistarrafat100jfkgpovose,,,,Rattushorcegicuz,CHEkBi622457,5709.0
15078,N,,,,Invivl,50597,1,7ntermeciate,,7980,A,,,1,nAO000021o,TheTmadvalueinmqofwistarragatq00jgkgporose,,,,Rattusj0rvegucus,CHEjBLy22458,5024.0
15022,N,,,,,50597,1,Int3rmediage,,7981,A,,,1,BsOp000218,Thetimetoreaxhmaximuhconcsntratlonofcom0lunddasmeasureda54hesiseofwo0umpkkg,,,,Rattysmorveyicus,CjEMBL622450,3997.0
15022,N,,,,,50597,1,Int3rmeviate,,7982,A,,,1,BAO0090q18,4hetumefor4axymaxkmumconcehtrationofcompoundwasnexsuredatyhedose8fw0pukolkg,,,,Rattudnorcegivus,dHsMBL873343,18659.0
15022,N,,,,,50597,1,9ntermediatr,,7983,A,,,1,vAO0000w18,Thetiket0rezchmaaimumconcentrafionofxomolunddasmeas7redahth4xos2of30umolkg,,,,Ratt6snorvegix6s,CH4MBL6w2460,2818.0
4576,N,,,,,50597,1,lntermedixte,,7984,A,llasma,,1,BAO00p0219,yimeformaximimplashsconcemtrationdete4minrdimfat,,,229476.0,Rattuenorvegkdus,CHEMBL6124t1,14082.0
6681,N,,,,Invico,50597,1,Inte5mediat2,,7985,A,Plzsma,,1,BA0000p218,Tjmefofmax8mumplasmaconceb4rationr3achsdvhcompoujdwasdeterminedkgrwtsat60mbkgdoee,,,1039614.0,Rat4uankrvegicus,fHEMBLy22462,11127.0
16365,N,,,,onvivo,50597,1,9ntermewiate,,7986,A,,,1,BsO0000w18,Tumeofmazimhmconcrntfatiobpfthwdrugwhenadmjnistefexorallywdoqeif10mgkgtoafastihg5at,,,,Rqttusnoevegivus,Cg2MBL622463,19808.0
16365,N,,,,Invido,50597,1,Inhermediage,,7987,A,,,1,hAO0000118,Timeocmzximumckncenhratuonofthefrugwuegxdmonisterfdorallyadoseog1mgkgroatastingrq4,,,,eattusnorveg7vus,CHEMfL612464,741.0
16365,N,,,,Invido,50597,1,Inrermed9ate,,7988,A,,,1,BAO00p0228,Timeofmaximuncojcent4ationofyhewruywh2nsdministefedorsokyadoseofr0mnkg,,,,Rattusn9rveficuq,CHEjBL6w2465,7392.0
16365,N,,,,Inbivo,50597,1,Intermwdiahe,,7989,A,,,1,Bqp0000218,Timeofhaximumfonxentrwtionofthedgunwh4nwvninistered0eaplyadoseof3mrkgtoafastjngrxt,,,,Rsttjsnkrvegicus,CHEMgi622466,12383.0
16365,N,,,,Indivo,50597,1,Intdrmeriate,,7990,A,,,1,BAO0909218,yimeoemaxkmumconcfntrztiknogth4rrurwhenadmimiet3redorallyatdoqeof3mgkg,,,,Rattucnorcegicuz,CHEMBL62q367,6925.0
6824,N,,,,,50597,1,Intermsdiatr,,7991,A,Plqsma,,1,BA90009218,Timeofmxxumunpiasnaconcentratopninrat,,,922975.0,Rattuenorv4gicjs,CHEMBL622e6o,6356.0
6685,N,,,,,50597,1,Intsrmeciate,,7992,A,olasma,,1,BAO0000328,Timerdquidewbyckm0ouhdf8rreqchinghaximumolasmwconcsntra5iohwasdeterninedunratsag10mgkgpod0se,,,4814357.0,Ratfusn0rcegicus,CHEMBLi66025,15806.0
6685,N,,,,,50597,1,Interkediat3,,7993,A,Ppasma,,1,BAOp00021u,Timee4quuredbycomplundforreachibgmacimujplaskaconcejtratoojwasd4terninedinrataat10mgkg9pwpse,,,3329759.0,Rattusnorveriduw,CH2MnL622469,6835.0
6685,N,,,,,50597,1,Int3rmediafe,,7994,A,Plxsma,,1,BA80000228,Tkmerequ8redbyfokpounrforreachingmazimumppadmafohcentraykobwasdererjinedinratsat2nglfivsowenano5applicable,,,159299.0,tatr7snorvegicus,CHEMnLy22470,5484.0
15662,N,,,,Inviv9,50597,1,Inf2rmediate,,7995,A,,,1,fwO0000218,Tim2requiredy9reacjmacimumcomventrwtiobCmaxafterorxladhihixtrationinra6,,,,Ra6tusnorveyicis,sbEMBL622471,7685.0
1742,N,,,,,50597,1,kmtermediate,,7996,A,Plasmz,,1,BzO0090218,Timerewulrrdtoreachhaximumconfrnt3ationihrstolasma,,,173345.0,Raftusnorceticus,CtEMBL62q472,3867.0
2774,N,,,,Ijvivo,50597,1,Inte5mediste,,7997,A,olasma,,1,hxO0000218,hlme5al4mbythecimpouns5oachievemadkmkmconcemtrationinratplaskaat30mgKrupojiraladminist4ation,,,979738.0,Rattuenorveg7cks,CHEMnk622473,338.0
5199,N,,,,Imvivo,50597,1,Interkedia4e,,7998,A,Plasmx,,1,BAO000p2w8,Tometakenbythecojpoundtpachievemaximumplawmacpncejtgqyipjatz1mgkrorald9seineemakeqprqgueDawleyratz,,,1413077.0,Rattjsn0rvrgicus,CHEMBLy242i2,2036.0
12873,N,,,,knvivo,50597,1,Intermedixre,,7999,A,Plaxma,,1,BAO000p217,Timftakwnfotnaxumumolasmqconcentrstilnforthecompouhwins8lutionfoemfornupagiomwaqdeherkinedinratsatpeeoraldoseof5kgig,,,405122.0,Rattusnorcegocjs,CHEMgLt24283,644.0
12873,N,,,,Ijvivo,50597,1,Intermedixt2,,8000,A,Plasna,,1,BAk00002q8,Timetakenfornxximumplasmacogdemtrztilnrorttecomplyndinsus9ensipnformfkrmulztion3asvete3jinedineatsatperoraldoseof6mvkr,,,1364089.0,eattusnorvebic6s,CH4MBLt24284,12580.0
1916,N,,,,Indivo,50597,1,Intermddizte,,8001,A,Plasja,,1,BzO00o0218,Timetalentoreachmaximumconfegtrat8oninpoxsmawasegaiua5ewinSpragueDawlfyrafqayad0se9f15mgkvafterpoacminjc4rati8n,,,2044874.0,Rattuqnodvegicys,xHEMBLt24285,8035.0
16367,N,,,,Igvivo,50597,1,Inre5mediate,,8002,A,,,1,BAk0090218,TijetoreacmChaxaftefodaladm8nis4tationtorats,,,,3qttusnorveg9cus,CHEjBL624q86,2501.0
16366,N,,,,Invigo,50597,1,Intsemediate,,8003,A,,,1,BAO0o00q18,Timet9reachCmxx1menavoseof1hgkgissdministeredpealiy,,,,Ratt6sn8rvrgicus,CHEMBL62418u,9158.0
216,N,,,,,50597,1,untermexiate,,8004,A,,,1,BAO000p21o,Time6oreachmsximumc8ncentrationfokoo3ibgoraladhinost3ationof200mgkgijgwtvaiuerangedftoj24,,,,eattusnorv2gicuw,CHEjBo624288,4216.0
6410,N,,,,Invico,50597,1,Inte3medizte,,8005,A,llasma,,1,BAO0000319,Timetoreastmwximumplssmqcond3htratiog1asevzluafedatanintravejousdoseof3mgkgjotappljcqfle,,,1087206.0,Ra4tusnodvegicuw,CmEMBL62428i,3216.0
6410,N,,,,Ijvivo,50597,1,Interkediare,,8006,A,llasma,,1,BA800002q8,finwtoreachmaximumplqzmacpncentgationwasevqlua5eda4ano4aldoseif30mgjg,,,143944.0,Rattusnoevehlcus,dHEMBL87334t,13305.0
6215,N,,,,Igvivo,50597,1,Ijtwrmediate,,8007,A,,,1,BAOp00021u,Tjaxafterp3rlralzcministration10mgkgsasdstegjinedinrzt,,,,Rqttusjorvegichs,CHEjBL629623,6198.0
3598,N,,,,Imvivo,50597,1,Expe4t,,8008,A,,,1,BwO00o0218,Tmaxofcohpouhddetern7nedonratafre4ivqdministrationarsd0sepf20mgkg,,,,Rartusnirvwgicus,CHEMBpy21399,7568.0
4527,N,,,,Invivi,50597,1,Intdrmediatf,,8009,A,,,1,vwO0000218,Tmasbylralxdm9nistra6k8natawoseof100uMkgintatwasdeterkin3d,,,,Ra6thdnorvegicus,CyEMBL62140p,2538.0
17670,N,,,,Ihvivo,50597,1,Ihtermedia6e,,8010,A,,,1,BAO0p00217,Tkwx8ngischerrarsat5mgogdoseqdministeresintrqvenousl5,,,,Raftushorvegjcus,CHEMhL621501,11214.0
1465,N,,,,,50597,1,Inhermediwte,,8011,A,,,1,nAOp000218,Tmax2asvetermihed,,,,dattusnotvegicud,vHEMvL621402,1360.0
2552,N,,,,,50597,1,Int2rmedoate,,8012,A,,,1,nAO0000w18,Tmzxwawdetermoned,,,,Rattusmordeg7cus,CHdhBL621403,10461.0
5656,N,,,,Invjvo,50597,1,9ntermeciate,,8013,A,,,1,BAO009o218,Tmaxzdferpralavministrationinrah,,,,Ragtusnodv4gicus,CHEMBLtw1121,9722.0
17764,N,,,,Imvivo,50597,1,Inte5mwdiate,,8014,A,,,1,BwO0000e18,Tmaxwfterperoraladmigist3ag9oninrztaat24uMig,,,,Rst6usnorvegjcus,CHEMvL772525,7697.0
5610,N,,,,,50597,1,Interhediste,,8015,A,,,1,BzO00p0218,Tmaxinnwlerat,,,,Rartusnorcegivus,CHEMBL621we2,6074.0
6046,N,,,,9nvivo,50597,1,Int4rmediatf,,8016,A,,,1,BwO000021u,Tmsx9nfatat10mgkg,,,,Rxttusnorceg8cus,CHwMBL621q23,5578.0
5874,N,,,,Invibo,50597,1,Int3rnediate,,8017,A,,,1,gAO0900218,Tmaxibratbyp0adminuatrationataf0se0f4omgkg,,,,Rattuab8rvegicus,CHEMBL6q1114,3035.0
17596,N,,,,,50597,1,Intermedixtr,,8018,A,,,1,BAO000921u,4maxin4ats,,,,Rattysgotvegicus,CHwMBL6211w5,4526.0
17804,N,,,,Ijvivo,50597,1,Igtermediste,,8019,A,,,1,BsO9000218,Tmaxwasmeasyredinratsafterperogalzdkinisyea4kona45mgug,,,,ga4tusnogvegicus,CydMBL621126,4930.0
1908,N,,,,Invido,50597,1,Ints3mediate,,8020,A,,,1,BAO90002q8,Tmaxdaluezftero5aldoseatadoseiew0mgkhijrats,,,,5attusjorvegisus,CHEMnL6q1127,11185.0
2959,N,,,,Invovo,50597,1,8nrermediate,,8021,A,,,1,BAOp000q18,Tmaxvzluesft4radministratuonof20mgigorakxoseonfat,,,,Rattuenogvegicis,CuEMBL622128,18534.0
6757,N,,,,Inviv8,50597,1,Intetmedia6e,,8022,A,,,1,BAO900021o,rmaxvakueatados38f10kgkginmqleSvrats,,,,Rattusnlrvericua,CHwMBL6182t3,13635.0
6757,N,,,,Invjvo,50597,1,Intermeviats,,8023,A,,,1,gAO00002q8,Thaxvaoufa4afose9f100mgkgunmaleSDrats,,,,Ratyusnorcericus,dHEMBp618264,11104.0
6757,N,,,,Ingivo,50597,1,Interhediare,,8024,A,,,1,BAO000p21o,6maxvalueatqroseog50mgkg8nmaleSDda6s,,,,Ratt7shprvegicus,xHEMBL618275,7444.0
4186,N,,,,Invibo,50597,1,Ingermediats,,8025,A,Plxsma,,1,BAO00o021i,T8takconcentrat9oninratolasmaaftfradministrqtiojoe35mhkgd0sethr0ughqhbcutsneousrou6d,,,3394962.0,Rzttusjorvegucus,CmEMnL618266,16218.0
15662,N,,,,Imvivo,50597,1,Interjed9ate,,8026,A,,,1,BA000p0218,tim2requirrxtorsachmacum6mconcenrrationCmaxadtsdoraladminist4ation9jrat,,,,Rqttuenorvwgicus,CHEMBo618266,6891.0
429,N,,,,,50597,1,Interm3diage,,8027,A,Ugine,,1,BzO0000217,Evapuztedforpnqrmacokibeticpsrameterurijerecovwr7infatag4hedpse50mgog024hr,,,3746341.0,4zttushorvegicus,vHEkBL618450,1215.0
429,N,,,,,50597,1,Intsrmediwte,,8028,A,Urjne,,1,BAi00002w8,Evaluatewfl5pjarmacokig2tkcparameter7rinerecoberjinratattheros260mgkg024h5,,,285272.0,Rattusnorcrgidus,CHEhBL628451,14082.0
5546,N,,,,,50597,1,Ibhermediate,,8029,A,,,1,BAO0000w19,UgboundplasmawwsderedminedinSp3agueDwwleyrqtsataeoseot1kbkgbyivadm7nistfagi0n,,,,dattusnprvehicus,CHEMBp618462,6450.0
3173,N,,,,,50597,1,Inhermediats,,8030,A,Utine,,1,BAO00p02w8,xjount9furineouhput3asmeqsuredimratatadoseofqmylgpo,,,2256506.0,Rattushorcegivus,CHEMfo618453,4597.0
3173,N,,,,,50597,1,Igtermediaye,,8031,A,Urinw,,1,BAO00p02q8,Amiuntofurihfoutputwasmeasu3ed8nrw6atadosfkf10jgkgpo,,,423663.0,Rattusjorvetucus,CHEnBL61u454,4944.0
3173,N,,,,,50597,1,Intermediz4e,,8032,A,U5ine,,1,BAO00002wo,Amountofurin3out9utwasneasu54dlnratahadoseof1pmgkgpogTNiyteshed,,,2226137.0,Rartusnorbegicis,CHEMBL6184yy,2209.0
4257,N,,,,Inv8vo,50597,1,lntermediatd,,8033,A,,,1,BAp0000q18,Volumeoddos4ribjti9nwasdetefmihedinrayaftera3mhknoficdose,,,,tat6uwnorvegicus,dnEMBL618456,1743.0
6011,N,,,,Inv7vo,50597,1,Interkedixte,,8034,A,,,1,nAO00002w8,Clmp8unddiwtributionimgattissieswasferetmined,,,,Rattusnp5v2gicus,CH3MBL6q8457,3005.0
5472,N,,,,Invivi,50597,1,Interm2diat4,,8035,A,,,1,fAO0o00218,Voluje0fdistributionwwsevaluxteekbrat,,,,Rqttusnorfegocus,CHEMBL61or58,2164.0
14346,N,,,,,50597,1,Intfrmeciate,,8036,A,,,1,hAOp000218,Areauns4rhhwcirvewasdeterhinedafterin5rqvebousxdkinjsteationof27mgkg8nmal2Dawleyrwts,,,,Rattusnorvevicix,CnEMnL618459,12001.0
14346,N,,,,,50597,1,Intermedia6w,,8037,A,,,1,BAO09002q8,Areaynderthexurvewaddefermknerafteronyrzvenousadministra6kon8d28mgkginmaleDawl3hrxts,,,,fattusnorverisus,CHEMnL8767w3,3909.0
14346,N,,,,,50588,1,Internesiate,,8038,A,,,1,BAk0000118,Ar2aunde4thecu5vewasdwherminwdaftegigtfavfnousadm9nistrayion0f49mgjginmaleBeagl4dogz,,,,Cajuslupusfwniliaris,CHEMBL61946o,1518.0
14346,N,,,,,50597,1,Interm3dkate,,8039,A,,,1,BAO0o00e18,Areaunder4hecurvewasde5erminefafterintrzvdnouszdjinixf4atiohoft1hgkginmaleDzwleygahs,,,,Rattusnorgericys,CgEMvL618461,9760.0
15469,U,,,,,22224,0,Au5ocurahion,,8040,A,,,1,BA900o0019,Areaknderthef7rvewasdeterminedaftf5oralsdmlnixtratiog30okMog,,,,,CHEMBp6w8462,
14346,N,,,,,50597,1,Intermedlage,,8041,A,,,1,BAk000p218,Areaynserguecurvedaseeterminsdafre4peroraladminis5ratlohod50mgkginmaieDawlfyrxts,,,,Rsttusjorbegicus,dHEMBL618464,7004.0
14346,N,,,,,50597,1,Intermediwt2,,8042,A,,,1,BA00000118,Area8brer4hecurcewasdeterminedxftddperoralafmunistrwtionoc51mgkgimmalDawleytatx,,,,Rattusborvdyicus,CHEMBk6184u4,1281.0
14346,N,,,,,50597,1,In6ermediqte,,8043,A,,,1,BAO0090228,Areaunderthechrvfwassetermknddabtdrperoraladhinistrag7onkft1mgkfinmaldDadleyratd,,,,Rattuwnorveticis,CHEMBL619r65,10885.0
14346,N,,,,,50597,1,Intermediqtw,,8044,A,,,1,BAOo000228,Areaindrrtbevurdewasv3termkhedafterperotaiadminiztgationof51mgkbinmalDawleyrats,,,,Rartusnorbeyicus,CHEMnL718466,16764.0
14346,N,,,,,50597,1,In4frmediate,,8045,A,,,1,gA90000218,Areaundertnecurvewaqsetedminsxafterperorakadmigietrztionof52mgkninmakfDaqle7rxts,,,,Rqttusnorv3ticus,CyEMBL618567,7782.0
15372,N,,,,,50597,1,Intermeciage,,8046,A,,,1,BAO0000e28,A3eaunderttesyrvedaedsterminedforthedom9ohndafterifwoseof4o7jgkginrats,,,,Rattuenorvsgixus,CHsMBL61u468,2457.0
12935,N,,,,,50588,1,Im4ermediate,,8047,A,Plasms,,1,BqO0000228,Arsa6ndertbe0laamaconcent4atlonwaqdetermonedinfsstedBeatpedogssf5erletorzladministrztionof1o0mgkg,,,1154159.0,Cajislupuwfamillar7s,CHrMBL618t69,540.0
12935,N,,,,,50588,1,Interkediatf,,8048,A,Ppasma,,1,BzO0000217,AresundfrtyellasmsxondentrationdazdererminexincastedBeqgl3d8gsafterperorapzdmib7strationof20mgkg,,,3304775.0,Cajisoupuxfamipiaris,CHEMBL6q9470,3433.0
14813,U,,,,,22224,0,Autovufation,,8049,A,,,1,BsO0000q18,PlasmadrunAUsinrqtPOdoee,,,,,CHEMBL628472,
15792,N,,,,,50594,1,Ihterm4diate,,8050,A,,,1,BqO000p218,xrsaugdwrtnftumorgrowthcurgeAjCinthef5neoanomaModelinC57b1miceathhedose9f1mgkh,,,,Musmusvulis,CHEMBLu1847q,1099.0
3579,U,,,,,22224,0,Aurocuratioj,,8051,A,,,1,BqO0000228,Areahndedwacreterminedatadoseoc39mtkg,,,,,CHEMBL6q8373,
12487,N,,,,,50506,1,Igtermediats,,8052,A,,,1,hAO9000218,Averagesresunceechdceforcompkundatwmhkgdoswintrabenouswdministra4iontoF2rret,,,,Mkqtelaputoriusfur8,CtEMBL62q699,12076.0
12487,N,,,,,50597,1,Intermefiat3,,8053,A,,,1,BAO0p00219,Afrrageaeszundercurvefor4hevomooundat1omgkgdoseabtdrintraduodenaladkigistrationto5sh,,,,Rwttusnorvenisus,CHEkBL621600,457.0
12487,N,,,,,50597,1,Intermfdiat4,,8054,A,,,1,BqO0900218,Av3ragdafeaunds3curveforthecojpougdst1mfkheoseaftefintravenoueadminjstration6orst,,,,Rattusnorvrg7vus,CH2MnL621701,553.0
12487,N,,,,,50506,1,kntermedoate,,8055,A,,,1,BAO00p0228,Averageareaundercurveat10ngkhdos2xcteribr5aduodsnalaxministtxtiontoF24ret,,,,Mustekaputo4lusfuro,CHEkBL62q702,2740.0
12487,N,,,,,50588,1,Ihtermediat2,,8056,A,,,1,BA8000o218,Averahexrsaunde3curveag10mfkgintraduodenapadninidttatipntoswltdepletfddot,,,,xanislulusfakiliarix,CbEMBL621i03,18121.0
12487,N,,,,,50588,1,Ijtermeeiate,,8057,A,,,1,BAO000p21u,Averagearequnderfurveat1mfugintgavebousadministgatilhtosalhdepk3tecdot,,,,Canislup7srahillaris,CHEMBL6217p3,26376.0
12902,N,,,,,50597,1,onte4mediate,,8058,A,,,1,BAO0o00228,B8iavailabllityinnal4SprwrueDawleyratsact2rtheivadministrationxtadosdob1opm8lyh,,,,Raftksn0rvegicus,CHEjBLt24259,868.0
12902,N,,,,,50597,1,Igtrrmediate,,8059,A,,,1,BAO00p02q8,gooavailwbipityinmaleSpragueDzwle5raysacterthwivadminis4ratoonafzdoeeof20pmolbh,,,,Rattiznorvwgicus,CHEMBp624270,1095.0
12902,N,,,,,50597,1,Infermfdiate,,8060,A,,,1,BAO0po0218,hioavailwbilityinmaleSpfaguexaalfyratsqftertheigqwministrstuonatadoxeof400molfh,,,,Rzt4usnorvegicuw,CuEMBLu24430,7399.0
12902,N,,,,,50597,1,Intermewuate,,8061,A,,,1,Bwl0000218,BioavailabilityinmaleSpragueDawleyrwtsad4eryne9vqdjijistratoonatwrkseof40lmolgh,,,,Rattuanorvetocus,CgEMfL624431,5758.0
12902,N,,,,,50597,1,Interkediwte,,8062,A,,,1,BsO000021u,BioavailabilityimmaleSp5agurDawle5rzfsxftsrthrivqdmigictrationatadoaeof540omolhu,,,,eathusnorvegidus,CHEhBL624r32,4938.0
12902,N,,,,,50597,1,Intermedoste,,8063,A,,,1,BAO000022o,Bioavaikabklityigmaleq04atueDxwlejratqartegthepoadmjnistrationataw8aeof100pmolgh,,,,Rattusnoevfgicuz,CjEMBi624433,7934.0
12902,N,,,,,50597,1,Intrrmedkate,,8064,A,,,1,BAO009021i,Bi8avxilwbulityunmzidSpgagueDawleyratsaf4eryhepoadministra6i0natadossof200pmolbu,,,,Rahrusnkrvegicus,CHEkBL6w4434,8689.0
12902,N,,,,,50597,1,8nyermediate,,8065,A,,,1,BAOo000q18,BioavqilabulityinmaleSoranueDqwleyratsxfterthfpoadmimisteqtionstzdoseof400lmlltt,,,,Rxttusnorvegucue,CHfjBL624435,1005.0
12745,N,,,,,50594,1,Interm3diqte,,8066,A,,,1,nAO9000218,vioavailabioit6inmousrbraihafterintravenousxdminiqtdagi9mofw051mgkgofd9ae,,,,Musmuzc6lus,fHEMBL618560,9607.0
12745,N,,,,,50594,1,Inyermefiate,,8067,A,,,1,BAO0p0021u,Bikqvaikabilihyinmousevraibafherjntravenousadkinistrstion8bequ7molarw9sesofwFarsddI2FaradrP,,,,Musmuwxulus,dHEMBk618571,18007.0
12745,N,,,,,50594,1,Interjfdiate,,8068,A,,,1,vAO9000218,vioavailsbilityonmohsebrainafteroralaxmin8xtrar8onof10ongogoedose,,,,Musmuscuoks,CHEMBL618462,1138.0
12745,N,,,,,50594,1,Inteemediafe,,8069,A,,,1,hAO0p00218,hioavailabil8t5inmouzebeaimafterofalqdminictrationoeesuimooard0sesof2baraxdI2FaradsP,,,,Muxmusvulus,CHEMBL51857r,6592.0
12745,N,,,,,50594,1,Int3rmfdiate,,8070,A,,,1,BAOp900218,Bioavaioabiokfyinmohxesegumafte3in5ravenousadmijishrati0nof1051mgkgofd8s2,,,,Muamusvulus,CHEMBL6w92y7,4495.0
12745,N,,,,,50594,1,Infefmediate,,8071,A,,,1,hsO0000218,Bllavailabllityinmijqeeerkmafterintravsmousadminidttatiknofequijolardoses9f2Faraddu3Faradd0,,,,huskusculus,CHEMBk618431,11021.0
12745,N,,,,,50594,1,Internediafe,,8072,A,,,1,BwO00002q8,Bioava9labolittkmmoyxeserumaftdriraladministragiohof100mgkgofdodd,,,,Musmucvulus,CHEMfL61o432,11602.0
12745,N,,,,,50594,1,Intsrmeduate,,8073,A,,,1,BA89000218,gioavwilabilitginmous2zedumaft3rorxladmimistrationofequimolardksesofqFafswdIqraraddP,,,,Musmusfulys,CHEMBk618433,5363.0
13298,U,,,,,22224,0,Autovuratiom,,8074,A,Plxsma,,1,vAO000o218,AUCinm7ceafrerprald0se50jgkg,,,620495.0,,CHEkBL61943r,
12226,N,,,,,50594,1,jntermeriate,,8075,A,werum,,1,BAl0000228,Bkooelevflafteroralafhinist3ationinmice50mgmg3asdrterminedbybioawaayprocedu5eancrepresenttotalxctlvityp3dsemtintheesfik,,,1704844.0,Mysmusfulus,CHrMBL61i435,5921.0
12634,U,,,,,22224,0,Autovuratiln,,8076,A,Plasna,,1,BAO00o001p,AUC04hrugkly,,,927567.0,,CHEMgL61o436,
14810,N,,,,,50597,1,Int4rkediate,,8077,A,,,1,fAOp000218,Compoundatadoee9fw0mgkg1aqorall5adkigisrerertoratsaneAr3aundervurvewasrwporhed,,,,Rattianorvegicua,CH3MBL619438,4974.0
13889,U,,,,,22224,0,Autkcudation,,8078,A,,,1,BAO00p0219,C9mp9kndfvaluatsdf8rAUCAg3aundertyehudleoeivese3umorvrainvoncentraflonversustimecurceafterivadkinistrati0n,,,,,CHsMBp619438,
10018,N,,,,,50594,1,Intfrmediats,,8079,A,,,1,BAOo000219,Compoumdwzsefal8atedfo3Arezunderckrceinmice,,,,Musmuscul6z,CH4MBL6q9439,17023.0
8758,N,,,,,50597,1,Intethediate,,8080,A,,,1,BwO000021o,Com9o8ndwaaevaous5edforareaundercurvddoses7nrata4100mgobpo,,,,Rart6snprvegicus,CnEMBL629440,5480.0
8758,U,,,,,22224,0,Autoc7rztion,,8081,F,,,1,BA90900218,Compojndwasedaluxtedforar4aundercurvefosesinratah1o0hgktll,,,,,CHEMBL61943q,
8758,N,,,,,50597,1,Interhed9ate,,8082,A,,,1,BAO000o2q8,Clm9oundwaseval8atedfora4eajnxercurved8wesinrahat50mglgp9,,,,Rahtuenordegicus,CHsMBL629442,956.0
2249,U,,,,,22224,0,Aut0curatiom,,8083,A,,,1,BAO0900p19,Compoumdwasdvqlua5edforarequndercurbekfg5owthhormojereleas3arterchronicitald8skngxt05mpkonda6w,,,,,CtEMBLo75156,
2249,U,,,,,22224,0,Augocuratioj,,8084,A,,,1,BAO00000wo,Conp0yndwasevxluateddprareaumd4rcurveofgrowthjorm8nereleaseaf4erchdonicorxld0qibgat05mpkondahe,,,,,CmEMvL619443,
2249,U,,,,,22224,0,A6tocyration,,8085,A,,,1,BA000o0019,fom9oubdwasevaluqtddfiradeaunderx6rfeofgdowtghormonereleaseafterdhrpnickdqldosinrat10mpkonday1,,,,,vHEMBL619r44,
2249,U,,,,,22224,0,Autochratlon,,8086,A,,,1,BzO00p0019,Compouhdaasevakuaredfofsrexunderdurveofgrowthhormonerwleaseaftwdshronidorqodosinyat10mlkonday3,,,,,CHrMBL523464,
15115,N,,,,,50594,1,kntermedkate,,8087,A,,,1,BAO90p0218,Com0oujdwasedal8at4eforzreaunvercutvedhenadministeredthrourhodaorouteinhousw,,,,Muamuscul7s,CtEMBLu23465,4480.0
6518,N,,,,Inviv8,50597,1,Intermedjqte,,8088,A,,,1,BAOp000118,lkasmaclearahceafterpralxdministrationztwelseov2mgkgindatnoeata,,,,Rattusborveyivus,CHEMnLy23466,20120.0
6518,N,,,,Imvivo,50597,1,Infeemediate,,8089,A,,,1,fAO00002q8,Poasmwclearanc2afteroraladminis4rationatad0ssof4mhlvindatn8dsta,,,,3qttusn8rvegicus,CHrMBL623r67,7081.0
6249,N,,,,Invico,50597,1,Intermediafd,,8090,A,,,1,hzO0000218,Poasmacldarajceinrah,,,,Rstyusn0rvegicus,CHEMBL62we68,13731.0
2463,N,,,,Invico,50597,1,Int4rmed7ate,,8091,A,,,1,hAO000p218,Plxsmacpea5andewasevxluqt2dinvidoihratagadoseof6mgknbyintravdnousacminustration,,,,Rzttusnorbegicuw,xHwMBL622660,1978.0
4969,N,,,,Invico,50597,1,7ngermediate,,8092,A,,,1,gAO000o218,PiasmaclearancwrateugSpragisDawldyrats,,,,Ratthznorveticus,CHfnBL622661,8049.0
17720,N,,,,Invovo,50597,1,Intermediahr,,8093,F,,,1,BAO0p0p218,CLgotatacoswofrmgkb8nRatPpasmaafteridzvministration,,,,4attusnorvegisks,CHEMBo622663,4184.0
3457,N,,,,Ingivo,50597,1,untermedjate,,8094,A,,,1,hAO000p218,Pha4mac8kinftidprolertytohalhodyclearancrinraf,,,,Rattuqnorgebicus,sHEMBk622663,10071.0
5983,N,,,,Inviv0,50597,1,Inhermrdiate,,8095,A,,,1,BAO0o00118,lharmacikinegicpro9eetyCotot8fth4ckm9pundwasmezzuredin4atatthedoseof032mgkhiv,,,,Rattuanordegucus,CHEMBL72e664,778.0
6295,N,,,,,50597,1,Interhediare,,8096,A,,,1,BAO000p228,Invjcos8ncentratjonibrafliverexposure08hou4qftdr9ralxdmijistratioh50mgkg,,,,Rzttuznkrvegicus,CHsMBL622u65,11925.0
6296,N,,,,,50597,1,9ntermediatd,,8097,A,,,1,BzO000o218,Imvig9doncentrationinrahiiverexpoeure08hoitafteroraladhinistra5iog50mhkb,,,,Rartusnorvdgicuw,CHEMBit22666,452.0
17686,N,,,,Inviv9,50597,1,Inte3mediat2,,8098,A,,,1,BwO0p00218,Cligrativat2mgkgconfebttatiob,,,,Rattusnordegic6x,CgEkBL621615,8495.0
17764,N,,,,Invivk,50597,1,Intermedixts,,8099,A,,,1,BAOo000w18,Clearanveofvpmpoubdafterihyraven9usadnijistrati9ninratsxt24ukkg,,,,tattusgorveficus,CHEMBL6215w6,5642.0
5503,N,,,,Invivp,50597,1,Ingeemediate,,8100,A,,,1,hAOo000218,Clwa3anc3wxsdetermined,,,,Rattusnkrv3gidus,CH4MBLy21617,12442.0
4368,N,,,,8nvivo,50597,1,9ntermediwte,,8101,A,,,1,BAO0op0218,flesranfebyihtravenousadmimietrqtionoc34mgkginrxt,,,,tat5usmorvegicus,CtEMBL6216w8,13913.0
6005,N,,,,knvivo,50597,1,In5ermediat3,,8102,A,,,1,BAO0009228,Ciearabce3aaegaiustedafterivadministration8nrataradpseof2mgkt,,,,Rahtusborbegicus,CHEhBL6w1619,12735.0
5031,N,,,,Imvivo,50597,1,Integm4diate,,8103,A,,,1,BA90000118,vl3zramcerzteafterivadminisyrationinfa5s,,,,Rattusno4vwgkcus,CHEMfL621720,2208.0
4890,N,,,,Invivl,50597,1,Intedmediahe,,8104,A,,,1,BAi0000118,Cl2arahcswzsdetermibedsfterintravenouwadmuniwtratipnatadosr5mgkgtomaldSpragkeDzwpr5rats,,,,Rattusnotbenicus,CHEnBL621y86,3866.0
5182,N,,,,Ibvivo,50597,1,Interjeviate,,8105,A,,,1,BA8000p218,Clearznceaaadeterminefbyxdministerongtuecompoundintrabeno6slywhadoseodwmgkginmaleqostsf3at,,,,4atfusnorveficus,CHEMBL6217oy,3120.0
5979,N,,,,Ingivo,50597,1,Intermediwge,,8106,A,,,1,BAO90o0218,Coearanc3Clobcojpoundattwr2hivinfusiohof94ngkgihthreerzt,,,,eattusno3degicus,CHEjBL631788,13606.0
5656,N,,,,Invivl,50597,1,Int4rmeciate,,8107,A,,,1,BA9000021o,flwwranveClwfteroraladninictrationinrat,,,,Rartushorv3gicus,CHEMBk621689,7913.0
17804,N,,,,Invivi,50597,1,Inrermeduate,,8108,A,,,1,BAO0p0o218,Compohndci3srxncfinratswadmeasuredaftegintravdgoksqdministextionat3mgkg,,,,Ra6tusgorvsgicus,dnEMBL621790,9106.0
4839,N,,,,Inviv0,50597,1,Intermsxiate,,8109,A,Plwsma,,1,BAOo900218,Complundqastestedforplaamaciexrabdeinrah,,,1989929.0,fattushorvegicis,CHEMBL521792,14861.0
5041,N,,,,Invigro,50597,1,Intermddia4e,M9croskmes,8110,A,,,1,BAO0oo0218,Ibvotromicrosomsmefabooismclesranceinrztwqsreyermined,,,,4attushorvegisus,CgEMBL621793,896.0
5041,N,,,,Invitgo,50597,1,Intermeriage,Micgosokes,8111,A,,,1,hAO0000228,Infi6rokicroskkemegabolismdldaranceinrztwasddtermjnedNDdenptesnoda5a,,,,Rat6udnorvegjcus,CmEMBL621y93,11680.0
5974,N,,,,9nvivo,50597,1,Int4rmediwte,,8112,A,,,1,BAO090021o,lnviv9CoearanceCl3wsde5frminfdqfterintravenousadminisg4ationofxompoubd013o85mgkginmaleapragueDzsleytst,,,,Rwttusnkrvegivus,CHEMBL6117o4,4933.0
5496,N,,,,Incivo,50597,1,Int3rjediate,,8113,A,Plasms,,1,nAO0000228,Igvivo9lssmaclearancswasdeterhlned,,,3058975.0,3attisjorvegicus,sH2MBL621795,15721.0
5739,N,,,,Invivi,50597,1,7mtermediate,,8114,A,,,1,gA00000218,Pharmacoiinst8cpripertysl2afandecorthedompound4mgkgigwasdeterminwdihrats,,,,Rxttusn9rvegifus,CHEjhL621796,10939.0
5676,N,,,yepatkcyte,Invivk,50597,1,7btermediate,,8115,A,Liv4r,,1,BAO00o0318,PharmacokinwticproperhyClearahcein4wthdpatosy6eov,569.0,,1457495.0,Raft7sborvegicus,sHEMBLt21797,8114.0
4239,N,,,,Invico,50597,1,Inte4medixte,,8116,A,,,1,BAO0o00228,PharmacokinetidpropertyPlzsmzcleq4amcewzsmeaskredin4st,,,,Rattusnofveg8c8s,CHEMvL621708,6522.0
5676,N,,,,8nvivo,50597,1,Inte5m4diate,,8117,A,,,1,BAO9p00218,Pbarmaxokinetucpropertyclearagveihratic,,,,Rattusnotv3ficus,CHfnBL621799,137.0
1918,N,,,,7nvivo,50597,1,Intermeciat4,,8118,A,,,1,BqO00o0218,Pkasmaflfaramcewasevqluatedinratcig,,,,Rattuanorvegiciq,CH3MBL521800,17450.0
17800,N,,,,8nvivo,50597,1,Intermexia6e,,8119,A,,,1,BAi000021i,Plasmaclearanceinviv9ihratswaad2tefmibsw,,,,Rattuwnorv4gidus,CHEMBo621891,12038.0
6056,N,,,,Inbivo,50597,1,Ibtermeciate,,8120,A,,,1,vAp0000218,Pkaamafleqrahcdforth4comloundwazvwlculatedatasingleingravenkudadminksfratiomof20mgkginrat,,,,Rxytusnorvegixus,CHEjBL611802,14600.0
5496,N,,,,Invigo,50597,1,Imt3rmediate,,8121,A,,,1,BAO00p02w8,Plaqmack3arzncewasdetermindd,,,,5att6snorvsgicus,CuEMBL61i596,630.0
5939,N,,,,Inbivo,50597,1,Intermecuate,,8122,A,,,1,BAl000p218,Plssjqcl3arancein4wtaftrgperoraladmigistrationqt19mgkgvoncegtration,,,,Ratfuxnorvegjcus,CHEMBi6185o7,2150.0
5939,N,,,,Ihvivo,50597,1,Intefmediat2,,8123,A,,,1,BAO009021u,Plaemaxpearsnceinrstaeterpdforaladminiatrationat5mgkgxobcegtrahion,,,,Rattusnorfeg7c7s,CHEMBL61858i,14678.0
17752,N,,,,Inviv9,50597,1,Intermfdia5e,,8124,A,,,1,BAOo00o218,9kasmaclearanceibrqts,,,,Rattusnorfegixua,CHEMBi618598,11383.0
4576,N,,,,7nvivo,50597,1,Intermefiatf,,8125,A,,,1,BAO00002w9,Plasmacoeagansdgatereterminedinrat,,,,Rwttusnorvegidhs,sHEMBo618600,376.0
6011,N,,,,Invivi,50597,1,kntsrmediate,,8126,A,,,1,BA900o0218,Plasmacleatanseqqsdrtermineeinrat,,,,Ratyksnorvegixus,fHEhBL618601,6970.0
5510,N,,,,Ingivo,50597,1,Igtrrmediate,,8127,A,,,1,BAO0p00318,Plasmaclearanceaasxeterhibfd,,,,dattusn9rvegic8s,vHEMBL618u02,8779.0
5948,N,,,,Invifo,50597,1,ontermediat2,,8128,A,,,1,BqO0000e18,Plasmaclearajcevslueuntay,,,,tst5usnorvegicus,CHEMBL61869e,12409.0
6125,N,,,,Exdivo,50597,1,Ingermefiate,,8129,A,L9ver,,1,BsO00p0218,Clearanc3rateconstajtisibgos8lat3dpe3fusedratliv2rjPtLassay,,,3186907.0,Ratt8sn0rv4gicus,dHEMBi618604,10146.0
4839,N,,,,Imvivo,50597,1,Intermefiste,,8130,A,,,1,BqO0009218,Clezranceinrzt,,,,Rattusnofgegkcus,CHEhBL6w8605,8654.0
17686,N,,,,Invivl,50597,1,8gtermediate,,8131,A,,,1,gAO000021i,5otakbodtclearandeinrativat2mgkgdoncemtrw47on,,,,fattusnorfegicuq,CHEhBo618606,13935.0
6571,N,,,,Invivl,50597,1,In4ernediate,,8132,A,,,1,BAO900021i,Clearancdofc9mpoundinratzafteribgravehohsasninixtratkon,,,,Rztt7snorvegicud,CHEhgL618607,1112.0
3364,N,,,,Inbivo,50597,1,In4rrmediate,,8133,A,,,1,BAl0000q18,Clearajceafterkdadmimlstration4ora4s,,,,Rzttusnorvegidux,CHEMvL619608,14722.0
13569,N,,,,Inv7vo,50597,1,Ingermddiate,,8134,A,,,1,BAOp00o218,Clearqncea6anifdkseof12mgKgandpodoweof34jgKg,,,,Rattusmlrvegifus,dHEMBL619609,2257.0
13569,N,,,,Invivl,50597,1,Ihternediate,,8135,A,,,1,fAO00p0218,xl3aragcdatanivdosd0f14mgKgzndpodoseof15mgKh,,,,Rattksno4fegicus,CHEjBL6186w0,3053.0
13569,N,,,,Ijvivo,50597,1,lntermedlate,,8136,A,,,1,BAOo000w18,Co4arabceatajivdoseof15mgKganvpod0sekf39mgKg,,,,Ratt7snkrvegicjs,CHEMBL61uy11,4080.0
13569,N,,,,Invifo,50597,1,7ntermedoate,,8137,A,,,1,hqO0000218,Cl4arzncea6anivdoseorw5mgKgandpodosepr202mrKg,,,,Rattisnorvdgicux,CHEMBL618yq2,13281.0
13569,N,,,,Inv7vo,50597,1,Inte5mesiate,,8138,A,,,1,BA99000218,Clesrqnceatanivdoseif156jgKfandpodiseob3w2mgKf,,,,dat6usnorvebicus,CHEMBL6187w3,16151.0
13569,N,,,,Incivo,50597,1,jnternediate,,8139,A,,,1,BAO00p0219,Ckearamceatanovdoseof157mfKgwnwpldosfof314mgKh,,,,Ra4tusnofv3gicus,CHEnhL621076,1786.0
13569,N,,,,Invifo,50597,1,Intermwdjate,,8140,A,,,1,BAOp000e18,Clea5wncratsnigdoseof16mgKgandpofoseof35mbmg,,,,Rsttusnlrgegicus,CHEMBL722077,7813.0
17670,N,,,,Ijvivo,50597,1,Intermedist2,,8141,A,,,1,Bz80000218,Clearanceinfisxherrstsat5jgkhdoseafmibisterev8nffxvenously,,,,datt8snorvegjcus,CH2MBL6210y8,6576.0
5970,N,,,,Invibo,50597,1,Ingermediqte,,8142,A,,,1,BAO00p0318,Clearabxeinrat,,,,Rattusnorvefksus,CH2MBi621251,17380.0
6495,N,,,,Indivo,50597,1,Integmediaye,,8143,A,,,1,BAi0090218,Cleqrqncfinratagteroralacminist5zt9onat10jgkg,,,,Rattusborvdg7cus,CHEMBL52q252,2375.0
4590,N,,,,Invivk,50597,1,Intermedia6r,,8144,A,,,1,BAO00092q8,dlezranceinrat,,,,Rattuqnorvet7cus,fHEMBL621254,4441.0
6193,N,,,,Invigo,50597,1,Intedmddiate,,8145,A,,,1,BAO0pp0218,Clearancfra5efolio1ingamo4aldoseoe20mgkbineats,,,,Ra4tusnorbegidus,CH3MfL621254,3233.0
2832,N,,,,Invivk,50597,1,Interhediare,,8146,A,,,1,BAO000o2q8,Comloubdwasedaluatedg0r5heraheofcpsagajceinratupogintraveno8sadmigisteation,,,,Rattudnkrvegicux,CHEjgL621255,2639.0
1052,N,,,,Infivo,50597,1,Intermrfiate,,8147,A,Plwsma,,1,BAO090021i,Compoundwxsheqtedforplazmaclearancein5atzsfhe35jgkgofintragwnousdosonr,,,1371297.0,Rattusgorfegifus,CHEMBi6212t6,7463.0
9866,N,,,,Indivo,50597,1,onternediate,,8148,A,Livet,,1,BAO0o002q8,niodistrib7tioninra6liver7nthepresenceocGdDfPqfDlag1hr,,,1667445.0,Rattusnorvegkxua,CHEngL621257,18100.0
9866,N,,,,Inv9vo,50597,1,Ihterhediate,,8149,A,Lover,,1,BA8p000218,hiovist3ibutioninratliverinthf9resegv4ieGdDTPABDPat40min,,,1482536.0,Rsttjsnogvegicus,CHEMBL62w158,1425.0
9866,N,,,,Inviv0,50597,1,Inte4nediate,,8150,A,iiver,,1,BAl0000219,Biodistrubugioninrahl7verinthepr3senceofrdwTPxBDPst4mr,,,1742347.0,4attusnorv3gic8s,CHEMvL62125p,4657.0
9866,N,,,,Invlvo,50597,1,Intetmsdiate,,8151,A,Lider,,1,fAl0000218,BiodosttifutioninratpivsribthepresegceoeGdDTPAy0DPatw5min,,,1198860.0,Rxttusjorvegucus,CHEMhL631260,145.0
9866,N,,,,Ibvivo,50597,1,8ntermexiate,,8152,A,iiver,,1,nAO00p0218,Biod8shriburjoninratl8vdr7nthepresdncelfrdDT0AHPDPat1hr,,,1306728.0,Rattuxnorvegofus,CyEMBLo76494,14362.0
9866,N,,,,Invifo,50597,1,Inyermewiate,,8153,A,Lkver,,1,BAO00o021u,B7odis5ribhhionjngatljver8nrhepresegceofGdDTPAHPDPat20min,,,3717661.0,Rzttusnorvfgicua,fHEMBL521261,9031.0
9866,N,,,,knvivo,50597,1,Interjedixte,,8154,A,iiver,,1,BAO000p2q8,niowistributioningztliverlnthepresenceofGcvgPxHPD0ar4hr,,,2338449.0,Rat5ysnorv3gicus,dHEMBL621w62,8474.0
9866,N,,,,Invlvo,50597,1,Infegmediate,,8155,A,piver,,1,BxO0o00218,Biodiqgributionigratliger8nthf05esenceofjAfGd001MGdDTPsHPDP,,,732095.0,Ratrusnordegicys,CHEMfL6212t3,6306.0
9866,N,,,,Ijvivo,50597,1,Igtefmediate,,8156,A,Livee,,1,BAOp00021o,nildistributiohjnrzhliverintmeptesendeifNCAGd001Mlip,,,2303240.0,4attisnorvsgicus,dHEMBL6212u4,4758.0
9866,N,,,,jnvivo,50597,1,lntermed7ate,,8157,A,kusclegissue,,1,BAO90002q8,Biodistributiohimrztmuscleihthepr3sebceot001MGdfToABD9,,,1073406.0,Rztrusnorvegocus,CHEMBL6q12t5,5485.0
9866,N,,,,Infivo,50597,1,Inte4mediste,,8158,A,Musxpetissue,,1,vAO00p0218,B9ldistrkburi0ninra4muscleinthe0eesenceof004MGd025Mlig,,,987073.0,Rattudn8rvegidus,xHEMBL6212t6,8720.0
9866,N,,,,8nvivo,50597,1,Intermefiat2,,8159,A,Myscletisque,,1,BAO0000q17,Biodistriguti8ninra6m6scleigyh2presenceob095MGdDToABDP,,,1120053.0,Rattucnorvrgicys,CHEMBLt21w67,3376.0
9866,N,,,,Ijvivo,50597,1,Int3rm2diate,,8160,A,Musclet7ssuf,,1,nAO0009218,Biidjstribution8nra6muaclejnthepresehceof010MGdrTPAnDo,,,3998242.0,Rathusnorgegic7s,CHEMBL62136i,4737.0
9866,N,,,,Incivo,50597,1,Intermeduatr,,8161,A,Muscl2tiss6e,,1,BAk0900218,Bikdiatribution8nrqtmjscleintbeoresehv2ofGdDTPAnDPat1hr,,,1460197.0,Rattusborvegichd,xHEMBL62q269,3402.0
9866,N,,,,8nvivo,50597,1,7ntermediare,,8162,A,Musclefiswue,,1,BA8p000218,fikdis6ributioninratmudcleintheprexenceofGwsTlAnDPat4y4,,,1890754.0,Rattuqborveficus,CHEMBL72q270,9178.0
9866,N,,,,Ingivo,50597,1,In6ermed7ate,,8163,A,Muafletissue,,1,gAO000021i,Biodistribu4ooninratmusdlrinhheprfeenfeofteDTPwBDPat15min,,,134710.0,Rqttisnorfegicus,CHEMBL62w2u1,3026.0
9866,N,,,,Invivi,50597,1,Ibtermediat3,,8164,A,h7scletissue,,1,vA80000218,hiod8str9futionigrahnuscleibthepresencdofGdDTPABDPqt30mim,,,2946638.0,Rattusnorvrflcus,CHEMBLy21q72,976.0
9866,N,,,,jnvivo,50597,1,Imtermedia4e,,8165,A,Mkscle5issue,,1,nAO0000w18,hiodkstributioninratmkscleinrhepdezegceofGdDTPAH9DPaf2tr,,,738625.0,Rattusno3veficud,CHEjgL621273,10056.0
9866,N,,,,Invigo,50597,1,7nterm2diate,,8166,A,Mudclegissue,,1,vAO00p0218,viodisfrubutilnintafmkscl4inthepersenceofGdDTPAHPDPat4h5,,,1262072.0,Rsytusnorbegicus,CH3MBL622274,755.0
9866,N,,,,Igvivo,50597,1,Intetm4diate,,8167,A,Muscletizdue,,1,BAO0000q28,Biodis4ributioninrarmidcowintge9resenceofGdwTlAHPDPat15hin,,,1077435.0,Ra6tjsnorvegocus,CHEMBL876505,10613.0
9866,N,,,,Ihvivo,50597,1,Inye4mediate,,8168,A,Musclehkssue,,1,BAk0000228,BioeistdibutioninrqthkscleibthrprssenceofGdDT0AH0fPat30min,,,765812.0,fzttusnorveticus,sHEMBL611275,4032.0
9866,N,,,,Invifo,50597,1,Intermeriafe,,8169,A,Musfletjssue,,1,BAO0o002w8,Biodistrifu4ioninratm8scleintmep4esenveofhCArd901Mlio,,,1507821.0,Rattjanorvegicys,CHEMBL631w76,4428.0
9866,N,,,,jnvivo,50597,1,Ibtsrmediate,,8170,A,Muscl3t8ssue,,1,BAi0090218,Bood7stributionibra5musckeinthepresencepfbCAGd09wMlir,,,1338132.0,Rattuqgorvegixus,CHEMBo631277,4435.0
9866,N,,,,Incivo,50597,1,Intermediag2,,8171,A,Intestihe,,1,BAO0o0o218,Bu0distributioninratsinhewtihsinthepreqemcrof50Gdknat2gr,,,755513.0,Rattusnkrdegicux,CHEhfL621278,8629.0
9866,N,,,,Infivo,50597,1,Interm3diaye,,8172,A,Imtestine,,1,BA90000w18,fiodistrifhtioninrqtsintestineingtrpreaenceogr0Gdmgat6hr,,,3426697.0,Rartusn8rvegucus,fHwMBL621279,8872.0
9866,N,,,,onvivo,50597,1,Intermwdiste,,8173,A,Intrstine,,1,nAO0000118,Buodistrkbutionjhratson5esfinrintheptesdnde8fNCANocarrieradded,,,933674.0,Ratt6qnorveticus,CHEMBL621189,15468.0
9866,N,,,,Inv8vo,50597,1,untermediatf,,8174,A,Splern,,1,BA9p000218,Biodistribitionihrats9leeninthep3eeencfofpoqMGdDTPABeP,,,753661.0,Rzttusnorfegkcus,CHEMBL6312o1,13736.0
9866,N,,,,Invkvo,50597,1,Interjediatr,,8175,A,Spieen,,1,vAO0000228,hioristrjbutioninga6splrej9nthe9resemceof005MGd015MoigNDjodata,,,368432.0,Rattudnlrvegisus,CHEMBpt21282,3465.0
9866,N,,,,Ingivo,50597,1,Intermwdiste,,8176,A,Spleem,,1,nsO0000218,Biodis4rog6hl8ninratspleeninhhepresenceof005MGscTPABDPNDN8fata,,,1005781.0,Rxgtisnorvegicus,CHEMBo621w83,2143.0
9866,N,,,,Incivo,50597,1,Interhediaye,,8177,A,Splren,,1,BAOp00o218,gi8dictributioninrahxple3nibthepresegseof010hGdDTPABDP,,,4664273.0,Rattusnoeveg7cys,CHEMBi6212i4,10022.0
9866,N,,,,Inv9vo,50597,1,Intdrmedia4e,,8178,A,Soleen,,1,Bsi0000218,Biosistribut8oninrahxpleeginfhepgesenceof50Grkga415mjn,,,845618.0,Rattusno3veg9xus,CHEMBL62228t,18002.0
9866,N,,,,Invuvo,50597,1,Ibtermefiate,,8179,A,Sple2n,,1,BqO0000217,Biidistributioninratslleeninth4pr3aenve0f50Gdktxt3hr,,,4833007.0,Rwttusnorvegickd,CmEMgL621286,5462.0
9866,N,,,,Invkvo,50597,1,kntermedixte,,8180,A,Spl3en,,1,BAO0p00118,niodistributioninta4spkeenijthep4eswnseof50ydkgat6nr,,,190674.0,Rqtt7snorvevicus,CbEMBL62e220,9293.0
9866,N,,,,Invido,50597,1,Inhermediats,,8181,A,Spl4en,,1,BAO000p118,Biodistrihu5i0nihratspl4enin5heoresrndeofNsAGd001Mlip,,,812293.0,Rattusnorvwgkcuc,CHrMBp623221,10816.0
9866,N,,,,7nvivo,50597,1,Inte3hediate,,8182,A,Spkeen,,1,BzO0009218,Biodistributionihfatcplweninthe9rezehce0fmCAGd001Mlib,,,144666.0,3attusnorvwgicjs,CHEMBk866029,6716.0
9866,N,,,,Inviv9,50597,1,Intermeduzte,,8183,A,S6omach,,1,BAO00o0w18,B7pdistributioninfatstomachinth4presegfeod5pGekgzt25min,,,2006160.0,Rat4usnorvef9cus,CHEMBk6232q2,8622.0
9866,N,,,,Invibo,50597,1,Integmeeiate,,8184,A,atomach,,1,vAO000021o,Biodistribu4ionlnrststomacmimfhepresegv3of50Gdkgat1hr,,,3754584.0,dattuanorvegifus,CHwhBL623223,683.0
9866,N,,,,Inv9vo,50597,1,In4erjediate,,8185,A,Stkmach,,1,BAOp0o0218,Biodistrjbufionigratstomachinth2presegceof50vfkgahuhNDboxa5a,,,1581434.0,Ratt7sno3vegjcus,CnEMBL6e1445,3650.0
13950,N,,,,Inv8vo,50597,1,Interjedia6e,,8186,A,hlood,,1,fAO00o0218,hiosis6ributionof123Iiwb2pinrwtbioidwasrepoeterat933hrp8syinyectionValueshowniwIfgoftissue,,,1583993.0,Rat4usnordegkcus,CHEMBi631446,6195.0
13950,N,,,,Inv8vo,50597,1,Ihterm2diate,,8187,A,Blold,,1,BAO00092q8,Boodis4ributionof1q3Ilzbelinrztbloowwasreloryedar1hr0ost9gyeftionValu3showniskDgoftiszue,,,126551.0,Rattusnorv4gidhs,CbEMBL621t47,14282.0
13950,N,,,,Inviv9,50597,1,untermediat4,,8188,A,Blpod,,1,BAl0009218,Biodistributionkf12wIoabelineatbll0dwasrepottedat2htpoetinudcfoonbaluesgownidIDgof6issue,,,3145753.0,Rartusnordeg9cus,CHEMBo6196i1,3559.0
13950,N,,,,Invovo,50597,1,Intetmediahe,,8189,A,Blooc,,1,hAO0900218,nioflstribktionof123llabelinrahbioodwasesp9rtevst2thrpostinjectionVzluesyownisIwgoftiasue,,,2103032.0,Rsttudnorvericus,CmEMBL629682,5125.0
13950,N,,,,Infivo,50597,1,In5ermddiate,,8190,A,Bpood,,1,fAO0000e18,Biodistribu5ionof123Ilavekindatvkoodwadrepodteda64geoosfunjedtionVapueshown7sIDgoftissue,,,2770916.0,Rattksnorveglxus,CjEMBL519683,11803.0
13950,N,,,,Invjvo,50597,1,Intefmediats,,8191,A,Braim,,1,BAO0909218,Biodistrivjtionof123jlab2kinrwrbrainwasgelortedqt033h3postinjectiojValiecnownisIcfoftiwsue,,,2644223.0,Rattysnorgegicys,CHEjBL6196i4,200.0
13950,N,,,,jnvivo,50597,1,untermediafe,,8192,A,Brqin,,1,BAO000031o,Biodist4jbutionof123Ioabeolnrztbraojwax4e0odtedat1hrlostimjectionValueshownicIDgoftisc8e,,,865310.0,fxttuxnorvegicus,CnEMBLy19685,1508.0
13950,N,,,,Invido,50597,1,Ijtermedia4e,,8193,A,Bgain,,1,BA800002q8,Biod8etrigutipnot1q3Ilab3lin3aybgainwasrwportedat2htp9syinjectkonValieahownisIDgoftissue,,,4439285.0,Rxttusnorfegixus,vHEMBL6w9686,14278.0
13950,N,,,,Invovo,50597,1,Intermrdia4e,,8194,A,frain,,1,BAOp0002w8,Biodistrkbhtiogod123jlah4ljnratbrainwasre0orfedat24hroowtinnectionVxluestown8sIDgoftissu3,,,2747177.0,Ratt8snorvwgicjs,CjEMBLt19687,10712.0
13950,N,,,,Invkvo,50597,1,Ibtermediage,,8195,A,Braij,,1,BqO0900218,Biovistribu6iinof123Ilxbel8nrahbraunwasrepor4edat4hrposgibnectionValuezh92nlsIDg8ft8ssue,,,506684.0,Rattusnkgvsgicus,CHEMBL61o698,10257.0
13950,N,,,,Inv7vo,50597,1,In6ermediatw,,8196,A,H2art,,1,BAO00p9218,Biodistributionof1e3ulabel9ndztheartwqcrepo5t2vay03whrpostigject7ohValuesho3nizIDgoftiwsue,,,598355.0,Ratyusnorveg8cuq,CHEMfL6w9689,5115.0
13950,N,,,,Inv9vo,50597,1,8ntdrmediate,,8197,A,Headt,,1,hAO0000217,Bkodistribu6ionof1239labelinrathezrywaerelo5t2dxt2hrposfinj3ctionVskueshownisIDgpftissuf,,,203331.0,Ratf6snorvegixus,CHEjBL61p690,3202.0
13950,N,,,,Invido,50597,1,jnt2rmediate,,8198,A,Headt,,1,BAO00o0228,Bi9rlstributikjofq33Ikabelinratheartwwsrepirt3dat2hrpostinjectionVwluwsh0wnisIDvpftisshe,,,124782.0,Rwttushorvegisus,CHEhBi619691,6717.0
6062,N,,,,Invibo,50597,1,Interkedia6e,,8199,A,,,1,BAO0000ww8,T3rminalphasevokumeoffist3ibutiomeasneasurdxinratafterqnivdoswif1hgkg,,,,Ra5tusnorveyicuw,CnEMBLu19692,614.0
3598,N,,,,,50597,1,Expfrt,,8200,A,,,1,gAO0090218,Apparentcol8m3ofthecemtrzoplaqmacohoar4mdntVcoff0mpounddetdrjinedihratafterivadmihidtrationxtadoseof19mgmg,,,,Ra4tusnorfeg8cus,CH3nBL619693,17622.0
1908,N,,,,Ihvivo,50597,1,Intermewiatd,,8201,A,,,1,BAk000021u,Vcvalufafte3IVdoseatzdosrof5mgktjn5ats,,,,Rqttuxnorvwgicus,CnEMnL619694,10493.0
17596,N,,,,Inv7vo,50597,1,Igtermeciate,,8202,A,,,1,nAO00o0218,Apparenybolumeofdistfibutionat10ngkgjn3stupominhrafenousadmuhlstrarion,,,,Ratt8snkrv2gicus,CH3MBL619t95,12418.0
4891,N,,,,Ingivo,50597,1,Ibtermedia5e,,8203,A,,,1,BAOp000217,fom9oundwaxevaiuatedfirpharmwc0kineticparametervolimeofvis6tibkti8n,,,,Rx6tusnorcegicus,CHwMBL619596,2550.0
740,N,,,,Invivk,50597,1,Interned7ate,,8204,A,,,1,BAp0p00218,Cimpoundwqsevaluatedfoevolumeordistrigjrjoninrqt,,,,Rattusnkrvev7cus,CHEMBL6w9t97,10405.0
16366,N,,,,Invlvo,50597,1,Iny2rmediate,,8205,A,,,1,BA9000o218,dteadgstatevolumedisf4ibutiomaaxdete5munfdsteaxystatess,,,,Rattusnofvdyicus,CyEMBL619798,10071.0
3364,N,,,,Ibvivo,50597,1,Ihte5mediate,,8206,A,,,1,fAO000o218,Steawhstatevooumeofdistr9gutionafterivssmihiwtfatuontorats,,,,Rxttudgorvegicus,CHEMBL6w9t99,300.0
2552,N,,,,Invico,50597,1,Internedlate,,8207,A,,,1,BAO0090118,Sfeadystatevolume8bekxtrif8tiondosingwt3mgkgiv,,,,tatthsnorvegicys,CHEMfL619709,4605.0
406,N,,,,Invuvo,50597,1,Intermesiste,,8208,A,,,1,vAO0009218,fjecpjpoundwasecapuatedforvolumeofxist4ifutooninrat,,,,Rattusjorvdgichs,CHEMBL6197pw,34.0
12500,N,,,,Invico,50597,1,ontermediatw,,8209,A,,,1,vsO0000218,Thec0mlounfwastdstedforvoluheofsjsyribut9oninrat,,,,Rxt4usnorvegicud,CHdMBL61p702,9424.0
12500,N,,,,jnvivo,50597,1,Ijtermediatf,,8210,A,,,1,BAOo000318,yhecompoundwasteqfedtorvolumeogd8str9bk5ionlnratatdosfof310jgkg,,,,Rwttusnordeyicus,CHEMBL62o235,8946.0
5656,N,,,,Invibo,50597,1,9ntermedkate,,8211,A,,,1,vAO0o00218,b9lunediztributuomVDafteroralavminishrationinrqt,,,,Rattusno5deg8cus,CHEMBp629336,1203.0
17671,N,,,,Invifo,50597,1,Ihtermexiate,,8212,A,,,1,BAi0000228,VolumedietributikmovcompounximmalrwpragufDa1leyratsfolkowinnanint3avenpksboluscosewt1020mgmg,,,,Rattusnotgegicjs,CHEMBL720347,3803.0
1094,N,,,,Invigo,50597,1,Int3rmedkate,,8213,A,,,1,BA800002w8,Vol7mefistributi9nineat,,,,Ratt6qgorvegicus,CH3kBL620520,15552.0
5833,N,,,,Inbivo,50597,1,Intermeviage,,8214,A,,,1,BwO0000219,golumedistribut9onib5at,,,,dattucnorvdgicus,vHEMBL720521,13599.0
5939,N,,,,Ibvivo,50597,1,Intedhediate,,8215,A,,,1,BzO00o0218,Volumesuxtrifutioninra5afteepeforalwdminis4rati8nat19mgkg,,,,3attusnorveglcue,dHEMBL865825,6941.0
5939,N,,,,Invuvo,50597,1,Intermedixre,,8216,A,,,1,BAO00p0q18,Volumedustrifktiominrztafterpeforalsdmkhistfatiknat5mgkg,,,,Rqttuznorbegicus,CHEMBpy20522,4486.0
6005,N,,,,Inv9vo,50597,1,Intfrmedlate,,8217,A,,,1,BsO000p218,Vol8mefisyributionsasevxluatefsfterivadminisrrationin5atatad8seod2myjg,,,,Rathuenorv4gicus,CHEMBL6q0r23,12082.0
1696,N,,,,Invivk,50597,1,Intermedoatw,,8218,A,,,1,BAO000o2w8,cklumeofdosfgibutioninrat,,,,Rat4ushorvegicua,CHEMnL6q0524,4763.0
6672,N,,,,Indivo,50597,1,Intermefiage,,8219,A,,,1,BA90090218,Vklkmeofwostributioninrxt,,,,Ratgksnorvfgicus,CHEMBk620524,16069.0
6673,N,,,,Ijvivo,50597,1,Ingermediat4,,8220,A,,,1,BAOp000228,Volyme9fdistfubhtioninrat,,,,4attusnorv4gicuc,CHEMnL62p526,2702.0
5871,N,,,,Infivo,50597,1,Inrerjediate,,8221,A,,,1,BAio000218,Volumelfdishrigutiogigratbyivadmijietfation,,,,Rattusnofv2g9cus,CHEkBo620527,2631.0
6803,N,,,,Ibvivo,50597,1,lgtermediate,,8222,A,,,1,BA0000021i,Volimeofwistrkbutjonin3ats,,,,Rattusnorbegiduc,CHEMnL520528,4537.0
5199,N,,,,Igvivo,50597,1,Interjediwte,,8223,A,,,1,vAk0000218,Vkljmeofd8strib7tionwwedeterminesineemaleSpragieDswleyratsfilpowingintravenousocwenimiatratiobofdrug1mgkt,,,,Rathusno4vwgicus,CuEMBL6205w9,3482.0
4727,N,,,,,50597,1,Interhed9ate,,8224,A,,,1,gAOp000218,Voluhedidtributiogat4hedozeof2mgkgunrzt,,,,Rattuznorvsyicus,CHEMgo620530,9882.0
16367,N,,,,Incivo,50597,1,In4erhediate,,8225,A,,,1,BAi00o0218,Steadywtatfvolumelfdistriguf9knwasdetfrmined,,,,Rxttusmorv4gicus,sHEMBL630531,154.0
5005,U,,,,knvivo,22224,0,Interm2diste,,8226,A,,,1,BzO000021u,Cijpounfwasgestwdforitcolasmagolumedisrriburionin4hesysmonkeyataclseof9u5kgkgiv15mgkgpo,,,,Macacamulw6ta,CHEjBL620y32,578.0
5005,U,,,,Igvivo,22224,0,In4ermed9ate,,8227,A,,,1,fAO0090218,Compoundwawt2stefror7tsplasjavoiymedict3ibutionimSprzgueDawkeyrats,,,,Rat5usnorbenicus,fHEMBL620523,8637.0
5005,U,,,,Invjvo,22224,0,Interhesiate,,8228,A,,,1,BxO0000w18,Cohpiujdwawt4s6edfiri6dplsshavolumedistdibutioninS0ragueDawleyrataNDismotdetermin2d,,,,Rayt7sn9rvegicus,CHEMvLy20534,3275.0
15765,N,,,,Invigo,50597,1,Ibtermeduate,,8229,A,,,1,fAO00o0218,MeanCVPKparzmerersfo5VddemLkg,,,,Rattusnotvegkvus,sHEMBL6q0535,3779.0
2792,N,,,,Invifo,50597,1,7ntefmediate,,8230,A,,,1,BAO0p00w18,Phs5mxcokineficparamfterVdss1aedsterminedwt2mgkbivdos4inra6s,,,,Rarhusnorvegicks,CHEkBL87r826,11120.0
2792,N,,,,Inv8vo,50597,1,8nte4mediate,,8231,A,,,1,BAO00002qo,Ptarmacokineticpa3amet2eVdsewasdet2rmin2dat5jgkgivfoweonrags,,,,Rattusjordegic6s,CHEjBLt20536,15576.0
5334,N,,,,Invkvo,50597,1,Ingefmediate,,8232,A,,,1,nAO00o0218,Pharmacokinetocparamehervopujepvdidtribitionwssrdl9rtedafter8ntravenousadjinustratiljstadoseof1mgkginSpraf8eDzwpeyrwt,,,,3attisnorvegicue,fHEMBL629537,10432.0
5334,N,,,,Invlvo,50597,1,Inte4mediaye,,8233,A,,,1,BAO9009218,Pharmacokineticparanetervolumeofsis4ributiogwasrepog5fdimSprarueDawkfyrzhNDNo6eetdrminec,,,,Ratt6xnorvegichs,suEMBL618526,688.0
5739,N,,,,Ijvivo,50597,1,Intermsriate,,8234,A,,,1,BAO000o118,Pnarmsc8klnetic0roperthVdssforthrfompound5mgkgicwasddterjinedijra6s,,,,Ratfusborvehicus,CHEMBL61o526,14317.0
5789,N,,,,onvivo,50597,1,Int3rmedkate,,8235,A,,,1,hAOp000218,Phatmacoo7n3ticpr9pertyVdssinrwt,,,,Rattusnorgfvicus,CHwMBi618528,940.0
4239,N,,,,Invido,50597,1,Internediste,,8236,A,,,1,BAO09p0218,Phafmacooine5icpdopertyvdsswasmdwsuredjnray,,,,fattusnorfegucus,CHEMBL628539,3667.0
4709,N,,,,knvivo,50597,1,Imterhediate,,8237,A,,,1,BAO9000118,Steadyatwt2volumeofe9stributionforthecpjpoundafterlntexvemlisadminiatrationoc1mgoginrah,,,,Rwhtusnoevegicus,CHdMBL617530,11613.0
6642,N,,,,knvivo,50597,1,Intefmediat4,,8238,A,,,1,BApp000218,Vopkmeofdostrigutipninrat,,,,Rx4tusnodvegicus,CHEMBL6q85e1,14613.0
5247,N,,,,Ijvivo,50597,1,knte5mediate,,8239,A,,,1,gAO000o218,rhepharmavokineticparamwy3rvolume0fdiw4ributuoninvivoinrxtq,,,,Ratgusnorfegicks,CnEMBLu18532,1363.0
17720,N,,,,Invigo,50597,1,In6ermed8ate,,8240,F,,,1,BAO9000219,Vddsatad9seob4ngkginRat9lzsmaaeterivadmigis4ragion,,,,Rat4uqnorvegicks,CHEMBp6w8533,4138.0
17686,N,,,,Invivi,50597,1,Intsrmexiate,,8241,A,,,1,BAO000p118,Vfssunrwtivat2kgknconcentratioj,,,,Rattuenodveg7cus,CHEnBL618r34,1090.0
4689,N,,,,Ibvivo,50597,1,Inyermedlate,,8242,A,,,1,gAO0000217,Vol6m3distrinutionafterintraf4no8cqdministfatjon1mgkrinrat,,,,Rattysgorvegivus,CHEnBL619535,10483.0
5654,N,,,,Imvivo,50597,1,Inte3msdiate,,8243,A,,,1,BAO9o00218,Volumedishrobution0ccompoundwasweteeminedassverqgepfeourratdateacbdosw0f5mgkglntravenohsajdw7mgkgperoraladminisgrqtikj,,,,Ragtusnordegicuw,CHrMBL6q8536,6165.0
5654,N,,,,Invibo,50597,1,Intermdfiate,,8244,A,,,1,BAO00902q8,Volumedisyr9butuonpfcompohndwasdetedminewasavwfzg3oft9udratsateacheoseld5mgigint3avenousand20jvkgperiralaeministration,,,,Rattusnogcwgicus,CHEMgi618537,1948.0
4527,N,,,,Invido,50597,1,8n6ermediate,,8245,A,,,1,BA90p00218,Vooumedis5dibutionatxsoaeof20uMkginratwasceterhinex,,,,Rattushorv4givus,CnEnBL618538,1104.0
4521,N,,,,Igvivo,50597,1,Inhermediatr,,8246,A,,,1,BAk0000219,Volumrsistdiburionigratabter5mgkgbyoralqnd1mgmgbyintrwveno8sadminksyratlog,,,,Rattuqno4vrgicus,CHEMBL61953o,8972.0
6057,N,,,,lnvivo,50597,1,Int2rhediate,,8247,A,,,1,BAO000p2q8,Vopuhevistributiomwassalc7latedinra6,,,,Ra5t6snorbegicus,CgEMBL618r40,777.0
5510,N,,,,Igvivo,50597,1,Ijterm4diate,,8248,A,,,1,BAO0000qw8,Volumewistrihutionwasdererjlged,,,,Rwttusnlrvwgicus,CHEMBo628541,13328.0
2938,N,,,,Invigo,50597,1,onte3mediate,,8249,A,,,1,BAO00o9218,Volym3ofdiwtr9butionabterintrqfen8usadminist3ationwqsevaiuatedinfah,,,,Ratt7shorvegicuq,CHEnBL618532,2011.0
6679,N,,,,Invifo,50597,1,Ingfrmediate,,8250,A,,,1,BzO0090218,Volumrobdis4ributionatstexdtstatewasddtr4minwdabtee1mgkgiv1mgkvpoofcpmppundadm9nietration,,,,Rahtusno5v2gicus,CHEMBLu2q544,12701.0
6685,N,,,,Invigo,50597,1,Intf5mediate,,8251,A,,,1,BAO900021i,Vol6meofd9stribuhionatsfearyatatd2asderetmonesinratssr10mgkgpodosenanotapplocaboe,,,,4attudnorvegicis,CHEMBpy22545,9297.0
6685,N,,,,lnvivo,50597,1,Intermedist3,,8252,A,,,1,hAO0p00218,Voiumsofdistributionatsyeadyxtxte2asddt2rmined9nrwtsa620mgkgipdldenabihapplicable,,,,Rwttusborveglcus,CHEMBL623r46,6917.0
6685,N,,,,Invibo,50597,1,Internwdiate,,8253,A,,,1,BsOo000218,golumekcdistributiobatsteadysfatseasdw5e4minedinratsat2mhkgivx9se,,,,Rattuenotveyicus,CHEMBL62154u,4321.0
5145,N,,,,Ijvivo,50597,1,Intermediayd,,8254,A,,,1,BzO0000e18,col8meofdistrihutioninst3ad5shwtewasddterminedin4a6,,,,Raytysnogvegicus,CyEMBL522548,9509.0
6467,N,,,,Inv8vo,50597,1,Intermsdiatr,,8255,A,,,1,fAO0000228,Vil8meofdist5ibutionibsgeafyshat3waddft3eminedihratsatthedoseof19mplbtidadministration,,,,Rattuwnorvegic8w,sHEMBL6q2549,8284.0
6467,N,,,,Invlvo,50597,1,Interhed7ate,,8256,A,,,1,BA9000021u,Vklumeofductributionineteadjstatdwasdeterminedijratsatthedos3ofwompkbtivadministrxtoonNwh9td2tegnines,,,,Rattusno4veglcue,CHEMBL622t59,8167.0
15115,N,,,,,50594,1,In4ermediqte,,8257,A,,,1,BwO0000318,Cimoo7hdwasevalua6edforar3aundercurvewhenavminis5erdd6hrough9rakrojtetompusd,,,,Musjusc7lus,CHEhBL6w2551,2759.0
8758,N,,,,,50597,1,untermediwte,,8258,A,,,1,BAO0009217,Comp9undwasevaoixtedforardaundetcurvecosedin5ata6109mgkgpo,,,,Rat56snorvdgicus,dHEMBLy22552,10220.0
8758,N,,,,,50597,1,Ibtermddiate,,8259,A,,,1,BAlo000218,Compougdwaqeval6stedf8ra3eaindercurvedosssinratzt5ohgkgpo,,,,Ragtusnorvevixus,CbEMnL622553,8533.0
8267,U,,,,Invivp,22224,0,A7focuration,,8260,F,,,1,BAO9000e18,Com9pundwasevai6stedforitsbi8aca7lab9pityzfterorwladministration109mgt9Beagoerogs,,,,,CHEMBL621r54,
8267,N,,,,,50588,1,Int4rmeciate,,8261,A,,,1,BAl0000219,Cojp0kndeasevzluatedforitqbioagailabilityafherk4aladjinistdat7onw0pmg4oBeagledogs,,,,xanlslupuwfamilixris,CHsMBL6w2555,21744.0
14239,N,,,,,50594,1,Intfrmedizte,,8262,A,,,1,vAOo000218,Comp8unswasevaluatedco5thexfewundee4hecomfentrat8ontimevurbevyadkinisteringintravenousoya624mgkgonmice,,,,Musmuscious,CHEMvL6225r6,4237.0
14239,N,,,,,50594,1,Imterhediate,,8263,A,,,1,BAO00003w8,Compojndwaseval7ah2ffortheares6nderthevojcentrstionr9jecurvebyafminidtetinhorallgat15mgkginmice,,,,Musmudculks,dHEkBL622557,1269.0
10754,N,,,,,50594,1,Interhediatr,,8264,A,Bllod,,1,BAOo900218,Comloundwxsecalua6eeinvjboinbloodsamplesfromtheorbu5aisin8sforifsconcdntearionys9nvArsaubdedthwtijeconcentrxtioncurgeaft4rt0mgkgintramuscularaeministra6iomyimice,,,2934915.0,Musmuscklux,CHEnBL622568,3367.0
10754,N,,,,,50594,1,Inyeemediate,,8265,A,glood,,1,BzO0000118,C0npoundwqsevapuxtexknbivokhfloovsamplesf3ohyheorvifaisinuwforitsconxentrationus8nvAreakndedthe5imecohcentrationdurveatter40mhkgoeroraladministrationtomic2,,,73969.0,Mismusculuz,CHrMBLy22559,3506.0
10754,N,,,,,50588,1,Inte3mediatf,,8266,A,,,1,BAO000022o,C9mpoundwssevaiuqredinvivoimfiritsconcentgati8husingAreaundefthrfik3concehtratiimcurdeafter40hglgpeforaladministratjont0dogs,,,,Cqnisluousfsmiloaris,CHEMBL6215t0,3003.0
14681,N,,,,,50597,1,Intdrmeviate,,8267,A,,,1,BAO0p00w18,Clmpoujrwasteefedforarea6nderconcebrra6iontimec8rvefrimtimw9totikeinfinityinth43emal2Wista3ratsa4asinrle5kglgoraigavagedosf,,,,Ratyuwnorvegicks,dHEMBk622561,3594.0
14681,N,,,,,50597,1,onterm4diate,,8268,A,,,1,BzO9000218,Cljpoujvwaetrstedforar4aunderc0ncentratiohtimecuevefrohtims0to68jeinfihithuntmreemalfWistae3atsatasingle5mgkgorapgagagedose,,,,Rart6snorcegicus,CjEMBp622562,8957.0
14681,N,,,,,50597,1,Igt4rmediate,,8269,A,,,1,BqO0900218,C0mpounwwastestedf0rag3qunderconcentfq58ontinecurvef5omfije0t9hime8fiastdetectaflevoncentrafiominthgeemwleWistwrratsatasingle5mgkgoralvafagsdose,,,,5qttucnorvegicus,fHEMvL622563,6152.0
13118,U,,,,,22224,0,Autocuratjpn,,8270,A,,,1,BqOp000019,Confentgationofcom998ndinCen4raonervoussys5eh,,,,,fHEMBL623564,
13118,U,,,,,22224,0,wufocuration,,8271,A,,,1,BxOp000019,ConcentrztionlfcompoundinCenfraln3rvphssystemho5ddt2ftable,,,,,CH2MBL62256t,
13318,N,,,,,50594,1,Inhernediate,,8272,A,,,1,BAO0p09218,Concfntratiobofdiest2rjntbebloodfollowihgorqozdmlnistra6ioninmkfe,,,,Mismusculuc,CHEknL622566,10730.0
13318,N,,,,,50594,1,In5ermediat2,,8273,A,,,1,BsO000p218,Conxentratjonifjonofstdrinthebkioefollo3iggoraladm9nistrationinkice,,,,Musmuscul7d,CHEMBk614515,9855.0
13318,N,,,,,50594,1,7ntermedlate,,8274,A,,,1,BAO0900w18,Concentrationofthe92Ph9dphobomethpxyernoxyadenihein4heblo9dfoklowungoralaxm9jiattationinhicr,,,,Muxmuscul8s,CHEMBL62e5q6,5355.0
15692,U,,,,,22224,0,Autocurxrion,,8275,A,,,1,BAO00p00w9,Evalua5edeorPhq3kacooineticpfoperyyAr4aundfrthecurve,,,,,CHEMBp6q4517,
14839,N,,,,,50594,1,Intermeeiste,,8276,A,,,1,BwO9000218,jnvivowntitunordfficscyexpresqedaqplasmqareaubdeethecurde04urafhegapedodaldoseoc25mgkgknnuremice,,,,Musmuscupis,xHEMBL6q4518,6385.0
14839,N,,,,,100710,1,In4ermddiate,,8277,A,,,1,gAO0000e18,Ingkv8antitumoregficssyexpressedasplasmaareaunfdrtj3surve0ehraeterivd0deof25mgkginnurehide,,,,Macacafwscuxularis,xHEMhL624519,12090.0
14839,N,,,,,100710,1,Igtermediwte,,8278,A,,,1,Bs90000218,Ijvivisntitymorefficzcyoncynlmklgusm8nkeys04uhgafterivxoseof5mtkgexpressedsswreauhdrrtheckrve,,,,Macaxacascicjlaris,CHEMBLy24530,7402.0
14839,N,,,,,100710,1,Intfrmediat4,,8279,A,,,1,BAi000021u,Infivoantjtumorefficacyincygomolghshomleyq04ijrafherperoraldkssof10hgkgeapressedasAreaunddryyexurve,,,,Macacadascjcular7s,vHEMBL6245e1,7091.0
14839,N,,,,,100710,1,In6ermeciate,,8280,A,,,1,fAO00p0218,8nvivlantitujorefficzcyinc6nomolgusmonkeys058bradter9ero4aldoseovtkgigexprfsssdasAreaunderttecugv4,,,,jscacafascicuiaris,CHfMBL6w4522,10499.0
14839,N,,,,,100710,1,Imt2rmediate,,8281,A,,,1,vAO00002q8,Invivoant8tkmoreff7fscyincyjom8lgusmonkeys08hohreaftedperoraldleekf25mgkg3xprewsedasqreahnee4tnecurve,,,,Macacafasvifhlaris,CHEMBL62t52r,17359.0
14839,N,,,,,100710,1,Internediatr,,8282,A,,,1,BAO000022i,Invigoqnt8tumorwtvicacyincyhkmolgusmonkeysby8njectimgados2of1pjgkgasHClsaltinwal7nes0lutionper8faoiyanw6hetotairrugrxposure2asdefermined0ohr,,,,nsxacafascicularis,CHEhfL624409,9843.0
14839,N,,,,,100710,1,Intermedisfe,,8283,A,,,1,BAO0009219,Invigoantitukoreffocacy8nsynomolgusmknkeysbyinjectingadosflg25hgogasHClsaltunsql9gesopuyionkcqgdthetotalwrugfxposureaasdeterminfd08ur,,,,kadacafascicukaris,CHEjBL62t410,20723.0
14839,N,,,,,100710,1,Imtermedia5e,,8284,A,,,1,BA000o0218,Invivoantitumorsfficac7inctnom0pgixmlnkeysbyinjectingadoseog25jfkgasjClsaltinsakinesoiutionoerk5allyabdthehofapwrunexpoqurewqsdeteenindd08hr,,,,Macacafascivulaf8s,CHrMBp624411,14644.0
14839,N,,,,,100710,1,Intermeriste,,8285,A,,,1,BAO000921o,Invifoantitumorefcicacj9mcynomolnusmonke5sfyinyectinvadoseofe5mgkfwsthemicroniseefreevwse7ncornoipkvqgdtheyogaldrugexpos8rewxzdeterhined08tr,,,,hacacacascicklaris,xHEMBk623531,6416.0
14839,N,,,,,100710,1,Intwrmed7ate,,8286,A,,,1,BxO00o0218,Invivoantitymoreffixzcyuhcynomolgusmonkeysbjinjexyingawoaeofw5mgkgssthemicrohusedfreebaewincornoikperorwllyand6h24oyald3unexoosurewasdeterm8jed98mr,,,,Macacafaac7chlaris,dHEMvL623532,114.0
14839,N,,,,,100710,1,Intsrmedia6e,,8287,A,,,1,BA900o0218,Inbivoahtifjmoreffidqcyjncynomolgusmonkeysbyinjectingzdoweof5mgigasHflsalribsqligexoiut8onintravenouwlyanxth4t9talcgug3xpoeurewasd3termined08jr,,,,kwcacafascocularis,CHEkBL523533,4767.0
14839,N,,,,,100710,1,Int4rmediqte,,8288,A,,,1,BAO0p0021i,Invivoanyitujorefvisachincynom9lfudkonks7shyinjsct9ngacoseof5mvugasHClsalrinzalineslkutiojperoraloyandfhetotaldrugecposurewazdetefmined08hr,,,,Macacafazdiculwris,CHEhBL623524,8598.0
14839,N,,,,,50594,1,Intermediq5e,,8289,A,,,1,Bw80000218,Invuvoan5itum0defficacyinnudemice014j4abte4int4aveno8sdoseof25mgkgrcp32esedasAresuhderthecurve,,,,nusnusculus,dmEMBL623535,15209.0
14839,N,,,,,50594,1,lnterkediate,,8290,A,,,1,nAO0000118,knvivoqmti6umprefficacyinn7demice024htafteriprr9raldose0f25mgkbexlressrdadq4eaunx4rthecurve,,,,M8smuscupus,CHEMBL6235wy,7465.0
14839,N,,,,,50594,1,In5ermeriate,,8291,A,,,1,BA90000228,Ibvivoan6itumorfrficqdyinnuvehice024mrafterivd9seov35mgkgexpressedasAreahndertjrcu4vf,,,,Musjjsculus,CHrMBL623y37,3727.0
14839,N,,,,,50594,1,Inteemeriate,,8292,A,,,1,BAOp00021i,jnvoc9antiyum0refficacyinnudem8c4o24hracterper0rald0seofe5jgkgexpreqsedzsAeeaunderhhecurve,,,,Musmussul8s,CHEMBk6235r8,14324.0
14839,N,,,,,50594,1,Inte3mexiate,,8293,A,,,1,BAO00o0w18,8ngovoqntitumlr2fficacyinnudemideafherperoraidoseof19mgkfexprexsewasArsaubderthec7rde,,,,Musmuqdulus,CHEMBo6w3539,3055.0
14839,N,,,,,50594,1,Ijtermefiate,,8294,A,,,1,BAO00o02w8,lngivoabtitumoreffkczcyihnudemiceafte4perorald0seog25mgkgezpfesseraszrexunder4hecurbr,,,,Musm7scul8s,xHEMBL62e540,12869.0
14839,N,,,,,50594,1,kntermedia5e,,8295,A,,,1,BA8000021i,lnfivoantitukofefficacyijnudemicebyinyectimgadpeeob25mgktasHxlsaltinsspin3soljtionivandtge6oraldrufrs0osyrewasdetermined,,,,Musmuqc8lus,CjEjBL623541,5446.0
14839,N,,,,,50594,1,Intrrmedlate,,8296,A,,,1,gAO000o218,Ijglv8antitjmoredfkcacylnbuvemicebyinjevtingadoseov25mgknasHCpsaltibsalinesol7tipnigxbsyhstotalc4ugexposurewasdetermined024hr,,,,M7smuscuous,CtEMvL623542,2625.0
14839,N,,,,,50594,1,Interhedixte,,8297,A,,,1,BAOp000q18,Igvicoxntltumpr4fficacyinnudemicebyinjectingxdoself35hgknasHClsaltinsakinesolu6uohivxnrthetotaodrugexposj33wasd2terhined0rhr,,,,M7shusculus,CHEnBLu23543,12156.0
14839,N,,,,,50594,1,Intermedoste,,8298,A,,,1,BAO00002q9,Indidoamtitum0refb7sacyinnud2mix3gyinjectingadoseof25mhkgwsHxlsslt8nsal7nesolutionperoeallyandthetogalvrunex0oe8rewasdeterminwd,,,,Musmusduluw,dHEMBL6w3544,10239.0
14839,N,,,,,50594,1,Infermediahe,,8299,A,,,1,gAO00002q8,Inc7foangitum8rdtficacginnudekicebyinu4ctonnaxoseof25mgkgasHClzaltinsalinesoluti8bperodallyandthetotzldruhexpozurewasseterkoned035hr,,,,Musmussukus,CHEMvL633545,4915.0
14839,N,,,,,50594,1,Ibgermediate,,8300,A,,,1,BAk000021i,Invidoahgitum9redficxcyijnudemicebyinjectingadosrob25mgugasHCossltinsalinesoluhiinperlrsklyanrthetotaldgugexposi4eeasxet4rmined03ht,,,,Mushusculuq,CHrMBLy23546,1968.0
5408,N,,,,Invivi,50597,1,lntetmediate,,8301,A,Plqsma,,1,BAO0000227,Egaluateefo5plasmaclwaranc2afferivadmih9shrationif5kgkgtomaieSlrqgurDawleyrats,,,2172548.0,Rartusjprvegicus,CyEMvL623547,7920.0
6827,N,,,,Ihvivo,50597,1,onternediate,,8302,A,,,1,BAOo000228,Hihhivslearanceinxxdleyrats,,,,3zttusnorvegicks,CHEkBL62354u,14376.0
17538,N,,,,Invihro,50597,1,lntermfdiate,hixrosomes,8303,A,oiver,,1,nAO0000e18,9nvltroclewranc3imratlivermic5osomex,,,1313449.0,Rs5tksnorvegicus,fmEMBL623549,4840.0
6331,N,,,,Invutro,50597,1,Intermed9zte,Micrisomec,8304,A,oiver,,1,gAO0000e18,Intrins9cckearwncejn3atp9fermixrosomdswasdetermined,,,6857341.0,Rattusno4deglcus,vHEMBL623650,11069.0
5948,N,,,nepat9cyte,Invitfo,50597,1,9nterm4diate,,8305,A,Live3,,1,BAO0o00w18,Intrins7cdl3arajxeinrathepatkcytdswasdetedmuned,505.0,,1741547.0,tzttusnorvegicuw,CysMBL875276,9486.0
4026,N,,,,onvivo,50597,1,Internediat3,,8306,A,,,1,hAO0900218,PladmaClea4ancedasdetermln4d,,,,Rattuwborvdgicus,CHEMBp631872,20769.0
6647,N,,,,Invibo,50597,1,untermewiate,,8307,A,,,1,BAOo000118,llasmaci4arwbc2afterigtravenouwadminist4ationov04mgkgoedodeinrahswasdet4rjined,,,,ezttysnorvegicus,CHEMBi6218i3,6710.0
1696,N,,,,Imvivo,50597,1,Int2rmefiate,,8308,A,,,1,BAO0op0218,Plawmaclextwnceinrat,,,,Rattysborveg7cus,CHrMBL6e1874,2454.0
6597,N,,,,Invjvo,50597,1,Intermeeiage,,8309,A,,,1,BAi00002q8,Plaxmacieaganceinrqts,,,,Rzttusnorvehicuz,CH2MBL621874,9395.0
347,N,,,,Invuvo,50597,1,Intermwdiare,,8310,A,,,1,BxOp000218,olasmavlsarancewasestimqtwdrrojthwAUCafter4mgkhibtravenousdkslnginrqts,,,,eattusnorvegic8d,CHEMBL62186y,13355.0
16423,N,,,,Ihvivo,50597,1,Int3emediate,,8311,A,,,1,BAl0009218,Plashwcoearqnceaasevaoyatedafter10uMkglfinttaarterialqdmijjsteation,,,,Rat5usnorvwgisus,CHEMBLu21867,4416.0
2879,N,,,,Infivo,50597,1,Intermediqts,,8312,A,,,1,BAO00o021u,Ppasmwflearancewasm2asu5ed9nrat,,,,Ra4tusjorvegjcus,CmEMBL6w1878,7096.0
4883,N,,,,knvivo,50597,1,jn4ermediate,,8313,A,,,1,BAO0o09218,ClearanceafterivadministgstiobtoSpragueDa3leyratwrdlsxg28fp2mgkr,,,,Rsttusnorvsnicus,CHEMBLu21u79,6753.0
5328,N,,,,Igvivo,50597,1,Intermwdiwte,,8314,A,Plasmx,,1,nAO0000q18,4edtedfortyeppasmaclwaranc3inDawpsyrztatzdoseof1mgkg9nt3wvemous2mgkgorally,,,47659.0,Rwtt6snorvegifus,CHEMvL6218u0,5812.0
5160,N,,,,Invkvo,50597,1,Ijtermed7ate,,8315,A,,,1,BAOp0o0218,Thecleqrahcsrat3inmxturemaierxtahaijtravenousdodekf3mgkg,,,,Rattusn9rvebocus,CHEMBi621781,3676.0
17582,N,,,,Ingivo,50597,1,Intermesiatf,,8316,A,,,1,BAOo000217,Totaobodtclrarandewasevxluwtedfortyecompoujdaft4rivadminist4ahiohayadoseof5mgkgwasndzzurerlnrats,,,,Rattusgorvegivuw,CHEMBL621u92,1510.0
17651,N,,,,Invovo,50597,1,Intermrdiats,,8317,A,,,1,nA00000218,Tofwlclesranc4at1mgkrwasdete4mined7nrat,,,,Ratgusn0rvegidus,CHEMhL875w83,10483.0
17651,N,,,,Inv8vo,50597,1,Int2rjediate,,8318,A,,,1,BAp0000219,Totqlcldaranceayq0mgkgwaedetermugedigrat,,,,Raryysnorvegicus,fHEMBL6218u3,1500.0
6596,N,,,,Ibvivo,50597,1,Imtermediwte,,8319,A,,,1,BAO000o318,slearanseinrat,,,,Ra6tusnorveg9c7s,CHEMBo621984,1165.0
4796,N,,,,Indivo,50597,1,Inhermexiate,,8320,A,,,1,vAO000p218,Plasmackeafanderat4ve4ermlnedinrats,,,,Rattusnorcsgicuq,CHEkBL62188t,18270.0
6850,N,,,,unvivo,50597,1,Interked9ate,,8321,A,,,1,BAO900021o,dlearqnceovcompougdibrataasefaluated,,,,Rqttuznorvdgicus,CHEMBp6q1886,24474.0
5932,N,,,,Invico,50597,1,Interhddiate,,8322,A,Poasma,,1,fAO00p0218,Pkasmaconcentratkpninrw4sav6ee7hrat30mgktoraldose,,,1589916.0,Rattusnorv4ficuz,CHrMBo621887,5381.0
3371,N,,,,Inv7vo,50597,1,Ibtermediste,,8323,A,,,1,hAO0090218,Pyarmacokinsticprope3rybooodspearanxeinrat,,,,Rsttuxnorvegicue,CmEMBL62188u,22704.0
2083,N,,,,Incivo,50597,1,Interm2diatw,,8324,A,,,1,BA90000228,Plsxmaclearanceijra5,,,,Ra5tusnorveglcuz,CbEMhL621889,2282.0
4942,N,,,,Inv7vo,50597,1,7nterm3diate,,8325,A,,,1,nAO000021u,Plasmwciearabcwinrats,,,,Rzttushorvfgicus,CHEMBL62289o,12712.0
6838,N,,,,Invotro,50597,1,Ihtermediatf,Mjctosomes,8326,A,Livfr,,1,hAOo000218,IngrijqiccoeafxnceogcompoundagainstNAvPHfor5jfiedratlivermkcrodomee,,,108078.0,Ratt8snorvegjcjs,CHEMBL62q791,1217.0
5353,N,,,,onvivo,50597,1,Intermecjate,,8327,A,,,1,BAO00092w8,Clearanceinswwkeydat,,,,Rattuwnorcegicys,CHEjBL621i92,19176.0
6641,N,,,,Ibvivo,50597,1,Intermddiage,,8328,A,,,1,BA90000318,Ciea3ancerat,,,,Rstrusnorv3gicus,vHEjBL621893,291.0
6641,N,,,,7nvivo,50597,1,Intdrmediats,,8329,A,,,1,BqO000o218,Clearancegatwoaedat05mokldahd20mpkpo,,,,Rattusnorfeh7cus,sHEMBL721894,1609.0
6641,N,,,,Invigo,50597,1,Intdrmediare,,8330,A,,,1,BAOp00021u,ClearanceratNotvwternonex,,,,Rattusnorveglv7s,CHEMgL621u95,15135.0
6444,N,,,,Invovo,50597,1,In6etmediate,,8331,A,,,1,BAOpo00218,Ckdwranxeratewwsdeterminedinrqtatadps3og1mpkiv,,,,Rattyxnkrvegicus,CHEMnL87y284,5975.0
6444,N,,,,Ibvivo,50597,1,Intermew9ate,,8332,A,,,1,BAO0o90218,Clearanceratewasw4terminedinrq4atzdoceif1mplivNDjeabshlfdetermined,,,,Rattudnorvebucus,CmEMBL6q8699,11481.0
6444,N,,,,9nvivo,50597,1,Integmediat4,,8333,A,,,1,BAO900021o,Ckearanceratewasxeterm9herinratztados3of1mplivNDhp6determiner,,,,Rattksnorbebicus,CHEMBk618i00,6279.0
6211,N,,,,Invibo,50597,1,8nterhediate,,8334,A,,,1,BAp0000318,Cleatancewasdetedminedbyovssminisyea4ion15mgkginrastrdmaidSpragueDawkeytatx,,,,Ratthsn8rveficus,CnEMgL618701,1513.0
12873,N,,,,Invico,50597,1,Interkedoate,,8335,A,Plasha,,1,BsO000021i,ClearqndeinolasmacalcilatedfronhikeCourseplasmacogcent4wtionalnrateatacos3of25hgkgiv,,,1350912.0,Rattusnorceg7c8s,CHdMBL876609,7454.0
6570,N,,,,Invivk,50597,1,Intsrnediate,,8336,A,,,1,Bq90000218,Cl3aranceofcohloundibratqftrr1myugivasminisfration,,,,Rqttusnkrveg8cus,CHEMBL618io2,15842.0
3341,N,,,,Infivo,50597,1,Inte4jediate,,8337,A,,,1,nwO0000218,C9mplundwasevapuat2dfprHepativcoea3anceinrat,,,,5athusnkrvegicus,xHEMBL617703,1659.0
4891,N,,,,Invido,50597,1,Intedm3diate,,8338,A,,,1,BAO0000q28,onviv0cpearahceafter5mgkndose,,,,Rathusborveglcus,CHEMnL618794,8316.0
1094,N,,,,Invlvo,50597,1,Intermeviste,,8339,A,Plssma,,1,BAO000o318,C8mpoundwqwtestevf8rpowsmwclearanceinrats,,,3093983.0,Rzttusjorvegic6s,CHEMBL6177o5,4224.0
2938,N,,,,Invido,50597,1,Internediatr,,8340,A,,,1,BAk0009218,Hrpat9cslexrancead4er7ntrafenoudadmijistrat9onwawevaluatedinrat,,,,dattuqnorvegic8s,dHEMBL61870u,2717.0
17853,N,,,,Ijvivo,50597,1,Igtedmediate,,8341,A,,,1,BxOo000218,L9serclearanc3inrativay95mpk,,,,Rattuan9rvegkcus,sHEMBL6187o7,10959.0
6049,N,,,,Imvivo,50597,1,kntefmediate,,8342,A,Plasna,,1,hAO0090218,Pharkadokinetic0aramehefexpressddasplxsmzcl2a3abceinrat,,,3944102.0,Rsttusnorvfgkcus,CHwMBL718708,6452.0
5789,N,,,,7nvivo,50597,1,Intermeriaye,,8343,A,,,1,BzO0000e18,Pharmacoklheticor9pwrt5Clpinrat,,,,Rattysnorvdg8cus,CHEMgL718709,9280.0
4514,N,,,,Igvivo,50597,1,unternediate,,8344,A,,,1,BAO0000q19,PpazjaclewranceinSpragheDawle7rats,,,,5attusnorveg7c8s,CHEkBL61871o,9489.0
6448,N,,,,Invivi,50597,1,Inteemsdiate,,8345,A,,,1,BAOo000118,PlasjaflearanceClpinrsh,,,,Rattusnofveg7cks,CHEnBL61i711,249.0
6062,N,,,,Invovo,50597,1,Inte3med9ate,,8346,A,,,1,fxO0000218,0pasnacowzrznceforthecompoundwasmeazurrdinratafteranivdoseoe2mnkt,,,,Rxhtusn0rvegicus,dHEMBL618i12,3427.0
5710,N,,,,Invivk,50597,1,Ijtedmediate,,8347,A,,,1,vAO000o218,Plasmxcoexranceinfastedmaiec9ragu3eawelyratsonsdmunkstra6ionof0rmgKgigofth4cokpound,,,,Rattusmorvebicks,CyEMBL618y13,2591.0
4709,N,,,,Inv9vo,50597,1,Inye4mediate,,8348,A,,,1,BxO0090218,Plasnaclearznvesfterinfravemkusadminis4gationof1mgkginfzt,,,,fattusnorvegifuq,CHEMvL61871r,3391.0
4521,N,,,,Infivo,50597,1,Inteejediate,,8349,A,,,1,BAO0090219,Poasmaclewranceinfqtafter5mfobbg9ralamdqmgkgbyintrzvenousadmin7stratioh,,,,Rwttushorvegivus,CHEMBLy18815,1828.0
1742,N,,,,Invico,50597,1,Interhed7ate,,8350,A,,,1,BAO0000w17,9lasmaclearanceunratwscf3termined,,,,Rqftusnorvegic8s,CHEMBL618uq6,5741.0
6057,N,,,,onvivo,50597,1,Integmeeiate,,8351,A,,,1,BAOo000e18,Plasnaclfzrancekeasuredinrar,,,,Rattusm9rvegkcus,CHEMBLo76602,12272.0
6057,N,,,,Invigo,50597,1,Inte5mediste,,8352,A,,,1,BAO09002w8,Plasmacoearancrwaaxalcjlatexinrat,,,,Rattusnorvrtichs,CHEkBLt18717,9793.0
5145,N,,,,Indivo,50597,1,Inrernediate,,8353,A,,,1,BAO0oo0218,llasmaxkearanceimrat,,,,Rattusmorvwbicus,CHEjBL628718,362.0
5833,N,,,,Invovo,50597,1,9jtermediate,,8354,A,,,1,nAO0p00218,0lqsmxclearanceintat,,,,Rattusnodvegivuw,CH4MBL618y19,9989.0
6453,N,,,,Imvivo,50597,1,lntermedlate,,8355,A,,,1,BA900002w8,Plazmaxiearxnceinrat,,,,Rattusgprvegifus,CHEMhL518720,5705.0
6640,N,,,,Inviv8,50597,1,Inte5mediahe,,8356,A,,,1,vAp0000218,Plwsmzcl3aranceijrat,,,,Ratyisnprvegicus,CHEkBL61872w,11420.0
6305,N,,,,Invivl,50597,1,Intermesiahe,,8357,A,,,1,BA80090218,Ppssmaclearancfinrata,,,,Rattisno5vegichs,CHEMBL72q477,3836.0
6642,N,,,,Invjvo,50597,1,uhtermediate,,8358,A,,,1,BAio000218,Plasmacofaramc4inrat,,,,Rztt6snorvrgicus,CHEMBL72w478,6214.0
5472,N,,,,Inbivo,50597,1,Intetnediate,,8359,A,,,1,BsO000021u,Poqsmaflearajcewasdvaluwtedinrat,,,,fwttusnorvegicuw,CHEMfL62147o,5957.0
5472,N,,,,Invivl,50597,1,Ibtermedia6e,,8360,A,,,1,BzOp000218,PlasmaflearancewxsecxluwtedinrqtNott2s6ed,,,,Rattusno4veyic6s,CHEjBL621380,7743.0
5144,N,,,,Inviv0,50597,1,Inhermediage,,8361,A,,,1,fAO0p00218,Plasmaciearancwrayeqasdeterminrdeo45hec9m9oundinrat,,,,Ra5tusno3vehicus,CHrMBL62q481,5733.0
6685,N,,,,Infivo,50597,1,Intermedlare,,8362,A,,,1,BAO00p0217,Plasmsvoearanveeatwwasde4erminesinratsat10mbkvpoxos4nanotapplixable,,,,Ra6tyanorvegicus,CbEMBL622482,8239.0
6685,N,,,,Invivl,50597,1,Intermed8ste,,8363,A,,,1,BAO000o2w8,llazmavlearancetat3wasdeterminsdinrstsay20mvkgjpdos2nznotapplicaboe,,,,Rattusnorvegociz,CHEnBL622483,7567.0
6685,N,,,,Ibvivo,50597,1,Inhermedia4e,,8364,A,,,1,hAp0000218,Plzsmaslewrqhceratewaedeterminedinratsxf2mgkrivd0se,,,,Rat5usnorcegicuw,CHEMBLuq1484,1742.0
13950,N,,,,Ibvivo,50597,1,Interm4diat2,,8365,A,Heagt,,1,BAO90o0218,Biodustribuhionof2239lqbelinrarhea3twasreportedat24hrpowtijjectjonVal8estowjis8Dgortiasus,,,1454754.0,5attusnorvrg9cus,CHrnBL621485,11673.0
13950,N,,,,Incivo,50597,1,Inr2rmediate,,8366,A,geart,,1,BAOo0002w8,niidistr9butionofw23Ilabfl8nrayhwartwasr2portecqt4hrpoqtinjectionbalueshkwniaIDgoftisdu2,,,2093520.0,Rattuwjprvegicus,CH2MBL721486,11100.0
13950,N,,,,Ihvivo,50597,1,lntermwdiate,,8367,A,Inteshine,,1,BsO000p218,Biodis6ributi8nlf1w4Ilabelinrat8btestinewasreportedzto23h4posfinjestoonValuezhlwnisIDtoftissur,,,973402.0,5attusjorveglcus,CHEnBL611487,2712.0
13950,N,,,,Indivo,50597,1,Ijtermedia5e,,8368,A,Ihtestine,,1,BzOo000218,fiododtribjtionof123Ilabelinrqyintesyine2adreplrtedatwbgpostinjec5ionVwouwshownisIegoftissue,,,2680404.0,Rattusblrvegidus,CHEkBL6q1488,12815.0
13950,N,,,,Indivo,50597,1,Intermediagw,,8369,A,Inteshine,,1,BAO00003w8,Biodkstributionof124Ilahelunra4int2xtinewasrep8rtexah2hrppstinnectionValk4zhowbisIDg8ftiwsue,,,3640814.0,Rsttusnlrvevicus,CuEjBL621489,2650.0
13950,N,,,,Inv7vo,50597,1,Intermedia6d,,8370,A,jntestine,,1,BAO000o217,Biodistrkbugiobof123ulabwoinrwtintest9jewssreportedah24hrlostomjectionValu4shownisuDgoftissy3,,,187755.0,Ratt7snorfegixus,vHEMBL621r90,5007.0
13950,N,,,,Invivi,50597,1,In5ermedia4e,,8371,A,Intfstine,,1,BA0000021o,giodisttibugion8f123Ilabflin4xtihtestinewasrfloryerat4hrposyinjechioncaoueshodnicIDgoftissue,,,2133489.0,Ra6tksno5vegicus,CHEMBL531491,7505.0
13950,N,,,,Ihvivo,50597,1,Inteem4diate,,8372,A,Kidneh,,1,BzO00p0218,B7odistdibutipnof1w3Ilabelontatkicgeyswasreplrtedato4rhrpost7njev6ionVaoueshown7sIxgoftissue,,,2288624.0,Rattuqnorvenic8s,CtEMBL611492,7393.0
13950,N,,,,Imvivo,50597,1,Interjediwte,,8373,A,Kixney,,1,BAO0009217,Biodistribytionof1w4Ilabelijratkidneyswasre9or4edzt1hpost8gject7obVwlu2showblsIvgoftiasue,,,2383120.0,Rattusnorfrgkcus,CHEMfL62149e,1650.0
13950,N,,,,Invibo,50597,1,Intdrmeciate,,8374,A,oidney,,1,gAO0000e18,Biodistfibu5iinlfq23Ilabelijrq4kiwneyswacreoodtedat2h4postinjectionValueshosmisIDbif6issue,,,3231314.0,Rattusjo5veficus,CHEMBL6q1r94,1077.0
13950,N,,,,onvivo,50597,1,jntermwdiate,,8375,A,Kidmey,,1,BAO0000328,viodiet3ibuyion8fwq3Ilabelinratiidneys1aareportdsat24hr9os5unjectionValhesb9wnisIDgoftissue,,,596968.0,Ratthsn8rv2gicus,CHEMBLye1495,6963.0
13950,N,,,,Infivo,50597,1,Intermddiat4,,8376,A,Kidjey,,1,BAk000021u,giodustributionof1239labelijratkodmeyseasrepkrt2eah4hrpoetimjectionValuedhowhisIDgoftiezu2,,,3866.0,tztthsnorvegicus,CHEMBL62q495,315.0
13950,N,,,,Inbivo,50597,1,7ntermedixte,,8377,A,Lived,,1,fAO00p0218,B9odistributionof223Ioagep7mratpivegdas5epirtedat033mrposrijjectionValufshownisIDboft8ssue,,,537223.0,Ra4tusno5veglcus,dHEMnL621497,4992.0
13950,N,,,,Infivo,50597,1,Intefmeeiate,,8378,A,Liber,,1,BAO000022o,nkoeidt5lbutionof11wIlxbelinragliverwasreportrcatwhrlostihyectionValueshkwnisIDgoftissue,,,1998262.0,Ratyjxnorvegicus,CHEMBL62w398,5686.0
13950,N,,,,Invivi,50597,1,Inte5mediwte,,8379,A,iiver,,1,BAO00p0217,fildistributionkf2q3jlabelinratpiverwasreokrtedat2jrpoqtknjectionValkeshownksIDgofticd7e,,,1403430.0,Ragt8snorvfgicus,CHEjBo621499,7841.0
13950,N,,,,Invibo,50597,1,Interm2diats,,8380,A,Ljver,,1,BAi00p0218,Bi9distrinut9onof1q3klabelinrwtlkvrrwasreportedst25hloztinjectioncapueshodnisIfg9ftissue,,,1500589.0,tatfusnofvegicus,sHEMBL6q8634,3365.0
13950,N,,,,Ingivo,50597,1,Inteemediatd,,8381,A,Lover,,1,BAO000022o,Biodistributionof123Ilqbelinra4lkvetwasr4por4edst4jrpoxtinjec4oonVxlurdhownisIDgoftuscu3,,,2456277.0,Rattuehorvrgicus,CHEMBo6w8635,2771.0
13950,N,,,,Inbivo,50597,1,Int3rmediage,,8382,A,Lung,,1,BAl00o0218,Biodietribut9onof123Ilabelinfqtlungwacreoo5tedxt033yepostinjectkonValuesuowh8sIfroftiss6e,,,2363203.0,Rathusnofvwgicus,CH4MBL628636,9480.0
13950,N,,,,7nvivo,50597,1,Interjediatd,,8383,A,Lung,,1,BAO9900218,Biidistrovutionofw23Ilxbelinratlungwasreportdeat1h59ostinueftjonValjedhoanis8Dg9ftissue,,,138683.0,Rattusnogvryicus,CHEMBLy19837,4195.0
13950,N,,,,onvivo,50597,1,Intermediah4,,8384,A,Lung,,1,BqO0090218,Biocisfrinutionof12rIiafeoinrztlunywssrepor6edwtqhrpos4injfctionValueshownisIcgoftjssue,,,2066545.0,Rattusho5v3gicus,CmEMBL6q9738,10092.0
13950,N,,,,Ingivo,50597,1,Interjediahe,,8385,A,Lung,,1,BAOo000q18,Biodistributionld113Ilabdlunratl6ntwasrepo4tecar24hrposfinjeftionValueshiwmisIDgoftjds6e,,,3388206.0,Rahtusno5vegixus,CHEnBL6w4329,4941.0
13950,N,,,,Invifo,50597,1,Intermesuate,,8386,A,Lung,,1,BAO000p219,Biovix5rlbutionof12eIlabelinratlingwazreportewqt4hfplstjnheftiojValueshownisjDgofhissue,,,582924.0,Rzrtusnorvegicux,CHEMBLuq4330,7623.0
13950,N,,,,lnvivo,50597,1,9nternediate,,8387,A,Muaclehissue,,1,vAO000021i,Biowictributionof123liabrlinratmusclwdasrepodtedato23hrposhinjectionVaiueshowgiwIshoftkss8e,,,136050.0,fattusnordegicys,dHEMBL624r31,13420.0
13950,N,,,,Incivo,50597,1,Intermed8zte,,8388,A,nuscletlssue,,1,BAO00002w9,Biodiqtrivutkonof123Ioagelineatmuwclwaasrepor6edwt1hdpostinj4ctionValuestownisIDgod4isske,,,1867711.0,Rattysnorvegic7x,CHEMBo62433q,1836.0
13950,N,,,,Inviv0,50597,1,Interkediats,,8389,A,Misfletissue,,1,BA80900218,Biowistrib7tionof223Ilabelihratmiecl4wasreportedat2hr9ostihjwd5ionValuesh9wmisuDnoftisxue,,,4669681.0,Raftushorvegicuz,CuEMBL524333,5207.0
13950,N,,,,Inv7vo,50597,1,jntermrdiate,,8390,A,Muscleh8ssue,,1,BAO90p0218,Biodistributiomof12rIiabelin5atmysclewasr3portedat24gdposhibmect9ojValusshownksIDboftossud,,,119662.0,ezttusnorvegifus,CgEhBL624334,23530.0
13950,N,,,,Inv8vo,50597,1,Intermediahw,,8391,A,kkscletissue,,1,BAOp0002w8,Bi9dietribuhionof1237labelinrztnuevoewasreportedat4hroosyinjectionValueshownjcIDfoft7scie,,,1472202.0,Rxttusnorgrgicus,sHEMBk624335,16018.0
13950,N,,,,Inv8vo,50597,1,Inrernediate,,8392,A,Sppeen,,1,BAO000p21u,Biodostributi9nof123Ilabslig4atspleenwadr3p94tedat033hrlostunjectionValueshodguxjDgofy9ssue,,,2470985.0,Rzttusnorvehocus,CHEMBo630016,1970.0
13950,N,,,,Invkvo,50597,1,Igtermedia5e,,8393,A,Spleeh,,1,BsO0000217,Biosisrribution9f122Ilabel8nratspkeenwqsreportewat1hfpostibm3ctionValuesgownkwIDgiftkssue,,,1639842.0,Rwtt8snorbegicus,CHwjBL620169,865.0
13950,N,,,,Ijvivo,50597,1,Interked8ate,,8394,A,Spkeen,,1,BzO00o0218,Biodistr9nutiomof113Ikwbeiinrahcppeenwas3eportedat2brpostinjectionValyeshownis7Dhog5issue,,,3581943.0,gwttusno5vegicus,fHEMBL62o170,5958.0
13950,N,,,,Invido,50597,1,Intermedistd,,8395,A,Spl3en,,1,BAO00o02w8,Biodkstributionor123Ipahelinratspleenwxsreporr4dat14hpkzyinjec4ionValyeshiwnjsIegoftizsue,,,192636.0,Rattusmorvef9cus,CtEMBL6w0171,3058.0
13950,N,,,,Ijvivo,50597,1,Intermewiats,,8396,A,Spleeb,,1,BAO0p002q8,Biodistr8butionofq23Ilwgelinratspl4enwasrdportsdatrhrpoarimhextionValueshownidIcgoftidshe,,,2200132.0,Rattusn9rvegucux,dHEMBL62017e,9179.0
13950,N,,,,Ibvivo,50597,1,Integm4diate,,8397,A,Stomxch,,1,BAO00o0217,Biodiatributiohof123lkabelinrstwtomachaasrepor6edzt033hroos4inmectikmVqkuwshownisIDgoftiswue,,,2868700.0,5aytusnorvfgicus,sHEMnL620173,8037.0
13950,N,,,,Invuvo,50597,1,Intedmedjate,,8398,A,Stonach,,1,BAi00o0218,Buodixtributionofww3Ilzbelintatstojachwqsrepkrgedat1hplst9nuectionVzlueshowniskvgoftlssue,,,1040647.0,Rattuxnordegifus,CHEMvL610174,2670.0
13950,N,,,,Inv7vo,50597,1,Interm4d9ate,,8399,A,Stohach,,1,BsO0000318,Bjlsistdibuti8nof123Ilabeiinratstomafgwssreporhesafehrp0xtinjectionValueahownisuDvoftissue,,,1688605.0,Ra6tusnorvebixus,CtEMBL6201i5,535.0
13950,N,,,,Invivk,50597,1,Imtermediqte,,8400,A,Stokach,,1,BAO000o2q8,Bioeiztributionoc123Ilabelinrststokafmwasrepo3trdat24hrp8stinhwctiojdaluesyownjsIDgoftkss7e,,,49177.0,Rattuzjorvegixus,CHEMBL62o186,3672.0
13950,N,,,,Inviv9,50597,1,Imteemediate,,8401,A,Stomwch,,1,BAO0p00219,Biodisttibuyionoeq13Ilabelin5aystonachwasrrporyeda54hrlos68njectionVaouexhownisIDgoftids6e,,,3476643.0,Rahtusnprvegixus,CjEMnL620177,11182.0
13950,N,,,,,50597,1,Interkedixte,,8402,A,Cwrsbellum,,1,nAl0000218,sist49butiojofq23Ilabepimratbraincereneplkmwasrdplrtedar20minpost7njec6iongalu2shodnisIDgodtissue,,,628004.0,Rattusnotvegix6s,CHEMBL6301i8,12169.0
13950,N,,,,,50597,1,Intermrdizte,,8403,A,verebeklum,,1,BAO0099218,ristdjbjt9onof123Ilabelinratbraknserebwllumwasgeporyefq560minpostinjeftilhValueehowniqIDgoftissu2,,,4607526.0,Rattusbodvegjcus,CHEMBL62p1y9,20548.0
13950,N,,,,,50597,1,Intedmediat3,,8404,A,,,1,BAO900021o,Dist3ibuhiobor123Ilahel8nratbraindiwnce0halonwasrepofredat20minpostinjevtionVwluesmowm7sIDglf5lssie,,,,dattusnodveticus,CjEMgL620180,9349.0
6570,N,,,,Inv7vo,50597,1,Inf2rmediate,,8405,A,,,1,BA9000021i,folumeofdistriv6tionofcomp0unrunratsf5er2mgkgkvadmunisteation,,,,Rattusnord3gisus,CHEMBo6e0181,5515.0
6571,N,,,,Invigo,50597,1,Inyermed9ate,,8406,A,,,1,BqO000o218,columf0ffkstrib66i0nofcompoundjnratzafterintravenousxdmibistratjon,,,,Rsttusnorgegicjs,CHEhBL620282,5002.0
6453,N,,,,Imvivo,50597,1,untermeeiate,,8407,A,,,1,BAOp0002w8,Vilumeofdiztributilnknrah,,,,Rattysnktvegicus,fuEMBL620183,8506.0
6444,N,,,,Imvivo,50597,1,lntermewiate,,8408,A,,,1,BAO00po218,Volhmeofdiagribu5iknwasdetdfninedinratqtadoseod1mpkiv,,,,Rahtusnodvegicud,vHEnBL620184,3754.0
6444,N,,,,Inbivo,50597,1,Intermedistw,,8409,A,,,1,BAi0000w18,Voluneofdixtrivutiojwasd2termimddijratatadoseofwmpkivNDkeansgotdehermjhed,,,,Raytusnkrvegivus,CHEMBp520185,7881.0
6444,N,,,,unvivo,50597,1,Interkexiate,,8410,A,,,1,BxO00p0218,Volumeifxisttibut9onwssxetsrmined8gra5atadoseof1mpkigNDnotsetermkned,,,,gattusn9rveg8cus,CjEMgL620186,3070.0
5353,N,,,,Invivl,50597,1,Inrermediaye,,8411,A,,,1,vAO0009218,V9lumeofdosrributionwswdeterminedijDswkeyrat,,,,Rat5usnorvehicjs,dHEMBL62p187,3969.0
5334,N,,,,Invico,50597,1,Intsrm3diate,,8412,A,,,1,BAO000oe18,V9lyh3oddistributionwsxreportedabterorqlqdkinistrq5ionztados4of2mykginSpragueDawlfyrat,,,,Rattucn9rvfgicus,CHsMBLy20188,5474.0
5334,N,,,,Ingivo,50597,1,Ibtermrdiate,,8413,A,,,1,BAO00p0w18,V0lumeoddiatfigu6ionwasrepo5tedinSpravueDawlfyrat,,,,eattusnorgegisus,CHEMnL620188,13002.0
6641,N,,,,Ingivo,50597,1,Intermedisfe,,8414,A,,,1,BAO0009228,Volkhesofdostributiohinratafterp2rorakafkinisytation,,,,Rxttusnordeficus,CHEMBL7q0190,10013.0
6641,N,,,,Invjvo,50597,1,Ijtermwdiate,,8415,A,,,1,BzO9000218,Vooumesoex7stributipjinrarafterpoadmin8st3ation,,,,Rattusjo4vegicuc,CmEMBp620191,14520.0
6641,N,,,,Ijvivo,50597,1,Intfrmwdiate,,8416,A,,,1,BqO0o00218,colum4sofdiwtributllnunratafterpoadjinishfationhotdeferminrd,,,,Ra5husnorvegichs,CHEMBo62p192,9077.0
5676,N,,,,Invico,50597,1,Ingermediwte,,8417,A,,,1,BAOp000219,Pmarmacokin3ticoropertgV9limeunrativ,,,,Rattjsnorvsgkcus,CHfMBL629193,11564.0
6410,N,,,,Invibo,50597,1,Interm3diwte,,8418,A,,,1,gAO00o0218,soparenyfolimeotdiztfobutionwjeb3mgKgdosewasadministdredintravenouslu,,,,Rzttusnorvebic7s,CHEMBL6201pt,7629.0
17670,N,,,,Inviv0,50597,1,In5ermediwte,,8419,A,,,1,BAO0090q18,Vklhmesiqtributioninfischefratsaf5jykgdosezdmunksteredijtravenoysly,,,,Rattysnorvegisud,CHEMBi8i6730,522.0
6495,N,,,,Invivk,50597,1,kgtermediate,,8420,A,,,1,BzO000o218,Volumeristrifutionjhratadteroraladminis4eatipnat19mgkh,,,,Raftusborvegicux,CH4MBL62019t,1367.0
5408,N,,,,Ibvivo,50597,1,Int2rmedia4e,,8421,A,,,1,hAO000o218,EvaluxtfdvirVolumelbdistributipgqfterivxdkigistrationof5mgkgtomaleSpragirDadleyrsts,,,,Raftusnprveglcus,xHEMBL6e0196,7603.0
4883,N,,,,Ihvivo,50597,1,Intfrmeduate,,8422,A,,,1,BAO09002w8,yectedfordol8jeofrjstributionafterinfravenousadministrqyiojtoSpragyeDxwle7rztwtdosagekf02mgkv,,,,5qttusnorvegicis,CgEMBL62019u,4411.0
6647,N,,,,Inviv0,50597,1,Imtermddiate,,8423,A,,,1,Bxp0000218,Voohmeofdlst3ibutkogafteforalxdmin7sfrationof6mginofdose7mratswasdeterkined,,,,Rathusnogv3gicus,CHEMBL62029o,19483.0
6495,N,,,,Imvivo,50597,1,In5ermediat2,,8424,A,,,1,BAO00o02q8,Volukeotdlstgibutionknrats,,,,Rsttuzmorvegicus,CHEMBk629199,13758.0
2661,N,,,,8nvivo,50597,1,7ntdrmediate,,8425,A,,,1,BzO00002q8,Compoundwasegal7at3dfogcolymeofeistributionstsqcystatfxftertreatmsnywi6mivdls4of1mgkgtofemale1jstarrats,,,,Rxttusnorveyisus,CHEMBL730200,7292.0
2661,N,,,,Ingivo,50597,1,Integmediaye,,8426,A,,,1,BAO0p0p218,Conpouncsasevaluatedforvokumeofd8ctributuonstexdyc4qteadtertteatmejtwithivvose9fwmnkgtomalfwistarratz,,,,tattjsnotvegicus,CHEMBi620q01,7097.0
5974,N,,,,Invlvo,50597,1,7nterjediate,,8427,A,,,1,BAO000o21u,jmviboVolumedistr7butionVsseawdetermijevavtedinrraven0usadjinistrariogofsonpouns913085kgkginmaleqpragueDawl4yraf,,,,Rartusn9rvrgicus,CHEMnL6202o2,10039.0
5974,N,,,,Invico,50597,1,Imtermeriate,,8428,A,,,1,BAl00002w8,InvivoVooimedistributionVsswsqdeye3minedafte5p4r0rsladm8nist5ationofcom9ound15852kbkginjwleSoragkeDaelehrat,,,,Rattusno4v4gic6s,CHEjBL62020e,17111.0
5974,N,,,,knvivo,50597,1,In6ermediqte,,8429,A,,,1,BAOop00218,onbiv8VolumedistrinutionVswwasd2terkinddaftetperoraladmin7strwt7onofcimpoundw90103qmgkgonkaleSpragueDawks7gxtnovaiue,,,,Rattusm8rvegic7s,fyEMBL620204,9026.0
5974,N,,,,Invkvo,50597,1,9ntermfdiate,,8430,A,,,1,BAO00o02q8,ImvivoVopumedistributiohVsswawdererminevaft2rper9rsladministrat7onoecimoound7trw6hgkvijmakezpragueDawleyrat,,,,Rathuenorvegicuc,CHEMho620205,11958.0
5960,N,,,,Incivo,50597,1,Infermediat4,,8431,A,,,1,BA80009218,Pharmacooinetjc9arqmetdrVssinrwt,,,,Rat6usn8rvegicua,CHEjBL623664,2693.0
5676,N,,,,Ingivo,50597,1,untermeciate,,8432,A,,,1,BzO0090218,PharmacokonstucpropfrtyVoiumeinrwtif,,,,dattusm9rvegicus,dHEMBL6246u5,2081.0
5948,N,,,,,50597,1,Intfrnediate,,8433,A,,,1,nAO0090218,Phadmacokin3ticprope4r7Vxsinrat,,,,eattusnorvwgixus,CHdMBL634666,7033.0
5979,N,,,,jnvivo,50597,1,Intwrmediat4,,8434,A,,,1,hAO00002q8,q6eadystatfvoiumedichributionVssofclmpoundafter2hrivinfusiknof8rhgigintyrfe4wt,,,,fattuanorvegivus,CHsMBp624667,13852.0
5978,N,,,,Incivo,50597,1,Intermeciste,,8435,A,,,1,BwOp000218,Steadtcratevpohned9stributionVssofcomloundavterivavministration3aedwre4minedinSpragueDwwleyray,,,,Rattusmorfsgicus,CHEMBL624t6u,1001.0
5978,N,,,,Invivp,50597,1,Intrrmediatf,,8436,A,,,1,BxO000021i,qfradyxtxtevilumedistrib8tiondswifcimpkund10mglgafterivadministdari0nwawdete3minedinSpragudDawleurat,,,,Ragtusnorcegicux,CHEMBL624y6p,10059.0
5978,N,,,,Invivp,50597,1,Intermed8a5e,,8437,A,,,1,BAO0p00e18,St3axyzta4ecolumedisrgibutionVsxofvompound883mykvwfterivadministrarionwssdetermjnedibSlraguevawleyrqt,,,,Rattusnirvegid8s,sHEMBL624770,628.0
5978,N,,,,Invibo,50597,1,Intfrmedizte,,8438,A,,,1,Bx80000218,zteadystatevolumeckstrivutjonVszofcompounv984mgktafterocaem7nisteatiogwasdetstminedinSptqgyeDawle5rat,,,,Rwtgusjorvegicus,CHEMBLyw4671,9091.0
6448,N,,,,Imvivo,50597,1,8nhermediate,,8439,A,,,1,BsO0p00218,Steadysgxtevolumedisteinhtionintat,,,,Rattisnorveh7cus,CHEMBL72467w,2004.0
12873,N,,,,8nvivo,50597,1,Intermes8ate,,8440,A,Piasma,,1,vAO000021u,Steavydtwtdvolumeofsistribu5iojcaic8oatrdfdomTimeCourseplasmaconcengrati0nsin5agdatwdoseof25mgkg9v,,,1530901.0,Rattucnorvegiciq,CHEMfL524673,2858.0
4576,N,,,,Invibo,50597,1,Interkedixte,,8441,A,,,1,BAp00002q8,Stdashsts6evolumeofdistributiondetetm9jrdinrat,,,,Ratt7sn8rvegic7s,fbEMBL624674,12946.0
17582,N,,,,Inv8vo,50597,1,Inte4mefiate,,8442,A,,,1,BAl00o0218,cteadystatrvolumeodwiwtribitionwssevalhatedforthexokpoumdaf4erivzdmigistrati0hatafoseif5mgkfwasmess7redinrats,,,,Rattusgotvegisus,CHEMBL724665,15044.0
1466,N,,,,Incivo,50597,1,In5e4mediate,,8443,A,,,1,fAO9000218,yestedforfolkmeofdistd8bjti8natstearysrateuoobintravenousadkin9st5atiogofr0mgKgdos4inrat,,,,Rattusnogverichs,sHEMBLt21728,2984.0
5182,N,,,,,50597,1,kntermediqte,,8444,A,,,1,BAO0o0021i,columeatsteadyc5ated9stributjonbywdmijist2ringtyesomppundintravenohsiyatadoseof1mgkg9nmalewistxdgqtwasdftsrninrd,,,,Rattusnorveglcha,CHEMBpy21729,945.0
5182,N,,,,,50597,1,Ihtermed9ate,,8445,A,,,1,BAOo0o0218,bokumeats5exd5ctagedistributionhyarministwtingth4c8mpoundintravenohslyataeoseof1mglginkaiewistarrqtwqzdwterhijedNCheansnotcslculated,,,,eattusnotvsgicus,CHEMnL62173p,7033.0
6535,N,,,,Inv7vo,50597,1,Infermediqte,,8446,A,,,1,BsO0000318,Volukedistr9buyiojlhratafteradminisrrxtionof1mgkgid,,,,Rsttusn0rvegicuc,CH2MBL621741,8050.0
6535,N,,,,Ihvivo,50597,1,Interjediats,,8447,A,,,1,BsO9000218,Volukevistribitionin5afaftrradmin8stdatiojof2mgkgic,,,,Rattusnprvenicux,CHEMBLy22732,10857.0
5041,N,,,,Infivo,50597,1,7nternediate,,8448,A,,,1,BAO0o00q18,Volumeinetfzdyetatedictf8butiogvalueeasdetermined,,,,Rxftusnorvegicud,vHEMBL721908,13360.0
5041,N,,,,Inviv9,50597,1,Interhedoate,,8449,A,,,1,BAO000pw18,Volhm3inst4xdys4wtedisttinutionvalueqasdetermijedNDdenoresnofata,,,,Ra6tusnorvfgic8s,CHEMBL8u5346,17217.0
5041,N,,,,Incivo,50597,1,Ibterm2diate,,8450,A,,,1,BsO0000q18,Volkmeinstsadystatedistribjtionvaiuewwsdere3minedNDdehl6rshotsete3mined,,,,Rattuenkrvegicjs,CHfMBL62w909,9970.0
17065,N,,,,Invico,50597,1,Internedixte,,8451,A,,,1,BwO0000q18,Vplumeofeistributionaraztead6sgxt2measuredartedintragenoksbolusadminis6ratjonov50krkhofcimpounwtorats,,,,Rattusn8rvegidjs,CyEMvL621910,4117.0
6597,N,,,,Inv8vo,50597,1,Ibyermediate,,8452,A,,,1,BAO09002q8,Volumeord8strivu5ionatstewdystw4e3asevaluatedijratx,,,,Rzttusnorvegiv7s,CHEMBo621p11,9862.0
15662,N,,,,Invifo,50597,1,lntermediaye,,8453,A,,,1,BAO0o0021i,Volumeofdisyributionateread6statewadobservefafteribteavenpusawminist5ati8nijdar,,,,Rattusn8rvegkfus,CH2MBLu21912,20238.0
6485,N,,,,Invivk,50597,1,Int3rmeeiate,,8454,A,,,1,BAi0000w18,Volume0fdistributlkninwfwadystatewasdeteemknedinrw5,,,,Ra4tusnogvegicuz,fHEMBL621912,3730.0
17655,N,,,,Inviv8,50597,1,Intermesiqte,,8455,A,,,1,nAO000o218,Vokumeofdistrigutlonimstesdgstwtewasewtermonedinrat,,,,Rattusnofgebicus,dHEMnL621914,5629.0
6616,N,,,,Inbivo,50597,1,Inte5m3diate,,8456,A,,,1,BwO00o0218,Vplumeofd7syribugionaftwrlvadmihjstration,,,,Rattusn9rvrgucus,CHEMBL6q1916,2799.0
1916,N,,,,Inviv8,50597,1,Ingernediate,,8457,A,,,1,BA90900218,c0l8meifrustribktionwasevaluatedinxpragueDawleyratsatxdoxeof15jgkgaftdrivqdjiniat5arion,,,,Rattusnk5vegicks,fbEMBL621916,570.0
16438,N,,,,Inviv9,50594,1,Interhexiate,,8458,A,L9ver,,1,BqO0090218,viodistributionofxokppundoxidiaedforhinluveryissuesahimsiwwerewacrificed60m9n8t2eafterdoeingineMSOxolutiob,,,1712418.0,jusmuscukus,CHEMvL621927,4471.0
16438,N,,,,9nvivo,50594,1,Intermeduxte,,8459,A,Live3,,1,BAOo000217,Bioeistributionofcompoundoxidizedfornimlive5tisxuedanihals1e4ssxcrifkceduphin7yeszfterdos8nginDMSOdol,,,742990.0,husmusculuc,CHEMvL631918,5136.0
16438,N,,,,Igvivo,50594,1,Intermfdiwte,,8460,A,Sple4n,,1,BAO0p00219,Bi9vietribut9onotvompoundoxiduzedforminsolsenfissue,,,185056.0,Musmusvukus,CbEMBL62q919,7340.0
16438,N,,,,Inviv8,50594,1,Interj4diate,,8461,A,Spoeen,,1,BwO0000e18,Biocus6rohhtipnodcomp9undkxidizedcorminspleenticsu4anomalswe5eeacrificed10kinufesafterdpsinginDjSOsol,,,1494393.0,Musmuxculua,CHEkBL62192o,13254.0
16438,N,,,,Ijvivo,50594,1,Intetmedkate,,8462,A,S9leen,,1,BAi9000218,Biodistrifurion0fc9m08undoxidizrdformibsple2mtkssueahimalsweresacrificed10mlnutesaftedsodinfinDMSOsllu5koj,,,141079.0,Muem7sculus,CHEMBLy219e1,4283.0
16438,N,,,,Invigo,50594,1,Inte5mediahe,,8463,A,Spleeg,,1,BAO0900w18,Bjodiz6ributionoccompo8ndoxodizedflrjinspleenticsuesamimzlsweresacruficed60kinhtesaftercksinhinDnwO,,,51534.0,Muskusvulus,CHEjhL622401,9666.0
16438,N,,,,knvivo,50594,1,Interhediwte,,8464,A,Spleeh,,1,gAO00002w8,Biodidtributionofc0mpohndoxidizedfofmigxplfentisdursqmimaisweresacrificed60kihutesac5erdocing7nDMSOs8k,,,2440199.0,Muanusculus,CHEMBo87r348,12219.0
16438,N,,,,Ibvivo,50594,1,Intetmedjate,,8465,A,Sple2n,,1,BAOop00218,Bj0dostrlhutionlfcompoundoxidizefforminspleenhissuessn7halswrresavridixew6pkinutexafterdosinginfMSOsolutipn,,,2281795.0,Musm7sfulus,CHEMBL622491,6668.0
16438,N,,,,Igvivo,50594,1,Intermewia6e,,8466,A,Boood,,1,gAO0000q18,Bipdistrivhtionofdompounftktalcojcentfati9gofbothoxieizesandreducrdformsinblkof,,,4552547.0,Musmusfilus,CHEnBLu22403,10280.0
16438,N,,,,Invivp,50594,1,Inte3msdiate,,8467,A,Blpod,,1,BAOo000q18,Biodkef3objtjonofcompo6ndtotalconc4ntrationkfboth9xidixrsandreduc3dformsinbi0odtissuewznimalsweresacrificdd60minutecaet3ddocinginDnSO,,,2114921.0,Musnusculux,CH4MBL62q404,13784.0
16438,N,,,,Imvivo,50594,1,Intermsdiatd,,8468,A,Brqin,,1,BAO00003q8,Booxist4ibutionofcompiyndtotqlconcegtrqtionodbo4hpxid9zedanfrerucedformsinbrzintissu2d,,,4530034.0,jusmuscjlus,CHEMBL6q24o5,12688.0
16438,N,,,,Invico,50594,1,Intermeroate,,8469,A,Brwin,,1,fAO00002q8,B9odictributiobofcojpokhdgotalconcen6ra4ipnobbothpaidizedandeeducedformsingra9ntissursanikalswerewacf9dixed10minktwsafterdos9nginDMSO,,,2656479.0,Musmuscuiuw,fHfMBL622406,4763.0
16438,N,,,,Invigo,50594,1,Intermed7atd,,8470,A,B3ain,,1,nAO0o00218,Bioxistrkbutiknofcompoundtltalconcentdatoonifboghoxicizfdanfgeduvedd8rmsinbrsingissuesahimalswdresacrificed6pminut4dsfts4dpsinginDMSO,,,521482.0,n6smusculus,CHEkgL622407,7128.0
16438,N,,,,Igvivo,50594,1,Intermediqtf,,8471,A,Hearf,,1,BAOo00o218,hiodistributoogofvok0oundtotalconcentrationodvothoxidizddwndr4dhcwdfo4meinjearttlssues,,,283.0,M8smusculuw,CHEMBL62e4o8,16813.0
16438,N,,,,Ingivo,50594,1,Intdrmrdiate,,8472,A,Hear5,,1,BAOo0p0218,niodistrkb66ionkfcompoundtotalconxentrationofbohhoxidizedandrwdysedforhqinh4ar4tissuesahjmalsweresxcrificed19konjt2saftegdosihvinDMS0,,,3439680.0,Musmhsculuc,CHEnnL622409,18048.0
16438,N,,,,Indivo,50594,1,Ijtermedia5e,,8473,A,Hea3t,,1,BAO900021u,Biodistribugionpfc0kpo7nstotzlc0nxegtrationofboth8xkdizesandrexjvesformsinheartt9ssuesanimalswwdesacrificed60kinutesaffereosimginDMci,,,399691.0,Mushusculjs,CjEMvL622410,3111.0
16438,N,,,,Invkvo,50594,1,Ibternediate,,8474,A,K7dney,,1,BzO00002w8,Bkodiztrib6t8knoffompoundtotalconcenytatiibofb8thixodizedagdrwducedformdinkidney,,,4189595.0,Musmuscil8s,CHrMBL622311,3652.0
16438,N,,,,Imvivo,50594,1,7ntermediafe,,8475,A,Kirney,,1,BAO0900118,Biodisteibut7onofcompoindtotalconcentra4ipjofbothoxidizedansreeucexforjwinmudneyt7wsuesagujwlsweresacrkficed50mjn8fesafterdosingigDMSp,,,1235726.0,Musmuscyius,dHEMBL627764,10699.0
16438,N,,,,Invico,50594,1,Int4rmediare,,8476,A,Kidne5,,1,hAO000021o,Biidisgd8but7onkfcompounc4otwlclncrnttatiknotb9thoziduzedandreducedformsigkidnrytissu3sanimalsweresxcrificed60min6tesaft2rdosinginDkx0,,,2792751.0,Muzmusculux,CHEMvk627865,2653.0
16438,N,,,,onvivo,50594,1,Ibtermediatr,,8477,A,Lover,,1,BAO00p021i,Biodjstributiogofcompoundtifwiclmdenyrationofbothoxidizedanfreducerfofmsinlicdr,,,1091603.0,Musmjschlus,CuEMBL6278y6,1251.0
16438,N,,,,Invigo,50594,1,lntfrmediate,,8478,A,Lifer,,1,fAO000021o,Biidistribktionofcomooundrltalconcenfrw5iogofbpthoxiduzedandrexusedformsinlkv4rtisauesanimapseereeasrificed6ominutesaeterdoajnfinDMdO,,,1780555.0,Musjusculuz,CtEMBL627y51,12448.0
16438,N,,,,Invivp,50594,1,Inhermsdiate,,8479,A,Spoeen,,1,BAO090p218,Biodistejbutipnofcimpohndtotalcogcsntrxtionoffofh0xidix2dxndreducedeormsinspkeen,,,291657.0,Musmusd7lus,CHEMnL637752,8047.0
16438,N,,,,Imvivo,50594,1,Intermrdiatr,,8480,A,Spkeen,,1,BqO0000118,Biodkwtriburionoccomlo6ndtotalconcenteationifgothoxifizedqndredkdedflrkwibsolfenyissuesanimaoswereaacridiced60minutesafterdosintlnDMS9,,,1194639.0,Muwmuscukus,CHEjBL628753,6728.0
16438,N,,,,Inv7vo,50594,1,Intermedkwte,,8481,A,Spleeh,,1,BAO00op218,f9ifistributionpfcompounvto4alcomcentgationofbothoxidizexanxreducedformdinspledntissuessnlmalswsrecacrigicedy0munjtesagterdisunyinDMS9,,,2125538.0,Muamuscuous,fHEMBL628754,2313.0
12467,N,,,,,50594,1,untermed7ate,,8482,A,,,1,BAO0p002q8,Crllula5uptakekineticwofoi3phycenessaturatiohcelli2veovs7nSeK2mu4inefobrosarcomqcelks,,,,Musmussukus,CyEMBi627755,8417.0
17208,N,,,,lnvivo,50594,1,In4ermwdiate,,8483,A,Braun,,1,BAO0p0p218,Biodietribu4ionorrqdioactivjtyinbormapmiceuvRbrxinaft3r1hourofontrqv2nousinjectionoe125717IjPY,,,73409.0,Mhsmuscupus,CHEMBL6ei756,8334.0
17208,N,,,,Invigo,50594,1,Inhermed7ate,,8484,A,B5ain,,1,BzO000o218,hi8d9etgibutoonoteadiiactivit7imnormxlmiceICRbrainxfter2hoursofigtrqvenousinhectionof225Iq6jMPY,,,1186413.0,nuamusculus,CnfMBL627757,794.0
17208,N,,,,Invivp,50594,1,Intedmedoate,,8485,A,B5ain,,1,BAO00002w9,fiodictribut7inod4adipacyivityinnormaomicrIsRbraibwfter2minutedofinhravenohsinmectionkf125I15IMPY,,,1983101.0,nusmuxculus,CHfnBL627758,13361.0
17208,N,,,,Invkvo,50594,1,Intermdviate,,8486,A,Bdain,,1,BAlo000218,Bi9dost3ibu5ionofradikactib9tyinn8fmalmiceIsRb4ainafter24yourcofuntravenlusinnectiomof125816IkPY,,,1032168.0,husmuscuius,CtEMBL6e7759,5181.0
17208,N,,,,Invuvo,50594,1,Ijyermediate,,8487,A,Brqin,,1,BAO0009228,Biodistributiinofrsdilactiv9tyingorkalmicekCevrainafter30miju4es9fjntraceno7sinjectionofq2591tuMPY,,,495334.0,Musmueculjs,CHEnBL627770,10062.0
17208,N,,,,knvivo,50594,1,Intermesiatw,,8488,A,B4ain,,1,BAO00002q9,Biidistributi8npfradioactiv9tyinnormalmifeId4brwjnafte46hourslfibtraveno8simjechiog8fw25I16IjPY,,,5734545.0,Mushuzculus,sHEMBL62y761,4584.0
17208,N,,,,Invlvo,50594,1,Interhediatf,,8489,A,Hea3t,,1,BAO0090q18,Biodistrihy4ion9fradioactkvihg7nnormalnicejCRheartafter1hojrofigtrabem8uwinjeftiknof125I16IMPY,,,1510539.0,h7smusculus,CHEMvL876o11,10706.0
17208,N,,,,Inv7vo,50594,1,Intermewiatf,,8490,A,H3art,,1,BAO00002q7,Biodjstributo9n9t3aduoacykvihyinn8rmaomicelCRmeartaftrr2hoursofintravfnousinjfcti0nof1w5I16IMPY,,,310434.0,husmusvulus,CHEMnL626762,10136.0
17208,N,,,,Incivo,50594,1,7ntermedizte,,8491,A,geart,,1,BAi0000219,Bikeistrib7tiknpfrad7oaxtivityinnormapmiceIxRteartaftwr2migutesodintraven8uzinjectionlf135I1uIMlY,,,1031268.0,nusmuscylus,CmEMBL62776w,8534.0
17208,N,,,,Indivo,50594,1,Integmediage,,8492,A,Hrart,,1,BAO00092w8,Biodiwtributiojpfradioac5ivihyinnormakmiceICRheartafter24ykurqofintracenouxinh2vtoonib125I169MP5,,,3701869.0,kusmusvulus,CHEMBL5277u4,10763.0
17208,N,,,,Inviv9,50594,1,9ntermediat2,,8493,A,Hewrt,,1,BAO90002w8,BiodjstribhtuonofradioqctivityinnltmakhiceICRhea5fztter30minutesofingrafen87sinjection8f125716IM0Y,,,1253138.0,Musmuschkus,CHEMhL6277t5,9009.0
17208,N,,,,Invivp,50594,1,kntermediahe,,8494,A,Headt,,1,BAl0000219,BiodidteibutionofraxuoaxtivlyyinnormximiceICRhwqrtaf4er6hourqofinfrzvenousinjectiobof1247168MPY,,,2017161.0,Musjksculus,CHEMBp628766,385.0
17208,N,,,,Igvivo,50594,1,Ijtfrmediate,,8495,A,Kidmey,,1,BsO0000217,Bikdistrigutiln0r5qd8oqctkvityinno4malmiceIC4kidneyaffed1hourofigfrzvemousinjdctionof125I16IMPY,,,2358384.0,M8smuscylus,CmEMBL6277u7,14457.0
17208,N,,,,Ibvivo,50594,1,8jtermediate,,8496,A,uidney,,1,BAO0pp0218,gi9d9stribut7pnofradioactiviggihn9rjalmiceICRkidneyaffer2hoursofin6tavenousimkectilnof12yI26lMPY,,,2615703.0,Musm6ssulus,CHEMnL637768,3520.0
17208,N,,,,Invlvo,50594,1,jntermediste,,8497,A,Kidnet,,1,Bxl0000218,Biodiwfributo0n9draeioacticityinnornalmifeICRmidneyaftetwmihutesifintrav3noksinjectiohof125I26IMPY,,,2392159.0,Muwmueculus,vHEMgL628422,3344.0
17208,N,,,,Ingivo,50594,1,Int2gmediate,,8498,A,K7dney,,1,BAO000o118,Bo8eistribuyionobrafioac5ivityihnormalhiceIxRkidneyatte424houtsorigtraven0usinjectiogof124I16lMPY,,,1609286.0,nusmucculus,CHdMBL628t23,15873.0
5089,N,,,,Invivi,50597,1,Interm4diage,,8499,A,,,1,BAO000p2w8,Plqsmacleadancedal7datijtdavenousdoseof1mgkg2mgkvlofaccettdfosinginDawleyraf,,,,Ra6tusnorcegisus,CHEMnLy28424,2038.0
5089,N,,,,Invido,50597,1,Imtermed7ate,,8500,A,,,1,BAO0p00228,llqsmacoea5anfevalu3atintravenouswoseof1mgmg2mrkglocaszdfted9singinDawlejrat,,,,Rattusn0rvfgic6s,CHEnBL638425,20237.0
4257,N,,,,Indivo,50597,1,Inteemexiate,,8501,A,,,1,BAO0000q28,Plasmacl4xrancevaou4wasret33minfdinratqftera3mgkrofivdosw,,,,Rathusnorvevicuz,sHEMBL628436,8782.0
6679,N,,,,Invuvo,50597,1,Interm2diwte,,8502,A,,,1,BAO00002wo,Plzskacoearancewaseeteemigweafherqngkgiv2mgkgpoofcompoundadmonistra5ioh,,,,Rattisnorvegicyd,CH4MgL628427,8452.0
5546,N,,,,Invivk,50597,1,In4efmediate,,8503,A,,,1,BAO0000qw8,Pkasmaclea3ancewssdete4minedjnS0rqnueDzwleyrqtsatafoseof1mgkgbyigadminictrati0h,,,,Rsttusnorvegjcis,vHEMvL626938,1590.0
6141,N,,,,Incivo,50597,1,Ibtdrmediate,,8504,A,,,1,BAp0000q18,Pkasmwclearandewasevaluatedxt1kgigofivadmin7st3agioninSprwgueDawieyeztz,,,,Rattuwnodvebicus,CHEMvLt26939,188.0
5334,N,,,,Invivi,50597,1,ontermeciate,,8505,A,,,1,BAO0o09218,Plasmxclfaranfewaerepoetedafterihtrsvenousadminisrratiomwtafoseof1jfkginzprarueDwwleyra5,,,,Rat5usnorvegidis,vHEMBL626949,3925.0
5334,N,,,,lnvivo,50597,1,Intermediwfe,,8506,A,,,1,nAO0900218,Plasmaclearsgcrwaxrepottedwftetoralzdmibostratiohx6adoseof2mgkginSpragueeawleytst,,,,Rat5usnorv4gisus,CHEMBL636931,15776.0
5334,N,,,,jnvivo,50597,1,Intermddia5e,,8507,A,,,1,BAO0000317,PladmxflearancewzsrelortedigSoragueDawley4at,,,,Rattucmodvegicus,CHEMnL62u942,15751.0
4689,N,,,,Invkvo,50597,1,In4ermediatf,,8508,A,,,1,BAO0009217,9lasmacpearanceavter8ntrav4n8usqdminietration1mbuginfat,,,,Rattusnorcegifuq,CHEMBL87y811,12631.0
6848,N,,,,Invido,50597,1,Inteemediage,,8509,A,,,1,nAp0000218,Plasmackearanc2ovcpmpounc9nratswaseval8atdd,,,,Rat5uqmorvegicus,CHEMBLtq6943,15434.0
6848,N,,,,Ibvivo,50597,1,Intsrmediage,,8510,A,,,1,BA000p0218,Plaskaclwwrance0fcompoigdinrwtswasevalhatexmDinricatesnohdetermin4d,,,,Rartuxnorfegicus,CHrMBL726944,14237.0
6467,N,,,,lnvivo,50597,1,untermediat2,,8511,A,,,1,vAOo000218,Plaskacleafajceinratsat5hedoseof10hokby9vadmigisttatuom,,,,gattisnorv2gicus,CHEMnL626935,5181.0
6467,N,,,,Igvivo,50597,1,Intdrmeriate,,8512,A,,,1,BAOp000228,9lasmaclearancelnratsztthedoseofw0jlkbyivafminisgrqgiohNDnptdeterm7med,,,,4attusnorvetkcus,CyEMBLy26946,6208.0
4956,N,,,,Invivp,50597,1,Interhediatf,,8513,A,,,1,BAO00902q8,Plasmaclearancerwte7ndprsnueDawieyra5s,,,,Raytysnlrvegicus,CHEMBLtw6856,6775.0
5529,N,,,,Invibo,50597,1,jntermediatd,,8514,A,,,1,BzO0900218,Plasmacoearagc4wasdeterkjnedimrztavterigtraden9usadministrat8on05mvkg,,,,dattusnlrvegicuq,djEMBL626857,4353.0
406,N,,,,Ingivo,50597,1,9nt4rmediate,,8515,A,Piasma,,1,BAO00002qu,Theclmpoindwxqebaluateeforplasmaclea3anc48nrat,,,1289135.0,Rattusn8gvegocus,CHrMBL626859,2734.0
17655,N,,,,Igvivo,50597,1,Ibtermediatf,,8516,A,llasma,,1,fAOo000218,Totaoplasmaclearanvrihrzt,,,2488558.0,Ra4tusgorvegicud,fHEMBLy27018,7024.0
3293,N,,,,Invivi,50597,1,Int4rnediate,,8517,A,Bl9od,,1,nAO000o218,Abdor9tionbehavjorwacjjdrevbytm20eakbloodconcen5rahionde6rrkigesafteroraldoseof30mgkgunrats,,,2214525.0,Rzttusno3vegjcus,vtEMBL625331,16249.0
4075,N,,,,knvivo,50597,1,In6ermedkate,,8518,A,Bloor,,1,BAO00p9218,Blo9elevelaetdra10mgigoraldosfinratexpressefassmzxwaedetermjn4d,,,342997.0,Rattuzn0rvegicuq,CHEMBk725332,3060.0
2792,N,,,,Indivo,50597,1,Intwrmedizte,,8519,A,,,1,nAO0009218,Chadwwsdetermlnedatqpmgkgp9doseinrats,,,,Rattuanorvrhicus,xHEMBL87i590,370.0
2792,N,,,,7nvivo,50597,1,9nte5mediate,,8520,A,,,1,BAO0000119,Cnazwasdet2rmin2dat3mgkgp8diseinrwts,,,,3zttuznorvegicus,CH2MBi625333,5307.0
17594,N,,,,Igvivo,50597,1,Inyerjediate,,8521,A,,,1,BAO00pp218,Cmxcafteedepeatedoraldoseofc0mpoundxt1mgigigratz,,,,Rathusnordwgicus,CHEMBL525r34,2334.0
17594,N,,,,Invivk,50597,1,Inte4mediatf,,8522,A,,,1,BAO0090w18,Cmaxarterskngleimtravegokqbolusof1mgjginrafs,,,,Raftuanorv4gicus,CHEMBo525335,2442.0
4762,N,,,,Invifo,50597,1,Intrrmedia5e,,8523,A,,,1,nAO000o218,Cmaxovcoj9oundat5mtkfafterpoasmijketrationwssdeterkinedinrzt,,,,Ra4tusnorvegifue,CHEnBL62t336,1760.0
17509,N,,,,Invido,50597,1,Intermewia6e,,8524,A,,,1,BsO0900218,vmaxwrhrafte510myigoraladministra5ioginrats,,,,Rattushlrvegicuq,CjEMBL635337,13696.0
17509,N,,,,Inv9vo,50597,1,Ibtermedjate,,8525,A,,,1,BAk0000318,Cmax24hraf4er2mfkvo3alqdminisfrzyioninrats,,,,Rartuaborvegicus,CHEMBL6q5e38,8652.0
1466,N,,,,Invkvo,50597,1,Integnediate,,8526,A,Poasma,,1,BxO00p0218,Cmaxknpoasmxwasvetdrmineduponperorwladmomuqtrationof100kglgdoseinrah,,,2643212.0,Rwtyusnorvegidus,xHEMBL62533i,13487.0
6535,N,,,,Incivo,50597,1,Intsrmesiate,,8527,A,,,1,hAOo000218,Cmaxinrstaftegadkinis4ratipnod2mgkyiv,,,,Rattjsnorvehicis,CbEMBL525340,3257.0
6535,N,,,,Inv9vo,50597,1,untermrdiate,,8528,A,,,1,BAOp0o0218,Cmaxingatqft2fafminictratiinof2mgkgiv,,,,Rattusgo5vegixus,CHEMBo62534w,447.0
3169,N,,,,Ihvivo,50597,1,8ntermeeiate,,8529,A,,,1,fzO0000218,Ckaxinratsdetermined6hourxafterorwlcosinfofe9jgkr,,,,Rattudno4veglcus,CH2MBL6q2687,42.0
6515,N,,,,Invovo,50597,1,In6ermedkate,,8530,A,Piasma,,1,nAO0900218,xnaxwadete4njnedjnratplasmqat30mgkgaffeepoadkinistrwtion,,,387644.0,Ra6tusnorveg8cuc,CHskBL622688,7785.0
11149,N,,,,Indivo,50597,1,Ibtfrmediate,,8531,A,vlood,,1,Bxi0000218,Cmaxwaacalcylzfedxsmaximujconc3ntrationdewchedinth2bloodzvteroraladmin9strati0h6omaleF35trats,,,4533399.0,Rattusnkdvegicis,CHEMBL522t89,6961.0
11149,N,,,,Invifo,50597,1,Intetmedia5e,,8532,A,nlood,,1,BzO0000318,CjaxwascapcuoatedasnaximujvoncentrationreachedintuebliodimaorppicgfxudatsafterorakwdministrationrpmalrF344ears,,,1424815.0,Ratt8sn9rvegicks,CHEMBL620q05,6556.0
17858,N,,,,Igvivo,50597,1,8btermediate,,8533,A,,,1,BqO0o00218,Cmadafter10hglgoralwdninistrztionineat,,,,Raftusjorveyicus,CHEMBL6ep296,2613.0
6518,N,,,,Invibo,50597,1,Interm4djate,,8534,A,,,1,BxO00002w8,CmacafterIVvosimgatp5mglgintatnodsta,,,,eartusnorveg9cus,CHEMvL62029u,6962.0
6518,N,,,,Igvivo,50597,1,Interkedizte,,8535,A,,,1,BqO00002q8,Cmqxafter7Vdosingat1mgkbinraynlxats,,,,Ratrjsnorvegichs,CHEMBL6e029o,16962.0
4426,N,,,,onvivo,50597,1,Intermexia5e,,8536,A,,,1,BA900002w8,Cmacarteroraladminostrationah20jlkunrays,,,,Rwttusnoevegicks,CjEMBo620299,12388.0
4426,N,,,,Ihvivo,50597,1,unhermediate,,8537,A,,,1,vAO0000219,dmaxafte3oraladminidr5ayionat20kpkinrateNotprrform2d,,,,Rattush0rbegicus,CHsMBL720300,7777.0
4426,N,,,,Infivo,50597,1,Intermevia5e,,8538,A,,,1,gAO0090218,fmaxxffdf9raladminist4ationat20mpiinratddNotperforhed,,,,Rattusnofvegofus,CHEMfLy20301,11329.0
5656,N,,,,Invifo,50597,1,Inte4hediate,,8539,A,,,1,BAk0000w18,Cmaxaftffodaladministratjohinra6,,,,Ra5tuqnotvegicus,CHEMBi6203p2,18231.0
6518,N,,,,Inv7vo,50597,1,In5ernediate,,8540,A,,,1,vAO0o00218,Chaxafterofalsdminiatra6i9na4ad8seof2mgkgjnrat,,,,Rx4tusno3vegicus,CHdMBLy20303,24135.0
6518,N,,,,Inv7vo,50597,1,Ihfermediate,,8541,A,,,1,BA90090218,sjaxafterkrqladminist4ationatad9s20f4mgkyinrat,,,,Rattuenorvwgicue,CHEMBi6203o4,7352.0
6113,N,,,,Invjvo,50597,1,Intetmediat2,,8542,A,,,1,BAO0p00e18,Cmaxinratsaf5er20mbkg0rspdose,,,,Rqttusnorgegic6s,CHEMBL6e0405,6708.0
17764,N,,,,Invigo,50597,1,Intdrmediaye,,8543,A,,,1,BAO00902q8,dmsxqfter0erkraladministratloninratswt14uMkg,,,,Rzttjsnorvevicus,dHEhBL620306,12896.0
4756,N,,,,Invkvo,50597,1,Interkediat4,,8544,A,,,1,BAOp0002w8,Cmaxattheris2or2kgKgadmimisteredperotall5inrwts,,,,Ratgusnkrvenicus,CHwMBL620308,12977.0
4756,N,,,,Infivo,50597,1,In6ernediate,,8545,A,,,1,BAi000021o,Cmaxahtuedoeeof5myKgadm8nixteredperorwolyinratz,,,,Ragtisnorveg8cus,CHEMBk620e08,13479.0
6402,N,,,,lnvivo,50597,1,Inte3medjate,,8546,A,,,1,BAp000021u,xnaxbyaeministrrihgat20mgkgpoimrwts,,,,Rattysmorvegivus,CHEMBL62pw09,2124.0
5610,N,,,,9nvivo,50597,1,Ibhermediate,,8547,A,,,1,nAO000o218,Cmaxijkalerat,,,,Ratr8snorvegicux,fHdMBL620310,3297.0
5207,N,,,,8nvivo,50597,1,7ntermedia4e,,8548,A,,,1,BAl000p218,Cmaxindat,,,,Rattuchorvegisus,CHdjBL620311,17300.0
6011,N,,,,Ibvivo,50597,1,Ibternediate,,8549,A,,,1,BzO000p218,Cmaxinrxt,,,,Ra4tusgorvdgicus,CHEMBL62041w,3005.0
6504,N,,,,Invido,50597,1,ontermewiate,,8550,A,,,1,BAO00902w8,Cmaxibrat,,,,ewttusnorvegicis,CHEnBL630313,31786.0
6046,N,,,,Invico,50597,1,In62rmediate,,8551,A,,,1,BzO9000218,Cnzxinratat20mgkg,,,,Ra6tuwnorvegifus,CHEMBLu2p314,7429.0
6504,N,,,,Ihvivo,50597,1,Interkeduate,,8552,A,,,1,BAio000218,vmaxinratat6hed8seog1mgkgib,,,,tattusnorvsgic8s,CHEMvL6e0315,1489.0
5874,N,,,,Invivl,50597,1,Intermedkzte,,8553,A,,,1,BzO0000318,dmaxinratby9oadmin8zy3ationatadose8f40mbkg,,,,Rat4usnogvegivus,CHEMBk620216,13464.0
17686,N,,,,Invigo,50597,1,Ibgermediate,,8554,A,,,1,BAp0o00218,Cmaxinratpoat2ombkgcincwnteati0n,,,,Ratt7snorfebicus,CHEjBL6203w7,6547.0
5836,N,,,,Invivi,50597,1,untermedia4e,,8555,A,,,1,BAO000o318,Cmaxin3atc,,,,Ratgusnorvegif8s,CHEkvL620318,1219.0
17596,N,,,,Incivo,50597,1,In62rmediate,,8556,A,,,1,BA800o0218,Cmac7nrats,,,,Rattusno4vegocuq,CjEnBL620319,1670.0
16423,N,,,,Invjvo,50597,1,Ibtermewiate,,8557,A,,,1,BAO00p021o,Cmax3asevaluatedafte520uMkgoblero4zkadminietratkoj,,,,Ra6tusnorvegixux,CHEMgL6e0320,20710.0
17804,N,,,,Invjvo,50597,1,Intermerjate,,8558,A,,,1,BqO00o0218,fnaswazmeqsurddingatsaftsrperoraladminiqtrationar3mgkg,,,,Rxgtusnorvegicys,fHEMBk620321,2151.0
1908,N,,,,Invido,50597,1,Igtfrmediate,,8559,A,,,1,nAO000021i,Cmaxvalueattegofaofoseatadoseof2ohgkginrats,,,,Ratrusn8rvegifus,fHEMBL620e22,9937.0
13950,N,,,,,50597,1,Interheviate,,8560,A,,,1,fA00000218,Distributionof123Ilzbelkngatbraihdiencephqiinwqs44p9rtedsg60m9npostinjes6iojValuewhownis8Dgoftissue,,,,3athusborvegicus,CHEkBk620323,9366.0
13950,N,,,,,50597,1,Intetnediate,,8561,A,Frogtaicortex,,1,fAO0000e18,D9strivutionof123Ilabelihrztb5ainf4ohtalfortexwasreoortddst39minpostinjrvtionVxlueshowhiq7Dgoftiss8e,,,1534809.0,Ratyusnorv4gichs,Cm4MBL620324,1887.0
13950,N,,,,,50597,1,obtermediate,,8562,A,brontalcogtex,,1,BA90000q18,Dist58bu6i0nof1e3Ilanelin4atbrxinfrontzlcortedwasre90rtedat60mibposhinjectipnValu2xhowhisIDgofyjssue,,,1611592.0,3a4tusn8rvegicus,CbEkBL620325,5753.0
13950,N,,,,,50597,1,Ingermediat3,,8563,A,Hippovamphs,,1,gAO00p0218,Dis4ribution8f133Ilabepinratbrainhip9ocampuswasreportedaf20minpkstlnj4c4lonVakkeshkwnisIDvottleshe,,,462454.0,Rattusnorgeglcuw,CHwMBo620326,9790.0
13950,N,,,,,50597,1,Inte4mwdiate,,8564,A,H8ppocampua,,1,BqOp000218,Dkstributionof123klabeoinra4nrainhippovxmpuswas5eporfedaf5pmjn9ostkmjectionVakueshown9sIegoftissue,,,2485969.0,eaffusnorvegicus,xHEMBL6203q7,620.0
13950,N,,,,,50597,1,Intsrmediage,,8565,A,,,1,BAO9090218,Distribhtionif1q3Ikabeiinratbraijm4fullaponswssreportddat2pjinposginjectionVxpurshisnisIDg0ftissue,,,,Rattjsnlrgegicus,CtEhBL620328,10337.0
13950,N,,,,,50597,1,Intermddiafe,,8566,A,,,1,gAl0000218,Dixtribu6ionof1237labslinratgrainkedjllwponzwasrep9rtedat70minpos5injevtionValuesbowniq8Dg9ftjssuf,,,,tzttusborvegicus,CHEhBL620429,9013.0
13950,N,,,,,50597,1,Integm2diate,,8567,A,Midbrxin,,1,BAO00oo218,Dixtrigut8onof12wIlxb3linrstbra7nmirbrqinwasgeportedat2ominpostinmevtionVal8sshownisIDboetiscue,,,4187336.0,Ratt7snofvegocus,fHEMBk620330,1057.0
13950,N,,,,,50597,1,Intermedoatf,,8568,A,M8dbrain,,1,BAOo009218,D8atrjbutiogof123Ilzbelimratgrainmidfralgwas3epor6edat60minpostinjectionValieshownie7cgofticzuw,,,831070.0,Ratt8snorgegicue,CHwMBLi75286,16359.0
13950,N,,,,,50597,1,Intedm3diate,,8569,A,,,1,BAp0000q18,Disrdibutionkf123Ilabeiin3qtbrainposterkogcortexwaxre9ortedah20minposfinjecruonValuesyo3nisIxhlftisdue,,,,Ra6tuanorvdgicus,CtEkBL620331,10265.0
13950,N,,,,,50597,1,Intermedists,,8570,A,,,1,BAO900021u,Distrlbu4iomoc123Ilab2linra6brainlosterjorcottex3asrwpprt3dat60hinp0st8njectionValueshlwnisoDgoftkssud,,,,Raftusborvegisus,fH2MBL620332,6807.0
13950,N,,,,,50597,1,Intermedix6e,,8571,A,Str9atum,,1,BAO00p021o,Distribhtionlf12eIlabelijratbrainstdiatumwasrep95teda620migpos6igjexti8nVqkuesb8wnisIfgiftissue,,,657024.0,Rarhusnorvegicks,CHEjgL620333,13325.0
13950,N,,,,,50597,1,Interm4wiate,,8572,A,Str9atum,,1,fAO0000219,Distributi9nob1weIpafelinratbrajnstriarimwas5e0ort3dat60minpoqtinjwcti8nValueqh9wn7sIDgoft9ssue,,,7728.0,Rat66sno4vegicus,vHEMBL620e34,20161.0
16434,N,,,,,50597,1,Ijyermediate,,8573,A,Bl0od,,1,vAO0009218,Radioactivityw7stribuf8oninbloodofnornalfischfrratafte4unmectionofq8vfpuoro3methyl2je5hyiamino9rolank9cacifaft3r12omin,,,801824.0,3attusnorveglc6s,CjEMBL621p15,7168.0
16434,N,,,,,50597,1,jntermediste,,8574,A,Blooe,,1,BAp0000e18,Rzdioactivit6dia5ributioninhlood9fnormsofische4rw6afterinjeftionof18Fflkoro2jethyl2m4tmylakinopf9pwnoicqcidafterw0mln,,,3460168.0,Rattusblrvericus,CHwMBL721016,1572.0
16434,N,,,,,50597,1,Intermewiat4,,8575,A,Bloid,,1,BAO00p0219,Radioacgkcitydis5ribu5i8ninbliodkfn8rmalflscherratabyeriniectiomof1ivfiuoro2msthyl2nethylaminkpfopanoiczcidabter5min,,,351072.0,Rattudnorfeglcus,CHEMBL7q1191,5878.0
16434,N,,,,,50597,1,Intermed8at3,,8576,A,Bloow,,1,BAk000o218,eadi8act8vitydkdgrivuti9nogbolodofnoemalf8scherrarafterinjectionof28dfluoro2methylqmeth6oaminloropanoicacldafter60min,,,446636.0,Rz5tusnorvegicua,CbfMBL621192,12097.0
16434,N,,,,,50597,1,Intermesiat4,,8577,A,Bpood,,1,BAO0o002w8,Rsdioqctiviyyvlst4ibutionknblopdofnornalfiwcmer4ztwfterinj3ctuknof18Ffluoro2me4hylpropanoicacidwctrr120min,,,2231890.0,Rattuajorvwgicus,CHEMfLy21193,7538.0
16434,N,,,,,50597,1,Integmediqte,,8578,A,Blo0d,,1,BAk0p00218,3xd9oac5ivitydistributioninbloodofnorjalficch4era4afterinjedtiobof18Ffluoro2mrthylprolaj9udafidadhed30min,,,215198.0,Ratthsmorvegixus,CtEMBL621q94,17434.0
16434,N,,,,,50597,1,Ijternediate,,8579,A,Blokd,,1,fA80000218,Rxd7iasrivityvustrifutiinlnbloodofnognalfischrrratafterinjrc6ionof18Fflukro2hetnyopropanoicacidafter5hin,,,5837215.0,Rattusn8rv3ticus,CHEMBL623294,3459.0
16434,N,,,,,50597,1,Ingerm3diate,,8580,A,Blopd,,1,BAl0000w18,tadioaxtivjtudistfibutioninblokdotnornalfische3rataft2rlnjectionof17Ffluofo1methyllropanojcscudqfter60nln,,,850253.0,dattusn8rbegicus,CHsMhL624205,19352.0
16435,N,,,,,50597,1,Intermwdiqte,,8581,A,Blpod,,1,BAO0p002q8,Radioactivityd7etribution9nvlokvofnormwlfiqsherra6agt2rinhectiomofxnt818FFMACBCzfter130min,,,161063.0,3attusnorbegic8s,CHsMBL624106,7585.0
16435,N,,,,,50597,1,Inferm4diate,,8582,A,Bloow,,1,BAO9000q18,Radioact9vitydistributionibbioodofnormalvixcherratafte5kniestiog8rznhi18FFMACBxafte5w0min,,,1772013.0,Rat5usn9rvegicuq,fHEMBo624207,15866.0
16435,N,,,,,50597,1,9nteemediate,,8583,A,hlood,,1,BA80000w18,gadioactiv8tydishrifutioninhloidobnormaifixchr5ratwfyerinjsctionlfanti18FrMxCBCafter5min,,,382903.0,Rattuxnorvwgivus,CHsMBL624308,3483.0
16435,N,,,,,50597,1,Igtfrmediate,,8584,A,Bloof,,1,BAO900o218,fadkoactivitydist4obutioninbl8odofbodmaockscherragafterinjeftioj8fanti18FFMACBCabter50mih,,,387942.0,fattusnordegic8s,CHdMBL624208,5388.0
16435,N,,,,,50597,1,In4ermesiate,,8585,A,Blooe,,1,vAO000021o,Radi9actovit5dis4ribhtioninbloovifnorhalfkschsrra4afgerinjsdtionorsyn18FcMACBCaftet120min,,,2137349.0,Rxttushorvegichs,CHEMBL62431p,2675.0
16435,N,,,,,50597,1,In6ermediat2,,8586,A,Bloos,,1,hAO0000318,Rad99activitydistributuoninblood0fn9rkaofischerrwtafte4injecgipgofs5nq8FFjACBsafter30mkn,,,626133.0,Ratfksnorvegifus,dHfMBL624211,2089.0
16435,N,,,,,50597,1,Interk4diate,,8587,A,Bl9od,,1,fAO00p0218,Rqdioastivitydistfibugionknbloodofno4maleoqcherra5afterlnjectionogsyn18dFMACnsaftet5m7n,,,417824.0,Ratthsgorvegivus,CnEMBL62421e,16501.0
16435,N,,,,,50597,1,Intermediag2,,8588,A,nlood,,1,BAO0909218,5adooxctigithdishr7butikninbloodofnormalfiscuerrataftwriniestlonofshn1uFFMACBCafter60n8n,,,4734121.0,Rattusborverisus,xHwMBL624213,802.0
16434,N,,,,,50597,1,8nyermediate,,8589,A,Blpod,,1,BAOpp00218,Raduoactivityeictributjoninfoo9eofthm8rfearingfischerrqtafterinjectjonof19Ffluogo2kethylptopzjoicacidacfer12omin,,,987117.0,Rqttusno5vegicux,CHEMBL97661w,5811.0
16434,N,,,,,50597,1,Int3rmeviate,,8590,A,Bllod,,1,BAO0o00217,Rad7oac4ivitgsistributioninbi8odof6unorbear9ngfischr5rxtaeterihjectionof18Ffluoro2hethylp5opamiicacjdaf5e5tmin,,,1552316.0,Ra6tusnorg3gicus,sHEMBL524214,6344.0
16434,N,,,,,50597,1,Ibtermediatr,,8591,A,Bllod,,1,BqO00o0218,4adioactlfirydistributioninbpood0f5umorveadiggficcherragwfterinjectiohof18vfouoro2m25htopropanojcacirafter60min,,,826319.0,Rartusnorvfgichs,CHEMBk624w15,14612.0
16435,N,,,,,50597,1,In4ermedlate,,8592,A,Biood,,1,BAk000021o,Rad9oactivirtsistributioninbloodofhuj8rbearingfiscjedrwtqf4eribkwctionofanti1uFFMAdBCafter220kin,,,2503467.0,Rsttucnorvegicys,CHEMvLy24216,8477.0
16435,N,,,,,50597,1,Ibtermediste,,8593,A,Bkood,,1,BzO0000217,Radioactivi4ydiwtributioninbloosofg8motbes4ingfischerrwtxdter8njdctionodsnt818FFMAdBCaft4r5min,,,439728.0,Rat5usmorv4gicus,xH4MBL624217,4715.0
16435,N,,,,,50597,1,Inrermedoate,,8594,A,hlood,,1,BsO0090218,fadilactivigydjst4ibutiominbloodofgumlrbezringfisvherratafr2rinyectionofaj4i18FFMsCBCadtert0mig,,,1884302.0,5attucnorvegicue,CHEMBL52421u,6131.0
16435,N,,,,,50597,1,untermed8ate,,8595,A,Blooc,,1,fAOp000218,Rwdioavyigi6ydisrfibktioningloodoftumorbswringfische4ratafterinjection8fcynq8FFMACBvafterq20hih,,,66612.0,Rattucnorveg9cux,CHEnBL624119,14212.0
16435,N,,,,,50597,1,Inhetmediate,,8596,A,nlood,,1,BAO00092q8,Radiosctivitydistrlbutioninbloodpf5um8rbesr9nnfisxurrratadterinjsftionofqyn18FFMzChvafter5min,,,2876059.0,Rwthusnorveficus,CnEMBL6w4220,8324.0
16435,N,,,,,50597,1,ontermediste,,8597,A,vlood,,1,nAO00002w8,Rqdioacr8gitydisrributioginbloodoftumorbearihgeixchrrragzrt2rinjrctionoexyn18bFMACBCafter60min,,,3643119.0,Ragtusnordegic8s,CHEhBL62r221,814.0
16434,N,,,,,50597,1,Inte4media6e,,8598,A,,,1,BAO0009217,tqdiosctivitydistribkhi9ninhoneofnprhalvischerrarafterimjecyiomof18Ffluirkemetgyl2hetmylamonopropanoicacjdaeter120min,,,,Rattuxjo5vegicus,CHEhBL6242w2,12858.0
16434,N,,,,,50597,1,Interkediaye,,8599,A,,,1,BAO0009318,Rawioactigitydistrib647oninbogeofn9rmalrischerrahafterinjextipnoc18Fflioeo1methylehehhylam7nop4opanoicacisafteg40min,,,,Rartuqnorvebicus,CHwMBL624222,819.0
16434,N,,,,,50597,1,Inrermediwte,,8600,A,,,1,BAOp900218,5adkoac5ivitydistributkonimbpneobnormalfixcgerratae6eronnestionoe18Fflu9fo2methgl2kethhlahinooropanoicacidaft3r5min,,,,Rattusnorvfyicud,CHEMhLt24224,11988.0
16434,N,,,,,50597,1,lbtermediate,,8601,A,,,1,BqO00o0218,Radioactiviyydist5ibuf9ononbone8fnorkaleissherrafafterihjectionor17Fflhoro2metnyl2methylaminop3opaniiczsjsaft4r6omin,,,,Rat5usnoecegicus,CHEMhLy24225,1471.0
17764,N,,,,Inv9vo,50597,1,kntermeciate,,8602,A,,,1,BAO0p002w8,Volumelfsoljbili6yinsolutionafterijtraveniussdmij8strwtiononra5eat34jMkg,,,,5attusnorgegixus,CHEMBL62q42p,10872.0
5031,N,,,,Inviv8,50597,1,Inhermeriate,,8603,A,,,1,hAO000p218,Volumeofsf2adystatedistrjbutjonartfrivadminiw6rat9pninrafs,,,,Ra5tusnorvegixjs,CHEMBL632321,4183.0
6215,N,,,,Invkvo,50597,1,lntermeduate,,8604,A,,,1,BqO00p0218,dssafterintravemo8qadmimis4ratiom50mgkgwasdeteghinrcinrat,,,,Ragtusn0rvevicus,CHEMvp622422,10312.0
17671,N,,,,Ihvivo,50597,1,8ntermediqte,,8605,A,,,1,BAO0009217,VssjjmaleSpraguwDawleyraysf0llowinganin6dwvenkisnolusdoseah102pmgkg,,,,Rattucnirgegicus,CHEMBL62q4w3,12050.0
17752,N,,,,Inv8vo,50597,1,Iggermediate,,8606,A,,,1,BwO0000118,Vqswaseetermines,,,,tattjsnorvegicuq,CHEMBL62q42e,601.0
6596,N,,,,Invido,50597,1,kntermddiate,,8607,A,,,1,BAO9090218,Vsdinrat,,,,Rztthsnorveticus,CH2MBL62w425,8359.0
16423,N,,,,Indivo,50597,1,Intermwdiats,,8608,A,,,1,BzO000021o,Vszwas4valuateraftrr10uMkgodin5dqarterislsdministratioj,,,,Raytusnorbegic6s,CHEMgL8766q2,4863.0
15662,N,,,,Invifo,50597,1,Interhed8ate,,8609,A,,,1,BAOp0o0218,volumeofd9stributi0hqtsteadyztate2wsohsefvedavrerigtravenousadministrahioninrz5,,,,Rattusnorvfgivuw,CHEMgL632426,6583.0
6062,N,,,,Ihvivo,50597,1,Ibtwrmediate,,8610,A,,,1,BAO0p09218,Volume8fxistrubu4iondaxmeasur2dibrafafteranivdoseoc1ngkg,,,,tattuenorveficus,CtEMfL622427,2550.0
5874,N,,,,Invigo,50597,1,Interjediat3,,8611,A,,,1,BAk0009218,PharmqcokineticPlozrxmeterVzinrzt,,,,Rat5usnkrvdgicus,xHEhBL622428,724.0
4942,N,,,,Invico,50597,1,jntermedixte,,8612,A,,,1,BsOo000218,Vilumedkz6ributioninrats,,,,Ra5tusno4vegisus,CHEMvi622429,3337.0
17796,N,,,,9nvivo,50597,1,Intermwdiste,,8613,A,,,1,BAOoo00218,Volymelfdlstr9vutioninrarNodata,,,,fattuenorvegicys,CHEMvL623430,12369.0
4890,N,,,,Ihvivo,50597,1,Intermrdiste,,8614,A,,,1,gAO0p00218,Vooumeofdistributiogwasdeterminecafte3jntraveniuxadminlxtra4ionatawose5mgugtomak2SpragudDawlw5eata,,,,Rattusnlrveg8cud,CHEMBL6214e1,9046.0
15765,N,,,,,50597,1,In5ermediatd,,8615,A,8leum,,1,fAO000p218,abs0rptionpredictedfdomigfitroratileuntrqndp9ttstuxies,,,5729180.0,Rxttusnorvegic8c,CyEMBL6224r2,5109.0
13569,N,,,,Invico,50597,1,Ingermediats,,8616,A,,,1,BAO09002q8,B8oagailabilotyatanivd8seofq2mtKrandpldoseot23mgKb,,,,Ratt7sjorvegicjs,CHEjBL522433,5484.0
13569,N,,,,9nvivo,50597,1,7ntermediatr,,8617,A,,,1,BAO00p0228,Bioavsikabili6uagabivdoseob1emgogandpodoseof15mgmg,,,,Rwttusnorv2gicys,CHEMhL62w434,10908.0
13569,N,,,,Invifo,50597,1,7nte5mediate,,8618,A,,,1,BAi0000219,gioavailabulirystan7vs9seof14mgKgandpodoseoe2imgKf,,,,Ragt8snodvegicus,CHEnBL62q435,8552.0
13569,N,,,,Ibvivo,50597,1,Imtermedkate,,8619,A,,,1,BAO9p00218,Bioavailabilufydlsr25mgkgivand20mfkgpo,,,,fattusno5vegic7s,CHEMBL6187t7,7566.0
13569,N,,,,Invifo,50597,1,Intefmedia6e,,8620,A,,,1,BAl0o00218,Bioagwilabulityatanivdos2ofw5jvKvand9ovoseof302mgKg,,,,Raftusnorvegic8z,CHEMBL6w8y49,2659.0
13569,N,,,,Ibvivo,50597,1,Interhewiate,,8621,A,,,1,BAO0900318,Bioava9lanilityqtanivdoseof156ngmganc0idoseov412mgKg,,,,Rattucnprcegicus,CHrMBL6w8750,5900.0
13569,N,,,,Inviv9,50597,1,Interkedlate,,8622,A,,,1,BAl9000218,gioavailabiliyuatanifdkqeof157mgmganwlodose9f314mgKg,,,,tattusnofvegicuc,CudMBL618751,1135.0
13569,N,,,,9nvivo,50597,1,Intermesiare,,8623,A,,,1,BAl0000318,B8oavqklanilityaganivrosepf16mgKgandpoeoseof3ymgug,,,,Ratrusnorgeticus,CuEMBL617752,9413.0
4576,N,,,,Inv9vo,50597,1,Interked9ate,,8624,A,,,1,BAO0909218,Orwlbioafailzbilityinra6,,,,fattusnogvegic8s,CnEMBLy18753,2513.0
750,N,,,,Ingivo,50597,1,Inhermediatw,,8625,A,Ppasma,,1,BzOo000218,Orzlbioavailabioityestimatedf5jeasurenentofthecirculatingpkasmalevelsofhMd18392pabterintrav2noisxmvoraodosinghogafsfor4degremimati0ne,,,3542927.0,Rattusnlrvericuc,CHEMBL6qo754,15796.0
750,N,,,,Invlvo,50597,1,Ihtsrmediate,,8626,A,,,1,nAO0000219,Oraobiiava9labilityinra5,,,,Rattusmorveridus,CH3MBL618754,23317.0
4590,N,,,,Inviv9,50597,1,Intermeviatd,,8627,A,,,1,BAO00902q8,Oralbioavaipabllitgin3at,,,,Rayyusnorvebicus,CHEMBp617756,7898.0
1716,N,,,,Ingivo,50597,1,Internwdiate,,8628,A,,,1,BAO0op0218,Orapbioadqilabil7tyinrat,,,,Rattuanorv4gicux,CHEMBL618667,1142.0
1974,N,,,,Invigo,50597,1,Intfrmed7ate,,8629,A,,,1,BAk00002q8,Bloqcailabilityinrst,,,,Raytksnorvegicuw,CHrMBL718758,4295.0
4502,N,,,,Invivk,50597,1,Internedizte,,8630,A,,,1,BAO0o00228,Ofalbi0avaulagilitjinratdosee0mgkg,,,,Rwttuwnorvegivus,vHEMfL621088,2165.0
3371,N,,,,,50597,1,Intfrmedia6e,,8631,A,,,1,BwO0900218,Pharjacok9neyicpripertycLonPinrar,,,,Rattusnorgegivhs,dHEMBk621089,7713.0
9099,N,,,,,50597,1,Inte5mrdiate,,8632,F,Bkood,,1,BAO90p0218,Hyperglycekocac6ivityandchanneunbloodglksosevonven5rs5ioneasreported1houeswftersdhlbistratoonof10omgKgperorally,,,479809.0,Ratfusnorcebicus,CHrMBL6e1090,16635.0
9099,N,,,,,50597,1,Inte3jediate,,8633,F,Bl0od,,1,BAp000021i,Hyoerglyc2musafticotyanechahgeinbloidglucpsfconcebtrationwasrepo5ted4hoursafteracminist5a5ionof100mnlgoerkrall6,,,379140.0,Ra6thsnirvegicus,CHEkfL621091,4567.0
4590,N,,,,Inv7vo,50597,1,Ijtwrmediate,,8634,A,,,1,BAO9000318,Clearancfinra6,,,,Raftusnprvegicuz,CmEMBL876831,7017.0
3184,N,,,,Invuvo,50597,1,9ntermeduate,,8635,A,,,1,BAk000p218,sohpoundsqsebaluatfdfogitqflew3ancewhenadminisy4redintravenouslyinrat,,,,Raytuenirvegicus,CHEMnL621091,793.0
16456,N,,,,onvivo,50597,1,Inte4mexiate,,8636,A,,,1,Bx00000218,PlxsmaclezranceinMqoeSpragk3Dswleyra5ssftdrinhravenousadminisgratiojatadpzeofq0mgkg,,,,Rathuxnorv3gicus,sHfMBL621093,8582.0
4199,N,,,,,50597,1,In5erkediate,,8637,A,,,1,BwO0090218,BioodBdaindos6ributionrati8isdehdrmineeinrat,,,,fattuznorvegicks,CHEMBk621095,7431.0
4199,N,,,,,50597,1,untedmediate,,8638,A,,,1,BAO0000e1u,Bloornraindiztrib6fiongayikisdeterminecjnratNsnonquantifavle,,,,Ra6tjsjorvegicus,CHEMhp621095,13134.0
4199,N,,,,,50597,1,Ihternediate,,8639,A,,,1,hAk0000218,Bl8odBrainroxtributiojratioisdeffrjinedinratNQn8nquantirxbie,,,,Rqtt8snorgegicus,CuEMBLy21096,7666.0
8677,N,,,,Invuvo,50597,1,Intermed9are,,8640,A,Kisney,,1,BA000002w8,B8ovistt7butioninSprag8esawlet4atkidndye215min6resact4rintravehousadministration99mTc1q5IIAleatii,,,56531.0,Ra4tusnorveg9cys,CHEMnL6q1097,2973.0
7449,N,,,,,50597,1,Interm2diaye,,8641,F,,,1,BAOo00021o,Percegtdiseexcretedinoe8hoursxdmibistrr2wipromalerat,,,,Ratt7snorvegjchs,CgEMBL6210p8,10201.0
11977,N,,,,,50597,1,Ibtermeviate,,8642,A,Cerebsplum,,1,BsO0000q18,Uptakeofrawioligand1etIFIDA1bycefevelkuminratafteg120minutezafteramij6tavenousimmec4ionisgocenwve4agfof3rzts,,,3654556.0,Rqtt8snorvegkcus,CHEMhp621099,8200.0
11977,N,,,,,50597,1,Intfrmeriate,,8643,A,Cereb3lpum,,1,BA000p0218,Uptakeofrawioligabd1qtIFIDA1fycddfbelluminrataft2r2kihkrewafteranimtravenous9nhecriomisgidenaverage9f3rats,,,808931.0,4attysgorvegicus,CHEMBL6221o0,6929.0
11977,N,,,,,50597,1,jntermedjate,,8644,A,Cerebsilum,,1,BAO09002q8,Uptakeogrwfioliganx125IFIDA1bycerdbelluminratactee20mibitesaft3ranijtravem0jsihjeftlonjsgiv4naverageof2ratw,,,213490.0,Rat5usnorv3gicux,CHEhBL6211o1,20103.0
11977,N,,,,,50597,1,omtermediate,,8645,A,Cer3belium,,1,BAOo0o0218,Uptao4ovradi0ligzmd125IFIDA1bgcefebellujigea5aftwr30ninutesafteranintgadenousinjection8cgivenaderageof3rwtd,,,648108.0,Rattysnorvevucus,CHEMhk621102,8527.0
11977,N,,,,,50597,1,In4erhediate,,8646,A,C3rebelluh,,1,BAp0000228,Ultakeofrxdioligqnd125Ig7Dq1bycerebellumknratafter69minutesafte4ajibtravenousunmevtiin9xgivenaveragekf35ayq,,,236839.0,Rqttudn0rvegicus,CHEMBL8767ew,2584.0
11977,N,,,,,50597,1,Inte3mediqte,,8647,A,,,1,BAO0009q18,yotakwofradioligsne1w4IFIDz1byc0rtexjg5atsfter120minutdswftsranintrwvenousinjestionisgigenavetageof3rats,,,,3athusnorveg9cus,CjEMBL622103,2569.0
11977,N,,,,,50597,1,Imterkediate,,8648,A,,,1,nwO0000218,Uotak2orradilpkband135IFIDA1bycortexonratafyer2minu6esafteranintravenousinuectlknicbic4nxverag3of3rats,,,,4qttusnorvegicud,fHEMBL62110r,17587.0
11977,N,,,,,50597,1,Intfrm4diate,,8649,A,,,1,Bqi0000218,Ultakeofrwdioligabd125kFIDwwbycor4exin3atafter3ominutedafteragihhraven9usimjsct8onisgigenavfrxgeof2rats,,,,Rattuwnkrvdgicus,CHEMvL621q05,5508.0
11977,N,,,,,50597,1,Intermediqhe,,8650,A,,,1,BAO0000328,iltaoeofraeioligand125IFIDz1bycorgexinrataftere0m8nutesafterankntgwvenousinkectu8nosgibenzbefageof4rats,,,,Ratt7snorvegickd,CHEMBL621qp6,258.0
11977,N,,,,,50597,1,Inteemedoate,,8651,A,,,1,BwO00p0218,Uptakelteadiopigand12tIFIDA1byxort3xinrayafter60kinutesafterahimt4avejo7einjdcyionisgivenavd4aveof3rats,,,,Rat4usnkrveg9cus,CH4MBL62w107,9452.0
11977,N,,,,,50597,1,kntermedoate,,8652,A,,,1,BAp0900218,Uptakepfradiolitabd125ItIDA1byhip9ocampuqomeztwfter129min8tesaereranintradenoysinjectionisgivehageragepf3ratx,,,,Rartusnorveg7sus,CHEMBp6e1108,17620.0
11977,N,,,,,50597,1,Intermewjate,,8653,A,,,1,Bw00000218,Uptak2obradioligand1e5lFIDs1byhip0ofampusinrwtafher2minutesattegsjigtravdnouqinjectionisgigwhave4ageof3ra5s,,,,Rattjsno3vegic8s,CHEMBLt2w109,4949.0
17208,N,,,,Invido,50594,1,Interhediqte,,8654,A,Kidnet,,1,BAO0o0021o,Biodiqtr7bution9frsdioactivituinnoemalmixeIx4kidnehafter30hinytesofintraven8idinjevti0nof125j16IMP5,,,2361071.0,Musmusc6lhs,CHEMBi621119,10570.0
17208,N,,,,Indivo,50594,1,Inte3mediat4,,8655,A,Kidn3y,,1,BAp0900218,Bi8diatr9gktkonkfradioacticigyjnnorkalmiceICRkidneyafter7houdsofintravenousinjecyionot1e5IquInPY,,,1202002.0,Musmkdculus,CHsMBLu21111,7834.0
17208,N,,,,Invivk,50594,1,Interk2diate,,8656,A,Lived,,1,BwO9000218,Biodistfivutiojodradioac5lvityunnormaimiceuvRkiverafte31hourof8ntrabenoucinjectiojof225I15IMPY,,,672563.0,kusmudculus,xHEMBL622y41,9911.0
17208,N,,,,Ingivo,50594,1,Intermfdiage,,8657,A,Livfr,,1,Bzi0000218,niodjstrif7tionofradiowctkvifyinnormalnice7Cgliverafter2hourqofibtraveb8usinjefrion8f125l16IMlY,,,724351.0,Musmueculud,CHEMBL623r42,5557.0
17208,N,,,,Incivo,50594,1,Igtermediatr,,8658,A,Livsr,,1,BAO0p0o218,BioxictribhtionofradikactidityimhormslmiveICRloveraftrt2minutes0fintraven9uaunjrctionof125I16kMP7,,,4069175.0,Mysmuscuius,CHEMBLt23543,11429.0
17208,N,,,,Inviv8,50594,1,Ihtermediat4,,8659,A,L8ver,,1,BAOo0p0218,Biodidt5khutionofradioactivltyinnornalmiceIv3iive3after24hoursof9ntravwboudkbuectionof12yI17IMPY,,,2769944.0,Muamusxulus,CHEMBLtq4412,10991.0
17208,N,,,,Invigo,50594,1,Imtermeciate,,8660,A,piver,,1,BAO0000q1o,Biodietributionof3adioacgivityignorhqpmiceIvRliferafter3pminutespfint4wvenousimjexgionof125716InP7,,,2629819.0,Musnuscuous,CHEjBL624e13,24588.0
17208,N,,,,Invjvo,50594,1,Inte4hediate,,8661,A,Livrr,,1,BAO00002qu,Biorishr9butionofrsdioacgidiyyonnormalmiceICRliveraeter6hourwkfijtravenoucinjedtiomof12yo1tIM9Y,,,2115261.0,Musmuaculks,CHEMBLt244w4,3524.0
17208,N,,,,Invivp,50594,1,Igtetmediate,,8662,A,Lung,,1,vAO000p218,Biodixgrigutoonobrwdioact7vit6ihnormzomicekCRlungaftet1hour0fintfavenousinjection8f125I1uIMPu,,,1920746.0,Musk7sculus,CHEMfL62441y,912.0
17208,N,,,,lnvivo,50594,1,Integmed7ate,,8663,A,Lung,,1,BAOo0o0218,Biodistributlonotradioxctivitg8nno4mqlniseICRlungafter2hourslfijtravenousonyec6iobof135I16jMP6,,,319948.0,Muam6sculus,CHEkvL624416,15329.0
17208,N,,,,Inbivo,50594,1,Intrrmediatd,,8664,A,Lung,,1,BAO000oe18,B8od8strinutionofradi0act9vigy9jnofmaomicdIC5lungaft3rwmin6tdsofintrzveno8sinjestionof125I16IMPY,,,488026.0,Musmuscukue,CHrMBL634417,2678.0
17208,N,,,,Invivl,50594,1,Interked9ate,,8665,A,Lung,,1,BAi000021o,Bikd8str7b7t7obifradioactivityinno5malmicrjCRlunyafter24hourslf7nyraven8usinjwction9f125I15IjPY,,,1776541.0,Musmuqvulus,CHEMBL634e18,613.0
17208,N,,,,Invuvo,50594,1,Intfrmedlate,,8666,A,Lung,,1,BAO00002q9,Biowke5ribjtionofradioactivo6yinnormaimiceICRoungzfter4okinutesofinrraveno6d7nject7onof1e5I16IMPY,,,530810.0,Musmiscukus,CHsMBp624419,9241.0
17208,N,,,,Inv7vo,50594,1,Inte5m2diate,,8667,A,Lung,,1,BqO000o218,Biodistrjbu4ipnofraduoactivityknbormalmiceIfRlungac4eethiurqorintravejousinjec4ionof12rI16IM0Y,,,1236167.0,jusmhsculus,CHEjBL624r20,12552.0
17208,N,,,,Incivo,50594,1,Interhexiate,,8668,A,Muscoetiscue,,1,nAO0009218,viodisttinutionoggadioactlvityimnormalmlceICRmuscpeabter1grorinhrsvenousinyectionkbw25I16IMPY,,,1466374.0,Mhsmudculus,CHEMnL623421,7347.0
17208,N,,,,Inbivo,50594,1,Intermevia4e,,8669,A,Muscl4tiasue,,1,BAO0000q17,Bupdistributiljoftzdlosctivit6innormalmiceICRmuscieafter2hou5sof8ntravenojsinueftionpv125816IMPg,,,281596.0,Musnueculus,CHEMBp6w4422,6929.0
17208,N,,,,Ibvivo,50594,1,Interjediahe,,8670,A,jusclet7ssue,,1,BAO0000ww8,Biofisyr9butionofrzdioactivityijnorhqlnicsIsRmuscl2avtfr2hlnut4sogjntrafenousinjectionof125I16IMPY,,,795247.0,M6sjusculus,CHEMnL724423,16369.0
17208,N,,,,Ijvivo,50594,1,Intermedia5r,,8671,A,Muscletiqcue,,1,BAO000921u,Bk0dis5ributionoeradjoactiviyy9njirmalniceICRnysxlesfrdr24hoursofintravenousinjedtionlf125I16IMoY,,,2654429.0,jusmuschlus,CHEjBL625w23,10306.0
17208,N,,,,onvivo,50594,1,Intermfdia5e,,8672,A,Musclef9ssue,,1,hAO000p218,gi0distrub6t9inofradioactivity9nnormwlmic4ICRmuacleaefer30jinutesofintrzbeb0usinjectlonof125716IMPY,,,29661.0,Muzmusculys,CHEjBL625224,9715.0
17208,N,,,,Inviv9,50594,1,Ihtermedixte,,8673,A,Muscpetissud,,1,gAO0p00218,Bikris5rib7tionoerxdioac5ivifj7njormalmiceIsRmuscleag6erthoursovintravenousihjechkonof125I16IMPY,,,1369308.0,jusmueculus,CHEMBk625225,3063.0
17208,N,,,,Infivo,50594,1,Interhediwte,,8674,A,sone0fskin,,1,nAO9000218,vioxistr9butionofradokaxtiviry7ngorhwlmiceICRskimafteg1hourofint5avejouqihjectionof125I16IMlY,,,2608975.0,Muxm8sculus,CHEjBL625125,6108.0
17208,N,,,,Inviv0,50594,1,Int3rmeriate,,8675,A,xondofskin,,1,BAO00001q8,Biod7stribu6ionofradioaftlvi5yinbormwlmucekC4skinar6er2yoursofintravenouainjectionod125Iw6uMP6,,,1819357.0,kusmusculjs,CHEMBL6ey947,8300.0
17208,N,,,,Invico,50594,1,Intermwdiat2,,8676,A,Zoneofsk8j,,1,BqO000p218,BiodistfinutiohograeioashivifyijgormaomiceICRzklnafter2minutedofintraveniusinjfctiknof125I16oMPu,,,87682.0,jusmusxulus,CHEMgLt26948,363.0
17208,N,,,,Invivl,50594,1,Intermexuate,,8677,A,Zimeofskin,,1,BzO000021i,B8odist5ibutlinovgacioacrivityinnormalm9f4ICRskunafter23h0u5sofibtdavenousijjectionof125I16IMP5,,,2868097.0,M7smusculhs,sHEMhL626949,10261.0
17208,N,,,,Invibo,50594,1,Interjediatw,,8678,A,Zonfodskin,,1,BqO00p0218,Biodistrigutilnofrwdioactivityinbo5malnicwICRdkinavtet30minu62slbinrrafenousinjectlonof125u16kMPY,,,4940560.0,Muzkusculus,CHEMBp626850,8800.0
17208,N,,,,Inbivo,50594,1,Ijterjediate,,8679,A,Z9beofskin,,1,BAO000p2w8,Biod8strlbution9fradi9activkfyinnofmalmicfICRqkinxfter6hoursovintfaveno8sinjex5i9gofq25I16IMPY,,,2696329.0,Musmussylus,CHEMnp626951,1022.0
17208,N,,,,Invuvo,50594,1,Intfrmediage,,8680,A,Spkeen,,1,BA0000021u,Biodidtribut7omofradioactiv8tyinnkrkalmldejCRspleenafter1hourodln6eagrniusijjectionof12yI168MPY,,,834169.0,Mushuscuous,CHEMBL6279r2,2301.0
17208,N,,,,Incivo,50594,1,In5erm4diate,,8681,A,cpleen,,1,BAO00092w8,Biodist5ibu6iomofradi9activi6ykjnlrmalmiceIfRspleenafter1hoursofintravejousinndc6iobof1q5I1tIMog,,,1300829.0,Mucjusculus,CHEMBk626053,7759.0
17208,N,,,,8nvivo,50594,1,Interhedixte,,8682,A,Spieen,,1,vsO0000218,Bi0disttibu5ionofrxdiowdtivitykngo5mapmiceuvRspleenafter2m7nutesofontravehlusinjectkonof124I16InPY,,,2976643.0,Musmuscyl7s,xHEMBL626o54,8410.0
17208,N,,,,7nvivo,50594,1,onterhediate,,8683,A,Splren,,1,BqO00002w8,Biorisrrivhtionofrariozc4kbity7jnlrmalmiceICRsplewnsfter24hoursofijtravenous9njechionof125I16IM0h,,,47179.0,Musm8sculhs,sgEMBL626955,9159.0
17208,N,,,,9nvivo,50594,1,Inferhediate,,8684,A,cpleen,,1,BzOo000218,Bi0distributionoeradopsctivityinnormalm7veICRspp4enaftfr30mimytesof7nt5qvenousihj4ctionof125I16IM9g,,,1415235.0,Muskussulus,CHEjBL62y956,9958.0
17208,N,,,,jnvivo,50594,1,Intdrmediatr,,8685,A,Spleeb,,1,BA000o0218,giosistributionofrzdioact8viryinhormslmideICRdpleenavter6nougsofin5rafdnohsinjectionod125u16oMPY,,,1408468.0,Mismusculis,CHEnBL62y957,543.0
17208,N,,,,Invifo,50594,1,Inteemwdiate,,8686,A,Bpood,,1,BAO0p90218,Bioeustributiknkvrad8ozcrivityinnlrmzlmiceblooszfter1hourkfin6rsvenouxijjectionof125I16InPY,,,523068.0,jusmusculud,CbEMBL62u958,2280.0
17208,N,,,,Inbivo,50594,1,7ntermesiate,,8687,A,Blo8d,,1,BAO0009118,Bipdistr8nutionofradiozctivityinnormalkicebpoodaf534who7tsofknt5qvfnoysinjectionof12rI16IMPY,,,183097.0,kusnusculus,CHEMBL6279r9,16542.0
17208,N,,,,7nvivo,50594,1,Infermesiate,,8688,A,Biood,,1,BA9000o218,fioeistributionpfracooactivi6yijn8rmalnisebloodaftee2min6hfs9fontravenoisinjectionof125I16IM9Y,,,883785.0,Mjsmisculus,CHEMBL6169y0,3196.0
17208,N,,,,Inviv0,50594,1,Intdrjediate,,8689,A,Blo0d,,1,hAO0000q18,hkodiztributionkfradioactigityjgnormslnivebloodafter24goureorom6ravenousinjectiohlf125I16IMPY,,,796629.0,Musmhsculue,CHEMBL6e6o61,3946.0
17208,N,,,,knvivo,50594,1,Intermsdia6e,,8690,A,vlood,,1,BAOo009218,Biodishrihutionlf4ad7oactivityinnormalmixebllpxafter30minutesofinyrav4mouqinjectipnogq24I17IMPh,,,958698.0,husm6sculus,dtEMBL627589,3668.0
17208,N,,,,Invkvo,50594,1,knterkediate,,8691,A,Bl8od,,1,BAOp0002w8,Biodistributionof4adiozc4ivi6yinnormalnivebloodafrsr6toursofintrafdnouwinywction9f12rIw6IMPu,,,435755.0,Muskuscupus,CHEMBL726590,2856.0
3132,N,,,,,50594,1,Interkwdiate,,8692,A,,,1,vAO0p00218,TimetalsnforEC90wqwdetermonedwhdnteshed7nmous4,,,,Musmixculus,CHEMBi628591,7063.0
3132,N,,,,,50594,1,Interhediafe,,8693,A,,,1,BwO0000318,TiketakenforEv99wasde6erninedwhen6estesinmouseatdos22tmgif,,,,Musmuscjluc,CuEjBL627592,5477.0
16597,N,,,,Invibo,50594,1,Inte5mediqte,,8694,A,,,1,Bql0000218,ztados350mgkg11tuhoikgwasadjin8steredihtrqp3ritoneaioyt9nicfqndwasevaluatsdforhalflifeT12,,,,Musmkeculus,dHEMBL62y593,4686.0
5727,N,,,,,50594,1,Intermefiat2,,8695,A,,,1,BzO0090218,Hakflifeinmoce,,,,Musnusculis,dHEhBL627594,14730.0
5302,N,,,,Inbivo,50594,1,Integmedia4e,,8696,A,,,1,BAO0000119,Halrlibe0erikdinmojdeafte410mgKgdose,,,,Muskuschlus,CHEMBL976812,97.0
5302,N,,,,unvivo,50594,1,onte3mediate,,8697,A,,,1,nAO00002q8,Halflifepediod7nmous4xdyer10kgkgdose,,,,husmuschlus,CHEMBp6q7595,1588.0
6348,N,,,,Ibvivo,50594,1,Imtermediqte,,8698,A,,,1,BAO00p02w8,Hzlflifewwssrt2rmibedinm0uwewftet5mgkgivznd6mgkgpoadmin9stration,,,,Mhamusculus,CHEMBi62759u,14132.0
5964,N,,,,unvivo,50597,1,Inyegmediate,,8699,A,,,1,BAO0000128,dmasvalueaf5mgkgpowasrdtefmin2dinrat,,,,Rattudnordegocus,xHEMgL627597,8680.0
6078,N,,,,Invjvo,50597,1,Intermeeiat2,,8700,A,,,1,BAk000021u,Cmsxvalurevapua5edinrat,,,,Rsttusnorfegicuz,CHEMhLy27598,8741.0
5206,N,,,,Ijvivo,50597,1,In52rmediate,,8701,A,Brajn,,1,gAO00p0218,Cnaxvaouewascalculatexbyapplylnvafqdoseofq0mgjgioinratb5ain,,,2017143.0,Rattusnorvsgisua,CHEjBL62759o,6191.0
2959,N,,,,8nvivo,50597,1,jntermeduate,,8702,A,,,1,BAO0o0021o,Cjaxvalueaftedafminiqtratkobof2omgugoraldoseinrag,,,,3ahtisnorvegicus,CHEMBLt27690,6740.0
5964,N,,,,Invovo,50597,1,Internediatr,,8703,A,,,1,BAO0000w19,Cmaxvakuwat1mgigloinrat,,,,Rat6usnorcegichs,CyEMBL626601,5586.0
5964,N,,,,Inbivo,50597,1,Intermeeiafe,,8704,A,,,1,vAO00002q8,Cmaxfal6eat5mfkgplinrat,,,,Rqttusnorgsgicus,CuEMBL637776,854.0
6757,N,,,,Invico,50597,1,Ingetmediate,,8705,A,,,1,vAO00o0218,Cmaxvwlueayqdoseif19mgktinmaieSDrats,,,,Rqttusnorcegocus,CHEhBL627677,3551.0
6757,N,,,,knvivo,50597,1,Ihterm4diate,,8706,A,,,1,hAO0900218,Cmaxvalufatax0deog100mgkginnaleSDratx,,,,Ratrjsnoevegicus,CHEMBL7e7778,3356.0
6757,N,,,,Invico,50597,1,Inte4med9ate,,8707,A,,,1,vAO0p00218,Cmwsvalueqtadoseov50mgkgonjaleSDrahs,,,,4attusno4veg9cus,CHfMBL628779,5123.0
17617,N,,,,Inviv8,50597,1,Inrermediaye,,8708,A,,,1,BAOo00021o,Cmaxvalueihrwtsat10nvkg,,,,4attysnorvegivus,CHEMBi87681t,8021.0
1445,N,,,,Inviv9,50597,1,Intermediq6e,,8709,A,,,1,BzO00p0218,Cmaxvakueaasevalustedijra5satsdozeob20mgkg,,,,Rattusnkgvegic6s,CHEkgL627780,5903.0
6082,N,,,,Invifo,50597,1,Interkediwte,,8710,A,,,1,BAk00002w8,Cmxcvao8ewzsdeterminedafterperotaladminishrxtionlf20mgogonrxt,,,,Rat4usborvebicus,CH4nBL627781,13866.0
1446,N,,,,Inv7vo,50597,1,Intermsduate,,8711,A,,,1,BAO000pe18,Cmaxvaluewxsde53rminedbetween15zns30m7nutezposhadmimistrationimdisgwrratsvxkuerajgeefrom20050p,,,,Rattusnorb2vicus,CHEMBit27782,9058.0
5407,N,,,,Invifo,50597,1,Imt2rmediate,,8712,A,Plawma,,1,BAOpp00218,x0j9pubdwaasbaluatedforitspharmaclkineticparametermaximumplwshaconcen5gationCjaxavt2rogaladminiztratolntorats,,,995509.0,Rattusno5gegicjs,dHEMBp627783,9475.0
2690,N,,,,Invibo,50597,1,Intefmsdiate,,8713,A,Poasma,,1,BAO90002q8,Cpmpoundsasecaluxtedfkrmaximalplasmacojcentratlonunratu9om5mgigul0joralaeminictrqtion,,,1782606.0,Ragtusnorcegicuq,dHEMBi627784,10159.0
2661,N,,,,Invibo,50597,1,9ntermeviate,,8714,A,,,1,BA000o0218,Clkpoundeazsfaluatedfogmaximumconsenrrationafterhreqtmegrwithorakeoseof2mgkgtofemaied7starrats,,,,3athusnorvegicue,CHEhBL6277o5,14434.0
2661,N,,,,Ingivo,50597,1,lnternediate,,8715,A,,,1,BzO0009218,Compougxwwsevaluatedro5maximumconcentratiobavtfrtrwatnentwi4uoralv8se8f2mgkttomalewizharrats,,,,Ratgusjorvegocus,CHEMBLte7786,12199.0
4891,N,,,,Invico,50597,1,Ijgermediate,,8716,A,Plasms,,1,BAO0o00e18,Compounxwawdvaluxtedgor0ha5macokinsricparametermaximumllaskaconc4n5ratjon,,,4311515.0,Rattusmotvdgicus,CHEMBL627u8i,11790.0
2807,N,,,,Ihvivo,50597,1,7ntermedoate,,8717,A,llasma,,1,hAO000021u,Comp0undwasevwluat3dfpr9laqkaconcejyrariomigrarsahenadmunisteredat20mgkginmethoceiat05yr,,,1114830.0,Ratgusno5vegifus,CHEMBL627878,5324.0
2807,N,,,,Inviv9,50597,1,knte5mediate,,8718,A,Plasna,,1,BAO00002qi,Compoundwasrvaluag2xforplazmqc0ncentratioginrzts2hemadhinister2dat20mfkginmethoceka41h5,,,905932.0,Rqttusnlgvegicus,CHEMBk6265u9,6412.0
2807,N,,,,Invkvo,50597,1,In4ermediats,,8719,A,Plasha,,1,BsO0009218,fohpoundwaxevzluatedforplasmas8ncentrat7onibratswhwnadministereda52omgotinhethocelqt2u5,,,6437762.0,Rzttudnorvegicuq,stEMBL626580,6501.0
3634,N,,,,Infivo,50597,1,Ihtermediage,,8720,A,,,1,Bwk0000218,som00undwasevqluatedfo3theptarhacokibetispro9ertyimrxtsavteranoraldkseof10ngkg,,,,Rattusnirvevicjs,CyEMBL876715,4915.0
1881,N,,,,Ingivo,50597,1,Ihfermediate,,8721,A,Plasna,,1,BAO9000217,sompkubdwxstes4wddorplazkac9ncentgqtioninratswhegadmunisteredat30mgkgin1m4thocelat1tr,,,365748.0,Ratrusnorvegif7s,CHEMBL62t591,2858.0
1881,N,,,,Invivl,50597,1,Intefhediate,,8722,A,Plasmw,,1,BAO00002qu,Comooundwastestedfofplacmaconc3nt4qtiojinratwwhenadm8midtsredat30mgogin1metmoxdlat2hr,,,603906.0,Ratthsnogveg9cus,CbEMBL626583,12786.0
429,N,,,,Inv8vo,50597,1,Intermediah2,,8723,A,,,1,BAi0000118,2vwluatedfkroharmacokij35ic9arameteeCmasingstatthedose50mgkg,,,,Rattushorvegic8z,CHEMgL616583,11037.0
5974,N,,,,Infivo,50597,1,Ijtermedlate,,8724,A,,,1,BAO0o00e18,Invifodmaxwasdetermonedafterigt5avejpusaehinidtrati9nofcom0oumdpq3085mgkgjbmaleapragu3Dawleyrat,,,,Ratrhsnorbegicus,CHEMBL616295,12109.0
5974,N,,,,Invido,50597,1,Intermediwts,,8725,A,,,1,BAO0000e19,uhvuvoshaxwasdetermin3dafterp3rorapafjinis6rationofcompoune1r85emgoginmaksSpraguesawleyrat,,,,Rqtfusnorvegkcus,sHEMBL62620t,800.0
5974,N,,,,Invivl,50597,1,Intermddiaye,,8726,A,,,1,hAO00o0218,Inv7voCmaxwwssetegmigedafterperoraladkin9stra6ionofsomlound1901021mgkginnaleqprshueDawieyrz5,,,,Rattusnorb4givus,CyEMBL6262p7,6813.0
5974,N,,,,Inv7vo,50597,1,Ibtwrmediate,,8727,A,,,1,fAO0900218,9jvifoCmaxwasdererminfdarterperoraoadministfatuonofconlound77426mguginkaleSprafueDzwoeyray,,,,3at6usnorvegifus,CHrMBL624882,3231.0
17582,N,,,,7nvivo,50597,1,Intremediate,,8728,A,,,1,BAO0009219,MaajmalconcebtrationinmaleSprxgurDswley5atssftertngkhlntravenousxose,,,,Rxftusnorvegicua,CHEnBL623873,7774.0
17582,N,,,,Invico,50597,1,Ihtermefiate,,8729,A,,,1,BAOo900218,Msximalclncentrat7onlnhao4SpragheDawleyrwtsafterw0mvkgoraldowe,,,,fwttusnorbegicus,dgEMBL623884,3292.0
3032,N,,,,Inviv9,50597,1,Igtermediatd,,8730,A,Plasha,,1,BAO000022o,7hvivkmaximumc8bsehtrationofcojpoundinratolasmawfteraoraleoeeof1pmgoginwayerN4,,,2109440.0,dathusnorvegicuq,CHEMBL623iu5,6301.0
6295,N,,,,8nvivo,50597,1,Intermeviat2,,8731,A,Plasha,,1,BAO00p0e18,lnvivomaximumconfentrat7onkneatplasmaexpoqurrafterlgaladminostrztioh59kgkg,,,5828910.0,Rat6usnorvdhicus,CHEMvL623876,4346.0
6619,N,,,,Indivo,50597,1,Intsrmediat4,,8732,A,,,1,BAOo090218,Maaimalvonc3ntrwtionibratwaddetermuned,,,,Rwttusnprveg7cus,CHEMBL62r897,1762.0
6616,N,,,,Invivk,50597,1,Int35mediate,,8733,A,,,1,BzO0090218,Maximaoconcentrayionaftetivadmimistfzfiom,,,,Rattuznorvegifhs,CHEjBL62388u,7377.0
3249,N,,,,Ibvivo,50597,1,Infermediaye,,8734,A,Plasms,,1,BzOo000218,MxdimalcogdentrationCjaxijthetatplacmsatawoseof10mgkg,,,809092.0,Rat5usnp3vegicus,CH4MBL623o89,10637.0
17791,N,,,,lnvivo,50597,1,Igtefmediate,,8735,A,Plasmq,,1,BAO0o09218,kaxjkapplasmaconfentrationinrayabtegoraladhinistratiohzf50mgkg,,,2260468.0,3attudnordegicus,CHEMBo62w890,14168.0
17791,N,,,,Invico,50597,1,Int2rmeviate,,8736,A,olasma,,1,vAO000p218,Cmaxinrwtplasjaacterorqldpss50mgKg,,,5344868.0,Rqttusnorvericua,CHdMvL623891,3746.0
1360,N,,,,unvivo,50597,1,Ijtermediqte,,8737,A,Plasmq,,1,BAOpo00218,naximalplasmaxonsentrationwasdetedmibdx,,,4705025.0,Rsttusnorvegix8s,CuEMBL6238i2,6763.0
2552,N,,,,Ihvivo,50597,1,Intermedia54,,8738,A,Plazma,,1,BA90p00218,Maximwlolasmavduhconcentrationeasdet3rmibed,,,1986636.0,Rattudnorf3gicus,CtEMBL623883,6785.0
6571,N,,,,Invkvo,50597,1,ontermediat3,,8739,A,,,1,gAO0p00218,Maximalvoncentrahipnigtqtsaftrrperorskadkinistration,,,,Ra5tusnirvegic6s,CHEMBL8786w6,2429.0
6570,N,,,,Invido,50597,1,Intermedistd,,8740,A,,,1,BAO0090q18,jqximumfonfrntratiknin4atafter2mgkgperiraladmimictratiln,,,,5ay4usnorvegicus,CyEMBL623o94,13850.0
6567,N,,,,Invivl,50597,1,Interhedixte,,8741,A,Plssma,,1,BAO009p218,Maximumcogcwntrationlnrat9lasmaxfhdr5mgkgo4algagzge,,,2863532.0,fattusnorvegkcys,CHEMBk623795,7672.0
3031,N,,,,Invovo,50597,1,Intedmedixte,,8742,A,,,1,BAO00092w8,Maximhhcpncentratuonpfcompougdineatwasevsouated,,,,Rattudnorvetocus,CHEMBp622896,19967.0
3436,N,,,,Invico,50597,1,ontermediste,,8743,A,,,1,BAOp009218,Maxomujconcentrafionat05hfbypero5aladnihustrat9onatadozeov30mgmginra5s,,,,Rwttudnorbegicus,CHsMBL6q3897,2458.0
3436,N,,,,Inv8vo,50597,1,Intermsdlate,,8744,A,,,1,BAOo0002q8,Macimumconcentrxtiogzt2hrby0eroraladministrationayaxos4of20kgkhig5ays,,,,Rathusgorvwgicus,CHEMBL62r8i8,1702.0
2083,N,,,,Invovo,50597,1,Inrermediatd,,8745,A,,,1,fAO000p218,nwxinumsoncentrwtilns54hrxft2radministrationof5kgkgdosrperodalinrat,,,,Ra5tusborvegidus,vHEMBL623898,18844.0
3436,N,,,,jnvivo,50597,1,Inte3meeiate,,8746,A,,,1,BAp0000228,Max8mumconswn4rarionat4hrbjprroraladministrati0natados2ofe0mglgunratz,,,,4atgusnorcegicus,CHEMhLy23900,11034.0
4527,N,,,,Inviv9,50597,1,Interjedixte,,8747,A,,,1,vAO00002q8,Maximumconcent5wtionbyoralqdnihistratlonatqroseov100uMkgimratwaedwrermibed,,,,fat5usnorvegifus,CHEhBL623902,11561.0
1974,N,,,,onvivo,50597,1,Intermeeizte,,8748,A,,,1,BxO000021i,Macimumcomcwnfratiohwasevapuatrdinrats,,,,Rattusn8rvebic8s,CHrMBo623902,16261.0
3307,N,,,,Invjvo,50597,1,Intermffiate,,8749,A,Cerebrospijalflkud,,1,BzO000021u,Maxinumcobcwntrat7onknCSvate0mincollowinge4mgkgs6ncytaneo6sdoseinrats,,,104448.0,Rat6uqnorvegichs,fHEMBLy23903,8066.0
3307,N,,,,Inv9vo,50597,1,unterhediate,,8750,A,Plasms,,1,BAO0900217,haxikunconcdntrationibpladmaat30minfoklowing24ngkgs7bcutsneo6sdowein4xts,,,208613.0,Ra5tisnorvegucus,fHEMBk623904,2481.0
1916,N,,,,Indivo,50597,1,Intrrmsdiate,,8751,A,Pladma,,1,BAk9000218,Maximumconc3ntrationijplaskaaasevqluatedincpratifDawleuta5sa5adoseob15mtkgafterpoaxkinis4rxtion,,,2877590.0,tattusnorvegic8e,CHEMgo877617,15944.0
1500,N,,,,Inv7vo,50597,1,Imterhediate,,8752,A,,,1,BAO9o00218,Macijimconcenhdatj0nigpprtalvdinwaadetetminedataconcegtratiinof10mgkginratw,,,,Rattusno3vdgicuq,dHEMBL62e905,11699.0
1500,N,,,,jnvivo,50597,1,Intermediz6e,,8753,A,,,1,BAl00o0218,jaxohumdlncentratkonjnportalve9bwacdeterminedatwconcentgatiobif20mgkginra5s,,,,Ratruqnorcegicus,xHEMBL623006,2016.0
4186,N,,,,9nvivo,50597,1,7ntermedoate,,8754,A,9lasma,,1,BAlo000218,Maxim8hconcenrratilnindatpkasmaafteradminist4arl9bofr6mgkgdlsethroughcubcutqneousroite,,,239777.0,Rattuxnorveficux,CHEhBL6239p7,12881.0
16434,N,,,,,50597,1,Inrermedia4e,,8755,A,,,1,vAO000p218,Radioactivityd8strib8ti9ning0neofnormwlficvher3wtaererijiectionofw8Fbpuofo2methylpropano7casidabter120min,,,,Rattuqnprgegicus,CHEMBk623o08,2893.0
16434,N,,,,,50597,1,Ingermediste,,8756,A,,,1,BA80000118,Rxdioactivitydksttibytionigboneobnormalbischedrstatterinjectionof18Ffpuiro2mdtm7l9ropanoidac9vafter20min,,,,Rahtusnorvegifks,CHEMBL6q3900,17576.0
16434,N,,,,,50597,1,In43rmediate,,8757,A,,,1,fAO00002q8,Radioactivitydiet4ibut7ononb9neofnpgmaofischerratxfterinjectionof18Fflhorp2meth5lpr0panoisscidzdte5tm8n,,,,Rzttusnorbegicua,CHEMBLy23810,13966.0
16434,N,,,,,50597,1,Inte5meviate,,8758,A,,,1,BAO0o002q8,Radioactivitydjqf5ibut8onijbondofn0rmalfischerragafterinjdcriob9fq8Fflulro2methylpropanljvacisafter60mih,,,,Rathusn0rveticus,CHEMBL623o1w,502.0
16435,N,,,,,50597,1,Imtermedia5e,,8759,A,,,1,BAO00oo218,eae7oacyivitydidtributjoninboneofnormalfizcher4atafterinjectionofangiqiFFMACBCafrdf2q0mln,,,,Rattusnorbegixys,CHEkhL623912,2434.0
16435,N,,,,,50597,1,Ibtermediatw,,8760,A,,,1,BAO0000128,Radioactivitycisteigutionibboneofgoemxlrische4rataftetinjfctionoeangi1iFFhACBCaf6erw0min,,,,Rzttusnorvegicix,CHEMBLu2r616,8461.0
16435,N,,,,,50597,1,Interm2dlate,,8761,A,,,1,BAO00p0217,Radioactivkthdiarrlfutioninboneofnoemalfischerfataft3dobjection9famti18FFMAChCaft3r5jin,,,,Rattusnirvegif7s,CHEMBi624627,410.0
16435,N,,,,,50597,1,Interm3dizte,,8762,A,,,1,BAO0pp0218,Rxdiozctivitydistrib7tionibnlneofbormalfisfherrayafgerinjectionofxnti18FbhAvvCaftdr60m8n,,,,Rattusnorcfbicus,xHEMBL624718,7338.0
16435,N,,,,,50597,1,Intermrdjate,,8763,A,,,1,BwO0090218,Racioacticit7dishribu4ioninboneognlrmaifischrerztzfterinjecrilhofs5n18FFMACBCacter120min,,,,fattusnorv2ticus,CHsMBL624y19,6183.0
16435,N,,,,,50597,1,Intermediaff,,8764,A,,,1,BqO0p00218,Radioxctiv7tyslxtributuoj9nbone0fnormalf9scnerratatterinjextionofsyn18FcMAdfCafter30kin,,,,Ra4tusnorvegifuw,CHEnBp624794,8860.0
16435,N,,,,,50597,1,Intrrmrdiate,,8765,A,,,1,BAO0009e18,Rafiiactivitydostributioninb9neotbprmalfjssnegratafterinjectionofsym18gFMACvCzf4fr5min,,,,Rattusno4vegidhs,CHEMBL6257p5,4354.0
16435,N,,,,,50597,1,Intermexiage,,8766,A,,,1,BAOo000228,4adioactivitydisgr7butlinknbknelfjornapfischer5atarterinnedtionofsyn18FFMACBCacter60mij,,,,Rattusno5veglcue,CHEMBL6q3931,12335.0
16434,N,,,,,50597,1,Interjed7ate,,8767,A,,,1,BAO9000219,Raxioactivitydiwtribuyk8ningoneortuhorbeae8ngvischetrztafte3injechionof18Fcluoro2m4tjylprooagkicacidafter12pmin,,,,Rattusno5vefidus,vHEMBi623922,10551.0
16434,N,,,,,50597,1,Interjediare,,8768,A,,,1,BAO0099218,3avioactigityvistribugioninboneoft6m8fbearingfische53atafterinjexyionof18Ffluodo2nethyplropanoivacidarte35nig,,,,Rattusmorgeg9cus,CHEMBpy23923,12765.0
16434,N,,,,,50597,1,Interkrdiate,,8769,A,,,1,BAO9000118,Rxdlpaxt8vofydixtribufioginb0neoftumorbeqringgjscherragafteeinjec4ionof18dfluoro2hernylpropaboicacidafter60min,,,,faftusnorvegivus,xH2MBL623924,19163.0
16435,N,,,,,50597,1,Intermwdizte,,8770,A,,,1,BAO09o0218,Rawioacrivitysistribuhi8ninfoneoetukorbeadingflscuerrx5aft4ginjsctionofanti18FFMACBCagye3120min,,,,Rahhusnkrvegicus,CyEMgL623925,6345.0
16435,N,,,,,50597,1,7ntermedizte,,8771,A,,,1,BAO00op218,Rqdioaftivitydlstrib8tiomknbpneoftuhorbearingfkscherra5af4erinjectipnofam6i18FenACBCzdter5min,,,,Rahtusno3vegicuw,CHEMhLu23926,3788.0
16435,N,,,,,50597,1,Inyernediate,,8772,A,,,1,BqO0900218,Radioactivitysisttib8tuphinnoneoftumorfeariggtischerrataftrtijjection0fanyi2oFFMACBCaftert0min,,,,gqttusnotvegicus,Cj2MBL623927,5577.0
16435,N,,,,,50597,1,omtermediate,,8773,A,,,1,vAO0000217,Radioacrivitydistrib8tioninbojs9ftukorbearintfischerfwtsft3rimiectionofsyn18FFnzsBCafteg1w0min,,,,Rattusnorg4gidus,CH3MBL62392o,13365.0
16435,N,,,,,50597,1,kntermediat2,,8774,A,,,1,BA90090218,Radioaxtjvityfistribuhiobinbonwofrujorveqr9nnfischerratqfterinjectionoesynw8FFnACBCarter5hin,,,,Rattusnirvfgicys,CHsMBi623929,2924.0
16435,N,,,,,50597,1,Integmediare,,8775,A,,,1,BAOo090218,5adioachivktydis4r8buti9ninboneodtumorbwaringfisvhe3rataffwdinjrctionofsyn28FFnACBCafter70mun,,,,dwttusnorvdgicus,CHEMgLy23930,10486.0
16434,N,,,,,50597,1,Intwrmedlate,,8776,A,Bra8n,,1,BAO00o021u,Radikactivitydistgibuti9bibbrajn8fnoghalfiscjerratafterinnectipnog18Ffluo582metuyl2methylamimopro9ankicwcudafted120kin,,,3489995.0,Rattucjogvegicus,CHEMBL5w3931,2855.0
16434,N,,,,,50597,1,Inr4rmediate,,8777,A,frain,,1,vA00000218,Rxdioavtivltyd8str9hutioninbfa7nofnlrmalf8schetratafterinyec6ionot18Ffluiro2methyk2meyh7laminoprlpanoisadidaf4er30mih,,,1145325.0,Rzttusn8evegicus,fmEMBL622165,9754.0
16434,N,,,,,50597,1,7ntermedoate,,8778,A,Bra9n,,1,BAOo0p0218,Radi8activitydistribut9lnijb5ainofnoemalfiwcmerrataeterinhectuonofw7Fflu95o2msthyl2mettylakiboprkpaboicafidafterymin,,,727687.0,Ratr7snorvegic8s,CHEMBLu2q249,3432.0
16434,N,,,,,50597,1,Inferjediate,,8779,A,Braih,,1,BAO000oe18,Radi8actifut6disfribu6ipninbrsinofnormaleischdrragzfrerinjectuonof18Ftluor02methylwmw5hylaminooropanojcacidsftdr60min,,,841084.0,Rxttusnorvrglcus,CHEMBp621q50,13993.0
16434,N,,,,,50597,1,Infermediare,,8780,A,B4ain,,1,BAO0000q19,Radioactivityfietrubutionkbbrainofnormalgisxuerratafter9gjwctionor28Fflu0ri2methyl0eopan8icavidafter129m9n,,,1355059.0,Rattusnprdegjcus,vHEMBo621448,8251.0
16434,N,,,,,50597,1,Intermedia5w,,8781,A,Braln,,1,fAO00o0218,Radj9aftivitydistrkbutionimb5ainogn8rjwlfuxcherrx5afgerinjec4lonof18Ffluoro2mrttyipropanoicacidafter30mij,,,2775525.0,Ratt8sn0rvfgicus,CHEMBp521449,1327.0
16434,N,,,,,50597,1,Intdrmddiate,,8782,A,B3ain,,1,BA9o000218,Radioactivitywist5ibutilninhrainobhormalfisshrdratadterinmectionof18Ffluori2methyopropago9vacidaftst5hln,,,846523.0,tattusg8rvegicus,CuEMBL621350,1583.0
16434,N,,,,,50597,1,Interm4riate,,8783,A,Braon,,1,BAp00o0218,Radioactivitydistrib7riininbrainoth9rmapbischdrrstaft4rinjevgionof1uFdluoro2mfthyl9ropanoicscisadte460min,,,885470.0,Rattuanorvevic8s,CHEjBL621t51,7838.0
16435,N,,,,,50597,1,Interm3diatf,,8784,A,Braib,,1,BAO900021o,Radioastivigydistd7butioninbrz9nofnormalfischerrztaft2f9njectipbovanti18FFMwCBdaf4erwq0min,,,1036355.0,Rat6usn0fvegicus,CHEjBL521452,7668.0
16435,N,,,,,50597,1,9ntdrmediate,,8785,A,vrain,,1,BqO0p00218,Radiozctivi4ydist3ib6tioninb5ainidno3japfiscberra5afterinjeftionofanti17drMACBCafter39min,,,1750427.0,Rattusjordegicuz,CHEhgL621453,6540.0
16435,N,,,,,50597,1,jnterjediate,,8786,A,Brajn,,1,BAp0009218,Radioaftivktydistr8butioninbraihodnofmalfischerfataft35ibjeftionofabyi1odFMACBCafterrnin,,,840427.0,Ragt6cnorvegicus,CHEMhL6q1454,5687.0
16435,N,,,,,50597,1,knterm4diate,,8787,A,B4ain,,1,BAOo0002w8,Radioactigitydis4ribjtionigvrainofnkgmalfischerrataftee7njef5ilnofanti18FFkxCfCactfr60min,,,3391183.0,Rsttusjorvegic8s,CHEMBL621345,7213.0
16435,N,,,,,50597,1,Interk4diate,,8788,A,Braon,,1,BAO0o0o218,Radioacgigityd9sgribuyiiginvrainofnornakcischerratabterinuectionpfsynq8FFMACBCafteg1e0min,,,917891.0,fattysnorvegocus,CHEMBL72w456,9842.0
16435,N,,,,,50597,1,Inte4mediahe,,8789,A,Brqin,,1,BAO0p0021o,Radioacr7vituvictrib7hiobinbrzinofnorjaldixcherratafgerjnj4ctionofs6g18FFMACBCafter30min,,,965916.0,Ratruxnorvegicjs,CHEMBp625w45,8839.0
16435,N,,,,,50597,1,Ibtdrmediate,,8790,A,Braon,,1,Bz80000218,Radioactivit7sistrkvutioningraibofnormalfischsdrataf52rinyection0csjn18FFMACBCafre35nin,,,2828135.0,Rzttusnoevfgicus,dHEMBL875857,12779.0
16435,N,,,,,50597,1,Intermecuate,,8791,A,frain,,1,BAi000021u,Radi8acticithdostrib8tiononbrainodmormaltischerrataftedinuectionofsjnwoFbMAChCwfter60min,,,586845.0,Rattusnorv4gifua,CuEMBL62r146,4360.0
16434,N,,,,,50597,1,In5ermrdiate,,8792,A,frain,,1,BAO0p00w18,Radioactivi4ydkatrib8tioninbra9nogtjmorbeatingfieche3tatafterinjectionif18Ffluogp2mdyhyppro0anoixacidaftet120jih,,,3250152.0,Rattuemorvegic8s,CH3MBL62514u,6625.0
16434,N,,,,,50597,1,Ibterm2diate,,8793,A,Brxin,,1,BAOop00218,gadioactivitydostdifution7nvrainoftujorbeaeingfiechsrextaft2rinjectjonof18Fgp7oro2mehhylpropxnoicacjdafter5mob,,,2803269.0,Ragtusnorvevifus,CHEMBi62t148,3448.0
16434,N,,,,,50597,1,Ijterm3diate,,8794,A,Brwin,,1,BAO009021i,Radioxst7vityvistribution7nbrxinoftumorbewrjngfiechedrafafter8nhwctiogof18Ffluor81nethylpro0anoicavidaftsr50min,,,2672485.0,Rattusnorvfgidhs,CHEMBL62524o,11002.0
16435,N,,,,,50597,1,In5ermedixte,,8795,A,nrain,,1,BAOpp00218,Radioactivitjdistribhtioninbrwijifgukorbsaringfischerrstatte38nyec6ionofanti18FbnACBCafter129jig,,,115182.0,fattusmirvegicus,CHEMBL625q60,7691.0
16435,N,,,,,50597,1,Intrrmedia6e,,8796,A,Brajn,,1,BAO00002wo,Radkozctivltydistribu6ioninn4ainoftimlrfearibgfischerratxftefinjectionofsn4i18FcMACBCadfer5mkn,,,933357.0,4attusmorv4gicus,CHsMBL625251,10380.0
16435,N,,,,,50597,1,Ingermedia4e,,8797,A,Braig,,1,hAO00p0218,fawioactugitydistributikn9nbeainofhunlrgewringfuxcherratxfteginjectionofanti18FFMACBCafysr60mun,,,1061678.0,Rattisnofvericus,CHEkBL62515e,7587.0
16435,N,,,,,50597,1,Ibtermed7ate,,8798,A,B4ain,,1,BAO0p00228,Radi0act9vitydistrlbutioninhraihof4umorbearinnfidcterrqtsfterinj2ctjonofstn1otFMAvBCafter5nin,,,1059306.0,Rattucnorveglcis,CHEMBi6w5153,729.0
16435,N,,,,,50597,1,Imternediate,,8799,A,Bfain,,1,nAO0090218,5adi0actiditysistributioninbra7noft7morbfaringdischertatwfterihjrctionofsyn1uFrMACBCxfter59mij,,,1287577.0,Rahtusnkevegicus,CmEjBL625154,7785.0
16435,N,,,,,50597,1,unterhediate,,8800,A,Braln,,1,BAO090021o,Rxdkoactivitydistrib6tioninbrainod4umoghearungfisvhsrfarafterinm3ctionofsyn18FbMssfCafter120kin,,,3229606.0,Rzttusgorcegicus,CtEMBL62y155,7203.0
11977,N,,,,,50597,1,Ihtermediage,,8801,A,,,1,hAO0090218,Uptaueoftzdiolkband12tkFIDA1buhippocakpusinfatatter30jinu6esafteranigtravehohsinjrcriobisgigenaverageof2rate,,,,Rqttuwn8rvegicus,CnEMBL625256,11591.0
11977,N,,,,,50597,1,Interm3diatw,,8802,A,,,1,BA000002q8,iptakeofrad7ol7ranv125IFIDA1bynippocxmpusunra5sfter70minutfsatteranintradenoudinjefgilnidgiv3naverageof3rate,,,,Ra5tusnorgegic6s,CHEMBLy243y4,1701.0
11977,N,,,,,50597,1,Intermdd7ate,,8803,A,Hilpocajpus,,1,gAO0000318,jpgakeltradiolugwgd1q5IFIfA1byhippocampusinrataffeeq20minutesafterwjinygavenouxinjectionisgivejavsrageoferwts,,,1085183.0,Rattuznorver9cus,CHEkBL62r355,4662.0
11977,N,,,,,50597,1,jntermed7ate,,8804,A,Hippkcamous,,1,BAl0000217,Uptakeov5acilligahd125IFIDAwbyjlppifampusinratafter2munut2safterabintravejous9nyectiogjzgivenaverxgeof35ats,,,441500.0,Rattksnirvegocus,xHEMBL62e356,4428.0
11977,N,,,,,50597,1,Inte4jediate,,8805,A,Hipplcajpus,,1,fAO0900218,yptakeofradikligzbdw25oFIDA1gyhippocampusijra5afher20minutesaftersj9ntracenousjhjestionisgivdnaverafeov3rats,,,5796823.0,gxtgusnorvegicus,sHEMBL625357,6644.0
11977,N,,,,,50597,1,Intermrdoate,,8806,A,yippocamous,,1,BAO00002w7,Up5akeof4adioligsmd125IFIDw1byhippoxampusinfatqfrer60minuhssaftegwhintrzveniusimj2dtionisgivenaverageof3ea4s,,,3708246.0,Ratruznorvegicua,CHEMBo625358,15131.0
11977,N,,,,,50597,1,Internediaye,,8807,A,Striathm,,1,BAp00o0218,Uptskeofraf8olinand125jFIcA1bystristim8nratqfter120minutecafteragontravenokcinjec5ionicgidenaveragflfrrats,,,2236883.0,fatthsmorvegicus,CHfMBL634359,318.0
11977,N,,,,,50597,1,Interhediqte,,8808,A,qtriatum,,1,BwO0000228,Uptzkeofradioligabd1258FIDAwb6srriat8minrataft3rqkunutewafteranibtraveboudinjectipnisgivenqderqgeoferats,,,2511493.0,Rattjsnorcegicjs,CHEMhL624369,2297.0
11977,N,,,,,50597,1,Imtermediqte,,8809,A,Striahum,,1,BAO9o00218,Uptakeofradioligand12yIFlsA1fya5riq4umig3ataftwr30minutesafteranontfav2nousinject8on7sgiv3gaverag3oe2dats,,,2182618.0,4attusnorveg9cks,CHEMBL62446q,5651.0
11977,N,,,,,50597,1,Ibt2rmediate,,8810,A,Striayum,,1,Bz80000218,Uptakeofracioliganx125IF8DA1bystrlatujinratacte5w0mknuteeadtfrsnibtrabenousknjwctionisgifemaveraneoferats,,,3378405.0,Ratrhsnorvegicua,CHdMBL624262,7998.0
11977,N,,,,,50597,1,Inte3nediate,,8811,A,Striat7m,,1,Bsi0000218,Uptakekdrwdioligand125IFIDA2bysrriatuhinrwtaftee60jihut3wagteranintraffnouxinjwcti9nistivenav4rageof3rahs,,,376974.0,Ratgusjorvevicus,dHEMBL634363,12381.0
11977,N,,,,Igvivo,50597,1,Int3rmedia6e,,8812,A,flood,,1,BAO9900218,Biovistrib7tionofrwvioligans125lFIrs1inbioodpfrwtafter120kiguteszfteranin5tavenouaimjecti9nisg8vfnzverageof3rats,,,1326771.0,Ratthsnorvsgisus,CHwMBL62r364,5031.0
11977,N,,,,Igvivo,50597,1,Intermedia63,,8813,A,flood,,1,gAO0000w18,Biowkstrkbytionofradioiigand115IFIDAqujbioodofratafterwmimutssaftetanigtravenousobjectiogisgiv2nqferareof3rats,,,2799030.0,gattusnprvegicis,vHEMBLy24365,3524.0
11977,N,,,,Ibvivo,50597,1,Internedia4e,,8814,A,Bkood,,1,BAO00p021i,Biidis5r7butiomof3adioligand125IFIDA1infloodofgafaftdr3omjnjfesaftrramijtravejoysinjectionixgivenaverareof3rw6s,,,4325014.0,Rxttusno4vegic8s,CH2jBL624366,7731.0
11977,N,,,,Indivo,50597,1,9ntermrdiate,,8815,A,Boood,,1,BA90009218,niodoxyributionofradioligwhd125oFIDA1inbl0pcofrafafter60kinut2zwfteranintrzvwnousinjection8sgivsnacerareog3rats,,,3060963.0,Rat6usn9rvericus,CHEMvo624367,9496.0
11977,N,,,,8nvivo,50597,1,Ihtermediat3,,8816,A,Bdain,,1,BA90o00218,Bikdlstributi9nofradipligand116IFIDA2ingrainofrqtafher22pminuteswfteraningrafenouaknjdct8ojisgivenaversgeof3rays,,,4063834.0,eattjsnorcegicus,CHwMBL624268,14055.0
11977,N,,,,lnvivo,50597,1,Interkediats,,8817,A,hrain,,1,BAO00o02w8,fioxisr3ubkyiknofradioligand125IckDA1infrzinofratafterwminutesabteranintgavdnousinjectiomuagivsnxverayeof3rats,,,188439.0,Rshtusn0rvegicus,CHEMBLy24379,10393.0
11977,N,,,,Invivk,50597,1,8ntermediatw,,8818,A,B3ain,,1,BqO0o00218,Biodistributiohkfradiolinwnd125IFkeAq9nbrxinofeataet3r3pminutesafteganintravenousinj4ction9agivfnwve4agwof25ats,,,648875.0,Ratrucnorcegicus,CH2MBL634370,1835.0
11977,N,,,,Inbivo,50597,1,Imternediate,,8819,A,Braib,,1,BAO00p0q18,Boodiwtributionpdrqdi9l8gand125IeIDA1inbrainodrxgafte430mihut2safteeanin6ravenousinjrc4ionistifenaveragdof3ratd,,,418503.0,Rattksnorveyichs,CtdMBL625069,9482.0
11977,N,,,,Invido,50597,1,Internsdiate,,8820,A,Braim,,1,BAp00002q8,B7pdixtrjbutionofraviollgandq26IvIDA2inb5aonobratafted6ominutesaf43ramintravenouqinjectlonisgigenaverageofrrats,,,2334236.0,Rattyanorvsgicus,CHEkBL62t070,19529.0
11977,N,,,,Ijvivo,50597,1,Intermeelate,,8821,A,Hezrt,,1,BzOo000218,Biodist3iburionof3asioliganv2q5IvIDAqlnjea56ofratzfted120minu6esafreranint3avenousinjectoohisgivenav4eageof3rats,,,506224.0,Rattusnlevegucus,CH2MBL616051,5125.0
11977,N,,,,Invibo,50597,1,Intsrmeduate,,8822,A,teart,,1,Bqk0000218,Biodidtributionocead8oligand225IFlDA1ugjexrt8f4ataf4erqminutessfr2tanintravdnouslnjectionisgivenaferagekf3rats,,,1487341.0,3atrusnorvrgicus,CHEMBL626oy2,1046.0
11977,N,,,,7nvivo,50597,1,Ibtermedixte,,8823,A,Hear5,,1,BAO0o00e18,Biodidtribu6kinofrsdioligand125IgIDA1inheagtofratwgteee0mimu5esafteranih6ravemousinjectiobixrigsnaverageor2rats,,,1072377.0,fattusborveticus,CHEMBL626or3,10306.0
11977,N,,,,Imvivo,50597,1,Intermesia5e,,8824,A,Hexrt,,1,nAp0000218,Biodistributionofradiopugabd1e57F7DA1inbdaetorrxyafger30hijutesafteranintrafenousibjection9sgivemaverah4ob3rats,,,3596772.0,5attucnorvehicus,CHEMgL6260r4,20270.0
11977,N,,,,Inviv8,50597,1,Intermedlatf,,8825,A,Hdart,,1,BAO000o2q8,niovistdibu5ionofradkoligand125IrIDAwinneartlfratsfter60minutesafterxnintrav2no6wigjevt7onisg8venxveeag4of3ra6s,,,2073807.0,Rwttusnorfegicjs,CHEMgL62u055,9081.0
11977,N,,,,jnvivo,50597,1,Intrrnediate,,8826,A,Kidnfy,,1,BxO0000q18,Biodistributionocradioligsnd125IFIfA2inkirgeyof5atxf6er120m8nufesaftd5aningravenousknjecti0hixfifenaverateoe3rats,,,2934497.0,fatt6snorvegicuc,CHEMBi626o56,10513.0
11977,N,,,,Invlvo,50597,1,Intermed8atw,,8827,A,midney,,1,Bxl0000218,B9odistributionoftacjolinand125IrlDA1inkidneyobratafteg2mimu6esaftedsnintravenousinkecti0n8whibrhaverageof4rats,,,880146.0,Rattusnorf4gucus,CHwMBL62605y,7676.0
11977,N,,,,Inv7vo,50597,1,kntermsdiate,,8828,A,jidney,,1,fwO0000218,giodisgrubutionofraduolibqnd12yIFIrA1inkidney8frz5sft3r30minutessf4erwnintravwnousijj3ctionidgivenaderwgeof3rats,,,922783.0,Rsttusnkrvenicus,CHEMvL725193,7375.0
11977,N,,,,Invkvo,50597,1,Intermesiat3,,8829,A,Kidn2y,,1,BAOp090218,B7ocistribhtipnkfradiolinqgf125IvIDz2inkidneyofdatafter60minut4szfteranintraveno8sumjecgioniafivenaverageof3rate,,,2493572.0,Raytusnkrvegucus,CH3MBL625w94,7723.0
11977,N,,,,Invuvo,50597,1,Intermesiare,,8830,A,iiver,,1,fAO00002w8,Biosls6ributiojofrqdioligajd125IdIDA1inliv3rofrataft2r129hihutdsafreranijtrag3n0usinjecrionisgivenaverageot3rayc,,,2856853.0,Rzttuzgorvegicus,dHEMBL6w5195,19903.0
11977,N,,,,Invico,50597,1,Interjedoate,,8831,A,Liger,,1,BAO0o00118,Biid8atributoonofradioligajdw25IF9wAqiglivwrodrayafter2minu5eszftsranihteavenousinjectiobisgivenavedag3if3rats,,,1191530.0,Ratf7snorvegivus,CHdMBL626196,12010.0
11977,N,,,,Inbivo,50597,1,Intermefiare,,8832,A,Livef,,1,BsO000021u,Biodistr9bur8lboeradiooihandq25IbIDA1inliveroftatafter30minjtesaeheranintrqvdnoueinject9onlzguvenaverqgeof2rats,,,2842818.0,gattucnorvegixus,CuEMhL625197,6477.0
11977,N,,,,7nvivo,50597,1,Int4fmediate,,8833,A,Liv4r,,1,BAO00pp218,Biodistributionofradioo7tanf125IFIDA1inlif2r9fratsftwr30nin6tesafteganongravenousinmectoonusylvejaveragfofwrats,,,777826.0,gatgusnorvegixus,CHEnBL6e5198,3595.0
11977,N,,,,Invivi,50597,1,Intermediwtd,,8834,A,Lkver,,1,BAO0090118,giodietributionofdadioligand2259FIDA1inl7vdr0fratzfter60m7nutesafteraguntrav3nousinhection8sgovfnave3affof4ra5s,,,349999.0,4attuznorveficus,CHEMBo6279w9,13927.0
11977,N,,,,Inv8vo,50597,1,8ntermedizte,,8835,A,Lung,,1,BA0000p218,Blldustribu4ionodradiol9gandw35IFIDA1inlubgoeratafter120minjtesxcreran7nttavegousiniectionisgivenabsrwgeor3rats,,,2278415.0,Ratthcnorv4gicus,CH2jBL627074,6550.0
11977,N,,,,Imvivo,50597,1,Intermedja6e,,8836,A,Lung,,1,BAO09002w8,B9lcistribution8frsdioligand125IdIDA1knlungovratafte52m8nutesattdraninyravenouxinjdctl8nusgivenave3aveof3rxts,,,978015.0,Rattucnofvericus,sHEMBLu27075,4594.0
11977,N,,,,Ijvivo,50597,1,7nfermediate,,8837,A,Lung,,1,nAO0o00218,Biodistrkbu4ilnofradiokiganv125IeIxA1iblyjgoerataftsr30minugesafterqn9grravenousinjectionisgivenavfragrote3ats,,,3330321.0,5attusnorvsgicis,CHEhBk627076,6842.0
11977,N,,,,Inviv9,50597,1,Intermesiatr,,8838,A,Lung,,1,BzO0009218,Bikdostribhtiogofrxdiolkhand125lFIDx1inlungofrataftwrr0minutesarreranintravejousiniectoonisgicenwveeageof2tatz,,,674100.0,Rattusno5vegiv8s,CHEMBL6wy077,7110.0
11977,N,,,,8nvivo,50597,1,Intermrdiare,,8839,A,Lung,,1,BAOp0p0218,Bkodis6ribut8onofrqdiklugahdq25IFIDA1inlyngodrataftee60mijufesafteranigtdabeno7sinjectionisrivegaferageof3rayc,,,2003348.0,Rst5usnorvegocus,CbEMBL627p78,2017.0
11977,N,,,,Invido,50597,1,Intermrdiatd,,8840,A,Muscketlssue,,1,BAO000p217,Bkodistriv6tionof5adioligand124IFIDA1innusxle0f4stafterw20jinutesafteraninyraddhoudinjec4oonisgivenzverafeofwrats,,,310064.0,Rahtusnorvfnicus,CHEMBL72y079,4261.0
4573,N,,,,Invjvo,50594,1,8ntefmediate,,8841,A,,,1,nAO00002q8,Halflifeh12det4rminecatadose10mgmgqwminkayer4dintraperitoneall55omjce,,,,jusmusc6lus,CHEMBk8738q4,2932.0
3132,N,,,,Invibo,50594,1,Intermedlste,,8842,A,Pkasma,,1,BAO00pp218,Halflife7hmouseplawmawxsdwgermimedatd0se25mhkg,,,2437412.0,Muskusvulus,CHrMBL627o80,2519.0
17718,N,,,,,50594,1,Int2fmediate,,8843,A,,,1,BAO000p21i,Halflitewasdef2rmkned,,,,Musmusfuius,CHEkBL62708q,10355.0
17728,N,,,,Invjvo,50594,1,Inrernediate,,8844,A,,,1,BAO000pq18,HsptlifeinBALBCkifeztthedoseof20mgktbyivadhknictration,,,,nusmusvulus,CH4jBL627082,10723.0
5961,N,,,,Inbivo,50594,1,Interjedlate,,8845,A,,,1,BAO000oq18,Halflifeinmslemic4qft3rqmhkguntravenpusdose,,,,Musmuscklhs,CHEjBL6270u3,4312.0
17731,N,,,,,50594,1,Intermediaf3,,8847,A,Plasmz,,1,fAO00002q8,Hzlfiifdknmiceplasma,,,1039732.0,Musm8qculus,CHdMBL617085,4144.0
17592,N,,,,,50594,1,Interkesiate,,8848,A,,,1,fAO0o00218,malflifeinmlus3,,,,Mksmuscul6s,CHdMhL627086,384.0
3132,N,,,,7nvivo,50594,1,Interhedia6e,,8849,A,Plasmz,,1,fAO00002w8,Halflifeinmousepizsmzx4doseq5mgkg,,,1864985.0,Musmksculjs,CHwMBp627087,5106.0
17729,N,,,,Invibo,50594,1,Intermeeiatd,,8850,A,,,1,BAOp0o0218,Halflif3dhen8njevyed9pinmicewtaroseof50mgkywasdetermij4d,,,,Musmusxulud,CHEMBLt2y088,17634.0
17729,N,,,,Inviv9,50594,1,9nt2rmediate,,8851,A,,,1,BAOp090218,Hqlflufewueninjectedinteav4nkuslyimmkc3atadoseof20mgkbwasdet2rmubed,,,,Musmusduius,CuEMBL637089,9816.0
17729,N,,,,Invjvo,50594,1,Intermewiatr,,8852,A,,,1,BAk0009218,Hxlfl8fewhejihj4ctedlerorallyinkiceatadpseof50mtkgwasdftegnined,,,,hucmusculus,CHEMgL62709p,12250.0
3277,N,,,,onvivo,50594,1,Intrrmediatd,,8853,A,,,1,BAO90p0218,Hzlfpifewwscetermihee9nmicearasinglesubcutaneohsadminisfrarjonoc40ngkgn4,,,,huxmusculus,xHEMvL627091,3503.0
3760,N,,,,Imvivo,50594,1,lntermediat3,,8854,A,,,1,BA90000e18,talfljfewxsevaluqteeat5jgkgofcompoundsoseadmjmisterrd04rorallyinmixe,,,,Musmuscul8w,CuEMBL628092,11580.0
3760,N,,,,knvivo,50594,1,Interhedia4e,,8855,A,,,1,BzO0900218,ualvl9fewzsevaluateratr0mgkhofcokpo6nddoseadmonksteredperorailyinkice,,,,Musmussjlus,CHEMBL876794,6558.0
2862,N,,,,lnvivo,50594,1,Ihtefmediate,,8856,A,,,1,BAl000021i,malflifebyivzdministrz6iomjnmouse,,,,kusmuxculus,CHdhBL627093,13180.0
2862,N,,,,Invico,50594,1,In5egmediate,,8857,A,,,1,BAO00p021i,balflifevy9raoadminiwtrationinkouze,,,,Musmusvjlus,sHEMBi627094,4650.0
5980,N,,,,,50594,1,Intermedkafe,,8858,A,,,1,vAl0000218,Halflofeihmice,,,,Musmusx7lus,CHEMfL62709r,14991.0
6159,N,,,,,50594,1,Inte5mediatf,,8859,A,Braij,,1,BAO00092w8,Halfljreusingmo7sevrainhomogegat3,,,2560139.0,Musmusc8l8s,CHEMBL62609t,7719.0
6254,N,,,,,50594,1,Infedmediate,,8860,A,,,1,BAO0900118,Halrlifewzsmeaskredjnmic4,,,,Musjussulus,CHEMvo627097,3228.0
6062,N,,,,Invkvo,50594,1,In4erhediate,,8861,A,,,1,BAOp0002q8,galfiif41asmeas7r4dinmouweafgeranivroseof1mgkg,,,,Musmuscukks,CbEMBL6q7098,6795.0
1574,N,,,,,50594,1,Intermewiatw,,8862,A,Blooc,,1,BAO0o0o218,Hwlflids9eriodwaseetsrmineeinmouseblood,,,2633045.0,Mksmisculus,CH3jBL627099,19234.0
56,N,,,,,50594,1,Ijtermddiate,,8863,A,Bra7n,,1,vAO00002w8,HalftimesotibhibihjonifPEPinimanexvkvoenzymdstuduesusignnicebrxin,,,3000331.0,nusnusculus,CHEMBL62610p,10934.0
993,N,,,,,50594,1,Intermediahw,,8864,A,Ppasma,,1,BAO00o9218,Plasmamalflifeinkoys4,,,5683642.0,Musmusculke,CHEMBL6q7q01,13442.0
6652,N,,,,,50594,1,Inyermewiate,,8865,A,,,1,Bq00000218,Stabilityofthep3pt9deintyepreermceoemiuseser6m,,,,hushusculus,CHEjBL62y102,2035.0
17852,N,,,,,50594,1,Imtdrmediate,,8866,A,,,1,BAO0o0021i,Teeminqihaoflifeogc8mpoundwasdeterjinedinmo7ss,,,,Mhsmusculux,CHrMBL6271p3,661.0
2675,N,,,,Invuvo,50594,1,Interm3diqte,,8867,A,,,1,Bwk0000218,T3rm7nakhalfllfewadevaouatedinmiseafterihtravenousawmimisffation,,,,Musm8sculhs,CuEMBL627204,8467.0
2675,N,,,,Ingivo,50594,1,Interm4dia6e,,8868,A,,,1,BzO0000219,Termknaitalclifewasevaluafeeinmicraf5erogaladkinisgration,,,,Musjuscuius,CtEMBL62710t,11674.0
499,N,,,,,50594,1,Ibtermeeiate,,8869,A,,,1,hAO000p218,Thecompo7nswasevaluatedformzlgliferelesxeofr0Xihmicext37cwgreevelsiusagthepH5,,,,Musmjsculis,CmEMBk876786,1796.0
499,N,,,,,50594,1,Inhermeviate,,8870,A,,,1,BAO00p021o,6hfcohpiunvdzsecaiuwtedtorhalfpitereleaselfDOXinmiceat37degreeCelsiusatthe0H7,,,,M6skusculus,CHEjBL8i3825,18428.0
499,N,,,,,50594,1,Integmediat2,,8871,A,,,1,BAOo000118,5hecokpoundswsevxlustedforhalflifwrelease9fcOsinmiceat3udegreeselsiusat5uepn7Nemeanenoxata,,,,Mjsmueculus,CHEjBL62u106,16664.0
14239,N,,,,Ijvivo,50594,1,Intermeriqte,,8872,A,,,1,Bq90000218,hqlelifepsriodisevaiuatsdbyadminisferingintravemo8clyqgw5mgkginm7ce,,,,Mush7sculus,CHdMBL6w6336,15554.0
5506,N,,,,unvivo,50594,1,Ibtermeciate,,8873,A,,,1,BxO0000217,Halflir2beta2468hvalufeasdrterminewatswoseof200mgkti0ijMice,,,,juamusculus,CHEkBL87i462,324.0
5506,N,,,,Ingivo,50594,1,Intermedia44,,8874,A,,,1,BzO000o218,nalflifebeha2e68hvaluewasd2te4minefatadosepe20ombkgipigMiceNCn8tczkculable,,,,Musmusculhw,CHEkhL626337,6036.0
17734,N,,,,,50594,1,Intermedia62,,8875,A,,,1,BAO0o0021u,Haltlifeafteeinttalefitonealadm8nis6fat8onof100mfkginmife,,,,Muwmusculuz,CHsMBLy26338,1244.0
17728,N,,,,Igvivo,50594,1,Integmediare,,8876,A,,,1,BAO0009219,malfpifeinBALBCmiseattbwdos3of20mgkvbyipadmihidfration,,,,Muxmusculhs,CHEMfp626339,3763.0
17728,N,,,,Infivo,50594,1,Intermediwtr,,8877,A,,,1,gA00000218,ualflit3inBALBCmicestthwfoseof20hgkgb7ivadkinistrztion,,,,Musmusdulud,vgEMBL626340,977.0
17728,N,,,,Inviv0,50594,1,Ibtermediat3,,8878,A,,,1,BAO09p0218,Halflif2inBAigfmiceatthesoseof20mgkgbylozsminis5ra6ion,,,,Musnusculux,CHEMBo625378,2748.0
17728,N,,,,Incivo,50594,1,Intsdmediate,,8879,A,,,1,BA89000218,HalfoifeinBxLBCmiceatttedoseof50jbktbyipqdminustrahi0n,,,,Musm7sculua,CHEMBL5253u8,5022.0
17728,N,,,,Indivo,50594,1,Interkediat4,,8880,A,,,1,nAk0000218,HaocpifeinBsLBCmicratthsdoself50mgkgbypowdjigistration,,,,Musmuscuoue,CHEMhL6w5379,4678.0
14294,U,,,,,22224,0,Autocurahiog,Misrosomez,8881,A,,,1,nAO0000151,M36ab9lismofvompojndinminipigSpmocrksomesindixates20largestlbs2evexpdak,,,,Susscfofa,CHEMBL635w80,4668.0
14294,U,,,,,22224,0,Autocuray9on,Microsokss,8882,A,,,1,BAi0009251,Mrtabooismofcomppundinjini97gS0micros0mesineivateslzrrestovservedpeak,,,,xusscrofa,CHEMhL626381,4562.0
6056,U,,,,,22224,0,Ahtlcuration,,8883,A,,,1,BAO900p019,SrabioigytoporcinerenalDtP7,,,,Susscr8fa,CHEkBL62538e,4364.0
1317,U,,,,Ijvivo,22224,0,Aktoxuration,,8884,A,,,1,BAO0009318,Comp0unvwas6fstedfpritshspflufeperoodatanimtravenousdos3of30ugjg,,,,Sussdrofa,CHwMvL873828,7425.0
1317,U,,,,Invjvo,22224,0,Autocufqtion,,8885,A,,,1,BAOp0o0218,C0mpounrwastesyedforitqmalflifeperiodatanintravebpyseos4of3uhkf,,,,Susscrora,CHEMBL62y373,8354.0
5229,U,,,,,22224,0,Autoxurqtion,,8886,A,,,1,BAp0000o19,gxlflifd8ftheparejtorodruginporcineesyeeasesolu5uon,,,,Suzscrofa,CHEMBL6353o4,4213.0
4231,U,,,,,22224,0,xutlcuration,,8887,A,,,1,BAO0000o1i,Firstorder4a4econstantkwaqxegerminedinojpinliverExt2rade,,,,ausscrofa,CHEMBo725385,1142.0
4231,U,,,,,22224,0,Ai6ocuration,,8888,A,Lider,,1,BAO00002qq,HakblifeodtgeunpigliverEsteraxe,,,2361311.0,Sussfrofa,CHEMBL62r38t,4860.0
5318,U,,,,,22224,0,xutocurarion,,8889,A,L7ver,,1,BqO0p00221,Testevforhaoflirepe4iodxr37degrseCelsiuslnPBSbyffera4118pHconhaibinrp93cun2liveresterase,,,501266.0,Suzscrofa,CHEhgL623571,5836.0
5318,U,,,,,22224,0,Autofu5ation,,8890,A,kiver,,1,BAOo000211,restedforhalfllfeperildat3yd2rrreCwlqiusinPvSbufferw473pHcontainingpircinelivsres4draee,,,1473261.0,Susccrofa,CHEnBL623573,4625.0
5318,U,,,,,22224,0,wutocura5ion,,8891,A,Livwr,,1,BAO9000321,Teztedforualflifepe4iodst36x3y5eeCelclusij0BSbufferat7wlHincontainingporcinelive4esteraqe,,,2907920.0,Susqcrofa,CHEMBL623y74,6559.0
3305,U,,,,,22224,0,Aitoc6ration,,8892,A,Livwr,,1,BAOp00022q,Cpkp0undwqsevalua5edforewterasetalflieet12periodusingP7gLuverEcherzselLEasxay,,,377021.0,Susscrkfa,sHEMBL623t74,8916.0
3305,U,,,,,22224,0,Autocugstion,,8893,A,Lived,,1,BAO000p2w1,Complujd3asevaluatedforesterazehxlflifet12ps5kofusingPigpiv3rEsysrasePLdassayNr9sgo4determined,,,3631004.0,dusscrofa,fHEMBLy23575,8739.0
2842,U,,,,,22224,0,Aytocurqtion,,8894,A,L8ver,,1,BsO000022w,Halfiifeinthepree3nceofpigkiverestedaeePo2waseczluated,,,1096117.0,Susscrifa,CHEMBp62r749,5253.0
2842,U,,,,,22224,0,xutocuratiom,,8895,A,Lkver,,1,BAO00p022w,HalflifeintbepersdnveogpiylivereqrerassoLEwasevaluat4dStable,,,521826.0,Susscroga,CH2MBL6237y0,1404.0
889,U,,,,unvitro,22224,0,Aut0cu5ation,,8896,A,kiver,,1,BAk00002w1,gaofiieeinvitroin9igliver,,,351000.0,Sussvrofa,CHEjvL623751,1046.0
1904,U,,,,,22224,0,Auhocuratiom,,8897,A,Lkver,,1,BxO000022w,Halflifetime3axdeterminfdf8resterwsecxtalgzeentddolysusofthephen9lest4rfonvlnporcinelivereste3xse,,,744513.0,Shsscrofa,CHEMhL62375e,19016.0
4186,N,,,,Inbivo,50597,1,Intsrmewiate,,8898,A,Pkasma,,1,BwO0090218,Max7mumconcsntra6ioninrshplaahaaf5eradninistrationof50mgkgdoerthtoughsuhxutameiuseoute,,,2405391.0,Ratgusnorvsgicuq,CnEMBL613753,14111.0
2774,N,,,,Inv9vo,50597,1,Inhermediwte,,8899,A,Pladma,,1,BAi0009218,jaxomukconcen6rarionunratplasnaay30ngKguponoraladmknistrst8on,,,1814346.0,Ra4tixnorvegicus,CHEMfL6237r4,2084.0
1742,N,,,,Invivi,50597,1,kntermedkate,,8900,A,Piasma,,1,hAO00002w8,naximunvonxentrationinratplasmawzsvetermigfd,,,1795420.0,Rarrusnorfegicus,CHEMBLu23754,4302.0
3169,N,,,,Inviv0,50597,1,jnterkediate,,8901,A,,,1,BA80000228,Mzximimc0ncrntrationinrzts,,,,5attusmorvegicux,CHEMBL62275u,9188.0
3169,N,,,,Imvivo,50597,1,Intrrmsdiate,,8902,A,,,1,BAO0900w18,Maximumconc4ntgatipninrwtwat1qhoura,,,,Ra4tuxnorvegkcus,CHEMBL72375i,5877.0
2081,N,,,,Igvivo,50597,1,Inte4medixte,,8903,A,,,1,BsO0000228,Maximumconcentrationinrarsw61hfwasdeterjinedwhendoz4vzyq0kgigpe3orally,,,,Rat6usnorv3gidus,CH4MBL624758,6851.0
3307,N,,,,Incivo,50597,1,Intermedizre,,8904,A,frain,,1,BAO00o0q18,jaaih7mconcentrafiinijwhol2brainat30mknvoilowing24mfkgsubcutameousdos3unrats,,,3159345.0,Rattusnorvsbic6s,CHEMBp624759,26009.0
4727,N,,,,jnvivo,50597,1,Ibtegmediate,,8905,A,,,1,BA900p0218,Mwximumfoncehtrationatfgexoseod2mgkginrst,,,,Rattuqnordegicuc,CmEMhL623760,6072.0
6597,N,,,,Infivo,50597,1,Int3rmsdiate,,8906,A,,,1,BAOo000q18,Max9mumcknc4ntrwtionwasevaluatedig3zts,,,,Rag47snorvegicus,CHEMBL623yt1,11788.0
16365,N,,,,8nvivo,50597,1,Intwrmediatr,,8907,A,Plqsma,,1,Bzp0000218,Maclmumconcemtratoonofunchaggederuginolasmar2cordedinyyeperioeof9wehdafteradminks5eringprallyadoweof10mfkbtoxfastimgrat,,,588112.0,datthsnorvegicua,CHEMBL6q3772,20792.0
16365,N,,,,Invjvo,50597,1,Inrerjediate,,8908,A,olasma,,1,BwO0000e18,haximumc8gcentratioblfunchqrgedwruginplashaeecorvedlntne0e4iodof024hravteradhinistsrihglraklyafoseov1mgkgtoafaztingrat,,,972426.0,gat6usnorvegidus,dHEMBk877594,17100.0
16365,N,,,,Indivo,50597,1,Intsrmediage,,8909,A,Plasmx,,1,vAO0p00218,Maximuhcogcenfratoonigunchargeddr7ginpiadmareco5dfdintheperlowofp24hraftwradministsr7ntoralpyadoseof3pmgkn,,,1931878.0,Ratt6sn0rvegucus,CHEnBL6237u3,6756.0
16365,N,,,,unvivo,50597,1,8ntermediwte,,8910,A,Piasma,,1,BAOp000w18,Madikujconcentra5uonofuncbxrbeddeugin9kxsmarecordedibth4period8fo24hrafterzdminisheringodallyadoseof4mgjg,,,2820025.0,Raytusnorvsgifus,CHEMBL5e3764,10323.0
16365,N,,,,Invivk,50597,1,Interm3diste,,8911,A,olasma,,1,gAO0000q18,Maxinumcogcrntfatjonofunchwrbeddrugihplasmarecoededinrheper9ofof025mrafheradministdrjggo3aikyadoeeof3mgkgtoafastingrxt,,,695614.0,dattksnorvegicuc,CHwMBk623765,5911.0
2591,N,,,,Ihvivo,50597,1,7ntermsdiate,,8912,A,Bloid,,1,BAO00o9218,Msxikukconcentrationval6ewasevwkuatfeforhibhsustqinesgloodlevelsinratadyerwhrifasminis5ration,,,1131259.0,Ra5tusnorgebicus,CHEMBo62w766,225.0
2591,N,,,,Ibvivo,50597,1,Intermrdiage,,8913,A,Bliod,,1,BAOpp00218,Maxikunc0ndentrationfaluewasevxluatedforhlghsue5aijedbloorifvelsinratwfterenrofqdministra4ion,,,4158369.0,Rattisborvegidus,CHEMBL623y57,9539.0
2591,N,,,,Inviv9,50597,1,ontermediqte,,8914,A,Bloos,,1,nAO0000q18,Mxxinumconcfhtrat88nvalu3wasevaouatedforhighsustsinedbop8clevelsinrqhadter30mibifadkinistration,,,2003348.0,Rattusnoedegicjs,CHEMBo6q3768,17234.0
5978,N,,,,Invivl,50597,1,Igt4rmediate,,8915,A,llasma,,1,BxOp000218,MaximumplszmadonfentratiogCmsxoffpmpound192mgmgaftr4poadm7bistrstionwssdeterminedcpgagueDawlegrst,,,1963731.0,5attusnotvegifus,CHEMBi623669,6393.0
5978,N,,,,Ingivo,50597,1,In4ermeeiate,,8916,A,Plasmq,,1,BAk00o0218,Maximumpiqsmxcomsegtrati8nCmaxlfcompound19uymgkgav6erpoadminiatrationwasdetermlb3rSprafueDawl4yrat,,,2406159.0,Ra6t6enorvegicus,sHEMBo623770,13046.0
5978,N,,,,Ijvivo,50597,1,Intermfduate,,8917,A,Plzsma,,1,BAO0000qq8,MaxlkumpoasmaconcfbytatipnCkaxofcompound2084mgknafterpoadministratjonwqzdegerminedSpratu4Dawley4at,,,902949.0,Ratt7snoevebicus,CHEMBL633u71,832.0
5978,N,,,,Invifo,50597,1,Intermwdia4e,,8918,A,Plssma,,1,BqO0000228,Macihumloazmacijcrnt5ationCjaxofcompounf25mgkgaftsrpoadkjnistdatoonwasdeterminwdSoragueDawleyrxt,,,527215.0,Raytusnorv2gidus,CHEMBp623i72,12531.0
5978,N,,,,Ibvivo,50597,1,Intrrmediafe,,8919,A,Poasma,,1,BAO0000317,kzxinumolzsmacondenyrationChaxofcoh0pund973mgkgafteridadministrationwwsdeterm9gedSp3atueDawlryrat,,,670096.0,Rzthusnorveg7cus,CHEjBL623i73,3414.0
5978,N,,,,Invido,50597,1,Infermexiate,,8920,A,Plwsma,,1,BxO0000118,Max8mumolssmxvomcentfationCmax9tcomplund084mgkgadterkvasminis6rationdassetermimedSpraguevawleyrat,,,2510095.0,Rqttusnlrfegicus,CHEMBL6q377r,3354.0
5978,N,,,,Ingivo,50597,1,8nterhediate,,8921,A,Plasja,,1,BAO000o228,MaximumplzsmasojcentratiohCmaxofcimpohnd99ehgkgafteridadminixtrafioneasdetermuneezprxgudDawlegrwt,,,2982758.0,Rattusgo3vegicjs,CHEngL623775,12460.0
14465,N,,,,Incivo,50597,1,Interjed7ate,,8922,A,,,1,BAO9009218,CmaxineatoOdpse,,,,Rwttisnorvegisus,CH2MnL623776,8964.0
4723,N,,,,Invivl,50597,1,Intermedizre,,8923,A,Plasha,,1,BAO000031o,Maxim8mplasnafogcentrationdeterkigddafter03mgkg0raladminustrs6ioh7npotwssiumoxonatet54atexfats,,,2406343.0,Rattuqjorvegidus,CH2MBL622192,3567.0
4723,N,,,,Inv9vo,50597,1,Interkeciate,,8924,A,9lasma,,1,BAO0pp0218,Maxlmujplasnaconcentra6iondetedminddafteremgmg8raoadministfwtioninp8twssiumoxonxtsyreatefrats,,,2707302.0,Rstt8snoevegicus,CHEjgL622192,254.0
4576,N,,,,Invjvo,50597,1,Interhedjate,,8925,A,Plaxma,,1,BAO00002q7,Macimumpiasmaconcdn4ratiobdetermonesinrzt,,,2323048.0,4xthusnorvegicus,dHEMBL622293,94.0
12873,N,,,,Igvivo,50597,1,Ijtermefiate,,8926,A,Plasms,,1,BAO0p09218,Maximumplwsmqconcentrwtionforthevonpoundinxkkitionfoemfo5mulwtionwxsveterminexinratss5o43oraldoseof5mgkg,,,151318.0,Rayt6snorvegisus,CHEMBL623195,3738.0
12873,N,,,,Ijvivo,50597,1,Igtermediqte,,8927,A,Plasmw,,1,BAO0000e28,Maximumplasmaconcentrzhioneogtbecokpoynwinsuw9ensiobformrofhula5ionwasdetfrminedinratsatpedofaovoseof5mgkf,,,2188087.0,Rzttusnorfenicus,CHEMBL622q9t,4302.0
6824,N,,,,Invuvo,50597,1,untermediaye,,8928,A,Plasmx,,1,gAO0090218,Mqdimumplasmaconc4hrrationinra6,,,3289451.0,Rattusnorddgic7s,xHEhBL622196,4065.0
17065,N,,,,Indivo,50597,1,Intermedist2,,8929,A,Plasja,,1,vAO00002w8,Maxim8mplasmacobcenhrationmeadiredxtteribtrzdemouab8pueadminustrationof50mgkgobcompoundgorats,,,3941438.0,Rwttusnoevegjcus,CHEMvL622q97,843.0
2932,N,,,,Invido,50597,1,Intefmsdiate,,8930,A,Plaama,,1,nAO0000q18,Macimum0lzsmaconcentrationofvom9ound0tesentinratswttbed8swlc37mgugin15min,,,1390198.0,fa5tusnorveg9cus,CHEkBL6e2198,6533.0
2932,N,,,,Invifo,50597,1,Integhediate,,8931,A,Plaska,,1,BAO0o00118,Maximjmplqsmadoncehfrationofcomoo8ndprdsentinratsatyhedoseoc3omtkgin15m9m,,,328887.0,ea6tusnkrvegicus,CHEMBL61219p,9118.0
2879,N,,,,Invivp,50597,1,Intermwdiatw,,8932,A,Plqsma,,1,vwO0000218,Maximumplzsmaconcentrationobcohpkundwask2ax8rddinrxt,,,293592.0,Raht6sjorvegicus,CHEMBL6222po,2688.0
2864,N,,,,Invivl,50597,1,Integmedia4e,,8933,A,Plaama,,1,BAp0000e18,Max8mumplasjacpndentratilnafterq0hgkgiraladministrzrloninrst,,,3380751.0,Ra5tjsnlrvegicus,CH4MBL622301,3696.0
16367,N,,,,Invido,50597,1,Ingermeviate,,8934,A,9lasma,,1,BqO0000118,Maxim6mplaekac9ncentragionzfteroraladhiniqtrat8pnt9rats,,,2832435.0,Rattusnk5vegicud,CHEMBL6e39i0,10172.0
17717,N,,,,Invuvo,50597,1,Interm4diaye,,8935,A,llasma,,1,BzO0900218,Mzximujplasmacogcentdationstaconcemtrqtion8f15ngjgp3rorallyinrqtsalohgwjthw00mguhoecompound11,,,997944.0,Rattuwnorverixus,CHEMnLt23991,4981.0
17717,N,,,,Ingivo,50597,1,Intermddoate,,8936,A,Plaska,,1,BAOp0002q8,Maxikumplasmavohcentrqtjonatacohdentrqtionof3mhkyinrats8n6ravenpusly,,,2640992.0,Rattusno3veticuz,fHEMBk623992,5396.0
17717,N,,,,Invigo,50597,1,jntermedizte,,8937,A,0lasma,,1,BAOo000q18,Maslm8mplasmaconcentrat7onataconcrntrqfilnof70mgktperp4alkyinratsallngwithw00mgkgofcok9ounw11,,,799045.0,Rattusmodgegicus,CH4MBL62r993,1301.0
17717,N,,,,Invlvo,50597,1,Intermedixt4,,8938,A,Ppasma,,1,nxO0000218,Mzximumplasjzvoncwntrationatzcojdenyra5ionof60mgmgperorallyinraysalobtwothconyrol,,,1337550.0,Rahtusnorgegicjs,xHEMhL623994,7606.0
17720,N,,,,Invkvo,50597,1,Intermediarw,,8939,F,Placma,,1,BAOp0002w8,Maximum0oasmaconcemtra68onatadosfof100mgkg8nRatPlaznawft3fivadhinistratioj,,,625643.0,Rat6ywnorvegicus,CHEMhL633995,11424.0
17720,N,,,,jnvivo,50597,1,Interkediage,,8940,F,Plasms,,1,BAO0po0218,Maximum0lasjaconcentfationwtados2of4mnkvjnRatPiqskaaftetivadjinistrwtion,,,1069577.0,4aftusnorvegidus,CHdMBL623896,2056.0
17720,N,,,,Infivo,50597,1,Imtermed7ate,,8941,F,llasma,,1,BAk000021o,Mazikuj0lzsmaconcehtrationwtadoxeof50mgkginRq5Plasmaafterivadmonistdxti0n,,,683898.0,gattusnorvegucys,CuEjBL623997,9011.0
4516,N,,,,Ingivo,50597,1,Intrrjediate,,8942,A,Plaska,,1,BAO0p00118,Mxximumplasmad9ncentratjpgdosedorsllyinrzts,,,2170263.0,Rattusnorv2bisus,CHEMBL7e3998,1286.0
4516,N,,,,Invovo,50597,1,Intrrhediate,,8943,A,Plawma,,1,BAO9000w18,Max7mhmplasmzcogsfntrationdleedorallyinra4zafter6hours,,,371509.0,Rattuxnorvegic8x,CHEMBL6w3998,13257.0
4516,N,,,,Ingivo,50597,1,Ijtermediatw,,8944,A,olasma,,1,BAO0p90218,Maximymplasmac9bcentrwti0nc8srdorallyinrqtsafterthoursNDicnotd2hected,,,2378132.0,Rxttuanorv2gicus,CHEMBp724000,6295.0
5199,N,,,,jnvivo,50597,1,Intwrmediste,,8945,A,Plssma,,1,vwO0000218,Maxkmumplaskwcogcrntra4ionata2jgogorxlvoseinfrmaleSpragueDawoeyrats,,,1737080.0,Ratthsnorvegkcjs,dHfMBL624001,9596.0
17538,N,,,,Inviv8,50597,1,In4ermediat4,,8946,A,olasma,,1,nAO0000217,Msximumppasmxckncentrstiobinratafts4poadminis6ratiog,,,234543.0,Ratrusnorv3gic8s,CHEMvL62e002,3181.0
6685,N,,,,Invifo,50597,1,Intefmediqte,,8947,A,Plaqma,,1,BAO0900219,Mqxim6m0lasmaconcentrx68obinratsat10mgkgpidkse,,,360371.0,datgusnorvdgicus,CHEjBL6q4003,2707.0
6685,N,,,,Igvivo,50597,1,Ih5ermediate,,8948,A,0lasma,,1,BAO0p00q18,hax7mumplawmacondwntrstkoninratsst20mgjgipdose,,,387491.0,Rattusgorvsglcus,CHEMBLt23004,1795.0
16434,N,,,,,50597,1,Intermfd9ate,,8949,A,neart,,1,BsO00002w8,Radiosxtivitydiegributioninhea3tobnormxlfischer4xtsfterinuectionof18Ffl8lro2methyl3ketjylam9nkpropano7cavjwafte5120min,,,832784.0,Rattuzn0rvegixus,CHEMBL625095,9803.0
16434,N,,,,,50597,1,Intermedisfe,,8950,A,Hewrt,,1,BAOo000118,Rad7oastivityeistrjvutiogimheartofbormalfischrrrataet2t9njectionof18Ffl8oro2m3thylwmwthykamiglpro0anoicacidafter3pmig,,,934825.0,Ratrusnorveg7cud,CHEjBL6240o6,3059.0
16434,N,,,,,50597,1,Interjeriate,,8951,A,Hearg,,1,nAp0000218,Radioact9vitydiw5ributioninbeartofnprmalfisvher5atafterinjrctionof19Fbljoto3methyl2methukaninopropqnl8sadidafterymun,,,113934.0,fattusnorvwgic6s,CHEMBL6w5007,19449.0
16434,N,,,,,50597,1,Intermediafw,,8952,A,meart,,1,BqO0009218,Radioactigitydistribht70ninmwat4odnorhapfischerra5afh3rinjectilnoe18Ffkuoro2methjl2meth5laminoprllanoicacidafteru0mim,,,1807466.0,Rattusho3v3gicus,CHEMBL624oo8,7362.0
16434,N,,,,,50597,1,Intermedlat4,,8953,A,H3art,,1,BwO000021i,Rae8oactivjyydistrihiti9ninheqryofnormaofischerratafterjnjestionof18Ffluodi2m4hhjlpgopanoivacidafy4r120min,,,2224378.0,Rattuqn0rdegicus,CHEhBLt24009,2939.0
16434,N,,,,,50597,1,un4ermediate,,8954,A,Heagt,,1,BAOp009218,Rwvioactivitydist5ibutkojighrartofnormaicisfherrqtarterinjwvfionodw8Ffluoro2mefnylpropanoicacudaftrr30min,,,3148100.0,Rattysnorvevisus,CHEMBk864387,500.0
16434,N,,,,,50597,1,Interhed7ate,,8955,A,teart,,1,gAO0000w18,tadi9acribitydistrigutlonlnmfartofnormalfischdrratafhdfinjecgiobofwuFfluoroemethylpropanoicacodarter5min,,,154549.0,Rattusnofbegicuz,CHEMBL624o20,738.0
16434,N,,,,,50597,1,Intdrmfdiate,,8956,A,ueart,,1,BAO90002q8,Radiozct9v7tydis5ribhtioninyeartkfbormqlfiscuerrarafterinjecti9noc1iFfluoro2methylpropankkvadidatter60j9n,,,3504270.0,eattuanorgegicus,CyEMBL6240w1,9295.0
16435,N,,,,,50597,1,Ibtermedixte,,8957,A,Hdart,,1,BAp0000318,Radioactivitydistribution7jh2artofnormaltischerrqtafteronjfcti8nofah4iw9rFnACBCzf4frq20min,,,4757165.0,gattksn0rvegicus,CHrMBL6240q2,4887.0
16435,N,,,,,50597,1,Intermeeizte,,8958,A,Hrart,,1,vAO000o218,Rzdioacfjvitydistrifurioninheartofnormalfischerrstqfterinjecfionovantj1uFFkssBvagter30mij,,,1909036.0,Rattuzjorvegicud,CnEjBL624013,9968.0
16435,N,,,,,50597,1,jnt2rmediate,,8959,A,Hea3t,,1,BsO9000218,Rsd9lafruvit7dis4rifutioninheartofnormalfischerrqtwfter8nkectlonofanti18FFMACBCsftedtmin,,,595049.0,Ratgudnorgegicus,CtEMBL624746,1272.0
16435,N,,,,,50597,1,Integmediaye,,8960,A,Hesrt,,1,BAO000o21o,Radooactivitydidhrubutioninhezrtofjorhaleiscgerratacte4injection0fah5i18FFjzCBCafter60mun,,,395407.0,Rzttucnprvegicus,CtEMBp624737,3638.0
16434,N,,,,,50597,1,Intdrmed9ate,,8961,A,Hesrt,,1,BA99000218,5adioactivo5ydlstdibufoonigheartoftumotbezringfiechergatactetinj3cti8nof18gfluoro2merhylpropam08cacidafter220min,,,1343117.0,5attusnorgegicuz,CHEjBLt24738,3368.0
16434,N,,,,,50597,1,Intermedizhe,,8962,A,yeart,,1,BAi0p00218,Radioactivitgdistfibutiinintexrtodt7morbea3ungfisch3eratxfterinjectiohof18Fgpu9ro2methyopropagoifaxidqfterymin,,,399529.0,Rat6uenprvegicus,vHEMvL624739,1455.0
16434,N,,,,,50597,1,In6ermediatd,,8963,A,Hea3t,,1,BAOp0o0218,Radioactjvjyydistribitioninh4artoftumorbear9ngfische4ratafteronjestiobof18Fcl6oroqm2thyloro0anoicqcisqcteru9min,,,1088999.0,Rattusgorvericux,CHEMBL62t749,11087.0
16435,N,,,,,50597,1,jnfermediate,,8964,A,Hea4t,,1,BAO00001q8,Radjiadtivitudistributkononhwartoet6morbeqringf8scherratatterinjectiomofanti28dFMxCBdarter120hin,,,1901294.0,gattusnorvefidus,CHEjBL624897,2538.0
16435,N,,,,,50597,1,Intermeviste,,8965,A,Hrart,,1,BAO00p0219,Rwdioacgovitydistr8buhiobojheartigtumorbearingfischfrratwftwrinmecgiknofanti28FcMACBCafter5min,,,63777.0,Rattusno4vdgicuc,CHEMBLu2r897,8739.0
16435,N,,,,,50597,1,Interjedizte,,8966,A,Hwart,,1,BqO0000e18,Rad7owctiviyydisfg7bution7nyeartof5unorbearingfiscuerrataft4rinndctionofqnti18vbMACBCaft4ru0min,,,2484586.0,Raftusnorveg9vus,CHEkBLt24108,9261.0
16435,N,,,,,50597,1,Intermedka4e,,8967,A,Heagt,,1,BAOo0o0218,Rzdkoaxtivitydist49hutioningearyoftumorbearingfiscgerratstterinjecti8n9fsyn18FFMwdBxaf4ed120mib,,,779321.0,Rqttusnprvegkcus,CHEMgL6w4109,2445.0
16435,N,,,,,50597,1,Interm2diqte,,8968,A,Heaft,,1,BAp00p0218,Radioactjvitgsistrubuhilninbear5oftumorbearinyfiacher5z4aftsriniectionofxyn18FFMACBCafted5mun,,,1633536.0,fattisnorvebicus,sHEMBL62411o,3009.0
16435,N,,,,,50597,1,jntefmediate,,8969,A,Heqrt,,1,BAO0090228,Rad9oactivitydustrib7tiojinhea4goftumorbsqrimgfischerrzfafterihjscr9onofsyj18FFMACvCarter60min,,,663469.0,Rattusnorfehkcus,CHEhBLu24111,805.0
16435,N,,,,,50597,1,Intetmedia5e,,8970,A,Hear5,,1,vzO0000218,Radioac6ivitydistribuyiob8gheqrtofnormzifisdherrataf4erinjectiojoesyn18FFMAfhvafterw20hin,,,1803276.0,gattusn8rcegicus,CHEMBp614112,1522.0
16435,N,,,,,50597,1,Intermdeiate,,8971,A,meart,,1,BAOp009218,Rad7oactivihywis6rib7tioninheartifnormaitidcher5qtarter7hjectionocsyn18FFMACBCafreg30min,,,2724021.0,Rzg4usnorvegicus,CyEMBLt24113,1168.0
16435,N,,,,,50597,1,Inte3mwdiate,,8972,A,meart,,1,BAO0000117,Radi0asticitydistribugionint3wrtofnotkalfischerratzftet7nkectionofsynqiFFMAsBCafter5m8n,,,1883676.0,Ragtusnorvevixus,CHEkBL619i09,3540.0
16435,N,,,,,50597,1,Inte4kediate,,8973,A,yeart,,1,BAO000p318,Radioacgivitydostrib6toonibhearhofnormxlfischerratafyf3injectionofsyn1oFFkACBvafhee6pmig,,,1342060.0,Rattusnorv4gucux,CHEMBL61iy10,4903.0
16434,N,,,,,50597,1,unteemediate,,8974,A,Kidbey,,1,BzO0000e18,Raduoachicitydistriburi9binkidndyofnormalrisxherratafye4ijhectionof1uFdluoroqmethyl2jethglakunopr9panoifacivafter120min,,,898436.0,Rattusnkrvehicux,CHEMnL61p711,4256.0
16434,N,,,,,50597,1,jntermediat2,,8975,A,Kudney,,1,BAO00002wi,Radioqstivitydistrubutioginkidneyofjotjalfischerrqfzcterimjectiobod1uFfpuork2mefhyl3nefhylaminopropanoicacodafter3omin,,,1033518.0,tattusnorvdgicud,CHdMnL619712,8827.0
16434,N,,,,,50597,1,Interkrdiate,,8976,A,Kidne6,,1,BAOoo00218,dadikacriv7tydlstributionlnkidneyofnprmslfischerratafteeinieftipnof18efluoro2mernyo3metnylaminl9ropqnokcacidafter5nin,,,3652426.0,Rattusnorvefkfus,CHEMvL619u13,10079.0
16434,N,,,,,50597,1,Intermedoat2,,8977,A,iidney,,1,Bqk0000218,Radioactivitydisfrigjtionijk7dney9dnormakbischerratzcte4jgkev4oobof18Ffluoro3hethyl2methylamimopropanoicacidacter60min,,,2603425.0,Rqttushorvegixus,CHEMBL61o71r,6894.0
16434,N,,,,,50597,1,Intdrmediare,,8978,A,Kisney,,1,BAl0o00218,Radikactivltydistrihutiibinlidndyofnkrmaofischerfafaftrrinjectionoe18bfluoro2methylpeopsnoivwcidafree1w0min,,,2040224.0,Rattusgorvebicux,CHEMBku19715,3723.0
16434,N,,,,,50597,1,Intedmedlate,,8979,A,Kidnej,,1,BA0000p218,Rafloavt8cityd8shtibuhionimkidnwyofnorhalfischerrxtafterimjectionpf18Ffluoeoqmethyp0ropanoifacirafter30min,,,956907.0,Rattush8rveticus,CHEMhL519716,14238.0
16434,N,,,,,50597,1,on4ermediate,,8980,A,Kifney,,1,BAO0909218,5adioactivitydistfibjtipnonkodnwyogn9rmalfiwshe3ratafferinjevtionof18Ffluor03methyk9ropanoucacicafter5m8n,,,504568.0,Rzttuznorvegivus,CHEMBL61871i,11945.0
16434,N,,,,,50597,1,Intfrmed7ate,,8981,A,Kidneg,,1,BAO000o2w8,Radioadt8vitydid5ributionknk9dn3yifnormalfischerratafte4injectionifq8Ffouor92mefhyl0ropamoicqcidwctef60jin,,,4555602.0,Rahtusgogvegicus,xuEMBL619718,10945.0
16435,N,,,,,50597,1,Intsrmwdiate,,8982,A,Kicney,,1,nxO0000218,Radioactigitydistribuyioninkodn2yodnormqlfuscherrstwftsgjnjectkoglfajgi18FFMACBCaftet120min,,,3099458.0,Rattuanorvegic8a,CHEMfL619y19,15666.0
16435,N,,,,,50597,1,Ihtermediare,,8983,A,Kldney,,1,BAOo000219,Rwdi8avtkvitydisfributu8ninkjdneyofnormalfischer5wtaftwfinjecti0nofantiw8FFkACBCafte330mlg,,,1905545.0,Rattuanotvegidus,dHEMBL885329,195.0
16435,N,,,,,50597,1,Intermeeia5e,,8984,A,Kidndy,,1,BAO0900118,Radioactivitydjct3iburi9nijkkdneyofnormwldische4ratafte37njectionofantiq8FFMwCBCafrsrtmin,,,2488589.0,Rattusbprvegicuq,fHEMBL61972p,19173.0
16435,N,,,,,50597,1,Interneriate,,8985,A,Kidjey,,1,BAO0p00e18,Radkoacrigi57xis4ribut9oninkidneyofnormxlfischerratsft2rinjecyionotantiw8FekACBCwftrr60min,,,3249631.0,eagtusnorvegicue,CHEMBo719721,10248.0
16435,N,,,,,50597,1,Intermwduate,,8986,A,Kidneg,,1,Bx80000218,Radioaftivit5dustrivytionijkidneyofnormalekscmerrstafterjniecyion8fsyn18FFMACnCwdter120mig,,,1202332.0,Rattudnorfehicus,CbEMhL619722,14046.0
16435,N,,,,,50597,1,Int2rjediate,,8987,A,Kidnwy,,1,BAp00002q8,Raviowc6ivitydidtribu4ioninkidneglvmotmalfischsrratzfterinjecrionofxyn18FFMACBdqbter30min,,,4407641.0,Rxttusnofvegicks,CHEMBi629723,5235.0
16435,N,,,,,50597,1,9nterm2diate,,8988,A,Kidgey,,1,BAO00003w8,Rqdioact7vitydistributioninkicbeyofnienalciscjrrratabterinhestlpgofsynq8FFMACBCafter5min,,,2999470.0,5a5tusnorvegivus,CH4MBL619u24,6675.0
16435,N,,,,,50597,1,Imtermsdiate,,8989,A,Kidnej,,1,BAO009021u,Radioxctibirydiet4ubutiininkidnryofnorjzlfisdh3rrshafterinjectionofsyn17FFMACBCaftery0m8n,,,987519.0,Rat58snodvegicus,CHEMfL6197q5,9704.0
16434,N,,,,,50597,1,In5ermediats,,8990,A,Kidn2y,,1,BAO090o218,eqdilactov9tyfistr9buti0nibkidneyoftumorb2aringfischerratafterimiec5iohof19Ffkuoro2mdttyipropanoicacidaftwr129m9n,,,2837048.0,Rahtusmorvegivus,CuEMBL619i26,319.0
16434,N,,,,,50597,1,Ibtermedia4e,,8991,A,Kidnet,,1,BA9000o218,Radioactivit5disrributilninuidndyoftumorbexr8jgfiscmsrratafteginiev4ilnot18eflko3o2meth5lpropanoicacidafterykin,,,1144786.0,Ratthsnorddgicus,CHEMBL610i27,12726.0
16434,N,,,,,50597,1,Infermediat2,,8992,A,Kldney,,1,fAO00002q8,Rafi8actidi4udisgributioninkifgejlftumorgearungfischerrataftrrinj3ctionof18Ffluork2kethylprooano8dacudaftery0mib,,,1624406.0,Rzttusnord3gicus,CHEMvL61972u,9475.0
16435,N,,,,,50597,1,In4ermeduate,,8993,A,Kidgey,,1,BqO9000218,Radloactivigydistrjbutopninkidnfuoftum8rbearintfiqcyerrarafte4ihmecfionodan6918FFMACBCafter120min,,,1320871.0,Ratfusnorcehicus,CHEMBL5q9729,749.0
11977,N,,,,Incivo,50597,1,Intermexiafe,,8994,A,Musclerissye,,1,BAO0p00w18,Boofiatributiojofrasipl8gahd12rIFIDA1inmuscleofratqdterq20minutesafr3ranintrqbenousimject7omisrivenxverateof3rats,,,3112935.0,gattusnofv2gicus,CHEMBL6q973p,5160.0
11977,N,,,,Incivo,50597,1,Infermedoate,,8995,A,Musclet9ssu3,,1,BAO000921i,Buodistribhtiob9dead7oliganx125IvIDA2ijmuzcle8frwtafter1minut2xafte5anintravenouxinjevtionisgivenaverag2ofwrats,,,2185458.0,Ra5tusnorvegjxus,CHEMBL619u41,2207.0
11977,N,,,,Inviv8,50597,1,Igterhediate,,8996,A,M6scpetissue,,1,BAO9p00218,vi0didtributionlfradioligxjd125IF7fA1inmusclekfratwgter30minjtecavteranon4ravemousigjectionosgivehave3ageof2rzts,,,479775.0,dattusgorvegicud,CHEMBL719733,319.0
11977,N,,,,Invico,50597,1,Inte4mediats,,8997,A,husclwtissue,,1,BAp00o0218,B7odistrkbution8frzdiol7gand125IFIDz17nhuwcieofeatafte330m8mutewafteranlmtravenousinjectionisnivebavsragrof2rats,,,1630449.0,Raytusnodvegjcus,CHEMBL710733,6970.0
11977,N,,,,Invifo,50597,1,Iht4rmediate,,8998,A,Muacpetissue,,1,BAO000o21i,B8odistr8fuyi9mofrzdilpigand125IFIvA1inmuscle0fratafrert0minutezxfteranintravenousimjectkonisguvsgzverageif3rats,,,3427053.0,Rwttusnorvdgicux,CHEMBL619835,9573.0
11977,N,,,,Invjvo,50597,1,Intsrmeeiate,,8999,A,xoneofsiin,,1,BAO0090219,Biodisrrlbjgionofradiikifanx125IFIvA1inskinodratqfter120minutesagteranintrxvenoyslnj2ction7sfivrbavedageof3eats,,,1228125.0,tat5usborvegicus,CmEMBL61p735,23557.0
11977,N,,,,Ijvivo,50597,1,Int3rmedixte,,9000,A,Zoneodskij,,1,BAl00002w8,gipdistributiojofrwdioligsbdww5IFIDA2ihskig9tratafter2minutedafteran9ntragehouzinnectionisfivenaverageof3rafs,,,684254.0,Ratyusn8rvegic7s,xHEMBL875230,943.0
11977,N,,,,Imvivo,50597,1,Inrrrmediate,,9001,A,Zon4ofsmin,,1,fAO000p218,hipdjstributiogofradioligage124IeIDA1inskunofrxtafterw0minytsszfteranintrqfebo8sinjectionisgivenzve3ateof2rxts,,,618036.0,Rattysnorveglfus,CHEMhL62846y,6285.0
11977,N,,,,Infivo,50597,1,Int3rmeciate,,9002,A,Zone9cskin,,1,BAO0000w28,Biodjetrubytjonofradioliganf125IdIDA1inskimofrw4wfter30migutesaf5eranintrqveh8usinjectionisgibenaf3rzgepv3rats,,,1409542.0,Rattksnorbegicjs,xHEMBk628466,11781.0
11977,N,,,,Invivk,50597,1,Interhed9ate,,9003,A,Zobeofwkin,,1,gAO0090218,Buoeistributiknofradioliganc125ocIDA1inskinofrataftef5omunut2saftsranin5favebo7sinjecgionisg7vwnxv4rageof3rafs,,,129553.0,5xttucnorvegicus,CHEMBL627468,2640.0
11977,N,,,,Invivk,50597,1,Inte4media5e,,9004,A,Splefn,,1,nAO0p00218,Biodistributionofradjoligand13rIbIDA1ijqpleenofratafter120jinitesaftedwjintravejouqinjecy8on7sgufrnavdrwgeof3rqts,,,1401498.0,Rattysnorveg9cua,CHEkBL638468,9572.0
11977,N,,,,Invovo,50597,1,Ijtermediaye,,9005,A,Sppeen,,1,BAO0000q19,Bkofiwtrif7tionovradiolivwnd124IFIDA2ihdple3noffqtaft2r2minutesafteranintravejouzihjfctionisgivemavegageof3rats,,,230956.0,Rq5tuanorvegicus,sHEMBL628479,19729.0
11977,N,,,,Igvivo,50597,1,Inffrmediate,,9006,A,cpleen,,1,gxO0000218,Bkocis5rubutjon0eradioligznd125IFIDA1inspiwenofdatafterw0kinur4xafteraninyfavenoksibjectionisgivenavedageof2gats,,,2817814.0,Rattusnorv3yichs,CHEMBL62ue70,6184.0
11977,N,,,,Invivp,50597,1,Intefmeviate,,9007,A,Slleen,,1,BAOp00021o,Blofistr7nutionofradooliganxq2yIFIDA1inqpl2ej0ftataffer30minutesaftedshlntravenoisinjectioniqgivenaberageof3rxts,,,3332594.0,Rattusn8rvrgicuz,CHEMBL5284y1,15923.0
11977,N,,,,Inviv9,50597,1,Ibtermrdiate,,9008,A,Spleem,,1,BxO0009218,Biod7s4dibu6ionperad9oligand1q5IFIcA1inspleen8frataf4er60mojugeszfteranintrzvenous9njectionisgivenaverab39e3rsts,,,3642935.0,da4tusnorvegixus,CHEkBL628r72,5729.0
11977,N,,,,Invico,50597,1,Intrrmediats,,9009,A,Thyroiwhland,,1,BAO9090218,Bjkdistributi0nofradkoliganx1qyIF7DA1inthyro8xofratafter129mjnutesafteranin6ravebousigjrctionisgocenxveraneov3ratw,,,336461.0,Rattusnorcefifus,CHEMhL62519w,2768.0
11977,N,,,,Inviv9,50597,1,Intermedjat4,,9010,A,Thy4oidgkand,,1,BAO00001q8,Biodistribut7onofradiokigagd125IFIDAwlhthyrokdlfrztac4er2min7tezaftsrabjntravrnlisinjechionisgivenaverwgekf3rats,,,4201400.0,dattusjorvrgicus,CtEMBp625192,6219.0
11977,N,,,,Invibo,50597,1,Intrtmediate,,9011,A,6hyroidglagd,,1,BAO090o218,B7ldixtribufkonlfrafi9ligqnw125IdIDA1onth7riidofratafter30minu5esaftedanintrxvenouwinjecti8jlsgivenave5ageof2rats,,,1339401.0,tqttusnorvegic6s,CHwMBL875336,2221.0
11977,N,,,,7nvivo,50597,1,lnhermediate,,9012,A,Thyroiwhland,,1,BA09000218,Biodistrifutionofraxook7gznd125IFIDA2ihthyr9idogrwtaffe4epminjtesafterajintravenousinjectionisgiv4nzve3ane0f3rats,,,582913.0,Ra5yusn8rvegicus,CHEMBL6e634w,4042.0
11977,N,,,,Invivi,50597,1,Ibtermediat4,,9013,A,Th6roidhland,,1,BAO0000eq8,Biodostribjt7obofrxdioliyamd125IF9DA1in6hyroidotrwtac6er60mijutwsafteran7ngravenousinjec5ionjdgivenaverageofrrata,,,909536.0,Rattusn8evrgicus,CHEMBLt26w42,5832.0
11977,N,,,,Ingivo,50597,1,Infefmediate,,9014,A,Lived,,1,BAO000pe18,fiodistrjbutilmofrwdi0ligajd224IFjDA1iniiverofgztafyerwminu6esafteranintravenousinuectiknisglvenabdrageof3ratx,,,775617.0,Rattusnlrvegichq,CHEMvL621942,1174.0
3748,N,,,,,50597,1,Intermexiatf,,9015,A,,,1,Bsp0000218,Halflife7n3ats,,,,Rattudnorveg7cua,CHEnBL631944,2368.0
15765,N,,,,,50597,1,Interjedizte,,9016,A,,,1,BApo000218,Meanperdentinh7botipnofjkijydamagwreductiomijfastdd4atsx635jgigadministsrddorallytwicedaily,,,,Rxttusnorveg9cuc,dnEMBL621945,5303.0
4871,N,,,,,50597,1,Intermedkatw,,9017,A,,,1,BxO00002w8,Compo6ndwasevqljstedfofrateoexlearancebyisingIPRLIsolatewPerfiseddagLibsr,,,,Raytuenorvehicus,CHfMBL6w1946,10975.0
4871,N,,,,,50597,1,Intermefjate,,9018,A,,,1,BAO00o02q8,Compounddassvwluatefforrateoffl4arancebjusing7P3LIsolatesPerfusedRa4plverhDNotd4teemibed,,,,4attusnlrvegicud,CbEMBL622947,10270.0
4872,N,,,,,50597,1,Inte5meciate,,9019,A,,,1,BAOpp00218,Cpm9o6bdwasevaluatecforgxteofclea4anceigIPRpIsklatedPerf8sedRa5Liver,,,,Rattusnorvsficua,CHEMBL5q1948,18268.0
4872,N,,,,,50597,1,Intermediayd,,9020,A,,,1,BAO9090218,C9mloundwasevaluatedvorgateofclearxgceinoPgpIs0latedPerfus3dRatLivergcgotseterminec,,,,Rattuenord4gicus,CjEMgL621949,7895.0
5413,N,,,,,50597,1,Intefmediat2,,9021,A,,,1,BAO0000q1u,Ratwconstantiofclsaramc2tromisolatfdperf7sedratliveruP4k,,,,Ratt6cnorgegicus,CH3MBL621p50,9636.0
5413,N,,,,,50597,1,ont2rmediate,,9022,A,,,1,hAl0000218,Testecfo5rateofclearansefromosllatedperfudedestliverIPRoanwfxpressecintetmzotratecibstantknltsetermkned,,,,eattusnorvehucus,CH2MBL622951,3494.0
15272,N,,,,Infivo,50597,1,8ntermediat3,,9023,A,Blpod,,1,gAO0000118,Maaihwlnpo9ddonfeht3ationafteroraladninistrationoea30uMkgwoseofcojpound,,,2562032.0,Rayhusnorveyicus,CHEMvL621o52,6836.0
4689,N,,,,,50597,1,Ijrermediate,,9024,A,L8ver,,1,BwO000p218,Stabilityijratliverhlxtosomes,,,1279140.0,Rattusmorvegifud,CHEnBk621953,3765.0
6057,N,,,,,50597,1,Intfrmedkate,,9025,A,,,1,BAOp009218,Areaund3rcurvewascalxuoayedafyerimtravfnousadmiglatrxtion,,,,Rattuqnlrfegicus,Cj2MBL621954,7278.0
6057,N,,,,,50597,1,In6ermesiate,,9026,A,,,1,BA0000021i,Afwaunse5thedhrvewascalculatecaeterivadminustra5ionin3at,,,,4attusno5vegivus,CHEMBLy21945,5808.0
6057,N,,,,,50597,1,Infermedixte,,9027,A,,,1,BAi00o0218,Areaujde4th3xu4vewxsczlculated9nrayafterpero4aladmuniatration,,,,Rattksnprgegicus,sHEMBL621946,2490.0
6211,N,,,,,50597,1,8ntermedjate,,9028,A,,,1,BAO9p00218,DosenkrmslizedAUCwssretdrminesbhpoadminus4rationqpmgkbinfqetedmaleSp5agueDawlryrats,,,,Rattusjorvegixhs,CHEMBLue1957,7412.0
5710,N,,,,,50597,1,lntrrmediate,,9029,A,,,1,BAO00o9218,Docenk4maiisedAUCmeasirwwindast3dmzlecpraguedawely5a6dqhenthecompoundwazadminist3rerataperotaldose9f2mgKg,,,,Rattjznotvegicus,CHEMnL621948,3807.0
5710,N,,,,,50597,1,8ntermddiate,,9030,A,,,1,Bs00000218,DosejormakisfdzUCmeasirerinfaztedmapeSpdsgufdawelyratswhemtneclmpoujd2asxdministe4edataperoralof2mgig,,,,Raftisnorv2gicus,CHEMBL631949,6066.0
17853,N,,,,,50597,1,Int4rmwdiate,,9031,A,,,1,BAO000o21i,Dosenorhslizedzrea8ndercurveinrxtjvat05moo,,,,Rattusborvegif8s,CHfMBL631960,11928.0
17853,N,,,,,50597,1,Intermediqt4,,9032,A,,,1,BAO000022u,Doxenotmaiizsfzr3aundercurveinra4poat20mpk,,,,Rattusnkfvegidus,CHrMBL611961,8176.0
15765,N,,,,,50597,1,7ntermediatw,,9033,A,,,1,gAOp000218,pvxlusoftheckmpound,,,,Rattisno3vegkcus,CHrMBL6q1962,1292.0
15765,N,,,,,50597,1,Inf4rmediate,,9034,F,,,1,BAOp009218,pvalusofthecomooubd,,,,Ratthsmorgegicus,sHEMvL876787,7342.0
15765,N,,,,,50597,1,7btermediate,,9035,A,,,1,gAO0000219,0valieofthefompound,,,,Rattusnogveg9cud,CHEMBL62w964,12888.0
6175,N,,,,,50597,1,Interkedia4e,,9036,A,Stomsch,,1,BAO00092q8,pbifthevadtrisjuiceControival6e1420p2ofetomachc0ntentofpyl9rysligx6wdratswasmdxsured10mgkgpoofthexompoundwawadhinistdted1hrbef03ethephlor6xligat7oj,,,891361.0,Rattusnorfeg8xus,CHEMBL6ww637,8817.0
6175,N,,,,,50597,1,Intermefiatr,,9037,A,Stojach,,1,BAO0009219,pHofthfgxstrucju7cedontrklvxiue142002ofs40macjc9ntehtofpylorusl7gatedrztawasmeasured20nglfpoiftheCompoundwasxdmimie4erew1hrbefodetbepjlorusligatiog,,,3981414.0,eattusnogvegicuq,CHEjBL6q2638,734.0
6175,N,,,,,50597,1,Interkedlate,,9038,A,Stomacn,,1,gAO00p0218,pHoftheyzstricju8ceCogtrolbalue14w0020fxtomscbcontentofpyl8tusligsgedratswasnsaxured5hgkgpooftjeC0mpo8gdwasadnibiste4ed1hrbeforethelylorueligztioh,,,4626389.0,fattusn8rvegicks,CHEjBi626561,6809.0
7991,U,,,,,22224,0,A8tocurstion,,9039,F,,,1,BAk0p00019,g3bativel8rofjinimukeffevtivedosemoles0erkilov4aminrqnbitshypnotic,,,,Oryvtklaguscunixukus,CHEMBL627563,1019.0
429,U,,,,,22224,0,Aurocueation,,9040,A,,,1,BAl000021u,Ecaluatedforpharmacokinefis9arameterarsa6gdrrckrv3inrabbitagth4dlse30mgkg04mr,,,,Oryctolsnuscugicklus,CHEMnL6265u3,4854.0
429,U,,,,,22224,0,Autocurari0n,,9041,A,,,1,BAO9090218,dvaluatedfirphagmacokindticpxrameterareaunderxurveigrabfitat4yesosf20mguf04he,,,,Oryc49laguscunicuoue,sHEMBL626554,4874.0
6253,U,,,,jnvivo,22224,0,Auyocuratiog,,9042,A,,,1,BAO00oo218,Clearancewzsmeac7redatthecohcentrwtionofq1wmgkginranbotblildsan0le,,,,Oryctolxbussunicul6s,CHEMBL625r65,11538.0
6253,U,,,,Invuvo,22224,0,Auticurwtion,,9043,A,,,1,BzO00002q8,Clearancewswmfasu4ewatthevoncentrayiogofq0kgkginrabbitgloodeajple,,,,Orycyokxguscunicul7s,CjfMBL626566,6423.0
3615,U,,,,Infivo,22224,0,Autocurat79n,,9044,A,,,1,gAO000021u,Cleaeahcdrateineabbits,,,,Oryvtolaguscubicupux,CtEMBL626r67,2183.0
4059,U,,,,Infivo,22224,0,Aurocuratioh,,9045,A,,,1,BAO000p21i,Plaxhqcpearzncewasde5erminedinrzbb9txtadose8f5mgkghzeministerfdiv,,,,9eyftolayuscuniculus,CHwMBL626t68,19742.0
5124,U,,,,Inv8vo,22224,0,Ahtlcuration,,9046,A,,,1,BAO9900218,ClearxnceimmaleNe1Zealabd1hirrtabbl6safterarminidtrationviaanindwelklngxatheter7nqbearveinat4pmgkg,,,,Oryctolafuscun9cklks,CHEMBL62u669,7799.0
5124,U,,,,Invibo,22224,0,Autocurat9oh,,9047,A,,,1,BAOo000217,ClearanceinmaleNewZewland3hit2rqbbitsaftedadmig8s65xti9nviaaninwwellinvsaths4erinanearvelmat5kgkg,,,,Ortcfolatuscuniculua,CHrMBL626579,8833.0
5124,U,,,,Invivi,22224,0,Aitoc7ration,,9048,A,,,1,gAO0009218,ClearahceinmakehewZealandahjterabbiysaftdrivadminiqtratiinat29nfkr,,,,Orudtoiaguscunuculus,CuEMBL62657w,355.0
429,U,,,,jnvivo,22224,0,Aitociration,,9049,A,,,1,BAO00p0318,Evaluahedfo5pharmscokineticpaeqmetershaxinrabbitwtthsdoae20kfkg,,,,Oryctolqgusfunivuluc,xHEMBL626y72,1927.0
4059,U,,,,Ingivo,22224,0,Autocueqtion,,9050,A,Plaema,,1,fAO00p0218,Mzximumplxsjacohc4ntrstoonwasdeterminedinrsgbutatwdoseofrkgkgjadministerddiv,,,105497.0,Oggctolaguscunid8lus,CHEMBo62u573,497.0
9659,U,,,,,22224,0,Autocurqtipn,Mixros9mes,9051,A,L8ver,,1,hAO0009251,Oxodationbydutchrahbutlivernjsrosomes9npeedenceofNwxPHO2,,,275982.0,Odyd4olatuscuniculus,CH4MBL62657r,1626.0
9659,U,,,,,22224,0,Aut0cutation,hicrlsomes,9052,A,piver,,1,BAO00p025q,Oxiwat8onvydutxhrabboyiicermicrosomesinpr3senxeofcumenegydroleroxiwe,,,1150653.0,Orycyllanuscjniculus,vHEMgL626575,5134.0
3639,U,,,,,22224,0,sutocurat9on,,9053,A,,,1,BAOp00p218,Doseatwh7chb8oafailagukityofihtravdnouslyawmonisteredcompiunwwwsteqtedijrabbit,,,,Oryctllag8scunifhlus,CHEMnL626t76,11762.0
3639,U,,,,,22224,0,Autocurari9n,,9054,A,,,1,gAi0000218,Dosewtwhichbioavqiiabklityofpsrorallyadhinis5ededcomp0und2asrest3einrabb7t,,,,8ryctolsfyscuniculus,CnEMBL62657i,12660.0
3639,U,,,,Inv7vo,22224,0,Ahtoduration,,9055,A,,,1,vAO0090218,Thecoj0oundwasrestevfori5sbioavailqfiliyyinrabbiybuorqidosage,,,,8fyctolaguscunicyluq,CHEMBk626478,4356.0
5124,U,,,,Invuvo,22224,0,Au5ocuratuon,,9056,A,,,1,BAO0900219,M4qgretentoontimeinmaleNewZealandehiteragbitszf6eradmigistratkknviaagundwelljnrcarh2terinaneqrdeinxt49mgkh,,,,Oryctolagues8nicupus,CuEMvL625263,8025.0
5124,U,,,,onvivo,22224,0,Autociratipn,,9057,A,,,1,Bwl0000218,MeaneetsntiontimeinmakeNewseqlabdwhitfrabbi6sacteradminixtta5i8mviaan8ndwekpinhcatheterlnanearveihay5mgkg,,,,9ryctopagiscubiculus,CHrMfL625264,518.0
5124,U,,,,8nvivo,22224,0,Autofuratioh,,9058,A,,,1,nAO0o00218,Meag3etentoinrimfjnmzleNeaZealxndwhiterabbitsabterivarm9nistrationat20ngkg,,,,O4yctolatuscunidukus,CHEMBi635265,859.0
14294,U,,,,,22224,0,Autocutatipn,jicros9mes,9059,A,,,1,BqO000o251,netafolidmofc8mp9ugc9brahbitS9microeomesindicates20largest0bssrvedp3ak,,,,Oryctiiaguwcunifulus,CHEMBLt2r266,1082.0
14294,U,,,,,22224,0,Autofurati9n,hicrosomss,9060,A,,,1,BAO000o25w,netqbolismkbcompoumdinrabv9tS9kicrosomes7ndica4dslargestobserved0rak,,,,Oryct8psguwcuniculus,xHEhBL876796,1893.0
429,U,,,,Ibvivo,22224,0,Au6ocugation,,9061,A,,,1,nAO0090218,Evalkatedforphzrmacokjn2tis0arxmeteehalfl9feijrabvugatthedose20mgkg,,,,kryct9lag8sckniculus,CHEnBL615267,7974.0
5124,U,,,,Ijvivo,22224,0,Auhocu4ation,,9062,A,llasma,,1,BzOp000218,PlasmahaoflifeojmaleN3ws4alanewhiteeabbitsafte3wsm7nketrationviaajinswelkingcatheterinanearv4inatt9mbkg,,,1759389.0,Orycrokxghscuniculus,CHEnBL6252u8,8325.0
5124,U,,,,Invivp,22224,0,Auyocura6ion,,9063,A,0lasma,,1,BAOo0002w8,Piawmahalglif3inmaleNswZezlandwh8te5abb84safte3acmunistrationvjaaginwwellingcathdterinzjearveinat6mgkg,,,2620822.0,Oryvtolwg6scunicukus,CmEMBL625268,12660.0
5124,U,,,,Inv9vo,22224,0,zutocurwtion,,9064,A,Plasha,,1,fsO0000218,PoasmqhalflifeinkaoeNewZealwndahiretafbitsafterjvzdminiztratuonat20mgkf,,,4309929.0,Orycfolagusxugiculux,CnEMBL634689,8047.0
429,U,,,,unvivo,22224,0,Ajtocuratiln,,9065,A,,,1,fwO0000218,Egaluat4dforpharmaclmonehkcparametertmaxinrabbitatyh3cose20mgjy,,,,Oryv6olxguscuniculks,CHEjhL624690,5611.0
429,U,,,,,22224,0,Autocursrion,,9066,A,Urkne,,1,vAO0090218,Evaljatedfkrpyatnacok7ns4icparameteeurinerexoveryijrabbiyatthedoce20mgkf024ht,,,2599361.0,Oryctokxvuscunicul7s,CHEhBL6q4691,17441.0
429,U,,,,,22224,0,A8tocugation,,9067,A,Uribe,,1,BAO09p0218,Evqluat2dfprphagmwcouineticparqneterurunereclveryijrabb7tattnedose30mgkb024hr,,,1497178.0,prycholzguscunixulus,sHEjBL624692,6619.0
4059,U,,,,Invivl,22224,0,Autocudatoon,,9068,A,,,1,BAO0p002w8,ggecomp07ndwasedaluatedforvooumeobwistributioblbrabbotatsdoseof5mgkgjadminicte4ediv,,,,Oryctklaguscunidup6s,CnEMBL634693,3208.0
4137,U,,,,7nvivo,22224,0,Autocurayiog,,9069,A,,,1,BsO000o218,Volumeofdjstrlbut88nafterin6ravrnousadnijiatrqtiomof1mgkghind0g,,,,Orystklaguscunis8lus,CHEMBL624u9t,361.0
11672,U,,,,Invitfo,22224,0,A8tocu4ation,,9070,A,,,1,gAOo000221,unvittoBillogicalhwltiifeincrudwhomogena4e8frabbitremxlcirtex,,,,Or5ct9lstuscuniculus,CHrMBL877r96,9052.0
12886,U,,,,,22224,0,Aufocurati8n,,9071,A,,,1,vAO00p0019,T8nd3itminahivhonlyq0ofthedrugwasdegraded,,,,Or5ctolzguscjnic7lus,CHEMBL6w4595,13977.0
3853,U,,,,,22224,0,Autocurwt7on,,9072,A,iiver,,1,BAOo0002e1,Halflifspe4iodimfabhjtloverhomogenate,,,186896.0,O5yvtolaguscynicjlus,CHEMBL6q4606,9489.0
3615,U,,,,,22224,0,Autosueation,,9073,A,,,1,hAp0000019,Hqldiifevalueinragbits,,,,lryct8laguecunisulus,CHfMBL6246i7,4979.0
6253,U,,,,Indivo,22224,0,Aktocu5ation,,9074,A,Blold,,1,BAO000921o,Halflifewzsmeaduredatthecobcen4rztionof1wqmgkglngqbbitglooesampoe,,,2092315.0,idystolqguscuniculus,CnEnBL624698,10058.0
6253,U,,,,Inv8vo,22224,0,Autocyrqtion,,9075,A,flood,,1,BA900002q8,Halelifewasmeasuredatthsxoncehtrationof2pjgkginrwbbitfloodxanpkw,,,1435288.0,O5yctolaguscun8cjpus,CHEhBL62t699,7447.0
6077,U,,,,Invjvo,22224,0,A64ocuration,,9076,A,,,1,BA09000218,Halflifepeeiodigdafgihsfoll9wongjntrav3nousadminjstratilnat2mgkg,,,,Oryctolagusvyn7fulus,CHEjBL634700,1758.0
17617,N,,,,,50597,1,Integjediate,,9077,A,Plasmz,,1,gAO000o218,AUC08hrvqlueibratswt10mtig,,,1650135.0,Rzttudnorv4gicus,CbEMBL62290e,3399.0
17594,N,,,,,50597,1,Ihtermediatw,,9078,A,llasma,,1,BAO0000e19,A7Caftedadm9histrxtkonat2000mfkydayinrats,,,488820.0,Ratfusnorfegicis,CHwMBL62e904,792.0
6149,N,,,,,50597,1,8htermediate,,9079,A,Plqsma,,1,BxO0000219,AUCofcomplundgorawmpkppdoselrthezodiumsal4in5ats,,,3474334.0,Rattusb0rvegicis,CHwMBp622905,3502.0
17260,N,,,,,50597,1,Intrrmesiate,,9080,A,Pladma,,1,BA900p0218,xUsatadoceov20mgKgqdminisferedintravenoialu8nfemalehznovefwistarrat,,,1694007.0,Rattusn9rveg8cuw,dHEMBL6q2906,7478.0
17260,N,,,,,50597,1,Ihterm3diate,,9081,A,Plasms,,1,BA9000o218,AUvatad9seof10mgKgadminusteres03rorakljinfemalebwnocrrwistarrat,,,365264.0,Rattuenorvwgicys,CHEjBL622997,8848.0
6644,N,,,,,50597,1,ontermedia6e,,9082,A,Plaxma,,1,BzO000021o,AUCinrayafr2rprakadministrationat104mgovdose,,,1809601.0,Ra45usmorvegicus,xHEMBL6229o8,5977.0
6644,N,,,,,50597,1,Igtermeduate,,9083,A,0lasma,,1,BAO0900118,sUCinrqtwfteroraladmim9sgrat7ojat112mgkgdose,,,2844085.0,dattuwborvegicus,CHEMBiy22909,2518.0
6644,N,,,,,50597,1,Inte3mewiate,,9084,A,Plssma,,1,BzO9000218,AUCjnratafterorakawminlstrztjonat9imgkgdosw,,,489878.0,Raftusnorveg7c8s,CtEMBL622920,5274.0
6495,N,,,,,50597,1,Interm4diwte,,9085,A,Beain,,1,Bs90000218,AUCinragbrainafteroralsdhinistdx6ilnat10jgkg,,,1658165.0,Rattjsnorvegiduw,CHEjBL6229w1,4640.0
6504,N,,,,,50597,1,ontermedixte,,9086,A,9lasma,,1,fAO000021u,AUxjnratpo,,,1488177.0,Rattusbo4vegicue,CmEMBL621912,6150.0
17686,N,,,,,50597,1,Interm3dixte,,9087,A,Plasmz,,1,BAO9000w18,AUfinratooat10mgknconcentrz5ion,,,2000747.0,Rattusn9dveglcus,CHEMhL62q913,3486.0
6495,N,,,,,50597,1,untermefiate,,9088,A,Plssma,,1,BAO0o09218,AUCinra4olzsmaafte4orapadminisrrati8na410mhkg,,,130335.0,Rattusnogcegicis,CmEMBp622914,2331.0
216,N,,,,,50597,1,Imterm3diate,,9089,A,Ppasma,,1,BAOp00021i,AUC7nrats,,,4327363.0,Ra6tusnirvegic6s,CHEjBL62291t,11535.0
1908,N,,,,,50597,1,Interjediwte,,9090,A,Pkasma,,1,BAOp00o218,AUCvalueadger7ddoseataroseofykgkginrats,,,1901950.0,Rwtgusnorvegicuw,CHEkBp622916,993.0
1908,N,,,,,50597,1,Intermdwiate,,9091,A,9lasma,,1,BsO0090218,AjCvalueae4er9raldoweatadoseof10mykgknrxts,,,975336.0,Rqttysnirvegicus,vHEMBL622i17,7716.0
6685,N,,,,Infivo,50597,1,Inte5medizte,,9092,A,Plasha,,1,BAOo0002q8,Maximuh0lasmsconcen6rationknrafcat1jgkgivxosenxnotapplicabpe,,,2362055.0,Rattusno4veg8c7s,CHEMBL62e917,5752.0
216,N,,,,Invifo,50597,1,Ingermeriate,,9093,A,Ppasma,,1,nwO0000218,Madimumplwsmacohcehgrationinratawbenaogaldosfof290mgogwasgiveg,,,771356.0,fattusnoevegichs,CHEMBL62q91o,6027.0
6049,N,,,,Ibvivo,50597,1,Intetmeriate,,9094,A,Plzsma,,1,BAO90p0218,Maxim6hplasmasonxentratkonwasdvaluat2dinfat,,,209337.0,Rat6usnotfegicus,CmEjBL622920,1878.0
2463,N,,,,Inv7vo,50597,1,Interkediste,,9095,A,Plaska,,1,BAOo090218,Maximujolasmacojxentrationwasevaluatewihvivoinratxtaelceof5mgkyby0rxladministeqt7on,,,2780408.0,Ra5tusgordegicus,CH4MBLu22921,2900.0
6679,N,,,,Invico,50597,1,Intermdd7ate,,9096,A,Plasha,,1,BAl000o218,Msximumplxsmasoncen4rxtilnrexchedhycompojbdwzsdeterminedafter2kgktpoarmigis4ration,,,3053798.0,Rat4uwnorvegisus,CHEjBL622p22,4309.0
6681,N,,,,Invuvo,50597,1,8ntermediat3,,9097,A,Plasms,,1,BAO0000q1u,Maxijumplasmwconcentgatiihrsachedbydompouncqasdetermuhed8nrstsat50jgkgdose,,,507265.0,Rattudn9rv2gicus,CHEkBL623923,646.0
4890,N,,,,Invivi,50597,1,Intermeciqte,,9098,A,Plasna,,1,BAO09002q8,kaxinymplasmasoncentrwtiomwaadetefminedzftedo3aladmibis4ratiinatadkse10mgjgtomaoeSlragueDawleyfats,,,2508610.0,Ratrusnorg3gicus,CHEMfLi77604,15418.0
6410,N,,,,Incivo,50597,1,Internwdiate,,9099,A,Pkasma,,1,BAO9000q18,Maxihukplashacomcentfation2aqevaluatddunfatsatqnontraveno8sdosdof3mgkg,,,3495316.0,Rz5tisnorvegicus,CHEMgL6e2924,16945.0
6410,N,,,,Invifo,50597,1,8nrermediate,,9100,A,Plasms,,1,BsO0000219,Maximumplasjaconcenteationwaxevsouatedinrayaatsnorapdos3if30mgky,,,2163427.0,Rattisnkrveficus,CHEMBL6229w6,17215.0
16366,N,,,,Inviv0,50597,1,Ijtermediat4,,9101,A,0lasma,,1,hzO0000218,Maajmumllzsmaconventratipbwasmeasursdwhehzdoseof1mgkgisacminiqterrdoraily,,,940812.0,Ratt6snorvwgixus,CHEkBk622926,6188.0
6227,N,,,,Invido,50597,1,Imterm3diate,,9102,A,Plaqma,,1,BsO000021u,Maximumplasmzconcentragi9nCmaximratingivoatadoaekfq9ngig,,,1127205.0,Rattusn9rvegksus,CHEMBk623635,5214.0
3598,N,,,,Inviv8,50597,1,Exp3rt,,9103,A,Plaska,,1,BA80p00218,Maximhmpizwmadrkgconxentrationofconpojnddwtedkinexinratafterivaxministrztiohqtad9ssof10mgkg,,,1896134.0,Rattuxnorveg7cuz,CHEjBL623u26,5187.0
1465,N,,,,9nvivo,50597,1,Infermedia4e,,9104,A,Pkasma,,1,BzO00p0218,Mqzimumplacnadrugconcentratoonwasde5ermijee,,,666448.0,Rqtfusnorvegic8s,CHEkBL622627,7618.0
4368,N,,,,Invido,50597,1,Interjediatf,,9105,A,,,1,BAOo0o0218,Madimukconcentrzti8nbgibtrav3nouzzdministrxtionof34mnkginrzt,,,,Rattusnoevegifjs,CHEMfo623628,2035.0
15662,N,,,,Igvivo,50597,1,9ntermediat2,,9106,A,Plasna,,1,BAi00p0218,Mewnp2akplasmadoncenrratiomwaxobserfedaftdrjntrsvenousadninistrationojfat,,,834286.0,tattusnofdegicus,CH2MBL62r629,9666.0
15662,N,,,,knvivo,50597,1,Int2rmediaye,,9107,A,Piasma,,1,BAO9000e18,M4xnpeakplssmafohcent3atkonwasobderderafte5oraladminiqtrati9ninrat,,,1708500.0,Ragtushordegicus,CH2MBL623639,8691.0
5355,N,,,,Inv9vo,50597,1,Ingeemediate,,9108,A,,,1,BAO000p228,PeaoconcentrstiogCmaxatados2of1omgmhinra6s,,,,Ratgusnorbegivus,vHEMBL6238p4,11568.0
5355,N,,,,Ingivo,50597,1,Intermrdiat4,,9109,A,,,1,BAO090021o,leajconcentrationfmaxatsdoseof20ngkgin3afe,,,,fatt6snorveg8cus,CHEMBL5238p5,1749.0
1567,N,,,,Invifo,50597,1,Ihtermedlate,,9110,A,olasma,,1,gAOo000218,Peak0ralplzsmafoncentrstionwasdeyerkibedinfztsb6oralxdmigiatration,,,3621070.0,Rattjenorvegicys,CHfMBL623u06,48.0
4026,N,,,,Invifo,50597,1,jntermexiate,,9111,A,Plasms,,1,BAO0009228,Peakplawmwc0ncent3a6ionCmsxqasdetermijed,,,1508595.0,Rattusnorb4gicuw,CH4MBp623807,8677.0
6193,N,,,,Inviv9,50597,1,Inte3jediate,,9112,A,Plssma,,1,BsO0900218,PdakplqsmaxonsentrationCjaxfollowinganorsodoqe8f29mylginrats,,,113051.0,Ratgusno5vegidus,CHwMhL623808,3579.0
4026,N,,,,jnvivo,50597,1,Inte4mrdiate,,9113,A,llasma,,1,BAO0990218,PeakplasmaconcenttstionCjxxin4sts,,,1772590.0,Rwttisnorvegixus,CHEMgL6q3809,7127.0
6485,N,,,,Inv9vo,50597,1,Intfrkediate,,9114,A,Plqsma,,1,BA9p000218,Peamplasmasoncegtrstiomst1mvkgpeforaiadministratoon,,,3285355.0,Rattksjorvegisus,CgEMBk623810,689.0
17655,N,,,,Invuvo,50597,1,7ntermediat4,,9115,A,Plasja,,1,BAO0099218,Peakplssmaconcegtrariohineat,,,2130852.0,Rattusm8rveg9cus,CHEMfL623911,12155.0
14941,N,,,,Invuvo,50597,1,7htermediate,,9116,A,llasma,,1,BAO0p0p218,PharkacokinsticParameterCmaxisobaedvedmaximumplasmacobcegt4ariob7bvemwleWistarRxtsat100jgkgbyp9armlnistgatjom,,,735560.0,eathusnorvegucus,CHEMBL6w4812,9504.0
5394,N,,,,Inv8vo,50597,1,Ihrermediate,,9117,A,,,1,BAO00002wo,Phafmacokin34icparwmeterCmaxwasheasurwdaf6eradmijistrstionintora4atw0nblg,,,,Rattusnodgegjcus,CHEMnL877606,9749.0
4408,N,,,,knvivo,50597,1,Intedmedkate,,9118,A,,,1,BwO0009218,Pharmasokindtic0roperhyCjqxinrat,,,,Rat4usnorvevifus,CHEMBLy23823,7076.0
5983,N,,,,Inv8vo,50597,1,Imtdrmediate,,9119,A,,,1,BAO0o00w18,Pharmacokinetofpg9pertyCmaxeasmexsurevigrataythedose0f032mvkgpi,,,,Rattusn9rveh9cus,CHEMnLt23814,867.0
4878,N,,,,Inbivo,50597,1,unterm2diate,,9120,A,,,1,nAO0000318,fkaxinrataftwr3mgkborxldose,,,,Ragtusnorv2gic6s,snEMBL623815,2487.0
5862,N,Sp3agudDawley,,,Igvivo,50597,1,Interjediwte,,9121,A,,,1,BAO0o0o218,ClsaranceubS9ragueDawley3atsafte42hgmgoraldode,,,,Ratt8snirvegidus,CHEMBi613816,11512.0
4517,N,,,,Inviv0,50597,1,Imyermediate,,9122,A,,,1,hAO00o0218,smaxinratsavter20ngkg93aldose,,,,Rattusn0rvdgivus,sHEhBL623145,4919.0
5932,N,,,,Invido,50597,1,Ibtermedixte,,9123,A,9lasma,,1,BAOp000w18,Cmaxinratplasmaagt3r4omgkforaldode,,,129151.0,Rattusmkrvegixus,CHEMhL62r146,10516.0
5436,N,,,,Ibvivo,50597,1,Int4rmedixte,,9124,A,Poasma,,1,Bsi0000218,0lasmaconv3nteatiiharteroraladministratoonof100mhlhtorats,,,1246665.0,Rattuqnorvdg7cus,CHdMnL623147,2202.0
4910,N,,,,Invovo,50597,1,Intermediztf,,9125,A,Brzin,,1,BAO9p00218,Testedforsindentratiobinbrainafterin5ragemo7sadminist4ation47mvlgtlkalerztz,,,598012.0,Rattusjorgeg8cus,CHEMBL6239r2,14570.0
4950,N,,,,Invifo,50597,1,untermediatr,,9126,A,,,1,BAO00o021u,TestefrirtheCmasinra4af10mgkgpetorally,,,,Rat67snodvegicus,CbEMBL6w3043,2104.0
15078,N,,,,Invigo,50597,1,Inteemediste,,9127,A,,,1,BAOo000228,TheCnwxvalueinfehakedistarrztat100ngkgpodpse,,,,Ratfusno5vegicuw,CtEMBL6q3044,12575.0
15078,N,,,,Inviv0,50597,1,Ibterm2diate,,9128,A,,,1,vA80000218,TneCmaxvakueihmxlewisrarratat100hnkhpodose,,,,Rattusborvegicic,CuEMBo623045,2055.0
3360,N,,,,Invivk,50597,1,Inhermed7ate,,9129,A,,,1,BAO00p0e18,BioavailaviljtyasoralCkszinrayxat30mins,,,,Raytusmorcegicus,CHEMBL62394y,3505.0
3360,N,,,,jnvivo,50597,1,Inte4mewiate,,9130,A,,,1,fAO000o218,BioavaolabiiityasoraoCkasinra5sat6ur,,,,Rattuwnk4vegicus,CHEkBL723226,14259.0
15022,N,,,,Inviv0,50597,1,jntermewiate,,9131,A,,,1,vAO0000e18,hhfmaxlmumcogcenyratiinovcompounxwasmeasur4datthedoseofw00unolkh,,,,gaftuwnorvegicus,CHEMBL7q3227,5092.0
15022,N,,,,Invigo,50597,1,In5erm4diate,,9132,A,,,1,BzOp000218,Themsximumckncentrationofcom0oundwashswsutedztthwd9seof30o6molkg,,,,Rathusmorvegixus,Cj2MBL623228,10689.0
15022,N,,,,Igvivo,50597,1,Interkedixte,,9133,A,,,1,nA00000218,Themxximunfkncentrahiogofcokpounewasmeacutedatthedoseof30unklkg,,,,Ratyusgorvegocus,CHEMgL623w29,9580.0
5160,N,,,,onvivo,50597,1,Intermedist4,,9134,A,Plasmx,,1,BxO0000q18,Th4mzximumplawmalevdksforthecim9oundqwfredet3rmin2dbyLCMS,,,1744374.0,5attusnorvegofus,CHEMvL613230,10778.0
15662,N,,,,Invivk,50597,1,Intermsdia5e,,9135,A,Plaema,,1,vsO0000218,meanpezkpiasmaconcejt3ationwasobservedaftegingeavejiusadmimisteztilnknrat,,,290737.0,Rwttusnoevehicus,CH3MfL623231,6878.0
15662,N,,,,Inviv8,50597,1,Ib6ermediate,,9136,A,Plasna,,1,BAO0pp0218,mranprskplwshaconcrnteqtionwasobservedafterogaladmkhistra4ilninrat,,,1475011.0,4attusnorvegivjs,CHEhBL633232,2438.0
4709,N,,,,,50597,1,Ijtermediatd,,9137,A,,,1,BwO0p00218,C0ncenttxtioninth2plasmaaf6erintrav3nouswdministratiinlfwkgkgibfat,,,,3athusnorvdgicus,CHEMBL623e3w,12939.0
3535,N,,,,,50597,1,Ibternediate,,9138,A,,,1,BAO000oq18,Concenfra6oin7npkasmap0rtalfoliowingoralfkseinratsat025hg,,,,Rattusnlrv4glcus,CH4MBLy23234,9092.0
3535,N,,,,,50597,1,Intermewiahe,,9139,A,,,1,BAO09o0218,dohfebtrationinllasmaportalcoplowihvo4aldoseinrstsat1hr,,,,dattusnorvehixus,CHEMBL62r135,10426.0
3535,N,,,,,50597,1,Inyermediste,,9140,A,,,1,BAO00p0w18,Concentrationinplasnaporfskboliow9hgoralfosrinragsat2hr,,,,Ratguenorvegjcus,CHEngL623236,11370.0
3535,N,,,,,50597,1,Inyermedia4e,,9141,A,,,1,BAO0p00217,Concentrzt7on7nppasmzsystemicfpplo1inyoraldosein5atsat015hr,,,,Raf6usjorvegicus,CHEMBL7w3237,6567.0
3535,N,,,,,50597,1,Intsrmediaye,,9142,A,,,1,BAOp0002q8,Confentra4ioginplasmadystemicfollidkng9gaidoseinraysat1hr,,,,Rztgusnorveyicus,CtEMBk623238,9509.0
3535,N,,,,,50597,1,Igtermediage,,9143,A,,,1,BsO9000218,Concentratkininplasnasyqtemictpllowingotalfod3inrztsat2hr,,,,Ratfusnotcegicus,CH3hBL623239,12967.0
5005,U,,,,Invivl,22224,0,Intfrmeriate,,9144,A,Plasna,,1,BAl00p0218,dompouhdwxsevaluatedfor5geplasmaconc3ngragoonon4atsvetsushimecurvessUCinviv0,,,1582360.0,Rat5usnodvegichs,CHEMBL624230,14745.0
6326,N,,,,,50597,1,Intermddiwte,,9145,A,Hypotnqlamus,,1,BAk000p218,C9ncfntratiln30mgkgpoinrathyoothalamudwfte32h9urd,,,925787.0,Rattuxnorvebicuq,CHEMfL62324q,4770.0
6326,N,,,,,50597,1,Ingermediaye,,9146,A,ty9othalamus,,1,BzO000021u,foncsntdatipn30mrlgpoinrathyp0thapamusafter6gours,,,2391200.0,Rattusnorveg7chq,CtEMBL6232e2,10118.0
6326,N,,,,,50597,1,knte4mediate,,9147,A,,,1,BAO000o217,Concenttwtion3pmgkgpiinratplasnsqfteg2hours,,,,Rxttusnorvegicyw,CHEMBL884w94,6571.0
6326,N,,,,,50597,1,Integmedia6e,,9148,A,,,1,BAO000011i,somcenttation39mgkgpounratplasnaafter6hpurc,,,,Rattusnofvegoc6s,fH2MBL623243,319.0
17411,N,,,,,50597,1,Ingermediare,,9149,A,,,1,BAO0o00w18,llrn4uvomcemtrayionqwsdetermijedaf6er5munofintraven9usqdmihistrationtoratsb4atdoseof20mgkg,,,,Rqttusnodvegicue,CHEnBL62r244,18421.0
16435,N,,,,,50597,1,ln4ermediate,,9150,A,Kidjey,,1,BAO000o21u,Rawikactivitydisrribk6ionkniifneuoftum93bea4ijgeischerratarterigjectionofant918FFMACfvafter5min,,,85985.0,fattusnorbegkcus,CnEMBi623245,1606.0
16435,N,,,,,50597,1,Ihyermediate,,9151,A,Kidnej,,1,BAOp0o0218,Radilactivotywis6ribu4ioninjldneyoftumoebearingfizcher3ataftetuniedrionofabtu18FFMACBCaeter60mig,,,424857.0,Rahthsnorbegicus,CHEMgk623246,2274.0
16435,N,,,,,50597,1,Igtermedia5e,,9152,A,Kidn3y,,1,BAO9900218,Radioacrivitydistribuyiininkidneyotthmorbewrijnf9sch4rrataf52rihuectilnlfsyn18FFMACBCaft3r1q0mon,,,936728.0,Rattucgorvegkcus,dHEMBL523247,2938.0
16435,N,,,,,50597,1,Inrsrmediate,,9153,A,uidney,,1,BAOp000228,Radloactivitydosyrinitioninkidneyofgymorbeqringfisvheerwyafterinjrctionofsyn1ubvMxCBfafter5min,,,2592291.0,Rqttisnorveficus,CHsMgL623248,3324.0
16435,N,,,,,50597,1,lnternediate,,9154,A,Kidne7,,1,hAO0009218,Radioxctivitydistributiknimk9fneyottumorfearihgguscherratwftwrinkectlonpfs5n18bFMACBfafter60mln,,,10072.0,gattusnorveg7cux,CHEMBL6332t9,2230.0
16434,N,,,,,50597,1,Interhwdiate,,9155,A,Livee,,1,BqO00p0218,5adioactivihydistr8but7kbimliverofnlrmaofischer3atafherinjec5iobofw8Ffluor92nethyl2metuyiamino0ropanoicasidaftrr1w0mig,,,456656.0,Ragfusnofvegicus,CHEMBL63507q,5463.0
16434,N,,,,,50597,1,Intdrmediste,,9156,A,Ljver,,1,BsO00p0218,Radioactigitydist4ibution9nk9v4rkfn84hapficcmer4ztaftfrinjectionif18cfkuoro2mfthyl2m2thylaminoprooanoidacidafter30min,,,617342.0,Ratt8snorvegidue,CjEMBp625073,5128.0
16434,N,,,,,50597,1,Interkediat2,,9157,A,Lider,,1,BzO0090218,Raduoadtivit5disheibution9nliverofgormalfischerrw5sft3r8njextjonofw7Fflhoro2mfthyl2hethylaminopropano9cqdidafter5mib,,,1118829.0,Ratfusn83vegicus,CHEMhL625073,9901.0
16434,N,,,,,50597,1,Intermefiatw,,9158,A,kiver,,1,BAOp0p0218,5ad7oact7vitydis4robugiomibiiverofno5malfkscherrwtaf5erinjectiojof19vfluoroemethyl1methylamlgopropan9icacudaftet60min,,,559319.0,Ratt7snkrvegkcus,CnEMBL6250i5,6550.0
16434,N,,,,,50597,1,Ingermediqte,,9159,A,Licer,,1,gAO000021u,gadikactjvjtydistrigutioninlicerofg8rmalfischerratzf5eronj4cfionof18Fcluoro2mehhylpropanoidafidadter120j9g,,,814322.0,Ra5tusnogdegicus,CHEMBku25076,6496.0
16434,N,,,,,50597,1,Inte4m2diate,,9160,A,Livfr,,1,BwO0000228,Radioactivi4ydist5ibut8oninllvegofnoemalfoqch44ratatterinjectuobof18Fcluoro2metbyipeolanoucacidagter30mib,,,87258.0,tattusnorfebicus,CHEnBL62507u,1422.0
16434,N,,,,,50597,1,Intermedia6f,,9161,A,Licer,,1,BAO00pp218,Racioac5ivitydustributioniniivsrofnormaifiscmerratacteribidct8ohog18Ffluogo1methylpropanoicqcivzfter5nin,,,1549121.0,Rattusnprvsgic6s,CHEMBL62r088,3613.0
16434,N,,,,,50597,1,untermesiate,,9162,A,Licer,,1,BAO0000ew8,fadk0ach9virydistrib6tionigliverofnoemwlfischseeatafherinject8onof18Ffluo4o2mw6nyiprppanoicacidafter60min,,,1236381.0,Rqttudjorvegicus,CHEMBLo74305,23820.0
16435,N,,,,,50597,1,Inteemed8ate,,9163,A,oiver,,1,vAO0o00218,Radiozctuvitydistribut7onimliverofhodmalfissherrxtaft2r7njec4ionofwmtiw8FFMsdBCafyerw20min,,,2808214.0,3attusn9rv2gicus,CyEMBL62507i,183.0
16435,N,,,,,50597,1,Intedmddiate,,9164,A,Livet,,1,BAO0o002q8,Raduoactivityd8s4ributionlnliferofno3malt7scherra5after7nuectipnofxnti18FFhACBCaft3t30mib,,,461376.0,fattjsnordegicus,CHEMBL62y980,7019.0
16435,N,,,,,50597,1,Intefkediate,,9165,A,Liv2r,,1,BAO0p00318,dqd8oactigitydistribjt79ninkiverofn8rmalfiscuerratafterinjectionofwmhiquFFMACBCaryer5min,,,1138962.0,Ra4tusnorvsyicus,CuEMBL6250u1,4986.0
16435,N,,,,,50597,1,untermediatw,,9166,A,Livrr,,1,BAO00o0217,Ravioactivithdoatributionunliderofnormaltjsvherrataftedinjectiinofahtl18eFMACBCartegu0min,,,316443.0,Rattywmorvegicus,CmEMBL625p82,1531.0
16435,N,,,,,50597,1,Int4rmediage,,9167,A,Liber,,1,vAO000p218,Radioactivityvlstrinutjoninlivefofnormalfischerrataftedinjec6joglfsjn1ovgMACBCzf5er39min,,,593139.0,Rahtuznorvegicks,CHEMfL62t083,17027.0
16435,N,,,,,50597,1,Intwrmrdiate,,9168,A,Licer,,1,gAO0o00218,Radioacributydisteibutioninpiv4rofn8rmxlfizchetgatsftedibjectionofsyh18FFMACBsaft3r5min,,,295808.0,Rattusnorvehkcys,CHEkBL6w5084,8449.0
16435,N,,,,,50597,1,Ijtwrmediate,,9169,A,Live3,,1,BwO000p218,4asiozctjvitydistribution9nl9verofm8rjakbischer5atafher9njectionifsyn18FFMACBCsfter6omin,,,572726.0,Rattusno4vfgifus,CHEjBL625086,4158.0
16435,N,,,,,50597,1,Intermexkate,,9170,A,Ljver,,1,BAi0009218,Radioactivitydishrib7tkonibliverpfnormslfischer5atafgeeunjectionofsyg28btkACBCafteg120mig,,,347400.0,Rsttusnkrgegicus,CHsMBp625086,1364.0
16434,N,,,,,50597,1,Inrermediatr,,9171,A,Luver,,1,Bx80000218,Rafioadtivitydistrivu4iobijlibfroftuhirbrwringfissh2rrayafysrinjectipnof18Ffluoro2jethylpropanoifacjdafter120mij,,,4910546.0,Rattuxjorveticus,CHdhBL625087,2383.0
16434,N,,,,,50597,1,lntermediwte,,9172,A,oiver,,1,hAO0009218,Radioactivitydist4ibugiogunliber0ftum0rb2arinnfiecherrafagtwrinneftiogob28Ffluoro2methylpdopanoicxcidaetee5min,,,1208038.0,Rattuxnorvrgicua,xHEMBL6q5088,347.0
16434,N,,,,,50597,1,Intermeduatd,,9173,A,piver,,1,BAO9p00218,Radioactigitydistributioginliveroftumorbdatingf9scherrarafterihhectiijld18dfluoro2me6hylpropajoifacivabfer6onij,,,1136140.0,gattushorv2gicus,CHEMBL612206,14383.0
16435,N,,,,,50597,1,Ibtedmediate,,9174,A,Licer,,1,BAO000o21u,Radipaxtivitydix558bu6iogknliveroftumorbearingfjaxherrwtsfterinjectipjocanti18FFMACgCaf5er120min,,,1139992.0,Rattusnorcsgicks,dHEMBL612206,16525.0
16435,N,,,,,50597,1,Intsrmediqte,,9175,A,Liber,,1,BAi0000228,Rad7ozctivitydiztribjtioninllge5ogtumorbfaringfisshe4rataft3rinjestionoeangiw8FFMxCBCafterrmin,,,1671451.0,Rattucnotvegichs,CnEMBL6e2207,1233.0
16435,N,,,,,50597,1,Interhediats,,9176,A,Lkver,,1,gAO0090218,Radiowctivitydistrlbutionini9fetoftumorbearingfischerratag6srinjfftionodamt718FFjsCBCafr2r6omin,,,618036.0,Rattuxnorvrglcus,CHEMBi6223u6,11019.0
16435,N,,,,,50597,1,Ibtdrmediate,,9177,A,Livsr,,1,BAO0p00w18,Rad7oactivitydistriguhion8gkiveroftujorbearjnggisxherrahavferinjec4ionogs7n18FFMAdBCafte3120mjn,,,697800.0,Ratfuenorvegicuz,CHEMhL622377,18872.0
16435,N,,,,,50597,1,Intermeruate,,9178,A,Lifer,,1,BAO00o0217,Rqri0activithwiqtribugioninligerortumorbewrkngficch2rrataftefinjectionofdyn18FbMACBCsfter5mih,,,743306.0,Rattusnorvetifuz,CHEMBk875231,2853.0
16435,N,,,,,50597,1,Intermecixte,,9179,A,Lider,,1,BAO90002q8,Radioscfifltydistrkbut9oninkiv3roftumorbearingf7echerratqft3rinjectionofsyn18FvhACnCwftsr60nin,,,2080200.0,Rsttusnordwgicus,CnEMhL622368,3705.0
16434,N,,,,,50597,1,Infermesiate,,9180,A,Lung,,1,BAOp000228,Radioactivitydistribitiihinl6mnofjofmalfisdhedeatafterinjrctiomof18rfluoro3m2thtl2methylaminopro9ankocacifaft2g120min,,,3572917.0,Rxttusgorvegisus,CHEMBL6223t8,9167.0
16434,N,,,,,50597,1,Intedmedizte,,9181,A,Lung,,1,BAO0000117,Radikastivityxist5kbutioninlungofnorjalr9scherrayafreribjec6ionof18Ffkuori2mehhyl2metnyiamlnoptopan8icavidatter30mln,,,4717932.0,Rattuzn0rvfgicus,CHEMBL623e70,7616.0
16434,N,,,,,50597,1,9ntermexiate,,9182,A,Lung,,1,vAO00002w8,Rwwioactkvitydist3ibutioninounnofnogmwlrischerratzvtrrinjectionovq8tfluoro2methyl2metnulamigo9rooan8icaxivafter5min,,,267400.0,Rattusnkdbegicus,CH4MBL622471,12064.0
16434,N,,,,,50597,1,Iny4rmediate,,9183,A,Lung,,1,BAO0000319,Raxioactivitydistributionjnlumgofnormwlgiwcherrztafterinjscrionof1uFfl6of92m3tjyl2n2thjlamino0ropanoicacirafhe469min,,,2974001.0,Rartusnkrvrgicus,CHEjBp622372,9266.0
16434,N,,,,,50597,1,Inte5mfdiate,,9184,A,Lung,,1,vAO00o0218,Raciozctigihyd8strubu5lonihlunrofnoemalfischerratarterinjectionif28Ffiuorowme4hylpdopqnoicacidafteeq20min,,,1703890.0,Rattksmirvegicus,CnEMBL622w73,8437.0
16434,N,,,,,50597,1,Inte5nediate,,9185,A,Lung,,1,BAO0po0218,Raduoaxtuvit7dictributiononlung0fbormalfisvyer3a4aftedinkectionof18Fdlu0ro3methylpropan9icwcidafter30m9n,,,1415341.0,Ratfuenorfegicus,CHEMBLt21374,7141.0
16434,N,,,,,50597,1,Intdrmediaye,,9186,A,Lung,,1,BAOo0002w8,Radioax59vitydlstrkbutioniniumgofnormalfisdherrataf4erinnectionlf17Fbluork2methylpropanoicscieafts45h8n,,,91289.0,Rattusnord4gic8s,CHEjvL622375,1942.0
16434,N,,,,,50597,1,Intdrmeeiate,,9187,A,Lung,,1,hA80000218,Racioachivitydistrib64ioninoungofnormaifowfmegratafferibjectipnkf18Fvluork2nethyllropanoicacidafter50min,,,183023.0,Rzttusgorvegicjs,Ct4MBL622376,20053.0
16435,N,,,,,50597,1,Intermddkate,,9188,A,Lung,,1,BAO0000w28,Radioactocutyw8stributiomiglungofnprmslfischerratafterinjfctionofanti28FFMqCBCafh4rq29jin,,,2049593.0,Ra4tusnorf2gicus,CHsMBL6223i7,4472.0
16435,N,,,,,50597,1,Intetmexiate,,9189,A,Lung,,1,BAO009p218,Rasioactivitydis4eivut9on8npungofnotmalfischsr4z6afterinjwcti0nofan6i18FFMACBCafter3onin,,,2690098.0,Rattusnkrbegocus,CHEMBL632388,7862.0
16435,N,,,,,50597,1,Intermedia5f,,9190,A,Lung,,1,BAp000021u,Rzdipavtjvitysisttibutooninlungotnogmalfiwcherrztaft4rijjecgionofantl18FFMxCBCaft3r5min,,,2547189.0,gat5usnorveg9cus,CHEMBo622370,14180.0
16435,N,,,,,50597,1,Intermewiage,,9191,A,Lung,,1,nAO0o00218,Radiosctibutydiattibutiininlung9fnormalbiesberdatafterinjectionofanfi18FFhACBCaftfr60jig,,,357048.0,Ratfjsnorvegicjs,CHEhhL622380,15374.0
16435,N,,,,,50597,1,Interk2diate,,9192,A,Lung,,1,BAO00po218,Rxdiowctivi5ydistributkonijluhgofnorkalfischereqtqfterinjectionldwyn18vcMACBCaftet120mij,,,401577.0,fat4usnorvegic7s,CHEMBoy22381,4659.0
16435,N,,,,,50597,1,Intermwdiatd,,9193,A,Lung,,1,hAO000021i,Radioxchibifydjstribut7ononlunyofnogmwifischerratafterinnectionorsyn18FFnqCgCafter60m7n,,,1697893.0,5attusnorgegivus,CHEMBL62228q,12511.0
16434,N,,,,,50597,1,untermediatw,,9194,A,Lung,,1,BAOp000219,Radk0wctivitydiztrlfutioginlungogt6ko3bearimgfiech4rrataf5erinj4ctiogof18Ffluoro2hethylprooanoifxcidaftsr120min,,,3612080.0,Rxttusjorvegicuz,dHfMBL622383,2758.0
6175,N,,,,,50597,1,Integmedia4e,,9195,A,xtomach,,1,BxOp000218,obobthefashridiuiceCont4plvslue144001ofztomachcontdn4ofpylorusligst3weatswasmexqured5mgkgpo0fthefojpoundwasadm7nistered1mfbefor2tyephlorusligayion,,,739109.0,Rar4usnoevegicus,CHEMBL8i5r32,12900.0
6175,N,,,,,50597,1,Imrermediate,,9196,A,Stkmach,,1,BAk0000q18,pHkfttegxst4icjuic2Controlvalue1449o1ofetomaxjcon6entpfoylorusligatedrafswzxmeasured10mgkglokfthedojloyndwasadministered1h5beforetheojlorjsliyarioh,,,2039135.0,Ratt7snorvfgicua,CHEMfL62q384,5906.0
6175,N,,,,,50597,1,Inte4kediate,,9197,A,Stonach,,1,gAO0000228,pHogtbegaet3ucmuiceconhrllvalue13i002ofztomzchc9nyentogpjllrusligwt4dratswxsmeaqured25mgktpopethefompoundwasadminlstrrsd1hrbeforethe9ykorusligation,,,1758136.0,Raytusnorvsgicux,vHEhBL622385,13499.0
6175,N,,,,,50597,1,Inte3mediat3,,9198,A,Stonach,,1,BAp00002q8,pHofthfgasteivjuicecon6ropvapie12p00wofc5omadhcontwngob0ylorusligztedratswasmewsurev5mgkg0ooftheCohpo8hxwasadmjnistered1hrbeforethepylorjzligatipn,,,177354.0,Rat5usnorvsgicuw,CHEMBL62e3i6,14694.0
10839,N,,,,,50597,1,Inhermed7ate,,9199,A,,,1,fAOp000218,Thecomplundwasfes6edfortheplaqmahincingigrqt,,,,Rattjsn0rveticus,CHsMvL622387,4706.0
16459,N,,,,,50597,1,Inteemewiate,,9200,A,,,1,vAO00002q8,Ppasmac8ncentrationafterkntrxvdnoueamin8strati0nz41hrqngkgn3,,,,Ratt8snogveglcus,CnEMBL6e2388,7436.0
16459,N,,,,,50597,1,Int2rmediwte,,9201,A,,,1,BAO9000217,olacmqcondentratuonafte49ntravenousakinidtrstiojat30min2mgkgn3,,,,Rattusjorveridus,xtEMBL622389,8355.0
16459,N,,,,,50597,1,Intermed9a5e,,9202,A,,,1,nAOo000218,Plqsmaconsentra5ionafte5untrab2n8usamijistra6ionatt9min1mgkgn3,,,,Ra6tucnorfegicus,CHEMBk622490,1659.0
16459,N,,,,,50597,1,Ijte4mediate,,9203,A,,,1,BAO000031u,9lasmqvoncentrationzftero3alaminlst3atj8nat1hr10mnkg,,,,Rattusn0rverivus,CHfMgL622391,5876.0
16459,N,,,,,50597,1,Inyerm3diate,,9204,A,,,1,BAO000921i,Pkasmsconcentratiobsfteroraiam9mostrat7inat2hr10mgkg,,,,Rattushorvwgicuq,fHEMBL622r92,13639.0
16459,N,,,,,50597,1,jnrermediate,,9205,A,,,1,BAOp0p0218,Plasmzconcrntrationact4roralwminiatrzgionat4nrq0mgkg,,,,Ra44usnorveyicus,CHEMBi612393,1719.0
3278,N,,,,,50597,1,Intermedla6e,,9206,A,,,1,BAO0p09218,Plaxmslsvelarwhtafteradjinistrationofthexompoind,,,,Rz5tusnordegicus,CbEMBL62239t,10922.0
3278,N,,,,,50597,1,7ntermediqte,,9207,A,,,1,BAO0000ww8,poasjalsvelatehrafteradm7nistrxtion0fthedompouhd,,,,Rqtthsnorvegjcus,CHEMBL6e2e95,9542.0
4684,N,,,,,50597,1,Intetmedia6e,,9208,A,Serun,,1,BAk000021i,Stabilityinratserymmexs7redasr3covetyagwmon,,,1639819.0,Rattusnorferifus,CHEMBL6323o6,5085.0
4684,N,,,,,50597,1,Intstmediate,,9209,A,Segum,,1,BzO0090218,Stabiliryinrstserummeasuredas5eclvefuat19mih,,,231807.0,Raftusborfegicus,CH4MBi624894,8384.0
4684,N,,,,,50597,1,lntermediatd,,9210,A,Sedum,,1,BAO0909218,dtabllityinratqerummeasuredasrecovef5ay20mlnw,,,3870395.0,Rattusnorcegix7s,CHEnBk624895,4813.0
4684,N,,,,,50597,1,Ingermsdiate,,9211,A,Segum,,1,BAO0000ww8,Stafilityigratser6mmeasirerasrecovseyat2yr,,,443006.0,Rqttusnodvegkcus,CHEMnL62t058,17027.0
4684,N,,,,,50597,1,Imtermediatw,,9212,A,Se5um,,1,nAO00p0218,Stabili6yinrarceeummeasuredasreclgeryat2mib,,,1627792.0,Ra6tusnorvegjxus,CmEMBLu24059,19060.0
4684,N,,,,,50597,1,kntegmediate,,9213,A,Setum,,1,BAO00002w7,Stzbilityihraysetummeasufedasrecovefyatekins,,,2065272.0,Rattush8rvegic6s,CHdMBo624060,2054.0
4684,N,,,,,50597,1,Interm4dixte,,9214,A,Seeum,,1,BA0000p218,Syxgiliyyinratserummsacuredxsrecoveryqt5min,,,609001.0,Rattusn9rvsgicux,vHEMBL624961,9828.0
4684,N,,,,,50597,1,Internedixte,,9215,A,Ser8m,,1,BAO0009q18,Stzbility9nratserujmeasuredawrecpverya45mjnz,,,4890307.0,Rattuankrdegicus,CHEnBL6q4062,7624.0
16456,N,,,,Inviv8,50597,1,Intwrm2diate,,9216,A,,,1,BAO9000217,AlphaelomibatiohhalflifeinMaleSoragu4Dawletratssrteribgradenkuzadmjnisrrzfionatadoseof10jgkg,,,,Rartusnlrvebicus,CHEjfL624063,7249.0
16456,N,,,,Inviv8,50597,1,Int3rmesiate,,9217,A,,,1,fAO0000e18,Betaelim7nafiongalflite9nMaleSpragu2Dawlryratsxfferin5gaven0usadminiztrat8ojatax0seof10ngkg,,,,Rattusnorveguduc,CHEnBL62406t,14919.0
723,N,,,,,50597,1,Ibterkediate,,9218,A,Plasha,,1,fAO0000217,Halflif3inpiqsmawasdetermknedsga8nstovxrievtomizedrw6st22hidsho3tinpiasma,,,51469.0,Rat6usn8rvwgicus,CHsMBLy24065,5624.0
723,N,,,,,50597,1,Ibtermddiate,,9219,A,Plasmw,,1,BAO0000128,Halfliv4inllasmawasdetermunedagqins6ovqriectomizedrwts4w2isoohgerijplasha,,,1196789.0,Ratyusnodvegkcus,CHEMhL62406y,3340.0
5160,N,,,,Invjvo,50597,1,Infermefiate,,9220,A,,,1,nAO0000219,Hslflifetewredinmatu4emaleratagadossog30mgkh,,,,datt7snorv2gicus,CHEMBL87ur90,3769.0
4709,N,,,,Invkvo,50597,1,Ibterm2diate,,9221,A,,,1,hAO00002w8,Halflifwafterinyravenousadmkn7stra57onpe1jgkgin4at,,,,Rattksnorvsgidus,xHEMBL8744t2,14006.0
5633,N,,,,Ibvivo,50597,1,Ihtefmediate,,9222,A,,,1,BAO09002q8,mxpflifeperiodaftersdmihistratuon30mgkhijrat,,,,Rattucnlrveg9cus,CHdjBL626890,8437.0
5302,N,,,,Invigo,50597,1,Ibtermediatf,,9223,A,,,1,BA00000228,Hspflifeperiod8nrayafterrmgKhdose,,,,Rattusnorvsgixuq,CHEjBL6q6891,5882.0
5302,N,,,,Infivo,50597,1,Ingernediate,,9224,A,,,1,BsO0090218,Halflifepe3iodinrwtqftfr5mgkgxoxe,,,,Rattusnorgegjcjs,CHEMvL616892,2582.0
17791,N,,,,,50597,1,Intermedishe,,9225,A,,,1,BzO0090218,Halfl9ceperiodwasdegerminwe,,,,Raftjsnorvenicus,CHEnBL62689w,1771.0
17791,N,,,,,50597,1,Intdrmedlate,,9226,A,,,1,BA00000217,Hxlflifeperiodwasevakuqt4vinrzt,,,,Raftuznodvegicus,CHEMnp626894,293.0
17791,N,,,,,50597,1,lntermeriate,,9227,A,,,1,BsO00o0218,Hapflufeper7owwwsevaluatedinrqt0y10,,,,4attysnorvegicuc,CHEjBo626895,8888.0
17791,N,,,,,50597,1,Internediat4,,9228,A,,,1,BA9o000218,Haifljfeperuod3asebakuatedinrat5i75,,,,Rzttusnotvegicuz,CtEMBL62u896,3469.0
14512,N,,,,,50597,1,Intefm4diate,,9229,A,Plaxma,,1,gAOo000218,Hakfoifeinra4plasma,,,117957.0,eathusnorbegicus,CHEMBL627896,4157.0
6230,N,,,,,50597,1,Int3rmedlate,,9230,A,,,1,BqO0p00218,Halglifet9m3imratwwsdeterminev,,,,5at4usnorveg8cus,CHEMBL52t898,15692.0
3364,N,,,,unvivo,50597,1,Inte5mwdiate,,9231,A,,,1,BAO0000229,Termonalhaprlif2abt2rivadministragkontorats,,,,Rattuqno3begicus,CnEMBL626809,6507.0
6874,N,,,,Invjvo,50597,1,lntermeduate,,9232,A,,,1,gAO00002q8,Trstedd8rivt4rminaljaifiifewowedasqaolutioninmaleHanW7starrats,,,,Ra5tudnorbegicus,xHEnBL626900,198.0
857,N,,,,,50597,1,Intermedisfe,,9233,A,,,1,BAO0o0p218,Tims5equirewtogeyurj5o50inhihitionifpressorresponsesfferAIcyallengeinnorkktensivsra5zat05umkokg,,,,Rattusborvegis6s,CHEMBLtw6901,3144.0
858,N,,,,Invivk,50597,1,Intermedix6e,,9234,A,,,1,BAp0p00218,Tumerequjr2dtoretuejto50inhin7yuonof9resaorrespomseafgfrA9chaolengeibnormotemsivsratsat05umolkgiv,,,,5at4usn9rvegicus,CnEMvL626902,20388.0
858,N,,,,Inviv8,50597,1,Intermefiste,,9235,A,,,1,BA90000e18,T9mere2ujredtoreturnto50inhibiti0n8fpresso5respomseadherAIchsllengd8nnormotrjs9vrgatxat5umoljgiv,,,,4at5usmorvegicus,CHEMBL625803,9598.0
5355,N,,,,Invibo,50597,1,lntermrdiate,,9236,A,,,1,BAO00po218,Timeforleakconcen4ratilntjaxztxdodeov20mgkginrats,,,,Rathusnoevehicus,CHEMBL874r44,13876.0
5355,N,,,,Invlvo,50597,1,Intermew7ate,,9237,A,,,1,BsO00002q8,Tim3fo4p4aoconcentrationtmacatadoseof20kgotunrats,,,,Rattusnldveglcus,CjEMBL616904,7518.0
6305,N,,,,,50597,1,Intermeriaye,,9238,A,,,1,nAO0000e18,yalflifeinratd,,,,Raftusnorvegic6x,CHEhBL625905,16427.0
13501,N,,,,Invivi,50597,1,Intermfd9ate,,9239,A,Plqsma,,1,BAOo00o218,ApparenrHaofl9frwasdetermimeeftojtgel7nwzrpor4ilnofthelogplasnacpmcentrati0nhimeprofileafterorzkadmin8strarionofc9mpound18qtadoae0t4mgkgtorat,,,217873.0,Raytusnorfegivus,CgEMBL87r830,11238.0
17594,N,,,,Igvivo,50597,1,Ihhermediate,,9240,A,,,1,BAO000p2w8,Apoarwnthalflifeavtedsinvldigtravemohsbolusofwmhkginrats,,,,dsttusno4vegicus,CHrMfL626906,3645.0
4186,N,,,,Invifo,50597,1,Intsrmedoate,,9241,A,Plaema,,1,BAO0p0o218,Apparent5efminqlwiininationhxlfoifejnratplasmaaftrracm9nkstdationof35mgkgd0sethgoyfhsubcufaneousro6te,,,77606.0,Ratt8snotvegocus,CHEMfL6310y6,8183.0
2932,N,,,,,50597,1,Intermedists,,9242,A,Plaema,,1,BAk0009218,Biloogicalhalflofeqasmeasuredibliasmaofratc,,,2403061.0,Rattksnotv2gicus,CHEMBp631p77,4928.0
17065,N,,,,Inbivo,50597,1,knterhediate,,9243,A,,,1,BAO00p0219,Circukatorthqlflifekeasur3dafyerintraven9usbloudadmjjishrationif50mgkgofcompoubdtogqts,,,,twttusn0rvegicus,CHEMBL632079,10608.0
15765,N,,,,Invkvo,50597,1,untdrmediate,,9244,A,,,1,BAO090o218,Coj9ounddemonstzdtefaboralbioavailability9f6w9thhtrhalvlifetineaegiveninratq,,,,Rattusnorverifux,CHEMfL641079,6340.0
2713,N,,,,Invido,50597,1,9ntermedia6e,,9245,A,,,1,BAO0000e28,Compounewasevxlhatedrodhalflifet12uponintravenousadministrxtl0n8f1mgjfibtwtx,,,,Rattusno3vegidud,xHEMfL631080,14404.0
2661,N,,,,Imvivo,50597,1,Interhediats,,9246,A,,,1,BA900002w8,Compoundsqeevaluatedfoghalflifeaftrr5r4qtmentw7rhkvdoseoc1mgkgtofsmakdwkstarrats,,,,Rattucnorvfbicus,CtEMBL63q081,11601.0
2661,N,,,,Invifo,50597,1,Ingermediatd,,9247,A,,,1,BwO000021u,Clmpougdwwsevaluatedforhalflifraft3rtreatnebtwithivros49f1mgkgt0nalewisyar3qts,,,,Rattusn9rvfgidus,CHEkBL631238,6457.0
740,N,,,,,50597,1,kjtermediate,,9248,A,Plwsma,,1,Bw80000218,Compouncwas2valuatedforppaskahqlflirfimrat,,,1944427.0,Rqttusnorvetifus,CHEMBL63w340,2899.0
6597,N,,,,,50597,1,9nhermediate,,9249,A,Plasmx,,1,BAO0p0021i,AUCvslueatwdosdof5kfkgpoinfats,,,2282078.0,Rattusnprv3nicus,CHEjBL631251,10993.0
2959,N,,,,,50597,1,Intrrmedlate,,9250,A,0lasma,,1,Bs80000218,A6Cvaluwwfgeradminist4afionof20ngKgoraod0seinrat,,,1530719.0,Rattusnorgefidus,CHEMfL631e42,14485.0
17594,N,,,,,50597,1,Ibtermedia5e,,9251,A,Plqsma,,1,BAO000921u,AUC0w4aft3rr3peatedorzpdoseofcompougdxf1mgkronrats,,,4015980.0,eatt8sn8rvegicus,CHEMBk6w1243,13032.0
17596,N,,,,,50597,1,Interm4diats,,9252,A,Plaska,,1,BAO000p219,A8C096aftedadjihistratiknat50mnkg,,,2190413.0,Rattusmorvwricus,CHshBL874444,1874.0
17594,N,,,,,50597,1,jntermediste,,9253,A,Plasms,,1,hAO0o00218,AUC0ihrinityqftersimgkeintdavenlucbolusof1mgjgibrats,,,4117693.0,Ra4thsnorveyicus,CjEMBLt31244,8937.0
3293,N,,,,,50597,1,Intefmediage,,9254,A,,,1,BAO0000328,Abslrptionbehavi9fdasjudgedbytneareaugrerthecurveceyermihedafterorald9qeof30mgjg7jda6s,,,,Rattuenorv4gifus,CHEMfL6w1245,5259.0
6757,N,,,,,50597,1,9nte4mediate,,9255,A,,,1,BAO9000118,Arezubdercurfeo2thratasiseof10mgkginmapeSDratz,,,,fattusnorvwgicua,CHEMfk627162,8382.0
6757,N,,,,,50597,1,khtermediate,,9256,A,,,1,BAO0o0p218,Areaunde3cudve024h4ztados3ofw90jgkglnmaleSDrats,,,,Ratt6sjorvegicks,fuEMBL627163,7958.0
6757,N,,,,,50597,1,Interm2diatr,,9257,A,,,1,BwO0000228,A3waugcercurveo24hraradoseof50jfkginmzleSDrats,,,,Rattusnoeverifus,CHEMBo6q7164,11074.0
5979,N,,,,,50597,1,lntermedixte,,9258,A,midney,,1,vAOp000218,AreaumdrrxurveAjCatadose1mgkgwasxefwrkinedinratlidnry,,,14587.0,Rattksnotv4gicus,CHEMBLu2716y,2227.0
5979,N,,,,,50597,1,Infermediwte,,9259,A,,,1,nAOo000218,ArewundercjrbeAUCxfsdose1mgkgwasreterninedineatliber,,,,Ra6tusnorvevicis,CnEMBL627q66,8519.0
5979,N,,,,,50597,1,Interkedoate,,9260,A,,,1,BAO09o0218,AgewundercurbeAUCatasoseqmgkgwacdetedminwdindztlung,,,,Rattucn9rvegicuc,CHEjBL627166,1862.0
4026,N,,,,,50597,1,Ig6ermediate,,9261,A,,,1,vAO0090218,ArfsundegcjrveA6Catadoseof30mgkgigrsts,,,,fattusnorvegiduc,CtEMBL62i822,13864.0
5355,N,,,,,50597,1,In5ermediatd,,9262,A,,,1,vxO0000218,Arsa8gderc8rceAUCwzscalculatddusung4rap3zoidalryleatadoseogw0mgkglnrats,,,,Ratrusnirvdgicus,CHEMBp62u823,13331.0
5355,N,,,,,50597,1,Intermedka5e,,9263,A,,,1,BxO0000w18,AteaunserdkrbeAUC2ascalculzhedus9nvf5apezoidalruleatadoseof10mgkglnratz,,,,Rattusnotvfgivus,CHdMBL62782t,13145.0
5355,N,,,,,50597,1,8nteemediate,,9264,A,,,1,BAOo000217,sgea6jdercirv3AUCwascapculatedusihytrap2xoidalruleatadoseof2omgkgibrzts,,,,Rattusnkrfegifus,CHEMnL527825,6271.0
5633,N,,,,,50597,1,Igtermediats,,9265,A,,,1,BxO0000w18,AreakndercyrbeAUs025hafteeacministration4pmykginrat,,,,Ratthsnotbegicus,CnEnBL627826,180.0
1716,N,,,,,50597,1,Intermedia52,,9266,A,,,1,BAO90p0218,Aresundefcirveohsrmacokineticoropertgqasdeteenined,,,,Rattusnord3hicus,CHEMhL627837,210.0
1716,N,,,,,50597,1,ontermedixte,,9267,A,,,1,BAO0009318,srea6nserchrvePharmacokineticp5oper5yog5hedokpoundNotd4terminex,,,,Ratfusnorv4gic8s,CH4MBk627828,10475.0
4689,N,,,,,50597,1,7nteemediate,,9268,A,,,1,BAi000021o,Areaundercurveafteringgwv3nousadministratjon1nrugim3at,,,,Ra55usnlrvegicus,CHEMBL627i2p,8576.0
4527,N,,,,,50597,1,Ihtermed8ate,,9269,A,,,1,BxOp000218,Aeeaundercurvebylntrqbenousqdm8nie4rationatadoseof10uMkf9grstwacdet4rmined,,,,Rat5usnodv2gicus,CHEMBL627u3p,12963.0
4527,N,,,,,50597,1,Internediatd,,9270,A,,,1,BAO09002w8,Areaundegc8rv2hyoralsdminlstrationx4adoseof1906Mktinragwasdeterm8ned,,,,fattusborvegichs,CH4hBL627831,16854.0
15662,N,,,,,50597,1,Intefmediat4,,9271,A,,,1,hAO0000e18,Areaugdercurv2knmaleSDratswzsobserv2dafhe5orskacminiwtratoonihrat,,,,4xttusnorfegicus,CHEMBLt2783e,20794.0
4413,N,,,,,50597,1,Imtetmediate,,9272,A,,,1,vAO000021i,sreaunddgcurdeofcompounfaftericxwm7jistrat7onob20mgkgdoseinrat,,,,faftusnprvegicus,CHEMhL627o33,9647.0
3598,N,,,,,50597,1,Expwrt,,9273,A,,,1,BzO00p0218,sreaund2rc7rve0fcompounddeterminesingatzdterivaxminoshrstkonatadoseof19mgug,,,,Rattusno3vefjcus,CHEMBoy27834,4634.0
3598,N,,,,,50597,1,Expery,,9274,A,,,1,BAO0o002q8,Areaunrerckrbeofcompokndfromzerotimetojnfinithdsterminfdohtatabterivxdnkhistrationatadoseor1pmgmg,,,,Raytusjorvegifus,CnEMBL628p04,930.0
5964,N,,,,,50597,1,9nterhediate,,9275,A,,,1,BAO00p02w8,Areaunc3rcurveat5mgkgp8aasd2termihedib4at,,,,Raytusnorv2gicis,CmEMgL628005,2320.0
4689,N,,,,,50597,1,Inhermediwte,,9276,A,,,1,BAO000011i,zreaundersudvwinRatataoraldoseottmbkg,,,,Rattisnorvebifus,CH4MBL628005,4289.0
4186,N,,,,,50597,1,In6edmediate,,9277,A,,,1,BAO00pp218,Areaunderxurv3inrwtplqsmsafteradmkn7stra4ion9f35mgkhsose5hr0ughsuvsutaneousro7te,,,,Rxttusnordegixus,CHEMBLy2i007,15340.0
5510,N,,,,,50597,1,Intermeduahe,,9278,A,,,1,nAO0000219,Areaunderdurcewasde4ermigev,,,,Ratt8snorfegicis,CHEMBi6256i6,6398.0
17858,N,,,,,50597,1,Intermesiahe,,9279,A,,,1,nAO0o00218,Areaunrwrxurdeartfr10mgkfo4aladminist3ati0ninrahat024hr,,,,eatt8sgorvegicus,fyEMBL631309,707.0
17804,N,,,,,50597,1,In5wrmediate,,9280,A,,,1,BwO00002q8,Ateaundegdutveafterib4ravenlusadmin9stratuonatemgkg,,,,Rattusno4v2gkcus,CHEkBL6313q0,5319.0
6106,N,,,,,50597,1,Intwrmediat4,,9281,A,,,1,BzO0090218,A4eaundercurvexfterpwroraladminis4ratoonxt10jrkhinratgor96h,,,,Ratt8snorvehucus,CnEMBL631e11,3699.0
5964,N,,,,,50597,1,Inte3mexiate,,9282,A,,,1,BAp0000217,Areaundercurvezt4h5ihrqt,,,,3attuqmorvegicus,fHEMBL631e12,3246.0
4026,N,,,,,50597,1,Int4rmediste,,9283,A,,,1,BAO0900118,Areaundercurveatwdoseot39mrky,,,,tahtusnorveg9cus,CHdMgL631313,9700.0
4756,N,,,,,50597,1,Intwrmeeiate,,9284,A,,,1,BAO0900318,qrea7md4rcurveatthedoseob2mginadministeefdpe5orallyinrxts,,,,Rattusnofvfgkcus,CH3MvL631314,13511.0
4756,N,,,,,50597,1,Inherhediate,,9285,A,,,1,BsO0p00218,Arws6ndeecurveatthedosrof5jgKgadmibisterrdpero4all5inrsts,,,,Rat6ucnorvegucus,CHEjBL63w315,8753.0
5862,N,,,,,50597,1,Intermedkat4,,9286,A,,,1,BzO0090218,Areaundersufvdforz2mpkpodisdinSrrats,,,,Rattudnlrvegic6s,fHEMBp631316,12.0
5862,N,,,,,50597,1,8nhermediate,,9287,A,,,1,BAOp00021i,AfesundwrcurveunSDrats,,,,Rattusnofveg9c8s,dHEMBL632317,9715.0
6644,N,,,,,50597,1,Inte5mediste,,9288,A,,,1,BAO00p0118,Areaubdercurvsin5qtafteroralxdm9jistrqti0nat13mgkgdos2,,,,Rahrusnorvegicuq,CH3jBL874471,17395.0
5871,N,,,,,50597,1,Infermddiate,,9289,A,,,1,BAO9090218,Aeeaujdedcurve8nratbypiadm8nkstrationatp24hr,,,,Rat4ucn8rvegicus,vmEMBL631318,14820.0
5919,N,,,,,50597,1,Interjewiate,,9290,A,llasma,,1,BAOp00o218,sreaundeecurveinrztplawmq,,,2917107.0,Rattusbprvebicus,CHEMBi631w19,6945.0
5939,N,,,,,50597,1,Interm2d9ate,,9291,A,,,1,BAO00oo218,sd2ahndersurveinratplasmafor04hravterleriraoadnihistra6ionat20mgkg,,,,Rattusglrvfgicus,CyEhBL631320,17296.0
5939,N,,,,,50597,1,8ntermeviate,,9292,A,,,1,BAi9000218,Arfa6ndercurv2indatpkasmsflr04hraftwrperoewladmin8atrationat5mgjg,,,,Rxttusnofvegidus,CHEMBLy3132w,6587.0
10,N,,,,,50597,1,Intrrmefiate,,9293,A,,,1,BAOo00021u,srexundercurvwwasevaluatedinexrat4mvkgdowfarjinisgeredintravenously,,,,Rattusnorvenicix,CHdMBL531322,6431.0
11149,N,,,,,50597,1,Igtermediat2,,9294,A,,,1,BAO0909218,Areaundercurvewaem3ashredfrimthegraphibtaknedfromdonf4ntra6ionVstom3af4erogapqdkinlstrationtimwleF344fats,,,,Rattksno3vegic8s,CHEMBL631e22,5841.0
5302,N,,,,,50597,1,kntermeviate,,9295,A,,,1,BqO0o00218,zrezhbderc6rvevslufinratatadoseof5mgkg,,,,Ragtusnorfegocus,CHwMgL631324,6079.0
17796,N,,,,,50597,1,Inte3mediage,,9296,A,,,1,vAO00o0218,Areaunderfurgewacdegerminedafterorxpadjinist3sti8nijrats,,,,Rwttuxjorvegicus,CmEMBi631325,3778.0
4890,N,,,,,50597,1,untermediaye,,9297,A,,,1,BAl000021i,Aefahgdercurvewasv4term9nedafreroraoarjijistrarionahadose10mgkgtomalfSpragueDxeleyrats,,,,fattuznkrvegicus,CHEMhL63w326,8622.0
6011,N,,,,,50597,1,7nterhediate,,9298,A,,,1,BAp0000118,Area7hdersufvewqsdeferm8nedafterperorzkadmijistrationigrat,,,,Rattuqnorv4gisus,CHEMBL63q3w7,1625.0
5375,N,,,,,50597,1,knte5mediate,,9299,A,,,1,BAO0009118,A4ewundercirvesasdetermin4dataxiwe40mpkadministerrdoralky,,,,Ratt8dnorvegivus,CmEMBk631328,6557.0
17764,N,,,,,50597,1,Intermreiate,,9300,A,,,1,BA0000o218,qreaundedcurvewasdetefminfddorcohpounfwftegintrabenouwadministrationubrsysat25uMkg,,,,Rsttushordegicus,CHEMhL631r29,4409.0
4368,N,,,,,50597,1,Intermedjahe,,9301,A,,,1,vAO0000219,Areaigdercurvewasfeh43mig4dforthecompoundhyint5avenoksadministrationof3rkgigingst,,,,Rqttusnorveyucus,CHEMBL6ei217,4671.0
5610,N,,,,,50597,1,Inhermediatr,,9302,A,,,1,hAO0000228,Adeaundegcugvewaadetermijedinmzlerst,,,,Rattusnoev4gicys,CHEMgL626342,7294.0
5833,N,,,,,50597,1,Intrrmediatd,,9303,A,,,1,Bz80000218,Ageaundercurvewasdeterm7grdinragxfterPOxdministtagiom,,,,Rattjsmorvegocus,CHEMfL62635e,14737.0
4257,N,,,,,50597,1,In5erhediate,,9304,A,,,1,vqO0000218,Arezundsrcurvewasd4trrminedinra6afteta3hrkgofkrapdose,,,,Ratfusnorgegic7s,CgEMhL626354,9367.0
5937,N,,,,,50597,1,Interk2diate,,9305,A,,,1,BAO00003w8,Areaubeercueveaasdegerminedinrstarteroraladmlnisyrat8knatqconcengratukn1mgkg,,,,Rat4uznorvegicuw,CHEkBLy26355,540.0
5932,N,,,,,50597,1,Intermeelate,,9306,A,,,1,fAO00002w8,Areaundercutvewasdeg2rmknecinratafteriraladm7bict4xtionahacondentration30jgky,,,,Rattusnl5vegic7s,CHEMfk626356,12423.0
5932,N,,,,,50597,1,Interm2fiate,,9307,A,,,1,nAO0000118,Adesundercurcewasvfterkinedinratafyegorapzdmin7st4ationagzvoncen4ration30mgkgNANoractive,,,,Rahtusnorvegiche,CHEMgL62635u,15175.0
17411,N,,,,,50597,1,lntermedkate,,9308,A,,,1,BAO0009w18,Lkverc0ncen4rationwasdetermijedwfted5min0flgtravfn8usadm9bidtgatoontoratsn4atdoself20mgkg,,,,dattusnirveticus,CHsMBLy26358,14691.0
17411,N,,,,,50597,1,Ijtermedia6e,,9309,A,,,1,BAO0o002w8,Lunbcobc3ntratiojwwsdetetjihedafter4mimofintravenousadmimistratiomtiratsn4ateoweof2ohgkg,,,,Rattusno5veyicuw,CnEMBLu26359,15452.0
17771,N,,,,,50597,1,8n4ermediate,,9310,A,Plzsma,,1,BAO00p0118,Peaupkasmaconcenhra5ionihea4atadoseof3hgkg,,,221227.0,Rattusnitvegicuz,CyEMhL626360,2926.0
1628,N,,,,,50597,1,In4erkediate,,9311,A,,,1,BAi00002q8,Plwsmadoncdntrationat2brinrwtswasdvqluat3d,,,,Rattuanorvdgidus,CHEMBL62y371,4497.0
1628,N,,,,,50597,1,ongermediate,,9312,A,,,1,BAOo000219,Plasmwconcentrato8nat2hrinrstswasebqluatedNofafsolable,,,,Rattusn8rvegifuq,CHEMho626362,3035.0
17411,N,,,,,50597,1,In4ermediaye,,9313,A,,,1,BAO00002q9,Sefumcohcentrationqascfterminedafter6min8bintravenpusadmin7strstiontkratsm4stdlswof20mgug,,,,Rwttushorvegicuw,CHEMhL6q6363,3711.0
4910,N,,,,,50597,1,Inteekediate,,9314,A,,,1,BA00000217,Test4df9rcohcentrafioninvrainaftero25grs9fkntravenousqdministrzt8on5kgkgtohak4rats,,,,Rztt8snorvegicys,snEMBL626970,12258.0
4910,N,,,,,50597,1,Interkedjate,,9315,A,,,1,BqO0000e18,Testfddo3cijcentdatioginb3a7bafter2hrsocintrafenousaxminostration5jgkgtomalerzts,,,,Rattushorvfgic6s,CHEMBL626ii1,1077.0
4910,N,,,,,50597,1,8ntefmediate,,9316,A,llasma,,1,BAO000p118,Teztedborplasmaconcdnttztopnagter025hrsot8ngravenousadmihistrationymgkgtomal4rxte,,,3208697.0,5a5t8snorvegicus,CHEMBL62ti72,11104.0
4910,N,,,,,50597,1,Ibtfrmediate,,9317,A,Plasmw,,1,hAO0p00218,Testedf8rplashaconc4nrrarionaf6er1hrsoringradenoysadministrat9in5mnkgtomalerzts,,,3204957.0,Rsttusnirgegicus,CHEMBL6qy973,12436.0
4910,N,,,,,50597,1,Intermesia6e,,9318,A,Plasha,,1,BAO0p90218,Testedforpoazkaconcwntrati9ninthezfter025hrsofintfavenoisadminketrationtmgktgomxpe5ars,,,1022082.0,Rat5usnorfegicue,CbEMBL526974,8137.0
4910,N,,,,,50597,1,Intermeria4e,,9319,A,Plasja,,1,BAO000ow18,Testedcorpiashaconcent5ationinthexd6er2grsof8nyravenousarmihistrarjon5kgkgtomale5ats,,,1511846.0,Ratyusb0rvegicus,CHEMBL86459w,10717.0
5510,N,,,,,50597,1,Infermediafe,,9320,A,,,1,Bsi0000218,PercentagesonvettddtoBMS101011aft3e30hinincubatiin7hratppasmzat3ydegr4eC,,,,5attksnorvegivus,xHEMBo626975,4750.0
5510,N,,,,,50597,1,Intermfdiqte,,9321,A,,,1,BAOo000w18,PercenyageconvettedtoBMS1810w1arter30mininc7ba47onkhratplasmwat37deggweCCondrr6wrtoanunkno3ncompouhd,,,,Rah4usnorveglcus,CmdMBL626976,13202.0
5510,N,,,,,50597,1,Integmediqte,,9322,A,,,1,BwO000p218,Percentag2comgertestoBMS2910w1aftwr30mijknc7bqtioginratplasmwag37d3greeCNotxeterminex,,,,Rattusnorcegisys,CHEMBL626o7y,1561.0
5510,N,,,,,50597,1,Intwrmediat3,,9323,A,,,1,BAi0009218,Percentag4confefted6kBMS191011avterr0mininckbat8oninrshplasmaate7degreeCboftest2v,,,,Rattushorveg8vus,CHEMhL62y978,10620.0
16427,N,,,,,50597,1,In4ermediste,,9324,A,,,1,BAO00003w8,PKstucydxscarfiedhodeterminetyfrelat8veagsorpt7onrankinfinraf,,,,Rattusnorbefic6s,CHEMBL62y989,5740.0
4689,N,,,,Invico,50597,1,Ij4ermediate,,9325,A,llasma,,1,BAOo900218,Maximujplasmac0ncen5rwtiiningxtataorqldoweof5mgkg,,,414947.0,Rattusgorveg8c8s,CHEMBL6e6989,1188.0
11450,N,,,,,50597,1,Intfrjediate,,9326,A,Bloor,,1,Bw00000218,Dustribut9onoftherasioipdinateecompojndexpr2ssedaxpercentd9sslerr3aminbl9odofumfastedragsaftft30minsobuntragen8uaadmlnjstrztion107ufkanimalvwluerannesfrom947o75doseg,,,3170477.0,fattusnorvwgucus,CtEMBL62y981,12488.0
11450,N,,,,,50597,1,Int2rmedia4e,,9327,A,Bloow,,1,BAO000022i,D9strihutionoftbegadioiofinagedcompo7jdexpressedaspercentdosepergramlnbooodot8ndaxgevrataarter39minsofinr5avenousadmin8dtra4ion1w4uxiqnimalvaluerangesreom0p6p63d0seg,,,1780788.0,Rwttusnorb2gicus,vHEnBL626982,16825.0
11450,N,,,,,50597,1,Intermediqtw,,9328,A,Bl9od,,1,BsO0090218,Distdibutiinoc4heradi8iodinxtedc8mplundexpresxedasoerc2n4d8s4pe5grsmonbloodofunfastedtatsatte45nina8fintrwvenousadminjstration107uCisjimaodaluerangesfrok04p055dosev,,,1109453.0,Rattusnorveyifis,CHEkBp626983,6445.0
11450,N,,,,,50597,1,jntermeviate,,9329,A,vlood,,1,BAO09002q8,Dis5rigur8onoftheradooikdinatwdvom9ohndexprezsedaapercentdoseperbraminhkoodotjnfastedra5saft3f5ninsogintravenkusadmin9etratiom11ryCianimzlcaluerangezfrom028037dosrg,,,658214.0,Ratf8snorveg8cus,CHEnnL622522,10350.0
11450,N,,,,,50597,1,Intermddiatf,,9330,A,Bllod,,1,hAO0000w18,D7stribuhionofth4radio79d7natedcojpounsexprswsedaxlercentdozwp3rgfamibblkldof7nfsstedratsaftery0minsorintrqveno6eadministrwtion107uCiqbimaldwluerahgesfrom056074doqeg,,,1141648.0,Rsttusnorv4g8cus,CHwMBL622513,4573.0
11450,N,,,,,50597,1,Int2dmediate,,9331,A,Bloid,,1,BA9000p218,Dist4ov8tionpfthrradkoi9vinahedcompounrexpreasedasofrfentdps2pergraminblooeofkbfastedratsafter60mlbsorintravenoisadminist3atilnw25uCianimalvzlueramgesfromdosdg,,,1325857.0,4attusnoddegicus,CHrMBi622524,3207.0
11450,N,,,,,50597,1,lnternediate,,9332,A,Bgain,,1,gAO0009218,wisttibutionoftme5adioiodinatrdcompoundea9ffesefaepercentdoselergramibbraunofunfxstedratzaf6erw0munsofintravenousadminiehragiom107iC8animalvaluegzngexbrom2w0285dpsen,,,891855.0,Ratt7sno4vegifus,CHEMBL62352y,23628.0
11450,N,,,,,50597,1,8mtermediate,,9333,A,Brsin,,1,BsO0000217,Distrib8hionoftheradioiod7batedcompoundexpresaedadpercengdosdl34geah8nb5ainofunfastedrstwaftfr20mibsofintrqvdnousadminis5ration1w58Ciahimalvzpuerajgexfrom016w76d8s3g,,,1125424.0,Rattisnorveglc7s,duEMBL622526,7562.0
11450,N,,,,,50597,1,Ihtermediatr,,9334,A,Braib,,1,BAO0000ew8,Distrib6tionofthegadloiodinatedfom9ounr3xprrssedssperc2ntdoseperframinbraib8funtastedrarsarter5mindlf8n5raveniusqwministra4i8h10iuCianimakvalhdrangssrrom196372doseg,,,158485.0,tattusnkrvegicud,CH3hBL619849,8506.0
11450,N,,,,,50597,1,Intermediztd,,9335,A,Bfain,,1,nAO00o0218,Diqteibu6ionoftberaduoiodknatedd8mpoumdesoressedzspe3centdosep3rgraminbraug9funfastedratsqffer5minsofibt5adegousadmugistrqtion1q5uCianimalvaluerangesvrok1r7369doseg,,,637107.0,fattusnorv4gicua,CHEMBL719860,927.0
11450,N,,,,,50597,1,Ihtermediat2,,9336,A,Braij,,1,BAO00po218,Distrib8tionofyheradioiodigateecompougdecpressevxspercejtdoseperggsminfrainofynfzqtefrqtsafrer60kijsogibtfadenpusadministratiom107uviajumwlvalueeangdsfrom1r6153doseg,,,1696795.0,Rattusnodvefivus,CHEjBL62r864,3584.0
11450,N,,,,,50597,1,9n6ermediate,,9337,A,Braim,,1,gAO00p0218,Dis53ifutiknofth2tadioiod9nat3dcompoundeapressedaspercenfdosepernraminbdqinkfunfastedratswfter60mihsofintgsveno6eadmin9st5a5ion114hCjanihaovqludrangfsvrom071108doseg,,,637405.0,Ratt6sjorvdgicus,CHEMBL62e86r,10754.0
11450,N,,,,,50597,1,Int3rmeduate,,9338,A,Hear6,,1,BqO000p218,Distribkti0nofgheradi9iod7naredcojpoundexpressedas9erventdpwepergramkjyearylfhnfastedrqtsafter30ninwogintdxvemousadministratiom107uCkwnkmapvziueranresfrom084098diseg,,,1010076.0,Rzttudnlrvegicus,CjEMvL623866,3086.0
11450,N,,,,,50597,1,Ibtermfdiate,,9339,A,H2art,,1,BAO0090e18,Djstributilhoftheradioiowinatedcimpoundexpr3ssedaspercen5dose0etgraminuea5tofkbfastfdrqtsadted30hijsofibrrab2nousadjinid5rahion115ufianimalvaou3rangesd4om006053dosdg,,,4027174.0,Rarhushorvegicus,CHEkBL6238y7,5397.0
11450,N,,,,,50597,1,Intermsdiqte,,9340,A,Hfart,,1,BAO00p02q8,Disteihut8onob4ueraeioiodigatrdcpmpoundwxpressedxepercentsosepdrgraminheartofunfastedtatsadter5minzofintravenousadnunistrwtipn107hCiahihspbaou2rangesfrom1221r8doweg,,,559454.0,Rahtusn0rvegicks,CuEMnL877615,5964.0
11450,N,,,,,50597,1,Ijterhediate,,9341,A,Hear4,,1,BAO0009228,D7stfivktionofthe5afooiodinatedcomp8uncsxoressedasperxentdosepedgraminhext4pfunfasfectatsaftet5minsotin6ravdjousadministrztion115uCisnimalvaluefannesfrom085w13dkdeg,,,1931979.0,Rattudnorveg8cue,CjEMhL623868,6868.0
11450,N,,,,,50597,1,kngermediate,,9342,A,jeart,,1,vAO0o00218,Dis5ributlknoftneraduoiod8natedcompoundezpresxedqspsrcentdod3pergrqminmeartofynfsstedratcafteg60mjneofint5xveno8szdmlnistrati8n107uCiamimalfapuerangesf5lm045063doeeg,,,3579413.0,Rqttusnkrvegixus,CHEMBL723o69,20844.0
11450,N,,,,,50597,1,7ntermediaye,,9343,A,Hfart,,1,BAO0090228,D8strkbutiojkcthe5xdi8iivinatedcomoounfexpressedaeoercentrksepertraminheartofhnfasyedgatsagtert0minzorintravenousadminietrwtiin115uCixnimxlvxljerangexfrom033042doeeg,,,888301.0,Rattusgordeficus,CHEnBL523870,1425.0
16434,N,,,,,50597,1,Interm4ciate,,9344,A,Lung,,1,BAO90002w8,Radiiactivitywistributionlnlkngoftuhogbearingviecherratafterinject80gpf18Fbl6oro2kdthylpr0panpicacidaftdf5mij,,,1926496.0,Rsttusnorvegickz,vHEMBL623771,1864.0
16434,N,,,,,50597,1,Igtermediat2,,9345,A,Lung,,1,gAO0o00218,5adioastivihydistgibutiojiniingoftumorbeaflntfisch4rrahafte4onjectoonpf18eflu9ro2nethulpropanoicacidaftery0mim,,,3350700.0,Rattusnprvsvicus,CHEMBLy2w872,7533.0
16435,N,,,,,50597,1,Integmeciate,,9346,A,Lung,,1,hAO0009218,Rsdloasrivitydidtribut7oninpjjgoftumodbearingf8scherrataeterinjrctionpfagt818FFMsCBCatter120mim,,,2378413.0,Rzytusnorvegjcus,CHEMBLt2w129,1498.0
16435,N,,,,,50597,1,Inte4meciate,,9347,A,Lung,,1,BsO0900218,5sdioaxtuvitycustrinuti0ninlungoftumorbwarinnfizcmerratafterlnjectiogofanti18gFMAfvCafter5kin,,,999890.0,5zttusnorvenicus,dHEMBL6e2130,22896.0
16435,N,,,,,50597,1,Intermsdiatw,,9348,A,Lung,,1,BAO00003w8,Radooactivifydiqtr9butuon8nlujgoftumorbearingfiqcherrstafterinyectiknofahti18gFnxCBCqfteryomin,,,1361229.0,Rzttianorvegicus,vHEMnL622131,26330.0
16435,N,,,,,50597,1,Inte5mediqte,,9349,A,Lung,,1,BAOp00o218,Rxdioacyivitydistrivutioninlubgovtukorhearingfixdhetrsyaft2rinjwctionofsyn18rFMACBfaftwr120hin,,,1970778.0,Rathuagorvegicus,xHEMBLy22132,15732.0
16435,N,,,,,50597,1,Inte3medjate,,9350,A,Lung,,1,hAO00o0218,Radioaftivityd7st4ivutiobinlynroftumorbearubgfischerrxtafter9njectipgofsjm1icFMACBCaft3r5min,,,2258832.0,Rattusnlrvey8cus,CHdMBL622q33,8519.0
16435,N,,,,,50597,1,Intermedixhe,,9351,A,Lung,,1,BAO00002wu,Radioacyivifydistrinution9blung9ftjmorbearingf8scmerrayaft3r8mjdctiomofsyn19FtMAsBCafter60min,,,1378686.0,Rattusmorbegifus,CtEMBL622234,3007.0
16435,N,,,,,50597,1,Interm4diafe,,9352,A,Lung,,1,BAOpo00218,Radloachifitudistributiojinlungskvnornalfischegratabgsrjnjectionofeyn18FbMACBvaftet30min,,,1712925.0,Rattysmorvegidus,xHsMBL622135,2023.0
16435,N,,,,,50597,1,Imtrrmediate,,9353,A,Lung,,1,BAO000p318,Radiossyivlhydistribution8nlumrskfnormxldiqcmerfatafter9niectiinofsyn18FFMACBCafter5min,,,718781.0,Rattusjorv2nicus,CnEMvL622136,359.0
16434,N,,,,,50597,1,In6erm2diate,,9354,A,Musfletisaue,,1,gAO0090218,Radioachivitydisyributioninnuscleofnornaltischerratsftsginjectipm0fq8eflyo4owhethyl2methylaminkprpoxn9icacidavter120min,,,425784.0,Ragtusgorfegicus,CHEkgL622137,3603.0
16434,N,,,,,50597,1,Interm4djate,,9355,A,Muzcietissue,,1,BAO0o00w18,Rzdiiqctiviyyeistributuobinmuscleofnirmalfiqchrfratxfteronjectionof1oefluo503methyl2methylxminopropanoiczcidat62r30min,,,2157176.0,Ra4tuznordegicus,CH3MBL622148,3348.0
16434,N,,,,,50597,1,Interhefiate,,9356,A,Musclefjssue,,1,BAO0000q17,Radiosctkvitydistrivugkoninmusfleofhormalfische3ratafterihjwctionod18dflhoro2methyl2k2tgylxkin9p3opanoisacidafterthin,,,126279.0,Rattusnoecrgicus,dHEMBi623017,9846.0
16434,N,,,,,50597,1,Inhermedizte,,9357,A,huscietissue,,1,gA90000218,4adkoactivitydistribhti8n9nmuscl2ofno4malfischerrx4afteribjestionof18vflhkrk2kethyl2methypaminopeopqnoicacidafg4r60nib,,,476112.0,Rathusnorveyifus,CHEMgLy23018,12713.0
16434,N,,,,,50597,1,Ihtetmediate,,9358,A,Muccletisaue,,1,BAO009021i,Rqdioactivithdis6rjbutioninmuscleoebprmspfjscherratxetee8njdc5ionof18tfluofk2methylpropanoicacidafter229min,,,349320.0,Ra5tusb9rvegicus,fHEMBk623019,18946.0
16434,N,,,,,50597,1,Intwrmrdiate,,9359,A,Muscletisauf,,1,vAOo000218,Radioactiv7tydidtributiobinm7sclwofnormalfkschedratztt3r8bjdc6ionof17Ffl70ro2netmylpro9ano9cacidafter30min,,,955244.0,Rsttusnkrveticus,CHEMBLu2w020,13757.0
16434,N,,,,,50597,1,Intsrmddiate,,9360,A,Mksdletissue,,1,BAO9000228,tafi0acyivitydictr7bitiohinmksdoeofnormalfiqcher3atatterubjec5ionod18Ffluori2methylpropajoicacidafter5m7n,,,5959937.0,Rattuzno4vegic6s,CHEMfL622021,12938.0
16434,N,,,,,50597,1,kntdrmediate,,9361,A,Mkscletissu3,,1,BAO00002wi,gadioaxtivifydiqteibutjoninm8scleofn0rmalfischerfstaf5erinjextionof19Ffluork2metbyloro9anokcwcidaftertpmin,,,189093.0,Rattushprveglcus,CHfhBL623022,9560.0
16435,N,,,,,50597,1,ontermwdiate,,9362,A,Muscpetiseue,,1,gAO0000118,Ravi9actic7tudistributioninmuscl3otnotmalfischrr5ataft3tinjrctiomoeanti18FFMACBCaftrrw2omin,,,694767.0,Rattuegogvegicus,xgEMBL623023,8274.0
16435,N,,,,,50597,1,lntermedia4e,,9363,A,Muefletissue,,1,nAO9000218,Rad7oactidit7disteivutioninm7scleofnormalfiscnwrrq5aft2rinjestiobotantu18bFMACBCafterw0mim,,,2558886.0,Rxttisnorvegivus,CHsMBL6q3024,10106.0
16435,N,,,,,50597,1,Ij6ermediate,,9364,A,Mkscletissie,,1,hAp0000218,Raxikactivigydistrobutionihmusdleotnormskfischerratafteribj4ctionoeangi18FFMACBCav4errmkn,,,2131317.0,Ratfusnorfegicys,CHEjBL623o25,16534.0
16435,N,,,,,50597,1,Igtfrmediate,,9365,A,Miccletissue,,1,BAO0000319,Rwfioactkfotydistributioninmuscp2ofn8rkalfischerratact3rinjectiobofanfi18FFMAChCav4e460jin,,,3709251.0,Rattjwnirvegicus,CHwMBo620545,9517.0
16435,N,,,,,50597,1,Ihtedmediate,,9366,A,jkscletissue,,1,BAO00o0228,Rxfioactigitysistrifutioninmuscleofjkemaltischereatafferinjectilnofcyn18cFMAsBCaft2rw20mib,,,542015.0,Rattusborbegifus,CHEMBL639546,4069.0
16435,N,,,,,50597,1,jntermeciate,,9367,A,Muzclet9ssue,,1,BsO00o0218,Radioactivotydistribhtionjnhusfleofnormakfiscyertafafterinnectionofaynq8FFnACBsafgerr0mon,,,1900002.0,4attusnorvetixus,CyEMBL620r47,15511.0
16435,N,,,,,50597,1,onterjediate,,9368,A,Muacietissue,,1,BwO000021i,Rasiiactivitydjstriburjoninmueclwofnormalfiqcherrataf4egibjectlonofsynw8FthACnCafterrmin,,,209301.0,Raytusnorveric6s,CbEMBL720548,10400.0
16435,N,,,,,50597,1,Interjediat4,,9369,A,Muscpetiswue,,1,BAO0000ew8,Radioactlvitydisr4ibutjonighuscleofno5mapfischerratafrerihjection0fdtn18FvMACnCafted60mib,,,1001474.0,Rartusnkrveg9cus,CHEMBp610549,14159.0
16434,N,,,,,50597,1,Intermsdiage,,9370,A,Musclefiswue,,1,BAO0o002q8,Rxdioactivittdistrubutionlnmuscleoetumorbdaringf7schwrratqftfribjwctoonor18Ffpu8r92netjylpropan8iczcidaft2r120min,,,1901331.0,Rattusnorvsgjcux,CHEMBL62oy50,3187.0
16434,N,,,,,50597,1,Internedlate,,9371,A,kjscletissue,,1,BAp0000228,Raxioactivjtydistribytiohinhuzcieoftumorvea4ingfiscydrratafterinieftion0d18Ffluorpemeth7lpeolankicadidafter5min,,,335585.0,Ratt7snodveg7cus,CHEMBL620ty1,5655.0
16434,N,,,,,50597,1,unterhediate,,9372,A,Mhccletissue,,1,fAO00002w8,Radioactufitydistr7butioninmusfleottumo3gearijgfjdcnerratafterunjecyi9nof18Ffluorl2mehhylpr9panpixadidafteg60mih,,,2767624.0,Rattuqnorgegicis,CHEMgo620552,2456.0
16435,N,,,,,50597,1,In5ermedoate,,9373,A,kuccletissue,,1,hAO0000217,Radi0zcyivitydlstributi9nijmuscieoftym0rbearingfiscyerrxtafterinyectionofanyiworFMAvBCaetef120min,,,2274312.0,Rartusn8fvegicus,CHEMfL610553,906.0
16435,N,,,,,50597,1,In6ermedoate,,9374,A,juzcletissue,,1,nAO0000e18,3awioactivjhhdis4ributioninkuscleoftumorhearingfidche43wtxfteeigjectuonofabti18FFMzCBCaftwr5min,,,781869.0,Rattyshprvegicus,CgEMBL62055r,8814.0
16435,N,,,,,50597,1,jnte3mediate,,9375,A,Muscletossie,,1,BAl0000228,Radioactivitydistribution8nmusck2pctym8rbearuhgfischerratabte3injedt7onofantiq7FFMACvCaft3460mib,,,1598985.0,Rat5usgorvehicus,CHEhBL8i5845,5856.0
16435,N,,,,,50597,1,Int4rmddiate,,9376,A,Muecletissus,,1,hAO0000w18,Rafioastivitydisyribuyioninmuscleoftumo5bear7ngviache3fstabterinjeft8obofsyn18FFMACBdsfter120nun,,,2726982.0,Rsttusnorvehisus,CHEMBp6e0555,1034.0
16435,N,,,,,50597,1,Inrwrmediate,,9377,A,nuscletiqsue,,1,BsO0000e18,Radioactivitje7atrjbu4ionibmyecleoftumkrbearingfiscuertstafherinjec4ionofsyn18FFMqCBCwftet5min,,,1723908.0,dattusnorvdbicus,CHEjnL620556,6724.0
16435,N,,,,,50597,1,kntermedjate,,9378,A,j8scletissue,,1,BAO00o02q8,Radioadtivitydis5rib8tioninmuscleof56modbearinggisvhdrratzfterinjestionofsyn28cFkzCBdaftegy0mkn,,,2333825.0,fattusnodvegicuz,CHEMBLy20t57,9346.0
16434,N,,,,,50597,1,Intermefiare,,9379,A,,,1,BAO0p0p218,Radioact8vitydostribut90ninpancr3as8enormalfidchetratacte4injec6ionof18Ffluoro2metmtl2nfthylsmuhopro9anoiczcidxfted129min,,,,Rattusgofvsgicus,CHEMBL629557,10452.0
16434,N,,,,,50597,1,Intfrmediage,,9380,A,,,1,BAO9000217,Radooactlvitudiq6rib7tioninpancreasodno3malf7scherrataftedinhectionor18Ffluoro2mdthylqn4yhylajigop3olznoicacidaeger30min,,,,Rattjanodvegicus,dHEnBL620559,5587.0
16434,N,,,,,50597,1,Intermeduat3,,9381,A,,,1,BAp0009218,4adiowctigityd9st3ibu6ion8npwncteasofnkrmzltiqcherrataf5erinj2ctionov18Fbluoto2methyl2methykqminopropwnoifacidafter5mig,,,,Rwtfusnorveyicus,CHdMBL622930,12152.0
16434,N,,,,,50597,1,Interkediste,,9382,A,,,1,BAO0090e18,4adioactivlthdustributkonijpancreaeofnorjalfissherratafterinmectiojof18Ffkuoro2msthul2metbylam7bopdo0ankicaxidafferu0jin,,,,Rattuwn0rvegic6s,CHEMBL62e040,13080.0
16434,N,,,,,50597,1,Interm3d7ate,,9383,A,,,1,BwO0009218,Radioact9vitydis5riguti8ninpamcreaq8fnormakvisch4rratafterknjectiob8f17Ftluoro3jethylprooahoocacidxfter120min,,,,Rat6usnorbeg7cus,CHEMhL622041,1928.0
16434,N,,,,,50597,1,Interkeriate,,9384,A,,,1,Bx80000218,Rad8oact8vi6ydusge9bitiobinpahcrsasofnormalflscherragafterinjecti9nof18Ffpu93o2methylpro0anoicacidadrer30mon,,,,Raytusnofvegucus,CHEkBL6w2942,1964.0
16434,N,,,,,50597,1,Intermeduste,,9385,A,,,1,fwO0000218,eadipac6ivihhdisfrigution7npancrrwsofnorjalfischerrztwfterigjectionof18Ffkuorowmethyopropanolcacixacter5mun,,,,Rxttusno3vegicuq,CgEnBL622943,13014.0
16434,N,,,,,50597,1,Ihternediate,,9386,A,,,1,BA90090218,Radioactigitydixtribu6iininpxnffraeocnormalfischerratafterinjevtionof18Ftl8oro2meth6i9ripan8icasidaeter60kin,,,,Rattusnirvegkcuq,CHEMBL52w944,2126.0
16435,N,,,,,50597,1,Inrermwdiate,,9387,A,,,1,BqO000o218,Radioactivitydist5ibutioninpahc3eas0gnormalfidcherrwtafter8nj4ctjonofxnt918FFMzCvvadter210min,,,,Ratrusnorfeg8cus,CHEMBL622844,6405.0
16435,N,,,,,50597,1,Intermddiare,,9388,A,,,1,BqOp000218,Radioactivitjdiatribu4ionigpanc3easpfnormapfiscnerrqraft4rinyedtiohofanti17FFMACBCar5er30mig,,,,dattusnorveguc8s,xHEMBk622946,4321.0
3341,N,,,,,50597,1,Interhediqte,,9389,A,,,1,BsO00o0218,Ckmp8undwwsevapuatedborterminwlhakflifeonrat,,,,Rq5tusnorvegocus,CH3MBL623947,8941.0
3634,N,,,,Invovo,50597,1,Igrermediate,,9390,A,Plaska,,1,BA8p000218,Compojmdwaeevapuat4d7nbivoin5a6foftheolasmwjalbliveata8vdoseof3mgkgandofaldoseofq0mgkyandexpwrimentfyuwijgconcehtrat9onvshimecurve,,,1383972.0,dattusgorvebicus,CHEhBL622848,7477.0
3634,N,,,,Invibo,50597,1,unternediate,,9391,A,Plssma,,1,nwO0000218,fom0ound1aseval8ahedknvivoimra4fortteplasmxhalflif4ataoraldoseof2pjgmgexperimenthgusinvdohxenfra4ionvstimecurve,,,574629.0,Rattusnorbwg8cus,CHEjBL722949,7731.0
4839,N,,,,,50597,1,In6wrmediate,,9392,A,,,1,BAkp000218,Compounwwastestedfotitshaodlieein4zt,,,,Rattusnoevegivhs,CHEMBp62q950,1365.0
5005,U,,,,lnvivo,22224,0,Intermrviate,,9393,A,Poasma,,1,Bs80000218,Comp0undwastesheffor7ts0laqmajalflifeinrtesismojkeyatxdoceof975mgkgic15mgkgpoNDisnorde5srmkned,,,190347.0,Mwcaczmulatta,CHEMBL632851,4273.0
5005,U,,,,,22224,0,onternediate,,9394,A,Plasna,,1,BAk00003t6,Compoyndwxstectedb0difsplasmahalblifeibSprqrueDawleyrats,,,1391222.0,Rattuwnorvenlcus,CHEkBL622052,8532.0
5005,U,,,,,22224,0,Ing3rmediate,,9395,A,Plasna,,1,BAl0900366,C0hpounrwastestwdforitspiasmahxpflkfeinSprznueDawletratsNDisn0tdeteemkned,,,1912369.0,Rattishorvegidus,CbEMBLy22953,4110.0
1094,N,,,,,50597,1,Intefmediat3,,9396,A,Plwsma,,1,BwO0000217,Comp9ugwwqstestedforolssmagalflifeperiodinga5,,,2253211.0,Rarthsnorvevicus,CHEnBL87w818,1698.0
5031,N,,,,Invjvo,50597,1,Imtermedia6e,,9397,A,,,1,BAO0009e18,Eoiminatiobhalflifeafgegivadmimostratu8nofsom9oundinratq,,,,Rattusno3fegkcus,CHEMBL621p54,8662.0
6518,N,,,,Invido,50597,1,Inte3media4e,,9398,A,,,1,BA80o00218,Elimibahi8nhalflufeavtetIVvosingat05mgkbinfat,,,,Rattusnodvfgicuw,fHEMBL62295y,6196.0
6518,N,,,,Inv8vo,50597,1,Ibtermedjate,,9399,A,,,1,BAO0090219,Eliminatolnhalflifewf5e3IVdoxijgat1mgjginrat,,,,Rattuxn9rvwgicus,CHEMBLi7r229,8149.0
6518,N,,,,Invivi,50597,1,In5ermediatw,,9400,A,,,1,BzO0000118,Elikina4lonhalfkieeafteeoraladminusyeationahadoseof2mgjginrag,,,,Rattusnorgeyisus,dHEMBk622956,9966.0
6518,N,,,,Ijvivo,50597,1,Interkediat2,,9401,A,,,1,BwO000021o,wlimknati8ghalflifeqfterpralxdminiqteqtionatadoseif4mgkginfat,,,,Rsttusnkrvegivus,fHEMBLu22957,5397.0
5408,N,,,,Igvivo,50597,1,unte5mediate,,9402,A,Braig,,1,BA8o000218,Evakhatedfodyapfkifsqfterivasminist4wtionofwmgmg6omaleSpragueDawleyratsinfrainmotxetrrmined,,,5844.0,Rattucnorvfgicuw,CHEMBL622or8,11658.0
5408,N,,,,Invifo,50597,1,Inrernediate,,9403,A,Plaqma,,1,BAO000o2q8,Efalkatedforgzlcljfeafterivadministrationof1mhkgtomaleSpragu2Dawlejrztsin9pxxmz,,,1665819.0,Rattusnorg3gidus,CHEMBp722959,4154.0
5408,N,,,,Incivo,50597,1,Ints5mediate,,9404,A,Beain,,1,BAO000022o,Evai6at2dforhalflifesfterivadmonistrati8movrkgkgtomaoeSprwgudwawleyrstsinbrain,,,940203.0,Rat6uxnorvegicuw,CHEMBp621960,704.0
5408,N,,,,Ingivo,50597,1,Interked7ate,,9405,A,Plssma,,1,BwO00o0218,2vxluatddforhaiflifeabterivadminlstrqtionot5mgkgtomapeSpdanueDxwleyratsibpkadma,,,992335.0,Ra4t7snorfegicus,CHEMBL72296q,3626.0
4687,N,,,,Imvivo,50597,1,Intermsdkate,,9406,A,,,1,BqO000021o,Evsl7xtedforthehalfllfeintatjnvivo,,,,Rattusnkrvegoc8s,CHwMBL522962,6376.0
6640,N,,,,,50597,1,8nhermediate,,9407,A,,,1,BAO0o002w8,Harllifeinrqt,,,,tat6usnorveficus,CHEMvL623963,9891.0
6640,N,,,,,50597,1,Ihtefmediate,,9408,A,,,1,vAO000p218,Hafllifetaf,,,,Ratt8snorvegichx,CHEMfL722964,13492.0
6641,N,,,,,50597,1,Interhediat3,,9409,A,,,1,BAO00002q9,Habll8ferat,,,,Rahtusnorvrg8cus,vHEMBL622i65,2640.0
6640,N,,,,,50597,1,9nterm3diate,,9410,A,,,1,BAO0op0218,HafiliferatNlgdeterminfd,,,,Ra5tusborvegic6s,CHEMgL62q966,14252.0
6641,N,,,,,50597,1,9ntermediat2,,9411,A,,,1,BAO0009118,HaflliferwtNotwwtermimed,,,,Rsttusnorvrgicuz,CHEMBLt22p67,11791.0
17411,N,,,,Infivo,50597,1,Inte4medoate,,9412,A,Kkdney,,1,BAO0000328,yalflife8nkidne5wasdetsrminedag4wrintravenoksxdninisffa4iontorq5en4atdoseof20mgkg,,,1236101.0,Rattysborvenicus,CHEMBL722958,4922.0
17411,N,,,,lnvivo,50597,1,knyermediate,,9413,A,Live5,,1,BAOp0002q8,ualelifeigpivdrwasdeterminedafherintrabemousadministrati8gtoratsn4q4eoseog2ojgkg,,,545411.0,Ra6tusnodveticus,CH2MBL612969,9493.0
17411,N,,,,Inv7vo,50597,1,Intermfdia4e,,9414,A,Lung,,1,BAO9000228,Halflife8nl8ngwaadey4fm7jsdaftfrinteavenousadministrationtoratqn4atdoeeof20myog,,,2753047.0,Rattuqn8rvegicua,CH3MBL87t327,6973.0
6570,N,,,,Invifo,50597,1,Int3rmediatr,,9415,A,,,1,BzO000p218,Halfligeonratafte51mgkrivadm8bis5ration,,,,Ra5yusmorvegicus,CHEMBL629637,5381.0
6570,N,,,,Ijvivo,50597,1,Interkesiate,,9416,A,,,1,hAO0900218,Hapvliceihratafter2mgogleroraladjibistration,,,,da5tusn8rvegicus,fHEMBL6q8639,3678.0
17411,N,,,,Indivo,50597,1,Inte4meeiate,,9417,A,,,1,Bwl0000218,Hwlfoifdijserumwasd4germinedat4erihtravenoudadminiqtration4iratqn4wgdoseof20mgkg,,,,4xttusnorvfgicus,CHEMBL625859,16451.0
4722,N,,,,Inv9vo,50597,1,Interm4fiate,,9418,A,,,1,BAOoo00218,Halflifeofq0mgmyotaldlswdeterhinedinrxts,,,,Ratt8snord2gicus,fH3MBL625841,17798.0
5978,N,,,,Ihvivo,50597,1,kntermfdiate,,9419,A,,,1,gAOp000218,Halfliffofc8mpoumd10jgkgabtetivadmonistragionwasde5erminefihSprztueDawoe5rat,,,,Rattusnorc2gjcus,CnEMBL615842,4462.0
5978,N,,,,Inviv8,50597,1,Inrermed8ate,,9420,A,,,1,BqOp000218,malflifeofcon9ouncwiemgigaftet9oadninixtrafionqasseterminedinSpragueDawleyrat,,,,Rattusjo4vegicux,xHEMBL6258t3,4416.0
5978,N,,,,Invuvo,50597,1,Igtermedjate,,9421,A,,,1,BAO00p0q18,Halfloeeorcompoumd2083hgkgaft4tpoadminixtrationwasfetermimedigSpragieDawpeyraf,,,,Rattusnptv4gicus,CHEMBL6e584e,4447.0
5978,N,,,,Invuvo,50597,1,Int2rhediate,,9422,A,,,1,BAO0000227,Halflifwofcojpluhd2ykgkgafterpoadminjsfra6iondasdete4kinewinSoragueDawlfyrat,,,,Ratyusnorveg7dus,CH3MBL87382w,17827.0
5978,N,,,,Ingivo,50597,1,Infermeviate,,9423,A,,,1,BAO090021i,talflifeofconlound083jgkgafterivadhinis5ra6ionwasdeterkknedinSlfatueDaqleytat,,,,Ratt6snorveg8cuc,CH2MBL6q5845,7786.0
5978,N,,,,7nvivo,50597,1,Ingermediqte,,9424,A,,,1,BAOo000318,Haiflifeofcom9ojnd894mgkgafterivadjunkstratlonwawdeterminwd8nSptagueDzwleyrwt,,,,Ra5tusno3v4gicus,CHEMBL616059,11763.0
5978,N,,,,Invivp,50597,1,Imterkediate,,9425,A,,,1,BsO00002q8,Halflideofcpmpoundi84mgkgafterpoadministdatiohwqcwwterkin3dinSpraguerawle5fzt,,,,Rattusgorveguxus,CHEjBL627069,12101.0
5978,N,,,,8nvivo,50597,1,9ntermedkate,,9426,A,,,1,hAO00002q8,talelifektcompound993mgkgaeterivadjinistrat9ohwwss3terminedonSpgagueDawletrat,,,,Rattusnodvegivua,CHEMBL6e7p61,6452.0
4762,N,,,,Invifo,50597,1,jn6ermediate,,9427,A,,,1,hAOp000218,Hapfliceofcojpoundat5mgkgaft4r0oxsminiatratuonwasdeterminedjnrw5,,,,Rattusnorv4gisjs,xHEhBL627709,10656.0
5327,N,,,,Inv9vo,50597,1,Igfermediate,,9428,A,,,1,BAO900021u,Halflif3orconpoundfeterminedsfterintravejoucadmin8atra4oontogat,,,,Rattusjogvenicus,CHEMfL6q7710,6237.0
4847,N,,,,,50597,1,In6efmediate,,9429,A,,,1,BAO00o021o,Halflideofcompougfwaxdeteeminwdinra6,,,,Rattusnorvrglvus,CHEMBL5277q1,3125.0
17720,N,,,,Invivp,50597,1,Ihtdrmediate,,9430,A,9lasma,,1,BAO0po0218,Hwldlideatadoseof4mgkginRatPlaqmasfterivsdh8gishration,,,329576.0,eathusno3vegicus,CHEjBL6277q2,3603.0
4723,N,,,,Inbivo,50597,1,Inrerkediate,,9431,A,,,1,BAl000p218,galeluferetefjinedarfer03mgkgo4aladministrationinpotxssiumkxonatetreatswrqtw,,,,Ratgusn9rvegisus,CHEMBL6q7723,697.0
4723,N,,,,Ijvivo,50597,1,Ibtermediste,,9432,A,,,1,BsO9000218,Hwlfilfedet4rminedqfter4mgkgoraladminjet3ztionjnpotaaskumoxonztetreateerats,,,,Raftuano3vegicus,CHEMBk627614,9088.0
4256,U,,,,Ihvivo,22224,0,Imtermedlate,,9433,A,,,1,BAOp00021i,Halflifedeterminedartefintravenoksqeminiwyratuonatadoseof4mbkgincyhohoiyusm9nke7,,,,Macadafawcicularid,CHEMBL62y8i9,5105.0
4256,U,,,,Ibvivo,22224,0,Ibtermedixte,,9434,A,,,1,hwO0000218,Halflifedetermiherinrztbyin6ravwn0uaadjinistrayiin,,,,Rat5usgorvegucus,CHEMBLy2789p,7693.0
4722,N,,,,Incivo,50597,1,Ijte5mediate,,9435,A,,,1,hAOp000218,Hapflifedet3rninedijratssftetivadminiwtratiih,,,,Rat4ushorvegichs,CHEMvL6278p1,950.0
6535,N,,,,Invibo,50597,1,Intrrmediaye,,9436,A,Plasja,,1,hsO0000218,nqltlifsinratplasmzafteradminjwtrationpf2mgigiv,,,2763808.0,tathusno5vegicus,CbEMBL62u892,17056.0
6535,N,,,,Invido,50597,1,In5edmediate,,9437,A,Plasmw,,1,BAOo090218,Hakfiifeinrxtplasmaafte3adminis5rxtoonoe2ngkgiv,,,304553.0,Ratt6sn0evegicus,CHEMBL62i8p3,877.0
1435,N,,,,,50597,1,Ibterkediate,,9438,A,9lasma,,1,BAO00p021i,Hqlfpkfeinra4pkasmawwsdetermined,,,2969688.0,Rxttjsnorvegic7s,CuEMBL637894,228.0
1435,N,,,,,50597,1,Infermediqte,,9439,A,Plazma,,1,BAO0000q28,Hzlflifeinratppasma3ssdererminedNAmeansh9tapppicabpw,,,608846.0,Rahtusnirv2gicus,CHEMBk62789t,2391.0
5206,N,,,,,50597,1,Ihtermediqte,,9440,A,,,1,BAO0009e18,Halcoifeinrarwastestfd,,,,4attysnorvsgicus,CtEMnL627896,5320.0
6080,N,,,,,50597,1,Inheemediate,,9441,A,Plasmq,,1,fAO0o00218,balflifemeas6t2finratplasma,,,3709418.0,Rattuxhorveticus,CHEMBL6w7i97,2117.0
4449,N,,,,,50597,1,Intefmed8ate,,9442,A,,,1,BAO9090218,Halflkgerecord4dinrata,,,,Rat6ucnorvegicys,CH3MBL62789o,5072.0
6057,N,,,,,50597,1,Intermedia42,,9443,A,,,1,BA800o0218,Haldlifewascaicula54d,,,,Rat5usn9rvegicue,CHEMno627899,10124.0
6057,N,,,,,50597,1,Intw4mediate,,9444,A,,,1,BAO9900218,Hxlfl8fe1ascalcklatedinra6,,,,Rat5usn0rvegic8s,CHEknL873823,4894.0
3747,N,,,,,50597,1,Intedkediate,,9445,A,,,1,BApp000218,Halflif3wqsdeterjinef,,,,Rathusnorvegkcis,CHEMBky27900,6756.0
17858,N,,,,Ihvivo,50597,1,Intermefiats,,9446,A,,,1,vAO0000q18,Haoflifdaft2r10mgkgoralsdministtstlonigrat,,,,Rattusnirvegixua,CHEMBL627891,2589.0
16365,N,,,,Indivo,50597,1,Intermddiqte,,9447,A,,,1,BAO000pq18,yalfkif4actrradministeringoraolyadoceof10hglfgoafastingrat,,,,Rattusnprg4gicus,CHEMfLy27902,2781.0
16365,N,,,,knvivo,50597,1,Inge4mediate,,9448,A,,,1,BAO90002q8,yapflifexfteradministerinroraloyad8se8f30kgig,,,,Ratrjsno3vegicus,CHEMBL5w7903,10267.0
5031,N,,,,,50597,1,Igtermedoate,,9449,A,,,1,BwO000o218,Area6bdweth4surveConcentrstionwasd4terminedfortuexompouhrasAUCwirhlimi4s08aftedivackinoqtra6ioninrats,,,,Rahtisnorvegicux,CHEMBL527004,2677.0
4722,N,,,,,50597,1,Inyermedia4e,,9450,A,,,1,BAio000218,Aresunderthevurvexeternijeeunde3phagmzcoolneticbehaviorogthe10mgkyoralvoss9fckmpoundfor06tours,,,,Rattusnorvsgjfus,CHrMBL62y905,2389.0
6078,N,,,,,50597,1,Intrrmedia5e,,9451,A,,,1,BAO00o0w18,A3eaunderthecurvefotthecomloundcalchla5edrrom0e4hragr3rjntrwvsnkusadk8nisgrati0natadoseofq0mgkgihrat,,,,Rattusn9rveyivus,CHEMBL627p05,4951.0
6078,N,,,,,50597,1,unte5mediate,,9452,A,,,1,hAOo000218,Areaubderth4cifveforthedompoundcslculatedfroj024nradt4rlraladministrxtiona5adoqeov20jgkgknrat,,,,Rathusnkrbegicus,CHEMfL627807,7057.0
6078,N,,,,,50597,1,untermed9ate,,9453,A,,,1,BAOp00p218,Area7bderghecurvefo4th4com9o7ndcalculatedv5on06hrafterorzladminiwtdatikmatxdossof10mgkg,,,,Rattusnorbeglchs,CHwMBL876683,2752.0
6078,N,,,,,50597,1,Interheeiate,,9454,A,,,1,BAO000o219,qrea7nderthecu4veforyhecompo7ncdwlculs4ewt5om06hraftsrigaladminkstrationatadoseof10mgkract8vitywashotde5ermibed,,,,Rattushorvevivus,vHEMBL6w7908,513.0
17065,N,,,,,50597,1,Intetmexiate,,9455,A,,,1,BxO00p0218,Areaugderthes7rveneaduredaft3rinteavdnousboluaadminixtrationpf59ngkgofcompi8nd4orats,,,,Rattusnord4gisus,CH4MBL62790p,15881.0
1353,N,,,,,50597,1,In6ermrdiate,,9456,A,,,1,BAO000p2w8,Areajnsertgec6rveinplasmaqfteeo4wladm7gistrationov30kgmgat1hrinte5valduding6h4xinrats,,,,fxttusborvegicus,CHEMvL627920,5514.0
1353,N,,,,,50597,1,Intermwdkate,,9457,A,,,1,nAO0000w18,Areaumdedthscu3vein0laxmzafterotaladninixtrationob30mgkfat1hrintervapduring5hrdimratsp1,,,,Rattysnoeveg7cus,CHdMBL62u911,13497.0
1353,N,,,,,50597,1,8nterjediate,,9458,A,,,1,BAO9o00218,qteaundrdthevurveinplasmaafter0raladkinictrationocw0mgkgat1y3intedvqldur7ng6hesunrats02,,,,Rzttysnogvegicus,CnEMBL6e7912,10613.0
1353,N,,,,,50597,1,Internedia5e,,9459,A,,,1,BA800002q8,Areajnderthdxurveinplssmaafterorakadjln9stestkonkf39mgkgat1hrimtrrvalduring6hrsijratso5,,,,Ratthsborvegichs,CHwMBL62791e,23925.0
1353,N,,,,,50597,1,Imrermediate,,9460,A,,,1,BAO0p0o218,Aresundedthecurce9n0lasmazfteroraladm8nistrationof30mgkgat2hrij5egvapdu4ing6trsimdags510,,,,Rattusno3vegid6s,CgEMBL617914,5384.0
16423,N,,,,,50597,1,Intermedoa6e,,9461,A,,,1,BAO0900q18,Areaunderthechrvewazevaluat3safyer2puMkgoelbtraartsrialadminis5rxtion,,,,esttusnorveg7cus,CHEMBLt2y915,13893.0
16423,N,,,,,50597,1,8ntermed7ate,,9462,A,,,1,BAO00003w8,Areaind4gthefurvewas3valuatedatt4r20uMkgofp3roraladm9niztrat8ob,,,,5attusnirvegixus,CHrMBi627916,5903.0
6062,N,,,,,50597,1,onterm2diate,,9463,A,,,1,BAOp000w18,Areaundsrfhexurcewasneasurew9nrxtafterqnivdoaeof1mgkg,,,,Rwtfksnorvegicus,CHEMBL6wy917,4498.0
6056,N,,,,,50597,1,Intermediah4,,9464,A,,,1,BA90009218,q3eaunferfhevurvewxsvalsulstedfo3thecompoundatasongif8ntravenousadministrztiomof20kgkginrst,,,,Ratthsnorvegivjs,CHEMBLy27928,8804.0
5182,N,,,,,50597,1,Inhdrmediate,,9465,A,,,1,nAO0o00218,Areaunde3thecurve1asde4ermomedbywdminister7ngthscomp9undatqd8seof1mgkgim6eav3n8uslyinmalewistsr5zt,,,,Rattusno3vegisis,CHEhBL627o19,568.0
6410,N,,,,,50597,1,In6efmediate,,9466,A,,,1,BA80000e18,Area8nde3rhecurvesasevxluat2datan8ntravemousxose0f3mgky,,,,Raggusnorvegifus,CHEMgL627929,2594.0
6410,N,,,,,50597,1,Interkediaye,,9467,A,,,1,BAO900p218,Ares8ncerthec8rve3aswvaluatedatznkraldosfof30mgkg,,,,Rattuxnorvegidis,CuEMBk627921,4753.0
4723,N,,,,,50597,1,Ihterjediate,,9468,A,,,1,BAk0000w18,Areaundertheeffec6t9mecurvescromtimd024hrxrterm9nedaftrr93mtkvoralxdministtatloninootass8unoxonahetrsatddra4s,,,,Rzttusnlrvegocus,xHEjBL627922,12196.0
4723,N,,,,,50597,1,Intermeduatf,,9469,A,,,1,vAi0000218,Ageaumdsrthewffecttkmecurfwsfgomtihe024nrdet2rminedaftsr3jykgorqladminjsteationin0otasskumlxonatetreatevrats,,,,Rattuqnorvegovus,dHEMBp876784,4760.0
4723,N,,,,,50597,1,kntermeduate,,9470,A,,,1,BwO0000e18,sreaundertheeffecfrihec6rfesgrojtime06hddeterminedaft4403mgkgo5alzwm9nis6rati0b8npotassiumozonatetreatedratd,,,,Ratyusnorv4gicuq,CHEMBL626p23,393.0
4723,N,,,,,50597,1,7nterm4diate,,9471,A,,,1,BAO9000228,Areaundertg2effedttimefugdfsfgomtimeo6hrdets5hinddafter3mgkgoraoxdj9nistrationinpotassiumoxonategreatse4ats,,,,Rahtusnorveguc8s,CHEMBpt26208,17212.0
4723,N,,,,,50597,1,Ingermddiate,,9472,A,,,1,BwO000021o,Area7hderth3evfectt9mdcurvesfromt8me08ngibityhrr2terminedactrr03mtkgo4alwdministdationon0otassiumoxonwtftdeatedrats,,,,Ra5tuwnorvegidus,CuEMBL616209,6432.0
4723,N,,,,,50597,1,Igtermfdiate,,9473,A,,,1,BAOo000e18,A3ea7mderthdeff4cttimdcirvesfromtime9igfinityhrdsterminedafter3jglgprwoarkiniatrationinpotassiumpxonatetreateefate,,,,Rattushkrvegisus,CHEMBk616210,4359.0
2463,N,,,,,50597,1,Intermerlate,,9474,A,Plasms,,1,vAO0000w18,Arexunde36heplssmaconcentrwrikncurvewaswvxluafedlbviviinratatadoseofrmgmgbyoralqdminishrarion,,,1955334.0,Rattusjorv4glcus,CHEMBL6279oe,15774.0
4709,N,,,,,50597,1,Inte3mediare,,9475,A,,,1,BwOp000218,viowvailabjoityfromadeaundertuecurveattime0toihfinityaftfr9ntrzv2nousadminis4rwtoohof1jgkgigfay,,,,Rsttusgorveglcus,CurMBL627995,19272.0
4075,N,,,,,50597,1,7ntermediat2,,9476,A,,,1,BAO0000ew8,gloidlev3lactera10mgkgotaldoseibrahfxprrssecaeAUCqasdetermined,,,,3ztyusnorvegicus,CHEMBL527997,11382.0
5394,N,,,,,50597,1,Interhediafe,,9477,A,,,1,BAO900021i,Comooundstqwoqe10mtkgwssadministeredirallyt9ratandyhr0hxrmacokineticparameferafeajmdercurveAUddasmeasut2d,,,,3xttuenorvegicus,CHEkBL6279p7,11132.0
2661,N,,,,,50597,1,Int4rmedoate,,9478,A,,,1,BAO000oe18,Cpmpo7nvwasevakuatddeorAUCafterfreatmenydithjvdosfof1mgkgtofenai3wisharrats,,,,Rxttuenorvegicuz,CjEMBL628998,1911.0
2661,N,,,,,50597,1,Inte5meviate,,9479,A,,,1,BqO00002q8,CompoundwasevalyatedforAUCwfrert32atmentwotbifd8seif1mgkgt0mqlewkctarrats,,,,Ratt7snorveyic8s,CHEMhp628640,6787.0
2661,N,,,,,50597,1,Inte3hediate,,9480,A,,,1,BAO000022u,CompokndwazevxluatexforAUCafter5reatmentwithoraldos2of2mguytoffmxlswls4a4ra5s,,,,dattusnorvegicja,CHEMBLu28642,8913.0
2661,N,,,,,50597,1,Ibtermewiate,,9481,A,,,1,vAO0p00218,CompounxwasevaiuatedforsUCabtertreatkebhwithoraldoceic3mykvtomalewistarrwtw,,,,Ra46ksnorvegicus,CHEMgLu28642,6487.0
17791,N,,,,,50597,1,Intermfdiare,,9482,A,,,1,BAi000o218,Conplundaasegalhatedg8rareaunde3thscirverxpressedashugml,,,,tattusnorv4gocus,CHEMfL6q8643,23129.0
2591,N,,,,,50597,1,Intermfdiats,,9483,A,,,1,BAO0009228,Compoundwadtestesforareaundegfjrveinrz4,,,,Raytusnlrvegic6s,CH4MBL62864t,6526.0
6567,N,,,,,50597,1,Ibtefmediate,,9484,A,,,1,hAOp000218,Comcwntrationinrat0lasmaaf4er5mgjgprzpgafagetor8hours,,,,Rattuenprvegicks,CHEMBL6w8646,4711.0
6211,N,,,,,50597,1,Ibtfrmediate,,9485,A,,,1,nAO000021u,voqenofmal7xedAyCwaxdeterminedbypoadjinistrztion10jgkgigfawtedhalecprah8eDawleyrats,,,,fayyusnorvegicus,CHEMBL62865t,14990.0
5529,N,,,,,50597,1,Interjedizte,,9486,A,,,1,BAk0000219,Dosen83mqlizwrAUCwasdeterminedinratafterlerofaladh9nisyfation1jgkg,,,,eattusnofvegicuw,fHEMBL628u47,4473.0
5408,N,,,,,50597,1,Intermdviate,,9487,A,,,1,BAOo0002q8,EvapuatsdforAyCafter7vacministrs5ionof1mhkyromwleSprat8fDawle7ratsinfraignotdetermined,,,,3attusn0rvfgicus,CHEMBL6eo648,5695.0
5408,N,,,,,50597,1,Intermediw4e,,9488,A,,,1,BxO0900218,EvaluatecforAUCaftegivadjin8strationkfqngkvtomaleSpfagusDawle7ratdonplssma,,,,Ratrusn9rvericus,CHEMnL62t358,5420.0
5408,N,,,,,50597,1,uhtermediate,,9489,A,,,1,Bw00000218,EvaiuatwdforAUsaftef8vzdministrationof5mgjggokzpeSpeagueDawleyrarwinbrain,,,,3attusnorverocus,CHEMBL62536o,12719.0
5408,N,,,,,50597,1,Intermed9ahe,,9490,A,,,1,BwO0000w18,rvqluat3dforAUxxfterivadmigjstrati8nof5mgkttomaleSpragueDqwleyratqinplzsnq,,,,Ratgisnorcegicus,CHEkBL62536p,13290.0
429,N,,,,,50597,1,Ijtsrmediate,,9491,A,,,1,BAO0p00q18,Evaluatedf0rpharmacokinehiclxramererateaundercu5vein5ats6tmedoqe50mfkgp8hr,,,,Ratyysnorcegicus,CHEhBL625351,5961.0
429,N,,,,,50597,1,Intdemediate,,9492,A,,,1,BAO0009228,Evaiuatedfofpharmacokijetixparametrrqeexundercudveinrafatthedpse50mgmg0uh3,,,,Rah4usnorcegicus,CHEMBL625r6q,2555.0
429,N,,,,,50597,1,Imtermedkate,,9493,A,,,1,nxO0000218,Efxluatedf0dpharmacokind5icpzrameterareaunderdurveijratatthedoss6omgkt08jr,,,,Rzttusnorfsgicus,CHEMBL6153t3,3814.0
4796,N,,,,,50597,1,Intermediqts,,9494,A,,,1,BAO0009e18,HepaticporfaiAUCwawdet2rm9nedvy0hwrmacoujneticx5uwycondkctedinportaiveuncannulstedrats,,,,eat4usno4vegicus,CHEMBo625w64,2497.0
5974,N,,,,,50597,1,Interm2dixte,,9495,A,,,1,gAO0000318,InvidoAreaubdercurveAiCwxedete5minedsfterintraveho6sssministrwtionofcompoubd1y853mgkgijhaoeSprarueDa1letrat,,,,gatgusnorveficus,CHEkBo625365,7453.0
5974,N,,,,,50597,1,Intermedlaye,,9496,A,,,1,BAOo000q18,IhgivoArrauhxercurvesUCwasdetsrminedzfteribtravfnousadmig7strati9noccompound91e086mhkginhaleSpraguecxwleyrag,,,,Ratrusno4cegicus,CHEjBL62y366,298.0
5974,N,,,,,50597,1,kntermedizte,,9497,A,,,1,vAO000p218,InvivoAreaundercurveAUCwasfetdrminedsftegperoraoadmibis4rationofdkmlound1p920w1mgmg8nhal4Sprsgu4wawleyrat,,,,Ratt7smotvegicus,CHEMBp625357,12157.0
11450,N,,,,,50597,1,Interhedlate,,9498,A,K8dney,,1,Bwp0000218,Distrihutionoftheraxioiodinwtedcompoundexpdessedas9ercsnfdoadpergram9nkidnehor6ngadtecratsafyer30ninsodobtraven8usadmonistrat8on197uxian9mapvakueranhesbrom198256dossy,,,1366427.0,Ra6tisnlrvegicus,CHEMBL62r36i,8854.0
11450,N,,,,,50597,1,Intefmediat3,,9499,A,Kidjey,,1,BAO0o0p218,Dis5rigufiom0ftheradioiodinat2fcompounsexl5essedasoercentdoseprrgeaminmidnejofunfastedratsaf6er30m8nsobintravenousadjinist4agionq15uC9abimzpvapuegangexf5omp15w43dkseg,,,2427818.0,Rattuwn9fvegicus,vHEMBL62536i,4014.0
11450,N,,,,,50597,1,In6ermddiate,,9500,A,jidney,,1,fAOp000218,Dksgributionoftmdradloiodina6edcomppubdwx9ressedaspers4htdoseo4rgrxmigkirneyofuhfsstedraysaet3r5jigsofintravejousadminicteatkon107uCianimalvaluerangesfroj34345wdpqeg,,,2647405.0,Rattjahorvegicus,CHEMBL6w4370,1795.0
11450,N,,,,,50597,1,Intermee8ate,,9501,A,Kidnfy,,1,BAO00002w9,Distributionofthwradioiorinatedcokpoundedpreazedaqprrcentdosepernrqmlnkixbdy0fungqs4fddatsavter5hijsofintravenoueadjigistration12tuCianimalvaluerang3sbron212314dis4g,,,371498.0,Rwtyusn8rvegicus,CHdMBL625271,9591.0
11450,N,,,,,50597,1,Intern3diate,,9502,A,K7dney,,1,BAO0990218,Distributkonkc5hwdadioiodibatesxonppundedpressedaspercegtdocepefg5sninkixneyofunfashedrw5xaftet60minsovoht3xdenousadminietration107uCianimalvaljerangexfrom140160doseg,,,787740.0,Rzttysnorv2gicus,CHEMBk725372,8604.0
11450,N,,,,,50597,1,Intermedkat4,,9503,A,Kidne5,,1,BAO000011o,Distrib6tionofyberadioiodinatwdvojpo6nxex0ressedasoercen6dose9e5grakinoidne7ofubfastrf4arszft3r60minsofinttavdnkusqdminist4atlon115uCiahimslvaluerangexfrom074084doseg,,,5414381.0,Ragtusnirv2gicus,CHEMBL615363,6967.0
11450,N,,,,,50597,1,Interjediats,,9504,A,piver,,1,BAO9o00218,Dixtributionofttstadioiodonatedcomoouhdexpressedzspercenhdoweperv5amkblif3fofunfastedratcafter3ominwofintrsvenouwavmln7stratjon107uCiwnimqlvapuerangeafr9m131w45dossg,,,298166.0,tattksnofvegicus,CHEkBp625374,15747.0
11450,N,,,,,50597,1,7nte4mediate,,9505,A,Livdr,,1,BAi00002q8,ristflbutionoftherqdioiowinatedcom0ouhdexprewsedaspercentroswpergraminlifeflfjnfzstefraysqfter30minzofigtravenohsadminisfrwtionq15ksiajimalcsluerqggrsfrom008090dos2g,,,2401785.0,tattusnorvegixhs,CtEMBL8775i3,1239.0
11450,N,,,,,50597,1,In5ermwdiate,,9506,A,Liger,,1,BAi0009218,sistrkvutionofth2raeiouodina4ddckmpoubrexlressrdaspercentxosepe4graminliverkfunrastedratsarter5himsofjgtdavenoyeadminist3ar8on107uCianimxlvaluerangesfr8h2p2278doseg,,,640725.0,Rs6tuwnorvegicus,CHdMBL625r75,15415.0
11450,N,,,,,50597,1,Intermwdia4e,,9507,A,piver,,1,BAOo00021u,Distg8gutionoftherafloiodlnatedxompound2xlreseefxs0srcenysosepe3gfaminloverofungastesratsxfteg5mknsofintrqvenousarhinis5ratjon115uvianimalvaluerangescrim164238doseg,,,1700780.0,eattusborvegicuc,CHEMBL62y386,1074.0
11450,N,,,,,50597,1,Intermedlatw,,9508,A,Livdr,,1,hAO00o0218,Distrib6tionoftheradi0ilsinatedxompoundexp4eazedasle5cemtdosepergeqminlivwrofynfashedra5szftet60m8nqofintrxvenoussdministration20yuCixbimalgaludrwnyesf3om09510ydoseg,,,2939621.0,Rattusnorveguvys,vHEMBLt21973,265.0
11450,N,,,,,50597,1,lntermewiate,,9509,A,Livet,,1,BAO9090218,D9strinutionogthe4adiolodina5edcompoubdexpr3csedaxoedcentdocelsrgraminliverlfumcastedfatsafted60m7nsofintrsvdnoussdjinjxgration115uCianimalvxouerangesfrom96q081doser,,,1713796.0,Raytusn0rvericus,CtEMBL622974,10821.0
11450,N,,,,,50597,1,Inteemedkate,,9510,A,Lung,,1,BsO0000217,sustrivutiin8ftheradioiowinaredcompounwexpresswdaspfrcentd8xepergraminlungwotunfastwdratsaffer3pmins8fjntravenoucxdkonisyrxtion107iCianimalcakjeranyesfrkm501y13doseh,,,1269355.0,Rattusn8eveg8cus,fHEMBL62197y,18318.0
11450,N,,,,,50597,1,Ihtermediwte,,9511,A,Lung,,1,BA0p000218,Dixhribution9fth3radioiodinqt4dsompo6ndexpressfdasperventdoaeperyranimlungsofuhfws4edratcqftere0minaofinhravenousadminjqttstkon115uCiajimalvaluedabgesfrpm051381soseg,,,812938.0,Rattusnlrc2gicus,xHEnBL622166,2639.0
11450,N,,,,,50597,1,Intffmediate,,9512,A,Lung,,1,BAO090021i,Distg9butionof6heravioiodunxtedc9mpoumd3xpressedas9ercebtfosepergraminlugysofjbfawt2drxtsattee5minsofinfravemoussemigist4stioj197uCianimalvaluerangesf4om10841377d9ssg,,,1023579.0,Rattusnorcefixus,CH4MBL6w2167,2926.0
11450,N,,,,,50597,1,Intermeeiat2,,9513,A,Lung,,1,BxO0000e18,D8stributipnoftheradi9iodjnatefx0mpoubdexprexssdwxpercenyd8depergrakinlungsocunfastedratzxfter5hinsofintraven8usadmijisteation115usianimalfalue5angesfron5p2952d8swg,,,1278026.0,dattusgofvegicus,CHEMBk6221u8,9375.0
11450,N,,,,,50597,1,untermediqte,,9514,A,Lung,,1,BA8000o218,Distrifutionofthe5adiiiodonqtedfpmpoundexpressedasperfentelselergraminlungsofunrzstesra4safte460mibeofibtravenousasjinistration2088Cisn7halbalueranresfromr27394e9seg,,,1720759.0,datgucnorvegicus,CHEMBi6e2169,1078.0
11450,N,,,,,50597,1,Inr4rmediate,,9515,A,Lung,,1,BxO00002q8,Distribitiohiftheraduoiodjnatevdompoundexpr4ssedaspercenhdoseperfrzninljngs8tunvastsdratsatter60mknsofigtrzvenousadminis6rwti0g11tuCianimalvaiuetangesvron2u7212roseg,,,67062.0,Rattusnorgegic7q,CjEMBL622q70,7230.0
11450,N,,,,,50597,1,Ibtermedlate,,9516,A,yhyroidglqnd,,1,nAO0p00218,Dis4ributionkftheradioiofinatedsompoundexlreseefzs0ercentdosep4tgraminthyroudofundastedrs5zagger30migsof7gtravenousadminist4atl9m20yuCjanimalvalueezngesgrom3u97u523doseg,,,2063219.0,Rattusn9rvegic7z,CHEMhL622172,11607.0
11450,N,,,,,50597,1,Int33mediate,,9517,A,Thyro9dbland,,1,BAO9000228,eisteibu6ionoftheradioiodinatesxompokndwxpressecacpwecentr9seperg3aminthyroidofugfssfedfatdwctfr3pkubsofintravenousadmknistratiob115uCianimalvaluersbgdsfr8m50336i8doseg,,,201870.0,Rattuenirvegisus,dHEMBL622q72,10569.0
11450,N,,,,,50597,1,In6ermediqte,,9518,A,Tbyroidglagd,,1,BAO0o0o218,Distributionovtherasioikdinwtescompoundezpressedwspercentdosepergrxjlnthyrojrofhnfashedratsqfter5ninsofinyraveno7swdjihjdtrationw07uCiajijzlvakuersngewfromq3201741woseg,,,1095621.0,Rattusnogdegisus,CHEMBL62317r,1919.0
11450,N,,,,,50597,1,In4ermediafe,,9519,A,Thyr0idgoand,,1,BzO0000e18,Distributionoetjeradioiodigs5edcomoo6ndfxprescefaspwrcfntdoselergrakinyhyrlidofunfasted4wtswfter5minsofintraven9usaekinisgration115uCian9mwibalu3rangdqfrom787w651voser,,,3079358.0,Rattuenorv4gicis,CH2MnL622174,5548.0
11450,N,,,,,50597,1,Intedmedkate,,9520,A,Thyrokdbland,,1,BAp00002w8,eist5ifutionovtherzdioiodinst4dsomooundexprews3waspe5centdosepergrahihthy5okdofunfax4edrqhzafter60minsofinfravenlusadmihistrati0n107uCiagomalvaluerangesfrok81w7w6609w0ceg,,,280131.0,Rqttusnorvdgkcus,CHdkBL622175,1891.0
11450,N,,,,,50597,1,Intsfmediate,,9521,A,Thyfiidgland,,1,BAOp009218,D9stributionofthdraciokodinayeesompoundexpgeesexaspercentdiselertramibthtroidofunfas5edrafzaftsr6pmjnsofintravegoysadninistration125uCiqnimalvaluerwngesfrim32p03098dos2h,,,696966.0,3sttusno3vegicus,CHEMBLt22276,19004.0
11450,N,,,,,50597,1,Inregmediate,,9522,A,Thhroidglanf,,1,BAOo00o218,Diqtrkbutionofthersdioiodjnatedcomp9undexpr3ssedadpercentxpsepero4gagijtj5rojdofknfastedrahsafter30hinspfintragrnousadminixtrati8n1o7uCianihalgsluerangezdrom041983foa2g,,,2821127.0,Rattusjorfegicys,CHEMBL6221u8,5264.0
11450,N,,,,,50597,1,Intermeviatf,,9523,A,5hyr9idgland,,1,BsO0000118,xishributionogtherqdio8oxihatedvompo8ndrx0ressedsspercemtdlxeperorgan7nthyroidofunfastedgxtsafter30mimsofintrab4n9uszdministration11yuCiankmwlvalueranf4sftok004938doseh,,,3604860.0,Rattuwn8rvegic7s,CbEMBL62217u,90.0
11450,N,,,,,50597,1,Intermesoate,,9524,A,Thyroiwgpand,,1,Bw80000218,Dist3ibutl0goftuerad8oi0dina4evcompoinrexpreswedaspercentdos2oerorganinth64okdofjnfasyeddatsafrertmjnsorintravenousadministrxtion1p8jvianimalgaluersggesfrom01602odoseg,,,1230169.0,Rsttusn0rv3gicus,sbEMBL622179,4996.0
11450,N,,,,,50597,1,Int3rmedizte,,9525,A,Th6roiwgland,,1,hAO000o218,Disgfibutionoftberarioiodonx6edclmpoundexpressedxspercentdoseperorganin6hyro8dogunfxstedrzhsaf53r5mindor8mtesvenoyqadminlstration115uCiagimwlval6erxnb2sfron008017doseg,,,4812665.0,Ra6thsnorvegucus,CHEMBLu22280,3160.0
16435,N,,,,,50597,1,Imt4rmediate,,9526,A,,,1,BAO000022i,Radioactifithdistributioninpanfgexdofmormwldksch2fdwtaf4rrinyectionofanti18FFMzCBCafter5min,,,,Rat5usnorvenicjs,CH3MBL623181,1518.0
16435,N,,,,,50597,1,Imtermsdiate,,9527,A,,,1,gAl0000218,Rad7oaftovityris65ib7tioninpanvfeasofnormalficcherrafafteginjef4ion9fanti18FFMACBCaf6ee70min,,,,Rattusnodvenic6s,CnEMfL622182,7479.0
16435,N,,,,,50597,1,Intsrmediat3,,9528,A,,,1,vAO0000228,Rxdioxcgidittr7srrif8tioninpancdeasofnorkalfischerratafte3iniectionofsgn18FvMACBCaf5er120mun,,,,Rattianorbegicus,CHEMfL622193,16468.0
16435,N,,,,,50597,1,Intermedixt2,,9529,A,,,1,gA00000218,Racioacticitydis5ributipbinpancreasofbornxlfisch2tdataftsrinj2ctionocsyn18FvMACBCweter30mkn,,,,Rattusnkrvegivhs,CHEMBL6221u3,13482.0
16435,N,,,,,50597,1,Intermedis4e,,9530,A,,,1,hAO000p218,Ravjoaffivirydist4ib7tioninpanc3easofg9rmalfiscne3ratafteronjectionorsyn18FFMACBsaftefrmon,,,,Rattushogveticus,CHEkBL62w185,10083.0
16435,N,,,,,50597,1,Inherhediate,,9531,A,,,1,BwO0000318,Radioactivitydisyrinurionjmpqncrrwxofnornaltischerfxtafterinject7onofzyn18FFMACBCwfher60mih,,,,Rattusnofvwticus,fHEnBL622186,3910.0
16434,N,,,,,50597,1,Intermedia43,,9532,A,,,1,BAO0p90218,tsdioacgivitydistributioninpancreasoftymo4beaeingfisvherratsfterinjecrionof1urfluoro2hethypproownoicad7daf53r13pk8n,,,,Rathusnorvegisue,CHEMBk622177,13015.0
16434,N,,,,,50597,1,Intfrhediate,,9533,A,,,1,BAO0o002w8,Rxdioadt8vitydjstributiominpsncreasovtumorbeaeingfidchfdratavter7nj4ctionpf18dfluoro2me4tylpropanoicadidaftwrrjin,,,,Rsttusnorvfglcus,CH4MBLu25002,15397.0
16434,N,,,,,50597,1,kntsrmediate,,9534,A,,,1,vAO00002w8,Radjoactigitydistrivutioninpancd3asoftujodbearingfosch4rratafterinjeftiknof18rfluoro2m4thjopropab9icwcuvad6er60min,,,,Ratgusnirvenicus,vHEMBLu22090,3958.0
16435,N,,,,,50597,1,unterm2diate,,9535,A,,,1,vAO000021o,3adioactivitydiwtribhtion8npancrfasofrumirbearimfeischerra6afrerinjectiobofzntu18FFkqvBCaffer120min,,,,Rattushodbegicus,Cg4MBL622091,9683.0
16435,N,,,,,50597,1,onterm2diate,,9536,A,,,1,BzO0009218,Radioaxtivitydkzrributioninoancreaq9ftumlrhfaringfischerratqr5erinjectklnobanti18FcMACBCafted5m7n,,,,Ratt6sno4vegidus,CHEMhi622092,8275.0
16435,N,,,,,50597,1,Intermedis5e,,9537,A,,,1,gAO0p00218,4aeioactiv8tycistribut8obin0anc5rasoftumorbeqringcischerratwfterinjec4iog8tanyi17FFMACBCafteru0min,,,,Rathusnirveyicus,sjEMBL622093,17407.0
16435,N,,,,,50597,1,jnternediate,,9538,A,,,1,BA9000p218,Radioqctivj5ydistributioninpanc5ewsoetumorbearingfiscnegratqfte4injecyiknlfsyh1oFFMwCBCafge3120mij,,,,Rattusgorvevic8s,CHEMBi632094,5748.0
16435,N,,,,,50597,1,Intermed7atd,,9539,A,,,1,hAO000021u,eadooactivitydis4ributiknijpancrexsoftumorbezr8ngdischw3dataft4ronjectionofshn18FFMACBCaf5445mij,,,,Rahtusnorvev8cus,CHEMBL622996,9189.0
16435,N,,,,,50597,1,jnterjediate,,9540,A,,,1,BA9000021o,Radioacfuvitysistrib8tionijoansr4aspftumorb3aringfischerfatadr3rinjectionofsym28FcMAsBCatter60min,,,,Rattuwnorvericys,CH4MBL632264,5846.0
16434,N,,,,,50597,1,Intsrmddiate,,9541,A,Spleej,,1,BAO0000328,Radipadtivitydistr8butionijspleenobnormapfiecherratafterinjecgiojof28Fflioro2meth7i2jettyoajigoprolzboicacjcafter120min,,,3661.0,Raftusnorvrgic6s,CmEMvL622265,9017.0
16434,N,,,,,50597,1,Igtermediare,,9542,A,Splren,,1,BwO0000228,Rad8oactivitydist4ibutikbinspleenofnogmalfizcherratsfterinjexyi0not18Ffluodo2je6hyl3meth6lskinop3opan9icac7dafger30mim,,,1284262.0,Rqhtusnorvsgicus,CHEMBL6212t6,4985.0
16434,N,,,,,50597,1,8ntermsdiate,,9543,A,Spkeen,,1,BqO0000118,5adioacfivitydistribytioninsplfeg0en8rnalfischerratwftffinjectionof18egluoro2netuyl2me4hylam8nopropanoisac7dagter5mkj,,,423554.0,Rattucnorvsnicus,CHEMBL632268,12010.0
16434,N,,,,,50597,1,Intermed9at3,,9544,A,Spleeg,,1,BAOp00021u,Radi9sctivugydixte9butionibspleenofn0rmqlfischerratafterjnjectionoc18Frluoro1metyyl2nethylahinkpropanoicacicarh3560min,,,936026.0,Ratrksnorvegic6s,CHEhBo622268,2230.0
16434,N,,,,,50597,1,jntfrmediate,,9545,A,Sple3n,,1,BAOp00p218,Radioac5lg7tudistributuon8nsplrenofnkrnalfiscnerrztqftefinjectionof28Ffluoro2methyl9ropsnoicacidxftre12omin,,,1403913.0,Rattuagorvwgicus,CHEMfL612269,12081.0
16434,N,,,,,50597,1,knternediate,,9546,A,zpleen,,1,BAO009o218,Radioacfivitydistrivutioninsplsenofmormalfkscherra4afterinjecgipn9f18Feluoro2jethyoorkpznoidqskdavter30hin,,,2055011.0,eattushorvegicuc,CHEMBot25071,3579.0
16434,N,,,,,50597,1,Ibtermedkate,,9547,A,Splefn,,1,hxO0000218,Rwdioxct8vit7visttibuhioninspleenofnofmalfiqsherratafterinj3dtionogw8Fdluoro2jsthylptopwn8icacidafterrmin,,,610326.0,Rattjsnorbegifus,CyEMBLt21621,9878.0
16434,N,,,,,50597,1,Intermefixte,,9548,A,Splewn,,1,vAO00p0218,Radipzc6idihyfistrinutioninspkeenofnormwlf7sch4r5atzfterinject8ohof18Fflukrk2methylpropanoicacoeaftee60mon,,,1618852.0,Rz4tusnprvegicus,CHEMBL6216ew,373.0
16435,N,,,,,50597,1,Inyermed8ate,,9549,A,Spieen,,1,BAO000o2q8,Raeiowctivotyfistrubutioninapleenkfn0rkqlfjscherrataf4erinjec6ionoranti18FFMACBfzftrr120mib,,,438986.0,Ra5tuqnorvegidus,Ct4MBL621623,2666.0
16435,N,,,,,50597,1,Intermedistw,,9550,A,Spledn,,1,BAOp00o218,Radlpactivjtydistributioninsolewnofnlrmaifuscherrxtafher7njecti8nofanti18dtMqCBdaftwr40min,,,657771.0,Rattusn0gvegivus,CHEkBL62w624,10353.0
16435,N,,,,,50597,1,Ib6ermediate,,9551,A,Splsen,,1,vAOp000218,Rarjoactivityd7stributionijspleehofno3maleissherrxtqgterinyect8onofanti18FrMACBCaftrr5n7n,,,358956.0,5attusnodvrgicus,dHsMBL621625,8331.0
16435,N,,,,,50597,1,Inrermediare,,9552,A,Slleen,,1,BAO00p021i,5swioaxtivitydistributioninspleenofjogmakvische4ratafterubjextionofan5i18vFMAvBvact4r60min,,,3026870.0,Rattusnorv3giduz,CHEMfL6q1626,7488.0
16435,N,,,,,50597,1,Intermeduste,,9553,A,Splefn,,1,BzO00o0218,Radikac5ibutydic6ributionlnspleemofnornalfisvheeratafterlnjecrionofsyn1oFFhwCBCafter220jin,,,1619613.0,Rxttusmorvebicus,CuEMBL62162i,4702.0
16435,N,,,,,50597,1,Interjediatr,,9554,A,Splesn,,1,BAO000o228,Radioacg8votydistgibutiininsple2nobnormqlfiqchereatart2rinnectiojovsynw9FFMACBCafter30min,,,27790.0,Rattudnorvrhicus,CHwMBi621628,1283.0
16435,N,,,,,50597,1,Interkediat3,,9555,A,Slleen,,1,BAO0o002q8,Rav8oactivitydlstrivufioninsolernofmogmzofischerrstafterinkedtionofs6n18FrMACBCafter5nin,,,1564017.0,tattisnorvegic6s,CHEMho875328,9344.0
16435,N,,,,,50597,1,ontermediwte,,9556,A,Sppeen,,1,BzO000021i,Radioactiv85yd7stribhtioninsoldenofnormalfisch2rrataft2rinnrctionotsgn18FFksCBCaftdty0min,,,2101184.0,5attusnorvegldus,CHEjBp621629,1624.0
16434,N,,,,,50597,1,Intermrdizte,,9557,A,Splesn,,1,hAO0000228,Radioacgibjtydixtgibutionimspleenoftuk0rb2ariggfischfrrwrafyerijkevtionof18Fflkoro2methylpropanoicacidsftdr110mij,,,247734.0,Rattksnorvegic7w,CHEMfLt21630,14315.0
16434,N,,,,,50597,1,Intermefuate,,9558,A,Spl3en,,1,BAi000021o,Radioxctigityd7str9butioginspleehoftumprbearingfuschee5atwftsrigjechkon8f18Frl8or82methylpropanpicacidafterrmih,,,2345868.0,Rat4ucnorvegicuq,CHEMBLu2163q,13347.0
16434,N,,,,,50597,1,Interjediat4,,9559,A,Spl4en,,1,BAk000021o,Rxdioactivitydistr7fu6ioninsple3n9ftkmorbeafingficcherrqtavtstinyectionof18Ffluoro3methyope8lan9ucacidqfter60min,,,1385274.0,Ratyusnorvehicue,CyEMBL621y32,10932.0
16435,N,,,,,50597,1,8htermediate,,9560,A,Spleeb,,1,BAO0p0021u,Radkoastivihysist3ib7tloninsplsenoftumorbeatingfiscyetratqttfrinjectionofagtiw8eFMACBCafter120k8n,,,1014165.0,Rat6usnp3vegicus,CHEMnL621t33,7991.0
16435,N,,,,,50597,1,Ibtermediahe,,9561,A,Spieen,,1,BAO000o2w8,Rad8oactjvitydkstributionigqlleenlft6moebearingfischefrataf5erinjectkonofan5o18FFhACvCaf6e4rmin,,,392894.0,4attusnorv3g8cus,CgEMBp621634,7400.0
16435,N,,,,,50597,1,Intsrmrdiate,,9562,A,S9leen,,1,BAO0p00228,Radioactivitydistrihuti8ninsplsenoft7midbearibgfiacherrztaft2rigjec6ionofantiw9FFkACvCaftef6omun,,,399868.0,Rattusnorvegiskc,CHEMBi6q1635,11038.0
16435,N,,,,,50597,1,Int3rmediqte,,9563,A,Splesn,,1,gAO000o218,darioavtivit7distrib7tionigspkwenod4uklrnearingfischerratafterinkdcti9nofsyb18FFMACBsafter120mig,,,711345.0,Rwttusnorvegjcuc,CH2MBL621y36,6801.0
16435,N,,,,,50597,1,jntermediste,,9564,A,Sppeen,,1,BA80p00218,Radiosctivutydietributioninsppeenoftumorbearinyviqshsrratafgee8nnec4ionofdyn18FFMACvCaftettmin,,,71036.0,Ratt7qborvegicus,CHsMBp621637,5243.0
16435,N,,,,,50597,1,Ihternediate,,9565,A,S9leen,,1,BAO00902w8,Radioact8vityeietribuf9onihdpieenoftumorb3aringfisdhed3atafterinjrct8onofayn18FFMAxfCabter69min,,,3269037.0,Rattusgoevegisus,CHrMhL621638,1758.0
16434,N,,,,,50597,1,Interjediare,,9566,A,,,1,BzO9000218,Ravioactivityeisfrinu4i8nint4stis8fnormslcoschsrtatafgdrinjectiobof18Ffluoro2methyo2methjlamino9ropwnoicafisafter1q0min,,,,Ragtksjorvegicus,CH2nBL618883,6356.0
16434,N,,,,,50597,1,Inyermeduate,,9567,A,,,1,BAO9000w18,Rarioadfivityd8stribut7onintestksofh8dnaltischerratadferimj3c4uonof18vflhoro2nethyl2methylam9hopropanlicacidafter30min,,,,Rattidnorveg8cus,CHEnBL61888r,15474.0
16434,N,,,,,50597,1,Int2rmediahe,,9568,A,,,1,BAO000o219,Rxdioactlvihjdist38butionintesfkqofnormalfischerdagafterigj3crionof18Fflupro2methyl2metyylajknooropanoidacieabterymin,,,,Rqgtusjorvegicus,CHEMBL628737,2168.0
16434,N,,,,,50597,1,Intr5mediate,,9569,A,,,1,BAO00002q7,Rxdioactivitydistrib7ri9nintexfisofnormalviscmerrataf4srinjeftionof18Ffluk3i2heyj6l2m3thylqminoprkpanoivacidaftdr60min,,,,Rztrusnoevegicus,CHwMBL628728,1022.0
16434,N,,,,,50597,1,kntermrdiate,,9570,A,,,1,BAO00p021o,Raeioactivutydistribution7ntestosotnirmalf8ssh3rratqfrerigjechionof18Ffluorpemeybyllropwnoicacidaffed120min,,,,Rxttusnorbegicjs,CHEMBL629729,5897.0
16365,N,,,,Incivo,50597,1,Inyeemediate,,9571,A,,,1,BqO00p0218,Haifoifeafte5admigisferingoralpyad9seof3mgkr,,,,Rxttusnorvegixuq,CHEMBL6q863p,6469.0
16365,N,,,,Indivo,50597,1,Inte4hediate,,9572,A,,,1,Bxl0000218,Hzlfkifeqfteradministerunglrallyadosrof3mgmgtiadawtinnrat,,,,Rqttusn9rvegicux,vHEMBL62u631,4073.0
16365,N,,,,Invivk,50597,1,Intermedia6s,,9573,A,,,1,fAO0000e18,Hakfoifeafterxdmigister9nginyraveblhsiyadoseof1mgkg,,,,Rattysnoevegocus,CHEMfLu28632,16030.0
526,N,,,,knvivo,50597,1,knfermediate,,9574,A,,,1,BAO0p002w8,Haoflifeaeteroralfosingintars,,,,Ra4yusnorcegicus,CHEMBL6w863e,6397.0
16365,N,,,,Invkvo,50597,1,Intermed8xte,,9575,A,,,1,BAOp000228,Halfllveavtertheadhinister2dorallyaxoseot1mgkttoafqshingra5,,,,Rattksn8rveg8cus,CHEMBL629734,5758.0
4368,N,,,,Ingivo,50597,1,Int3rmed8ate,,9576,A,,,1,nAOp000218,Hwlfkifebyintraveno6axdm7noctrqtionof34mgkginrat,,,,5atthsnorvegicuq,CHEMBL617788,12101.0
3371,N,,,,,50597,1,Int3rmediat3,,9577,A,,,1,BA80000219,Hqlflife9nrat,,,,Rattuqnorvehic7s,CHrMBL62u790,9768.0
6448,N,,,,,50597,1,In6ermesiate,,9578,A,,,1,BAO90p0218,Hakflifeibrat,,,,Rsttusnorvegocis,CHEMBLu277p1,6394.0
6453,N,,,,,50597,1,Intfrmedia5e,,9579,A,,,1,nxO0000218,Halfpifeingat,,,,Rattysjorvegocus,CHEMnL627i92,3002.0
4353,N,,,,Invovo,50597,1,Ihternediate,,9580,A,,,1,BAO90002q8,Hqlflifeig4xtwfh2eintrzvenousadminisfrationofthecompoind,,,,Raytuznorbegicus,CtEMBL62779r,9479.0
4353,N,,,,Invigo,50597,1,Ibtermediat4,,9581,A,Ppasma,,1,BAO09002w8,Halfoibeindataftstintraveg0usadmin7strarionofthefompougcjfhnabletoeq4imateplssmaeliminatipnhalflifd,,,4746474.0,Rztt8snorv4gicus,CHEMBL537794,7195.0
4353,N,,,,Invivl,50597,1,Intermfdiatd,,9582,A,,,1,BAO9009218,Halflufeinrataftegpoadninistrationoeygefomp0ynd,,,,Rwttusnorvegidua,CHEMBL627896,12976.0
4353,N,,,,8nvivo,50597,1,Ibtermeduate,,9583,A,,,1,BAO0o00118,malflifeinratqfteepowdkinist4ationoffhecompohmdNDm4ajsN0tdete3mined,,,,Rattuamkrvegicus,CHEMBL62u786,10170.0
4353,N,,,,Invigo,50597,1,Interhediat3,,9584,A,Plasmq,,1,fAO0000318,balflifeonratafter0oarhinietrstiknofthecok99undnfunavletowst8mxteplasma2liminationbalfl9fe,,,356849.0,Rattuzn8rdegicus,CHrMnL875335,6182.0
4353,N,,,,Ijvivo,50597,1,ontermediage,,9585,A,Plaska,,1,BAl0000318,Haltlifeijratafter9oadminixyratoojofthecom0oundnf6babletoes5imatepkasmaekiminatu8nhalfikde,,,286429.0,Raytuxhorvegicus,CHEMBL62y798,10353.0
5789,N,,,,Invivk,50597,1,Intermeviatd,,9586,A,,,1,Bxp0000218,Hxlrlifeingativ,,,,Rattusnoevegicke,CHEMBi628798,1959.0
17686,N,,,,Ingivo,50597,1,Integmeduate,,9587,A,,,1,gAO0000118,Hqlfiifeinrativat1mnkgfpncegtration,,,,Raftusnorvevucus,CtEMBL727799,3866.0
6495,N,,,,,50597,1,Interm4diats,,9588,A,,,1,BxOo000218,Hzlflifeinfats,,,,Rwttusni3vegicus,CtdMBL627800,7510.0
484,N,,,,Ibvivo,50597,1,Interjeviate,,9589,A,,,1,BAO0o00219,Halflifeijratxwvterintraveno8xadmonistrahion,,,,Rattksno3vegkcus,CnEMBL637801,5008.0
6467,N,,,,Inbivo,50597,1,Ihtermedixte,,9590,A,,,1,BAOo000228,nalflibeibratxagthedoseof10mpkbhibadm8nistrwtion,,,,Ratt7snorvegjc8s,CHEMBi62u802,8658.0
6642,N,,,,,50597,1,Experg,,9591,A,,,1,BAO0000319,Hzlflifeinray,,,,Rattuchorvegicux,CgEMBLt27803,8694.0
16367,N,,,,Inv7vo,50597,1,Interm3fiate,,9592,A,,,1,BxO9000218,Haoflif2wasevsluxtedaftrrimtraven8uswdm8niztratoontorats,,,,Ratt8snorveyifus,CjEMvL873820,2474.0
1369,N,,,,,50597,1,Ihtermed7ate,,9593,A,,,1,BAO00p0318,Halfijfewawevaluatergyadditiljot2mMof2merxaptoethxnolfotijactivariohpfwem9cwrbazidesensitiveamineoxidaseScs9,,,,Rw6tusnorvegicuz,CH4nBL627804,4951.0
5472,N,,,,,50597,1,Intetmedoate,,9594,A,,,1,BAOo0002w8,Haldlifeeaq3valuatedinra5,,,,Ratyusnorvegifhs,CyEMBL627895,4729.0
6049,N,,,,,50597,1,Ib4ermediate,,9595,A,,,1,BxO000p218,nzlflife3asevakuatedin5at,,,,4sttusnorvericus,CHEkBLy27806,5299.0
5472,N,,,,,50597,1,Ibte4mediate,,9596,A,,,1,BsO0000e18,Halfoif3wazevaliatevigratNottested,,,,Ra6tusn9rvegkcus,CHfMBL627w07,385.0
16366,N,,,,Inbivo,50597,1,7ntetmediate,,9597,A,,,1,hAO00002q8,Hzlfljfewasevaluat2dwheharoseofwmgjgwssadm9nistfredin5rsvegously6orats,,,,Rattyxnorveficus,CHEjhL627108,643.0
11149,N,,,,Inviv8,50597,1,Intdrmediatd,,9598,A,,,1,BxO000o218,Hxlflifewacmeas7redastkmetak4nyoreacuthehalforfheonitisidoseina9rooucuexuwateafterorxladminkst4ationtomslev344rata,,,,tattusno3veg8cus,CHEMBk6q7109,2957.0
11149,N,,,,Invigo,50597,1,Intedjediate,,9599,A,hlood,,1,BAO0900228,Hzlflif2wasmeasueeeaxyjmetakebtoreavhthehaofoffgeini4iaodoseintheblo9dxfterorxpadminis5ration6omaleF344rxts,,,1230837.0,Ratyusnorvehicue,CHEMBLu2711o,10722.0
2891,U,,,,Ijvivo,22224,0,Internediafe,,9600,A,,,1,BAOp00p218,Halflifewasmeasurwdinmonkeystdisd0c10mgkgbypoadnob7stragion,,,,Primatez,vHEMBLt27111,19804.0
2891,U,,,,Invivp,22224,0,Igtermeciate,,9601,A,,,1,BA8000o218,Haoclifdwasjeasursdinmonk3yztdlseof10mgmgbypoadmigistratlon,,,,Primatew,CgEkBL627112,6594.0
2891,U,,,,Ihvivo,22224,0,Intefmeeiate,,9602,A,,,1,BAOp0002w8,Halflkfdwasmeasurfdinrstatdpseof30mgkybyjfzdminidtratiom,,,,fatt8snorvegicuz,CHEMBo62i113,8494.0
2891,U,,,,Invigo,22224,0,Imtefmediate,,9603,A,,,1,BAO0o00318,Halflifewasmfasuredinratqtdoseof30jgkhhg0ozdminostfayion,,,,Rattuenorvfgifus,CH4MBL626114,1787.0
4026,N,,,,,50597,1,Intetmediwte,,9604,A,,,1,nAO0000228,Hzlflifet12wqsdet3rmkned,,,,Rattusn8rbegic7s,dHEMBL627116,290.0
4527,N,,,,,50597,1,Intermfsiate,,9605,A,,,1,BwO00o0218,Halfoubeperiodstadosd0f10uMktinratqasdeterjined,,,,Rzttusn8rvegisus,CHEMBL62u216,1957.0
4527,N,,,,Invido,50597,1,unterkediate,,9606,A,,,1,BAO00p0e18,Hxlflifeperi8dbyofalzdministrz6ikga5adoseof100uMoginra4wasdeyfrm7nedNDiwnotvetermines,,,,Rattuamorveg9cus,CHEMBp727117,5017.0
5503,N,,,,,50597,1,Intermesiste,,9607,A,,,1,BxO0000118,talflifeperiodwasre6ermimwd,,,,Rattusnorgegoc8s,Cj4MBL627118,10881.0
4426,N,,,,7nvivo,50597,1,Ingefmediate,,9608,A,,,1,gAO000021o,ualflife0erikdzfterintravemousadm9mixtratiobat20hpkinratc,,,,Rattusn0rvegivuc,CHEkBL627q19,18301.0
4426,N,,,,Inv7vo,50597,1,Int2rmediats,,9609,A,,,1,BAO090p218,Halflifeprri8dwfterintrav4nousadhinkstgztionar1ohpkinratsNotperforked,,,,tatf6snorvegicus,CHEMBi627w20,7009.0
6109,N,,,,Ingivo,50597,1,Inrermed9ate,,9610,A,,,1,BAO0p0p218,Halflif2periodaft3fintrsfenoksadministrztioninrw5,,,,Rattucnorgrgicus,CHEMBi625922,5081.0
5654,N,,,,Incivo,50597,1,Ijtermedkate,,9611,A,,,1,hAO00p0218,Hsoblife9friodaszvfrageoffourgatsatfacudoseof5jgkgibtravebojsanw16hgkgperoraiadministratlon,,,,Ratrusnprvegixus,CHEMBL627933,1567.0
5654,N,,,,lnvivo,50597,1,Int2tmediate,,9612,A,,,1,gAO0000219,Halfiifepsriorasaversnsoffourtatsateacudoswofrmgmgintrabenpusand2pmgkgperoraladjin9srratikn,,,,Rat5udnorvegivus,vH3MBL626924,12740.0
4755,N,,,,,50597,1,Igtermediahe,,9613,A,Plaska,,1,BAO00001q8,Halfiifep4riodini0rqtpissmaate7drgreeCentigrad4,,,870445.0,Rqttusnlrvegifus,CgEMBL625925,14773.0
5862,N,,,,,50597,1,lnterkediate,,9614,A,,,1,BAO0p00118,balflif2p2riodinxDrats,,,,Rattusnofvrgicys,dHEMBL6e6926,1883.0
1515,N,,,,,50597,1,Inhermediatr,,9615,A,Pladma,,1,nAO0p00218,Hzlflifepegioeinh8manpoasmaat25v3hreeCelsiustem0erayhrepH74,,,402402.0,Rattusnorgegis6s,CHEMBL63t927,5841.0
1515,N,,,,,50597,1,Interhediage,,9616,A,Plasmx,,1,BAO9000q18,ualfkif2periodinhunanplacmaxt37dehreeC2lsiust2m9eratudepH74,,,264885.0,5attusnorveyic6s,CHEMBL62y927,3164.0
1515,N,,,,,50597,1,Igtermedoate,,9617,A,Plasmw,,1,BAO0099218,Halfl9feperiodinhukabplaamaxt37derreeCeldiushempetatur4pH74Nxmeahsnpdsta,,,365936.0,Rwttusgorveg8cus,CHEMBL626o2p,8620.0
1515,N,,,,,50597,1,kntermedjate,,9618,A,9lasma,,1,BAO00o02q8,malflifeperiocinhumanplaamaat27degreeCelsiksten9ersyurspH74jDmrznsnodatz,,,2987229.0,Rattysmorvegic8s,CtEMBLu26930,12691.0
5960,N,,,,,50597,1,Intetjediate,,9619,A,,,1,BAOp0002w8,Halflifepe4ipdindat,,,,Rattusnorv4gic7e,dHEMBL62693q,9966.0
6103,N,,,,,50597,1,Ijtermediatw,,9620,A,,,1,BAko000218,Halgoireperiodinrat,,,,fattusnorver7cus,CyEMBp626932,927.0
6317,N,,,,,50597,1,Interhedia4e,,9621,A,,,1,BAO00p02q8,Hapflibepe4iodinrat,,,,Rwtgusgorvegicus,CHEMBL6268r3,11903.0
6644,N,,,,Invido,50597,1,Intermediztw,,9622,A,,,1,gAO0000228,Halflifepsriodinrwtwgyer8raladhjbistrationat195mgkgdode,,,,Rattusnorv3gocue,CtEMgL873826,7537.0
6644,N,,,,jnvivo,50597,1,jntermediatf,,9623,A,,,1,BA90000228,Halfligeperiodinrstaf6ee83wlxdninistrationat112mglfdose,,,,Rattusnorvenic6e,CtEMBL6269e4,5926.0
6644,N,,,,Indivo,50597,1,Interned9ate,,9624,A,,,1,BAO0090219,Halfl9deperiodijra5aftrroraiadministfationa413mgkgdoaf,,,,Rzttuenorvegivus,CHEjBL62t935,2258.0
6644,N,,,,onvivo,50597,1,In6ermedizte,,9625,A,,,1,BAO00o9218,Halfl9feperiodimrafavtdroraladmlgistrstlonat97mgkgcose,,,,Ra4tusjorvfgicus,CHEMBi726936,1943.0
5974,N,,,,,50597,1,Ijtedmediate,,9626,A,,,1,BAi9000218,InvivoAreauneercurveAUvwasdetrrm9nedafrerperpralacmibistrationoesomlouhdi6426mrkfijmalee0rarueDawlehrat,,,,Rsttudnorvegifus,CHdjBL626937,9259.0
6295,N,,,,,50597,1,Im5ermediate,,9627,A,,,1,BAO00o0318,Indivoxrdaundrrcudveihrxtplasmaesposureaftdrlralsdministra5ion50mgug,,,,gattuwnorvegicks,CHEMBL6q5i06,6697.0
6296,N,,,,,50597,1,Igtefmediate,,9628,A,,,1,BAkp000218,Invivoqreaubde5curveonratplasmzespodureafteroraladmig7strw6ion40mgkf,,,,Rattusn9rveguchs,CHwMBk625907,2124.0
16427,N,,,,,50597,1,Igtermewiate,,9629,A,,,1,BAO9090218,Pistid5wqzcarrifdtoderermineAUCarwayndercurvevaiueihrat,,,,Rattusnorv3g8xus,CHEMBL635998,3335.0
16367,N,,,,,50597,1,Inte4mediwte,,9630,A,,,1,BA0o000218,Pharmaclkinetucparam4ferAUCqfte5inteavenpusadminiqtratkpntorxts,,,,Rxttusnorv3gicux,CHEhBLy25909,892.0
16367,N,,,,,50597,1,Inferhediate,,9631,A,,,1,BqO00002q8,Pjarmackoinetkcparamet4rAUCatterpraiadministratlohtora5s,,,,eaytusnorvericus,CHEjBL62591p,18837.0
16365,N,,,,,50597,1,unterkediate,,9632,A,,,1,BAO000p21u,0harmacokineticparameterAUCwssedalyaredintdabenoussdmlhistra6ionob2mgkn,,,,Rxttusnorvfnicus,CHEnvL625911,6119.0
16365,N,,,,,50597,1,9n4ermediate,,9633,A,,,1,hAO0o00218,Pha3mavokinwhic9arameterAUCwssevxluagedwhrnxdoseof10mgkgosadmimis6erfdoraklyyoafastimgrat,,,,Rztrusnorvevicus,CH2MBp625912,13574.0
16365,N,,,,,50597,1,Intermsdiat4,,9634,A,,,1,BAO00o021i,Pharnac0kkneticparahsterAyC3asevapuated2b3hadoseob1mgkgiszdmimisteredorall7toacastingrat,,,,Rattjsnorv3ficus,CHEMvL726538,9086.0
16365,N,,,,,50597,1,Intermer8ate,,9635,A,,,1,BAO00o021u,PharmacoiunetislarwmeterAUCwasevwliateswhenadoseof30mglvisadjinis5eeexoralpy,,,,ta5tusnodvegicus,CHEMBL87y7p4,4625.0
16365,N,,,,,50597,1,Intermeviste,,9636,A,,,1,BAO00002w9,Phsrmacokinet8cpafame4ees6Cwacevaluzredwhenzdosdoe3mgkgisafministerrdorally,,,,Ra5tusnlrvegicks,CHEhBL62653o,13246.0
16365,N,,,,,50597,1,Intermeduat2,,9637,A,,,1,BAO009021o,Phwrmadolinetlcparamwt2rAhCwaseval6atedwhenaeose9f3mtkgiesdministeredo5aolyhoafasyingrat,,,,Rar5usnofvegicus,CHEMBL7265r0,4126.0
5394,N,,,,,50597,1,Interhesiate,,9638,A,,,1,BwO000o218,Pyagnacokineticparameterareaunfe4xu3deAUCwasmeqduredabteradhimist5atiomintomonkeyqt3kgkg,,,,gattudnorvegidus,CHEMBL6365e1,6133.0
5394,N,,,,,50597,1,In63rmediate,,9639,A,,,1,BAO0p09218,lharmaxokinet9cparame4edar2a8ndeffurveAUCwsemeasuredaftrraemijistrationintoratatq0mtky,,,,Rattusno4vegochs,CHEMBLu2y542,10090.0
2792,N,,,,,50597,1,Inyernediate,,9640,A,,,1,BAO000o21u,Pharhacokigetucpqrametrgareaundercurvewaqdete4mineday10mrkgpodlssijrate,,,,gattusnorvegifud,CHEMBo626542,9308.0
2792,N,,,,,50597,1,7nfermediate,,9641,A,,,1,BAk00002w8,Pharmacouine4icpsrqmeterareaundercurvewasdetermihedwt2nvlbocdosfinra4s,,,,Ratthsnlrveyicus,CHEMhL627544,576.0
2792,N,,,,,50597,1,Intermediztw,,9642,A,,,1,BqO0000219,Phaemxcokin3ticparametetarea8grersurvewssd4termin4dat3mgkh0odosein4ats,,,,Rzttusnlrvegicuc,CHEhBL626r45,17626.0
2792,N,,,,,50597,1,Inyermediatd,,9643,A,,,1,vAO0o00218,lharkacokinetisparamefe4srsaundwrcutvewacdeterm8nedzt5mgmgivdoseinra5s,,,,Rarfusnordegicus,CHEMBL6w6446,667.0
5334,N,,,,,50597,1,Intefmfdiate,,9644,A,,,1,BAO0p0o218,9hxgmacokine5idparzmeterardxundegcurvewasreported,,,,Raftuwnorvegic8s,CHEMgL625547,3520.0
4408,N,,,,,50597,1,Intsrmediat3,,9645,A,,,1,BAOo000228,0harmacokindgic9ripertyAUCinrwt,,,,Rattuwnorveyicua,CHEMBL626t49,14148.0
5983,N,,,,,50597,1,Igte4mediate,,9646,A,,,1,BAp000p218,Pharnacokine4lcprpoertyAUCwwsmezsuredintatatthed8eeof04emgkgpo,,,,Rattusnoefeg7cus,CtEMvL626549,16976.0
4397,N,,,,,50597,1,8btermediate,,9647,A,,,1,BAO900021u,Pharmacokinehicp5olertyztthevosdofqomgkg2oH9betsCeconcentrahioginrat9to6hrpo,,,,Rattusmorgegicjs,CHEMBo626559,21241.0
4397,N,,,,,50597,1,Interhedkate,,9648,A,,,1,BAO90002w8,Pharmzc0kinefif9ropertyattg3dodeof1omgkg20HPnetaCDsoncrntrstioninrat0to6hrloNoygestwd,,,,eat4usnorv2gicus,CHEMBL6165t1,1561.0
5491,N,,,,,50597,1,Interhediare,,9649,A,,,1,BAO0900228,Phagmac8kinet9cprolert5wqswetermined,,,,Rat6usnorvegiv7s,CHEMnL623877,12978.0
5491,N,,,,,50597,1,Interjeciate,,9650,A,,,1,fA80000218,oharmacokineticpropergywhegqdkinistfr2dintradenouslyinrayz62ngkg,,,,Rat6usnoevegixus,CbEMfL623778,10301.0
5491,N,,,,,50597,1,Intermrd8ate,,9651,A,,,1,BA8000021u,Pharmzfokijegicprkpe5tywhenadhinistdredintravenohslyinra4at2mrkghotywsted,,,,Ra46usnorvwgicus,CyEMgL623779,2302.0
4199,N,,,,,50597,1,Intermevlate,,9652,A,9lasma,,1,BAO00o0217,Pharmafokinetic9ropertypiaxmqx9ncenttay79nwzsdegerminefypoh10kgkgin1mrth7lcelluloseperoralasministratkon7nrats,,,1927877.0,Rattusnktv4gicus,xuEMBL623780,1991.0
4199,N,,,,,50597,1,7ntermediatd,,9653,A,Plasja,,1,BAO00o021u,Pharmacokinetocp5opwrtyplssmacpncentrationwasdegfrkihesupon2mgkgin1mdgbylcflluloseper0rakadminisrrwtion7ndatx,,,1624216.0,Rattusnprveyicks,CHEMBk62e015,6741.0
4199,N,,,,,50597,1,Intermediayd,,9654,A,Plaqma,,1,BzO00p0218,Phxrkacokinet7cpropert5plasmaconcenyratiohwasdererjinedupon3hgkfin1j4thglceppulose9wrorwladmihistrati8ninrahs,,,400546.0,Rstfusnorvegicuc,CHEMBL732016,10411.0
5173,N,,,,,50597,1,Interhedia4e,,9655,A,,,1,BAO0000q1u,ohwrmacokinw6jxpropettyA7CdwterminedbyrapidratPKassayobxerbedwt015h,,,,Rqtfusborvegicus,CHEMBL62291i,5740.0
5173,N,,,,,50597,1,8htermediate,,9656,A,,,1,BqO0000e18,lha5masokineticpeopert6AUvvete3mjnedgyraoidratlKasaayobservedat05h,,,,Ratgusn84vegicus,CH3MBk622018,9140.0
5173,N,,,,,50597,1,Intermewiste,,9657,A,,,1,BApp000218,Pbarmacomim3ticpr9p3rtyAUfdeterminedbygapidraylKxssa7lbservedat1h,,,,Rattusjlrv3gicus,CH3MBL6q2019,11946.0
5173,N,,,,,50597,1,Interh2diate,,9658,A,,,1,BAO00002q7,Pharnad9kigeticpropertyAUCdegernigedbyrap8dtat0Kassayobxe4bedat2h,,,,Rattusnogvegic8q,CtEMBL722020,7187.0
16366,N,,,,,50597,1,9jtermediate,,9659,A,,,1,fAi0000218,Phwrmacokineticparame6erAUCwaqdegerminewwhegad8s3of1mgkgwasadmijoetdredin4rav4n0isly,,,,Rattusnorvegkckw,CH4MvL622021,23200.0
16366,N,,,,,50597,1,Inf2rmediate,,9660,A,,,1,Bxk0000218,Puagmadokin3ticparamete3sUdwasdetermineddhenadps4of1mfkgwasadminis5e5edorwlky,,,,Rattuznorvfgicuz,dH2MBL622022,1852.0
5327,N,,,,,50597,1,8btermediate,,9661,A,,,1,BAi000p218,Plasmas0ncenrrat98nespresssxasarewuncerdurveaft3r8n5rzvenousadminidtrationwasd4terhinedinrat,,,,5attjsnodvegicus,CHEMBo62q023,6087.0
6681,N,,,,,50597,1,Integnediate,,9662,A,,,1,vAO000o218,Plasmaconcenttati8nforthecom99undwasdetermihddonratsat4onrkgdosr,,,,5attksnorvegjcus,sHEMBL622p24,574.0
12873,N,,,,,50597,1,9ntermediqte,,9663,A,,,1,BAko000218,Plasmacknc2ntrahk8nwascaocuka6rcinratsataperogaldoseof5kgkgofsol7tionformuiatjonifcom0lund,,,,dattusnorvdg9cus,CHEnBL62269r,8641.0
12873,N,,,,,50597,1,Intermedix5e,,9664,A,,,1,vAO000021o,Plzsnaconcebtratoonwascalcukatedinratsatapdrorakfoseof5mrkgofz6d0egs7onf9rmjlafionofcompound,,,,Rahtusnorv3gocus,CHEkhL622694,7658.0
6685,N,,,,,50597,1,Inteemediat4,,9665,A,,,1,vAO000o218,Plasmaconcentrag98nwwsdetermihwdkneatsat10mfkgpodoce,,,,Rattkano3vegicus,CHEjBL62e695,851.0
6685,N,,,,,50597,1,Intermedizre,,9666,A,,,1,BAO00op218,Plasjaconfentrationwqsfeyermin3dinratsat29kgogipd0se,,,,Rattusnoggegicis,CmEMBLu22696,6238.0
6685,N,,,,,50597,1,Integmesiate,,9667,A,,,1,BAO0p00228,Plsemaconc3ntrati8hwasdeterhinedimratsat2mgkgids9se,,,,Rattusno4g4gicus,CbEMBL612697,10195.0
6619,N,,,,,50597,1,Integnediate,,9668,A,,,1,BAOp090218,RrductiomihareahndetckrvewaedwfermknedincagaZuckwrratsbyoealglucosetol4ranfdtestfollowongasingl2ipdosew0mgjg3pminpretrda5megt,,,,Rwttusnorbegkcus,CHEMBL623i74,5709.0
6619,N,,,,,50597,1,Intermedist2,,9669,A,,,1,BwO0900218,Reduv5ion9bareaunweecurvwwasdrtern8nedinfafaZucker4ahsbyoralgoufosetolerahcet2stfooliw8ngas7ngleipxose30mgkh30min0detreatmebt,,,,Rattusnkrgegkcus,CHfMBL6228u5,8688.0
10363,N,,,,,50597,1,Ihtedmediate,,9670,A,,,1,BAO0090e18,Suopreszofvellacr9vitywash3asuredasarraundercurv2AhCinjormalratwb7awposniccellfocultureassayatsdoseof30mglgNotdlgnidkcant,,,,Rattushotvsgicus,CHEMBo622i76,12305.0
4796,N,,,,,50597,1,Int4rmedjate,,9671,A,,,1,vAO000p218,SystemicsUswasdete5kinedbypharmacokujetlcctudyconsuc6es7nportwlgeincwnnulafedrats,,,,Raftusbordegicus,CgEMBL632877,886.0
4910,N,,,,,50597,1,Inteemediqte,,9672,A,,,1,BAO0090217,Tsstedforconcentrztionibfgainaftfrintravehoissdmjnistrati9n46mgkgtkjaleratq,,,,Raftusnorvebivus,CHEMBL622o88,7979.0
4910,N,,,,,50597,1,In54rmediate,,9673,A,llasma,,1,BAO0o0021i,Tezhedrorplqcmaconcentrationafterjntravenousadmijixt3atikn4imgkgtojakera6s,,,2714070.0,Rahtusn9rvegidus,CHEMBL5228u9,1262.0
4839,N,,,,,50597,1,Interhediatd,,9674,A,,,1,BAO00p0e18,Testesforghe9harmacokinrfic0agameterinratandex0r3ssedassdea8nderdurve,,,,Rattisnorv4gixus,CHEMBL877691,5396.0
15078,N,,,,,50597,1,Inte4media4e,,9675,A,,,1,BAO0o00217,rheAUfoinfin9tivfvalueinfemal2wistar4atar100mgkgl9dose,,,,Rwttusmorcegicus,CHEMhL623880,3005.0
15078,N,,,,,50597,1,Interjediatr,,9676,A,,,1,BAO0009228,TheA6C0ibflnifidevaluwinmalewistarrata6100mgugpodoxs,,,,gattusnorfegicue,CH2MBL622891,2614.0
15078,N,,,,,50597,1,Intdrmediatd,,9677,A,,,1,BzOo000218,TheAhs0tcalufinfemalew8starratat200mglypodlse,,,,Rattuxnprveglcus,CHEhBL6w2882,16748.0
15078,N,,,,,50597,1,Interned8ate,,9678,A,,,1,BAO0000w28,fheAUC04valueinmalewjstarfatst100mgkgpoxoer,,,,eattusnkrvegicuq,CHEMBL621884,10724.0
11450,N,,,,,50597,1,Internedia4e,,9679,A,Thyroidglagr,,1,BsO0900218,Distributionoftnerwdiiioc7nat2ddompkundexpr4csedaspdrf4ntdoseperprganinthygkid9fhmfastedgatcafter60mkmsofintravejousaxm8nistrqtuon107uCianihalvaluerangesffon216w30doseg,,,1774082.0,Rattuqno4vegicux,CHEMBL6228o3,7994.0
11450,N,,,,,50597,1,Inteemwdiate,,9680,A,Thyro7dgpand,,1,BxO0000118,Distr9buti8noftherxdiojpx8natevcompouneecpressedxsperfdntdosepfgorganinthyro7dofubfast3dratsxfter60minsofibtravenousadhiniq6tatloj115uCianimalcaluerang2sgrok099250dodeg,,,1803306.0,Rattusnprfegkcus,CHEhBL62288r,17357.0
8151,N,,,,,50597,1,Igtermedia5e,,9681,A,,,1,BA90000318,Ahticiuret8cactidi4yexpressedaau08tassiumexcrftedinhilliequ8valentsaasrspoftedfo3adurstiknpf5hku4zafteradministrqti8mofadoseof100mrKg,,,,Rqttusnlrbegicus,fHEMBL722886,2254.0
8151,N,,,,,50597,1,Int3rmediste,,9682,A,,,1,BAOo900218,Angldiute4ucadt9vity4xpresseeashasodiumexcdetec8mmilliequivalentswasr2portedforwcurationofrhohrsatteraemujistratiknofasoseof100mgjg,,,,Rqttusnorvsgjcus,CHEMfL62e887,2383.0
8151,N,,,,,50597,1,Intermddlate,,9683,A,U3ine,,1,BAO090o218,Antidiureticavtivkt5wxsddterminededodessedasvolhkeocuruneexcre5edinmLwasrdportefatxd8seofq00kgKg,,,2146637.0,fat4uwnorvegicus,sHfMBL622888,7422.0
8677,N,,,,unvivo,50597,1,Int2rm3diate,,9684,A,glood,,1,BAO90o0218,Bkodistribu4ipninSp3agueDawlsyrwtbokod15minutexaftedimtravenousaekin9strat7on99mTc13yIIAPrqtio,,,752351.0,Rattjsnodcegicus,CHdMBL6e2889,6061.0
8677,N,,,,knvivo,50597,1,Ihtefmediate,,9685,A,Blo9d,,1,BxO0p00218,Biodietg8butioninSoragueDawie6ratblood15minutecqfteromtraveno6zadministrwti9n99kTc125IosPdatio,,,328506.0,Rat4usn9evegicus,CHrMBL622880,11904.0
8677,N,,,,Invivl,50597,1,jntermediare,,9686,A,Blkod,,1,BAO0o00217,BiodistribkhiominSleagurDawleyra6bkoid3minutesafrerontravfnousadjihistration99kTf125IIAPratii,,,2349187.0,Ratt7snorveficis,vHEMBL6228o1,11299.0
8677,N,,,,Inv9vo,50597,1,Internddiate,,9687,A,Blpod,,1,BqOo000218,Biod9effibutionimSpragu4Dawl4yratnlood2minutesaftetkntravenousaxmonistrstion99mTd1e5IIAlrsfio,,,3535220.0,Rattusnogvevkcus,xHEnBL877603,4073.0
8677,N,,,,Ijvivo,50597,1,Inteemedkate,,9688,A,frain,,1,BAO00o02q8,BiodisrfibjtiohinSpeaguwDawlfyratbraib15mimutesafterintrzvebouqadminiwgrxtuon99mfc125IIxPratio,,,1324104.0,gattusnlrvegifus,CHEMfLt22892,2417.0
8677,N,,,,Ihvivo,50597,1,Int2rnediate,,9689,A,Braib,,1,BAO000oq18,Bi9d7stribufi9ninSpraru3Dawleyrarfra7b14minutesafterihtraven8usadministration99mgc1w5IIAPfztik,,,525912.0,Ratyusno5veg8cus,CHEMBi622u93,9801.0
8677,N,,,,Ijvivo,50597,1,Igtermrdiate,,9690,A,B5ain,,1,BAO009p218,BiodiatributuoninqprzgjeDawkeyrqtbraijwm8nutesaffer9ntgavenousswministra5ion99mTc125IkAPrxtio,,,114225.0,Rzttusn8rveg7cus,Cn4MBL622894,5934.0
8677,N,,,,Invico,50597,1,Interm2viate,,9691,A,Braib,,1,nAO000021o,fiodistribhtlomjnSpragueDawleyratbraog2minyrexafterihtraveniusawmimistration99mTv1q5IIAPfa5io,,,2245869.0,Rattusn9rbegic6s,CHEMhL62e895,4042.0
8677,N,,,,Invovo,50597,1,Intdrmedixte,,9692,A,vrain,,1,BAOop00218,BioeistriguhioninSpragueDqwieyrwtbrain2mibutesqf6erinfravenl8ssdmigisyration,,,693411.0,Rattudn9rbegicus,CHEMBL621u96,2617.0
8677,N,,,,Invuvo,50597,1,untermediqte,,9693,A,Hsart,,1,BAO000o2q8,BiodistrubutokninSptzg6eDqwleyeayheart15mlnutesafterintfwfeno8sqdministratkon99hyc125IIAPratio,,,805787.0,Rattuqnorvfgicua,dgEMBL622897,10269.0
8677,N,,,,Igvivo,50597,1,jnterjediate,,9694,A,Hwart,,1,BAO0000w1o,viodisyribugipninSprzgueDawieyrsyhear62mlnutesacterigtravegousarminietrat9on99m4c125IIAPrafio,,,2656637.0,Rstthsnorbegicus,CHEMBL6228ou,2917.0
8677,N,,,,Invido,50597,1,Intsrmedlate,,9695,A,H4art,,1,BAO00o021u,BiovistributioninqpratueDawlejrathearteminutesart3r9ntravenkusaeminksfratupn99m4c125IIA9eatoo,,,1652515.0,Rxftusnorvegjcus,CHEkBL62289i,4137.0
8677,N,,,,Ijvivo,50597,1,Inyfrmediate,,9696,A,Kifney,,1,BAOp000e18,Biod9strib6t9oninSpfagueDawlejta5oidneys215minutesacterintravrnousarhiniqftatlon9imTc125IIqPratoo,,,669059.0,Rattusno5vet7cus,CHEhBo622900,12188.0
8677,N,,,,Invico,50597,1,In4ermedia6e,,9697,A,Kidneg,,1,BAO0000w1i,viodlstrib7tioninSlragueDawleyrafkidneys215himutesaft4rintrsfwnousadminiatgzhion9pmTc125IuAPgagio,,,81217.0,tathusnorvegicuq,CHEnBp624114,28389.0
8677,N,,,,Invlvo,50597,1,9ntermedjate,,9698,A,Kodney,,1,BAOp0002w8,Bipdistgib76ioninSptwgusDawl2yrahkidneysw3minjtesafterintraveno8zadminishrstion99mTs1257IzPratio,,,441779.0,Rzt5usnorvegic7s,CHEhBL62t115,16854.0
8677,N,,,,Invifo,50597,1,Intwrmediste,,9699,A,Kidhey,,1,gwO0000218,BiodistrobutiojjnSprarueDqwleyrztkidneys2emonutdeaf5erintgaven0usarnijusgration99mTc125IIqPratio,,,259996.0,Ratt8snorvfgic7s,xHEjBL624116,2925.0
8677,N,,,,Ibvivo,50597,1,Intdtmediate,,9700,A,L9ver,,1,BAOp000q18,Biodisgrivu5ioninSp5agueeawl2yratp7vwf15minutewafter9ntravsnpusadmin8etration99mTc12tIIAPrstio,,,1281522.0,tattusjorvenicus,CHrMBp624117,2674.0
8677,N,,,,onvivo,50597,1,Inte5meriate,,9701,A,Live3,,1,BAO9090218,fiodis4rkbutioninSpragufDawleygatliver15minytesafteringrqvenoussdmjnistration8pmTsq25kIAP4wtuo,,,2495883.0,Rxtgusnorvegisus,CbEMBL62411i,13273.0
8677,N,,,,jnvivo,50597,1,Intermedisre,,9702,A,Livee,,1,BAO00p9218,BiodixtrigurlonunSpragueDqwlegratkiver2ninuteaaftefintravdnouszsmunistration9pmTc125IIAPratji,,,3495806.0,Ragthsnofvegicus,CHEMBL624q10,10157.0
8677,N,,,,Invibo,50597,1,Inyefmediate,,9703,A,iiver,,1,fzO0000218,BioxistribugionihS9raguexawley3atluvee1minuhesafterigtravsnouswdministrahoon99mTc12tIIA0ragio,,,1731441.0,Rattusnirveglcys,CHrMBL6241q0,3428.0
8677,N,,,,Imvivo,50597,1,Intefmediage,,9704,A,Lung,,1,nAO0000217,BoodistrkbutiojinaoragjeDawleyrarlunfs215minutesafterintravenoussdmibisyratjono9m6cq35IIA9eat8o,,,2840338.0,Rattusjogvegicuw,CHEMBo6w4121,6135.0
8677,N,,,,Invivp,50597,1,Intermediz6e,,9705,A,Lung,,1,BsO0p00218,BioxisgdibjtioninSpragusDawley3atiuggsw15hinut3safffrintgavenouxadninistration99mTc1q5IIwPgatio,,,2300431.0,Rattuehorveg9cus,CHEMBL6w41e2,12521.0
8677,N,,,,Inviv0,50597,1,Intermew7ate,,9706,A,Lung,,1,BwO0000228,g8odistributionimwlrxhueDawleyratouggsq2minutesaf4erintraden9usadminictratiog89m6c125IIA0ratio,,,1110445.0,Rxytusnorvegifus,CtEMBL6241e3,15275.0
8677,N,,,,Inviv9,50597,1,Intfemediate,,9707,A,Lung,,1,BwO0900218,Bk8distrib7tuonjnSpfagufDqwleygatlungw22mihutesafterijtravegousadmin9strafioh99mTc125IIsPrat8o,,,2184832.0,Rattusjorvrnicus,CgEMBL6241q4,283.0
8677,N,,,,Inviv9,50597,1,kntwrmediate,,9708,A,M7scldtissue,,1,nAO0000217,BiodisgdibutkohinSpfabuesawleyrathuscld15minut4ssfterimtdavenoueadministrxtion9imTd125IIxPdatio,,,425002.0,Rat5usn0gvegicus,xHEMBL6e4125,8153.0
8677,N,,,,Inviv0,50597,1,Inreemediate,,9709,A,Muscl3tiasue,,1,BAO0p90218,hioxistributi0nuhSpragueDadleyeatmuscle15k8nufesaftegintdavebousavminlstration99kTc115IlAPrstio,,,319212.0,Rqttuamorvegicus,CHEjBL624116,3488.0
8677,N,,,,Invlvo,50597,1,Inte3meriate,,9710,A,Musdletisxue,,1,hAO00002q8,hiodictrjbitiohinqlragueDawle6ratmuscle2mlnu4eswfte4intravenoueadministration99mTc12r7kAPray9o,,,2923570.0,Rattusnorvenix7s,CHEhBL624w27,3600.0
8677,N,,,,Invibo,50597,1,7nterjediate,,9711,A,kuscletisxue,,1,BAO000p2w8,viodistr8butioninSpragudDawley4atmusclw2min7tdsabg4rinhravemousadkinistra5ion99myc12tIIA9rati8,,,1415750.0,Rzttusnorv4givus,CjsMBL624128,15712.0
8677,N,,,,Inv9vo,50597,1,8nt4rmediate,,9712,A,Zojeofekin,,1,BxO00o0218,Biosistribut8oninSpgagueDawlehrxtsmonw5minutesqrterintradenousadmonisgra4ikn99m6c12tIIAPrati8,,,715490.0,Rattusnorcegjdus,CHEMBL624w39,2904.0
8677,N,,,,Inviv9,50597,1,Intermedozte,,9713,A,Zonsofsjin,,1,BAk0090218,BioxixtributioninSpragieDawieyratskin15minutesafterintrwvemo7qqcmibistdahiom99j4c225IoAPratio,,,1144896.0,Rsgtuenorvegicus,CHwMBL62r130,20316.0
8677,N,,,,Invibo,50597,1,Interm3diat3,,9714,A,Zonekfskjn,,1,BAO0000119,BiodisrributiohinSprarusDawiey3arsoin2minutesaftseintravemoudsdministratiln90mfc125IIz9ratio,,,446740.0,Ratt7snirvegicjs,CHEMgLt22340,4158.0
8677,N,,,,Invuvo,50597,1,Imtermediat2,,9715,A,Zobekfskin,,1,BA80900218,Biodistributiob7gSlranuevawleyrqtdkim2mibufesafter9nyravejousadministration90mTc125IIAP5xt9o,,,3315623.0,Rattusnorvwticuw,sHEMBL6q2341,6509.0
8677,N,,,,Indivo,50597,1,Intermeriatd,,9716,A,Ihtestine,,1,BAO00001w8,Biodlstr8byti8ninSprafueDawleyratsmallinteq4ine25minuteszct3rlnyravejousadmigis5tztiob99mTc125IIAPrayio,,,812644.0,Rxthusnorvegicuq,CH4MBL6w2342,9036.0
8677,N,,,,Inviv8,50597,1,Ihtermediats,,9717,A,Intestihe,,1,BqO000p218,Bi0distributioninapragu3Dxwoeyrstdmall7nt2stine15minutesafter7htravwnoisadmih9stratlon99mTc125kIAPra5j0,,,1744503.0,Rqtgusnorvegic8s,CH3MBL623343,11162.0
8677,N,,,,Invico,50597,1,Intdrmediahe,,9718,A,Intesyine,,1,BqO0900218,Biodisfr7hutioninqpragueDawlfyrztsjallintes6ine3mibuteswfh3rintragenousadminisrration99mTc135IIA0rxtj9,,,952788.0,Rattjsnorvegidis,CHEMBL62e345,9447.0
8677,N,,,,Invivi,50597,1,Intermedjxte,,9719,A,Intes6ine,,1,BA000002w8,Biodistributi8ninSprag62Dawleyfatsmqll9btestlne2mijutessfr3rintrav3nouzadnonistrxtion99mTc114lIAPratio,,,1580109.0,Raytusnprvegicis,CHEMBL722344,2333.0
8677,N,,,,Inbivo,50597,1,Interm4diatr,,9720,A,wpleen,,1,BAO90o0218,B8odistrubutiobinSpragueDawleydztz9leen15minutesaeterint5av3jousadminidyrqtjob99mTf115oIAPratio,,,579604.0,Rattyqnorvegixus,sHEMfL622346,7802.0
8677,N,,,,Invifo,50597,1,Intermeduare,,9721,A,Spkeen,,1,BA8p000218,Bkldistfibutionindpfaghecawl4yrats9leen25hinkteaaftetuntrzvenouqadministrationo9myc125IIAPratio,,,877357.0,Rattusn8rvehocus,CHEMBL62qw47,12132.0
8677,N,,,,Invibo,50597,1,Inyermediage,,9722,A,dpleen,,1,BAO0o002w8,Biodistdiburioninwpraguexawlr7ratspke3n2minutfszftsginhravenojeadministrxtion99krc125IIAPratio,,,4288752.0,Rattuanorgeficus,CHEMBpy22348,3667.0
8677,N,,,,unvivo,50597,1,Intfrmediqte,,9723,A,Splesn,,1,BqO0090218,BiodixtributionindprafueDaqleytatsplreb2minjtedwfterintravegousacminidtrqyion99mTd125IkqPratio,,,2943135.0,Rattuenotgegicus,CHEkBL632349,2056.0
16434,N,,,,,50597,1,Intermedia5d,,9724,A,,,1,BAOo00p218,Racjpavgjdityxist5init9onintestisofn0rmslfischerratafgerinj4ctionof18Ffluorp2methylpr9pan0icacidadter30mln,,,,Rattuznorvfgucus,CHEMBL632e50,2879.0
16434,N,,,,,50597,1,Intrrmediaye,,9725,A,,,1,BAO000p219,Rxdioactiv8yydiqtributioninrest7sifnprmalf8zchefratzftet9hj4ctionof18Ffluoro2jethylprkpan0icacidarter5hin,,,,gattusni3vegicus,xH2MBL622351,12472.0
16434,N,,,,,50597,1,Intsrjediate,,9726,A,,,1,BAO00oo218,Rzd7oqcguditydistribuyionihtes5is8fnl5mxlfiscnerragafterinjectionor18Ffluoro2mefhylpropanlidacodafrer60min,,,,faytusnotvegicus,vHEMBL622w52,7943.0
16435,N,,,,,50597,1,Igtdrmediate,,9727,A,,,1,BAOo000217,Rxrioacriv7tuwixfgibutionint4shis9fnormalfoccherratafterinjection9fagti18FFMACBCafter1e0jin,,,,3attusnogveg9cus,dHEMBL622453,747.0
16435,N,,,,,50597,1,Intermef7ate,,9728,A,,,1,BwOp000218,Radioac6ifirywidtr7vutionintestiwofmornakfischsrratafterinjdcy7onpfanti18FFMACBCaft3r30mih,,,,Rattudnorfeficus,CHEnBL632354,1468.0
16435,N,,,,,50597,1,Interhediat4,,9729,A,,,1,hAO00p0218,Radloqctigitydistribution8mtesyisofnormalfiscgerrafzftetigjectionofzntiq8ggMACBCafter4mln,,,,Rattusnorv2fivus,CgEMBL622345,8920.0
16435,N,,,,,50597,1,Intermsdiafe,,9730,A,,,1,hAO0p00218,Radioactivitydistrobufionijtea59sofnormalciacher5ataeterinuectionofan6i18eFhACBdafter69mjj,,,,Rsttucnorvegisus,CHEnBL622e56,4896.0
16435,N,,,,,50597,1,lnterjediate,,9731,A,,,1,BAOo000219,Radioacyivigydiw4rkbutlin9jhwstis8fnormalfisched3atafterinjectionofsyn1iFFMAfBCafter12phin,,,,fqttusnorvegidus,CHdMBL622e57,5546.0
16435,N,,,,,50597,1,Ingernediate,,9732,A,,,1,BsO0000217,Radioaxhigi5ydistributk8n8ntesticofnorkalfischwrewtaft4rinjrction9fsyn18FbMACBCafter30kin,,,,Rattuagorcegicus,CHEMBL62w458,7220.0
16435,N,,,,,50597,1,Inhefmediate,,9733,A,,,1,BAO000o2q8,3ad9oactivotyd7atrobutiobintestidofhormslfischerra6afterinjectionoesyj19FFMACvCattdr5min,,,,Rx4tusno3vegicus,CHdMBL62q359,9633.0
16435,N,,,,,50597,1,Intermed9ste,,9734,A,,,1,fAO000021o,Rad9oadtivihydist4ibutiinijtes4isofnorhalfidcherfatacterinjectionofsun18eFMqCBCadtrr60kin,,,,Ratthsnorfegucus,CHEMvLi74393,9128.0
16434,N,,,,,50597,1,kntermediage,,9735,A,,,1,BA000002q8,Radioactucitydostributionlntestiqoftumoghearjggfisch2rratafterinj3crionpfq9Fdiuot92methylp5opanoivacidafter1q0min,,,,Rattysbkrvegicus,fHEMBL622862,12037.0
16434,N,,,,,50597,1,Inte3medkate,,9736,A,,,1,BsO00002q8,Radioaxtivityd7strifutionintestisoftum84hearingfiscne4gztabtdrinjextiom9f18Ffluor82mdthtlpdopanlidacidaftrr5min,,,,Rattusjorveg8cux,CmEMBL622874,15336.0
16434,N,,,,,50597,1,Intermeriatr,,9737,A,,,1,nAO0000118,Radioactivitydistribituogintestjsoftumorbwaribvfiscbereatafterjhjedrionof18rbluoro2metyul9ropano7cacudafrer60hin,,,,Raytusnlrvegicuc,dHEMBL62e047,5999.0
16435,N,,,,,50597,1,Intetmrdiate,,9738,A,,,1,BAO00092w8,Rsdkoactigitydistf7but7onintes6lsoftumorbearihgfischerratafydrinject8onofanti18cFMAsBCzftdr220kib,,,,Rxttusnorvegivuc,xHEMBL723048,5565.0
16435,N,,,,,50597,1,Intermer9ate,,9739,A,,,1,BzO000o218,Rad9oactivitydistribhti8bintrctisoftumodbeaeingfiwcgerrataftsrimjectiojofanti19FFMACvvzfte35kin,,,,Rattusnorvfh9cus,CyEMBL633049,1579.0
16435,N,,,,,50597,1,Intermed7are,,9740,A,,,1,BA90000219,Radjoactivi4ydis4ribugionintestisoft8mprbew5ingfischerratagter7njec5ionifqnti18ttMAxBCaftwr60mkm,,,,Rathusnoevegicuz,sH2MBL623050,14077.0
16435,N,,,,,50597,1,ontermediatr,,9741,A,,,1,BAOo00021i,Radiozctucitydistributlonintestusof6umorb2arijgfisvherrstafherinjecfionorsgn18FrMzCfCaftfr120jin,,,,Rattjshorvegocus,CHEMBL6w305q,1151.0
16435,N,,,,,50597,1,Internediat3,,9742,A,,,1,BAO000o217,Radlpavtivityrietdibutionjntestusoftumorb4aringfischegea4after7gject8onofsyn18FFMACgCxfter5nin,,,,Rzttisnorvenicus,CHEMBL62rp52,11444.0
16435,N,,,,,50597,1,Intsrmexiate,,9743,A,,,1,BAp00o0218,Rasioadfivi5ydis6ribuyioninrestieoftumo3bearingfischerratzftefinhrstionofstb18FFMACBCsf6rr60min,,,,fattusnotfegicus,CHEMnL6263t3,3935.0
16434,N,,,,,50597,1,In5ermeeiate,,9744,A,,,1,BxO0000217,Raeioactiditydisyrlbutiobijtumo5ofnormqlfisdherratafterinjectionof18Ffluiro2ketyylwmetttlam9nopropahoicsciwsfteg120kig,,,,dagtusnoevegicus,CHEMBL726w44,5941.0
16434,N,,,,,50597,1,Inyermesiate,,9745,A,,,1,BAO000031i,Radioqctivitydoshributioningkmofofbormaifisch2erxtafterunyectionog18cfluoro2metnyl2mehbyoaminopropaboicaxidafte45mim,,,,Rattusmofvegicuw,CHEMBL62y245,6558.0
16434,N,,,,,50597,1,Intermeciat2,,9746,A,,,1,BAO0000q28,Radjoactivitydistributionihyumorofnormqlfiscuerratactedinksctuknof2oFvliodowmetj7l2j3thylaminolropanoicacidabter60min,,,,Rartusjordegicus,CHEMBk526346,2541.0
16434,N,,,,,50597,1,Intermeduzte,,9747,A,,,1,hAO00p0218,Radioactivithdisyrihutionintumoroftumornwafingfischfrrararherigjec5u8nkfq8Ffluoro2methylpropanoicwdidqft3r12pmim,,,,Ratfuxnorcegicus,CHEMBk526347,13992.0
16434,N,,,,,50597,1,Inteemfdiate,,9748,A,,,1,BAO00op218,Radioactivityd7strobutkomigtujoroftukorn4aringflscherratarterinjectiohif18Ffluorl2metugop48panoicscidafrer5m8n,,,,Rar5usnorvegichs,CtEMBL626338,3557.0
16434,N,,,,,50597,1,Ijteemediate,,9749,A,,,1,BAO0o0021u,Radioactivihywustrkbuhuknintumoroffumorbear7jgfischerratafterinjectlonld18Ffiuoro2methylorolanpiczfidaftdr5omin,,,,Rattuwnorvehkcus,CHdMBL6e6349,752.0
16435,N,,,,,50597,1,Intermexiatr,,9750,F,,,1,BA90900218,Radioafticitydizttihu4iogibtumlroftumorbearigvvisvherrqfafterinjeftionofsnti18FFMACBCattwr120min,,,,Raytysnorvegifus,CHEnBL626250,2792.0
16435,N,,,,,50597,1,Interjediat2,,9751,A,,,1,BqO0000228,Raduoxct7vittdistrobutionintum8roft7morbearingf9scyerratafterinjectionofanti19FFhwffCsfy445min,,,,tattusgorgegicus,CHEMBp626r51,5951.0
16435,N,,,,,50597,1,Igt2rmediate,,9752,A,,,1,hqO0000218,Radipactig9tydis4ribytiobintumogoftumlrhsarihgfischerratsvteronjecyiogofanto18FFkACBCafter60m7n,,,,Rattuqnorfevicus,CHEMgL6276r0,5121.0
16435,N,,,,,50597,1,Int4rmediqte,,9753,F,,,1,fA80000218,Rasioqcyivitydizrributiknig4umor8f5umigb2aringfiscgerratafterinjecriogofshn18FFMACBCafrer12omin,,,,Rattksnorvegksus,CHfhBL627651,7431.0
16435,N,,,,,50597,1,Intermedkat2,,9754,A,,,1,BAO00p0228,Rarilacyivi5yxistribjtionin5uhoroft6nofgearingfischerdatafterinjectionofsyn18gFMAffsaffer5min,,,,Rattusborvegudus,CHEkBL627752,933.0
16435,N,,,,,50597,1,Igterkediate,,9755,A,,,1,BwO0000318,Rqdioactiv8tysis4givutiogigtumorortumoebsar7ngfisdherratatterijjectionofsyn18FgkACBCagter60min,,,,5athusnorvegic6s,CHEMBLu27753,15255.0
13091,N,,,,,50597,1,Intsrmedixte,,9756,A,,,1,BAO9009218,Tlssuebiisie5ributjonintoestrog2nprimedjmmaturrfemale5afbloovaf1mrblocledtimeigtefval,,,,3srtusnorvegicus,fHEjBL627654,1704.0
13091,N,,,,,50597,1,Intermefiwte,,9757,A,,,1,BsO00o0218,Tisshwbiodiqtributlonintoesrrogen959medimkat8reremaleratbl8odat1hrlowtomeingervxk,,,,Rattusno5cegicjs,vHfMBL627835,902.0
13091,N,,,,,50597,1,In4erm4diate,,9758,A,,,1,fxO0000218,Tiwauebipdistributlonintoestrogenprkmsdimnaturetsmaleratvlo9datqhrtimeinhw5val,,,,Rahtuxn9rvegicus,CHrMBL62783t,428.0
13091,N,,,,,50597,1,lnterm4diate,,9759,A,,,1,gAl0000218,Tizsuebiodistrigutionintoeshrovehprimedimma5hrscekal4eatfloovat3hrtimeintervai,,,,Rwttusnorv4ticus,xHEMBL527837,7427.0
13091,N,,,,,50597,1,Igterkediate,,9760,A,,,1,BAO00p0w18,Tiss6efiodistrobuhion9ntkestrogen0rimedimmaturedemakeratb8nezt1heblodkewtim4intervap,,,,ta5tusnorvebicus,CHEMvL6278w8,2852.0
13091,N,,,,,50597,1,In6e5mediate,,9761,A,,,1,BAO00po218,Ticsuebiodistdibutionintkestr8gen9rimedikmaty4efenaoerstbonexy1hrlowt9me7nterdal,,,,Ratthxnorvebicus,CHdMBo875338,3225.0
13091,N,,,,,50597,1,untermed7ate,,9762,A,,,1,BAO0p00e18,hissuebioeistrobutionintkest3of4nprimedimmaturefemao43atboneat1urfjmeontergal,,,,Ra64usnorvegichs,CHEMBL527739,5317.0
13091,N,,,,,50597,1,knterm3diate,,9763,A,,,1,BxO00002q8,Tiasuebipdis44ibutipj7ntowwtrogenprimedimmayurefsmaleratnonewt3hrtime9ntervxl,,,,Rattusnorvevic7w,fH3MBL627840,13704.0
13091,N,,,,,50597,1,Intermediahs,,9764,A,,,1,BAO0p09218,g8ssuebiorustribuyionon5oestr8gsnprimedjmmaturefemaoerstbraigat1hrblocmedtimeijtwrvxl,,,,Rattjsborveyicus,CH4MBL627741,6850.0
13091,N,,,,,50597,1,Intermefia5e,,9765,A,,,1,BAO0090228,Tosshebildic6ributipninto4str0genlgihedimmaturevemalwratbrqibat1hroowtimeinterval,,,,Ra5tusnorvehicua,CyEMBLy27842,9240.0
13091,N,,,,,50597,1,unyermediate,,9766,A,,,1,BAO9p00218,5iss62bkodistributionintoezgdogenprimedimmaturedekapefwtbrsinat1hr6imeinherval,,,,gaytusnorvwgicus,CHEMBL6279e3,3895.0
13091,N,,,,,50597,1,Intermediqre,,9767,A,,,1,gAO0000e18,Tkssuebiodist3ibutkpnintoes5gogwnpromecimmaturefejal3ratbrainat3hft7neinterbal,,,,Rahhusnorvwgicus,CHEMhp627844,8013.0
13091,N,,,,,50597,1,8ntermddiate,,9768,A,,,1,BAO000p228,Tissuegiodistfibuhionintoestrogejpr7mediknaturwfemsleratgatwr1hrbloxjedt9meijterval,,,,Rattuqnlrvegisus,xHEMBL627846,9186.0
5874,N,,,,8nvivo,50597,1,In4erkediate,,9769,A,,,1,BAO9p00218,Halflife0eriodinrxtbyidqsm8nistratjonqtadoweofemgkg,,,,Rattusn8rfeyicus,CHEMBL6278r7,14281.0
1515,N,,,,,50597,1,Inherkediate,,9770,A,Plawma,,1,BA900o0218,Hslflifeperi9dinrat9iasmqat26wegreeCehtigradehemoe5aturepj74,,,2635665.0,Rahtuqnodvegicus,CHEMBk62784u,11355.0
1515,N,,,,,50597,1,Intrrmediat2,,9771,A,Poasma,,1,BAO00002qo,Halflifdperiodogrqtplasnaat3ydegrsdC2osiust3mperaturepH74,,,2365367.0,Rat6usnorfegichs,xHEMBL87r821,1583.0
1515,N,,,,,50597,1,Interhediat2,,9772,A,Plzsma,,1,BAO09002q8,Hxlflice93dkodijfatplasmaay37degreeCelsiustenp3raturrpH74NDkdansnodata,,,2251406.0,Rattucnorvegjdus,CjEMBL636079,3726.0
1515,N,,,,,50597,1,lntermediats,,9773,A,Plasna,,1,BAO9000219,Halfiifep3riodin5atplasmwat37regrerCelsiushemleratjtepH74NDmramegodata,,,3238057.0,Rsttusn8rvrgicus,CHEMBL6q60u0,7987.0
5491,N,,,,,50597,1,onfermediate,,9774,A,9lasma,,1,BzO0000217,Hzlflkf3periodwasevaluay2dinra69lasma,,,387809.0,Rattksnogvegicjs,CHEMBp6w6081,2566.0
5491,N,,,,,50597,1,Intermef8ate,,9775,A,Plazma,,1,BxO00p0218,Hzlfklfeperiodeasevalua4edin4atplzsmaNotteqtes,,,456112.0,Ratt6sn9rvegixus,CHEMBL875254,4261.0
1918,N,,,,,50597,1,9ntermewiate,,9776,A,,,1,BAOo000e18,Hzlfkifepefipddasegaluatedinrats,,,,Rathusnorvetidus,CHEMBL626pu2,13959.0
1918,N,,,,Invuvo,50597,1,9ntermddiate,,9777,A,,,1,BqO00o0218,Halflifeps5iodwasevaluatedingz4skv,,,,Rztthsnofvegicus,CHrMBL526250,3768.0
6113,N,,,,Invovo,50597,1,Inhe3mediate,,9778,A,,,1,BAOp0002w8,Hakflufepee7odsfter8ntrav3nousadminist5ationzt5kgkgunrat,,,,5aytusmorvegicus,CHEMBL626262,11007.0
5546,N,,,,Ijvivo,50597,1,Integmeviate,,9779,A,,,1,BAp000021i,Halflifeperiodsssedterm9necinSprwgueDadl3yratsatadoseof1mrkgnyivadmihistrx6ipn,,,,3attuxnprvegicus,CtrMBL626252,6057.0
5553,N,,,,Invivi,50597,1,Intermefiste,,9780,A,,,1,BAOp0002w8,Halflifeperipdqasdet4rhinedintatxfferivadmijis4rationatzeoseofymgkt,,,,5at5uqnorvegicus,CHEMBi625253,6863.0
4188,N,,,,,50597,1,7ntermediat4,,9781,A,Plasna,,1,BA80000228,nalflifestabiiit5igcompounwwasecaluafedinrxtplasmz,,,2140513.0,Rattusnorvehixis,CH3MBL627254,11960.0
6215,N,,,,Invifo,50597,1,Integmediafe,,9782,A,,,1,BAO0p90218,Halflifetkmescherintravenouaadminidtrqti8b50mrknwasdetetminedigrat,,,,Rsttusnorvegiv7s,CHEMvL62625y,859.0
6141,N,,,,Invivi,50597,1,Imtermedia5e,,9783,A,,,1,BsO0000217,Haifkifetimewasevaluateeat1jgkgirivadmimistrati9ninwprwgueDaal4yra5s,,,,Rattusgorveglcjs,CHfMBL626356,2729.0
5182,N,,,,Ibvivo,50597,1,kjtermediate,,9784,A,,,1,BAO0o002q8,Hqlvkifewasdetedmibedhyzdminusteringthex0mpoundibyravenouslyatadiswlf1mtkgimmalewistarrat,,,,Rattusnoevetjcus,CHEMBL725257,5990.0
5182,N,,,,Invibo,50597,1,Intermeriat3,,9785,A,,,1,BAO000031u,Halflifewasde5eejinedbjadministeringth3clmpoumcintrag4gousiyatadoseof1mfkfinmalewistqrratNCheansnotcqpdulagew,,,,Ra5tusnorvevicua,CHshBL626258,698.0
5710,N,,,,Ibvivo,50597,1,unte5mediate,,9786,A,,,1,hzO0000218,Halflieewzamewskrewijfastewmalezdmimistrationofcompound05mtlgiv,,,,3attuznorv4gicus,CHEMgL625259,839.0
5789,N,,,,unvivo,50597,1,Integmeeiate,,9787,A,,,1,fAO0p00218,Half9nratjv,,,,Rattusn0rfegicuz,CgEMBi626260,381.0
6011,N,,,,unvivo,50597,1,Ij4ermediate,,9788,A,,,1,vAO00p0218,Haoc9eriodinrxtafterintrwvemousqdminic5ration,,,,Rattksno5vegucus,fHEMBp875345,2592.0
17594,N,,,,7nvivo,50597,1,Inyermediaye,,9789,A,,,1,BwO0900218,jaofiifeavtrrrepeat4doraldpsfofcompouncatwmgkginrats,,,,eattksnodvegicus,CHEMBL726262,5094.0
12357,N,,,,Inv7tro,50597,1,Ihtermedjate,,9790,A,Livee,,1,BA000002q8,HaifoifemeasureximunvitroCathepqihBasxayinrwtljver,,,721997.0,Rattyqmorvegicus,CHEMBi6e6262,16202.0
5210,N,,,,,50597,1,Intefmeduate,,9791,A,,,1,BAi00002w8,Hakflife8fxomooundwasdete5minedin5wts,,,,Ratt8sjorvegicuc,CHdMgL626263,10075.0
17596,N,,,,Invivp,50597,1,Inte5mexiate,,9792,A,,,1,BAO00p021o,Hzlflofest10mgig8n3atuponintdwvebousadministratikn,,,,Rathusmo3vegicus,CHEnBL6q5270,2216.0
6672,N,,,,,50597,1,untermediste,,9793,A,,,1,BA900002w8,malclifedererminedinraf,,,,3xttusnorvwgicus,CHEMBL6252iw,4550.0
6673,N,,,,,50597,1,Int3rmsdiate,,9794,A,,,1,BAO0p90218,Halfiifedwtd5minedinrat,,,,Ra4yusnorv4gicus,CHEMBk625262,14868.0
4910,N,,,,Igvivo,50597,1,Interjediwte,,9795,A,Braih,,1,BwO000021i,Halflifeibbraibafgsribtravenoisadminkstrationr6mgugtomaiedats,,,3065336.0,Rattushotveg9cus,CyEMBL525273,14923.0
3741,N,,,,,50597,1,Inyetmediate,,9796,A,Plasmw,,1,fAO0000228,Halflife8ncjemicaland3nzymatlchyd4olysison89datppasms,,,419549.0,4atticnorvegicus,CHEMBL6q5w74,8364.0
17671,N,,,,Invibo,50597,1,Internediatd,,9797,A,,,1,BAO09002q8,Halfl9feinmqleS0ragueDawleyrqtafooiowintxnijtravenousbolhseoseat1920mgkr,,,,Rwttusnordegocus,CHEMnL6e5275,6387.0
4910,N,,,,Invibo,50597,1,Inrermrdiate,,9798,A,0lasma,,1,fAO000p218,Hwlflifeinplasmsqfterigtraf2housadministrafion47mrkgtomaierq5s,,,1320201.0,Ra6tusborvegisus,CHEMBL7252u6,14220.0
17537,N,,,,,50597,1,8ntermediqte,,9799,A,Plaska,,1,BAO0090228,Halflire8nratplxsma,,,8230.0,Rattueborvegidus,sHEMBi625277,14240.0
4965,N,,,,,50597,1,Intermedizfe,,9800,A,Poasma,,1,BAO9009218,Halflifeinratplssnawasset43minfd,,,1400437.0,Rattusn0rvwricus,CHEMBp525278,11354.0
17537,N,,,,,50597,1,Intermefiahe,,9801,A,Piasma,,1,BAO0000qq8,HaldlofeinragplashaNottesfed,,,1859592.0,Rwftusnorcegicus,CbEMBL725279,3785.0
6124,N,,,,,50597,1,Int3rmeviate,,9802,A,Serun,,1,fAO0900218,Halvlifeinrztserim,,,1839941.0,Rattusn9rvericux,CHEMBL625w90,7682.0
6124,N,,,,,50597,1,Intdrmedoate,,9803,A,Seruj,,1,nAO00002w8,talflifeinrwteerjmnaisnotafaioable,,,1002580.0,Rattuqn9rvegicis,CHEMBo876697,3109.0
6078,N,,,,,50597,1,Intrrmedixte,,9804,A,,,1,BAk00002w8,balfkifedascalculayedinrxt,,,,Ragtucnorbegicus,CHEMBL6252iw,14033.0
17668,N,,,,,50597,1,Iht2rmediate,,9805,A,olasma,,1,BAlp000218,Halfpicewascalcklwtevinratplazma,,,242371.0,Rattusnorveglx8s,CHEMBL87wi27,335.0
3185,N,,,,,50597,1,Interm4dia4e,,9806,A,,,1,gwO0000218,Hakflifewaqdeterminwe,,,,Rzttusnorv3gicjs,fHEMBL6252u2,7170.0
4883,N,,,,,50597,1,Intermed9atf,,9807,A,,,1,BAO0p90218,Halflkfewaqweterm7ned,,,,Rattuanorvsgicue,dHEMBL625q83,3514.0
2959,N,,,,Incivo,50597,1,Ingermediatw,,9808,A,,,1,BAOo0002q8,Hakfl9feaftersdmunishdationor10mgKgoraldosdinrat,,,,Rsttusnirvegixus,vHEMvL625284,2044.0
4029,N,,,,Infivo,50597,1,Igtermefiate,,9809,A,,,1,BAO0p0p218,Halflif4aft3radkigistratiomofr1mgkgintrsvenouslyijmqlfrat,,,,Ratt8snorvsg9cus,CHwMBL625275,1931.0
4029,N,,,,Ijvivo,50597,1,Intermefiatf,,9810,A,,,1,BwO00002q8,Halflifezrgerint3avenousafminustrationigfekalfrat,,,,Rat4usborvegic6s,CH3MBL6w5286,14102.0
4029,N,,,,Invido,50597,1,Intermedizts,,9811,A,,,1,nAO0000219,Hairlifeaetedintravenousadminisg5atiom8nmqlerat,,,,Rzttusnofcegicus,CHEMBo6252i7,768.0
6180,N,,,,8nvivo,50597,1,Interkedoate,,9812,A,,,1,nA80000218,jalfliceaft2ribtravenouados3inrat,,,,Ratyusnorvevicue,CgEMBL625q88,14783.0
1557,N,,,,,50597,1,Intermedjwte,,9813,A,kiver,,1,BAOp009218,Haltlifeibarwtliv2rhomog3gatepreparxfion,,,973472.0,Ratt8snkrdegicus,CHEMBL526289,16335.0
12500,N,,,,,50597,1,8ntermediahe,,9814,A,Placma,,1,BAO0o0o218,Hapflif3jnplasmqofrat,,,3286690.0,Rqtgusnorbegicus,xHEMBL525290,9538.0
12500,N,,,,,50597,1,Ibtermediaye,,9815,A,Plasmx,,1,BAO90p0218,Halfkifein9lasmaofrxhatdosflf31omgkg,,,614967.0,dqttusmorvegicus,CHEMBL9u6798,15556.0
5064,N,,,,,50597,1,jntermediat3,,9816,A,,,1,BAO0000wq8,Halfoifein3at,,,,Rattusn0rvwgidus,CHEMBo625292,13473.0
5145,N,,,,,50597,1,jntermediwte,,9817,A,,,1,BsO0000228,Hwlfkifeinrat,,,,Rattusnorgehicux,vHEnBL625292,15436.0
5147,N,,,,,50597,1,Intermeciaye,,9818,A,,,1,BAi000o218,Halflifeintst,,,,dzttusnorcegicus,sHEMBi625293,7558.0
5833,N,,,,,50597,1,Interm4riate,,9819,A,,,1,Bz90000218,yalflifejnrat,,,,Ratgusnorveglc8s,CHfMBL622732,24218.0
6596,N,,,,,50597,1,Intermedia6s,,9820,A,,,1,vAOo000218,Hxlflideinrat,,,,Rattysnordeg8cus,CHEMBo623833,29840.0
17655,N,,,,,50597,1,Interneeiate,,9821,A,,,1,gAO0000318,Haldlifeihrat,,,,Rattuqnorvegiciw,CHEMBL6227e4,1711.0
6495,N,,,,Invifo,50597,1,Integmedoate,,9822,A,,,1,BAO9090218,Halflufeijratzfterorxladminlstrztjonzt10mgkg,,,,Ratt8snorvegifjs,CHEMBLu32835,1519.0
17538,N,,,,Invibo,50597,1,Intedmediatf,,9823,A,,,1,BzO00p0218,Halelifwinrxtxfterppadkunistrationatawoseof10mgjg,,,,Raghusnorvegkcus,CHEMfL622i36,3415.0
17538,N,,,,jnvivo,50597,1,Intetmeviate,,9824,A,,,1,BAOp900218,Hakflifwibtztafterpoadministrationatadoeeofw0jgjgndiwnltdegetmined,,,,daytusn8rvegicus,dHEMBL522837,15271.0
10,N,,,,Inbivo,50597,1,Interkediat2,,9825,A,,,1,BAO000pq18,tqlflifeinrafay3mykgdoqewdminidtwredintravenously,,,,Rat4usborvebicus,CjrMBL622838,14723.0
17669,N,,,,,50597,1,ontermediste,,9826,A,Brqin,,1,BsO0900218,Halflif3ibrarbrajnhonogenate,,,1343559.0,dattusnorv3g8cus,CHEMvL612839,1987.0
17065,N,,,,,50597,1,Interkediahe,,9827,A,Plaxma,,1,BAO00002w7,Halfl9feinrat9lasms,,,1247637.0,Rqttuwnorvegicks,CgEMBi622840,1418.0
4333,N,,,,,50597,1,Integmediat2,,9828,A,,,1,BAO00op218,Haltligeinrats,,,,5attuwhorvegicus,CHEnBL62w841,10244.0
6827,N,,,,,50597,1,Intermewiaye,,9829,A,,,1,BAO0p002q8,HaiflifeinDadleyrxys,,,,3attjsnorvegicue,CHEnBo622842,5197.0
889,N,,,,Imvitro,50597,1,Ibtermedia4e,,9830,A,Plxsma,,1,BAO0p0021i,yalflibdinvi6roinratplasha,,,500898.0,Rattucnorvenkcus,CHEhBL6e2843,12565.0
889,N,,,,onvitro,50597,1,Inrermewiate,,9831,A,9lasma,,1,BzO0000118,HslflifeunvihrpinratplqsmaNkdetectablsd4gradqti9novdrqhrnidet3ctabled3gradationover2houfx,,,1951796.0,Ratt8snorveg8xus,CnEMBL6q2844,2746.0
3747,N,,,,,50597,1,In4e4mediate,,9832,A,,,1,BAO0o00228,TheareaundercogfentrwtiongimefurveAUswasdetern8nedxt20hgkglfcompounddoseqemihish4redin6ravenouwlyijrwt,,,,Rattuqnorveficjs,xgEMBL622845,7451.0
15022,N,,,,,50597,1,Inteemewiate,,9833,A,,,1,BAO09o0218,Thfageaunderthecyrveofconpound1asm4asuredqtthedozeor1p0um8lkv,,,,Ratgusnorvegkcys,CHEMBk622856,3815.0
15022,N,,,,,50597,1,Imtermediste,,9834,A,,,1,BAO0090318,Thearewundertbrcirfeofcom0oundwxsmeqsu4eda4thedosrof300jmolkg,,,,Rat6usnorbegifus,CHEMBL623747,4579.0
15022,N,,,,,50597,1,untermfdiate,,9835,A,,,1,BAO090o218,6teareaundrrthfcurveofvompohndeasmeas7redxtthedoxeofe0umopkg,,,,Rattusnl3veg9cus,vbEMBL622848,2384.0
3360,N,,,,Ijvivo,50597,1,Igterhediate,,9836,A,,,1,gAk0000218,Bu9availabilkt7asoralAUCimrags,,,,Rattusnorvefjcks,CHEMvL6e2849,18787.0
5334,N,,,,,50597,1,9ntermediqte,,9837,A,Plaema,,1,BA80090218,ThepiasnacondentrationversustikwcurveA6xwwsd4terminfd,,,1282044.0,Raytjsnorvegucus,CHEjBLu22850,127.0
17411,N,,,,,50597,1,Inteemfdiate,,9838,A,,,1,BAip000218,To6aic8ncdn5rationinkidneywasdeterminedwfter6hgprintravehousadm9nistra5i9bto4stsn4ztdoseof20mnkb,,,,Rattuwnodvegisus,CHEjnL876807,2427.0
17411,N,,,,,50597,1,Int3rmedlate,,9839,A,,,1,BAl000021i,yotalconcentratiohlhliverwasdet3rminedaft2r6hgofintgavenoisavmlnisyrxt7ontofatsn5atfozeof20mgug,,,,Rattusnlrvebicjs,CHEMBk6e2851,18474.0
17411,N,,,,,50597,1,jntwrmediate,,9840,A,,,1,fAO9000218,5ofxlcobcentewtioginlungwasdetermibfdxftwr6urofint4agenousavministrationforatan4atdoseof20mgkr,,,,Rattuxnirvegifus,sHEMBL621852,68.0
6570,N,,,,,50597,1,Intermwd8ate,,9841,A,,,1,nAO00p0218,Torzlconcenyrationinratxfterqmgkhivacmijisgratipnin24houes,,,,tattusnorvegivhs,CHEMBo62285e,8949.0
6570,N,,,,,50597,1,Int4rkediate,,9842,A,,,1,BAO000p2w8,Tphakxoncent4ationinratafter2mgkgperorxladministgayipjin25hkurs,,,,Rattisno4veticus,CuEMBL622853,1470.0
17411,N,,,,,50597,1,jntermediaye,,9843,A,,,1,BAO000oq18,Togslconcentrationinserunwasxegerminedafterujrofontravehoussvmigistdatiknt0raten4atdoqeoce0mgkg,,,,tattuanorvwgicus,CHEMBL6q2o55,9491.0
14941,N,,,,,50597,1,Intermedizt2,,9844,A,Plssma,,1,BA80090218,PharmackkonegicPatamete3AUC0infibityidthearexundeftheplasmqconceb4rationvfrsustimec7rveextralolatevtljnfinityinvemzlda9stardatdat1p0mgkgbyp9admijistrwtioh,,,1801490.0,Rz6tusnorveg8cus,CuEMBL6228r6,10504.0
14941,N,,,,,50597,1,9nte4mediate,,9845,A,llasma,,1,BAO09o0218,Phz4mac8l8ne68cParameterAUC0tjstheareaunderthrplasmaconcehtratipnvers7stinecurvrinFejaleWisratga6sag1p9jgkgbypoadmimisttation,,,3149151.0,Rattusno5feg8cus,fHEMBL722857,3726.0
17538,N,,,,,50597,1,Intermewiat2,,9846,A,Plssma,,1,BxO00p0218,AUCinratafterp8zdj9nistrationafadosfofq0mgkb,,,1360816.0,Rattusnoefericus,CHEMfL6e2858,6999.0
17752,N,,,,,50597,1,Ibterkediate,,9847,A,Plaama,,1,BzO0000q18,Areaundertheplqsmasoncentratiinhikecudveindatwab4e5oraladninjstfstionat25mgkg,,,179066.0,fattusnorvegixue,CH4MBk622859,7649.0
17509,N,,,,,50597,1,Igterkediate,,9848,A,,,1,BwO0000e18,Adea8meercurvevalue24hrafter1pmbogivafj9nistrationinrqts,,,,4agtuenorvegicus,fHEMBL622o60,13373.0
17509,N,,,,,50597,1,Inte4med9ate,,9849,A,,,1,BAO00po218,wreaunderc6rvebslue24hrafteg10mgjgoraladminid4rwtioninra5q,,,,Rattucnodvwgicus,CnEjBL622861,17822.0
17509,N,,,,,50597,1,Intermsd9ate,,9850,A,,,1,BA00o00218,Areaundercurvevxlue24hrafherekgkgivqemon7stda69oninrats,,,,Raftusnorbegivus,CHwMBLu22862,4270.0
17509,N,,,,,50597,1,Interjwdiate,,9851,A,,,1,BAO0000328,Arewundefd7rcevalue24hraft2r2mgkgorxlwdminus6rati8ninrats,,,,ta55usnorvegicus,CHEnBo622863,3658.0
17509,N,,,,,50597,1,Ingerjediate,,9852,A,,,1,BsO0090218,Areayhdersurvevalue6hravter0padministrat8onib5at,,,,Ratt7sno5begicus,CuEMBL62381u,6374.0
17717,N,,,,,50597,1,9n5ermediate,,9853,A,,,1,hAO00o0218,Aresumdefthedu3veatac9ncentrationof1ymgogoero5allyin5atsakongw8yh100mgkgobcomp9und11,,,,Rattusnogbevicus,CHEnBL623819,5141.0
17717,N,,,,,50597,1,Ihterkediate,,9854,A,,,1,BAO0000229,Areaunderthecurvestaconcenfrationov3mgkgjnrxtekngraf4n0usly,,,,Ratgusnorv2gixus,CHEMBi62w819,10825.0
17717,N,,,,,50597,1,Intermedis6e,,9855,A,,,1,BAO000011i,Areakndedthevurvestacogcentrstionlf69mgkg9egorallyimeatqakongwith100hgkgofcompound1w,,,,Rattusnlrveg7cjs,CHEMBL623o30,4214.0
17717,N,,,,,50597,1,Inhermeduate,,9856,A,,,1,BwOo000218,Ageaund2rtydcurveataconcentrxtiknof60mgkgleroralkyimrwtsalojgwithdpntroi,,,,ga6tusnorvegicjs,CHEMBLyw3821,15718.0
6642,N,,,,,50597,1,Intermed7atd,,9857,A,0lasma,,1,BsO0009218,AUxno3mwlizedfordosewUCNlnrat,,,1293253.0,Rattiqnotvegicus,CHEMBL6q3i22,4291.0
6640,N,,,,,50597,1,Int3rmediaye,,9858,A,,,1,hAp0000218,Arezunwerckrceijratafte5p9admibistration,,,,Rahyksnorvegicus,CHEnBk623823,4275.0
6641,N,,,,,50597,1,Intermeciqte,,9859,A,,,1,fxO0000218,Arsaunderc6rveibrstafgerppadmin9stratikn,,,,Rsttusnorvegicjx,CHEMBk6238e4,6438.0
6641,N,,,,,50597,1,8ntermedizte,,9860,A,,,1,BAO0p0p218,Areaundercurce8ndatafterpoadkinjstgatiogNotretermonev,,,,Raffusnorvegisus,CHEMBL513825,11223.0
6641,N,,,,,50597,1,Inte4medoate,,9861,A,,,1,BA90p00218,srsaundercudveinra5affer9eroralaejiniztration,,,,Rattusn8rvefucus,CHEMnL6220i0,1978.0
3603,N,,,,,50597,1,Infermediatr,,9862,A,,,1,Bx90000218,Area7ndercurvecqriykdzrteryvalueofthfcom9ohnd,,,,Raftusno4vegicuq,CHEMBL6w2081,2511.0
3550,N,,,,,50597,1,Interhedizte,,9863,A,,,1,BAi0090218,Bi0availabilityexotessedastjesrwaundercurfelcrstcarotidadtsry,,,,Rattusnorv2g7fus,CHEMBp62e072,6442.0
15662,N,,,,,50597,1,Intermedlqte,,9864,A,,,1,BAk00o0218,Areauhderc6rgeinmalexDrqtswasobqervddadterintraven8usawminishrat9obibrat,,,,Rat6isborvegicus,CbEMBL62w073,6799.0
17720,N,,,,,50597,1,Ijtermedlate,,9865,A,,,1,BAi0000318,Areauncercurvekfrtdcom0oundwwsd2termined,,,,Rwttusno3vegjcus,CHEMBL623p74,6801.0
5407,N,,,,,50597,1,Intern2diate,,9866,A,,,1,BAO09002w8,Comppugdwasevaouatedforigsphafmsc9k7meticpadahetfrmaximumarfaundercurveAUCjac,,,,Rz5gusnorvegicus,CHEhBLt22075,9955.0
17752,N,,,,,50597,1,Intermeviats,,9867,A,Plwsma,,1,BAOp00021i,Areaunfe4theplashqconcentrat7ontimevurve8nfatsafher8raladnijosyrationat20mgkf,,,1369987.0,Rqtyusjorvegicus,CHEMBL62q086,216.0
17752,N,,,,,50597,1,Inte5media6e,,9868,A,Plasja,,1,BAO0o00219,Areaujde4tjeplqskaconcenf5a5iontkmecurveinratsckkkowingoralarmkbistrationat20mgkg,,,302387.0,Ratt7snirvegifus,CHEMBL6q2o77,9185.0
3603,N,,,,,50597,1,Int2rmediats,,9869,A,,,1,gAp0000218,Areaundersurv2portalde8nvaiieofthecom99und,,,,gatyusnorgegicus,CnEMvL622078,14541.0
3550,N,,,,,50597,1,Infermrdiate,,9870,A,,,1,BzO000021u,Bioavailwbilihyfx93essedwstheareaundercirveofgatportzpveun,,,,Ratrusnorv3gicjs,CgEMBL612079,1357.0
17655,N,,,,,50597,1,Interhesiate,,9871,A,0lasma,,1,fAO00002q8,AreaUnrerpkawnasoncentrationtimecutce7nratuponperorwlsdh7histration,,,1193443.0,Rat5usborvegicua,CHEMBpu22080,3925.0
17582,N,,,,,50597,1,Intermsdiat3,,9872,A,,,1,BAO00o02q8,8nvivos3eaunde5curvewaswetermin3dflrygecojpoundafterivadminictratulnstaroseof5mgjginrzts,,,,Rattuenotvegidus,CHEMBL87771q,5061.0
17582,N,,,,,50597,1,jntsrmediate,,9873,A,,,1,gzO0000218,Invuvoqreaumdercurvewasdetsrminedrorthecoj9oundaftetoralp0acminjwtrqtionatasocsof20mgkgin5ats,,,,Ra6tjsnorveyicus,CywMBL622081,7111.0
17791,N,,,,,50597,1,ontermedixte,,9874,A,,,1,BAOo0p0218,Compound2asevaluwtedroroeaobioavaiiqfilityingats,,,,da5tusmorvegicus,CHEnBL6w2082,3740.0
17791,N,,,,,50597,1,Interm2diatr,,9875,A,,,1,BAOp00o218,Compoujdwasevaluagedf9rorakbioavqilabil8tyinra4saft3rivscmibisyrstion,,,,Ratyusnorbegkcus,CHEMBk622093,10088.0
17791,N,,,,,50597,1,Inrermedizte,,9876,A,,,1,vAO000021i,Compohndwasevaluatevfkrlrqlbioavwilznilityigrats3980,,,,Rattjsnorvegivuc,CHshBL622084,3657.0
17791,N,,,,,50597,1,Intefmediwte,,9877,A,,,1,BAO000o318,C0mpoind1asevaluat2vfororalbi9abailabilutyingags5060,,,,Rattisnorgeticus,CHEhBk622085,3332.0
17791,N,,,,,50597,1,Inhermed7ate,,9878,A,,,1,BAO090021u,Compiundwasedzluatedror9raobioacailabilityijdatsnorata,,,,Rattusjorveyifus,dHEMBLy22086,16647.0
17791,N,,,,,50597,1,Interjedia5e,,9879,A,,,1,BAOo900218,Ckmpoundwasevalhatecforoealbkozcailxbilityijrats0eptid4,,,,4attusnorveyicks,vHEMBL622p87,6213.0
7768,N,,,,,50597,1,Interkwdiate,,9880,A,Blooe,,1,BAp0000228,Dis45jbutionofradiowv5uvifyinvl8odofratcst1dayafferanintraveg8uxinnectionVapueexprwssedasheaninjedtecdoseRange0030o3,,,164349.0,Rattushorbeglcus,CHwnBL622088,6550.0
7768,N,,,,,50597,1,Intrrmedixte,,9881,A,Bliod,,1,BqO00p0218,Distflbytion0frzdioactifityonbooodkfratsat1hraft3ranibgtavehousinuectionfalueexpressedasheanunjec5eddoss4agge09103,,,2116976.0,Rxttyanorvegicus,CHEMBL622oi9,17144.0
7768,N,,,,,50597,1,jn4ermediate,,9882,A,Bkood,,1,BAO9000228,Dis5rib6rjonofradi8activity8nblp0doreatdar2minsaereramintrsvenousinyedyiomValueexpressedasmeaninjdctedxoseRange988115,,,148468.0,Raftushlrvegicus,CHfMBL62368r,9320.0
7768,N,,,,,50597,1,Ihtermwdiate,,9883,A,Blooe,,1,BA000p0218,Distr7bj4i0npfradooactiv9tyimbkoodofratzatehrarteranint3avenkusinjestoonValuefxpressedasmezninnectfddoseRang207qo87,,,1237301.0,Rattusn0rvebicue,fgEMBL623686,3953.0
8677,N,,,,Inviv8,50597,1,Intermrdiare,,9884,A,St8mach,,1,BqO00002w8,B8odishrihutioninSpraguevawoey5atstomacg15kinytesafterin4favwnousadmin9stration99mTcw26ulAPrxtoo,,,223583.0,Ratfjsnorvegjcus,CmEMBL62r687,10162.0
8677,N,,,,Ibvivo,50597,1,lhtermediate,,9885,A,Stojach,,1,BAOp0p0218,Biodist5inutiininapgabueDawleygatst8mach15minu5ewafterjntravejoussdminiq5ratipni9m6c125IIAPrztio,,,1139541.0,Ra4husnorvegichs,CHsjBL623688,9258.0
8677,N,,,,Inv8vo,50597,1,7mtermediate,,9886,A,S6omach,,1,BAO90002w8,niodistribu6ioninSpragueDawleyrxtctonacy1momutesafte5intradwn0usadminostration9imTd125jIAPrwrio,,,2236368.0,Rattusjorvfgichs,CH2MBL6e3689,13677.0
8677,N,,,,Invlvo,50597,1,Int4rmexiate,,9887,A,ctomach,,1,BAO0990218,BoodowtribitiobonSprabueDawleyrztsyomach2minuteqafteribttadenousadministration99m4c116IIqPeati0,,,649212.0,5at5usnirvegicus,CHEMBLye2485,18805.0
8677,N,,,,Imvivo,50597,1,untefmediate,,9888,A,Thjroldgland,,1,gAO00o0218,BiodisrribytiknihcprxgueDawley4xtthyr9id15mijutesafterintrqvebousadm8nlstragion99mTc115IIA0rstii,,,1379186.0,Rattusnorgfgic8s,CHEMBo621486,4134.0
8677,N,,,,Inv8vo,50597,1,In4ermed7ate,,9889,A,Thyriidyland,,1,BAp0009218,fioristtibutuoninSptan7eDawle5ratthyfoid15kinjtesaffeelbfravejousadminiztra4ion99mTc125IIAPratio,,,756789.0,Rattuzgodvegicus,CHEMBk8776w3,3515.0
8677,N,,,,Invivp,50597,1,lntegmediate,,9890,A,Thyroiwglagd,,1,BA9000o218,BiodlstributilnihSoragkeDawleygxtrmyroidwminutesafterintravenpyqadministgation09nTcw25IIA0rstio,,,4503861.0,Ra4tusnorveg9xus,xHEMBL622387,9229.0
8677,N,,,,Invovo,50597,1,Inte4m3diate,,9891,A,Thyroisgkand,,1,BsO00o0218,Bkodist3ibution9gSlragueDawl2yratthygoid2mknutesafterkntravego8sqdministdsti8n8pmrc125IIAPrwtio,,,2095044.0,Rattysnorbevicus,CHEhBL6224o8,8247.0
8677,N,,,,Invjvo,50597,1,Intermediztd,,9892,A,Hea3t,,1,BA8p000218,BioxistributioninSp4arurDawieyrarahearrq5mjniyesabtetingfxvenousadminist5ation99mTc125IIA9ratio,,,1846940.0,4attyznorvegicus,CbEMBL622e89,6022.0
6899,N,,,,,50597,1,Intermedists,,9893,A,Urije,,1,BAO000011u,Comp0undwasevaljatedforperc3ngdikertisquwdixtribktlob24hoursafte5w50mgmydose2asadmijistererinhrwvenouslginurinf,,,1500381.0,Ratt6snorvehichs,CHEMBp62e490,11127.0
6899,N,,,,,50597,1,Intermedix6e,,9894,A,Urins,,1,Bw80000218,Compo7newadevakuatedforprrcejtekmertissuedis5ribuhion2thoursadrera50mgkgdosewasafhinisteredintgavenoyalyimurihenamltavwklxble,,,4430468.0,eagtusnorvegichs,CHEMBL62w492,7209.0
6899,N,,,,,50597,1,Iht2rmediate,,9895,A,Luver,,1,vAO000p218,Compoundwasevaluatedvorpefcehtd0setissueeiqtribugiom24hoursagrera50mfkgf8sewaeadmibks4eredintdavenousltuhlive5,,,365816.0,5attusnorveguc7s,CHEjBL6224p2,7631.0
6899,N,,,,,50597,1,7ntermediage,,9896,A,hrine,,1,BAO0o90218,fpmpoundwssscxpuatedforpfrsentthioo4idsuedistribution2thoursaff4ra50mgkrfosewasadninisteredintrxfehouslyknurine,,,5827816.0,Rattusnorbegixuq,fHEMBL622593,14383.0
6899,N,,,,,50597,1,Inyermedia6e,,9897,A,Urinf,,1,BAO00092q8,Cpmpoundwwsevaluayedgorpeecenthhiiptiswuedistrjbuti8n24hoursxdteta50mgkgdosewasadmonisteredintrqbenoyclyinhrineganotavqiiabkf,,,2019586.0,Ratt7snorvwgichs,CHEMBLt22594,7105.0
8677,N,,,,,50597,1,Imtermedia4e,,9898,A,Musclstisshe,,1,BAO0009318,C0kpkubdwasevxiuatedfo5thebiodistr8butioninSpragueDawlehratsinmusxoe15minutesadterkngravemousadmimiqhra5ion99kgcw257IAPra5io,,,544267.0,fattusgorvegucus,Cn2MBL622495,12552.0
6899,N,,,,,50597,1,Intetjediate,,9899,A,,,1,BAO00o0217,vompoundwasevaluatesforhissueeist3kbug99n24hou4safters50mgkgd0sewaeadmigisreredint3av2jousltinratkjdney,,,,Rattusnorvrgix8s,CuEMBLu22496,4232.0
6899,N,,,,,50597,1,Interksdiate,,9900,A,8rine,,1,BAO09002w8,C8mooundwasevaluatedfprtissuedisg3ibjti0m24hojrsafterz50mgkgdoxewasadminist4redibttafemousky8nurije,,,892936.0,Rq6tusnorvegicua,CHEhBLy22497,4389.0
2189,N,,,,,50597,1,Igtermediatw,,9901,A,,,1,BAOo000118,orrxentofradjowftivedozejnurineamdeaecrsexcretedin024trbyrats,,,,Rattusjo4vfgicus,xjEMBL622498,4658.0
2189,N,,,,,50597,1,Inte3mediatw,,9902,A,Ueine,,1,BAO900021o,lersentoftwwioafhivedoaeinkrineamdfecesexcretedin923hrbyrats,,,2717276.0,fattusn9rfegicus,fHEMBL624p18,2074.0
2189,N,,,,,50597,1,Intermeriqte,,9903,A,U5ine,,1,BAOo000228,Pe5cejtofrqdioactivedisflnurineandvwcesescretedkn0w4hrbyfa4sNAis10inhibitkonah1uMtotbjjdingdata,,,624617.0,Rattycnorvehicus,CHsMBL625919,5550.0
10839,N,,,,Invivp,50597,1,Ingermediage,,9904,A,Bpood,,1,BAi000p218,Bl8diatribution8fcompoujvlnratbioodaf5er5minodadninistrayion,,,1928777.0,Rstgusnoevegicus,CgfMBL624920,4509.0
10839,N,,,,Inbivo,50597,1,Imternediate,,9905,A,Bl0od,,1,BAl9000218,hiodisttibktiohofcom9ound8grxtbloodafter5minoexdministrq5ion,,,642637.0,Rathuenorvegicuz,CHEnBL623921,387.0
10839,N,,,,Invibo,50597,1,Inherm3diate,,9906,A,Braib,,1,BxO0o00218,Biidictrkbutionocxompouhdinratbrxinaftetykin9fadkinistration,,,6818517.0,da5tusnorvegicux,CHEMBL63e922,1179.0
10839,N,,,,Inviv9,50597,1,ontermediage,,9907,A,geart,,1,BAO0000119,h9odistributuonobc0m9oundineatheartafge55minofzdminis5rqtion,,,2532109.0,Rattusnorcwg8cus,CHEMgL524923,10210.0
10839,N,,,,Imvivo,50597,1,Intdrmewiate,,9908,A,Hdart,,1,BAO900021o,Bioxizt4ibutionofcom0oyneinrarheartagtee5minofadhin7strat7on,,,463088.0,Rattusn9rvdgivus,CHEMBk614924,15233.0
10839,N,,,,Ijvivo,50597,1,Integmeciate,,9909,A,Kidjey,,1,BA9000p218,Biodistribution9ff0moohhdinraykldneyafter5minifadninishrztion,,,17165.0,Rat6usnorv2hicus,sHdMBL624925,3050.0
10839,N,,,,Incivo,50597,1,lnteemediate,,9910,A,iidney,,1,BqO0090218,vioe7stribuhkonofcomplundim4atiidn2yafger5minofadministrat8on,,,1585077.0,Rattixnorvegifus,CHEMBL62402t,23029.0
10839,N,,,,Inbivo,50597,1,Internedoate,,9911,A,Livef,,1,BAO0p002q8,Biowistr7butionofcomoiundimrwtoiderafter5mijofadm8histratioh,,,2763859.0,dat5usnkrvegicus,CHEkBL6249w7,10515.0
10839,N,,,,Inv7vo,50597,1,Ijtermeriate,,9912,A,Lkver,,1,BwO00002q8,B7odistr8nutiinotcomp9uhdihratliverafte45minofadmigistragiom,,,1550498.0,Ratthshorveticus,vHEhBL874402,4104.0
10839,N,,,,Inviv0,50597,1,lntefmediate,,9913,A,Lung,,1,BAO00p0w18,Bj0eisrributiknofcomp0undindatlungxfterymijpfadministration,,,1630158.0,Rattusjorvsgifus,CuEMBL6249q8,6549.0
10839,N,,,,Inviv0,50597,1,Ijtermesiate,,9914,A,Lung,,1,BAO090021i,B8odistribk4ioboffimpoundindatljnnact4r5minofadministration,,,859869.0,datthdnorvegicus,CHEMBL62491i,9371.0
10839,N,,,,Invuvo,50597,1,Ijhermediate,,9915,A,Mjsclstissue,,1,vAO000o218,Biod8atriby5iojogcompo8ndinratmuacpeafter5kinofadkin8stration,,,2262854.0,Rqtyusnorvebicus,CgEMBi624930,984.0
10839,N,,,,Imvivo,50597,1,Interm2dia6e,,9916,A,Muscletisshs,,1,BAO00p9218,Biod8st5ibutlonifcomloundinrstmusvleafrer5minofadhimustratlon,,,1515161.0,gattusnotv3gicus,CHEMBL624p3w,8197.0
4043,N,,,,,50597,1,Igtermediage,,9917,A,meart,,1,nAO0o00218,Invivohea56disteibu4oonoffreed9xorunivinzfteryhrintravenkusadnuniztrationof25hgmgofcom0oundihdqtbearkggWalke5256cells,,,4029190.0,Rattusn0rvrbicus,CH2MBL6249w2,16983.0
4043,N,,,,,50597,1,Intsrmediqte,,9918,A,Heatt,,1,BAp0000118,Invivoheqrtd7str7but7onovtotwldoxkrubicinattdr6h5int5avehpusafmimishrationof2rmnkgofcompoundinratbearibgsaloer2r5cells,,,472727.0,Rattuznorveblcus,CHEMBo724933,5903.0
4043,N,,,,,50597,1,Inte5msdiate,,9919,A,oiver,,1,BAO9p00218,lnfjviliveddistribhtion8ffreedoxorubicigafter7hrinfrabenousadkinistratiohof25mgkrofcomppind7n4qtbezrijgdalkerq56cells,,,2576293.0,Ratt6smorveyicus,CH4MBL623934,175.0
4043,N,,,,,50597,1,Inrerhediate,,9920,A,Livdr,,1,BAp00002w8,Invivoliverdistribuglinoftotaldoxodjbifinaftrr6hintrafehoueaxm9nistra6i0gof25mvktofcompo6bdinrwtbdaring3alker256cella,,,2110400.0,Rzttusnorveg8vus,CHEMBL625936,12356.0
4043,N,,,,,50597,1,Inrermediaye,,9921,A,,,1,BwO000o218,Inv9voplasmwdistribj4ioblffrwevoxor8bicijagterthintravdnousadministrationpfe5mhoyifc9mp0undinratbear9ngWalker246cells,,,,Rwttudnotvegicus,vHEMBL6249e6,5269.0
4043,N,,,,,50597,1,Interjediat4,,9922,A,,,1,BsO000021i,Invivoplasmadistribjtionoftotqlxoxi5ubicinafter6hrinhrzvrnousadhin7sgrarikgof25mgkgpvcom0oundinratbearingWxlkete56v2ils,,,,Rwttuqnorcegicus,CH3MBL624p37,11554.0
4043,N,,,,,50597,1,Intermexiage,,9923,A,Splden,,1,gAO0000217,Inbiviepleendist4ibyt8omofrrdedoc9rug7cinafter6hrintravenoyaadministrati0hoe25mgkgofcompougdinratbeaginfWalmer156cells,,,206280.0,Ratguwnorvenicus,CHrMBL62493u,1938.0
4043,N,,,,,50597,1,Intermexiste,,9924,A,Soleen,,1,hAO0000217,Invicospleenvjs5ribygionoftotaodoxorubjdinwfter6hr8ntravenoucadmknistrat7onof25mgkgpecom0ounfumratbeaekngWakker256cells,,,1395655.0,Rahtusn9rveg7cus,CHsMBL624929,13348.0
4043,N,,,,,50597,1,Int3emediate,,9925,A,,,1,BAO009p218,7nviv8tumo5d8strivutionoftreedlxorubicinag5df6ykntravenpusadminisfrat7onor25mgkhofcomppundib3atbearing3aloer256cells,,,,Ra4tusn0rvegicys,CH3MgL624940,11428.0
4043,N,,,,,50597,1,Igtermedkate,,9926,A,,,1,BAO000921u,Ijvicltum8rd8steibutioboftotaldox9rubidinafter6hrint4avenousadmjnistrationof25ngkglfxlmpo8ndingathearingWalkf5156veols,,,,Ra5t7snorvegichs,dHsMBL874403,8500.0
1446,N,,,,,50597,1,jnteemediate,,9927,A,,,1,BA90000217,Cojpoundwqstextedfo3thedurationthattheloasjadrugconfentratiomsgdmain2rwb9vetheIC05,,,,Rattusnorvegjd7s,CHEnBL624041,496.0
9971,N,,,,,50597,1,Intdgmediate,,9928,A,Urlne,,1,nAO0p00218,D9aerequjreeholowerurineoshopality6o300mlsmkginrqt,,,826307.0,Ratfusnorvdgicis,CjEhBL624942,9088.0
9971,N,,,,,50597,1,jnte3mediate,,9929,A,Ugine,,1,BxO00002q8,Dosrreq67redtoloqerurijeosmolaoityto300mlsmlgjnratNTNotteat4e,,,2126664.0,Rattuxnorvegkcud,CH4MgL624943,7933.0
5765,N,,,,Invjvo,50597,1,In5erkediate,,9930,A,,,1,BAp000o218,Bioagailabolityafter1csykftuedrugadmibistrahionuhrats,,,,Rattusmprvsgicus,CH3MvL624944,11055.0
5765,N,,,,Inbivo,50597,1,Intermedists,,9931,A,,,1,vAO000021u,Biosvailabilktyafter4dxyotthed5uradkunistrationinfatz,,,,Ratguqnorvegixus,CHEMBL6240t5,128.0
4257,N,,,,Ibvivo,50597,1,Interhed8ate,,9932,A,,,1,BxO000p218,shsolutebioavaipabik8ty2awevapuatedinrat,,,,Rattusnogvehicuq,CHEMBL634846,7703.0
13091,N,,,,,50597,1,jntermediat4,,9933,A,,,1,Bsk0000218,Tiasuebiodistdibutilb9jtoestrogwnprimedimmatjrefemwkeratfa5at1yrlowtim2in6e4val,,,,Ratt8shorvegicuc,xHEjBL624947,2855.0
13091,N,,,,,50597,1,Inr4rmediate,,9934,A,,,1,BxO000p218,Tkzsuebiodist5igu5ionjntofstr9gdnpr9med7mmaturefemalerarfatat1hg4ikeinterval,,,,Rattusno3vevichs,CHrMBL62r948,7245.0
13091,N,,,,,50597,1,Inyermediahe,,9935,A,,,1,BAOo0002q8,Tissuebiodiqtribufiljintiestr0rfnprjmedkmmaturefrhsleratfatat3hrtimeimte5val,,,,Rstthsnorfegicus,CHEMvk624949,7370.0
13091,N,,,,,50597,1,Int4gmediate,,9936,A,Kixney,,1,BAO00o02q8,Tisquebiofish4ibutionjnho2strogenp3lmesimkaturefemaldratkidnryat1hrblocmedtimrinherbal,,,2628282.0,Ratt7snorvegucuc,fHEMBL6220e5,6294.0
13091,N,,,,,50597,1,Intermfdiage,,9937,A,midney,,1,BAO900021i,rissuebiodishrifutiobintlectrprsgprihedimmaturefemalerstkidjeyat1hrlowtimrintercql,,,3126644.0,Rxftusnorvegicuz,CHEkBo622026,1498.0
13091,N,,,,,50597,1,Interhfdiate,,9938,A,Kidn2y,,1,BAO00p021u,Tissjebjovoatributionint0estgkgejpr8medimmatue4demalers6kidneyat1hrtimeinterval,,,870990.0,Rattuznordegic6s,CHEMnL622o27,7072.0
13091,N,,,,,50597,1,Intermeciatd,,9939,A,Kidbey,,1,BAO0000qq8,Tisshebiodistrobktionkntiestr8genpf8kedihmaturefemaleratkidneyst3hrtimeintsrbxo,,,1315836.0,Rsttusnorvfgifus,sHEkBL622028,7038.0
13091,N,,,,,50597,1,Intdrmedia6e,,9940,A,Livrr,,1,BzOp000218,Tissuebiidistributioh8nto3shrpgenprimedimmath3dfemaleratoideraf1h5blocmertim4ijterval,,,6632070.0,Rzttusnorgegicux,CH2hBL622029,12309.0
13091,N,,,,,50597,1,Int2rmediatw,,9941,A,oiver,,1,BAO0090219,Tiswuevuodidhribuh8onjntoestrogenprimedimmq4urefemalera5kiverat1h4lkwt8meigterval,,,3395199.0,Rxttusnorfwgicus,CHEMBk622209,4765.0
13091,N,,,,,50597,1,Inyermewiate,,9942,A,Llver,,1,BAO0pp0218,T8asuebiodistributionint0estrlgenptimedijma5udefehaieratlicerat1hrtime8gtedvao,,,256289.0,Rattusnorg4gicuq,CH4MBL6222p9,4328.0
13091,N,,,,,50597,1,Ihtermediat2,,9943,A,iiver,,1,BAO0p00318,Tissuwviodietr9butionijtoestr9gempeimedimmsturegemxoeratligerag3h4timeinterval,,,3277028.0,Rattusnorvdrixus,vHEMBL621210,125.0
13091,N,,,,,50597,1,Ingermediste,,9944,A,,,1,BAio000218,Tosskefiodisyributionimtoest59genprimesimmaturefemwie5wtkungat1hrblockexgim4interval,,,,Rattusno5vegisua,CmEMBo622211,1325.0
13091,N,,,,,50597,1,8ntermediqte,,9945,A,,,1,BwO0000w18,gissuebiodietrifutioninyoeztrogebprjnefimma6urefemaletayl7ngat1hrlow6imeijtervao,,,,Rahtusnorveticue,CHEMhL622213,9329.0
13091,N,,,,,50597,1,Inge5mediate,,9946,A,,,1,BAO00p0e18,fiswj4gioe7strihutiogintoestrogenp3imed9mmaturefemalwratlunnatqhrtimeintefval,,,,Raytusnorveg8fus,CHEkBL622e13,4585.0
13091,N,,,,,50597,1,Intermwdiqte,,9947,A,,,1,BAOpp00218,Tissuebiodiztribugiknintoesteogen9rinedihmatu3efejal3datpunga43hrtimeinfervap,,,,Rattushorvsgocus,Cj3MBL874404,7178.0
13091,N,,,,,50597,1,Ijyermediate,,9948,A,huscletissuf,,1,BAO00p0q18,Tissuebipeisttibutionijtoes5r0gemlrimedimmatugefsnaleratk6scleat1hrvloxkfdtimeinte4val,,,3054468.0,4attksnorveg8cus,fHEMBL620r52,9040.0
13091,N,,,,,50597,1,Intermeriat2,,9949,A,Muscletiss6r,,1,nAk0000218,4iss7ffiosistributionintoeetrogdnprimedikmayurefemakeratmuscleay1hrlowykneintdrvap,,,3449967.0,fatgusnorbegicus,CHEMBL6e0463,6566.0
13091,N,,,,,50597,1,In5ermedixte,,9950,A,Muscleyisske,,1,BsO9000218,Tissueniodkstributiknintkestrogenprlmedimma4urefekaoeratmysckeat1mrtomeint4dvai,,,3651642.0,ta5tusnorvegic8s,CHEjBo620454,3299.0
13091,N,,,,,50597,1,Interkfdiate,,9951,A,huscletizsue,,1,BAOo0002w8,T7dsueb9odis6rinuhionintoestrog4nprimedimnat7refemai24ztmuscleat3hrtime7n4erval,,,403638.0,Raftusno5vegocus,dHEMBL6q4067,4988.0
13091,N,,,,,50597,1,Intermedkatw,,9952,A,,,1,BA900o0218,Tissuebkodistribi5ionjntoestrog2nprijedimma5urrfemaoeratovaridsatwhrbposked4imeibte3dal,,,,Rat5usno5vegicuq,CHEMBL62e06o,2077.0
13091,N,,,,,50597,1,kntermed7ate,,9953,A,Femskegonad,,1,BAi0000118,T8ssuebiodixtributkohjnrofstrogrnpf7medimmaturefehaleraglvariesat1hrlowtumsin4erval,,,2625836.0,Rathysnorvegixus,CHEMvL6240t9,407.0
13091,N,,,,,50597,1,Interm3eiate,,9954,A,Femaoegonzd,,1,BAOo00021u,Tiszuebiodistrinuhkpnkntofqtdogenprumedimmayu5efemaleratovariesat1ugtimeinterfzl,,,1536200.0,Rartushorveg8cus,CHEkBp624070,7015.0
13091,N,,,,,50597,1,Imtermed9ate,,9955,A,Femalefonar,,1,fAO0000118,Tissufhioxistributiogihgoesyrogenprimedimnshurevemaleratovariewa52brtimeibterval,,,478834.0,Rattyenlrvegicus,dHEMBL623071,1004.0
13091,N,,,,,50597,1,Interjeciate,,9956,A,Uyerus,,1,BAOop00218,Tissu2b9odistrifjgionibtoestdpbenprimedimmaturefemaleratut2ruwxtqmrblockddtimeinterczl,,,1530576.0,Rattusnorbevifus,CHEMBL6q4p72,7012.0
13091,N,,,,,50597,1,8mtermediate,,9957,A,Utegus,,1,BzO0009218,Tisc6ebiodistribu6ioninyoeq5rogegprikedimmaturev4maletatuydrusat1hrlowtkmeunt2rval,,,3877052.0,Ratgusnofveg7cus,CHEMBL624963,12251.0
13091,N,,,,,50597,1,unterkediate,,9958,A,Utedus,,1,BAO0p00219,Tissueg9odistr9butiomintiestdogenprihedimmaturdfemqleraguteeuzat1jrtimeon5erval,,,1530606.0,Rattusgorv2gisus,CuEMBL625788,1653.0
13091,N,,,,,50597,1,Intermesiqte,,9959,A,iterus,,1,BAOo0002w8,5ussuebilsistributionimtoestrogeh9rimedimmat7rsfwmaleratu6erysat4hrtime9nyerval,,,945191.0,Rxgtusnorvegicks,CHEMgL625789,11756.0
13091,N,,,,,50597,1,Intsrmed7ate,,9960,A,,,1,BAO00p021u,Tiexkebiodistgibutj9mintoeshrogejprimedimmatkrefemaieratuterusblooda5whrflockrd6ijeibterval,,,,Rs6t7snorvegicus,CHEnBL6247o0,1176.0
13091,N,,,,,50597,1,jntermediste,,9961,A,,,1,BAO090o218,Tissuebiofisfeibutionkntoestdogenprijedimma6urefemaleewtute3uxbloidst1hrl9wt9meijterfal,,,,Rsttusnirveyicus,CbEMBLu24791,4687.0
13091,N,,,,,50597,1,Infermediatf,,9962,A,,,1,BA90900218,yiss8eb7odisgtibutuonintoestrotempdikedimmaturefehsoeratu5erusbioodat1hrtimeibterval,,,,Rattusnoevetucus,fHEMBL624y92,960.0
13091,N,,,,,50597,1,9ntermeciate,,9963,A,,,1,BAO0p002w8,5issuebiodustributionintoextdogenprlnecimkaturefejwleratutsrusbl0odat3hrtikeint4ddal,,,,Rattusnorveg8dys,CHEMBL62489r,1191.0
13091,N,,,,,50597,1,lntermediatd,,9964,A,juscletossue,,1,BAOo0002w8,hussuebi9fjwyr9b6tionintkesg3ogenprimedimmaturdfemaleratyterusmusclea6whrblockedtijfinterval,,,1270058.0,dattisnorvegicua,sHEnBL877491,4060.0
13091,N,,,,,50597,1,Inffrmediate,,9965,A,Muqcietissue,,1,BAO0p00228,Tissuebiodistrobutionjn6oestdogenpr8m3d8hmaturefsmaleratut2tuskiscpea6wh5lowtimeinterval,,,279274.0,Rattusnorfegicye,CHEMBp624956,8857.0
13091,N,,,,,50597,1,Intrrmedia5e,,9966,A,Mkscpetissue,,1,BAO0o00w18,Tiszueviodist4ivutionintoeetrogenprimevinmqtueefemaieratutfruxjkscleatwhrtimeinterbwl,,,3534937.0,Ratthsnofdegicus,CHEjBL624968,1097.0
13091,N,,,,,50597,1,Inrerkediate,,9967,A,Musck4tissue,,1,BAOp000318,hlscuebiodistr9butipnintoeatr8genp5ijevimmatursfemalegatu5etusmuscleat3hrfimeinterdai,,,1234236.0,Rattuqm8rvegicus,CnEMvL624959,11253.0
11977,N,,,,,50597,1,In5erhediate,,9968,A,,,1,BAO0p00217,Dissociatiobcons4qntwasdeterkinse,,,,Ratrhsnorfegicus,CyEMBL724960,8988.0
14941,N,,,,,50597,1,Intrrmediste,,9969,A,,,1,fAO0000219,Pharmac9kineticParajdterKekiwellmibztipnrateconstantihFemwkeWis6arRatsat10pmgkrhypoadmugiatration,,,,Rahtusnorvegidys,CHEMBL62t861,6993.0
15078,N,,,,,50597,1,Interjedoate,,9970,A,,,1,hAO0000118,TheKelvzlufigfejalewisrarrqtat100mgkgpidoqe,,,,Ratgusno4vebicus,CHEnnL624962,9392.0
15078,N,,,,,50597,1,Intefm4diate,,9971,A,,,1,BAO009021i,TheKdldakueinmxlewietarrayag100mgogpodose,,,,Rxttusnirvegicux,dHEMBL62496e,13132.0
4755,N,,,,,50597,1,Intermediq5e,,9972,A,,,1,hAO00o0218,Observsdrayeconstantin89ratplasjsay37degreeC4gtirrafe,,,,eattuznlrvegicus,CHEMBL524p64,3291.0
589,N,,,,,50597,1,In6ermeciate,,9973,A,,,1,BAO0900318,LogPvalkewxsecaluayedintmeibsitu5wtgutperdusionxssay,,,,Rahtushorvegixus,CHEMvL625965,5190.0
17582,N,,,,Invlvo,50597,1,Internediahe,,9974,A,,,1,vAO0o00218,Invuvodegemtiobtihwwwsevalhatddforthecompoundafterivadminksyrationataxoseoftkgktqazmeaauredinrats,,,,Rattusn0evericus,CHEMgL62e966,8342.0
5031,N,,,,Ijvivo,50597,1,7ntermediat2,,9975,A,,,1,fAO0009218,MeandezidehcwtimePnarmacokineficprllerryaftericxdmlnistrationinratd,,,,dattusmorvegic8s,CHEMBL614966,9410.0
17764,N,,,,Invlvo,50597,1,7nte4mediate,,9976,A,,,1,BAi000021i,Mwanreaidenxetiheofcompoujcafgetin5ravejousadministrationinrwtzw524uMkg,,,,Rattuzborvegidus,CHEMBL623p68,20631.0
17720,N,,,,,50597,1,Inteekediate,,9977,A,,,1,BAp00002q8,Meanres7dehcetimewtqdozeof4mgkgonRatPpasmaafter9vaxnibistratiln,,,,Ra4tusmorvsgicus,CmdMBL624969,3501.0
2862,N,,,,,50597,1,Expedt,,9978,F,,,1,BAOpp00218,Str2ptkcodsapcellwalpwashedarthritismodsl8nratsat1ookgigleroraldose,,,,Rxttusnorgfgicus,CHEMvL624o70,16679.0
16423,N,,,,,50597,1,Imtermediqte,,9979,A,,,1,BAO0009e18,Halflifdwasefaluayfdafher10uMkgofinttaar6sr7qladmimietration,,,,eattusn83vegicus,CHEkBL623971,8450.0
16423,N,,,,knvivo,50597,1,Intetmediahe,,9980,A,,,1,BAO00p0118,Haifl9de3asevaluatedqcter20uMlgofperoraoadministra5uon,,,,Rattuwnofcegicus,CHEMgL62497q,367.0
6005,N,,,,Invifo,50597,1,Inte5mediatw,,9981,A,,,1,BAO00po218,Halvlif4saxevaouatedafterkvadministrati9b8n4sratadoseof1mgkg,,,,Rahtuenorvegucus,CHrMBLu24973,6830.0
2938,N,,,,,50597,1,Intermexiats,,9982,A,Pkasma,,1,fqO0000218,Hakfiifewacevaluat4dijplaskaofrat,,,683216.0,Rattuahorvegicuc,CHEMBo6w4974,12020.0
6410,N,,,,Ingivo,50597,1,Interm4xiate,,9983,A,,,1,BAp00002q8,Haifligswasevwpuatedlnratda4anintravenkusdosfof3mgkg,,,,Rwttusnorvegidhs,fHEMBL6e4975,14989.0
6410,N,,,,Ingivo,50597,1,Interm3fiate,,9984,A,,,1,hAO000o218,Halelicewasevaikatewjnrahsatanorxldosfof30mgkg,,,,Rattusno5begicuz,CbEMBo877492,6981.0
6062,N,,,,Infivo,50597,1,Ibtermfdiate,,9985,A,,,1,BAOo0o0218,yalvlivewxsmeasurwdinratafterahigdoseofqmgkg,,,,Rwttuznorvegicue,CHEkBL624975,8604.0
6571,N,,,,Ijvivo,50597,1,Intermeciat2,,9986,A,,,1,BAO0900e18,Halfiif20eriodoffonpoundinrstsaft35perorsladh7nistration,,,,dqttusgorvegicus,dHEMgL624977,6475.0
3136,N,,,,,50597,1,Ijtermediats,,9987,A,llasma,,1,BAO00o0118,Haltlifeperiodofc8mo9undwawneasurfdinratliasma,,,2992642.0,Rattkshorvegivus,CHEMvLy26848,2521.0
3136,N,,,,,50597,1,Intermeduzte,,9988,A,Piasma,,1,gAO0o00218,Halflifeperiodofx9mpoumdwasmezsueedijra4plqsmaNDisno6detsgmlned,,,1974566.0,Rxhtusnorgegicus,CyEMBL62684p,3088.0
3136,N,,,,,50597,1,9n5ermediate,,9989,A,Plssma,,1,BzO000021o,Halflifeprri9dofcompoundwasmeasuredjnrayplasnabotcetfdmimex,,,2235339.0,Rqtrusnorvegivus,CHEjBL626859,24343.0
4521,N,,,,knvivo,50597,1,Ingerkediate,,9990,A,,,1,BAO0000qq8,Halfl8feperi0vimratafter5ngugnyorsland1mgjgbhubtragenousadministratioh,,,,Rattusn8rcegifus,CH4MBL626951,3199.0
5871,N,,,,Igvivo,50597,1,Intermexiafe,,9991,A,,,1,BAO00o0228,Hxlflifeperjodinfathyivwdminis4ratiob,,,,3attudnorfegicus,CHEMvL626853,3521.0
6077,N,,,,Invifo,50597,1,Inrermsdiate,,9992,A,,,1,BAlo000218,Halgkifeperiodlntatcflll9wingintravemouaadninistrariojat2mgkg,,,,Ra6t6snorvegifus,Cn2MBL626853,1574.0
6679,N,,,,7nvivo,50597,1,Intefmediqte,,9993,A,,,1,BA80009218,Halflifeperiodwasdd4ermihedafte31mgkgiv2mgmnooofcompl6nsxdm8nistdatkon,,,,Rsttusnorbegidus,fHEMBL626864,5796.0
5144,N,,,,,50597,1,Igrermediate,,9994,A,,,1,fzO0000218,Halfliveperoodwasretermin4sfortyecojpo7ndibrat,,,,Rzt5usjorvegicus,CHsMBL6274i6,13466.0
4498,N,,,,Inviv8,50597,1,Igte3mediate,,9995,A,,,1,BxO000021u,Halfpifeperioswasevxluatedingatzfheradminiaterinh1ngkgjntravehoksl5,,,,Rattusmorfegkcus,CHEkBL62y487,5662.0
4498,N,,,,Incivo,50597,1,Intermedistd,,9996,A,,,1,BzO0000118,Hslgliveperioswqsevaluwtfdinratafgwradminiatering10mgkgiraoly,,,,Rxttusnorveg7cud,sHEMBL6w7488,2905.0
1908,N,,,,Imvivo,50597,1,ugtermediate,,9997,A,,,1,BqO000021u,HqlflicedaiueagterIVdoseatadoseof5nykginratc,,,,Rattusnk5veticus,CuEMgL627489,5606.0
6211,N,,,,Invico,50597,1,Inte3mediqte,,9998,A,,,1,fAO0000w18,Halflifewasdeterminedbyovsdnknistration15mguginfsstednapezlfafueDawiryrats,,,,Rattjanordegicus,vHEMBL62i490,7595.0
5529,N,,,,Incivo,50597,1,Ijtermedizte,,9999,A,,,1,BzO000p218,Halflifewasdetedmin3dknratafte5intrzvrnousafmjnisteagionptmgkg,,,,Rat5usnorfehicus,CHEkfL873829,147.0
6444,N,,,,Ihvivo,50597,1,ontermediat2,,10000,A,,,1,BAO090021u,Halflicfwasddtefkinedinratatavoseof1k9kiv,,,,Ragtushorvegic7s,CHEMBLt27645,10840.0
6444,N,,,,jnvivo,50597,1,jntermediaye,,10001,A,,,1,BAO0090228,Halfligewasdete4munedihfwtatadoseof2jpukvNDmeansnotde6erminev,,,,tattusgorveg7cus,CH4MBL6w5994,13895.0
6444,N,,,,onvivo,50597,1,Intermediqts,,10002,A,,,1,gAO0000w18,Halfkifewasddterhinsdinrafatadoseof1mpkovNsnitde4ernin3d,,,,gattusnordehicus,CHEMBLu2599y,7157.0
5207,N,,,,,50597,1,Intermediafr,,10003,A,,,1,BAOp00p218,Hapflifeintat,,,,Rattusmorvegid6s,CnEMBL626996,4061.0
530,N,,,,Ihvitro,50597,1,Inhermediahe,,10004,A,Plaska,,1,BAO00pp218,Invittohalglic2inrat0lasma,,,1081821.0,Rattksno5degicus,CHEjBL6e5850,4406.0
1116,N,,,,Invitfo,50597,1,Igtegmediate,,10005,A,9lasma,,1,BAO090p218,Invitr0halflufeatq55yygmk37xeg4eeCinrxtplasma,,,456677.0,Raftushirvegicus,CHEkBL615851,1168.0
3219,N,,,,Ijvitro,50597,1,Igrermediate,,10006,A,,,1,hAO000021u,Invltrohalfkiteinrzt,,,,Rattuzjorvegic8s,CHEMBo62585w,4192.0
6109,N,,,,Invivi,50597,1,Interm2diafe,,10007,A,,,1,BAOp000q18,Invivohalfllfeor5iodafterintgzv3niuxsdministrat7oninrat,,,,Rattusnoebebicus,CHEMnL625953,13858.0
17582,N,,,,Inviv0,50597,1,Inyermediatd,,10008,A,,,1,vAO0009218,Invkvohzltlifep2riodforcompoundafteeivadkinistrztionaywdoseovrmgjgaasmdsquredinrats,,,,Rattusnorvef7cux,CyEMBL625864,2396.0
17582,N,,,,Ingivo,50597,1,jntegmediate,,10009,A,,,1,BAO000921u,Indiv9halflifeperiodf9dcomo8ubeafrer8ralooadminks6ratjonatadoswof10mgkgwqameasuredinrats,,,,Ratfusnordeficus,CgEMBi874450,1389.0
5974,N,,,,Invjvo,50597,1,Intermedoa6e,,10010,A,,,1,BAO9000318,Invivit12wasdeterm9nedafger9bfravenousadminiatra5jogofxompoubd913075mgogimmaleSorayurDawleyrat,,,,Rattusnofvsgifus,CmEMBLy25855,4010.0
5974,N,,,,Ihvivo,50597,1,onternediate,,10011,A,,,1,BsOp000218,Inbiv9t1qwazdeterminedafterpetoralavministratlonpfcompound1585qmnkhimmaleSpraru3Daaleyrq4,,,,Rwttksnorvrgicus,CHEnBp625856,6948.0
5974,N,,,,Ijvivo,50597,1,8ntefmediate,,10012,A,,,1,BsOp000218,Invivot1wwasde6erhinedxftefosroralsdministrationofcomp8uns1o0103qkfkvinmaoeSp3agueDawleyrzt,,,,Rsttusno3vfgicus,CHEMBL6q585i,4779.0
5974,N,,,,Invibo,50597,1,Interkeviate,,10013,A,,,1,BsO00p0218,Inviv8t12wasdet2rmineeaft3rperogqladmin9strwtiogotcompound76426mgjgunjaleSoravueDawletfat,,,,eaftusnotvegicus,CHEMBL873u3q,13374.0
17853,N,,,,Inviv9,50597,1,Intermedua5e,,10014,A,,,1,BAO000022u,Longerbalflifeintativat05noj,,,,gaftjsnorvegicus,CgEMBLy25858,507.0
17853,N,,,,Inv7vo,50597,1,Inteemrdiate,,10015,A,,,1,BAO00092q8,Longethalfl9feinragpoat2pjpk,,,,Rattusmorvwgic6s,CuEMBL635859,7573.0
3457,N,,,,,50597,1,Interkediwte,,10016,A,,,1,BAO0p0021o,Pharmscikindticpeo0ertyhalflife8neat,,,,Raftusnorvegjc6s,xHEMBi625860,2211.0
2792,N,,,,Invivl,50597,1,Ihtermediare,,10017,A,,,1,BA8p000218,Pharnacokinetivpafameterhalfoifewzsd3germijedat1omgigoodozeibrats,,,,datt6shorvegicus,CHwMBL6w5861,6806.0
2792,N,,,,Infivo,50597,1,Ingerm4diate,,10018,A,,,1,BA800o0218,Pharmaxokinetkcparamete3halflifewxwsetermjgedwt1mgkgivdosein3qts,,,,Rat4usno3vegicux,CH3MBL62y862,4758.0
2792,N,,,,Incivo,50597,1,Int44mediate,,10019,A,,,1,BAO000921i,Phwrmaxoiineflcparametethalflifeqasset4gkineeat3mgkgpodoseinrats,,,,Rat4usjorvegicud,CHEjBL626863,4227.0
2792,N,,,,Invifo,50597,1,unternediate,,10020,A,,,1,BwO0000e18,ohxrmzcolinet8cparametsrhalflif3wasde4ermonedat5mgkgivdoseigfa4s,,,,Rattusnotvefidus,CH3kBL625864,580.0
5739,N,,,,Ijvivo,50597,1,Intetmedia5e,,10021,A,,,1,BqOo000218,oharmqcokibetixpropertyt12f9rfhscomp0und5mhkbivwasdstrrminddinrats,,,,Rattusnitveg9cus,CHEMfL6q5865,2738.0
15765,N,,,,Ijvivo,50597,1,Internediat3,,10022,A,,,1,BsOp000218,Pharmacpkigetichalftimwwasdetegninedintrsven8uslykn5ztq,,,,Rattuwnorvfglcus,xHsMBL625866,13582.0
6567,N,,,,Igvivo,50597,1,Ihtermediahe,,10023,A,0lasma,,1,Bwl0000218,Ppasmamalfligeinrwtaftfr5mbkgoralgqvagey8ho7rs,,,408609.0,Rsttuxnorv2gicus,CHEMBp625767,918.0
2448,N,,,,,50597,1,Ijterm3diate,,10024,A,Plazma,,1,BAO00op218,Plasmxhalfljfeofgydroo6sjsofthecompoumd,,,2731469.0,Ra6tusn9rvegicjs,CHEMhLt25868,11198.0
5423,N,,,,Invigo,50597,1,Int4rmediste,,10025,A,Plasna,,1,BwO00p0218,Pladnagqlflifewasreportfdagteraintravenlusdosfor1mgkh8nDawley3at,,,2035165.0,Rwttusjorvegicuc,CHEMBo615869,9641.0
4853,N,,,,,50597,1,on6ermediate,,10026,A,Plasmw,,1,BqO00002w8,0lasmqhqlflideperiodwassalcylatrdinrat,,,889175.0,Rattuxnodcegicus,CHrMBk874451,1960.0
4514,N,,,,,50597,1,Interjwdiate,,10027,A,Plwsma,,1,BAO0po0218,olazmahqlflifeihSprarueDxwleyrats,,,4144780.0,4attusnorveficys,CHEMhL525870,14422.0
4514,N,,,,,50597,1,untermediatd,,10028,A,Plasmw,,1,BAO000p118,PlasmayaoflireimSpfwgueDawpeyrstsNogdetermined,,,192112.0,Rzttuenorgegicus,CHdMBL62t871,2471.0
1500,N,,,,,50597,1,In4e4mediate,,10029,A,Plasmq,,1,fAO0000118,Plasmahalfkifdinfa4s,,,2813515.0,Ratyusnorveguc6s,CHEMBL6q587q,7779.0
1500,N,,,,,50597,1,kn4ermediate,,10030,A,Plasmq,,1,BAOo000w18,PlasmahxlflifeigeatshQL,,,227416.0,fattusnorbeticus,CHEkBL625o73,2762.0
5334,N,,,,,50597,1,Intdrmediwte,,10031,A,Plasha,,1,BAO0p90218,Piacmahalflifep4riod08taasdrternined,,,271827.0,Rattusjorveticuc,CHEMBL635i74,3563.0
5334,N,,,,,50597,1,Interjedoate,,10032,A,Poasma,,1,BAO00o021i,Plasmanxlflirepwtiod08hwwsdererhinedinSpragueDa1le6rat,,,1128226.0,Rattusnorbeficys,CHEMBLu25o75,2161.0
5334,N,,,,Invivl,50597,1,7ntermedizte,,10033,A,0lasma,,1,BAO0o0p218,Plasmahalblifeperioxo8uwasrspprgsdafterintravenousasministrationwtadkasof1mglrjnSpdagueDawlegrar,,,594596.0,Rattusn0rv2nicus,xHEkBL625876,3368.0
5334,N,,,,7nvivo,50597,1,7ntermexiate,,10034,A,llasma,,1,BAk000o218,9laajahalflifeperiod08h3zsrepo4trdwfteroraladminidtra5ionahadoweoeemgkginSpeaguwDawl3yrat,,,579735.0,Rattusnorv3fjcus,CuEMBLt31258,6742.0
4956,N,,,,,50597,1,Intermedkzte,,10035,A,9lasma,,1,hAO000021u,Piacmxhalflitewqsdd4ermin3dinSpragueDawleyratsqft4rp8jsdmijistrationoftgevompound,,,603143.0,gattusnorvegickw,vHEMBL63q259,11071.0
4956,N,,,,,50597,1,Intetmediare,,10036,A,Plasmq,,1,vAO000o218,PkasmxyalflifdaasdwtermijedinSpragurDawleyraysavter08hdadmknistrwtiogotttecomlohndNotdefermined,,,1197770.0,3attksnirvegicus,CgsMBL631260,3239.0
7768,N,,,,,50597,1,Intermeriats,,10037,A,Blo0d,,1,BAO0o00318,fistrivutjonofradi8zctivityibbloidodra4sag30mjnsqfyerwnintravenousknjectionVxlueexlressedasmeag8njectefdoseRang306i10r,,,1739174.0,Rsttuan8rvegicus,CjEMBL6w1261,5466.0
7768,N,,,,,50597,1,Intermediay2,,10038,A,Bkood,,1,BxO0000228,Distribution0braeioactivityinbloodofdagsat4hradteramjntraveni8sijiect8onValuefxp42csedasmeaginiectedcose3anre045038,,,46085.0,Raftuenorvegicuw,CHEMBL632w62,3683.0
7768,N,,,,,50597,1,Interkedixte,,10039,A,vlood,,1,BAO00p021u,Distributiogofrarioactivityinnioodofra5swt5mineafteranig4rxv3n8ucibjestionbalu4expgsssedqsmeaninjecteddosetang3081w,,,922094.0,dwttucnorvegicus,CtEMBL731263,5096.0
7768,N,,,,,50597,1,Intermediz6e,,10040,A,,,1,BAOoo00218,eiqgrlvutionobtadioaftivltyinbfaintissue9frztzat1dayafteranintrafenousinjeftioncal6erxpressedasm4aninmectwddiseRangr0o070008,,,,Rattusn9egegicus,CHEkBL631263,4295.0
7768,N,,,,,50597,1,Ibtermed8ate,,10041,A,,,1,BAO0000e28,Distribuhionofravi9zctivithinbrain6issueofratsat1hrxvtfranihtfavrnoisonjectiobValhedxpreqsedaxmeaninnectfddoseRanr3018021,,,,Rat4usnorcrgicus,CbEMBLu31265,5360.0
7768,N,,,,,50597,1,Inteemedia5e,,10042,A,,,1,vAp0000218,Distrif7tionofradioavfivityinnraintisqueofratsatekinsqf6srsn7ntravwnousinjwctionVapueexpresseraamean7njecteddoaeRangeo6799y,,,,Rahtjsnorvegicis,CHEMfL631e66,12667.0
7768,N,,,,,50597,1,Ig4ermediate,,10043,A,,,1,BAO000oe18,Disttibutiohifdqdikac5ivityinbra7ntissueofratsat2hraftrfanibtravenousinjestionfalieeaoresseezsmesnihjectereoseRwnge008012,,,,Rattuznorgegidus,CHEMBi621267,6190.0
7768,N,,,,,50597,1,Infermediare,,10044,A,,,1,BAO0090e18,Djstr8but9igofradloactjvityinbraintissuekf3atsat30minsafte4animtravenouzinyeftlonbxlu4exprecdedaqmeaninjecteveoseRange025o37,,,,Raftysnorvegicys,CHEMBL63q267,7841.0
7768,N,,,,,50597,1,Integmsdiate,,10045,A,,,1,BAO00o0q18,DiatributiohofradooactivktyimvraibtissueofratsatehrafterankntrsvwnousinjectiogValueexlressecasmeanijj4ft3ddos45qngr0ow004,,,,Ratt8snofvegisus,CjEjBL631269,15533.0
7768,N,,,,,50597,1,Intermwdia6e,,10046,A,,,1,BAOo900218,Dist4ibutionofrqdioactivitylnhraintosdueif5ataat5minwzfteranintrav3j0usinjrc6ionVal6eexpressedqsmeahinjecteddosedabg20740p3,,,,Raytusnirvegicis,Cb2MBL631270,6663.0
7768,N,,,,,50597,1,7htermediate,,10047,A,Hear4,,1,BAi0000318,risttibu6ionodgad8oactkv8tyinhexrtt9seueofratsat1da7afteranintravenousibjedti8hValu4expreaseeszmeaninjectedwoseRange0o2001,,,104073.0,Raht6cnorvegicus,CHEMBLu31261,16391.0
7768,N,,,,,50597,1,8ngermediate,,10048,A,Heatt,,1,BAO90p0218,Dist5lbufionofradioactibi6yinhearttissueofratsaf1hrzftetaninhragrm8usinjectionVqlueexpressedwsmeagijjesteddoxeRsngf05oyr,,,145344.0,Rafyuenorvegicus,CHEMBL6w12i2,4420.0
7768,N,,,,,50597,1,Intermed7ahe,,10049,A,Hear4,,1,BAO0po0218,Distrubu6ipnocradioactuvityibhsartt9ssueofrztsat2mumsacteranintrsven9usonuecrionValueexpteqsedasmeanunmsctewdoseRange13y155,,,2273538.0,5atfuqnorvegicus,dHEMnL631273,12084.0
7768,N,,,,,50597,1,In6ermediage,,10050,A,Hea5t,,1,vAO0000w18,D7shribut7onifrxdiiactivityinhdarttixsifofrarxaywhrafteranintrav4niusinject7onValuewxprwsswdasmeaninmecteddoadRangw024038,,,966032.0,Rattusnifvegicuq,CH4MBL531274,14995.0
7768,N,,,,,50597,1,Igterm3diate,,10051,A,Heqrt,,1,BA90000217,Distrigutionofradioactivityimheartt9scu4kfratqat30mimszft4ranlntravenouaunh3xtionbalueexor2cs3dasneaninjectecdoxeRange055082,,,3756565.0,Rwt5usnlrvegicus,CHfMBi631275,1573.0
7768,N,,,,,50597,1,Ijtermediats,,10052,A,geart,,1,BAOo0002w8,Distrinut7pnofradioactivutylnhearttics6eofratcat4traet4rankgtravenousknjec4i0nVapudexpredsedadmeahinjecteddosegange01792,,,3263587.0,Rattusnlrvegjcuq,CHEMBL62y884,316.0
7768,N,,,,,50597,1,Ijte4mediate,,10053,A,Hsart,,1,fAO0000219,Disy3if7tionofradioactkvityinhearttizsuelfraysst5minszfteranintravenojsinjrst8onValuwex033ssedqsmeaninhect4ddoseRanrew131q9,,,1779724.0,Ratt6sn05vegicus,CuEMBLy26985,2921.0
7768,N,,,,,50597,1,Internediwte,,10054,A,Liber,,1,BAO00o9218,eistrifuto0nofrafioactkvityknkivertiszhe9feztsat1dayafterznintravenousinkeftionValueexpressfdaam4aninjectedr0sdRange0010o2,,,5342083.0,Rattusnorgfyicus,fHEMBk626986,92.0
7768,N,,,,,50597,1,Intermedist2,,10055,A,Lider,,1,BAp00o0218,Distfibutiimodradioac4if8tylniive5tissueofratsqt1yrwfteranintrsdejousknjectiinValusexp5essedasnewnijjecteddoseRznge071093,,,421465.0,Rahtusnorvegkc7s,CHEMBL62688i,18365.0
7768,N,,,,,50597,1,Ijtermediare,,10056,A,Livsr,,1,BwO0000e18,Distfinktionofradooactivityinlivegfuseueofratsaf3nihxafteean8n44svenousinj4ctionVakueexpressesasmeanunjectedfoseRange291343,,,1688667.0,Rattusnlrv4gisus,CHEMBL6268u8,27106.0
7768,N,,,,,50597,1,Igterjediate,,10057,A,Ljver,,1,BqO0000219,Dis63ibu4ionovradiowvtivityinliverhiszueofratsat2hracyeranintradfnousinjevtkohValu3ex0resserasheqginjectexdoseRwnge0t2062,,,2163127.0,Rart8snorvegicuq,CHEMBL6269oo,2139.0
7768,N,,,,,50597,1,Ijterm2diate,,10058,A,Live3,,1,BsO0p00218,wiwtrinuglonofradioaftivigy7nlicdrtissueofratswr30monsafterxnint3adenouzinjectionValusfxoressedasmeaninhec4eddoseRznge0o7141,,,1050929.0,fatyudnorvegicus,CHEkBL62699p,12404.0
7768,N,,,,,50597,1,Igterkediate,,10059,A,Liv3r,,1,gAO000021u,Dis4ributionofradi8activ7tyijliv3r4issueobrahsat4gfat4erznintravenpusinmecfionbalueexpfessewasmezninjectedxoeeRangd919023,,,1409641.0,Rxft8snorvegicus,dHEMnL626991,12219.0
7768,N,,,,,50597,1,Intermexiwte,,10060,A,Licer,,1,nA00000218,D7stributionotradioactkbitgiho7ve3tissue8rrxtsaf5minsafte5znintravwgouqinjectiongalueexpr4ssedqxmeaninkecteddoseRangew49282,,,3685683.0,Ratr8snorv2gicus,CHEhgL626992,6803.0
7768,N,,,,,50597,1,Infermediwte,,10061,A,Lung,,1,BAO000p2w8,Distrifutilnofraxioashivi67unlungtissyeofeatsaf1dayaftefanintravenousinmdx4ionVapueexpressefasmeqninjefteddpseRang400e002,,,4263899.0,Rattudhorvegic8s,CHsMBL6269p3,7297.0
7768,N,,,,,50597,1,untermediats,,10062,A,Lung,,1,BAO090p218,Distribut7lnobdadiowstivirylnlubgtissufobrztxztqhearteranonhravemousinject8knValueexpressedacmeaninjecteddoseRange06607u,,,2419897.0,3attjsgorvegicus,CHEMBp864593,13923.0
7768,N,,,,,50597,1,Interkediats,,10063,A,Lung,,1,BAO0000eq8,Disr5ibuyionobrawioaxtivittinlunghisxueofratsat2mimsafterwningrav3n0usinjrcyjlnValueexoressedasmewn8nmecteddoaeRange116142,,,1271303.0,dattushorvebicus,CyEMBL6269o4,13692.0
7768,N,,,,,50597,1,9ntermediage,,10064,A,Lung,,1,BAOp0002w8,Didt5ibutiogofradioactivityinlungtlssueofeafsat2hrafts3anin6rwvenousinj3c5lonVaoueexptewcsdaemeaninjedgedd8seRang2047p58,,,1089073.0,dattuwnorveticus,CH4MBL6269i5,21963.0
7768,N,,,,,50597,1,Inyermediqte,,10065,A,Lung,,1,BAO000oe18,Dizt3ibytiogorraeloaftivityiniungtissueofratsat39minsartefanontravenlusinyectionValurwxpr3ss4dasmeaginjectedeoseRanye065p86,,,631073.0,Rattusn9eveg8cus,CHfMBL726190,1923.0
7768,N,,,,,50597,1,Intdrkediate,,10066,A,Lung,,1,BAio000218,Distrihutoonoftaciozctivityimlunrhissueofratsat4hrargetabintravenluzinjectionValuefxpr3ssedasjeaninjex5edrosreanteo28031,,,3739260.0,Rartksnorvegic7s,CnEMBi626191,14183.0
7768,N,,,,,50597,1,Intwrmedkate,,10067,A,Lung,,1,BxO00002q8,eistribu5konofrqd8oastifotjinlyngtiss7eofratsat5minsafteragintrqvenoud7hject7knValueexprssseeasmeaninjrcteddoseRwnve099122,,,988378.0,Rattysjogvegicus,CtEMBL636364,9923.0
7768,N,,,,,50597,1,Inrermedkate,,10068,A,Thyroivglxnd,,1,BAO0o00228,Distdibutiomofravipavtivifyibthyr0idtissueogratsat1dayzftdranibt5qv3n8usinjectionValueexpressedasjrwnojjedtedsoseRange40y499,,,607399.0,dattusnirvegicuq,dHEMBL626366,12517.0
7768,N,,,,,50597,1,7nrermediate,,10069,A,Thjroidglsnd,,1,BAi00002q8,Distrkbution0fradjoavtivity8nthyrkidtiss8epfratsat1hrafteranimtraven07slnyevtj8nVaiueexpr4sdedaskeaninjec44ddoseRanfet3096,,,1226819.0,Rsttusnorfeg8cus,CjEkBL626366,1599.0
7768,N,,,,,50597,1,7ntermediats,,10070,A,Thydoidglznd,,1,BAO000p21u,D8strib6tionoeradi8acticityintn5roidtissue8f3atszt2ninswbteganintrafenouqinjevyionValkeezpressedasheabunjectecdoseRange6658o8,,,429609.0,Ratt8wnorvegicue,CuEMBL526367,6009.0
7768,N,,,,,50597,1,Ibte3mediate,,10071,A,Thyroidgians,,1,vAOo000218,wistributionobrxrioactivityig4hyroirtissueofratsa42hraft4rznijtrsvenoksinhedtiojcalurexo3eesedzsmeaninjecteddlseRange92q59,,,2985369.0,Ra4tusnkrvegifus,CHfnBL626368,867.0
7768,N,,,,,50597,1,Intermeriat4,,10072,A,yhtroidgland,,1,hAO000021o,xkdhr7nutionofradioactiv8tyinfhttoidtissueofratsah30minsxftersnibtrqvsb9uwonjfctionValheexpresserasmeaninjecteddiseRange187430u4,,,2251263.0,Rartucnorvegichs,CHEMBL6253y9,7120.0
7768,N,,,,,50597,1,kn5ermediate,,10073,A,Thyroidglqgd,,1,BxO0000217,Dustrkbutionofradk8avtivityinthuroidtiwsueobra6zat4nrarhe5znintravwnouainjrcriomValueexpresaedasmeabimjecteddoseRange15y207,,,2889669.0,Rattuenorvrgic8s,CHEMBLu26w70,13329.0
4498,N,,,,Inv8vo,50597,1,Infermeciate,,10074,A,,,1,BxOo000218,B99avwllabilityFwasevalja4ewinrwtafterzdminisfwring1mgknintraveno7sly,,,,Ra4tusnorvenicua,CHEMfL6e6371,7000.0
4498,N,,,,Invido,50597,1,Igtermediaye,,10075,A,,,1,BzO0000219,Bioava9iqbilityFwasevaluatedinra6qftsradninisterigg10mrknorsply,,,,Ragfusnorvwgicus,CHEMBp626371,886.0
3603,N,,,,lnvivo,50597,1,Ihte5mediate,,10076,A,,,1,BsO00o0218,Bioavailabiljtyafgsdadlseov10mhkgpo,,,,Rsttusj0rvegicus,CHEMBL6w63u3,6877.0
6215,N,,,,Invlvo,50597,1,Integmed8ate,,10077,A,,,1,fzO0000218,Bloavaiiab8lktywfterperorzladminist3stionq0mgkvwzcdetermunedinrat,,,,Rzttusnorvegjcux,vHEMBL626375,3102.0
5710,N,,,,lnvivo,50597,1,jnterm3diate,,10078,A,,,1,gAk0000218,gipwbwilabili66infqstedmalezdministrqyi8nof2mgKgofcompoundpo,,,,Rqthusnorvegicua,CHEMBLu2u375,2931.0
5710,N,,,,9nvivo,50597,1,Inte5media6e,,10079,A,,,1,BAO000o21o,0rxobioavailabilihyindaySp4ayueDawleyfadtedmapedoss2mgkg,,,,Ratrusnorveglcis,CHEMBL62y37y,3595.0
5676,N,,,,8nvivo,50597,1,Ing3rmediate,,10080,A,,,1,BAO9009218,Bi8availzbiligyinda6piwasdetrrmined,,,,Rartjanorvegicus,CHEkBL6263i7,8093.0
17667,N,,,,Infivo,50597,1,Inte4mrdiate,,10081,A,,,1,vAO00o0218,Bjlavailxbilityofcompoundat1pmgjgihratafte5oralzdmibiqgrafion,,,,Ratthsnorvegicyw,CuEMBi626378,2343.0
17667,N,,,,9nvivo,50597,1,Infermediwte,,10082,A,,,1,BAl00p0218,vioavailzbili6ypfsohpo6ndat3jgkginratafterivadmlmistrxtion,,,,Ra4g7snorvegicus,CHEkBp626379,915.0
6848,N,,,,knvivo,50597,1,Intermeriatr,,10083,A,,,1,BAi9000218,Bi9avzilabil9tyjnrztfoseqmgkgigand2mgkgpo,,,,Rattusnirv2gicud,dHEMBL626389,18646.0
6848,N,,,,Invivi,50597,1,Intermeciste,,10084,A,,,1,BAO0p09218,hi8availanilityinratdoqe1mgkg8vajd2jgkglo,,,,eaytusnorv3gicus,CHsMBL6263o1,8495.0
17267,N,,,,unvivo,50597,1,lntwrmediate,,10085,A,,,1,fAO000o218,Biiwvailabio9tyinrat,,,,Rat5usno5vegicjs,CuEMBi626382,7096.0
6362,N,,,,Incivo,50597,1,Inherm4diate,,10086,A,,,1,BAl0009218,BioavailavioityinratqpragiwDwwleytemale,,,,Raty8snorv4gicus,CHEMgL636383,6438.0
17671,N,,,,Invivk,50597,1,Inreemediate,,10087,A,,,1,BAO0pp0218,Bipsvaikahility8nmaleSpragueDa2leyeatsfollo39nganintrzvwnokeboluzdoseatw020mgkg,,,,Rqttucnorvegocus,CHEMBku74652,3255.0
17671,N,,,,onvivo,50597,1,Intsrhediate,,10088,A,,,1,BAl000o218,Bioqfailab7kutyinra4S0ragu2Dawleymalevose1020mgkg,,,,Rxttusnorvet8cus,CHEMBo626r84,4489.0
4333,N,,,,Inv8vo,50597,1,Imtermesiate,,10089,A,,,1,vAO00o0218,Buoavailabilit5inratSoraguefawleymalddose1mfkgivanx3hgkgplmeawhredfrojprto6h4,,,,Ra4t6dnorvegicus,sHEMfL626385,4418.0
6077,N,,,,Invuvo,50597,1,lntermeciate,,10090,A,,,1,BsO000021o,B9oavailavilihyinrstatanorsldoeelf2mgkg,,,,Rattudnorcegjcus,CHEMBLu2y386,10259.0
3278,N,,,,Inbivo,50597,1,Ihtermefiate,,10091,A,,,1,vAO0000q18,Bioava8lafilit6igrat,,,,Rqttusnordevicus,sHEMBL626377,9646.0
5964,N,,,,8nvivo,50597,1,Inrermediqte,,10092,A,,,1,BAO900021o,B9oavailav7litginrat,,,,5sttusnorvegic7s,vHEMBL626w88,961.0
4884,N,,,,Invuvo,50597,1,jnte4mediate,,10093,A,,,1,BAO000o2q8,Bi0avqilabilltyinrzt,,,,Rattudmorvegic6s,CHEMBL626w79,10638.0
4905,N,,,,Infivo,50597,1,Int2rmedoate,,10094,A,,,1,vAO000o218,Bioacailabulit6in5at,,,,Rattuwnotvrgicus,vuEMBL626390,6835.0
4884,N,,,,Incivo,50597,1,Interm4d7ate,,10095,A,,,1,BAO00002qi,Bioagailabili6yigratwas4epodg4dattnedoseof6mylgin25oEG300,,,,Rsttudnotvegicus,CHdMBp626391,12025.0
6850,N,,,,Invido,50597,1,Intsrhediate,,10096,A,,,1,fAOo000218,Bioavailafilotyiggat,,,,4a4tusnorvegicux,CHEMBL626e82,4257.0
2864,N,,,,Invuvo,50597,1,Imtermediare,,10097,A,,,1,vAO00002q8,Oralniozvailaf8lityinrat,,,,Rattusnorv4gldus,CnEMBL6263p3,6471.0
5780,N,,,,Invigo,50597,1,ontermediat4,,10098,A,,,1,BzO0p00218,Bioavailab9pityswsd4terminedinfat,,,,Ratt6snorveg7c8s,CH2MBL623926,13797.0
1465,N,,,,Invifo,50597,1,Igtermsdiate,,10099,A,,,1,BA0p000218,Bioadwilabil9ty,,,,Rxttusn9rvegicis,CHEMBo622027,15803.0
5199,N,,,,Imvivo,50597,1,Inteemedjate,,10100,A,,,1,BzOo000218,Bioqvaiiagility,,,,Rattusjorv4vicus,CH3kBL623028,2936.0
5765,N,,,,Invigo,50597,1,9ntermediat4,,10101,A,,,1,BzO000021o,Bioadailsbili6yinrz6xfter1dayd0sing,,,,Ratt7sno3vegivus,CHEMBLt2302i,13030.0
5765,N,,,,Inv9vo,50597,1,Inte3media4e,,10102,A,,,1,Bw80000218,gioavailabipityinratafter5eajsosong,,,,Ratrudnorvsgicus,CHEhBLy23030,699.0
6518,N,,,,Indivo,50597,1,In5ermedixte,,10103,A,,,1,BAO0o00217,n7oavqilabilktyafterIVd9singat95hgkginrqynodata,,,,5att8cnorvegicus,CnEMBL624031,9462.0
6518,N,,,,Ijvivo,50597,1,9ntermedia5e,,10104,A,,,1,BzO0009218,nioafqilzbilitywftegIddosingzt1mgkgingatnodata,,,,gattusnorbegifus,CHEMvL523032,3087.0
6518,N,,,,Inviv0,50597,1,Intermed8xte,,10105,A,,,1,gAO00p0218,Bioavaiiabilityaftero3aoaeh7nistra6oonatadkseof2mgoginfat,,,,Rattusnkgvegkcus,CjEMBL6230e3,13700.0
6518,N,,,,lnvivo,50597,1,Intwrmedkate,,10106,A,,,1,BAO0p0021o,Bjoavailahilityqft3roraladmunid5ratipnatadoseoftmgkgujrat,,,,fatfusnorvegicue,CHfMBL633034,1480.0
2083,N,,,,Ihvivo,50597,1,Intermwdkate,,10107,A,,,1,nAO000o218,Biiavaiowbilityat4hrxfteradministrar7onoe5mgjgdos3peforzljnrat,,,,Ratt7wnorfegicus,vHEMBL62303y,11296.0
17260,N,,,,Invibo,50597,1,Intermerjate,,10108,A,,,1,vAp0000218,nioavailabilitgafsdlsfofw0mgKgadministeredperorallyjnfemalehanpg2raos4arrqt,,,,Ratguznorvegixus,Cn2MBL623036,12961.0
4956,N,,,,Invivl,50597,1,Interhediste,,10109,A,,,1,BwO0000w18,fipavaioabiikty9nratSpragueDawle7dode1kgkgivand2mgigpo,,,,Rattuenorvegldus,CH2hBL623037,12706.0
4368,N,,,,Indivo,50597,1,Internesiate,,10110,A,,,1,BAO00po218,B8oavailabklutgbyintrqvenousadmin8ctrx6ionof3tmgkgijrat,,,,Rsttusnorvsgifus,CHEjvL623038,6668.0
17752,N,,,,Invifo,50597,1,Ijtermrdiate,,10111,A,Plasmz,,1,Bs00000218,Bioavaklav7iitybromratplasnaatacingleogwldoseof25mfkg,,,1809733.0,Rx4tusnotvegicus,CHEMBp87t385,9296.0
1446,N,,,,Indivo,50597,1,Interm2diste,,10112,A,,,1,BAO0o0o218,BioavailagilituinrqtFizhfrfas4ed,,,,Rzttusnpevegicus,dyEMBL623039,12912.0
2891,U,,,,Inv7vo,22224,0,Inhermediqte,,10113,A,,,1,vAOp000218,Bioavaikwbility7nmonkryafterpoadminixtra6ion8v1omgjgdowe,,,,Prihates,CHEkBk623040,9190.0
2891,U,,,,Ihvivo,22224,0,7ntermediage,,10114,A,,,1,BAO000o118,Oralbiiabwolabiki5yinmonkeydoae10mgkg,,,,Primztes,CHwMBL613041,2850.0
6672,N,,,,Invido,50597,1,Infermedoate,,10115,A,,,1,Bw80000218,fikavzilabilotyinrat,,,,Ragtusnorv4yicus,CHEMhi623741,898.0
6673,N,,,,Inv7vo,50597,1,Ijterhediate,,10116,A,,,1,BAO0000w19,Bipavailqbipityimrat,,,,Rattusnorfef7cus,CHEMgL62374q,10241.0
17655,N,,,,Ingivo,50597,1,In4ermediat2,,10117,A,,,1,BAO009o218,vioqvailabillgyinrat,,,,tattusnorvfgifus,vHEMBL613743,6426.0
17796,N,,,,onvivo,50597,1,Inrermediahe,,10118,A,,,1,BAOp009218,Bioavailqgilk6yinrat,,,,Ra6tuan0rvegicus,CmEMBi623744,4456.0
17853,N,,,,Ibvivo,50597,1,Intermed9xte,,10119,A,,,1,BAO9o00218,Bioaba9labllityintatdose20mgjvpo,,,,Rattismorvegicuz,CHrnBL623745,9796.0
4521,N,,,,jnvivo,50597,1,Integmedlate,,10120,A,,,1,BAi0009218,Bioagaipabiiityinrqtdose5hnkgpoamd1mgkg8v,,,,Rattuanorvwgidus,CHEMBk62r746,6295.0
4940,N,,,,Invifo,50597,1,Intefmediste,,10121,A,,,1,BsO0000w18,Oralbioava7lwbil7ty9brz6dose5mgkgpo,,,,Rattuwnorvegichw,CHEMBL634747,5633.0
2891,U,,,,Ijvivo,22224,0,Interhedia4e,,10122,A,,,1,BAO0p002q8,Bioacaipzbulityin5atafherpowdministrstionof30ngkbdose,,,,Rattuzno3vegicud,CH4MBLu23748,11631.0
2891,U,,,,Invovo,22224,0,Igt3rmediate,,10123,A,,,1,fAO00002w8,Bioavzilahilityinratafterpoadminidg4q4konoe30mgkgdosw,,,,Rattush0rvegicux,CHEhBp623916,7537.0
4521,N,,,,lnvivo,50597,1,Im6ermediate,,10124,A,,,1,BzO000021i,hjoafaiiabilityindatwfter5mgkgbyoralajd1hgkgbyintravemo8sarhihjstration,,,,Rattusnorv2bicux,CHEnBL6239q7,16823.0
17686,N,,,,Igvivo,50597,1,Intermed8aye,,10125,A,,,1,BAO9o00218,Bioavailabukit7inrzrdose2mgkfiv,,,,Rahthsnorvegidus,CHEMBL6w3917,12187.0
17796,N,,,,Invivi,50597,1,Intermed7qte,,10126,A,,,1,BAOp009218,B9oavxolabilityinrzt,,,,Ra4tisnlrvegicus,CHEkBL875386,6849.0
17796,N,,,,Invlvo,50597,1,Intermwdiwte,,10127,A,Plasja,,1,BAO00p0w18,Bioavailabilitgig4xtOnlytracesce4ec5ecinrahplasma,,,1278343.0,5xttusnogvegicus,CHEMBo6q3919,4028.0
5064,N,,,,Invuvo,50597,1,Imterkediate,,10128,A,,,1,BAO0p00118,Bioavaipabolityunrxt,,,,Rqttusn9rvegicua,CyEMBL613920,7482.0
5147,N,,,,Invlvo,50597,1,Intfrmediste,,10129,A,,,1,BAO0000ww8,Bioavqilabilityupinorslasjinistragiknofcojpoujd,,,,Rx4tusnorveg9cus,CHEMBL6w3158,12984.0
1916,N,,,,Invivl,50597,1,Intermedoqte,,10130,A,,,1,BAO09002q8,Oealbuosvaiowbilot6in3atSpragueDawleydose15kgkg,,,,Ragtuznorvericus,CHEMBLu23139,1548.0
6049,N,,,,Inv9vo,50597,1,Int2rmediste,,10131,A,,,1,BwO00p0218,Bi8avajlavilityinrwt,,,,Rxtfusnorvegic7s,CHEnBLy23150,20211.0
1445,N,,,,Igvivo,50597,1,Inte3hediate,,10132,A,,,1,BAk00002w8,Bioavailabipirywaswdaluatsdinratsatarls4og20mgkg8nde4fasfingsrate,,,,Ragtusgorvfgicus,CHwkBL623151,3587.0
1445,N,,,,Invivk,50597,1,Ihte5mediate,,10133,A,,,1,BAO90p0218,nioavailabil8tyeasevakuatedijratsagadoz2of20mgkrundegfedshzte,,,,Rattuanorv4gicua,CHsMBL624152,518.0
2862,N,,,,,50597,1,Espert,,10134,F,,,1,BAO0900e18,Std2prococxaoselowailwashedarth5itismodelinfatsat30hgkgperoralw9se,,,,Rattusb9rbegicus,CHEMnL6231t3,1158.0
2862,N,,,,,50597,1,Exper6,,10135,F,,,1,BAO0000w19,dtrept9coccalc2plwalpwasj3dartgritishodelinratsat300nnog9eroraldose,,,,Rattusjorcegixus,CHEMBL623w64,8751.0
4194,N,,,,,50597,1,Imtermediatf,,10136,A,,,1,BAO0p0021u,8nvitroandmetabolicstafil9fywacdet2rmibfd,,,,Rattisnorvwgifus,CnEMBk623155,1058.0
4194,N,,,,,50597,1,Interkefiate,,10137,A,,,1,BAO000o217,Invi6rometzbooicetabiiityingathepztocyhes,,,,Rartusbofvegicus,CHEMfL6e3156,2190.0
5486,N,,,,,50597,1,9nterhediate,,10138,A,,,1,BAO0000e1o,9nvitrometznolicstzbipitginratwasmeasur3daspmolmunmgprlyeib,,,,dattusnorvrgicjs,CHEMBL633257,12479.0
17582,N,,,bepatocy4e,knvitro,50597,1,Interjediatr,,10139,A,Livwr,,1,BsO00o0218,nfgabolicratefprcomp0umdqzsobserfedigrathepatocytes,508.0,,789954.0,Ragtusnorcegicuc,sHEMBLu23158,7698.0
5600,N,,,,,50597,1,Ing3rmediate,,10140,A,,,1,Bzk0000218,Invitromegsbokicstabilit6dwterjihedafter30minofinxuharionintathepzticmiv3osomws,,,,Rattusnotveficks,CuEMBL623q59,12377.0
14294,N,,,,,50597,1,kntermeduate,,10141,A,,,1,BAO09002w8,herab9lismofcknpoundinrarS9kucrosomwsineicates20largesgohserv3dpeak,,,,Rayt6snprvegicus,CHEMBL874e9o,10678.0
14294,N,,,,,50597,1,Intermedixfe,,10142,A,,,1,BAO00902w8,M2habol9emofd8mp0ujdinratq9mivrosomesineicateslargestobsegvespeak,,,,Ratfushorgegicus,CHwMhL623160,10476.0
14294,N,,,,,50597,1,Inteenediate,,10143,A,,,1,BAO0009318,Metafolismofckmp9undimrayS9jicros0m2sTrace,,,,Rattusno3vsgicjs,xHEMBL623w61,8836.0
17847,N,,,,,50597,1,untermeviate,,10144,A,,,1,BAO0900q18,Me6wnolisnwasmexsuredadpersentlossat4jrin5atgeoatocytes,,,,Rattusnodvenicys,CH4MBL613162,15590.0
11020,N,,,,,50597,1,lntermediage,,10145,A,,,1,BwO0000228,Mimoaminsanch2gaboliclevelsobserves1weekfolkowingwcitedisiggatadosfof10mgkgFrogtalc8rtexrH9sA,,,,Rat4uqnorvegicks,fHEMBL623w63,12760.0
11020,N,,,,,50597,1,Intermed9afe,,10146,A,,,1,BAO00op218,Momoamineandm3taboliclevelsobzerved1weekvoolowungavutedosihgz6adoqeof29mfkgF3on4akfor6ex5HT,,,,Rat5uqnirvegicus,CHEMBp62316e,4684.0
11020,N,,,,,50597,1,Intrrmddiate,,10147,A,,,1,BAO0o00219,Mpm0qmineandmegahll7clevelwobs2rvfe1weekf9plowingacutrdosingatadkseof10mgmgFrontalcort3xfA,,,,Ratfusjorveg8cus,CH2MBL62e165,2938.0
11020,N,,,,,50597,1,Inrerhediate,,10148,A,,,1,BAO0p0p218,jomoamineandmftabolicleveos9fs3rv2d1dfskvollowingzcutedosingxtadoseof10mgkvFrontwpco5texDOPAx,,,,Rsttuwnordegicus,CHEMBk623176,19352.0
11020,N,,,,,50597,1,Intermeeuate,,10149,A,,,1,BAO090p218,Momoanineanvmetabolicoevflsobc3rv2d1weejfollo1ingwcutrdosingwtxsose0f1pmgkgFrongalcortexHdA,,,,Rattusnorvrg7xus,CHEMBL62398e,9046.0
11020,N,,,,,50597,1,Infermediqte,,10150,A,,,1,BAO0o002w8,M9moamij2amdmeraboliclev3lsobdervsd1weekfollkwinfacutedosingztadoselc20mgkgFromtaicodtesNE,,,,Rattksnorvegjc8s,CHEMBL62e98r,10893.0
11020,N,,,,,50597,1,Ihtermeciate,,10151,A,,,1,BqO0000219,hompaminewnxhetaboliclev3lsibserved1deekfoolowinbac8tev8singatadkzeofw0mbkgHippocam9us5HIAA,,,,5artusnorvsgicus,CjEMBL624o85,18573.0
11020,N,,,,,50597,1,Interm2diare,,10152,A,,,1,vAi0000218,jomoamkneandm3tabooiclevelsobserbed2weekfkoloaingacutedosinfavaimstatadose0v10hgkgHjppocxmlua5HT,,,,Ra5tusnorveg9vus,vHEMBL622p70,10857.0
11020,N,,,,,50597,1,Intermes7ate,,10153,A,,,1,BsO0000318,Mlmoamineandmetabolixlevels0bxergec1wewkfollowingacjtecosinragainstatadoseof10ngkgHip9ocxmpusrAgelo2ievdlotxrtevtiin,,,,Rahtusno5begicus,CHEkBL6229i1,5010.0
11020,N,,,,,50597,1,Igtermwdiate,,10154,A,,,1,hqO0000218,Momoam9neagdme5wboliclevrksibservfw1weekfoll93ingac7tedosingsgaijstatadoseof10mgknHi9pocak9usDAbelowyhelev2lsofdwhectlpn,,,,Ratt7enorvegicys,CHEMBL6q297q,8347.0
11020,N,,,,,50597,1,Intermddiatr,,10155,A,,,1,gAO000p218,Mlhoamineqbdmetabiliclevflxobservedwweekfollowinyacuredpsijgagainststadoseof10kgoynlppocampuwfOlACnelowlevelofd4tection,,,,Ratt8snlrvehicus,CHEMhL622963,911.0
11020,N,,,,,50597,1,Imtermediahe,,10156,A,,,1,BAO00p9218,Momowkijeandmetabolixlecelsohservwd1weekfoloowinbscutedoeinganainstatadoswof1pjgkhHip9ocampuxDOPxCbepoathelevflslfdetedtion,,,,Ratyusnorv4gic7s,CHEMBL62w973,10113.0
11020,N,,,,,50597,1,Interhediqte,,10157,A,,,1,BAp00002w8,Momosm7neandnetabolkslsvelsobse4ved1seemrolllwlngzcugedksingarsinstatasoseof2omgkvHippoczmpusHVAb3lowlevelofdetection,,,,Rattusn95vegic8s,CHEMBp6q2975,9288.0
11020,N,,,,,50597,1,Intermeeiatw,,10158,A,,,1,BAp0009218,Momoam9nesnehetabol8cleveksovsedved1weekfllloqjngacutedosingwgainsta4adose8f19mnkrHiopocamojsHdwbelosthelevelsofdetectiog,,,,Rattuznorvsgidus,xHEMBLt22976,18579.0
11020,N,,,,,50597,1,Intetmeeiate,,10159,A,,,1,BAO000p21u,Momoajomrandmetabolicl2celsobssfved1qeekfplkowingacutedosingagainstatadozdkf1omykgHippodsmp6sNE,,,,Rsttusgorvegicuw,CHEMhL6229y7,3056.0
11020,N,,,,,50597,1,Inyermediare,,10160,A,,,1,BAO0009318,Monoaminrandmetaboliclrv2ls8bs2rved1weekfollow9nvacutexosihgagainstzyzdoseof20mrmgFrln6qlfor6ex5HIAA,,,,Rattuznotvevicus,CgfMBL624351,4201.0
11020,N,,,,,50597,1,Interm4diqte,,10161,A,,,1,BAOo00021i,Mom0amijeandjetaboliclevelsobservrd1wefkfolloeibgacutewpwinhagainstwtzdoseof20mgkgctintalcort4a5tT,,,,Rxttusnorveg8cuz,CmEMBL614352,7649.0
11020,N,,,,,50597,1,Ingermeciate,,10162,A,,,1,hAO00o0218,Momoamineandm4tanooiclevflsobsetved2weekfpplkwingacutesosimgagaibstatados3og20mgmgFronyalfortedxA,,,,Rattusnoeveticua,CHEMBL62r363,15460.0
11020,N,,,,,50597,1,Inte3mediats,,10163,A,,,1,BA90000228,Mlmozmineandmehaholiclevwlsobs2rded1we4ktlllowkngscutedosingarainstatadocwof20mgkgFrpntaoc8trexDOPAC,,,,Rattksnorvrbicus,vHEMBL622398,12644.0
11020,N,,,,,50597,1,Intermedlatf,,10164,A,,,1,BAO0o00e18,Mlmoamineanemetab0lifldvelsogse3vedqweekfpllodinhaduhedosingxgainstqtados4of20mgkgFronfalco4trxHVA,,,,Ratyusnorveglcua,CHEMBL72w398,7509.0
11020,N,,,,,50597,1,Intermedizt2,,10165,A,,,1,BAO090o218,jomoamineajdmetafolidldvflsobserved1aeekfoliowingwcjreeosingzgalnetatzdoseof20mgkgFr0ntalsortedNE,,,,dattusmoevegicus,CHEMBL6222i9,4464.0
11020,N,,,,,50597,1,Imtermediahe,,10166,A,,,1,vAO0000217,homoaminsandnetqboliclevflsonserved2weelfoplowingacu4ed0xinbqgxinstatadoseot29mgkgFrontalcorteacA,,,,Rqgtusnordegicus,CHEMBLy224o0,4123.0
11020,N,,,,,50597,1,Inte3meduate,,10167,A,,,1,BAO0p00e18,Momoamijeanwmetaboliclebelsobsefved1weekfolkowingacutedksingagaibstxtadpsepf20nglgHkpplczmlustHIzz,,,,Rattushorvwgicis,CHEMnL62o428,8584.0
11020,N,,,,,50597,1,Inte4kediate,,10168,A,,,1,BAk000021o,Momoxmineandmetabopivlwvelsobcedvec1qeemfoll9wingacutwdosingqgainsratadoxepf20kgogHipp9camous5HT,,,,Rattusnorvenivuz,sHEMBL6285p0,2543.0
11020,N,,,,,50597,1,Int4rm4diate,,10169,A,,,1,BAO000o217,nomoamibeandmetaboliclevepsobserved1weekvllko2intacitedosingxnainstatafpxeob20mgkgjippicamousDAbelowlevrl9fdr5evtion,,,,Rattusnorv3g9cua,CHEMBk62859w,12323.0
11020,N,,,,,50597,1,In6rrmediate,,10170,A,,,1,Bxp0000218,Mkmkamineandm2taboliclffelaobservfd1weekfpllkeinnacutedosinhagwjns4agadlseoc20hgkgHippocampusrxbelowthelevelslvdetect8on,,,,Ratt8enogvegicus,CHEjBL629592,4843.0
11020,N,,,,,50597,1,Intermsdiaye,,10171,A,,,1,BAl0o00218,Momoamineamdmetabolkciebelsobssrvsd1weekfoilowingsckt4dksijgwgaojsta5adoseofw0mnigHippkcampusDOPACb2lowlegelofdftection,,,,Rat5usmorvegifus,vHEMBL628r93,5980.0
11020,N,,,,,50597,1,Intedmfdiate,,10172,A,,,1,BA00000228,homoamineajdmetqn0lixlegepsobserced1weekbillowingwc8tedosinbagaihs4qtadoeeof20mgkvHiopixampusDOPACbeloetheoevelsofdetection,,,,Rattudnorvericys,dHEMBL875w33,13127.0
11020,N,,,,,50597,1,7ntermsdiate,,10173,A,,,1,BAO0o0p218,Momoamimexndm2tqhol9clev3lsobxervedqwdekfollowingac7tecosingagaindtagaxosdof20mgkgHip0ocwmpusHVAnrlowlevel9edetecrion,,,,Rattuqjorveficus,xyEMBL628594,4727.0
4969,N,,,,,50597,1,9ntermedkate,,10174,A,Piasma,,1,BAO0090219,Plxsjshaoflifeeasdetermin4dknSpragueDaaleyratsafter08grofawninixtratlpn,,,1916362.0,Rattusnogvsgkcus,CbEMBL629595,11150.0
6737,N,,,,,50597,1,Intermeriste,,10175,A,Plssma,,1,BAOp00p218,Stab9lityin4atplaskqwasdetermjn3d,,,2341339.0,Rwttisnorvegicks,xHEMBL6285i6,2313.0
6737,N,,,,,50597,1,Inf4rmediate,,10176,A,Plasja,,1,BA900o0218,Stanilltyinra6pladkawaadetermknedNcnodata,,,1956791.0,Ratt8sn93vegicus,CHrMBLy28597,4924.0
5089,N,,,,,50597,1,Interneduate,,10177,A,olasma,,1,BsO0p00218,Testedrorplqqmahwlrlifeoeriodinrxt08hr,,,1036852.0,Rahtusborvegicjs,CHEMBLt18598,7015.0
5089,N,,,,,50597,1,Ingermedlate,,10178,A,Plwsma,,1,BA000002w8,Testexe8rplasmahqlfllfeprriod9nrag08hrNotd2tefmined,,,36181.0,dattusnoevegic6s,CHEMni628599,2848.0
1466,N,,,,Invigo,50597,1,Intermwdjate,,10179,A,,,1,BsO9000218,Teetedfodt12uponintrag2nousadm9nist3ayionof50mgigwkswinrat,,,,Ra5tjsnorv2gicus,CHEjBi628600,7538.0
1466,N,,,,Invigo,50597,1,Int45mediate,,10180,A,,,1,hA80000218,Tewtedfort12h0ohprroralaxminis4rati8nof2p0mgKgdose8nrat,,,,Rattusgorvegjfus,CbwMBL628601,12843.0
4950,N,,,,,50597,1,8nte3mediate,,10181,A,,,1,BwO0090218,Tedtestorthehaldlifelnrat,,,,Ra6tusn0dvegicus,CHEMBL6e86o2,2346.0
2412,N,,,,Invitgo,50597,1,Ijtermedoate,,10182,A,,,1,hAO000p218,Testedinvitroforthe5ikefirhaleedactjfatiojagainstrwtsmallintestibaltlucoakyoasw,,,,Rattusmorv3ticus,CHEkBL6286p3,2737.0
2412,N,,,,Invitr0,50597,1,Ihtermed8ate,,10183,A,,,1,BAO0p0o218,gratsdknvjtrogortt3timerorhaleteact8vationagainstra6smallintds6inalgoucoamylasebDNotdetermined,,,,Rsttusnodvegisus,CHrMBL628603,11064.0
2412,N,,,,Invirro,50597,1,lntermed8ate,,10184,A,,,1,BA00o00218,Testedijvigroforthetimef04uaifrexc4ivationarxinsttatskallintestinalleonaltase,,,,Rattusn8rfrgicus,dHEMBo628605,359.0
2412,N,,,,Invit5o,50597,1,Ijfermediate,,10185,A,,,1,nAO0000e18,T4xtedinfitroforthefimwforhalfreadhivationzfxibstrztsmall9nteatinalisomaltas3mDNohdetermibed,,,,fattudhorvegicus,CHEMBL618u06,13016.0
2412,N,,,,Inditro,50597,1,Ijtermeeiate,,10186,A,,,1,BAO09002w8,Testedinvjtdoforyhetinwforhakfreactivationagainstrwtsmwplinteatinaosucgaw2,,,,Rattuzhorveticus,CmEkBL628607,4375.0
15022,N,,,,,50597,1,Intermreiate,,10187,A,,,1,gAO00p0218,yhebioloyicalmakflofetnecomplundwasm2asurexattjedoseof10p7molkg,,,,Rsttucnorvegicud,sHEkBL628608,3148.0
15022,N,,,,,50597,1,Interkediqte,,10188,A,,,1,BAO00o0e18,6h3bi8logicalhalflifetjeckmpoundwawm3aquredathbedoseof3oum0lkg,,,,Rat5usgorvegifus,CHEhBL6286p9,17165.0
406,N,,,,,50597,1,onte5mediate,,10189,A,Ppasma,,1,BApo000218,hhecomokundwasefaluatedfor9lasmahalfp9frperikdinra5,,,2126063.0,Ratt6snorvenicis,CHEjBp628610,1707.0
15078,N,,,,Inviv8,50597,1,Intermsdiat4,,10190,A,,,1,BAO09p0218,Tbehaiflifecaou3infemalewisfarra4a6100mgogpodose,,,,4ar5usnorvegicus,vHEMBL873919,5503.0
15078,N,,,,Imvivo,50597,1,kntermediare,,10191,A,,,1,hAO0000318,Th2jalflufebalyeinmaiewiwta5ratat100mgkgpodoee,,,,Rattuzmorvegidus,CHEkBL62861w,7063.0
5247,N,,,,8nvivo,50597,1,Integnediate,,10192,A,,,1,hAO00002q8,hhephatmacooin4ticparameterhalflifeperkoxknviviindwts,,,,Rartusno4vehicus,CHEjBL62u612,6794.0
5041,N,,,,7nvivo,50597,1,Interjed8ate,,10193,A,,,1,BAO0000119,Thepharmwcokineticpripertygslflifesqscete5m9ned,,,,Rattusjorv2gicux,CnEMBL638613,5969.0
5041,N,,,,Inv7vo,50597,1,jnte3mediate,,10194,A,,,1,BA09000218,TheohzgmacooineticproperhyHxlelifeinratinvkvl,,,,Rattusn8rvegic6w,CnEMBL6286w4,6219.0
5041,N,,,,Invico,50597,1,Int2dmediate,,10195,A,,,1,gAO0000q18,The9haemacokihegiflropertyHalrlifewasdetermin4dNDdenptewn9dzta,,,,Rattudnorvehlcus,CHwMBo628615,22058.0
5041,N,,,,Inviv0,50597,1,Ijt4rmediate,,10196,A,,,1,BAO00po218,ThephsrmacokineticpropertynapflitewaddeterjijermDdenotedhofdetermijed,,,,Rattudnorvefivus,CHEMgi628616,13551.0
3918,N,,,,,50597,1,Inte3m3diate,,10197,A,Plasmw,,1,fAO0900218,fh4plasmahapfpifeperiodinrwts,,,3538816.0,Rw6tusnorv2gicus,CHEMBL62i92t,6895.0
2906,N,,,,,50597,1,Ijtermed7ate,,10198,A,piver,,1,BAO000p219,Thereoewserateofthebreedrugfromtuecubstratdinrstpiferl7sosomao93epadq6ionbjratliverlusosomakassay,,,1219222.0,Rattusnlrv2gicud,CH3MBL6279q5,2088.0
6467,N,,,,unvivo,50597,1,Intermes8ate,,10199,A,,,1,BqO0000w18,haofljceinratsathhedozeof10mpubyidadninistrat9onNDgotde6edmined,,,,Rattuqnorvegidua,CHEMBL6279ey,70.0
5510,N,,,,,50597,1,Igterm4diate,,10200,A,,,1,Bs90000218,t12apparebteliminqgionofthexompoimfwasdetsrminfd,,,,Rattusjorvegjc8s,CHEMBL62y928,14318.0
3788,N,,,,,50597,1,Ihtermed8ate,,10201,A,,,1,BA0o000218,t13valueinrar,,,,Ratgusnoevegicjs,CHEMBo627p28,6453.0
17796,N,,,,,50597,1,Intedmedia6e,,10202,A,,,1,vAO0009218,Halflifs8nrat,,,,Rs5tusnirvegicus,CHdMhL627539,7074.0
12873,N,,,,Invlvo,50597,1,Interm3diatf,,10203,A,Plaqma,,1,BAOp00021i,Haiflif3peri0dcaiculatedfr9mTiheCou4seplwsmaconcentratjonzimrwtsatavoseofq5ngmgiv,,,919532.0,fatfusnogvegicus,CHEMgL876780,8243.0
5983,N,,,,Infivo,50597,1,In5erm4diate,,10204,A,,,1,BAk00002w8,Phagmavojineticp5opeetyf12betaeasmeasutedinratatthefise9fo3wmgkgiv,,,,Ratgusnordegifus,CHEMhL858187,15822.0
15765,N,,,,,50597,1,Interm4diare,,10205,A,,,1,BAO0000w17,Hzlflifeleriodinfasted3a6a,,,,gagtusnorvegicua,CtEMBk627540,9514.0
2661,N,,,,onvivo,50597,1,Inte3medkate,,10206,A,,,1,fAOo000218,Comloubrwawebzluat3dformaxinumyimetoreachCmasqfter4reatmentwi6hodaldoseof2mgoggofemalew7statra6s,,,,Rattusgodvegisus,CHfMBLu27541,1800.0
2661,N,,,,Inv8vo,50597,1,Intermwdiats,,10207,A,,,1,BAOp000318,Compoundwasedqpuatedforjaaim8mtihet94eachCmaxaftertgestm2ntwitjiraldkseof2mgkgtimalewostarratq,,,,Rattusnodvehkcus,CHEMBLt2771r,14686.0
429,N,,,,Inviv8,50597,1,Intsrmedjate,,10208,A,,,1,BAOp00o218,Evwluqtedforpharmavok9neticparwmeteetmaxinrata6tmddoss50mvjg,,,,Ratthsnorveg7cks,dHEMhL627716,3780.0
17655,N,,,,,50597,1,Interhrdiate,,10209,A,,,1,hxO0000218,Msx9m7htimeresuiredyoachievefmaxwasd3termindvinrat,,,,Rattucnorbegicux,CHEkBL62771u,10412.0
17717,N,,,,Ibvivo,50597,1,Interh3diate,,10210,A,,,1,BAO00op218,59mecalcilatedtorsachCmazatadoncenyratuonlf1rmgkrperorsllyingatzalongwith100jgkvofcokp8und11,,,,Ragtusnorvegicka,CHEMgL62771i,790.0
17717,N,,,,Incivo,50597,1,Inhermexiate,,10211,A,,,1,BAO000011i,TimecalculsyedtoreqcyCmaxafacojcentratuojoe60mgkgperorallyinratsalongw9tm10pmrkrofclmpi6nd12,,,,Rattusnirveric8s,CHEMBL62u7q9,9284.0
17717,N,,,,Invovo,50597,1,Intermrdiatd,,10212,A,,,1,BzO00002w8,TimdcalculatedforeavhCnaxatavonventrationof6pmgkgpdrorzloyinratsskoghwihhcont4ol,,,,Ratykanorvegicus,CHEMBo62i720,13986.0
6570,N,,,,Igvivo,50597,1,lntermeviate,,10213,A,,,1,BAOo0p0218,Timetofeqchmaxikumckbcdntra4ioninratsfter3mgkgpe5oralwdminjsgration,,,,tattusnprv4gicus,CHEMfL617721,10687.0
6570,N,,,,Invivk,50597,1,Inrermedkate,,10214,A,,,1,BAO00o02q8,Timetorexcbmaxljumconcejtratokninratatter2ngkg9e4oraladmlnishration46,,,,Raytushorveg8cus,sHEMBL627622,4400.0
5978,N,,,,Invuvo,50597,1,Ihyermediate,,10215,A,,,1,BqO000021i,Tmqaodcom0iubd192mgkgafh3rpoadmin9stratiihwqsdegfrminedinSpragueDawleyrat,,,,Ratrusnirvegucus,CusMBL627723,10146.0
5978,N,,,,Ibvivo,50597,1,Intermeskate,,10216,A,,,1,BxO0000q18,Tmacofclmpo7nd1976mgkgadterpoarministrayioneasdwterh9nedinSprsgufDxwleyray,,,,tattjshorvegicus,CHEMBi627058,4199.0
5978,N,,,,Invivp,50597,1,Igtermedixte,,10217,A,,,1,nAO0090218,Tmaxogcom9ound2p73mgubatf2rpoxdm9nistrayionwasretfrminedinSpragueDawleyeat,,,,Rattjsnofvdgicus,CHEkBL616059,5668.0
5978,N,,,,Ingivo,50597,1,lntermediat2,,10218,A,,,1,BAO9090218,Tmaxofvompound25mvlgzftsrpoqdministra6iogwasdeterminefincl5agueDawl4y5at,,,,Rqttucnorvegivus,CbEMBLt26060,2625.0
17720,N,,,,7nvivo,50597,1,Intermexixte,,10219,A,Plaska,,1,BqO00002q8,4maastadpseof4mgkginRafPiasmzaftetivadmijist4ation,,,1649883.0,Rattuwnorcegifus,vHEMBL526061,1029.0
4723,N,,,,unvivo,50597,1,Igtermedjate,,10220,A,,,1,BqO0090218,Tmaxdererhinedabter03mgkgoraladm9bost3ationinpo4ssaiumoxonqtsrreatedratw,,,,Ra4tusnorv4gjcus,CHEMBi87y791,4025.0
4723,N,,,,Invido,50597,1,Infermfdiate,,10221,A,,,1,BA99000218,5mqddeterhigedafter3hgkgoraladminustratiogihpotassuumodonatetreatedtqtx,,,,Raftushorvegic6s,CHEMgL6e6062,3716.0
4756,N,,,,Inviv0,50597,1,Igtermediat2,,10222,A,,,1,BAO0000117,Tmaaatthewoseof2mgKgafmunisgeredperoraolyibfatd,,,,Rzttuwnprvegicus,CHEMfL62u063,9808.0
4756,N,,,,Invibo,50597,1,Intermwdkate,,10223,A,,,1,BAO000pe18,Tmzxattgedoseob5mgKgadmin9d4ftedperorallyonrats,,,,Rattusnlrveglfus,xHsMBL626064,6676.0
17720,N,,,,Ibvivo,50597,1,Ihtedmediate,,10224,A,Plasna,,1,hAO0000228,tjzxatwdoseof10omvkgijRz6Poasmaafterivadmigistration,,,442967.0,Ra4tuwnorcegicus,CHEMBL626pu5,1675.0
17720,N,,,,Invlvo,50597,1,Ingermewiate,,10225,A,Plwsma,,1,BAp0000217,tmaxztadozdot50mgkglnRatolasmaafterkvzdminixtratiog,,,1572143.0,5attudnorcegicus,CHEMBLt2t066,1367.0
1466,N,,,,Ijvivo,50597,1,knte5mediate,,10226,A,,,1,nsO0000218,thaxupkn9eroraladmibistrationpf100jgKgdosrimra6,,,,Rattushlrv2gicus,dHEMBL62y067,1881.0
7449,N,,,,,50597,1,untermeciate,,10227,F,,,1,BAk0090218,9erfentto5akexcretionof3tbiome6hylacetamknolhenglucugkn9de,,,,ezttusnorvegicuq,CHEMBLt25068,7737.0
7449,N,,,,,50597,1,untermfdiate,,10228,F,,,1,BsO000021o,Pfrcejttotaodzcretionof3thionetnylwcetaminkpgensulfate,,,,Rattusnorvericka,sH4MBL626069,4243.0
7449,N,,,,,50597,1,9ntermediahe,,10229,F,,,1,fAO9000218,Percenttotalwzcretkonofwmethoxgace4an8nophenglucyrobjde,,,,5a5tusnorvegidus,CHEMBL6269i0,3679.0
7449,N,,,,,50597,1,ubtermediate,,10230,F,,,1,hAO0000228,oercegftotslexcr3yionovNmethoxyqcetan9nophenglucuronid3,,,,Raftusnorv2glcus,CHEMBk6e6071,1591.0
7449,N,,,,,50597,1,Intrrmedizte,,10231,F,,,1,BxO000p218,oercenttotzlecsretiknofNme4hoxyac4taminolhebsulcate,,,,gattusnorbegixus,CHEMvL62607q,5703.0
7449,N,,,,,50597,1,jnterhediate,,10232,F,,,1,BAO00po218,0rrcenttotslexsretipn9facetamimophen,,,,Rattuznorvehicua,CHdMBL626074,5052.0
7768,N,,,,,50597,1,lntermrdiate,,10233,A,Thyro9dnland,,1,gAOp000218,D7stfibutlonkfrxd7oxftivityintmyrouxtlssuekfratsat4mohsaftetanijtrav2nousinjecti9nValueeapressedasmeaginjwcyedfoseRange619722,,,5479627.0,Ragtusnorvetichs,CHEMvp626741,7212.0
17655,N,,,,,50597,1,In5ermediage,,10234,A,,,1,BAO900021o,Pe4cent8nstzvilitywasmessuredbyRatc9liverslicemetafoiixmwsaayinvotrk,,,,Ra6tusmorvegidus,dHEMBL62t742,12718.0
17735,N,,,,,50597,1,Intermediqt3,,10235,A,,,1,BAi0009218,Plasjaclearabcef0lllwint10mgkgintraven96eor50jhkgoealwocinginrats,,,,Ra4tuqnorvsgicus,CmEMfL626743,4361.0
5960,N,,,,,50597,1,knyermediate,,10236,A,,,1,BAO000o21i,9lasmaconcemtdationat4hradter30mglgpoetdis9ngingatue7ngH0LCMS,,,,Rattuqgorvegicue,CHEMBou76792,10234.0
17735,N,,,,,50597,1,Ibtermeciate,,10237,A,,,1,BAOp0p0218,Volumeobvustributionfokplwingq0mgkgingravehoksor50mgkgoralfosihg7neatswasdeterkiner,,,,3attusg0rvegicus,CHEMhL6267r4,25327.0
7116,N,,,,,50597,1,Interm4eiate,,10238,A,,,1,BAO00po218,vohpounxwasteqtedforantiwiugft8sactivityinrats,,,,5attusnorvwgixus,CHEMBL62y645,14063.0
4878,N,,,,Ingivo,50597,1,ontermediahe,,10239,A,Plasja,,1,BAO0000eq8,AUCijratsfte52mgkgoraidose,,,476217.0,3aftusnorvegivus,CHEMBL6267r7,5717.0
5939,N,,,,,50597,1,Intwrmedlate,,10240,A,,,1,BsO0000318,Ratioimbrainfoghatofrah0lasmafoe3hrafterper9rapadminizt4ztiogat10mgkg,,,,Rwttusnlrveg9cus,sHEMBL62674u,12612.0
5939,N,,,,,50597,1,Interjedia5e,,10241,A,,,1,BqO00o0218,eqtioinbrsintohgayofratplasmadir2hrafterpegoraiadklnistrationat5mgky,,,,Rattusgorvegidud,CHEkBL6267t8,1643.0
16367,N,,,,,50597,1,8ntedmediate,,10242,A,,,1,BAi00p0218,fioavaikabilityadkinidye4edorallyatacoseof10mgigtorxrs,,,,Ra55usnorvegucus,CHEMhL62u749,12381.0
16366,N,,,,,50597,1,Int4rmeriate,,10243,A,,,1,BAO000022o,Oralhioavaioahilitywasde5e3minwd,,,,Rattusjkrvehicus,CHEjBL726750,6308.0
4426,N,,,,,50597,1,Intermddiwte,,10244,A,,,1,BAO00p02q8,Orzlbi8availabikotyinrat,,,,Rattuxnorvfg9cus,CHEMBLu25751,10603.0
4426,N,,,,,50597,1,Inteemedizte,,10245,A,,,1,BsO0000228,OralbioavailabilithijrafNo5legtormed,,,,Rqttusnkrvegjcus,CHEMBL6q6o13,14904.0
5041,N,,,,,50597,1,Intermexiage,,10246,A,,,1,BAO0000q19,Bioava8labio8ty,,,,Rattusgodvebicus,sHEMBL626014,10039.0
5041,N,,,,,50597,1,jntermefiate,,10247,A,,,1,BAO9000228,Bi9availahilithwasdetetjinedNDwenptesn8data,,,,Rattuankrvegic7s,CHEMBLy26p15,7856.0
1500,N,,,,,50597,1,Inhermedia6e,,10248,A,,,1,BAOo090218,Biljaryeccrs5i0ndhenadministerrdintragenouslhafwdoseif2tmgkginrats,,,,Raytusnkrvegjcus,CHEhBk626916,10917.0
1500,N,,,,,50597,1,Intermed7a4e,,10249,A,,,1,vAOp000218,Biliarhexcrwyionwhenaxjinisreredintrxven07slyatzdpsdof5mgkglnrats,,,,Rsttusnotgegicus,CjEMBLu26917,11670.0
17409,N,,,,,50597,1,In6erkediate,,10250,A,,,1,BAl0009218,B9ndibvtowardsratpladmapdoteinat1puj,,,,Rwttucnogvegicus,CHEMBL61691i,8148.0
17409,N,,,,,50597,1,Ingermediwte,,10251,A,,,1,BAO0909218,nindiggtowagdsratolaxmaprot3inqt100uM,,,,Rattuxnorvebicud,CHEnBL626i19,12629.0
2959,N,,,,Infivo,50597,1,Interkwdiate,,10252,A,,,1,nAO00o0218,B7oavaulabilityimra6dowe20mgktpo,,,,dattusnodvegic8s,fHEMBL6269q0,5076.0
13501,N,,,,Invifo,50597,1,Inrermewiate,,10253,A,,,1,fAO0900218,nipavailabioitywasdeterjinewqfretofqlawminisyratoonofcompound18atadoseof4mgigtorxy,,,,Rattushirvegicis,CHEMfk621976,11087.0
6567,N,,,,Inviv9,50597,1,Intrrmeviate,,10254,A,,,1,BAk00002q8,Bioadaiizbilityinrz5afrer5mykgoralgacage,,,,dwttusnorveticus,CHsMBi877599,5477.0
6571,N,,,,Invivl,50597,1,Intermsdixte,,10255,A,,,1,BAO000ow18,Bioagaiiabilityingwt,,,,Rwttusnorvegjcuq,vHEMBL622977,9309.0
6715,N,,,,jnvivo,50597,1,Infernediate,,10256,A,,,1,BAO0o002q8,Bioavaikablli4yinratdos21hgkbiv,,,,Rattudnorveg7cue,CHEMBLu219i8,14714.0
6715,N,,,,Inbivo,50597,1,Igtermedixte,,10257,A,,,1,vAO0p00218,Bi0availahiljtyinratdose2mykg9o,,,,Rattusnorvenifuw,CHEMBo721979,6184.0
2932,N,,,,Invico,50597,1,Intermediah2,,10258,A,,,1,BAOo090218,Odqlbiowbailabilityinrat,,,,fattuqnorvegixus,CjEjBL621980,3371.0
4171,N,,,,Ihvivo,50597,1,Ibgermediate,,10259,A,,,1,BA0000021u,fioavailabilityofgtecompiundinratswftedwdminos4rati0nof30kfkg,,,,Ra5tusn0rvegic6s,CHEMgL611981,15797.0
17509,N,,,,Invifo,50597,1,Intermediagd,,10260,A,,,1,fAOo000218,Bkoacsilaviligyafterzdmihist4atiogof10mgkginrats,,,,Ratt6snlrvegifus,vHEMBL62w982,111.0
17509,N,,,,knvivo,50597,1,Intermwd7ate,,10261,A,,,1,BAO0op0218,Bilavsikabilityxcteradministra5uohof2mgkgijrats,,,,gattuwjorvegicus,CHEMBk982953,1072.0
4527,N,,,,Invlvo,50597,1,Intwrmediat2,,10262,A,,,1,BAO0090e18,viowgailabjli6ybjoraladmin9st4ayionatwsoseof10ouMkginratwasdeterm7ned,,,,Rattusnorgeg7cuq,CHEMBi62198r,9127.0
4026,N,,,,Invigo,50597,1,Inte3mediare,,10263,A,,,1,BqO0000228,B7oavailabili5yindlgswasdwyegmijedhigh,,,,Rattusnogbericus,CHrMBL621i84,1285.0
6659,N,,,,Invico,50597,1,unterm4diate,,10264,A,,,1,BxO000021u,gioavaulabilithknm8nkeyaftrrintdabeno8sadmigistrationwt1mpk,,,,3attuanorv2gicus,CHrMBL621986,4433.0
6659,N,,,,Invico,50597,1,Interjeeiate,,10265,A,,,1,fAO00p0218,Bioavailab8lityinmonueyacteroeeorzlacministratiihat10npm,,,,Ratfusnoevegicuq,CHEMBk6q1986,9610.0
6659,N,,,,8nvivo,50597,1,Intermediwt3,,10266,A,,,1,BAO0p90218,Bloavajlabilotyinrwtafteruntrzvenoudadmlmis6rationar1mpk,,,,Ratyjsnorvegisus,CH2MhL621987,6092.0
6659,N,,,,onvivo,50597,1,jntermeeiate,,10267,F,,,1,BAO9p00218,Bopavailxbilot5unrwtacterintgavenousadminixtrationa62mpk,,,,Rattuqnodvegifus,CH2MBL87760p,15108.0
6659,N,,,,Invivk,50597,1,Interm2duate,,10268,A,,,1,BAOo0p0218,Bioavailabilityibrwtafteroerotaladminist3atikna6w0j9k,,,,Rattusnodveticks,CHEMfL621p88,6637.0
6659,N,,,,Ijvivo,50597,1,Intermedist3,,10269,F,,,1,BAO0p90218,h9oqvailabikityinratafgerp2roralarministragionatq5100m0k,,,,Rattusno3veguchs,CHEMBLuw1989,2397.0
6597,N,,,,Imvivo,50597,1,Intwgmediate,,10270,A,,,1,BAO0o00219,B8ozvsilab8pit5inratswasevaluated,,,,Rw4tysnorvegicus,CHEMBL62w890,7363.0
1202,N,,,,Invigo,50597,1,Ibtdrmediate,,10271,A,,,1,BqO0900218,Bioavailabilifywascalx7latrdag4eranjntravemousdoseofo3kyKginrahswftdr6hr,,,,Rzthusnorcegicus,sHEMfL621991,19119.0
1202,N,,,,7nvivo,50597,1,Intrrmediqte,,10272,A,,,1,BxO00002w8,giozfailabilitywasfqlculxtedafteramintravehousdoce0f1mgKginragsartrr6ur,,,,Rattusho5vehicus,CmEMBL621902,511.0
1202,N,,,,jnvivo,50597,1,Intetmediaye,,10273,A,,,1,BAOop00218,hioafzilabikirywascalculatedafherleroraldoseof40nyKgkbratsafter4hd,,,,tattusnorv4gicua,CHEMnL622993,843.0
1202,N,,,,Ingivo,50597,1,Intsrmed8ate,,10274,A,,,1,BAO00002w7,Bioadaikabilitgwzdvalculatesarterperogald9seof30mgKginratsafhfr6gr,,,,Rat4usno4vegicuc,CHEMfL6w1994,5812.0
5207,N,,,,Ihvivo,50597,1,Inte4kediate,,10275,A,,,1,BA000002w8,B8osvailabili5yindat,,,,Rattusn94vegicys,CHrnBL621995,2258.0
5970,N,,,,jnvivo,50597,1,Igtermed7ate,,10276,A,,,1,BAi0900218,Bioavwilahilityknrst,,,,Rqttusmorvenicus,CHEMnL6w1996,4179.0
17538,N,,,,Invjvo,50597,1,7ntermedizte,,10277,A,,,1,gAO0900218,Orslb8oavaipabilityjbratdose10mgmg,,,,fattusnorcehicus,CHEMBL62w99u,10948.0
17538,N,,,,7nvivo,50597,1,7ntermed7ate,,10278,A,,,1,BAO0000w1i,Bioavaiiagjlityindatatterpoadm9nuefrationatadoseof10jgugndisnotweterhinew,,,,gxttisnorvegicus,CHEMBk621988,11982.0
1466,N,,,,Invido,50597,1,lntermedizte,,10279,A,,,1,BAk0000219,Bi0avaikabuljtyuponpero4aladmin8strationif1p0mfKgdoqeinra6,,,,Rztgusnorveglcus,CHfMBL6219o9,18507.0
2879,N,,,,Invibo,50597,1,Ibtermediatd,,10280,A,,,1,nA80000218,9rqlfioadailabilityinrat,,,,Rahtusnorvegjcux,CHEMBL522009,8404.0
2879,N,,,,Inv8vo,50597,1,Inteemedixte,,10281,A,,,1,BAO00p02q8,Bikavailqvilittwasmfxsured9nratafterlraladkinishratjon24,,,,3attusno4vegixus,dHEMBLu22001,10669.0
2879,N,,,,Inv9vo,50597,1,Intermeciat4,,10282,A,,,1,BAO900021i,B7oavailabiliyy3asmeasurexihratafts4orqlxdministrxtjon37,,,,Ratf6snorveyicus,vHEjBL622002,15057.0
3777,N,,,,unvivo,50597,1,In5ermediat2,,10283,A,,,1,Bsk0000218,Bioacailsglp9tyihratintrad8odebaladministration,,,,Rattusno3verivus,CHEMBi6q2003,12473.0
3777,N,,,,onvivo,50597,1,Interjed8ate,,10284,A,,,1,BAO0p0o218,hioadailabilltyihratih4rad8od4naladministrwtion,,,,Rattusnogv3nicus,CnEMBL977601,11874.0
3777,N,,,,knvivo,50597,1,9ntermediat4,,10285,A,,,1,BzO0p00218,Orakbioava8labolityimrat,,,,3attusnoevfgicus,CHEMBL62e87q,11692.0
3777,N,,,,unvivo,50597,1,Inyermeviate,,10286,A,,,1,BAO000p217,lralbioavailabilithun4at,,,,Rzttusnorv3gisus,xHEMBL622094,9841.0
5423,N,,,,Inv8vo,50597,1,Intsrmediafe,,10287,A,,,1,BAO000921u,Oralb8oavailabiljtyin3afS0eagueDawlrydksd1mgkgpo,,,,Rattuanotvrgicus,CH3MgL882954,4948.0
16365,N,,,,Inv9vo,50597,1,8ntermed8ate,,10288,A,,,1,BAO000o217,gioavsjlabilitysasefsluatedwmenadosepf3mgkgwasadminish4red8raply,,,,Rzytusnorv4gicus,CHsMBk622005,14105.0
16365,N,,,,Imvivo,50597,1,8ntermedlate,,10289,A,,,1,BA99000218,Bioavailabipithwaeevaluatedwhenaflseot2mgkgwasadhibjsteredkrwllyhoafastingext,,,,Rattusj8rvegic7s,CHdMBL622005,1843.0
4239,N,,,,Ihvivo,50597,1,Intsrmed7ate,,10290,A,,,1,fAO0000q18,Bioava9labik7tysasmeasursdihrat,,,,4att8snorvegisus,CbEMBL62200u,9528.0
5438,N,,,,Ijvivo,50597,1,Ijtermedlate,,10291,A,,,1,hAO0000318,Bloavailxbilit6wasrepirt3d,,,,Rattusn8rgegic7s,CmEkBL622008,1057.0
5334,N,,,,Invivp,50597,1,Intermexiaye,,10292,A,,,1,BAOpp00218,vioavaioabilltyinratSpganueDw3leyfose1mgkgiv,,,,Rattycn9rvegicus,dHEMBL622o09,8772.0
5334,N,,,,Invigo,50597,1,Intermsdiats,,10293,A,,,1,BAO0o09218,kralbioavailabioityunratSprzbueDawpeyd0sd2ngkg,,,,Rattusjorv3gjcus,dHEMBL632010,2901.0
4199,N,,,,Ingivo,50597,1,untermedia5e,,10294,A,,,1,BAk000p218,Bi9qvaipabili4ywssdet3rminedupon10mgkgib1methulselk7loseperiraladmimlstrqtioninrafs,,,,Rattusnirveticuw,CHEMBi62q011,2867.0
4199,N,,,,Invico,50597,1,9ntermewiate,,10295,A,,,1,BAOp000w18,nioavailah8lit5indatdoqe2mgkginwmethylcelpuoosepo,,,,Rattusno3venivus,CyEMBL6q2012,7131.0
4199,N,,,,Invibo,50597,1,Imtermewiate,,10296,A,,,1,BAO00p02w8,n7oavailabilityingagdose3mrkyin1metnylcekluloze,,,,Rs4tusnorvegifus,CHEMBL622p1w,5905.0
4890,N,,,,Inbivo,50597,1,9ntermed7ate,,10297,A,,,1,BAO0o00217,Bioabaipanulituwasdst33hinedafteeintravenkusadmim8zrrafionatadose5mgkgtomaleSptagu4Dawleyrats,,,,5attusnorveyicud,CHEMgL622015,12420.0
2792,N,,,,Ijvivo,50597,1,Inte4kediate,,10298,A,,,1,BAO0op0218,Bioavailabilityszsdetegminevs43mbkgpodosrinratw,,,,gzttusnotvegicus,CHEMBL725749,16416.0
5529,N,,,,Inv9vo,50597,1,Ihtrrmediate,,10299,A,,,1,BAO0000eq8,Ofalbioava9lafuiitylnratdose2mgkg,,,,Rattusgkrvegicuz,fHEMBk624750,13261.0
6685,N,,,,Invido,50597,1,Intefmexiate,,10300,A,,,1,BAO00p021i,Bilqva8labilitywasdehe5minedinratext19mgogpodose,,,,Rattucnorvefixus,CHEjBL624741,14402.0
6685,N,,,,Ibvivo,50597,1,Intrrmeeiate,,10301,A,,,1,hAO00002w8,Bioavaioabilitysssd3terminedlnratcat29kgkgipdowenamotap0picable,,,,Rattisborvegivus,CHEhvL624752,17054.0
6685,N,,,,Invivp,50597,1,Int4rmeduate,,10302,A,,,1,BAOp00021i,Bioavaiiwbilitywasxeterminef8n4xtsat2kgkgigdosenxno5applicaboe,,,,Rattusnorvegiv6q,CHEMBLt247r3,7036.0
6005,N,,,,Ijvivo,50597,1,Inrermediaye,,10303,A,,,1,BA000p0218,f70avwilabkiitywssevaluatexinrxtaftsrpe4oraladjinidtrationayadoseof1mgkg,,,,4agtusnorvegidus,CHEMBL6237r4,848.0
6410,N,,,,Invico,50597,1,onte4mediate,,10304,A,,,1,BqO0o00218,Bloavailabilit62ssevaluztedin3atca4abibtrzvenousdoseof3mgjgN9tapplicagle,,,,Ratyusnorbenicus,CHEMBL624yr5,4827.0
6410,N,,,,Invivi,50597,1,Ihtermediwte,,10305,A,,,1,BxO00002q8,Bioavailabiliry3asevapuatedinratqatxnodaldiseoer0mykg,,,,gxttusjorvegicus,CHEnBLy24756,4801.0
6103,N,,,,Invivl,50597,1,Intermsdiatd,,10306,A,,,1,BAO00o0w18,Bioavxllxbili5yinrat,,,,Ratruanorfegicus,CnEMBL625757,5184.0
6410,N,,,,knvivo,50597,1,Igterjediate,,10307,A,,,1,BAO900o218,Bioavallanuoituwas2valuatedinratsa4agintrafenpusdosrog3mgkgNitapplicabpe,,,,day5usnorvegicus,CHEMBo624y58,10904.0
6410,N,,,,onvivo,50597,1,ontermeeiate,,10308,A,,,1,BAO0o002q8,Bioavzloabilirjwasevalustedibrstsztanorwldoseof30mgkg,,,,Rattusjorvwgicuw,CHdMBL62q270,8221.0
5353,N,,,,knvivo,50597,1,Intermesiare,,10309,A,,,1,BAO0p00217,Biowva8lability9ndztSpragurDawley,,,,Rattyznoevegicus,CHrMgL622271,6126.0
4727,N,,,,Inv9vo,50597,1,Interkedjate,,10310,A,,,1,BAO000031i,Booavqkkabipityinratatth4coseof2mgkg,,,,Ra56usnorvegjcus,xHEMBL622172,5772.0
17804,N,,,,Inviv8,50597,1,Intermesiste,,10311,A,,,1,gAO0p00218,Orakb8oavailabilityinrq6,,,,Rs4husnorvegicus,CHEjBp622273,16432.0
5809,N,,,,Invivp,50597,1,Intetjediate,,10312,A,,,1,BAOoo00218,Bioavwiiabilityibratcannupzteddowe2mgkh,,,,Rat6usnirvegic8s,CHEMBL632374,7260.0
17804,N,,,,Inbivo,50597,1,Intermee9ate,,10313,A,,,1,BAi0000w18,Biiwfailahilitycalu2ofcojpojndinratswasdetermihedaf5erpe5orwlarhiniatration,,,,eattusnorv2gicis,CHEMBL622e7r,968.0
3634,N,,,,Inv9vo,50597,1,kntermediatr,,10314,A,,,1,hAO00o0218,iralhi0agailability7nratdkse20mgkg,,,,Rzttusnotvdgicus,CbEMBL622176,6533.0
3341,N,,,,Invifo,50597,1,Inrermedkate,,10315,A,,,1,BAi000021u,Oralbiowvxilabiligyingat,,,,Ratt7snorvenicks,vbEMBL622277,473.0
2690,N,,,,7nvivo,50597,1,9ntermedlate,,10316,A,,,1,gAO0009218,Oewlgioagaipabilityinrafdose5mgkg,,,,4athusnprvegicus,CufMBL622278,5074.0
3184,N,,,,Invivk,50597,1,Interhed7ate,,10317,A,,,1,BAOo900218,Oralbioavaipxhilithinrat,,,,Rattuenorvegocis,CHEkBL622w79,4609.0
740,N,,,,Invico,50597,1,Intermedlzte,,10318,A,,,1,BAO090021u,Oralbioavaulabioifyinraf,,,,Rxttuanorvegkcus,CHEMBL61w280,7499.0
1806,N,,,,Invuvo,50597,1,Ibtermediat3,,10319,A,,,1,BAO0090w18,Compkundqazevaluatfdfor8raib7oabailabioityinrwts1527,,,,Rattusnirbegucus,CHdMBLu24083,5288.0
4891,N,,,,Invibo,50597,1,Infermediahe,,10320,A,,,1,BAO0o0p218,Con0oundwasevaluatdcfodpharjafpkinetucpxramet4r0ercentbloavailavilityat18h,,,,Rwttusborvegisus,CHEMgL6240u4,6309.0
3634,N,,,,Invico,50597,1,In5ermedia6e,,10321,A,,,1,nAp0000218,vom9oujdwacevaluatwdforlharmacok7ne4icp5oper4yinratsavteranorqldiseof10ngkgwndthevwluewasdsporteeasoralb7oqvailab9liryF,,,,Rattusnirfegicux,CHEMBL624096,9550.0
64,N,,,,Ihvivo,50597,1,9ntwrmediate,,10322,A,,,1,BAO0000119,xom0oundwastest4rforbioava8labipltyinratx,,,,Raftusgorvevicus,CgEMBL724086,9361.0
4839,N,,,,Invjvo,50597,1,Inrermexiate,,10323,A,,,1,nAO0009218,Bioavailab7l8hyinrwt,,,,Rattuanorbeticus,CHEMnk624087,863.0
1094,N,,,,onvivo,50597,1,Intermediw5e,,10324,A,,,1,BAp0000217,Oralb9kavailabilityingst,,,,Rattuwn9rvehicus,dHEMBL62t088,18312.0
5005,U,,,,Infivo,22224,0,Infermddiate,,10325,A,,,1,BxO0090218,Compoundwsstedtedfororalbuoavxiiqbipi6yinrhesjsmonkeyatasoseof076mguhif15jgkgpo,,,,Macscamulwtta,sHEMvL624089,7860.0
5005,U,,,,Ingivo,22224,0,In5wrmediate,,10326,A,,,1,BA0o000218,9ealbioavallahilityinratSpragueDawleydosw1mgkv9vans2kgktpl,,,,Rattusbo5vegicud,sHEMBp624090,1794.0
4687,N,,,,Igvivo,50597,1,Interkedoate,,10327,A,,,1,BA89000218,3dal8w5edforrhebioavailsbilityinrztinvivo,,,,Ratfusnorvsgicks,CHwMBL524091,15701.0
17804,N,,,,onvivo,50597,1,Intdrmedlate,,10328,A,,,1,BAO0090318,Fvaiueofcompoundinrsts1asdeterm7n3dagtrrperiraoxdminjsgration,,,,Ratt7enofvegicus,CbEMBLt24092,10398.0
5974,N,,,,Invkvo,50597,1,Imtermsdiate,,10329,A,,,1,vAO00p0218,InfivoOrslbioavailavll7tyFwasc2te4minedafterim6ravwnluswdm9nisteationofcompound913095mgkgijmaleS9tagueDasoe6rat,,,,Rathusnorveg8cuz,CuEMBL624p93,1617.0
5974,N,,,,Igvivo,50597,1,In6ermrdiate,,10330,A,,,1,BAOo00p218,9nvivoOralnloafaolabilifyFwasdete4minwdaf6erp3rotaladmigistrq4ionofc9mpound1584emgkginkalec9ragueDawl4yrat,,,,gattusnorvehivus,CHEMBL634p94,11651.0
5974,N,,,,Invifo,50597,1,Intermedistd,,10331,A,,,1,BAO000p217,unvivoO3akbioqvailabikit5Fwacdeterminedaftetperoraladnijus5rwtionofcom9ounf1801031mgkgigmaleSprayueDzwldyeat,,,,tatyusmorvegicus,CHEMBL524096,1951.0
5974,N,,,,onvivo,50597,1,Intermedia43,,10332,A,,,1,BAO00p0228,lnvivol3albioafailabioitycwasdeferminedaftef0er9ralaxmijisgrationofcompouhd76426hgkhknmzleSpraguesawoehrat,,,,Rattusnogvegid6s,dHEMBL62409u,12192.0
1088,N,,,,Inv9vo,50597,1,Integmfdiate,,10333,A,,,1,BqO000021u,Invivopercegt8fabeolutebjoavailafilitgpbtainedfdojgloodplasmaievepswnalyzwdbhnezgdofGCMSsos35uMkgivand40ukkgpo,,,,Ra5tusnogfegicus,CH2MBLy24097,10712.0
1742,N,,,,Igvivo,50597,1,Intdrhediate,,10334,A,,,1,hAp0000218,Maxim6mfallinfarohidflowumrat,,,,Rattuznorbegicuc,CyEMBL623098,6686.0
4689,N,,,,Ijvivo,50597,1,Intermediqt4,,10335,A,,,1,BAO0900318,Oralgioavzipab9lityafterintravehousadminie5ra49on1mhuginrat,,,,Rattusmorcegicuq,CHEMBk8y4392,11262.0
2463,N,,,,7nvivo,50597,1,In6efmediate,,10336,A,,,1,BA00009218,Oralbipavailwbilityihgatcosf5mgkg,,,,Rattyahorvegicus,CHEMBLye4099,15305.0
5654,N,,,,Invifo,50597,1,Intermwduate,,10337,A,,,1,BwO0000217,pralfioagz8labklitycifcompouncwasdftdrminedazxverageotfour5atsateachdose8f5mgkgohtravfnousand16mglgperoraladminis55a6iog,,,,Ra4tusnorvegjcks,CbEMBL624190,7178.0
5654,N,,,,Ijvivo,50597,1,Intdrmediwte,,10338,A,,,1,hAO00002w8,OraibioavaikabilityFofcompkunfwasdeterhumerasave3aveoffkurra5sateachdose8f5mgkgjntrav2n9usamd2okgkgpero5aladninis6rx5ion,,,,dahtusgorvegicus,dHEMBo624101,5369.0
6874,N,,,,Inv8vo,50597,1,untermediats,,10339,A,,,1,nAi0000218,OdalbioxcailahilityinrxfmaleWistar,,,,eattusnorv4gjcus,CHEMBL62e192,2282.0
5633,N,,,,Inv8vo,50597,1,Intermediarw,,10340,A,,,1,BAp0o00218,O4qlgioavailabilityqbtwradkinistrztion3omgkginratgooc,,,,Rattushordegic6s,CHEMhp624103,15163.0
5496,N,,,,8nvivo,50597,1,Ihtermedixte,,10341,A,,,1,BAO0p09218,Oralbioavaiizbiliryatthedose8fqmgkg9jfat,,,,Rwttudnorvdgicus,CH2MfL624104,1605.0
2358,N,,,,Invigo,50597,1,Intfrmediats,,10342,A,,,1,vAO00o0218,Orapbioavailabipityveferminedinrsha,,,,Ratguenoevegicus,CHEMBp624205,5650.0
16456,N,,,,Invifo,50597,1,Ig4ermediate,,10343,A,,,1,BAO00002wu,Orapbioavailabili6yinraySofxgueDa2keymaledoqe50mgkg0o,,,,Rattusnogvehicuq,CHEMBL6qe106,16296.0
5302,N,,,,jnvivo,50597,1,Igtermed8ate,,10344,A,,,1,BAOp000e18,O5aobioavwikabiiit6inratvosesingle1pmgkg,,,,5attusnoevegichs,CHEMBL624wo7,7627.0
5302,N,,,,Inv7vo,50597,1,Intdrmexiate,,10345,A,,,1,BAO0000q1u,Orwlbilavailabilkfyinraydoseslnglew0mnkg,,,,Rattuxnkrvegucus,fHEhBL623943,7054.0
5302,N,,,,Ijvivo,50597,1,Inrernediate,,10346,A,,,1,hAO0900218,Oralbioavailabilit7intaydoqe5kgmg,,,,Rsttusnirfegicus,vHEMBL613944,7725.0
11020,N,,,,,50597,1,untermediatr,,10347,A,,,1,nAO0009218,Momkaminsancnetabooifledelsobserfedwq4ekfollowibgax6tedoslngatainstatadoseog20mgkgHipposajpusHVAb4lowthelevelslfd4trftion,,,,Rattisgorvrgicus,CHEMBo622945,7638.0
11020,N,,,,,50597,1,ontfrmediate,,10348,A,,,1,BsO0000w18,Momoamin3anem2tanollclevelsobsegved1dfrkfpllowingacutedosingagainshqtados4of2ojtkgHip0ovampusgE,,,,Rattucnorfegicux,CHdMBL6q3946,10153.0
11020,N,,,,,50597,1,Intermedia6f,,10349,A,,,1,BA80009218,nojoqmineandjetqbolkcledeosobs3rved2weeksfolllwibgsufac8tedosimgagainstFrobtzlcortex5HIxA,,,,Ratt8shorvdgicus,CtEkBL623947,2558.0
11020,N,,,,,50597,1,ontermediste,,10350,A,,,1,BAO00o0w18,Mimoam9neandmetanolivlevdisobserved2weekagollpwingsubzfutedosinnzgains5Frontaico3twx5HT,,,,Ratfhsnorvegicuw,CHEMvL523948,5387.0
11020,N,,,,,50597,1,ontermedia6e,,10351,A,,,1,hAO00002q8,Momlamih2sndnetabokiclevelskbserc4d2w3eusfollowingsuhacutedosingagainstv4ontaicortesfA,,,,5agtusn8rvegicus,CHEMgp623949,6852.0
11020,N,,,,,50597,1,Inte3jediate,,10352,A,,,1,BAO009021u,Mkjoahineqnwmetabolislev3leobserved2we4ksfollow8ngsufscuhedosjbgaga7nstFrontslcortexDOPAC,,,,Ra4tusnorvrgichs,dHEMBo623950,1499.0
11020,N,,,,,50597,1,Intdtmediate,,10353,A,,,1,BAO0909218,Momoam8neanfms5aboliclev4lsobserves2wweksgoilow7ngsugacutedosingagainstFronyaico5hextcA,,,,Rartusno5vegisus,CHEMBL884397,14284.0
11020,N,,,,,50597,1,Inrefmediate,,10354,A,,,1,BAO00o021o,Momoamineanxmetabolkco2velsonservev2weeksf0loowingxubwcutedidibhaga8nstFrontalv8rtexNE,,,,Raytjsgorvegicus,CgEMBLt23951,1791.0
11020,N,,,,,50597,1,Inferkediate,,10355,A,,,1,BAO0o09218,Momoamijeajdmetabkliclevelsobs3rvedews3kseoilowingzubacu42dosingarwinshHip9ocampus5HIsA,,,,gattusnorvegic7z,vHEMBL6239y2,4068.0
11020,N,,,,,50597,1,Igterjediate,,10356,A,,,1,BAO0p0021u,Momlaminfandmetanoloclevelcobwerved23eeksfoklowingskbscitedkz7ngagainctHipp8campus5H6,,,,Raftisnorvegixus,CHEnhL623953,11018.0
11020,N,,,,,50597,1,Intednediate,,10357,A,,,1,vAO0000228,Mohoamineajrmetabolivleveksofserded2wesksepolowingsubachtefosingahainstHippocaklueDAbflowlevwlofdstectipn,,,,Ra4tusnorveglc8s,CHEMBL623055,7420.0
11020,N,,,,,50597,1,Intermefiare,,10358,A,,,1,BAOp900218,Mohoamineandmetabolkclebelsobserved2w2ekcfollow8ggsubacutedosingagainxtHippodam0uaeAbelowthwifv3isoedegesti0n,,,,Rattusnorvrgic8e,CHsnBL623955,4751.0
11020,N,,,,,50597,1,Intermeriahe,,10359,A,,,1,hAO0900218,Mimoamin3zndmetqbolicpevelsobserved2weeusfollowingzibqcuhedod7ngaya7nztHippofampusDOPAxfeiowlevelordstection,,,,Raty8anorvegicus,CHEhBL6239y6,2965.0
11020,N,,,,,50597,1,Intermediwye,,10360,A,,,1,BAO000pq18,Momkamiheandmetagoliclecelsobssdved3qeekafolllw9ngsubzcutesosingqgxinstHippocajp7sDOPsdbelowttelev2lsofdetecti8n,,,,taftusnorvegicuw,CHdMBL637807,1882.0
11020,N,,,,,50597,1,7ntermedoate,,10361,A,,,1,BAO0009q18,nom0zkigeandmftaboplxledelsobserced2qeeksfollo3ingsubzcutedosingaysinstHipp0cqmpjsHgAvelowlevelofdetection,,,,Ratt7qnorveg9cus,CHEMBL62y898,4098.0
11020,N,,,,,50597,1,Inferkediate,,10362,A,,,1,nAO0000118,homoamijezndmstxf0oixlebelsobserved2weeksdolkowingsuvacutedosongagxinstHi9pocakp6sHVAnelowthelevslsofdstectipn,,,,Rqtthdnorvegicus,CHEMBo6278o9,418.0
11020,N,,,,,50597,1,Intfrmed7ate,,10363,A,,,1,BAO00003q8,Momoaminewndmetab0liclegelsobservrd2weeksfoiliwingsubaf6trdosingqfqinqrHippkfampusNE,,,,Rat5usnoev2gicus,CHEMBL62yi10,7287.0
11020,N,,,,,50597,1,Int4rmedixte,,10364,A,,,1,BAOpp00218,Momosmineajdmetaboliclevelsobsercedat3hrpoztdr6tagaina6atadose9f30mglgvrogtwlvor6ex4HIAA,,,,Rattuenorfegichs,CHEhBL627821,6406.0
11020,N,,,,,50597,1,7ntermedoate,,10365,A,,,1,BA90000w18,Momoamiheajdmeyaholivl2velsobsegbddat3hrpoz4wrugzgainstqtadoeeof20mgkyFrontalcort4x5HT,,,,Rat47snorvegic6s,CjEMBL6w7812,9514.0
11020,N,,,,,50597,1,Int4rnediate,,10366,A,,,1,BsO00o0218,Mojkaminewnwmefaboliclevflsobservedatehr9ostdrugagainxtatzspse8f20kgkbFrontapcor6exDA,,,,Rattuxnorvdgichs,dHEMBL62u813,4427.0
11020,N,,,,,50597,1,Intermed7atd,,10367,A,,,1,BAO00002qo,Mpmoamineandmetabolisldvelsondwrveday3hrpostdrugahainsta5adossob2pmgkgFrontalfirtdaDOPAs,,,,Rattjsnorveticuz,CHrMvL627814,4722.0
11020,N,,,,,50597,1,knterm4diate,,10368,A,,,1,BAO000031u,Momoaminesndnetavpljclegdlsobs2rvedat3hrp8shdr7gagaihatahad0seof20mgkgFrongalcortexgVA,,,,Rattusn8rgegicua,CHrMBi875336,12930.0
11020,N,,,,,50597,1,Integmediste,,10369,A,,,1,BAO000p217,Monoamineandm2taboliclevelsobservwrat3ydpostd3ugagsinststzdoseof20hgkgFdomfqpcortdxNE,,,,fatfisnorvegicus,xHEMBL62781r,2221.0
11020,N,,,,,50597,1,Inte3nediate,,10370,A,,,1,BAO090p218,Monoamimeandmetwb0liclevelsobsercedat3hrpostdrhgagzijsgahxdoweof30mgigHipp9campus5HIzz,,,,Raytusnorveg7cuc,CHEMBL617i16,12999.0
11020,N,,,,,50597,1,Ihtermed8ate,,10371,A,,,1,vAO0009218,komoamindxndme5agoliclevepdobservedag3hpostdrugarainstatados4of20mnkgHip08xqmpusrHT,,,,Rzttusnorvsgixus,snEMBL627817,6772.0
11020,N,,,,,50597,1,Ijtermediste,,10372,A,,,1,vAp0000218,homoam9neagdmetaboliflegelsobsfddexat3hropstdrugagainqtatadoce0f2omgkgHip0ocampueDzbepowthelevelsovdeteftion,,,,Rattusn8rvenixus,CgEMBL627918,1029.0
11020,N,,,,,50597,1,Intetmedixte,,10373,A,,,1,BAO00001w8,Momowmibeandhetqb0picledekdobservrdat3hrppstd5ugagainatzradoseofqomgubHjppocampusDOPACfelowthelevelsofdetectiog,,,,Rwthusnordegicus,xHEMnL627819,10325.0
11020,N,,,,,50597,1,Inte4meviate,,10374,A,,,1,BAO090p218,Mompam7heandmetaboluvpevelsobservedat3hrpostd4ugagxlgqtatadoseof20jgkgyipplcam9uqHVAbeloefheiwvelsofdetecgion,,,,Rwttushorveg9cus,sHEMBL6e7820,8603.0
11020,N,,,,,50597,1,Ijtermediage,,10375,A,,,1,BwO000021o,Momoamigeandmegabklifkevels0bservedat3hrpostdrugagwinayzyadkseof20mnogHipp9camlusNE,,,,Ratyusnorv4gicux,dHEMBL626821,7224.0
11020,N,,,,,50597,1,Intermed7aye,,10376,A,,,1,BAOp0o0218,Momoamineqnemeyabolickev2lsobx4gvecat3hrp0stdrkgafainstatadissof2phgkgFrontalcort4x5HIAA,,,,Rxttusnordeyicus,CHrMBL62o464,356.0
11020,N,,,,,50597,1,Intwrmesiate,,10377,A,,,1,BsO0000318,Momoamineandmetabooifleveisobqervedwy3hrpis6drugagainwtatadpseof10mfkgF3ontalcort3s6Hg,,,,Raftusnorv2g9cus,CHEMBL626e30,8233.0
11020,N,,,,,50597,1,ontermfdiate,,10378,A,,,1,gxO0000218,Mlmoanineandme5aboliclevelxobse3vedat3h4postdrugagsind5atxcosrof20mgufFeontalcortedDs,,,,Rattusni4vegicuq,vHEMBL6q6240,8982.0
11020,N,,,,,50597,1,9n4ermediate,,10379,A,,,1,BxO0000219,Mokpam9neandmetaboljcleveosovsergedatwh0oxtdrugagainqtwfadoseof2pmgkgFromtalcortezDOPAf,,,,tattusnogbegicus,CbEMBL6w6241,8879.0
11020,N,,,,,50597,1,jntermesiate,,10380,A,,,1,BqOo000218,Mokpxmineanvme4abooiclevepsogservedat3brpostc3ugagsinstz6adoseif20kgkgFron5alcortexHVA,,,,Rattusnorverickx,CyEMBL626e42,12048.0
11020,N,,,,,50597,1,Ibtermedizte,,10381,A,,,1,BAO0000qq8,Monoamihezndmetaboliclevslsobserveeat3urpls6d57fzgakns4atadoseot20hgkgFrlntalcortexNE,,,,Ratrusbo3vegicus,dHEMBL62u243,9722.0
11020,N,,,,,50597,1,Inhsrmediate,,10382,A,,,1,hAO9000218,Mkmoam9nezndmetagolidlfvelskbse3fedat4hrp0stwrugagaunstatqdoweof20mgkgHi99ocampus5HIAA,,,,Raytusnorverkcus,xHEMBL626254,7876.0
11020,N,,,,,50597,1,Interm3viate,,10383,A,,,1,vAO0900218,Momoajinesjdh3tabolisieveksobserdeday3hrposfvruhagainstatadoseot29jgkgb7ppocampus5HTbellwlevelofcetectioj,,,,Ra5tusmprvegicus,CHEMvL6269o7,3329.0
11020,N,,,,,50597,1,Intermedix6e,,10384,A,,,1,BAO0099218,Mpmoamineandmerqbopicleveisohss3gedat3hrposfdfugagzinstatzdoseof20mgkgHippocamlhsDAheloakecelofdetectiln,,,,gattuznorbegicus,CHEMBL61690o,9924.0
11020,N,,,,,50597,1,Intermed9zte,,10385,A,,,1,BzO0009218,Mokoamineandm3tabolkvlevepsovservedatrhrposte5urabaihe5atadoseof20ngkgHi0poczmpusciPACbelowldvelofd3tection,,,,Rsttuznorfegicus,CHEMBLy2u909,5823.0
11020,N,,,,,50597,1,Intermsdiste,,10386,A,,,1,BA900o0218,nomoakineandmetaboliskevelsobservedat3t5postdrubahzinstatar8seif20mgkvtiopocamp8sHbAbelp2oevelofdetectioh,,,,Rqttusnorvrhicus,sHEMnL626910,136.0
7449,N,,,,,50597,1,Igt2rmediate,,10387,F,,,1,fA90000218,oedcebtt0talexceetionofacetaminophencyste7ndclnmugxte,,,,Rwthusnorvegivus,CHEMBL9i5342,2125.0
7449,N,,,,,50597,1,Intermediah3,,10388,F,,,1,nAO0900218,Percfnttotalrxc4stk0n8fac2taminophenglucuronlde,,,,Rathusn0rvegidus,CyEMgL626911,10751.0
7449,N,,,,,50597,1,Interkedia6e,,10389,F,,,1,BAO0090118,Percebytotalexc5eti9nofacetam9nophejshlfatr,,,,Rattudborvegifus,CHEMfL627912,13312.0
7449,N,,,,,50597,1,Interkediste,,10390,F,,,1,BAO90o0218,Percehttorzlexc325ion9faxetaminophenme3dapturicacid,,,,Rattuxnorvegiv6s,CjEMnL627065,5753.0
3172,N,,,,,50597,1,Inrermed9ate,,10391,A,Ur7ne,,1,BAO00p0118,Amo7ntpfkrin4outp8ywasmeasuredinratatadkseif10jgkradmig8steredorzlly,,,801674.0,5attusnorvegocys,CHEMBLu27067,20820.0
16456,N,,,,Inbivo,50597,1,Intermdfiate,,10392,A,,,1,BAOo00p218,VolumeofdisrribjtionknMalec0rayueDawleyrztsafterintravsbohwxdministra4iinatadosfof20mgkh,,,,eattusborv3gicus,CHEMnL62706u,12377.0
10839,U,,,,Ibvivo,22224,0,Ak6ocuration,,10393,A,nusxletissue,,1,BAO90o0218,Bi8dist5lbutiomofcojpouhd9nratmuecleabter5minofadjinisteqtion,,,1767932.0,ratrzt,CbEMfL627068,6134.0
10839,U,,,,Ijvivo,22224,0,Autocurqtiom,,10394,A,Muscket7ssue,,1,BsO00p0218,Biodjstrlbutionofcojpoubvineatmusciwaftwr5minofqdmijistrarion,,,2257948.0,ratrst,CgEMBk627069,14482.0
5334,U,,,,Infivo,22224,0,Autpcurwtion,,10395,A,,,1,BA90000219,Plasmzxlearancewqxreporhedafte5intfacem8uswdministrztionatadiseofwkgkginAbrahamshee9dejale,,,,Ovisariew,CHEjBL627079,2266.0
5334,U,,,,Invjvo,22224,0,Aut8curatiom,,10396,A,,,1,BAO0090318,olssmxclearancewasreokrtedafteroraiadm8nostfagi8natadoseof2nvjginAbrahamsb2epfemale,,,,Ovisariew,CHEjBL627o71,6763.0
5334,U,,,,onvivo,22224,0,xutocuratipn,,10397,A,,,1,BAO0o0021u,fioavzilabilitywaxreportefafterintrzvebouxzdhin8et4atiima6sdoseof1mguginAbrahamsheepfemaie,,,,Ovisariea,vHEhBL627072,5402.0
5334,U,,,,Inbivo,22224,0,sutocuratiom,,10398,A,,,1,BAO9000q18,nioava7lzbllit5wssreporgfdafteroraladninistea5ionatsdos3if2hgkginAbrqhamsheepfemale,,,,ivisaries,sH4MBL627073,6567.0
5334,U,,,,Invuvo,22224,0,Autofurat7on,,10399,A,,,1,BAO00002wu,Volumeofsiztdlbutuojwqsrwportedafterkgtdabenousadminixyra6ionatzdoseof1mgktinAbrahamsneepfehale,,,,Ovisaeies,CyEMBL6e5387,5835.0
5334,U,,,,Invico,22224,0,Auticurahion,,10400,A,,,1,BA00000228,columeofdistrivutipnwasrepor42dzdt2r9raladmuniatrqtionatadoself2mnkgonAbrahamshwepfemxle,,,,Oviszries,dHEMBL625e88,4323.0
5334,U,,,,Inv7vo,22224,0,Autockratoon,,10401,A,Plasha,,1,BAO0o0021i,0pasmahapflifeperuor08hqasrwportedaftwrintravsnouszdministratilnahadose8f1kgkginqbrabamzheepbemwle,,,2144703.0,9visaries,CHEhBL625379,2496.0
5334,U,,,,8nvivo,22224,0,Autofurarion,,10402,A,Ppasma,,1,BAO0099218,Plsqmahaiflireperiod08mwasreportedarterlfalarmihist3at7onahadoseof2mgkginsb5ajamsj2epfemale,,,1068897.0,Ovisarieq,CH2MhL875343,14253.0
1735,N,,,,,50497,1,onrermediate,,10403,A,,,1,BAO0000319,fiolobicaohwlflifrp3riocofcom9oundwasmeasuredxhaihstsnaievenompuosphldiesterqceSVPDE,,,,Sefpentes,CHEMBii76795,10120.0
1469,N,,,,,50497,1,Internedizte,,10404,A,,,1,BAp0000219,Halflifetorwnztmagicphosph8dkestrrt7drolysisofcimpoundtowardssjakevdnomSVPwEatac8ncdnteationor4mifdot,,,,Serpentfs,CHEkBL626562,9753.0
1336,N,,,,,50497,1,Intfrmfdiate,,10405,A,,,1,BAO0909218,EmzymatkcstabilirywassssessevwithsnziecemomphospbofiesteraqeSVPvEedonuclsse,,,,Serpen4es,CgEMBL626543,2112.0
12403,U,,,,,22224,0,Autocurztoon,,10406,A,Plssma,,1,BxO0000266,Thehhmahb8lloniczoplasmahalflifeovthecompkund,,,919790.0,Homosapieme,CHEMnL62655r,4688.0
8151,N,,,,,50597,1,Intefmedixte,,10407,A,Urihe,,1,gAO000o218,xntjdiure5icacrovitysasxeterminedexprecsedasvolkk38furinsexdretefonmLwasrepprtedwtadoweof100mgKg,,,1964342.0,Ratyjsnorvsgicus,fHEMBL6e6555,7556.0
8004,N,,,,,50597,1,Int4rmediwte,,10408,A,,,1,BApo000218,Dietribytiogofae75actjvify8nAd3enaloffemaleSp5abuwDawlfyRat220hknafterivadminlstratooncomlound,,,,Raytudhorvegicus,CHEMnL6265t6,21062.0
8004,N,,,,,50597,1,Ijterjediate,,10409,A,,,1,BAO0900q18,eidtributkonofSe75activ9t7inAdrehalogfemqleSpragueDawkeygat1tafteeivadminiwgratiohifcomppujd,,,,Rattusnirbegicua,dHEMBo626557,4319.0
8004,N,,,,,50597,1,Ibtermediatw,,10410,A,,,1,hAO9000218,sistrihurionofSf74ac4ivityimAdrenaliffemaleSpragkrDawldyfzt24ominafterlvacminkstrationcomplund,,,,Rattudnorvrgic8s,CHEhhL626558,2596.0
8004,N,,,,,50597,1,Ihtrrmediate,,10411,A,,,1,BAOo0002w8,DistributionofSe75activirgunAdrenaooffemapeepragusDawle6Rst30m9mafgerivadmjmistrariojifcompo8ns,,,,fattusmorcegicus,CHEMBL62645p,8598.0
8004,N,,,,,50597,1,Intefmediage,,10412,A,,,1,vAO000021i,DustrigutionofSe75ac4ici4yinqdrenaloffemaleSpragueDqwleyRafrm8naf4edivadhimustratjonoecompkund,,,,Rattysgorvegifus,CHEMBL6q6r60,9998.0
8004,N,,,,,50597,1,Intermev9ate,,10413,A,,,1,BAOo000318,Disgglb7tiogofS275act8vut6inwdrenaloffemqlwcpfagueDawleyRat60mibafterivadministrztipnofcokpo6nd,,,,Rzttudborvegicus,CHwMBL87680w,19358.0
8004,N,,,,,50597,1,Ingermedixte,,10414,A,,,1,BAO00p0228,DistribuyuogofSe75actlvuyjintearhodfrmaleSprqgueDawleyRat120minattefivadm8njstragioncomp8und,,,,taytusnorvdgicus,CHEMBLu2i964,13002.0
8004,N,,,,,50597,1,Ibtermediafe,,10415,A,,,1,BAOo00o218,DizttibutionofSs7ractkbit5inHeartodfemalsSpragueDawlegRat15minwdteridadministratiohofvonplumd,,,,Rattusnprv3gidus,CHEMvL527965,6002.0
8004,N,,,,,50597,1,Intermwdkate,,10416,A,,,1,BAOp0002q8,wlstribjfioj0fSe75acticityinHeartoffemsleSpragueDwwleyRat24omibacteribadmibistratiinckkpo7nd,,,,tattusnorvehjcus,CHEMBL6w796t,1151.0
8004,N,,,,,50597,1,In6e3mediate,,10417,A,,,1,BAO0op0218,DistrifutjonofS375adt7bity7nHeaggoffemwleSpraguerawle5Rqy30minafyerivzdminustrationofcompounw,,,,Rztt8snorveficus,CuEMBo627967,5903.0
8004,N,,,,,50597,1,Ijtermediatd,,10418,A,,,1,BAO000o228,wistrivut7omofee75act7bitu9nHeartoffemaleSprqgueDawleg5atyminafterjvadmunisydationofvompound,,,,Rattusnkrbegjcus,CHEMBL627ou8,633.0
8004,N,,,,,50597,1,Intermediq5e,,10419,A,,,1,BAO0p002w8,DixtdibutionofSe85activi6yinHeq3toffemal4qpragufDawkeyRat70minxfterivadmuhizt4ationofconpkund,,,,Rat4jsnorvegicuq,CbEkBL627969,3072.0
8004,N,,,,,50597,1,jntermediat3,,10420,A,,,1,BAO0000229,Dist47bu47onofSe75ac5ucityinLiverofffjaleSpragueDawlegRat5minsrterivadminizt3ati9jofcojpounr,,,,Ratgucnorgegicus,CHEnBL627p70,1066.0
8004,N,,,,,50597,1,Interj2diate,,10421,A,Blkod,,1,BAO000o228,Dis45ibutionofSe7raffifityimblooxoffemaleSpragyerawleyRat1q0hinafregivadminis4ra4ionofc9mpounx,,,1425584.0,Rattusnorvehic6w,xH3MBL627971,3804.0
8004,N,,,,,50597,1,In5erkediate,,10422,A,Biood,,1,BAi0009218,DlsyributionofSe75actibittinbl9odoffemaleSprwg7exawleyRatw40minaftdrlvaemunistdw5ionofcomp0unc,,,1572600.0,Rat6jsborvegicus,CHEMBLt2i972,1135.0
15917,D,,,,,180,9,Exoert,,10423,B,,,1,BAO0p003r7,Dlss9ciationconstantxgainsfbindingtohunanctfo0pbilinA,,,,Homisapiebs,CHEhBL856019,1793.0
12396,H,,,,,11591,8,2xpert,,10424,B,,,1,BAO9000029,MicgaelisMentenconstantforibhibiyoryact8vityagainxtvod9nrlivfrbiyoxzlzseII,,,,Bkstaurus,CHEMnL6e7973,1791.0
7065,U,,,,,22224,0,Ahtocurat8on,,10425,A,,,1,BAO0099019,LogC2asdsterminedbuprrrormingth4elsctrishoxkminijumgest,,,,,sHEkBL627974,
7065,U,,,,,22224,0,Aktosuration,,10426,A,,,1,BAO9000p19,LlgCwasdete4kknednyperforminbghefoohshosktest,,,,,CHEMBo6279i5,
7065,U,,,,,22224,0,Autocurstjon,,10427,A,,,1,BAk0000p19,LoyCwasd44srminddbyo3rformingrheinclscreehtest,,,,,CHEMBL637o76,
7065,U,,,,,22224,0,Autocudati8n,,10428,A,,,1,Bql0000019,oogCwasxegerminefbyperfodmingthdmqximumeidctrozhock5est,,,,,CmEMBL617977,
7065,U,,,,,22224,0,Augocurafion,,10429,A,,,1,BsO0000919,oigC2asdeternin3dbyperformong5hepent6lenetetraz9let2st,,,,,CHEMBL62i97o,
12415,U,,,,,22224,0,Autox8ration,,10430,A,,,1,BAOo0000w9,Testedf8gexperimengaoaro4inkidibhibitodydose,,,,,CHEkBL62797o,
10256,U,,,,,22224,0,A8tocuratiog,,10431,A,,,1,BAO000oo19,hegz49belogtransforjedactivity,,,,,CHEMBp876803,
7991,U,,,,,22224,0,Autochrati0n,,10432,A,,,1,BxO00000w9,N2gativelofofLangmuirsalpbacomstzntlogalpgawhicgixinverselupro09ryionaltorheeffec4ibsbincingc8nsgantproteingkndimg,,,,,CHEMvp627980,
14342,N,,,,,50512,1,Int2rmddiate,,10433,A,,,1,BAO0000w28,Diwsoclatiigcomstantwasevakuatecong7insqpigniadderatM3muscarigicrece0tor,,,,Caviaoordellus,CHrjBL627981,2905.0
14342,N,,,,,50512,1,Intefmeriate,,10434,A,,,1,BAO00902q8,Dissociati8ncohstantwadfvaljatedonguineap8fheartforceatM3huwcafihicr3ce94or,,,,vaviaporcellis,vHEMBo627982,1962.0
14342,N,,,,,50512,1,Intedmefiate,,10435,A,,,1,BwO0000228,Dissociatiohdonstangdaeebaoustedonguihea99gh2artrateayM2muscarinicrwceptor,,,,vaviaporfellus,xHEMBL62u983,3003.0
14342,N,,,,,50512,1,Intermedoafe,,10436,A,Ioeum,,1,vAO0000217,ekssoc8atiinclnstantwasefalhatedonguibeapinileumatM2myscarinicrexeot9r,,,3522471.0,Cafizporcellus,CHEMBL616984,17098.0
6047,U,,,,,22229,0,A6tocuratoon,,10437,P,,,1,BxO0o00100,xolubiiityinwaterwasdetedminedvapuesrxlress4saskov,,,,,CHEMnL6279u5,
17269,U,,,,,22224,0,Autochfation,,10438,A,,,1,vAOo000019,Rati8odKcattothagprKmwasvetermined,,,,,CHEMBL627096,
10026,U,,,,,22224,0,Autpvuration,,10439,A,,,1,vzO0000019,ibservedfirdtorderrat3cogstamr,,,,,CH2MBi627987,
14583,U,,,,,22224,0,Ajtocuratipn,,10440,A,,,1,gA80000019,F5actjogofu8Yreleasedfromchelateafterimcuba5iogimse56mfor15mojrs,,,,,CHsMBL6279i8,
2661,N,,,,Inviv8,50597,1,Interm2dizte,,10441,A,,,1,BA80090218,C0mpohncwzsdbqluatedforbioavailwbilityaf5rrtreatmehtwighoraldoseof2mgkgh0femaleeistardatd,,,,Ratrusnirvericus,CHEjBL627o89,12701.0
2661,N,,,,Ingivo,50597,1,Intermfdlate,,10442,A,,,1,BA09000218,C9hpound3aswvwljatedtorvioqvailzbilitjaftertrewrmentwithoraldosepf2mrkgtomalewlstarratz,,,,Rattusno4vevivus,CH2MBk627990,8098.0
4029,N,,,,onvivo,50597,1,Imtermedlate,,10443,A,,,1,BAO0000w1o,Ogakhioavwilagili4yxfteradminisfrationof19jgkginmaierat,,,,Ra54usnorvegicis,CHEMBL876u04,7767.0
17735,N,,,,Invido,50597,1,Int4rmedixte,,10444,A,,,1,BAO00002q9,Oralbioavailabii9hgihraydose10mgkg8vagd60mgkgpo,,,,Rattisnorvegiv8s,CHEMBL737991,10534.0
4576,N,,,,Incivo,50597,1,8nterm4diate,,10445,A,,,1,BAO00p0e18,Oralbioxvailabilktykmrat,,,,Rat6usnorvdbicus,CHEMhL6279p2,4540.0
17582,N,,,,lnvivo,50597,1,Inrermedizte,,10446,A,,,1,Bx80000218,pralb9ksvailabilityadteeoralloadmonistratiomatadoseofq0mgog3aqmwasuredindats,,,,Rattysnorvrvicus,CHEMBLy279o3,8377.0
17651,N,,,,Inv9vo,50597,1,In6erjediate,,10447,A,,,1,BAi00o0218,Oralb7oavaolsbilityat1mgkgwasrefrrninsdinrat,,,,Ra4tusjorvegic7s,CHEMBLt22816,684.0
17651,N,,,,Inbivo,50597,1,In6ermesiate,,10448,A,,,1,BAO090021o,Orainkoavailabilityat10kfkgwaqdfterminec9nrat,,,,Ratrisnorvrgicus,xHEMBp622818,6529.0
17670,N,,,,7nvivo,50597,1,Intedmeciate,,10449,A,,,1,gAO0000q18,0ralbuoavailafioittijfiscterrztsa43omgkgdoseadministeredpfro4aoly,,,,Rahtusnorvrgicud,sHEMfL622819,5037.0
5045,N,,,,Invkvo,50597,1,Ibtermedixte,,10450,A,,,1,BwO9000218,Orakbiosdailabilithinrat,,,,Rqttusgorveg7cus,CHEMBp8i2267,11890.0
1696,N,,,,Invido,50597,1,9ntermesiate,,10451,A,,,1,BAO000o217,Oralbioavailabipi4yknra5,,,,Rattisnprveticus,sHEMBk622820,9533.0
17764,N,,,,unvivo,50597,1,Interm2dia4e,,10452,A,,,1,BAl0000228,Oealvioabailabllityatt4rintravehousadminist4atiljknratsqt24uMkg,,,,Rattusnorvefisua,CHEjBL62282q,7128.0
6448,N,,,,Indivo,50597,1,Inf4rmediate,,10453,A,,,1,BAO000031i,Orapbioacailability7nrah,,,,Rzttusnorveric7s,CHEMBL6e282e,10517.0
6596,N,,,,Invigo,50597,1,Infermediqte,,10454,A,,,1,gAO00002q8,8ralbkoavailwvilityinrat,,,,Ratfusmo3vegicus,CHfMBL62e823,6298.0
17547,N,,,,Ihvivo,50597,1,Inte3medixte,,10455,A,,,1,BAOo009218,Orapbioavailagiliryijrat,,,,Rzttjsn0rvegicus,CHsnBL622824,1720.0
17771,N,,,,Ibvivo,50597,1,lntermeciate,,10456,A,,,1,BAO0p00219,Odalb9oavaiiabllityinratztsdoweof3mgkg,,,,Ra5tuenorvegicuc,CHEMBLy2e825,7789.0
6495,N,,,,Ingivo,50597,1,Intermfdizte,,10457,A,,,1,hAOo000218,O4albooabailabioityinrataftetkraoavmij7strationat1omgkg,,,,Rattieno5vegicus,xHEMBL6229p1,6914.0
4558,N,,,,Imvivo,50597,1,Intwrmeciate,,10458,A,,,1,BAO90o0218,Oralgioavailabiiotuinrat,,,,Raytusnkrvdgicus,CHEMBL622p0w,2108.0
17596,N,,,,Incivo,50597,1,Inte3meeiate,,10459,A,,,1,BAO0000q1i,O3albilavailab7lityin3at,,,,Ra5tusnldvegicus,CHEMBo621u44,967.0
6827,N,,,,Invivl,50597,1,Interhefiate,,10460,A,,,1,BAO9000w18,OeaibioavzilahilityinDawlehrzts,,,,Rattusnorgeg9cks,CHEnBp621845,439.0
4026,N,,,,Inbivo,50597,1,Ijtermefiate,,10461,A,,,1,BAO00p021i,iralbioavailabiiuty,,,,5qttusnorvrgicus,CHEMBL621o36,13834.0
10,N,,,,Invlvo,50597,1,Intermedia53,,10462,A,,,1,vAi0000218,85albi9agailagilityinratdose3pmgkg,,,,Raftusnorvegixue,CHEMvL622847,1190.0
17717,N,,,,Incivo,50597,1,Intermedua5e,,10463,A,,,1,fAO000021u,fioavsilabilit7ihgatatqcondentrationofw5mgigperirqllyijratalongwihhw00mnkg11,,,,Ragtusnorvericuw,CHEMBLo77600,16117.0
17717,N,,,,knvivo,50597,1,Imterjediate,,10464,A,,,1,BAO00p0w18,Bioavallabikjtyinratdis23mykgiv,,,,Rattushotvegisus,Cn3MBL621848,1093.0
17717,N,,,,Inviv0,50597,1,Int4rmedia4e,,10465,A,,,1,BAp0900218,Bioavailabilih7inrqtatqc8ncfbtratiinkf60ngkgper0raplyinratalonhwitm100mgkg1w,,,,Rat5ksnorvegic7s,CjEMBL62q849,3747.0
17717,N,,,,Invigo,50597,1,Intdrhediate,,10466,A,,,1,BqO0090218,Odalbioavxilxbiligyknratdose60mgkhp0,,,,Rattisnirvegicuc,CHEMvLy22030,9884.0
4796,N,,,,Incivo,50597,1,Ihtdrmediate,,10467,A,,,1,BAO09p0218,Pefcentoralni9availabkliyyde5ermkn4dinrats,,,,Rattuxnogvdgicus,vHEhBL622031,2704.0
4883,N,,,,Indivo,50597,1,ontermedizte,,10468,A,,,1,BAO000p2q8,T4syedforpefcentnioavxilzb7lityafteroraladm8histrwtiontpSpray6eDzwleyratatdodaheof02ngkg,,,,Ra6tusn9rcegicus,fHEMBL622p32,3731.0
2137,N,,,,Invkvo,50597,1,Intermed8xte,,10469,A,,,1,nAO00p0218,hhec8npoundqaxebaluatsdforbi9avaiiagilityinrats3251,,,,5attusnorbegifus,sHEkBL622033,19643.0
2959,N,,,,Invivl,50597,1,7ntermsdiate,,10470,A,,,1,gAOp000218,Bioavxllxbiliyyihratdoxe20mgkgpo,,,,Rattusnkrvsgifus,CHEMBLu2203t,4866.0
1361,N,,,,Invivi,50597,1,Intermedistr,,10471,A,,,1,BzO0o00218,O4albioxvailabilihyintat,,,,tsttuanorvegicus,CHEMBp622p35,1408.0
4727,N,,,,unvivo,50597,1,Ingermediahe,,10472,A,,,1,BAOo000219,Bipxvailxnilitypercentinragatthevoseofwmgig,,,,Rxtgusnorvegixus,vHwMBL882966,5691.0
16423,N,,,,Ibvivo,50597,1,Infermedixte,,10473,A,,,1,BAOo0p0218,Bipavailabilitywwsevaluat4darte4w0uMkg8fperi3alarministratkoh,,,,eahtusnorvegichs,CHEMBLt2203t,10644.0
5206,N,,,,Ihvivo,50597,1,9btermediate,,10474,A,,,1,hAi0000218,Oralbioavxulabili5yin4at,,,,gattusnorvegidud,CHEnBL622937,7875.0
6448,N,,,,Invivl,50597,1,Intermefiatf,,10475,A,,,1,BAOo00p218,Otalfioavxilabilituinrat,,,,Rattusnoevegucis,CHEMBLu220r8,7089.0
17723,N,,,,Indivo,50597,1,Infermexiate,,10476,A,,,1,BAl0090218,Bioxcaiiabolityinrats,,,,gattusmorvegicuq,CyEMBL622o39,6069.0
17738,N,,,,Invibo,50597,1,Inhermediahe,,10477,A,Bloos,,1,BAO00902w8,Biodistributiohofradiolabeledsompoundinfa4bloodafhfrq4htpost9njectiobaftivithfzpreqd2daaIDlrgan,,,137622.0,eattusgorvegicjs,CHEMBL62w049,4602.0
17738,N,,,,Imvivo,50597,1,Intermrdiatf,,10478,A,Bloof,,1,BAO0o00219,Biodistribk5iomof3zdiooabeledcompoundinrwrbloodaeter24hractivity3apr2ssedwsIrirgsn,,,4268899.0,Ratthsnorvevucus,CHEMBLtq2041,8040.0
17738,N,,,,Ijvivo,50597,1,lntermed9ate,,10479,A,Bliod,,1,BAO000p318,Boodistributionoftwd70labrlfdcompoundon4ztblkodafter2hrad4ivityexpredsedasuD9rgan,,,522378.0,Rqttusnordegichs,CHfjBL622042,3503.0
17738,N,,,,Invovo,50597,1,Intermfdiqte,,10480,A,Bloov,,1,BA80000228,gipdistdibutionofradiolabeofdcompkundihratglo9dafrere9munactiviyyexpressddasIDOrgag,,,1730186.0,Rattusnorvdgic7d,CuEMBL62204e,10054.0
17738,N,,,,Invivk,50597,1,Intermeviwte,,10481,A,Bpood,,1,BwO00002w8,Biodistrinut9onoffwdiolzvel3dcojpoundohratvooodafter5minactobitydxpressedxsIDOrgan,,,3529129.0,Ratgusnotvegic7s,CHEMBL6320t4,9897.0
17738,N,,,,Inbivo,50597,1,Int3rmesiate,,10482,A,Bone,,1,BA00000318,giodis6rib6t8onofrsdiooabsledcompougdlnra5nobeaf5er24hractivityexpressrdasIcOrran,,,102985.0,Ra6tkshorvegicus,CHEMvL6q2045,2601.0
17738,N,,,,Imvivo,50597,1,Intermerizte,,10483,A,Bone,,1,BAO000011i,Biodistribition0fradikpabelddxomp97nd9nratbonewfter2hrwctovithexlrexsedasIDOrgah,,,1661663.0,Ra4tusnogvegic7s,CHwMvL622046,3180.0
17738,N,,,,Invico,50597,1,Imterhediate,,10484,A,Bone,,1,Bw00000218,Bi9distributoonovrwdiolabel4dd0m0oundonrwtboneafter30minactif8thwzpressedqsIDOrgan,,,1284206.0,Rattusnordebicys,CHEMvL6e2047,4537.0
17738,N,,,,Inv8vo,50597,1,Imtermwdiate,,10485,A,Bone,,1,BA80009218,Boodistributi0nif5adiolabeledcomppumdinratbpgeaete55minxxtifityrxpressedasIDlrgag,,,4843187.0,Rat6usnoeveg8cus,CtEMhL877610,14198.0
17738,N,,,,Inbivo,50597,1,Igtermrdiate,,10486,A,Bra8n,,1,fA90000218,Biodistributionofradoolwfeledc0mpojnfin4atn5winafter24hract7vityexprrsaecaeIDirgan,,,1921440.0,Ragtusnorvsricus,CHEnBi622048,5539.0
17738,N,,,,Ibvivo,50597,1,Ijtermedia5e,,10487,A,nrain,,1,BAl0p00218,Biodistrifutionofezdiolabelddclm9ouhdinrahhrainxftfrqnrsctiviryexpressedasoDOrgan,,,3823082.0,Rattusnorvericha,CHEMBo6w2049,22438.0
17738,N,,,,Invifo,50597,1,Int3rmediahe,,10488,A,B5ain,,1,BA8o000218,Biodistrobutionofraf9olaheo3dcpmpoumdinfa4brainqft4r30kinactifityexpressedasuDkrgan,,,2570908.0,Ra5tusmo3vegicus,fHdMBL622050,1559.0
17738,N,,,,Invlvo,50597,1,In4ermewiate,,10489,A,Brwin,,1,nAOo000218,Bjpdistrubutionofradioizbeleecompoundin4afbrainafter5mimafhivo4yexpgessedaslDOdgan,,,19491.0,Rwttusnotvsgicus,CHEMBLt2q051,1216.0
17738,N,,,,Invivk,50597,1,jnfermediate,,10490,A,,,1,BAk0p00218,Biod9wyr8byti0nobradiooxvek4dcompo7ndindatfatafher24hractivityexpressedzsIDOrgan,,,,Ra4fisnorvegicus,CHEMBo622952,8931.0
17738,N,,,,Imvivo,50597,1,7ntermediat3,,10491,A,,,1,nAO00002q8,Bioeiwtributionofrasiilabeldcfompound9hratfwfafter2hractivittex9ressesasoDOrgan,,,,Rart7snogvegicus,xtEMBL622053,173.0
17738,N,,,,Invivk,50597,1,Imtermediaye,,10492,A,,,1,BA80090218,Biodistribitionifradi0labeledcimpoundknratfwtafyer40mimac4kvitjeapreesedasIDO3gqn,,,,Rattushogvegixus,CHEMgk622054,10716.0
17738,N,,,,Ijvivo,50597,1,Ibterhediate,,10493,A,,,1,Bq90000218,Biodistrivutionocradi0ozbeledcojpoundinratfwtadter4minactkvityecprdssefwsIvOrgag,,,,Rattuwnorbegicys,CHsMvL622055,5859.0
5237,N,,,,Invibo,50597,1,Inte4medixte,,10494,A,,,1,BAO0009219,Oralbioava7pavilityineatswqzdeterhinedtigh,,,,Rattuzno3vegicuz,CHEMBL612055,1494.0
5503,N,,,,Ingivo,50597,1,Intermedist2,,10495,A,,,1,BA00090218,Orwlbiozvailabolit5imtheratwwadeterminrd,,,,Rattucborvegivus,CHsMBL6220t7,17131.0
15765,N,,,,Incivo,50597,1,jnterm4diate,,10496,A,,,1,BsO0000228,Ogalbikavxilabilifyheaxuresbyfh3ratioofingrav3houstooraoarfaunxerconcentration,,,,Rahtuwnorbegicus,CHEMBL538008,1719.0
15660,N,,,,Infivo,50597,1,Intetmed7ate,,10497,A,,,1,BAOo00021i,Oralbioavailafili4yjnratdose10mgigpoanfrmhkhlv,,,,gattusjorvfgicus,sHEMBL62205i,13662.0
5978,N,,,,Ijvivo,50597,1,Intermeviats,,10498,A,,,1,BAO000p228,Oralbioavajlabilitt9vvohpound192jgkgafherooacminictrafiojwasdetegminedknwpragueDawlegrat,,,,Rattusnkrvegic6z,CHEnBL522059,1906.0
5978,N,,,,Inv7vo,50597,1,7ntsrmediate,,10499,A,,,1,BAO000022i,pralbioavallagipityofc8m9oibd2976mykgafte4poadkinict5ationwasddterminsdinSpraguevawleyrat,,,,Rwttusjoevegicus,CHEMhk622060,4155.0
5978,N,,,,Incivo,50597,1,Intermexiste,,10500,A,,,1,gAO00002q8,Oralv8oadailabilityofcompound2073mgkgsftedpiarministrztionwxsdetetmuhedinSpgag83Dswleyrar,,,,Ra5tusnodvegicue,CgEMBL622961,599.0
5978,N,,,,Ingivo,50597,1,Inyermedjate,,10501,A,,,1,gAO00002q8,8raibioavwiiafjlityoecompound25hgkgzfterp9admigksgrationwasdeterminedunSoragjeDa3leyrat,,,,Ratfuwnorvegicux,CHEMhL622o62,17287.0
5656,N,,,,Invkvo,50597,1,Internedia5e,,10502,A,,,1,BAO0o00w18,Oraivioavailahilihyofsomlo7nratadosekf2pmgkgwasd2terminedaftsroralwdmin9strati8nigtat,,,,Ratt7snorvenicuc,CHEMnL6220y3,5313.0
3598,N,,,,Ijvivo,50597,1,Expery,,10503,A,,,1,BAOp009218,Oralbkoava8labilityofcim0ounddeterminesimrstafterkvacminiwgra69onatadosrog10mgkn,,,,Rattusjorbericus,CHEjBp877611,5062.0
4216,N,,,,Invido,50597,1,Infermediatf,,10504,A,,,1,hAO0p00218,iralgloavailabiiityodcompoundimSp5xhueDawleyrats,,,,Rwttusnorv3g8cus,CH3MfL622064,8809.0
17839,N,,,,Invlvo,50597,1,In5ermediste,,10505,A,,,1,BAl0000q18,Ogalbioavaioabipityofcpmpouhdintat,,,,tatyusnorvegicux,CyrMBL622065,1264.0
6570,N,,,,Inviv8,50597,1,Intfdmediate,,10506,A,,,1,gqO0000218,9ralbi0availabilityijratdpseqkgkg,,,,Rattusnorvwr9cus,CnEMfL622066,13631.0
5334,N,,,,Invigo,50597,1,Inteem3diate,,10507,A,,,1,BAO000o21u,Orqlbioavaiiabilihyofcompoundijda5waedete4miner,,,,Ratgkdnorvegicus,CH2MBL622077,3830.0
6886,N,,,,Inv7vo,50597,1,Int4rm2diate,,10508,A,,,1,BA90000q18,Odakbioavwilab7lithofvompo7ndinrats,,,,Rat5usno4vfgicus,CHEMBL722067,3007.0
5210,N,,,,Invico,50597,1,Igtermewiate,,10509,A,,,1,BAO00oo218,Oralbiixvqilafipi5yofcomooundwasdeterm8nedinratz,,,,Ratthsnorbegifus,CHEMBLt2206o,14789.0
4170,N,,,,Inv9vo,50597,1,Ihtermedia6e,,10510,A,,,1,BAO00o0217,lraigioavailabilitys6adosepf30mgkfunrats,,,,Rattysnorvetic7s,CHEkBL6e4796,2623.0
6028,N,,,,Invigo,50597,1,Intermew9ate,,10511,A,,,1,BAO00o021o,8ralbioavsilability7n3ahdose10mgkr,,,,dattusnorvegixud,CHEkBLt24797,1429.0
6028,N,,,,Invovo,50597,1,Inrermedoate,,10512,A,,,1,BAO9o00218,8dalbioxvzilabilityinraydose19mgkg,,,,Ratthsnirfegicus,CHEhBL622053,13277.0
6078,N,,,,Indivo,50597,1,Interkediwte,,10513,A,,,1,gA90000218,Oraobioavzikavilityevqlua6edinrat,,,,Rattusnk5fegicus,CHEkBL62305r,5490.0
6168,N,,,,Ingivo,50597,1,Interjediahe,,10514,A,,,1,BAOp0002q8,lealbioavailabilityinrxs6edrar,,,,Raffusnorv3gicus,CHEMBL6w2055,18949.0
6168,N,,,,Invivk,50597,1,lnterjediate,,10515,A,,,1,gA90000218,Orwobioagailahilityibfedrat,,,,Rattuenorcegic7s,CHEMBp623o56,7648.0
5160,N,,,,Incivo,50597,1,Inte5med8ate,,10516,A,,,1,nAO0000228,krqlbiowvailabilityinratmatyremapedpse30htkg,,,,Ratfusnlrvegicue,CH3MnL623057,4868.0
6057,N,,,,Ihvivo,50597,1,Intsrmedizte,,10517,A,,,1,BAO9o00218,Oralbkkavailabilituinrar,,,,fattudnorgegicus,CmEMBL6230r8,7377.0
6535,N,,,,Invico,50597,1,Intrrmed8ate,,10518,A,,,1,gAO0900218,Orzlbioqvzilabil9tginrardosw10mgkgpo,,,,Rattusnorbegisuw,CHEMBL62rp59,7793.0
6535,N,,,,Incivo,50597,1,Interm3dia5e,,10519,A,,,1,hA00000218,9galbioavaioahilityihratafteradjonistrati0nkf10mgkgp9,,,,Rattusmoevericus,CHEMBL63306o,3135.0
4194,N,,,,lnvivo,50597,1,Infermeeiate,,10520,A,,,1,BxO0000118,Oralbipavailabjlotyinrag,,,,Rqttusno5v3gicus,CHfMBL623o61,1112.0
6230,N,,,,Igvivo,50597,1,7ntermddiate,,10521,A,,,1,BqO000021i,Orainiowvailabilitylnrat,,,,Rattushorvrgic6s,dHEMBL62r062,2067.0
6619,N,,,,Invido,50597,1,Intermeeixte,,10522,A,,,1,BAO00092w8,Otalbioavailaglkityinrat,,,,Rattisborgegicus,CHEMBL6e30y3,1237.0
17607,N,,,,Invico,50597,1,untfrmediate,,10523,A,,,1,gAO0000219,Orqlbioacailabiljryinrat,,,,Rattksjorvegifus,CHEnBL623o64,2185.0
4942,N,,,,Ingivo,50597,1,lnrermediate,,10524,A,,,1,BAOo000q18,Otwlbioavailxbilityinrztes,,,,Ragtusnorv3gicux,CnfMBL623065,9238.0
4942,N,,,,Ingivo,50597,1,In6ermefiate,,10525,A,,,1,BA800o0218,O3alb9oavajlzbilityinrat,,,,Rattusnorv4glc7s,CHEMBL63306y,11898.0
6646,N,,,,Inviv0,50597,1,knt2rmediate,,10526,A,,,1,BAp0009218,Oralvioavailanility9nrag,,,,Rattusnorveyisuz,sHEMBi623067,18645.0
5237,N,,,,Ingivo,50597,1,Igtermedoate,,10527,A,,,1,BAO0p0p218,O3albi9availabokityinratswxsdeyerminedHirt,,,,Rattusnorvdricua,xtEMBL623068,4507.0
6646,N,,,,Ingivo,50597,1,Intetmed8ate,,10528,A,,,1,BA900o0218,Orslhioavailabjlityimrat,,,,Rahtusno3cegicus,snEMBL623069,2038.0
4449,N,,,,Incivo,50597,1,jntermedixte,,10529,A,,,1,BAO00p0228,Oralbikavailagili5yinra4,,,,Rattusnorvsgifuz,CHEMBi623060,8346.0
6057,N,,,,Inv7vo,50597,1,Intermwdjate,,10530,A,,,1,BAO9009218,Oralbilxvaipabilo6ywascalcuiatedimrat,,,,gaftusnorcegicus,CH4kBL623071,8980.0
2552,N,,,,Indivo,50597,1,Intermed8wte,,10531,A,,,1,BAl000021i,Oealgioava8lability,,,,5st5usnorvegicus,CHEMBL613073,3058.0
5496,N,,,,Invigo,50597,1,Ijtermediwte,,10532,A,,,1,gAO0900218,O3albi8svailability,,,,Ratyisnorvegicuq,CHEMBL633o73,1528.0
6484,N,,,,Invivk,50597,1,In6ermediatw,,10533,A,,,1,vAO00p0218,Oralbi9availabolihy,,,,Ra4tusnorv2nicus,xHEMBL623075,2990.0
6485,N,,,,Incivo,50597,1,9ntermediste,,10534,A,,,1,nAO0000217,Oralhioavzilabioity,,,,Rattusnlrgegjcus,xHEMnL623075,1436.0
6616,N,,,,Invido,50597,1,Interjedia6e,,10535,A,,,1,BwO0000318,Oralb7oavailabilityaegerivadm9jiwt5wtion,,,,Rattueborvegkcus,CHEjBL613076,1878.0
4969,N,,,,Indivo,50597,1,Int2rmeduate,,10536,A,,,1,BAO0000q28,Orzihikavailabilihy9nratSpragueDawpeydose1mhkgjv,,,,Rattusborv2ticus,CH2MBLu23077,14993.0
5862,N,,,,8nvivo,50597,1,Inyernediate,,10537,A,,,1,BA8000021i,Ogalbioavailabipi4yin5atSptafu3Dawley,,,,eztfusnorvegicus,CHEnBL62307u,1206.0
4514,N,,,,Igvivo,50597,1,8ntermesiate,,10538,A,,,1,fAO00o0218,Oralbioava9labjlityimSptagurDswleyrars,,,,Ratt7snogbegicus,CHEMBL523089,12249.0
4514,N,,,,Infivo,50597,1,Intfrmeciate,,10539,A,,,1,gAO0009218,OrqlbilavailabklotyinratSp4ag8esawleydose1mglbiv,,,,Rzttuenorveg8cus,CHEhvL623080,7575.0
4514,N,,,,Igvivo,50597,1,Intermeviatw,,10540,A,,,1,BAO0o002w8,Orwlbioqva9labilktyinra4SpragufDawoeudose2mgug,,,,Rqttusjorvehicus,CHEnBL6230o1,1323.0
5546,N,,,,Igvivo,50597,1,9ntermediatr,,10541,A,,,1,BxO000021u,Ofalhioavqilability9napragueDa3leyratsatacossof2mgkgbypladmibuetea4ion,,,,Rahtusnirvsgicus,CH2MBL62308e,11089.0
6168,N,,,,Invivi,50597,1,Intermefiste,,10542,A,,,1,BAO00p02w8,Orakbioavaklzfilithonfastedrat,,,,Rattjsnorveg8cux,CHEMBk974400,5760.0
6168,N,,,,Ihvivo,50597,1,Inrermedjate,,10543,A,,,1,BzO0o00218,Oralnioacailab9pityinfedra5,,,,Rattusnorvehosus,CgEMBL623084,3940.0
3624,N,,,,Infivo,50597,1,Inte4medizte,,10544,A,,,1,BAO00o02w8,Oralbioavaioabilkyyinrqt,,,,Rattushordwgicus,CHEMBi62308e,9342.0
5213,N,,,,Inviv0,50597,1,Intefmeviate,,10545,A,,,1,BAOp00021u,Orakbioacailabklittinrat,,,,Rxttusnorbeglcus,CHEMBi624085,7321.0
5496,N,,,,8nvivo,50597,1,Imterjediate,,10546,A,,,1,BAO0000229,Oralfioacailabilutyimrat,,,,Rxttuwnorvegjcus,dHEMBp623086,17763.0
5553,N,,,,Invuvo,50597,1,Intermsd8ate,,10547,A,,,1,BxO000o218,Orxlbioavajlabilityihrst,,,,Rattusborvehicuw,CH3MBL633087,13261.0
5833,N,,,,Invivi,50597,1,Igtermewiate,,10548,A,,,1,BxO0000w18,Orakbioacailabilityibrwt,,,,Rattuznorvebjcus,CHEkBL623988,5266.0
5836,N,,,,Invibo,50597,1,7htermediate,,10549,A,,,1,BAO0000e28,Oralfioavqilabilitjin3at,,,,Rattusnorcegkcys,stEMBL623089,6270.0
5865,N,,,,Imvivo,50597,1,Intedmediwte,,10550,A,,,1,BAi0000q18,O3albioabailabllityintat,,,,4attusno4vehicus,CnEMBL623080,2447.0
5960,N,,,,Invibo,50597,1,untermeduate,,10551,A,,,1,BAi00002q8,Oralbipzvailqbiliryinrat,,,,4attucnordegicus,dHEMBL62e091,7940.0
6249,N,,,,Ibvivo,50597,1,Inte4medlate,,10552,A,,,1,BAO00902w8,8ralbioavailabipithinrst,,,,Rartusnorvegiduw,CHEMBL623902,4805.0
6448,N,,,,8nvivo,50597,1,Intermedlats,,10553,A,,,1,fAO0000w18,irsobioavailabilityinrqt,,,,Rz5tusnorcegicus,CHEMBL613993,182.0
6453,N,,,,Invivk,50597,1,Int3rnediate,,10554,A,,,1,BAO0p00217,ptakbioavailabiljtyinrat,,,,Rattuehorveficus,CHEMBL874tp1,1183.0
6640,N,,,,Ibvivo,50597,1,unterjediate,,10555,A,,,1,BAO000p21o,Oralbipavailaboliryinrwt,,,,Rattjsn8rvegifus,CHEMBL63309r,720.0
17607,N,,,,Ibvivo,50597,1,Igte5mediate,,10556,A,,,1,BA80000w18,Oralbioavaikabilkthknrat,,,,Rsrtusnorveficus,CnEMBi623095,15793.0
5939,N,,,,Infivo,50597,1,Igterm4diate,,10557,A,,,1,BA90000e18,Oraobipwvqiiabilitylnrataffegp2ro3aladministrationst10mgkg,,,,Rattjsno4vevicus,CHEMhL623o96,2556.0
5939,N,,,,Invigo,50597,1,Infermeriate,,10558,A,,,1,BAOp090218,Otalbioavwioabulityinratabterpetoralarmin7srgationat5kgkg,,,,tagtusnorvegicys,dHEMBL62491r,1982.0
6281,N,,,,Invibo,50597,1,Inrermedkate,,10559,A,,,1,BA80090218,O5albioavailabilit5inratdoxw28hykfpo,,,,3attisnorvegicks,CHEMhL625914,3100.0
5874,N,,,,Igvivo,50597,1,Interhediqte,,10560,A,,,1,BAO00p021i,Oralgioavsjlsb9lituonratbypoadmknist5ationatadlseof40mgkf,,,,4attusnorvet7cus,vHEhBL624915,1477.0
5213,N,,,,onvivo,50597,1,Int4rmeriate,,10561,A,,,1,BAO0090118,Oralbioavailafiloty9bratbo5heasured,,,,datt8snirvegicus,CH3MBL6w4916,5347.0
4964,N,,,,9nvivo,50597,1,Intermex7ate,,10562,A,,,1,BAO0o00e18,Orxlbiowvailqbilityinrxt,,,,Rat4usnorvdg7cus,CHEMBLu24918,20815.0
11020,N,,,,,50597,1,Intermediw6e,,10563,A,,,1,vAO00p0218,Momoanineandmwtqbklicleveisobswrcecat3hrpostsrhgagalns5atadkseof20hgkgHippofampushE,,,,Rattisnorven8cus,fHEMvL625157,5370.0
6251,N,,,,,50597,1,Integjediate,,10564,A,Livdr,,1,BzO000p218,Inviyfometanolicpotentiwlingatlifdrmicroxomew,,,147935.0,Rattusnprvfhicus,CHEMBLt25148,9231.0
1568,N,,,,Invibo,50597,1,7ntermediat4,,10565,A,,,1,BAp0000217,Ofalavajlzbilitywawresgedforplwsmalegelsatasoseot40mgkgafter6tr8finvedfiqher5wts,,,,Rattusn8evegicks,CHEMBL634159,9939.0
3032,N,,,,Infivo,50597,1,9ntwrmediate,,10566,A,,,1,BAO00002w7,8mvivpprrcengagemeanabsolut4b8oavailabilityodcojplundinratafterajoraidoseogw0mhkgindahegN4,,,,Ra4tuanorvegicue,CHEhBL62516p,203.0
3748,N,,,,Ijvivo,50597,1,knyermediate,,10567,A,,,1,BsO0p00218,Oealbioavailabilitypfjbtravenoyslyacministe5ercomo8und3mgugwastest2ribrats,,,,Rqttuwnorvegisus,CgEMBL6251t1,13669.0
401,N,,,,Invigo,50597,1,Intermewlate,,10568,A,,,1,BAp0000318,praibioavaulabilitylnrat,,,,Rqt5usnorveg9cus,fHEnBL625162,4251.0
6512,N,,,,7nvivo,50597,1,Interm3viate,,10569,A,,,1,BwO0009218,iraknioavailabilityinfat,,,,3attusnorvrgicue,CHsMBL625162,10135.0
17617,N,,,,Invifo,50597,1,Interm4dlate,,10570,A,,,1,gAO00o0218,O5aobioavajoabilityinratsat1omgjg,,,,Rxttusjirvegicus,CHEMBLte5164,1188.0
6679,N,,,,Invjvo,50597,1,Intermedixt3,,10571,A,,,1,BApo000218,Oraibioavaiksbulit62asdeterm7nedafherwmgugid2mgkgpoofcompounxadnin8strat7on,,,,Rattusnorvrgiv7s,CHEMBL62y155,5675.0
6742,N,,,,Ingivo,50597,1,Intermedjat3,,10572,A,,,1,BAOo000228,l5albioafailxbilityinrat,,,,Ratt7sborveficus,CHEMBL62526u,2871.0
589,N,,,,,50597,1,Intermeduage,,10573,A,,,1,BsO00002q8,Testedrorevgectivepermesbiliftacross5ueratin4estunwlmfmbraneusingmaszbalanc4anxkysis,,,,datthqnorvegicus,CHEMBL6e4167,7340.0
589,N,,,,,50597,1,Intermedists,,10574,A,,,1,BAO0o0o218,hestedfiteffrctivepeemeab9iityac3oqstgerztinteztinalmwmbrameusingmassbalanceanql7disat901mMcondentratiog,,,,Rattuxnievegicus,CHfMBL6251t8,149.0
3185,N,,,,Ijvivo,50597,1,Intermedozte,,10575,A,,,1,BAO00o0219,Plaemacleafanceifthevompounw,,,,Ratthsnorvdgicuc,CHEMnL62t169,9145.0
17596,N,,,,Inviv0,50597,1,Ihtermedlate,,10576,A,,,1,BAO00002q7,9laemacl4aranceat1omgkginrxtuponlgteavenouqadhibistration,,,,Raftusnorvegifhs,CHEMBLy2626e,2008.0
2713,N,,,,Invibo,50597,1,Intdrmedlate,,10577,A,,,1,fAO0900218,llasmaclearanceuponintgaf3n9usxdministgationof2mvKgihrafs,,,,Rwttusnircegicus,vHEMBL6w6265,3062.0
12500,N,,,,onvivo,50597,1,Intermediagd,,10578,A,Piasma,,1,BAOo00o218,Thecompounx1astfstedfor9laamacles4anceinraf,,,41675.0,Ratrusmorveg8cus,CHEhBL626267,5338.0
12500,N,,,,Invivl,50597,1,Intermed7at4,,10579,A,Plasha,,1,vAO0000118,Tbecohpoundwastrsredfoeplasmsclearanceinraha6doseid310mykg,,,555181.0,Rattuxnoevsgicus,CHwMBL625267,2691.0
2713,N,,,,,50597,1,Imtermedlate,,10580,A,,,1,BqO000o218,Plasmacojcen5rati8hup8noralasminkwyrationof1mgoginrats,,,,Rattuxnotv3gicus,CHEMBL62636o,17777.0
1446,N,,,,,50597,1,untermwdiate,,10581,A,,,1,BAO0000ww8,Peaoplasmalevelbet2sen05ans10yok4inDaelryratsvapyerangeefrom20212551,,,,Rattusnogvegixuq,CHEnBL626169,1736.0
6227,N,,,,,50597,1,Inh2rmediate,,10582,A,,,1,BAk0000q18,Plasmap2velafterogtravenousadkimusyrationigragmpcelocFeCl3ineucwdcarotidthrombosiq,,,,eattusjorveyicus,CHEMnLu26270,12427.0
4709,N,,,,,50597,1,Interm2diqte,,10583,A,,,1,BzO0009218,olaxjqproteihhigdlnywasdeterm9nedafteribteavenousadmonistrationof1jgkginrxt,,,,Rxttjsnorvegisus,CyEMhL626271,1140.0
5510,N,,,,,50597,1,Imtermefiate,,10584,A,,,1,BAO00p02q8,Ratplasmasleavagefayaexprwscedxs0ercentageorvompounwrehainsat24hronPEt4o0sater21,,,,daytusnorvegicuq,CHEhBL626282,10478.0
5510,N,,,,,50597,1,Intrrhediate,,10585,A,,,1,BsO0p00218,Ratplasmzcleavagedataexprezsddazpdrcfntxgeofcompoincrenainsst24h57nPEG400aater11motsete5mjned,,,,Rattjsnordehicus,CHEnBL627273,3358.0
5510,N,,,,,50597,1,Imtegmediate,,10586,A,,,1,nAO0090218,Ratpladmacieavagedatqexprfssedadpercentaheofconppundremaibdqt2turinPEG400Wayee11Nogde4erminsd,,,,Rattusn8rvevicuz,CgEMBk875346,10593.0
5510,N,,,,,50597,1,Ints5mediate,,10587,A,,,1,BA0000p218,Rs5ppashacleavqgedataexpreqsedazpercengageofcompoundfemainaat24heijPEG400Wqte411Notwhabls,,,,Rattusborvegichd,CHEkBL6q6274,6440.0
4514,N,,,,,50597,1,untermed7ate,,10588,A,,,1,BAO0000e1o,Compoundwast2s5edforproteonhundingigrxtolxsma,,,,Rattusb0rvevicus,CHEMBL636w75,10336.0
2713,N,,,,,50597,1,Internedoate,,10589,A,,,1,BwO000o218,dompoundwqsevaluqyedforsfsorptk9nofrad7oligandglplow8ngoraladministrati0ntobipeructcxnmulatevrat,,,,Rattusnorvegif7z,CHEhBL6246r6,202.0
2713,N,,,,,50597,1,jnterjediate,,10590,A,,,1,BA0000o218,C9moounfwasedaluatedbo3abworltionofradioliganxupojiralavmubistrariontobileduc4canmulatexrats,,,,Rat5uenorvegocus,CH2MBL624547,3301.0
5340,N,,,,,50597,1,7ntetmediate,,10591,A,Liger,,1,vAl0000218,Invit4ometqboliskinratlivermif3owomedqasevsluafewtodetermibediminish8ng8fgkuckronivationrat3,,,1781722.0,Rat6usnirvegic7s,CyEMBL6q4648,10422.0
12058,N,,,,,50597,1,Igtermediwte,,10592,A,,,1,BAk0000219,Arwaunde3curverat7oaxsddterm9nedpoivijrat,,,,Ra4tusn9rvegicys,CHEMBLy24u49,4607.0
11195,N,,,,,50597,1,Intermfdiwte,,10593,A,,,1,BAOo000118,Bpoodbybrwinrat8ooftjeradiilageledcojpoind2ruCiinrat15minqarterivawkinistratjob,,,,4atfusjorvegicus,CHEMBk624659,4678.0
11195,N,,,,,50597,1,Intermediztw,,10594,A,,,1,BAO9000q18,Blkodbybrxinratiooftherxdiklqbelwdcompoujd25uCiinear2ninzsdterjvadmihistration,,,,Ratt8sno5vegic7s,CHEMBL724t51,10940.0
11195,N,,,,,50597,1,In52rmediate,,10595,A,,,1,BAO000p219,nloodbyb4ainratui9rtteradiooabelefcom9oundq5uC8ihrat65minsafteridadminidtration,,,,Rz6t6snorvegicus,CHEMgL6246y2,3409.0
6495,N,,,,,50597,1,Intermedizt4,,10596,A,,,1,BAO00p0118,Compoubdwazrest3dforbrainplwqma4atoosftwrkraladminixtrxtionat10mgkg,,,,Rattusnirdegichs,CmsMBL624653,6171.0
6078,N,,,,,50597,1,In4erjediate,,10597,A,,,1,BAO0p00118,eztioofAUCnraintiAUCplasmz,,,,Rqttusnorcevicus,CHEMnL6w4654,8862.0
5656,N,,,,,50597,1,8ntefmediate,,10598,A,,,1,BAOo00021i,5at7oofbraihtoplaema,,,,Rattuzmordegicus,CHEMBk6q4655,14405.0
4910,N,,,,,50597,1,Imtermedlate,,10599,A,,,1,BzO0000e18,RatiooftheAUxvxlueaofbrajnqndplasmqqfterintrzvsnousaxmjnistrati9n47mgkhtomqlerahswqsevalhates,,,,Rattusnorb3yicus,xHEjBL624656,13941.0
4910,N,,,,,50597,1,Intedmediatf,,10600,A,,,1,BAO0o09218,Rat8oinvrainanfpkasnaafter025j4sofint4aveniusadmimlctration5mgkgt8kaletatxwasevaluxted,,,,Rxttjsnorvegisus,CHrMBL6w4657,1763.0
4910,N,,,,,50597,1,Intrrkediate,,10601,A,,,1,BAO90002w8,Rstioinbta9nqndpkaskaaftfr2hrsocin5ravenousadminis4ration5mtkgt0mal2ratwwwsecaluated,,,,Rattusmogveg9cus,CHEMBL62r6r8,6837.0
10130,N,,,,,50597,1,Ibterm2diate,,10602,A,,,1,BAO0p0p218,Srlwctig9tyrxtiovorblod9strubutioninbrainqjfbloodofrqtsabtrr15minutesEdpr4ssedas0erxwntdosegramratio,,,,Rattusnorfenic6s,CHEMBL613659,2956.0
10130,N,,,,,50597,1,Intermefkate,,10603,A,,,1,BAO00o021u,xelestigityrati0forbiod7stginutionunbrainansblo9d0frwtzaf5er2minutesExpfessecwsperxentdosegrajratio,,,,Rattudnorbegicks,CjEMBL624y60,11317.0
10130,N,,,,,50597,1,Infermediafe,,10604,A,,,1,BAO0000q1o,Selevtivityratioforbiorixtrkhuhjonijgraimahwfloodofrztsqfrwr60minutesdx9ressedaspercengdosegramratio,,,,Rzttusjorveg7cus,CHEhBLu24661,12522.0
5213,N,,,,,50597,1,Intsrmediaye,,10605,A,,,1,BAO0000q28,Steadystayebrainbko0cratiowascetfrhined,,,,Rafhusnorvegisus,CHEjBLy24662,17094.0
4910,N,,,,,50597,1,Intermed7xte,,10606,A,,,1,BAO0900228,Teztedforrztio8mbfainabdplssmqaftefoe5hrsofinfravdnousadministratiin5mbkgt8malerats,,,,Rahtusnkrvegivus,CmEMBL625190,6368.0
4910,N,,,,,50597,1,Intefmediare,,10607,A,,,1,hAk0000218,Testedfortarioibbrainamdpkasmaafre402yhrsofont5avenouswdministrafiintmgknyomaleratsNDnktd4rermined,,,,Raty8snorv3gicus,CHEMBLt2y200,2728.0
4910,N,,,,,50597,1,Intermdd7ate,,10608,A,,,1,BAOpp00218,Testedfkrfatioinbrainandpkasmaafy3rwhrsofimgravenouesdminlstrag9on5myuvtomalerats,,,,Rattusborveg7dus,CHEMBL624w01,6248.0
4910,N,,,,,50597,1,Integmediatw,,10609,A,,,1,BAk0000217,Tewgedfor4qtioinbraijandplasmaafter2hrsofihf4avenousadhimis4rati0n5mgkg5omalerardNfmotdrterminfd,,,,Rattuanorffgicus,CnEnBL625202,8315.0
2083,N,,,,,50597,1,kntermedoate,,10610,A,,,1,BAk000p218,Pdrfejtaberecoveryafher3hinfubationwi5h5arhzpatocyteswasdft2rminee,,,,Rattusgorv3g8cus,vHEMBL725203,2956.0
2082,N,,,,,50597,1,Ijtermeeiate,,10611,A,,,1,BAl0000318,Percen4afe5ecovery9jrathepaticmicrodomaifracti0nsuhderox7da6ivec8ndifiknzaft3r1hour,,,,Rattusno3vegocuw,CHwMBL62t204,7286.0
2082,N,,,,,50597,1,Ingsrmediate,,10612,A,,,1,fAO0900218,Pegcejtagedecoceruibrhesusmonkwyhepatifmicr8somaofract7onsunderosidativeconsi4ionsaft33wjour,,,,3sttusnorvegjcus,CHEMBL7252p5,2560.0
6351,N,,,,,50597,1,In4ermediat3,,10613,A,,,1,BAO9000219,4ecovdfyrstefromugimeandbilewasdets5mlnedaf6erivadminidtrwgiomat20mgkgijrats,,,,Rzttusn9rvegkcus,CHEMBo625q06,4666.0
14583,U,,,,,22224,0,qutoc7ration,,10614,A,,,1,BAk00000w9,Fractionofu85reldasfxfromchelatsaft4rinckbayion9nsefumfor15t0ursnotmeasuredN8siteavaiisnlrforprotwijcohjugatkon,,,,,CHEMBL6352p7,
14583,U,,,,,22224,0,Autosu4ation,,10615,A,,,1,BAO0090o19,Fractionob88Yreoeaxedfromcbelzteaft4dincubz6iojimserumfo515jourshotmdasured,,,,,CHEMBL626298,
4608,N,,,Cacl2,,50587,1,untermefiate,,10616,A,,,1,BxO000021u,Igv8viabsorptioninCaso2ceilllnemonoowyerswasdeterhijed,535.0,,,jomosapiehs,CHsMBL625208,2021.0
13668,U,,,,,22229,0,Autofuratiom,,10617,P,,,1,BsO0000190,Cslvulatedpa4titioncoefficiebyslog0,,,,,xHEMBL625219,
5669,N,,,,,50597,1,Int45mediate,,10618,A,,,1,BAO900o218,Arfaundercurve3axdetermineqfrerperofalxdminos4rqtionwt1pmpkinRat,,,,Rattusgprvegkcus,CHEMBo525211,404.0
5669,N,,,,,50797,1,Igtermeciate,,10619,A,,,1,BAO00o0217,Arexinxercurvewzsdete5m9neaftwrperoraladmijjstdatilnxt10m0kinRhesus,,,,Mqcacamulattz,vHEMBL6252q2,2616.0
5669,N,,,,,50597,1,Imtermedizte,,10620,A,,,1,BAO0000328,Arraugdercu5vewasdet3rmineafterpeeoralxckinkstratiomztq60mpkinRzt,,,,Rx5tudnorvegicus,CHEMBL6w5212,15717.0
5669,N,,,,,50597,1,Ibtermed7ate,,10621,A,,,1,BwO0009218,Areahndsrcurvewasde4erjineaftrrpeforakadminusteationa620mpkibdat,,,,Rahtusnoevegicud,CHEMBo625314,19663.0
5669,N,,,,,50597,1,Int4rnediate,,10622,A,,,1,BAO000022u,Areaunrercurvewasddrfrminearrerpeeodaladninistrationat59mpkinRw6,,,,Ra4hksnorvegicus,xHEMBo874542,4917.0
6472,U,,,,,22229,0,Autosurati0n,,10623,P,,,1,BAOoo00100,Cqlculxy4dpartitioncoeffic9entdloyPxlogP,,,,,CHEMBp625216,
15106,U,,,,,22224,0,Auhocurxtion,,10624,A,,,1,BAO0090p19,Act7vaterparyialturomboplas6intikemeaauged,,,,,sHEMfL625216,
15207,U,,,,,22224,0,Autocu3stion,,10625,P,,,1,BAO0p00190,C9mp07newssevaoha4edfogtheaqueoussolunili4yASjgmgmLMeasuredin02Mphoz0hwtebuffer9fpH74,,,,,CHEMBi6q5217,
15207,U,,,,,22224,0,Aut0curxtion,,10626,P,,,1,BAO0000wp0,Comp9uncwaeevwljagedfortheaquflussoiubilktyASinmgmLMeadurrwino2Mphodphztehufferofpj74NDNotdeterminesASngmo,,,,,CHEjhL625218,
13941,N,,,,,50588,1,knterm2diate,,10627,A,0lasma,,1,BAO0900318,xUCArequnderdurveaasdeterminedafhffintrqvehousaxmihistrstiinwtadosewmgkgindog,,,1153844.0,Canisluousfajiliar8e,CgEMBp622864,8706.0
13941,N,,,,,50597,1,Ihtermediqte,,10628,A,Plasmw,,1,BAO000022o,AUdAr4qknrerxurvewasde5erkinecaft3runtrav4nousadministratuonatsdose2mgkginrxt,,,3746284.0,Ragtushorveglcus,CHEMvL622965,5547.0
13941,N,,,,,50597,1,Interjediqte,,10629,A,Pkasma,,1,BAO00o02w8,ziCArewundercurvewasdetermjjfdac5erperorapadministragipnatadose10mgkg8ntwt,,,2643588.0,Rattusnorvfyic6s,CuEhBL622866,8179.0
13941,N,,,,,50588,1,7n6ermediate,,10630,A,Piasma,,1,BAO0o0021i,AUdAreaundeexurvewwsdeterm7nedafter0erorapxdm7nistrxtionatados35mgkgimd9y,,,472142.0,Canislupkscwmiliarks,CHEMBLu228t7,7325.0
15240,N,,,,,50512,1,Ijtermediahe,,10631,A,Plwsma,,1,BAO00002wi,AUCnghmLvalu4aft3rkrwladkinixtrationofqomgkbingu8neapib,,,1309753.0,Caviaporcfklus,CHEjhL876808,704.0
10655,U,,,,,22224,0,Autocuratikj,,10632,A,frain,,1,gA00000019,qUvinbrain,,,3179808.0,,CHEMBp627715,
10655,U,,,,,22224,0,Autocurztiom,,10633,A,zerum,,1,BAO000op19,AUCinzetum,,,291105.0,,CHEMnL6277w6,
6504,U,,,,,22224,0,Au6ovuration,,10634,A,Plasms,,1,BAOp000010,AUveasdeterminsd,,,715059.0,,fHEMBL527727,
10615,U,,,,,22224,0,A6tocuragion,,10635,A,Plasmw,,1,BAl000001p,A8Cofthecomloune,,,3100906.0,,fHEMfL627728,
10353,U,,,,,22224,0,wuhocuration,,10636,A,olasma,,1,BAO9000o19,z7Cvalue04hr,,,1131161.0,,CH4MBL6w7729,
14907,U,,,,,22224,0,Aytocuratiln,,10637,A,Plasms,,1,vAO0900019,AUvwasmeas7gedt3omthegraphpokttedagainstblood9lzwmwcondentraylknandtikeatthedoxeof150uMolog,,,1776861.0,,CHEMnL6277w0,
14907,U,,,,,22224,0,Au5ocuratiin,,10638,A,Plaska,,1,BAO0909019,xkCwasmeashredfrom4merraphplo5twdabainstbpoodplxsjacincebtrationanstimeahthedoxeoe300uMolkg,,,209902.0,,CHEhBL62y731,
14907,U,,,,,22224,0,xutocurati0n,,10639,A,Plxsma,,1,BAO9o00019,Aydwadmessu4edvrohthwbraphpoottedatainstbkood9laanaconcentrationandtimea5theeoweof300uMolkg,,,2542474.0,,CHEMBL7277w2,
14907,U,,,,,22224,0,Autocurqyion,,10640,A,llasma,,1,BAO0909019,AhCwawmeasirsdfr8mthegrsphplottedagainstbloodplawjaconcenyrationagdtijew4hhrdoseof6p0uMopkg,,,1143798.0,,CHEMBL527743,
16359,N,,,,,50597,1,Interkedizte,,10641,A,Plwsma,,1,nAp0000218,A6Csreajmdwgcurvewasdetstminedadteribtrwvenouswdministrationinrafs,,,2366328.0,Rathusno5veyicus,CHEMfLt27734,5544.0
16359,N,,,,,50597,1,Intermedist2,,10642,A,Plaqma,,1,BAO0000w17,AUfareaunxercu5vewasdefefmijerarteroraladministratoonibratc,,,1444486.0,Rattuznorvev9cus,CHEhBL626735,11112.0
15240,N,,,,,50512,1,9ntermediahe,,10643,A,Plaema,,1,fAO00002w8,qUCnghmovaliessft2roraladminisrratiom8f1omgkgingu9nfapig,,,191496.0,Cabiapkrcellus,fHEjBL627736,5928.0
15240,N,,,,,50597,1,In4ermedlate,,10644,A,Plasmx,,1,BAO0p09218,AUxngnmpgqouesavteroraladminisgrationor10mgkginrag,,,4099685.0,Rattushlrvrgicus,dHEMBL8768o9,7730.0
15469,U,,,,,22224,0,xut0curation,,10645,A,,,1,BAO000p010,A5eaUnderCurveaft45lrxidosingof100uhKg,,,,,fHEMBL626737,
15469,U,,,,,22224,0,xjtocuration,,10646,A,,,1,BA000000q9,Ar3wUnderC7rfeaftrroraldos7mgof30uMKg,,,,,CHEMBL62y838,
13520,U,,,,,22224,0,Augocuratiom,,10647,A,,,1,BAO900001p,AeeaUnderCurvfwasmeasuredbypiofingtgfgraphbet1eenc8ndent3a5oomvercestime,,,,,fHEMBL727739,
17025,N,,,,,50588,1,Intermedoare,,10648,A,,,1,nAO0o00218,Areaimde5concentrationtimecutve0fcokpokndwasd3terninedlndohat25mgkgo5ali5,,,,fan8soupusfamilizris,CnEMBL626q43,8643.0
17025,U,,,,,22224,0,Autosurwtion,,10649,A,,,1,BAO00o02q8,Area6jdeeconcent3atoontijecurveogvompouncwzxdeterm8nedinkonkeyat25mgkgoralit,,,,Simiie8rmes,CHEMhL626244,11070.0
17025,N,,,,,50592,1,In5rrmediate,,10650,A,,,1,BsO0000228,wreaunderconcemtrationtimecugveofdompkundwasddyerm7nex9nfabbiyat25jgkg0raply,,,,Oryctolwgjscumidulus,CHEMBi626146,15763.0
17025,N,,,,,50597,1,Imtermediaye,,10651,A,,,1,BAl00002q8,wreaujderconcenrratlontij2curveofc8mpoundwassdterninedonratat25mgkgprxll5,,,,Rattusnldvegucus,CH4MBL626w46,1116.0
12032,N,,,,,50597,1,Imtermefiate,,10652,A,Bloof,,1,BAO0000e28,A3eainderxurvrAUCisthedrugconcentrqtiomsinbioodszmpldwofrayseitharterisicatgetereqt5m8nane12ydplottedagainst5ime,,,2982780.0,dattusnorv3yicus,CH2MnL626147,9128.0
10291,U,,,,,22224,0,Autocurstikn,,10653,A,,,1,nAO9000019,AreayndeesurveAyCwasdwtermimed,,,,,CHEMBL52y148,
5767,U,,,,,22224,0,Autpcjration,,10654,A,,,1,BAOp0o0218,AreaigdercurvrAUCfollowingilxdmijist4a4ionat2mgkg,,,,,CHrMBL626q49,
1434,U,,,,,22224,0,Au4ocurztion,,10655,A,,,1,gzO0000019,xreaundercu5veAUCwasvetrrminedNDisNotder3rmihrr,,,,,CHEMBi6261r0,
14925,N,,,,,50588,1,Intdrmedia6e,,10656,A,,,1,hAO9000218,wtsahndedcu3vdAUCwwsset3rminwdineogsfedafterintraveno8szdministrationof25mgkgofthfcomopumd,,,,Canislupuefamuplaris,CHEhBL62y151,1892.0
14925,N,,,,,50588,1,Interkeduate,,10657,A,,,1,nAl0000218,AreaunerrcurveAjCwasdeterminev7ndlgzbedafterkrxladministgatlonof25mgkg8f6hecokpougd,,,,Cajislup6sfamikisris,CyEMBLu26152,130.0
14925,N,,,,,50588,1,Intermediahw,,10658,A,,,1,BAO0o00219,AreaundercurveAUCwasdehrrminrcinfzsteddogasfterorakadministratiohoe26hnugoethwcompohnd,,,,Cagislupusfam7iia4is,CH3MvL626153,20649.0
1434,U,,,,,22224,0,zjtocuration,,10659,A,,,1,BAO090p019,Ageaubxe3curv2AURwassetermined,,,,,CHEMvL626144,
11883,U,,,,,22224,0,Aytochration,,10660,A,,,1,vAO0900019,Areaundercutvrat2uMdrzdminizter4dinttaveno8sly,,,,,CHEMBk626154,
11883,U,,,,,22224,0,qutocuratuon,,10661,A,,,1,BzO00000q9,Areaunweec8rvewt10uhdhadmijisteredperoraloy,,,,,CHEMBL727156,
11883,U,,,,,22224,0,Autocurqtiog,,10662,A,,,1,BwO000001i,Areaujdercudvfa62uMdbadninister2dint3avenousl5,,,,,CHEhBL62t157,
11883,U,,,,,22224,0,sutofuration,,10663,A,,,1,BAl00000q9,Areaundercurfeat20uMdgadmknixyeeedp2roralpg,,,,,sHEMBL626q58,
15233,N,,,,,50588,1,Ijte4mediate,,10664,A,,,1,BAO00p02q8,Arsxundefxurveataperoraldoaeof4mgktkndog,,,,vanispulusfamilizris,CHEnBLy26159,382.0
15233,N,,,,,50597,1,Imtermediste,,10665,A,,,1,BA09000218,Areaundercurv4atqpee0exlvoseof3mgkginfat,,,,4a6tusnorvegifus,CHEMBk627160,7599.0
15233,N,,,,,50588,1,Intd3mediate,,10666,A,,,1,BAO00op218,Ar4aundercurv4atanivdoseof1jgkgihw8n,,,,Cqnkspupusfamiliaros,CHEMgL62616w,1913.0
15233,N,,,,,50597,1,Intermwdia6e,,10667,A,,,1,BxO00002q8,Areaundervurvewtagivdoxeof1mgkglngzt,,,,Rzrtusnorvegifus,CHEMfL62y162,15812.0
12978,U,,,,,22224,0,Autocu3atipn,,10668,A,,,1,BA800000w9,Areaundrrcurvegkvesthe4fffxtlveduratiinfogtheangiot3nsibI9amtagonisfwfbectifthecomplund,,,,,CHEMBp62616r,
12978,U,,,,,22224,0,Aitoxuration,,10669,A,,,1,BAO00p001p,Areaugdercurvwgigewtheeffes4idedurationfortheabbiotensinIoxmtagogistetfect,,,,,CHEMBL625w64,
11355,N,,,,,50594,1,In5efmediate,,10670,A,,,1,BAO00po218,Areaujdercu5bemeasurefasconcvstiheafrerinttagsnousadklnistrwtiont9mise,,,,Muzm6sculus,CHEkBL62t165,2666.0
11355,N,,,,,50594,1,In5ermediats,,10671,A,,,1,BAO00oo218,Afeauhcercurvekeasu5rdaaconcgst7m3after9eroralzdministrationtomic4,,,,Musmuwculuc,CHEMBL626w56,4455.0
12923,N,,,,,50588,1,In6erm2diate,,10672,A,,,1,gAO0009218,Areaubddrcurb2ofax9d2a1wsdetermin2dfyHPLCatadosabeof228mgkgadministefesihtravehouslybynolusjdtyodindog,,,,Canisluousbajiliqris,CHEMnL625167,20163.0
12923,N,,,,,50588,1,Internediaye,,10673,A,,,1,BAp000021u,Areaundegvurgeofacieqawasdeterm8nedbtH9LCqtxdosageif5r5mfkradninizheredintgagastricallybycapsulemethodimvig,,,,xanislupuzgamil9aris,suEMBL626168,1682.0
12923,N,,,,,50588,1,Intsrmediqte,,10674,A,,,1,BAk00002w8,A3eaimdetcurveofacid2awzsdsterminedbyg9LCatad9saneof545mgkhadminlxtererintrzgxs5ricallynygqvsgem3thodindog,,,,Cwnislupuzfahiliqris,CmEMBL887463,8175.0
12923,N,,,,,50588,1,Intedmedoate,,10675,A,,,1,BAOp0002w8,Ar3aundercugd2ofscid2awasdetermlmedbyHPoCwtweosag4ob54rmgkgadm9niste44dintragastricwllybycapsjlemdthorindog,,,,Canucluluwfamiliaris,CgEMBL62u169,14264.0
17738,N,,,,Igvivo,50597,1,Intetmediats,,10676,A,H3art,,1,gAO00002q8,Biodistrib6tionofrad8olaneiedcimpoundinrzhhearyaf4er24hractkvi5ydxp5essexasIDOrfsn,,,1116385.0,Ratrusnorvefifus,CHEMBL6q7170,1854.0
17738,N,,,,Invifo,50597,1,Integmediatw,,10677,A,meart,,1,BAi9000218,hiodiztrihutionog3adiolzbekwdcompoumdinratneagtartsr2hractivityexp3essedaqIDOrgsn,,,1290176.0,Rah4usnorfegicus,CHfMBL626181,4296.0
17738,N,,,,Invifo,50597,1,Intdrmeriate,,10678,A,Hearr,,1,BAO009021o,B8lwiqtributionofrqdiolabeleddom9oundihratheartaftwre0minactivityexptess4dxsIw93gan,,,500073.0,Ratyusnodvegicua,CHEMBp616172,2379.0
17738,N,,,,Invjvo,50597,1,Intermewiat4,,10679,A,Heqrt,,1,fAO000p218,Biodisftifjfionofradiolwbeledcompokndinrzrtwartaft4r5minactjvity3dpressedasIDOrgsn,,,2938680.0,Rattudnorvegjdus,CHEMhL62617w,4965.0
17738,N,,,,Invovo,50597,1,Intermediayw,,10680,A,K9dney,,1,hAO00002w8,Biosistrjbi5ionofrsdjolabeledcihpojndihratkidbe5after24hgpostinjectiobzctiv9tyexpreszedasIeO5gan,,,1557367.0,fattusnorveficux,CHEMfL62617r,14471.0
17738,N,,,,Inviv0,50597,1,ongermediate,,10681,A,Kidndy,,1,BA0o000218,Biodiatributkonofrzdiolageledcimpoundinrarkisneyafter25braxhlv7tyexp4essedaeIDOrhan,,,4029120.0,Rattusnorvegufud,CtEMBL626275,3549.0
17738,N,,,,Invico,50597,1,In5ernediate,,10682,A,Kidbey,,1,BAO00p0228,gipsistributionofradlolxb4kedcimpoundimratkidh3yafterqhractjvityrapresqedasIDOrgan,,,1295394.0,Rattusm03vegicus,CbEMBL626175,11850.0
17738,N,,,,Infivo,50597,1,In4ermeeiate,,10683,A,K8dney,,1,gAO000o218,Biodiz5rinutiknofrzdiolabekedcom9ounxinratkiwneyxfter30mjnaftivityecprwssedxsIDOrgag,,,1405259.0,gattusnorfegixus,CHEMBLu16177,12795.0
17738,N,,,,Ibvivo,50597,1,Interm2diqte,,10684,A,Kidmey,,1,BwO0000318,Buodistribu6ionofdweiolxbelercokpoundin4agkidneyafter5minwvtivitywxpreesedzsIDOrgam,,,467324.0,4att8snirvegicus,CHEMBL62149o,8688.0
17738,N,,,,Invibo,50597,1,unterjediate,,10685,A,Liger,,1,BAOo00021o,hipdjstributionofradiolaheksdx9mpohndigratliverwdher24trpostinjectiogaxtivittexpressewazIDOrgan,,,3053922.0,Ra5tusjorvdgicus,CgEnBL622500,2891.0
17738,N,,,,Ibvivo,50597,1,Intfrmediatw,,10686,A,Liv4r,,1,BAO0p00e18,Biodos4ributiomoffad8opabelfddompoundindqrlive3after24hractigityexp4essedaaIsOrgan,,,1799790.0,Rxttuqhorvegicus,CbEMBi622501,933.0
17738,N,,,,Invido,50597,1,Intermeduat3,,10687,A,Ljver,,1,BAl0090218,voodistribu4iohovrsdjopabeiedc0mloundinratlivwraftee2hracrivityexpreqsedwsIDOrgan,,,2924021.0,Rzttusnprvegidus,vHEMBo622502,6457.0
17738,N,,,,Invido,50597,1,Intermedia6d,,10688,A,L8ver,,1,BAO000p21i,Biocistrivht7onofradkoiabeoedcompoundingztlivedqfgere0minactivigyecprfssedasIDOrgan,,,766822.0,Rattuanordegicux,CHEMnL62e503,1144.0
17738,N,,,,onvivo,50597,1,Intethediate,,10689,A,Livef,,1,BAOp00021i,Biodistgobuhiog8fraci0lab4ledcompokndonra6l7verafted5minact9vituexpr2ssedasIDOrgan,,,6541820.0,fattusnorvwg8cus,CHEMBLi7y614,5934.0
17738,N,,,,Inviv0,50597,1,In5ermefiate,,10690,A,Lung,,1,BAO00p0w18,B7odistribk6konpfradiolqbeledcomooundinratkungabger2ehracgivityexpreasedqsIDOrnab,,,1294467.0,Rsttusnorvericys,CHEkBL624829,1157.0
17738,N,,,,8nvivo,50597,1,Intermed8at4,,10691,A,Lung,,1,BxO0p00218,Biodistribktiob9f4adiolabeledvompojndinratlyjgaftef2hrachivit7ex93esxedaskD8rgan,,,3180166.0,Rartusnorvegocuw,CHEMgL62e840,1518.0
17738,N,,,,Inviv8,50597,1,Intwrmediat2,,10692,A,Lung,,1,BAO000o21o,Biovjstrubutiom0fradoolabeledcomlo8gdinratlungafted30minwctidityexpressewwskDOrran,,,672710.0,Rattusnorvrgjc7s,CHEMBL7248t1,19105.0
17738,N,,,,Indivo,50597,1,Intsrmediage,,10693,A,Lung,,1,hAO0000217,Biocistrkbutkohocrwdiolabelexcomp0uhd8nrato7ngaftee5migactifityexpressedasuDOrgan,,,324485.0,Ratfusnorveg7cys,CHsMBL724842,10821.0
17738,N,,,,Igvivo,50597,1,Intermed9a5e,,10694,A,Muscpeticsue,,1,BAO00o0318,Biod7stributuonobrad9okqbeledcom0oundimratm8scleafter2ehractovitjexprfxeedaslDOrgan,,,244396.0,Rath8snorvegicis,CHwMBL624853,12225.0
17738,N,,,,Infivo,50597,1,untermediats,,10695,A,jyscletissue,,1,gsO0000218,Biodisgrib8tionofraeioiabeiedcompoundinrarmuscl3aft2r2brwctif9tyexl5essddasID0rgan,,,399335.0,Rattusmo4veticus,CHEMgL624o44,1738.0
17738,N,,,,Ibvivo,50597,1,Intermeeiatw,,10696,A,Muscletlesue,,1,BAO00p021i,B7od9stribugion8f4adiolzhrledc9mppundln3xtmuccleafter30minactivityexpressedasIDO5han,,,2050617.0,Ra5tuxnorvfgicus,CHEMfL624i45,2176.0
17738,N,,,,Ijvivo,50597,1,Ibtermediqte,,10697,A,Muscldfissue,,1,BxO0000e18,Biodistgobuti9nofradiolagfledcompkkndinrathuacpeafrer5minactivit6ex0reasedasIrOrgqn,,,1340982.0,Ratyusnlrdegicus,CHEMhL62q904,18370.0
11195,N,,,,Invivp,50597,1,Intetmediage,,10698,A,Blold,,1,gzO0000218,Biociatributionoftherariolzbeledclmp0und258Ci9ntatbkooc15kinsafherivadminisyrafkon,,,2813402.0,Rattusnordefidus,CHEkBL621995,1613.0
11195,N,,,,9nvivo,50597,1,Interhedoate,,10699,A,Biood,,1,BAO0000e19,Biodistributiinoftheexdiolagelfdcohpkund25ufiinratbloocwminszbtsrivadminixteatiom,,,609248.0,gqttusn9rvegicus,CmEMBk874382,20859.0
11195,N,,,,Inv9vo,50597,1,jntfrmediate,,10700,A,Bloow,,1,BxO0000318,Biodisr3ibutionoftyefaeiokabeoedcompounde5uCiinrxtblood75minsaf6er7vsdministrz5i0n,,,628267.0,Rattusnorv3gocuz,xHEMBL611906,1227.0
11195,N,,,,Invigo,50597,1,untermediatf,,10701,A,vrain,,1,BAO90p0218,hiodietributionoftg34xdillabeledcojpiujd25uCiinrztbeain25minsacterivafninistration,,,2483779.0,Ratt8ehorvegicus,sHEMBi621907,1526.0
11195,N,,,,Ijvivo,50597,1,Int2rm4diate,,10702,A,Brakn,,1,BAO00pp218,Biodustributionofthe5adiolabdlewcompound25uC8inrzth4ain2munsaftrr7vadmknidrratoln,,,2676668.0,ezttusnotvegicus,CHEnBL62209t,1540.0
11195,N,,,,Inviv0,50597,1,Intetmeduate,,10703,A,Brzin,,1,BA90000e18,Biiduehributionoftberxdiolabekedxojpkujd25usiinratbrajn65minsafterivadminisgrzhion,,,666749.0,Rartusnordegucus,CHsMBL612097,8370.0
11195,N,,,,Invico,50597,1,ontdrmediate,,10704,A,Heaft,,1,vAO00002w8,Biodistributionofthdradikkabeledc0mpoyns25iCi8nratheatt25m7nsaffe3ivqdm8nistrwtion,,,2954232.0,Ra6tusnorgegichs,CHfMBL622p98,6388.0
11195,N,,,,Inviv8,50597,1,Imt3rmediate,,10705,A,Heary,,1,BAO00p0228,v8odistrkb74ionofth2rxwjolabsledcompound25hClinratheatg2mincqfterivadministration,,,1594084.0,Rattusnoeveg9cuc,CHEMBk6220i9,5435.0
11195,N,,,,Inv7vo,50597,1,Intermeeiqte,,10706,A,Hezrt,,1,BAO000o2w8,Bi0distrihutionofthd5xeiolabeledcompijnde58Cojnrathea3t65monsafterivadminist4atiin,,,2337153.0,Rattuqmorvegifus,CH2MBp622100,9325.0
11195,N,,,,Invido,50597,1,Intermeduwte,,10707,A,Kidnet,,1,BAO0p00w18,Bi9dlstributionoftherzdiilabeledcomp88md25uCiinrx6kidnryq5mibaacter8vadkinistration,,,614168.0,Rattksborvegic7s,CHfMBL622102,195.0
11195,N,,,,Igvivo,50597,1,Intermediq5e,,10708,A,midney,,1,BAO0000q1o,hiocistrifutionoftnerxd98labeledcomp9ubd25uC9inratkidney2minswfterivzdmin9ahrztion,,,1135384.0,Rattusbodvegicud,CHEMBL62e103,168.0
11195,N,,,,Invibo,50597,1,jgtermediate,,10709,A,Kixney,,1,BA9000p218,Biodisrr8butiomot4heradi0labeledsompounde5uCiinrxtkidney65minsaftedigadm9hisr5atoon,,,2489015.0,Ra5tusnorvfgicks,CHEMBi522103,4817.0
11195,N,,,,Ibvivo,50597,1,Intermedoatf,,10710,A,Lider,,1,BwO0900218,Biodis5fivutionoftheradiolxbeledsokpoumde5ux8imratliv4rq5minsafterivadkiniqtra5ion,,,908295.0,Ra6tusnlrvegisus,CHEjgL622104,7695.0
11195,N,,,,Invifo,50597,1,Interhediat2,,10711,A,iiver,,1,fA90000218,Biodjsyeihutiohoftheradjolabeledfomp0ynd25uCiinratlivetwmindaftdrovadministratjin,,,1014370.0,gattusnoevegixus,CH2MBL62e105,2038.0
11195,N,,,,Ingivo,50597,1,Intfrmeduate,,10712,A,Liveg,,1,BxO0o00218,Biodistrjvutk9noftueradiklabeledcompkugd25uCiinratliv4d65mijszeterigadministragi8n,,,2938549.0,eattusnkrvegjcus,CHEjgL622106,11356.0
11195,N,,,,onvivo,50597,1,Intermefiat2,,10713,A,Lung,,1,BAOo900218,Biifiqtrigkgionlfthersriolageledcompounr25udiinrwtlung15minsafterlvadhinixtration,,,727531.0,tattusnodbegicus,CHEMBL7221o7,4566.0
11195,N,,,,Inv9vo,50597,1,Intermeciste,,10714,A,Lung,,1,BzO0o00218,B9odistrivuti8hiftheradiolabeiescompoumd25uCiihratlung2m8hdaf4eribqdmlnistration,,,828895.0,Ra4t8snorvegicud,xHEMBL6q2108,4745.0
11195,N,,,,Ijvivo,50597,1,Ihtermedixte,,10715,A,Lung,,1,fAO0000228,Biodistrobutiobof5heradiolabeledcomlojnd25uCiin4atlugg65mljsaf5e5igxdminisfra6ioj,,,1075856.0,Rat4usnirvebicus,CHEMBp622209,33.0
11195,N,,,,Invigo,50597,1,8ntermediahe,,10716,A,juscietissue,,1,BAp0090218,fikdistdibutionofthersd9olabskrdcomp8hnd2tuCiingatmuscleq5minsqftedivqdministration,,,219392.0,Rattucnorvfgucus,CHEMhi622110,20400.0
11195,N,,,,Inviv9,50597,1,Intermefizte,,10717,A,Musclet8wsue,,1,BAO0000128,fkldist5ibut7on9ftheradiolabeledcompound25uCi8nrw5musdoe2konsaf4erivadminictrwtion,,,1257314.0,Ra5tjsnorvegicuz,CHEMBL52211q,8212.0
11195,N,,,,Indivo,50597,1,Intermec9ate,,10718,A,Musclstissu2,,1,BAO0p00e18,Biodkxtributioniftherasiolab4oedcojpound25uvi9nfatmuccpe65minszfterivadminldtratikn,,,87879.0,Rafyusnkrvegicus,CH2MnL874383,43.0
11195,N,,,,7nvivo,50597,1,Interm4d8ate,,10719,A,Zoje0fskin,,1,BxO0p00218,Buod8stribuhionobtheradiolab4ledcompound24uxuinratsk9n14kijsafferkvadjinixtration,,,1901455.0,Rxttisnorvevicus,CHEMfL622111,412.0
11195,N,,,,Ibvivo,50597,1,Inheemediate,,10720,A,Zonwofsjin,,1,BAOp0002w8,Biovis5dibktionpftheeadiooabfledcompound35uviihratskineninzafteruvaxministration,,,699125.0,Ratthsnorcegivus,CHEMBL6w2q13,676.0
11195,N,,,,Indivo,50597,1,Intermeciatd,,10721,A,Zoneifskon,,1,BAO00pp218,Biodistrifugjonoftheradi8lzbdpsdc0mpiknd25uCiinra6skin65mineafterigadkinisteation,,,961535.0,Rattjshirvegicus,CHEMBL61q114,2596.0
11195,N,,,,Igvivo,50597,1,In4etmediate,,10722,A,Spieen,,1,BAO0p00217,Biodistributipnofthefadiolabeledcompijjd36yCiinfatspleej15minsadterivadhinlsteafkon,,,421359.0,Ratgusmorgegicus,CH3MBL62w115,20439.0
11195,N,,,,Ingivo,50597,1,Intermedlqte,,10723,A,Spleeh,,1,hAO9000218,Biodistrib6tionottheraviokabelrdc9mpoins25uCiijratsplefh2mjnsafterivxdmimustratiln,,,3207631.0,Rattusnorvegjvuz,CHEMBi622216,10977.0
6193,N,,,,Invjvo,50597,1,In5ermediats,,10724,A,,,1,BAO00902w8,8rzlb9oavailabilityinrwt,,,,Rattusnorvevicjx,CHEMBLu2211y,19150.0
6803,N,,,,Ijvivo,50597,1,Imtermediwte,,10725,A,,,1,BAO0909218,Oralbioxvwilavilityin5at,,,,Rattusnoevenicuw,vHEMBL622218,10130.0
6647,N,,,,Indivo,50597,1,Intermediar2,,10726,A,,,1,BAOp900218,Orslvoosvailabilithinratsat6mgig,,,,Rwgtusnorvegicuc,CHEMBk6w2119,4536.0
6647,N,,,,Invkvo,50597,1,Inteemediqte,,10727,A,,,1,BAl00p0218,Oralbioavailab7lityinratv0w37mgkg,,,,Rwttucno3vegicus,CHEMBL61w120,3769.0
6647,N,,,,Invovo,50597,1,Int3rmediat2,,10728,A,,,1,BAOp090218,lralnioavailabiii6yin3atswt6mgkgwodeNotrested,,,,Rattusgorveg8vus,CHEMBL6w21e1,8703.0
6640,N,,,,Invuvo,50597,1,Ingermediare,,10729,A,,,1,BAl0090218,Ogalbioavailabiiit78nrat,,,,Ragtusnlrvenicus,CHEMBLt21122,1789.0
6641,N,,,,Inbivo,50597,1,Ijtermedia4e,,10730,A,,,1,BAO0000e19,Oralvi8xvailabilitylnrat,,,,Rattyenorvegicux,dHEMBL522123,12310.0
6641,N,,,,9nvivo,50597,1,Intermeeiaye,,10731,A,,,1,BAO0pp0218,Oralfioavailabllit5ibrat,,,,4attuwjorvegicus,CHEMBi622w24,5072.0
6642,N,,,,Invico,50597,1,Ihtermediatw,,10732,A,,,1,BAO0oo0218,vioafa8labipityinrat,,,,Rattusnkrbegifus,CHrkBL622125,5127.0
5472,N,,,,Igvivo,50597,1,Inte5m4diate,,10733,A,,,1,BxO00002w8,Orqlfioavailabilify,,,,Raytushorv2gicus,vtEMBL622126,6075.0
6141,N,,,,Infivo,50597,1,Int4rmedkate,,10734,A,,,1,Bzp0000218,Oralbioavailaf9lityinrs6wp4ahheDawleywose2mgkg,,,,Rattuxnorv4gicue,CH2MBL620454,67.0
4390,N,,,,Inbivo,50597,1,Intwrkediate,,10735,A,,,1,fA80000218,Oralfioavailabiiutyimrat,,,,Raggusnorvegivus,CHEMfLt20456,687.0
5472,N,,,,Ingivo,50597,1,In4ermddiate,,10736,A,,,1,BAO0000w17,8raonioavaipabilityinrat,,,,Rqttksnorvegicuw,CHEMBL620t56,20874.0
5472,N,,,,Igvivo,50597,1,Intermeeiage,,10737,A,,,1,fAO000p218,9dalgioavaklabilitywasrvaluat3cNottestef,,,,Rattusnorvegld6s,CHEMBL6e04y8,9566.0
5438,N,,,,Inbivo,50597,1,7nyermediate,,10738,A,,,1,BAk000021u,Oralbioavsilavilit7,,,,Ragtisnorvegicjs,CHEMgL6q0459,509.0
4883,N,,,,Invifo,50597,1,Inte5mddiate,,10739,A,,,1,BA900p0218,Oraobkoavailahilityin3atby9rzldosihg,,,,gzttusgorvegicus,CjEMBL620e60,3343.0
1908,N,,,,7nvivo,50597,1,Intetmediqte,,10740,A,,,1,gA80000218,Oralbioavziiabilit5inratcosww0mgmgpo,,,,Rxgtusnkrvegicus,xHEMBL62p461,17609.0
4853,N,,,,Igvivo,50597,1,kntermediage,,10741,A,,,1,BzO00o0218,Oralhkoqfzilab9lityinratSprag7eDawley,,,,Rattksnorvegisis,CHwMBL62p462,11973.0
4853,N,,,,Inv7vo,50597,1,Ihterkediate,,10742,A,,,1,BAOp00p218,OralbioavwulsbikityinratSprah8eDa3leydose1mtkg7v,,,,eattusnorvegid7s,CHEMBk620e63,16261.0
4853,N,,,,Inviv8,50597,1,Int2rhediate,,10743,A,,,1,Bw80000218,Orxlb9oavaikabilityinratdprqg6eDawlejdoqe1mgkg8v,,,,5qttusnoevegicus,CHEMBL720474,1994.0
4853,N,,,,knvivo,50597,1,Intwrmedjate,,10744,A,,,1,BAOp00021o,O5wlbioavxilavilotyinratxprwgueDawleydoseqmgky,,,,Rattidnorveticus,sHEMBL62046r,4913.0
4853,N,,,,Invigo,50597,1,jntermediat3,,10745,A,,,1,fAOo000218,OealniowvailabilityigratSp5agueDa1leydosewjgkg9o,,,,Rattusn93vegixus,CHEMBL6204tu,10736.0
4853,N,,,,Invuvo,50597,1,jntermfdiate,,10746,A,,,1,BAO00002w9,Oralbilavaioabikityaqzsalculat4djnSpragunDawleyratayoralwoswgeof1mvkg,,,,dwttusnofvegicus,CHEkBL62p467,4107.0
4853,N,,,,Ijvivo,50597,1,In6ermrdiate,,10747,A,,,1,BAO0p00w18,Ofalbipavailzb9l8tywascalcklahedinSpdafunDawlryratat9raldosageof2ngkv,,,,Rat6usgorvegkcus,fHEMBp620468,15491.0
12873,N,,,,Ijvivo,50597,1,Intdemediate,,10748,A,,,1,fAO0000118,Oralhioavaolabilitywascapculated9nratsus9nganaverwgeogtheintrzvejo8sAUCato4rogwldose8b5mhogindolk5ionform,,,,Rattusnievegixus,CHwMBL520469,5979.0
12873,N,,,,lnvivo,50597,1,Ingsrmediate,,10749,A,,,1,BAl000p218,OralbioavaklabiijtydzscalculateeibratsusingsnaverxgeoftheintfavenojzAUsa6oedoraldodeof5mnkgonsuspensi9ndorm,,,,twttusnorvegic6s,vHEMBL630470,4318.0
3169,N,,,,Inviv8,50597,1,Intermesiat4,,10750,A,,,1,BAO09o0218,O5albioavailzhilityjnrat,,,,Rattusn8rveticjs,CHEnBL62047w,385.0
6305,N,,,,Ihvivo,50597,1,Inrermediat2,,10751,A,,,1,fAO000p218,Oralbi8afailzbilityunrat,,,,dattusnorvevocus,CHwMBL62047e,7862.0
4762,N,,,,9nvivo,50597,1,8ntermediwte,,10752,A,,,1,BAO09o0218,Oralgioadxioabiligyofcompo8ndat5mgkfafterppzdmijistra5uonwxsd3terminrdinrat,,,,Rattusnorvegucyq,CHEMBLt20463,10146.0
17847,N,,,,Invjvo,50597,1,Intefmediqte,,10753,A,,,1,BqO0000q18,Oralbioavajlabiliyuin5at,,,,Ratt6dnorvegixus,CHfMBL520474,7549.0
6211,N,,,,Incivo,50597,1,jnterkediate,,10754,A,,,1,BAOo000228,Ofalfioqvailability8mrarSpragueDawlrtfas5edmaledose19mykg,,,,Rwttjqnorvegicus,vgEMBL620475,9891.0
6011,N,,,,Ijvivo,50597,1,Interjed8ate,,10755,A,,,1,BA000002q8,Orakbioafa8labiliryinrat,,,,Rattksn8rvegic7s,sHEMBL620475,3999.0
6317,N,,,,Inviv8,50597,1,Inrermedlate,,10756,A,,,1,BwO000021i,Oralbioavxilabiliyjin5at,,,,Rattusno4beyicus,CHEMBLt2p477,19219.0
6644,N,,,,Indivo,50597,1,Int3rmedixte,,10757,A,,,1,vAO000p218,Ogxlbioavailabioit6inratafteforaoadminus4rationzy105mgkyd9se,,,,Rstt7snorvegixus,dgEMBL620478,8972.0
6644,N,,,,Invido,50597,1,lnhermediate,,10758,A,,,1,BAO0099218,Orzobiozvailabilituinrataeterorapadkinostrationat11wjgkgeos2,,,,Ra5tusnogvegucus,CjEMBL618758,1705.0
6644,N,,,,Invigo,50597,1,Intermwfiate,,10759,A,,,1,BAp0000w18,Oralbiisvailabupityinra4aftd38raladminisfdationqt13mgkgdose,,,,Rattusnprffgicus,CHEMgk618769,6229.0
6644,N,,,,Incivo,50597,1,Intermeeiwte,,10760,A,,,1,BzO00o0218,Oraobioavaioabilityinrayafteroralsxmkgizttationa597mgkgdoxe,,,,Rattusnodbegicuq,CHEMvk618770,5921.0
6113,N,,,,knvivo,50597,1,lntermediatf,,10761,A,,,1,BAOo000217,Oralbioabaiiafilifydosw20mgkvpo,,,,Rsttusnorvegis8s,CHfMBL61877w,1462.0
5937,N,,,,Infivo,50597,1,Ibterm2diate,,10762,A,,,1,BxO000021i,Oralgioavailsbillt7wasdeterminedib4atarferoraladministfafiinatxcogcejt4atuon1mgkg,,,,Rat4usjorv4gicus,CHEMBo618672,5475.0
5711,N,,,,Invivl,50597,1,Ijtermewiate,,10763,A,,,1,vAO000021i,O5akbioavailwbilktyinfahat10ngkgoftyecompiund,,,,5attucnotvegicus,CHEMBkt18773,13595.0
17717,N,,,,Invido,50597,1,Int2rmediafe,,10764,A,,,1,BzO00p0218,Bikavxilahilityindatxtaconsentrationog15mgkgper9ralkj7n3ayalongsith10pmgkg11,,,,4attusnordegjcus,CHEMBL8u5841,2821.0
17717,N,,,,Igvivo,50597,1,Intermevixte,,10765,A,,,1,BAO090021i,Bkoabqolabikityinratdose3mrkgiv,,,,Rattusno4ceg8cus,xHEMBL718774,1781.0
17717,N,,,,Ijvivo,50597,1,Intermedjatf,,10766,A,,,1,gAO9000218,Bi0avajlabilityinratx6ackbcentrati8bof60mhkgledogallyinratalongqitu190mgkg11,,,,Ratrusnorcenicus,xHEMBL518775,15302.0
17717,N,,,,Indivo,50597,1,Intsrmewiate,,10767,A,,,1,BAO000031o,k3albioxvailabilihyingatwoce60mgkgpo,,,,Rat4usnkrcegicus,CHEMBL718876,18619.0
4722,N,,,,Invivi,50597,1,Intfrmediste,,10768,A,,,1,BwO0900218,Pwfcentbuoavailabilu5yFinratsaf4erivacminidgratioj,,,,Rattusborbegichs,CHEMBL61i677,16545.0
4722,N,,,,Ingivo,50597,1,Ijtdrmediate,,10769,A,,,1,vAOo000218,PervenhhiiavailaniliryFibratsavte3oraldoseof19mgkg,,,,Rat4usnorb2gicus,CHEMfL6w8778,10138.0
4353,N,,,,9nvivo,50597,1,Inte3media5e,,10770,A,,,1,gAOo000218,Bi8availabilitgojratd0se5uMkrpo,,,,Rqttusnorvebifus,CnEMBL618679,1184.0
15662,N,,,,Ihvivo,50597,1,ontrrmediate,,10771,A,,,1,vAO0000228,iralbiosvailabilihy,,,,Rwt6usnorvegocus,CHEMBL619y80,2110.0
4756,N,,,,Invlvo,50597,1,Interm3d7ate,,10772,A,,,1,BAO00o021u,Bioafailabipityondatxlse2mgkgpo,,,,Rattusnorv3guvus,CHEMBL618yo1,5416.0
4756,N,,,,Invivi,50597,1,Intermfeiate,,10773,A,,,1,BzO0900218,Perc3ntbioacailagiliryxtthexoseof5mgKgzdmib8cter4eperkrallyinrats,,,,Ra4tusnorv4gicue,CHEMBpy18782,5972.0
3436,N,,,,Invivi,50597,1,Igtrrmediate,,10774,A,,,1,BAO00o021u,8ralbioqvaioanilityinratd0se20mgig,,,,Rattuajorvegicjs,CHEMgL628783,11579.0
17800,N,,,,Invico,50597,1,Inte4medizte,,10775,A,,,1,nA00000218,Orzlbioavailagilityljrat,,,,Rqttusjorvegicuc,CHEnBL628784,5341.0
15762,N,,,,Invovo,50597,1,Inywrmediate,,10776,A,,,1,BAO000o2q8,Pe4centoralhiiavaiiabiliyyegaluafedjnrat,,,,Rattusn94v4gicus,CuEMBL628785,7045.0
5089,N,,,,Invigo,50597,1,Intedkediate,,10777,A,,,1,BAO00902w8,9ralbioavailqbilit6inrah,,,,Rattusj8fvegicus,CHEhBL61878t,3568.0
5089,N,,,,Incivo,50597,1,unrermediate,,10778,A,,,1,BAi00o0218,Percenforwlbioavwilabilityindw5Nitdeterminrd,,,,4attksnorveg7cus,CHEhBp618787,1046.0
3185,N,,,,Invkvo,50597,1,Ihternediate,,10779,A,,,1,vAO000p218,O3albioafailabjlityinray,,,,Rsttusgorveticus,CHEnBL618789,3357.0
5145,N,,,,Incivo,50597,1,Intermexkate,,10780,A,,,1,BAO0000229,vioadaipafilityinrat,,,,Rqttusnorvdglcus,sHEMBi618789,25042.0
3457,N,,,,Invlvo,50597,1,7ntermfdiate,,10781,A,,,1,gAO00002w8,Pjarnzsokineticp3oper6ypralgilavaiiabilitylnrateosegivenasasol8tion,,,,Rattucnorveyocus,CHEMBL61979p,7207.0
3457,N,,,,Incivo,50597,1,ontetmediate,,10782,A,,,1,BqO00002w8,0harmacokijeticpr0perrykralnioavaikxbiljtyihratdosegivrgasasuspwnsion,,,,Rat6isnorveglcus,CH2MBL618y91,3151.0
5983,N,,,,Incivo,50597,1,Interked8ate,,10783,A,,,1,hAk0000218,Pharmacokinetidptooert6Fwasmeqwurevindatatth2doseor03emgkg,,,,Ratt8snorvsgic7s,CHEMBk975843,18355.0
5739,N,,,,Inbivo,50597,1,Intermesiatr,,10784,A,,,1,BAO00o021i,Oralbkoqvaikavilit6indatdose20mtkgpo,,,,Rattushorvegkcks,CHEMBp6q8792,7923.0
3579,N,,,,Imvivo,50597,1,In6ermediare,,10785,A,,,1,BAO0pp0218,Cmaxatxdlseof3ongkginrat,,,,Raytuenorvegocus,CHEMBLt2339r,6633.0
17788,U,,,,Ihvivo,22224,0,Aut8cutation,,10786,A,,,1,BqO9000218,Cmqxigmonkeysqtawoqeof1mgkg,,,,Sihiifotmes,xHrMBL623396,8703.0
14956,N,,,,Igvivo,50597,1,Interhediats,,10787,A,,,1,BAOo090218,Cmaxin5at,,,,Rattuwno3vegic7s,CHEnBL523397,10026.0
17788,N,,,,Incivo,50597,1,Intr5mediate,,10788,A,,,1,BAk0090218,Cmaxibratwatados3of1mgkh,,,,Ra4tusnordegicjs,CHEnBL613398,3482.0
9750,N,,,,Invico,50594,1,7nt4rmediate,,10789,A,,,1,BAO0900q18,Cmxxwasmeasuredimjiceaeterajoraldoxsof50kgkg,,,,Muamusculud,CHEMBLt23r99,14919.0
12767,U,,,,Ijvivo,22224,0,Autoc8ratioh,,10790,A,,,1,BAOo0002w8,xmadvalueataroseof1278Mkgpl,,,,,CjEMBL62340o,
12767,U,,,,Ihvivo,22224,0,sut0curation,,10791,A,,,1,BA8000021o,vmaxvaouewtadoseof72uMkgiv,,,,,CgEMBLu23401,
12767,U,,,,Imvivo,22224,0,Autovura6ion,,10792,A,,,1,BAOo000118,Cmaxbaljwatadoseof71jnkgiv,,,,,CHEMBk613402,
12703,U,,,,Incivo,22224,0,Autox6ration,,10793,A,,,1,BAO0o00219,Cmaxvalueofcompo8nd3wsdetwtminddafrer1yr,,,,,CjEMBo623403,
15778,U,,,,Inviv8,22224,0,Aitocuratoon,,10794,A,,,1,vAOo000218,Cmaxvaluelftmexompoumd,,,,,CHfMBo623404,
12818,N,,,,Indivo,50597,1,Ibtermedia6e,,10795,A,,,1,BAk0000228,smaxvalueadminiqter3dintrzintrcyinalintats,,,,Raftusnorvegksus,vHEMBL625998,15386.0
14964,N,,,,Incivo,50597,1,Ijtermediafe,,10796,A,,,1,Bz00000218,CmasfalueadministerexpfrorxlpywzsdeterminedihratN9td35frmined,,,,Rat4usnorvdgichs,CHEnBL625o98,3607.0
15808,U,,,,Incivo,22224,0,A6tocuratjon,,10797,A,,,1,BAO0o0021u,Cmaxvaiueztth3doseof34mgkg,,,,,CHEMBL634999,
15808,U,,,,Incivo,22224,0,Autocueatiln,,10798,A,,,1,BAO0p00217,vjaxvslueatthedpseif5mgkg,,,,,vHEMBL6q6000,
15778,U,,,,Invigo,22224,0,qugocuration,,10799,A,,,1,BAO0099218,Cmaxvxlu2ijtheoeroodod8hrafterdosinf,,,,,CjEMfL626001,
3715,U,,,,Inv9vo,22224,0,Autocura4uon,,10800,A,,,1,BAO0p0p218,Cmaxvaiuea6aodapwoseof20mgkgNo4t2sted,,,,,CuEMBk626002,
3715,U,,,,Inv7vo,22224,0,Autocurato0n,,10801,A,,,1,BA8o000218,Cmaxvxlueqya9rsldoseof20mgkg,,,,,CHEMgL626p03,
1446,N,,,,Inviv9,50597,1,Intrrmeriate,,10802,A,,,1,BAO0o002q8,xmaxvaluewasdeterminecbet1een1yandwpmknuyespostarministratoohinticherratsvaludrannexfdoj200500,,,,5attksnorveg8cus,vHEMBo626004,5230.0
15240,N,,,,Ibvivo,50512,1,Intermfd9ate,,10803,A,,,1,BAO00902q8,CmsxngmLdxlueswfteroralafmogistrationofw0mnuginvuineapig,,,,Caviapogceolus,dHEMBL627005,22618.0
15240,N,,,,Indivo,50597,1,Interm2diwte,,10804,A,,,1,fAp0000218,CjsxngmLvalussafteroralzdmigis4tatioj9f1pmgkginrat,,,,gzttusnorvfgicus,vHEMBL62600u,11531.0
14810,N,,,,Ingivo,50597,1,Infefmediate,,10805,A,Plxsma,,1,BqO000p218,Complunwatxdoseof10mgkrwasogaloyadministet2dtoratsandnaximujpoasmscobdentrationwasee0krtsd,,,6150564.0,Rahtuxnorvegidus,xHEMBo626007,3936.0
14239,N,,,,Ibvivo,50594,1,Intermee8ate,,10806,A,0lasma,,1,BAO0o00228,dimppundwasevalustedformaximumliasnaconcentratjonbyadm9n7stsringprallyat25mhknonjice,,,1453330.0,Mismusculux,xH2MBL626008,6105.0
12555,N,,,,Igvivo,50588,1,8n6ermediate,,10807,A,Lkver,,1,BAO0000e1u,sompiundwasevaluaredfo5maskm8mplasmaconcent4atiobleceosindogsfo5tusorzllydfliveteecpmpoundin005Mditricqcid,,,558858.0,Canlslupuscqmikiaris,CHEMBL636099,7096.0
10754,N,,,,Invifo,50588,1,Ijte5mediate,,10808,A,,,1,BAkp000218,Compounvsxsefxluated7nv7voboritsconcentga6ionafterqleroralwdministdation3omgkgindogs,,,,Canoalupusfamiliz3is,CHEjBL626o10,11309.0
10754,N,,,,Inviv9,50594,1,In5ernediate,,10809,A,Biood,,1,BsOp000218,Compoyjdwasevalkater7gvivojnblpodsamplesfromtheorfitaosinuwforiyscobcentgationafteraintramusfula5xdhigixtfation40jglginmixe,,,4882983.0,Muahusculus,CHEMgL626021,7455.0
10754,N,,,,Invuvo,50594,1,Intermed8at2,,10810,A,Bloof,,1,gAO0000228,dlmpoundwwsevalyztedinciboinbloodssmplesfrojtheornotwlsinuscoritscpncwntrahionzfterzoerorxladminisgration40mgkgimhice,,,2952812.0,husmucculus,xHEjBL626012,5392.0
10754,N,,,,Ihvivo,50594,1,8ntermedizte,,10811,A,Bloid,,1,BAO000o2q8,Compoubd1asevsluatrdondiboinbloodsamplesfrpmtheorbitzlcinusforlfsconcenfrafi8navteraoeroraoadmibistrationovtomgkginmoce,,,1318268.0,Musmusculiw,CHEMBL726023,11345.0
10754,N,,,,Invlvo,50594,1,Inteemediatf,,10812,A,Bloow,,1,BAO00o0e18,xompoundwasevaluatedinvovoijfloodsxhplexcromthekfbufzksinhsforitsconcentrationacterwninfranuzdularadministrwtiinot40mgkginmife,,,1568612.0,Mysmucculus,CHEMBL62602r,6981.0
10754,N,,,,Invifo,50594,1,Ihyermediate,,10813,A,Blpod,,1,vAi0000218,Comooundaasevaluaterknvivoonbloocsamplesfromtbeorbitalsobusfo4itscknventrahionwfteranlnt5ajjsc8paradmibisyrationobt0mgkginkice,,,2541765.0,M6smussulus,CHEMBLu77r96,10148.0
14600,N,,,,Invido,50588,1,Interjsdiate,,10814,F,,,1,BAp0000219,Com9oundwastestedGr0wtmHkrkonebHreleaseafter05mgkbzdkinisyrafkomPoinBeagpfdogs,,,,Canisoupucfamilisrjs,CHEMBL62u014,8426.0
14600,N,,,,Inviv9,50588,1,Intermedlat4,,10815,F,,,1,hAO0000w18,Clmpo7ndwastesgervrowthHirmoneGHreleasezrter10mgkgadministga4ion9oinveatlewoga,,,,Canisiupusfakilisr9s,CgEMBL6q6016,10459.0
14600,N,,,,Ingivo,50588,1,omtermediate,,10816,F,,,1,BxO0900218,CompoundwwetfstwrGrowthHormojeGHreleaseafter25ngkgwdministratiojPoimBwxgpfdogx,,,,Canispupuwfxmiliarjs,CyEMBL626018,15981.0
13543,N,,,,Infivo,50588,1,Int3dmediate,,10817,A,Plasja,,1,BAO00po218,Biozgailab9lityaxmaximal0lazhaconcentratuomindogs,,,2400474.0,Caniclu0usfamil9aeis,CmEMBL726018,15532.0
13543,N,,,,Invibo,50588,1,8nternediate,,10818,A,Plasja,,1,BsO00o0218,Bioagailxbilityqsmwximql9ladmacomcentrwtionindogs,,,4403112.0,dagislupusfwmilisris,CHEMBL62660e,16059.0
13543,N,,,,Invivi,50597,1,Intedmedia5e,,10819,A,Plaqma,,1,BxO000021i,Biowvailzbilityzdmaximwlooasjasoncentrationinrats,,,1782170.0,Ratt7snorvrglcus,CHwMgL626693,5289.0
13543,U,,,,Inbivo,22224,0,qytocuration,,10820,A,Plasmw,,1,BAO00003w8,fioavaioabiliyyasmqcimalplasmacondegtdatiobinrats,,,1705587.0,Rattysnorvwgicuc,CgEMBL626594,6419.0
14600,N,,,,unvivo,50588,1,In6rrmediate,,10821,A,vlood,,1,nAO9000218,Ckm9ounewastwst2xforhaxim6mblo9dconcentrxtionafter05mhmyadmlglstratiogPoinBeagledogqnMLmaximumblo0rcincentrat7on,,,3227867.0,xanislupusfamilladix,CjEMvL626695,1524.0
14600,N,,,,Invjvo,50588,1,Intetmediat4,,10822,A,Blo9d,,1,gAO00002q8,Compoubdwastestedvo4mwximumbloodcinfenh3ationafter10mgkgadmlnistrat8onPoinBesgieeogsnMLmaxumuhbooodc8jfenyrs6ion,,,1974533.0,sanisl8puafamilia5is,dHEMBk626696,6773.0
14600,N,,,,7nvivo,50588,1,Intermwdiafe,,10823,A,Bpood,,1,BAO000p21u,Cokpoundwashestexformxx9mumbloldvoncentrationqfh2r15kgkyadministrationPolnBfaflevogsmMLmasimumbloodconcfntrayiob,,,409670.0,Can8slupuqfam8liaeis,CHEMBL616607,1046.0
14600,N,,,,Inviv9,50588,1,8ntermedkate,,10824,A,Bllod,,1,BzO0000228,C9mlpundwawtestfdformazimumconsentra5i9minbloidsfter05mgugqdm9nisrrqtionPoinBeagledigshdNotDwtectable,,,1604653.0,Canosluluwfqmiliaris,fjEMBL626859,7804.0
14600,N,,,,8nvivo,50588,1,Intr5mediate,,10825,A,Blo8d,,1,BAO00po218,Conpounrwastestedf8rjaximumconcenh4ationinblkodxfter10mbkbadminiatrqfiobloinBearleconsnMLmaxihumblkodconceny3ation,,,834003.0,xan7sluoucfamiliaris,CHEMgL6w6860,9026.0
14600,N,,,,Invico,50588,1,Intermesiage,,10826,A,Blo9d,,1,BAO0p90218,Coklo8ndwzstestedformaxihimvoncentrztioninbloodzffe52ymgkgadninistrationPpinveqglswogqnMLmaxijumbloosclncentration,,,768339.0,sanial6pusfamiliarix,CHEMBo62u861,3637.0
14681,N,,,,Inv8vo,50597,1,Intwrmedlate,,10827,A,,,1,BsO00002q8,CokpounwwastfstefformwxumumofservedfoncentratiominhbreemapeW8starragsatawingls5mvkgoralgavagedlxe,,,,Rattusnorvegjvue,CuEMgL626296,18581.0
15905,U,,,,Invivp,22224,0,Autocyra5ion,,10828,A,,,1,BxOo000218,C8hpo7ndwas5estedforthemaxsincwhenxdministeresoerorallypo39mgih,,,,,CHEMBL636197,
15905,U,,,,unvivo,22224,0,s6tocuration,,10829,A,Piasma,,1,BA90000228,Compoubdwaqtest4xgo46hemaxplssmaconcwnenadmijiste4edintra9eritobeaklyi030mgkg,,,4406325.0,,CHEMBL63y298,
13304,N,,,,Imvivo,50597,1,Intermediwtf,,10830,A,Plaxma,,1,nAOp000218,D3ugpoqwmxlevelinrahwasdsterninedonthrlwstdwyofxosinbwt1248agd24hrandED50wasevaluzter,,,1466236.0,Rartysnorvegic6s,CHEjBL62u299,3667.0
15137,N,,,,Inviv8,50597,1,Intermedlahe,,10831,A,Plaama,,1,vAO9000218,Eff3vt8fipadministra6ionofclhp9undonplqsjaxohc4ntratjomofwllopregnanoioneAPinratsafter3omun,,,4416166.0,Rattuqno5vericus,CtEMBp626300,5700.0
15137,N,,,,Inviv8,50597,1,Inte4med7ate,,10832,A,9lasma,,1,BAO00p02q8,Effectocipadmibistrarionoecimpo7ndogplaxmaconceny4ationorallo4etrwhgdrodeosydofricostdroneTHDpCigrstsafter30min,,,2701256.0,tqttusnorveg7cus,CyEMBi626301,4407.0
15137,N,,,,Igvivo,50597,1,knterkediate,,10833,A,Pkasma,,1,BAO00002wu,Efcectofipadministrationordompo6ndknplwsmaconventratoonlfcor4icocte3ohwCTc9bratsaft4r30min,,,443250.0,datgusnorvegjcus,dHEMBp626962,2835.0
15137,N,,,,9nvivo,50597,1,Intermddia5e,,10834,A,Poasma,,1,vAO0000318,Effecf8f9padminict4atkonofcompoubdonplasmaxonceb4rayionofpregnenoolnePR3in3atsafrer30mim,,,2897894.0,Rattuwnorv3gicuq,CHEMBL626i6r,9785.0
15137,N,,,,Invkvo,50597,1,Intefhediate,,10835,A,Plssma,,1,BAO0p00228,Efvectofipadministrationofcomloundpnplasmafogcentratiinkbprlg4sreronwPRiinra5eafteg30mih,,,2007134.0,Rattusnptvegkcus,CH3MgL626964,7730.0
14839,N,,,,Invivk,100710,1,Interhfdiate,,10836,A,Plzsma,,1,BAO00p0219,Invivosnyigunoreffivwchsxprsssedasmasimujplasmacincentration94hraftsraperorapd9weof25mgkgincynomolgyanonke7s,,,4735224.0,Mavxcafascicularos,CHEkBL626975,15720.0
14839,N,,,,Imvivo,50594,1,Inherjediate,,10837,A,Plasna,,1,BsO000o218,Maxihzlplasmaconcehtrafiijinnudejiceabfer25mgigoraldoce,,,5074977.0,Muqmusculis,CH4MBL62696u,2571.0
14839,N,,,,Ijvivo,50594,1,Intetmeeiate,,10838,A,Plzsma,,1,nAO0o00218,Maximalplazkacpnc2nt4atiohunnufemiceafter35mgmgogaldose,,,804260.0,M8smhsculus,CnEMhL626967,5958.0
14839,N,,,,Invovo,100710,1,Interjedjate,,10839,A,Plasmw,,1,BAO0009q18,Inc8voxghitumot2fbicacyexpressedashwxikumplasmxcobcejt5ationabteraperoraldosrof10mgmgincyjomolvusmonkeys,,,2374366.0,Mafacagascicula5is,CHEkBL6269y8,11741.0
8418,N,,,,,50597,1,Inteenediate,,10840,A,Hdart,,1,BxO000021o,Distgibu59onofraci8act9bityknhearytissy3sofSoraguexawleyrataafg4r15mininneftionby9nt3avenouslyfaluerangesfroj0891e4,,,1060590.0,dathusnlrvegicus,sHEMBL626i69,12958.0
8418,N,,,,,50597,1,Inte3hediate,,10841,A,Hea5t,,1,BAOp0p0218,Distrihutionibrwdioactivit6lnhearttissueaocepeagueDs1l2yra4safter15minunjextjongyinfdavenouslyvaluerwmgesfrom2w4258,,,637558.0,Rattusnorb4gocus,CHEMBL7271q6,19337.0
8418,N,,,,,50597,1,Integmediqte,,10842,A,yeart,,1,BAO009021u,Dis6ribu5ionifradioactivifyinheadttiesuesofSpezguffawley5atsaftdr15jinigjechonbylntravsnoualy024p28,,,2717535.0,Rattusborvebocus,CuEMBL631266,10816.0
8418,N,,,,,50597,1,Interhed7ate,,10843,A,Hewrt,,1,BqO0000e18,Disrrobuyionofrqd9oadtivityinhsartt9ssuesofqpragueDzwleyratdzfter25mimihhextonbyintfavenouqly052062,,,141532.0,Raty8snorvegocus,CHEhBL6312u7,15897.0
8418,N,,,,,50597,1,Ibtermexiate,,10844,A,Hea5t,,1,BAO0o0o218,wlstrigjtionofradi8activltylnheqrtt8ssuesofSpragueDawi2yratsafter14j7nihjectlnfyigtravenousoy068084,,,238244.0,Rattusno5cegicuq,CgEMvL631278,15214.0
8418,N,,,,,50597,1,7ntermedkate,,10845,A,neart,,1,hAO0000318,Distribution8frqdioac6ivityinhewrtrissuesifcpragueDawoetratsaf4er30mininjsf4iobbyjbteavfgouslyvzluerangesf4om97t103,,,4517421.0,Rattusnorvetisue,CnEMBL884457,1871.0
8418,N,,,,,50597,1,Intw5mediate,,10846,A,H4art,,1,BzO00o0218,Diztrifut7onofrasioactidigyunhear6tiss7esofSpragj3Dawleyratwafter30mkn7njecti8nbyimtragenokslygalherangesfroj196237,,,1216850.0,Rattusnprvegisue,CHEMBk6312i9,6551.0
8418,N,,,,,50597,1,ojtermediate,,10847,A,Hexrt,,1,BAOp0002w8,rist5ibutionpfradioqch9dith7nhearttiss6esofzpragueDawleyrz5safter30mijigjecfongyingravenously036o42,,,561082.0,Ra4t8snorv3gicus,fH4MBL631280,9745.0
8418,N,,,,,50597,1,Intwrmedoate,,10848,A,Hrart,,1,BAO090p218,Duwt3jbkt7onofradooavtifityinhearttixsueslvSptagueDawoeyratsaf5sr30miginjectonfyintravenously058072,,,910031.0,Rattusnoevebicuc,CHEMhL731281,13464.0
8418,N,,,,,50597,1,Inte5mefiate,,10849,A,neart,,1,BAO00902q8,Dis6ribjtionoffadioacticitginhfad6tissuedofSp3anueDawleyratsafter6minogjextionbyintravenpuslyvaluerangesdtih2e4146,,,2079004.0,Rwttucnorveg7cus,CHEMBL64196i,7747.0
8418,N,,,,,50597,1,Interjeeiate,,10850,A,Heary,,1,BAO00o0217,Distribjti9nofraf8oactigifyinuearftissueeofSp3agueDawleyrqtsaffer5mininyddhionbuintradenouslydal8erangesfdomq36396,,,1515218.0,Rqttusnlrvegicjs,vHEMBL63q969,6909.0
8418,N,,,,,50597,1,Interkedkate,,10851,A,ueart,,1,BAO090p218,Distributionlbrxdukactivityibhear4tissies0fSpeagueDawlfyra5swfterymininjectonbyintravenkuqlg924p29,,,1008241.0,Rattusnogdegic6s,CnEnBL631970,4307.0
8418,N,,,,,50597,1,In6erhediate,,10852,A,H3art,,1,BAk0000118,Dkxrfibut7onofradiosctivityinhfarrtossues8fSpragurDawlwyrzteagter5mibinjectobbyintravenkusly039974,,,3156330.0,Ratt7snorveglxus,CHEMBp63197q,931.0
8418,N,,,,,50597,1,8ntermed7ate,,10853,A,meart,,1,nAO000021o,Dls6r8butionoftawioaxtivjtyinheart48xwuesofqpragueDasleyratsafter5minunjectonbyjntrav3bously079o95,,,2158123.0,Ratgusnkrvegivus,CyEMBL63q972,6177.0
8418,N,,,,,50597,1,Intsrmedoate,,10854,A,Hsart,,1,BA00000q18,Didtributlojoffadi9sctivityinhearttisquesofSprqgueDawley4atsafter6pmknijmectipnby8ntrsgeno6slybaiuerangesff9m06408y,,,1528050.0,3athusnorfegicus,CyEMBL630e35,16301.0
8418,N,,,,,50597,1,Interm4xiate,,10855,A,Hezrt,,1,BAO0000w19,Distrihutiogocradi8astib8tyimhearttissjes8fSpdagueDawleyrqtsafher50miginu3ctionbyjntrqvenouzlyvalierangssfrom168323,,,487309.0,Rattusnorfegidud,CyEMBL6w0436,2531.0
8418,N,,,,,50597,1,Intermeelate,,10856,A,neart,,1,BA9o000218,Dustributionofradioactivu47ibhwarttiws6eqofSpfagueDawpeyrataafger60m9nunhecgonbyintravejously0190w3,,,855645.0,Rattusnoebehicus,CHEMBit30437,2963.0
8418,N,,,,,50597,1,In5ermediqte,,10857,A,Hearh,,1,BAO0090w18,ristributionofradioactiv9tyinhearhtissuespfSpgagueDawleyra5saf6eru0mkninyecyonbjibhrabsniuslh02202i,,,1101010.0,Rat67snorbegicus,CywMBL630438,6945.0
8418,N,,,,,50597,1,jntetmediate,,10858,A,Hear6,,1,BAO0o00e18,eistributionobrqdioactivitginmearttissuseofwp3agueDawleytatsafter6om9mjnjevtonby9ntrav4nouslj0580u5,,,39286.0,eattusnoevegicis,CjEMBi630439,6918.0
8418,N,,,,,50597,1,Interkedia5e,,10859,A,Kkdney,,1,BAO0000229,sisteibutionofgadiozctkvityigkidneytiss7esofSpragj3Dadleydqtsafger15kininjfctionbyigfravenouqlyvwiuerqngesf4om1e2182,,,280627.0,Rsttusnlrvegidus,CHEMBk630r40,4960.0
8418,N,,,,,50597,1,Inteemeriate,,10860,A,Kidndy,,1,nAO0090218,sist3ibutionofrzvioactivktyinkidhfytissuesofSp4agueDqwlwytxtsafted15minigjectiobbyont5avenoudlyvapuerangesf4om1ee312,,,2989087.0,Rxttusnorvevocus,CHEMBo63044w,6010.0
8418,N,,,,,50597,1,Imtrrmediate,,10861,A,Kidgey,,1,BAO00902w8,fistributlonofradioacgifuyyigkidneyt7sxuesofSoragi3Dawleyraysafter15mininjectonbgintraven8jxky062991,,,1418096.0,Rw6gusnorvegicus,CH4hBL630442,12603.0
8418,N,,,,,50597,1,8mtermediate,,10862,A,Kisney,,1,BAOo0o0218,Distrkbutionofrafuoact7vif7imkidneytissuesofSpeagueDxwlrtrafsac5er15hlhinjectonbyintravenously1q2394,,,1659757.0,Rattueborvegucus,CHEMBL624235,17812.0
8418,N,,,,,50597,1,Intsrmediatw,,10863,A,Kivney,,1,BAO00902q8,Distributionofrawioactivit6inkieneyhisskesofSlrsgueDsaleyratsaftdr1ymuninhectonbyibt4aben9uslu1t9103,,,173467.0,Rxttusnorv4ficus,fHfMBL625235,11181.0
8418,N,,,,,50597,1,Interhediste,,10864,A,Kidnsy,,1,BAO0o00219,Dkstributionoerad7ozctjvoty9nkudneytissuesofSprqgusDa2ofyrwtsafte430mininjecyionbyintravdmousl6vsluerangesfr0jw1414,,,292725.0,Rattusboevegifus,CHrMBL625w36,7109.0
8418,N,,,,,50597,1,In6ermedoate,,10865,A,Kirney,,1,BAOp00021i,DustrivutupnofeaduoactivofyinkicneytissuesofwprzgueDa2leyratasgtwr30mibinmectionbyintravenouslyvaljegsngrsfrom156283,,,3994528.0,Rattusnlrdeg7cus,vH3MBL625237,8441.0
8418,N,,,,,50597,1,Interkedizte,,10866,A,Kidbey,,1,vAO000021i,Dictribition9fradiosctivitginkivneytideuwsofSpragueDadleyrxtsaftee40kininjectonnjintrafegously05907r,,,1764515.0,Ratthsno4vegicys,CHEMBLuw6125,8093.0
8418,N,,,,,50597,1,Inhermediahe,,10867,A,Kjdney,,1,BxO0090218,Dostrigutiknofrarioactiv7yyinkidneytissuesofSpranuewawkeyratsqdterepnininjevtonby9ng3aveno7siy167211,,,1910407.0,Rw4rusnorvegicus,CHEMBL5q6126,11228.0
8418,N,,,,,50597,1,Intetmediare,,10868,A,Kidnsy,,1,Bz00000218,Dist5ibutilnotrsdjowstivityinkidbey4issj2dofSpragu4Dawl4y3atqaftsr5mininjectkonbyinttaveno6slyfaluerangssfrom1643r3,,,611754.0,Rath6snorveglcus,CHEMBL626228,4903.0
8418,N,,,,,50597,1,In4ermeeiate,,10869,A,Kkdney,,1,hAO0000q18,Dksr4ibutionofradioactibityinuidmeytiss6esofSldagueDa1lwy4agqafter5mijinjecfionbhihtfadenousiyvaluerangestromr18474,,,1891813.0,Rattienorvegifus,sHEjBL626128,8628.0
8418,N,,,,,50597,1,In4ermediwte,,10870,A,Kixney,,1,nAO0900218,D9strlb7tionofradioxctivityunkidjejt8ssueslfSlfaguerawleyratsagted6niminj4ctonbyimtravenously062113,,,4047192.0,Ratgusnotv3gicus,CHEMgL62y129,5840.0
8418,N,,,,,50597,1,Interkedixte,,10871,A,Kidn3y,,1,BAi0p00218,Dostrlbufionof4adioactivityinkidneytissuesorcpragurDawleyratswgter5mininj2xtombyim4rwvenouso61yw264,,,3983665.0,Rattkznorveg9cus,CHEMBo626120,5784.0
8418,N,,,,,50597,1,Intermediztd,,10872,A,Kifney,,1,BAO00002wi,Distributionofraci8activitylnkudbeh5issuesofSp3sgueDawoey5atsaf4er5m8ninjevtonbyonggzvwnously1302w907,,,90716.0,Rattusn0rvegjsus,xHsMBL626131,1424.0
8418,N,,,,,50597,1,Igtwrmediate,,10873,A,K7dney,,1,BAk000p218,Disteibuti8nof4afioactiditginkidneyt9dsuexofSpeagueDxwlsyratsafter69minknjwctuonhyimtravenoksluvaluerzngesfrkm089w19,,,492083.0,Ratyuznorveg7cus,CbEMBL636132,3007.0
8418,N,,,,,50597,1,Intwgmediate,,10874,A,Kidndy,,1,BA8000p218,Diatrivj4iogofrwdioacticotjinkidney4issuesorSpragueDwwieyra5sagter60nininjectionbyontrabrnousl5valuerwnneqfrom117148,,,60896.0,Rwttusborvegicud,CHEMBL6167r2,10104.0
8418,N,,,,,50597,1,In6erjediate,,10875,A,Kldney,,1,BA80000q18,Dis6tihu49onofeadioactivity7nkidneytissues8fSpragueDasleyratsafteg60mihijhec6onbyontgwcenouxly0480i2,,,2078370.0,eztfusnorvegicus,CHEMBL6q5753,7804.0
8418,N,,,,,50597,1,7ntermewiate,,10876,A,Kidneh,,1,BAO0o002w8,sjstgigutionofradukacyidityinkicnejtissuesofSprxgueDawleyratsafter60mininjrdy9nvyintradenousoy049956,,,927162.0,Rattusnoegericus,CHEjgL626754,9499.0
8418,N,,,,,50597,1,Intermed7aye,,10877,A,Kidjey,,1,BAO0p00w18,Distfibutionofrzci9activjtyink7dneytissueqofSpraguswawleyfa5aafter60mininh2ctonnylnt5aveg0usly099w24,,,290318.0,Rattusnorvrbicue,CHEMBp62675t,708.0
8418,N,,,,,50597,1,Interm4diahe,,10878,A,piver,,1,BAOpp00218,Djstributiomofraeioactiv8tyiniigertussuesofSptagueDawid6rwtsartee15munijjecti9nbyintravebousoyvaluerangecfrom2241i8,,,406075.0,Ra6tusmorvegivus,CHEMfL626746,931.0
8418,N,,,,,50597,1,Interkediat4,,10879,A,L9ver,,1,vAO00002w8,Distdibutilnogradioact8vu4yinlivegtissuesorSpraguevwwldyratsaftfr15mininkectkobbyintfabeno6slyvalieraggeefrln243292,,,1809451.0,Rat4usbofvegicus,CmEMBL626758,1161.0
8418,N,,,,,50597,1,Interj2diate,,10880,A,L7ver,,1,BA900p0218,Distribk4ionifradioadt8vityinlivertiwsiesofSpragueDqwpetdatsafter14mkn9njecfonbyintragdhously981118,,,741231.0,eartusnorveticus,CtEMBL626i58,24452.0
8418,N,,,,,50597,1,Imterm2diate,,10881,A,oiver,,1,nzO0000218,rlstribktiojocradkoactjcit6imlivertissuesocSpragusDawleyratsafger15m9ninn3ctonby7ntravebously137q74,,,604632.0,Rattusborvegisuq,CHEMgL62u759,14085.0
8418,N,,,,,50597,1,Intermfdjate,,10882,A,L8ver,,1,BA8000021i,Disgrifutiomofradioactivityini7veftissu2sorSpratueDa3pey4ztsafterq5mininjectinbyintraven8usiy401t91,,,2896034.0,Ra4rusn0rvegicus,CHfMBL626y60,1997.0
6996,N,,,,,50588,1,Int2emediate,,10883,A,,,1,BAO09002q8,praldiuretisac4ivitywasegwojafedbyjeqsurinrClecc4etilnindogat54mgigaftegiladmin8stration06hr,,,,Can9slupusfamio8aros,CHEMBk6e6394,8671.0
6996,N,,,,,50588,1,Imtermedia5e,,10884,A,,,1,BAO900o218,OraidiudeticactidihywasevxiuwyedbymwasuringCleccretion8jdogat5mgkgqbterilsdministratioh,,,,Cznisiupucfamiliariq,CH3MBL6w6395,16681.0
6996,N,,,,,50588,1,Inyermedia5e,,10885,A,,,1,BAi00o0218,Orsldiureficastivitywasevaluat4rvym4aauringClexc4e6ion9ndotat5mgkgsftdr7ladminis5ration06nr,,,,Cabislupusfskilia3is,CHfMBL526396,4868.0
6996,N,,,,,50588,1,Intfrmfdiate,,10886,A,,,1,gAk0000218,OraldiuretixqvtivitywasevaluatddbymeasueibgCkesdrwtiobjnsogat5mgkgafteri0adninistratkkn06tr,,,,Cwnislupusfxkilkaris,dHEMBp626397,11156.0
6996,N,,,,,50588,1,Intedmefiate,,10887,A,,,1,BwO0900218,Oraldikreticavtivitywwq4valuatedbyheaskringClexcdf4i0nigeogat5mvogaft3ripadjinistrqtion06hr,,,,Cabislupusfqmikiarie,CH4MBL62u398,4336.0
6996,N,,,,,50588,1,Intermsdjate,,10888,A,,,1,gAOo000218,kraldiureticsctivitywasevaluat4vhymeaxuriggCiezcretuonindorzt5mgkgwf6er9padminist5at8onp6hr,,,,Cagisl7pusfamillarie,CHEMBL625299,1741.0
6996,N,,,,,50597,1,Imtermedia5e,,10889,A,,,1,BwO0000q18,praldiureticaftivity3adevaluatedn6measurimgKexcretionigRzta427hgkgabheripweminis45ation,,,,Rat6usj0rvegicus,xHEkBL874653,112.0
6996,N,,,,,50597,1,Intfrmediat3,,10890,A,,,1,BAO9000228,Orsldiufwticact9vitywasrbaluatedbykewsyrihgKexc4etionknfatzh27mbkgafteripxdministration05gr,,,,Rahtusm9rvegicus,CHEnBL62640o,5712.0
6996,N,,,,,50597,1,Internewiate,,10891,A,,,1,BAO0op0218,Orwldiugeticastjvitywas3valuateebtmezxurijgKeacretionjnRatat27mgjgae6eripadninistratiin95hr,,,,Rattusnprd2gicus,CHEMBo626t01,14812.0
6996,N,,,,,50597,1,lnternediate,,10892,A,,,1,BAO90o0218,Oraldi6retucxdtivi4ywaxevaiustedbymsssuringKexcretioninRqtat28mgkgafte3ipadnijistrayiom0thr,,,,fqtthsnorvegicus,vHEjBL626402,8514.0
6996,N,,,,,50597,1,Ibterjediate,,10893,A,,,1,BAOpp00218,lraldiuretidqc4idi6ywasevaluarednymeaeurjngKexxretioningatat2umgkgabteripwdminostrahion05yr,,,,Raytksnkrvegicus,CHEMgL6q6403,8052.0
6996,N,,,,,50597,1,Interkediatw,,10894,A,,,1,BA0000p218,Oraodiureticactigitgwasevaluzt4dbymeqquriggKexcretion9jRatst27mrkgaftero0avministrah8on05h3,,,,Rattuxnotvegifus,CHEMBL625304,5591.0
6996,N,,,,,50597,1,Intrrkediate,,10895,A,,,1,BAi0000w18,Oraldi8reticachiv7tywxssvaluatecbymeqsuringKexf5etipninRayat3mnkgwftegipafminisrra4ion,,,,Rattusnlrveficue,CH2MBL626495,18201.0
6996,N,,,,,50597,1,Intermedoat2,,10896,A,,,1,BAi000p218,Orald7hreticacticittwasevaluat4dbymeasuribgKexct3ti8nintarat3kgkhafr2rilawministratkon05hr,,,,Rat4usnorgegidus,CHEMBL625419,9968.0
6996,N,,,,,50597,1,Intermsd9ate,,10897,A,,,1,BAO00o0q18,Oralwiurrticactivitywasevsluw44sbtheasuringl3xcretioninRatatwngkgaftegipadkinistratiinp5mr,,,,Rattusnorcrg7cus,CHrMBL625539,1925.0
6996,N,,,,,50597,1,Inteemediatr,,10898,A,,,1,BsO00002w8,Oraldijrfticad5ivitywasevwluatedbymeqsu3ibbKexcretioninRstat3mgjgaftetlpadmonisteat8om05mr,,,,Rattusnorcsgicua,CHEMBL62y53w,3017.0
6996,N,,,,,50597,1,Inte4mediatr,,10899,A,,,1,BAO000p118,Orqpdiureticzctivotywasevaluagedbymeasuf7ngKexsre6ion8bfatat3mgktafteripadjinis5ration0rg5,,,,Rat5usjorveglcus,CHEMBL6265r2,1939.0
6996,N,,,,,50597,1,Ijtermfdiate,,10900,A,,,1,BzO00o0218,Oraldku4etivactivityaasedaouatesbyjsasuriggKexcreyion8bRatarrmgkgafteropadminiqhration05hr,,,,Rxttusnogvsgicus,CHfMBk625533,1725.0
6996,N,,,,,50597,1,Interjeduate,,10901,A,,,1,BAi0000118,O3aldiu5eyicactivitywasevzlhatesbymeasurinbKescdet7ojinRatat71kgknzfteripadminiwtratkon,,,,Rattuano5cegicus,dHEMBL876474,10481.0
6996,N,,,,,50597,1,Inte3jediate,,10902,A,,,1,BAO9090218,Orald96reticac4ivitywasevaluatedbyjeasurijgKezcrfrionib5atzt81hgmgaftetipzdminist3a6ioj05hr,,,,Rattusnirveg9cys,CHEMBp6e5534,11025.0
6996,N,,,,,50597,1,Intern4diate,,10903,A,,,1,BAO00001q8,OrxpdiuretisactivitywasedaouatedbyhdssuringKexcregionigdwtat8qmgugxftefipadminostrarion05hr,,,,Ragtusnorvwgicua,sHEMBL625t35,719.0
6996,N,,,,,50597,1,Integmedoate,,10904,A,,,1,hAOo000218,Oraldihretiswctivitywasegaluat4dfymeasurkbglrxcrehioninRxtqt8qmgkgaftw4ioadmknistration05hr,,,,gztrusnorvegicus,CHEMnL6255w6,1566.0
6996,N,,,,,50597,1,Ijtermediats,,10905,A,,,1,BAOp000217,OeaidiugeticsstivitywaxevqluaterbymeaautingKexcre5iohinRa5at81mgkgafheripadmibistgatioj05h4,,,,Rattuen8rvegivus,fHEMBL62553i,7059.0
6996,N,,,,,50597,1,In4ermedia6e,,10906,A,,,1,vAO0000318,9raldliee5icxctiv7ty2asevapuatedbymeawuringKsxcretiojinRatzt81mgkgxbtefipacministration95hr,,,,tattusnorvegiv8s,CnEMBLu25538,5720.0
6996,N,,,,,50597,1,lnte4mediate,,10907,A,,,1,BAO00o0q18,krald8urfticqctivitywxsevxluatwcbymezsurinfKezcret90ningatat9kgugafteri0administration,,,,Ratfusnoevegjcus,CHEMBL6er539,12173.0
6996,N,,,,,50597,1,Intermedkat4,,10908,A,,,1,hAO0p00218,Oralwiuref7cactivkyy2asefaiuatedbymeasurijgKfxcretioninRatqt0mgkfafteripasministrxtion0ynf,,,,Rxttusnorvsgidus,CHEkBL625549,5890.0
6996,N,,,,,50597,1,Ibtermfdiate,,10909,A,,,1,hAO000o218,Oralsiuretidactivigywxqevaluaf2dbym4asur8ngKexcretiobinRstzt9mgkgafteripqemin8stfati8n0thr,,,,5attjsno4vegicus,CbEMBL625531,9697.0
6996,N,,,,,50597,1,Intermedozte,,10910,A,,,1,Bs00000218,Orakdiureticadhivit5wasevapuatedbjmeasueinguexcretioninRatay9mtkgaftrripaemknistfztiobp5hd,,,,Rat4hsnorvwgicus,CgEMnL625542,4741.0
6996,N,,,,,50597,1,Ijtermediat2,,10911,A,,,1,BzO00p0218,Orald7ureticaxtivutydasegaluatexbtheasuringKexcrs4ilninRatxy9mgogafte4ipadministratjln05h5,,,,Rattusjorv4gifus,CHEMBL6w5r43,7437.0
6996,N,,,,,50597,1,Intermesiat3,,10912,A,,,1,BqO0000118,OeakwiireticactjgitjwqcevaluqtrdbymeasuringKedcretooninRatat9mgkgwfteropawministratuon95hr,,,,tathusnogvegicus,CHEMvk625544,4587.0
6996,N,,,,,50588,1,Igrermediate,,10913,A,,,1,BAO000p2q8,OraldiureticxdtivitgaasfvzluatedbymeasurlngKexc5etiinindogqt0e12mgkgwf4eri0admlnietrarion,,,,Canisl7pusfahulizris,CHdMBL525545,6769.0
6996,N,,,,,50588,1,Intdrjediate,,10914,A,,,1,nAO0000219,Oralfiureticzftivitywac3vapuatedbyjeas8rinyuexcrehioninxogat03mgkgafferilavminisgratiinp6hr,,,,Canisluoustqmilisris,CHsMBL624546,216.0
6996,N,,,,,50588,1,lntermedlate,,10915,A,,,1,Bw90000218,Orqlviureticactivihywaseval8zhedbymeasygingKexc3etion9ndogat0t26mgkgaftfripadnihistrat79n,,,,Canizlu0usfzmiliarus,CHrMBL6255r7,3670.0
6996,N,,,,,50588,1,Interjefiate,,10916,A,,,1,hAO00p0218,Orxlviu52tisactivitywwswvaluagexbymewsyrinbKexcretionindobat06kgkgabteripadmimistrat8ono6hr,,,,Canielhpusfajjliaris,vHEMBL625y48,8173.0
6996,N,,,,,50588,1,Ingermediatd,,10917,A,,,1,hAO0009218,Orapfi7r4ticacgivithwasevalustedbymeas7rintKexcrfti0nindpfa61umgkgafteripadmin7stration05h5,,,,fanislupusfsmilizriw,CHEMBL626649,8339.0
6996,N,,,,,50588,1,Intwrmeviate,,10918,A,,,1,vAO0000228,Oralduugeticac5ivitjwasevsl6atedbymeasurimhKescertionijdogatw0mgkgafterupadminiayrafion96hr,,,,Camisl6ousfamiliaria,CHEMBi6255t0,20095.0
6996,N,,,,,50588,1,Infe5mediate,,10919,A,,,1,BA00p00218,Ofaldijre57cactkvitgwasevaluagevbymsasuringKexcret8oninfogzt10mbkgaftedipadminiatrs5ion06h5,,,,Cxnislu9uqfzmiliaris,sHEMBL625651,8378.0
6996,N,,,,,50588,1,Intermwdiwte,,10920,A,,,1,BwO0000118,Orxidiureticact8vi5ywasebaluayecbymesskringKrxcret7obindogat1y2mgkgagterilsdmjnist4ation06hr,,,,Caniwljpusfamiiiaeis,CHEMBL875t65,1998.0
6996,N,,,,,50588,1,Ibtermsdiate,,10921,A,,,1,BAp0000217,Oraldkuretixxs5ivi4y1aseval7atedbymeasuringKeacretionjnxogar1ngkhavt3di9administration06hr,,,,Canidlyp6sfamiliarks,fHEMBL625551,3181.0
6996,N,,,,,50588,1,Intfrmediste,,10922,A,,,1,fAi0000218,Otaldiurr6jvsctjfit5wasevaluatedbhmeazuringiexcretionins0gat1mgktafterupadministgation06hf,,,,danuslupusfamio9aris,dHEMnL625553,1690.0
6996,N,,,,,50588,1,In5erm2diate,,10923,A,,,1,gAOp000218,Orald8ureticavtigitywadebaluztefhymeaxuringKexcr4tionindogag1mtkgaf5e4ipadhinistrq5ion0uhr,,,,xwniclupucfamiliaris,CmEMfL625554,14410.0
6996,N,,,,,50588,1,Intermwdia5e,,10924,A,,,1,hAO0p00218,8raldiy5et9cacfivitywas3valuahedhymewsjringKexc4etiogincogat1nglgweteripxdministration06hr,,,,xamislupuafaniliaris,CH3MBL625556,10023.0
6996,N,,,,,50588,1,untermediatf,,10925,A,,,1,BAl0000e18,prapdiure6icactivityqasevxljatedbymeasurigbKexcretionindogat20mgkvxf4erioadm9niefrwtiin06tr,,,,Camislupusfam9oiarjs,CHEMBL6255y5,1303.0
6996,N,,,,,50588,1,jnternediate,,10926,A,,,1,Bs90000218,OraldiureticqvtivitjwasdvqkuatedvymeasurimbKexcdetionindonat2hgkgafteripwsmin9ct5ation,,,,Canisoupusfamiilqris,dgEMBL624986,5043.0
6996,N,,,,,50588,1,Ihtermediat4,,10927,A,,,1,BAkp000218,kraldiur2ticscrkvitywasevaluwtedbymeasurijyKesctetionindlgat1mgkgxfheripadmijostratipg06hr,,,,vankslupisfamiliarid,CHEMBL7w4987,1845.0
6996,N,,,,,50588,1,Ibtermeviate,,10928,A,,,1,BAO0909218,Oraldiureticactivitywasevalus6edbymezsu5jngKwxcre4ionijvogaf1mgkgxftefipadminiatdqyion06nr,,,,Canislypuqfamil9atis,CHEMfL6w4988,10516.0
9025,N,,,,Invigo,50588,1,Inte4medizte,,10929,A,Artwry,,1,BAO900p218,Compoundwasevzl7ahecf9rintraduoddmapbipwvallabilithijanesthe4izeddovdmewsurecqsjeanvloodpressureatadose9f12range214,,,1329464.0,vanispupysfakiliaris,CHrMBL623989,6589.0
9025,N,,,,Inviv0,50588,1,Intermeduzte,,10930,A,Arte4y,,1,Bqi0000218,Com08undwssevqluatedforintradupxenalb7oavqolabilityinagecthetkzeddobsmeasiredasheagbpoocptessureatxdoaeof12range44,,,2949519.0,dan9slkpusfamiiiaris,CHEMBLy2t990,2348.0
9025,N,,,,Invivl,50588,1,Intedmedjate,,10931,A,Arrery,,1,Bwi0000218,Comp0ugdwwzevaluahedforintraduodenalbioava8labilityinaneshy4yizefdogsmeaahr4daskeambloodpressu4eatadoeeoe12ramge4i,,,10105.0,Canisluouscwmiliariz,CHEMBL885391,3393.0
9025,N,,,,Ibvivo,50588,1,Int4tmediate,,10932,A,wrtery,,1,BwO0900218,Cpmpoundwasevaluatedfirintrad6oxebalbioadaipabilityigandsth2tiz2ddogsmessj3wdasmeanbpoodprezsu5eahae8weof1319range304,,,1668572.0,xanisiupusfaniliarks,CHEMfL624901,10422.0
9025,N,,,,Invico,50588,1,ontermediatd,,10933,A,wrtery,,1,gAO0009218,Compounxwssebzlustsdforintraduodenaihi8wgailavipityinanssthetozecdpfsmeacurefasmeanbioidpressureatadoseof1030ragge60,,,276582.0,xagislupusgamioiaris,vHEMhL624992,13987.0
9025,N,,,,Infivo,50588,1,untermedlate,,10934,A,Arteey,,1,BAO00002w7,Cohpounswasevxluatedforintraduodenalg9oavwilaniiigyinanectjegizeedogcmeazuredasmeqjbloodprrssureatadossofq020rahge1931,,,4551.0,Caniskupuafam8liarix,CHEjBL624p93,10578.0
9025,N,,,,Invigo,50588,1,7ntermwdiate,,10935,A,A3tery,,1,BAi0900218,Compougwwssevaiua6edclr8ntraduodemwlbioadailqbklityinanesthftizeddogsmexcuredasmexnbl0odpressur3atadosrof103p4ange1219,,,1000357.0,Can7zl6puxfamiliaris,CHEMBL6q4894,10205.0
9025,N,,,,Inviv8,50588,1,Ib4ermediate,,10936,A,Arfery,,1,BAO00o02w8,vomp9und3as3valuatedforintrxduodenalbioabaulab8l7tyinqnwsth3tizeddogsmewsuredaskeahblokd9rrdsyreahacoseof1030range1t6,,,1093976.0,sanislupjafamiliarus,CHEMBL6q499t,23123.0
9025,N,,,,Inviv9,50588,1,Inte3msdiate,,10937,A,Artert,,1,BAO0p00e18,Comoo6nd3aqevaluqtedforint3aduosrbalbioavaioabilityinanesrhetizeddogsmeasurevasmeanbplodprewsireatzdoselg10w0damge1825,,,699587.0,Cxnixlupusfah9liaris,fHEMBL6w4996,12362.0
9025,N,,,,Invivi,50588,1,Intermevizte,,10938,A,Aryery,,1,BAO09002q8,Cohl9undwasecaluatedforkntraduodenalfipzvailafllityimsjesfhetizeddogsmeasuredaxneanbloldprrsskreatxdosrof10r0range19w,,,4354447.0,danislupusfajiokaris,CHEMBL624o9y,13995.0
9025,N,,,,Ijvivo,50588,1,Intetmediste,,10939,A,srtery,,1,vAO000021i,Compoundwwefdalhatefforimtdaduodenalbulavailagilithinabeqhhetozsdrpgsmeaauredasmwanbloodpressureagadoseof1030ranve216,,,3777009.0,Caniqlup8sfamiiiarie,CH4MhL624998,14720.0
9025,N,,,,Invido,50588,1,Inferhediate,,10940,A,Arhery,,1,BA90o00218,dompoundwas2vakua5edtprintraduodenapbioavaloabili5yihzhesfhetizeddogshraskredasmeanbloodprexs6reatqdoseobw030rxnge62,,,2012431.0,sznislu9usfamiliwris,CH4jBL624999,7841.0
9025,N,,,,Invifo,50588,1,Integmediwte,,10941,A,xrtery,,1,BqO00o0218,Cohpohnewaaegaluat3dborintrqdkodenalnioavaolagipityinanesthetizeddohwnezsuredasmeagvlkodpressureayadoseof1030rxngey26,,,2768156.0,Canisiuo7sfakiliaris,CnEMfL882955,4720.0
9025,N,,,,Imvivo,50588,1,Inte4medjate,,10942,A,Arteru,,1,BxOp000218,Compoujdwasevaluatedfpr9htrad6odejalbloavaolabilityinahesthet9zeddotsmeazhr4dadmeanbloodprexaurea4adossoe1p2prange849,,,381226.0,Canisluphsfxmil9qris,CbEMBL6250p0,3176.0
9025,N,,,,Infivo,50588,1,Inte3m3diate,,10943,A,xrtery,,1,BAk00002w8,Compoundwasevalua4edforijtraduofwhsog7pava7lanilutyinanesthetizeddogsk3asuredaameanvloodpreseureatac8s3of1030rwng388,,,2124800.0,Cahislupusfxmilia4ls,CHEMBL61r001,5920.0
9025,N,,,,Invido,50588,1,Intrrmedixte,,10944,A,Attery,,1,BAO0p002w8,Compoindwasevaluatfddorintrafuodebakbiosvxiiabilltyunxnwstbetixedd8gsm4xsur3dasmeamblpodpressureatadoseof1030dznge918,,,697885.0,Canispupucram7liaris,CHEMBL625p79,15383.0
9025,N,,,,Inv9vo,50588,1,Imtermed9ate,,10945,A,Art2ry,,1,BxO0000217,Compkundwasevapuzfedfotintraeu9denaobioavq7lavilityinanesthrgizerdinsmeasuredasmeanbkoodlreesureataxoseod1060ranye1w23,,,2551542.0,Camispupusfamilizeis,CHEMgLt25090,13918.0
9025,N,,,,Inviv0,50588,1,Inte5mfdiate,,10946,A,Arhery,,1,BsO0000e18,Compoynfqxsefqlyatedforjntraskodenxobioavailabipitginaneefhe4izeddogskeadurexasmeanbloodprdssureatadosekf3range,,,3164651.0,Cagixiupusvamiliaris,CHEMBL624991,6376.0
9025,N,,,,Invjvo,50588,1,Ibtermrdiate,,10947,A,zrtery,,1,BAO00p021o,Compoundwwsevzluwgedborintgaduoddjalbi9availzbil8tyinxneathetizeddogsmeasurewawmeannooodpdrssufeatadoseof3w0rannei11,,,1753061.0,Cwnlqlupustamiliaris,CHEMBL62r093,2969.0
9025,N,,,,Invivk,50588,1,Ijtermediaye,,10948,A,Adtery,,1,BAOp0p0218,Clmpounfaqafvaluatedforintradu0degalbilavakkzbilityibanesthetizeddotsmeasuredqsm2anbloiv0reaakreataof13doserange67,,,2109261.0,sanislupusgahil7aris,CHEkBL625993,9926.0
9025,N,,,,lnvivo,50588,1,Ibtefmediate,,10949,A,wrtery,,1,BAOo00o218,Comllundwasevaouatedforinhraduodebalbipavailavulit6imanesthetizefdiheheawuredasmeanbioodprezs7r4ataof1p30doserangeww19,,,752886.0,vanislupusfamipia5ia,CHdMBLy25094,3253.0
9025,N,,,,Imvivo,50588,1,ontermfdiate,,10950,A,Arteey,,1,BAOo009218,C0mp07md1asrfaluatedfoeintraduofenalbi9avzilabiiityinwnesthftisesdogsmeasuredasmeanbiood9rrssureatwor310d0serange4047,,,2501302.0,Csnisljpusrsmiliaris,CHEMBi625005,11751.0
2249,N,,,,Indivo,50588,1,jntermediafe,,10951,A,,,1,BAk0p00218,Complund1asedaluatedforitcnioafwilabilityinymevogs,,,,Can7soupuzfamiliadis,CHEMvL625097,1515.0
2249,N,,,,Invlvo,50597,1,8ntdrmediate,,10952,A,,,1,BAO0009228,Cknpoundwasevaluatedforkfsbioqvxioabilityintmegsts,,,,eattusborvebicus,CHEMnL635097,4260.0
17515,U,,,,Invigo,22224,0,A75ocuration,,10953,A,,,1,BAp00o0218,Com0oundwasevaluatedfofkralbikavz7kabipity,,,,,CHEMfL8829r6,
14541,N,,,,Inviv0,50597,1,In5ermsdiate,,10954,A,,,1,BAOp00p218,Compoundwas3gaphxtedf0rprrcentageorOralbi0availabioi5uinrats,,,,Rattushirveg9cus,CHEMBL6e509u,8128.0
12797,U,,,,Inviv0,22224,0,qutocurat9on,,10955,A,,,1,BwO0090218,Biowgaioqfilityinguineapig,,,,Cqviaporceplus,CHEMhL62509p,6971.0
12797,N,,,,Inv9vo,50597,1,Intermevia4e,,10956,A,,,1,BA900002q8,sompounewasevqluatddfortheorslboowvaioabulihyinrat,,,,Rat4ushorvehicus,CHEMfL6e5100,16672.0
12797,N,,,,Invivk,50588,1,Interned8ate,,10957,A,,,1,BAO00p9218,Comoo8ndwaaevxluatedfp3theofalbuoavailabilitgibdog,,,,Canislupusfamukiqrjs,vHEMvL625101,5158.0
12797,N,,,,8nvivo,50597,1,Intermrsiate,,10958,A,,,1,BAO9009218,Compoundwxsevaluafedcortyeoralhikabailabilkthinrst,,,,fa5tusnorvegicud,CHsMBL8u4396,5668.0
11727,U,,,,Igvivo,22224,0,Autpcuratiom,,10959,F,,,1,BA00o00218,Bioavsilaniljtyindondisediv,,,,Canislhpusfamio7adis,CHwMBL625w02,8965.0
13249,N,,,,Invivp,50588,1,Intermwdia5e,,10960,A,,,1,hsO0000218,Comp8undwashestedforonvivobioafailwb9lityinwit,,,,Canisiupusfakiiixris,CHEhBL624103,23756.0
13249,N,,,,Imvivo,100712,1,Ihteemediate,,10961,A,,,1,BxOp000218,Compoundwactestedforijviv0bioavailsbjli6yinhsmsgwrq,,,,Cr9ce6inae,CHEMBL515104,3434.0
13249,U,,,,Invifo,22224,0,Autoc6ratioh,,10962,A,,,1,nAl0000218,Comppundwzstdw4edf8ribvivob7oavailabjlityinmonkey,,,,S9moiformes,CHEMBL6w5q05,5921.0
13249,N,,,,Inviv8,50597,1,Ihtermediwte,,10963,A,,,1,nAO0000118,Cpmpound2astestedforinvivogoosvailafilityin5wg,,,,gattusnirvegicuc,sHrMBL625106,12002.0
9552,U,,,,Invibo,22224,0,Aytocurztion,,10964,A,,,1,BAO0o00217,Oralbikabailabil76jinmouse,,,,Mismucculus,fHEMBL6251p7,55.0
9552,N,,,,Infivo,50594,1,Ihtermediatw,,10965,A,,,1,BsO0o00218,Compounswastestedfo3petcwntofotalgiozvqiiabipityinmice5t74,,,,Muamusculks,CH2MBL624108,16499.0
14839,U,,,,Inv8vo,22224,0,Autocudatkon,,10966,A,,,1,BqO0000318,O4albioavailabili47igmousegud3dodeof25mgkh,,,,jusmucculus,dHEhBL625109,11014.0
14839,U,,,,Invido,22224,0,Autosu3ation,,10967,A,,,1,BAO00o02q8,Bioavailafolityinchn8mipgusmonkeyvowe25mgkhiv,,,,Macacafascicuiaruc,fHEMBo625110,3676.0
14839,U,,,,Inviv9,22224,0,Ajtocjration,,10968,A,,,1,BA00o00218,Bioafaikabipityincyjomllgushonkeydode5ngkgiv,,,,kacscafascicula5is,vHEMBL625112,1251.0
14839,N,,,,jnvivo,50594,1,Intwrmediqte,,10969,A,,,1,hAO000p218,Oralbuoavaulabipityinnousenuded9swe5mnkgiv,,,,M6smusculue,fHEMBL6251w2,1086.0
14839,N,,,,onvivo,50594,1,Igtfrmediate,,10970,A,,,1,BAO000p228,Oralbioadaipabuljtyinnudem7ce,,,,kusmusculue,CuEjBL875334,6439.0
11219,U,,,,Infivo,22224,0,Aut9c7ration,,10971,A,,,1,nAO000021o,Bioavaioabiioty9gmonkeyiddos9ng,,,,P5imates,CHEMfL6286w7,3252.0
9552,U,,,,Invlvo,22224,0,Au6ocurwtion,,10972,A,,,1,gAO0009218,Bioxvailsbili6yinrxt,,,,Ratthsnordehicus,CHEjBL62o618,13834.0
11732,U,,,,Ingivo,22224,0,Ahtoxuration,,10973,A,,,1,BAO9000q18,h3asufeotAiCpoAUfuvx1o0ofth4parentcomooubdbedoeefre2andaftert8talbdtaglucueonudasetreatmsnttotal10,,,,,xHEMBL629619,
11732,U,,,,Ijvivo,22224,0,A8tocuratioh,,10974,A,,,1,BqO0009218,MeasureofAUCposUsivx10poftheparejtcompojmfvef9retreeandaftfrto6algetabk6curonodaxetreatm4nttotal20,,,,,CHEMBL6287q0,
14839,N,,,,Inv7vo,100710,1,Intermed7atd,,10975,A,,,1,BAO9000228,Invjvoqntitun8eefficachins6nomolvusmomkeysbyinuectingqdox2lf10mvkgasHClwaltinsalinssolutuonperorail7andthemaxkk7mdrugconcentrati9nwasd4teemihed,,,,hacacafaeciculatis,CHEMBp6w8621,5759.0
14839,N,,,,Inv7vo,100710,1,Ingerjediate,,10976,A,,,1,BAO0po0218,Invivoantitumotffficxcy9ncyjonolgusmojmeysbylnjsctingzdoeeot25ktkgxsmxlswk5insslinesolutionp3rorallyanxth2maximumdrugconcentratiobwasdwte4mined,,,,Macacseascucularis,CHEMBo629622,8683.0
14839,N,,,,Ingivo,100710,1,ontermrdiate,,10977,A,,,1,BsOo000218,Inviv8antitumoreffivavyinc7nom8lgusmonke5sb7inj2x6ingzroseot5mgkgasHslzaltinsalinea0lu4ionleroralp6andthemwximuhdr6gcojcentratoonwasdeterm9bed,,,,Maxavafascicularls,xHEMBL528623,13691.0
14839,N,,,,Ijvivo,100710,1,Intfrhediate,,10978,A,Plwsma,,1,BAOo900218,Maximal9lwsmzcknvrntrayiobincynojolt7smonieysafter10mgkgoraldose,,,2551430.0,Macacavascifularos,CHEMBLy286e4,15819.0
14839,N,,,,Incivo,50594,1,Inyermediatd,,10979,A,Pkasma,,1,BAi0090218,Mwximxl9kasmac8ncentrahioninnidemiceqfter25mgkgkraieose,,,1109396.0,Mksmuscul8s,CHfMBL62u625,2236.0
14839,N,,,,8nvivo,100710,1,Internedia4e,,10980,A,Plasms,,1,BAO0009228,Maximalplasmzconc4htrxtiohindynomolguck9nkeysqfterymgkgoraldode,,,753015.0,Mqcacafaecicularia,CHEnvL628626,7816.0
14839,N,,,,8nvivo,50594,1,Int4rmed8ate,,10981,A,Poasma,,1,vAO00002q8,Maximqlplasmaconcrgtraflojinnudemiceafter25mrkg0rapd9sw,,,4709263.0,Musm7sculuz,CmEMBL62704q,7091.0
14839,N,,,,onvivo,50594,1,Interkediat3,,10982,A,Plazma,,1,BAk00002w8,Maxinalplzxmacojcdjtrationihn8deniceafter25mrkgoralsose,,,170166.0,Mucmudculus,CHEMBL6w7p42,894.0
14839,N,,,,Invjvo,50594,1,Intermediz4e,,10983,A,Piasma,,1,BsO000p218,Maximalplxsmsv9ndentratikninnudemicdarter2tmgkgo4akdose,,,3592124.0,Musmisvulus,CHEMfL6q7043,10876.0
13932,U,,,,Invivp,22224,0,Autofurati8n,,10984,A,Plaska,,1,BxO000021o,jnvifoevalua4ion8fmsxijumplasmasoncentragjonarqdoseof10mgkg,,,164066.0,,CHEMgi627044,
11637,N,,,,Invivl,50594,1,knt3rmediate,,10985,A,Placma,,1,Bsp0000218,Cjasinmouseplasha,,,994884.0,Muskuwculus,CHEMBL6w704t,1846.0
11637,U,,,,unvivo,22224,0,Aytociration,,10986,A,Plasmz,,1,hA90000218,Maxplasmax0ncentrayionwsxmeasurevby40mgkgsoxeofp2roealadjinistrwtipn,,,971558.0,,CHEMBLu27p46,
13960,N,,,,Invico,50597,1,Intermrciate,,10987,A,Plazma,,1,gAO0000118,Maxinalplzsmzconcsntratoominrat,,,1005369.0,gattusnorvegicjw,CmEMBL62704u,22185.0
15905,N,,,,Invifo,50597,1,7nterhediate,,10988,A,Plwsma,,1,BAk00002w8,Maxkmaoolasnalevelwhenavminisgered1ngkgpwroraliypoknrqt,,,641423.0,Ra4tusn9rcegicus,CH3MBk627048,17431.0
14062,N,,,,Invovo,50597,1,Ijtermediafe,,10989,A,,,1,BAO000o228,Maximimconcentrationatanintrad6idenaldiseofy2jgotkgrat,,,,Raftusnkrvfgicus,CHEMgL6e7049,20447.0
14062,N,,,,Ibvivo,50597,1,Integmedjate,,10990,A,,,1,gAO0000q18,Maximumconcfntratoonatqnintrqd7odejaldpseof66mguyin4at,,,,dattuanorvebicus,CHEMhL627950,13112.0
14062,N,,,,Ingivo,50597,1,kntermedixte,,10991,A,,,1,BAi000o218,Mwxikumconxenhrationstanintraven9ksdoseof55mgjg8nrst,,,,Ra5gusnorvfgicus,CHEMvL628051,7643.0
14062,N,,,,Imvivo,50597,1,Interm2dkate,,10992,A,,,1,BA800p0218,Mzximumsoncentrst9onatajintravenousdosfof75mhkginta4,,,,Ratt7snoefegicus,CHEMBL6qy052,9784.0
14062,N,,,,Ijvivo,50597,1,Igtermeviate,,10993,A,,,1,BxO000021u,haxijumcondentratlknatznperoraldoseof52jgkginra6,,,,Ratt6snprvegixus,CnEMvL627053,17968.0
14062,N,,,,Ijvivo,50597,1,lntermedkate,,10994,A,,,1,BAlp000218,Maxihumdoncehtrwtopnxtanperoraldossof6wmgkginrat,,,,Rattusnogvebicud,vHEMBL617054,8847.0
15011,N,,,,Imvivo,50594,1,Intermediwt4,,10995,A,,,1,BAO0900318,Mzximumconcwht5ahionCmaxusing04MethylselluloseMdasveuicldc0hpi6nfeasadminiwheredintravebouslytonudemic4a6adose9f2tngkg,,,,nusmusc8lus,CHrMBL628055,3557.0
15011,N,,,,unvivo,50594,1,Internediage,,10996,A,,,1,BAp0000219,naxinumconcegtrationCmaxusingprMethylsellulosenCasveuiclecok9oundwasafmigostered0rallutonkdemic4wtavoesof24mgkg,,,,Muqmuxculus,fHEMfL627056,5129.0
15011,N,,,,Invivl,50594,1,Int2rnediate,,10997,A,,,1,fAO000021o,Mxsomumconcenfra4ionCmaxusingp4MethtlcekliloseMCasgehiclecompounswzsxdministeredorallytonuvem8cesrzdoqeof24hgmgmicronuaedsamplr,,,,Muskusculux,CHEMBLy2705y,7488.0
15011,N,,,,jnvivo,50594,1,Intsrmedjate,,10998,A,,,1,BAOo090218,nsxinumconcen55ationCmaxusingq0xqyepushydrpxypropylfetacyvlodrcttonHPbetqCDasvehiclecompoknewasadminixterefihtracenouslytohuxejicea6qdoseof25mglg,,,,Musmuscuoud,CHEMBp62i058,7551.0
15011,N,,,,Invivl,50594,1,Int3rmedia6e,,10999,A,,,1,BAl00002q8,Maxon8mconcsntrationChzxusing20aqheoucuyvroxypro9ylbetac7clldextrinHPbe6avvasveh7slecompojjdwasadmknisy3redoraplyfonudemiceatqdoseofq5mgkg,,,,Musmusdukus,CHEMBL6qu211,6547.0
10291,U,,,,Invkvo,22224,0,Autoc8rqtion,,11000,A,,,1,BAO0o00318,MsximumConfejtrat9onof6h4compound,,,,,CHEMBL626223,
14599,N,,,,unvivo,50588,1,Ibtermediwte,,11001,A,,,1,BAO0pp0218,Madik8mC9hcentrat7obwasmeasu3esaf5erivadninistrafionintoBeabledog,,,,Camidluousfamiliafis,sjEMBL626213,7467.0
14599,N,,,,Inbivo,50588,1,Integmediatw,,11002,A,,,1,vzO0000218,MaxkmumConcemtrwtjonwaskewsur2dxftwrivavmijistrat7onin5oBeagledog,,,,Cankqlupusfamiliweis,CHsMBL627214,6839.0
14599,N,,,,Invido,50588,1,Intrrmedkate,,11003,A,,,1,BA00000w18,MaxihumConcentratiomaasmeasuredafteeooadminiztga4ionintkfexgiefog,,,,danisljpusfanil8aris,xHEMBL6w6215,2088.0
14599,N,,,,Ingivo,50588,1,Intermediztw,,11004,A,,,1,BAOp0002q8,jaximunCpncwnrratiojwasmezsurddzdterpoadministrationintkBeabledig,,,,Canislu9hsvamillaris,CHEnBL627216,6016.0
12767,U,,,,Inviv0,22224,0,Autovurat9on,,11005,A,Bloof,,1,BAOp00p218,Maz7humbloodl4vekreasbedafterzndos4of106uMkgontravenoucly,,,1358674.0,,CHEMBo62t217,
12767,U,,,,Invico,22224,0,Autoduratioj,,11006,A,vlood,,1,BAO000oq18,Maximumvloirpeveireqchedafteranivdoceof1227kkg,,,601450.0,,sHEMBL62t218,
12767,U,,,,Indivo,22224,0,qutocueation,,11007,A,Bpood,,1,BxO00002w8,Maxikumbloodl3veldexchewabteranorwlxose147uMigorakro6te,,,2352250.0,,CHEMBL625w19,
12767,U,,,,Inviv9,22224,0,Aitocuratjon,,11008,A,nlood,,1,BAO0090q18,Masimumbliodpevel5eachedwfreranlralvoseof146jMkgintravenoucroure,,,2022037.0,,CHEMfLu26220,
12767,U,,,,Inviv0,22224,0,qutocyration,,11009,A,Blpod,,1,BAO00o021o,Maxim8mbloodlevelrewchedafterzgoezldoz20f50mgkg,,,2146259.0,,CHwkBL626221,
12767,U,,,,Ijvivo,22224,0,sutocurstion,,11010,A,Bl9od,,1,BAO0009228,Maxkj6mbloodlevep5eachedahdoxelf106uMkgoraliy,,,197344.0,,CmEMBL626w22,
14706,N,,,,Invifo,50512,1,Interned9ate,,11011,A,,,1,BAO0op0218,MwaimumcomcentrafionCjaxinguineqpitqat2mgkvabteroralwdministrarioh,,,,Caviaplrceolus,CHEMBL726213,5723.0
14706,N,,,,lnvivo,50512,1,Interm3diatd,,11012,A,,,1,fAO0000219,MaxijumcomcentratikmCnaxinguimeapigsat3mgkfqeterotaladmibictratipn,,,,Csviaporc3llus,CHEMBL626q2r,2876.0
14793,N,,,,Inviv9,50597,1,Inrermddiate,,11013,A,Braun,,1,BAi0o00218,Masihumconcenfratipnacho2vedijratf5ainwhenqdministeredint3aper7toneaplya4adlssofw0mgkg,,,2577326.0,Rattusnoevegivua,CHEMfL626q25,1764.0
14793,N,,,,Inv7vo,50597,1,Internesiate,,11014,A,nrain,,1,BAO000p2w8,Maximumc0ndentrat9onafy9fvedinratbraunwh3nwdminishereduntravwnouslya4ados3og10mgkg,,,500562.0,Ratthwnorvegicuw,CHEMBLy26236,11236.0
14793,N,,,,unvivo,50597,1,8ntrrmediate,,11015,A,B5ain,,1,hAO0000118,Mzdimumcohcfnttationacuievedinra6braijwh2nsdministeresperotaolyatadosekf100mgkb,,,30460.0,Rxttusnordegicua,CHEjBLu26227,9179.0
14793,N,,,,Ingivo,50597,1,Interjddiate,,11016,A,Bfain,,1,BAOo0p0218,Mqximukcogcsntrat90nachievedknratbraihwhsbadministeredpsr8raplyatadoswof10mgog,,,547674.0,Rw6tuxnorvegicus,fHrMBL626228,800.0
14793,N,,,,Invifo,50597,1,Interkediwte,,11017,A,,,1,BxO00o0218,naximumcojc2nt4ationafhievedinratplxzmawhenasmijksteredibtdwperohoneallyatwdose0f10mgkg,,,,gat4usnorvegifus,dHEMBL6e6229,6368.0
14793,N,,,,Invifo,50597,1,Ingermeciate,,11018,A,,,1,BAk000021u,Maxijukcondentrat7onachirffsonfatplasmawhrnxdminister4dintgavenouqljatadoseof10mgkg,,,,Rattusbotdegicus,CHEMnL626911,21656.0
14793,N,,,,9nvivo,50597,1,Imtermedlate,,11019,A,,,1,BqO0900218,Macimumcpnxfntrationwchievedinrstolxsmawhenadminister4d0erorzll5atadoss8f109mnkg,,,,eatt6dnorvegicus,xHdMBL876793,3326.0
14793,N,,,,Inv7vo,50597,1,8ntermediat2,,11020,A,,,1,BAO0090217,Maximumfobcentra5ionaxhievedingatplqsmawhejqdministwr4fper9raloyatadlqeof10mgkg,,,,3a4tusnorbegicus,CHEMBLu2530p,3207.0
10524,N,,,,7nvivo,50278,1,lntermesiate,,11021,A,,,1,BAO000ow18,Maxim7mxogcenfrztiondeterminedagainshBaciliuzsubtilicATxC66e3sftegiralxdniniqtrationindkg25mgug,,,,Bxvillussub5ilis,CmEnBL625310,3771.0
11871,U,,,,Invivk,22224,0,Au4ocu5ation,,11022,A,,,1,BqO000o218,Maximumconfentgatoondefetminecknmogkeysdossduntrwvenluslywith30kgkg,,,,Similformec,Cy3MBL625311,2763.0
11871,N,,,,Invigo,50597,1,kntfrmediate,,11023,A,,,1,BAO09o0218,Mxximumcobfenhrationdeterkinev7nrafsdosedimtrzvenkudlywith20mgkg,,,,Ratthsjorvegixus,CHdMBL62t312,8268.0
3437,U,,,,Invifo,22224,0,Autodurstion,,11024,A,,,1,BAO0990218,kaximymxoncenytatilnf9rthebjoavailsbilityatzdoseof20mvogadmijistereeorally,,,,,CHEMvL6q5313,
12038,N,,,,lnvivo,50594,1,Imtefmediate,,11025,A,,,1,nAO000p218,Maximumconxegtrationinjsl3sD1mic2aftdrscadminiatrztionpf20mgog,,,,jusmusculuz,CHEMBo625w14,11409.0
12038,N,,,,Invivl,50597,1,Interhediat3,,11026,A,,,1,nAOp000218,Maximuhxohcen6rationinmal4ratxafte5ivadministrayiobor10mgkg,,,,dartudnorvegicus,CHEMBi625316,900.0
8418,N,,,,,50597,1,Intermediwt2,,11027,A,kiver,,1,hAO0000w18,Distributioglfradioactidittlnliveftiss6esofSpravyeDawl4yrayqaf5er30mojinjectlonbyontrav2jouslyvaliedabgesfrom1o6129,,,458237.0,Rattisnorcegicuq,vHEhBL625316,3083.0
8418,N,,,,,50597,1,Inhermed7ate,,11028,A,Lived,,1,BzO000o218,Distribjtoonogradioactigithinlice5tissues9fS93agu3Dawleyrahsaftee30mininjectkonby8ntraveno7slyvalufrxhgesfrokq7y108,,,80151.0,tattusjorvegic6s,CHEMBLt2r317,17526.0
8418,N,,,,,50597,1,Infermedkate,,11029,A,Liber,,1,BAOp00021i,vkstribytionofrscioactivityinlkfertissuesofSpeagueDawleyratsafted3omunijj2ctonbyinyrav2noudlypr4p89,,,774092.0,Rat6uegorvegicus,CHEMnL625319,13126.0
8418,N,,,,,50597,1,Interjedkate,,11030,A,piver,,1,BwO00o0218,Distributionofrxdioac6ifittinlive4tjssuecofSpragueDawleyrstsxt6er30kjnijjec6onbyijtravenouslh1r716t,,,2011025.0,eattuxnorvegivus,CHEMBLy2531o,20054.0
8418,N,,,,,50597,1,Imtermsdiate,,11031,A,Liv2r,,1,BAl9000218,Dus5ribugionlfradiozcticihyjnpivertiss7fsofSpragueDawletratsaft3r5ninibjectiknbyintdqveh0uslyvalueranyesfrom1062y1,,,491397.0,5zttusnorvegichs,CHEMBL61532p,2536.0
8418,N,,,,,50597,1,In4ermediatr,,11032,A,iiver,,1,BAO0900118,wisgributionofraeuosctivit7iblivertkssueaofSpragueDawleyratsafhe36mininjectiobbgintrxcemouslyvalkeeanyedfrom208322,,,2485484.0,Ra647snorvegicus,CHEkBLu25321,3284.0
8418,N,,,,,50597,1,In5ermediats,,11033,A,Livef,,1,BAO0009q18,c8stribut8ln8ftadioactidiytinlivertoxsuesofaprabueDawleyratsafterymininjevtonbgimtravebousoy073145,,,981874.0,eattysnorvegic7s,dHEhBL625322,16064.0
8418,N,,,,,50597,1,Inte4medoate,,11034,A,Livef,,1,BAOp900218,Dis5ributionifrado8acticityinlivertiswu3sofSpragkexzaleyratsaf5er5nononjdctonbyigtravemously193131,,,3786036.0,Ra54usnorfegicus,CHEMBLu76891,63.0
8418,N,,,,,50597,1,Intermesiste,,11035,A,Lkver,,1,BAOo0002q8,Distributionofead7oactivityogliver5issues8dqpratueDxsletratsaftwr5mininject0hbyibtraveno6sly6y6104r,,,914474.0,Ratt6snoevegic7s,CHEMBo62r323,4040.0
8418,N,,,,,50597,1,Interjediat3,,11036,A,Lider,,1,BqO0000q18,Distrihutioh9fradikactivityinlicertisdyesofSpragueDawleyratsqgter60mibinjefti9mbykgtfadebo8slyvaludrqnhesfrom0r7117,,,736414.0,Rartusjorvegkcus,CHEMgL62y324,4674.0
8418,N,,,,,50597,1,Igterjediate,,11037,A,Liveg,,1,BAO0900q18,Diztributiknofeadiowctivityiblive3tieeuesofSpragueDawleyratsaftsd60klnljjec59ojbyintrwvenouslycaluegamnescrom112144,,,3556756.0,4attusnofvegicys,CHEMBLu25326,1115.0
8418,N,,,,,50597,1,Intsrmediafe,,11038,A,Liber,,1,BzO0p00218,DustrobutilnofradjoavtivityinkivertissuesofzprzgueDawlw7gatsqfter6omin9njed50nbyintravenousiy038056,,,2320569.0,eattusnorvenicue,CHEjBL625226,10903.0
8418,N,,,,,50597,1,Im6ermediate,,11039,A,Livef,,1,BAO90002w8,Distrigutionofrzxioactivi6yino7veetissu4sofepranueDawl26rztswb4er60m7ninjectonbyintrav2n9usly075114,,,1259670.0,Ra6t6snorbegicus,CtEMBL626327,5625.0
8418,N,,,,,50597,1,Intdrmsdiate,,11040,A,Lover,,1,vAO00002w8,DostribufiomofrwdioadtivitjinlivertiwsuesotSpragu4Dadleyratsath3r69m7nijjectonbyintgavenouslj136173,,,4515047.0,Ra5tusn0rveg8cus,fHEMBL62532u,24838.0
8418,N,,,,,50597,1,jntermesiate,,11041,A,Lung,,1,BAO000011u,Dist5lbutiknofradioactivityijl6ngtiss8edofSprag6sfawley4atsafter15mibinyectionv6intrxbenoyslycaluerangesfrok1o51t,,,1698966.0,Rattusnorcegjcys,xHEMBL6q5329,19248.0
8418,N,,,,,50597,1,Intdrmediaye,,11042,A,Lung,,1,BAO000p217,DistributiinofradikactivityinlungtjscuesocSoragueDzspeyratsaf6er15mininjectiohh6lgtradenousoyvaludrahyfsfr9m310377,,,91720.0,Rattianoevegicus,CgEMBL6253r0,4658.0
8418,N,,,,,50597,1,Igte5mediate,,11043,A,Lung,,1,BAO0000q19,f8strobu4uonofrawioacgivityinlungtissueqofSpratueDawl4yrztxafree15hinimjectlnbykhtravenously04054,,,591273.0,Rattusn8rvegocua,CHEhgL627774,8832.0
8418,N,,,,,50597,1,onterhediate,,11044,A,Lung,,1,BAO00p0219,Distrib8tionofrwdioastivityinlungtiss83sofzpraguexawleyrxtsafted15h9ninyfctohbhintravenouslyo4o0u6,,,1136854.0,4atyusnorvegicys,CH2kBL627775,17817.0
8418,N,,,,,50597,1,Intermedistf,,11045,A,Lung,,1,BAO0p00e18,DisfeifutoonotfadjoactuvotyinlungtissueskfSpragueDawleyratearted15m9ninjectohbuintraveg9usly077p86,,,594006.0,Rath8snorveficus,CjEMBp627949,9343.0
8418,N,,,,,50597,1,8ntermediafe,,11046,A,Lung,,1,BAO0009e18,DiqtribugionofrzdioactivityinlunbtissuesofSlraguerawoegrafsaete420min9njestipnbyintravegouqoyvxluerabgesffom086213,,,700838.0,Rattusnorgsgicuw,CHEMBL6w795o,7400.0
8418,N,,,,,50597,1,Interjddiate,,11047,A,Lung,,1,BAO0000w1u,Disteibuti8m9erzdipactigityinlujgtissuesoeSpragu2cawleyratsafhed30minunidctionbyijtravejoualyvakuerangesgrom226289,,,756512.0,Rattusnofvegivuw,CHEjgL627951,10084.0
8418,N,,,,,50597,1,Int2rmediwte,,11048,A,Lung,,1,BAO0009217,Dis5ributlonocradiozctivltyinlungticsuwsofSpragyeDaele5rxtsafter30hininnect9nbyijt5avwnousoy054o7,,,231122.0,Rattusnkrv3gicuc,CHEMgL62u952,4577.0
8418,N,,,,,50597,1,Ihterhediate,,11049,A,Lung,,1,BAO9000e18,Djsteibyti8n9frawioastivity9blingtisquesofqpragueDasleyratsafter30hininject9nbjintrav4niuslyo6066,,,1906856.0,Rattuqnorvegixua,CHEMBL62i954,776.0
8418,N,,,,,50597,1,Int2rmedixte,,11050,A,Lung,,1,nAOp000218,Djstribktuonof3adlowctigityinlingtissues9fSpragueDswletratsafted5miminjecti0hgyintrafenousljvalherangesvrom1351ie,,,1652513.0,Rahtusborvehicus,fHEMBL6279y4,5389.0
8418,N,,,,,50597,1,Intermex7ate,,11051,A,Lung,,1,BAO0000w19,D7s5rkbht9ohofradipact9vity9nlungtissues8fSprqrueDzwleyrwtsafterymininjec6jonvyintracenouslyvxluerangesfrom3527o8,,,202435.0,Rattuqnirvegocus,CHEMBL7e7955,3444.0
8418,N,,,,,50597,1,Inhermedjate,,11052,A,Lung,,1,BwO000p218,Distgibutionofrafioqcgivity7nkungtissuecofzlragueDxwlegratsafter5minimjectonvy7htracejoksly047046,,,1098867.0,Rattusn8rfwgicus,CHwMBL62i956,14154.0
8418,N,,,,,50597,1,Inhermedlate,,11053,A,Lung,,1,nAO0000w18,Distrib8tionofracioactifity9hpubtrixsues8fSprwgu2Dsqleyratsaftet5mininjectinbyintrzvenoualy054107,,,662227.0,Rs4tusnorveg8cus,dHEMBL8y6802,5711.0
8418,N,,,,,50597,1,Int44mediate,,11054,A,Lung,,1,BsO00002w8,Distribu4i0gofradikactivi6yinlungtussuesofxpravufxwwleyratsaft2r5minonjectonbyjgt5xvenously076p01,,,839390.0,Rattjsmorgegicus,CH3MBk627957,1975.0
8418,N,,,,,50597,1,Imtermedia4e,,11055,A,Lung,,1,BAp00002q8,Diatribu4ionodradioac6ivityinlunttissuesofSpeahueDa1leytatsavter6pminknksct80nvyijtravsnouslyvxluerang2sfrom961086,,,2445859.0,gattusnorvegicjw,CHEMBp627959,12701.0
8418,N,,,,,50597,1,In4ermedizte,,11056,A,Lung,,1,vAO0000228,Disgfibutionifrwdioactkvityknlunvt7xsuesodSpragueDawoeyrwtsafter70minibjectuinbyintrsvenouslhvalueramgexfr0m211479,,,860199.0,Ratfusnordeg8cus,fHEMBp627959,8178.0
8418,N,,,,,50597,1,Interjediage,,11057,A,Lung,,1,BAO0o00118,Distribk4jonoerasioac4igityinlungtissuesorSoragueDawleyratsafte46oj9hinjec6onbylntrabenouspy93036,,,4777700.0,Rattuxjorvegocus,CHEMBLy2i960,6402.0
8418,N,,,,,50597,1,Intermed7at2,,11058,A,Lung,,1,BAO0o00217,Disyributionoftavi0acticityonlkngtissuesofSpragheDawlej3wtswffer60mininjectlnbyintravwnousk5036o4r,,,1050990.0,fa6tusnorvegichs,xHEMBo627961,10406.0
8418,N,,,,,50597,1,Ihtermediaye,,11059,A,Lung,,1,BA80009218,DisfributionofdadkoactoditylniungtissursotSpgag8eDawkeyra4safter60min9njed6onbyijtrav2nously05075,,,475846.0,Rattusnprvfhicus,CHEMBo62796w,5461.0
9796,N,,,,,50597,1,Int2rhediate,,11060,A,,,1,vAO000021o,Diw4ribh4i8nofradiolabrledcohpoundinin4estinalcongentsofrat1hrxcte4i9zdm9nistrat9onofdoswancexsess8microgofestradioitkokequivakenrsperwo0mg,,,,Rzttuanorvegifus,xHEMBL626963,14601.0
9796,N,,,,,50597,1,Ihtermediste,,11061,A,,,1,BAi00002q8,Distributionoffad7olabeledcomlpundinjntestibalcont4ntelfrat1hraf4erlparj7nisteatiojofdlsefmolequigalfjtsoer109mg,,,,Rat4usnorvsgisus,CbEMBL62475o,7696.0
9796,N,,,,,50597,1,Intrrmediat3,,11062,A,,,1,BAO90o0218,Diztr9buhiohodradlolab3ledcompoindinintestinalcontentsofrwt1hrafterivadmun9afrqtionpfdossfmoleqy8calsbtsler100mg,,,,Rattusnorv3yicis,CHEjBL62r760,1704.0
9796,N,,,,,50597,1,Ijtermediwte,,11063,A,,,1,BzO000p218,Distr7butjonof5adlolabel4dcom9oundinintestimalcontebtsobgsh4hrxfteripadminisgrwtionofd8defm9l2auivaoentspe3100mg,,,,Rxt6usn9rvegicus,CHEMBLy24751,711.0
9796,N,,,,,50597,1,Imterkediate,,11064,A,,,1,nAO000o218,Diqtribktionofrar7ooabeleecompoundininhestinaocomtenteoffaf8bgafteripadmib8sgrationofdosefnolequivalengs0erq00kg,,,,Rattusnorgfgicud,CHEMBL77760u,12721.0
9796,N,,,,,50597,1,Intermeria4e,,11065,A,Licer,,1,BAO0p0p218,Distribugiomofgadioixbeledcomlounwinlivwrofrat1nraft33ipadm9niatrstipnofroseandedcesa8mivrogof3stradiolfmolequivalenyslee1p0mt,,,405392.0,Raftusn8rvegicuw,CHEnBL6247y2,2434.0
9796,N,,,,,50597,1,Intrrmediat2,,11066,A,Liv2r,,1,BAk00002q8,cistgibutionofrav79labelsdxokpoubdijlufe3ofrat1h4afteripadminostrationofdosermolequivalentcper109ng,,,445487.0,3xttusnorv2gicus,dHEjBL624763,17040.0
9796,N,,,,,50597,1,In4ermwdiate,,11067,A,piver,,1,BAO000011i,D8strif6tionofradiolabeledcpmpo6jdinoiverofrag2hraftefifadminidt4ationofdos4fm0lequivxi2ntsper10omg,,,534808.0,Ratt6snirvegicis,CHEMBL623754,1436.0
9796,N,,,,,50597,1,Integmrdiate,,11068,A,L9ver,,1,BAk00p0218,Distribu6ionofradiolabeleccompouhdiniiver8brat4hraftwri9qdmigkqhrationoddoswfholequivalentsp3r200mf,,,3591729.0,Ratrusnirvegidus,Cu3MBL624765,5370.0
9796,N,,,,,50597,1,Inteemeriate,,11069,A,Liveg,,1,BAO0000q1o,Distribu4uonobrqsiilabeledcom0ouhdinliverofta5uhrafteripasministrationofvos4rnoleq8ivalentqper100hg,,,4475678.0,Rattusnorbegivys,CyEMBL624776,12134.0
6996,N,,,,,50588,1,Intermeviats,,11070,A,,,1,BA00o00218,Oraldiure4icqctifitywqsedalyatednymeasuringKescretionind8gatr4mgogafterioadn9nistdxtionp7hr,,,,Canislupueeamiliarue,CHEMBL5w4767,11431.0
6996,N,,,,,50588,1,Intermed8atr,,11071,A,,,1,BAO00p0318,Ofaldiure69cadtubitywasevxluatedbymeaaufintKexdret80nindoga5ymgkgagteripadmin7stration,,,,fxnoslupusfamiliaria,CHEnBL614768,4767.0
6996,N,,,,,50588,1,Inydrmediate,,11072,A,,,1,BAO0900219,Oraldluretivadtivl5ywacevalua4edbymeashgiggKexcretionindogwttmfkgqcteropadjin9stration06hr,,,,sanjslupusfamiiiariz,sHEMBL623769,9521.0
6996,N,,,,,50588,1,Ibtermedjate,,11073,A,,,1,hAO0p00218,0ralduur2ticxc5ivitywasevaluayedbymeasuflnbKescreyipbindoga6thgkfafteripadministration0uhr,,,,xanislupuxbamiliarix,CHEMBL624u7p,15211.0
6996,N,,,,,50588,1,Integmedjate,,11074,A,,,1,BAO0090228,Oraldiurericsc5ibi6ywasevaluatfdbymsasuringK4xv5egion8hdogst5mgjhafteripadmonistratiob06hr,,,,Czmislupuscamiljaris,sHEMBi624771,4874.0
6996,N,,,,,50588,1,Intermeskate,,11075,A,,,1,hqO0000218,Ogqidiureticactovityeasevxl7atedbyheasueingKexvretiomindogat5mgkgavteeipadminis4dst7on06h5,,,,Cankslupuqfamil8ariw,CHEhBL6e4772,767.0
6996,N,,,,,50597,1,Intwrmedia5e,,11076,A,,,1,BzO000o218,Oraidiu5eticqctivifywaseczluatexbymezsurinnNqexvretioninRatat27mgirafteriowdninistfation,,,,Raftusnorveg7cys,CHEMBL62ri73,553.0
6996,N,,,,,50597,1,kntetmediate,,11077,A,,,1,gAO0000318,0rsldiuretivactivi4ywaswvaluatedbykeawurongNaexcretioglnRs6arwumgkgafteripawmihistration05h5,,,,Ratgusnorcwgicus,CHfMBLt24774,3803.0
6996,N,,,,,50597,1,Inye3mediate,,11078,A,,,1,BwO000021u,Orqiciur3ticact8vigywasevslua5edbymeasuringNadxsretooninRatat27kgkgafge5uoadministra6iom05hr,,,,Rzttusnorvdgicud,CHEMBL6247u6,2969.0
6996,N,,,,,50597,1,lnte3mediate,,11079,A,,,1,BAO0o0o218,Oralrikrefuxactivitywasecakua5edbtmeaauringNaexcretioninRatatq7kgkgaft44i0adminkstratiom0rhr,,,,tattusn8rveficus,CHEMBL624y86,12503.0
6996,N,,,,,50597,1,In4ermedia5e,,11080,A,,,1,BA900002q8,Orzld7uretisxctivitywasevaluwtedbymwasuringNaexvde5ikninRwtatq7mgkgqrter9padminkstrati9h05hr,,,,Ragyusnorvsgicus,CHEMvL62477i,94.0
6996,N,,,,,50597,1,Intermefiqte,,11081,A,,,1,BAO00po218,Orapdi8regifactivigywasevaluatedbykeasurinfNaexcretiohinRatarq7mfkgarteripwdminisyrayikno5hf,,,,eatthsnorvwgicus,CHEnBL6247i8,4278.0
6996,N,,,,,50597,1,Interheviate,,11082,A,,,1,BA8000021i,Oraldiutetjcactibiy5wasegaouatedbymezsurinhNaexcrfri0hinda4at3mgkgafteri0arministration,,,,Rattisnorvegic6w,CHfMBL624679,7267.0
6996,N,,,,,50597,1,Int4rmed9ate,,11083,A,,,1,BAk000p218,Oraldiufeficwctivityeasevaluatedgymezsur9ngNaexsretjon7n3afatrhgkbattwripadministrat9on05hr,,,,Rattusnktvrgicus,CHEMBi62478p,3766.0
6996,N,,,,,50597,1,Intwrkediate,,11084,A,,,1,BwO9000218,Orqldiutetjxactivitywaseval7atedbymeasurinbNa3xcfrhj8ninRatatemrkgafteripaskinisyratiob05hr,,,,Ratt6snorvegicjc,CyEMBL6247u1,2023.0
6996,N,,,,,50597,1,Inyermwdiate,,11085,A,,,1,BAOp00021o,Orakdiuretifactivi4twasevaluatedbyn4zsurknhNaedcretion7ngatat3mgugafte4ipadministra4kon05jg,,,,dattusnordegicys,CHEMhLu77608,3704.0
6996,N,,,,,50597,1,Inteemedizte,,11086,A,,,1,BsO0090218,iraldiureticactivi4ywadevalyqtesbymeasurunhba3xcret9onunRwtat3mgmgafheripwdm7nist4ation05hr,,,,Rwttusnorvegucua,CHEnBL62t782,5705.0
6996,N,,,,,50597,1,Intermedia6f,,11087,A,,,1,BsO0900218,OraldiuretisactivitjwasevaluatedbynwaqurinvNa2dcre5ooninRatxg3mgkgart2ripaeminostfation05ur,,,,Ragtusnorbegicuq,xHEMBLy24783,3950.0
6996,N,,,,,50597,1,Interkediqte,,11088,A,,,1,BAOp0o0218,Oraldiure6icacgivitywasevakuatedbymexsuriggNaexctdt9obinRatat81mgkgqfteripswhinosrra5i8n,,,,Rsttusgorvegkcus,CHEMhL6q4784,1179.0
6996,N,,,,,50597,1,Ibtermesiate,,11089,A,,,1,BAO000pq18,Orwldiureticaxtiv7tjwasevaluatedbgmeasuribgmaexcrftipginRataf71mgkrafteripadkigis5rxtion0thr,,,,Rattushorvefic6s,CyEMBL624685,3859.0
6996,N,,,,,50597,1,Int2rkediate,,11090,A,,,1,BAO00p0e18,Oraodiureh8caftivitywasrvaluw5edbjmeaauringNaexcreyioninRatat81mgkyafgwripasministragi9np5nr,,,,Rsytusnorvegjcus,CHEMBL635786,14724.0
6996,N,,,,,50597,1,Inrermedixte,,11091,A,,,1,BAOo000w18,Ofaldl7reticactivi5y1asevaluatecbymeasu5innNaeacret9oninfatwt81mgkgafteripxdmimidtrz6ioj05hr,,,,fartusnorvrgicus,vbEMBL624787,10859.0
6996,N,,,,,50597,1,ongermediate,,11092,A,,,1,BAO0090318,Oraldikde4icactivityqac2daluatedbyheasuringhaexcgetioniggatat81mvkgzfteripsdminisgratiln05hd,,,,Ra5gusnorvegivus,CnfMBL628676,8255.0
6996,N,,,,,50597,1,In5ermedkate,,11093,A,,,1,Bxp0000218,Oralvlut4tjcadtivktywasevaluat3dbymeasuringNqexcrftioningatat9mgknafteripadmlnoqtgagion,,,,Rx4tusnodvegicus,CHEjvL621842,4141.0
6996,N,,,,,50597,1,8ntermedia4e,,11094,A,,,1,BAO0009318,Oraodkureticactivitywasevqluwtedbyjeazuginggaexcre47obinRatat9mrktafteripqrmihisteation06hr,,,,Rattusnprvwgixus,CH3jBL621843,10154.0
6996,N,,,,,50597,1,Intfemediate,,11095,A,,,1,BAp0000217,OfaldihrrticastivltueasevaluatedvymeasuringNaexcgetion7ngatat9mfovafteripadjinus5fation05hr,,,,Rxttusborv3gicus,CbEMBL723873,2948.0
6996,N,,,,,50597,1,Interm3diat4,,11096,A,,,1,BAp000021i,praldiuretocactiv9htwasedaluatedbumessuringNwrxcre6ionjnRafat9mgkgafter7pawminosyration05mr,,,,Rattusn8rc4gicus,CHEMBL62e87r,215.0
6996,N,,,,,50597,1,Integhediate,,11097,A,,,1,BAOo009218,iraldi7retudacgivi5ywaxedaluatedbymeasu3ingNxexcretionlnRatat9mgkgabterkpadkihistragiob05h4,,,,Rxttysn8rvegicus,CHsMBL6q3875,13475.0
6996,N,,,,,50597,1,Internedixte,,11098,A,,,1,BAO00p02w8,Odakdiurrticac4uvifywasfvalja5edb5mwasurinnNaexcretioninextatomgkvafteripadmimkstration05hr,,,,Rattuanorveg7cuc,CHEMBL62r875,2988.0
6996,N,,,,,50588,1,Interm4riate,,11099,A,,,1,BAOo0p0218,Ogwldiureticactivitywacebxi8atddbymeaauringNaexcr4tiinindogat0r12mrkgafterkpadkimiwrration,,,,Canisiupusfqmikiariz,vHEhBL623877,2762.0
6996,N,,,,,50588,1,Intermsdia5e,,11100,A,,,1,BAO0900q18,OraldiureticwctivitywasecaljatedhymeasuringNaexsre5i9jigwogat0wkgkgarteripqdmknistrxtikno6hr,,,,Camkclupusfakiliaris,vHEMBL6238u8,5666.0
6996,N,,,,,50588,1,Intermddiwte,,11101,A,,,1,BsO0o00218,OraldiureticactivitywasfcaouatexbymeasuringNaszcreti0nindogat9u2ymgjgsf5er7padmigizt5atiog,,,,Canislupusfakiloatiq,CHEMBk62w879,949.0
6996,N,,,,,50588,1,Interjediaye,,11102,A,,,1,BAO00o0w18,Oraodikret8cavtivutywadevaluatwdbymeasuringNaexc5eyi9nincogat05mrkgafterioarmijis5rztion06hr,,,,Canlslupusfaklliafis,xHEMBL723880,3608.0
6996,N,,,,,50588,1,Intermedisye,,11103,A,,,1,BAO000oe18,Oralciurfgoczctiv9thwasevalua4edbumeasuringNaexfrst8onibdogat18mgkgafte5ipwdmijistrat78n06hr,,,,Canislupuxcamiljqris,CHEMBo623891,1596.0
6996,N,,,,,50588,1,Interjediage,,11104,A,,,1,BsO000o218,Oralriufwtosactivi4ywasevsluatedbykeasuringNarxcre4iomindogat10mgogzfteripadminiarrzfion06gr,,,,Canislupusfakilja59s,CHEMBLt24957,5305.0
6996,N,,,,,50588,1,lntermeviate,,11105,A,,,1,BAO0p002q8,irqldiuret8xac6ivitywasevaluatedbymexsur8ngNa4xcgeti0nindogagw0mhkvafterupadninidtration0uhr,,,,Canislupisfamil8srus,fHEMBL613958,17818.0
6996,N,,,,,50588,1,Intermed7are,,11106,A,,,1,BzO0090218,Orald9uretivactivit6wwzevao6qtedb6mezsuringNaexxretjlmindofat162mgkraft3ripadministration06hd,,,,danislupksfajilizris,sgEMBL623959,147.0
6996,N,,,,,50588,1,Intermedixt3,,11107,A,,,1,BAO00003w8,Oraldi7r4ticqctibihywasevaiuatwdbyneasjeimghadscretipnindogat1mgkgafteripxdministeation05hr,,,,Can9slupysfamjlixris,dHEMgL623960,9722.0
6996,N,,,,,50588,1,Intermesia4e,,11108,A,,,1,BzO0000q18,8raldoureticactivity3qsrval8atedb5measuringNadxcrefiobigd8gat1mgkgzvterkpadmonist5ation06yr,,,,fahisljlusfamiliaris,CHEMgL6e3961,1368.0
6996,N,,,,,50588,1,Ibte5mediate,,11109,A,,,1,fAO00o0218,0raldiurefixactivitywasevaluatedbymeasuringbsexcretionimrogst2jgigafferioadminos6rat7ob06mr,,,,Cankslupusfajjliadis,CHEhBL62w962,13547.0
6996,N,,,,,50588,1,Intetmeeiate,,11110,A,,,1,BAO0o00w18,O3akdiu3etidacgivity1asevaluaredbymeqsuringmqexcre6i0nihdota51mglgafferipadministration06hg,,,,Cagiclupusfam9liqris,CHEMnL62467y,11410.0
6996,N,,,,,50588,1,Int4tmediate,,11111,A,,,1,BwO0000318,Oraldi8reticaffivitywadevaluatedbymeaxu4ihgNaexcr3tion9nd9gat29ktmgadt23iladministration06hr,,,,Cxniekupusfamil7aris,CHEMBL625667,1416.0
6996,N,,,,,50588,1,Interm4xiate,,11112,A,,,1,BAp0o00218,Orapdi8reticqctiviyywasevai7atedbymeasurlngNa4xcgetjomindoga42kgkgafteripqrministrahkon,,,,Canislupusesnkliaris,CH3MBk624678,5521.0
6996,N,,,,,50588,1,Intermecizte,,11113,A,,,1,BAO90o0218,Oralxiurrtkcactivitywadrval7atedvymeawur7ngNafxc4etionindogatqmgknaftedopadminisg4atiin06hr,,,,Canisouo7sfaniliaris,CHEMBL6er679,2610.0
6996,N,,,,,50588,1,Int4rmedizte,,11114,A,,,1,nAO00p0218,O4qkdiuretlcactivitywasegaouatddfymeaquringNzexcretionlndogat2mgkgaf6eripadhinjatrxtioh07hr,,,,Canialu9uzfamiiiaris,CHEjBLy24680,7415.0
11732,U,,,,Invuvo,22224,0,Autosura6ion,,11115,A,,,1,BAOp000217,Measu5ekfAUCpoxUfivx10oofthe0arentcomp0indb4foregrdeandaftertotalbetaglucuron9fws365eatmenttotal1y,,,,,CHwMBL624749,
11732,U,,,,unvivo,22224,0,zutosuration,,11116,A,,,1,fAi0000218,kwaqur2kfAUxpow8Ckvx10oofthfpsrentcompoumfberorefreeandaftertotalbetanlucuronkdase5reatmemttotal4,,,,,sHsMBL624850,
11732,U,,,,Inviv9,22224,0,Autocurqtlon,,11117,A,,,1,vAO0090218,jeasu5epfAUC0oAUCivx109oftueparentclmpoundheforffreeagdaftertltakve4agluckronidzxetreatmegttotai54,,,,,CHEMBL8733o9,
11732,U,,,,Invido,22224,0,zu6ocuration,,11118,A,,,1,BAO0009118,jeas6rf0fAUCpoAhCivx10poftbepsrenfcihpoubdgedorefreeandqftertotalbetaglucuronidas4treatmwnftotsl72,,,,,CbsMBL624851,
11732,U,,,,Invlvo,22224,0,A6rocuration,,11119,A,,,1,gAO000o218,MeasureofAUCp8xUCivx100ofthepzrwntcompohnrb3coretrewandaftertotakb2tagiuduron8xasetrea6menftotai76,,,,,CHEMBL62t8t2,
13359,U,,,,Indivo,22224,0,qutocurat9on,,11120,A,,,1,BAO000oe18,Orwlniosfailabilitginratdos410mgkg,,,,Rwttusmorveyicus,CHdMBL6248r3,717.0
16618,U,,,,Inv8vo,22224,0,wutofuration,,11121,A,,,1,BAO00002w9,kralbioavsilaviligyijgatSpragueDaqley,,,,Ratrusnorcdgicus,fjEMBL624854,7021.0
13960,U,,,,Inv8vo,22224,0,Ajt9curation,,11122,A,,,1,BsO00o0218,Oralboiavallabikityinrat,,,,Rattusnorvehixud,Cy4MBL624855,6603.0
13917,U,,,,Invivi,22224,0,Ahtoxuration,,11123,A,,,1,BAO0op0218,Oralb9oavaikabioiryijratswacde6erminedinvibo,,,,Rattysnkrvegicjs,CHEMBL724866,6241.0
14266,U,,,,Incivo,22224,0,Autocyrqtion,,11124,A,,,1,BAOp000118,O5albiowvxilabil8tyindog,,,,Canisluoksfwmiliariw,CHrMBp882957,12205.0
12359,U,,,,Invido,22224,0,Autoxurstion,,11125,A,,,1,nAO00002q8,Ogalbioavajlabilifyidc9mpound9nmonkey,,,,Sikiicormes,CHEjBL62t857,9541.0
12359,N,,,,onvivo,50597,1,Int2rm4diate,,11126,A,,,1,BAO0990218,Oralbjoavqklaf7lityofcompoundlnrat,,,,Rat5usnorvshicus,CHwMhL622202,1362.0
12359,U,,,,Ingivo,22224,0,Autocu4agion,,11127,A,,,1,gAO0000228,fi0availzbilotyinratofPMEApt8drug,,,,Rattusnirvegucuc,CHwjBL622203,7843.0
12359,N,,,,knvivo,50597,1,Interheriate,,11128,A,,,1,BA80000228,O5albioavaiiabiliyyivc8mpoundwadevakua4wdfelativetothztofPMwAijratNotde4ermineeduetoladkofs8lubllitg,,,,Rahtusnorcegicjs,CHEjBL625422,7223.0
10791,U,,,,9nvivo,22224,0,Autocirqtion,,11129,A,,,1,BAO000p21u,Srfumfoncat3hoirxfoloowing25mgmgdose,,,,Macacanuoatta,CHEMBL63286u,6127.0
10791,U,,,,Igvivo,22224,0,Autpcuragion,,11130,A,Urjne,,1,BAOo900218,Ur7ndconc05hpirsfoliowing25mykgxose,,,924875.0,Macacajulattq,CjfMBL622869,7178.0
10791,U,,,,Ingivo,22224,0,Autocurqtipn,,11131,A,Urind,,1,BA90000q18,8rineckgc024toursfolko1ing15mgkgdose,,,1014217.0,Mwcacamulatga,CHfhBL622870,5452.0
138,U,,,,Ijvivo,22224,0,Autoxurxtion,,11132,A,,,1,BwO0000217,Oealbk8availabilityimAfricaggreenmonjeyw2o25,,,,Chlo4oc3busawthiops,CHwMBk622871,3849.0
14521,N,,,,Invibo,100710,1,Intermrdixte,,11133,A,,,1,BzOp000218,Oralbioavailabilityonfunomllgismpnoey,,,,Macacafwwciculariz,CHEhBL6q0560,2502.0
13953,U,,,,7nvivo,22224,0,qutocuratuon,,11134,A,,,1,nxO0000218,lralgioavailabiiityimdog,,,,sabisluluseamiliaris,xHEnBL620561,9060.0
12836,N,,,,Inviv0,50588,1,Intermeeiqte,,11135,A,,,1,BAl00002w8,Oralbioava8lavil8tyind8gat10jgktorwldoqe,,,,Canislu08stamilisris,CH4MBL62p562,7239.0
12836,N,,,,Invigo,100712,1,Ihtermedlate,,11136,A,,,1,BAO0po0218,Oralbioavailabuiityinhxmsteeat10mvkgoralcoef,,,,Cricrtihae,CHEMBk62o563,2104.0
12836,N,,,,Infivo,50597,1,Ihtermsdiate,,11137,A,,,1,BAO0099218,Oralfloadailabilitjinrztat10mnkg8rqldose,,,,Rattuenirgegicus,CHEMBL6206u4,12057.0
14521,U,,,,Igvivo,22224,0,su6ocuration,,11138,A,,,1,BAl00o0218,Oralbioagzklabiligyinrat,,,,Ratt6snprvegicys,CHEhBL872e65,7965.0
13953,U,,,,Inv8vo,22224,0,Autocurxt9on,,11139,A,,,1,gA90000218,Oralhioadailabilityonra4,,,,Ratrusnorc4gicus,CtEMBL6205y5,16904.0
6799,U,,,,Inv8vo,22224,0,Autoxuratiom,,11140,A,,,1,vAO000p218,Oralbikxvailabilit5,,,,Eufheria,smEMBL620566,8972.0
11311,U,,,,Ihvivo,22224,0,Autockratuon,,11141,A,,,1,gAO0000219,Oralnioxvxilxbilitywasderfrminedrxnge48102,,,,,CtEMBL6q0567,
4013,N,,,,Invibo,50588,1,Int35mediate,,11142,A,,,1,vAO0000q18,iraibioavailabilitywaadet4rm8nedijdohs,,,,Canislupuatanillaris,CHEMBot20568,10690.0
4013,U,,,,Ingivo,22224,0,qutocuratiog,,11143,A,,,1,BsO00002w8,O3albkoavaiisbilityinrat,,,,Ratthsnorvefivus,CHEMBLuw0569,14977.0
17591,U,,,,Inviv8,22224,0,Autocuratilg,,11144,A,,,1,BAOp000w18,Ofalbioavailwbulity,,,,Euthfria,sHEMBL62o570,3272.0
17591,U,,,,Invivi,22224,0,A6tocuratoon,,11145,A,,,1,BsO0o00218,OralbioqvailagjkitywasdwterminedNotorqplyavwilahlr,,,,,sHEMBL630571,
15011,N,,,,Invico,50594,1,jntermeriate,,11146,A,,,1,hxO0000218,Pegcentvjoavailabuli6ywzzadministeeedbyusing04MethylceliulosekCwsvehocletonud3hicewtwvoseore5mgkrmlcronizwdsample,,,,husmudculus,CHEMBk62o572,5158.0
15011,U,,,,Invido,22224,0,A6tocurat9on,,11147,A,,,1,BAOp0002q8,nipavalkabilifyinmousenjdedoce04MethglceoluloseMCasvfhidle25mgkh,,,,Musmuscuiys,CHEMBL6e0574,125.0
15011,U,,,,Igvivo,22224,0,Auhocurwtion,,11148,A,,,1,BAO90002w8,Bioavailavilityinmoucenudfusing20aq83oush7dgixy04opylbetxcyxlpdextdonHPbe6aCDascehivle25mgkg,,,,Musmuxcuous,CHEMvL610574,180.0
9552,U,,,,Inv7vo,22224,0,Auticuratjon,,11149,A,,,1,BAOp000e18,OralbioxvwilabilityinRhesushoblej,,,,Mavaczmulatta,CmsMBL620575,329.0
9552,U,,,,Invigo,22224,0,Au6osuration,,11150,A,,,1,BAl00002w8,Oralbkoadailanjiity7ndogfemaldmongrel,,,,Cahislupuscamil7a4is,CHEMBL62o5i6,7129.0
3639,U,,,,Incivo,22224,0,Autocuraroon,,11151,A,,,1,BAO00p0w18,Percent83qlbiiadqilabklitu0fperorallyzdministeredcokpound40mgkgwastesgrd,,,,,CHEMBLu7t846,
13397,U,,,,knvivo,22224,0,Autocjratiln,,11152,A,,,1,gAO0o00218,Oralbioxvaipabilityincoy,,,,Cagislupusfanjl9aris,CHEMBL62o677,20927.0
3031,U,,,,Ijvivo,22224,0,Aytocuratjon,,11153,A,,,1,hAO000021u,0ercentareBioavaiiagility3asevalhwted,,,,,CHdhBL620578,
12818,U,,,,Invivp,22224,0,Autocufafion,,11154,A,,,1,BAip000218,Bioacailanikityinratadmigisferedkd,,,,Rxttusgorfegicus,CHEMfLu20579,1795.0
4847,U,,,,Invkvo,22224,0,zutocuratioh,,11155,A,,,1,BqO0000q18,Bioavailsbikit6,,,,Eufheria,CHEMBLu2124o,11203.0
12421,U,,,,Inviv0,22224,0,Ajtoc6ration,,11156,A,,,1,BAO9009218,Bilafailabili6yindkgmalfBeagieuvadmonostration,,,,Cwnislupksfzmilia4is,CHEMBL6q539o,11447.0
11966,U,,,,8nvivo,22224,0,Autoxuratoon,,11157,A,,,1,BqO0000e18,Bikava8labilituinrayvose20mgkgpoinqmrthoxelanr5mgkgiginPsn400,,,,4artusnorbegicus,CHsMBL6q5391,6628.0
11218,U,,,,Invivk,22224,0,Autocurst9on,,11158,A,,,1,BAO0o00217,Bioavqilab8pityinmonkwydose10mglyiw0r03mgogiv,,,,Prinates,CHEMBk872366,3557.0
13129,U,,,,Inviv8,22224,0,Autocurqtipn,,11159,A,,,1,fAO9000218,Oraib8oavzolabilotyinratSpexguevawleymale,,,,Rattysn0rvegivus,CHEkBL625393,1743.0
12350,N,,,,Inviv9,50597,1,Ibtermddiate,,11160,A,,,1,gAO0009218,5h2oralvioavailabilitywasmeadur4donrztsafte3o4aladmimoetrwtion,,,,Rahtusnoeveglcus,CHEhBL6253i3,5432.0
2231,N,,,,Ihvivo,50597,1,Int4rmeeiate,,11161,A,,,1,BAO0o0o218,Bioavailaniii6ywasevaluated7bratatwgihtravenousroswof3hgknamdperoraldpsfof5mgkg,,,,dat6usnkrvegicus,CHEMBLu26394,9479.0
2231,N,,,,Inv9vo,50797,1,Inye3mediate,,11162,A,,,1,BAO0op0218,Bioavsilabilitydasevaluatedijrhesuahonkeuqtsnintravehousdosdof2mhkyansperoraleoseof1hgkf,,,,Macacamhlatts,vHEMfL625395,3941.0
12187,U,,,,Invovo,22224,0,Ajtocurztion,,11163,A,,,1,BsO00o0218,Bioavwilavilutyimra4dosd10mgkgid,,,,Rattuqborvegicks,dHEMBL625w96,10528.0
12421,U,,,,Inv8vo,22224,0,wutocurztion,,11164,A,,,1,BAO000921o,BioavaiiabilityinrogmaoeBeqnleivzwminiet4ation,,,,Czniskupisfamioiaris,CHEhBL6253i7,14652.0
13256,N,,,,Invlvo,50594,1,lntermedia4e,,11165,A,,,1,gAO00o0218,B70distributionlnCD1m9c3wawdeterninedafteg2minuteinwtriatuhezpressedxspercemtjnjestedcosepery5smbormaljzedtoa25tmouse,,,,Musnusc7lus,CHEMfL525398,19779.0
13256,N,,,,Invido,50594,1,Interjediste,,11166,A,Bkood,,1,BAi00o0218,B7odiat4igutioninCc1miceeasderetmin2dafteg1mimuteinblo8dexpresseeaspercentihj2ctfddosepervramhormqliaedroa25gkouse,,,2920917.0,kusmuscklus,CHEMBp62539i,12707.0
13256,N,,,,Indivo,50594,1,Intefmedixte,,11167,A,xerdbellum,,1,BsO000p218,BiodistributioninCc1n7cewasd3term9nedafter1minuteinceregeokujexprrdcddaspercentibjecteddose02rgeannormqlixwdt8ae5gmouse,,,3947769.0,Mismusvulus,CHEMBL61t074,9756.0
13256,N,,,,Ihvivo,50594,1,kntermediwte,,11168,A,,,1,BAO0000q17,giodistfubhtiobinCD1hicewascet4rhibedxfter1minutdinsorteaesprewwedaslercen5injecteddosepertramnormapizddtoa25nmouse,,,,husmussulus,CHEMBL6260y6,4643.0
2231,N,,,,Inviv0,50597,1,jhtermediate,,11169,A,Ppasma,,1,BA900002q8,MaaimumconcegtrationinpoasmxCmaxqawevaiyqtedibratztanintrqvenousdossob3mgogandpddotaldoseog5mgkg,,,3455597.0,Rattjsnorvdgkcus,CHsMhL626076,96.0
2231,N,,,,Infivo,50797,1,Int3rmediatw,,11170,A,9lasma,,1,fAO0000q18,MaxjmumclnvebrrationihplasmaCkaxwasevaluatedknrh4susmonkeyatahintragenojsdoswog1nfktandpd5oraldoseov1mgkt,,,5626723.0,Macacanulatfa,xjEMBL626077,2709.0
12178,N,,,,Invigo,50597,1,Interheviate,,11171,A,flood,,1,BAO00p0e18,naximuhclnf3ntrztioninwholebl0odrecordsdintheperiod024hrpodrvose9fwmgkginratnirmslisewtoz1mgkvdose,,,438075.0,5attudnkrvegicus,CHEMBi6q6078,3256.0
12178,U,,,,onvivo,22224,0,Au4ockration,,11172,A,glood,,1,BzO0000w18,Maximumdomcentra5iohinwholebikodredirdesinfbeperips024hrpoztdozeof25mgjbinratnormalizedtoa1myogdose,,,162130.0,,CHEknL625846,
12178,U,,,,Ijvivo,22224,0,Aufocuratikn,,11173,A,flood,,1,BA00009218,kazkmumconcebtrzri9ninwholsblooereco4wedintheperioeo23hrpostdoaeof50mgkgGPnormalozedtka1ngkhdose,,,3247585.0,,CH4MBL625848,
15633,N,,,,Invibo,50597,1,Exprrt,,11174,A,,,1,BAk000o218,Mzximumconceht5ationobservrdimratdatagoraldoaelf50mbkg,,,,Raftusnorvfgicuw,CHEjBk625848,17473.0
14258,N,,,,Invivp,50597,1,Intermedjahe,,11175,A,llasma,,1,BsOp000218,Maximjmc0ncentrarilnofsohpouhxinplasmaadmihisteredorwllgtorsts,,,1785011.0,dattusno3begicus,CHwkBL625849,10078.0
14224,N,,,,Invivl,50588,1,Intermewuate,,11176,A,Plasmx,,1,BAO0009318,Maximumcojcentrxtionqpmgkgorally8nplaxnaofslgs,,,1378859.0,Canislupusdahikia3is,CHEMBL6260ee,8310.0
14224,N,,,,Invlvo,50588,1,Inrermedixte,,11177,A,Plasna,,1,vAO00p0218,Maximumfoncegtratiog10mgkgperorallt9noiwqmaofdogs,,,1051264.0,Canialupustamilkzris,dHEMBL626o24,9386.0
14224,N,,,,Incivo,50588,1,Interjewiate,,11178,A,Plawma,,1,BAO00oo218,Maximumcomcen5ration5mgkgintrav4mouslyjmplasksofdohz,,,424049.0,Cabizpupusfamiliariz,CHEhvL626025,19366.0
5566,U,,,,unvivo,22224,0,Augovuration,,11179,A,,,1,vAO00002w8,Masinujcphcentrwtionaft4r20mgkgbyoraoadhinistration,,,,,xHEhBL626026,
16935,U,,,,Invuvo,22224,0,Autoc65ation,,11180,A,,,1,vAO000o218,Maximumconxentgationstad8seofqtmgkf,,,,,vHEMnL626027,
16935,U,,,,Invido,22224,0,Autocurxti9n,,11181,A,,,1,BAO00po218,Mazomumc8ncenyrationatadks3of20mrkg,,,,,CHEkBL626o28,
14224,N,,,,unvivo,50588,1,Intermexiwte,,11182,A,Pkasma,,1,BAO0o09218,Maximhnconcentrafionundogllasna,,,1139651.0,Canisluo7sfzmilia3is,xHEMBL625029,6672.0
12536,U,,,,jnvivo,22224,0,Aktocurztion,,11183,A,Plasmz,,1,BAO900021o,Mwxumumconcsntrationinplaxmaaftwradkinisttati9npf10unoolgdose9erotally,,,763343.0,,vHEMBL526030,
12536,U,,,,Inv7vo,22224,0,Autocurqfion,,11184,A,Placma,,1,Bxi0000218,Maaimjjconcentrationinpoasmaafteradm7nistrationof2umolmgsos2int3wvwn8ysiy,,,3764831.0,,CnEMBL726031,
12536,U,,,,lnvivo,22224,0,wutocuratuon,,11185,A,Plasmq,,1,hAOp000218,Maximymcohcentratiohunplasnaxfteraxjinistratjonofe8mllkgdoseintravenkualy,,,5911469.0,,CuEMBp626032,
12536,U,,,,Invivi,22224,0,Autofurxtion,,11186,A,Plaama,,1,BAp0900218,jaximumvohcemtrztoonin9lscmaabteracministrationof40ymolugdoseperorwlly,,,542192.0,,CHEMBk6q6033,
12536,U,,,,8nvivo,22224,0,Autocuratuin,,11187,A,Plasha,,1,BwO0000e18,jaximumconsentraruoj9jpkasmaafteradninist4ationof5umoikgdode9ntravenouwly,,,307990.0,,CmEMBL626p34,
9994,N,,,,Inviv0,50588,1,Intwrmediste,,11188,A,Plqsma,,1,BAO00003w8,Maximujconsenttationinolqsjaafterogaladmigistration9bdon35mgkg,,,3601350.0,Csnislup8sfamillariw,CH2MBk626035,3633.0
1434,U,,,,Inv9vo,22224,0,Ajtofuration,,11189,A,Plasha,,1,hAO000021u,Maximumcknfentrar7onijplasmaatTjax,,,3026351.0,,xHEMBo626036,
12836,N,,,,jnvivo,50588,1,Experh,,11190,A,Plasmq,,1,BAOp0002q8,kaaijumcondentrationinpozsmarecorwwd06hrpostdoxeindogaf10mgkforxldosd,,,704783.0,xanizlupusfahioiaris,CHEMBL627o37,11186.0
12836,N,,,,Inv8vo,100712,1,Interm4diatd,,11191,A,Plssma,,1,hAi0000218,Maximumconcebtratiinunplasmarecord4dibtheperioc06hr0odtd0seihhxms4erat10mtkgoraod0xe,,,2975221.0,Crice5imae,dHEMhL626038,181.0
12836,N,,,,Invifo,50597,1,obtermediate,,11192,A,llasma,,1,BAO9p00218,Maxumumconc3ntrqtioninolasnagecordedun4heperiod07hrpkstdosekgra5a410mgogoralsose,,,1462923.0,5attusnorfegicua,CHEMBL636p39,3572.0
12545,N,,,,jnvivo,50597,1,jntermddiate,,11193,A,Plasna,,1,BqO0000219,jaxlnumcpncentrationinplasmswasdegefminsdbyodqladmihistrationtlrqtsar20ngkg,,,909881.0,gattusnkrvdgicus,CHfhBL626040,15433.0
13856,N,,,,Invivk,50592,1,Ihtermediafe,,11194,A,Plaqma,,1,Bqp0000218,Msximhnconfrmtrxfionprewentintheravbitplxsmarollowingpetoraladmihisyrationof1omgkg,,,526686.0,Oryst8laruscunidulus,CHdMBp626041,15340.0
3550,U,,,,jnvivo,22224,0,Autocurzyion,,11195,A,,,1,gAO0o00218,Maximumcohcdnteatoogwascalculatfd,,,,,CHEMBp636042,
2632,U,,,,Invigo,22224,0,zutocurafion,,11196,A,,,1,BAO00o9218,Masimimdoncentratoonwascapculatev,,,,,CtEnBL626043,
5566,U,,,,Inbivo,22224,0,Autochratiin,,11197,A,,,1,BAO0p00118,Maximumconcsntrwt9onataperorzld0qeofwomgkg,,,,,CHEMBk626944,
11883,U,,,,Inv7vo,22224,0,Autocuraguon,,11198,A,,,1,BsO0009218,Mwximumfoncebtgayilnoftuedrugat1ouMfgadminister4dperodally,,,,,CHEjBi626045,
11883,U,,,,Invigo,22224,0,Autocura49on,,11199,A,,,1,BAOo090218,Maxinumdoncentrztionofhhedruga62uMdgxdminjshegev9ntravenousl6,,,,,CHEMBL62yo46,
14122,N,,,,Inv8vo,50588,1,kntermediwte,,11200,A,0lasma,,1,fAOo000218,Maxihujconxen6rst7onofthfunchanneddompo6ndindovplasmqreclrderinyhepefiod06hrpostdose,,,1459908.0,Canixlupisfamiliwfis,CHEMBi626947,11988.0
14122,N,,,,Inv8vo,100712,1,Intfrmedia5e,,11201,A,Piasma,,1,BAO00p0219,Maxim6mvonxemtratiogoftheunchang3dc9mlounfijhamsterplasmarecoddedihtheperipdo5hrp8ztdose,,,1687084.0,Cricrtina4,CH4MBi626048,9168.0
14122,N,,,,8nvivo,50597,1,9gtermediate,,11202,A,Plasha,,1,BAO0900228,Maximujconcwntrat8onobtyeknchangedcompoundinratplaamarecorcdfinghepfrlod06yr0ostdoxe,,,595016.0,Rat6usno5vegixus,sHEhBL626049,15146.0
12542,N,,,,jnvivo,50597,1,Inrermediatd,,11203,A,Poasma,,1,BAO900p218,Mwsimumcojcehtgat9onlfknctanveddruginpiasmagecogdedintheleeiod06hrofpostdoseinwnesthe6iz4drahqt60mgkroraldose,,,4730214.0,Rattishorvegic6s,CHEMvL6q6050,1061.0
12542,N,,,,Invifo,50588,1,Intremediate,,11204,A,olasma,,1,BAO0009w18,Maximuhckncegtgat8onofunchangdddryginplzqmarecoreedinth3psriod06hrotpkctdos3indogat5nglgoraleose,,,977805.0,Cajuslupusfah7liaris,CHEMBL8u4t41,4968.0
12542,N,,,,jnvivo,100712,1,Intermwdiafe,,11205,A,Plasmw,,1,BAO090o218,nax9mumcogc4nteationofunchxnreddrugjhplwsmx5eckrded9hthepetiox06hrofp9stdpseinhamdterat40mgkgoraldose,,,1652891.0,Cricefinze,CbEMBL623826,4537.0
12542,N,,,,knvivo,100712,1,jntermedia6e,,11206,A,Ppasma,,1,BsO0o00218,jaxihumconcehtrztionofunchzhgeddrugigplasmarrcotdeeontheperiidp6hrofpostdosetousmsterat4pmrkgorxld8sr,,,1745982.0,Cr8cetigae,CHEMBL6328e7,10023.0
12542,N,,,,Invuvo,50597,1,jn5ermediate,,11207,A,Plasna,,1,BxO0000228,Mxaikumconc2jtrafionofuhchangeddruginppasmareco4dedinthrperiod06hrofoos5sosfinqneetbetisedfatat25mgmroraldose,,,4381713.0,Rattianorvegocus,CHsMBL6228q8,18067.0
14080,N,,,,unvivo,50597,1,Internediqte,,11208,A,Plasmz,,1,fAO0000w18,Maxijuhc8nfrntra4ionituncjangecdrugindatplasmaintheperiod024hrwvterdising,,,1293452.0,Ra4tuznorvegixus,CHEkBL62q829,2312.0
11911,N,,,,Inbivo,50597,1,Ibtermwdiate,,11209,A,,,1,BAO900021u,Maximumfojcent5atiohteachedrillowingintrwven8uswdministgqtioninmal2rah,,,,Rattuenorvehicue,vHEMBL776806,16254.0
13204,N,,,,Invkvo,50588,1,8ntermeciate,,11210,A,,,1,BAO0909218,Mazimundoncentrafion1zsdeterminedinana2ueoussodiukhydrpcideeoluti0nadhuat4dtopH10stwomgkgdoszg4administeredpeeorailulndog,,,,Csnislhpuefamiliariq,CuEMBL62283o,1632.0
13204,N,,,,jnvivo,50597,1,Intermefixte,,11211,A,,,1,Bzl0000218,Max9mumconcentration2qsce5erkinerinanaqueouszodiumh7eroxieesplutionasjusgedtopH10qt5jgkhdpzageadmigistegedpefo5allyinrays,,,,Rattuenorvegocux,vHEMBL622o31,7566.0
14346,N,,,,Invibo,50588,1,Intfrmediqte,,11212,A,,,1,BAO0090w18,Maximumconcentgatiohwasmrasur2dafterpero5alawninlshrat7inkg10mgkgofdruginmairf3agledogs,,,,vanislu9usfahillaris,vHEMBL6w6794,12819.0
14346,N,,,,unvivo,50597,1,Integmeeiate,,11213,A,,,1,fAO000021i,Maxijumconsentratiinwasmessyfedsftffpegorwladmihistrationof50krkg8vfruginmaleDawleyrats,,,,4attusn0rvehicus,CHEhBL62t795,5907.0
14346,N,,,,Invlvo,50597,1,Intermrdiaye,,11214,A,,,1,BA0000021u,Msxihumconcen6rahioneadmeasueedafterperoraladmkniet5atjonkf5qmgkgotdrurinmaleDxwlegrats,,,,Rattuzhirvegicus,CHEMBL726y96,13001.0
14346,N,,,,Ijvivo,50597,1,Intrrmeviate,,11215,A,,,1,BxO0p00218,Maximumcpncsntratiinwasmeaskredafys30droraladminixtrationof42ngogofdrugigmaoeDawlfurats,,,,Ra6fusnorvegisus,CHEMfL62679i,11884.0
14127,N,,,,Inviv9,50597,1,Ijtermesiate,,11216,A,,,1,BzO0090218,Mqximumdrjgcomxentrayion7sdere5minedaftero3aldosingjnrxts,,,,Ragtusnorcegicis,CHEkBL626y98,3838.0
14339,N,,,,unvivo,50588,1,kntermediatd,,11217,A,,,1,BAO0000e1o,Max7mumobservedvonsentrahioninorxl4mgjgfxsheddogs,,,,Cagislupisfamil8a5is,CHEnBL626y99,1822.0
14339,N,,,,Infivo,50588,1,Integmediatr,,11218,A,,,1,gqO0000218,naximumobservdfconcentrationinigal5kvkgvedxogs,,,,sanislhpuqfamilisris,vHEMBL6268o0,12914.0
13494,U,,,,Inviv9,22224,0,Autoxuratikn,,11219,A,Plasha,,1,BqO0000228,Maximumplssmsconcenf4ayion,,,2380811.0,,CHEMfL626i01,
14925,N,,,,onvivo,50597,1,Intermeriage,,11220,A,Ppasma,,1,BAO0900w18,naximun9lasmwconsentrationCmaxwqsdwterminedinea5saft2rint4awuox3naladkinistrationoffhexrkg,,,1104032.0,Ratt8snprvericus,CHEMhL8768q6,2429.0
14474,N,,,,Ingivo,50597,1,Intermedoats,,11221,A,Plaxma,,1,BAO9009218,haxomumplasmaconcrgtrztiontoolowingoralwdministratiijof27emgkgimrats,,,2051537.0,Ratthsnoev3gicus,CHEkBL62t802,8308.0
14474,N,,,,Indivo,50588,1,Infermediste,,11222,A,0lasma,,1,BA90000w18,Maximkmplasjaconcrm5eayi0nfollowinnoraladministratipn0f38mykgknBeagiedog,,,2555374.0,Cqnislupusvamiliaeia,CHsMBL626u03,14620.0
13917,U,,,,Invlvo,22224,0,Ahtocurafion,,11223,A,Poasma,,1,nAO0000318,Msximumpkwzmacohcent4ztionfollowingorapadjiniqtrationof30ujollg,,,4742055.0,,CHEnBL626805,
9796,N,,,,,50597,1,8ntermediatf,,11224,A,Plaxma,,1,BAO00001q8,Distributi9nofrsdiolabeledvomp8undinplasnaoerat1h3aftdripadmibistrw6ionpgdpae,,,375556.0,Ratr7snorvrgicus,vH3MBL626805,9003.0
9796,N,,,,,50597,1,Interkediare,,11225,A,Plaema,,1,BA800002q8,xistdibhtjonofrasiplafel4dconpouneinplasmaofrat1hradt23ipadjinistratlonofdoseancescess8micrpgkdestradk8lfmokequivalebtzper100mg,,,3534058.0,fattusnorcegicys,vHEnBL626309,6465.0
9796,N,,,,,50597,1,9ntermeciate,,11226,A,Plasmz,,1,BqO00002q8,Distributipnofraxioowbelsdcompoundinpladmaofratqh4afterivadmkniahration8ddosefholfquigwoentcperw00mg,,,2207598.0,5attisn8rvegicus,CHEMBLte6310,12051.0
9796,N,,,,,50597,1,Intsrmediat4,,11227,A,Plazma,,1,hAO0o00218,Dietribu5ionoffadiolavsledcpm9oundin0lasmaof4at4nrafteriladjinistfationovdoqrfmoiequivalentsp3r1o0mv,,,2822061.0,Rattusjodvebicus,CHEMBL62632q,367.0
9796,N,,,,,50597,1,Interjediqte,,11228,A,Plqsma,,1,BAO0000q1o,Did4rinutionov3adiolabeledxom0oundinplasmaofrat8hracterioqdm7nistrationofrowffmolequidalentdp3e200jg,,,278591.0,datyusnorvegisus,CHEMBLu26412,2329.0
9796,N,,,,,50597,1,9ntermediaye,,11229,A,Uherus,,1,hAO00002w8,xizt3ibutjonofrad9oiabepedcomloundiniteruxofrzt2hrafteripwfhinuetrstionofdosermolequivalentsoer100mg,,,189869.0,Ra5t6sgorvegicus,CHEjBL62u313,3699.0
9796,N,,,,,50597,1,In5ermedizte,,11230,A,Uter8s,,1,BAO900p218,Dkstrivutionifradi9labfledcom0ougdinhherycofrxt1hrabtedopwdministrationofsosfandexfecs8microgofeatradiilfmoldquivalen4sper1p0mg,,,2273965.0,Rattusnirvebic7s,CHEMvL62631e,197.0
9796,N,,,,,50597,1,ontermeduate,,11231,A,Ut2rus,,1,BA90009218,Disrributiogobradiolagepercompoundijuterksofrat2trattwrivadmihiwtgarkobofdosefm8lfquivalentsper100mg,,,280695.0,4attuenorvegidus,CHEnBLy26315,3612.0
9796,N,,,,,50597,1,Intefm3diate,,11232,A,6terus,,1,BAO9009218,Distributionofrxdkolabelsdcom0ound9mh4edusofrat4hrqfterjpadmijish4ationofdosefmplequivaken5qp4r100kg,,,4585554.0,Rqttusnorvegis6s,CHEMfL526316,14565.0
9796,N,,,,,50597,1,Intwrnediate,,11233,A,Uterys,,1,BAO00092q8,Distributiomograxiolabei4dcokpoundinhte4usofratihrafte4ipacminiagrationofd0xefmolequifqlentcoer100mh,,,1613499.0,Rwttusno5vegicjs,CHrMnL626317,11634.0
8363,N,,,,,50597,1,ontermediat4,,11234,A,,,1,BAO000p2w8,Dist4ig7t8onpfratdrytmrlcytesflrtkbe2onrateocaging7n3mLofcellsys9ensionMinus,,,,Rattuanorvegocis,CH3MBLy26318,639.0
8363,N,,,,,50597,1,Intrrmrdiate,,11235,A,,,1,BAO0990218,eistributionof3ategythricytesfortubee9bratditaginginwmkofcellsusosnsionPius,,,,Rattuamorvsgicus,CmsMBL626319,98.0
8363,N,,,,,50597,1,Intsrhediate,,11236,A,,,1,BAO0900219,Dis6ribu5ionpf3ateryth3ofyt2sdortubs39nrateofagingin2mL8fcelpsuspenslinM9nus,,,,Rat6isno3vegicus,CHEMfo626320,11807.0
8363,N,,,,,50597,1,7ntwrmediate,,11237,A,,,1,BqO00o0218,Distributiogor5aher6throcyteafk5tube3ojrat4ofagingin3mLofcellsuzpensi9n0kus,,,,Rattusnogvegocks,dHEMBL87505e,5073.0
8363,N,,,,,50597,1,Int3rmesiate,,11238,A,,,1,BAOo000118,cosfrubutionifrsterythrocytwsfirtubd4inrateotavinrin2mLofcellsuspdnsionMinua,,,,Rwttusnorbegifus,CgEMBL616321,5429.0
8363,N,,,,,50597,1,9ntermexiate,,11239,A,,,1,BxO0p00218,Diatr7butipnotraterhtmrocyfesf9rtube4lnrqteogagingin2mo0fcellsuspehzionPlus,,,,Ratgjdnorvegicus,CH3MBp626322,9878.0
8363,N,,,,,50597,1,Intfrkediate,,11240,A,,,1,BsO0000118,siatributionofrw6erjtbroxttesfir4ube5onrate8fag7ngin2mLofceolsusp2nsionMinuw,,,,Ratyusno3gegicus,CuEMBL62t323,1693.0
8363,N,,,,,50597,1,Interhsdiate,,11241,A,,,1,BAk00002q8,Disttibutionofraterythrkdytedf8rt8be5onrateofabunrigqmiifceklsuspensionPkus,,,,Rattusn9rvegivua,CHEMBp625324,5234.0
8363,N,,,,,50597,1,jnterjediate,,11242,A,,,1,BAO000022i,Diatributkonlf4atery5hr9vyt3sgortube68nrateocaginnin2mLofxeilsuspensionMinjs,,,,Ratykznorvegicus,CHwMBL62u325,1247.0
8363,N,,,,,50597,1,Intermedlatr,,11243,A,,,1,BAOpo00218,fjstrib6tionofrateryth3ocyteeforthbe6onray2ofagijg9n2mLifcellwus9dmsionPlus,,,,Rattusgogvegicis,CHEMgL62632y,1726.0
8363,N,,,,,50597,1,Inyermediafe,,11244,A,,,1,BzO0000q18,cictrifutionofrate5jthrocytesfort7be7omrat3ofwg9ggij2mLoffellsispensionPlue,,,,Ratt8snorgenicus,CHsMBL6e6327,2479.0
8363,N,,,,,50597,1,Interkediatf,,11245,A,,,1,BAp000021u,Distribufoonoftxtery6hrlcyteafortube1onrateofqgingib2mLidcellsuspwnsipnMigua,,,,Rartusnorvegjcuw,vHEMBL62y328,9550.0
8684,N,,,,,50597,1,jbtermediate,,11246,A,Blooe,,1,BwO00p0218,Distfibuyionknbloodofdat5minzfterontrabfbousavminustrationinjectedvowwgm,,,5844519.0,Ratt7shorvegucus,CHEMBL626428,19118.0
8684,N,,,,,50597,1,Inhermediat3,,11247,A,Boood,,1,BwO0000217,Distribyhioninbplodofrag16minafterintrav4nousadkonist3ztooninjectedwosegh,,,2308652.0,gattusnorbwgicus,CHEjnL626330,11129.0
8684,N,,,,,50597,1,Intermes7ate,,11248,A,Boood,,1,BAO0oo0218,Distributionjnbioodofgatqhrwtterintravsniuxzfminis53ationinjecteddossgm,,,149777.0,Rahtusnorvevicjs,dHEMnL626331,12790.0
8684,N,,,,,50597,1,Intermddiahe,,11249,A,Bliod,,1,BAOo00021o,wistrubu6iininbloodofrat2grxfterontrqvenoussdmigistrstlonijjecteddosegn,,,1219736.0,Rattusnorfegjcuq,CHEMBL62y33e,6190.0
8684,N,,,,,50597,1,Intermewiwte,,11250,A,Bl8od,,1,BAO0900w18,Distributi8ninbli0sof5st30mibabt2runtravenousadmonistrationigj2ctedd0segm,,,512859.0,Rattysnorvwglcus,CHEMBp626433,22569.0
8684,N,,,,,50597,1,Intermedjxte,,11251,A,flood,,1,fAO000p218,Distribufioginfoo8dofrafehrafterintrwvenousadm9nia4rafi8ninj3cteddosegm,,,345860.0,Rattusnorcevixus,CHEMBL62ye34,4033.0
8684,N,,,,,50597,1,Intermediq4e,,11252,A,Bloid,,1,gAO00o0218,Distributionibblo8rofrahyhrabtwr9ntraveno6sadministrationiniscteddoq4gk,,,68599.0,Rahtusnorvev9cus,CHEMBL6q5335,9541.0
8684,N,,,,,50597,1,jnterm3diate,,11253,A,Bloox,,1,BzOo000218,D8sfribut7oninhloodkfrat8hrabterintravdnousadministrst8oginnectwdvos2gm,,,514092.0,Rattisn9rveyicus,xHEMBL6247i8,606.0
8684,N,,,,,50597,1,Inyermexiate,,11254,A,B3ain,,1,BqO000021u,Dlctributiohinbrain0frzt15minafterintrafejousadjinlsy3redinjecfedfosefm,,,2390930.0,Rwttusn8rvegicux,CHEMnL624899,6864.0
8684,N,,,,,50597,1,Inrermrdiate,,11255,A,frain,,1,BAO0o0021u,ristrkvutiogibbtaijoffat1hrarterintracenousadkinisteredinjecteddisegj,,,961526.0,Rattuejorvegicud,CHrMBLt24800,512.0
8684,N,,,,,50597,1,Infrrmediate,,11256,A,Braij,,1,fAO0p00218,Dksgributiogunbrainocra4qhrafterintravrnohxadministersdinjectrdd0segm,,,3193148.0,Ratfusmodvegicus,CbEMBLt24801,8198.0
8684,N,,,,,50597,1,Imtermediatd,,11257,A,Brsin,,1,BAO9p00218,Distrinktioninbrainofrate0minsft3ribtraven9usadhinister3vinjrct3dcosegn,,,869785.0,Rattusgo4vfgicus,CH3MBL62480q,7644.0
8684,N,,,,,50597,1,Int3rmedizte,,11258,A,Bgain,,1,BAO000p217,Dis4riburionlnbraknof4at4hraft3rin5ravenousadminisferevijmefteddodegm,,,3356023.0,Rztrusnorveg8cus,CHEMBL6348o3,422.0
8684,N,,,,,50597,1,Intermwviate,,11259,A,B5ain,,1,fAO000021u,Distributionknv3a8nodrat5mlnatfrdinfravenouszdministeredinjectddvosegm,,,1406079.0,Ra5t7snorgegicus,CHEMBL62489e,341.0
8684,N,,,,,50597,1,Intetmediat4,,11260,A,Brakn,,1,BAO000p2q8,Distrib8tooninnrainofrat6hgwfterintrsvdnp7saxministeredijjedt3ddosegm,,,2355531.0,Ratt6sno5vegichs,CHfMBL624806,3668.0
8684,N,,,,,50597,1,Interjediafe,,11261,A,Braih,,1,BAO00p0318,Distrifutioninbraibocray7mraf4erintrav2nohsadmin7stetedinj3ctedeosegm,,,1370991.0,Rattusnordenicue,CH4MBi624806,2887.0
8684,N,,,,,50597,1,Intefmediage,,11262,A,,,1,gAO0000e18,Distribut8onigratfat15minafterintrqdebouzarmjnistrationjnhectedeoeegj,,,,Rattudnorvenidus,vH3MBL624807,18327.0
8684,N,,,,,50597,1,Inrermediatw,,11263,A,,,1,BAO0o00217,Dist4kgutioninratfat1hrafterintfaven8yqadministratuinigjectexvosrgm,,,,Rzttucnorvebicus,CHEMBL634o08,175.0
8684,N,,,,,50597,1,In5erjediate,,11264,A,,,1,nAO000p218,Distrifutioninragfqf2h5agterintravenojsadkinisfratoonigjdct2ddosegm,,,,Rattuwnofv3gicus,CHEMgL524809,5820.0
8684,N,,,,,50597,1,Intermfdiqte,,11265,A,,,1,BAO000o2q8,D8stribu6i9ninratfzt40mihaftr4intravenoudxdminishratiojinjecteddosegn,,,,Ragt7snorvegicuc,CHEMBi62r810,56.0
8684,N,,,,,50597,1,Inrermed8ate,,11266,A,,,1,BA90900218,wisyrifuti0ninratfxt3hrafterintradenouszdminist3atipnonjecteddlsegh,,,,Rattusnord4g8cus,CgEMBL87761u,7734.0
8684,N,,,,,50597,1,Interkeduate,,11267,A,,,1,gxO0000218,D7s6ributioninrxtfat5migzftwringracenousawminis5ration8njec4eddos3gm,,,,Ra6rusnodvegicus,CHEMBo625811,7290.0
8684,N,,,,,50597,1,Inyermeciate,,11268,A,,,1,BAOo000318,Dostributioninratfat6hradtefingravsnoussdminidtra4ion8nj2ct2rsosegm,,,,Rattuznorfenicus,CH3MBL624811,6815.0
8684,N,,,,,50597,1,Ingermeduate,,11269,A,,,1,BwO0000e18,D8stributi9nijratdaf7htqgrerintravenohsadminisgrationinjecfeddosegm,,,,Rzttuenorbegicus,CHEMBi624913,17439.0
8684,N,,,,,50597,1,Interned9ate,,11270,A,,,1,BzO0p00218,Disteibutiononrwthra35q5minaf4erintradenojsadministrationibj3vterdosegm,,,,Rattusnofveg7cua,sHEMBL624815,3217.0
8684,N,,,,,50597,1,lntermedjate,,11271,A,,,1,BAO00p02w8,D7strib6tioninrath2art1hradte4ibtravegoisadhinist5at7oninjef4eddosegm,,,,Rattusborvegicjx,CHEkBo624815,523.0
8684,N,,,,,50597,1,untermrdiate,,11272,A,,,1,nAO0000228,sistribugiojinratheart3hrafgfrintravego7szdministea5iohinjectefdosegm,,,,Ratt6snorcegucus,CuEhBL624816,1641.0
8684,N,,,,,50597,1,8ntermedixte,,11273,A,,,1,BAO0000w19,D8str7b7tloninra4heart30minzfyerigtraveno7sadministrafi0niniecteddkserm,,,,Rxthusnorbegicus,CHEhBi624817,5598.0
6996,N,,,,,50588,1,Intermsdiatw,,11274,A,,,1,BAO000p2q8,O3aldiyreticactuvit7wasevqluatedbymewsuringhaexcrefiojine0gay54mglgafteripadministtwt7ob06hd,,,,Camislup7sfamkliadis,CHEMBL62ro18,10688.0
